<SEC-DOCUMENT>0001213900-24-025316.txt : 20240325
<SEC-HEADER>0001213900-24-025316.hdr.sgml : 20240325
<ACCEPTANCE-DATETIME>20240325092551
ACCESSION NUMBER:		0001213900-24-025316
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		115
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240325
DATE AS OF CHANGE:		20240325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inspira Technologies OXY B.H.N. Ltd
		CENTRAL INDEX KEY:			0001837493
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40303
		FILM NUMBER:		24777130

	BUSINESS ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
		BUSINESS PHONE:		972-9-9664488

	MAIL ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>ea0202167-20f_inspira.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 25 13:11:05 UTC 2024 -->
<html xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iinn="http://www.inspiratechnologies.com/20231231" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES<br/>
SECURITIES AND EXCHANGE COMMISSION<br/>
WASHINGTON, DC 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-21194">20-F</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentRegistrationStatement" id="ixv-28"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric>
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport" id="ixv-40"><span style="font-family: Times New Roman, Times, Serif">&#9746;</span></ix:nonNumeric>
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-21195"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-21196">December 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-21197">2023</ix:nonNumeric></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="ixv-56"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric>
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentShellCompanyReport" id="ixv-68"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric>
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File No.: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-21198">001-40303</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-78"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Exact name of registrant as specified in its
charter)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>Translation of registrant&#8217;s name into
English: Not applicable</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>State of <ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="ixv-21199">Israel</ix:nonNumeric>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><i>(Jurisdiction of incorporation
or organization)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-21200">2 Ha-Tidhar St</ix:nonNumeric>.,</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-21201">Ra&#8217;anana</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-21202">4366504</ix:nonNumeric> <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-21203">Israel</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>Tel: <ix:nonNumeric contextRef="c1" name="dei:CityAreaCode" id="ixv-21204">+972.4</ix:nonNumeric>.<ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber" id="ixv-21205">6230333</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><i>(Address of principal
executive offices)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName" id="ixv-115"><b>Dagi Ben-Noon</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1" id="ixv-21206">2 Ha-Tidhar St</ix:nonNumeric>.,</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown" id="ixv-21207">Ra&#8217;anana</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode" id="ixv-21208">4366504</ix:nonNumeric> <ix:nonNumeric contextRef="c1" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-21209">Israel</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>Tel: +972.4.6230333</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><i>(Name, Telephone, E-mail
and/or Facsimile number and Address of Company Contact Person)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered or to be registered pursuant
to Section 12(b) of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; width: 32%"><span style="font-size: 10pt"><i>Title of each class</i></span></td> <td style="vertical-align: top; text-align: center; width: 2%">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; width: 32%"><span style="font-size: 10pt"><i>Trading Symbol(s)</i></span></td> <td style="vertical-align: top; text-align: center; width: 2%">&#160;</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center; width: 32%"><span style="font-size: 10pt"><i>Name of each exchange on <br/>
which registered </i></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: center"><ix:nonNumeric contextRef="c2" name="dei:Security12bTitle" id="ixv-153"><span style="font-size: 10pt"><b>Ordinary Shares, no par value</b></span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c2" name="dei:TradingSymbol" id="ixv-158"><span style="font-size: 10pt"><b>IINN</b></span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-size: 10pt"><b><ix:nonNumeric contextRef="c2" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-21210">Nasdaq</ix:nonNumeric> Capital Market</b></span></td></tr> <tr style="vertical-align: top; "> <td style="text-align: center"><ix:nonNumeric contextRef="c3" name="dei:Security12bTitle" id="ixv-167"><span style="font-size: 10pt"><b>Warrants to purchase Ordinary Shares</b></span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c3" name="dei:TradingSymbol" id="ixv-173"><b>IINNW</b></ix:nonNumeric></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-size: 10pt"><b><ix:nonNumeric contextRef="c3" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-21211">Nasdaq</ix:nonNumeric> Capital Market</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered or to be registered pursuant
to Section 12(g) of the Act: None</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities for which there is a reporting obligation
pursuant to Section 15(d) of the Act: None&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate the number of outstanding shares of each
of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-21212">15,652,176</ix:nonFraction> ordinary shares, no par value, as of
December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-21213">No</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this report is an annual or transition report,
indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act of 1934.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
<ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-21214">No</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the
past 90 days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
<ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-21215">No</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-21216">Yes</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span>
No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of &#8220;large
accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 2%">&#160;</td> <td style="text-align: justify; width: 25%"><span style="font-size: 10pt">Large accelerated filer </span></td> <td style="text-align: justify; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="text-align: justify; width: 30%"><span style="font-size: 10pt">Accelerated filer </span></td> <td style="text-align: justify; width: 21%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-269"><span style="font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td style="text-align: justify"> <span style="font-size: 10pt">&#9746;</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Emerging Growth Company </span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntityEmergingGrowthCompany" id="ixv-276"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company that prepares its
financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section 13(a) of the Exchange
Act. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityExTransitionPeriod" id="ixv-282"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8224;The term &#8220;new or revised financial
accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification
after April 5, 2012.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag" id="ixv-297"><span style="font-family: Times New Roman, Times, Serif">&#9746;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If securities are registered pursuant to Section
12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction
of an error to previously issued financial statements. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-303"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s
executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark which basis of accounting
the registrant has used to prepare the financial statements included in this filing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" name="dei:DocumentAccountingStandard" id="ixv-21217">U.S. GAAP</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">International Financial Reporting
Standards as issued by the International Accounting Standards Board <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If &#8220;Other&#8221; has been checked in response
to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
Item 17 <span style="font-family: Times New Roman, Times, Serif">&#9744;</span> Item 18</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this is an annual report, indicate by check
mark whether the registrant is a shell company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-348"><span style="font-family: Times New Roman, Times, Serif">&#9746;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_001"><span style="font-size: 10pt">INTRODUCTION</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii</span></td></tr>
  <tr>
    <td colspan="2" style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_002"><span style="font-size: 10pt">CAUTIONARY
    NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">v</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_003"><span style="font-size: 10pt">SUMMARY
    RISK FACTORS</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii</span></td></tr>
  <tr>
    <td colspan="2" style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_004"><span style="font-size: 10pt">PART
    I</span></a></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_005"><span style="font-size: 10pt">IDENTITY
    OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 2.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_006"><span style="font-size: 10pt">OFFER
    STATISTICS AND EXPECTED TIMETABLE</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 3.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_007"><span style="font-size: 10pt">KEY
    INFORMATION</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_008"><span style="font-size: 10pt">[Reserved]</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_009"><span style="font-size: 10pt">Capitalization
    and Indebtedness.</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_010"><span style="font-size: 10pt">Reasons
    for the Offer and Use of Proceeds</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_011"><span style="font-size: 10pt">Risk
    Factors</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_012"><span style="font-size: 10pt">INFORMATION
    ON THE COMPANY</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_013"><span style="font-size: 10pt">History
    and Development of the Company</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_014"><span style="font-size: 10pt">Business
    Overview</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_015"><span style="font-size: 10pt">Organizational
    Structure</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_016"><span style="font-size: 10pt">Property,
    Plants and Equipment</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4A.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_017"><span style="font-size: 10pt">UNRESOLVED
    STAFF COMMENTS</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 5.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_018"><span style="font-size: 10pt">OPERATING
    AND FINANCIAL REVIEW AND PROSPECTS</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_019"><span style="font-size: 10pt">Operating
    Results</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_020"><span style="font-size: 10pt">Liquidity
    and Capital Resources</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_021"><span style="font-size: 10pt">Research
    and development, patents and licenses, etc.</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_022"><span style="font-size: 10pt">Trend
    information</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_023"><span style="font-size: 10pt">Critical
    Accounting Estimates</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 6.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_024"><span style="font-size: 10pt">DIRECTORS,
    SENIOR MANAGEMENT AND EMPLOYEES.</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_025"><span style="font-size: 10pt">Directors
    and Senior Management.</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_026"><span style="font-size: 10pt">Compensation.</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_027"><span style="font-size: 10pt">Board
    Practices</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_028"><span style="font-size: 10pt">Employees</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_029"><span style="font-size: 10pt">Share
    Ownership</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_030"><span style="font-size: 10pt; text-decoration: none">Disclosure
    of a registrant&#8217;s action to recover erroneously awarded compensation</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">101</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 7.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_031"><span style="font-size: 10pt">MAJOR
    SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_032"><span style="font-size: 10pt">Major
    Shareholders</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_033"><span style="font-size: 10pt">Related
    Party Transactions</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">102</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_034"><span style="font-size: 10pt">Interests
    of Experts and Counsel</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">103</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 8.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_035"><span style="font-size: 10pt">FINANCIAL
    INFORMATION</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">103</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_036"><span style="font-size: 10pt">Statements
    and Other Financial Information</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">103</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_037"><span style="font-size: 10pt">Significant
    Changes</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 9.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_038"><span style="font-size: 10pt">THE
    OFFER AND LISTING</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_039"><span style="font-size: 10pt">Offer
    and Listing Details</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_040"><span style="font-size: 10pt">Plan
    of Distribution</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_041"><span style="font-size: 10pt">Markets</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_042"><span style="font-size: 10pt">Selling
    Shareholders</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_043"><span style="font-size: 10pt">Dilution</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_044"><span style="font-size: 10pt">Expenses
    of the Issue</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 10.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_045"><span style="font-size: 10pt">ADDITIONAL
    INFORMATION</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_046"><span style="font-size: 10pt">Share
    Capital</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_047"><span style="font-size: 10pt">Memorandum
    and Articles of Association</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_048"><span style="font-size: 10pt">Material
    Contracts</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">106</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_049"><span style="font-size: 10pt">Exchange
    Controls</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">106</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_050"><span style="font-size: 10pt">Taxation</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">106</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_051"><span style="font-size: 10pt">Dividends
    and Paying Agents</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">113</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_052"><span style="font-size: 10pt">Statement
    by Experts</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">113</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_053"><span style="font-size: 10pt">Documents
    on Display</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">114</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_054"><span style="font-size: 10pt">Subsidiary
    Information</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">114</span></td></tr>
<tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_055"><span style="font-size: 10pt">Annual
    Report to Security Holders</span></a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">114</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 11.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_056"><span style="font-size: 10pt">QUANTITATIVE AND QUALITATIVE
    DISCLOSURES ABOUT MARKET RISK</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">114</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 12.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_057"><span style="font-size: 10pt">DESCRIPTION OF SECURITIES
    OTHER THAN EQUITY SECURITIES</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_058"><span style="font-size: 10pt">Debt Securities</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_059"><span style="font-size: 10pt">Warrants and rights</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_060"><span style="font-size: 10pt">Other Securities</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_061"><span style="font-size: 10pt">PART
    II</span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 13.</span></td>
    <td><a href="#a_063"><span style="font-family: Times New Roman, Times, Serif"><span style="font-size: 10pt">DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</span></span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">116</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 14.</span></td>
    <td><a href="#a_064"><span style="font-family: Times New Roman, Times, Serif"><span style="font-size: 10pt">MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</span></span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">116</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 15.</span></td>
    <td><a href="#a_065"><span style="font-family: Times New Roman, Times, Serif"><span style="font-size: 10pt">CONTROLS AND PROCEDURES</span></span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">116</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16.</span></td>
    <td><a href="#a_066"><span style="font-family: Times New Roman, Times, Serif"><span style="font-size: 10pt">[RESERVED]</span></span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">117</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16A.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_067"><span style="font-size: 10pt">AUDIT COMMITTEE FINANCIAL
    EXPERT</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">117</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16B.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_068"><span style="font-size: 10pt">CODE OF ETHICS</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">117</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16C.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_069"><span style="font-size: 10pt">PRINCIPAL ACCOUNTANT
    FEES AND SERVICES</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">117</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16D.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_070"><span style="font-size: 10pt">EXEMPTIONS FROM THE LISTING
    STANDARDS FOR AUDIT COMMITTEES</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">118</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16E.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_071"><span style="font-size: 10pt">PURCHASES OF EQUITY SECURITIES
    BY THE ISSUER AND AFFILIATED PURCHASERS</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">118</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16F.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_072"><span style="font-size: 10pt">CHANGE IN REGISTRANT&#8217;S
    CERTIFYING ACCOUNTANT</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">118</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16G.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_073"><span style="font-size: 10pt">CORPORATE GOVERNANCE</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">118</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16H.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_074"><span style="font-size: 10pt">MINE SAFETY DISCLOSURE</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">121</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">ITEM
    16I</span></p></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_075"><span style="font-size: 10pt">DISCLOSURE REGARDING
    FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">121</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">ITEM
    16J</span></p></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_076"><span style="font-size: 10pt">INSIDER TRADING POLICIES</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">121</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">ITEM
    16K</span></p></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_077"><span style="font-size: 10pt">CYBERSECURITY</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">121</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_078"><span style="font-size: 10pt">PART
    III</span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 17.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_079"><span style="font-size: 10pt">FINANCIAL STATEMENTS</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 18.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_080"><span style="font-size: 10pt">FINANCIAL STATEMENTS</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 19.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_081"><span style="font-size: 10pt">EXHIBITS</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_082"><span style="font-size: 10pt">SIGNATURES</span></a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">123</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Inspira Technologies Oxy B.H.N. Ltd. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>INTRODUCTION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a specialty medical
device company engaged in the research, development, manufacturing, and marketing of proprietary life support technology with a vision
to supersede traditional mechanical ventilators, or Mechanical Ventilation, which is the standard of care today for the treatment of acute
respiratory failure. Although it may be sometimes lifesaving, Mechanical Ventilation is associated with increased risks, costs of care,
extended lengths of stay, frequent incidence of infections, ventilator dependence and mortality. Using our state-of-the-art life support
technology, our goal is to set a new standard of care and to provide patients with acute respiratory failure an opportunity to maintain
spontaneous breathing and avoid the need for intubation, coma and various risks associated with the use of Mechanical Ventilation. As
part of our strategy to reach this goal, and in parallel to pursuing regulatory approvals, we are actively working to establish collaborations
with strategic partners, globally ranked hospitals, medical device companies and distributors both for endorsement and early clinical
adoption. We plan to target intensive care units, or ICUs, general medical units, operating theaters, and small urban and rural
hospitals, with the goal of making our solutions more accessible to millions of patients worldwide. We expect for these activities to
support our strategy plan to reach market penetration and adoption of our life support technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing the following
products:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>The INSPIRA<sup>TM</sup>
ART </b>(Gen 2)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The INSPIRA ART device (Augmented
Respiratory Technology) (also known as the INSPIRA ART500, ART system or ART), described herein as the INSPIRA ART, INSPIRA ART (Gen2),
INSPIRA ART device or INSPIRA ART system, our flagship product, is a life support technology targeting to utilize direct blood oxygenation
to boost patient saturation levels within minutes while the patient is awake &amp; spontaneously breathing. It is designed to perform
Adaptive Blood Oxygenation, by continuously measuring the patient&#8217;s blood parameters in real-time, delivering needed oxygen volume straight
into the blood. The aim of our products is to treat patients without the need for Mechanical Ventilation with the potential to reduce
associated legacy risks, complications and high costs and potentially allowing for treatment of larger patient populations in and beyond
ICU settings. The INSPIRA ART is being designed as a new intent of use for long-term (longer than 6 hours) life support that provides
assisted extracorporeal circulation and physiologic gas exchange (oxygenation and CO2 removal) of the patient&#8217;s blood in adults
with acute respiratory failure, targeting to allow for treatment of patients while they are awake. The INSPIRA ART is being designed to
potentially prevent the need for invasive mechanical ventilation, targeting acute respiratory failure patients in ICUs and general medical
units. The break-through INSPIRA ART, which is still in development and has not been tested or used on humans and is expected to be submitted
to the U.S. Food and Drug Administration, or FDA, for regulatory approval via the pre-market approval application or De Novo regulatory
pathways.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>The INSPIRA<sup>TM</sup>
ART100 (Gen 1)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The INSPIRA ART100 device
(previously referred to as the ALICE, Liby or ECLS system), described herein as the INSPIRA ART100 (Gen 1), INSPIRA ART100, or the INSPIRA
ART100 device, an advanced form of life support system better known by the medical industry as a cardiopulmonary bypass system, or CPB,
is being designed for use in surgical procedures requiring cardiopulmonary bypass for 6 hours or less. The INSPIRA ART100 device was submitted
to the FDA for 510k clearance in September 2023, and we expect a response by the end of the first half of 2024. The INSPIRA ART100 is
designed to be a new generation CPB system with potential advantages to medical device design with ergonomic configuration and intuitive
user-centric software and display to increase functionality, as well as a large touchscreen with novel colorful graphical representation
that increases the visibility and functionality of data displayed to the medical staff. The INSPIRA ART100 device is being designed to
be lightweight and highly durable and will be equipped with long battery life to maximize its portability. The INSPIRA ART100 device,
designed as a CPB, shall be indicated for use in surgical procedures requiring cardiopulmonary bypass for 6 hours or less. The device
is designed to be versatile, working with certain disposables manufactured by leading market players in the space.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>The HYLA<sup>TM</sup> Blood
Sensor</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The HYLA blood sensor, described
herein as the HYLA or HYLA blood sensor, originally designed as a key and core technology for the INSPIRA ART (Gen 2), is being developed
in its first variant (HYLA 1) to be compatible with the INSPIRA ART100 with plans to also be a stand-alone device to be integrated or
used in extracorporeal procedures. The HYLA is designed as a non-invasive optical blood sensor designed to perform real-time and continuous
blood measurements, to potentially alert physicians of changes in patient&#8217;s clinical condition. The HYLA blood sensor is being designed
as a clip-on sensor, attached to the outer walls of a blood tube, that may potentially reduce risks, complications, and costs. The HYLA
blood sensor may have broad application potential, benefiting patients undergoing procedures such as cardiopulmonary bypass operations,
Extracorporeal Membrane Oxygenation, or ECMO and Cardiopulmonary bypass, pending regulatory approvals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have a goal to set a new
standard of care in various areas of patient care. As part of our strategy to reach these goals, and in parallel to pursuing regulatory
approvals, we are actively working to establish collaborations with strategic partners and globally ranked health centers to provide endorsement
and clinical adoption for regional deployments of our products and technologies. We plan to target ICUs, general medical units, Operating
theaters, and small urban and rural hospitals, with the goal of making our solutions more accessible to millions of patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an Israeli corporation
based in Ra&#8217;anana, Israel and were incorporated in Israel in 2018 under the name Clearx Medical Ltd. On April 10, 2018, our name
was changed to Insense Medical Ltd. and on July 30, 2020, our name was changed to our current name, Inspira Technologies Oxy B.H.N. Ltd.
Our principal executive offices are located at 2 Ha-Tidhar St., Ra&#8217;anana, 4366504 Israel. Our telephone number in Israel is 972
996 644 88. Our website address is&#160;<i>www.inspira-technologies.com</i>. The information contained on, or that can be accessed through,
our website is not part of this annual report. We have included our website address in this annual report solely as an inactive textual
reference.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain information included
or incorporated by reference in this annual report on Form 20-F may be deemed to be &#8220;forward-looking statements&#8221; within the
meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements are often
characterized by the use of forward-looking terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221;
&#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;believe,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;intend,&#8221;
&#8220;project&#8221; or other similar words, but are not the only way these statements are identified.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These forward-looking statements
may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections
of results of operations or of financial condition, expected capital needs and expenses, statements relating to the research, development,
completion and use of our products, and all statements (other than statements of historical facts) that address activities, events or
developments that we intend, expect, project, believe or anticipate will or may occur in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Forward-looking statements
are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking statements on
assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions,
expected future developments and other factors they believe to be appropriate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among other things:</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our planned level of revenues
and capital expenditures;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our available cash our ability
to obtain additional funding;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify">Our ability to market and sell our products;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our expectation regarding the
sufficiency of our existing cash and cash equivalents to fund our current operations;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our ability to advance the development
of our products and future potential product candidates;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our ability to commercialize
our products and future potential product candidates and future sales of our products or any other future potential product candidates;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our assessment of the potential
of our products and future potential product candidates to treat certain indications;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our planned level of capital
expenditures and liquidity;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our plans to continue to invest
in research and development to develop technology for new products;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our ability to maintain our
relationships with suppliers, manufacturers, distributors, and other partners;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Anticipated actions of the FDA,
state regulators, if any, or other similar foreign regulatory agencies, including approval to conduct clinical trials, the timing and
scope of those trials and the prospects for regulatory approval or clearance of, or other regulatory action with respect to our products
or services;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The regulatory environment and
changes in the health policies and regimes in the countries in which we intend to operate, including the impact of any changes in regulation
and legislation that could affect the medical device industry;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our ability to meet our expectations
regarding the commercial supply of our products and future product candidates;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our ability to retain key office
holders;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our ability to internally develop
new inventions and intellectual property;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The overall global economic
environment;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The impact of competition and
new technologies;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The possible impacts of cybersecurity
incidents on our business and operations;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">General market, political and
economic conditions in the countries in which we operate, including those related to the recent unrest and actual or potential armed
conflict in Israel and other parts of the Middle East.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The impact of competition and
new technologies;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our ability to internally develop
new inventions and intellectual property;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Changes in our strategy; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Litigation</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Readers are urged to carefully
review and consider the various disclosures made throughout this annual report on Form 20-F which are designed to advise interested parties
of the risks and factors that may affect our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should not put undue reliance
on any forward-looking statements. Any forward-looking statements in this annual report on Form 20-F are made as of the date hereof, and
we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise, except as required by law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the section of
this annual report on Form 20-F entitled &#8220;Item 4. Information on the Company&#8221; contains information obtained from independent
industry sources and other sources that we have not independently verified.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Unless
otherwise indicated, all references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;Inspira&#8221; refer
to Inspira Technologies Oxy B.H.N. Ltd. References to &#8220;U.S. dollars, &#8220;dollars,&#8221; and &#8220;$&#8221; are to currency
of the United States of America, references to A$ are to Australian dollars, and references to &#8220;NIS&#8221; are to New Israeli Shekels.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Beginning with the year ended December 31, 2023, we transitioned from
preparing and reporting our financial statements in accordance with the International Financial Reporting Standards, or IFRS, as issued
by the International Accounting Standards Board, or IASB, to preparing and reporting our financial statements in accordance with generally
accepted accounting principles in the United States, or U.S. GAAP, which may cause our financial results to differ from results, or impact
the comparability to our financial statements, prepared in accordance with IFRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Notwithstanding the foregoing, we have retroactively converted the historical financial statements
that were prepared in accordance with IFRS and included in this report to present such financial statements in accordance with U.S. GAAP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">All
trademarks or trade names referred to in this Form 20-F are the property of their respective owners. Solely for convenience, the trademarks
and trade names in this annual report on Form 20-F are referred to without the &#174; and &#8482; symbols, but such references should not
be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.
We do not intend the use or display of other companies&#8217; trademarks and trade names to imply a relationship with, or endorsement
or sponsorship of us by, any other companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">This
Form 20-F contains various depictions and illustrations of the various products we are developing. These illustrations are representative
of the current expected designs for our products and are subject to change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vi<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Summary Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The risk factors described
below are a summary of the principal risk factors associated with an investment in us. These are not the only risks we face. You should
carefully consider these risk factors, together with the risk factors set forth in Item 3D. of this annual report on Form 20-F and the
other reports and documents filed by us with the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our financial statements for
the year ended December 31, 2023, contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going
concern. This going concern opinion could prevent us from obtaining new financing on reasonable terms or at all and risk our ability
to continue operating as a going concern;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The market price of our securities
may be highly volatile, and you may not be able to resell your securities at or above the price that you paid;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our
principal shareholders, officers and directors currently beneficially own approximately 23.6% of our securities and may therefore be
able to exert control over matters submitted to our shareholders for approval;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We have a limited operating
history, and we have incurred significant operating losses since our inception and anticipate that we will incur continued losses for
the foreseeable future.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We have not generated any revenue
from product sales and may never be profitable.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We will need to raise substantial
additional funding, which may not be available on acceptable terms, or at all. Failure to obtain funding on acceptable terms and on a
timely basis may require us to curtail, delay or discontinue our product development efforts or other operations;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Raising additional capital would
cause dilution to our existing shareholders, and may adversely affect the rights of existing shareholders;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We are highly dependent on the
successful development, marketing and sale of our products and on receiving the required regulatory approvals;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our success depends upon market
acceptance of our products, our ability to develop and commercialize new products and generate revenues and our ability to identify new
markets for our technology;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Medical device development is
costly and involves continual technological change which may render our current or future products obsolete;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our customer acquisition strategy
may not succeed;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We are dependent upon third-party
service providers. If such third-party service providers fail to maintain a high quality of service, the utility of our products could
be impaired, which could adversely affect the penetration of our products, our business, operating results and reputation;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We expect to be exposed to fluctuations
in currency exchange rates, which could adversely affect our results of operations;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We manage our business through
a small number of employees and key consultants;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We may need to expand our organization
and we may experience difficulties in recruiting needed additional employees and consultants, which could disrupt our operations;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">International expansion of our
business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside
of the United States or Israel;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">If third-party payors do not
provide adequate coverage and reimbursement for the use of our products or services or any future product candidates, our revenue will
be negatively impacted;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our product candidates and operations
are subject to extensive government regulation and oversight both in the United States and abroad and our failure to comply with applicable
requirements could harm our business;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We may not receive, or may be
delayed in receiving, the necessary clearances or approvals for our products and failure to timely obtain necessary clearances or approvals
for our products would adversely affect our ability to grow our business;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Failure to comply with post-marketing
regulatory requirements could subject us to enforcement actions, including substantial penalties, and might require us to recall or withdraw
a product from the market;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our products may cause or contribute
to adverse medical events or be subject to failures or malfunctions that we are required to report to the FDA, and if we fail to do so,
we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations. The discovery
of serious safety issues with our products, or a recall of our products either voluntarily or at the direction of the FDA or another
governmental authority, could have a negative impact on us;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Healthcare legislative and regulatory
reform measures may have a material adverse effect on our business and results of operations;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Legislative or regulatory reforms
in the United States or the European Union may make it more difficult and costly for us to obtain regulatory clearances or approvals
for our products or to manufacture, market or distribute our products after clearance or approval is obtained;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">If we are unable to obtain and
maintain effective patent rights for our products and services, we may not be able to compete effectively in our markets. If we are unable
to protect the confidentiality of our trade secrets or know-how, such proprietary information may be used by others to compete against
us;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We may be subject, directly
or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy and security laws.
If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our business and operations
might be adversely affected by security breaches, including any cybersecurity incidents; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Potential political, economic
and military instability in the State of Israel, where our headquarters, members of our management team and our research and development
facilities are located, may adversely affect our results of operations.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->viii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART I</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT
AND ADVISERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 2. <span style="text-transform: uppercase">OFFER
STATISTICS AND EXPECTED TIMETABLE</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 3. KEY INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>A.</b></span> &#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">[Reserved]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_009"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-size: 10pt"><b>B.</b></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Capitalization and Indebtedness.</b></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_010"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-size: 10pt"><b>C.</b></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Reasons for the Offer and Use
of Proceeds.</b></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_011"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-size: 10pt"><b>D.</b></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Risk Factors</b></span></td>
</tr></table><div>
</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should carefully consider
the risks and uncertainties described below, together with all of the other information in this annual report on Form 20-F. If any of
these risks actually occurs, our business and financial condition could suffer, and the price of our securities could decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Business and Industry</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are highly dependent on the successful
development, marketing and sale of our products and on receiving the required regulatory approvals.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products, focused on the
treatment of respiratory failure, is the basis of our business. As a result, the success of our business plan is highly dependent on our
ability to develop, manufacture and commercialize our products, and our failure to do so could cause our business to fail. Successful
commercialization of medical devices is a complex and uncertain process, dependent on the efforts of management, manufacturers, local
operators, integrators, medical professionals, third-party payors, as well as general economic conditions, among other factors. Any factor
that adversely impacts the development and commercialization of our products, will have a negative impact on our business, financial condition,
results of operations and prospects. We have limited experience in commercializing our products and we may face several challenges with
respect to our commercialization efforts, including, among others, that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we may not have adequate financial
or other resources to complete the development of our products;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we may not be able to manufacture
our products in commercial quantities, at an adequate quality or at an acceptable cost;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we may not be able to establish
adequate sales, marketing and distribution channels;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 11; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">healthcare professionals and
patients may not accept our products;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we may not be aware of possible
complications from the continued use of our products since we have limited clinical experience with respect to the actual use of our
products;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we may not be able to compete
with existing solutions for respiratory failure;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">technological breakthroughs
in the respiratory support solutions may reduce the demand for our products;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">third-party payors may not agree
to reimburse patients for any or all of the purchase price of our products, which may adversely affect patients&#8217; willingness to
use our products;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we may face third-party claims
of intellectual property infringement; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we may fail to obtain or maintain
regulatory clearance or approvals in our target markets or may face adverse regulatory or legal actions even if regulatory approval is
obtained.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to meet any
one or more of these challenges successfully, our ability to effectively commercialize our products and services could be limited, which
in turn could have a material adverse effect on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;<b><i>Our success depends upon market acceptance
of our products, our ability to develop and commercialize new products and generate revenues and our ability to identify new markets for
our technology. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have developed, and are
engaged in the development of, respiratory support technology. Our success will depend on the approval and acceptance of our products
and any future products in the healthcare market. We are faced with the risk that the marketplace will not be receptive to our products
or any future products over competing products and that we will be unable to compete effectively. Factors that could affect our ability
to successfully commercialize our current and any potential future products:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the challenges of developing
(or acquiring externally developed) technology solutions that are adequate and competitive in meeting the requirements of next-generation
design challenges; and</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the dependence upon referrals
from physicians for the sale of our products and provision of our service.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
cannot assure that our products or any future products will gain broad market acceptance. If the market for our products fails to develop
or develops more slowly than expected, our business and operating results would be materially and adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to maintain existing strategic
relationships with Innovimed, Glo-Med, our other distributors, or are unable to identify additional distributors of our products or any
future products and technologies, our revenues may decrease.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently expect to derive
a significant amount of our revenues through our strategic relationships and distribution agreements with Innovimed Sp. z o.o, or Innovimed,
Bepex Ltd., Anita T&#233;cnica S.L, or WAAS Group, Glo-Med and CIO MED GROUP, CORP, as well as other distributors for the deployment
of our products. If our relationships with our distributors are terminated or impaired for any reason and we are unable to replace these
relationships with other means of distribution, we could suffer a material decrease in revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may need, or decide it
is otherwise advantageous to us, to obtain the assistance of additional distributors to market and distribute our future products and
technologies, as well as to market and distribute our INSPIRA ART (Gen 2) device, INSPIRA ART100 device, HYLA blood sensors, VORTX Device
and Inspira disposables to existing or new markets or geographical areas. We may not be able to find additional distributors who will
agree to and are able to successfully market and distribute our systems and technologies on commercially reasonable terms, if at all.
If we are unable to establish additional distribution relationships on favorable terms, our revenues may decline. In addition, our distributors
may choose to favor the products of our competitors over ours and give preference to them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to our agreements
with the aforementioned distributors, we will be responsible for obtaining and maintaining any and all regulatory approvals for our products.
If we are unable to obtain or maintain such approvals, or if the parties to the distribution agreement fail to purchase the agreed upon
products at the agreed upon pricing, it may adversely impact our relationships with these distributors, and we may never realize any revenues
from these agreements ships as a result.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Medical device development is costly and
involves continual technological change which may render our current or future products obsolete.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market for medical device
technologies and products is characterized by factors such as rapid technological change, medical advances, changing consumer requirements,
short device lifecycles, changing regulatory requirements and evolving industry standards. Any one of these factors could reduce the demand
for our devices or require substantial resources and expenditures for, among other things, research, design and development, to avoid
technological or market obsolescence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success will depend on
our ability to enhance our current technology and develop or acquire new technologies to keep pace with technological developments and
evolving industry standards, while responding to changes in customer needs. A failure to adequately develop or acquire device enhancements
or new devices that will address changing technologies and customer requirements adequately, or to introduce such devices on a timely
basis, may have a material adverse effect on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We might have insufficient
financial resources to improve our products, advance technologies and develop new devices at competitive prices. Technological advances
by one or more competitors or future entrants into the field may result in our present services or devices becoming non-competitive or
obsolete, which may decrease revenues and profits and adversely affect our business and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may encounter significant
competition across our product lines and in each market in which we will sell our products and services from various companies, some of
which may have greater financial and marketing resources than we do. Our competitors may include any companies engaged in the research,
development, manufacture, and marketing of respiratory support solutions and technologies, as well as a wide range of medical device companies
that sell a single or limited number of competitive products and services or participate in only a specific market segment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our customer acquisition strategy may not
succeed and although we have executed distribution agreements with various parties in various geographic region, we may never realize
any revenues from such agreements</i>.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business will be dependent
upon success in our customer acquisition strategy. To date, we have executed various distribution agreements in various geographic regions
which are subject to regulatory approvals. If we do not obtain regulatory approval, or if the parties to the distribution agreement fail
to purchase the agreed upon products at the agreed upon pricing, we may not realize any revenues from such agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if we fail to
maintain a high quality of device technology, we may fail to retain or add new customers. If we fail, our revenue, financial results and
business may be significantly harmed. Our future success depends upon expanding our commercial operations in the United States, Israel
and Europe, as well as entering additional markets to commercialize our products and any future products. We believe that our expanded
growth will depend on the further development, regulatory approval and commercialization of our products. If we fail to expand the use
of our products in a timely manner, we may not be able to expand our markets or to grow our revenue, and our business may be adversely
impacted. If people do not perceive our products to be useful and reliable, we may not be able to attract or retain new customers. A decrease
in costumer growth could render less attractive to developers, which may have a material and adverse impact on our revenue, business,
financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Our business and
operations would suffer in the event of computer system failures, cyber-attacks or a deficiency in our cybersecurity.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Despite
the implementation of security measures intended to secure our data against impermissible access and to preserve the integrity and confidentiality
of our data, our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses,
malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet,
attachments to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a security
breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber
terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world
have increased. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of
our drug development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could
result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent
that any disruption or security breach was to result in a loss of or damage to our data or applications, or inappropriate disclosure of
confidential or proprietary information, we could incur material legal claims and liability, including under data privacy laws such as
the General Data Protection Regulation, or the GDPR, damage to our reputation, and the further development of our drug candidates could
be delayed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are dependent upon third-party manufacturers
and suppliers, which makes us vulnerable to potential supply shortages and problems, increased costs and quality or compliance issues,
any of which could harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products are comprised
of a number of components. We are planning to sell an assembled product as well as its disposable respiratory support unit. The components
of the assembled product and the disposable unit consist of both proprietary and off the shelf components. Proprietary components will
be manufactured on our behalf at good manufacturing practices, or GMP, approved production plant to adhere to regulatory requirements,
whereas off the shelf components will be sourced and manufactured by GMP suppliers. GMP sub-contractors will assemble proprietary and
off the shelf components together to create our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Therefore, we rely on third
parties to manufacture and supply us with proprietary custom components. Although we rely on a number of suppliers who provide us materials
and components as well as manufacture and assemble certain components of our products, we do not rely on single-source suppliers. Our
suppliers may encounter problems during manufacturing for a variety of reasons, including, for example, failure to follow specific protocols
and procedures, failure to comply with applicable legal and regulatory requirements, equipment malfunction and environmental factors,
failure to properly conduct their own business affairs, and infringement of third-party intellectual property rights, any of which could
delay or impede their ability to meet our requirements. Our reliance on these third-party suppliers also subjects us to other risks that
could harm our business, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we are not currently a major
customer of many of our suppliers, and these suppliers may therefore give other customers&#8217; needs higher priority than ours;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we may not be able to obtain
an adequate supply in a timely manner or on commercially reasonable terms;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our suppliers, especially new
suppliers, may make errors in manufacturing that could negatively affect the efficacy or safety of our products or cause delays in shipment;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we may have difficulty locating
and qualifying alternative suppliers;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">switching components or suppliers
may require product redesign and possibly submission to the FDA or other similar foreign regulatory agencies, which could impede or delay
our commercial activities;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">one or more of our suppliers
may be unwilling or unable to supply components of our products;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the occurrence of a fire, natural
disaster or other catastrophe impacting one or more of our suppliers may affect their ability to deliver products to us in a timely manner;
and</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our suppliers may encounter
financial or other business hardships unrelated to our demand, which could inhibit their ability to fulfill our orders and meet our requirements.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able to quickly
establish additional or alternative suppliers, if necessary, in part because we may need to undertake additional activities to establish
such suppliers as required by the regulatory approval process. Any interruption or delay in obtaining products from our third-party suppliers,
or our inability to obtain products from qualified alternate sources at acceptable prices in a timely manner, could impair our ability
to meet the demand of our customers and cause them to switch to competing products. Given our reliance on certain suppliers, we may be
susceptible to supply shortages while looking for alternate suppliers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be exposed to geopolitical risks
related to the geopolitical and military tensions between Russia and Ukraine in Europe.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we do not currently
conduct business in Russia and Ukraine, the escalation of geopolitical instability in Russia and Ukraine as well as currency fluctuations
in the Russian Ruble has had a negative impact on worldwide markets. Such impact may negatively impact our supply chain, our operations
and future growth prospects in that region. As a result of the crisis in Ukraine, both the U.S. and other countries have implemented sanctions
against certain Russian individuals and entities. Our global operations expose us to risks that could adversely affect our business, financial
condition, results of operations, cash flows or the market price of our securities, including the potential for increased tensions between
Russia and other countries resulting from the current situation involving Russia and Ukraine, tariffs, economic sanctions and import-export
restrictions imposed, and retaliatory actions, as well as the potential negative impact on our potential business and sales in the region.
Current geopolitical instability in Russia and Ukraine and related sanctions by the U.S. and other governments against certain companies
and individuals may hinder our ability to conduct business with potential customers and vendors in these countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have limited manufacturing history on
which to assess the prospects for our business and we anticipate that we will incur significant losses once we initiate our in-house manufacturing
until we are able to successfully commercialize our products globally.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our future manufacturing
operation or any current or future contracted manufacturing operations become unreliable or unavailable, we may not be able to move forward
with our intended business operations and our entire business plan could fail. There is no assurance that our manufacturing operation
or any third-party manufacturers will be able to meet commercialized scale production requirements in a timely manner or in accordance
with applicable standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to replace our manufacturing
capabilities in a timely manner.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our future manufacturing
facility or any current or future contracted manufacturing operations suffer any type of prolonged interruption, whether caused by regulator
action, equipment failure, critical facility services (such as water purification, clean steam generation or building management and monitoring
system), fire, natural disaster or any other event that causes the cessation of manufacturing activities, we may be exposed to long-term
loss of sales and profits. There are limited facilities which are capable of contract manufacturing some of our products and product candidates.
Replacement of our current manufacturing capabilities may have a material adverse effect on our business and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are dependent upon third-party service
providers. If such third-party service providers fail to maintain a high quality of service, the utility of our products could be impaired,
which could adversely affect the penetration of our products, our business, operating results and reputation. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The success of certain services
and products that we provide are dependent upon third-party service providers. Such service providers include manufacturers of proprietary
custom components for our products. As we expand our commercial activities, an increased burden will be placed upon the quality of such
third-party providers. If third-party providers fail to maintain a high quality of service, our products, business, reputation and operating
results could be adversely affected. In addition, poor quality of service by third-party service providers could result in liability claims
and litigation against us for damages or injuries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Non-U.S. governments often impose strict
price controls, which may adversely affect our future profitability.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
may be subject to rules and regulations in the United States and non-U.S. jurisdictions relating to our products or any future products.
In some countries, including countries of the European Union, or the EU, each of which has developed its own rules and regulations, pricing
may be subject to governmental control under certain circumstances. In these countries, pricing negotiations with governmental agencies
can take considerable time after the receipt of marketing approval for a medical device candidate. To obtain reimbursement or pricing
approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other
available products.<b>&#160;</b>If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at
unsatisfactory levels, we may be unable to achieve or sustain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>We manage our business
through a small number of employees and key consultants.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 22, 2024, we had thirty-seven (37) full-time employees
(including our senior management team), five (5) part-time employees, and three (3) additional independent contractors and consultants.
Our future growth and success depend to a large extent on the continued services of members of our current management including, in particular,
Dagi Ben-Noon, our Chief Executive Officer, and Joe Hayon, our President. Any of our employees and consultants may leave our company at
any time, subject to certain notice periods. The loss of the services of any of our executive officers or any key employees or consultants
would adversely affect our ability to execute our business plan and harm our operating results. Our operational success will substantially
depend on the continued employment of senior executives, technical staff and other key personnel. The loss of key personnel may have an
adverse effect on our operations and financial performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>We may need to
expand our organization and we may experience difficulties in recruiting needed additional employees and consultants, which could disrupt
our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As our development and commercialization
plans and strategies develop and because we are leanly staffed, we may need additional managerial, operational, sales, marketing, financial,
legal and other resources. The competition for qualified personnel in the medical device industry is intense. Due to this intense competition,
we may be unable to attract and retain qualified personnel necessary for the development of our business or to recruit suitable replacement
personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management may need to
divert its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities.
We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational
mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could
require significant capital expenditures and may divert financial resources from other projects, such as the development of additional
medical device products. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our
ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial
performance and our ability to commercialize medical device products and services and compete effectively will depend, in part, on our
ability to effectively manage any future growth.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>International expansion of our business
exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the
United States or Israel.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than our headquarters
and other operations which are located in Israel (as further described below), our business strategy incorporates significant international
expansion, particularly in anticipated expansion of regulatory approvals of our products. Doing business internationally involves a number
of risks, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">multiple, conflicting and changing
laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements
and other governmental approvals, permits and licenses;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">failure by us to obtain regulatory
approvals for the use of our products and services in various countries;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">additional potentially relevant
third-party patent rights;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">complexities and difficulties
in obtaining protection and enforcing our intellectual property;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">difficulties in staffing and
managing foreign operations;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">complexities associated with
managing multiple regulatory, governmental and reimbursement regimes;</span></td>
</tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#8239;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">limits in our ability to penetrate
international markets;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">financial risks, such as longer
payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for
our products and exposure to foreign currency exchange rate fluctuations;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">natural disasters, political
and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other
business restrictions;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">certain expenses including,
among others, expenses for travel, translation and insurance; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">regulatory and compliance risks
that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign
Corrupt Practices Act, or the FCPA, its books and records provisions or its anti-bribery provisions.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Any
of these factors could significantly harm our future international expansion and operations and, consequently, our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>We face intense
competition, and we may be unable to effectively compete in our industry.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market participants in
the ICU and the acute respiratory care space include Boston Scientific Corporation (NYSE: BSX), ResMed Inc., (NYSE: RMD), Masimo Corporation
(Nasdaq: MASI), Becton, Dickinson and Company (NYSE: BDX), Chart Industries, Inc. (Nasdaq: GTLS), Philips Healthcare, Medtronic plc (NYSE:
MDT), Fisher &amp; Paykel Healthcare Corporation Limited, Dr&#228;gerwerk AG &amp; Co. KGaA, Dr&#228;gerwerk AG &amp; Co. KGaA, Hamilton
Medical AG, Smiths Medical Inc (acquired by ICU Medical Inc.)., Siemens Healthineers AG ADR (OTCMKTS: SMMNY), Baxter International (NYSE:
BAX), Getinge (OTCMKTS: GNGBY), GE HealthCare, Terumo Corporation (TYO: 4543, Nikkei 225 Component), LivaNova PLC (Nasdaq: LIVN), Fresenius
SE &amp; Co. KGaAO (OTCMKTS: FSNUY), Johnson &amp; Johnson (NYSE: JNJ) , Resuscitec, and Spectrum Medical. These companies have either
developed or acquired respiratory care devices and solutions, such as ventilators, ECMO devices and blood sensors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aforementioned companies, have substantially
greater brand recognition, research and development, and regulatory capabilities, as well as financial, technical, manufacturing, marketing
and human resources than we do and significantly greater experience and infrastructure in the research and development of medical devices,
obtaining FDA and other regulatory clearances of those devices and commercializing those devices around the world. Further, some of these
companies hold significant market share. Their dominant market position and significant control over the market could significantly limit
our ability to introduce or effectively market and generate sales of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of our competitors have
long histories and strong reputations within the industry. They have significantly greater brand recognition, financial and human resources
than we do. They also have more experience and capabilities in researching and developing testing devices, obtaining and maintaining regulatory
clearances and other requirements, manufacturing and marketing those products than we do. There is a significant risk that we may be unable
to overcome the advantages held by our competition, and our inability to do so could lead to the failure of our business. In addition,
we may be unable to develop additional products in the future or to keep pace with developments and innovations in the market and lose
market share to our competitors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competition in the medical
devices and more specifically respiratory support technologies and solutions markets is intense, which can lead to, among other things,
price reductions, longer selling cycles, lower product margins, loss of market share and additional working capital requirements. To succeed,
we must, among other critical matters, gain consumer acceptance for our products, as compared to other solutions currently available in
the market for the treatment of respiratory failure and potential future medical devices incorporating our principal technology or offering
other advanced respiratory support solutions. If our competitors offer significant discounts on certain products and solutions, we may
need to lower our prices or offer other favorable terms in order to compete successfully. Moreover, any broad-based changes to our prices
and pricing policies could make it difficult to generate revenues or cause our revenues to decline. Moreover, if our competitors develop
and commercialize products and solutions that are more effective or desirable than products and solutions that we may develop, we may
not convince our customers to use our products and solutions. Any such changes would likely reduce our commercial opportunity and revenue
potential and could materially adversely impact our operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If third-party payors do not provide adequate
coverage and reimbursement for the use of our products or any future products, our revenue will be negatively impacted.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products are not yet approved
for third-party payor coverage or reimbursement. Such reimbursement may vary based on the particular device used in providing services
and is based on the identity of the third-party. Our ability to obtain and maintain a leading position in the medical device market, and
specifically in the respiratory care market, depends on our relationships with private third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
expect to engage with private third parties to allow our customers to receive reimbursement from insurance companies for our products.
The loss of a significant number of private third-party contracts may have an adverse effect on our revenues, which could have an adverse
effect on our business, financial condition and results of operations. Over the past few years, reimbursement rates from certain third
parties have declined, in some cases significantly. There can be no assurance that this trend will not continue or apply on more third
parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, private third
parties may not reimburse any new products offered by us or reimburse those new products at commercially viable rates. The failure to
receive reimbursement at adequate levels for our existing or future products may adversely affect demand for those products, our revenues
and expected growth. This could have an adverse effect on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to litigation for a variety
of claims, which could adversely affect our results of operations, harm our reputation or otherwise negatively impact our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject to litigation
for a variety of claims arising from our normal business activities. These may include claims, suits, and proceedings involving labor
and employment, wage and hour, commercial and other matters. The outcome of any litigation, regardless of its merits, is inherently uncertain.
Any claims and lawsuits, and the disposition of such claims and lawsuits, could be time-consuming and expensive to resolve, divert management
attention and resources, and lead to attempts on the part of other parties to pursue similar claims. Any adverse determination related
to litigation could adversely affect our results of operations, harm our reputation or otherwise negatively impact our business. In addition,
depending on the nature and timing of any such dispute, a resolution of a legal matter could materially affect our future operating results,
our cash flows or both.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>We could become
subject to product liability, warranty or similar claims and product recalls that could be expensive, divert management&#8217;s attention
and harm our business reputation and financial results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business exposes us to
an inherent risk of potential product liability, warranty or similar claims and product recalls. The medical device industry has historically
been litigious, and we face financial exposure to product liability, warranty or similar claims if the use of any of our products were
to cause or contribute to injury or death. There is also the possibility that defects in the design or manufacture of any of our products
might necessitate a product recall. Although we plan to maintain product liability insurance, the coverage limits of these policies may
not be adequate to cover future claims. In the future, we may be unable to maintain product liability insurance on acceptable terms or
at reasonable costs and such insurance may not provide us with adequate coverage against potential liabilities. A product liability claim,
regardless of merit or ultimate outcome, or any product recall could result in substantial costs to us, damage to our reputation, customer
dissatisfaction and frustration and a substantial diversion of management attention. A successful claim brought against us in excess of,
or outside of, our insurance coverage could have a material adverse effect on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business may be impacted by changes
in general economic conditions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business is subject to
risks arising from changes in domestic and global economic conditions, including adverse economic conditions in markets in which we operate,
which may harm our business. For example, the COVID-19 pandemic has caused significant volatility and uncertainty in U.S. and international
markets. If our future customers significantly reduce spending in areas in which our technology and products are utilized, or prioritize
other expenditures over our technology and products, our business, financial condition, results of operations and prospects would be materially
adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disruption to the global economy
could also result in a number of follow-on effects on our business, including a possible slow-down resulting from lower customer expenditures;
inability of customers to pay for products, solutions or services on time, if at all; more restrictive export regulations which could
limit our potential customer base; negative impact on our liquidity, financial condition and share price, which may impact our ability
to raise capital in the market, obtain financing and secure other sources of funding in the future on terms favorable to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the occurrence
of catastrophic events, such as hurricanes, storms, earthquakes, tsunamis, floods, medical epidemics and other catastrophes that adversely
affect the business climate in any of our markets could have a material adverse effect on our business, financial condition and results
of operations. Some of our operations are located in areas that have been in the past, and may be in the future, susceptible to such occurrences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Unstable market and economic conditions
may have serious adverse consequences on our business, financial condition and share price.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The global economy, including
credit and financial markets, has experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability,
declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases in inflation rates and uncertainty
about economic stability. For example, the COVID-19 pandemic resulted in widespread unemployment, economic slowdown and extreme volatility
in the capital markets. Similarly, the conflict between Ukraine and Russia created extreme volatility in the global capital markets and
is expected to have further global economic consequences, including disruptions of the global supply chain and energy markets. Additionally,
the current conflict between terrorist groups in the Gaza strip and Israel might escalate the unrest in the Middle East and potentially
may have global economic consequences as well. Any such volatility and disruptions may have adverse consequences on us or the third parties
on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary
debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. Further, inflation
can adversely affect us by increasing our costs. Increased cost of living around the world has caused and may cause increased costs, such
as higher wages, increase direct service costs, increased freight costs and costs of components, and higher manufacturing costs. Any significant
increases in inflation and related increase in interest rates could have a material adverse effect on our business, results of operations
and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our management team has limited experience
managing a public company.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most members of our management
team have limited experience managing a publicly traded company, interacting with public company investors and complying with the increasingly
complex laws pertaining to public companies in the United States. Our management team may not successfully or efficiently manage our transition
to being a public company subject to significant regulatory oversight and reporting obligations under the U.S. federal securities laws
and the continuous scrutiny of securities analysts and investors. These new obligations and constituents will require significant attention
from our senior management and could divert their attention away from the day-to-day management of our business, which could adversely
affect our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We incur significant increased costs as
a result of the listing of our securities for trading on Nasdaq. Our management is required to devote substantial time to new compliance
initiatives as well as compliance with ongoing U.S. requirements.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a public company in the
United States, we incur additional significant accounting, legal and other expenses that we did not incur prior to being a public company
in the United States. We also incur costs associated with corporate governance requirements of the SEC, as well as requirements under
Section 404 and other provisions of the Sarbanes-Oxley Act. These rules and regulations increase our legal and financial compliance costs,
introduce new costs such as investor relations, stock exchange listing fees and shareholder reporting, and make some activities more time
consuming and costly. The implementation and testing of such processes and systems may require us to hire outside consultants and incur
other significant costs. Any future changes in the laws and regulations affecting public companies in the United States, including Section
404 and other provisions of the Sarbanes-Oxley Act, and the rules and regulations adopted by the SEC, for so long as they apply to us,
will result in increased costs to us as we respond to such changes. These laws, rules and regulations could make it more difficult or
more costly for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forced to accept
reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these requirements
could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees,
or as executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are not able to attract and retain
highly skilled managerial, scientific, technical and marketing personnel, we may not be able to implement our business model successfully.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific
personnel. We are highly dependent upon our senior management as well as other employees, consultants and scientific and medical collaborators.
Our management team must be able to act decisively to apply and adapt our business model in the rapidly changing markets in which we will
compete. In addition, we will rely upon technical and scientific employees or third-party contractors to effectively establish, manage
and grow our business. Consequently, we believe that our future viability will depend largely on our ability to attract and retain highly
skilled managerial, sales, scientific and technical personnel. In order to do so, we may need to pay higher compensation or fees to our
employees or consultants than currently expected and such higher compensation payments may have a negative effect on our operating results.
Competition for experienced, high-quality personnel in the medical device field is intense. We may not be able to hire or retain the necessary
personnel to implement our business strategy. Our failure to hire and retain quality personnel on acceptable terms could impair our ability
to develop new products and services and manage our business effectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we engage in future acquisitions or strategic
partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities,
and subject us to other risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may evaluate various acquisition
opportunities and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies
or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">increased operating expenses
and cash requirements;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the assumption of additional
indebtedness or contingent liabilities;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the issuance of our equity securities;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.3pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">assimilation of operations,
intellectual property and products of an acquired company, including difficulties associated with integrating new personnel;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the diversion of our management&#8217;s
attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">retention of key employees,
the loss of key personnel and uncertainties in our ability to maintain key business relationships;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">risks and uncertainties associated
with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and
marketing approvals; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our inability to generate revenue
from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated
acquisition and maintenance costs.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are subject to certain U.S. and foreign
anticorruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences
for violations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Among other matters, U.S.
and foreign anticorruption, anti-money laundering, export control, sanctions and other trade laws and regulations, which are collectively
referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants,
consultants, contractors and other partners from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly,
corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws
can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments,
breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials
and employees of government agencies or government-affiliated hospitals, universities and other organizations. We also expect our non-U.S.
activities to increase over time. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent
registrations and other regulatory approvals, and we can be held liable for the corrupt or other illegal activities of our personnel,
agents or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business and operations might be adversely
affected by security breaches, including any cybersecurity incidents.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We depend on the efficient
and uninterrupted operation of our computer and communications systems, and those of our consultants, contractors and vendors, which we
use for, among other things, sensitive company data, including our intellectual property, financial data and other proprietary business
information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While certain of our operations
have business continuity and disaster recovery plans and other security measures intended to prevent and minimize the impact of IT-related
interruptions, our IT infrastructure and the IT infrastructure of our consultants, contractors and vendors are vulnerable to damage from
cyberattacks, computer viruses, unauthorized access, electrical failures and natural disasters or other catastrophic events. We could
experience failures in our information systems and computer servers, which could result in an interruption of our normal business operations
and require substantial expenditure of financial and administrative resources to remedy. System failures, accidents or security breaches
can cause interruptions in our operations and can result in a material disruption of our product development activities and other business
operations. The loss of data from completed or future studies or clinical trials could result in delays in our research, development or
regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or
security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary
information, we could incur regulatory investigations and redresses, penalties and liabilities and the development of our product candidates
could be delayed or otherwise adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even though we believe we
carry commercially reasonable business interruption and liability insurance, we might suffer losses as a result of business interruptions
that exceed the coverage available under our insurance policies or for which we do not have coverage. For example, we are not insured
against terrorist attacks or cyberattacks. Any natural disaster or catastrophic event could have a significant negative impact on our
operations and financial results. Moreover, any such event could delay the development of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in laws or regulations relating
to data protection, or any actual or perceived failure by us to comply with such laws and regulations or our privacy policies, could materially
and adversely affect our business or could lead to government enforcement actions and significant penalties against us, and adversely
impact our operating results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to receive health
information and other highly sensitive or confidential information and data of patients and other third parties (e.g., healthcare providers
who refer patients for scans), which we expect to compile and analyze. Collection and use of this data might raise privacy and data protection
concerns, which could negatively impact our business. There are numerous federal, state and international laws and regulations regarding
privacy, data protection, information security, and the collection, storing, sharing, use, processing, transfer, disclosure, and protection
of personal information and other data, and the scope of such laws and regulations may change, be subject to differing interpretations,
and may be inconsistent among countries and regions we intend to operate in (e.g., the United States, the European Union and Israel),
or conflict with other laws and regulations. The regulatory framework for privacy and data protection worldwide is, and is likely to remain
for the foreseeable future, uncertain and complex, and this or other actual or alleged obligations may be interpreted and applied in a
manner that we may not anticipate or that is inconsistent from one jurisdiction to another and may conflict with other rules or practices
including ours. Further, any significant change to applicable laws, regulations, or industry practices regarding the collection, use,
retention, security, or disclosure of data, or their interpretation, or any changes regarding the manner in which the consent of relevant
users for the collection, use, retention, or disclosure of such data must be obtained, could increase our costs and require us to modify
our services and candidate products, possibly in a material manner, which we may be unable to complete, and may limit our ability to store
and process patients&#8217; data or develop new services and features.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In particular, we will be
subject to U.S. data protection laws and regulations (i.e., laws and regulations that address privacy and data security) at both the federal
and state levels. The legislative and regulatory landscape for data protection continues to evolve, and in recent years there has been
an increasing focus on privacy and data security issues. Numerous federal and state laws, including state data breach notification laws,
state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, and disclosure of health-related
and other personal information. Failure to comply with such laws and regulations could result in government enforcement actions and create
liability for us (including the imposition of significant civil or criminal penalties), private litigation and/or adverse publicity that
could negatively affect our business. For instance, California enacted the California Consumer Privacy Act (CCPA) on June 28, 2018, which
took effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security
obligations of entities handling certain personal data. The CCPA provides for civil penalties for violations, as well as a private right
of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential
liability, and many similar laws have been proposed at the federal level and in other states.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we expect to
obtain health information that is subject to privacy and security requirements under the Health Information Technology for Economic and
Clinical Health, or HITECH, and its implementing regulations. The Privacy Standards and Security Standards under HIPAA establish a set
of standards for the protection of individually identifiable health information by health plans, health care clearinghouses and certain
health care providers, referred to as Covered Entities, and the business associates with whom Covered Entities enter into service relationships
pursuant to which individually identifiable health information may be exchanged. Notably, whereas HIPAA previously directly regulated
only Covered Entities, HITECH makes certain of HIPAA&#8217;s privacy and security standards also directly applicable to Covered Entities&#8217;
business associates. As a result, both Covered Entities and business associates are now subject to significant civil and criminal penalties
for failure to comply with Privacy Standards and Security Standards. As part of our normal operations, we expect to collect, process and
retain personal identifying information regarding patients, including as a business associate of Covered Entities, so we expect to be
subject to HIPAA, including changes implemented through HITECH, and we could be subject to criminal penalties if we knowingly obtain or
disclose individually identifiable health information in a manner that is not authorized or permitted by HIPAA. A data breach affecting
sensitive personal information, including health information, also could result in significant legal and financial exposure and reputational
damages that could potentially have an adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">HIPAA requires Covered Entities
(like many of our potential customers) and business associates, like us, to develop and maintain policies and procedures with respect
to protected health information that is used or disclosed, including the adoption of administrative, physical and technical safeguards
to protect such information. HITECH expands the notification requirement for breaches of patient-identifiable health information, restricts
certain disclosures and sales of patient-identifiable health information and provides for civil monetary penalties for HIPAA violations.
HITECH also increased the civil and criminal penalties that may be imposed against Covered Entities and business associates and gave state
attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and its implementing
regulations and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. Additionally, certain states have
adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Internationally, many jurisdictions
have or are considering enacting privacy or data protection laws or regulations relating to the collection, use, storage, transfer, disclosure
and/or other processing of personal data, as well as certification requirements for the hosting of health data specifically. Such laws
and regulations may include data hosting, data residency or data localization requirements (which generally require that certain types
of data collected within a certain country be stored and processed within that country), data export restrictions, international transfer
laws (which prohibit or impose conditions upon the transfer of such data from one country to another), or may require companies to implement
privacy or data protection and security policies, enable users to access, correct and delete personal data stored or maintained by such
companies, inform individuals of security breaches that affect their personal data or obtain individuals&#8217; consent to use their personal
data. For example, European legislators adopted the EU&#8217;s General Data Protection Regulation (2016/679), or GDPR, which became effective
on May 25, 2018, and are now in the process of finalizing the ePrivacy Regulation to replace the European ePrivacy Directive (Directive
2002/58/EC as amended by Directive 2009/136/EC). The GDPR, supplemented by national laws and further implemented through binding guidance
from the European Data Protection Board, imposes more stringent EU data protection requirements and provides for significant penalties
for noncompliance. Further, the United Kingdom&#8217;s initiating a process to leave the EU has created uncertainty with regard to the
regulation of data protection in the United Kingdom. In particular, the United Kingdom has brought the GDPR into domestic law with the
Data Protection Act 2018 which will remain in force, even if and when the United Kingdom leaves the EU.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Virtually every jurisdiction
in which we expect to operate has established its own data security and privacy legal framework with which we must, and our target customers
will need to, comply, including the rules and regulation mentioned above. We may also need to comply with varying and possibly conflicting
privacy laws and regulations in other jurisdictions. As a result, we could face regulatory actions, including significant fines or penalties,
adverse publicity and possible loss of business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we are preparing to
implement various measures intended to enable us to comply with applicable privacy or data protection laws, regulations and contractual
obligations, these measures may not always be effective and do not guarantee compliance. Any failure or perceived failure by us to comply
with our contractual or legal obligations or regulatory requirements relating to privacy, data protection, or information security may
result in governmental investigations or enforcement actions, litigation, claims, or public statements against us by consumer advocacy
groups or others and could result in significant liability, cause our customers, partners or patients to lose trust in us, and otherwise
materially and adversely affect our reputation and business. Furthermore, the costs of compliance with, and other burdens imposed by,
the laws, regulations, and policies that are applicable to the businesses of our customers or partners may limit the adoption and use
of, and reduce the overall demand for, our products and services. Additionally, if third parties we work with violate applicable laws,
regulations, or agreements, such violations may put the data we have received at risk, could result in governmental investigations or
enforcement actions, fines, litigation, claims, or public statements against us by consumer advocacy groups or others and could result
in significant liability, cause our customers, partners or patients to lose trust in us, and otherwise materially and adversely affect
our reputation and business. Further, public scrutiny of, or complaints about, technology companies or their data handling or data protection
practices, even if unrelated to our business, industry or operations, may lead to increased scrutiny of technology companies, including
us, and may cause government agencies to enact additional regulatory requirements, or to modify their enforcement or investigation activities,
which may increase our costs and risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Financial Condition and
Capital Requirements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Our financial statements
for the year ended December 31, 2023, contained an explanatory paragraph regarding substantial doubt about our ability to continue as
a going concern. This going concern opinion could prevent us from obtaining new financing on reasonable terms or at all and risk our ability
to continue operating as a going concern.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>To
date, the Company has not generated significant revenues from its activities and has incurred substantial operating losses. </span>In
part because we have incurred losses in each year since our inception, our audited financial statements for the period ended December
31, 2023 contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern. These events and
conditions, along with other matters, indicated that a material uncertainty existed as of December 31, 2023, that raises substantial doubt
on our ability to continue as a going concern. The financial statements for the year ended December 31, 2023 have been prepared assuming
that we will continue as a going concern. <span>Management expects the Company to continue to generate
substantial operating losses and to continue to fund its operations primarily through the utilization of its current financial resources,
sales of its products, and through additional raises of capital. </span>As of December 31, 2023, we incurred accumulated losses of approximately
$55.5&#160;million. A going concern opinion could materially limit our ability to raise additional funds through the issuance of equity
or debt securities or otherwise in the future. Further financial statements may also include an explanatory paragraph with respect to
our ability to continue as a going concern. Until we can generate significant recurring revenues, we expect to satisfy our future cash
needs through existing cash, debt or equity financing. We expect to require additional financing to fund our operations in the near future.
We cannot be certain that additional funding will be available to us on acceptable terms, if at all. If funds are not available, we may
be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization efforts with respect to
our products and it risks our ability to continue operating as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our principal shareholders, officers and
directors currently beneficially own 23.6% of our Ordinary Shares. They may therefore be able to exert control over matters submitted
to our shareholders for approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 22, 2024, our
principal shareholders, officers and directors beneficially own approximately 23.6% of our Ordinary Shares. As a result, these shareholders,
if they acted together, could influence matters requiring approval by our shareholders, including the election of directors and the approval
of mergers or other business combination transactions. The interests of these shareholders may not always coincide with our interests
or the interests of other shareholders.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have a limited operating history, have
incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a development-stage
medical device company with a limited operating history. To date, we have focused almost exclusively on developing our INSPIRA ART(Gen
2) device, INSPIRA ART100 (Gen 1) device followed by our HYLA Blood Sensor, VORTX device and Inspira disposables. We have funded our operations
to date primarily through our initial public offering, convertible loans and royalty-bearing grants that we received from the Israeli
Innovation Authority, or the IIA, formerly known as the Office of the Chief Scientist of the Ministry of Economy and Industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have only a limited operating
history upon which you can evaluate our business and prospects. In addition, we have limited experience and have not yet demonstrated
an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving
fields, particularly in the medical device industry. To date, we have not generated revenue from the sale of our product candidates (see
&#8220;Item 5. <i>Operating and Financial Review and Prospects</i>&#8221; for additional information). We have incurred losses in each
year since our inception, including net losses of approximately $11.3 million and $15 million for the years ended December 31, 2023 and
2022, respectively. As of December, 2023, we had an accumulated deficit of approximately $55.5 million. Substantially all of our operating
losses resulted from costs incurred in connection with our development of our products and from general and administrative costs associated
with our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect our research and
development expenses to increase in connection with our planned expanded studies. In addition, if we obtain marketing approval for our
products, we will likely incur significant sales, marketing and outsourced manufacturing expenses, as well as continued research and development
expenses and costs associated with operating as a public company. As a result, we expect to continue to incur significant and increasing
operating losses for the foreseeable future. Because of the numerous risks and uncertainties associated with developing a medical device,
we are unable to predict the extent of any future losses or when we will become profitable, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to continue to incur
significant losses until we are able to commercialize our products, which we may not be successful in achieving. We anticipate that our
expenses will increase substantially if and as we:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">continue the research and development
of our products;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">seek regulatory and marketing
approvals for our products;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">establish a sales, marketing,
and distribution infrastructure to commercialize our products;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">seek to identify, assess, acquire,
license, and/or develop other product candidates and subsequent generations of our current product candidate;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">seek to maintain, protect, and
expand our intellectual property portfolio;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">seek to attract and retain skilled
personnel;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">create additional infrastructure
to support our operations as a public company and our product candidate development and planned future commercialization efforts; and</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">experience any delays or encounter
issues with respect to any of the above, including, but not limited to, failed studies, complex results, safety issues or other regulatory
challenges that require longer follow-up of existing studies or additional supportive studies in order to pursue marketing approval.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
amount of our future operating losses will depend, in part, on the rate of our future expenditures. Even if we obtain regulatory approval
to market our products or any future product candidates<sub>,</sub> our future revenue will depend upon the size of any markets in which
our products or any future product candidates receive approval and our ability to achieve sufficient market acceptance, pricing, reimbursement
from third-party payors for our products or any future product candidates. Further, the operating losses that we incur may fluctuate significantly
from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication
of our future performance. Other unanticipated costs may also arise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have not generated any revenue from product
sales and may never be profitable.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
have no products approved for marketing in any jurisdiction and we have never generated any revenue from product sales. Our ability to
generate revenue and achieve profitability depends on our ability, alone or with strategic collaboration partners, to successfully complete
the development of, and obtain the regulatory and marketing approvals necessary to commercialize our products or any future product candidates.
We do not know when, or if, we will generate any such revenue. Our ability to generate future revenue from product sales will depend heavily
on our success in many areas, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">complete research and development
of our products and any future product candidates in a timely and successful manner;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">obtain regulatory and marketing
approval for any product candidates;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">maintain and enhance a commercially
viable, sustainable, scalable, reproducible and transferable manufacturing process for our products and any future product candidates
that is compliant with current good manufacturing practices, or cGMPs;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">establish and maintain supply
and, if applicable, manufacturing relationships with third parties that can provide, in both amount and quality, adequate products to
support development and the market demand for our products and any future product candidates, if and when approved;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">identify, assess, acquire and/or
develop new product candidates;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">launch and commercialize any
product candidates for which we obtain regulatory and marketing approval, either directly by establishing a sales force, marketing and
distribution infrastructure, and/or with collaborators or distributors;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">accurately identify demand for
our products or any future product candidates;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">expose and educate physicians
and other medical professionals to use our products;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">obtain market acceptance, if
and when approved, of our products and any future product candidates from the medical community and third-party payors;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">ensure our product candidates
are approved for reimbursement from governmental agencies, health care providers and insurers in jurisdictions where they have been approved
for marketing;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">address any competing technological
and market developments that impact our products and any future product candidates or their prospective usage by medical professionals;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">negotiate favorable terms in
any collaboration, licensing or other arrangements into which we may enter and perform our obligations under such collaborations;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">maintain, protect and expand
our portfolio of intellectual property rights, including patents, patent applications, trade secrets and know-how;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">avoid and defend against third-party
interference or infringement claims;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">attract, hire and retain qualified
personnel; and</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">locate and lease or acquire
suitable facilities to support our clinical development, manufacturing facilities and commercial expansion.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Even
if our products or any future product candidates are approved for marketing and sale, we anticipate incurring significant incremental
costs associated with commercializing such product candidates. Our expenses could increase beyond expectations if we are required by the
FDA, or other regulatory agencies, domestic or foreign, to change our manufacturing processes or assays or to perform studies in addition
to those that we currently anticipate. Even if we are successful in obtaining regulatory approvals to market our products or any future
product candidates, our revenue earned from such product candidates will be dependent in part upon the size of the markets in the territories
for which we gain regulatory approval for such products, the accepted price for such products, our ability to obtain reimbursement for
such products at any price, whether we own the commercial rights for that territory in which such products have been approved and the
expenses associated with manufacturing and marketing such products for such markets. Therefore, we may not generate significant revenue
from the sale of such products, even if approved. Further, if we are not able to generate significant revenue from the sale of our approved
products, we may be forced to curtail or cease our operations. Due to the numerous risks and uncertainties involved in product development,
it is difficult to predict the timing or amount of increased expenses, or when, or if, we will be able to achieve or maintain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>We will need to
raise substantial additional funding, which may not be available on acceptable terms, or at all. Failure to obtain funding on acceptable
terms and on a timely basis may require us to curtail, delay or discontinue our product development efforts or other operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023, our
cash and cash equivalents, short-term deposits and long-term deposits were approximately $7.4 million, not including restricted cash of
$89 thousand, and we had a working capital of approximately $4.8 million and an accumulated deficit of approximately $55.5 million. Based
upon our currently expected level of operating expenditures, we expect that our existing cash and cash equivalent will only be sufficient
to fund operations through the next six months. We expect that we will require substantial additional capital to operate and to commercialize
our products and we need to expect to seek additional funds to enable us to fund our operations for the text twelve months. Our future
funding requirements will depend on many factors, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the progress, results and costs
of our ongoing and planned studies and, if applicable, clinical trials of products and any future product candidates;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the cost, timing and outcomes
of regulatory review of products and any future product candidates;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the costs of maintaining our
own commercial-scale cGMP manufacturing facility, including costs related to obtaining and maintaining regulatory compliance, and/or
engaging third-party manufacturers therefor;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the scope, progress, results
and costs of product development, testing, manufacturing, preclinical development and, if applicable, clinical trials for any other product
candidates that we may develop or otherwise obtain in the future;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the cost of our future activities,
including establishing sales, marketing and distribution capabilities for any product candidates in any particular geography where we
receive marketing approval for such product candidates</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the terms and timing of any
collaborative, licensing and other arrangements that we may establish;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the costs of preparing, filing
and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related
claims; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the level of revenue, if any,
received from commercial sales of any product candidates for which we receive marketing approval.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any additional fundraising
efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize
our products and any future product candidates. In addition, future financing may not be available in sufficient amounts or on terms acceptable
to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of holders of our securities and
the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price
of our securities to decline. The incurrence of indebtedness could result in increased fixed payment obligations, and we may be required
to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to
acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct
our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage
than otherwise would be desirable, and we may be required to relinquish rights to some of our technologies or product candidates or otherwise
agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. Even
if we believe that we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions
are favorable or if we have specific strategic considerations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to obtain
funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development
programs or the development or commercialization, if any, of our products or any other product candidates or be unable to expand our operations
or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and
results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Raising additional capital would cause dilution
to our existing shareholders, and may adversely affect the rights of existing shareholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may seek additional capital
through a combination of private and public equity offerings, debt financings and collaborations and strategic and licensing arrangements.
To the extent that we raise additional capital through the issuance of equity or otherwise including through convertible debt securities,
your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights
as a shareholder. Future sales of our Ordinary Shares or of securities convertible into our Ordinary Shares, or the perception that such
sales may occur, could cause immediate dilution and adversely affect the market price of our Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>Risks Related to Product
Development and Regulatory Approval</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates and operations are
subject to extensive government regulation and oversight both in the United States and abroad and our failure to comply with applicable
requirements could harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect our products and
any future products we develop to be regulated by the FDA as medical devices. Our product candidates are subject to extensive regulation
in the United States and elsewhere, including by the FDA and its foreign counterparts, the U.S. Department of Justice, or the DOJ, and
the U.S. Health and Human Services-Office of the Inspector General, or the HHS. The FDA and foreign regulatory agencies regulate, among
other things, with respect to medical devices: design, development and manufacturing; testing, labeling, content and language of instructions
for use and storage; clinical trials; product safety; establishment registration and device listing; marketing, sales and distribution;
pre-market clearance and approval; conformity assessment procedures; record keeping procedures; advertising and promotion; recalls and
field safety corrective actions; post-market surveillance, including reporting of deaths or serious injuries and malfunctions that, if
they were to occur, could lead to death or serious injury; post-market approval studies; and product import and export.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The regulations our product
candidate is subject to are complex and have tended to become more stringent over time. Regulatory changes could result in restrictions
on our ability to carry on or expand our operations, higher than anticipated costs or lower than anticipated sales for any approved product.
Failure to comply with applicable regulations could jeopardize our ability to sell our future products, if cleared or approved, and result
in enforcement actions such as: warning or untitled letters; fines; injunctions; consent decrees; civil penalties; customer notifications;
termination of distribution; recalls or seizures of products; administrative detention of medical devices believed to be adulterated or
misbranded; delays in the introduction of products into the market; operating restrictions; total or partial suspension of production;
refusal to grant future clearances or approvals for new products, new intended uses or modifications to our products; withdrawals or suspensions
of current approvals, resulting in prohibitions on sales of our products; and in the most serious cases, criminal prosecution or penalties.
The occurrence of any of these events would have a material adverse effect on our business, financial condition and results of operations
and could result in shareholders losing their entire investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not receive, or may be delayed
in receiving, the necessary clearances or approvals for our products and failure to timely obtain necessary clearances or approvals for
our products would adversely affect our ability to grow our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, before
we can market a new medical device, or a new use of, new claim for or significant modification to an existing product, we must first receive
either clearance under Section 510(k) (which we must receive for our INSPIRA ART100 device) of the Federal Food, Drug, and Cosmetic Act,
or the FDCA, and/or approval of a PMA from the FDA, unless an exemption applies. In the 510(k) clearance process, before a device may
be marketed, the FDA must determine that a proposed device is &#8220;substantially equivalent&#8221; to a legally-marketed &#8220;predicate&#8221;
device, which includes a device that has been previously cleared through the 510(k) process, a device that was legally marketed prior
to May 28, 1976 (pre-amendments device), a device that was originally on the U.S. market pursuant to an approved PMA and later down-classified,
or a 510(k)-exempt device. To be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate
device, and either have the same technological characteristics as the predicate device or have different technological characteristics
and not raise different questions of safety or effectiveness than the predicate device. Clinical data are sometimes required to support
substantial equivalence. In the process of obtaining PMA approval, the FDA must determine that a proposed device is safe and effective
for its intended use based, in part, on extensive data, including, but not limited to, technical, pre-clinical, clinical trial, manufacturing
and labeling data. The PMA process is typically required for devices that are deemed to pose the greatest risk, such as life-sustaining,
life-supporting or implantable devices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Modifications to products
that are approved through a PMA application generally require FDA approval. Similarly, certain modifications made to products cleared
through a 510(k) may require a new 510(k) clearance. Both the PMA approval and the 510(k) clearance process can be expensive, lengthy
and uncertain. The FDA&#8217;s 510(k) clearance process usually takes from three to twelve months but can last longer. The process of
obtaining a PMA is much more costly and uncertain than the 510(k) clearance process and generally takes from one to three years, or even
longer, from the time the application is submitted to the FDA. In addition, a PMA generally requires the performance of one or more clinical
trials. The FDA may not approve or clear any device which we may seek to have approved or cleared. Any delay or failure to obtain necessary
regulatory clearances or approvals could harm our business. Furthermore, even if we are granted regulatory clearances or approvals, they
may include significant limitations on the indicated uses for the device or other restrictions or requirements, which may limit the market
for the device.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, we expect
to take a multi-step approach to the regulatory clearance process. As a first step, we intend to submit a Q-Submission, or Q-Sub, application
to the FDA for our advanced INSPIRA ART (Gen 2) device and may also choose to do so, for the VORTX device. The pre-IDE program was established
in 1995, to provide sponsors a mechanism to obtain FDA feedback on future Investigational Device Exemption, or IDE, applications prior
to their submission. An IDE allows an investigational device to be used in order to collect safety and effectiveness data required to
support a premarket approval application or a premarket notification submission to Food and Drug Administration. Over time, the pre-IDE
program evolved to include feedback on PMAs, Humanitarian Device Exemptions, or HDEs, De Novo requests, and 510(k) submissions, as well
as to address whether a clinical study requires submission of an IDE. To capture this evolution, the Secretary of Health and Human Services&#8217;
(HHS) 2012 Commitment Letter to Congress regarding the Medical Device User Fee Amendments of 2012 (MDUFA III) included FDA&#8217;s commitment
to institute a structured process for managing these interactions, referring to them as Pre-Submissions, or Pre-Subs. The Q-Submission
Guidance, published on June 2, 2023, named &#8220;Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program&#8221;
implemented the broader Q-Program, which includes Pre-Subs, as well as additional opportunities to engage with the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Early interaction with the
FDA on planned non-clinical and clinical studies, risk determination, and careful consideration of the FDA&#8217;s feedback may improve
the quality of subsequent submissions, shorten total review times, and facilitate the development process for new devices. The FDA believes
that interactions provided within Pre-Subs are likely to contribute to a more transparent review process for the FDA and the submitter.
We intend to align and update our regulatory and clinical plans based on the FDA&#8217;s feedback as part of this Q-sub process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We submitted a 510(k) application
for our INSPIRA ART100 device in September 2023. The review process is an iterative process which is still ongoing and may be more costly
and time consuming than we expect and we may not ultimately be successful in completing the review process and our 510(k) application
may not be cleared by the FDA in a timely manner or at all. If cleared, any modification to our INSPIRA ART100 device that has not been
previously cleared may require us to submit a new 510(k) premarket notification and obtain clearance, or submit a PMA and obtain FDA approval
prior to implementing the change. Specifically, any modification to a 510(k)-cleared device that could significantly affect its safety
or effectiveness, or that would constitute a major change in its intended use, design or manufacture, requires a new 510(k) clearance
or, possibly, approval of a PMA. The FDA requires every manufacturer to make this determination in the first instance, but the FDA may
review any manufacturer&#8217;s decision. The FDA may not agree with our decisions regarding whether new clearances or approvals are necessary.
We may make modifications or add additional features in the future that we believe do not require a new 510(k) clearance or approval of
a PMA. If the FDA disagrees with our determination and requires us to submit new 510(k) notifications or PMA applications for modifications
to our previously cleared products for which we have concluded that new clearances or approvals are unnecessary, we may be required to
cease marketing or to recall the modified product until we obtain clearance or approval, and we may be subject to significant regulatory
fines or penalties. If the FDA requires us to go through a lengthier, more rigorous examination for future products or modifications to
existing products than we had expected, product introductions or modifications could be delayed or canceled, which could adversely affect
our ability to grow our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA can delay, limit or
deny clearance or approval of a medical device for many reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our inability to demonstrate to the satisfaction of the FDA or the
applicable regulatory entity or notified body that our product candidates are safe or effective for their intended uses;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the disagreement of the FDA or the applicable foreign regulatory body
with the design or the interpretation of data from pre-clinical studies or clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">serious and unexpected adverse effects experienced by participants
in our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the data from our pre-clinical studies and clinical trials may be insufficient
to support clearance or approval, where required;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our inability to demonstrate that the clinical and other benefits of
the device outweigh the risks;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the manufacturing process or facilities we use may not meet applicable
requirements; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the potential for approval policies or regulations of the FDA or applicable
foreign regulatory bodies to change significantly in a manner rendering our clinical data or regulatory filings insufficient for clearance
or approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to sell our products
in member countries of the European Economic Area, or EEA, our products must comply with the General Safety and Performance Requirements
of the EU Medical Devices Regulation (Regulation (EU) 2017/745). Compliance with these requirements is a prerequisite to be able to affix
the Conformit&#233; Europ&#233;ene, or CE, mark to our products, without which they cannot be sold or marketed in the EEA. To demonstrate
compliance with the general safety and performance requirements we must undergo a conformity assessment procedure, which varies according
to the type of medical device and its classification. Except for low-risk medical devices (Class I non-sterile, non-measuring devices),
where the manufacturer can issue a European Community, or EC, Declaration of Conformity based on a self-assessment of the conformity of
its products with the general safety and performance requirements of the EU Medical Devices Regulation, a conformity assessment procedure
requires the intervention of an organization accredited by a member state of the EEA to conduct conformity assessments, or a Notified
Body. Depending on the relevant conformity assessment procedure, the Notified Body would typically audit and examine the technical file
and the quality system for the manufacture, design and final inspection of our devices. The Notified Body issues a certificate of conformity
following successful completion of a conformity assessment procedure conducted in relation to the medical device and its manufacturer
and their conformity with the general safety and performance requirements. This certificate entitles the manufacturer to affix the CE
mark to its medical devices after having prepared and signed a related EC Declaration of Conformity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of our products may also
need to comply with the following European Directives in order to be sold in the EEA:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">ROHS Directive 2011/65/EU of
the European Parliament and of the Council of June 8, 2011 on the restriction of the use of certain hazardous substances in electrical
and electronic equipment, as amended by (EU) 2017/2102.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify; text-indent: -17.85pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">WEEE Directive 2012/19/EU of
the European Parliament and of the Council of July 4, 2012 on waste electrical and electronic equipment.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify; text-indent: -17.85pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">RED Directive 2014/53/EU of
the European Parliament and of the Council of April 16, 2014 on the harmonization of the laws of the Member States relating to the making
available on the market of radio equipment and repealing Directive 1999/5/EC Text with EEA relevance. Applicable as of June 13, 2016.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify; text-indent: -17.85pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Machinery Directive 2006/42/EC
of the European Parliament and of the Council of May 17, 2006 on machinery, and amending Directive 95/16/EC</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Regulation (EU) 2016/679 of
the European Parliament and of the Council of April 27, 2016 on the protection of natural persons with regard to the processing of personal
data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation)</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products may be required
to comply with additional EU Directives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a general rule, demonstration
of conformity of medical devices and their manufacturers with the general safety and performance requirements and essential requirements
must be based, among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal
conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions
of use, that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of
its intended performance, and that any claims made about the performance and safety of the device are supported by suitable evidence.
If we fail to remain in compliance with applicable European laws, regulations and directives, we will be unable to continue to affix the
CE mark to our products, which would prevent us from selling them within the EEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to comply with post-marketing regulatory
requirements could subject us to enforcement actions, including substantial penalties, and might require us to recall or withdraw a product
from the market.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we receive regulatory clearance
or approval of the products or other future products, we will remain subject to ongoing and pervasive regulatory requirements governing,
among other things, the manufacture, marketing, advertising, medical device reporting, sale, promotion, import, export, registration,
and listing of devices. For example, we will be required to submit periodic reports to the FDA as a condition of 510(k) clearance. These
reports include information about failures and certain adverse events associated with the device after its clearance. Failure to submit
such reports, or failure to submit the reports in a timely manner, could result in enforcement action by the FDA. Following its review
of the periodic reports, the FDA might ask for additional information or initiate further investigation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The regulations to which we
are subject are complex and have become more stringent over time. Regulatory changes could result in restrictions on our ability to continue
or expand our operations, higher than anticipated costs, or lower than anticipated sales. Even after we have obtained the proper regulatory
clearance to market a device, we have ongoing responsibilities under FDA regulations and applicable foreign laws and regulations. The
FDA, state and foreign regulatory authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements
could result in enforcement action by the FDA, state or foreign regulatory authorities, which may include any of the following sanctions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">untitled letters or warning letters;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">fines, injunctions, consent decrees and civil penalties;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">recalls, termination of distribution, administrative detention, or
seizure of our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">customer notifications or repair, replacement or refunds;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">operating restrictions or partial suspension or total shutdown of production;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delays in or refusal to grant our requests for future clearances or
approvals or foreign marketing authorizations of new products, new intended uses, or modifications to existing products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">withdrawals or suspensions of product clearances or approvals, resulting
in prohibitions on sales of our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">FDA refusal to issue certificates to foreign governments needed to
export products for sale in other countries; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">criminal prosecution.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these sanctions could
result in higher than anticipated costs or lower than anticipated sales and have a material adverse effect on our reputation, business,
financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the FDA or state
or foreign authorities may change their clearance and approval policies, adopt additional regulations or revise existing regulations,
or take other actions, which may prevent or delay clearance or approval of our future products under development on a timely basis. Such
policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain new clearances or approvals,
increase the costs of compliance or restrict our ability to maintain any approvals we are able to obtain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our products must be manufactured in accordance
with federal, state and foreign regulations, and we could be forced to recall our devices or terminate production if we fail to comply
with these regulations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The methods used in, and the
facilities used for, the manufacture of our products must comply with the Quality System Regulation, or ISO 13485 standard requirements,
as basic reference for requirements to establish a Quality Management System for the company, which is a complex regulatory scheme that
covers the procedures and documentation of the design, testing, production, process controls, quality assurance, labeling, packaging,
handling, storage, distribution, installation, servicing and shipping of medical devices. As manufacturers of electron radiation-emitting
products, we are also responsible for compliance with the radiological health regulations and certain radiation safety performance standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, we are required
to verify that our suppliers maintain facilities, procedures and operations that comply with our quality standards and applicable regulatory
requirements. The FDA enforces the Quality System (QS) Regulation, or QSR through periodic announced or unannounced inspections of medical
device manufacturing facilities, which may include the facilities of subcontractors. Our products are also subject to similar state regulations
and various laws and regulations of foreign countries governing manufacturing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our third-party manufacturers
may not take the necessary steps to comply with applicable regulations, which could cause delays in the delivery of our products. In addition,
failure to comply with applicable FDA or state or foreign requirements or later discovery of previously unknown problems with our products
or manufacturing processes could result in, among other things: warning letters or untitled letters; fines, injunctions or civil penalties;
suspension or withdrawal of approvals; seizures or recalls of our products; total or partial suspension of production or distribution;
administrative or judicially imposed sanctions; the FDA&#8217;s refusal to grant pending or future clearances or approvals for our products;
clinical holds; refusal to permit the import or export of our products; and criminal prosecution of us, our suppliers or our employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these actions could
significantly and negatively affect supply of our products. If any of these events occurs, our reputation could be harmed, we could be
exposed to product liability claims and we could lose customers and experience reduced sales and increased costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The misuse or off-label use of our products
may harm our reputation in the marketplace, result in injuries that lead to product liability suits or result in costly investigations,
fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly
to our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Advertising and promotion
of our future products that obtains approval in the United States may be heavily scrutinized by the FDA, the DOJ, HHS, state attorneys
general, members of Congress, and the public. In addition, advertising and promotion of any future product that obtains approval outside
of the United States will be heavily scrutinized by comparable foreign regulatory authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that, if cleared
or approved, our products will be cleared by the requisite regulatory authorities for specific indications. We expect to train our marketing
personnel and direct sales force to not promote our devices for uses outside of the FDA-approved indications for use, or any other regulatory
authority approved indications for use in a relevant territory, known as &#8220;off-label uses.&#8221; We cannot, however, prevent a physician
from using our devices off-label, when in the physician&#8217;s independent professional medical judgment, he or she deems it appropriate.
There may be increased risk of injury to patients if physicians attempt to use our devices off-label. Furthermore, the use of our devices
for indications other than those approved by the FDA or approved by any foreign regulatory body may not effectively treat such conditions,
which could harm our reputation in the marketplace among healthcare providers and patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the FDA or any state or
foreign regulatory body determines that our promotional materials or training constitute promotion of an off-label use, it could request
that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance or imposition
of an untitled letter, which is used for violators that do not necessitate a warning letter, injunction, seizure, civil fine or criminal
penalties. It is also possible that other federal, state or foreign enforcement authorities might take action under other regulatory authority,
such as false claims laws, if they consider our business activities to constitute promotion of an off-label use, which could result in
significant penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, exclusion
from participation in government healthcare programs and the curtailment of our operations. We may become subject to such actions and,
if we are not successful in defending against such actions, those actions may have a material adverse effect on our business, financial
condition and results of operations. Equivalent laws and potential consequences exist in foreign jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if our products
are cleared or approved, healthcare providers may misuse our products or use improper techniques if they are not adequately trained, potentially
leading to injury and an increased risk of product liability. If our devices are misused or used with improper technique, we may become
subject to costly litigation by our customers or their patients. As described above, product liability claims could divert management&#8217;s
attention from our core business, be expensive to defend and result in sizeable damage awards against us that may not be covered by insurance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our products may cause or contribute to
adverse medical events or be subject to failures or malfunctions that we are required to report to the FDA, or any other regulatory authority
in a relevant territory, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial
condition and results of operations. The discovery of serious safety issues with our products, or a recall of our products either voluntarily
or at the direction of the FDA or another governmental authority, could have a negative impact on us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our products or our other
future products receive clearance or approval, we will be subject to the FDA&#8217;s medical device reporting regulations and similar
foreign regulations, which require us to report to the FDA when we receive or become aware of information that reasonably suggests that
one or more of our products may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction
were to recur, could cause or contribute to a death or serious injury. The timing of our obligation to report is triggered by the date
we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware
within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if
it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product.
If we fail to comply with our reporting obligations, the FDA or other regulatory bodies could take action, including warning letters,
untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device clearance
or approval, seizure of our products or delay in clearance or approval of future products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA and foreign regulatory
bodies have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design
or manufacture of a product or in the event that a product poses an unacceptable risk to health. Generally, a regulator&#8217;s authority
to require a recall must be based on a finding that there is reasonable probability that the device could cause serious injury or death.
We may also choose to voluntarily recall a product if any material deficiency is found. A government-mandated or voluntary recall by us
could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing defects, labeling or design
deficiencies, packaging defects or other deficiencies or failures to comply with applicable regulations. Product defects or other errors
may occur in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depending on the corrective
action we take to redress a product&#8217;s deficiencies or defects, the FDA and any other regulatory authority may require, or we may
decide, that we will need to obtain new clearances or approvals for the device before we may market or distribute the corrected device.
Seeking such clearances or approvals may delay our ability to replace the recalled devices in a timely manner. Moreover, if we do not
adequately address problems associated with our devices, we may face additional regulatory enforcement action, including FDA warning letters,
product seizure, injunctions, administrative penalties or civil or criminal fines.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Companies are required to
maintain certain records of recalls and corrections, even if they are not reportable to the FDA. We may initiate voluntary withdrawals
or corrections for our products in the future that we determine do not require notification of the FDA or to any other regulatory authority
in a relevant territory. If the FDA or any other regulatory authority in a relevant territory, disagrees with our determinations, it could
require us to report those actions as recalls and we may be subject to enforcement action. A future recall announcement could harm our
reputation with customers, potentially lead to product liability claims against us and negatively affect our sales. Any corrective action,
whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital, distract
management from operating our business and may harm our reputation and financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>We may be subject,
directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy and security
laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many federal state and foreign
healthcare laws and regulations apply to medical devices. We may be subject to certain federal and state regulations, including the federal
healthcare programs&#8217; Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, offering, receiving,
or paying any remuneration, directly or indirectly, in cash or in kind, to induce or reward purchasing, ordering or arranging for or recommending
the purchase or order of any item or service for which payment may be made, in whole or in part, under a federal healthcare program such
as Medicare and Medicaid; the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and
civil liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or
knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with
the delivery of, or payment for, healthcare benefits, items or services; the federal Civil Monetary Penalties Law, which authorizes the
imposition of substantial civil monetary penalties against an entity that engages in activities including, among others (1) knowingly
presenting, or causing to be presented, a claim for services not provided as claimed or that is otherwise false or fraudulent in any way;
(2) arranging for or contracting with an individual or entity that is excluded from participation in federal healthcare programs to provide
items or services reimbursable by a federal healthcare program; (3) violations of the federal Anti-Kickback Statute; or (4) failing to
report and return a known overpayment; the federal False Statements Statute, which prohibits knowingly and willfully falsifying, concealing,
or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using
any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry, in connection
with the delivery of or payment for healthcare benefits, items, or services; the federal civil False Claims Act, or the FCA, which prohibits,
among other things, knowingly presenting, or causing to be presented claims for payment of government funds that are false or fraudulent,
or knowingly making, using or causing to be made or used a false record or statement material to such a false or fraudulent claim, or
knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government;
and other federal and state false claims laws. The FCA prohibits anyone from knowingly presenting, conspiring to present, making a false
statement in order to present, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for
items or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary
items or services. This law also prohibits anyone from knowingly underpaying an obligation owed to a federal program. Increasingly, U.S.
federal agencies are requiring nonmonetary remedial measures, such as corporate integrity agreements in FCA settlements. The DOJ announced
in 2016 its intent to follow the &#8220;Yates Memo,&#8221; taking a far more aggressive approach in pursuing individuals as FCA defendants
in addition to corporations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The majority of states also
have statutes similar to the federal Anti-Kickback Statute and false claims laws that apply to items and services reimbursed under Medicaid
and other state programs, or, in several states, that apply regardless of whether the payer is a government entity or a private commercial
entity. The Federal Open Payments, or Physician Payments Sunshine Act, program requires manufacturers of products for which payment is
available under Medicare, Medicaid or the State Children&#8217;s Health Insurance Program, to track and report annually to the federal
government (for disclosure to the public) certain payments and other transfers of value made to physicians and teaching hospitals as well
as disclosure of payments and other transfers of value provided to physicians and teaching hospitals, and ownership and investment interests
held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations. Our
failure to appropriately track and report payments to the government could result in civil fines and penalties, which could adversely
affect the results of our operations. In addition, several U.S. states and localities have enacted legislation requiring medical device
companies to establish marketing compliance programs, file periodic reports with the state, and/or make periodic public disclosures on
sales, marketing, pricing, clinical trials, and other activities. Other state laws prohibit certain marketing-related activities including
the provision of gifts, meals or other items to certain healthcare providers. Many of these laws and regulations contain ambiguous requirements
that government officials have not yet clarified. Given the lack of clarity in the laws and their implementation, our reporting actions
could be subject to the penalty provisions of the pertinent federal and state laws and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The medical device industry
has been under heightened scrutiny as the subject of government investigations and enforcement actions involving manufacturers who allegedly
offered unlawful inducements to potential or existing customers in an attempt to procure their business, including arrangements with physician
consultants. If our operations or arrangements are found to be in violation of such governmental regulations, we may be subject to civil
and criminal penalties, damages, fines, exclusion from the Medicare and Medicaid programs and the curtailment of our operations. All of
these penalties could adversely affect our ability to operate our business and our financial results.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we do not obtain and maintain international
regulatory registrations, clearances or approvals for our products, we will be unable to market and sell our products outside of the United
States.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of our products outside
of the United States are subject to foreign regulatory requirements that vary widely from country to country. Approval procedures vary
among countries and can involve additional testing. The time required to obtain approval outside of the United States may differ substantially
from that required to obtain FDA approval. While the regulations of some countries may not impose barriers to marketing and selling our
products or only require notification, others require that we obtain the clearance or approval of a specified regulatory body. Complying
with foreign regulatory requirements, including obtaining registrations, clearances or approvals, can be expensive and time-consuming,
and we may not receive regulatory clearances or approvals in each country in which we plan to market our products, or we may be unable
to do so on a timely basis. The time required to obtain registrations, clearances or approvals, if required by other countries, may be
longer than that required for FDA clearance or approval, and requirements for such registrations, clearances or approvals may significantly
differ from FDA requirements. If we modify our products, we may need to apply for additional regulatory clearances or approvals before
we are permitted to sell the modified product. In addition, we may not continue to meet the quality and safety standards required to maintain
the authorizations that we have received. If we are unable to maintain our authorizations in a particular country, we will no longer be
able to sell the applicable product in that country.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulatory clearance or approval
by the FDA does not ensure registration, clearance or approval by regulatory authorities in other countries, and registration, clearance
or approval by one or more foreign regulatory authorities does not ensure registration, clearance or approval by regulatory authorities
in other foreign countries or by the FDA. However, a failure or delay in obtaining registration or regulatory clearance or approval in
one country may have a negative effect on the regulatory process in others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Legislative or regulatory reforms in the
United States or the European Union may make it more difficult and costly for us to obtain regulatory clearances or approvals for our
products or to manufacture, market or distribute our products after clearance or approval is obtained.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, legislation
is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulation of medical devices.
In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take
other actions, which may prevent or delay approval or clearance of our future products under development or impact our ability to modify
our currently cleared products on a timely basis. Over the last several years, the FDA has proposed reforms to its 510(k) clearance process,
and such proposals could include increased requirements for clinical data and a longer review period, or could make it more difficult
for manufacturers to utilize the 510(k) clearance process for their products. For example, in November 2018, FDA officials announced forthcoming
steps that the FDA intends to take to modernize the premarket notification pathway under Section 510(k) of the FDCA. Among other things,
the FDA announced that it planned to develop proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates.
These proposals included plans to potentially sunset certain older devices that were used as predicates under the 510(k) clearance pathway,
and to potentially publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate
devices that are more than 10 years old. In May 2019, the FDA solicited public feedback on these proposals. The FDA requested public feedback
on whether it should consider certain actions that might require new authority, such as whether to sunset certain older devices that were
used as predicates under the 510(k) clearance pathway. These proposals have not yet been finalized or adopted, and the FDA may work with
Congress to implement such proposals through legislation. Accordingly, it is unclear the extent to which any proposals, if adopted, could
impose additional regulatory requirements on us that could delay our ability to obtain new 510(k) clearances, increase the costs of compliance,
or restrict our ability to maintain our current clearances, or otherwise create competition that may negatively affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2019, the FDA
finalized guidance describing an optional &#8220;safety and performance based&#8221; premarket review pathway for manufacturers of &#8220;certain,
well-understood device types&#8221; to demonstrate substantial equivalence under the 510(k) clearance pathway by showing that such device
meets objective safety and performance criteria established by the FDA, thereby obviating the need for manufacturers to compare the safety
and performance of their medical devices to specific predicate devices in the clearance process. The FDA has developed and maintains a
list device types appropriate for the &#8220;safety and performance based&#8221; pathway and will continue to develop product-specific
guidance documents that identify the performance criteria for each such device type, as well as the testing methods recommended in the
guidance documents, where feasible. The FDA may establish performance criteria for classes of devices for which we or our competitors
seek or currently have received clearance, and it is unclear the extent to which such performance standards, if established, could impact
our ability to obtain new 510(k) clearances or otherwise create competition that may negatively affect our business. In September 2023,
the FDA introduced draft guidance regarding best practices for selecting a device in 510(k) submissions to enhance the predictability,
consistency, and transparency of the 510(k) Program. The recommendations focus on characteristics of the predicate, including selecting
a predicate device that was cleared using well-established methods, meets or exceeds expected safety and performance, is without unmitigated
use-related or design-related safety issues, and is without an associated design-related recall. According to the FDA, these practices
will encourage the evolution of safer and more effective medical devices in the 510(k) program over time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Similarly, particular common
specifications, or sets of technical and/or clinical requirements (other than a standard) that provide a means of complying with the legal
obligations applicable to a device, process or system, are issued by the EU&#8217;s competent authorities and are mandatory as part of
the CE certification process. The EU competent authorities may establish performance criteria for classes of devices for which we or our
competitors seek or currently have received certification and it is unclear the extent to which such performance standards, if established,
could impact our ability to obtain new CE certifications or otherwise create competition that may negatively affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, FDA or any other
relevant regulatory authority, regulations and guidance are often revised or reinterpreted by the FDA or any other regulatory authority,
in ways that may significantly affect our business and our products. Any new statutes, regulations or revisions or reinterpretations of
existing regulations may impose additional costs or lengthen review times of any future products or make it more difficult to obtain clearance
or approval for, manufacture, market or distribute our products. We cannot determine what effect changes in regulations, statutes, legal
interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among
other things, require: additional testing prior to obtaining clearance or approval; changes to manufacturing methods; recall, replacement
or discontinuance of our products; or additional record keeping.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA&#8217;s and other
regulatory authorities&#8217; policies may change, and additional government regulations may be promulgated that could prevent, limit
or delay regulatory clearance or approval of our future products. We cannot predict the likelihood, nature or extent of government regulation
that may arise from future legislation or administrative action, either in the United States or abroad. For example, certain policies
of the Biden administration, as well as decisions by the United States&#8217; legislative or judicial branches may impact our business
and industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 27, 2020, the United
States Supreme Court reversed a Federal Circuit decision that previously upheld Congress&#8217; denial of $12 billion in &#8220;risk corridor&#8221;
funding. Congress may consider additional legislation to repeal, or repeal and replace, other elements of the Patient Protection and Affordable
Care Act, as amended by the Health Care and Education Reconciliation Act, or the PPACA, On June 17, 2021, the U.S. Supreme Court dismissed
a challenge on procedural grounds that argued that the PPACA is unconstitutional in its entirety because the individual mandate was repealed
by Congress. Thus, the PPACA will remain in effect in its current form. Prior to the U.S. Supreme Court ruling, on January 28, 2021, President
Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through
the PPACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies
and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that
include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid
or the PPACA. In addition, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or the IRA, into law, which
among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in PPACA marketplaces through plan
year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering
the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. It is possible that the PPACA will
be subject to judicial or Congressional challenges in the future. It is unclear how such challenges and the healthcare reform measures
of the Biden administration will impact the PPACA and our business. We continue to evaluate the PPACA and its possible repeal and replacement,
as the extent to which any such changes may impact our business or financial condition remains uncertain. If we are slow or unable to
adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory
compliance, we may lose any marketing approval or clearance that we may have obtained and we may not achieve or sustain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the European Union, similar
political, economic and regulatory developments may affect our ability to profitably commercialize any of our product candidates, if approved.
In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state
level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare
in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is
almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers
have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context.
In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement
of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those
wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate
post-approval activities and affect our ability to commercialize any products for which we obtain marketing approval. Political, economic
and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has
been obtained. Reference pricing used by various EU member states, and parallel trade, i.e., arbitrage between low-priced and high-priced
member states, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations
for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries.
In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted
price ceilings on specific products and therapies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 5, 2017, the European
Parliament passed the Medical Devices Regulation (Regulation 2017/745), which became effective on May 26, 2021 and repeals and replaces
the EU Medical Devices Directive. Unlike directives, which must be implemented into the national laws of the EEA member states, the regulations
would be directly applicable, i.e., without the need for adoption of EEA member state laws implementing them, in all EEA member states
and are intended to eliminate current differences in the regulation of medical devices among EEA member States. The Medical Devices Regulation,
among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EEA for
medical devices and ensure a high level of safety and health while supporting innovation. Among other things, the Medical Devices Regulation:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Strengthen the rules on placing devices on the market and reinforce
surveillance once they are available;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Establish explicit provisions on manufacturers&#8217; responsibilities
for follow-up regarding the quality, performance and safety of devices placed on the market;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Improve the traceability of medical devices throughout the supply chain
to the end-user or patient through a unique identification number;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Set up a central database to provide patients, healthcare professionals
and the public with comprehensive information on products available in the EU; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Strengthened rules for the assessment of certain high-risk devices,
which may have to undergo an additional check by experts before they are placed on the market.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These modifications may have
an effect on the way we conduct our business in the EEA. We expect that these and other healthcare reform measures that may be adopted
in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price
that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result
in a similar reduction in payments from private payors. Further, there is no guarantee that we can use existing reimbursement codes or
receive reimbursement at all. The implementation of cost containment measures or other healthcare reforms may prevent us from being able
to generate revenue, attain profitability or commercialize our drugs, once marketing approval is obtained. We cannot predict what healthcare
reform initiatives may be adopted in the future. However, it is possible that there will be further legislation or regulation that could
harm the business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Healthcare legislative and regulatory reform
measures may have a material adverse effect on our business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our industry is highly regulated
and changes in law may adversely impact our business, operations or financial results. The Patient Protection and Affordable Care Act,
as amended by the Health Care and Education Reconciliation Act, or the PPACA, is a sweeping measure intended to, among other things, expand
healthcare coverage within the United States, primarily through the imposition of health insurance mandates on employers and individuals
and expansion of the Medicaid program. Several provisions of the law may affect us and increase certain of our costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, other legislative
changes have been adopted since the PPACA was enacted. These changes include aggregate reductions in Medicare payments to providers of
2% per fiscal year, which went into effect on April 1, 2013. These reductions went into effect in April 2013 and, due to subsequent legislative
amendments to the statute, will remain in effect until 2031.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2013, President
Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several
types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three
to five years. These and new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material
adverse effect on our customers and, accordingly, our financial operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We anticipate that the PPACA,
as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and an additional
downward pressure on the reimbursement our customers may receive for our products. Further, there have been, and there may continue to
be, judicial and Congressional challenges to certain aspects of the PPACA. For example, the U.S. Tax Cuts and Jobs Act of 2017, or TCJA,
includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain
individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual
mandate.&#8221; On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the PPACA is unconstitutional
in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Further, prior to the U.S. Supreme Court ruling,
on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 26, 2021 through
August 15, 2021 for purposes of obtaining health insurance coverage through the PPACA marketplace. The executive order also instructed
certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among
others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary
barriers to obtaining access to health insurance coverage through Medicaid or the PPACA. In addition, on August 16, 2022, President Biden
signed the Inflation Reduction Act of 2022, or the IRA, into law, which among other things, extends enhanced subsidies for individuals
purchasing health insurance coverage in PPACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221;
under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly
established manufacturer discount program. Additional legislative and regulatory changes and judicial challenges to the PPACA, its implementing
regulations and guidance and its policies, remain possible. However, it remains unclear how any new legislation, regulation or challenges
in court might affect the prices we may obtain for any of our products for which regulatory approval is obtained. Any reduction in reimbursement
from Medicare and other government programs may result in a similar reduction in payments from private payers. The implementation of cost
containment measures or other healthcare reforms may prevent us from being able to generate significant revenue, attain profitability
or commercialize our products in scale.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the delivery
of healthcare in the European Union, including the establishment and operation of health services, is almost exclusively a matter for
national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to
the delivery of health care and the pricing and reimbursement of products in that context. Coupled with ever-increasing EU and national
regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our products or
any future product candidates, restrict or regulate post-approval activities and affect our ability to commercialize any products for
which we obtain marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently unable to
predict what additional legislation or regulation, if any, relating to the health care industry may be enacted in the future or what effect
recently enacted federal legislation or any such additional legislation or regulation would have on our business. The pendency or approval
of such proposals or reforms could result in a decrease in the price of our securities or limit our ability to raise capital or to enter
into collaboration agreements for the further development and potential commercialization of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Disruptions at the FDA and other government
agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and
other personnel, or otherwise prevent new or modified products from being developed, cleared or approved or commercialized in a timely
manner or at all, which could negatively impact our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ability of the FDA to
review and clear or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory,
regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other
events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated
in recent years as a result. In addition, government funding of other government agencies that fund research and development activities
is subject to the political process, which is inherently fluid and unpredictable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disruptions at the FDA and
other agencies may also slow the time necessary for new medical devices or modifications to cleared or approved medical devices to be
reviewed and/or approved by necessary government agencies, which would adversely affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Environmental, social and corporate governance
(ESG) issues, including those related to climate change and sustainability, may have an adverse effect on our business, financial condition
and results of operations and damage our reputation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is an increasing focus
from certain investors, customers, consumers, employees and other stakeholders concerning ESG matters. Additionally, public interest and
legislative pressure related to public companies&#8217; ESG practices continue to grow. If our ESG practices fail to meet regulatory requirements
or investor, customer, consumer, employee or other stakeholders&#8217; evolving expectations and standards for responsible corporate citizenship
in areas including environmental stewardship, support for local communities, Board of Director and employee diversity, human capital management,
employee health and safety practices, product quality, supply chain management, corporate governance and transparency, our reputation,
brand and employee retention may be negatively impacted, and our customers and suppliers may be unwilling to continue to do business with
us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Customers, consumers, investors
and other stakeholders are increasingly focusing on environmental issues, including climate change, energy and water use, plastic waste
and other sustainability concerns. Concern over climate change may result in new or increased legal and regulatory requirements to reduce
or mitigate impacts to the environment. Changing customer and consumer preferences or increased regulatory requirements may result in
increased demands or requirements regarding plastics and packaging materials, including single-use and non-recyclable plastic products
and packaging, other components of our products and their environmental impact on sustainability, or increased customer and consumer concerns
or perceptions (whether accurate or inaccurate) regarding the effects of substances present in certain of our products. Complying with
these demands or requirements could cause us to incur additional manufacturing, operating or product development costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we do not adapt to or comply
with new regulations, or fail to meet evolving investor, industry or stakeholder expectations and concerns regarding ESG issues, investors
may reconsider their capital investment in our Company, and customers and consumers may choose to stop purchasing our products, which
could have a material adverse effect on our reputation, business or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>Risks Related to Our
Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to obtain and maintain
effective patent rights for our products and services, we may not be able to compete effectively in our markets. If we are unable to protect
the confidentiality of our trade secrets or know-how, such proprietary information may be used by others to compete against us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success and future revenue
growth will depend, in part, on our ability to protect our patent rights. In addition to the protection afforded by any patents that may
be granted, historically, we have relied on trade secret protection and confidentiality agreements with our employees, consultants, and
contractors to protect proprietary know-how that is not patentable or that we elect not to patent, processes that are not easily known,
knowable or easily ascertainable, and for which patent infringement is difficult to monitor and enforce and any other elements of our
product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered
by patents. However, agreements may be breached, trade secrets may be difficult to protect, and we may not receive adequate remedies for
any breach. In addition, our trade secrets and intellectual property may otherwise become known or be independently discovered by competitors
or other unauthorized third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no guarantee that
the patent applications that we submitted with regards to our technologies will result in patent registration. In the event of failure
to complete patent registration, our developments will not be proprietary, which might allow other entities to manufacture our products
or design our services and compete with them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, there is no assurance
that all potentially relevant prior art relating to our patent applications has been found, which can invalidate a patent or prevent a
patent from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our products
or services, third parties may challenge their validity, enforceability, or scope, which may result in such patents being narrowed, found
unenforceable or invalidated. Furthermore, even if they are unchallenged, our patent applications and any future patents may not adequately
protect our intellectual property, products or services and provide exclusivity for our new products or services or prevent others from
designing around our claims. Furthermore, there is no guarantee that third parties will not infringe or misappropriate our patents or
similar proprietary rights. In addition, there can be no assurance that we will not have to pursue litigation against other parties to
assert its rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Any
of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we cannot obtain and maintain
effective patent rights for our products and services, we may not be able to compete effectively, and our business and results of operations
would be harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot provide any assurances
that our trade secrets and other confidential proprietary information will not be disclosed in violation of our confidentiality agreements
or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information
and techniques. Also, misappropriation or unauthorized and unavoidable disclosure of our trade secrets and intellectual property could
impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our
trade secrets and intellectual property are deemed inadequate, we may have insufficient recourse against third parties for misappropriating
any trade secret.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Intellectual property rights of third parties
could adversely affect our ability to commercialize our products and services, and we might be required to litigate or obtain licenses
from third parties in order to develop or market our product candidates. Such litigation or licenses could be costly or not available
on commercially reasonable terms.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is inherently difficult
to conclusively assess our freedom to operate without infringing on third-party rights. Our competitive position may be adversely affected
if existing patents or patents resulting from patent applications issued to third parties or other third-party intellectual property rights
are held to cover our products or services or elements thereof, or our manufacturing or uses relevant to our development plans. In such
cases, we may not be in a position to develop or commercialize products or services or our product candidates (and any relevant services)
unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned or enter into
a license agreement with the intellectual property right holder, if available on commercially reasonable terms. There may also be pending
patent applications that if they result in issued patents, could be alleged to be infringed by our new products or services. If such an
infringement claim should be brought and be successful, we may be required to pay substantial damages, be forced to abandon our new products
or services or seek a license from any patent holders. No assurances can be given that a license will be available on commercially reasonable
terms, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is also possible that we
have failed to identify relevant third-party patents or applications. For example, U.S. patent applications filed before November 29,
2000 and certain U.S. patent applications filed after that date that will not be filed outside the United States remain confidential until
patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing
for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications
covering our new products or services could have been filed by others without our knowledge. Additionally, pending patent applications
which have been published can, subject to certain limitations, be later amended in a manner that could cover our services, our new products
or the use of our new products. Third-party intellectual property right holders may also actively bring infringement claims against us.
We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully
settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation
and may be prevented from or experience substantial delays in pursuing the development of and/or marketing our new products or services.
If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing
our new products or services that are held to be infringing. We might, if possible, also be forced to redesign our new products so that
we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could
require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Third-party claims of intellectual property
infringement may prevent or delay our development and commercialization efforts.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success depends
in part on our avoiding infringement of the patents and proprietary rights of third parties. Numerous U.S. and foreign issued patents
and pending patent applications, which are owned by third parties, exist in the fields in which we are developing new products and services.
If our business expands and more patents are issued, the risk increases that our products and services may be subject to claims of infringement
of the patent rights of third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Third parties may assert that
we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims
to materials, designs or methods of manufacture related to the use or manufacture of our products or services. There may be currently
pending patent applications or continued patent applications that may later result in issued patents that our products or services may
infringe. In addition, third parties may obtain patents or services in the future and claim that use of our technologies infringes upon
these patents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any third-party patents
were held by a court of competent jurisdiction to cover aspects of our processes for designs, or methods of use, the holders of any such
patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtain a license or until
such patent expires or is finally determined to be invalid or unenforceable. In either case, such a license may not be available on commercially
reasonable terms or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Parties making claims against
us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one
or more of our products or services. Defense of these claims, regardless of their merit, would involve substantial litigation expense
and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against
us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties,
redesign our infringing products or services, or obtain one or more licenses from third parties, which may be impossible or require substantial
time and monetary expenditure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patent policy and rule changes could increase
the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Changes
in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of any
patents that may issue from our patent applications or narrow the scope of our patent protection. The laws of foreign countries may not
protect our rights to the same extent as the laws of the United States. Publications of discoveries in the scientific literature often
lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until
18 months after filing, or in some cases not at all. We therefore cannot be certain that we were the first to file the invention claimed
in our owned and licensed patent or pending applications, or that we or our licensor were the first to file for patent protection of such
inventions. Assuming all other requirements for patentability are met, in the United States prior to March 15, 2013, the first to make
the claimed invention without undue delay in filing, is entitled to the patent, while generally outside the United States, the first to
file a patent application is entitled to the patent. After March 15, 2013, under the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith
Act&#8221;), enacted on September 16, 2011, the United States has moved to a first to file system. The Leahy-Smith Act also includes a
number of significant changes that affect the way patent applications will be prosecuted and may also affect patent litigation. In general,
the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications
and the enforcement or defense of any issued patents, all of which could have a material adverse effect on our business and financial
condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be involved in lawsuits to protect
or enforce our intellectual property, which could be expensive, time consuming, and unsuccessful. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competitors may infringe our
intellectual property. If we were to initiate legal proceedings against a third-party to enforce a patent covering one of our new products
or services, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent
litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity
challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement.
Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant
information from the United States Patent and Trademark Office, or USPTO, or made a misleading statement, during prosecution. Under the
Leahy-Smith Act, the validity of U.S. patents may also be challenged in post-grant proceedings before the USPTO. The outcome following
legal assertions of invalidity and unenforceability is unpredictable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Derivation proceedings initiated
by third parties or brought by us may be necessary to determine the priority of inventions and/or their scope with respect to our patent
or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to
attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license
on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in
substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have
a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs,
license necessary technology from third parties, or enter into development partnerships that would help us bring our new products or services
to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, because of the
substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential
information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results
of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative,
it could have a material adverse effect on the price of our securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims challenging
the inventorship of our intellectual property.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject to claims
that former employees, collaborators or other third parties have an interest in, or right to compensation, with respect to our current
patent and patent applications, future patents or other intellectual property as an inventor or co-inventor. For example, we may have
inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our products or services.
Litigation may be necessary to defend against these and other claims challenging inventorship or claiming the right to compensation. If
we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such
as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our
business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management and other employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to protect our intellectual
property rights throughout the world.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Filing, prosecuting, and defending
patents on products and services, as well as monitoring their infringement in all countries throughout the world would be prohibitively
expensive, and our intellectual property rights in some countries can be less extensive than those in the United States. In addition,
the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United
States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competitors may use our technologies
develop their own products or services in jurisdictions where we have not obtained patent protection to and may export infringing products
or services to territories where we have patent protection, but where patents are not enforced as strictly as they are in the United States.
These products or services may compete with our products or services. Future patents or other intellectual property rights may not be
effective or sufficient to prevent them from competing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many companies have encountered
significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries,
particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection,
which could make it difficult for us to stop the marketing of competing products or services in violation of our proprietary rights generally.
Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert
our efforts and attention from other aspects of our business, could put our future patents at risk of being invalidated or interpreted
narrowly, put the issuance of our patent applications at risk, and could provoke third parties to assert claims against us. We may not
prevail in any lawsuits that we initiate, and any damages or other remedies that we may be awarded, may not be commercially meaningful.
Accordingly, our efforts to monitor and enforce our intellectual property rights around the world may be inadequate to obtain a significant
commercial advantage from the intellectual property that we develop or license.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Ownership of our Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The market price of our securities is likely
to continue to be highly volatile, and you may not be able to resell your Ordinary Shares at or above the price that you paid.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since we completed our initial
public offering in July 2021, the trading price of our Ordinary Shares and Warrants have been volatile and is likely to continue to be
volatile. The stock market in general, and the market for medical device companies in particular, has experienced extreme volatility that
has often been unrelated to the operating performance of particular companies, which has resulted in decreased stock prices for many companies
notwithstanding the lack of a fundamental change in their underlying business models or prospects. Broad market and industry factors,
including potentially worsening economic conditions, inflation and other adverse effects, may negatively affect the market price of our
securities, regardless of our actual operating performance. As a result of this volatility, you may not be able to sell your securities
at or above the price you paid. The following factors, in addition to other risk factors described in this section, may have a significant
impact on the market price of our securities:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; ">Inability to obtain the approvals necessary
to commence further clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Unsatisfactory results of clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Announcements of regulatory approval or the failure to obtain it, or
specific label indications or patient populations for its use, or changes or delays in the regulatory review process; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Announcements of innovations or new products by us or our competitors;
</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Adverse actions taken by regulatory authorities with respect to our
clinical trials, manufacturing supply chain or sales and marketing activities; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any adverse changes to our relationship with manufacturers or suppliers;
</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any intellectual property infringement actions in which we may become
involved; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Achievement of expected product sales and profitability or our failure
to meet expectations; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our commencement of, or involvement in, litigation; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;&#160;&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any major changes in our board of directors or management; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our ability to recruit and retain qualified regulatory, research and development personnel; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Legislation in the United States relating to the sale or pricing of
medical devices; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The depth of the trading market in our Ordinary Shares and Warrants;
</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Economic weakness, including inflation, or political instability in
particular foreign economies and markets; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Business interruptions resulting from a local or worldwide pandemic,
such as COVID-19 or other health epidemic, geopolitical actions, including war and terrorism, or natural disasters; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The granting or exercise of employee stock options or other equity
awards; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Changes in investors and securities analysts&#8217; perception of the
business risks and conditions of our business. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the stock market
in general, and the Nasdaq in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate
to the operating performance of small companies. Broad market and industry factors may negatively affect the market price of our Ordinary
Shares, regardless of our actual operating performance. Further, a systemic decline in the financial markets and related factors beyond
our control may cause our share price to decline rapidly and unexpectedly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Future sales of our Ordinary Shares could
reduce the market price of our securities.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Substantial sales of our Ordinary
Shares on Nasdaq may cause the market price of our securities to decline. Sales by us or our security holders of substantial amounts of
our Ordinary Shares, or the perception that these sales may occur in the future, could cause a reduction in the market price of our securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The issuance of any additional
Ordinary Shares or any securities that are exercisable for or convertible into Ordinary Shares, may have an adverse effect on the market
price of our Ordinary Shares and will have a dilutive effect on our existing shareholders and holders of Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our principal shareholders, officers and
directors currently beneficially own 23.6% of our Ordinary Shares. They may therefore be able to exert control over matters submitted
to our shareholders for approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 22, 2024, our
principal shareholders, officers and directors beneficially own approximately 23.6% of our Ordinary Shares. As a result, these shareholders,
if they acted together, could influence matters requiring approval by our shareholders, including the election of directors and the approval
of mergers or other business combination transactions. The interests of these shareholders may not always coincide with our interests
or the interests of other shareholders.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have never paid cash dividends on our
share capital, and we do not anticipate paying any cash dividends in the foreseeable future.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid cash dividends, and we do not anticipate paying cash dividends in the foreseeable future. Therefore, you should not rely on an investment
in our securities as a source for any future dividend income. Our board of directors has complete discretion as to whether to distribute
dividends. Even if our board of directors decides to declare and pay dividends, the timing, amount and form of future dividends, if any,
will depend on our future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any,
received by us from our subsidiaries, our financial condition, contractual restrictions and other factors deemed relevant by our board
of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The JOBS Act will allow us to postpone the
date by which we must comply with some of the laws and regulations intended to protect investors and to reduce the amount of information
we provide in our reports filed with the SEC, which could undermine investor confidence in our company and adversely affect the market
price of our securities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For so long as we remain an
&#8220;emerging growth company&#8221; as defined in the JOBS Act, we take advantage of certain exemptions from various requirements that
are applicable to public companies that are not &#8220;emerging growth companies&#8221; including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the provisions of the Sarbanes-Oxley Act requiring that our independent
registered public accounting firm provide an attestation report on the effectiveness of our internal control over financial reporting;
and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any rules that may be adopted by the Public Company Accounting Oversight
Board requiring mandatory audit firm rotation or a supplement to the auditor&#8217;s report on the financial statements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to take advantage
of these exemptions until we are no longer an &#8220;emerging growth company.&#8221; We will remain an emerging growth company until the
earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the date of the completion of our initial public
offering, (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a large accelerated
filer, as defined in the rule under the Exchange Act, and (2) the date on which we have issued more than $1.0 billion in non-convertible
debt during the prior three-year period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot predict if investors
will find our securities less attractive because we may rely on these exemptions. If some investors find our securities less attractive
as a result, there may be a less active trading market for our securities, and our market prices may be more volatile and may decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>As a &#8220;foreign private issuer&#8221;
we are permitted, and intend, to follow certain home country corporate governance practices instead of otherwise applicable SEC and Nasdaq
requirements, which may result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our status as a foreign private
issuer also exempts us from compliance with certain SEC laws and regulations and certain regulations of Nasdaq, including the proxy rules,
the short-swing profits recapture rules, and certain governance requirements such as independent director oversight of the nomination
of directors and executive compensation. In addition, we are not required under the Exchange Act to file current reports and financial
statements with the SEC as frequently or as promptly as U.S. domestic companies whose securities are registered under the Exchange Act,
and we are generally exempt from filing quarterly reports with the SEC. Also, although the Israeli Companies Law, 5759-1999, or the Companies
Law, requires us to disclose the annual compensation of our five most highly compensated senior officers on an individual basis (rather
than on an aggregate basis), this disclosure will not be as extensive as that required of a U.S. domestic issuer. Furthermore, as a foreign
private issuer, we are also not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These exemptions and leniencies
will reduce the frequency and scope of information and protections to which you are entitled as an investor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The determination of foreign
private issuer status is made annually on the last business day of an issuer&#8217;s most recently completed second fiscal quarter and,
accordingly, the next determination will be made with respect to us on June 30, 2024. In the future, we would lose our foreign private
issuer status if a majority of our shareholders, directors or management are U.S. citizens or residents and we fail to meet additional
requirements necessary to avoid loss of foreign private issuer status. The regulatory and compliance costs to us under U.S. securities
laws as a U.S. domestic registrant may be significantly higher.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be a &#8220;passive foreign investment
company,&#8221; or PFIC, for U.S. federal income tax purposes in the current taxable year or may become one in any subsequent taxable
year. There generally would be negative tax consequences for U.S. taxpayers that are holders of the securities if we are or were to become
a PFIC.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the projected composition
of our income and valuation of our assets, we do not believe we were a PFIC for 2024, we do not expect to be a PFIC in 2025, and we do
not expect to become a PFIC in the future, although there can be no assurance in this regard. The determination of whether we are a PFIC
is made on an annual basis and will depend on the composition of our income and assets from time to time. We will be treated as a PFIC
for U.S. federal income tax purposes in any taxable year in which either (1) at least 75% of our gross income is &#8220;passive income&#8221;
or (2) on average at least 50% of our assets by value produce passive income or are held for the production of passive income. Passive
income for this purpose generally includes, among other things, certain dividends, interest, royalties, rents and gains from commodities
and securities transactions and from the sale or exchange of property that gives rise to passive income. Passive income also includes
amounts derived by reason of the temporary investment of funds, including those raised in a public offering. In determining whether a
non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly,
at least a 25% interest (by value) is taken into account. The tests for determining PFIC status are applied annually, and it is difficult
to make accurate projections of future income and assets which are relevant to this determination. In addition, our PFIC status may depend
in part on the market value of the securities. Accordingly, there can be no assurance that we currently are not or will not become a PFIC
in the future. If we are a PFIC in any taxable year during which a U.S. taxpayer holds the securities, such U.S. taxpayer would be subject
to certain adverse U.S. federal income tax rules. In particular, if the U.S. taxpayer did not make an election to treat us as a &#8220;qualified
electing fund&#8221;, or QEF, or make a &#8220;mark-to-market&#8221; election, then &#8220;excess distributions&#8221; to the U.S. taxpayer,
and any gain realized on the sale or other disposition of our securities by the U.S. taxpayer: (1) would be allocated ratably over the
U.S. taxpayer&#8217;s holding period for our securities; (2) the amount allocated to the current taxable year and any period prior to
the first day of the first taxable year in which we were a PFIC would be taxed as ordinary income; and (3) the amount allocated to each
of the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for that
year, and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each such
other taxable year. In addition, if the U.S. Internal Revenue Service, or the IRS, determines that we are a PFIC for a year with respect
to which we have determined that we were not a PFIC, it may be too late for a U.S. taxpayer to make a timely QEF or mark-to-market election.
U.S. taxpayers that have held our securities during a period when we were a PFIC will be subject to the foregoing rules, even if we cease
to be a PFIC in subsequent years, subject to exceptions for U.S. taxpayer who made a timely QEF or mark-to-market election. A U.S. taxpayer
can make a QEF election by completing the relevant portions of and filing IRS Form 8621 in accordance with the instructions thereto. We
do not intend to notify U.S. taxpayers that hold our securities if we believe we will be treated as a PFIC for any taxable year in order
to enable U.S. taxpayers to consider whether to make a QEF election. In addition, we do not intend to furnish such U.S. taxpayers annually
with information needed in order to complete IRS Form 8621 and to make and maintain a valid QEF election for any year in which we or any
of our subsidiaries are a PFIC. U.S. taxpayers that hold our securities are strongly urged to consult their tax advisors about the PFIC
rules, including tax return filing requirements and the eligibility, manner, and consequences to them of making a QEF or mark-to-market
election with respect to our securities in the event that we are a PFIC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to securities litigation,
which is expensive and could divert management attention.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the past, companies that
have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the
target of this type of litigation in the future. Litigation of this type could result in substantial costs and diversion of management&#8217;s
attention and resources, which could seriously hurt our business. Any adverse determination in litigation could also subject us to significant
liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If securities or industry analysts do not
publish or cease publishing research or reports about us, our business or our market, or if they adversely change their recommendations
or publish negative reports regarding our business or our securities, our share price and trading volume could decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading market for our
securities will be influenced by the research and reports that industry or securities analysts may publish about us, our business, our
market or our competitors. We do not have any control over these analysts and we cannot provide any assurance that analysts will cover
us or provide favorable coverage. If any of the analysts who may cover us adversely change their recommendation regarding our securities,
or provide more favorable relative recommendations about our competitors, the price of our securities would likely decline. If any analyst
who may cover us were to cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial
markets, which in turn could cause the price of our securities or trading volume to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>You may experience future dilution as a
result of future equity offerings.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to raise additional
capital, we may in the future offer additional Ordinary Shares or other securities convertible into or exchangeable for Ordinary Shares
at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering
at a price per share that is less than the price per share paid by investors in this offering, and investors purchasing shares or other
securities in the future could have rights superior to existing shareholders. The price per share at which we sell additional Ordinary
Shares, or securities convertible or exchangeable into Ordinary Shares, in future transactions may be higher or lower than the price per
share paid by investors in this offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may need additional financing in the
future. We may be unable to obtain additional financing or if we obtain financing it may not be on terms favorable to us. You may lose
your entire investment.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our current plans,
we believe our existing cash and cash equivalents will be sufficient to fund our operating expense and capital requirements for the next
six months. We expect that we will require substantial additional capital to operate and to commercialize our products and we expect to
seek additional funds to enable us to fund our operations for the next twelve months. We may be unable to obtain additional funds through
financing activities, and if we obtain financing it may not be on terms favorable to us. If we are unable to obtain additional funds on
terms favorable to us, we may be required to cease or reduce our operating activities. If we must cease or reduce our operating activities,
you may lose your entire investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have never paid cash dividends on our
share capital, and we do not anticipate paying any cash dividends in the foreseeable future.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid cash dividends, and we do not anticipate paying cash dividends in the foreseeable future. Therefore, you should not rely on an investment
in Ordinary Shares as a source for any future dividend income.&#160;Our board of directors has complete discretion as to whether to distribute
dividends. Even if our board of directors decides to declare and pay dividends, the timing, amount and form of future dividends, if any,
will depend on our future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any,
received by us from our subsidiaries, our financial condition, contractual restrictions and other factors deemed relevant by our board
of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>Risks Related to Israeli
Law and Our Operations in Israel</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Our principal executive
offices, most of our research and development activities and other significant operations are located in Israel, and, therefore, our results
may be adversely affected by political, economic and military instability in Israel, including the recent attack by Hamas and other terrorist
organizations from the Gaza Strip and Israel&#8217;s war against them.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
executive offices, corporate headquarters and principal research and development facilities are located in Israel. In addition, all of
our officers and directors are residents of Israel. Accordingly, political, economic and military and security conditions in Israel and
the surrounding region may directly affect our business. Any conflicts, political instability, terrorism, cyberattacks or any other hostilities
involving Israel or the interruption or curtailment of trade between Israel and its present trading partners could adversely affect our
operations. Ongoing and revived hostilities in the Middle East or other Israeli political or economic factors, could harm our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
October 2023, Hamas terrorists infiltrated Israel&#8217;s border with the Gaza Strip and conducted a series of attacks on civilian and
military targets. Hamas has also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s
border with the Gaza Strip and in other areas within the State of Israel. These attacks have resulted in extensive deaths, injuries and
kidnapping. Following the attack, Israel&#8217;s security cabinet declared war against Hamas and a military campaign against these terrorist
organizations commenced in parallel to their continued rocket and terror attacks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
intensity and duration of Israel&#8217;s current war against Hamas is difficult to predict, as are such war&#8217;s economic implications
on the Company&#8217;s business and operations and on Israel&#8217;s economy in general. The potential deterioration of Israel&#8217;s
economy, as a direct and indirect result of these events, may have a material adverse effect on the Company and its ability to effectively
conduct its operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
connection with the Israeli security cabinet&#8217;s declaration of war against Hamas and possible hostilities with other organizations,
several hundred thousand Israeli military reservists were drafted to perform immediate military service. Five (5) of our employees have
been drafted. Three (4) of those employees have since returned from reserve duty, but there can be no guarantee that they will not be
called in again. None of the employees called up holds a key position in our Company. Additional employees may be called up, for service
in the current or future wars or other armed conflicts with Hamas, and such persons may be absent for an extended period of time. As a
result, our operations may be disrupted by such absences, which in turn may materially and adversely affect our business, prospects, financial
condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the attack by Hamas
on Israel, Hezbollah in Lebanon has also launched missile, rocket, and shooting attacks against Israeli military sites, troops, and towns
in northern Israel. In response to these attacks, the Israel Defense Forces has carried out targeted strikes on sites belonging to Hezbollah
in southern Lebanon. It is possible that other terrorist organizations, including Palestinian military organizations in the West Bank,
as well as other hostile countries, such as Iran, will join the hostilities. Such hostilities may include terror and missile attacks.
Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its trading partners could adversely affect
our operations and delay in project timelines. Any armed conflicts or political instability in the region would likely negatively affect
business conditions with respect to fundraising and time to market. As of the date of this annual report, we are not experiencing, and
we do not anticipate any material change in our ability to operate in the field of research and development and our timelines regrading
all of our projects in process remain the same.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
State of Israel and Israeli companies have been the subject of boycotts, divestment and sanctions in the past from state and non-state
actors. These actions could expand in number and scope and may have an adverse impact on our operating results, financial condition or
the expansion of our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Israeli government has pursued extensive changes to Israel&#8217;s judicial system. In response to the foregoing developments, individuals,
organizations and institutions, both within and outside of Israel, have voiced concerns that the proposed changes may negatively impact
the business environment in Israel due in part to the reluctance of foreign investors to invest or transact business in Israel, increased
volatility in foreign exchange rates involving the Israeli new shekel, downgrades in the credit rating of Israel, increased volatility
in securities markets, and other changes in macroeconomic conditions. All of these risks have been compounded by the current war against
Hamas. To the extent that any of these negative developments do occur, they may have an adverse effect on our business, our results of
operations and our ability to raise additional funds, if deemed necessary by our management and board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The termination or reduction of tax and
other incentives that the Israeli government provides to Israeli companies may increase our costs and taxes.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli government currently
provides tax and capital investment incentives to Israeli companies, as well as grant and loan programs relating to research and development
and marketing and export activities. In recent years, the Israeli government has reduced the benefits available under these programs and
the Israeli governmental authorities may in the future further reduce or eliminate the benefits of these programs. We may take advantage
of these benefits and programs in the future; however, there can be no assurance that such benefits and programs will be available to
us. If we qualify for such benefits and programs and fail to meet the conditions thereof, the benefits could be canceled and we could
be required to refund any benefits we might already have enjoyed and become subject to penalties. Additionally, if we qualify for such
benefits and programs and they are subsequently terminated or reduced, it could have an adverse effect on our financial condition and
results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be required to pay monetary remuneration
to our Israeli employees for their inventions, even if the rights to such inventions have been duly assigned to us. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We enter into agreements with
our Israeli employees pursuant to which such individuals agree that any inventions created in the scope of their employment are either
owned exclusively by us or are assigned to us, depending on the jurisdiction, without the employee retaining any rights. A portion of
our intellectual property has been developed by our Israeli employees during their employment for us. Under the Israeli Patent Law, 5727-1967,
or the Patent Law, inventions conceived by an employee during the course of his or her employment and within the scope of said employment
are considered &#8220;service inventions.&#8221; Service inventions belong to the employer by default, absent a specific agreement between
the employee and employer otherwise. The Patent Law also provides that if there is no agreement regarding the remuneration for the service
inventions, even if the ownership rights were assigned to the employer, the Israeli Compensation and Royalties Committee, or the Committee,
a body constituted under the Patent Law, shall determine whether the employee is entitled to remuneration for these inventions. The Committee
has not yet determined the method for calculating this Committee-enforced remuneration. While it has previously been held that an employee
may waive his or her rights to remuneration in writing, orally or by conduct, litigation is pending in the Israeli labor court is questioning
whether such waiver under an employment agreement is enforceable. Although our Israeli employees have agreed that we exclusively own any
rights related to their inventions, we may face claims demanding remuneration in consideration for employees&#8217; service inventions.
As a result, we could be required to pay additional remuneration or royalties to our current and/or former employees, or be forced to
litigate such claims, which could negatively affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>We received Israeli
government grants for certain of our research and development activities, the terms of which may require us to pay royalties and to satisfy
specified conditions in order to manufacture products and transfer technologies outside of Israel. If we fail to satisfy these conditions,
we may be required to pay penalties and refund grants previously received.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
efforts have been financed in part through royalty-bearing and non-royalty-bearing grants in an aggregate amount of $800,000 that we received
from the IIA as of December 31, 2023. In addition, the IIA has approved the grant of an additional $400,000 for the year ended December
31, 2024 which has not yet been received. With respect to the royalty-bearing grants we are committed to pay royalties at a rate of 3%
on sales proceeds from our products up to the total amount of grants received, linked to the U.S. dollar and bearing interest. Until October
25, 2023, the interest was calculated at a rate based on 12-month London Interbank Offered Rate, or LIBOR applicable to US Dollar deposits.
However, on October 25, 2023, the IIA published a directive concerning changes in royalties to address the expiration of the LIBOR. Under
such directive, regarding IIA grants approved by the IIA prior to January 1, 2024 but which are outstanding thereafter, as of January
1, 2024 the annual interest will be calculated at a rate based on 12-month Secured Overnight Financing Rate, the SOFR, or at an alternative
rate published by the Bank of Israel plus 0.71513%; and, for grants approved on or following January 1, 2024 the annual interest will
be the higher of (i) the 12 months SOFR interest rate, plus 1%, or (ii) a fixed annual interest rate of 4%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regardless of any royalty
payment, we are further required to comply with the requirements of the Israeli Encouragement of Industrial Research and Development Law,
5744-1984, as amended, and related regulations, or the Research Law, with respect to those past grants. When a company develops know-how,
technology or products using IIA grants, the terms of these grants and the Research Law restrict the transfer of such know-how, and the
transfer of manufacturing or manufacturing rights of such products, technologies or know-how outside of Israel, without the prior approval
of the IIA. Therefore, the discretionary approval of an IIA committee would be required for any transfer to third parties inside or outside
of Israel of know-how or manufacturing or manufacturing rights related to those aspects of such technologies. We may not receive those
approvals. Furthermore, the IIA may impose certain conditions on any arrangement under which it permits us to transfer technology or development
out of Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to enforce covenants
not-to-compete under current Israeli law that might result in added competition for our products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have non-competition agreements
with all of our employees, all of which are governed by Israeli law. These agreements prohibit our employees from competing with or working
for our competitors, generally during their employment and for up to 12 months after termination of their employment. However, Israeli
courts are reluctant to enforce non-compete undertakings of former employees and tend, if at all, to enforce those provisions for relatively
brief periods of time in restricted geographical areas, and only when the employee has obtained unique value to the employer specific
to that employer&#8217;s business and not just regarding the professional development of the employee. If we are not able to enforce non-compete
covenants, we may be faced with added competition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Provisions of Israeli
law and our amended and restated articles of association may delay, prevent or otherwise impede a merger with, or an acquisition of, us,
which could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Israeli
corporate law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals
for transactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to such types
of transactions. For example, a merger may not be consummated unless at least 50 days have passed from the date on which a merger proposal
is filed by each merging company with the Israel Registrar of Companies and at least 30 days have passed from the date on which the shareholders
of both merging companies have approved the merger. In addition, a majority of each class of securities of the target company must approve
a merger. Moreover, a tender offer for all of a company&#8217;s issued and outstanding shares can only be completed if the acquirer receives
positive responses from the holders of at least 95% of the issued share capital. Completion of the tender offer also requires approval
of a majority of the offerees that do not have a personal interest in the tender offer, unless, following consummation of the tender offer,
the acquirer would hold at least 98% of our outstanding shares. Furthermore, the shareholders, including those who indicated their acceptance
of the tender offer, may, at any time within six months following the completion of the tender offer, claim that the consideration for
the acquisition of the shares does not reflect their fair market value, and petition an Israeli court to alter the consideration for the
acquisition accordingly, unless the acquirer stipulated in its tender offer that a shareholder that accepts the offer may not seek such
appraisal rights, and the acquirer or the company published all required information with respect to the tender offer prior to the tender
offer&#8217;s response date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Furthermore,
Israeli tax considerations may make potential transactions unappealing to us or to our shareholders whose country of residence does not
have a tax treaty with Israel exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share
exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances
but makes the deferral contingent on the fulfillment of a number of conditions, including, in some cases, a holding period of two years
from the date of the transaction during which sales and dispositions of shares of the participating companies are subject to certain restrictions.
Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes
payable even if no disposition of the shares has occurred. These provisions could delay, prevent or impede an acquisition of us or our
merger with another company, even if such an acquisition or merger would be beneficial to us or to our shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>It may be difficult
to enforce a judgment of a U.S. court against us and our executive officers and directors in Israel or the United States, to assert U.S.
securities laws claims in Israel or to serve process on our executive officers and directors and these experts.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
were incorporated in Israel. Substantially all of our executive officers and directors reside outside of the United States, and all of
our assets and most of the assets of these persons are located outside of the United States. Therefore, a judgment obtained against us,
or any of these persons, including a judgment based on the civil liability provisions of the U.S. federal securities laws, may not be
collectible in the United States and may not be enforced by an Israeli court. It also may be difficult for you to effect service of process
on these persons in the United States or to assert U.S. securities law claims in original actions instituted in Israel. Additionally,
it may be difficult for an investor, or any other person or entity, to initiate an action with respect to U.S. securities laws in Israel.
Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most
appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that
Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must
be proven as a fact by expert witnesses, which can be a time consuming and costly process. Certain matters of procedure will also be governed
by Israeli law. There is little binding case law in Israel that addresses the matters described above. As a result of the difficulty associated
with enforcing a judgment against us in Israel, you may not be able to collect any damages awarded by either a U.S. or foreign court.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Your rights and
responsibilities as a shareholder will be governed in key respects by Israeli laws, which differs in some material respects from the rights
and responsibilities of shareholders of U.S. companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
rights and responsibilities of the holders of our securities are governed by our amended and restated articles of association and by Israeli
law. These rights and responsibilities differ in some material respects from the rights and responsibilities of shareholders in U.S. companies.
In particular, a shareholder of an Israeli company has a duty to act in good faith and in a customary manner in exercising its rights
and performing its obligations towards the company and other shareholders, and to refrain from abusing its power in such company, including,
among other things, in voting at a general meeting of shareholders on matters such as amendments to a company&#8217;s amended and restated
articles of association, increases in a company&#8217;s authorized share capital, mergers and acquisitions and related party transactions
requiring shareholder approval, as well as a general duty to refrain from discriminating against other shareholders. In addition, a shareholder
who is aware that it possesses the power to determine the outcome of a vote at a meeting of the shareholders or to appoint or prevent
the appointment of a director or executive officer in the company has a duty of fairness toward the company. There is limited case law
available to assist us in understanding the nature of these duties or the implications of these provisions. These provisions may be interpreted
to impose additional obligations and liabilities on holders of our securities that are not typically imposed on shareholders of U.S. companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 4. <span style="text-transform: uppercase">INFORMATION ON THE
COMPANY</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_013"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt"><b>A.</b></span></td>
    <td><span style="font-size: 10pt"><b>History and Development of the Company.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; ">We
are an Israeli corporation based in Ra&#8217;anana, Israel and were incorporated in Israel in 2018 under the name Clearx Medical Ltd.
On April 10, 2018, our name was changed to Insense Medical Ltd. and on July 30, 2020, our name was changed to our current name, Inspira
Technologies Oxy B.H.N. Ltd. On July 16, 2021, our Ordinary Shares and the warrants issued in our initial public offering began trading
on Nasdaq under the symbols &#8220;IINN&#8221; and &#8220;IINNW&#8221;, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; ">Our
principal executive offices are located at 2 Ha-Tidhar St., Ra&#8217;anana, 4366504 Israel. Our telephone number in Israel is 972 996
644 88. Our website address is <i>www.inspira-technologies.com</i>. The information contained on our website or available through our
website is not incorporated by reference into and should not be considered a part of this annual report on Form 20-F, and the reference
to our website in this annual report on Form 20-F is an inactive textual reference only. Puglisi &amp; Associates is our agent in the
United States, and its address is 850 Library Avenue, Suite 204, Newark, Delaware 19711.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an &#8220;emerging
growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act of 1933, as amended, or the Securities Act, as modified by
the JOBS Act. As such, we are eligible to, and intend to, take advantage of certain exemptions from various reporting requirements applicable
to other public companies that are not &#8220;emerging growth companies&#8221; such as not being required to comply with the auditor attestation
requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act. We could remain an &#8220;emerging growth
company&#8221; for up to five years, or until the earliest of (a)&#160;the last day of the first fiscal year in which our annual gross
revenues exceeds $1.235&#160;billion, (b)&#160;the date that we become a &#8220;large accelerated filer&#8221; as defined in Rule&#160;12b-2
under the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur if the market value of our Ordinary
Shares that are held by non-affiliates exceeds $700&#160;million as of the last business day of our most recently completed second fiscal
quarter, or (c)&#160;the date on which we have issued more than $1&#160;billion in nonconvertible debt during the preceding three-year
period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a foreign private issuer
as defined by the rules under the Securities Act and the Exchange Act. Our status as a foreign private issuer also exempts us from compliance
with certain laws and regulations of the SEC and certain regulations of the Nasdaq Stock Market, including the proxy rules, the short-swing
profits recapture rules, and certain governance requirements such as independent director oversight of the nomination of directors and
executive compensation. In addition, we are not required to file annual, quarterly and current reports and financial statements with the
SEC as frequently or as promptly as U.S. domestic companies registered under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2023, 2022, and 2021 our
capital expenditures were $206,000, $263,000, and $182,000, respectively. Our current capital expenditures are primarily for computers,
research and development equipment and office improvements substantially all in Israel, and we expect to finance these expenditures primarily
from cash on hand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><div><a id="a_014"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt"><b>B.</b></span></td>
    <td><span style="font-size: 10pt"><b>Business Overview.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a specialty medical
device company engaged in the research, development, manufacturing, and marketing of proprietary life support technologies. Our technology&#8217;s
target is to supersede mechanical ventilators and revolutionize the global mechanical ventilator market estimated to grow to $19 billion
dollars by 2030.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our vision is to transform
external breathing assistance for the 20 million patients each year that require ventilation and oxygenation via external Mechanical Ventilation
machinery. Legacy systems for breathing assistance can cause multiple complications that can extend length of hospital stays and costs.
Patients are often put on Mechanical Ventilators when they cannot breathe for themselves and require assisted breathing using a machine.
Patients are placed under heavy sedation (or Coma) with a tube pushed down their throat, The ventilator forces oxygen-rich air into the
lungs to get oxygen into the lungs and other organs. Patients can often experience legacy complications, including delirium, lung infections,
lung injury, or possible death. Although it may sometimes be lifesaving, Mechanical Ventilation is associated with increased risks, costs
of care, extended lengths of stay, frequent incidence of infections, ventilator dependence and mortality rates as high as 50%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our intuitive technology is
designed to treat patients while they are awake or in relatively light states of sedation. As opposed to intubation and coma used in Mechanical
Ventilation, we target oxygen delivery straight into the patient&#8217;s blood to allow for oxygen to reach the body organs. In doing
so, our technology bypasses the sick lungs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_002.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b>Adaptive Blood Oxygenation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_003.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The INSPIRA ART (Gen 2) device is an
adaptive technology, designed to empower breathing in patients that are awake, by continuously measuring the patient&#8217;s blood parameters
in real-time, delivering needed oxygen volume straight into the blood. As the INSPIRA ART is to be equipped with the HYLA blood sensor,
it is being designed to continuously scan the patient&#8217;s blood, potentially allowing for real-time detection of changes in patient condition
and providing physicians with decision-supportive data.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to achieve this target,
we are developing the following core technologies:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><b>HYLA&#8482; Blood Sensor</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Our technology is designed to continuously
measure specific patient&#8217;s blood parameters in real-time, a significant advancement in our sensor technology. This breakthrough
in achieving 95% accuracy compared to standard blood gas analyzers allows for continuous and real-time blood monitoring capabilities,
as compared to traditional blood gas analyzer systems used in hospitals that typically require intermittent blood draws. This advancement
signals our potential entry into the disposables market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The development of the first HYLA&#8482;
variant, which is key to this advancement, marks a significant step towards its submission under a 510(k) pathway with the FDA, which
is expected in the second half of 2024. This sensor technology (in the form of the HYLA 1) is designed to be integrated with our INSPIRA
ART100 Cardio-pulmonary Bypass, a blood oxygenation device submitted to the FDA in September 2023, with clearance anticipated in the first
half of 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The HYLA&#8482; Blood Sensor line, the
HYLA or the Blood Sensor, is set to transform intensive care unit, or ICU, operations, offering continuous, real-time blood data collection
and analysis. This enhances patient care with critical insights and alerts, with the aim to improve medical procedures and device efficiency.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b>Key features of the HYLA Blood Sensor include:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">High Accuracy: Achieves 95% accuracy relative to standard
blood gas analyzers;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Non-invasive: Eliminates the need for blood draws;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Durability: Built to handle ICU and operating room environments;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="font-size: 10pt; text-align: justify">Versatility: Compatible with various medical procedures, including: the cardiopulmonary bypass, extracorporeal membrane oxygenation, continuous renal replacement therapy, and dialysis; and</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Modular Design: Engineered to complement existing medical devices, targeting the two-million annual open-heart
surgery patients globally.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In developing the Blood Sensor line,
we utilize in-house lab testing as well as hospital collaborations for the purpose of clinical research and development. This approach
has enabled us to define the Blood Sensor&#8217;s disposable materials and methods, with HYLA&#8217;s planned razor blade business model. While primarily
designed for INSPIRA ART devices, plans are underway also to offer a variant of the Blood Sensor as a standalone device.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><b>VORTX&#8482; Orbiting Blood Oxygenation Delivery System</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Our core technology has received the
first ever U.S. patent approval for an orbiting blood oxygenation delivery system, a core technology of the revolutionary INSPIRA&#8482;
ART (gen 2) device. This innovation has 16 claims found to be novel. The orbiting blood oxygenation delivery system, or VORTX&#8482;,
is designed to oxygenate blood without fiber membranes, and we believe it will revolutionize the medical landscape. The current fiber
technologies used for blood oxygenation causes substantial damage to the patient&#8217;s blood cells. Unlike the natural laminar blood flow
in blood vessels inside the body, in existing fiber oxygenators, the blood is &#8220;forced&#8221; to flow in a harmful turbulent flow through
many layers of fibers while experiencing friction and shear forces within the fiber walls. Since the fiber fabric is a significant resistor
to blood flow, high-pressure differences are formed and cause significant damage to the various blood components, including, high hemolysis
(breakdown of red cells), damage to white blood cells, activation of the inflammatory system in the body, activation of the immune system,
and blood clotting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">We believe that the orbiting blood oxygenation delivery system
is another potentially game-changing core technology of the INSPIRA ART (Gen 2) device, in targeting the $19 billion Mechanical Ventilation
market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>We Aim to Prevent Mechanical Ventilation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b><img alt="" src="image_004.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>Patient treated awake and without
Mechanical Ventilation </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">No Coma; No Tube in throat; Potentially
reduces hospital days</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>Oxygen is delivered straight into
the blood, with carbon dioxide removed</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">No lung infection; No lung injury</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>Blood parameters measured continuously
and in real-time</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Early detection of changes;
Provides decision-making assistance data</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>And aiming much higher&#8230;.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_005.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>We believe our devices will revolutionize the medical landscape.
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><b>INSPIRA ART100 (Gen 1) Device</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">We submitted our INSPIRA ART100, a
cardio-pulmonary bypass device, to the FDA via the 510(k) pathway, in 2023 with potential clearance expected during the first half of
2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_006.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding-right: 3pt; width: 48%; border: black 1pt solid; padding-left: 3pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Gen 1</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>Blood Oxygenation</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(Cardio-Pulmonary Bypass)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">HYLA-1&#8482; Blood Sensor 2025</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">(Integrated with INSPIRA ART100)</p></td>
    <td style="padding-right: 3pt; width: 52%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 3pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Gen 2 </b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Adaptive Blood Oxygenation</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">VORTX&#8482; Orbiting Blood Oxygenation</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">HYLA-2&#8482; Blood Sensor</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#9675;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Continuous
    blood monitoring</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#9675;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Real-time
    detection of changes</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#9675;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Provides
    decision-making assistance data</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_007.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><b>Disposables</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">We are also progressing in our plan
to launch single-use disposables to be used during the blood oxygenation procedure, currently in development, for our INSPIRA ART medical
devices. The disposables are intended to be compatible with various other life support machines, tapping into the disposable perfusion
systems market. The disposables, anticipated to be submitted for FDA authorization in 2025, are a single-use product designed to be used
for efficient blood oxygenation and carbon dioxide removal. The disposables have the potential to become a recurring revenue model. We
are focusing on making the disposables compatible with other medical devices such as certain types of cardio-pulmonary bypass machines.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">The Gap</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
strategic objective is to create and lead the early blood oxygenation market as a new treatment option that bridges the current treatment
gap between non-invasive measures (such as oxygen masks, bilevel positive airway pressure, or BiPap, continuous positive airway pressure,
or CPAP, and high-flow nasal cannulas) and Mechanical Ventilation. Multiple growth drivers, such as the potential for INSPIRA ART (Gen
2) to increase accessibility to treating millions of patients in small urban and rural hospitals, general medical units, and emergency
rooms units by unlocking the dependency on Mechanical Ventilation and ICUs. as we expect for patients to be treated while awake as opposed
to being in a state of coma. Millions of patients are placed on Mechanical Ventilation annually, and, therefore, we believe that the INSPIRA
ART (Gen 2) has a potential total addressable market of several billion dollars, based on a targeted patient treatment cost of a few thousand
dollars for each disposable life support unit sold, multiplied by the number of patients on Mechanical Ventilation annually (approximate
patient population with respiratory failure and acute exacerbation of chronic lung disease). The market size and cost assumptions may
be impacted by recurring revenue and high volume, mass production and sale of the disposable life support unit, without including the
base revenue derived from the INSPIRA ART (Gen 2) device itself.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">Need for INSPIRA ART (Gen 2)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Conditions
leading to respiratory insufficiency (a condition in which the lungs cannot perform sufficient gas exchange to support the body&#8217;s
metabolism) and respiratory failure happen quickly and are initially hard to observe. These conditions are often caused by a disease or
injury that affects breathing, such as pneumonia. Acute respiratory failure requires emergency treatment and is among the leading causes
of death globally.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In a report published in 2017,
the World Health Organization, or WHO, estimates that over 400 million people globally are affected by respiratory insufficiency. Each
year, an estimated 20 million people worldwide receive Mechanical Ventilation, which is primarily attributed to acute respiratory failure
(69%) and chronic lung disease (10%). In a 2017 report in the Forum of International Respiratory Societies, the global respiratory care
devices market size was estimated to reach approximately $29.86 billion by 2025. The major factors influencing this growth include the
high prevalence of respiratory diseases, the rapid growth of the aging population, the high prevalence of smoking, rising urbanization
and pollution levels and western lifestyle changes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The COVID-19 pandemic further
exposed the weaknesses and disadvantages of Mechanical Ventilation, which has both a high association with considerable medical risks
and iatrogenic complications that further burdens the healthcare system with long hospital stays and high costs of treatment. COVID-19
has seen the failure of some of the most advanced healthcare systems worldwide in their ability to respond flexibly, quickly and at scale
to rapid growth in demand for life support. COVID-19 led to a rise in the number of intensive care unit, or ICU, admissions worldwide
of patients suffering from respiratory failure and requiring life support solutions, such as Mechanical Ventilation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>INSPIRA ART - Redefining Artificial Respiration</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our vision is to supersede
mechanical ventilators with technologies designed to treat patients while awake and deliver oxygen straight into the blood so that it
can reach the body&#8217;s organs. Therefore, we have developed the INSPIRA Augmented Respiration Technology Device, or the INSPIRA ART
(Gen 2), designed to perform Adaptive Blood Oxygenation by continuously measuring the patient&#8217;s blood parameters in real-time, delivering
needed oxygen volume straight into the blood. The Adaptive Blood Oxygenation is designed to utilize both our HYLA Blood Sensor Technology
and VORTX&#8217;s Orbiting Blood Oxygenation Delivery System. Our devices utilizes a minimally invasive and U.S. patented dual lumen cannula
which is inserted into the jugular vein (in the patients neck) to withdraw and circulate the required volumes of the patient&#8217;s blood
with low oxygen levels through our device. As the INSPIRA ART(Gen 2) device is an intuitive technology designed to empower breathing in
patients that are awake, by continuously measuring the patient&#8217;s blood parameters in real-time, and delivering needed oxygen volume straight
into the blood. The oxygen enriched blood is circulated back to the patient through the same dual lumen canula to elevate and stabilize
oxygen saturation levels within minutes. The INSPIRA ART(Gen 2) will be equipped with the Blood Sensor and is being designed to continuously
scan the patient&#8217;s blood, potentially allowing for real-time detection of changes in patient condition and providing physicians with decision-supportive
data. The INSPIRA ART&#8217;s structure provides the potential to extend respiratory treatment beyond ICU environments making acute respiratory
treatment available in regions and medical facilities without the need for ICUs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Using the INSPIRA ART (Gen
2), patients can experience relief within a few minutes of treatment. The INSPIRA ART will enable patients to be treated while awake,
mobile and breathing spontaneously, therefore also potentially reducing the need or time of weaning. Accordingly, our INSPIRA ART device
has the potential to reduce patients&#8217; length of stay and costs in the ICU, rehabilitation period in the hospital, and re-admissions
as compared to Mechanical Ventilation. The INSPIRA ART device has yet to be tested in humans and, as such, these claims of a potential
advantage in humans are unproven and speculative.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
completed and tested the first lab unit of our INSPIRA ART in 2020. Throughout 2020, approximately 40 pre-clinical in-vivo feasibility
testing within a series of studies were performed in conjunction with our team and headed by the veterinary team at LAHAV CRO in Israel
to examine the feasibility of direct blood oxygenation to preempt the need for Mechanical Ventilation. The main goal of these studies
was to use our INSPIRA ART and show temporary increase of oxygen gas exchange during respiratory failure by transferring clinically significant
amounts of oxygen to the venous blood, while simultaneously extracting quantities of carbon dioxide. To date, the INSPIRA ART has not
been tested on humans and any future testing on humans will be subject to the request of the appropriate regulators, including the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
are also progressing several partnering opportunities for the manufacturing of key technological components of the INSPIRA ART (Gen 2)
and INSPIRA ART100 (Gen 1) devices. In December 2022, we announced the signing of an Original Equipment Manufacturing, or OEM, agreement
with Terumo Cardiovascular, a division of the leading global medical device company, Terumo Corporation. Terumo Corporation operates in
over 160 countries and regions around the world, providing patients in a variety of medical settings with over 50,000 products and services.
Terumo Cardiovascular are experts in the field of oxygenation systems, heart-lung machines and monitoring systems. The agreement provides
for the manufacture of a flow mechanism that is intended to be integrated into our products for use in the extracorporeal circulation
of the blood during the oxygenation process. Per the agreement, we will be responsible for obtaining and maintaining approval to market
and distribute the flow mechanism component. The agreement is set for a term of three years from its effective date and, unless terminated
earlier for cause or upon 120 days&#8217; written notice, renews thereafter for an additional period of time as mutually agreed by the
parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Clinical Studies and Expected Regulatory Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Based
on our regulatory strategy, for the key component sources we intend to pursue a Class II 510(k) pathway based on the assumption that we
do not currently expect to require human trials for FDA clearance. We are taking a multi-step approach to the regulatory clearance process.
In January 2022, we listed a component of our INSPIRA ART device (Gen 2) and INSPIRA ART100 (Gen 1) device on the FDA Class I 510(k) exempt
list. The component is intended to reduce the potential complications associated with jugular vein cannula movement, occurring during
a change of a patient&#8217;s posture in bed and/or during transportation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
development of the INSPRIA ART&#8217;s proprietary non-invasive blood sensors using optical technology and machine learning (ML) based
algorithms advanced during 2023. We identified the technology as an opportunity to also develop as a stand-alone product (the HYLA blood
Sensor), with a clinical commenced in the first quarter of 2023 at Sheba Medical Center. The data collection Clinical Study at Sheba Medical
Center on up to 100 patients undergoing open-heart surgery is designed to integrate clinical research into the product development cycle.
We are performing Verification and Validation (V&amp;V) testing prior to FDA submission via the 510(k) pathway, which is expected to occur
in the first half of 2024. Following FDA clearance, initial market penetration and adoption is expected to occur during 2025, alongside
the receipt of initial sales orders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2023, we announced
the first in-human of a patient undergoing open-heart surgery in the HYLA research clinical study <span style="text-decoration:underline">at Sheba Medical Center in Israel.
</span>The HYLA research clinical study is a first in human study designed to compare parameters measured by the non-invasive HYLA sensor
to a standard blood gas analyzer that requires blood draw from the patient. The prospective data collection will further support the final
product design.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
July 2023, we announced that we received&#160;International Organization for Standardization (ISO) 13485:2016 Standard Certification,
which is the international standard for quality management systems within the medical device industry, and a requirement for EU regulatory
approval. The ISO certification encompasses key aspects, including design, development, manufacturing, distribution and sales of extracorporeal
and blood monitoring devices and respiratory care devices. The ISO certification process also involved a comprehensive evaluation of the
Company&#8217;s quality management system, including documentation, risk management and continuous improvement practices. The assessment
was conducted by the British Standards Institution Group, an independent, third-party auditing firm specializing in medical device quality
management systems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2023, we submitted
the INSPIRA ART100&#160;to the FDA via the 510(k) pathway, with potential clearance expected during the first half of 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Any
modification that could significantly affect its safety or effectiveness, or that would constitute a major change or modification in its
intended use, will require a new 510(k), de novo or PMA. We are planning to apply for the break-through device designation with the FDA
for the INSPIRA ART (Gen 2)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;The
INSPIRA ART100, subject to regulatory approvals, is intended to be a commercial cardio-pulmonary bypass support device. When and if we
receive the necessary regulatory approvals, we plan to deploy the first INSPIRA ART100 in ICUs. We expect to commercially launch our INSPIRA
ART100 in the United States, subject to the receipt of the FDA clearance, and in Israel following the receipt of the AMAR approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Milestones Achieved in 2023 include:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Received approval from Sheba Medical Center to conduct clinical study of the HYLA<sup>TM</sup>&#160;Blood Sensor.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Announced First-In-Human of HYLA<sup>TM</sup>&#160;Blood Sensor in clinical study.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Announced the development of VORTX<sup>TM</sup> Blood Oxygenator, a Unique Technology for Saturating Blood with Oxygen and Removing Carbon Dioxide.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Presented the New INSPIRA ART100&#8482; Device at the World&#8217;s Largest Extracorporeal Life Support Conference.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Entered into a collaboration agreement with Perfusion Solution Inc., a U.S. based company that provides a platform of advanced medical devices, training and staffing to leading U.S. hospitals.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Received Certification of Medical Devices Quality Management Systems.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Completed INSPIRA ART100 Independent Usability Study in Boston Massachusetts.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Entered into an agreement with Innovimed for the expansion of clinical trials of INSPIRA&#8482; ART respiratory medical devices, to any European country.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Submitted the&#160;INSPIRA ART 100, to the FDA for clearance via the 510(k) pathway, which we expect to receive during the first half of 2024.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Unveiled the INSPIRA&#8482; ART Line of Medical Devices at the World&#8217;s Largest Extracorporeal Life Support Conference.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Entered into a distribution agreement with CIO MED GROUP, a technology and medical devices distributor in Central America.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Received a U.S Patent for INSPIRA&#8482; ART 500 Medical Device.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Received a grant from the Israeli Innovation Authority (IIA) for the VORTX&#8482; Disposable Blood Oxygenation Technology.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Entered into a collaboration agreement with Ennocure MedTech Ltd., or Ennocure, for development of proprietary bio-electronic treatment to prevent associated bloodstream infections in ICU patients.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Appointed Dr. Dan Gorfil to our Medical Advisory Board.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Achieved a <span>significant milestone in the Company&#8217;s sensor technology by our team of experts - 95% Accuracy Results for HYLA&#8482; Blood Sensor. The development of the first&#160;HYLA<sup>TM&#160;</sup>variant, key to this advancement, marks a significant step towards its submission under a 510(k) pathway with the FDA.&#160;</span></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While the Company intends
to execute on strategic distribution agreements, there is no guarantee any sales will occur pursuant to those existing agreements, and
agreements that may be executed in the future. The pre-conditional distribution agreements are for a period of up to seven years and subject
to completion of development, and the required regulatory approvals or clearances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Targeted Milestones (2024-2025):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.9pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are planning to advance
our pipeline of products over the next two years, with a clear strategy towards FDA regulatory approvals and initial market penetration
and adoption.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.9pt"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.9pt">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b>Milestones achieved in
the first quarter of 2024 include:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Entered into a strategic agreement with Glo-Med to deploy
531 INSPIRA ART devices in Saudi Arabia, United Arab Emirates and Bahrain.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Announced our plans to launch and target single-use disposable
blood oxygenator kits to exploit a new disposable perfusion market opportunity.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Entered into <span>a non-binding
Letter of Intent with Shamir Medical Center (Assaf Harofeh), a renowned healthcare institution in central Israel, which solidifies the
mutual commitment of both parties to assess the integration and performance of the INSPIRA&#8482; ART100 device within Shamir Medical
Center&#8217;s clinical environment.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Received a U.S. Patent approval for an orbiting blood oxygenation
delivery system, a core technology of the revolutionary INSPIRA&#8482; ART500 device.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Announced a new platform for bio-mimicking blood parameters
for development and testing of core technologies, including the development of the HYLA Blood Sensor and VORTX Orbiting blood oxygenation
delivery system, which are the core technologies of the Inspira ART500.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Progressed towards 510(k) clearance from the FDA for the INSPIRA&#8482;&#160;ART100
in the first half of 2024 and received approval from the United States Patent and Trademark Office for three patents have been approved
and an additional three patent applications are pending at the USPTO for certain core technologies.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Announced a core blood oxygenation technology of the INSPIRA
ART (Gen 2), which is designed to utilize adaptive oxygenation technology, leveraging the proprietary HYLA&#8482; blood Sensor and VORTX&#8482;
Orbiting Blood Oxygenation, to delivery oxygen straight into the blood.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Announced that U.S. patent backed technology, the orbiting
blood oxygenation technology (VORTX&#8482;), has met 100% of regulatory guideline requirements for blood oxygenation and carbon dioxide
removal, at various blood flow rates with the pressure gradient on the blood across the device remaining at zero level.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 17, 2024 we submitted
the INSPIRA ART100 (Gen 1) device to the Medical Device Division of the Israeli Ministry of Health, or AMAR for approval, in order to
launch devices in some of the leading hospitals in Israel. AMAR approval generally takes around 120 working days to obtain, and clinical
data may be required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the first half of 2024,
we anticipate the FDA 510(k) clearance for our INSPIRA ART100, Cardio-pulmonary bypass device. Once cleared we will work towards deploying
the device in medical centers for the purpose market penetration that may lead to eventual revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In late 2024, we plan to submit
the initial version of the HYLA Blood Sensor (HYLA 1) for what we believe may be a submission for a 510(k) clearance. The timeline and
regulatory pathway may be subject to change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2025 we plan to submit
&#8216;disposable components to be used with the INSPIRA ART100 for FDA (510k) clearance. The timeline and regulatory pathway may be subject
to change. We believe that the potential future clearance of the disposables, will expand the company&#8217;s potential offering to generate
revenue through the sales of disposables as part of the company&#8217;s plans to achieve a razor-razor blade business model.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Industry Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Overview of Respiratory Failure </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Respiratory failure is a condition
in which the blood either does not have enough oxygen, has too much carbon dioxide, or both. During inhalation, the lungs take in oxygen.
The oxygen passes into blood via the lungs, which carries it to the body&#8217;s organs that need oxygen to function. Carbon dioxide is
removed from the blood during exhaling. An excess of carbon dioxide in blood can harm the body&#8217;s organs. Inadequate gas exchange
during breathing can lead to respiratory insufficiency, which may lead to hypoxemia and hypercarbia, which are potentially life-threatening
conditions. Diseases that affect breathing, such as chronic obstructive pulmonary disease, or COPD, and various conditions that affect
nerves and muscles controlling breathing, can cause respiratory failure. Respiratory failure is the acute condition of respiratory insufficiency
and is classified as either Type I (involves low oxygen blood levels, and normal or low carbon dioxide levels) or Type II (involves low
oxygen blood levels, with high carbon dioxide levels). According to an article from 2020 by the Office of Disease Prevention and Health
Promotion, titled &#8220;Respiratory Diseases,&#8221; currently approximately 15 million American adults have been diagnosed with COPD
and it is believed that millions more suffer from COPD but have not been diagnosed and are not being treated. COPD is the fourth leading
cause of death in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The Key Problems the INSPIRA ART (Gen 2) device plans to solve in
relation to the risks and complications related to Mechanical Ventilation </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 15%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify; width: 40%"><span style="font-size: 10pt"><b>Invasive Mechanical Ventilation </b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify; width: 41%"><span style="font-size: 10pt"><b>INSPIRA ART </b>(Gen 2)</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Procedure </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Invasive mechanical ventilation is defined as the delivery of positive pressure to the lungs via an endotracheal or tracheostomy tube. During mechanical ventilation, sedation and analgesia are required.</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Patient can remain awake and breathe spontaneously while a minimally invasive cannula is inserted into the patient&#8217;s jugular vein for the purpose of extracorporeal oxygenation and carbon dioxide removal.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Induced Coma </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Medically inducing a patient into a coma requires sedation and analgesia to enable intubation for the delivery of oxygen using positive pressure into the lungs.</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patients are awake and spontaneously breathing
    (No induced coma):</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.7pt; text-align: justify; text-indent: -0.25in">&#9679; Delirium
    can be prevented</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.7pt; text-align: justify; text-indent: -0.25in">&#9679; Muscle
    loss can be prevented</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.7pt; text-align: justify; text-indent: -0.25in">&#9679; Patient
    can eat and drink</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.7pt; text-align: justify; text-indent: -0.25in">&#9679; Patient
    can communicate their symptoms and needs to the medical staff</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.7pt; text-align: justify; text-indent: -0.25in">&#9679; Patient
    can communicate with family and friends&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Complications &amp; Mortality Rate </span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#9679; Increased
    mortality</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#9679; Prolonged
    duration of ventilation</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#9679; Ventilator-induced
    lung injury (VILI)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#9679; Ventilator-associated
    pneumonia (VAP)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#9679; Ventilator-induced
    diaphragmatic dysfunction</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#9679; Pneumothorax
    &amp; tracheomalacia</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#9679; Delirium</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#9679; Muscular
    atrophy</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#9679; Inability
    to wean patient from ventilator</p></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bypassing lungs may improve patient outcomes &amp;
    is expected to potentially reduce iatrogenic complications:</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.7pt; text-align: justify; text-indent: -0.25in">&#9679; Reduced
    Ventilator -Induced lung Injury</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.7pt; text-align: justify; text-indent: -0.25in">&#9679; Reduced
    ventilator-induced diaphragmatic dysfunction</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.7pt; text-align: justify; text-indent: -0.25in">&#9679; Reduced
    Ventilator Associated Pneumonia (affecting 5-40% of patients receiving Mechanical Ventilation for more than two days)</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Hospital Days </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">May require prolonged hospital stays resulting from invasive mechanical ventilation complications. </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Hospital stays are expected to be reduced as a result of Mechanical Ventilation avoidance. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Weaning </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Patients have to be weaned off Mechanical Ventilation, extending ICU stay. </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">No need for weaning off the ventilator. This may contribute to reducing ICU and hospital stays. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Re-admissions </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">A 40% re-admission rate with patients eventually dying due to the consequences of prolonged Mechanical Ventilation. </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Shorter treatment times will potentially reduce complications and improve patient outcomes, reducing re-admissions. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Location </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Can only be administered in an ICU setting </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Applicable in ICU and might also be utilized in non-ICU settings (Including Ambulatory) </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Staff </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Requires highly specialized medical staff only available in ICU </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Might be used by less qualified medical staff. Minimizes need for a perfusionist</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>Table 1: Comparison of Mechanical Ventilation
to our INSPIRA ART</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although our INSPIRA ART (Gen
2) remains in development, has not been tested in humans, and is not cleared or approved by the FDA or similar foreign regulatory bodies,
we believe that our INSPIRA ART (Gen 2) device has competitive advantages over FDA-approved treatments because our INSPIRA ART (Gen 2)
presents a change to existing solutions, which have significant health risks, which are discussed in detail below. While any potential
benefits of our INSPIRA ART (Gen 2) device as compared to Mechanical Ventilation have yet to be observed in human trials, our INSPIRA
ART (Gen 2) is designed to provide a less invasive and traumatic alternative to Mechanical Ventilation, which requires patients to undergo
intrusive intubation and medically induced coma, and often adds complications to already diseased lungs. Unlike Mechanical Ventilation,
our INSPIRA ART (Gen 2) does not require intrusive intubation and inducing a patient into a medical coma, which means that the patient
can be treated while staying awake, mobile and breathing spontaneously. Moreover, we believe our INSPIRA ART (Gen 2) is a device with
multiple potential modalities because it can potentially be used independently in ICUs and general medical units and in combination with
Mechanical Ventilation in ICUs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently available solutions
used to provide respiratory support include oxygen masks and BiPap masks for mild to moderate cases of respiratory insufficiency, and
Mechanical Ventilation in more severe cases of respiratory failure, when other, less invasive methods cannot provide a satisfactory solution.
Mechanical Ventilation performs the work of breathing by providing air to the patient based on controlled pressure, flow and volume. According
to an article from 2016 by RT Magazine, titled &#8220;Managing the Patient on Mechanical Ventilation,&#8221; Mechanical Ventilation is
one of the most common interventions used in the ICUs, with more than half of the patients being placed on invasive mechanical ventilators
within the first 24 hours of their admission to the ICU.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Decisions about the initiation
and timing of invasive mechanical ventilation can be difficult and early discussion with critical care doctors is essential. Appropriateness
of ventilatory support may also be an issue requiring advanced discussion with patients and families. Once a decision to intubate has
been made, the transition from an awake and self-ventilating patient to controlled invasive ventilation can be very difficult in the critically
ill. Most patients will have evidence of developing or established organ dysfunction, particularly cardiovascular dysfunction (ischaemic
heart disease, sepsis), and commonly such patients are hypovolaemic. Both anesthetic induction agents and positive pressure ventilation,
which decreases venous return, produce cardiovascular depression and peri-intubation hypotension is common. In addition, cessation of
spontaneous ventilation can lead to very rapid desaturation in such patients, due to their marginal respiratory reserve and circulatory
problems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are several types of
approaches for Mechanical Ventilation: laryngeal mask airway, or LMA, standard endotracheal tube, or ET, tracheostomy and extracorporeal
membrane oxygenation, or ECMO. During the process for ECMO, large cannulas are used that require fluoroscopy, an imaging technique, for
initial positioning of the cannula, as this is a dangerous process that needs to be done very accurately. Also, Mechanical Ventilation
may lead to life threatening complications, including ventilator-induced lung injury, or VILI, ventilator associated pneumonia, or VAP,
pneumothorax and tracheomalacia. Patients are also predisposed to develop extrapulmonary complications, such as pressure sores and muscular
atrophy. When a patient is put on Mechanical Ventilation, the patient is given tranquilizers and sedatives to lower the discomfort associated
with non-physiological positive-pressure ventilation. Tranquilizers and sedatives prevent the patient from coughing, eliminating secretion
or the ability to communicate with his family. Once the individual no longer requires Mechanical Ventilation support, they are gradually
weaned from the ventilator. They must have adequate oxygenation, carbon dioxide elimination, respiratory muscle strength and reserve the
ability to protect their airway. Unfortunately, since respiratory muscles atrophy during the ventilation process, returning to normal
is quite difficult.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">VILI can result in pulmonary
edema, barotrauma and worsening hypoxemia that itself can prolong Mechanical Ventilation and lead to multi-system organ dysfunction, thus,
increasing chances of mortality. Alveolar overdistension, atelectrauma and biotrauma are the principal mechanisms of VILI. Alveolar injury
results in high alveolar permeability, interstitial and alveolar edema, alveolar hemorrhage, hyaline membranes, loss of functional surfactant
and alveolar collapse. Thus, adopting a ventilator strategy that reduces VILI is an important goal in ventilatory management. VAP, a type
of hospital acquired pneumonia which is also a common and serious problem in the ICUs, develops more than 48 hours after endotracheal
intubation. VAP is associated with an increased risk of death. All-cause mortality associated with VAP has ranged from 20 to 50% in different
studies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An enhanced awareness of the
complex and heterogeneous pulmonary pathophysiology of the various lung syndromes has illuminated the shortcomings of conventional Mechanical
Ventilation. In the United States alone, approximately 40% of the 5.7 million patients admitted annually to ICUs are placed on Mechanical
Ventilation; up to 70% of these patients end up dying either from the underlying disorder or from complications stemming from Mechanical
Ventilation. With a growing elderly population and more people being exposed to smoking and pollution, the population requiring Mechanical
Ventilation support is growing rapidly. Given this situation, attention has been focused on novel supportive measures for managing acute
pulmonary failure, which would not have the shortcomings of already available techniques described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ECMO is a technique used for
gas exchange in patients who are refractory to ventilator support, when lung function can be only maintained at the expense of further
structural lung damage or severe hemodynamic compromise. The guidelines for considering ECMO include hypoxic respiratory failure due to
any cause (primary or secondary), when the mortality risk is above 50%. The utilization of ECMO is limited by technical complexity, as
demonstrated below in Figure 4, resource implications and associated complications which include hemolysis, blood-borne infections, air-embolism,
blood loss, and others. Moreover, an ongoing effort is aimed towards determining which patients will obtain the largest outcome benefit
from ECMO, as some studies demonstrated Mechanical Ventilation-equivocal results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Respiratory failure and the
use of currently available solutions to provide patients with respiratory support are also associated with increased costs of care and
extended lengths of stay. In the United States, COPD alone results in 1.5 million emergency department visits, and 726,000 hospitalizations
each year. The Centers for Disease Control and Prevention reports annual financial cost of COPD to be $29.5 billion in direct healthcare
medical expenditures and roughly $20 billion in indirect morbidity/mortality costs in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_008.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>Figure 4: a patient connected to an ECMO device.
Source: clevelandclinic.org.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to an article published
in June 2020 by MarketWatch, total hospital stay costs for a patient admitted to ICU may reach hundreds of thousands U.S. dollars, especially
if infection is suspected. The daily direct cost of treatment for Mechanical Ventilation is $1,500 in ICU. For each mechanically ventilated
patient, additional time is required for weaning off the device, thus, incurring even more hospital resources and costs. Additionally,
Mechanical Ventilation patients are commonly subject to complications due to exposure to infections, such as VAP, with 8% to 28% of ICU
patients requiring an additional several days of treatment until healed by antibiotics, and mortality rates may reach 33% to 50%. Current
Mechanical Ventilation treatments require medical specialists and a team of nurses. The longer a person remains in the ICU, the higher
the probability that person will require prolonged ventilation, which in turn exposes the patients to further ventilation-associated complications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our INSPIRA ART (Gen 2) life Support Solution</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our lead product, the INSPIRA
ART (Gen 2) device, is a revolutionary form of life support designed to provide Adaptive Blood Oxygenation continuously measure the patient&#8217;s
blood parameters at real-time, delivering needed oxygen volume straight into the to elevate and stabilize declining oxygen saturation
levels while the patient remains awake, mobile, and breathing spontaneously with their compromised lungs. The INSPIRA ART is designed
to assure the patient&#8217;s body and vital organs receive the necessary amount of oxygen. We designed our INSPIRA ART (Gen 2) device
as a low cost, high volume solution for critical care patients requiring advanced respiratory support. It is intended to provide an alternative
to Mechanical Ventilation, so that patients with respiratory failure will be able to recover from their lung condition without being subjected
to the risk of developing the various common complications brought on by intubation and Mechanical Ventilation. Our goal is to support
healthcare systems by providing a practical and portable solution facilitating the treatment of respiratory failure, without the need
for Mechanical Ventilation, and with the ability to deploy INSPIRA ART (Gen 2) devices in and outside of ICUs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The INSPIRA ART (Gen 2) is
designed to utilize Adaptive Blood Oxygenation Technology continuously measure the patient&#8217;s blood parameters in real-time, delivering
needed oxygen volume straight into the blood, and works in tandem with the underperforming lung, supporting the patients while they are
being treated for their underlying medical condition. We believe this unique approach minimizes or prevents mechanical ventilator associated
complications and allows the lungs to rehabilitate as the patient is kept awake and relatively free of sedatives. Further, the technology
is highly applicable in a variety of settings, which makes it highly accessible, extending acute respiratory care that is currently limited
to the ICU, to an ambulatory treatment that can be administered in all hospital wards as well as in ambulances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_009.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>Figure 5: our INSPIRA ART.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While our INSPIRA ART (Gen
2) has unique advantages in comparison to currently available solutions used to provide life support, there are numerous potential risks
that might be associated with the use of our INSPIRA ART (Gen 2) device. Such risks may include low blood flow that could be associated
with generation of thrombi, mechanical damage to the superior vena cava, generation of a systemic inflammatory response due to bio-compatibility
issues, allergic reactions to catheter or its components, decreased venous returns, local venous bleeding following the extraction of
our INSPIRA ART (Gen 2) or erroneous puncture of an artery during the insertion of our product. Additionally, any foreign material in
a body increases the risk of infections and the patient&#8217;s membrane might be clogged for a short period of time. Finally, an individual
patient&#8217;s requirements for gas exchange might significantly differ from the average, which means that the use of our INSPIRA ART
(Gen 2) might not meet minimum requirements for blood saturation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a life support technology,
our lead product has the following unique advantages:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"/>
    <td style="width: 0.25in">&#9679;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Simplicity of administration</i></b>: one
    of the main advantages of our INSPIRA ART (Gen 2) device is that there is no anticipate need for an induced coma because there is no intubation
    involved, and the treated patient stays awake. Subject to regulatory clearances, our product will enable small medical teams to perform
    a simple bedside procedure, inserting our dual lumen cannula into the jugular vein.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"/>
    <td>&#9679;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Continuous and real-time measuring of blood monitoring</i>: </b>a core technology <b>w</b>ithout the need for blood samples to be taken by medical teams, the tube mounted Blood Sensor includes a non-invasive optical sensor that scan blood flowing through a tube. Our software measures the blood parameters. The Blood Sensor is expected to measure the patient&#8217;s blood parameters in real-time, triggering the delivery of needed oxygen volume straight into the blood. Additional benefits of the blood sensor include, continuous blood monitoring, monitoring trends and abnormalities, real-time detection of changes in patient parameters and possible condition as well as providing physicians with decision supportive data.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Orbiting blood oxygenation delivery</i>: </b>a core technology is designed to oxygenate blood without fiber membranes, and we believe it is expected to revolutionize the medical landscape. The current fiber technologies used for blood oxygenation cause substantial damage to the patient&#8217;s blood cells. Unlike the natural laminar blood flow in blood vessels inside the body, in existing fiber oxygenators, the blood is &#8220;forced&#8221; to flow in a harmful turbulent flow through many layers of fibers while experiencing friction and shear forces within the fiber walls. Since the fiber fabric is a significant resistor to blood flow, high-pressure differences are formed and cause significant damage to the various blood components, including, high hemolysis (breakdown of red cells), damage to white blood cells, activation of the inflammatory system in the body, activation of the immune system, and blood clotting.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Convertible dual lumen cannula</i>: </b>our convertible dual lumen cannula device uniquely intravascularly converts a single-lumen cannula into a dual lumen cannula after initial insertion, thus allowing for the same incision point to potentially have multiple uses. The convertible dual lumen cannula is designed to allow for switching from a single lumen to a dual lumen cannula, and vice versa, without the need for new incisions required when changing or adding additional cannulas. Our convertible dual lumen is designed to potentially allow for fast action and reduced risk, complications and additional infection points. Further, our INSPIRA ART cannula <sub>&#160;</sub>has numerous proprietary characteristics that makes it superior in comparison to existing commercial cannulas, such as small diameter 16-21Fr (depending on flow rate required) that allows the lumen to be injected directly into a patient&#8217;s jugular vein while the patient is awake and breathing spontaneously, short length that eliminates the need for positioning that requires fluoroscopy or other imaging and simplicity of cannulation and application.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Compact and portable allowing for deployment in various settings</i></b>: our INSPIRA ART (Gen 2) is relatively small in size, which allows it to be used both in ICU and non-ICU settings, including hospital wards and ambulatory settings, without significant financial burden.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our development team is now
working on prototype designs (including design, specifications, operational parameters and components). This will allow us to progress
towards the first production of the final product so that it can undergo safety tests prior to regulatory submissions to the FDA and foreign
regulatory agencies, including CE in future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Study Results - INSPIRA ART </b>(Gen 2)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have completed pre-clinical
feasibility in-vivo studies. In addition, we intend to continue to perform studies for testing and control purposes, including new purchased
and manufactured components, process integration and automation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Throughout 2020, approximately
40 pre-clinical in-vivo feasibility tests in a series of studies were performed in conjunction with our team and headed by the veterinary
team at LAHAV CRO in Israel to examine the feasibility of direct blood oxygenation to preempt the need for Mechanical Ventilation. The
main goal of these studies was to use our INSPIRA ART lab unit and show temporary increase of oxygen gas exchange during respiratory failure
by transferring clinically significant amounts of oxygen to the venous blood, while simultaneously extracting quantities of carbon dioxide.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The researchers placed seven
large-white X landrace pigs (chosen due to resemblance of the anatomy, size scale and other characteristics to humans), each weighing
approximately 90 to130 kilograms, into an artificial state of hypoxemia (a state when an individual has abnormally low levels of oxygen
in blood) with oxygen saturation levels dropping up to 80%. The oxygen gas concentration was lowered by mixing pure oxygen with medical
air and N2O to reduce the oxygen concentration levels to approximately 15%. The aim of oxygen decrease was to mimic a state of respiratory
failure of compromised sick lungs. When oxygen saturation level drops below 90%, many doctors will consider using Mechanical Ventilation
to increase the oxygen level.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, pre-clinical
feasibility in-vivo tests were conducted at Lahav C.R.O. in Israel, to test the INSPIRA ART&#8217;s ability to rebalance oxygen saturation
levels within minutes. In 20 out of the 25 hypoxemic induced events, INSPIRA ART treatment was provided with a blood flow rate of 1-1.5
liter per minute. The researchers used our INSPIRA ART lab unit, which was primed and then connected to pigs with our proprietary dual
lumen cannula, through the right jugular veins of the pigs. Our proprietary dual lumen cannula allowed simultaneous venous drainage and
reinfusion of blood via the jugular vein. Our INSPIRA ART includes a centrifugal pump activated to pump blood from the pig&#8217;s right
jugular vein through the dual lumen cannula&#8217;s outlet drainage tube. The blood was circulated through the system&#8217;s oxygenator,
providing the blood with an enriched oxygen content and decreased carbon dioxide levels. In a closed system, the oxygenated blood was
circulated back through the cannula&#8217;s inlet reinfusion tube.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pig&#8217;s oxygen saturation
was monitored at several intervals with blood sampling taken from the testing points. Our INSPIRA ART immediately elevated and stabilized
the pigs&#8217; oxygen saturation level, taking into account the possibility of subjects responding differently to a treatment. The procedure
was repeated multiple times on multiple subjects and at different periods to measure and prove consistency and repeatability of elevated
and stabilized blood oxygenation levels following the activation of our INSPIRA ART. This effect was achieved in all of our pre-clinical
in-vivo tests (studies). Moreover, our proprietary dual lumen cannula was inserted and removed without complications. Inspection of the
cannulas used in studies demonstrated intact structures without any sign of damage to the structure or unique characteristics.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>INSPIRA ART (Gen 2) - Pre-clinical Studies
Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><img alt="" src="image_010.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; ">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; "><img alt="" src="image_011.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><img alt="" src="image_012.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><img alt="" src="image_013.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><img alt="" src="image_014.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><img alt="" src="image_015.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><img alt="" src="image_016.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2022, we completed
an animal study that was conducted at Lahav C.R.O by leading ICU and respiratory specialists, who are members of our Scientific Advisory
Board. The completion of the animal study is an additional important step toward initiating human studies using the HYLA blood sensor.
During the animal study, the HYLA blood sensor performed measurements of blood parameters with results being compared to numerous blood
samples taken and analyzed using a routine blood gas analyzer, which is considered the standard of care used by hospitals today. The animal
study was performed following prior successful ex-vivo data obtained with the HYLA blood sensor in our laboratory. The lab results, accompanied
by the encouraging animal study data, are important steps toward human studies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2023, we completed
an INSPIRA ART100 usability study in Boston Massachusetts, U.S. The Usability Study included U.S. healthcare professionals who participated
in testing and examining the INSPIRA ART100 in a setting designed to consider human factors of the intended users, uses and use environments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>INSPIRA ART</b> - <b>Market Opportunity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The WHO estimates that in
2017, over 400 million people globally were affected by respiratory insufficiency. Approximately 20 million patients annually are admitted
to ICUs, requiring acute respiratory care. The respiratory care devices market size is expected to reach $29.86 billion by 2025, from
$16.09 billion in 2019. The major factors influencing this growth include the high prevalence of respiratory diseases, the rapid growth
of the aging population, the high prevalence of smoking, rising urbanization and pollution levels, the increasing incidence of pre-term
births and lifestyle changes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Growth
of the global respiratory care device market, which consists of therapeutic devices such as Mechanical Ventilation and ECMO, monitoring
devices, diagnostic devices, and consumables and accessories, is driven by the (i) rise in the geriatric population, which is prone to
respiratory disorders; (ii) high prevalence of chronic respiratory diseases; and (iii) increase in government expenditures on the healthcare
industry due to an improving of standard of care and extending the availability of treatment to more regions and areas. The aforementioned
factors magnify the need for available and accessible respiratory treatment to support a growing medical need with more people being diagnosed
annually with respiratory disorders as well as suffering from respiratory insufficiencies. However, a number of limitations are associated
with the use of Mechanical Ventilation, including its high cost of mechanical ventilators and risks associated with the use of Mechanical
Ventilation such as the rise in prevalence of ventilator-associated pneumonia, or VAP, which hinder the market growth. The urgency to
provide medical treatment and save lives are driving factors that increase the need for respiratory treatment for respiratory failure
and insufficiency. The limitations, risks and costs associated with current solutions are at multiple levels adding excessive strain and
burden on the healthcare system, having both a direct and indirect impact on patient outcomes. This may provide new opportunities for
existing market participants and for the entry of new companies with new technological solutions which are high in demand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The respiratory care devices
market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. In 2019,
North America accounted for the largest share of the respiratory care devices market. In the United States alone, more than 5.7 million
people annually require ICU admission, up to 40% of which require Mechanical Ventilation, which is the current standard of care in use
since the 1950s, pursuant to an article in the <i>Clinical Infectious Diseases</i> medical journal published in August 2020 by Oxford
University Press, titled &#8220;Patient Characteristics and Outcomes of 11,721 Patients with Coronavirus Disease 2019 (COVID-19) Hospitalized
Across the Unites States.&#8221; With a growing elderly population and more people being exposed to smoking and pollution, the population
requiring treatment is growing overwhelmingly. According to recent estimates in an article &#8220;Acute Respiratory Distress Syndrome:
Advances in Diagnosis and Treatment&#8221; published in February 2018 by JAMA, ARDS accounts for 10% of intensive care unit admissions,
representing more than 3 million patients with ARDS annually. Pursuant to an article &#8220;The High Cost of Surviving Respiratory Distress
Syndrome&#8221; published in April 2017 by John Hopkins Medicine, ARDS affects approximately 200,000 Americans every year, and ARDS survivors
often have long-lasting impairments such as cognitive dysfunction, mental health issues and physical impairments, all of which may affect
employment. According to an article &#8220;Diagnosis and Management of Acute Respiratory Distress Syndrome in a Time of COVID-19,&#8221;
published in 2020 by the <i>Diagnostics (Basel)</i>, ARDS is a serious clinical illness, defined by severe hypoxemic respiratory failure,
which continues to be associated with significant morbidity, mortality, and healthcare resource utilization. According to the same source,
ARDS comprises 7-10% of admissions and 15-25% of mechanically ventilated patients in the intensive care unit (ICU), is fatal in 30-50%
of patients, and costs on average over USD 90,000 per patient&#8217;s ICU stay. According to an article &#8220;How COVID-19 Will Impact
Employer-Sponsored Health Plans&#8221; by BKS Partners, the median total cost of an admission for a respiratory condition requiring 96
hours or more of ventilation is $88,114. Due to its growing geriatric population and environmental conditions that have favored the spread
of respiratory disease, COVID-19 severely affected the region and induced enormous growth in the demand for respiratory care devices.
As a result, participants in this and adjacent markets have focused on or collaborated to expand the manufacturing of critical care instruments
and respiratory care devices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Worldwide
demand for mechanical ventilators has increased substantially, due to the COVID-19 outbreak, resulting in a surge in ICU admissions worldwide.
This exponential increase in COVID-19 cases across the world requires long-term and short-term respiratory support and increased demand
for new solutions. Even prior to COVID-19, approximately 20 million patients were treated annually with Mechanical Ventilation in ICUs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; ">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Go To Market Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
go-to-market strategy is based upon providing affordable products, based on a razor-blade business model based on disposables and software
licensing to maximize our market reach while enhancing affordability and accessibility to medical care worldwide. We focus on this effort
comprehensively, understanding a multidisciplinary marketing and business approach is necessary to achieve our goals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Our go-to-market strategy includes, but
is not limited to:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Pursuing world-wide regulatory approvals</i></b><i>: </i>we plan
to pursue regulatory approvals in the United States, Europe, Asia, Central America, South America, Africa and the Middle East. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Collaborating with leading medical centers and health organizations</i></b>:
we are working with leading medical centers and health organizations as part of our strategy toward reaching regional deployment of our
products. This also includes collaborations with top ranked hospitals to expose our INSPIRA ART devices to physicians and the healthcare
industry. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Identifying potential customer profiles</i></b>: we will be targeting
leading medical centers, group purchasing organizations and medical device companies with a need for updated or revolutionary life support
solutions. We believe that due to many recalls within the perfusionist market, and a lack of innovation in the sector, Inspira is identifying
potential customers searching for a different experience and result.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Strategic partners</i></b>: we have entered into agreements with
medical device companies, manufacturers, distributors. We intend to target similar agreements with distributors in additional territories
across the globe, including the U.S., Europe, and Asia.&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Investing in marketing and public relations to increase awareness
of our solution</i></b>: in order to drive market demand for the INSPIRA ART (Gen 2), we are introducing the INSPIRA ART100 (Gen 1) a
CPB device, to be followed by disposables and the Blood Sensor (to be integrated with the INSPIRA ART100). We hope to expose the industry,
as we have in conferences such as the 2023 Annual Extracorporeal Life Support Organization conference in Seattle, to the caliber of technology
and devices that we plan to offer, To-date, the INSPIRA ART 100 (Gen 1) has been submitted to the FDA for 510(k) clearance and the INSPIRA
ART (Gen 2) and is in development. The devices have not been used or tested in humans and are not cleared or approved by the FDA or similar
foreign regulatory bodies.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Garnering appropriate reimbursement and insurance coverage</i></b>:
it is paramount for us to receive reimbursement and insurance coverage to enable hospitals and medical centers to provide treatment utilizing
our products. With intensive care becoming increasingly expensive, the INSPIRA ART may provide treatment at significantly reduced cost
and without compromising quality of care to patients. We are working on a health economics model as part of the reimbursement strategy.
Our goal is to publish medical literature to provide the Centers for Medicare and Medicaid Services, or CMS, actual data, presented by
us together with top-ranking hospitals.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Working to Establish Agreements </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
December 2022, we entered into an exclusive original equipment manufacturer, or OEM, agreement with Terumo Cardiovascular, a division
of Terumo Corporation, a leading global medical device company. The agreement provides for the manufacture of a disposable flow mechanism
that may be distributed with our INSPIRA ART devices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
July 2023, we entered into a collaboration agreement with Perfusion Solution, Inc., a leading U.S.-based company that provides a platform
of advanced medical devices, training and staffing to leading U.S. hospitals. The collaboration involves combining the INSPIRA ART100
product with Perfusion Solution&#8217;s broad commercial footprint and infrastructure across the United States. The collaboration includes
a summary distribution agreement that will be followed by a more comprehensive agreement. The agreement has an initial term of 5 years,
subject to completion of product development and meeting certain purchase targets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in November 2023,
we entered into a partnership agreement with Ennocure, a pioneer in the development of bioelectronic wound dressing, for Development of
Proprietary Bio-Electronic Treatment to Prevent Associated Bloodstream Infections in ICU Patients. At the core of our mission is a groundbreaking
approach to oxygenate blood directly to replace life support mechanical ventilation. Inspira seeks to include bio-electronic technology
as part of the INSPIRA ART and Company&#8217;s IP portfolio, to prevent the growth of bacteria that often results in a bloodstream infection
(sepsis) and has partnered with Ennocure for the development of such treatment. Once developed, we plan to combine the bio-electronic
novel physical stimulation technology, as a preemptive measure for potentially at-risk patients, providing a cost-competitive solution
to reduce complications. It is estimated that 250,000 bloodstream infections related to intravenous lines occur worldwide each year, leading
to prolonged hospital stays and increasing healthcare costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Working to Establish Distribution Partners
Around the World</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
seek to enter into strategic distribution agreements internationally to collaborate with local distribution networks to form a platform
for implementation of our go-to-market strategy. Distribution companies with which we have already entered into such agreements include
Innovimed (covering all European countries), Bepex, Anita T&#233;cnica S.L, or WAAS Group (covering Spain and Portugal), Glo-Med (covering
Texas, New Jersey, New York, Florida, North Carolina, South Carolina and Gulf States) and CIO MED GROUP (covering Central America). The
agreements are for a period of three to seven years and are conditional on the completion of product development and receipt of regulatory
approvals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we intend to execute
on strategic distribution agreements, there is no guarantee any sales will occur pursuant to those existing agreements, and agreements
that may be executed in the future. The pre-conditional distribution agreements are for a period of up to seven years and subject to completion
of development, and the required regulatory approvals or clearances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2021, we entered
into an exclusive distribution agreement with Anita T&#233;cnica S.L. (WAAS Group), one of Spain&#8217;s leading distributors and technical
service providers of medical equipment and supplies. According to the agreement, Anita T&#233;cnica S.L. (WAAS Group) is committed to
purchase a minimum of 1,040 INSPIRA ART devices and 35,360 disposable units for deployment at hospitals and medical centers within a seven-year
period, subject to regulatory approval for the sale and marketing of the INSPIRA ART devices in Spain and Portugal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
December 2021, we entered into an exclusive summary distribution agreement with Innovimed Sp. z o.o, or Innovimed, a master distributor
specializing in state-of-the-art medical solutions in Eastern Europe, Middle East and Africa. The agreement has an initial term of 7 years,
subject to completion of product development and regulatory approval. The parties will collaborate on the marketing and deployment of
the INSPIRA ART device. In order to maintain exclusivity in the territory, Innovimed has committed to purchase minimum orders of 1,552
INSPIRA ART devices and 59,040 disposable units for deployment at hospitals and medical centers, subject to regulatory approvals for the
sale and marketing of the INSPIRA ART devices in Poland, Czech Republic and Slovakia. In August 2023, we entered into an agreement expansion
with Innovimed to collaborate towards clinical trials for Inspira ART respiratory devices, which covers any European country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2022, we entered
into an exclusive summary distribution agreement with Glo-Med, a U.S company that aims to meet the continuously growing demand for innovative
medical devices and related products, for distribution across six states in the United States (Texas, New Jersey, New York, Florida, North
Carolina, and South Carolina). The summary distribution agreement will be followed by a more comprehensive agreement. The agreement entered
with Glo-Med has an initial term of 7 years, subject to the completion of product development and relevant regulatory approval. The parties
will collaborate on the marketing and deployment of the INSPIRA ART. Pursuant to the agreement, and in order to maintain exclusivity in
the territory, Glo-Med has committed to purchase a minimum order of 2,121 INSPIRA ART devices and 131,413 disposable units for deployment
at hospitals and medical centers over a period of 7 years, subject to regulatory approvals for the sale and marketing of the INSPIRA ART
devices in the 6 states in the United States, as mentioned above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2022, we entered
into a summary distribution agreement with Bepex Ltd., or Bepex, that includes the potential future deployment of our INSPIRA ART devices,
designed to prevent the need for invasive mechanical ventilation. Bepex is a leading Israeli medical technology company that imports,
markets and services medical equipment for global medical device companies such as Hamilton (mechanical ventilators) and LivaNova (ECMO-Extracorporeal
Membrane Oxygenation systems). As part of the collaboration with Bepex, the first systems are slated for deployment at the largest medical
centers in Israel. The summary distribution agreement with Bepex is expected to be followed by a more comprehensive agreement. The agreement
has an initial term of seven years, subject to the completion of product development and relevant regulatory approvals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2022, we entered into
an exclusive summary distribution agreement with Glo-Med, for the distribution of the HYLA blood sensor device and disposable units across
6 states in the United States (Texas, New Jersey, New York, Florida, North Carlina and South Carolina). The summary distribution agreement
will be followed by a more comprehensive agreement. The agreement has an initial term of three years, subject to completion of product
development and regulatory approvals. The parties will collaborate on the marketing and deployment of the HYLA blood sensor. Pursuant
to the agreement, and in order to maintain exclusivity in the territory, Glo-Med has committed to purchase a minimum order of 3,889 HYLA
blood sensors and 264,873 disposable units for deployment at hospitals and medical centers, subject to regulatory approvals for the sale
and marketing of the HYLA blood sensor device in the 6 states within the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2022, we entered
into an exclusive summary distribution agreement for the HYLA&#8482; blood sensor with Innovimed. The summary distribution agreement would
be followed by a more comprehensive definitive agreement. The agreement has an initial term of five years, subject to the completion of
product development and the receipt of regulatory approvals. The parties will collaborate on the marketing and deployment of the HYLA
blood sensor. In order to maintain exclusivity in the territory, Innovimed has committed to purchase a minimum order of 1,364 HYLA blood
sensors and 128,511 disposable units for deployment in hospital units and operating theaters in Poland, Czech Republic and Slovakia.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2023, we entered
into an exclusive summary distribution agreement for the INSPIRA&#8482; ART devices and disposable kits with CIO MED GROUP in Central
America. The Agreement to potentially generate $28 million, mainly in recurring revenues from disposable kits over five years, subject
to the receipt of regulatory approval.&#160;In addition to the INSPIRA ART100 device intended for patients undergoing CPB procedures,
the Agreement also includes both the flagship INSPIRA<b>&#8482;</b>&#160;ART (Gen 2) device and HYLA<b>&#8482;</b>&#160;Blood Sensor Technology,
as well as disposable kits to be used with these Inspira Technologies devices in the procedures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2024, we entered
into a summary distribution agreement to enter Gulf States with Glo-Med for deployment of 531 ART Devices. The agreement will potentially
provide Inspira Technologies with $32.6 million over a 5-year period, subject to regulatory approvals. Under such Agreement, Glo-Med shall
be designated as the Company&#8217;s distributor in Saudi Arabia, United Arab Emirates and Bahrain. We believe that Saudi Arabia&#8217;s
dual strategy to invest $65 billion and further privatize its healthcare sector, or Vision 2030, signals that the Territory is a burgeoning
market for medical innovation. The summary distribution agreement will be followed by a more comprehensive agreement. Under the Agreement,
Glo-Med shall undertake the role of Territory wholesale distributor, involving the promotion, marketing and sale of the INSPIRA&#8482;
ART (Gen 2) Device, the INSPIRA ART (Gen 2) Disposable Kit, the INSPIRA&#8482; ART100 Device and the INSPIRA ART100 Disposable Kit, to
approved customers in the Territory. Glo-Med shall be the exclusive Territory distributor provided that it meets the minimum purchase
targets amounting to 531 INSPIRA&#8482; ART devices and 8,794 disposable units from when the relevant regulatory approvals for the Devices
in the Territory are granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we intend to execute
on strategic distribution agreements, there is no guarantee any sales will occur pursuant to those existing agreements, and agreements
that may be executed in the future. The pre-conditional distribution agreements are for a period of up to seven year and subject to completion
of development, and the required regulatory approvals or clearances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Third-Party Reimbursement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 2024, we do not
have any third-party reimbursement agreements. We target to be use existing CPT Codes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Intellectual Property
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We seek patent protection
as well as other effective intellectual property rights for our products and technologies in the United States and internationally. Our
policy is to pursue, maintain and defend intellectual property rights developed internally and to protect the technology, inventions and
improvements that are commercially important to the development of our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our intellectual property
portfolio consists of five (5) patent families that include three (3) granted patents, two (2) in the USA and one in Israel; one US allowed
application, three International Patent Applications (PCT) two of which are exhausted and eighteen (18) pending patent applications that
include four (4) U.S. utility patent applications, and three (3) European patent application. twelve (12) additional national phase filings
(two (2) in Koreia, two (2) in China, two (2) in Israel and two (2) in Japan Our portfolio also includes four registered Israeli trademarks
for &#8216;INSPIRA&#8217; text and logo, for &#8216;INSPIRA ART&#8217;, and for our slogan &#8216;INSPIRA. BREATHING EMPOWERED.&#8217;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_017.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Extracorporeal oxygenation system (*Initiation
Module)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A novel automated self-priming module designed
for the INSPIRA ART (Gen 2) device, this unique innovative operating module further expands the INSPIRA ART (Gen 2) advancement to potentially
ensure patient safety with a proprietary built-in self-automated priming module aimed to ensure an emboli-free connection to the patient&#8217;s
vascular system, thereby potentially reducing risks of the formation of clots that reduces blood flow. The patent consists of nine distinct
claims, all deemed novel with inventive merit and practical applicability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A blood-gas exchange device and methods of
use</b> - Orbiting blood oxygenation delivery system (VORTX&#8482;)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This innovation has 16 claims found to be novel
and is designed to oxygenate blood without fiber membranes, and we believe it is expected to revolutionize the medical landscape. The
current fiber technologies used for blood oxygenation cause substantial damage to the patient&#8217;s blood cells. Unlike the natural laminar
blood flow in blood vessels inside the body, in existing fiber oxygenators, the blood is &#8220;forced&#8221; to flow in a harmful turbulent
flow through many layers of fibers while experiencing friction and shear forces within the fiber walls. Since the fiber fabric is a significant
resistor to blood flow, high-pressure differences are formed and cause significant damage to the various blood components, including,
high hemolysis (breakdown of red cells), damage to white blood cells, activation of the inflammatory system in the body, activation of
the immune system, and blood clotting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dual lumen cannula and methods of use</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The patent approval includes 20 claims that
were found to be novel, with inventive step and industrial applicability. Inspira Technologies&#8217; convertible dual lumen cannula
device uniquely intravascularly converts a single-lumen cannula into a dual lumen cannula after initial insertion, thus allowing for
the same incision point to potentially have multiple uses. The convertible dual lumen cannula is designed to allow for switching
from a single lumen to a dual lumen cannula, and vice versa, without the need for new incisions required when changing or adding
additional cannulas. The Inspira Technologies convertible dual lumen is designed to potentially allow for fast action and reduced
risk, complications and additional infection points</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cannula fixation device</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The component is intended to reduce the potential complications associated
with jugular vein cannula movement, occurring during a change of a patient&#8217;s posture in bed and/or during transportation. The component
can also be potentially utilized in the treatment of thousands of patients being treated each year by Extracorporeal Membrane Oxygenation
(ECMO). This component is expected to allow the medical staff a safer mobilization for the awake cannulated patients within and between
hospitals and medical centers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table comprises
our technology patents:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; margin-bottom: 5.75pt">
  <tr>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 25%; text-align: left"><span style="font-size: 10pt">Application; Publication No.</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 40%; text-align: center"><span style="font-size: 10pt">Title</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 17%; text-align: center"><span style="font-size: 10pt">Effective Filing Date</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: center"><span style="font-size: 10pt">Status</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">IL 286271</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">A Cannula Fixation Device</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10 Sep 2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">GRANTED</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">PCT/IL2022/050902</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">A Cannula Fixation Device</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">18 Aug 2022</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">FILED</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">EP 22856981.0; 4185347</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">A Cannula Fixation Device</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">18 Aug 2022</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">US 17/931,134</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">A Cannula Fixation Device</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">11 Sep 2022</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">CN 202180076037.0; 116472077</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Dual Lumen Cannula and Methods of Use</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10 Nov 2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">EP 21891360.6; 4199990</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Dual Lumen Cannula and Methods of Use</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10 Nov 2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">IL 302851</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Dual Lumen Cannula and Methods of Use</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10 Nov 2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">JP 2023550749; 2023548436</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Dual Lumen Cannula and Methods of Use</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10 Nov 2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">KR 10-2023-7019401; 20230107622</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Dual Lumen Cannula and Methods of Use</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10 Nov 2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">US 11,541,159</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Dual Lumen Cannula and Methods of Use</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10 Nov 2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">GRANTED</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">US 18/062,610; 2023/0095678</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Transformable Dual Lumen Cannula into a Single Lumen Cannula and Methods of Use</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10 Nov 2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">AU 2021390218</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates and Methods of Use</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">1 Dec 2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">BR 112023010627-3</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates and Methods of Use</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">1 Dec 2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">CA 3200492</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates and Methods of Use</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">1 Dec 2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">CN 202180091081.9; 116782964</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates and Methods of Use</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">1 Dec 2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">EP 21900219.3; 4228717</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates and Methods of Use</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">1 Dec 2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">IL 303362</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates and Methods of Use</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">1 Dec 2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">JP 2023533325; 2023552754</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates and Methods of Use</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">1 Dec 2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">KR 10-2023-7022195; 20230118594</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates and Methods of Use</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">1 Dec 2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">US 11,793,919</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates and Methods of Use</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">1 Dec 2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">GRANTED</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">US 18/216,565; 2023/0338634</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates and Methods of Use</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">1 Dec 2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">US 18/235,515</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">A Blood-Gas Exchange Device and Methods of Use</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">18 Aug 2023</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">ALLOWED</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">US 18/434,809</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Automated Monitoring of Extracorporeal Support Patient Care and Interactive User Interface Therefor</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">7 Jan 2024</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also rely on trade secrets,
know-how, and continuing innovation to develop and maintain our competitive position. We cannot be certain that patents will be granted
with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we
be sure that any of our existing patents or any patents granted to us in the future will be commercially useful in protecting our technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends, in part,
on an intellectual property portfolio that supports future revenue streams and erects barriers to our competitors. We are maintaining
and building our patent portfolio through filing new patent applications, prosecuting existing applications, and licensing and acquiring
new patents and patent applications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite these measures, any
of our intellectual property and proprietary rights could be challenged, invalidated, circumvented, infringed or misappropriated. Intellectual
property and proprietary rights may not be sufficient to permit us to take advantage of current market trends or otherwise to provide
competitive one. For more information, see &#8220;Item 3.D. - Risk Factors-Risks Related to our Intellectual Property.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Research and Development and Governmental
Grants</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain an active internal
research and development process, which also includes clinical activities and regulatory affairs. Our research and development team consists
of thirty-six people as of December 31, 2023. We incurred approximately $7.4million and $8.2 million in research and development and related
expenses during the year ended December 31, 2023 and 2022, respectively. The decrease in research and development expenses is primarily
attributable to <span>a decrease of approximately $1.7 million in share-based compensation expenses partially
offset by an increase in salaries and related personnel expenses of $1 million, as a result of an increase in the number of research and
development employees. Moreover, there was an increase of $0.2 million</span> in <span>materials and related
expenses related to in- house development.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
efforts have been financed in part through grants in an aggregate amount of approximately $800,000 that we received from the IIA as of
December 31, 2023. We received these grants for the development of a blood oxygenation system with the goal of providing life support
through direct blood oxygenation and elevation of the oxygen saturation level while removing carbon dioxide. In November 2023, we received
another grant from the IIA for the VORTX equal to 40% of the first year IIA approved budget of $1 million. We expect to receive the funds
along 2024-2025. These grants have no repayment obligation, however, once we reach commercialization stage, we will be required to pay
royalties for each grant at a rate of 3% of our revenues up to the total amount of grants received. Following the full payment of such
royalties, there is generally no further liability for royalty payment. Nonetheless, the restrictions under the Innovation Law will continue
to apply even after our company has repaid the full amount of royalty payable pursuant to the grants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Production and Manufacturing Activities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our INSPIRA ART (Gen 2) device
and or INSPIRA ART100 (Gen 1) device are comprised of a number of components. We are planning to sell an assembled product (device) as
well as a disposable unit to be used per patient treatment for both the blood oxygenation and blood monitoring. The components of the
assembled product and the disposable unit consist of both proprietary and off the shelf components. Proprietary components will be manufactured
on our behalf at good manufacturing practices, or GMP, approved production plant to adhere to regulatory requirements, whereas off the
shelf components will be sourced by Inspira team. GMP sub-contractors will assemble proprietary and off the shelf components together
to create our INSPIRA ART and or INSPIRA ART100 devices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
December 2022, we entered into a strategic OEM agreement with Terumo Cardiovascular. The agreement provides for the manufacture of a flow
mechanism that is intended to be integrated into our products for use in the extracorporeal circulation of the blood during the oxygenation
process. This may also include integration into the INSPIRA ART (Gen 2) and or INSPIRA ART100 (Gen 1) devices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
addition, we have begun discussions relating to additional contracted manufacturing and distribution agreements with leading turnkey OEM
vendors that provide end-to-end solutions. The outsourcing of the supply chain management (such as manufacturing, logistics, shipping
and after-market support) reduces capital expenditure, lead times and costs, while providing us with flexibility and agility.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
December 2022, we announced that our INSPIRA ART100 device is being contract manufactured by an end-to-end solution provider that offers
New Product Introduction, NPI, services to mass production capabilities for leading medical electronic device companies. This includes
full turn-key manufacturing, full system integration, including Printed Circuit Board, or PCB, manufacturing, assembly services, testing
and packaging in facilities that meet Good Manufacturing Practices, or GMP, compliance. INSPIRA ART100device manufactured were to undergo
the Verification and Validation phase prior to its submission to the FDA (FDA) for 510(k) clearance in September 2023. If FDA clearance
is obtained, the INSPIRA ART100device production line will be extended for Low-Rate Initial Production, or LWRIP, which is an important
operational stage in developing infrastructure to support serial manufacturing, quality control and shipping. Additional units are expected
to be assembled for the targeted future first deployments of the INSPIRA ART100devices in the U.S. and Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
medical device industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products.
There are many medical device companies, biotechnology companies, public and private universities and research organizations actively
engaged in the research and development of products that may be similar to our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
market participants in the ICU and the acute respiratory care space include Boston Scientific Corporation (NYSE: BSX), ResMed Inc., (NYSE:
RMD), Masimo Corporation (Nasdaq: MASI), Becton, Dickinson and Company (NYSE: BDX), Chart Industries, Inc. (Nasdaq: GTLS), Philips Healthcare,
Medtronic plc (NYSE: MDT), Fisher &amp; Paykel Healthcare Corporation Limited, Dr&#228;gerwerk AG &amp; Co. KGaA, Dr&#228;gerwerk AG,
Hamilton Medical AG, Smiths Medical Inc., Siemens Healthineers AG ADR (Nasdaq: SMMNY), Baxter International (NYSE: BAX), Getinge, GE Healthcare,
Terumo Corporation (TYO: 4543, Nikkei 225 Component), LivaNova PLC, Fresenius SE &amp; Co. KGaA, Johnson &amp; Johnson, Resuscitec, Spectrum
Medical etc. These companies have either developed or acquired respiratory care devices and solutions, such as ventilators, ECMO devices
and blood sensors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
aforementioned companies, have substantially greater brand recognition, R&amp;D, and regulatory capabilities and financial, technical,
manufacturing, marketing and human resources than we do and significantly greater experience and infrastructure in the research and development
of medical devices, obtaining the FDA and other regulatory clearances of those devices and commercializing those devices around the world.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Other Inspira Technologies
Products </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
flagship product is the INSPIRA ART (Gen 2) device, aimed to be a breakthrough technology that restructures the approach of acute respiratory
care, increasing its accessibility, safety and medical outcomes for patients worldwide. In order to achieve this goal, hawse have recognized
the need for the development of additional products to support this same effort. To this end, we are also developing the INSPIRA ART100
(Gen 1) device, an extracorporeal blood circulation device designed to provide cardiac and pulmonary support and the HYLA blood sensor,
a non-invasive optical blood sensor to measure blood parameters during extracorporeal procedures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
go-to-market strategy is focused and being based upon providing affordable products, based on a razor-blade business model to maximize
our market reach while enhancing affordability and accessibility to medical care worldwide. We focus on this effort comprehensively, understanding
a multidisciplinary approach to achieve its goals. From a base business-model to industry endorsements fueled by important clinical studies
that evidence our product&#8217;s effectiveness and safety of use, we are driven to forge forward towards achieving successful market
penetration and adoption of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We seek to include bio-electronic
technology as part of the INSPIRA ART and our IP portfolio to prevent the growth of bacteria that often results in a bloodstream infection
(sepsis). We have partnered with Ennocure for the development of such treatment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2020, we entered into
a collaboration and license agreement with B.G. Negev Technologies and Applications Ltd., or BGN, a wholly owned subsidiary of Ben-Gurion
University of the Negev in Beer Sheva. To date, we and BGN have developed and characterized a stable polymeric microbubble, or MBs, platform
that releases oxygen on demand. The development process required in-depth research to evaluate the procedures for oxygen engulfment in
MBs and observe oxygen release at the required rates. This novel proposed technology will be further developed with the aim to integrate
it into the INSPIRA ART (Gen 2) device. The defined X2 system is designed to extend the life of oxygenators and potentially prevent blood
clotting in the INSPIRA ART device. The project is currently in a moratorium until further notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Government Regulation
and Product Approval </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products and our operations
are subject to regulation by numerous worldwide regulatory bodies including the FDA and comparable international regulatory agencies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products are subject to
regulation as medical devices under the Federal Food, Drug, and Cosmetic Act, or FDCA, as implemented and enforced by the FDA. The FDA
regulates the development, design, non-clinical and clinical research, manufacturing, safety, efficacy, labeling, packaging, storage,
installation, servicing, recordkeeping, premarket clearance or approval, import, export, adverse event reporting, advertising, promotion,
marketing and distribution, and import and export of medical devices to ensure that medical devices distributed domestically are safe
and effective for their intended uses and otherwise meet the requirements of the FDCA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to U.S. regulations,
we are subject to a variety of regulations in the European Economic Area, or the EEA, governing clinical trials and the commercial sales
and distribution of our products. Whether or not we have or are required to obtain FDA clearance or approval for a product, we will be
required to obtain authorization before commencing clinical trials and to obtain marketing authorization or approval of our products under
the comparable regulatory authorities of countries outside of the United States before we can commence clinical trials or commercialize
our products in those countries. The approval process varies from country to country and the time may be longer or shorter than that required
for FDA clearance or approval. Medical devices are generally subject to varying levels of regulatory control based on risk level of the
device.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>FDA Premarket Clearance
and Approval Requirements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless an exemption applies,
each medical device commercially distributed in the United States requires FDA clearance of a 510(k) premarket notification, granting
of a de novo request, or approval of an application for premarket approval, or PMA. Under the FDCA, medical devices are classified into
one of three classes-Class I, Class II or Class III-depending on the degree of risk associated with each medical device and the extent
of regulatory controls needed to ensure its safety and effectiveness. Class I includes devices with the lowest risk to the patient and
are those for which safety and effectiveness can be assured by adherence to the FDA&#8217;s General Controls for medical devices, which
include compliance with the applicable portions of the QSR, facility registration and product listing, reporting of adverse medical events,
and truthful and non-misleading labeling. Class II devices are subject to the FDA&#8217;s General Controls, and special controls as deemed
necessary by the FDA to ensure the safety and effectiveness of the device. These special controls can include performance standards, post-market
surveillance, patient registries and FDA guidance documents. While most Class I devices are exempt from the 510(k) premarket notification
requirement, manufacturers of most Class II devices are required to submit to the FDA a premarket notification under Section 510(k) of
the FDCA requesting permission to commercially distribute the device. The FDA&#8217;s permission to commercially distribute a device subject
to a 510(k) premarket notification is generally known as 510(k) clearance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>The 510(k) Process</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the 510(k) process,
the manufacturer must submit to the FDA a premarket notification demonstrating that the device is &#8220;substantially equivalent&#8221;
to either a device that was legally marketed prior to May 28, 1976, the date upon which the Medical Device Amendments of 1976 were enacted,
and for which a pre-market approval, or PMA, is not required, a device that has been reclassified from Class III to Class II or Class
I, or another commercially available device that was cleared through the 510(k) process. To be &#8220;substantially equivalent,&#8221;
the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as
the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than
the predicate device. Clinical data is sometimes required to support substantial equivalence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After a 510(k) premarket notification
is submitted, the FDA determines whether to accept it for substantive review. If it lacks necessary information for substantive review,
the FDA will refuse to accept the 510(k) notification. If it is accepted for filing, the FDA begins a substantive review. By statute,
the FDA is required to complete its review of a 510(k) notification within 90 days of receiving the 510(k) notification. As a practical
matter, clearance often takes longer, and clearance is never assured. Although many 510(k) premarket notifications are cleared without
clinical data, the FDA may require further information, including clinical data, to make a determination regarding substantial equivalence,
which may significantly prolong the review process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;If the FDA agrees that
the device is substantially equivalent to a predicate device currently on the market, it will grant 510(k) clearance to commercially market
the device. If the FDA determines that the device is &#8220;not substantially equivalent&#8221; to a previously cleared device, the device
is automatically designated under the FDCA as a Class III device. The device sponsor must then fulfill more rigorous PMA requirements
or can request a risk-based classification determination for the device in accordance with the de novo process, which is a route to market
for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After a device receives 510(k)
marketing clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change
or modification in its intended use, will require a new 510(k) marketing clearance or, depending on the modification, a de novo grant
or PMA approval. The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k) (or a PMA)
in the first instance, but the FDA can review any such decision and disagree with a manufacturer&#8217;s determination. Many minor modifications
today are accomplished by a manufacturer documenting the change in an internal letter-to-file. The FDA can review these letters to file
during an inspection. If the FDA disagrees with a manufacturer&#8217;s determination, the FDA can require the manufacturer to cease marketing
and/or request the recall of the modified device until 510(k) clearance, de novo grant or PMA approval is obtained. In these circumstances,
we may be subject to significant regulatory fines or penalties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>De Novo Classification</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Medical device types that
the FDA has not previously classified as Class I, II or III are automatically classified under the FDCA into Class III regardless of the
level of risk they pose. The Food and Drug Administration Modernization Act of 1997 established a route to market for low to moderate
risk medical devices that are automatically placed into Class III due to the absence of a predicate device, called the &#8220;Request
for Evaluation of Automatic Class III Designation,&#8221; or the de novo classification procedure. This procedure allows a manufacturer
whose novel device is automatically classified into Class III to request down-classification of its medical device into Class I or Class
II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA application.
Prior to the enactment of the Food and Drug Administration Safety and Innovation Act of 2012, or FDASIA, a medical device could be eligible
for de novo classification only if the manufacturer first submitted a 510(k) premarket notification and received a determination from
the FDA that the device was not substantially equivalent to a legally marketed predicate device. FDASIA streamlined the de novo classification
pathway by permitting manufacturers to request de novo classification directly without first submitting a 510(k) premarket notification
to the FDA and receiving a not substantially equivalent determination. Under FDASIA, the FDA is required to classify the device within
120 days following receipt of the de novo application. If the manufacturer seeks reclassification into Class II, the manufacturer must
include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of
the medical device. In addition, the FDA may reject the request if it identifies a legally marketed predicate device that would be appropriate
for a 510(k) notification, determines that the device is not low to moderate risk, or that general controls would be inadequate to control
the risks and special controls cannot be developed. After a device receives de novo classification, any modification that could significantly
affect its safety or efficacy, or that would constitute a major change or modification in its intended use, will require a new 510(k)
clearance or, depending on the modification, another de novo petition or even PMA approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Clinical Trials</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials are almost
always required to support a PMA and are sometimes required to support a 510(k) submission. All clinical investigations of investigational
devices to determine safety and effectiveness must be conducted in accordance with the FDA&#8217;s Investigational Device Exemption, or
IDE, regulations which govern investigational device labeling, prohibit promotion of the investigational device, and specify an array
of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a &#8220;significant
risk&#8221; to human health, as defined by the FDA, the FDA requires the device sponsor to submit an IDE application to the FDA, which
must become effective prior to commencing human clinical trials. A significant risk device is one that presents a potential for serious
risk to the health, safety or welfare of a patient and either is implanted, used in supporting or sustaining human life, substantially
important in diagnosing, curing, mitigating or treating disease or otherwise preventing impairment of human health, or otherwise presents
a potential for serious risk to a subject. An IDE application must be supported by appropriate data, such as animal and laboratory test
results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE will automatically
become effective 30 days after receipt by the FDA unless the FDA notifies the company that the investigation may not begin. If the FDA
determines that there are deficiencies or other concerns with an IDE for which it requires modification, the FDA may permit a clinical
trial to proceed under a conditional approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the study must
be approved by, and conducted under the oversight of, an Institutional Review Board, or IRB. The IRB is responsible for the initial and
continuing review of the study and may pose additional requirements for the conduct of the study. If an IDE application is allowed to
go into effect by the FDA and the study approved by the reviewing IRB(s), human clinical trials may begin at a specific number of investigational
sites with a specific number of subjects as set forth in the study protocol. If the device presents a non-significant risk to the patient,
a sponsor may begin the clinical trial after obtaining approval for the trial by one or more IRBs without separate review from the FDA,
but must still follow abbreviated IDE requirements, such as monitoring the investigation, ensuring that the investigators obtain informed
consent, and labeling and record-keeping requirements. Acceptance of an IDE application for review does not guarantee that the FDA will
allow the IDE to become effective and, if it does become effective, the FDA may or may not determine that the data derived from the trials
support the safety and effectiveness of the device or warrant the continuation of clinical trials. An IDE supplement must be submitted
to, and allowed to go into effect by, the FDA before a sponsor or investigator may make a change to the investigational plan that may
affect its scientific soundness, study plan or the rights, safety or welfare of human subjects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During a study, the sponsor
is required to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting clinical investigators
and providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping and prohibitions on the
promotion of investigational devices or on making safety or effectiveness claims for them. The clinical investigators in the clinical
study are also subject to FDA regulations and must obtain patient informed consent, follow the investigational plan and study protocol,
control the disposition of the investigational device, and comply with all reporting and recordkeeping requirements. Additionally, after
a trial begins, we, the FDA or the IRB could suspend or terminate a clinical trial at any time for various reasons, including a belief
that the risks to study subjects outweigh the anticipated benefits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Post-market Regulation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After a device is cleared
or approved for marketing, numerous and extensive regulatory requirements may continue to apply. These include but are not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify; width: 0.5in">&#160;</td>
    <td style="white-space: nowrap; text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Annual and updated establishment registration and device listing with the FDA;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify; width: 0.5in">&#160;</td>
    <td style="white-space: nowrap; text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">QSR requirements, which require manufacturers to follow stringent design, testing, control, documentation, complaint handling and other quality assurance procedures during all aspects of the design and manufacturing process;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify; width: 0.5in">&#160;</td>
    <td style="white-space: nowrap; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Advertising and promotion requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify; width: 0.5in">&#160;</td>
    <td style="white-space: nowrap; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Restrictions on sale, distribution or use of a device;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify; width: 0.5in">&#160;</td>
    <td style="white-space: nowrap; text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Labeling and marketing regulations, which require that promotion is truthful, not misleading, and provides adequate directions for use and that all claims are substantiated, and also prohibit the promotion of products for unapproved or &#8220;off-label&#8221; uses and impose other restrictions on labeling;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify; width: 0.5in">&#160;</td>
    <td style="white-space: nowrap; text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The federal Physician Sunshine Act and various state and foreign laws on reporting remunerative relationships with health care customers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify; width: 0.5in">&#160;</td>
    <td style="white-space: nowrap; text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The federal Anti-Kickback Statute (and similar state laws) prohibiting, among other things, soliciting, receiving, offering or providing remuneration intended to induce the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as Medicare or Medicaid. A person or entity does not have to have actual knowledge of this statute or specific intent to violate it to have committed a violation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The federal False Claims Act (and similar state laws) prohibiting, among other things, knowingly presenting, or causing to be presented, claims for payment or approval to the federal government that are false or fraudulent, knowingly making a false statement material to an obligation to pay or transmit money or property to the federal government or knowingly concealing, or knowingly and improperly avoiding or decreasing, an obligation to pay or transmit money to the federal government. The government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statute;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify; width: 0.5in">&#160;</td>
    <td style="white-space: nowrap; text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Clearance or approval of product modifications to legally marketed devices that could significantly affect safety or effectiveness or that would constitute a major change in intended use;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify; width: 0.5in">&#160;</td>
    <td style="white-space: nowrap; text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Medical device reporting regulations, which require that a manufacturer report to the FDA if a device it markets may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify; width: 0.5in">&#160;</td>
    <td style="white-space: nowrap; text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Correction, removal and recall reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify; width: 0.5in">&#160;</td>
    <td style="white-space: nowrap; text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Complying with the federal law and regulations requiring Unique Device Identifiers on devices and also requiring the submission of certain information about each device to the FDA&#8217;s Global Unique Device Identification Database;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify; width: 0.5in">&#160;</td>
    <td style="white-space: nowrap; text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The FDA&#8217;s recall authority, whereby the agency can order device manufacturers to recall from the market a product that is in violation of governing laws and regulations if there is a reasonable probability that the use of the device would cause a serious, adverse health consequence or death; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify; width: 0.5in">&#160;</td>
    <td style="white-space: nowrap; text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Post-market surveillance activities and regulations, which apply when deemed by the FDA to be necessary to protect the public health or to provide additional safety and effectiveness data for the device.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA has broad regulatory
compliance and enforcement powers. If the FDA determines that we failed to comply with applicable regulatory requirements, it can take
a variety of compliance or enforcement actions, which may result in any of the following sanctions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify; width: 0.5in">&#160;</td>
    <td style="white-space: nowrap; text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Warning letters, untitled letters, fines, injunctions, consent decrees and civil penalties;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify; width: 0.5in">&#160;</td>
    <td style="white-space: nowrap; text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Recalls, withdrawals, or administrative detention or seizure of our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify; width: 0.5in">&#160;</td>
    <td style="white-space: nowrap; text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Operating restrictions or partial suspension or total shutdown of production;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify; width: 0.5in">&#160;</td>
    <td style="white-space: nowrap; text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Refusing or delaying requests for 510(k) marketing clearance or PMA approvals of new products or modified products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify; width: 0.5in">&#160;</td>
    <td style="white-space: nowrap; text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Withdrawing 510(k) clearances or PMA approvals that have already been granted;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify; width: 0.5in">&#160;</td>
    <td style="white-space: nowrap; text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Refusal to grant export or import approvals for our products; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 0.5in; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Criminal prosecution.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the European Union, or
the EU, we will be required to comply with the new Medical Device Regulation, or the MDR. The MDR was published in May 2017 with a 3-year
transition period, which has been extended. The CE Mark required to sell medical devices in the European Union is affixed following conformity
assessment and either approval from the appointed independent Notified Body or through self-certification by the manufacturer for particular
class I devices. The selected pathway to CE marking is based on product risk classification. CE Marking indicates conformity to the applicable
General Safety and Performance Requirements for the MDR. The MDR change multiple aspects of the existing regulatory framework for CE marking,
such as increased clinical evidence requirements and other new requirements, including Unique Device Identification as well as many other
post-market obligations. MDR also significantly modifies and increases the compliance requirements for the industry and will require significant
investment over the next few years to implement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also required to comply
with the regulations of every other country where we commercialize products before we can launch or maintain new products on the market.
Many countries that previously did not have medical device regulations, or had minimal regulations, are now introducing them. For example,
India is in the process of expanding its current regulations to include all medical device categories while many countries in the Middle
East and Southeast Asia are introducing new regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA and other worldwide
regulatory agencies and competent authorities actively monitor compliance to local laws and regulations through review and inspection
of design and manufacturing practices, record-keeping, reporting of adverse events, labeling and promotional practices. The FDA can ban
certain medical devices, detain or seize adulterated or misbranded medical devices, order repair, replacement or refund of these devices
and require notification of health professionals and others with regard to medical devices that present unreasonable risks of substantial
harm to the public health. The FDA may also enjoin and restrain a company for certain violations of the FDCA and the Safe Medical Devices
Act pertaining to medical devices or initiate action for criminal prosecution of such violations. Regulatory agencies and authorities
in the countries where we do business can halt production in or distribution within their respective country or otherwise take action
in accordance with local laws and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">International sales of medical
devices manufactured in the U.S. that are not approved by the FDA for use in the U.S., or that are banned or deviate from lawful performance
standards, are subject to FDA export requirements. Additionally, exported devices are subject to the regulatory requirements of each country
to which the device is exported. Some countries do not have medical device regulations, but in most foreign countries, medical devices
are regulated. Frequently, regulatory approval may first be obtained in a foreign country prior to application in the U.S. due to differing
regulatory requirements; however, other countries, such as China, for example, require approval in the country of origin first.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most countries outside of
the United States require that product approvals be recertified on a regular basis, generally every five years. The recertification process
requires that we evaluate any device changes and any new regulations or standards relevant to the device and, where needed, conduct appropriate
testing to document continued compliance. Where recertification applications are required, they must be approved in order to continue
selling our products in those countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Expected Regulatory Filings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, our systems have
not been tested on humans and any future testing on humans will be subject to the request of the appropriate regulators, including the
FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are taking a multi-step
approach to the regulatory clearance process. In January 2022, we listed a component of the INSPIRA ART (Gen 2) device and the INSPIRA
ART100 (Gen 1) device on the FDA Class I 510(k) exempt list. The component is intended to reduce the potential complications associated
with jugular vein cannula movement, occurring during a change of a patient&#8217;s posture in bed and/or during transportation. In September
2023, we submitted the INSPIRA ART100 (Gen 1) to the FDA Class II 510(k) for use as a cardio-pulmonary bypass device, based on predicates,
which we do not currently expect to require human trials for FDA clearance. Any modification that could significantly affect its safety
or effectiveness, or that would constitute a major change or modification in its intended use, will require a new marketing clearance,
depending on the modification, 510(k), a de novo or other type of approval. We are planning to apply for the break-through device designation
with the FDA for the INSPIRA ART (Gen 2).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 17, 2024 we submitted
the INSPIRA ART100 (Gen 1) device to the Medical Device Division of the AMAR for approval, in order to enter to some of the leading hospitals
in Israel and other Southeast Asia and South American Markets. AMAR approval generally takes around 120 working days to obtain, and clinical
data may be required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, as a part of
our strategy to bring our device to market and streamline reimbursement coding and clinical adoption of the INSPIRA ART (Gen 2) that offers
a new intent of use, we will collaborate with top ranking hospitals to perform a human observational study focused on (pending approvals)
: (i) proving that the INSPIRA ART (Gen 2)can prevent patient deterioration resulting in the need for invasive MV, and (i) assisting in
weaning patients off MV.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><div><a id="a_015"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Organizational Structure. </b>&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
are an Israeli corporation based in Ra&#8217;anana, Israel and were incorporated in Israel in 2018 under the name Clearx Medical Ltd.
On April 10, 2018, our name was changed to Insense Medical Ltd. and on July 30, 2020, our name was changed to our current name, Inspira
Technologies Oxy B.H.N. Ltd. Our principal executive offices are located at 2 Ha-Tidhar St., Ra&#8217;anana, 4366504 Israel. Our telephone
number in Israel is +972 996 644 88. Our website address is www.inspira-technologies.com. The information contained on our website or
available through our website is not incorporated by reference into and should not be considered a part of this Annual Report, and the
reference to our website in this Annual Report is an inactive textual reference only. The SEC also maintains an Internet website that
contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Our
filings with the SEC will also be available to the public through the SEC&#8217;s website at www.sec.gov.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Currently, we do not have any subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><div><a id="a_016"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt"><b>D.</b></span></td>
    <td><span style="font-size: 10pt"><b>Property, Plant and Equipment. </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our main business activities
are conducted in Israel. Our offices, research and development and manufacturing facilities are located at Melisron (Millennium Building),
2 Ha-Tidhar St., Ra&#8217;anana 4366504, Israel, where we occupy approximately 670 square meters. Our lease ends in August 2027. Our monthly
rent payment is approximately NIS 64,000 (approximately $19,600).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 4A. UNRESOLVED STAFF COMMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 5. <span style="text-transform: uppercase">OPERATING AND FINANCIAL
REVIEW AND PROSPECTS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_019"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Operating Results.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><i>The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial
statements and the related notes included elsewhere in this annual report on Form 20-F. The discussion below contains forward-looking
statements that are based upon our current expectations and are subject to uncertainty and changes in circumstances. Actual results may
differ materially from these expectations due to inaccurate assumptions and known or unknown risks and uncertainties, including those
identified in &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; and under &#8220;Risk Factors&#8221; elsewhere in this
annual report on Form 20-F. </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a specialty medical
device company engaged in the research, development, manufacturing, and marketing of proprietary life support technology with a vision
to supersede traditional mechanical ventilators, or Mechanical Ventilation, which is the standard of care today for the treatment of acute
respiratory failure. Although it may be sometimes lifesaving, Mechanical Ventilation is associated with increased risks, costs of care,
extended lengths of stay, frequent incidence of infections, ventilator dependence and mortality. Using our state-of-the-art life support
technology, our goal is to set a new standard of care and to provide patients with acute respiratory failure an opportunity to maintain
spontaneous breathing and avoid the need for intubation, coma and various risks associated with the use of Mechanical Ventilation. As
part of our strategy to reach this goal, and in parallel to pursuing regulatory approvals, we are actively working to establish collaborations
with strategic partners, globally ranked hospitals, medical device companies and distributors both for endorsement and early clinical
adoption. &#160;We plan to target intensive care units, or ICUs, general medical units, operating theaters, and small urban and rural
hospitals, with the goal of making our solutions more accessible to millions of patients worldwide. We expect for these activities to
support our strategy plan to reach market penetration and adoption of our life support technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception in 2018,
we have incurred operating losses. Our operating loss for the years ended December 31, 2023 and 2022 were approximately $12.1 million
and $14.9 million, respectively; and our net loss for the same period was $11.3 million and $15 million. As of December 31, 2023, we had
an accumulated deficit of $55.5 million. We expect to continue to incur significant expenses and operating losses for the foreseeable
future, and our losses may fluctuate significantly from year to year. We anticipate that our expenses will increase significantly in connection
with our ongoing activities, as we:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Continue clinical development of our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">File new applications seeking regulatory approval for the products pursuant to FDA&#8217;s Section 510(K) or other regulatory pathway in the United States;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Continue to invest in the preclinical research and development of any future product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Establish a commercial infrastructure to support the marketing, sale and distribution of the products if they receive regulatory approval;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Hire additional research and development and general and administrative personnel to support our operations;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Maintain, expand and protect our intellectual property portfolio; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Continue to incur costs associated with operating as a public company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have any product
candidates approved for sale and have not generated any revenue from product sales.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 16, 2021, we closed
our initial public offering, or IPO, whereby we sold 2,909,091 Ordinary Shares and 3,345,455 tradable warrants (inclusive of 436,364 tradable
warrants pursuant to the exercise of an overallotment option granted to the underwriters). The aggregate gross proceeds received by us
from the IPO were $16 million, before underwriting discounts and other offering costs. Prior to our IPO, we financed our operations primarily
through convertible debt, as well as grants from the Israel Innovation Authority, or the IIA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Current Outlook</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
have financed our operations to date primarily through proceeds from sales of our Ordinary Shares, convertible notes and loans and from
grants from the IIA. We have incurred losses and generated negative cash flows from operations since inception in 2018. Since inception,
we have not generated any revenue and we do not expect to generate significant revenues in the near future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">As
of December 31, 2023, our cash and cash equivalents and cash deposits were $7.4 million. On July 16, 2021, we closed our initial public
offering. The aggregate gross proceeds received by us from the IPO were $16 million, before underwriting discounts and other offering
costs. In October 2021, some investors exercised their tradable warrants, with aggregate gross proceeds of $9.3 million received by us
as a result.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
have an effective Form F-3 registration statement (File No. 333-266748), filed under the Securities Act of 1933, with the SEC using a
&#8220;shelf&#8221; registration process. Under this shelf registration process, we may, from time to time, sell our Ordinary Shares and
warrants to purchase Ordinary Shares, and units of two or more of such securities in one or more offerings up to a total dollar amount
of $50,000,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On
April 4, 2023, we entered into a Sales Agreement, or the Sales Agreement, with Roth Capital Partners, LLC, or the Sales Agent, pursuant
to which we sold an aggregate of 17,566 Ordinary Shares for a total of $26,000. We terminated the Sales Agreement effective October 23,
2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On
December 26, 2023, we entered into a private placement with an institutional investor providing for the issuance in a registered direct
offering of 1,375,000 Ordinary Shares at a purchase price of $1.28 and pre-funded warrants to purchase up to an aggregate of 1,656,250
Ordinary Shares at an exercise of $1.28 per share less $0.001 per pre-funded warrant. The Warrants were exercisable immediately upon issuance
and will expire three and a half years following their issuance. In addition, pursuant to the purchase agreement, the Company issued warrants
to the institutional investor to purchase up to an aggregate of 3,031,250 Ordinary Shares at an exercise price of $1.28 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">H.C. Wainwright &amp;
Co., LLC, acted as the exclusive placement agent for the offering. In connection with the Purchase Agreement, we issued to the Placement
Agent warrants to purchase up to a total of 7.0% of the aggregate number of Ordinary Shares sold in the transaction, or warrants to purchase
up to 212,188 Ordinary Shares, or the Placement Agent Warrants. The Placement Agent Warrants were substantially on the same terms as the
Warrants issued to the investor in the offering, except the Placement Agent Warrants had an exercise price of $1.60 per share. &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
expect that our existing cash and cash equivalents as of December 31, 2023 will enable us to fund our operating expenses and capital expenditure
requirements for the next six months. We expect that we will require substantial additional capital to operate and to commercialize our
products and we expect to seek additional funds to enable us to fund our operations for the next twelve months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
operating plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional funds sooner
than planned. Our future capital requirements will depend on many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; ">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the progress and costs of our research and development activities;</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the costs of manufacturing our products;</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the potential costs of contracting with third parties to provide marketing and distribution services for us or for building such capacities internally; and</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the magnitude of our general and administrative expenses.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until we can generate significant
recurring revenues, we expect to satisfy our future cash needs through debt and/or equity financings. We cannot be certain that additional
funding will be available to us on acceptable terms, if at all. This may raise substantial doubt about our ability to continue as a going
concern.&#160;The financial statements do not include any adjustments that might result from the outcome of this uncertainty. If funds
are not available, we may be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization
efforts with respect to our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Operating Expenses</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
current operating expenses consist of three components - research and development expenses, general and administrative expenses and marketing
expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Revenue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have not generated
revenue from the sale of any product, and we do not expect to generate significant revenue within the next year at least.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Expenses, net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
research and development expenses consist primarily of salaries and related personnel expenses, share-based compensation expenses, materials
costs consultants and other third parties who support the developments of our products and other related research and development expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>The
following tables discloses the breakdown of research and development expenses:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year
Ended<br/> December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic; border-bottom: Black 1.5pt solid">U.S. dollars in thousands</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Share based compensation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">663</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,392</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,792</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,429</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,458</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,543</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Subcontractors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">304</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">850</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">496</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Materials and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,081</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">204</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">IIA participation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(106</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">291</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">188</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">268</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">214</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">47</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,320</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">8,183</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,070</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
expect that our research and development expenses will materially increase as we continue to develop our products and recruit additional
research and development employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>General and Administrative Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">General
and administrative expenses consist primarily of salaries and related expenses, share based compensation, professional service fees for
accounting and booking, legal fees, facilities, travel expenses and other general and administrative expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
following tables discloses the breakdown of general and administrative expenses:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic">Unaudited</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic; border-bottom: Black 1.5pt solid">U.S. dollars in thousands</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">share-based compensation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">675</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,984</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,696</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,432</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,390</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Related funds raising expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">546</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Directors&#8217; fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">766</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">716</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">545</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Insurance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">557</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">363</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">129</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Travel abroad</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,063</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,375</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,937</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Comparison of the
Years Ended December 31, 2023, 2022 and 2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Results of Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
following tables summarizes our results of operations for the years ended December 31, 2023, 2022 and 2021:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended <br/> December 31,</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic; border-bottom: Black 1.5pt solid"><b>U.S. dollars in thousands</b></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2023</b></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2022</b></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2021</b></td>
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Research and development expenses</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">7,320</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">8,183</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">4,070</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4,063</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">5,375</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">6,937</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sales and Marketing expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">746</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,328</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,980</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses (income)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">4</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">7</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(23</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating loss</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">12,133</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">14,893</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">12,964</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Interest Income from deposits</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(318</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(192</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(1</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Financial expenses (income), net</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(529</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">275</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">4,230</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">11,286</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">14,976</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">17,193</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Loss attributable to holders of Ordinary Shares</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">11,286</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">14,976</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">17,193</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and Development Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>Our
research and development expenses for the year ended December 31, 2023, amounted to $</span>7,320,000 <span>representing
a decrease of $</span>863,000<span>, or </span>11<span>%, compared to
$8,183,000 for the year ended December 31, 2022. There was a decrease of $</span>1,729,000 <span>in share-based
payment expenses and an increase of $</span>971,000 <span>in salaries and related personnel expenses reflecting
an increase in the number of research and development employees with the efforts to support the research and development. There was also
a decrease of $</span>546,000 <span>in subcontractors&#8217; expenses related to development projects
that were outsourced during 2022 and but were performed internally by our employees in 2023, and additional increase of $</span>284,000
in <span>materials and related expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
research and development expenses for the year ended December 31, 2022, amounted to $8,183,000, an increase of $4,113,000, or 101%, compared
to $4,070,000 for the year ended December 31, 2021. There was an increase of $1,915,000 in salaries and related personnel expenses and
an increase of $600,000 in share-based payment expenses reflecting an increase in the number of research and development employees, an
increase of $354,000&#160;in subcontractors&#8217; expenses related to development projects we process by outsourcing, and an additional
increase of $877,000&#160;in materials and related expenses using in-house personnel. Additionally, we had research and development expenses
for the year ended December 31, 2021, includes IIA grants in the amount of $106,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>General and administrative expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
general and administrative expenses totaled $4,063,000 for year ended December 31, 2023, a decrease of $1,312,000, or 24%, compared to
$5,375,000 for the year ended December 31, 2022. The decrease was primarily attributable to a decrease of $1,309,000 in employees and
directors share-based compensation expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span>Our
general and administrative expenses totaled $5,375,000 for year ended December 31, 2022, a decrease of $1,562,000, or 23%, compared to
$6,937,000 for the year ended December 31, 2021. The decrease was primarily attributable to a decrease of $1,712,000 in employees and
directors share-based compensation expenses and a decrease of $546,000 in related IPO expenses which took place in 2021. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Sales and marketing
expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Marketing
expenses for the year ended December 31, 2023, amounted to $746,000 representing a decrease of $582,000, or 44%, compared to $1,328,000
for the year ended December 31, 2022. The decrease is attributable to a decrease of $414,000 in employee share-based compensation expenses
and decrease of $179,000 in professional fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span>Marketing
expenses for the year ended December 31, 2022, amounted to $1,328,000 representing a decrease of $652,000, or 33%, compared to $1,980,000
for the year ended December 31, 2021. The decrease is attributable to a decrease of $712,000 in employee share-based compensation expenses.
</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Operating loss</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">As
a result of the foregoing, our operating loss for year ended December 31, 2023, amounted to $12,133,000 representing a decrease of $2,760,000,
or19%, compared to $14,893,000 for the year ended December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span>Our
operating loss for year ended December 31, 2022, amounted to $14,893,000 representing an increase of $1,929,000, or 15.0%, compared to
$12,964,000 for the year ended December 31, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Financial expenses </i></b>(income)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial income consists
of deposit interest, revaluation of financial liabilities presented at fair value and foreign currency changes reflections.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognized interest income
from deposits in amount of $318,000 and financial income<span>, amounting to $529,000 representing mainly
exchange rate reflections and income </span>due to change in the fair value of financial liabilities for the year ended <span>December
31, 2023</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended December
31,2022 we recognized interest income deposits in amount of $192,000 and financial expenses<span>, amounting
to $275,000 representing mainly exchange rate reflections and income </span>due to change in the fair value of financial liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Total net loss</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>As
a result of the foregoing, our total net loss for the year ended December 31, 2023, amounted to $11,286,000 representing a decrease of
$3,690,000, or 25%, compared to a loss of $14,976,000 for the year ended December 31, 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>As
a result of the foregoing, our total net loss for the year ended December 31, 2022, amounted to $14,976,000 representing a decrease of
$2,217,000, or 13%, compared to a loss of $17,193,000 for the year ended December 31, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_020"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Liquidity and Capital Resources</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Overview </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023,
we had $<span>7.4 </span>in cash, cash equivalents and cash deposits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below presents
our cash flows for the year ended December 31, 2023 and December 31, 2022:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic; border-bottom: Black 1.5pt solid">U.S. dollars in thousands</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(9,756</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(9,647</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(6,685</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net cash provided by (used in) investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,594</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,383</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(182</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,453</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,195</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net increase (decrease) in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,709</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,030</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,328</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Operating Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our incorporation, we
have had ongoing losses and incurred negative cash flows from operating activities. For example, in the year ended December 31, 2023,
we had operating losses of $12,133,000. We have mainly financed our activities in the year ended December 31, 2023 through the funds received
from the issuance of Ordinary Shares and warrants Management plans to continue to commercialize our products and services and secure sufficient
financing through additional equity or debt financing. There are no assurances however, that we will be successful in obtaining the level
of financing needed for our operations or that such financing will be available on terms acceptable to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Net
cash used in operating activities of $9,756,000 during the year ended December 31, 2023, net cash used in operating activities of $9,647,000
during the year ended December 31, 2022 and net cash used in operating activities of $6,685,000 during the year ended December 31, 2021
was primarily used for payment of salaries and related personnel expenses, materials expenses, subcontractors, travel and office maintenance.
In addition, cash flows from operating activities are impacted by changes in operating assets and liabilities, which include trade account
payables and financial liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Investing Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by investing activities of $4,594,000
during the year ended December 31, 2023, consisted mostly of $206,000 used for purchasing property and equipment, and $4,800,000 representing
the proceeds from sale of short-term deposits. Net cash used in investing activities of $7,383,000 during the year ended December 31,
2022 consisted mostly of $263,000 used for purchasing property and equipment, and $7,120,000 for investment in short term deposits. net
cash used in investing activities of $182,000 during the year ended December 31, 2021, all used for purchasing property and equipment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Financing Activities </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities of $3,453,000 <span>during the year ended December 31, 2023</span>, consisted mainly of $2,128,000
from issuance of Ordinary Shares and $1,750,000 from issuance of warrants to purchase Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>No
cash was provided by or used in financing activities during the year ended December 31, 2022</span>. Net cash provided by financing activities
of $30,195,000 <span>during the year ended December 31, 2021</span>, consisted issuance of Ordinary Shares
and tradable warrants to purchase Ordinary Shares in the IPO, and exercise of warrants in October 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
have an effective Form F-3 registration statement (File No. 333-266748), filed under the Securities Act of 1933, with the SEC using a
&#8220;shelf&#8221; registration process. Under this shelf registration process, we may, from time to time, sell our Ordinary Shares and
warrants to purchase Ordinary Shares, and units of two or more of such securities in one or more offerings up to a total dollar amount
of $50,000,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">On
April 4, 2023, we entered into a Sales Agreement, or the Sales Agreement, with Roth Capital Partners, LLC, or the Sales Agent, pursuant
to which we may offer and sell, from time to time, through the Sales Agent, the Company&#8217;s Ordinary Shares, no par value per share.
The ordinary share will be offered and sold pursuant to our Registration Statement on&#160;Form F-3&#160;(File No. 333-266748), and a
prospectus supplement to the Registration Statement, filed on April 4, 2023 with the SEC. On October 23, 2023, notice was provided to
Roth to terminate the ATM Agreement, effective immediately. As of October 23, 2023, we have sold an aggregate of approximately $26,000
of Ordinary Shares pursuant to the ATM Program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><div><a id="a_021"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font-size: 10pt"><b>5.C</b></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Research and development,
patents and licenses, etc.</b></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a description of our research
and development programs and the amounts that we have incurred over the last two years pursuant to those programs, please see &#8220;Item
5. Operating and Financial Review and Prospects- A. Operating Results- Operating Expenses- Research and Development Expenses, net&#8221;
and &#8220;Item 5. Operating and Financial Review and Prospects- A. Operating Results- Comparison of the year ended December 31, 2023
to the year ended December 31, 2022- Research and Development Expenses.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_022"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-size: 10pt"><b>5.D</b></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Trend Information</b></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The COVID-19 pandemic has
impacted companies in Israel and around the world, and as its trajectory remains uncertain. As of the date of this annual report, our
management continues to examine the impacts of COVID-19 and are unable to estimate the full extent of its possible effects. No significant
adverse effect on our operations and on the results of our operation, is apparent at this stage. However, we cannot predict the future
impacts it may have on our business. Further, we cannot predict impacts, trends and uncertainties involving the pandemic&#8217;s effects
on economic activity, the size of our labor force, our third-party partners, our investments in marketable securities, and the extent
to which our revenue, income, profitability, liquidity, or capital resources may be materially and adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_023"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font-size: 10pt"><b>E.</b></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Critical Accounting Estimates</b></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We describe our significant
accounting policies more fully in Note 2 to our financial statements for the year ended December 31, 2023. We believe that the accounting
policies below are critical in order to fully understand and evaluate our financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beginning with the year ended December 31, 2023,
we prepare our financial statements in accordance with <span>U.S. GAAP</span>. At the time of the preparation
of the financial statements, our management is required to use estimates, evaluations, and assumptions which affect the application of
the accounting policy and the amounts reported for assets, obligations, and expenses. Any estimates and assumptions are continually reviewed.
The changes to the accounting estimates are credited during the period in which the change to the estimate is made. The preparation of
financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
in relation with stock-based compensation expense, fair value financial liabilities, recognition, measurement, and disclosure of contingent
liabilities, Interest rate used for lease liability measurement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 6. <span style="text-transform: uppercase">DIRECTORS,
SENIOR MANAGEMENT AND EMPLOYEES</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_025"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Directors and Senior Management.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information regarding our executive officers, key employees and directors as of the date of this annual report on Form 20-F:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 0%">&#160;</td>
    <td style="width: 4%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Age</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Dagi Ben-Noon</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">47</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer, Director</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Joe Hayon</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">50</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">President and Director</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Yafit Tehila</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">43</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Avi Shabtai</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">50</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Operations Officer and VP of Research and Development</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Daniella Yechezkeli Hayon </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">50</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Technology Officer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Prof. Benad Goldwasser <sup>&#160;(3)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">74</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chairman of the Board of Directors</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Lior Amit <sup>(1) (2) (3)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">58</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Tal Parnes <sup>(1) (2) (3)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">55</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director </span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Limor Rozen <sup>(1) (2) (3)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">50</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; ">
    <td style="width: 0.25in"><span style="font-size: 10pt">(1)</span></td>
    <td><span style="font-size: 10pt">Member of the Compensation Committee</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">(2)</span></td>
    <td><span style="font-size: 10pt">Member of the Audit Committee and Financial Statement Examination Committee</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">(3)</span></td>
    <td><span style="font-size: 10pt">Independent Director (as defined under Nasdaq Stock Market rules)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Dagi Ben-Noon, Chief
Executive Officer, Director</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Dagi Ben-Noon</i> has
served as our Chief Executive Officer since July 2020 and as a director since March 2020. Prior to that, Mr. Ben-Noon served as our Chief
Operations Officer from March 2018 to June 2020. Mr. Ben-Noon founded our company together with Dr. Udi Nussinovitch and Mr. Joe Hayon
in February 2018. Mr. Ben-Noon has over 15 years of experience in product development from idea inception to illustration, design, manufacturing
and product launch. Mr. Ben-Noon co-founded Nano Dimension Ltd. (Nasdaq: NNDN) and served as the company&#8217;s chief operating officer
and director from July 2012 to October 2017. As Nano Dimension Ltd.&#8217;s chief operating officer, Mr. Ben-Noon was in charge of the
company&#8217;s research and development, operations, production, quality and information technology. Mr. Ben-Noon has a BSc in Mechanical
Engineering from the Ben-Gurion University of the Negev in Beer Sheva, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Joe Hayon, President
and Director</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Joe Hayon</i> has served
as our President since August 2022 and as a Director since November 2020. Mr. Hayon served as a President and Chief Financial Officer
from June 2020 to August 2022. Prior to that, Mr. Hayon served as our Chief Executive Officer from March 2018 to June 2020. Mr. Hayon
founded our company together with Dr. Udi Nussinovitch and Mr. Dagi Ben-Noon in July 2017. Mr. Hayon has over 20 years of experience in
managerial roles. From 2001 to 2005, Mr. Hayon worked as a treasurer and cost accountant at Sanmina Ltd. (formerly known as Elscint).
From 2006 to 2007, Mr. Hayon worked as chief financial officer for Arazim Group. He worked for Plasan Sasa Ltd. from 2007 to 2018 as the
company&#8217;s chief information officer and group controller. Mr. Hayon has a B.A. in Business and Economics and an MBA with a major
in Marketing and Finance, both from the University of Manchester, as well as a Business Management Diploma from Damelin College.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Yafit Tehila, Chief Financial Officer</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Ms. Yafit Tehila </i>has
served as our Chief Financial Officer since August 2022. Prior to becoming our CFO, Ms. Tehila served as our Vice President of Finance
and Legal since February 2021. Ms. Tehila served as Director of Finance at Nano Dimension Ltd. (NASDAQ: NNDM) from November 2020 through
February 2021 and Financial Controller from February 2016 through November 2020. Ms. Tehila served as Financial Controller at Migdal Capital
Markets from August 2010 through November 2016. Ms. Tehila received has a B.A. in Accounting, Economics and business management from Tel
Aviv University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Avi Shabtai, Chief
Operations Officer and Vice President of Research and Development</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Avi Shabtai</i> has
served as our Chief Operations Officer since July 2020 and as our Vice President of Research and Development since June 2019. Mr. Shabtai&#8217;s
expertise lies in engineering, testing, quality management, regulation, risk management and production across a product&#8217;s life cycle
from concept to production. He has over 25 years of experience in management of high-tech companies, particularly in their research and
development and operations departments, including roles of vice president of research and development and vice president of quality and
engineering. From July 2015 to March 2018, Mr. Shabtai worked as vice president of research and development at Nano Dimension Ltd. (Nasdaq:
NNDN). Prior to that, Mr. Shabtai worked as vice president of research and development at ZutaCore from April 2018 to May 2019. Mr. Shabtai
is qualified as software quality engineer by the ALD College and the Israeli Standard Institute.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Daniella Yeheskely -Hayon, PhD, MBA, Chief
Technology Officer.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Daniella Yeheskely-Hayon
</i>has served as our Chief Technology Officer since January 2022. Dr. Yeheskely-Hayon has comprehensive project management experience
in biomedical engineering as well as in key roles within medical device companies. Since June 2016, Dr. Yeheskely-Hayon has served as
the director of research and development and chief of operations at O2Cure Ltd., a medical device company that specializes in the development
of long-term oxygenators and respiratory assist devices for hospitals. From October 2009 to May 2016, Dr. Yeheskely-Hayon served as a
senior research associate at the Technion Department of Biomedical Engineering. Dr. Yeheskely-Hayon holds a PhD in Biology from the Technion
Institute, Israel and an MBA from ONO academic college.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Prof. Benad Goldwasser,
MD MBA, Chairman of the Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Benad Goldwasser
</i>has served as chairman of our board of directors since February 2021. <span>Prof. Goldwasser is a
urologic surgeon, inventor, entrepreneur and venture capital investor with vast experience in leading high growth, publicly traded medical
companies. In 1993, Prof. Goldwasser co-founded Vidamed Inc., which was acquired by Medtronic Inc. (NYSE: MDT). In 1994, Prof. Goldwasser
co-founded Medinol Ltd. (NYSE: BSX). Prof. Goldwasser has served as chairman of the board of directors of Save Foods, Inc. (OTC: SAFO)
since May 2018 and as chairman of the board of directors of ScoutCam Inc. (OTC: SCTC) since March 2019, and as a member of the board of
directors of Innoventric Ltd. since September 2017. Prior to that, Prof. Goldwasser has served as chairman of the board of directors of
Medigus Ltd. (Nasdaq and TASE: MDGS) from September 2018 to December 2019, and as a consultant to Shanghai-Israel Investment Fund from
May 2016 to May 2019. In 2016, Prof. Goldwasser launched a venture capital fund partnered with Shanghai Alliance Investment Ltd (SAIL),
a Shanghai Government investment company. Prof. Goldwasser has also served on the board of directors of BioCanCell Ltd. (TASE: BICL) from
2013 to 2016. Prof. Goldwasser holds an MD and MBA from Tel Aviv University. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Lior Amit, Director</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><i>Mr.
Lior Amit</i> has served on our board of directors since August 1, 2021. Since 2014, Mr. Amit has served as a private financial advisor
for both high net worth individuals and companies and serves as a director in Scoutcam Inc., ICIC, an Israeli credit insurance company,
Nirplex and Ronimar LTD. Mr. Amit was the CFO of the BBR Saatchi &amp; Saatchi advertising group in Israel from 1996 to 2013, helping
to turn it into a leading local advertising company including advertising agencies, media operations and digital and content, growing
from 40 employees to 250 employees. Mr. Amit holds a Master of Business Administration ((Finance and Insurance) and a B.A. in Economics
and Accounting from the Tel Aviv University. Mr. Amit is a Certified Public accountant in Israel and holds an advisor license with the
Israeli Securities Authority.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Limor Rozen, Director
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span><i>Mrs.
Limor Rozen</i> has served on our board of directors since July 16, 2021. Mrs. Rozen has been working a senior consultant at Vecon Ltd.
from 2019. Prior to that, Mrs. Rozen was co-founded and served as a chief executive officer and general manager of zzoo from 2017 to 2020.
From 2012 to 2017, Mrs. Rozen served as a chief operating officer of 365 Technologies Ltd. Mrs. Rozen also served as VP of product and
customer projects of Collarity in Palo Alto, California from 2006 to 2011, served as senior team leader at Right Order</span>, Inc.<span>,
San Jose, California from 2000 to 2006 and as a team leader at Comverse Technology, Inc between 1999 to 2004. Mrs. Rozen holds an MBA
with specialization in Technology Management from University of Phoenix, Phoenix, Arizona, and a B.A. in Computer Science from Bar-Ilan
University. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Tal Parnes, Director </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Tal Parnes</i> <span>has
served on our board of directors since July 16, 2021. Mr. Parnes co-founded and served as a chief executive officer and president of
Zuta-Core Ltd. from 2016 to 2020. Prior to that, Mr. Parnes co-founded and served as a chief executive officer of HQL Pharmaceuticals
Ltd. from 2010 to 2015. Mr. Parnes also served as chief operating officer of Silynx Communications Inc. from 2007 to 2009, served as
a vice president of operations of Wavion Inc. from 2005 to 2006 and vice president of operations of Atrica Ltd. from 2002 to 2004. Between
1999 to 2001, Mr. Parnes also served as a chief financial officer and business development director of Printlife Ltd. Mr. Parnes holds
a B.A. in Economics and History from Tel Aviv University.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Scientific Advisory Board</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have a Scientific Advisory
Board of several active physicians and experts in the fields of respiratory disease, pulmonary diseases, cardiac disease and laboratory
animal science. The Scientific Advisory Board consults and assists us in the aforementioned fields by conducting clinical research and
participating in pre-clinical studies. The members of our Scientific Advisory Board receive compensation in the form of cash payments
or option grants. All members of the Scientific Advisory Board provided us with their consent to be named in this annual report on Form
20-F and any materials related hereto.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><i>Dr.
Avraham Abutbul, M.D.,</i> has held numerous positions at the Hadassah Medical Center in Jerusalem, Israel, since 2008. Currently, Dr.
Abutbul has served a senior physician the Hadassah Medical Center&#8217;s Medical Intensive Care Unit and its Pulmonology Institute since
2017, in addition to leading the Hadassah Medical Center&#8217;s nationwide research of chronic obstructive pulmonary disease. Prior to
his current roles, Dr. Abutbul completed fellowship at the Institute of Pulmonology in 2016 and the General Intensive Care Unit in 2014.
Dr. Abutbul also completed residency at the Department of Internal Medicine in 2012. Dr. Abutbul is a lecturer at the Hebrew University
of Jerusalem, Israel and at the Hadassah Medical School, Jerusalem, Israel. Dr. Abutbul received his B.Med.Sc. from the Ruth and Bruce
Rappaport Faculty of Medicine in Haifa, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><i>Professor
Daniel Brodie</i> is the Section Chief for Critical Care within the Division of Pulmonary, Allergy and Critical Care Medicine, the Director
of the Adult ECMO Program and the Director of the Center for Acute Respiratory Failure at the Columbia University/New York-Presbyterian
Hospital. Prof. Brodie is the President-elect of the Extracorporeal Life Support Organization (ELSO) and the chairman of the Executive
Committee of the International ECMO Network (ECMONet), two leading international organizations spearheading scientific knowledge in the
field of extracorporeal life support. He is currently on the Steering Committee of numerous ongoing and upcoming clinical trials in the
field. In addition, Prof. Brodie serves as a member of the National Heart, Lung, and Blood Institute&#8217;s (NHLBI) Protocol Review Committee
for the Prevention and Early Treatment of Acute Lung Injury (PETAL) Network. Prof. Brodie has served as a reviewer in influential scientific
journals, including the New England Journal of medicine, Lancet and JAMA. Prof Brodie has authored more than 300 peer-reviewed publications
and book chapters and has delivered nearly 400 invited lectures throughout the world.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Eddy Fan</i> is an
associate professor in the Interdepartmental Division of Critical Care Medicine and the Institute of Health Policy, Management and Evaluation
at the University of Toronto and a staff intensivist at the University Health Network/Mount Sinai Hospital in Toronto, Ontario. Prof.
Fan currently is the medical director of the extracorporeal life support program at the Toronto General Hospital. Dr. Fan received an
undergraduate degree from the University of Toronto, his medical degree from the University of Western Ontario and a doctorate in clinical
investigation from Johns Hopkins University. Among his most significant publications are: (1) &#8220;An Official American Thoracic Society/European
Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients
with Acute Respiratory Distress Syndrome&#8221; in the American Journal of Respiratory and Critical Care Medicine; (2) &#8220;Veno-venous
extracorporeal membrane oxygenation for acute respiratory failure: a clinical review from an international group of experts.&#8221; in
Intensive Care Medicine; and (3) Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in
intensive care units in 50 countries&#8221; published in JAMA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Orit Cohen Jacob</i>
is veterinary surgeon with a unique certified specialty in laboratory animal medicine. Dr. Jacob held numerous positions at the Israel
Institute for Biological Research in Ness Ziona, Israel, for 16 years, while leading the establishment of the biggest pre-clinical animal
facility and laboratories in Israel. At the Israel Institute for Biological Research, Dr. Jacob founded a GMP stable facility, for anti-serum
production for the State of Israel. Dr. Jacob participated as a surgeon and advisor, in her field of expertise, in a wide variety of research
studies, related to homeland security from 1999 to 2015. Dr. Jacob was a member of the national animal experimentation council of the
ministry of health, and head of the national ethics committee for animal experimentations from 2013 to 2018. Currently, Dr. Jacob is the
co-owner and chief executive officer of SeruMed GMP Ltd., which has been the sole manufacturer and provider of the anti-venom serum against
viper and echis snakes to the Ministry of Health of Israel since 2016. Furthermore, Dr. Jacob is the owner of BioSphera Consulting Ltd.,
through which she has been providing knowledge to bio-tech companies in all aspects of pre-clinical research, facility establishment,
GMP regulations, ethics and science since 2016.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Stefan Ledot</i> is
an expert in various clinical fields including critical care medicine, anesthesia, extracorporeal support and echocardiography. During
his career, he has undertaken a large number of educational duties, including advanced cardiovascular life support (ACLS) instruction,
critical care module for physiotherapists instruction, critical care module nursing school instruction, among others. Dr. Ledot is a highly
appreciated speaker in the critical care space. Dr. Ledot completed his accreditation for transesophageal echocardiography (TOE) from
the European Association of Cardiovascular Imaging and holds a European Diploma in Intensive Care. Dr. Ledot has served as a senior clinician
in critical care and anesthetics at Royal Brompton &amp; Harefield Hospitals in the United Kingdom and became the director of the extracorporeal
membrane oxygenation (ECMO) service and critical care. The Royal Brompton ECMO service is one of the largest in Europe and has been recognized
as a center of excellence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Yael Lichter </i>is
Director of the Medical Intensive Care Unit at Tel Aviv Sourasky Medical Center, where she completed her residency training in Internal
Medicine and Intensive Care. She also serves as Treasurer of the Israeli ECMO Society. Dr. Lichter served as a Captain in the IDF Medical
Corps, as a field doctor in combat units. She completed her medical training at the Tel Aviv University the Sackler Faculty of Medicine.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Sharon Marx</i> obtained
a PhD in physical organic chemistry from the Hebrew University, Jerusalem in 1996. Since 1996, Dr. Marx has worked at the Israel Institute
for Biological Research in the physical chemistry department. Dr. Marx was a fellow at the Israel Institute for Biological Researchand
is currently serving as the physical chemistry department head. From 2008 to 2010, Dr. Marx was an Assistant Professor (on sabbatical)
at the University of Pennsylvania and developed biocompatible fuel cells while there. Her research interests include sensor and biosensors
development, chemical sensor networks, molecularly imprinted polymers, chemiresistors, sensors for gas phase (air pollution, toxic materials)
and sensors for water quality.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Dekel Stavi, </i>medical
director, has considerable experience in leading Extracorporeal Life Support programs, and treating cardio and hemato-oncology patients
in the ICU. Prior to joining Critical Care at the University of Toronto, he served as a senior intensive care physician at the Tel Aviv
Sourasky Medical Center in Israel where he initiated its institutional extracorporeal membrane oxygenation (ECMO) program. Dr. Stavi&#8217;s
notable publications include &#8220;Outcomes of prolonged mechanical ventilation in patients who underwent bedside percutaneous dilatation
tracheostomy in intermediate care units - a single center study&#8221; and &#8220;Outcome and survival following tracheostomy in patients
&#8805; 85 years old.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Dan Gorfil </i>is a
distinguished specialist in cardiac surgery and intensive care medicine. Dr. Gorfil is both the head of the Cardiothoracic Surgery Intensive
Care Unit and the Extracorporeal Membrane Oxygenation program at the Department of Cardiothoracic Surgery at Rabin Medical Center, Israel.
Dr. Gorfil&#8217;s expertise is expected to significantly contribute to the deployment of the INSPIRA&#8482; ART100. U.S. Food and Drug
Administration (FDA) approval is expected in the first half of 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Family Relationships</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no family relationships
between any members of our executive management and our directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Arrangements for
Election of Directors and Members of Management</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">There
are no arrangements or understandings with major shareholders, customers, suppliers or others pursuant to which any of our executive management
or our directors were selected. See &#8220;Item 7.B. - Related Party Transactions&#8221; for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_026"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Compensation</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents
all compensation paid by us to our five most highly compensated officers for the year ended December 31, 2023. The table does not include
any amounts we paid to reimburse any of such persons for costs incurred in providing us with services during this period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All amounts reported in the
tables below reflect the cost to the Company, in U.S. Dollars, for the year ended December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Amounts paid in NIS are translated
into U.S. dollars at the rate of NIS 3.56 = U.S. $1.00, based on the average representative rate of exchange between the NIS and the U.S.
dollar as reported by the Bank of Israel during such period of time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Salary,<br/> bonuses<br/> and</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Related</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Benefits</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pension,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Retirement</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>and Other</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Similar</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Benefits</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Share<br/> Based<br/> Compensation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-size: 10pt">Dagi Ben-Non, <i>Chief Executive Officer</i></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">269,187</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">21,125</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">230,878</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-size: 10pt">Joe Hayon, <i>President and Director</i></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">271,727</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">21,125</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">230,878</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-size: 10pt">Yafit Tehila, <i>Chief Financial Officer</i></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">178,386</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">38,739</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">109,684</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-size: 10pt">Avi Shabtai, <i>Chief Operations Officer and VP of Research and Development</i></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">287,006</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">52,357</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">55,811</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10.25pt">Daniella Yeheskely-Hayon, Phd, Chief Technology Officer</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">178,396</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">38,739</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">62,313</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10.25pt">Adi Nir , Phd, Chief Medical Officer (until termination in October 2023)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">134,740</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">29,812</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For so long as we qualify
as a foreign private issuer, we will not be required to comply with the proxy rules applicable to U.S. domestic companies regarding disclosure
of the compensation of certain executive officers on an individual basis. Pursuant to the Companies Law, as a public company we are required
to disclose the annual compensation of our five most highly compensated officers on an individual basis. This disclosure will not be as
extensive as that required of a U.S. domestic issuer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Employment Agreements
with Executive Officers </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into written
employment agreements with each of our executive officers. All of these agreements contain customary provisions regarding noncompetition,
confidentiality of information and assignment of inventions. However, the enforceability of the noncompetition provisions may be limited
under applicable law. In addition, we entered into indemnification agreements, with each executive officer and director pursuant to which
we indemnify each of them up to a certain amount and to the extent that these liabilities are not covered by directors and officers insurance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">For
a description of the terms of our options and option plans, see &#8220;Item 6.E. Share Ownership-Equity Incentive Plan.<span style="font-variant: small-caps">&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-variant: small-caps">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Directors&#8217; Service Contracts</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Other than with respect to our directors that are
also executive officers, we do not have written agreements with any director providing for benefits upon the termination of his employment
with our company. In our general meeting, which took place in December 2021, we instituted a yearly fixed fee in the amount of $40,000
for each of our directors who are not also executive officers and fixed fee in the amount of $120,000 for the board chairman.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><div><a id="a_027"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Board Practices. </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Introduction</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors consists
of six members. We believe that Professor Benad Goldwasser, Limor Rozen, Lior Amit, and Tal Parnes are &#8220;independent&#8221; for purposes
of the Nasdaq Stock Market rules. Our amended and restated articles of association provide that the number of board of directors&#8217;
members shall be set by the general meeting of the shareholders provided that it will consist of not less than three (3) and not more
than twelve (12). Pursuant to the Companies Law, the management of our business is vested in our board of directors. Our board of directors
may exercise all powers and may take all actions that are not specifically granted to our shareholders or to management. Our executive
officers are responsible for our day-to-day management and have individual responsibilities established by our board of directors. Pursuant
to the Companies Law, our Chief Executive Officer is appointed by, and serves at the discretion of, our board of directors, subject to
the employment agreement that we have entered into with him. All other executive officers are appointed by our Chief Executive Officer.
According to the Companies Law, their terms of employment are subject to the approval of the board of directors&#8217; compensation committee
and of the board of directors (and in some cases are also subject to shareholders approval), and are subject to the terms of any applicable
employment agreements that we may enter into with them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each director, except external
directors, if applicable, that may be required to be appointed under the Companies Law under certain circumstances, will hold office until
the next annual general meeting of our shareholders following his or her appointment, or until he or she resigns or unless he or she is
removed by a majority vote of our shareholders at a general meeting of our shareholders or upon the occurrence of certain events, in accordance
with the Companies Law and/or our amended and restated articles of association.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, under certain
circumstances, our amended and restated articles of association allow our board of directors to appoint directors to fill vacancies on
our board of directors or in addition to the acting directors (subject to the limitation set forth in our articles of association on the
number of directors), until the next annual general meeting or special general meeting in which directors term may be terminated. External
directors, if applicable, may be elected for up to two additional three-year terms after their initial three-year term under the circumstances
described below, with certain exceptions as described in &#8220;External Directors&#8221; below. External directors may be removed from
office only under the limited circumstances set forth in the Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Companies Law, any shareholder holding
at least one percent of our outstanding voting power may suggest nominating a director in an Annual General Meeting of the shareholders.
However, any such shareholder may make such a suggestion only if a written notice of such shareholder&#8217;s intent to make such nomination
has been given to our board of directors. Any such notice must include certain information, including the consent of the proposed director
nominee to serve as our director if elected, and a declaration that the nominee signed declaring that he or she possesses the requisite
skills and has the availability to carry out his or her duties. Additionally, the nominee must provide details of such skills, and demonstrate
an absence of any limitation under the Companies Law that may prevent his or her election, and affirm that all of the required election-information
is provided to us, pursuant to the Companies Law. However, under a new exemptions applicable as of March 12, 2024, one or more shareholders
of an Israeli company whose shares are listed outside of Israel, may request the company&#8217;s board of directors to include an appointment
of a candidate for a position on the board of directors or the termination of a board member, as an item on the agenda of a future general
meeting (if the company sees fit), provided that the shareholder hold at least five percent (5%) of the voting rights of the company,
instead of one percent (1%) as required in the past.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, our
board of directors must determine the minimum number of directors who are required to have accounting and financial expertise. In determining
the number of directors required to have such expertise, our board of directors must consider, among other things, the type and size of
the company and the scope and complexity of its operations. Our board of directors has determined that the minimum number of directors
of our company who are required to have accounting and financial expertise is one.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors must
elect one director to serve as the chairman of the board of directors to preside at the meetings of the board of directors, and may also
remove that director as chairman. Pursuant to the Companies Law, neither the chief executive officer nor any of his or her relatives is
permitted to serve as the chairman of the board of directors, and a company may not vest the chairman or any of his or her relatives with
the chief executive officer&#8217;s authorities. In addition, a person who reports, directly or indirectly, to the chief executive officer
may not serve as the chairman of the board of directors; the chairman may not be vested with authorities of a person who reports, directly
or indirectly, to the chief executive officer; and the chairman may not serve in any other position in the company or a controlled company,
but he or she may serve as a director or chairman of a controlled company. However, the Companies Law permits a company&#8217;s shareholders
to determine, for a period not exceeding three years from each such determination, that the chairman or his or her relative may serve
as chief executive officer or be vested with the chief executive officer&#8217;s authorities, and that the chief executive officer or
his or her relative may serve as chairman or be vested with the chairman&#8217;s authorities. Such determination of a company&#8217;s
shareholders requires either: (1) the approval of at least a majority of the shares of those shareholders present and voting on the matter
(other than controlling shareholders and those having a personal interest in the determination) (shares held by abstaining shareholders
shall not be considered); or (2) that the total number of shares opposing such determination does not exceed 2% of the total voting power
in the company. Currently, we have a separate chairman and chief executive officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors may,
subject to the provisions of the Companies Law, delegate some of its powers to committees of the board, and it may, from time to time,
revoke such delegation or alter the composition of any such committees, subject to certain limitations. Unless otherwise expressly provided
by the board of directors, the committees shall not be empowered to further delegate such powers. The composition and duties of our audit
committee, financial statement examination committee and compensation committee are described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors oversees
how management monitors compliance with our risk management policies and procedures, and reviews the adequacy of the risk management framework
in relation to the risks faced by us. The board of directors is assisted in its oversight role by an internal auditor. The internal auditor
undertakes both regular and ad hoc reviews of risk management controls and procedures, the results of which are reported to our audit
committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>External Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Under
the Companies Law, except as provided below, companies incorporated under the laws of the State of Israel that are publicly traded, including
Israeli companies with shares listed on the Nasdaq, are required to appoint at least two external directors who meet the qualification
requirements set forth in the Companies Law. The definitions of an external director under the Companies Law and independent director
under Nasdaq Stock Market rules are similar such that it would generally be expected that our two external directors will also comply
with the independence requirement under Nasdaq Stock Market rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Pursuant
to regulations under the Companies Law, the board of directors of a company such as us is not required to have external directors if:
(i) the company does not have a controlling shareholder (as such term is defined in the Companies Law); (ii) a majority of the directors
serving on the board of directors are &#8220;independent,&#8221; as defined under Nasdaq Rule 5605(a)(2); and (iii) the company follows
Nasdaq Rule 5605(e)(1), which requires that the nomination of directors be made, or recommended to the board of directors, by a Nominating
Committee of the board of directors consisting solely of independent directors, or by a majority of independent directors. The Company
meets all these requirements. Our board of directors has resolved to adopt the corporate governance exemption set forth above, and accordingly
we will not have external directors as members of our board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Alternate Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
amended and restated articles of association provide, as allowed by the Companies Law, that any director may, subject to the conditions
set thereto including approval of the nominee by our board of directors, appoint a person as an alternate to act in his place, to remove
the alternate and appoint another in his place and to appoint an alternate in place of an alternate whose office is vacated for any reason
whatsoever. Under the Companies Law, a person who is not qualified to be appointed as a director, a person who is already serving as a
director or a person who is already serving as an alternate director for another director, may not be appointed as an alternate director.
Nevertheless, a director who is already serving as a director may be appointed as an alternate director for a member of a committee of
the board of directors so long as he or she is not already serving as a member of such committee, and if the alternate director is to
replace an external director, he or she is required to be an external director and to have either &#8220;financial and accounting expertise&#8221;
or &#8220;professional expertise,&#8221; depending on the qualifications of the external director he or she is replacing. A person who
does not have the requisite &#8220;financial and accounting experience&#8221; or the &#8220;professional expertise,&#8221; depending on
the qualifications of the external director he or she is replacing, may not be appointed as an alternate director for an external director.
A person who is not qualified to be appointed as an independent director, pursuant to the Companies Law, may not be appointed as an alternate
director of an independent director qualified as such under the Companies Law. Unless the appointing director limits the time or scope
of the appointment, the appointment is effective for all purposes until the appointing director ceases to be a director or terminates
the appointment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Committees of the Board of Directors </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
established two standing committees, the audit committee and the compensation committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Audit Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
board of directors of any public company must establish an audit committee. The audit committee must be comprised of at least three directors,
including all of the external directors, if applicable, (one of whom must serve as chair of the committee). The audit committee may not
include the chairman of the board; a director employed by the company or by a controlling shareholder of the company or by an entity controlled
by a controlling shareholder; a controlling shareholder or a relative of a controlling shareholder; a director employed by or providing
services on a regular basis to the company, to a controlling shareholder or to an entity controlled by a controlling shareholder, or a
director who derives most of his or her income from a controlling shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee is comprised
of Lior Amit, Limor Rozen and Tal Parnes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, our
audit committee is responsible for, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">(i)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">determining whether there are deficiencies in the business management practices of our company, and making recommendations to the board of directors to improve such practices; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">(ii)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">determining whether to approve certain related party transactions (including transactions in which an office holder has a personal interest and whether such transaction is extraordinary or material under Companies Law) and establishing the approval process for certain transactions with a controlling shareholder or in which a controlling shareholder has a personal interest; (see &#8220;Item 6.C. Directors, Senior Management and Employees-Board Practices-Approval of Related Party Transactions under Israeli law&#8221;); </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">(iii)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">determining the approval process for transactions that are &#8220;non-negligible&#8221; (i.e., transactions with a controlling shareholder that are classified by the audit committee as non-negligible, even though they are not deemed extraordinary transactions), as well as determining which types of transactions would require the approval of the audit committee, optionally based on criteria which may be determined annually in advance by the audit committee;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">(iv)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">examining our internal controls and internal auditor&#8217;s performance, including whether the internal auditor has sufficient resources and tools to dispose of its responsibilities; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">(v)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">examining the scope of our auditor&#8217;s work and compensation and submitting a recommendation with respect thereto to our board of directors or shareholders, depending on which of them is considering the appointment of our auditor;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">(vi)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">establishing procedures for the handling of employees&#8217; complaints as to deficiencies in the management of our business and the protection to be provided to such employees; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">(vii)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">where the board of directors approves the working plan of the internal auditor, examining such working plan before its submission to the board of directors and proposing amendments thereto.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee may not
conduct any discussions or approve any actions requiring its approval (see &#8220;Item 6.C. Directors, Senior Management and Employees-Board
Practices-Approval of Related Party Transactions under Israeli law&#8221;); &#8220;), unless at the time of the approval a majority of
the committee&#8217;s members are present.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
adopted an audit committee charter setting forth, among others, the responsibilities of the audit committee consistent with the rules
of the SEC and Nasdaq Listing Rules (in addition to the requirements for such committee under the Companies Law), including, among others,
the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">oversight of our independent registered public accounting firm and recommending the engagement, compensation or termination of engagement of our independent registered public accounting firm to the board of directors in accordance with Israeli law;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">recommending the engagement or termination of the person filling the office of our internal auditor, reviewing the services provided by our internal auditor and reviewing effectiveness of our system of internal control over financial reporting;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">recommending the terms of audit and non-audit services provided by the independent registered public accounting firm for pre-approval by our board of directors; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reviewing and monitoring, if applicable, legal matters with significant impact, finding of regulatory authorities&#8217; findings, receive reports regarding irregularities and legal compliance, acting according to &#8220;whistleblower policy&#8221; and recommend to our board of directors if so required.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Nasdaq Stock Market Requirements for Audit
Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Nasdaq Stock Market
rules, we are required to maintain an audit committee consisting of at least three members, all of whom are independent and are financially
literate and one of whom has accounting or related financial management expertise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As noted above, the members
of our audit committee include Lior Amit, Tal Parnes and Limor Rozen. Mr. Amit serves as the chairman of our audit committee. All members
of our audit committee meet the requirements for financial literacy under the Nasdaq Stock Market rules. Our board of directors has determined
that each member of our audit committee is an audit committee financial expert as defined by the SEC rules and has the requisite financial
experience as defined by the Nasdaq Stock Market rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, our
audit committee also carries out the duties of a financial statement examination committee. As such, the audit committee is responsible
for: (i) estimations and assessments made in connection with the preparation of financial statements; (ii) internal controls related to
the financial statements; (iii) completeness and propriety of the disclosure in the financial statements; (iv) the accounting policies
adopted and the accounting treatments implemented in material matters of the company; and (v) value evaluations, including the assumptions
and assessments on which evaluations are based and the supporting data in the financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compensation Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
board of directors of any public company must establish a compensation committee. The compensation committee must be comprised of at least
three directors, including all of the external directors (if applicable). The compensation committee is subject to the same Companies
Law restrictions as the audit committee as to: (a) who may not be a member of the committee; and (b) who may not be present during committee
deliberations as described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation committee,
acting pursuant to a written charter, consists of Lior Amit, Limor Rozen and Tal Parnes. Tal Parnes serves as the chairman of our compensation
committee. Our compensation committee complies with the provisions of the Companies Law, the regulations promulgated thereunder, and our
amended and restated articles of association, on all aspects referring to its independence, authorities and practice. Our compensation
committee follows home country practice as opposed to complying with the compensation committee membership and charter requirements prescribed
under the Nasdaq Stock Market rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation committee
reviews and recommends to our board of directors: with respect to our executive officers&#8217; and directors&#8217;: (1) annual base
compensation; (2) annual incentive bonus, including the specific goals and amounts; (3) equity compensation; (4) employment agreements,
severance arrangements, and change in control agreements and provisions; (5) retirement grants and/or retirement bonuses; and (6) any
other benefits, compensation, compensation policies or arrangements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duties of the compensation
committee include the recommendation to the company&#8217;s board of directors of a policy regarding the terms of engagement of office
holders, to which we refer as a compensation policy. Every three years (or following five years from its initial public offering), such
policy must be adopted by the company&#8217;s board of directors, after considering the recommendations of the compensation committee.
The compensation policy is then brought for approval by our shareholders, which requires a special majority (see &#8220;Item 6.C. Directors,
Senior Management and Employees-Board Practices-Approval of Related Party Transactions under Israeli law&#8221;). Under the Companies
Law, the board of directors may adopt the compensation policy if it is not approved by the shareholders, provided that after the shareholders
oppose the approval of such policy, the compensation committee and the board of directors revisit the matter and determine that adopting
the compensation policy is in our best interests.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 17, 2021, a general
meeting of our shareholders approved the adoption of a compensation policy for our officers and directors for a period of five years,
or the compensation policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation policy serves
as the basis for decisions concerning the financial terms of employment or engagement of executive officers and directors, including exculpation,
insurance, indemnification or any monetary payment or obligation of payment in respect of employment or engagement. The compensation policy
relates to certain factors, including advancement of our objectives, our business and long-term strategy and creation of appropriate incentives
for executives. It also considers, among other things, our risk management, size and the nature of our operations. The compensation policy
further considers the following additional factors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the education, skills, expertise and accomplishments of the relevant director or executive;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the director&#8217;s or executive&#8217;s roles and responsibilities and prior compensation agreements with him or her;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the relationship between the cost of the terms of service of an office holder and the average median compensation of the other employees of the company (including those employed through manpower companies), including the impact of disparities in salary upon work relationships in our company;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the possibility of reducing variable compensation at the discretion of the board of directors; and the possibility of setting a limit on the exercise value of non-cash variable compensation; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">as to severance compensation, the period of service of the director or executive, the terms of his or her compensation during such service period, our performance during that period of service, the person&#8217;s contribution towards the achievement of our goals and the maximization of our profits, and the circumstances under which the person is leaving the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation policy also
includes the following principles:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"/>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">with the exception of office holders who report directly to the chief executive officer, the link between variable compensation and long-term performance and measurable criteria;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the relationship between variable and fixed compensation, and the ceiling for the value of variable compensation at the time of its grant;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the conditions under which a director or executive are required to repay compensation paid to him or her if it was later shown that the data upon which such compensation was based was inaccurate and was required to be restated in the company&#8217;s financial statements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the minimum holding or vesting period for variable, equity-based compensation; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">maximum limits for severance compensation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation policy also
considers appropriate incentives from a long-term perspective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation committee
is responsible for: (1) recommending the compensation policy to a company&#8217;s board of directors for its approval (and subsequent
approval by the shareholders); and (2) duties related to the compensation policy and to the compensation of a company&#8217;s office holders,
including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">recommending whether a compensation policy should continue in effect, if the then-current policy has a term of greater than three years (approval of either a new compensation policy or the continuation of an existing compensation policy must in any case occur every three years);</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">recommending to the board of directors periodic updates to the compensation policy;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">assessing implementation of the compensation policy;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">determining whether the terms of compensation of certain office holders need not be brought to approval of the shareholders; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">determining whether to approve the terms of compensation of office holders that require the committee&#8217;s approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation policy is
designed to promote our long-term goals, work plan and policy, retain, motivate and incentivize our directors and executive officers,
while considering the risks that our activities involve, our size, the nature and scope of our activities and the contribution of an officer
to the achievement of our goals and maximization of profits, and align the interests of our directors and executive officers with our
long-term performance. To that end, a portion of an executive officer compensation package is targeted to reflect our short and long-term
goals, as well as the executive officer&#8217;s individual performance. On the other hand, our compensation policy includes measures designed
to reduce the executive officer&#8217;s incentives to take excessive risks that may harm us in the long-term, such as limits on the value
of cash bonuses and equity-based compensation, limitations on the ratio between the variable and the total compensation of an executive
officer and minimum vesting periods for equity-based compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation policy also
addresses our executive officer&#8217;s individual characteristics (such as his or her respective position, education, scope of responsibilities
and contribution to the attainment of our goals) as the basis for compensation variation among our executive officers, and considers the
internal ratios between compensation of our executive officers and directors and other employees. For example, the compensation that may
be granted to an executive officer may include base salary, annual bonuses, equity-based compensation, benefits and retirement and termination
of service arrangements. All cash bonuses are limited to a maximum amount linked to the executive officer&#8217;s base salary. In addition,
our compensation policy provides for maximum permitted ratios between the total variable (cash bonuses and equity-based compensation)
and non-variable (base salary) compensation components, in accordance with an officer&#8217;s respective position with the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An annual cash bonus may be
awarded to executive officers upon the attainment of pre-set periodic objectives and individual targets. The annual cash bonus that may
be granted to subordinate officeholders may be based entirely on a discretionary evaluation. Our Chief Executive Officer will be entitled
to recommend performance objectives to such executive officers, and such performance objectives will be approved by our compensation committee
(and, if required by law, by our board of directors).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The performance measurable
objectives of our chairman and Chief Executive Officer are determined annually by our compensation committee and board of directors. A
less significant portion of the chairman&#8217;s and/or the Chief Executive Officer&#8217;s annual cash bonus may be based on a discretionary
evaluation of the chairman&#8217;s or the Chief Executive Officer&#8217;s respective overall performance by the compensation committee
and the board of directors based on quantitative and qualitative criteria.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The equity-based compensation
under our compensation policy for our executive officers (including members of our board of directors) is designed in a manner consistent
with the underlying objectives in determining the base salary and the annual cash bonus, with its main objectives being to enhance the
alignment between the executive officers&#8217; interests with our long-term interests and those of our shareholders and to strengthen
the retention and the motivation of executive officers in the long term. Our compensation policy provides for executive officer compensation
in the form of share options or other equity-based awards, such as restricted shares and phantom, options, in accordance with our equity
incentive plan then in place. Share options granted to executive officers are subject to vesting periods in order to promote long-term
retention of the awarded executive officers. The equity-based compensation is granted from time to time and be individually determined
and awarded according to the performance, educational background, prior business experience, qualifications, role and the personal responsibilities
of the executive officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our compensation
policy contains compensation recovery provisions which allows us under certain conditions to recover bonuses paid in excess, enables our
Chief Executive Officer to approve an immaterial change in the terms of employment of an executive officer (provided that the changes
of the terms of employment are in accordance our compensation policy) and allows us to exculpate, indemnify and insure our executive officers
and directors subject to certain limitations set forth thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation policy also
provides for compensation to the members of our board of directors either: (i) in accordance with the amounts provided in the Companies
Regulations (Rules Regarding the Compensation and Expenses of an External Director) of 2000, as amended by the Companies Regulations (Relief
for Public Companies Traded in Stock Exchange Outside of Israel) of 2000, as such regulations may be amended from time to time; or (ii)
in accordance with the amounts determined in our compensation policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Internal Auditor </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
board of directors of an Israeli public company must appoint an internal auditor nominated by the audit committee. Our internal auditor
Chaim Yechezkely, CPA (Isr) who has been serving as our internal auditor since October 2021, is a Certified Public Accountant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The role of the internal auditor
is to examine, among other things, whether a company&#8217;s actions comply with the law and proper business procedure. The audit committee
is required to oversee the activities, and to assess the performance of the internal auditor as well as to review the internal auditor&#8217;s
work plan. An internal auditor may not be an interested party or office holder, or a relative of any interested party or office holder,
and may not be a member of the company&#8217;s independent accounting firm or its representative. The Companies Law defines an interested
party as a holder of 5% or more of the outstanding shares or voting rights of a company, any person or entity that has the right to appoint
at least one director or the general manager of the company or any person who serves as a director or as the general manager of a company.
Our internal auditor is not an interested party in the Company and not our employee, but partner of a firm which specializes in internal
auditing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Remuneration of Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, remuneration
of directors is subject to the approval of the compensation committee, thereafter by the board of directors and thereafter, unless exempted
under the regulations promulgated under the Companies Law, by the general meeting of the shareholders. In case the remuneration of the
directors is in accordance with regulations applicable to remuneration of the external directors then such remuneration shall be exempt
from the approval of the general meeting. Where the director is also a controlling shareholder, the requirements for approval of transactions
with controlling shareholders apply. In our 2021 general meeting of shareholders, we instituted a yearly fixed fee in the amount of $40,000
for all of our directors other than the chairman and the directors who are not also officeholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fiduciary Duties of Office Holders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law imposes
a duty of care and a duty of loyalty on all office holders of a company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duty of care requires
an office holder to act with the level of care with which a reasonable office holder in the same position would have acted under the same
circumstances. The duty of care of an office holder includes a duty to use reasonable means to obtain:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">information on the profitability of a given action brought for his approval or performed by him by virtue of his position; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">all other important information pertaining to these actions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duty of loyalty of an
office holder requires an office holder to act in good faith and for the benefit of the company, and includes a duty to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">refrain from any conflict of interest between the performance of his duties in the company and his performance of his other duties or personal affairs;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">refrain from any action that is competitive with the company&#8217;s business;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">refrain from exploiting any business opportunity of the company to receive a personal gain for himself or others; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">disclose to the company any information or documents relating to the company&#8217;s affairs which the office holder has received due to his position as an office holder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Insurance</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, a
company may obtain insurance for any of its office holders against the following liabilities incurred due to acts he or she performed
as an office holder, if and to the extent provided for in the company&#8217;s articles of association:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">breach of his or her duty of care to the company or to another person, to the extent such a breach arises out of the negligent conduct of the office holder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a breach of his or her duty of loyalty to the company, provided that the office holder acted in good faith and had reasonable cause to assume that his or her act would not prejudice the company&#8217;s interests; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a financial liability imposed upon him or her in favor of another person.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have directors&#8217;
and officers&#8217; liability insurance, providing total coverage of $5 million for the benefit of the Company and all of our directors
and officers, in respect of which we paid a twelve-month premium of approximately $210,000, which expires in July 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Indemnification</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Companies Law, and the Israeli Securities Law,
5728-1968, or the Securities Law, provide that a company may indemnify an office holder against the following liabilities and expenses
incurred for acts performed by him or her as an office holder, either pursuant to an undertaking made in advance of an event or following
an event, provided its articles of association include a provision authorizing such indemnification:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a financial liability imposed on him or her in favor of another person by any judgment concerning an act performed in his or her capacity as an office holder, including a settlement or arbitrator&#8217;s award approved by a court;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reasonable litigation expenses, including attorneys&#8217; fees, expended by the office holder (a) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (1) no indictment (as defined in the Companies Law) was filed against such office holder as a result of such investigation or proceeding; and (2) no financial liability as a substitute for the criminal proceeding (as defined in the Companies Law) was imposed upon him or her as a result of such investigation or proceeding, or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; or (b) in connection with a monetary sanction;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reasonable litigation expenses, including attorneys&#8217; fees, expended by the office holder or imposed on him or her by a court (1) in proceedings that the company institutes, or that another person institutes on the company&#8217;s behalf, against him or her; (2) in a criminal proceedings of which he or she was acquitted; or (3) as a result of a conviction for a crime that does not require proof of criminal intent; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">expenses incurred by an office holder in connection with an Administrative Procedure under the Securities Law, including reasonable litigation expenses and reasonable attorneys&#8217; fees. An &#8220;Administrative Procedure&#8221; is defined as a procedure pursuant to chapters H3 (Monetary Sanction by the Israeli Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative Enforcement Committee) or I1 (Arrangement to prevent Procedures or Interruption of procedures subject to conditions) to the Securities Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law also permits
a company to undertake in advance to indemnify an office holder, provided that if such indemnification relates to financial liability
imposed on him or her, as described above, then the undertaking should be limited and shall detail the following foreseen events and amount
or criterion:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">to events that in the opinion of the board of directors can be foreseen based on the company&#8217;s activities at the time that the undertaking to indemnify is made; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">in amount or criterion determined by the board of directors, at the time of the giving of such undertaking to indemnify, to be reasonable under the circumstances.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into indemnification
agreements with all of our directors and with all members of our senior management. Each such indemnification agreement provides the office
holder with indemnification permitted under applicable law and up to a certain amount, and to the extent that these liabilities are not
covered by directors and officers insurance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Exculpation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span>Under
the Companies Law, an Israeli company may not exculpate an office holder from liability for a breach of his or her duty of loyalty, but
may exculpate in advance an office holder from his or her liability to the company, in whole or in part, for damages caused to the company
as a result of a breach of his or her duty of care (other than in relation to distributions), but only if a provision authorizing such
exculpation is included in its articles of association. Our amended and restated articles of association provide that we may exculpate,
in whole or in part, any office holder from liability to us for damages caused to the company as a result of a breach of his or her duty
of care, but prohibit an exculpation from liability arising from a company&#8217;s transaction in which our controlling shareholder or
officer has a personal interest. Subject to the aforesaid limitations, under the indemnification agreements, we exculpate and release
our office holders from any and all liability to us related to any breach by them of their duty of care to us to the fullest extent permitted
by law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Limitations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span>The
Companies Law provides that the Company may not exculpate or indemnify an office holder nor enter into an insurance contract that would
provide coverage for any liability incurred as a result of any of the following: (1) a breach by the office holder of his or her duty
of loyalty unless (in the case of indemnity or insurance only, but not exculpation) the office holder acted in good faith and had a reasonable
basis to believe that the act would not prejudice us; (2) a breach by the office holder of his or her duty of care if the breach was carried
out intentionally or recklessly (as opposed to merely negligently); (3) any act or omission committed with the intent to derive an illegal
personal benefit; or (4) any fine, monetary sanction, penalty or forfeit levied against the office holder.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span>Under
the Companies Law, exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation
committee and the board of directors and, with respect to certain office holders or under certain circumstances, also by the shareholders.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated articles
of association permit us to exculpate (subject to the aforesaid limitation), indemnify and insure our office holders to the fullest extent
permitted or to be permitted by the Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing descriptions
summarize the material aspects and practices of our board of directors. For additional details, we also refer you to the full text of
the Companies Law, as well as of our amended and restated articles of association, which is an exhibit to this annual report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no service contracts
between us, on the one hand, and our directors in their capacity as directors, on the other hand, providing for benefits upon termination
of service.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Approval of Related Party Transactions under
Israeli Law</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>General</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Under
the Companies Law, we may approve an action by an office holder from which the office holder would otherwise have to refrain, as described
above, if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the office holder acts in good faith and the act or its approval does not cause harm to the company; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the office holder disclosed the nature of his or her interest in the transaction (including any significant fact or document) to the company at a reasonable time before the company&#8217;s approval of such matter.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Disclosure of Personal Interests of an Office
Holder</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Companies Law requires that an office holder disclose to the company, promptly, and, in any event, not later than the board meeting at
which the transaction is first discussed, any direct or indirect personal interest that he or she may have and all related material information
known to him or her relating to any existing or proposed transaction by the company. If the transaction is an extraordinary transaction,
the office holder must also disclose any personal interest held by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the office holder&#8217;s relatives; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any corporation in which the office holder or his or her relatives holds 5% or more of the shares or voting rights, serves as a director or general manager or has the right to appoint at least one director or the general manager.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">An
office holder is not, however, obliged to disclose a personal interest if it derives solely from the personal interest of his or her relative
in a transaction that is not considered an extraordinary transaction. Under the Companies Law, an extraordinary transaction is a transaction:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">not in the ordinary course of business;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">not on market terms; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">that is likely to have a material effect on the company&#8217;s profitability, assets or liabilities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Companies Law does not specify to whom within us nor the manner in which required disclosures are to be made. We require our office holders
to make such disclosures to our board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Under
the Companies Law, once an office holder complies with the above disclosure requirement, the board of directors may approve a transaction
between the company and an office holder, or a third party in which an office holder has a personal interest, unless the articles of association
provide otherwise and provided that the transaction is in the company&#8217;s interest. If the transaction is an extraordinary transaction
in which an office holder has a personal interest, first the audit committee and then the board of directors, in that order, must approve
the transaction. Under specific circumstances, shareholder approval may also be required. Generally, a person who has a personal interest
in a matter which is considered at a meeting of the board of directors or the audit committee may not be present at such a meeting unless
the chairman of the audit committee or board of directors (as applicable) determines that he or she should be present in order to present
the transaction that is subject to approval. A director who has a personal interest in a transaction, which is considered at a meeting
of the board of directors or the audit committee, may not be present at this meeting or vote on this matter, unless a majority of members
of the board of directors or the audit committee, as the case may be, has a personal interest. If a majority of the board of directors
has a personal interest, then shareholder approval is generally also required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Disclosure of Personal Interests of a Controlling
Shareholder</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Under
the Companies Law, the disclosure requirements that apply to an office holder also apply to a controlling shareholder of a public company.
Extraordinary transactions with a controlling shareholder or in which a controlling shareholder has a personal interest, including a private
placement in which a controlling shareholder has a personal interest, as well as transactions for the provision of services whether directly
or indirectly by a controlling shareholder or his or her relative, or a company such controlling shareholder controls, and transactions
concerning the terms of engagement and compensation of a controlling shareholder or a controlling shareholder&#8217;s relative, whether
as an office holder or an employee, require the approval of the audit committee or the compensation committee, as the case may be, the
board of directors and a majority of the shares voted by the shareholders of the company participating and voting on the matter in a shareholders&#8217;
meeting. In addition, the shareholder approval must fulfill one of the following requirements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">at least a majority of the shares held by shareholders who have no personal interest in the transaction and are voting at the meeting must be voted in favor of approving the transaction, excluding abstentions; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the shares voted by shareholders who have no personal interest in the transaction who vote against the transaction represent no more than 2% of the voting rights in the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, any extraordinary
transaction with a controlling shareholder or in which a controlling shareholder has a personal interest with a term of more than three
years requires the aforementioned approval every three years; however, such transactions can be approved for a longer term, provided that
the audit committee determines that such longer term is reasonable under the circumstances. In addition, under Companies Law regulations,
subject to certain terms, such transactions can be extended or approved after three years only by the audit committee and the board of
directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Companies Law requires that every shareholder that participates, in person, by proxy or by voting instrument, in a vote regarding a transaction
with a controlling shareholder, must indicate in advance or in the ballot whether or not that shareholder has a personal interest in the
vote in question. Failure to so indicate will result in the invalidation of that shareholder&#8217;s vote.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
term &#8220;controlling shareholder&#8221; is defined in the Companies Law as a shareholder with the ability to direct the activities
of the company, other than by virtue of being an office holder. A shareholder is presumed to be a controlling shareholder if the shareholder
holds 50% or more of the voting rights in a company or has the right to appoint 50% or more of the directors of the company or its general
manager. In the context of a transaction involving a shareholder of the company, a controlling shareholder also includes a shareholder
who holds 25% or more of the voting rights in the company if no other shareholder holds more than 50% of the voting rights in the company.
For this purpose, the holdings of all shareholders who have a personal interest in the same transaction will be aggregated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Approval of the Compensation of Directors and
Executive Officers</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation of, or an
undertaking to indemnify, insure or exculpate, an office holder who is not a director requires the approval of our compensation committee,
followed by the approval of the company&#8217;s board of directors, and, if such compensation arrangement or an undertaking to indemnify,
insure or exculpate is inconsistent with our compensation policy, or if the said office holder is the chief executive officer of the company
(subject to a number of specific exceptions), then such arrangement is subject to the approval of our shareholders, subject to a special
majority requirement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Directors</i>. Under the
Companies Law, the compensation of our directors requires the approval of our compensation committee, the subsequent approval of the board
of directors and, unless exempted under the regulations promulgated under the Companies Law, the approval of the general meeting of our
shareholders. If the compensation of our directors is inconsistent with our stated compensation policy, then, provided that those provisions
that must be included in the compensation policy according to the Companies Law have been considered by the compensation committee and
board of directors, shareholder approval by a special majority will be required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Executive officers other
than the chief executive officer.</i> The Companies Law requires the approval of the compensation of a public company&#8217;s executive
officers (other than the chief executive officer) in the following order: (i) the compensation committee, (ii) the company&#8217;s board
of directors, and (iii) only if such compensation arrangement is inconsistent with the company&#8217;s stated compensation policy, the
company&#8217;s shareholders by a special majority. However, if the shareholders of the company do not approve a compensation arrangement
with an executive officer that is inconsistent with the company&#8217;s stated compensation policy, the compensation committee and board
of directors may override the shareholders&#8217; decision if each of the compensation committee and the board of directors provide detailed
reasons for their decision.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Chief executive officer.</i>
Under the Companies Law, the compensation of a public company&#8217;s chief executive officer is required to be approved by: (i) the company&#8217;s
compensation committee; (ii) the company&#8217;s board of directors, and (iii) the company&#8217;s shareholders by a special majority.
However, if the shareholders of the company do not approve the compensation arrangement with the chief executive officer, the compensation
committee and board of directors may override the shareholders&#8217; decision if each of the compensation committee and the board of
directors reviewed and reapproved the terms of the compensation, considering that the shareholders did not approve the terms of compensation,
and provides detailed reasons for their decision. In addition, the compensation committee may exempt the engagement terms of a candidate
to serve as the chief executive officer from shareholders&#8217; approval, if the compensation committee determines that the compensation
arrangement is consistent with the company&#8217;s stated compensation policy, that the chief executive officer did not have a prior business
relationship or affiliation with the company or a controlling shareholder of the company, and that subjecting the approval to a shareholder
vote would impede the company&#8217;s ability to attain the candidate to serve as the company&#8217;s chief executive officer (and provide
detailed reasons for the latter).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The approval of each of the
compensation committee and the board of directors, with regard to the office holders and directors above, should be in accordance with
the company&#8217;s stated compensation policy; however, under special circumstances, the compensation committee and the board of directors
may approve compensation terms of a chief executive officer that are inconsistent with the company&#8217;s compensation policy provided
that they have considered those provisions that must be included in the compensation policy according to the Companies Law and that shareholder
approval was obtained by a special majority requirement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Duties of Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Under
the Companies Law, a shareholder has a duty to refrain from abusing his power in the company and to act in good faith and in an acceptable
manner in exercising his rights and performing his obligations toward the company and other shareholders, including, among other things,
in voting at general meetings of shareholders (and at shareholder class meetings) on the following matters:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">amendment of the articles of association;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">increase in the company&#8217;s authorized share capital;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">merger; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the approval of related party transactions and acts of office holders that require shareholder approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">A
shareholder also has a general duty to refrain from oppressing other shareholders. The remedies generally available upon a breach of contract
will also apply to a breach of the above-mentioned duties, and in the event of oppression of other shareholders, additional remedies are
available to the injured shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
addition, any controlling shareholder, any shareholder that knows that its vote can determine the outcome of a shareholder vote and any
shareholder that, under a company&#8217;s articles of association, has the power to appoint or prevent the appointment of an office holder,
or has another power with respect to a company, is under a duty to act with fairness towards the company. The Companies Law does not describe
the substance of this duty except to state that the remedies generally available upon a breach of contract will also apply in the event
of a breach of the duty to act with fairness, taking the shareholder&#8217;s position in the company into account.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><div><a id="a_028"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Employees.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 31, 2021, we had
twenty-three full-time employees and three part-time employees. On December 31, 2022, we had thirty-two full-time employees and five part-time
employees. On December 31, 2023, we had thirty-seven full time employees (including our senior management team), five part-time employees,
and three additional independent contractors and consultants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023, we
had 5 members of senior management (including our Chief Executive Officer), who are full-time employees of the Company. In addition, we
had 31 full-time employees, 5 part-time and 1 additional full-time employee located in France.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of our employees located
in Israel are represented by labor unions or covered by collective bargaining agreements. However, in Israel, we are subject to certain
Israeli labor laws, regulations and national labor court precedent rulings, as well as certain provisions of collective bargaining agreements
applicable to us by virtue of extension orders issued in accordance with relevant labor laws by the Israeli and Industry of Economy and
which apply such agreement provisions to our employees even though they are not part of a union that has signed a collective bargaining
agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our employment and
consulting agreements include employees&#8217; and consultants&#8217; undertakings with respect to non-competition and assignment to us
of intellectual property rights developed in the course of employment and confidentiality. The enforceability of such provisions is limited
by Israeli law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><div><a id="a_029"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>E.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Share Ownership. </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 7.A. Major
Shareholders&#8221; below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Incentive Plan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
2019 Equity Incentive Plan, or the 2019 Plan, was adopted by our board of directors on December 2019 (although no options were granted
until April 20, 2020) and amended on September 14, 2021. The 2019 Plan provides for the grant of options to our directors, employees,
officers, consultants and service providers who are our employees, officers, directors or consultants, as well as those of our affiliated
companies. In September 2021, our board of directors approved an amendment to the 2019 Plan to provide for the grant of restricted share
units, or &#8220;RSUs.&#8221; As of March 22, 2024, the total number of Ordinary Shares reserved for the exercise of options under our
2019 Plan was 7,178,569 The shares subject to our 2019 Plan may be either authorized but unissued Ordinary Shares or reacquired Ordinary
Shares, subject to applicable laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
2019 Plan is administered by the committee, consisting of our board of directors, regarding the granting of options and the terms of option
grants, including exercise price, method of payment, vesting schedule, acceleration of vesting and the other matters necessary in the
administration of this plan. Eligible employees, officers and directors, as well as those of our affiliated companies, would qualify for
provisions of Section 102 of the Israeli Income Tax Ordinance of 1961 (New Version), or the Tax Ordinance. Section 102 of the Tax Ordinance
allows employees, directors and officers who are not controlling shareholders and are considered Israeli residents to receive favorable
tax treatment for compensation in the form of shares or options. Section 102 includes two alternatives for tax treatment involving the
issuance of options or shares to a trustee for the benefit of the grantees and also includes an additional alternative for the issuance
of options or shares directly to the grantee. Section 102(b)(2) of the Ordinance, the most favorable tax treatment for the grantee, permits
the issuance to a trustee under the &#8220;capital gain track.&#8221; However, under this track we are not allowed to deduct an expense
with respect to the issuance of the options or shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
consultants and those of our affiliated companies and our employees, directors and/or officers and those of our affiliated companies who
are controlling shareholders prior to and/or after the issuance of Ordinary Shares underlying the options may only be granted options
under section 3(i) of the Tax Ordinance, which does not provide for similar tax benefits. In addition, the committee may, in its sole
discretion, grant restricted shares to our service providers, subject to terms and conditions of our 2019 Plan and the applicable restricted
shares agreement between the service provider and us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">As
a default, our 2019 Plan provides that upon termination of a service provider&#8217;s engagement for any reason, other than in the event
of death, disability or cause, all unvested options will terminate and the underlying Ordinary Shares will revert to our 2019 Plan, and
all vested options will generally be exercisable for 90 days following such termination, subject to the terms of the 2019 Plan and the
governing option agreement. Notwithstanding the foregoing, in the event the engagement is terminated for cause (including, inter alia,
due to dishonesty toward us or our affiliate, substantial malfeasance or nonfeasance of duty and conduct substantially prejudicial to
our or our affiliate&#8217;s business; or any substantial breach by the optionee of his or her service agreement) all options granted
to such service provider, whether vested or unvested, will not be exercisable and will terminate on the date of the termination of his
service agreement. If a service provider&#8217;s engagement with us is terminated six months following any exercise, payment or delivery
pursuant to an option or restricted share, the service provider shall pay to us the amount of any gain realized or payment received as
a result of the rescinded exercise, payment or delivery. Upon termination of a service agreement due to death or disability, all the options
vested at the time of termination and within 60 days after the date of such termination, will generally be exercisable for 12 months,
or such other period as determined by the plan administrator, subject to the terms of the 2019 Plan and the governing option agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">If
we are party to a merger, acquisition, reorganization or consolidation in which we are not the surviving entity or the sale, transfer,
exchange or other disposition of all or substantially all of our shares or assets, outstanding options and shares acquired under the 2019
Plan will be subject to the agreement of merger or consolidation, which will provide for one or more of the following: (i) the assumption
of such options by the surviving corporation or its parent, (ii) the substitution by the surviving corporation or its parent of new options,
or (iii) in the event that the successor entity neither assumes nor substitutes all outstanding options, then the option shall terminate
as of the date of a merger, acquisition, reorganization or consolidation in which we are not the surviving entity or the sale, transfer,
exchange or other disposition of all or substantially all of our shares or assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_030"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><b>F.</b></td><td style="text-align: justify"><b>Disclosure of a Registrant&#8217;s Action to Recover Erroneously
Awarded Compensation.</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not Applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_031"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 7. <span style="text-transform: uppercase">MAJOR
SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_032"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Major Shareholders. </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The following table sets forth information regarding beneficial ownership
of our Ordinary Shares as of March 22, 2024 by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">each person, or group of affiliated persons, known to us to be the beneficial owner of more than 5% of our outstanding Ordinary Shares;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">each of our directors and executive officers; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">all of our directors and executive officers as a group.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Beneficial ownership is determined in accordance with the rules of
the SEC and includes voting or investment power with respect to Ordinary Shares. Ordinary Shares issuable under share options or warrants
that are exercisable within 60 days after March 22, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Except
as indicated in footnotes to this table, we believe that the shareholders named in this table have sole voting and investment power with
respect to all shares shown to be beneficially owned by them, based on information provided to us by such shareholders. Unless otherwise
noted below, each beneficial owner&#8217;s address is: c/o Inspira Technologies Oxy B.H.N. Ltd., 2 Ha-Tidhar St., Ra&#8217;anana, 4366504
Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">No. of<br/>
 Shares<br/>
 Beneficially<br/>
 Owned</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Percentage<br/>
 Owned</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Holders of more than 5% of our voting securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Armistice Capital, LLC <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,528,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9.89</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Directors and Officers:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dagi Ben-Noon <sup>(2) *</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,304,398</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.15</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joe Hayon <sup>(3) *</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,604,398</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.02</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avi Shabtai <sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">434,722</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.71</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yafit Tehila <sup>(5)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">129,922</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.81</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniella Yeheskely Hayon <sup>(6)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.33</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tal Parnes <sup>(7) *</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,736</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.24</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limor Rozen <sup>(8) *</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,035</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benad Goldwasser <sup>(9) *</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">234,469</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.46</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lior Amit <sup>(10)*</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28,334</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">All Executive Officers and Directors and holder of more than 5% of our voting securities, as a group (10 persons)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,387,514</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">34.01</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Indicates director of the Company.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">This information is based upon a Schedule 13G/A filed by Armistice Capital LLC with the SEC on February 14, 2024. Mr. Steven Boyd has the voting and dispositive power over the shares held by Armistice Capital LLC. The mailing address of Mr. Boyd is 510 Madison Avenue, 7th Floor, New York, New York 10022.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">No. of shares beneficially owned consists of 326,739 Ordinary Shares,
(ii) 920,500 Ordinary Shares vested pursuant to issued and outstanding restricted stock units, (iii) 57,159 Ordinary Shares issuable
upon the exercise of options within 60 days.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">No. of shares beneficially owned consists of (i) 626,739 Ordinary Shares, (ii) 920,500 Ordinary Shares vested pursuant to issued and outstanding restricted stock units, (iii) 57,159 Ordinary Shares issuable upon the exercise of options within 60 days. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes options to purchase 57,144 Ordinary Shares that are exercisable within 60 days, at an exercise price of NIS 0.97 (approximately $0.29) per share, options to purchase 57,143 Ordinary Shares that are exercisable within 60 days, at an exercise price of NIS 0.37 (approximately $0.12) per share and 2,778 RSUs that will be vested within 60 days. Mr. Shabtai&#8217;s options have expiration dates ranging from April 20, 2030 to December 20, 2030.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes options to purchase 13,605 Ordinary Shares that are exercisable within 60 days, at an exercise price of NIS 0.37 (approximately $0.12) per share and 7,578 RSUs that will be vested within 60 days. Ms. Tehila&#8217;s options expire on March 16, 2031.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes 3,889 RSUs that will be vested within 60 days.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(7)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes options to purchase 9,402 Ordinary Shares that are exercisable within 60 days, at an exercise price of NIS 0.37 (approximately $0.12) per share and 1,668 RSUs that will be vested within 60 days. Mr. Parnas&#8217;s options expire on April 20, 2030.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(8) </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes options to purchase 4,701 Ordinary Shares that are exercisable within 60 days, at an exercise price of NIS 0.37 (approximately $0.12) per share and 1,668 RSUs that will be vested within 60 days. Mrs. Rozen&#8217;s options expire on April 20,2030.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(9)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes options to purchase 81,633 Ordinary Shares that are exercisable within 60 days, at an exercise price of NIS 0.37 (approximately $0.12) per share and 23,514 RSUs that will be vested within 60 days. Mr. Goldwasser options expire on March 16, 2031.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(10)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;Includes 1,668 RSUs that vest within 60 days.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in Percentage Ownership by Major
Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During
the year ended December 31, 2023, there was: (i) an increase in the beneficial ownership of Armistice Capital, LLC to 9.89%, (ii) a decrease
in the beneficial ownership of Joe Hayon from 11.86% to 10.02%, and (iii) a decrease in the beneficial ownership of Dagi Ben Noon from
11.86% to 8.15%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2022 and December 31, 2021, there was no significant change in the percentage ownership held by any major shareholders, other than
decreases in the relative percentage of ownership as a result of our initial public offering in July 2021 and the vesting of the RSU&#8217;s
granted in December 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Record Holders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 22, 2024, there were 18 shareholders of record of our Ordinary
Shares, which were located in Israel. <b>&#160;</b>We are not controlled by another corporation, by any foreign government or by any natural
or legal persons except as set forth herein, and there are no arrangements known to us which would result in a change in control of our
company at a subsequent date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><div><a id="a_033"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Related Party Transactions.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 6.B. Compensation&#8221;
for compensation to our directors and officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employment and Service Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
have entered into written employment agreements with each of our executive officers. All of these agreements contain customary provisions
regarding noncompetition, confidentiality of information and assignment of inventions. However, the enforceability of the noncompetition
provisions may be limited under applicable law. In addition, we have entered into agreements with each executive officer and director
pursuant to which we have agreed to indemnify each of them up to a certain amount and to the extent that these liabilities are not covered
by directors and officers insurance. Some members of our senior management are eligible for bonuses each year. The bonuses are payable
upon meeting objectives and targets that are set by our Chief Executive Officer and approved annually by our board of directors that also
set the bonus targets for our Chief Executive Officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Options/RSUs </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Since
our inception, we have granted options to purchase our Ordinary Shares and RSUs to our officers and certain of our directors. Such option
agreements may contain acceleration provisions upon certain merger, acquisition, or change of control transactions. We describe our option
plans under &#8220;Item 6.E. Directors, Senior Management and Employees-Share Ownership-Equity Incentive Plan.&#8221; If the relationship
between us and an executive officer or a director is terminated, except for cause (as defined in the various option plan agreements),
options that are vested will generally remain exercisable for three months after such termination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Shareholders Loans</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">When
we considered pursuing an initial public offering on the ASX, we focused on an intravenous oxygenation device. As the development of this
product did not progress as planned, we progressed with developing our INSPIRA ART product ahead of plans, reducing the time to market
by approximately two years, and decided to pursue an initial public offering on Nasdaq rather than the ASX. On November 27, 2020, we entered
into an agreement, or the Termination Agreement, with IML, the Founders and Newburyport to terminate the IPO Deed, the Deed of Variation
and the 2019 CLA, or the Previous Agreements. Pursuant to the Termination Agreement, we agreed to convert the loan amount and the interest
accrued under the 2019 CLA as of November 27, 2020, into 676,061 of our Ordinary Shares, at price per share of A$5.15 (approximately $3.45)
or A$5.88 (approximately $3.91), and to issue to Newburyport or its affiliates 80,273 of our Ordinary Shares as promoter shares, and options
to purchase 28,572 of our Ordinary Shares, to Daniel Goldstein, who promoted our contract with IML, at an exercise price of NIS 0.37 (approximately
$0.12 per share). We also issued 169,016 warrants to IML, exercisable upon our initial public offering on the Nasdaq Capital Market. IML&#8217;s
warrants are exercisable for three years. IML purchased its shares and distributed its holdings of our shares as a dividend to its shareholders
following our initial public offering on the Nasdaq Capital Market. Each party to the Termination Agreement agreed to release each other
party to the Termination Agreement from all the claims related to the IPO Deed, Deed of Variation and CLA. In addition, we agreed to hire
Newburyport and Peter Marks, another affiliate of IML, as our business developers, to identify, introduce and promote us to potential
investors, and to pay cash commission in the amount of 7% from the net proceeds received from an investment consummated within 12 months
of our introduction to the investor by Newburyport or Peter Marks. As of November 28, 2021, we have paid Newburyport and Peter Marks A$403,000
(approximately $321,000) each, as cash commission for investor introductions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><div><a id="a_034"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt"><b>C.</b></span></td>
    <td><span style="font-size: 10pt"><b>Interests of Experts and Counsel.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_035"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 8. <span style="text-transform: uppercase">FINANCIAL
INFORMATION.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_036"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Statements and Other Financial Information.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 18. Financial
Statements.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
be involved in various claims and legal proceedings relating to claims arising out of our operations. Regardless of outcome, litigation
can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. We are
not currently party to, and our property is not the subject of, any material legal proceedings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 6, 2021, Exchange
Listing, LLC, or Exchange, filed a complaint in New York state court against us in connection with a contract between the parties. The
contracted related to certain consulting services provided to us by Exchange in preparation for our initial public offering. On September
9, 2021, we removed the case to the United States District Court for the Southern District of New York. On October 15, 2021, Exchange
filed an amended complaint, or the Amended Complaint, asserting eight causes of action: fraud in the inducement, unjust enrichment, quantum
meruit, breach of the covenant of good faith and fair dealing, common law fraud, breach of written and oral contracts. Exchange seeks
damages of $1,000,000 plus interest, legal fees, attorneys&#8217; fees, and the issuance of at least 73,321 of our Ordinary Shares. On
December 16, 2021, we filed a Motion to Dismiss the Amended Complaint for failure to state a claim upon which relief can be granted based
on the language of the parties&#8217; written contract. On January 28, 2022, Exchange Listing voluntarily dismissed the matter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 4, 2022, Exchange
filed a complaint in the Federal Court for the Southern District of New York against us and our Chief Financial Officer, Joe Hayon, in
connection with a contract between the parties pursuant to which Exchange provided certain consultancy services to us in preparation for
our initial public offering. The precise damages sought are unclear, however Exchange is seeking approximately $250,000 plus 75,000 Ordinary
Shares or the cash equivalent. On July 1, 2022, we filed a motion to dismiss for failure to state a claim upon relief can be granted based
on the language of the written contract between the parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 8, 2023, the court
issued an order granting our motion in part and denying it in part. Specifically, the court dismissed all claims against Joe Hayon and
he is no longer a party in the action. The court also dismissed the breach of contract action (Count I) to the extent it was based improper
termination or frustration. The Court also dismissed Count IV (Quantum Merit on the written agreement), Count VI (Breach of Implied Covenant
of Good Faith) and Count VII (Fraud in the Inducement). The court allowed Count 1 (breach of written agreement based on alleged anticipatory
repudiation), Count II (breach of alleged oral agreement), Count III (Promissory Estoppel to the extent based on alleged oral agreement)
and Count V (Quantum Meruit based on alleged oral agreement) to survive the pleading or early dismissal stage. We will continue to defend
ourselves vigorously with respect to this matter. In July 2023, following a confidential settlement agreement reached between the parties,
this matter was voluntarily dismissed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 12, 2021, we terminated
our employment agreement with Dr. Udi Nussinovitch, who is one of our founders who served as our Chief Scientific Officer since March
2018. On February 24, 2022, we sued Mr. Nussinovitch for breach good faith and his fiduciary duties as a shareholder and former officer
of the Company. On November 9, 2022, we received notice of a complaint filed by Mr. Nussinovitch, as well as a complaint filed with the
regional labor court in Tel Aviv on November 8, 2022. Mr. Nussinovitch has alleged certain deficiencies in the Registrant&#8217;s <span>Extraordinary
General Meeting of Shareholders held on Friday, December 17, 2021, resulting from his status as a minority shareholder. In addition, with
respect to the labor dispute, Mr. </span>Nussinovitch is seeking renumeration and the issuance of Ordinary Shares. On July 19. 2023, a
partial hearing about the labor dispute was held, in which the parties were required by the court to file their positions on a stay of
the proceeding pending the decision on the case initiated by Mr. Nussinovitch in the District Court. On January 21, 2024, a partial hearing
about the civil case was held. During the hearing, the court suggested the parties consider the possibility of resolving the case through
an out-of-court arrangement or mediation. The parties agreed to a mediation process. <span>We </span>strongly
disagree with the claims and believe we have meritorious defenses and will vigorously defend itself against the claims.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividends</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid any cash dividends on our Ordinary Shares and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash
dividends, if any, in the future will be at the discretion of our board of directors and will depend on then-existing conditions, including
our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board
of directors may deem relevant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law imposes
further restrictions on our ability to declare and pay dividends. Under the Companies Law, we may declare and pay dividends only if, upon
the determination of our board of directors, there is no reasonable concern that the distribution will prevent us from being able to meet
the terms of our existing and foreseeable obligations as they become due. Under the Companies Law, the distribution amount is further
limited to the greater of retained earnings or earnings generated over the two most recent years legally available for distribution according
to our then last reviewed or audited financial statements, provided that the end of the period to which the financial statements relate
is not more than six months prior to the date of distribution. In the event that we do not meet such earnings criteria, we may seek the
approval of a court in order to distribute a dividend. The court may approve our request if it is convinced that there is no reasonable
concern that the payment of a dividend will prevent us from satisfying our existing and foreseeable obligations as they become due.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Payment of dividends may be
subject to Israeli withholding taxes. See &#8220;Item 10.E. Taxation&#8221;, for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><div><a id="a_037"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Significant Changes.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No significant change, other
than as otherwise described in this annual report on Form 20-F, has occurred in our operations since the date of our financial statements
included in this annual report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;&#160;</p><div>

</div><div><a id="a_038"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 9. <span style="text-transform: uppercase">THE
OFFER AND LISTING</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_039"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Offer and Listing Details.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since July 16, 2021, our Ordinary
Shares and Warrants have been traded on the Nasdaq Capital Market under the symbols &#8220;IINN&#8221; and &#8220;IINNW&#8221;, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_040"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Plan of Distribution.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_041"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Markets.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Ordinary Shares and Warrants
trade on the Nasdaq Capital Market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_042"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Selling Shareholders.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_043"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>E.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Dilution.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_044"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>F.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Expenses of the Issue.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_045"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 10. <span style="text-transform: uppercase">ADDITIONAL
INFORMATION</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_046"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Share Capital.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_047"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Memorandum and Articles of Association.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of our amended and
restated articles of association is attached as Exhibit 1.1 to this annual report on Form 20-F. The information called for by this Item
is set forth in Exhibit 2(d) to this annual report on Form 20-F and is incorporated by reference into this annual report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><div><a id="a_048"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Material Contracts. </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
have not entered into any material contract within the two years prior to the date of this Annual Report, other than contracts entered
into in the ordinary course of business, as otherwise described herein in &#8220;Item 4.A. History and Development of the Company&#8221;
above, &#8220;Item 4.B. Business Overview&#8221; above, &#8220;Item 6.C Board Practices - Indemnification,&#8221; &#8220;Item 6.E Share
Ownership - Equity Incentive Plan,&#8221; &#8220;Item 7.A. Major Shareholders,&#8221; or &#8220;Item 7.B. Related Party Transactions,&#8221;
above, or as otherwise described below:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Securities Purchase Agreement
by and between the Company and H.C. Wainwright &amp; Co., LLC See Item 5.A &#8220;<i>Operating and Financial Review and Prospects</i>&#8221;
for more information about this document.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><div><a id="a_049"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Exchange Controls.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are currently no Israeli
currency control restrictions on payments of dividends or other distributions with respect to our securities or the proceeds from the
sale of the shares, except for the obligation of Israeli residents to file reports with the Bank of Israel regarding certain transactions.
However, legislation remains in effect pursuant to which currency controls can be imposed by administrative action at any time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ownership or voting of
our securities by non-residents of Israel, except with respect to citizens of countries that are in a state of war with Israel, is not
restricted in any way by our memorandum of association or amended and restated articles of association or by the laws of the State of
Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><div><a id="a_050"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>E.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Taxation.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
following is a description of the material Israeli income tax consequences of the ownership of our securities. The following also contains
a description of material relevant provisions of the current Israeli income tax structure applicable to companies in Israel, with reference
to its effect on us. To the extent that the discussion is based on new tax legislation which has not been subject to judicial or administrative
interpretation, there can be no assurance that the tax authorities will accept the views expressed in the discussion in question. The
discussion is not intended, and should not be taken, as legal or professional tax advice and is not exhaustive of all possible tax considerations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
following description is not intended to constitute a complete analysis of all tax consequences relating to the ownership or disposition
of our securities. Shareholders should consult their own tax advisors concerning the tax consequences of their particular situation, as
well as any tax consequences that may arise under the laws of any state, local, foreign or other taxing jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General Corporate Tax Structure in Israel</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Israeli
companies are generally subject to corporate tax. As of January 2016, the corporate tax rate was 25%. As of January 1, 2017, the corporate
tax rate was reduced to 24% and as of January 1, 2018, the corporate tax rate is 23%. However, the effective tax rate payable by a company
that derives income from a Preferred Enterprise (as discussed below) may be considerably less. Capital gains derived by an Israeli company
are generally subject to the prevailing corporate tax rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Capital
gains derived by an Israeli resident company are subject to tax at the prevailing corporate tax rate. Under Israeli tax legislation, a
corporation will be considered as an &#8220;Israeli resident company&#8221; if it meets one of the following: (i) it was incorporated
in Israel; or (ii) the control and management of its business are exercised in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Law for the Encouragement of Industry (Taxes),
5729-1969</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Law for the Encouragement of Industry (Taxes), 5729-1969, generally referred to as the Industry Encouragement Law, provides several tax
benefits for &#8220;Industrial Companies.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Industry Encouragement Law defines an &#8220;Industrial Company&#8221; as an Israeli resident-company, of which 90% or more of its income
in any tax year, other than income from defense loans, is derived from an &#8220;Industrial Enterprise&#8221; owned by it. An &#8220;Industrial
Enterprise&#8221; is defined as an enterprise whose principal activity in a given tax year is industrial production.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
following corporate tax benefits, among others, are available to Industrial Companies:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">amortization of the cost of
purchased a patent, rights to use a patent, and know-how, which are used for the development or advancement of the company, over an eight-year
period, commencing on the year in which such rights were first exercised;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">under limited conditions, an
election to file consolidated tax returns with related Israeli Industrial Companies; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">expenses related to a public
offering are deductible in equal amounts over three years.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Eligibility
for benefits under the Industry Encouragement Law is not contingent upon approval of any governmental authority.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tax Benefits and Grants for Research and
Development</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Under
the Israeli Encouragement of Research, Development and Industrial Initiative Technology Law, 5744-1984, as amended, and related regulations,
or the Research Law, research and development programs which meet specified criteria and are approved by the IIA are eligible for grants
of up to 50% of the project&#8217;s expenditure, as determined by the research committee, in exchange for the payment of royalties from
the revenues generated from the sale of products and related services developed, in whole or in part pursuant to, or as a result of, a
research and development program funded by the IIA. The royalties are generally at a range of 3.0% to 5.0% of revenues until the entire
IIA grant is repaid, together with an annual interest. Until October 25, 2023, the interest was calculated at a rate based on 12-month
LIBOR applicable to U.S. Dollar deposits. However, on October 25, 2023, the IIA published a directive concerning changes in royalties
to address the expiration of the LIBOR. Under such directive, regarding IIA grants approved by the IIA prior to January 1, 2024 but which
are outstanding thereafter, as of January 1, 2024, the annual interest will be calculated at a rate based on 12-month SOFR, or at an alternative
rate published by the Bank of Israel plus 0.71513%; and, for grants approved on or following January 1, 2024 the annual interest will
be the higher of (i) the 12 months SOFR interest rate, plus 1%, or (ii) a fixed annual interest rate of 4%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
terms of the Research Law also require that the manufacture of products developed with government grants be performed in Israel. The transfer
of manufacturing activity outside Israel may be subject to the prior approval of the IIA. Under the regulations of the Research Law, assuming
we receive approval from the Chief Scientist to manufacture our IIA-funded products outside Israel, we may be required to pay increased
royalties. The increase in royalties depends upon the manufacturing volume that is performed outside of Israel as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Manufacturing Volume Outside of Israel</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Royalties to <br/> the Chief <br/> Scientist<br/> as a <br/> Percentage <br/> of Grant</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Up to 50%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">120</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Between 50% and 90%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">90% and more</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">If
the manufacturing is performed outside of Israel by us, the rate of royalties payable by us on revenues from the sale of products manufactured
outside of Israel will increase by 1% over the regular rates. If the manufacturing is performed outside of Israel by a third party, the
rate of royalties payable by us on those revenues will be equal to the ratio obtained by dividing the amount of the grants received from
the Office of the Chief Scientist and our total investment in the project that was funded by these grants. The transfer of no more than
10% of the manufacturing capacity in the aggregate outside of Israel is exempt under the Research Law from obtaining the prior approval
of the IIA. A company requesting funds from the IIA also has the option of declaring in its IIA grant application an intention to perform
part of its manufacturing outside Israel, thus avoiding the need to obtain additional approval. On January 6, 2011, the Research Law was
amended to clarify that the potential increased royalties specified in the table above will apply even in those cases where the IIA approval
for transfer of manufacturing outside of Israel is not required, namely when the volume of the transferred manufacturing capacity is less
than 10% of total capacity or when the company received an advance approval to manufacture abroad in the framework of its IIA grant application.
For applications to manufacture abroad submitted to the IIA after October 25, 2023, the maximum increased liability is up to 150% of the
IIA grants, plus interest accrued thereon, instead of 300%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
know-how developed within the framework of the Chief Scientist plan may not be transferred to third parties outside Israel without the
prior approval of a governmental committee charted under the Research Law. The approval, however, is not required for the export of any
products developed using grants received from the Chief Scientist. The IIA approval to transfer know-how created, in whole or in part,
in connection with an IIA-funded project to third party outside Israel where the transferring company remains an operating Israeli entity
is subject to payment of a redemption fee to the IIA calculated according to a formula provided under the Research Law that is based,
in general, on the ratio between the aggregate IIA grants to the company&#8217;s aggregate investments in the project that was funded
by these IIA grants, multiplied by the transaction consideration. The transfer of such know-how to a party outside Israel where the transferring
company ceases to exist as an Israeli entity is subject to a redemption fee formula that is based, in general, on the ratio between the
aggregate IIA grants to the total financial investments in the company, multiplied by the transaction consideration. According to the
January 2011 amendment, the redemption fee in case of transfer of know-how to a party outside Israel will be based on the ratio between
the aggregate IIA grants received by the company and the company&#8217;s aggregate R&amp;D expenses, multiplied by the transaction consideration.
According to regulations promulgated following the 2011 amendment, the maximum amount payable to the IIA in case of transfer of know how
outside Israel shall not exceed 6 times the value of the grants received plus interest, and in the event that the receiver of the grants
ceases to be an Israeli corporation such payment shall not exceed six times the value of the grants received plus interest, with a possibility
to reduce such payment to up to three times the value of the grants received plus interest if the R&amp;D activity remains in Israel for
a period of three years after payment to the IIA and maintain at least 75% of the research and development employees the Company had for
the six months before the know-how was transferred, subject to additional conditions specified in the regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Transfer
of know-how within Israel is subject to an undertaking of the recipient Israeli entity to comply with the provisions of the Research Law
and related regulations, including the restrictions on the transfer of know-how and the obligation to pay royalties, as further described
in the Research Law and related regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">These
restrictions may impair our ability to outsource manufacturing, engage in change of control transactions or otherwise transfer our know-how
outside Israel and may require us to obtain the approval of the IIA for certain actions and transactions and pay additional royalties
to the IIA. In particular, any change of control and any change of ownership of our securities that would make a non-Israeli citizen or
resident an &#8220;interested party,&#8221; as defined in the Research Law, requires a prior written notice to the IIA in addition to
any payment that may be required of us for transfer of manufacturing or know-how outside Israel. If we fail to comply with the Research
Law, we may be subject to criminal charges or to mandatory repayment of grants received by us (together with interest and penalties).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tax Benefits for Research and Development</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Israeli
tax law allows, under certain conditions, a tax deduction for expenditures, including capital expenditures, for the year in which they
are incurred. Expenditures are deemed related to scientific research and development projects, if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The expenditures are approved
by the relevant Israeli government ministry, determined by the field of research;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The research and development
must be for the promotion of the company; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">The research and development
is carried out by or on behalf of the company seeking such tax deduction.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
amount of such deductible expenses is reduced by the sum of any funds received through government grants for the finance of such scientific
research and development projects. No deduction under these research and development deduction rules is allowed if such deduction is related
to an expense invested in an asset depreciable under the general depreciation rules of the income Tax Ordinance, 1961. Expenditures not
so approved are deductible in equal amounts over three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">From
time to time, we may apply the Office of the Chief Scientist for approval to allow a tax deduction for all research and development expenses
during the year incurred. There can be no assurance that such application will be accepted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Law for the Encouragement of Capital Investments,
5719-1959</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Law for the Encouragement of Capital Investments, 5719-1959, generally referred to as the Investment Law, provides certain incentives
for capital investments in production facilities (or other eligible assets).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tax Benefits</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Investment Law grants tax benefits for income generated by a &#8220;Preferred Company&#8221; through its &#8220;Preferred Enterprise&#8221;
(as such terms are defined in the Investment Law) The definition of a Preferred Company includes a company incorporated in Israel that
is not fully owned by a governmental entity, and that has, among other things, Preferred Enterprise status and is controlled and managed
from Israel. A Preferred Company is entitled to a reduced corporate tax rate of 16% with respect to its income derived by its Preferred
Enterprise, unless the Preferred Enterprise is located in a specified development zone, in which case the rate will be 7.5%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Dividends
paid out of income attributed to a Preferred Enterprise are generally subject to withholding tax at source at the rate of 20% or such
lower rate as may be provided in an applicable tax treaty. However, if such dividends are paid to an Israeli company, no tax is required
to be withheld.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxation of our Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Capital
Gains Taxes Applicable to Non-Israeli Resident Shareholders. A non-Israeli resident who derives capital gains from the sale of shares
in an Israeli resident company will be exempt from Israeli tax so long as the shares were not held through a permanent establishment that
the non-resident maintains in Israel. However, non-Israeli corporations will not be entitled to the foregoing exemption if Israeli residents:
(i) have a controlling interest of 25% or more in such non-Israeli corporation or (ii) are the beneficiaries of, or are entitled to, 25%
or more of the revenues or profits of such non-Israeli corporation, whether directly or indirectly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Additionally,
a sale of securities by a non-Israeli resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax
treaty. For example, under Convention Between the Government of the United States of America and the Government of the State of Israel
with respect to Taxes on Income, as amended, or the United States-Israel Tax Treaty, the sale, exchange or other disposition of shares
by a shareholder who is a United States resident (for purposes of the treaty) holding the shares as a capital asset and is entitled to
claim the benefits afforded to such a resident by the U.S.-Israel Tax Treaty, or a Treaty U.S. Resident, is generally exempt from Israeli
capital gains tax unless: (i) the capital gain arising from such sale, exchange or disposition is attributed to real estate located in
Israel; (ii) the capital gain arising from such sale, exchange or disposition is attributed to royalties; (iii) the capital gain arising
from the such sale, exchange or disposition is attributed to a permanent establishment in Israel, under certain terms; (iv) such Treaty
U.S. Resident holds, directly or indirectly, shares representing 10% or more of the voting capital during any part of the 12-month period
preceding the disposition, subject to certain conditions; or (v) such Treaty U.S. Resident is an individual and was present in Israel
for 183 days or more during the relevant taxable year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
some instances where our shareholders may be liable for Israeli tax on the sale of their securities, the payment of the consideration
may be subject to the withholding of Israeli tax at source. Shareholders may be required to demonstrate that they are exempt from tax
on their capital gains in order to avoid withholding at source at the time of sale.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Taxation
of Non-Israeli Shareholders on Receipt of Dividends. Non-Israeli residents are generally subject to Israeli income tax on the receipt
of dividends paid on our securities at the rate of 25%, which tax will be withheld at source, unless relief is provided in a treaty between
Israel and the shareholder&#8217;s country of residence. With respect to a person who is a &#8220;substantial shareholder&#8221; at the
time of receiving the dividend or on any time during the preceding twelve months, the applicable tax rate is 30%. A &#8220;substantial
shareholder&#8221; is generally a person who alone or together with such person&#8217;s relative or another person who collaborates with
such person on a permanent basis, holds, directly or indirectly, at least 10% of any of the &#8220;means of control&#8221; of the corporation.
&#8220;Means of control&#8221; generally include the right to vote, receive profits, nominate a director or an executive officer, receive
assets upon liquidation, or order someone who holds any of the aforesaid rights how to act, regardless of the source of such right. However,
a distribution of dividends to non-Israeli residents is subject to withholding tax at source at a rate of 20% if the dividend is distributed
from income attributed to a Preferred Enterprise, unless a reduced tax rate is provided under an applicable tax treaty. For example, under
the United States-Israel Tax Treaty, the maximum rate of tax withheld at source in Israel on dividends paid to a holder of our securities
who is a Treaty U.S. Resident is 25%. However, generally, the maximum rate of withholding tax on dividends, not generated by a Preferred
Enterprise, that are paid to a United States corporation holding 10% or more of the outstanding voting capital throughout the tax year
in which the dividend is distributed as well as during the previous tax year, is 12.5%, provided that not more than 25% of the gross income
for such preceding year consists of certain types of dividends and interest. Notwithstanding the foregoing, dividends distributed from
income attributed to a Preferred Enterprise are not entitled to such reduction under the tax treaty but are subject to a withholding tax
rate of 15% for a shareholder that is a U.S. corporation, provided that the condition related to our gross income for the previous year
(as set forth in the previous sentence) is met. If the dividend is attributable partly to income derived from a Preferred Enterprise,
and partly to other sources of income, the withholding rate will be a blended rate reflecting the relative portions of the two types of
income. We cannot assure you that we will designate the profits that we may distribute in a way that will reduce shareholders&#8217; tax
liability.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>U.S. FEDERAL INCOME TAX CONSIDERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THE FOLLOWING SUMMARY IS INCLUDED
HEREIN FOR GENERAL INFORMATION AND IS NOT INTENDED TO BE, AND SHOULD NOT BE CONSIDERED TO BE, LEGAL OR TAX ADVICE. EACH U.S. HOLDER SHOULD
CONSULT WITH HIS OR HER OWN TAX ADVISOR AS TO THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND SALE
OF ORDINARY SHARES INCLUDING THE EFFECTS OF APPLICABLE STATE, LOCAL, FOREIGN OR OTHER TAX LAWS AND POSSIBLE CHANGES IN THE TAX LAWS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the limitations
described in the next two paragraphs, the following discussion summarizes the material U.S. federal income tax consequences to a &#8220;U.S.
Holder&#8221; arising from the purchase, ownership and sale of the Ordinary Shares, the Warrants, and the Ordinary Shares issued or issuable
upon exercise of the Warrants, collectively, the &#8220;securities&#8221;. For this purpose, a &#8220;U.S. Holder&#8221; is a holder of
securities that is: (1) an individual citizen or resident of the United States, including an alien individual who is a lawful permanent
resident of the United States or meets the substantial presence residency test under U.S. federal income tax laws; (2) a corporation (or
entity treated as a corporation for U.S. federal income tax purposes) or a partnership (other than a partnership that is not treated as
a U.S. person under any applicable U.S. Treasury regulations) created or organized under the laws of the United States or the District
of Columbia or any political subdivision thereof; (3) an estate, the income of which is includable in gross income for U.S. federal income
tax purposes regardless of source; (4) a trust if a court within the United States is able to exercise primary supervision over the administration
of the trust and one or more U.S. persons have authority to control all substantial decisions of the trust; or (5) a trust that has a
valid election in effect to be treated as a U.S. person to the extent provided in U.S. Treasury regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This summary is for general
information purposes only and does not purport to be a comprehensive description of all of the U.S. federal income tax considerations
that may be relevant to a decision to purchase our securities. This summary generally considers only U.S. Holders that will own our securities
as capital assets. Except to the limited extent discussed below, this summary does not consider the U.S. federal tax consequences to a
person that is not a U.S. Holder, nor does it describe the rules applicable to determine a taxpayer&#8217;s status as a U.S. Holder. This
summary is based on the provisions of the Internal Revenue Code of 1986, as amended, or the Code, final, temporary and proposed U.S. Treasury
regulations promulgated thereunder, administrative and judicial interpretations thereof, and the U.S./Israel Income Tax Treaty, all as
in effect as of the date hereof and all of which are subject to change, possibly on a retroactive basis, and all of which are open to
differing interpretations. We will not seek a ruling from the IRS with regard to the U.S. federal income tax treatment of an investment
in our securities by U.S. Holders and, therefore, can provide no assurances that the IRS will agree with the conclusions set forth below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This discussion does not address
all of the aspects of U.S. federal income taxation that may be relevant to a particular U.S. holder based on such holder&#8217;s particular
circumstances and in particular does not discuss any estate, gift, generation-skipping transfer, state, local, excise or foreign tax considerations.
In addition, this discussion does not address the U.S. federal income tax treatment of a U.S. Holder who is: (1) a bank, life insurance
company, regulated investment company, or other financial institution or &#8220;financial services entity;&#8221; (2) a broker or dealer
in securities or foreign currency; (3) a person who acquired our securities in connection with employment or other performance of services;
(4) a U.S. Holder that is subject to the U.S. alternative minimum tax; (5) a U.S. Holder that holds our securities as a hedge or as part
of a hedging, straddle, conversion or constructive sale transaction or other risk-reduction transaction for U.S. federal income tax purposes;
(6) a tax-exempt entity; (7) real estate investment trusts or grantor trusts; (8) a U.S. Holder that expatriates out of the United States
or a former long-term resident of the United States; or (9) a person having a functional currency other than the U.S. dollar. This discussion
does not address the U.S. federal income tax treatment of a U.S. Holder that owns, directly or constructively, at any time, securities
representing 10% or more of our voting power. Additionally, the U.S. federal income tax treatment of partnerships (or other pass-through
entities) or persons who hold securities through a partnership or other pass-through entity are not addressed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each prospective investor
is advised to consult his or her own tax adviser for the specific tax consequences to that investor of purchasing, holding or disposing
of our securities, including the effects of applicable state, local, foreign or other tax laws and possible changes in the tax laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span><b><i>Exercise
or Expiry of Warrants</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No gain or loss will be realized
on the exercise of a Warrant. When a Warrant is exercised, the U.S. Holder&#8217;s cost of the common share acquired thereby will be equal
to the U.S. Holder&#8217;s adjusted cost basis of the Warrant plus the exercise price paid for the common share. The expiry of an unexercised
Warrant will generally give rise to a capital loss equal to the adjusted cost basis to the U.S. Holder of the expired Warrant. The holding
period of the common share acquired thru the exercise of a Warrant includes the holding period of the Warrant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Taxation of Dividends
Paid on Ordinary Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not intend to pay dividends
in the foreseeable future. In the event that we do pay dividends, and subject to the discussion under the heading &#8220;Passive Foreign
Investment Companies&#8221; below and the discussion of &#8220;qualified dividend income&#8221; below, a U.S. Holder, other than certain
U.S. Holders that are U.S. corporations, will be required to include in gross income as ordinary income the amount of any distribution
paid on securities (including the amount of any Israeli tax withheld on the date of the distribution), to the extent that such distribution
does not exceed our current and accumulated earnings and profits, as determined for U.S. federal income tax purposes. The amount of a
distribution which exceeds our earnings and profits will be treated first as a non-taxable return of capital, reducing the U.S. Holder&#8217;s
tax basis for the securities to the extent thereof, and then capital gain. We do not expect to maintain calculations of our earnings and
profits under U.S. federal income tax principles and, therefore, U.S. Holders should expect that the entire amount of any distribution
generally will be reported as dividend income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, preferential tax
rates for &#8220;qualified dividend income&#8221; and long-term capital gains are applicable for U.S. Holders that are individuals, estates
or trusts. For this purpose, &#8220;qualified dividend income&#8221; means, inter alia, dividends received from a &#8220;qualified foreign
corporation.&#8221; A &#8220;qualified foreign corporation&#8221; is a corporation that is entitled to the benefits of a comprehensive
tax treaty with the United States which includes an exchange of information program. The IRS has stated that the Israel/U.S. Tax Treaty
satisfies this requirement and we believe we are eligible for the benefits of that treaty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our dividends
will be qualified dividend income if our securities are readily tradable on the Nasdaq Capital Market or another established securities
market in the United States. Dividends will not qualify for the preferential rate if we are treated, in the year the dividend is paid
or in the prior year, as a PFIC, as described below under &#8220;Passive Foreign Investment Companies.&#8221; A U.S. Holder will not be
entitled to the preferential rate: (1) if the U.S. Holder has not held our securities for at least 61 days of the 121 day period beginning
on the date which is 60 days before the ex-dividend date, or (2) to the extent the U.S. Holder is under an obligation to make related
payments on substantially similar property. Any days during which the U.S. Holder has diminished its risk of loss on our securities are
not counted towards meeting the 61-day holding period. Finally, U.S. Holders who elect to treat the dividend income as &#8220;investment
income&#8221; pursuant to Code section 163(d)(4) will not be eligible for the preferential rate of taxation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of a distribution
with respect to our securities will be measured by the amount of the fair market value of any property distributed, and for U.S. federal
income tax purposes, the amount of any Israeli taxes withheld therefrom. Cash distributions paid by us in NIS will be included in the
income of U.S. Holders at a U.S. dollar amount based upon the spot rate of exchange in effect on the date the dividend is includible in
the income of the U.S. Holder, and U.S. Holders will have a tax basis in such NIS for U.S. federal income tax purposes equal to such U.S.
dollar value. If the U.S. Holder subsequently converts the NIS into U.S. dollars or otherwise disposes of them, any subsequent gain or
loss in respect of such NIS arising from exchange rate fluctuations will be U.S. source ordinary exchange gain or loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Taxation of the
Disposition of Securities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as provided under the
PFIC rules described below under &#8220;Passive Foreign Investment Companies,&#8221; upon the sale, exchange or other disposition of our
securities, a U.S. Holder will recognize capital gain or loss in an amount equal to the difference between such U.S. Holder&#8217;s tax
basis for the securities in U.S. dollars and the amount realized on the disposition in U.S. dollar (or its U.S. dollar equivalent determined
by reference to the spot rate of exchange on the date of disposition, if the amount realized is denominated in a foreign currency). The
gain or loss realized on the sale, exchange or other disposition of securities will be long-term capital gain or loss if the U.S. Holder
has a holding period of more than one year at the time of the disposition. Individuals who recognize long-term capital gains may be taxed
on such gains at reduced rates of tax. The deduction of capital losses is subject to various limitations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Passive Foreign
Investment Companies</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Special U.S. federal income
tax laws apply to U.S. taxpayers who own shares of a corporation that is a PFIC. We will be treated as a PFIC for U.S. federal income
tax purposes for any taxable year that either:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">75% or more of our gross income (including our pro rata share of gross income for any company, in which we are considered to own 25% or more of the shares by value), in a taxable year is passive; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">At least 50% of our assets, averaged over the year and generally determined based upon fair market value (including our pro rata share of the assets of any company in which we are considered to own 25% or more of the shares by value) are held for the production of, or produce, passive income.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For this purpose, passive
income generally consists of dividends, interest, rents, royalties, annuities and income from certain commodities transactions and from
notional principal contracts. Cash is treated as generating passive income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that we will not
be a PFIC for the current taxable year, although we have not determined whether we will be a PFIC in the foreseeable future. The tests
for determining PFIC status are applied annually, and it is difficult to make accurate projections of future income and assets which are
relevant to this determination. In addition, our PFIC status may depend in part on the market value of our securities. Accordingly, there
can be no assurance that we currently are not or will not become a PFIC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we currently are or become
a PFIC, each U.S. Holder who has not elected to mark the shares to market (as discussed below), would, upon receipt of certain distributions
by us and upon disposition of our securities at a gain:&#160;(1) have such distribution or gain allocated ratably over the U.S. Holder&#8217;s
holding period for the securities, as the case may be; (2) the amount allocated to the current taxable year and any period prior to the
first day of the first taxable year in which we were a PFIC would be taxed as ordinary income; and (3) the amount allocated to each of
the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for that year,
and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each such other
taxable year. In addition, when shares of a PFIC are acquired by reason of death from a decedent that was a U.S. Holder, the tax basis
of such shares would not receive a step-up to fair market value as of the date of the decedent&#8217;s death, but instead would be equal
to the decedent&#8217;s basis if lower, unless all gain were recognized by the decedent. Indirect investments in a PFIC may also be subject
to these special U.S. federal income tax rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The PFIC rules described above
would not apply to a U.S. Holder who makes a QEF election for all taxable years that such U.S. Holder has held the securities while we
are a PFIC, provided that we comply with specified reporting requirements. Instead, each U.S. Holder who has made such a QEF election
is required for each taxable year that we are a PFIC to include in income such U.S. Holder&#8217;s pro rata share of our ordinary earnings
as ordinary income and such U.S. Holder&#8217;s pro rata share of our net capital gains as long-term capital gain, regardless of whether
we make any distributions of such earnings or gain. In general, a QEF election is effective only if we make available certain required
information. The QEF election is made on a shareholder-by-shareholder basis and generally may be revoked only with the consent of the
IRS. We do not intend to notify U.S. Holders if we believe we will be treated as a PFIC for any tax year. In addition, we do not intend
to furnish U.S. Holders annually with information needed in order to complete IRS Form 8621 and to make and maintain a valid QEF election
for any year in which we or any of our Subsidiaries are a PFIC. Therefore, the QEF election will not be available with respect to our
securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the PFIC rules
described above would not apply if we were a PFIC and a U.S. Holder made a mark-to-market election. A U.S. Holder of our securities which
are regularly traded on a qualifying exchange, including the Nasdaq Capital Market, can elect to mark the securities to market annually,
recognizing as ordinary income or loss each year an amount equal to the difference as of the close of the taxable year between the fair
market value of the securities and the U.S. Holder&#8217;s adjusted tax basis in the securities. Losses are allowed only to the extent
of net mark-to-market gain previously included income by the U.S. Holder under the election for prior taxable years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. Holders who hold our
securities during a period when we are a PFIC will be subject to the foregoing rules, even if we cease to be a PFIC. U.S. Holders are
strongly urged to consult their tax advisors about the PFIC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Tax on Net Investment
Income</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. Holders who are individuals,
estates or trusts will generally be required to pay a 3.8% Medicare tax on their net investment income (including dividends on and gains
from the sale or other disposition of our securities), or in the case of estates and trusts on their net investment income that is not
distributed to beneficiaries of the estate or trust. In each case, the 3.8% Medicare tax applies only to the extent the U.S. Holder&#8217;s
total adjusted income exceeds applicable thresholds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Information Reporting
and Withholding</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. Holder may be subject
to backup withholding at a rate of 24% with respect to cash dividends and proceeds from a disposition of securities. In general, backup
withholding will apply only if a U.S. Holder fails to comply with specified identification procedures. Backup withholding will not apply
with respect to payments made to designated exempt recipients, such as corporations and tax-exempt organizations. Backup withholding is
not an additional tax and may be claimed as a credit against the U.S. federal income tax liability of a U.S. Holder, provided that the
required information is timely furnished to the IRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to recently enacted
legislation, a U.S. Holder with interests in &#8220;specified foreign financial assets&#8221; (including, among other assets, our securities,
unless such securities are held on such U.S. Holder&#8217;s behalf through a financial institution) may be required to file an information
report with the IRS if the aggregate value of all such assets exceeds $50,000 on the last day of the taxable year or $75,000 at any time
during the taxable year (or such higher dollar amount as may be prescribed by applicable IRS guidance); and may be required to file a
Report of Foreign Bank and Financial Accounts, or FBAR, if the aggregate value of the foreign financial accounts exceeds $10,000 at any
time during the calendar year. You should consult your own tax advisor as to the possible obligation to file such information report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_051"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>F.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Dividends and Paying Agents.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_052"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>G.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Statement by Experts.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_053"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>H.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Documents on Display.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the information
reporting requirements of the Exchange Act, applicable to foreign private issuers and under those requirements file reports with the SEC.
The SEC maintains an Internet website that contains reports and other information regarding issuers that file electronically with the
SEC. Our filings with the SEC are also available to the public through the SEC&#8217;s website at www.sec.gov.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a foreign private issuer,
we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors
and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange
Act. In addition, we are not required under the Exchange Act to file annual, quarterly and current reports and financial statements with
the SEC as frequently or as promptly as U.S. domestic companies whose securities are registered under the Exchange Act. However, we file
with the SEC, within 120 days after the end of each fiscal year, or such applicable time as required by the SEC, an annual report on Form
20-F containing financial statements audited by an independent registered public accounting firm, and may submit to the SEC, on a Form
6-K, unaudited quarterly financial information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain a corporate website
www.inspira-technologies.com. Information contained on, or that can be accessed through, our website and the other websites referenced
above do not constitute a part of this annual report on Form 20-F. We have included these website addresses in this annual report on Form
20-F solely as inactive textual references.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_054"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>I.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Subsidiary Information.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Not
applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><div><a id="a_055"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>J.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Annual Report to Security Holders</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;&#160;</p><div>

</div><div><a id="a_056"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 11. <span style="text-transform: uppercase">QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the ordinary course of
our operations, we are exposed to certain market risks, primarily changes in foreign currency exchange rates and interest rates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Quantitative and Qualitative Disclosure About
Market Risk</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are exposed to market risks
in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse
changes in financial market prices and rates. Our current investment policy is to invest available cash in bank deposits with banks that
have a credit rating of at least A-minus. Accordingly, a substantial majority of our equivalents is held in deposits that bear interest.
Given the current low rates of interest we receive, we will not be adversely affected if such rates are reduced. Our market risk exposure
is primarily a result of NIS/U.S. dollar exchange rates, which is discussed in detail in the following paragraph.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Foreign Currency Exchange Risk</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We operate primarily in Israel,
and approximately 70% of our expenses are denominated in NIS. We are therefore exposed to market risk, which represents the risk of loss
that may impact our financial position due to adverse changes in financial market prices and rates. We are subject to fluctuations in
foreign currency rates in connection with these arrangements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently partially hedge
our foreign currency exchange rate risk to decrease the risk of financial exposure from fluctuations in the exchange rates of our principal
operating currencies. These measures, however, may not adequately protect us from the material adverse effects of such fluctuations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Interest Rate Risk</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not anticipate undertaking
any significant long-term borrowings. At present, our investments consist primarily of cash and cash equivalents, and short-term deposits.
The primary objective of our investment activities is to preserve principal while maximizing the income that we receive from our investments
without significantly increasing risk and loss. Our investments may be exposed to market risk due to fluctuation in interest rates, which
may affect our interest income and the fair market value of our investments, if any.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Impact of Inflation and Currency Fluctuations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Inflation generally affects
us by increasing our NIS-denominated expenses, including salaries and benefits, as well as facility rental costs and payment to local
suppliers. We do not believe that inflation had a material effect on our business, financial condition or results of operations during
the year ended December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><div><a id="a_057"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 12. <span style="text-transform: uppercase">DESCRIPTION
OF SECURITIES OTHER THAN EQUITY SECURITIES</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_058"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Debt Securities.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_059"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Warrants and rights.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_060"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Other Securities.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_061"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in"><span style="font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>American Depositary Shares. </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_062"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_063"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND
DELINQUENCIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_064"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS
OF SECURITY HOLDERS AND USE OF PROCEEDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2021, we completed
our initial public offering, or IPO, of Ordinary Shares and warrants pursuant to Registration Statement on Form F-1, as amended (Registration
No. 333-253920), whereby we sold 2,909,091 Ordinary Shares and 3,345,455 tradable warrants (inclusive of 436,364 tradable warrants pursuant
to the exercise of an overallotment option granted to the underwriters). All of these Ordinary Shares and warrants were sold at a combined
price of $5.50 per unit, yielding an aggregate net proceeds received by us from the IPO were $14 million, after underwriting discounts
and other offering costs. We continue to use the proceeds from the exercise of warrants related to this offering, as described in the
final prospectus filed with the SEC on July 15, 2021, under File No. 333-253920 and 333-257880.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><div><a id="a_065"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 15. CONTROLS AND PROCEDURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(a) Disclosure Controls and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, with the participation
of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures
(as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2023, or the Evaluation Date. Based
on such evaluation, those officers have concluded that, as of the Evaluation Date, our disclosure controls and procedures are effective
in recording, processing, summarizing and reporting, on a timely basis, information required to be included in periodic filings under
the Exchange Act and that such information is accumulated and communicated to management, including our principal executive and financial
officers, as appropriate to allow timely decisions regarding required disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(b) Management&#8217;s Annual Report on Internal
Control over Financial Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management is responsible
for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the
Exchange Act. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial
Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework and criteria
established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission
as of the end of the period covered by this report. Based on that evaluation, our management has concluded that our internal control over
financial reporting was effective as of December 31, 2023 at providing reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(c) Attestation Report of the Registered Public
Accounting Firm</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This annual report does not
include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting
due to an exemption for EGCs provided in the JOBS Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(d) Changes in Internal Control over Financial
Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2023, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely
to materially affect, our internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_066"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 16. [RESERVED]</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_067"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
determined that each member of our audit committee is an audit committee financial expert, as defined under the rules under the Exchange
Act, and is independent in accordance with applicable Exchange Act rules and Nasdaq Stock Market rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_068"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16B. CODE OF ETHICS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a written
code of ethics that applies to our officers and employees, including our principal executive officer, principal financial officer, principal
controller and persons performing similar functions as well as our directors. Our Code of Business Conduct and Ethics is posted on our
website at www.icecure-medical.com. Information contained on, or that can be accessed through, our website does not constitute a part
of this annual report on Form 20-F and is not incorporated by reference herein. If we make any amendment to the Code of Business Conduct
and Ethics or grant any waivers, including any implicit waiver, from a provision of the code, we will disclose the nature of such amendment
or waiver on our website to the extent required by the rules and regulations of the SEC including the instructions to Item 16B of Form
20-F. We have not granted any waivers under our Code of Business Conduct and Ethics.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_069"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ziv Haft., Certified Public
Accountants, Isr., BDO member firm, an independent registered public accounting firm, has served as our principal independent registered
public accounting firm for each of the two years ended December 31, 2022 and 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table provides
information regarding fees paid by us to Ziv Haft and/or other BDO member firms for all services, including audit services, for the years
ended December 31, 2022 and 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Audit fees <sup>(1) </sup></span></td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">170</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">140.5</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Review of registration statements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17.1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">187.1</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">168.5</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes professional services rendered in connection with the audit of our annual financial statements and review of our interim financial statements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pre-Approval of Auditors&#8217; Compensation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee has a
pre-approval policy for the engagement of our independent registered public accounting firm to perform certain audit and non-audit services.
Pursuant to this policy, which is designed to assure that such engagements do not impair the independence of our auditors, the audit committee
pre-approves annually a catalog of specific audit and non-audit services in the categories of audit services, audit-related services and
tax services that may be performed by our independent registered public accounting firm. If a type of service, that is to be provided
by our auditors, has not received such general pre-approval, it will require specific pre-approval by our audit committee. The policy
prohibits retention of the independent registered public accounting firm to perform the prohibited non-audit functions defined in applicable
SEC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_070"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS
FOR AUDIT COMMITTEES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_071"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16E. PURCHASES OF EQUITY SECURITIES BY
THE ISSUER AND AFFILIATED PURCHASERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_072"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16F. CHANGE IN REGISTRANT&#8217;S CERTIFYING
ACCOUNTANT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_073"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16G. CORPORATE GOVERNANCE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Nasdaq Stock Market
rules, we may elect to follow certain corporate governance practices permitted under the Companies Law in lieu of compliance with corresponding
corporate governance requirements otherwise imposed by the Nasdaq Stock Market rules for U.S. domestic issuers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with Israeli
law and practice and subject to the exemption set forth in Rule 5615 of the Nasdaq Stock Market rules, we have elected to follow the provisions
of the Companies Law, rather than the Nasdaq Stock Market rules, with respect to the following requirements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><i>Quorum</i>. While the Nasdaq
Stock Market rules require that the quorum for purposes of any meeting of the holders of a listed company&#8217;s ordinary voting stock,
as specified in the company&#8217;s bylaws, be no less than 33 1/3% of the company&#8217;s outstanding ordinary voting stock, under Israeli
law, a company is entitled to determine in its articles of association the number of shareholders and percentage of holdings required
for a quorum at a shareholders meeting. Our amended and restated articles of association provide that a quorum of two or more shareholders
holding at least 25% of the voting rights in person or by proxy is required for commencement of business at a general meeting. However,
the quorum set forth in our amended and restated articles of association with respect to an adjourned meeting consists of at least one
shareholder present in person or by proxy.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><i>Compensation of officers.
</i>Israeli law and our amended and restated articles of association do not require that the independent members of our board of directors
(or a compensation committee composed solely of independent members of our board of directors) determine an executive officer&#8217;s
compensation, as is generally required under the Nasdaq Stock Market rules with respect to the chief executive officer and all other
executive officers. Instead, compensation of executive officers is determined and approved by our compensation committee and our board
of directors, and in certain circumstances by our shareholders, either in consistency with our office holder compensation policy or,
in special circumstances in deviation therefrom, taking into account certain considerations stated in the Companies Law. See &#8220;Item
6.C. Directors, Senior Management and Employees-Board Practices-Approval of Related Party Transactions under Israeli law&#8221; for additional
information.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><i>Shareholder approval.</i>
We will seek shareholder approval for all corporate actions requiring such approval under the requirements of the Companies Law, rather
than seeking approval for corporation actions in accordance with Nasdaq Listing Rule 5635. In particular, under this Nasdaq Stock Market
rule, shareholder approval is generally required for: (i) an acquisition of shares/assets of another company that involves the issuance
of 20% or more of the acquirer&#8217;s shares or voting rights or if a director, officer or 5% shareholder has greater than a 5% interest
in the target company or the consideration to be received; (ii) the issuance of shares leading to a change of control; (iii) adoption/amendment
of equity compensation arrangements (although under the provisions of the Companies Law there is no requirement for shareholder approval
for the adoption/amendment of the equity compensation plan); and (iv) issuances of 20% or more of the shares or voting rights (including
securities convertible into, or exercisable for, equity) of a listed company via a private placement (and/or via sales by directors/officers/5%
shareholders) if such equity is issued (or sold) at below the greater of the book or market value of shares. By contrast, under the Companies
Law, shareholder approval is required for, among other things: (i) transactions with directors concerning the terms of their service
or indemnification, exemption and insurance for their service (or for any other position that they may hold at a company), for which
approvals of the compensation committee, board of directors and shareholders are all required, (ii) extraordinary transactions with controlling
shareholders of publicly held companies, which require the special approval, and (iii) terms of employment or other engagement of the
controlling shareholder of us or such controlling shareholder&#8217;s relative, which require special approval. In addition, under the
Companies Law, a merger requires approval of the shareholders of each of the merging companies.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify">&#9679;</td>
    <td style="text-align: justify"><i>Approval of Related Party Transactions</i>. All related party transactions are approved in accordance with the requirements and procedures for approval of interested party acts and transaction as set forth in the Companies Law, which requires the approval of the audit committee, or the compensation committee, as the case may be, the board of directors and shareholders, as may be applicable, for specified transactions, rather than approval by the audit committee or other independent body of our board of directors as required under the Nasdaq Stock Market rules. See &#8220;Item 6.C. Directors, Senior Management and Employees-Board Practices-Approval of Related Party Transactions under Israeli law&#8221; for additional information.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify"><i>Annual Shareholders Meeting. </i>As opposed to the Nasdaq Stock Market Rule 5620(a), which mandates that a listed company hold its annual shareholders meeting within one year of the company&#8217;s fiscal year-end, we are required, under the Companies Law, to hold an annual shareholders&#8217; meeting each calendar year and within 15 months of the last annual shareholders meeting.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify"><i>Distribution of periodic reports to shareholders; proxy solicitation.</i> As opposed to the Nasdaq Stock Market rules, which require listed issuers to make such reports available to shareholders in one of a number of specific manners, Israeli law does not require us to distribute periodic reports directly to shareholders, and the generally accepted business practice in Israel is not to distribute such reports to shareholders but to make such reports available through a public website. In addition to making such reports available on a public website, we currently make our audited financial statements available to our shareholders at our offices and will only mail such reports to shareholders upon request. As a foreign private issuer, we are generally exempt from the SEC&#8217;s proxy solicitation rules.</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shareholder approval is generally
required for officer compensation in the event (i) approval by our Board of Directors and our compensation committee is not consistent
with our office holder compensation policy, or (ii) compensation required to be approved is that of our chief executive officer or an
executive officer who is also the controlling shareholder of our company (including an affiliate thereof). Such shareholder approval shall
require a majority vote of the shares present and voting at a shareholders meeting, provided either (i) such majority includes a majority
of the shares held by non-controlling shareholders who do not otherwise have a personal interest in the compensation arrangement that
are voted at the meeting, excluding for such purpose any abstentions disinterested majority, or (ii) the total shares held by non-controlling
and disinterested shareholders voted against the arrangement does not exceed 2% of the voting rights in our company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, approval of
the compensation of an executive officer who is also a director requires a simple majority vote of the shares present and voting at a
shareholders meeting, if consistent with our office holder compensation policy. Our compensation committee and board of directors may,
in special circumstances, approve the compensation of an executive officer (other than a director, a chief executive officer or a controlling
shareholder) or approve the compensation policy despite shareholders&#8217; objection, based on specified arguments and taking shareholders&#8217;
objection into account. Our compensation committee may further exempt an engagement with a nominee for the position of chief executive
officer, who meets the non-affiliation requirements set forth for an external director, from requiring shareholder approval, if such engagement
is consistent with our office holder compensation policy and our compensation committee determines based on specified arguments that presentation
of such engagement to shareholder approval is likely to prevent such engagement. To the extent that any such transaction with a controlling
shareholder is for a period exceeding three years, approval is required once every three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A director or executive officer
may not be present when the board of directors of a company discusses or votes upon a transaction in which he or she has a personal interest,
except in case of ordinary transactions, unless the chairman of the board of directors determines that he or she should be present to
present the transaction that is subject to approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Independent directors. </i>Israeli law does not require that a majority of the directors serving on our Board of Directors be &#8220;independent,&#8221; as defined under Nasdaq Listing Rule 5605(a)(2), and rather requires we have at least two external directors who meet the requirements of the Companies Law, as described above under &#8220;Item 6. C. Board Practices - External Directors.&#8221; Notwithstanding Israeli law, we believe that a majority of our directors are currently &#8220;independent&#8221; under the Nasdaq Stock Market rules. We are required, however, to ensure that all members of our audit committee are &#8220;independent&#8221; under the applicable Nasdaq and SEC criteria for independence (as we cannot exempt ourselves from compliance with that SEC independence requirement, despite our status as a foreign private issuer), and we must also ensure that a majority of the members of our audit committee are &#8220;unaffiliated directors&#8221; as defined in the Companies Law. Furthermore, Israeli law does not require, nor do our independent directors conduct, regularly scheduled meetings at which only they are present, which the Nasdaq Stock Market rules otherwise require.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Shareholder approval. </i>We will seek shareholder approval for all corporate actions requiring such approval under the requirements of the Companies Law, rather than seeking approval for corporation actions in accordance with Nasdaq Listing Rule 5635. In particular, under this Nasdaq Stock Market rule, shareholder approval is generally required for: (i) an acquisition of shares/assets of another company that involves the issuance of 20% or more of the acquirer&#8217;s shares or voting rights or if a director, officer or 5% shareholder has greater than a 5% interest in the target company or the consideration to be received; (ii) the issuance of shares leading to a change of control; (iii) adoption/amendment of equity compensation arrangements (although under the provisions of the Companies Law there is no requirement for shareholder approval for the adoption/amendment of the equity compensation plan); and (iv) issuances of 20% or more of the shares or voting rights (including securities convertible into, or exercisable for, equity) of a listed company via a private placement (and/or via sales by directors/officers/5% shareholders) if such equity is issued (or sold) below a specified minimum price. By contrast, under the Companies Law, shareholder approval is required for, among other things: (i) transactions with directors concerning the terms of their service or indemnification, exemption and insurance for their service (or for any other position that they may hold at a company), for which approvals of the compensation committee, board of directors and shareholders are all required, subject to applicable relief, (ii) extraordinary transactions with controlling shareholders of publicly held companies, which require the special approval, and (iii) terms of employment or other engagement of the controlling shareholder of us or such controlling shareholder&#8217;s relative, which require special approval. In addition, under the Companies Law, a merger requires approval of the shareholders of each of the merging companies.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Approval of Related Party Transactions</i>. All related party transactions are approved in accordance with the requirements and procedures for approval of interested party acts and transaction as set forth in the Companies Law, which requires the approval of the audit committee, or the compensation committee, as the case may be, the board of directors and shareholders, as may be applicable, for specified transactions, rather than approval by the audit committee or other independent body of our board of directors as required under the Nasdaq Stock Market rules.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt; text-align: justify">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt; text-align: justify">&#9679;</td>
    <td style="font-size: 10pt; text-align: justify"><i>Annual Shareholders Meeting.</i> As opposed to the Nasdaq Stock Market Rule 5620(a), which mandates that a listed company hold its annual shareholders meeting within one year of the company&#8217;s fiscal year-end, we are required, under the Companies Law, to hold an annual shareholders&#8217; meeting each calendar year and within 15 months of the last annual shareholders meeting.</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_074"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16H. MINE SAFETY DISCLOSURE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_075"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS
THAT PREVENT INSPECTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_076"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16J. INSIDER TRADING POLICIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><ix:nonNumeric contextRef="c31" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="ixv-21218"><ix:nonNumeric contextRef="c31" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="ixv-21219"><ix:nonNumeric contextRef="c31" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="ixv-21220"><ix:nonNumeric contextRef="c31" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="ixv-21221">Not applicable</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_077"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16K. CYBERSECURITY.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company has developed and maintained a cybersecurity
risk management strategy, consisting of cybersecurity policies, procedures, compliance and awareness programs to mitigate risk and to
ensure compliance with security, availability and confidentiality trust principles. The cybersecurity process has been integrated into
the Company&#8217;s overall risk management system and process and is solely internally managed. Management is responsible for identifying
risks that threaten achievement of the control activities stated in the management&#8217;s description of the services organizations systems.
The risk assessment occurs annually, or as business needs change, and covers identification of risks that could act against the company&#8217;s
objectives as well as specific risks related to a compromise to the security of data.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The level of each identified risk is determined
by considering the impact of the risk itself and the likelihood of the risk materializing and high scoring risks are actioned upon. Risks
are analyzed to determine whether the risk meets company risk acceptance criteria to be accepted or whether a mitigation plan will be
applied. Mitigation plans include both the individual or department responsible for the plan and may include budget considerations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this report,
we are not aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely to materially
affect us, including our business strategy, results of operations or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Governance</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Chief Executive Officer
and Chief Financial Officer oversee our cybersecurity risk management and mitigation efforts. The board of directors receive prompt and
timely information regarding any cybersecurity incidents. Our Audit Committee periodically discusses cybersecurity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risk Management and Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">As
part of the critical elements of our overall risk management approach, our cybersecurity program is focused on the following key areas:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="padding-left: -0.125in; width: 0.25in">&#9679;</td><td style="text-align: justify">Collaborative Approach: The Company has implemented a comprehensive, cross-functional approach to identifying,
preventing and mitigating cybersecurity threats and incidents, while also implementing controls and procedures that provide for the prompt
escalation of certain cybersecurity incidents so that decisions regarding the public disclosure and reporting of such incidents can be
made by management in a timely manner.</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Technical Safeguards: The Company deploys technical safeguards that are designed to protect the Company&#8217;s
information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality
and access controls, which are evaluated and improved through vulnerability assessments and cybersecurity threat intelligence.</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                        </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Incident Response and Recovery Planning: The Company has established and maintains comprehensive incident
response and recovery plans that fully address the Company&#8217;s response to a cybersecurity incident, and such plans are tested and
evaluated on a regular basis.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><div><a id="a_078"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART III</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_079"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 17. <span style="text-transform: uppercase">FINANCIAL
STATEMENTS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have elected to provide
financial statements and related information pursuant to Item 18.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_080"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 18. <span style="text-transform: uppercase">FINANCIAL
STATEMENTS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial statements and
the related notes required by this Item are included in this annual report on Form 20-F beginning on page F-1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_081"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 19. <span style="text-transform: uppercase">EXHIBITS
</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; width: 9%"><span style="font-size: 10pt"><b>Number</b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: justify; width: 90%"><span style="font-size: 10pt"><b>Exhibit Description</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">1.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021066318/ea152692ex99-1_inspiratech.htm">Amended and Restated Articles of Association of Inspira Technologies Oxy B.H.N. Ltd. (filed as Exhibit 99.1 to Form 6-K (File No. 001-40303) filed on December 20, 2021 and incorporated herein by reference).</a></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">2.1*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="ea020216701ex2-1_inspira.htm"><span style="font-size: 10pt">Description of Securities </span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">4.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021015150/ea137365ex10-1_inspiratech.htm">Form
    of Indemnification Agreement (filed as Exhibit 10.1 to Form F-1 (File No. 333-253920) filed on March 12, 2021 and incorporated
    herein by reference).</a></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">4.2</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021054754/ea149458ex10-2_inspiratech.htm">Inspira Technologies Oxy B.H.N. Ltd. (formerly known as: InSense Medical Ltd.) 2019 Equity Incentive Plan (amended on September 14, 2021), filed as Exhibit 10.2 to Post-Effective Amendment No. 1 to Form F-1 (File No. 333-253920) filed on October 27, 2021, and incorporated herein by reference.</a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">4.3</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021066318/ea152692ex99-2_inspiratech.htm">Inspira Technologies Oxy B.H.N. Ltd. Compensation Policy for Company&#8217;s Executives, filed as Exhibit 99.2 to Form 6-K (File No. 001-4030) filed on December 20, 2021, and incorporated herein by reference.</a></span></td></tr>
  <tr>
    <td style="vertical-align: top">4.4</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021031503/ea140235ex4-2_inspiratech.htm">Form of Warrant Agent Agreement (filed as Exhibit 4.2 to Form F-1 (File No. 333-253920) filed on July 1, 2021 and incorporated herein by reference)</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">4.5</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021031503/ea140235ex4-4_inspiratech.htm">Form of Warrant (filed as Exhibit 4.4 to form F-1 (File No. 333-253920) filed on July 1, 2021 and incorporated herein by reference).</a></span></td></tr>
  <tr>
    <td style="vertical-align: top">4.6*</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="ea020216701ex4-6_inspira.htm">Form of Amendment of Warrant Agreement by and between the Company and American Stock Transfer &amp; Trust Company, LLC, dated August 8, 2022.</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">4.7</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021015150/ea137365ex10-7_inspiratech.htm">Form of Simple Agreement for Future Equity (filed as Exhibit 10.7 to form F-1 (File No. 333-253920) filed on July 1, 2021, and incorporated herein by reference)</a></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">4.8</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021034372/ea143325ex10-8_inspiratec.htm">Shareholder Loan Agreement, dated March 1, 2018, by and between the Company and Dagi Ben-Noon (filed as Exhibit 10.8 to form F-1 (File No. 333-253920) filed on July 1, 2021, and incorporated herein by reference).</a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">4.9</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021015150/ea137365ex10-8_inspiratech.htm">Form of Convertible Loan Agreement (filed as Exhibit 10.9 to form F-1 (File No. 333-253920) filed on July 1, 2021, and incorporated herein by reference)</a></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">4.10</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390023098916/ea190727ex10-1_inspira.htm">Form of Securities Purchase Agreement (filed as exhibit 10.1 to the Report of Foreign Issuer on Form 6-K filed on December 27, 2023, and incorporated herein by reference)</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">12.1*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="ea020216701ex12-1_inspira.htm">Certification of the Chief Executive Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934.</a></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">12.2*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="ea020216701ex12-2_inspira.htm">Certification of the Chief Financial Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934.</a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">13.1%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="ea020216701ex13-1_inspira.htm">Certification of the Chief Executive Officer pursuant to 18 U.S.C. 1350.</a></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">13.2%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="ea020216701ex13-2_inspira.htm">Certification of the Chief Financial Officer pursuant to 18 U.S.C. 1350.</a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">15.1*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="ea020216701ex15-1_inspira.htm"><span style="font-size: 10pt">Consent of Ziv Haft, a member firm of BDO, independent registered public accounting firm.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">97.1</span>*</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="ea020216701ex97-1_inspira.htm"><span style="font-size: 10pt">Inspira Technologies Oxy B.H.N. Ltd. Clawback Policy, dated November 28, 2023.</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">101*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">The following financial information from the Registrant&#8217;s Annual
Report on Form 20-F for the year ended December 31, 2023, formatted in XBRL (eXtensible Business Reporting Language): (i) Balance sheets
as of December 31, 2023, December 31, 2022 and December 31, 2021; (ii) Statements of Comprehensive Loss as of December 31, 2023, December
31, 2022 and December 31, 2021; (iii) Statement of Changes in Shareholders&#8217; Equity as of December 31, 2023, December 31, 2022 and
December 31, 2021; (iv) Statements of Cash Flows as of December 31, 2023, December 31, 2022 and December 31, 2021; and (v) Notes to the
financial statements.</p></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">104*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Filed herewith.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">%</span></td>
    <td><span style="font-size: 10pt">Furnished herewith</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><div><a id="a_082"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The registrant hereby certifies
that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this
annual report on Form 20-F filed on its behalf.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="2" style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt; width: 60%">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt; width: 4%">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt; width: 36%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Date: March 25, 2024</span></td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">By:</span></td>
    <td style="padding: 0pt; white-space: nowrap; border-bottom: black 1.5pt solid; text-indent: 0pt">/s/ Dagi Ben-Noon</td></tr>
  <tr>
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; vertical-align: top; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; white-space: nowrap; vertical-align: bottom; text-indent: 0pt"><span style="font-size: 10pt">Dagi Ben-Noon</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-indent: 0pt"><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">TABLE OF CONTENTS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Page</b></span></td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><a href="#a_083"><span style="font-size: 10pt">Report of Independent Registered Public Accounting Firm (BDO <ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-21222">Ziv Haft</ix:nonNumeric>; Tel-Aviv, Israel; PCAOB#<ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-21223">1185</ix:nonNumeric>)</span></a></td> <td>&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">F-2</span></td></tr> <tr style="vertical-align: bottom; "> <td style="width: 90%"><a href="#a_084"><span style="font-size: 10pt">Statements of balance sheet</span></a></td> <td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: center"><span style="font-size: 10pt">F-3</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><a href="#a_085"><span style="font-size: 10pt">Statements of comprehensive loss</span></a></td> <td>&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">F-4</span></td></tr> <tr style="vertical-align: bottom; "> <td><a href="#a_086"><span style="font-size: 10pt">Statements of changes in shareholders&#8217; equity</span></a></td> <td>&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">F-5</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><a href="#a_087"><span style="font-size: 10pt">Statements of cash flows</span></a></td> <td>&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">F-8</span></td></tr> <tr style="vertical-align: bottom; "> <td><a href="#a_089"><span style="font-size: 10pt">Notes to the financial statements</span></a></td> <td>&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">F-10-F-35</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The amounts are stated in thousands of U.S. dollars</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 134; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p><div>

</div><div><a id="a_083"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">To The Board of Directors and Shareholders of Inspira
Technologies Oxy B.H.N. Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Ha-Tidhar Street 2, Ra&#8217;anana, Israel</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Opinion on the Financial Statements&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying balance sheets
of Inspira Technologies Oxy B.H.N. Ltd. (formerly: Insense Medical Ltd.) (the &#8220;Company&#8221;) as of December 31, 2023 and 2022,
the related statements of comprehensive loss, changes in shareholders&#8217; equity, and cash flows for each of the three years in the
period ended December 31, 2023, and the related notes (collectively, the &#8220;Financial Statements&#8221;). In our opinion, the Financial
Statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results
of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2023, in conformity with accounting
principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Going Concern</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying Financial Statements have been
prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the Financial Statements, the Company is
at its development stage, therefore, it has suffered recurring losses and negative cash flows from operations since inception. As of December
31, 2023, the Company had incurred accumulated losses of $55.5 million. The Company&#8217;s operations have been funded substantially
through issuance of shares and warrants. Considering the above, the Company&#8217;s dependency on external funding for its operations
raises a substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s evaluation of the events
and conditions and management&#8217;s plans regarding these matters are described in Note 1. The Financial Statements do not include any
adjustments that might result from the outcome of these uncertainties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Basis for Opinion</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These Financial Statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on these Financial Statements based on our audits. We are
a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be
independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of
the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the Financial
Statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s
internal control over financial reporting. Accordingly, we express no such opinion.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the Financial Statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the Financial Statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the Financial Statements. We believe that our audits provide a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 67%"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-13286"><span style="font-size: 10pt">Tel-Aviv, Israel</span></ix:nonNumeric></td> <td style="width: 33%; text-align: center"><span style="font-size: 10pt">/s/ Ziv Haft</span></td></tr> <tr> <td style="vertical-align: bottom"><span style="font-size: 10pt">March 19, 2024</span></td> <td style="padding-left: 2.85pt; text-align: center"><span style="font-size: 10pt">Certified Public Accountants (Isr.)</span></td></tr> <tr> <td style="vertical-align: bottom"><span style="font-size: 10pt">We have served as the Company&#8217;s auditor since 2018.</span></td> <td style="vertical-align: top; padding-left: 2.85pt; text-align: center"><span style="font-size: 10pt">BDO Member Firm /s/</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_084"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(US dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Current Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 65%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-21224">5,041</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-21225">6,783</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsCurrent" scale="3" unitRef="usd" id="ixv-21226">2,320</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsCurrent" scale="3" unitRef="usd" id="ixv-21227">7,120</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">4</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-21228">432</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-21229">589</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-21230">7,793</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-21231">14,492</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Non-Current Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Right of use assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">7(B)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-21232">1,011</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-21233">1,263</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Property, plant and equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">5</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-21234">506</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-21235">411</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd" id="ixv-21236">1,517</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd" id="ixv-21237">1,674</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Total Assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-21238">9,310</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-21239">16,166</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Trade accounts payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" unitRef="usd" id="ixv-21240">198</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" unitRef="usd" id="ixv-21241">152</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Other accounts payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-21242">1,026</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-21243">1,216</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">7(B)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-21244">290</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-21245">268</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Financial liabilities at fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">8</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-21246">1,470</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-21247">26</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-21248">2,984</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-21249">1,662</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Non-Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">7(B)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-21250">588</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-21251">873</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total non- current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" unitRef="usd" id="ixv-21252">588</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" unitRef="usd" id="ixv-21253">873</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">COMMITMENTS AND CONTINGENCIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">7</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#160;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Shareholders&#8217; Equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Share capital and additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">9</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-21254">61,259</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-21255">57,866</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Accumulated losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-21256">55,521</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-21257">44,235</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Shareholders&#8217; Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-21258">5,738</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-21259">13,631</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Total liabilities and Shareholders&#8217; Equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-21260">9,310</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-21261">16,166</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: center; width: 30%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">/s/ Yafit Tehila</td>
    <td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; width: 30%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">/s/ Dagi Ben-Noon</td>
    <td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 36%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">March 19, 2024</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yafit Tehila</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Chief Financial Officer</p></td>
    <td>&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dagi Ben-Noon</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Chief Executive Officer</p></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Date of approval of Financial Statements</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>The accompanying notes are an integral part of the Financial Statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_085"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>STATEMENTS OF COMPREHENSIVE LOSS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(US dollars in thousands except for loss per
share)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-21262">7,320</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-21263">8,183</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-21264">4,070</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-21265">746</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-21266">1,328</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-21267">1,980</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-21268">4,063</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-21269">5,375</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-21270">6,937</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Other expenses (income)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" sign="-" unitRef="usd" id="ixv-21271">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" sign="-" unitRef="usd" id="ixv-21272">7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" unitRef="usd" id="ixv-21273">23</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.25in">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-21274">12,133</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-21275">14,893</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-21276">12,964</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Interest income from deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="3" unitRef="usd" id="ixv-21277">318</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="3" unitRef="usd" id="ixv-21278">192</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="3" unitRef="usd" id="ixv-21279">1</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Finance expenses (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">13</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-21280">529</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-21281">275</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-21282">4,230</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.25in">Loss before tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-21283">11,286</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-21284">14,976</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-21285">17,193</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Taxes on income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.25in">Total comprehensive and net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-21286">11,286</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-21287">14,976</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-21288">17,193</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><div style="-sec-ix-hidden: hidden-fact-7; -sec-ix-hidden: hidden-fact-6; -sec-ix-hidden: hidden-fact-5">Net loss per ordinary share, basic and diluted</div></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-21289">0.93</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-21290">1.39</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-21291">3.24</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"><div style="-sec-ix-hidden: hidden-fact-10; -sec-ix-hidden: hidden-fact-9; -sec-ix-hidden: hidden-fact-8">Weighted average number of ordinary shares outstanding basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-21292">12,095,477</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-21293">10,794,594</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-21294">5,306,225</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>The accompanying notes are an integral part of the Financial Statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p><div>

</div><div><a id="a_086"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217;
EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(US dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">For the year ended December 31, 2023:</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Ordinary Share Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/>
 shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Share capital and<br/> Additional Paid in Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated<br/>
 deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 52%; font-weight: bold">Balance as of January&#160;1, 2023:</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-21295">11,338,940</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-21296">57,866</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-21297">44,235</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-21298">13,631</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Changes during the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of ordinary shares and private warrants, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" unitRef="shares" id="ixv-21299">3,031,250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" unitRef="usd" id="ixv-21300">1,806</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" unitRef="usd" id="ixv-21301">1,806</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of placement agent warrants (Note 9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" unitRef="usd" id="ixv-21302">131</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" unitRef="usd" id="ixv-21303">131</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of ordinary shares (pursuant to At-The-Market (&#8220;ATM&#8221;) facility)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares" id="ixv-21304">17,566</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd" id="ixv-21305">26</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd" id="ixv-21306">26</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Exercise of share-based payments </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-21307">37,972</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-21308">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-21309">3</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Restricted share unit (&#8220;RSU&#8221;) vesting</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitRef="shares" id="ixv-21310">1,226,448</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-21311">1,427</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-21312">1,427</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify; padding-bottom: 1.5pt">Comprehensive and net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="3" unitRef="usd" id="ixv-21313">11,286</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="3" unitRef="usd" id="ixv-21314">11,286</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: justify; padding-bottom: 4pt">Balance as of December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-21315">15,652,176</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-21316">61,259</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-21317">55,521</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-21318">5,738</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US">Less than thousand dollars</ix:footnote></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217;
EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(US dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">For the year ended December 31, 2022:</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary Share Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share capital and<br/> Additional Paid in Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold">Balance as of January&#160;1, 2022:</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c17" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-21320">10,091,706</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-21321">52,987</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-21322">29,259</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-21323">23,728</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Changes during the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercise of share based payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-21324">7,030</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-19; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">RSU vesting</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="0" unitRef="shares" id="ixv-21325">1,240,204</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-21326">4,879</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-21327">4,879</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Comprehensive and net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="3" unitRef="usd" id="ixv-21328">14,976</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="3" unitRef="usd" id="ixv-21329">14,976</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Balance as of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-21330">11,338,940</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-21331">57,866</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-21332">44,235</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-21333">13,631</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Less than thousand dollars</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>The accompanying notes are an integral part
of the Financial Statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217;
EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(US dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">For the year ended December 31, 2021:</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary Share Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center"><b>Additional</b></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/>
 shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share<br/>
 capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Paid in<br/>
 Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/>
 deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; font-weight: bold">Balance as of January&#160;1, 2021:</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c24" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-21334">2,661,095</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-21335">304</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-21336">10,430</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-21337">12,066</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-21338">1,332</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Changes during the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Par value cancellation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="iinn:StockIssuedDuringPeriodValueParValueCancellation" scale="3" sign="-" unitRef="usd" id="ixv-21339">304</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="iinn:StockIssuedDuringPeriodValueParValueCancellation" scale="3" unitRef="usd" id="ixv-21340">304</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Initial Public Offering (&#8220;IPO&#8221;)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-21341">2,931,472</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-21342">13,969</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-21343">13,969</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Conversion of financial liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares" id="ixv-21344">2,113,905</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" unitRef="usd" id="ixv-21345">12,203</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" unitRef="usd" id="ixv-21346">12,203</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Tradable warrants exercise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="INF" format="ixt:num-dot-decimal" name="iinn:StockIssuedDuringPeriodSharesTradableWarrantsExercise" scale="0" unitRef="shares" id="ixv-21347">1,705,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd" id="ixv-21348">9,378</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd" id="ixv-21349">9,378</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">RSU vesting</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="0" unitRef="shares" id="ixv-21350">655,603</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Exercise of share based payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-21351">24,631</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-39; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-21352">6,703</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-21353">6,703</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify; padding-bottom: 1.5pt">Comprehensive and net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="3" unitRef="usd" id="ixv-21354">17,193</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="3" unitRef="usd" id="ixv-21355">17,193</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: justify; padding-bottom: 4pt">Balance as of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c17" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-21356">10,091,706</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-21357">52,987</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-21358">29,259</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-21359">23,728</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Less than thousand dollars</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>The accompanying notes are an integral part
of the Financial Statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_087"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>STATEMENTS OF CASH FLOW</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(US dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">CASH FLOW FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 9pt">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-21360">11,286</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-21361">14,976</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-21362">17,193</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Adjustments to reconcile net loss to net cash provided by operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-21363">111</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-21364">54</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-21365">25</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Share based compensation expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-21366">1,427</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-21367">4,879</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-21368">6,703</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Share based compensation &#8211; placement agent warrants (Note 9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" unitRef="usd" id="ixv-21369">59</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Revaluation of simple agreements for future equity (SAFE) and convertible loan at fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="iinn:RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue" scale="3" sign="-" unitRef="usd" id="ixv-21370">3,515</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Evaluation of financial liability at fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:EvaluationOfFinancialLiabilityAtFairValue" scale="3" unitRef="usd" id="ixv-21371">306</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:EvaluationOfFinancialLiabilityAtFairValue" scale="3" unitRef="usd" id="ixv-21372">108</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="iinn:EvaluationOfFinancialLiabilityAtFairValue" scale="3" sign="-" unitRef="usd" id="ixv-21373">480</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Issuance cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" unitRef="usd" id="ixv-21374">205</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Prepayments of lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:PrepaymentsOfLeaseLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-21375">7</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:PrepaymentsOfLeaseLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-21376">51</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="iinn:PrepaymentsOfLeaseLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-21377">12</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Decrease (increase) in right of use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInLeasingReceivables" scale="3" unitRef="usd" id="ixv-21378">5</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInLeasingReceivables" scale="3" unitRef="usd" id="ixv-21379">99</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInLeasingReceivables" scale="3" sign="-" unitRef="usd" id="ixv-21380">24</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Decrease (increase) in other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" sign="-" unitRef="usd" id="ixv-21381">190</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" sign="-" unitRef="usd" id="ixv-21382">99</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" unitRef="usd" id="ixv-21383">490</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">(Decrease) increase in trade accounts payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" unitRef="usd" id="ixv-21384">46</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" unitRef="usd" id="ixv-21385">59</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" unitRef="usd" id="ixv-21386">91</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">(Decrease) increase in other accounts payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" sign="-" unitRef="usd" id="ixv-21387">190</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" unitRef="usd" id="ixv-21388">496</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" unitRef="usd" id="ixv-21389">172</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-21390">9,756</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-21391">9,647</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-21392">6,685</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOW FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Purchase of property, plant, and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-21393">206</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-21394">263</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-21395">182</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Investment in short term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="3" unitRef="usd" id="ixv-21396">7,120</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Proceeds from sale of short-term deposits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="3" unitRef="usd" id="ixv-21397">4,800</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Net cash provided by (used in) investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" unitRef="usd" id="ixv-21398">4,594</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-21399">7,383</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-21400">182</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Receipt of simple agreements for future equity (SAFE) and convertible loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans" scale="3" unitRef="usd" id="ixv-21401">7,195</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Issuance of ordinary shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-21402">2,128</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-21403">14,279</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Issuance of private warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" unitRef="usd" id="ixv-21404">1,750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Issuance cost in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" unitRef="usd" id="ixv-21405">454</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Exercise of option</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd" id="ixv-21406">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Issuance of ordinary shares (issuances pursuant to ATM)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:IssuanceOfOrdinarySharesissuancesPursuantToATM" scale="3" unitRef="usd" id="ixv-21407">26</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="iinn:IssuanceOfOrdinarySharesissuancesPursuantToATM" scale="3" unitRef="usd" id="ixv-21408">8,721</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-21409">3,453</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-21410">30,195</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net increase (decrease) in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-21411">1,709</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-21412">17,030</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" unitRef="usd" id="ixv-21413">23,328</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash, cash equivalents and restricted cash at the beginning
    of the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-21414">6,839</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-21415">23,869</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-21416">541</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Cash, cash equivalents and restricted cash at the end of the period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-21417">5,130</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-21418">6,839</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-21419">23,869</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>The accompanying notes are an integral part of the Financial Statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_088"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>STATEMENTS OF CASH FLOW</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(US dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">APPENDIX A &#8211; NON-CASH TRANSACTIONS:</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Conversion of convertible loans to equity</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockAmountIssued1" scale="3" unitRef="usd" id="ixv-21420">12,203</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Tradable warrants financial liability at IPO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TradableWarrantsFinancialLiabilityAtIPO" scale="3" sign="-" unitRef="usd" id="ixv-21421">310</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Share based compensation &#8211; underwriters fees at IPO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationUnderwritersFeesAtIPO" scale="3" sign="-" unitRef="usd" id="ixv-21422">264</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Share based compensation-placement agent warrants against additional paid in capital (Note 9)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" scale="3" sign="-" unitRef="usd" id="ixv-21423">73</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">APPENDIX B &#8211; AMOUNT PAID DURING THE
PERIOD:</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Year ended December 31,</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>2023</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 64%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">Interest paid</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd" id="ixv-21424">93</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd" id="ixv-21425">106</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd" id="ixv-21426">29</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>The accompanying notes are an integral part of the Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_089"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt">In thousands $ (except share
and per share data)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CompensationRelatedCostsGeneralTextBlock-c0_cont_1" escape="true" name="us-gaap:CompensationRelatedCostsGeneralTextBlock" id="ixv-15772"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 - GENERAL:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">Inspira Technologies Oxy B.H.N. Ltd (formerly: Insense Medical
Ltd.) (the &#8220;Company&#8221;) was incorporated in Israel and commenced its operations on February 27, 2018. The Company operates
in the medical technology industry in the field of respiratory support technology engaged in the research, development, manufacturing
related activities, and go-to-market activities of proprietary products and technologies. The Company is developing the following products:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">The INSPIRA ART (Augmented Respiratory Technology), which
is a respiratory support technology targeted toward utilizing direct blood oxygenation to boost patient saturation levels within minutes
while the patient is awake and spontaneously breathing. The aim is to reduce the need for invasive mechanical ventilation, with the potential
to reduce risks, complications and high costs.</td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
     </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The HYLA blood sensor, which is a non-invasive optical blood sensor designed to perform real-time and
continuous blood measurements, potentially minimizing the need to take actual blood samples from patients.</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                    </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The INSPIRA ART100 Device, an advanced form of life support system better known by the medical industry
as a cardiopulmonary bypass system is being designed for use in surgical procedures requiring cardiopulmonary bypass for six hours or
less.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">2.</td><td style="text-align: justify">The Company&#8217;s products are in the development stage. The INSPIRA ART100 device and the INSPIRA ART
has not yet been tested or used in humans. The Company&#8217;s products have not been approved by the U.S. Food and Drug Administration (the
&#8220;FDA&#8221;). The INSPIRA ART100 device was submitted to the FDA for 510k clearance in September 2023, and the Company expect FDA
approval by the end of the first half of 2024.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">3.</td><td style="text-align: justify">On December 26, 2023, the Company entered into a purchase agreement (the &#8220;Purchase Agreement&#8221;) with an institutional investor in a registered direct offering (the &#8220;Registered Direct Offering&#8221;), pursuant to which the Company issued (i) an aggregate of <ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-21427">1,375,000</ix:nonFraction> of the Company&#8217;s ordinary shares (the &#8220;Ordinary Shares&#8221;) at a purchase price of $<ix:nonFraction contextRef="c32" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-21428">1.28</ix:nonFraction> per share, and (ii) pre-funded warrants, (&#8220;Pre-Funded Warrants&#8221;), to purchase up to <ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-21429">1,656,250</ix:nonFraction> Ordinary shares, at a purchase price of $<ix:nonFraction contextRef="c33" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-21430">1.28</ix:nonFraction>, less $<ix:nonFraction contextRef="c34" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-21431">0.001</ix:nonFraction> per Pre-Funded Warrant which were immediately exercised). In addition, pursuant to the Purchase Agreement, the Company issued warrants to the institutional investor to purchase up to an aggregate of <ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-21432">3,031,250</ix:nonFraction> Ordinary Shares at an exercise price of $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-21433">1.28</ix:nonFraction> per share (&#8220;Private Warrants&#8221;). The aggregate proceeds received by the Company from the registered direct offering were approximately: $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="3" unitRef="usd" id="ixv-21434">3,424</ix:nonFraction>, after deducting placement agent commissions and additional offering costs which totaled in approximately $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AdditionalOfferingCosts" scale="3" unitRef="usd" id="ixv-21435">454</ix:nonFraction>. In addition, pursuant to the Purchase Agreement, the Company issued Placement Agent Warrants to purchase up to a total of <ix:nonFraction contextRef="c36" decimals="3" format="ixt:num-dot-decimal" name="iinn:AggregatePercentage" scale="-2" unitRef="pure" id="ixv-21436">7.0</ix:nonFraction>% of the aggregate number of Ordinary Shares sold in the transaction, or warrants to purchase up to <ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-21437">212,188</ix:nonFraction> Ordinary Shares. The fair value of the Placement Agent Warrants on the issuance date was $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDerivativeIssuanceCosts" scale="3" unitRef="usd" id="ixv-21438">131</ix:nonFraction> and it was recorded as part of the issuance costs (see Note 9).</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">4.</td><td style="text-align: justify">The accompanying financial statements (the &#8220;Financial Statements&#8221;) have been prepared assuming
that the Company will continue as a going concern. To date, the Company is at its development stage. Therefore, the Company has suffered
recurring losses from operations and negative cash flows from operations since inception. As of December 31, 2023, the Company had incurred
accumulated losses of $<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" scale="6" unitRef="usd" id="ixv-21439">55.5</ix:nonFraction> million and expects to continue to fund its operations through fundings such as issuance of convertible securities,
Ordinary Shares and warrants and through Israeli governmental grants. There is no assurance that such financing will be obtained. Considering
the above, our dependency on external funding for our operations raises a substantial doubt about our ability to continue as a going concern.
The Financial Statements do not include any adjustments that might result from the outcome of these uncertainties.</td></tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">In thousands $ (except share
and per share data)</p><div>


</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 -
GENERAL: (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">&#160;</p><div>

</div><ix:continuation id="_CompensationRelatedCostsGeneralTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">5.</td><td style="text-align: justify">Our offices are located in Israel. On October 7, 2023, Hamas terrorists infiltrated Israel&#8217;s southern
border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Following the attack, Israel declared war
against Hamas and the Israeli military began to call-up reservists for an active duty. At the same time, and because of the declaration
of war against Hamas, the clash between Israel and Hezbollah in Lebanon has escalated and there is a possibility that it will turn into
a greater regional conflict in the future. As of the date of these Financial Statements, these events have had no material impact on the
Company&#8217;s operations.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">6.</td><td style="text-align: justify">Although we do not currently conduct business in Russia and Ukraine, the escalation of geopolitical instability
in Russia and Ukraine as well as currency fluctuations in the Russian Ruble has had a negative impact on worldwide markets. Such impact
may negatively impact our supply chain, our operations and future growth prospects in that region.&#160;As a result of the crisis in Ukraine,&#160;both
the U.S. and other countries have implemented sanctions against certain Russian individuals and entities. Our global operations expose
us to risks that could adversely affect our business, financial condition, results of operations, cash flows or the market price of our securities,
including the potential for increased tensions between Russia and other countries resulting from the current situation involving Russia
and Ukraine, tariffs, economic sanctions and import-export restrictions imposed, and retaliatory actions, as well as the potential negative
impact on our potential business and sales in the region. Current geopolitical instability in Russia and Ukraine and related sanctions
by the U.S. and other governments against certain companies and individuals may hinder our ability to conduct business with potential
customers and vendors in these countries.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">7.</td><td style="text-align: justify">These Financial Statements were authorized by the Board of Directors on March 19, 2024.</td></tr></table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-15875"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 </b>- <b>SIGNIFICANT ACCOUNTING POLICIES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying Financial Statements have been
prepared in conformity with the U.S. GAAP. The significant accounting policies followed in the preparation of the Financial Statements
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_1" escape="true" name="iinn:ConversionFromIFRSToUSGAAPPolicyTextBlock" id="ixv-15882"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>A.
Conversion from IFRS to U.S. GAAP-</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_2" id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has retroactively converted its historical
Financial Statements that were prepared in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;) to present
such Financial Statements in accordance with U.S. GAAP. This is the first Financial Statement presented according to U.S. GAAP.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_3" id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is an Israeli company, and its business
operates in the medical technology industry in the field of respiratory support technology and intends to focus its commercial efforts
mainly in the USA. The Company&#8217;s both long and short-term intentions are to conduct clinical trials in the U.S. with the goal to
receive FDA approval as a first and major milestone.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_4" id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The significant differences between IFRS and U.S.
GAAP as they relate to these Financial Statements are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 144; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">In thousands $ (except share
and per share data)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>NOTE 2 </b>- <b>SIGNIFICANT ACCOUNTING
POLICIES: (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:continuation continuedAt="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_5" id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(a) Leases</b></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_6" id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under IFRS, prior to the adoption of U.S. GAAP,
the Company, as lessee, applied the single lease model that is similar to the accounting for a finance lease under U.S. GAAP. The expense
recognition presented a higher portion of the total expense earlier in the lease term as a combination of straight-line depreciation of
the right-of-use asset and the effective interest rate method applied to the lease liability results in a decreasing rate of interest
expense recognition throughout the lease term. In addition, the presentation of the lease expenses in the statements of comprehensive
loss is different. Under U.S. GAAP it is presented as lease expenses, while under IFRS it is presented as depreciation and interest expense.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_7" id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under U.S. GAAP, there is dual classification
lease accounting model for lessees: finance leases and operating leases. The Company, as lessee, classified all its leases as operating
leases and recognizes a single lease expense, including both a right-of-use asset depreciation component and an interest expense component,
on a straight-line basis throughout the lease term.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_8" id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(b) Financial Liabilities</b></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_9" id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issued tradable warrants to investors
in its initial public offering (the &#8220;IPO&#8221;) and warrants to its pre-IPO investors. Under IFRS, warrants issued by the Company
were classified as financial liabilities and measured at fair value with changes recognized in profit or loss. However, under U.S. GAAP,
those warrants are classified as equity instruments due to the change in its functional currency.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_10" id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon transitioning to U.S. GAAP, the Company has
re-evaluated the classification of its warrants and determined that they meet the criteria for classification as equity instruments. Therefore,
the warrants have been reclassified from financial liabilities to equity in the Financial Statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_11" id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This reclassification has been applied retroactively
to all periods presented in accordance with the requirements of U.S. GAAP. Consequently, the Financial Statements for prior periods have
been adjusted to reflect the reclassification of warrants from financial liabilities to equity.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_12" id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the change in determining the warrants
classification, the Company had changed its IPO expenses allocation between equity and issuance expenses.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_13" id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(<b>c) Change in Functional Currency Reporting</b></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_14" id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under IFRS, the functional currency is determined
based on the currency of the primary economic environment in which the entity operates. However, under U.S. GAAP, the functional currency
is determined based on the currency of the primary economic environment in which the entity generates and expends cash.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_15" id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of this change, the Company has reassessed
its functional currency and determined that it now aligns with the currency of the primary economic environment in which cash receipts
and payments occur, in accordance with U.S. GAAP requirements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_16" id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This change in functional currency reporting has
been applied retroactively.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_17" id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management believes that this change in functional
currency reporting better reflects the economic substance of the Company&#8217;s operation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 145; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">In thousands $ (except share
and per share data)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>NOTE 2 </b>- <b>SIGNIFICANT ACCOUNTING
POLICIES: (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation continuedAt="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_18" id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(d) Government Grants </b></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_19" id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under International Accounting Standards (&#8220;IAS
20&#8221;) (under IFRS), the Company capitalized government grants according to revenue forecast and recognized financial expenses over
time.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_20" id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, under U.S. GAAP, the Company will recognize
royalties only when it starts to generate revenues. This differs from IFRS, where the Company recognized capitalized liability, financial
expenses and lower grant in the research and development expenses.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_21" id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>The conversion from IFRS to U.S.
GAAP based USD as our operational currency and following other U.S. GAAP differences, resulted in change of our financial results. </b></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p>

<ix:continuation continuedAt="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_22" id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfCondensedBalanceSheetTableTextBlock-c0_cont_1" escape="true" name="srt:ScheduleOfCondensedBalanceSheetTableTextBlock" id="ixv-16017"><b>U.S. GAAP differences as of December
31, 2022:</b></ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p>

<ix:continuation id="_ScheduleOfCondensedBalanceSheetTableTextBlock-c0_cont_1"><ix:continuation continuedAt="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_23" id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_22"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Note</b></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">IFRS<br/>
 (previously reported)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">U.S. GAAP</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Other current assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">2A(c)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-21440">591</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-21441">589</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Right of use assets, net</td><td>&#160;</td>
    <td style="text-align: center">2A(a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-21442">1,107</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-21443">1,263</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade accounts payables</td><td>&#160;</td>
    <td style="text-align: center">2A(c)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" unitRef="usd" id="ixv-21444">150</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" unitRef="usd" id="ixv-21445">152</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other accounts payables</td><td>&#160;</td>
    <td style="text-align: center">2A(c)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-21446">1,217</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-21447">1,216</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current lease liabilities</td><td>&#160;</td>
    <td style="text-align: center">2A(a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-21448">329</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-21449">268</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Financial liabilities at fair value</td><td>&#160;</td>
    <td style="text-align: center">2A(b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-21450">368</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-21451">26</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long term lease liabilities</td><td>&#160;</td>
    <td style="text-align: center">2A(a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-21452">728</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-21453">873</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loan from the Israeli Innovation Authority (&#8220;IIA&#8221;)</td><td>&#160;</td>
    <td style="text-align: center">2A(g)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherShortTermBorrowings" scale="3" unitRef="usd" id="ixv-21454">398</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign exchange reserve</td><td>&#160;</td>
    <td style="text-align: center">2A(c)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ForeignExchangeReserve" scale="3" sign="-" unitRef="usd" id="ixv-21455">1,928</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share capital and additional paid in capital</td><td>&#160;</td>
    <td style="text-align: center">2A(b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-21456">53,814</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-21457">57,866</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accumulated losses</td><td>&#160;</td>
    <td style="text-align: center">2A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-21458">39,064</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-21459">44,235</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left">Total Shareholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: center">2A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-21460">12,822</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-21461">13,631</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p></ix:continuation></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">In thousands $ (except share
and per share data)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>NOTE 2 </b>- <b>SIGNIFICANT ACCOUNTING
POLICIES: (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:continuation continuedAt="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_24" id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_23"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_CondensedStatementOfComprehensiveIncomeTableTextBlock-c0_cont_1" escape="true" name="srt:CondensedStatementOfComprehensiveIncomeTableTextBlock" id="ixv-16221"><b>U.S. GAAP differences for the year
ended December 31, 2021:</b></ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p>

<ix:continuation continuedAt="_CondensedStatementOfComprehensiveIncomeTableTextBlock-c0_cont_2" id="_CondensedStatementOfComprehensiveIncomeTableTextBlock-c0_cont_1"><ix:continuation continuedAt="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_25" id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_24"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">IFRS<br/>
 (previously reported)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">U.S. GAAP</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-21462">3,909</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-21463">4,070</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-21464">1,951</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-21465">1,980</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-21466">7,572</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-21467">6,937</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses (income)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" unitRef="usd" id="ixv-21468">23</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-21469">13,432</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-21470">12,964</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest income from deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="3" unitRef="usd" id="ixv-21471">1</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Finance expenses (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-21472">3,523</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-21473">4,230</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss before tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-21474">16,955</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-21475">17,193</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Taxes on income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-21476">16,955</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-21477">17,193</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Exchange (losses) profits arising on translation to presentation currency</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" unitRef="usd" id="ixv-21478">845</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-21479">16,110</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-21480">17,193</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p>

<ix:continuation continuedAt="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_26" id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_25"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><ix:continuation continuedAt="_CondensedStatementOfComprehensiveIncomeTableTextBlock-c0_cont_3" id="_CondensedStatementOfComprehensiveIncomeTableTextBlock-c0_cont_2"><b>U.S. GAAP differences for the year
ended December 31, 2022:</b></ix:continuation></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p>

<ix:continuation id="_CondensedStatementOfComprehensiveIncomeTableTextBlock-c0_cont_3"><ix:continuation id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock-c0_cont_26"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">IFRS<br/>
 (previously reported)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.
GAAP</b>  &#160;</span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-21481">8,054</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-21482">8,183</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-21483">1,325</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-21484">1,328</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-21485">5,391</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-21486">5,375</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses (income)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" sign="-" unitRef="usd" id="ixv-21487">7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-21488">14,770</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-21489">14,893</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest income from deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="3" unitRef="usd" id="ixv-21490">192</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Finance expenses (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-21491">4,497</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-21492">275</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss before tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-21493">10,273</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-21494">14,976</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Taxes on income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-21495">10,273</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-21496">14,976</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Exchange (losses)profits arising on translation to presentation currency</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-21497">2,138</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-21498">12,411</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-21499">14,976</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p></ix:continuation></ix:continuation></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "></p><div>

</div><!-- Field: Page; Sequence: 147; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">In thousands $ (except share
and per share data)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>NOTE 2 </b>- <b>SIGNIFICANT ACCOUNTING
POLICIES: (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-16621"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>B.
Use of estimates:</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_UseOfEstimates-c0_cont_2" id="_UseOfEstimates-c0_cont_1"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of Financial Statements in conformity with U.S. GAAP
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent
assets and liabilities at the date of the Financial Statements, and the reported amounts of expenses during the reporting period.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_UseOfEstimates-c0_cont_3" id="_UseOfEstimates-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Items subject to such estimates and assumptions include:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<ix:continuation continuedAt="_UseOfEstimates-c0_cont_4" id="_UseOfEstimates-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">stock-based compensation expense;</td>
</tr></table></ix:continuation>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<ix:continuation continuedAt="_UseOfEstimates-c0_cont_5" id="_UseOfEstimates-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">fair value financial liabilities;</td>
</tr></table></ix:continuation>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<ix:continuation continuedAt="_UseOfEstimates-c0_cont_6" id="_UseOfEstimates-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">recognition, measurement, and disclosure of contingent liabilities;</td>
</tr></table></ix:continuation>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<ix:continuation continuedAt="_UseOfEstimates-c0_cont_7" id="_UseOfEstimates-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Interest rate used for lease liability measurement.</td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_UseOfEstimates-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of issuance of the Financial Statements,
the Company is not aware of any material specific events or circumstances that would require it to update its estimates, judgments, or
to revise the carrying values of its assets or liabilities. These estimates may change, as new events occur and additional information
is obtained, and are recognized in the Financial Statements as soon as they become known. Actual results could differ from those estimates
and any such differences may be material to the Company&#8217;s Financial Statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="ixv-16662"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>C.
<span>Foreign Currency</span></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p>

<ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The currency of the primary economic environment
in which the operations of the Company are conducted is the U.S. dollar (&#8220;USD&#8221;). The Company&#8217;s funding and expected
revenues are mostly in USD. Thus, the functional currency of the Company is in USD.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Transactions and balances originally denominated
in USD are presented at their original amounts. Balances in non-USD currencies are translated into USD using historical and current exchange
rates for non-monetary and monetary balances, respectively. For non-USD transactions and other items in the statements of income (indicated
below), the following exchange rates are used: (i) for transactions &#8211; exchange rates at transaction dates or average exchange rates;
and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization) &#8211; historical exchange
rates. Currency transaction gains and losses are presented in financial expenses (income), net as appropriate. The functional currency
of the Company is USD.&#160;</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-16675"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>D.
Property, Plant, and Equipment</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; ">&#160;</p>

<ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost. Depreciation
is computed based on the straight-line method, over the estimated useful life of the assets.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock-c0_cont_1" escape="true" name="iinn:ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" id="ixv-21500">Annual rates of depreciation are as follows:</ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p>

<ix:continuation id="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock-c0_cont_1"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Computers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center"><ix:nonFraction contextRef="c41" decimals="2" format="ixt:num-dot-decimal" name="iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-21501">33</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Development equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><ix:nonFraction contextRef="c42" decimals="2" format="ixt:num-dot-decimal" name="iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-21502">20</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and office equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c43" decimals="2" format="ixt:num-dot-decimal" name="iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-21503">6</ix:nonFraction>-<ix:nonFraction contextRef="c44" decimals="2" format="ixt:num-dot-decimal" name="iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-21504">15</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Leasehold Improvements</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><ix:nonFraction contextRef="c45" decimals="2" format="ixt:num-dot-decimal" name="iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-21505">10</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p></ix:continuation></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 148; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">In thousands $ (except share
and per share data)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>NOTE 2 </b>- <b>SIGNIFICANT ACCOUNTING
POLICIES: (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-16755"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>E.
Leases</b></p></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_2" id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company implemented Accounting Standards Update
(&#8220;ASU&#8221;) 2016-02, Leases (Topic 842) (&#8220;ASU 2016-02&#8221;) using the modified retrospective approach for all lease arrangements
as of such date. The Company leases office space and vehicles under operating leases.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_3" id="_LesseeLeasesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Arrangements meeting the definition of a
lease are classified as operating or financing leases and are recorded on the balance sheet as both a right of use asset and lease
liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the
Company&#8217;s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the
right of use asset is amortized over the lease term.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_4" id="_LesseeLeasesPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The lease liability was measured at the present
value of the remaining lease payments, discounted using the Company&#8217;s incremental borrowing rate. The weighted-average&#160;rate
applied was <ix:nonFraction contextRef="c4" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-21506">9.60</ix:nonFraction>%. Right-of-use&#160;assets were measured at an amount equal to the lease liability.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For operating leases, interest on the lease liability
and the amortization of the right of use asset result in straight-line&#160;rent expense over the lease term. Variable lease expenses
are recorded when incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-16771"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>F.
Research and Development Costs.</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Research and development
expenses consist primarily of payroll, payroll related expenses, subcontractors, and materials. Costs are expensed as incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_GovernmentAssistancePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:GovernmentAssistancePolicyTextBlock" id="ixv-16778"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>G.
Government Grants</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_GovernmentAssistancePolicyTextBlock-c0_cont_2" id="_GovernmentAssistancePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company receives royalty-bearing grants from
the IIA for approved research and development projects. Under Israeli law, royalties on the revenues derived from products and services
developed using such grants, are payable to the Israeli Government.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_GovernmentAssistancePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Royalties payable with respect to grants received
under programs approved after January 1, 1999, are subject to interest on the dollar-linked value of the total grants received at an annual
rate of London Interbank Offered Rate (&#8220;LIBOR&#8221;) applicable to dollar deposits. In September 2021, the Bank of Israel, which
determines annual interest rates, published a directive which stated that annual interest at a variable rate linked to the LIBOR rate
for loans in USD will be replaced by the Secured Overnight Financing Rate, (&#8220;SOFR&#8221;), in January 2024. The amounts of grants
received and recorded into income should be disclosed for each period presented. The research and development grants are presented in
the statement of operations as an offset to related research and development expenses. Companies are required to pay royalties in connection
with such grants at specified rates, up to the total dollar-linked amount of such grants.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="iinn_FinanceIncomeAndExpensesPolicyTextBlock-c0_cont_1" escape="true" name="iinn:FinanceIncomeAndExpensesPolicyTextBlock" id="ixv-16788"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>H.
Finance Income and Expenses.</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="iinn_FinanceIncomeAndExpensesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finance income is composed of interest on deposits,
while finance expenses are composed of interest on senior secured credit facility, bank charges and net currency exchange rates differences.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 149; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">In thousands $ (except share
and per share data)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2 </b>- <b>SIGNIFICANT ACCOUNTING
POLICIES: (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-16826"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>I.
Current Taxes</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The current tax liability
is measured using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments
required in connection with the tax liability in respect of previous years. The Company has no tax liability due to its carry forward
losses.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-16834"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>J.
Share-Based Compensation.</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Share-based compensation
expenses related to employees, directors and subcontractors&#8217; options or restricted share units, (&#8220;RSU&#8221;) which recognized based
on their fair value, which is based on the fair value of the underlying Ordinary Shares as to the de-minimis exercise price using the
graded vesting method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes compensation expense for
grants of share-based awards to its employees based on the estimated fair value on the grant date. Compensation cost for awards is recognized
over the requisite service period, which approximates the vesting period. Share-based compensation is included in research and development,
selling and marketing and general and administrative expenses. Forfeitures of equity grants are recognized as incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All issuances of stock options or other equity
instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value
of the equity instruments issued.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DerivativesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:DerivativesPolicyTextBlock" id="ixv-16847"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>K.
Warrants</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DerivativesPolicyTextBlock-c0_cont_2" id="_DerivativesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issues warrants as part of its financing
activities or compensation arrangements. Warrants are derivative financial instruments that entitle the holder to purchase a specified
number of the Company&#8217;s ordinary shares at a predetermined exercise price. Warrants issued by the Company may have various terms, including
expiration dates, exercise prices, and conditions.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DerivativesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies warrants as either equity
or liabilities upon issuance, based on specific terms and conditions and in accordance with Accounting Standard Codification (&#8220;ASC&#8221;)
815, Derivatives and Hedging. Warrants are classified as equity if they meet the criteria for equity classification outlined in ASC 815-40.
Otherwise, warrants are classified as liabilities.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="iinn_SeverancePolicyTextBlock-c0_cont_1" escape="true" name="iinn:SeverancePolicyTextBlock" id="ixv-16857"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>L.
Severance</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="iinn_SeverancePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Israeli labor law generally requires payment of
severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The Company&#8217;s pension
and severance pay liabilities are covered mainly by insurance policies. Pursuant to section 14 of the Israeli Severance Compensation Act,
1963 (&#8220;Section 14&#8221;), the Company&#8217;s employees are entitled to monthly deposits, at a rate of <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" unitRef="pure" id="ixv-21507">8.33</ix:nonFraction>% of their monthly salary,
made in their name with insurance companies. Payments in accordance with Section 14 relieve the Company from any future severance payments
in respect of those employees and, as such, the Company may only utilize the insurance policies for the purpose of paying severance pay.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; ">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-16864"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>M.
Basic and Diluted Loss Per Share</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic and diluted loss per share is calculated
by dividing the loss attributable to equity holders of the Company by the weighted average number of Ordinary Shares outstanding during
the financial year, adjusted for Ordinary Shares issued during the year, if applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 150; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">In thousands $ (except share
and per share data)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 </b>- <b>SIGNIFICANT ACCOUNTING POLICIES:
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_8" id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-16902"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>N.
Fair Value Measurements</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures and discloses fair value
in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;), ASC 820, Fair Value Measurements and Disclosures (&#8220;ASC
820&#8221;). ASC 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value,
and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to
sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such,
fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing
an asset or liability. As a basis for considering such assumptions, there exists a three-tier fair-value hierarchy, which prioritizes
the inputs used in measuring fair value as follows:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 &#8211; unadjusted quoted prices are available
in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "><b>&#160;</b></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 &#8211; pricing inputs are other than
quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration
with observable market data.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "><b>&#160;</b></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 &#8211; pricing inputs are
unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the
non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant
management judgment or estimation. Level 3 inputs are considered as the lowest priority within the fair value hierarchy.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; "><b>&#160;</b></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This hierarchy requires the Company to use observable
market data, when available, and to minimize the use of unobservable inputs when determining fair value.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; ">&#160;</p>

<ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of cash is based on its demand
value, which is equal to its carrying value. Additionally, the carrying value of all other short-term monetary assets and liabilities
are estimated to be equal to their fair value due to the short-term nature of these instruments.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-16927"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>O.
Concentration of Credit Risk</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains certain cash balances in
a well-known Israeli banks and U.S based banks.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s operating expenses are denominated
mainly in New Israeli Shekel (&#8220;NIS&#8221;), and therefore, subject to foreign currency risk.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-16937"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>P.
Cash and Cash Equivalent</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_2" id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash equivalents are highly liquid investments
that are readily convertible into cash, typically with an original maturity of three months or less from <span>the
date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Restricted
cash consists of funds that are contractually restricted to bank guarantee due to rental agreements. The Company has presented
restricted cash separately from cash and cash equivalents in the balance sheets. </span>Bank deposits with maturities of more than
three months, but less than one year, and which are not restricted are included in short-term deposits. Such deposits are stated at
cost which approximates market value. As of December 31, 2023, December 31, 2022, the Company had short-term deposits in the amounts
of $<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="6" unitRef="usd" id="ixv-21508">2.3</ix:nonFraction> million and $<ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="6" unitRef="usd" id="ixv-21509">7.1</ix:nonFraction> million respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 151; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">In thousands $ (except share
and per share data)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 </b>- <b>SIGNIFICANT ACCOUNTING POLICIES:
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_9" id="_SignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-16980"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Q.
Segment Information</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
has a single operating and reportable segment. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), who is the Chief
Executive Officer, evaluates the performance of its business based on financial data consistent with the presentation in the accompanying
Financial Statements for the purposes of making operating decisions, assessing financial performance, and allocating resources.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-16988"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>R.
New accounting Pronouncements</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-indent: 0in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><span style="text-decoration:underline">Accounting
Standards Adopted in 2023</span></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><span style="text-decoration:underline">ASU 2023-03
</span></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In July
2023, the FASB issued ASU 2023-03 to amend various U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) paragraphs in the
ASC to primarily reflect the issuance of SEC Staff Accounting Bulletin No. 120. ASU No. 2023-03, &#8220;Presentation of Financial Statements
(Topic 205), Income Statement&#8212;Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity
(Topic 505), and Compensation&#8212;Stock Compensation (Topic 718): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin
No. 120, SEC Staff Announcement at the March 24, 2022 EITF Meeting, and Staff Accounting Bulletin Topic 6.B, Accounting Series Release
280&#8212;General Revision of Regulation S-X: Income or Loss Applicable to Common Stock.&#8221; ASU 2023-03 amends the ASC for SEC updates
pursuant to SEC Staff Accounting Bulletin No. 120, SEC Staff Announcement </span>at the March 24, 2022, Emerging Issues Task Force (&#8220;EITF&#8221;)
Meeting; and Staff Accounting Bulletin Topic 6.B, Accounting Series Release 280 - General Revision of Regulation S-X: Income or Loss
Applicable to Common Stock. These updates were immediately effective and did not have a material impact on our financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_5" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In June
2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820), &#8220;Fair Value Measurement of Equity Securities Subject to Contractual
Sale Restrictions&#8221; which clarifies that contractual restrictions on equity security sales are not considered part of the security
unit of account and, therefore, are not considered in measuring fair value. In addition, the restrictions cannot be recognized and measured
as separate units of account. Disclosures on such restrictions are also required. The amendments are effective for Fiscal years beginning
after December 15, 2023, and interim periods within those fiscal years on a prospectively basis. The Company expects that ASU 2022-03
will not have a material impact on its Financial Statements and related disclosures. </span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_6" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Accounting
Pronouncements Issued but Not Yet Adopted</i></b></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_7" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In November
2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU expands public
entities&#8217; segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the CODM and
included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items,
and interim disclosures of a reportable segment&#8217;s profit or loss and assets. All disclosure requirements under ASU 2023-07 are also
required for public entities with a single reportable segment. The ASU&#8217;s amendments are effective for all public entities for fiscal
years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption
permitted. We are currently evaluating the impact of this pronouncement on our Financial Statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 152; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">In thousands $ (except share
and per share data)</p><div>


</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 </b>- <b>SIGNIFICANT ACCOUNTING POLICIES:
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_9"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_8" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In December
2023, the FASB issued ASU 2023-08, Intangibles&#8212;Goodwill and Other&#8212;Crypto Assets (Subtopic 350-60): Accounting for and Disclosure
of Crypto Assets, which addresses the accounting and disclosure requirements for certain crypto assets. This ASU requires entities to
subsequently measure certain crypto assets at fair value, with changes in fair value recorded in net income in each reporting period.
In addition, entities are required to provide additional disclosures about the holdings of certain crypto assets. The ASU&#8217;s amendments
are effective for all entities holding assets that meet certain scope criteria for fiscal years beginning after December 15, 2024, including
interim periods within those years. Early adoption is permitted for both interim and annual periods. If an entity adopts the amendments
in an interim period, it must adopt them as of the beginning of the fiscal year that includes that interim period. We do not expect this
pronouncement to have a material impact on our Financial Statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In December
2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. Under this ASU, public entities must
annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that
meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than five percent of the amount computed
by multiplying pretax income or loss by the applicable statutory income tax rate). This ASU&#8217;s amendments are effective for all entities
that are subject to Topic 740, Income Taxes, for annual periods beginning after December 15, 2024, with early adoption permitted. We are
currently evaluating the impact of this pronouncement on our disclosures.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DepositLiabilitiesDisclosuresTextBlock" id="ixv-17070"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>NOTE 3 &#8211; DEPOSITS:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; ">The Company&#8217;s deposits consist of three short-term
bank deposits with maturities of more than three months but less than one year. The deposits are in dollars and bear annual interest.
<span>Interest earned is recorded as finance income, net in the statement of operations during the years
for which the Company held short-term deposits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, the Company had a
deposit in USD at Leumi Bank (Israel) in amount of $<ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Deposits" scale="3" unitRef="usd" id="ixv-21510">2,040</ix:nonFraction>, including interest that bore fixed annual interest of&#160;<ix:nonFraction contextRef="c4" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-21511">6.18</ix:nonFraction>% and a
deposit in NIS in amount of $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Deposits" scale="3" unitRef="usd" id="ixv-21512">280</ix:nonFraction> that bore fixed annual interest of&#160;<ix:nonFraction contextRef="c47" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-21513">4.85</ix:nonFraction>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, the Company had deposits
in total amount of $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Deposits" scale="3" unitRef="usd" id="ixv-21514">7,120</ix:nonFraction>.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock" id="ixv-17083"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>NOTE 4 - OTHER CURRENT ASSETS:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="ixv-17088"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" unitRef="usd" id="ixv-21515">176</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" unitRef="usd" id="ixv-21516">254</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Institutions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestBearingDepositsInBanks" scale="3" unitRef="usd" id="ixv-21517">164</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestBearingDepositsInBanks" scale="3" unitRef="usd" id="ixv-21518">276</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted Cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" unitRef="usd" id="ixv-21519">89</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" unitRef="usd" id="ixv-21520">56</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" unitRef="usd" id="ixv-21521">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" unitRef="usd" id="ixv-21522">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-21523">432</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-21524">589</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 153; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">In thousands $ (except share
and per share data)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-17183"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 5 - PROPERTY AND EQUIPMENT, NET:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-17188"><span style="text-decoration:underline">For the year ended December 31, 2023:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_PropertyPlantAndEquipmentTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leasehold<br/> improvements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Development<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Furniture<br/> and office<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; font-weight: bold">At January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-21525">121</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-21526">33</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-21527">229</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-21528">116</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-21529">499</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-21530">51</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-21531">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-21532">152</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-21533">206</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold">At December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-21534">172</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-21535">36</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-21536">381</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-21537">116</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-21538">705</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">At January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-21539">51</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-21540">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-21541">25</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-21542">8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-21543">88</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-21544">51</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-21545">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-21546">48</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-21547">8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-21548">111</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold">At December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-21549">102</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-21550">8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-21551">73</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-21552">16</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-21553">199</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Net book value:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; padding-bottom: 4pt">As of December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-21554">70</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-21555">28</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-21556">308</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-21557">100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-21558">506</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_PropertyPlantAndEquipmentTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">Less than thousand dollars</span></td>
</tr></table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:continuation continuedAt="_PropertyPlantAndEquipmentTextBlock-c0_cont_4" id="_PropertyPlantAndEquipmentTextBlock-c0_cont_3"><span style="text-decoration:underline">For the year ended December 31, 2022:</span></ix:continuation></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_PropertyPlantAndEquipmentTextBlock-c0_cont_5" id="_PropertyPlantAndEquipmentTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leasehold<br/> improvements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Development<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Furniture<br/> and office<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; font-weight: bold">At January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-21559">84</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-21560">7</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-21561">64</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-21562">81</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-21563">236</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-21564">37</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-21565">26</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-21566">165</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-21567">35</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-21568">263</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold">At December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-21569">121</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-21570">33</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-21571">229</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-21572">116</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-21573">499</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">At January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-21574">22</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-21575">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-21576">8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-21577">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-21578">34</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-21579">29</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-21580">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-21581">17</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-21582">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-21583">54</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold">At December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-21584">51</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-21585">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-21586">25</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-21587">8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-21588">88</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Net book value:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; padding-bottom: 4pt">As of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-21589">70</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-21590">29</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-21591">204</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-21592">108</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-21593">411</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_PropertyPlantAndEquipmentTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">Less than thousand dollars</span></td>
</tr></table></ix:continuation></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 154; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">In thousands $ (except share
and per share data)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="ixv-17926"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 6 - OTHER ACCOUNTS PAYABLE:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="ixv-17931"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Employees&#8217; salaries and related liabilities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-21594">388</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-21595">396</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccountsPayableToRelatedParties" scale="3" unitRef="usd" id="ixv-21596">354</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccountsPayableToRelatedParties" scale="3" unitRef="usd" id="ixv-21597">332</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-21598">267</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-21599">470</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-21600">17</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-21601">18</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-21602">1,026</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-21603">1,216</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-18004"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>NOTE 7 - COMMITMENTS AND CONTINGENCIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>A.</b></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Royalties to the IIA:</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 57.4pt; text-indent: -0.7pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In September
2019, the IIA approved an application that supports upgrading the Company&#8217;s manufacturing capabilities for an aggregate budget of
NIS&#160;<ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AggregateBudget" scale="3" unitRef="ils" id="ixv-21604">4,880,603</ix:nonFraction>(approximately $<ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AggregateBudget" scale="3" unitRef="usd" id="ixv-21605">1,500,000</ix:nonFraction>). The IIA committed to fund&#160;<ix:nonFraction contextRef="c65" decimals="2" format="ixt:num-dot-decimal" name="iinn:PercentageOfApprovedBudget" scale="-2" unitRef="pure" id="ixv-21606">60</ix:nonFraction>% of the approved budget. Eventually the project budget
concluded in the aggregate amount of NIS <ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ProjectBudgetAggregateAmount" scale="3" unitRef="ils" id="ixv-21607">4,623,142</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ProjectBudgetAggregateAmount" scale="3" unitRef="usd" id="ixv-21608">1,333</ix:nonFraction>) The program is for the period beginning October 2019 through
November 2020 and the Company received total funds in the amount of NIS <ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="3" unitRef="ils" id="ixv-21609">2,773,885</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="3" unitRef="usd" id="ixv-21610">800</ix:nonFraction>) from the IIA. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>According
to the agreements with the IIA, The Company will pay royalties of&#160;<ix:nonFraction contextRef="c67" decimals="2" format="ixt:num-dot-decimal" name="iinn:RoyaltiesPercentage" scale="-2" unitRef="pure" id="ixv-21611">3</ix:nonFraction>% to&#160;<ix:nonFraction contextRef="c68" decimals="3" format="ixt:num-dot-decimal" name="iinn:RoyaltiesPercentage" scale="-2" unitRef="pure" id="ixv-21612">3.5</ix:nonFraction>% of future sales up to an amount equal to the accumulated
grant received including annual interest of LIBOR linked to the USD. Repayment of the grant is contingent upon the successful completion
of the Company&#8217;s research and development (&#8220;R&amp;D&#8221;) programs and generating sales. The Company has no obligation to
repay these grants if the R&amp;D programs fail, are unsuccessful or aborted or if no sales are generated. The Company had not generated
sales as of December 31, 2023; therefore, no liability was recorded in these Financial Statements. IIA grants are recorded as a reduction
of R&amp;D expenses, net.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>During October
2023, the IIA has approved a support of another development project of the Company at an aggregate budget of NIS&#160;<ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AggregateBudget" scale="3" unitRef="ils" id="ixv-21613">3,850,869</ix:nonFraction> (approximately
$<ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AggregateBudget" scale="3" unitRef="usd" id="ixv-21614">1,062</ix:nonFraction>). The IIA committed to fund&#160;<ix:nonFraction contextRef="c69" decimals="2" format="ixt:num-dot-decimal" name="iinn:PercentageOfApprovedBudget" scale="-2" unitRef="pure" id="ixv-21615">40</ix:nonFraction>% of the approved budget. No funds have been received by the Company yet. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Research
and development grants deducted from research and development expenses amounted to&#160;nil, $<ix:nonFraction contextRef="c70" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-21616">106</ix:nonFraction> and $<ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-21617">694</ix:nonFraction> for the years ended December
31, 2021 and 2020, respectively. As of December 31, 2023, the maximum obligation with respect to the grants received from the IIA, contingent
upon entitled future sales, is $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ContingentUponFutureSales" scale="3" unitRef="usd" id="ixv-21618">871</ix:nonFraction> plus LIBOR interest. In September 2021, the Bank of Israel, which determines annual interest rates,
published a directive which stated that annual interest at a variable rate linked to the LIBOR rate for loans in USD will be replaced
by the SOFR, in January 2024.The Company has obligations regarding know-how, technology, or products, not to transfer the information,
rights thereon and production rights which derive from the research and development without the IIA Research Committee approval.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 155; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">In thousands $ (except share
and per share data)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>NOTE 7 - COMMITMENTS AND CONTINGENCIES</b></span><b>
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>B.</b></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Lease Commitments &#8211;
Operating Leases:</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span>In August 2022, the Company entered
into a lease agreement for its facilities in Ra&#8217;anana, Israel. The lease agreement is for a period of 69 months commencing September 1,
2021, and the Company began to pay lease and related expenses after completing 3 months of lease. The Company has the option to shorten
the period and terminates the lease agreement after completing 45 months of rent by paying an amount of NIS <ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="3" unitRef="ils" id="ixv-21619">500,000</ix:nonFraction>, (approximately $<ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="3" unitRef="usd" id="ixv-21620">153</ix:nonFraction>).
This amount of reimbursement will be deducted monthly in NIS <ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ReimbursementAmount" scale="3" unitRef="ils" id="ixv-21621">30,000</ix:nonFraction>, (approximately $<ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ReimbursementAmount" scale="3" unitRef="usd" id="ixv-21622">9</ix:nonFraction>) if the Company terminates the agreement after
45 months of rent. The annual lease payment, including management fees, as of December 31, 2023, is approximately NIS <ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ManagementFeeExpense" scale="3" unitRef="ils" id="ixv-21623">69,000</ix:nonFraction> ($<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ManagementFeeExpense" scale="3" unitRef="usd" id="ixv-21624">19</ix:nonFraction>). As
security for the obligations under this lease agreement, the Company provided a bank guarantee in an amount equal to three monthly lease
payments plus the Israeli value added tax and an unlimited guarantee according to the terms specified in the contract. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span>The total expenses related to
the leases were $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd" id="ixv-21625">371</ix:nonFraction>&#160;for the year ended December 31, 2023, and $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd" id="ixv-21626">333</ix:nonFraction>&#160;for the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span>The right-of-use asset and lease
liability are initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease
or, if that rate cannot be readily determined, the Company&#8217;s incremental borrowing rate based on the information available at the
date of determining the present value of the lease payments. The Company&#8217;s incremental borrowing rate is estimated to approximate
the interest rate on similar terms and payments and in economic environments where the leased asset is located.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_OperatingLeasesOfLesseeDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock" id="ixv-18083"><span>The Company has various operating
leases for vehicles that expire through 2027. Below is a summary of the Company&#8217;s operating right-of-use assets and operating lease
liabilities as of December 31, 2023, and 2022:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_OperatingLeasesOfLesseeDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December&#160;31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating lease liabilities, current</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-21627">290</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-21628">268</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liabilities long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-21629">588</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-21630">873</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-21631">878</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-21632">1,141</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Weighted Average of Remaining Lease Term</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c4" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-21633">3.33</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-21634">4.2</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Weighted-average discount rate - operating leases</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-21635">9.6</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-21636">9.92</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 156; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">In thousands $ (except share
and per share data)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>NOTE 7 - COMMITMENTS AND CONTINGENCIES</b></span><b>
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-21637">Lease payments for the Company&#8217;s right-of-use
assets over the remaining lease periods as of December 31, 2023, are as follows:</ix:nonNumeric><span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>&#160;</span></p>

<ix:continuation continuedAt="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_2" id="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd" id="ixv-21638">357</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitRef="usd" id="ixv-21639">290</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" unitRef="usd" id="ixv-21640">220</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" unitRef="usd" id="ixv-21641">144</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total undiscounted lease payment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-21642">1,011</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Interest*</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd">133</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-21644">878</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:continuation id="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US">Future lease payments were discounted by&#160;<ix:nonFraction contextRef="c67" decimals="4" format="ixt:num-dot-decimal" name="iinn:FutureLeasePaymentsDiscountedInterestRate" scale="-2" unitRef="pure" id="ixv-21646">7.98</ix:nonFraction>%-<ix:nonFraction contextRef="c68" decimals="4" format="ixt:num-dot-decimal" name="iinn:FutureLeasePaymentsDiscountedInterestRate" scale="-2" unitRef="pure" id="ixv-21647">15.04</ix:nonFraction>% interest
rate.</ix:footnote></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>C.</b></td><td style="text-align: justify"><b>Legal Claims</b></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">In the normal course of business, various legal claims and other contingent
matters may arise. Management believes that any liability that may arise from such matters would not have a material adverse effect on
the Company&#8217;s results of operations or financial condition as of and for the years ended December 31, 2023, and 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">On December 12, 2021, the Company terminated its employment agreement
with Dr. Udi Nussinovitch, one of its founders who served as the Company&#8217;s Chief Scientific Officer since March 2018. On February
24, 2022, the Company sued Mr. Nussinovitch for breach good faith and his fiduciary duties as a shareholder and former officer of the
Company. On November 9, 2022, the Company received notice of a complaint filed by Mr.&#160;Nussinovitch, as well as a complaint filed
with the regional labor court in Tel Aviv, Israel on November 8, 2022. Mr. Nussinovitch has alleged certain deficiencies in the Company&#8217;s&#160;Extraordinary
General Meeting of Shareholders held on Friday, December 17, 2021, resulting from his status as a minority shareholder. In addition, with
respect to the labor dispute, Mr.&#160;Nussinovitch is seeking renumeration and the issuance of Ordinary Shares. A partial hearing was
held in the regional labor court on July 19, 2023, and the parties were required by the court to file their positions on a stay of the
proceeding pending the decision on the case initiated by the Plaintiff in the District Court.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">A pre-trial was held in the district court on January 21, 2024. During
the hearing, the court suggested that the parties consider the possibility of resolving the case through an out-of-court arrangement or
mediation. The parties agreed to a mediation process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of the date of these Financial Statement, the Company believes that
the claims will result in no payments by the Company.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 157; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">In thousands $ (except share
and per share data)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" id="ixv-18318"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 8 - FINACIAL LIABILITIES AT FAIR VALUE:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FinancialGuaranteeInsuranceContractsClaimLiabilityTableTextBlock" id="ixv-18322"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December&#160;31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Financial liability (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" unitRef="usd" id="ixv-21648">11</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c74" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" unitRef="usd" id="ixv-21649">26</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Non-tradable warrants (2)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" unitRef="usd" id="ixv-21650">1,459</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" unitRef="usd" id="ixv-21651">1,470</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" unitRef="usd" id="ixv-21652">26</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>1.</b></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Financial Liability</b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company agreed to pay fees of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="iinn:PercentageOfPayFees" scale="-2" unitRef="pure" id="ixv-21653">7</ix:nonFraction>% from the
funds that will be received in an event of exercise of the Company&#8217;s tradable warrants which created a financial liability. The
financial liability was designated to be measured at fair value through profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial liability fair value as of December
31, 2023, and 2022 is $<ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" unitRef="usd" id="ixv-21654">11</ix:nonFraction> and $<ix:nonFraction contextRef="c74" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" unitRef="usd" id="ixv-21655">26</ix:nonFraction> respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>2.</b></td><td style="text-align: justify"><b>Private Warrants</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 26, 2023, the Company entered into
the Purchase Agreement (Note 1 and Note 9), pursuant to which it issued unregistered warrants, to purchase up to an aggregate of <ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockDividendsShares" scale="0" unitRef="shares" id="ixv-21656">3,031,250</ix:nonFraction>
Ordinary Shares at an exercise of $<ix:nonFraction contextRef="c36" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-21657">1.28</ix:nonFraction> per share. The Warrants were exercisable immediately upon issuance and will expire three and a
half years following their issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants include cashless exercise mechanism,
according to the terms specified in the agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants may create obligation to transfer
cash to the investors at fundamental transactions according to fair value of the black Scholes model that include variable inputs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Therefore, the Company accounts for the warrants
as financial liability instruments that measured at fair value and recognized financial expenses or income through profit and loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants fair value as of the issuance date
and December 31, 2023, were $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" unitRef="usd" id="ixv-21658">1,750</ix:nonFraction> and $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" unitRef="usd" id="ixv-21659">1,459</ix:nonFraction> respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The key inputs that were used in the Private Warrants fair value as
of issuance date were:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">risk-free interest rate <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-21660">4.00</ix:nonFraction>%</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">expected volatility <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-21661">66.71</ix:nonFraction>%</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">expected dividend yield of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-21662">0</ix:nonFraction>%</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">expected term of warrants &#8211; <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" id="ixv-21663">3.5</ix:nonNumeric> years.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The key inputs that were used in the Private Warrants fair value as
of December 31, 2023, were:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">risk-free interest rate <ix:nonFraction contextRef="c75" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-21664">4.00</ix:nonFraction>%</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">expected volatility <ix:nonFraction contextRef="c75" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-21665">66.63</ix:nonFraction>%</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">expected dividend yield of <ix:nonFraction contextRef="c75" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-21666">0</ix:nonFraction>%</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">expected term of warrants &#8211; <ix:nonNumeric contextRef="c75" format="ixt-sec:duryear" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" id="ixv-21667">3.5</ix:nonNumeric> years.</td>
</tr></table></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 158; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">In thousands $ (except share
and per share data)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-18485"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9 - SHAREHOLDERS&#8217; EQUITY (DEFICIT):</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfStockholdersEquityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" id="ixv-18494"><b>A.</b></ix:nonNumeric></td><td style="text-align: justify"><ix:continuation continuedAt="_ScheduleOfStockholdersEquityTableTextBlock-c0_cont_2" id="_ScheduleOfStockholdersEquityTableTextBlock-c0_cont_1"><b>Share capital:</b></ix:continuation></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:continuation id="_ScheduleOfStockholdersEquityTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Number of shares as of<br/> December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Number of shares as of<br/> December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 4pt">Ordinary shares</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-21668">100,000,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-21669">15,652,176</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-21670">100,000,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-21671">11,338,940</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since the Company&#8217;s incorporation in February
2018 and before its IPO, the Company issued the following Ordinary Shares: (i) an aggregate of <ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="iinn:AggregateOfOrdinaryShares" scale="0" unitRef="shares" id="ixv-21672">27,566</ix:nonFraction> Ordinary Shares for no consideration
to the Company&#8217;s founders and certain advisors; and (ii) <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iinn:OrdinaryShare" scale="0" unitRef="shares" id="ixv-21673">1,877,196</ix:nonFraction> Ordinary Shares as bonus shares for no consideration to existing
shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2020 the Company issued an aggregate of <ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="iinn:AggregateOfOrdinaryShares" scale="0" unitRef="shares" id="ixv-21674">756,333</ix:nonFraction>
Ordinary Shares to investors as part of a loan conversion and non-tradable warrants to purchase an additional <ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-21675">169,019</ix:nonFraction> Ordinary Shares
upon consummation of its IPO. The warrants are exercisable into Ordinary Shares of the Company at an exercise price equal to the initial
public offering price which was $<ix:nonFraction contextRef="c81" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-21676">5.50</ix:nonFraction> and are exercisable for three years after the IPO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 18, 2021, the Company&#8217;s shareholders
approved a <ix:nonFraction contextRef="c82" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-21677">12.5</ix:nonFraction> to <ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-21678">1</ix:nonFraction> reverse split of all shares (issued and unissued) on the basis that every <ix:nonFraction contextRef="c84" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-21679">12.5</ix:nonFraction> Ordinary Shares in the capital of
the Company be consolidated into <ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="iinn:OrdinaryShare" scale="0" unitRef="shares" id="ixv-21680">1</ix:nonFraction> Ordinary Share, such that the authorized share capital of the Company following such consolidation
is NIS <ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalUnitsAuthorized" scale="0" unitRef="shares" id="ixv-21681">310,000,000</ix:nonFraction> divided into <ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="iinn:OrdinaryShare" scale="0" unitRef="shares" id="ixv-21682">24,800,000</ix:nonFraction> Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2021, the Company&#8217;s shareholders
approved an amendment to the structure of the Company&#8217;s share capital (both authorized and issued) by cancelling the par value of
the Ordinary Shares in addition to implementing an additional <ix:nonNumeric contextRef="c88" name="us-gaap:StockholdersEquityReverseStockSplit" id="ixv-21683">reverse split at a ratio of 2.94 to 1</ix:nonNumeric>, pursuant to which holders of our
Ordinary Shares received one Ordinary Share for every <ix:nonFraction contextRef="c89" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-21684">2.94</ix:nonFraction>&#160;Ordinary Shares held.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2021, the Company&#8217;s shareholders
approved an amendment to the structure of the Company&#8217;s share capital (both authorized and issued) by cancelling the par value of
the Company&#8217;s shares such that each Ordinary Share with par value of NIS <ix:nonFraction contextRef="c89" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="ilsPershares" id="ixv-21685">0.125</ix:nonFraction> will become one Ordinary Share with no par value.
The authorized share capital of the Company following the reverse stock split was NIS <ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-21686">310,000,000</ix:nonFraction> divided into <ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="iinn:OrdinaryShare" scale="0" unitRef="shares" id="ixv-21687">8,435,375</ix:nonFraction> Ordinary Shares,
with no par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2021, the Company&#8217;s shareholders
approved an increase in the authorized share capital of the Company to <ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-21688">15,000,000</ix:nonFraction> Ordinary Shares of no-par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 16, 2021, the Company completed its IPO
on the Nasdaq Capital Market whereby the Company sold <ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="iinn:SoldOrdinaryShares" scale="0" unitRef="shares" id="ixv-21689">2,909,091</ix:nonFraction> Ordinary Shares and tradable warrants to purchase <ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="iinn:TradableWarrants" scale="0" unitRef="shares" id="ixv-21690">3,345,455</ix:nonFraction> Ordinary Shares
(inclusive of tradable warrants to purchase <ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="iinn:TradableWarrants" scale="0" unitRef="shares" id="ixv-21691">436,364</ix:nonFraction> Ordinary Shares pursuant to the exercise of an overallotment option granted to the
underwriters). The tradable warrants have an exercise price of $<ix:nonFraction contextRef="c90" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-21692">5.50</ix:nonFraction> and they are exercisable for five years after the IPO date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the IPO, the Company issued <ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-21693">2,113,905</ix:nonFraction>
Ordinary Shares and <ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="iinn:NonTradableWarrants" scale="0" unitRef="shares" id="ixv-21694">1,149,582</ix:nonFraction> non-tradable warrants to investors and <ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="iinn:NonTradableWarrants" scale="0" unitRef="shares" id="ixv-21695">16,587</ix:nonFraction> non-tradeable warrants to brokers in connection with the conversion
of Company&#8217;s previously issued financial liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate proceeds received by the Company
from the IPO were approximately $<ix:nonFraction contextRef="c78" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDividendsReceived" scale="3" unitRef="usd" id="ixv-21696">14,490</ix:nonFraction>, after deducting underwriting discounts and commissions and additional offering direct costs totaled
approximately $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OfferingCostsPartnershipInterests" scale="3" unitRef="usd" id="ixv-21697">1,543</ix:nonFraction>. The gross proceeds were $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="3" unitRef="usd" id="ixv-21698">16,033</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 159; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">In thousands $ (except share
and per share data)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9 - SHAREHOLDERS&#8217; EQUITY (DEFICIT) (Cont.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total non-cash direct expenses in IPO were as
following: (i) fair value of <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iinn:FairValueWarrants" scale="0" unitRef="shares" id="ixv-21699">436,364</ix:nonFraction> tradable warrants that were granted to underwriters totaled in $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentOfWarrantsGrantedForServices" scale="3" unitRef="usd" id="ixv-21700">589</ix:nonFraction>; (ii) The Company issued <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightUnissued" scale="0" unitRef="shares" id="ixv-21701">145,455</ix:nonFraction>
non-tradable warrants as underwriters fees; the warrants will be converted into Ordinary Shares of the Company at an exercise price equal
to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="iinn:PercentageOfExercisePrice" scale="-2" unitRef="pure" id="ixv-21702">125</ix:nonFraction>% of the IPO price and be exercisable for three years after the IPO. As of the date of the IPO, the tradable warrants fair value
was $<ix:nonFraction contextRef="c78" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentOfWarrantsGrantedForServices" scale="3" unitRef="usd" id="ixv-21703">264</ix:nonFraction>; and (iii) the Company agreed to pay to a promoter <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="iinn:PercentageOfExerciseOfTradableWarrants" scale="-2" unitRef="pure" id="ixv-21704">7</ix:nonFraction>% of the proceeds from the exercise of tradable warrants. The payment was
measured at fair value at the grant date. As of the IPO date, the fair value of the financial liability was $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" unitRef="usd" id="ixv-21705">310</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total non-cash expenses were $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" unitRef="usd" id="ixv-21706">1,163</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company had non-direct expenses
as following: (i) cash expenses amounted to $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoninterestExpense" scale="3" unitRef="usd" id="ixv-21707">722</ix:nonFraction> and (i) non-cash expenses amounted to $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="3" unitRef="usd" id="ixv-21708">123</ix:nonFraction> (<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-21709">22,382</ix:nonFraction> Ordinary Shares issued to service
providers).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total IPO expenses direct and non- direct, cash
and non-cash were: $<ix:nonFraction contextRef="c78" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoninterestExpense" scale="3" unitRef="usd" id="ixv-21710">3,551</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total IPO expenses allocated to the profit and
loss were $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BenefitsLossesAndExpenses" scale="3" unitRef="usd" id="ixv-21711">546</ix:nonFraction>. Total IPO expenses deducted from the equity were $<ix:nonFraction contextRef="c78" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BenefitsLossesAndExpenses" scale="3" unitRef="usd" id="ixv-21712">3,032</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year 2021 the Company issued an aggregate
amount of <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iinn:AggregateOfOrdinaryShares" scale="0" unitRef="shares" id="ixv-21713">655,601</ix:nonFraction> Ordinary Shares in connection to vested RSUs and additional <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-21714">24,631</ix:nonFraction> Ordinary Shares in connection with options exercise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 17, 2021, the Company&#8217;s shareholders
approved an increase in the authorized share capital of the Company to <ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonUnitAuthorized" scale="0" unitRef="shares" id="ixv-21715">100,000,000</ix:nonFraction> Ordinary Shares of no-par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2022, the Company
issued an aggregate amount of <ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="iinn:AggregateOfOrdinaryShares" scale="0" unitRef="shares" id="ixv-21716">1,240,204</ix:nonFraction> Ordinary Shares in connection to vested RSUs and an additional <ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-21717">7,030</ix:nonFraction> Ordinary Shares in connection
to option exercises.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 4, 2023, the Company entered into a
sales agreement (the &#8220;Sales Agreement&#8221;) with Roth Capital Partners, LLC, as sales agent, pursuant to which the Company could
offer and sell, from time to time, through the sales agent, Ordinary Shares pursuant to an At-The-Market facility (&#8220;ATM&#8221;).
During 2023, the Company sold <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares" id="ixv-21718">17,566</ix:nonFraction> Ordinary Shares under the ATM. On October 23, 2023, the Company terminated the Sales Agreement and
the associated ATM, effective immediately.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 26, 2023, the Company completed
the Registered Direct Offering, whereby the Company sold (i) <ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-21719">1,375,000</ix:nonFraction> Ordinary Shares at a purchase price of $<ix:nonFraction contextRef="c96" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-21720">1.28</ix:nonFraction> per share, and
(ii) Pre-Funded Warrants, to purchase up to <ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-21721">1,656,250</ix:nonFraction> Ordinary Shares, at a purchase price of $<ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-21722">1.28</ix:nonFraction>, less $<ix:nonFraction contextRef="c34" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-21723">0.001</ix:nonFraction> per Pre-Funded
Warrant. (iii) Private Warrants, to purchase up to an aggregate of <ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-21724">3,031,250</ix:nonFraction> Ordinary Shares at an exercise of $<ix:nonFraction contextRef="c34" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-21725">1.28</ix:nonFraction> per share (Note
8.2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Pre-Funded Warrants were exercised on the
same day and the day after the transaction in full in an exercise price of $<ix:nonFraction contextRef="c99" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-21726">0.01</ix:nonFraction> per share and the Company issued <ix:nonFraction contextRef="c99" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-21727">1,656,250</ix:nonFraction> additional
Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate proceeds received by the Company
from the registered direct offering were approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherUnderwritingExpense" scale="3" unitRef="usd" id="ixv-21728">3,424</ix:nonFraction>, after deducting underwriting discounts and commissions and additional cash
offering costs totaled in approximately $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="3" unitRef="usd" id="ixv-21729">454</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issued the Placement Agent in the
agreement a number of warrants equal to a total of <ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="iinn:PercentageOfAgreementWarrants" scale="-2" unitRef="pure" id="ixv-21730">7.0</ix:nonFraction>% of the aggregate number of Ordinary Shares sold in the transaction, total to <ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-21731">212,188</ix:nonFraction>
warrants to purchase up to <ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares" id="ixv-21732">212,188</ix:nonFraction> Ordinary Shares, were issued. The Placement Agent Warrants were substantially on the same terms as
the Warrants issued to the investor in the offering, except an exercise price of $<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-21733">1.60</ix:nonFraction> per share. The Placement agent Warrants were exercisable
immediately upon issuance and will expire five years following their issuance. The Company accounts for the Placement Agent Warrants as
equity-classified instruments (as part of additional paid in capital), based on an assessment of ASC 718. The fair value of the warrants
at the issuance date was $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDerivativeIssuanceCosts" scale="3" unitRef="usd" id="ixv-21734">131</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 160; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">In thousands $ (except share
and per share data)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 9 - SHAREHOLDERS&#8217; EQUITY (DEFICIT)
(Cont.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Those cash and non-cash issuance costs were accounted
proportionally to issuance expenses and decrease of additional paid in capital, according to the ratio of the liability versus equity
in the Registered Direct offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2023, the Company
issued an aggregate amount of <ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="iinn:AggregateOfOrdinaryShares" scale="0" unitRef="shares" id="ixv-21735">1,226,448</ix:nonFraction> Ordinary Shares in connection with vested RSUs and an additional <ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-21736">37,972</ix:nonFraction> Ordinary Shares in connection
with option exercises.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>B.</b></td><td style="text-align: justify"><b>Warrants reserves -</b>Composition and movements:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.8pt; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="ixv-21737">The following table reconciles the movement in warrants outstanding
at the beginning and end of the period:</ix:nonNumeric></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.8pt; text-align: justify"><b>&#160;</b></p>

<ix:continuation id="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted-average exercise price</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted average remaining contractual term</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in years)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Aggregate</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>intrinsic value</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold; padding-bottom: 1.5pt">Balance as of December 31, 2022</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c103" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares" id="ixv-21738">3,121,095</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c103" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-21739">5.58</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"><ix:nonNumeric contextRef="c104" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="ixv-21740">1.74</ix:nonNumeric></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c103" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" unitRef="usd" id="ixv-21741">4,667,915</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c104" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-21742">212,188</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c104" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-21743">1.6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c104" format="ixt-sec:duryear" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" id="ixv-21744">5</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c104" decimals="-3" format="ixt:num-dot-decimal" name="iinn:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued" scale="3" unitRef="usd" id="ixv-21745">131,555</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Balance as of December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c100" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares" id="ixv-21746">3,333,283</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c100" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-21747">5.47</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonNumeric contextRef="c104" format="ixt-sec:duryear" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms" id="ixv-21748">1.83</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c100" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" unitRef="usd" id="ixv-21749">4,799,470</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">2.</td><td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="ixv-21750">The following table summarizes information about the Company&#8217;s
outstanding warrants as of December 31, 2023</ix:nonNumeric></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Exercise Price</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Warrants outstanding</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December&#160;31,<br/>
 2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiration date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Aggregate</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Intrinsic</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>value</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><ix:nonFraction contextRef="c105" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-21751">5.5</ix:nonFraction></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c106" decimals="-3" format="ixt:num-dot-decimal" name="iinn:WarrantsOutstanding" scale="3" unitRef="usd" id="ixv-21752">1,640,455</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c106" format="ixt:date-day-month-year" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="ixv-18914"><span style="font-size: 10pt">15/07/2026</span></ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c105" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" unitRef="usd" id="ixv-21753">2,214,614</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><ix:nonFraction contextRef="c107" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-21754">5.5</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="iinn:WarrantsOutstanding" scale="3" unitRef="usd" id="ixv-21755">1,057,350</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c108" format="ixt:date-day-month-year" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="ixv-18930"><span style="font-size: 10pt">15/07/2024</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c107" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" unitRef="usd" id="ixv-21756">1,691,760</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><ix:nonFraction contextRef="c109" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-21757">5.5</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c110" decimals="-3" format="ixt:num-dot-decimal" name="iinn:WarrantsOutstanding" scale="3" unitRef="usd" id="ixv-21758">277,835</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c110" format="ixt:date-day-month-year" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="ixv-18946"><span style="font-size: 10pt">15/07/2025</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c109" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" unitRef="usd" id="ixv-21759">497,533</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><ix:nonFraction contextRef="c111" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-21760">6.875</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c112" decimals="-3" format="ixt:num-dot-decimal" name="iinn:WarrantsOutstanding" scale="3" unitRef="usd" id="ixv-21761">145,455</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c112" format="ixt:date-day-month-year" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="ixv-18962"><span style="font-size: 10pt">15/01/2027</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c111" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" unitRef="usd" id="ixv-21762">264,008</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><ix:nonFraction contextRef="c113" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-21763">1.6</ix:nonFraction></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c114" decimals="-3" format="ixt:num-dot-decimal" name="iinn:WarrantsOutstanding" scale="3" unitRef="usd" id="ixv-21764">212,188</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonNumeric contextRef="c114" format="ixt:date-day-month-year" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="ixv-18978"><span style="font-size: 10pt">28/12/2028</span></ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c113" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" unitRef="usd" id="ixv-21765">131,555</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:WarrantsOutstanding" scale="3" unitRef="usd" id="ixv-21766">3,333,283</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" unitRef="usd" id="ixv-21767">4,799,470</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 161; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">In thousands $ (except share
and per share data)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9 - SHAREHOLDERS&#8217; EQUITY (DEFICIT) (Cont.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.8pt; text-align: justify"><b>C. Loss per share:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="ixv-21768">Loss per share has been calculated using the weighted
average number of shares in issue during the relevant financial periods, the weighted average number of equity shares in issue and profit
for the period as follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Loss for the period</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-21769">11,286</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-21770">14,976</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-21771">17,193</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Total number of Ordinary Shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-21772">15,652,176</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-21773">11,338,940</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-21774">10,091,706</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Weighted average number of Ordinary Shares</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-21775">12,095,477</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-21776">10,794,594</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-21777">5,306,225</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-102; -sec-ix-hidden: hidden-fact-101; -sec-ix-hidden: hidden-fact-100">Basic and diluted loss per share</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-21778">0.93</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-21779">1.39</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-21780">3.24</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="ixv-19126"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 10 - RESEARCH AND DEVELOPMENT EXPENSES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" id="ixv-19131"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Salary and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" unitRef="usd" id="ixv-21781">4,429</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" unitRef="usd" id="ixv-21782">3,458</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" unitRef="usd" id="ixv-21783">1,543</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Materials and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLaborRelatedExpenses" scale="3" unitRef="usd" id="ixv-21784">1,365</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLaborRelatedExpenses" scale="3" unitRef="usd" id="ixv-21785">1,082</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLaborRelatedExpenses" scale="3" unitRef="usd" id="ixv-21786">204</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Share based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" unitRef="shares" id="ixv-21787">663</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" unitRef="shares" id="ixv-21788">2,392</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" unitRef="shares" id="ixv-21789">1,792</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Subcontractors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:Subcontractors" scale="3" unitRef="usd" id="ixv-21790">304</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:Subcontractors" scale="3" unitRef="usd" id="ixv-21791">850</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="iinn:Subcontractors" scale="3" unitRef="usd" id="ixv-21792">496</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationNonproduction" scale="3" unitRef="usd" id="ixv-21793">291</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationNonproduction" scale="3" unitRef="usd" id="ixv-21794">188</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationNonproduction" scale="3" unitRef="usd" id="ixv-21795">94</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">IIA participation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForParticipationLiabilities" scale="3" unitRef="usd" id="ixv-21796">106</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-21797">268</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-21798">213</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-21799">47</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 4pt"><span style="font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-21800">7,320</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-21801">8,183</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-21802">4,070</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="iinn:SalesAndMarketingExpensesTextBlock" id="ixv-19281"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 11 - SALES AND MARKETING EXPENSES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock" id="ixv-19286"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Professionals&#8217; fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" unitRef="usd" id="ixv-21803">348</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" unitRef="usd" id="ixv-21804">527</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" unitRef="usd" id="ixv-21805">520</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="3" unitRef="usd" id="ixv-21806">248</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="3" unitRef="usd" id="ixv-21807">282</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="3" unitRef="usd" id="ixv-21808">220</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" unitRef="usd" id="ixv-21809">89</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" unitRef="usd" id="ixv-21810">503</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" unitRef="usd" id="ixv-21811">1,215</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherSellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-21812">61</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherSellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-21813">16</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherSellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-21814">25</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-21815">746</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-21816">1,328</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-21817">1,980</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 162; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">In thousands $ (except share
and per share data)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="iinn:GeneralAndAdministrativeExpensesTextBlock" id="ixv-19415"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 12 - GENERAL AND ADMINISTRATIVE EXPENSES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" id="ixv-19420"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Professional fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" unitRef="usd" id="ixv-21818">1,432</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c116" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" unitRef="usd" id="ixv-21819">1,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" unitRef="usd" id="ixv-21820">1,390</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="3" unitRef="usd" id="ixv-21821">766</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c116" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="3" unitRef="usd" id="ixv-21822">716</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="3" unitRef="usd" id="ixv-21823">545</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Director&#8217;s fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LegalFees" scale="3" unitRef="usd" id="ixv-21824">241</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c116" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LegalFees" scale="3" unitRef="usd" id="ixv-21825">239</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LegalFees" scale="3" unitRef="usd" id="ixv-21826">111</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Related NASDAQ IPO expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLaborRelatedExpenses" scale="3" unitRef="usd" id="ixv-21827">546</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Funds raising expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="iinn:FundsRaisingExpenses" scale="3" unitRef="usd" id="ixv-21828">260</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21829">675</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c116" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21830">1,984</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21831">3,696</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Insurance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralInsuranceExpense" scale="3" unitRef="usd" id="ixv-21832">300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c116" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralInsuranceExpense" scale="3" unitRef="usd" id="ixv-21833">557</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralInsuranceExpense" scale="3" unitRef="usd" id="ixv-21834">363</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostMaintenance" scale="3" unitRef="usd" id="ixv-21835">129</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c116" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostMaintenance" scale="3" unitRef="usd" id="ixv-21836">102</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostMaintenance" scale="3" unitRef="usd" id="ixv-21837">91</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-21838">115</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c116" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-21839">104</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-21840">84</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Travel abroad</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TravelAndEntertainmentExpense" scale="3" unitRef="usd" id="ixv-21841">100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c116" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TravelAndEntertainmentExpense" scale="3" unitRef="usd" id="ixv-21842">105</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TravelAndEntertainmentExpense" scale="3" unitRef="usd" id="ixv-21843">65</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralExpense" scale="3" unitRef="usd" id="ixv-21844">45</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c116" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralExpense" scale="3" unitRef="usd" id="ixv-21845">68</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralExpense" scale="3" unitRef="usd" id="ixv-21846">46</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 4pt"><span style="font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c115" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-21847">4,063</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c116" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-21848">5,375</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-21849">6,937</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock" id="ixv-19628"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 13 - FINANCIAL (INCOME) AND EXPENSES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="ixv-19633"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left">Revaluation of financial liabilities at fair value through profit or loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue" scale="3" unitRef="usd" id="ixv-21850">306</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue" scale="3" unitRef="usd" id="ixv-21851">108</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="iinn:EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue" scale="3" sign="-" unitRef="usd" id="ixv-21852">3,995</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Interest on financial liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancingInterestExpense" scale="3" unitRef="usd" id="ixv-21853">59</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Foreign currency transaction income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ForeignCurrencyTransactionsGainBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-21854">233</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ForeignCurrencyTransactionsGainBeforeTax" scale="3" unitRef="usd" id="ixv-21855">530</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ForeignCurrencyTransactionsGainBeforeTax" scale="3" unitRef="usd" id="ixv-21856">113</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Finance expense in respect of lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:FinanceLeaseInterestExpenses" scale="3" unitRef="usd" id="ixv-21857">143</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="iinn:FinanceLeaseInterestExpenses" scale="3" sign="-" unitRef="usd" id="ixv-21858">42</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-21859">10</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" unitRef="usd" id="ixv-21860">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-21861">21</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"><span style="font-size: 10pt"><b>Total</b> expenses (Income)</span></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:DisposalGroupIncludingDiscontinuedOperationsOtherIncome" scale="3" sign="-" unitRef="usd" id="ixv-21862">529</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:DisposalGroupIncludingDiscontinuedOperationsOtherIncome" scale="3" unitRef="usd" id="ixv-21863">275</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="iinn:DisposalGroupIncludingDiscontinuedOperationsOtherIncome" scale="3" unitRef="usd" id="ixv-21864">4,230</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-19755"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 14 - TAXES ON INCOME: </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>A.</b></td><td style="text-align: justify"><b>Taxes on income:</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">The Israeli corporate
tax rate was <ix:nonFraction contextRef="c118" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" unitRef="pure" id="ixv-21865"><ix:nonFraction contextRef="c119" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" unitRef="pure" id="ixv-21866">23</ix:nonFraction></ix:nonFraction>% in 2023 and 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>B.</b></td><td style="text-align: justify"><b>Net operating losses carry forwards</b>:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Carryforward tax losses of the Company
as of December 31, 2023, amounted to approximately $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-21867">24,000</ix:nonFraction>; however, a full valuation allowance of $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" unitRef="usd" id="ixv-21868">7,000</ix:nonFraction> was recorded against the potential
future tax benefits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 163; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">In thousands $ (except share
and per share data)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 14 - TAXES ON INCOME: (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-21869">The deferred tax assets and liabilities
are composed of the following:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:continuation id="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net operating loss carryforward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-21870">5,519</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-21871">3,324</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-21872">80</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-21873">66</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">R&amp;D capitalization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" scale="3" unitRef="usd" id="ixv-21874">1,335</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" scale="3" unitRef="usd" id="ixv-21875">1,005</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Fund raising costs 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:DeferredTaxAssetsFundRaisingCosts2021" scale="3" unitRef="usd" id="ixv-21876">275</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fund raising costs 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:DeferredTaxAssetsFundRaisingCost2023" scale="3" unitRef="usd" id="ixv-21877">70</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd" id="ixv-21878">8</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-21879">7,012</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-21880">4,670</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:DeferredTaxAssetValuationAllowance" scale="3" unitRef="usd" id="ixv-21881">7,012</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:DeferredTaxAssetValuationAllowance" scale="3" sign="-" unitRef="usd" id="ixv-21882">4,670</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net deferred taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>C.</b></td><td style="text-align: justify"><b>Theoretical tax:</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfTheoreticalTaxTableTextBlock" id="ixv-19959"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left">Loss before taxation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-21883">11,286</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-21884">14,976</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-21885">17,193</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Theoretical tax credit at applicable statutory rate: <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-21886"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-21887"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-21888">23</ix:nonFraction></ix:nonFraction></ix:nonFraction>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" unitRef="usd" id="ixv-21889">2,596</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" unitRef="usd" id="ixv-21890">3,444</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" unitRef="usd" id="ixv-21891">3,954</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Non-allowable expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" sign="-" unitRef="usd" id="ixv-21892">244</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" sign="-" unitRef="usd" id="ixv-21893">1,026</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" sign="-" unitRef="usd" id="ixv-21894">1,527</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Temporary differences and tax losses for which no Deferred Tax Asset is recognized</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" scale="3" sign="-" unitRef="usd" id="ixv-21895">2,352</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" scale="3" sign="-" unitRef="usd" id="ixv-21896">2,418</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" scale="3" sign="-" unitRef="usd" id="ixv-21897">2,427</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Income tax benefit</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 164; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">In thousands $ (except share
and per share data)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-20087"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 15 - SHARE-BASED PAYMENT:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the Company established a share
option plan (the &#8220;2019 Plan&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The options to employees are granted under Section
102 of the Israeli Tax Ordinance, which enables the employee to pay a <ix:nonFraction contextRef="c120" decimals="2" format="ixt:num-dot-decimal" name="iinn:CapitalGainTaxRate" scale="-2" unitRef="pure" id="ixv-21898">25</ix:nonFraction>% capital gain tax upon exercise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company makes awards of options and restricted
shares under the 2019 Plan, which may be issued at the discretion of the Board of Directors from time to time. Under this 2019 Plan, each
option or RSU is exercisable into one Ordinary Share of the Company. The options may be exercised after vesting and in accordance with
vesting schedules which will be determined by the Board of Directors for each grant. The maximum term of the options issuable under the
2019 Plan is <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="iinn:OptionsIssuableTerm" id="ixv-21899">10</ix:nonNumeric> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following are the significant stock options
and RSUs transactions with employees, Board of Directors members and non-employees made during the year ended December 31, 2021 and the
year ended December 31, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 21, 2021, the Company&#8217;s Board
of Directors approved a grant of non-tradable shares options to purchase <ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-21900">13,605</ix:nonFraction> Ordinary Shares and share options to purchase <ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-21901">21,768</ix:nonFraction> Ordinary
Shares. The vesting period is <ix:nonNumeric contextRef="c123" format="ixt-sec:durwordsen" name="iinn:ShareOptionsVestingPeriod" id="ixv-21902">three years</ix:nonNumeric> commencing on the grant date. The exercise price per share was NIS <ix:nonFraction contextRef="c122" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21903">0.37</ix:nonFraction>($<ix:nonFraction contextRef="c124" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-21904"><ix:nonFraction contextRef="c125" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-21905">0.12</ix:nonFraction></ix:nonFraction>). The contractual
life of the options under the 2019 Plan is <ix:nonNumeric contextRef="c125" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="ixv-21906">ten years</ix:nonNumeric>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 16, 2021, the Company&#8217;s Board of
Directors approved a grant of <ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-21907">81,633</ix:nonFraction> non-tradable shares options to purchase up to <ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-21908">81,633</ix:nonFraction> Ordinary Shares to a director. The share options
vesting period is up to <ix:nonNumeric contextRef="c128" format="ixt-sec:durwordsen" name="iinn:ShareOptionsVestingPeriod" id="ixv-21909">three years</ix:nonNumeric> from the grant date. The exercise price per share was NIS <ix:nonFraction contextRef="c129" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21910">0.37</ix:nonFraction> ($<ix:nonFraction contextRef="c130" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-21911">0.12</ix:nonFraction>). The contractual life of the
options under the 2019 Plan is <ix:nonNumeric contextRef="c131" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="ixv-21912">ten years</ix:nonNumeric>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 12, 2021, the Company&#8217;s Board
of Directors resolved to increase the pool of options available under the Plan to <ix:nonFraction contextRef="c132" decimals="2" format="ixt:num-dot-decimal" name="iinn:EquityPercentage" scale="-2" unitRef="pure" id="ixv-21913">25</ix:nonFraction>% of the Company&#8217;s equity, on a fully diluted
basis. As a result of the increase, the number of authorized Ordinary Shares available pursuant the 2019 Plan was <ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" scale="0" unitRef="shares" id="ixv-21914">4,180,898</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">On November 2, 2021, the Company&#8217;s Board of Directors approved
a grant of <ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-21915">2,658,188</ix:nonFraction> RSUs to employees and officers. The RSUs represents the right to receive Ordinary Shares at a future time and vest
over a period of <ix:nonNumeric contextRef="c134" format="ixt-sec:durwordsen" name="iinn:RSUsVestPeriod" id="ixv-21916">three years</ix:nonNumeric>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 2, 2021, the Company&#8217;s Board
of Directors approved a grant of <ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-21917">10,000</ix:nonFraction> RSUs to the Company&#8217;s advisory board. The RSUs vest over a period of <ix:nonNumeric contextRef="c136" format="ixt-sec:durwordsen" name="iinn:RSUsVestPeriod" id="ixv-21918">three years</ix:nonNumeric>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 24, 2022, the Company&#8217;s Board of directors approved
a grant of <ix:nonFraction contextRef="c137" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-21919">536,141</ix:nonFraction> RSUs to employees and a grant of <ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-21920">22,500</ix:nonFraction> RSUs to the Company&#8217;s advisory board members and an additional consultant.
The RSUs represent the right to receive Ordinary Shares at a future time. <ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-21921">555,500</ix:nonFraction> of the RSUs in this grant, vest over a period of <ix:nonNumeric contextRef="c140" format="ixt-sec:durwordsen" name="iinn:RSUsVestPeriod" id="ixv-21922">three
years</ix:nonNumeric>, with a 1-year cliff period, and <ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-21923">3,141</ix:nonFraction> RSUs vested immediately on the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 24, 2022, the Company&#8217;s Board of
Directors approved a grant of <ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-21924">29,400</ix:nonFraction> Ordinary Shares options to medical board members, which are exercisable to <ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-21925">29,400</ix:nonFraction> Ordinary Shares.
The share options vesting period is up to three years from the grant date. The exercise price per share was NIS <ix:nonFraction contextRef="c143" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21926">10.84</ix:nonFraction> ($<ix:nonFraction contextRef="c143" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-21927">3.08</ix:nonFraction>). The contractual
life of the options under the 2019 Plan is <ix:nonNumeric contextRef="c144" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="ixv-21928">ten years</ix:nonNumeric>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.2pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 6, 2022, the Company&#8217;s Board of Directors approved a
grant of <ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-21929">285,713</ix:nonFraction> fully vested RSUs to an officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 19, 2022, the Company&#8217;s Board of Directors approved a
grant of <ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-21930">30,000</ix:nonFraction> RSUs to an employee. The RSUs vest over a period of <ix:nonNumeric contextRef="c147" format="ixt-sec:durwordsen" name="iinn:RSUsVestPeriod" id="ixv-21931">three years</ix:nonNumeric>, with a 1-year cliff period, commencing on the grant date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 165; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">In thousands $ (except share
and per share data)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 15 - SHARE-BASED PAYMENT (Cont.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">On November 22, 2022, the Company&#8217;s Board of Directors approved
a grant of <ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-21932">165,000</ix:nonFraction> RSUs to employees. The RSUs vest over a period of <ix:nonNumeric contextRef="c149" format="ixt-sec:durwordsen" name="iinn:RSUsVestPeriod" id="ixv-21933">three years</ix:nonNumeric>, with a 1-year cliff period, commencing on the grant
date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There was no grant of options or restricted shares during the year
period ended December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of all granted options was estimated
by using the Black Scholes model, which was aimed to model the value of the Company&#8217;s assets over time. The simulation approach
was designed to take into account the terms and conditions of the share options, as well as the capital structure of the Company and the
volatility of its assets, on the date of grant based on certain assumptions. Those conditions are, among others:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(i)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The expected volatility is
between <ix:nonFraction contextRef="c67" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" unitRef="pure" id="ixv-21934">50</ix:nonFraction>%-<ix:nonFraction contextRef="c150" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" unitRef="pure" id="ixv-21935">52.4</ix:nonFraction>%</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(ii)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The dividend rate <ix:nonFraction contextRef="c151" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-21936">0</ix:nonFraction>%; and</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt">(iii)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Expected term &#8211; <ix:nonNumeric contextRef="c151" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-21937">three years</ix:nonNumeric>.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The valuation was completed with the assistance
of an independent valuator based on management&#8217;s assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">During the year ended December 31, 2023, the Company recorded share-based
payment expenses to employees, directors and subcontractors in the amount of $<ix:nonFraction contextRef="c152" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21938">1,427</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">During the year ended December 31, 2022, the Company recorded share-based
payment expenses to employees, directors and subcontractors in the amount of $<ix:nonFraction contextRef="c153" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21939">4,879</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">During the year ended December 31, 2021, the Company recorded share-based
payment expenses to employees, directors and subcontractors in the amount of $<ix:nonFraction contextRef="c154" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21940">6,703</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-21941">The options to services providers and advisers outstanding as
of December 31, 2023, December 31, 2022 and December 31, 2021 were as&#160;follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_2" id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/>
 December&#160;31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended <br/>
December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/>
 December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average Exercise price NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average Exercise price NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>&#160;Number of options</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>&#160;Weighted average Exercise price NIS</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c155" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-21942">114,512</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c155" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21943">3.058</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c156" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-21944">87,833</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c156" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21945">0.37</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c157" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-21946">165,987</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c157" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21947">0.37</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Reclassified to employees and directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c160" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors" scale="0" sign="-" unitRef="shares" id="ixv-21948">71,260</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors" scale="0" unitRef="ilsPershares" id="ixv-21949">0.37</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c159" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-21950">29,400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c159" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21951">10.84</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c160" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-21952">16,326</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21953">0.37</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c161" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers" scale="0" unitRef="shares" id="ixv-21954">9,401</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c158" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21955">0.367</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c155" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers" scale="0" sign="-" unitRef="shares" id="ixv-21956">2,721</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c159" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21957">0.37</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c156" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers" scale="0" sign="-" unitRef="shares" id="ixv-21958">20,086</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21959">0.37</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c160" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod" scale="0" sign="-" unitRef="shares" id="ixv-21960">3,134</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21961">0.37</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Options outstanding</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c161" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-21962">105,111</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c161" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21963">4.085</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c155" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-21964">114,512</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c155" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21965">3.058</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c156" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-21966">87,833</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c156" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21967">0.37</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Options exercisable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c161" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-21968">94,242</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c161" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21969">3.267</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c155" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-21970">82,257</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c155" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21971">0.71</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c156" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-21972">62,715</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c156" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21973">0.37</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Share-based payment expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c158" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21974">19</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c159" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21975">54</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c160" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21976">279</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 166; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">In thousands $ (except share
and per share data)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 15 - SHARE-BASED PAYMENT (Cont.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="ixv-21977">The RSUs to services providers and advisers outstanding as of December
31, 2023, December 31, 2022 and December 31, 2021 were as&#160;follows:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock-c0_cont_2" id="_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/>
 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/>
2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/>
 2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c169" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-21978">18,266</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c170" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-21979">10,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c173" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-21980">22,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c174" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-21981">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c172" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-21982">10,833</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c173" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-21983">14,234</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">RSUs outstanding</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c175" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-21984">7,433</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c169" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-21985">18,266</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c170" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-21986">10,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">RSU&#8217;s Vested</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c172" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" scale="0" unitRef="shares" id="ixv-21987">25,067</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c173" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" scale="0" unitRef="shares" id="ixv-21988">14,234</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Share-based payment expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c172" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21989">9</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c173" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21990">33</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c174" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21991">16</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:continuation continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_3" id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_2">The options to employees and directors outstanding as of December 31,
2023, December 31, 2022 and December 31, 2021 were as&#160;follows:</ix:continuation></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year ended<br/>
 December 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year ended<br/>
 December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year ended<br/>
 December 31, 2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of options</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted average Exercise price NIS</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of options</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted average Exercise price NIS</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>&#160;Number of options</b></span></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>&#160;Weighted average Exercise price NIS</b></span></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c162" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-21993">386,260</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c162" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21994">0.37</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c163" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-21995">448,120</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c163" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21996">0.37</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c164" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-21997">296,038</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c164" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21998">0.37</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Reclassified to employees and directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c166" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors" scale="0" unitRef="shares" id="ixv-21999">71,260</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c166" decimals="2" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors" scale="0" unitRef="ilsPershares" id="ixv-22000">0.37</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c166" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-22001">95,238</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c166" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-22002">0.37</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c162" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers" scale="0" unitRef="shares" id="ixv-22003">4,309</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c168" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-22004">0.37</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c163" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers" scale="0" sign="-" unitRef="shares" id="ixv-22005">4,544</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c166" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-22006">0.37</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c165" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod" scale="0" unitRef="shares" id="ixv-22007">28,571</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c165" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-22008">0.37</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c168" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod" scale="0" unitRef="shares" id="ixv-22009">57,551</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c168" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-22010">0.37</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c166" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod" scale="0" sign="-" unitRef="shares" id="ixv-22011">9,872</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c166" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-22012">0.37</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Options outstanding</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c167" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-22013">357,689</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c167" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-22014">0.37</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c162" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-22015">386,260</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c162" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-22016">0.37</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c163" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-22017">448,120</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c163" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-22018">0.37</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Options exercisable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c167" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-22019">350,131</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c167" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-22020">0.37</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c162" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-22021">342,757</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c162" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-22022">0.37</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c163" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-22023">347,069</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c163" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-22024">0.37</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Share-based payment expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c165" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-22025">47</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c168" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-22026">174</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c166" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-22027">394</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><ix:continuation continuedAt="_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock-c0_cont_3" id="_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock-c0_cont_2">The RSUs to employees and directors outstanding as of December 31,
2023, December 31, 2022 and December 31, 2021 were as&#160;follows:</ix:continuation></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/>
 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/>
 2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/>
 2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at beginning of year</td><td>&#160;</td>
    <td colspan="2" style="text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-22029">1,727,842</ix:nonFraction></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-22030">2,002,587</ix:nonFraction></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 64%">Granted</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-22031">1,016,854</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-22032">2,658,188</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" unitRef="shares" id="ixv-22033">67,087</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" unitRef="shares" id="ixv-22034">65,626</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-22035">1,215,615</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-22036">1,225,973</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-22037">655,601</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">RSUs outstanding</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-22038">445,140</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-22039">1,727,842</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-22040">2,002,587</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">RSU&#8217;s Vested</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" scale="0" unitRef="shares" id="ixv-22041">3,097,189</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" scale="0" unitRef="shares" id="ixv-22042">1,881,574</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" scale="0" unitRef="shares" id="ixv-22043">655,601</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Share-based payment expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-22044">1,352</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-22045">4,618</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-22046">6,014</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>


</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>



</div><p style="margin-top: 0; margin-bottom: 0"></p><div>




</div><!-- Field: Page; Sequence: 167; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">In thousands $ (except share
and per share data)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-21049"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 16 - RELATED PARTIES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The following transactions arose with related parties:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Transactions and balances with related parties</span><b>:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">1.</span></td><td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="ixv-21067"><span style="font-size: 10pt"><span style="text-decoration:underline">Shareholders and other related
parties&#8217; benefits</span></span></ix:nonNumeric></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Salary and related expenses &#8211; officers and directors</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c176" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="3" unitRef="usd" id="ixv-22047">1,761</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c177" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="3" unitRef="usd" id="ixv-22048">1,923</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c178" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="3" unitRef="usd" id="ixv-22049">1,042</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share based payment &#8211; officers and directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c176" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-22050">1,009</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c177" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-22051">3,745</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c178" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-22052">5,876</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">2.</span></td><td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="iinn_ScheduleOfBalanceWithRelatedPartiesTableTextBlock-c0_cont_1" escape="true" name="iinn:ScheduleOfBalanceWithRelatedPartiesTableTextBlock" id="ixv-21122"><span style="font-size: 10pt"><span style="text-decoration:underline">Balances with related parties</span></span></ix:nonNumeric></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="iinn_ScheduleOfBalanceWithRelatedPartiesTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nature of transaction</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 11%; text-align: left">Officers</td><td style="width: 1%">&#160;</td>
    <td style="width: 64%; text-align: left"><ix:nonNumeric contextRef="c179" name="us-gaap:UnusualOrInfrequentItemNatureOfEventOrTransaction" id="ixv-22053">Salaries and related</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c179" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" unitRef="usd" id="ixv-22054">314</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c180" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" unitRef="usd" id="ixv-22055">292</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Directors</td><td>&#160;</td>
    <td style="text-align: left"><ix:nonNumeric contextRef="c181" name="us-gaap:UnusualOrInfrequentItemNatureOfEventOrTransaction" id="ixv-22056">Compensation for directors</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c181" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" unitRef="usd" id="ixv-22057">40</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c182" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" unitRef="usd" id="ixv-22058">40</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-21167"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 17 - SUBSEQUENT EVENTS:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 22, 2024, the Company&#8217;s Board of Directors
approved a grant of <ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-22059">320,000</ix:nonFraction> RSUs to employees and options to purchase an aggregate of <ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" unitRef="shares" id="ixv-22060">80,000</ix:nonFraction> Ordinary Shares to service providers under
the 2019 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date these Financial Statements, options
to purchase <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" unitRef="shares" id="ixv-22061">40,499</ix:nonFraction> Ordinary Shares are vested and <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-22062">133,329</ix:nonFraction> of the RSUs are vested and their underlying shares were issued immediately after
the grant approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 5, 2024, the Company&#8217;s Board
of Directors approved a grant of <ix:nonFraction contextRef="c185" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-22063">517,000</ix:nonFraction> RSUs to executives. <span style="-sec-ix-hidden: hidden-fact-144">None</span> of the total amount of RSUs are vested as of the date these Financial
Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 27, 2024, the Company&#8217;s Board of Directors
approved the issuance of warrants to purchase up to <ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" unitRef="shares" id="ixv-22064">220,000</ix:nonFraction> Ordinary Shares to a service provider in connection with certain investor
relations services. The warrants have a term of 6 months commencing on May 20, 2024, and an exercise price of $<ix:nonFraction contextRef="c187" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-22065">2.25</ix:nonFraction> per share. The warrants
will be forfeited in the event the Company terminates the service provider agreement.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-35</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c4" id="hidden-fact-0" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-2" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-3" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-4" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-5" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.93</ix:nonFraction>
<ix:nonFraction contextRef="c6" decimals="2" id="hidden-fact-6" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">1.39</ix:nonFraction>
<ix:nonFraction contextRef="c7" decimals="2" id="hidden-fact-7" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">3.24</ix:nonFraction>
<ix:nonFraction contextRef="c6" decimals="INF" id="hidden-fact-8" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">10794594</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="INF" id="hidden-fact-9" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">12095477</ix:nonFraction>
<ix:nonFraction contextRef="c7" decimals="INF" id="hidden-fact-10" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">5306225</ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-11" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-12" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-13" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-14" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-15" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-16" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-17" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-18" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-19" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-20" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-21" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-22" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-23" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-24" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-25" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-26" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-27" name="iinn:StockIssuedDuringPeriodValueParValueCancellation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-28" name="iinn:StockIssuedDuringPeriodValueParValueCancellation" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c28" id="hidden-fact-29" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-30" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c28" id="hidden-fact-31" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-32" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c28" id="hidden-fact-33" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-34" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c28" id="hidden-fact-35" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c29" id="hidden-fact-36" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-37" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-38" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c28" id="hidden-fact-39" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c29" id="hidden-fact-40" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-41" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-42" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c28" id="hidden-fact-43" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-44" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c17" id="hidden-fact-45" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-46" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-47" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-48" name="iinn:RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-49" name="iinn:RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-50" name="us-gaap:AmortizationOfFinancingCosts" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-51" name="us-gaap:AmortizationOfFinancingCosts" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-52" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-53" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-54" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-55" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-56" name="iinn:ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-57" name="iinn:ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-58" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-59" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-60" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-61" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-62" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-63" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-64" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-65" name="iinn:IssuanceOfOrdinarySharesissuancesPursuantToATM" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-66" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-67" name="us-gaap:ConversionOfStockAmountIssued1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-68" name="us-gaap:ConversionOfStockAmountIssued1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-69" name="iinn:TradableWarrantsFinancialLiabilityAtIPO" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-70" name="iinn:TradableWarrantsFinancialLiabilityAtIPO" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-71" name="iinn:ShareBasedCompensationUnderwritersFeesAtIPO" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-72" name="iinn:ShareBasedCompensationUnderwritersFeesAtIPO" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-73" name="iinn:ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-74" name="iinn:ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-75" name="us-gaap:OtherShortTermBorrowings" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-76" name="iinn:ForeignExchangeReserve" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-77" name="us-gaap:OtherOperatingIncomeExpenseNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-78" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-79" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-80" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-81" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-82" name="us-gaap:OtherOperatingIncomeExpenseNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-83" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-84" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-85" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c52" id="hidden-fact-86" name="us-gaap:PropertyPlantAndEquipmentAdditions" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c77" id="hidden-fact-87" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c104" id="hidden-fact-88" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c104" id="hidden-fact-89" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonNumeric contextRef="c104" id="hidden-fact-90" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" xsi:nil="true"/>
<ix:nonFraction contextRef="c104" id="hidden-fact-91" name="iinn:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c104" id="hidden-fact-92" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c104" id="hidden-fact-93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonNumeric contextRef="c104" id="hidden-fact-94" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerms" xsi:nil="true"/>
<ix:nonFraction contextRef="c104" id="hidden-fact-95" name="iinn:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c104" id="hidden-fact-96" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c104" id="hidden-fact-97" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonNumeric contextRef="c104" id="hidden-fact-98" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" xsi:nil="true"/>
<ix:nonFraction contextRef="c104" id="hidden-fact-99" name="iinn:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-100" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.93</ix:nonFraction>
<ix:nonFraction contextRef="c6" decimals="2" id="hidden-fact-101" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">1.39</ix:nonFraction>
<ix:nonFraction contextRef="c7" decimals="2" id="hidden-fact-102" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">3.24</ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-103" name="us-gaap:PaymentsForParticipationLiabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-104" name="us-gaap:PaymentsForParticipationLiabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c115" id="hidden-fact-105" name="us-gaap:OtherLaborRelatedExpenses" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c116" id="hidden-fact-106" name="us-gaap:OtherLaborRelatedExpenses" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c116" id="hidden-fact-107" name="iinn:FundsRaisingExpenses" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c117" id="hidden-fact-108" name="iinn:FundsRaisingExpenses" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-109" name="us-gaap:FinancingInterestExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-110" name="iinn:FinanceLeaseInterestExpenses" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-111" name="iinn:DeferredTaxAssetsFundRaisingCosts2021" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-112" name="iinn:DeferredTaxAssetsFundRaisingCost2023" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-113" name="us-gaap:OperatingLeasePayments" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-114" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-115" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-116" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-117" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-118" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-119" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-120" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c158" id="hidden-fact-121" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c158" id="hidden-fact-122" name="iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors" unitRef="ilsPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c159" id="hidden-fact-123" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c159" id="hidden-fact-124" name="iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors" unitRef="ilsPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c158" id="hidden-fact-125" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c158" id="hidden-fact-126" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="ilsPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c158" id="hidden-fact-127" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c158" id="hidden-fact-128" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="ilsPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c159" id="hidden-fact-129" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c159" id="hidden-fact-130" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="ilsPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c165" id="hidden-fact-131" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c165" id="hidden-fact-132" name="iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors" unitRef="ilsPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c165" id="hidden-fact-133" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c165" id="hidden-fact-134" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="ilsPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c167" id="hidden-fact-135" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c165" id="hidden-fact-136" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="ilsPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c171" id="hidden-fact-137" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c172" id="hidden-fact-138" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c174" id="hidden-fact-139" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c174" id="hidden-fact-140" name="iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c27" id="hidden-fact-141" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-142" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-143" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c186" id="hidden-fact-144" name="iinn:RestrictedStockUnits" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-22213">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-22214">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentPeriodStartDate" id="ixv-22215">2023-01-01</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-22216">0001837493</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="iinn-20231231.xsd" xlink:type="simple"/></ix:references>
<ix:resources><ix:relationship fromRefs="hidden-fact-19 hidden-fact-39" toRefs="ix_0_footnote"/>
<ix:relationship fromRefs="ix_0_fact" toRefs="ix_1_footnote"/>
<xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iinn:OrdinarySharesNoParValueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iinn:WarrantsToPurchaseOrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-26</xbrli:startDate>
    <xbrli:endDate>2023-12-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">iinn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:DevelopmentEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:DepositsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:DevelopmentEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:DevelopmentEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:DevelopmentEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:DevelopmentEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-09-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-31</xbrli:startDate>
    <xbrli:endDate>2023-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-01</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:PrivateWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">iinn:NonTradableWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">iinn:NonTradableWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-01</xbrli:startDate>
    <xbrli:endDate>2021-03-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-18</xbrli:startDate>
    <xbrli:endDate>2021-03-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrarGpi3WKEtaAw66u01Fz01dWXY8Co/0nt/EYPpxJQpmucNPntkKGDUIzqiVXTghuh97D+3HoPuNe26jHPIaw4lyMqYvKxFlhkbYBWIUcgKRoJ/travtspQtU2Bzfjb2zOjTVkVWS8tD/cenVlshsSuvI61kcurHTnf7bi/aiMvKs5kJ2lHUdB1A51Zvlxfi4hXCDE5TwMWPCsMitxojF1/teoN1QVVrLG9prqaFuEyJyEvdkwXe8IV] CSR-->
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-06-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-16</xbrli:startDate>
    <xbrli:endDate>2021-07-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-16</xbrli:startDate>
    <xbrli:endDate>2021-07-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">iinn:BrokersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">iinn:ExercisePrice55Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">iinn:ExercisePrice55Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">iinn:ExercisePrice55OneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">iinn:ExercisePrice55OneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">iinn:ExercisePrice55TwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">iinn:ExercisePrice55TwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">iinn:Exercise6875Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">iinn:Exercise6875Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">iinn:Exercise16Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">iinn:Exercise16Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-12-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:NonTradableSharesOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-21</xbrli:startDate>
    <xbrli:endDate>2021-02-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-21</xbrli:startDate>
    <xbrli:endDate>2021-02-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-02-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-02-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-21</xbrli:startDate>
    <xbrli:endDate>2021-02-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:NonTradableSharesOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:NonTradableSharesOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-16</xbrli:startDate>
    <xbrli:endDate>2021-05-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-16</xbrli:startDate>
    <xbrli:endDate>2021-05-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-16</xbrli:startDate>
    <xbrli:endDate>2021-05-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iinn:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-16</xbrli:startDate>
    <xbrli:endDate>2021-05-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-08-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-08-12</xbrli:startDate>
    <xbrli:endDate>2021-08-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-11-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-11-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-11-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:AdvisoryBoardMembersMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-24</xbrli:startDate>
    <xbrli:endDate>2022-03-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-24</xbrli:startDate>
    <xbrli:endDate>2022-03-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iinn:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-24</xbrli:startDate>
    <xbrli:endDate>2022-03-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-04-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-11-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-11-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:EmployeesDirectorsAndSubcontractorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:EmployeesDirectorsAndSubcontractorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:EmployeesDirectorsAndSubcontractorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:OfficersAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:OfficersAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:OfficersAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-22</xbrli:startDate>
    <xbrli:endDate>2024-01-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-05</xbrli:startDate>
    <xbrli:endDate>2024-02-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-27</xbrli:startDate>
    <xbrli:endDate>2024-02-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="ils">
  <xbrli:measure>iso4217:ILS</xbrli:measure>
</xbrli:unit><xbrli:unit id="ilsPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:ILS</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>ea020216701ex2-1_inspira.htm
<DESCRIPTION>DESCRIPTION OF SECURITIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 2.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Description of Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description
of the share capital of Inspira Technologies Oxy B.H.N. Ltd. (the &ldquo;Company&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo; or &ldquo;our&rdquo;),
provisions of the Company&rsquo;s articles of association<FONT STYLE="background-color: white">, as they may be amended and restated from
time to time </FONT>(our &ldquo;Articles<FONT STYLE="background-color: white">&rdquo;), and Israeli law</FONT> are summaries and do not
purport to be complete, and is qualified in its entirety by reference to, the provisions of our Articles as well as the Israeli law and
any other documents referenced in the summary and from which the summary is derived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As
of March 22, 2024, our authorized share capital consisted of 100,000,000 Ordinary Shares, no par value (&ldquo;Ordinary Shares&rdquo;),
of which 15,948,100 Ordinary Shares were issued and outstanding as of such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 22, 2024, we had
issued and outstanding warrants to purchase up to 1,640,455 of our Ordinary Shares issued in our initial public offering (the &ldquo;IPO
Warrants&rdquo;). Each IPO Warrant is exercisable for one Ordinary Share at an exercise price of $5.50 per share and expires five years
from the date of issuance, or July 16, 2026, and underwriter warrants to purchase up to an aggregate of 145,455 Ordinary Shares at an
exercise price of $6.875 per share, which expire five and half years from the date of issuance, or January 15, 2027, issued to Aegis Capital
in connection with our initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 22, 2024, we also had issued and outstanding warrants to purchase up to 1,335,185 Ordinary Shares issued in connection with
the termination of an investment agreement, certain other Simple Agreements for Future Equity (&ldquo;SAFEs,&rdquo;) and a convertible
loan, and their promoters in connection with such SAFEs and convertible loan (the &ldquo;Pre-IPO Warrants&rdquo;). Each Pre-IPO Warrant
is exercisable for one Ordinary Share at an exercise price of $5.50 per share, and expire three years from the date of issuance, or July
15, 2024, with respect to Pre-IPO Warrants to purchase up to 1,057,350 Ordinary Shares and the remainder of which expire four years from
the date of issuance, or July 15, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 22, 2024, we also had issued and outstanding warrants to purchase up to an aggregate
of 3,031,250 Ordinary Shares at an exercise price of $1.28 per share, which expire three and a half years following their date of issuance,
or June 28, 2027, issued to an institutional investor. In addition, we had issued and outstanding placement agent warrants to purchase
up to an aggregate of 212,188 Ordinary Shares at an exercise price of $1.60 per share, which expire three and a half years following their
date of issuance, or June 28, 2027, issued to H.C. Wainwright &amp; Co., LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 22, 2024, we had outstanding options to purchase
up to an aggregate of 542,800 Ordinary Shares and 993,650 unvested Restricted Share Units issued to certain employees, directors, consultants
and service providers who are our employees, officers, directors or consultants under our 2019 Equity Incentive Plan, which was amended
in September 2021 (the &ldquo;Plan&rdquo;). An additional 2,080,670 Ordinary Shares are reserved for future issuance of options or other
equity awards under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Name of Exchange on which Registered</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Ordinary Shares have been
listed on the Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;IINN&rdquo; since July 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our IPO Warrants have been
listed on Nasdaq under the symbol &ldquo;IINNW&rdquo; since July 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer of Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No transfer of shares may
be registered unless a proper writing or instrument of transfer (in any customary form or any other form satisfactory to the board of
directors (the &ldquo;Board of Directors&rdquo;)) has been submitted to the Company (or its transfer agent), together with any share certificate(s)
and such other evidence of title as the Board of Directors may reasonably require. The Board of Directors, may, from time to time, prescribe
a fee for the registration of a transfer, and may approve other methods of recognizing the transfer of shares in order to facilitate the
trading of the Company&rsquo;s shares on the Nasdaq or on any other stock exchange on which the Company&rsquo;s shares are then listed
for trading. The ownership or voting of our Ordinary Shares by non-residents of Israel is not restricted in any way by our Articles or
the laws of the State of Israel, except for ownership by nationals of certain countries that are, or have been, in a state of war with
Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Liability to Further Capital Calls</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors may
make, from time to time, such calls as it may deem fit upon shareholders with respect to any sum unpaid with respect to shares held by
such shareholders which is not payable at a fixed time. Such shareholder has to pay the amount of every call so made upon him or her.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Election of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our Articles, our Board
of Directors must consist of at least three (3) and not more than twelve (12) directors, including two external directors, if applicable,
which will be elected if and when required under the Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than external directors,
if applicable (who shall be elected and serve in office in strict accordance with the provisions of the Companies Law), directors of the
Company shall be elected solely at an Annual General Meeting and shall serve in their office until the next Annual General Meeting, or
until they cease to serve in their office in accordance with the provisions of the Articles or any law, whichever is earlier. Prior to
every Annual General Meeting of the Company, and subject to clause 39 (a) and (f) of the Articles, the Board of Directors (or a committee
thereof) shall select, by a resolution adopted by a majority of the Board of Directors (or such committee), a number of persons to be
proposed to the shareholders for election as Directors at such Annual General Meeting.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if a director&rsquo;s
office becomes vacant, the remaining serving directors may continue to act in any manner, provided that the number of the serving directors
shall not be less than three (3). If the number of serving Directors is lower than their minimal one, the Board shall not be permitted
to act, they may only act in an emergency or to fill the office of director which has become vacant up to a number equal to the minimum
number provided for pursuant to the Articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">External directors, if applicable,
are elected for an initial term of three years, and may be elected thereafter for up to two additional three-year terms under certain
circumstances, and may be removed from office pursuant to the terms of the Companies Law. Under certain circumstances, the term of office
for external directors for Israeli companies traded on certain foreign stock exchanges, including the Nasdaq Stock Market, may be extended
indefinitely in increments of additional three-year terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dividend Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors may
from time to time declare, and cause the Company to pay, such dividend as may appear to the Board of Directors to be justified by the
profits of the Company and as permitted by the Companies Law. The Board of Directors shall determine the time for payment of such dividends
and the record date for determining the shareholders entitled thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Companies
Law, the distribution amount is limited to the greater of retained earnings or earnings generated over the previous two years, according
to our then last reviewed or audited consolidated financial statements, provided that the date of the financial statements is not more
than six months prior to the date of the distribution, or we may distribute dividends that do not meet such criteria only with Israeli
court approval. In each case, we are only permitted to distribute a dividend if our Board of Directors and the court, if applicable, determines
that there is no reasonable concern that payment of the dividend will prevent us from satisfying our existing and foreseeable obligations
as they become due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Shareholder Meetings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, we
are required to hold an annual general meeting of our shareholders once every calendar year that must be held no later than 15 months
after the date of the previous annual general meeting. All general meetings other than the annual meeting of shareholders are referred
to in our Articles as special meetings. Our Board of Directors may call special meetings whenever it sees fit, at such time and place,
within or outside of Israel, as it may determine. In addition, the Companies Law provides that our Board of Directors is required to convene
a special meeting upon the written request of (i) any two of our directors or one-quarter of the members of our Board of Directors or
(ii) one or more shareholders holding, in the aggregate, either (a) 5% or more of our outstanding issued shares and 1% or more of our
outstanding voting power or (b) 5% or more of our outstanding voting power (the &ldquo;<B>Non Exempted Holding</B>&rdquo;), However, under
a new exemption applicable as of March 12, 2024, the Board of Directors of an Israeli company whose shares are listed outside of Israel,
shall convene a special meeting at the request of one or more shareholders holding at least ten percent (10%) of the issued and outstanding
share capital instead of five (5%) in the past, and at least one percent (1%) of the voting rights in the company, or one or more shareholders
holding at least ten percent (10%) of the voting rights in the company, provided that if the applicable law to companies incorporated
in the country which the company is listed for trade, establishes a right to demand convening of such a meeting for those holding a percentage
of holdings lower than ten percent (10%), then the Non Exempted Holding shall apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, one
or more shareholders holding at least 1% of the voting rights at the general meeting may request that the Board of Directors include a
matter in the agenda of a general meeting to be convened in the future, provided that it is appropriate to discuss such a matter at the
general meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the provisions
of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are
the shareholders of record on a date to be decided by the Board, which according to the Companies Law may be between four and sixty days
prior to the date of the meeting, as applicable according to the matters on the general meeting agenda. According to the Companies Law,
resolutions regarding the following matters must be passed at a general meeting of the Company&rsquo;s shareholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">amendments to the Company&rsquo;s amended and restated Articles;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the exercise of the Board&rsquo;s powers by a general meeting if the Board&rsquo;s is unable to exercise its powers and the exercise of any of its powers is required for the Company&rsquo;s proper management;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">appointment or termination of the Company&rsquo;s auditors;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">appointment of Directors (other than in the cases specified in the Company&rsquo;s amended and restated articles of association;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 48px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">approval of acts and transactions requiring general meeting approval pursuant to the provisions of the Companies Law and any other applicable law;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 48px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">increases or reductions of the Company&rsquo;s authorized share capital;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a merger (as such term is defined in the Companies Law) ; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">dissolution of the company by the court, voluntary dissolution, or by voluntary dissolution in an expedited procedure.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our Articles, we are
not required to give notice to our registered shareholders pursuant to the Companies Law, unless otherwise required by law. The Companies
Law requires that a notice of any annual or special general meeting be provided 14 or 21 days (as applicable) prior to the meeting, and
if the agenda of the meeting includes certain matters prescribed under the Companies Law and the regulations promulgated thereafter, among
others, the appointment or removal of directors, the approval of transactions with office holders or interested or related parties, approval
of the Company&rsquo;s general manager to serve as the chairman of the Board of Directors or an approval of a merger, notice must be provided
at least 35 days prior to such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Voting Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Every shareholder shall have
one vote for each share held by him of record, on every resolution, without regard to whether the vote thereon is conducted by a show
of hands, by written ballot or by any other means.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Quorum Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As permitted under the Companies
Law and as stated in the Company&rsquo;s Articles, the quorum required for the Company&rsquo;s general meetings consists of two or more
shareholders, present in person or by proxy and holding shares conferring in the aggregate at least twenty five percent (25%) of the voting
power of the Company. If within half an hour of the time set forth for the general meeting a quorum is not present, the general meeting
shall stand adjourned either (i) to the same day of the following week, at the same hour and in the same place (ii) to such other date,
time and place as prescribed in the notice to the shareholders and in such adjourned meeting or (iii) to such day and at such time and
place as the chairperson of the general meeting shall determine (which may be earlier or later than the date pursuant to clause (i) above).
If no quorum is present within half an hour of the time arranged, any number of shareholders participating in the meeting, shall constitute
a quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a special general meeting
was called following the request of a shareholder according to applicable law, and within half an hour a legal quorum has not been formed,
the meeting shall be canceled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Vote Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Articles provide that
all resolutions of our shareholders require a simple majority vote, unless otherwise required by the Companies Law or by our Articles.
Under the Companies Law, each of (i) the approval of an extraordinary transaction with a controlling shareholder and (ii) the terms of
employment or other engagement of the controlling shareholder of the company or such controlling shareholder&rsquo;s relative (even if
not extraordinary) requires the approval described under &ldquo;<FONT STYLE="background-color: white">Item 6.</FONT>C. <FONT STYLE="background-color: white"><I>Directors,
Senior Management and Employees</I></FONT><I>&mdash;Board Practices&mdash; Fiduciary Duties of Office Holders</I> and Approval of Related
Party Transactions under Israeli Law &mdash; Disclosure of Personal Interests of an Office Holder.&rdquo; Certain transactions with respect
to remuneration of our office holders and directors require further approvals described under &ldquo;<FONT STYLE="background-color: white">Item
6. Directors, Senior Management and Employees</FONT>&mdash;C. Board Practices&mdash; Fiduciary Duties of Office Holders and Disclosure
of Personal Interests of an Office Holder.&rdquo; Another exception to the simple majority vote requirement is a resolution for the voluntary
winding up, or an approval of a scheme of arrangement or reorganization, of the company pursuant to Section 350 of the Companies Law,
which requires the approval of the court and the approval of the majority of the shareholders voting their shares, other than abstainees,
holding at least 75% of the voting rights represented at the meeting, in person, by proxy or by voting deed and voting on the resolution.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Access to Corporate Records</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, shareholders
are entitled to have access to: minutes of the Company&rsquo;s general meetings; the Company&rsquo;s shareholders register and principal
shareholders register, articles of association and annual audited financial statements; and any document that the Company is required
by law to file publicly with the Israeli Companies Registrar or the Israel Securities Authority. These documents are publicly available
and may be found and inspected at the Israeli Registrar of Companies. In addition, shareholders may request to be provided with any document
related to an action or transaction requiring shareholder approval under the related party transaction provisions of the Companies Law.
The Company may deny this request if the Company believes it has not been made in good faith or if such denial is necessary to protect
the Company&rsquo;s interest or protect a trade secret or patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Special or Class Rights; Modification of Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If at any time the share capital
of the Company is divided into different classes of shares, the rights attached to any class, unless otherwise provided by the Companies
Law or the Company&rsquo;s Articles, may be modified or cancelled by the Company by a resolution of the General Meeting of the holders
of all shares as one class, without any required separate resolution of any class of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provisions of our Articles
relating to General Meetings shall, mutatis mutandis, apply to any separate General Meeting of the holders of the shares of a particular
class, it being clarified that the requisite quorum at any such separate General Meeting shall be two or more shareholders present in
person or by proxy and holding not less than 15 percent of the issued shares of such class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise provided
by Company&rsquo;s Articles, an increase in the authorized share capital, the creation of a new class of shares, an increase in the authorized
share capital of a class of shares, or the issuance of additional shares thereof out of the authorized and unissued share capital, shall
not be deemed to modify or derogate or cancel the rights attached to previously issued shares of such class or of any other class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Acquisitions under Israeli Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Full Tender Offer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, as a result of an acquisition
of shares, the acquirer will hold more than 90% of an Israeli public company&rsquo;s outstanding shares or of certain class of shares,
the acquisition must be made by means of a tender offer for all of the outstanding shares, or for all of the outstanding shares of such
class, as applicable. In general, if less than 5% of the outstanding shares, or of applicable class, are not tendered in the tender offer
and more than half of the offerees who have no personal interest in the offer tendered their shares, all the shares that the acquirer
offered to purchase will be transferred to it by operation of law. However, a tender offer will also be accepted if the shareholders who
do not accept the offer hold less than 2% of the issued and outstanding share capital of the company or of the applicable class of shares.
Any shareholders that was an offeree in such tender offer, whether such shareholder accepted the tender offer or not, may request, by
petition to an Israeli court, (i) appraisal rights in connection with a full tender offer, and (ii) that the fair value should be paid
as determined by the court, for a period of six months following the acceptance of the offer. However, the acquirer is entitled to stipulate,
under certain conditions, that tendering shareholders will forfeit such appraisal rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Special Tender Offer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law also provides
that, subject to certain exceptions, an acquisition of shares in an Israeli public company must be made by means of a &ldquo;special&rdquo;
tender offer if as a result of the acquisition (1) the purchaser would become a holder of 25% or more of the voting rights in the company,
unless there is already another holder of at least 25% or more of the voting rights in the company or (2) the purchaser would become a
holder of 45% or more of the voting rights in the company, unless there is already a holder of more than 45% of the voting rights in the
company. These requirements do not apply if, in general, the acquisition (1) was made in a private placement that received shareholders&rsquo;
approval, subject to certain conditions, (2) was from a holder of 25% or more of the voting rights in the company which resulted in the
acquirer becoming a holder of 25% or more of the voting rights in the company, or (3) was from a holder of more than 45% of the voting
rights in the company which resulted in the acquirer becoming a holder of more than 45% of the voting rights in the company. A &ldquo;special&rdquo;
tender offer must be extended to all shareholders. In general, a &ldquo;special&rdquo; tender offer may be consummated only if (1) at
least 5% of the voting power attached to the company&rsquo;s outstanding shares will be acquired by the offeror and (2) the offer is accepted
by a majority of the offerees who notified the company of their position in connection with such offer (excluding the offeror, controlling
shareholders, holders of 25% or more of the voting rights in the company or anyone on their behalf, or any person having a personal interest
in the acceptance of the tender offer). If a special tender offer is accepted, then the purchaser or any person or entity controlling
it or under common control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase
of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the
offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Merger</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law includes
provisions that allow a merger transaction and requires that each company that is a party to the merger have the transaction approved
by its board of directors and, unless certain requirements described under the Companies Law are met, a vote of the majority of its shareholders,
and, in the case of the target company, also a majority vote of each class of its shares. For purposes of the shareholder vote of each
party, unless a court rules otherwise, the merger will not be deemed approved if shares representing a majority of the voting power present
at the shareholders meeting and which are not held by the other party to the merger (or by any person or group of persons acting in concert
who holds 25% or more of the voting power or the right to appoint 25% or more of the directors of the other party) vote against the merger.
If, however, the merger involves a merger with a company&rsquo;s own controlling shareholder or if the controlling shareholder has a personal
interest in the merger, then the merger is instead subject to the same Special Majority (as defined below) approval that governs all extraordinary
transactions with controlling shareholders. Upon the request of a creditor of either party to the proposed merger, the court may delay
or prevent the merger if it concludes that there exists a reasonable concern that as a result of the merger the surviving company will
be unable to satisfy the obligations of any of the parties to the merger, and may further give instructions to secure the rights of creditors.
If the transaction would have been approved by the shareholders of a merging company but for the separate approval of each class or the
exclusion of the votes of certain shareholders as provided above, a court may still approve the merger upon the petition of holders of
at least 25% of the voting rights of a company. For such petition to be granted, the court must find that the merger is fair and reasonable,
taking into account the value of the parties to the merger and the consideration offered to the shareholders. In addition, a merger may
not be completed unless at least (1) 50 days have passed from the time that the requisite proposals for approval of the merger were filed
with the Israeli Registrar of Companies by each merging company; and (2) 30 days have passed since the merger was approved by the shareholders
of each merging company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term &ldquo;Special Majority&rdquo;
will be defined as described in section 275(a)(3) of the Companies Law as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">at least a majority of the shares held by shareholders who are not controlling shareholders and do not have personal interest in the merger have voted in favor of the proposal (shares held by abstaining shareholders shall not be considered); or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the total number of shares voted against the merger does not exceed 2% of the aggregate voting rights of the company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Borrowing Powers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Companies
Law and our Articles, our Board of Directors may exercise all powers and take all actions that are not required under law or under our
Articles to be exercised or taken by a certain organ of the Company, including the power to borrow money for company purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Changes in Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Articles enable us to
increase or reduce our authorized share capital. Any such changes are subject to the provisions of the Companies Law and must be approved
by a resolution duly adopted by our shareholders at a general meeting. In addition, transactions that have the effect of reducing capital,
such as the declaration and payment of dividends in the absence of sufficient retained earnings or profits, require the approval of both
our Board of Directors and an Israeli court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>IPO Warrant Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The IPO Warrants were issued
in registered form pursuant to the warrant agent agreement dated July 13, 2021, by and between the Company and VStock Transfer, LLC, as
warrant agent (the &ldquo;Warrant Agreement&rdquo;). On August 8, 2022 the Company and American Stock Transfer &amp; Trust Company, LLC,
as a successor warrant agent, entered into an amendment to the Warrant Agreement (the &ldquo;Amendment to the Warrant Agreement&rdquo;).
You should review a copy of the Warrant Agreement, the Amendment to the Warrant Agreement and the form of IPO Warrant filed as exhibits
to our Annual Report on Form 20-F for the year ended December 31, 2023, for a complete description of the terms and conditions of the
Warrants, the Warrant Agreement and the Amendment to the Warrant Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Duration and Exercise Price Adjustments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The IPO Warrants expire at
5:00 p.m., New York City time on July 16, 2026. The exercise price and number of Ordinary Shares issuable upon exercise is subject to
appropriate adjustments in the event of stock dividends, stock splits, reorganizations or other events affecting our Ordinary Shares and
the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Exercisability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The IPO Warrants may be exercised
upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form
completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by paying
in full, in lawful money of the United States by wire transfer to the warrant agent, for the number of Warrants being exercised. The warrant
holders do not have the rights or privileges of a shareholder of the Company and any voting rights until they exercise their IPO Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fractional Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No fractional shares will
be issued in connection with the exercise of an IPO Warrant. In lieu of fractional shares, we will pay the holder an amount in cash equal
to the fractional amount multiplied by the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Transferability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to applicable laws,
each warrant may be transferred at the option of the holder upon surrender of the warrant to the Company or its designated agent together
with a written assignment substantially in the form attached to the warrant as an exhibit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Warrant Agent</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The warrant agent for the IPO Warrants is American Stock Transfer &amp;
Trust Company, LLC, Inc. <FONT STYLE="background-color: white">Its address</FONT> is 6201 15<SUP>th</SUP> Avenue, Brooklyn, NY 11219.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Exchange Listing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The IPO Warrants are listed on Nasdaq under the
symbol &ldquo;IINNW&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>3
<FILENAME>ea020216701ex4-6_inspira.htm
<DESCRIPTION>FORM OF AMENDMENT OF WARRANT AGREEMENT BY AND BETWEEN THE COMPANY AND AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC, DATED AUGUST 8, 2022
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 4.6</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>FORM OF</B> <B>AMENDMENT
NO. 1 TO WARRANT AGENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">THIS
AMENDMENT NO. 1 TO WARRANT AGENT AGREEMENT (this &ldquo;<U>Amendment</U>&rdquo;), is made and entered into as of August 8, 2022,
by and among Inspira Technologies Oxy B.H.N. Ltd., an Israeli corporation (the &ldquo;<U>Company</U>&rdquo;), and VStock Transfer LLC,
as warrant agent (&ldquo;<U>VStock</U>&rdquo;), and American Stock Transfer &amp; Trust Company, LLC (&ldquo;<U>AST</U>&rdquo;). Capitalized
terms used but not defined herein shall have the meanings ascribed to such terms in the Warrant Agreement (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">WHEREAS,
the Company and VStock previously entered into that certain Warrant Agent Agreement, dated as of July 13, 2021 (the &ldquo;<U>Warrant
Agreement</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">WHEREAS,
pursuant to Section 7.14 of the Warrant Agreement, VStock has agreed to resign its duties as the Warrant Agent as of the date hereof,
and AST has agreed to serve as successor Warrant Agent from and after the date hereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">WHEREAS,
pursuant to Section 7.12 of the Warrant Agreement, the parties may amend the Warrant Agreement without the consent of the Holders with
respect to matters that the parties determine, in good faith, shall not adversely affect the interest of the Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">NOW,
THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, and intending to be legally bound hereby, the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">1   <U>Amendment
of the Warrant Agreement</U>. The parties hereby amend, effective as of the date of this Amendment, the Warrant Agreement as provided
in this <U>Section&nbsp;1</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">1.1   <U>Change
in Warrant Agent</U>. References to &ldquo;VStock Transfer LLC&rdquo; in the Warrant Agreement shall be replaced with &ldquo;American
Stock Transfer &amp; Trust Company, LLC&rdquo; and it shall be understood that &ldquo;Warrant Agent&rdquo; shall hereafter refer to AST.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">1.2   <U>Change
of Address of Warrant Agent</U>. Section 7.11 of the Warrant Agreement is hereby amended to direct that all notices, instructions and
communications under the Warrant Agreement to the Warrant Agent shall be delivered to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">American Stock Transfer &amp; Trust Company, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">6201 15<SUP>th</SUP> Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Brooklyn, NY 11219</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Email: Reorg_warrants@astfinancial.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">2   <U>Resignation
of Current Warrant Agent and Appointment of Successor Warrant Agent</U>. VStock hereby resigns as Warrant Agent under the Warrant Agreement,
and the Company hereby appoints AST to act as the Warrant Agent for the Company under the Warrant Agreement, and AST hereby accepts such
appointment and agrees to perform the same in accordance with the terms and conditions set forth in the Warrant Agreement as modified
by this Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-weight: normal">3
<U>Miscellaneous Provisions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">3.1   <U>Successors</U>.
All the covenants and provisions of this Amendment by or for the benefit of the parties hereto shall bind and inure to the benefit of
their respective successors and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">3.2   <U>Applicable
Law</U>. The validity, interpretation, and performance of this Amendment shall be governed in all respects by the laws of the State of
New York, without giving effect to conflicts of law principles that would result in the application of the substantive laws of another
jurisdiction. Each of the parties hereto hereby agrees that any action, proceeding or claim against it arising out of or relating in any
way to this Amendment shall be brought and enforced in the courts of the State of New York or the United States District Court for the
Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. Each of the parties
hereto hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">3.3   <U>Counterparts</U>.
This Amendment may be executed in any number of original or electronic counterparts and each of such counterparts shall for all purposes
be deemed to be an original, and all such counterparts shall together constitute one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">3.4   <U>Effect
of Headings</U>. The section headings herein are for convenience only and are not part of this Amendment and shall not affect the interpretation
thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">3.5   <U>Severability</U>.
This Amendment shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect the
validity or enforceability of this Amendment or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable
term or provision, the parties hereto intend that there shall be added as a part of this Amendment a provision as similar in terms to
such invalid or unenforceable provision as may be possible and be valid and enforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">3.6   <U>Effect
on Warrant Agreement</U>. Other than as specifically set forth herein, all other terms and provisions of the Warrant Agreement shall remain
unaffected by the terms of this Amendment, and shall continue in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">3.7   <U>Entire
Agreement</U>. The Warrant Agreement, as modified by this Amendment, constitutes the entire understanding of the parties and supersedes
all prior agreements, understandings, arrangements, promises and commitments, whether written or oral, express or implied, relating to
the subject matter hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">[Signature page follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">IN
WITNESS WHEREOF,&nbsp;the parties hereto have caused this Amendment to be duly executed as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:&nbsp;</TD>
    <TD STYLE="width: 31%"> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title: &nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">AMERICAN STOCK TRANSFER&nbsp;&amp; <BR>
TRUST COMPANY, LLC</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:&nbsp;</TD>
    <TD STYLE="width: 31%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title: &nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>4
<FILENAME>ea020216701ex12-1_inspira.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO EXCHANGE ACT RULE
13a-14(a) or 15d-14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Dagi Ben-Noon, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt">1.</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">I have reviewed this annual report on Form 20&ndash;F of Inspira Technologies Oxy B.H.N. Ltd. (the &ldquo;company&rdquo;);</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt">2.</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt">3.</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt">4.</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">The company&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">a)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">b)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">c)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Evaluated the effectiveness of the company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">d)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Disclosed in this report any change in the company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt">5.</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">The company&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the audit committee of the company&rsquo;s board of directors (or persons performing the equivalent function):</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">a)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">b)</TD>
    <TD STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 60%; font-size: 10pt">Date: March 25, 2024</TD>
    <TD STYLE="white-space: nowrap; width: 40%; border-bottom: black 1.5pt solid; font-size: 10pt">/s/ Dagi Ben-Noon</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">Dagi Ben-Noon</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>5
<FILENAME>ea020216701ex12-2_inspira.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO EXCHANGE ACT RULE
13a-14(a) or 15d-14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Yafit Tehila, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt">1.</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">I have reviewed this annual report on Form 20&ndash;F of Inspira Technologies Oxy B.H.N. Ltd. (the &ldquo;company&rdquo;);</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt">2.</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt">3.</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt">4.</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">The company&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">a)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">b)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">c)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Evaluated the effectiveness of the company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">d)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Disclosed in this report any change in the company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt">5.</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">The company&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the audit committee of the company&rsquo;s board of directors (or persons performing the equivalent function):</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">a)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">b)</TD>
    <TD STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 60%; font-size: 10pt">Date: March 25, 2024</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; white-space: nowrap; width: 40%">/s/ Yafit Tehila</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">Yafit Tehila </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">Chief Financial Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>6
<FILENAME>ea020216701ex13-1_inspira.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 13.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. Section 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the filing
of the Annual Report on Form 20-F for the period ended December 31, 2023 (the &ldquo;Report&rdquo;) by Inspira Technologies Oxy B.H.N.
Ltd. (the &ldquo;company&rdquo;), the undersigned, as the Chief Executive Officer of the company, hereby certifies pursuant to 18 U.S.C.
Section 1350, that, to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) the Report fully complies
with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) the information contained
in the Report fairly presents, in all material respects, the financial condition and results of operations of the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font-size: 10pt">Date: March 25, 2024</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 40%; font-size: 10pt">/s/ Dagi Ben-Noon</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Dagi Ben-Noon</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>7
<FILENAME>ea020216701ex13-2_inspira.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 13.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. Section 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the filing
of the Annual Report on Form 20-F for the period ended December 31, 2023 (the &ldquo;Report&rdquo;) by Inspira Technologies Oxy B.H.N.
Ltd. (the &ldquo;company&rdquo;), the undersigned, as the Chief Financial Officer of the company, hereby certifies pursuant to 18 U.S.C.
Section 1350, that, to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) the Report fully complies
with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) the information contained
in the Report fairly presents, in all material respects, the financial condition and results of operations of the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font-size: 10pt">Date: March 25, 2024</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 40%">/s/ Yafit Tehila</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Yafit Tehila </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Chief Financial Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>8
<FILENAME>ea020216701ex15-1_inspira.htm
<DESCRIPTION>CONSENT OF ZIV HAFT, A MEMBER FIRM OF BDO, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 15.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex15-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inspira Technologies Oxy B.H.N. Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2 Ha-Tidhar St.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rananna 4366504, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby consent to the incorporation by reference in the Registration
Statements on Form S-8&nbsp;(No. 333-259057) and Form F-3 (No. 333-266748) of Inspira Technologies Oxy B.H.N Ltd (&ldquo;the Company&rdquo;)
of our report dated March 19, 2024, relating to the financial statements of the Company which appears in this Annual Report on Form 20-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our report contains an explanatory paragraph regarding the Company&rsquo;s
ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 60%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; font-size: 10pt; text-align: center">/s/ Ziv Haft</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center">Certified Public Accountants (Isr.)<BR>
 BDO Member Firm</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel Aviv, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 25, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>9
<FILENAME>ea020216701ex97-1_inspira.htm
<DESCRIPTION>INSPIRA TECHNOLOGIES OXY B.H.N. LTD. CLAWBACK POLICY, DATED NOVEMBER 28, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 97.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.35pt; text-align: center"><B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD
(the &ldquo;Company&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.35pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.35pt; text-align: center"><B>CLAWBACK POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.35pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Effective as of November 28, 2023</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Background</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors of the Company (the &ldquo;<B>Board</B>&rdquo;)
believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity
and accountability and that reinforces the Company&rsquo;s pay-for-performance compensation philosophy. The Board has therefore adopted
this policy, which provides for the recoupment (or clawback) of certain executive compensation in the event of an accounting restatement
resulting from material noncompliance with financial reporting requirements under the federal securities laws of the United States (the
&ldquo;<B>Policy</B>&rdquo;). This Policy is designed to comply with Section 10D of the Securities Exchange Act of 1934, as amended (the
&ldquo;<B>Exchange Act</B>&rdquo;), Rule 10D-1 promulgated under the Exchange Act (&ldquo;<B>Rule 10D-1</B>&rdquo;) and the listing standards
of the Nasdaq Stock Market (&ldquo;<B>Nasdaq</B>&rdquo;) under Nasdaq Listing Rule 5608. In addition, this Policy is designed to comply
with the requirements under the Israeli Companies Law 5759-1999 (the &ldquo;<B>Companies Law</B>&rdquo;) with respect to clawback provisions
to be included in the Company&rsquo;s Compensation Policy, as may be amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Administration</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Policy shall be administered by the Compensation
Committee of the Board (the &ldquo;<B>Compensation Committee</B>&rdquo;). Any determinations made by the Compensation Committee shall
be final and binding on all affected individuals. Subject to any limitation under applicable law, the Compensation Committee may authorize
and empower any officer or employee of the Company to take any and all actions necessary or appropriate to carry out the purpose and intent
of this Policy (the &ldquo;<B>Authorized Officers</B>&rdquo;) (other than with respect to any recovery under this Policy involving such
officer or employee).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Covered Executives</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Policy applies to the Company&rsquo;s current
and former executive officers, as determined by the Board in accordance with Section 10D of the Exchange Act and the listing standards
of the Nasdaq (&ldquo;<B>Covered Executives</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Recoupment; Accounting Restatement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event the Company is required to prepare
an accounting restatement of its financial statements due to the Company&rsquo;s material noncompliance with any financial reporting requirement
under the securities laws, the Compensation Committee will require prompt reimbursement or forfeiture of any excess Incentive Compensation
(as defined below) received by any Covered Executive during the three completed fiscal years immediately preceding the date on which the
Company is required to prepare an accounting restatement. For the sake of clarity, recoupment is required in the event of any restatement
that either: (a) corrects an error in previously issued financial statements that is material to the previously issued financial statements;
or (b) corrects an error not material to previously issued financial statements, but that would result in a material misstatement if (i)
the error was left uncorrected in the then current period; or (ii) the error correction was recognized in the then current period. The
Company&rsquo;s obligation to recover erroneously awarded compensation is not dependent on if or when the restated financial statements
are filed. For purposes of determining the relevant recovery period, the date that the Company is required to prepare an accounting restatement
as described above is the earlier to occur of: (A) the date the Board, a committee of the Board, the Authorized Officers, or officers
of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the
Company is required to prepare an accounting restatement as described above; or (B) the date a court, regulator, or other legally authorized
body directs the Company to prepare an accounting restatement as described above. In accordance with Nasdaq Rule 5608(e), this Policy
is applicable to Incentive Compensation (as described below) received on or after October 2, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Incentive Compensation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of this Policy, &ldquo;Incentive
Compensation&rdquo; means any of the following, provided that such compensation is granted, earned or vested based wholly or in part on
the attainment of a financial reporting measure affected by the restated financial statements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
bonuses and other short- and long-term cash incentives.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
options.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
appreciation rights.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
shares.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
share units.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
shares.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
units.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial reporting measures are measures that
are determined and presented in accordance with the accounting principles used in preparing the Company&rsquo;s financial statements,
and any measures that are derived wholly or in part from such measures. Share price and total shareholder return are also financial reporting
measures. A financial reporting measure need not be presented within the financial statements or included in a filing with the Securities
and Exchange Commission. The Company&rsquo;s financial reporting measures may include, but are not limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
stock price.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
shareholder return.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
income.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings
before interest, taxes, depreciation and amortization (EBITDA).</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Funds
from operations.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity
measures such as working capital, operating cash flow or Free Cash Flow.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Return
measures such as return on invested capital or return on assets.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings
measures such as earnings per share.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Policy applies to all Incentive Compensation received by a Covered
Executive:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
beginning service as an executive officer;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Who
served as an executive officer at any time during the performance period for that Incentive Compensation;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Company has a class of securities listed on a national securities exchange or a national securities association; and</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three completed fiscal years immediately preceding the date that the Company is required to prepare an accounting restatement as
described in this Policy. In addition to these last three completed fiscal years, this Policy applies to any transition period (that
results from a change in the Company&rsquo;s fiscal year) within or immediately following those three completed fiscal years. However,
a transition period between the last day of the Company&rsquo;s previous fiscal year end and the first day of its new fiscal year that
comprises a period of nine to 12 months would be deemed a completed fiscal year.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Incentive Compensation is deemed received in the
Company&rsquo;s fiscal period during which the financial reporting measure specified in the Incentive Compensation award is attained,
even if the payment or grant of the Incentive Compensation occurs after the end of that period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Excess Incentive Compensation: Amount Subject
to Recovery</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount to be recovered will be the excess
of the Incentive Compensation paid to the Covered Executive based on the erroneous data over the Incentive Compensation that would have
been paid to the Covered Executive had it been based on the restated results, as determined by the Compensation Committee, and without
regard to any taxes paid by or withheld from the Covered Executive. If the Compensation Committee cannot determine the amount of excess
Incentive Compensation received by the Covered Executive directly from the information in the accounting restatement, then it will make
its determination based on a reasonable estimate of the effect of the accounting restatement. For Incentive Compensation based on share
price or total shareholder return, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly
from the information in an accounting restatement, the amount will be based on a reasonable estimate of the effect of the accounting restatement
on the share price or total shareholder return upon which the Incentive Compensation was received. In such case, the Company shall maintain
documentation of the determination of that reasonable estimate and provide such documentation to Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Method of Recoupment</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Compensation Committee will determine, in
its sole discretion, the method for recouping Incentive Compensation hereunder which may include, without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Requiring
reimbursement of cash Incentive Compensation previously paid;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seeking
recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based awards;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offsetting
the recouped amount from any compensation otherwise owed by the Company to the Covered Executive in accordance with applicable law;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelling
outstanding vested or unvested equity awards; and/or</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taking
any other remedial and recovery action permitted by law, as determined by the Compensation Committee.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>No Indemnification</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company shall not indemnify any Covered Executives
against the loss of any Incentive Compensation recovered under this Policy or from any consequence arising therefrom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Interpretation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Compensation Committee is authorized to interpret
and construe this Policy and to make all determinations necessary, appropriate or advisable for the administration of this Policy. It
is intended that this Policy be interpreted in a manner that is consistent with the requirements of Section 10D of the Exchange Act, Rule
10D-1, any applicable rules or standards adopted by the Securities and Exchange Commission or Nasdaq, and the Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Effective Date</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Policy shall be effective as of the date
it is adopted by the Board (the &ldquo;<B>Effective Date</B>&rdquo;) and, in accordance with Nasdaq Rule 5608(e), shall apply to Incentive
Compensation that is received by Covered Executives on or after October 2, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Amendment; Termination</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board may amend this Policy from time to time
in its discretion and shall amend this Policy as it deems necessary to reflect regulations adopted by the Securities and Exchange Commission
under Section 10D of the Exchange Act and to comply with any rules or standards adopted by Nasdaq. The Board may terminate this Policy
at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Other Recoupment Rights</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board intends that this Policy will be applied
to the fullest extent of applicable law. The Board and/or Compensation Committee may require that any employment agreement, equity award
agreement, or similar agreement entered into or amended on or after the Effective Date shall, as a condition to the grant of any benefit
thereunder, require a Covered Executive to agree to abide by the terms of this Policy. Any right of recoupment under this Policy is in
addition to, and not in lieu of: (a) any other remedies or rights of recoupment that may be available to the Company pursuant to the terms
of any similar policy in any employment agreement, equity award agreement or similar agreement and any other legal remedies available
to the Company, including termination of employment or institution of legal proceedings; and (b) any statutory recoupment requirement,
including Section 304 of the Sarbanes-Oxley Act of 2022. For the avoidance of doubt, any amounts paid to the Company pursuant to Section
304 of the Sarbanes-Oxley Act of 2022 shall be considered (and may be credited) in determining any amounts recovered under this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Impracticability</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Compensation Committee shall recover any excess
Incentive Compensation in accordance with this Policy unless such recovery would be impracticable, as determined in accordance with Rule
10D-1(b)(1)(iv) under the Exchange Act and the listing standards of Nasdaq. In order for the Company to determine that recovery would
be impracticable, the Compensation Committee must conclude the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">The direct expense paid to a third party to assist in enforcing
this Policy would exceed the amount to be recovered after making a reasonable attempt to recover such Incentive Compensation. Note that
the attempt(s) to recover must be documented by the Company and such documentation provided to Nasdaq;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Recovery would violate home country law where that law was
adopted prior to November 28, 2022. Note that the Company must obtain a legal opinion of home country counsel that such recovery would
result in a violation of local law and provide such opinion to Nasdaq; or</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c)</TD><TD STYLE="text-align: justify">Recovery would likely cause an otherwise tax-qualified retirement
plan under which benefits are broadly available to Company employees to fail to meet the requirements for qualified pension, profit-sharing
and stock bonus plans under Section 401(a)(13) of the U.S. Internal Revenue Code or the minimum vesting standards under Section 411(a)
of the U.S. Internal Revenue Code.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Successors</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Policy shall be binding and enforceable against
all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Exhibit Filing</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A copy of this Policy shall be filed as an exhibit
to the Company&rsquo;s annual report on Form 20-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ATTESTATION AND ACKNOWLEDGEMENT OF CLAWBACK
POLICY FOR INSPIRA<BR>
 TECHNOLOGIES OXY B.H.N. LTD (the &ldquo;Company&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By my signature below, I acknowledge and agree that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have received and read the attached Clawback Policy (this &ldquo;Policy&rdquo;) of the Company.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
hereby agree to abide by all of the terms of the Policy both during and after my employment with the Company, including, without limitation,
by promptly repaying or returning any incorrectly awarded Incentive Compensation to the Company as determined in accordance with the
Policy.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
hereby waive any claim against the Company, its Authorized Officers and the Board in connection with the implementation of the Policy.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-indent: -18pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 261pt">Signature:_________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 261pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 261pt">Printed Name:______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 261pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 261pt">Date:_____________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-indent: 261pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-indent: 261pt"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-indent: 261pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !] 68# 2(  A$! Q$!_\0
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MW_Z=#^OO]<]>/>MD_%*XNY8+>STK:;DD$&[.<YY' /3'?''K7I\-Y?>5^_\
MLWVGW/OZU\_]6RC-M<'TU]5:[_ ^@3QF$M];^6WEV;\CYOFL[BSXN(+FV'O_
M /K_ /U\U7KZ0EA^U_Z_[-<G_/IVXK'F\$:'>?\ +C]E/'_'H1],]>?YY%>?
MB<EM_N?X_P!>OYGL+$WMKVZ_\$\7JQ7I%Y\/?^?&^]2/M8_3C\._I[FN/UC0
M;[09;?[=G%UU^O<?Y^OU\?$X;&83N^_96.@QZ***Y_S.@*KU8JO6%GV?W/\
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MAOUWX\NZTR*[0'CEY$7T/.,YHKT#Y3ZU@M.;65E=\R71=+'F&I0_\>^J0?\
M;W_7C^1/^->7^-M-$-U;WT'^HNO\_IZ9%>H0_OK"XLL_YQ^O_P!;VK)U:S_M
M+PSJ!_Y;VI^VD]>.A_0G X_*OZOSO#?6L(VO73R79==#_)+*\3]5DD^LHIW>
MUVEK]^_DSS;P5%YWB*V'?_''I^>/RKZ'@[_C_2OGCP'_ ,C#;_4_^@BOH>#O
M^/\ 2N?AU6PCZ6=NWDSULQUQ4+];/[U?]30@[_C_ $K0\CW_ %_^M6?9]O\
M@5;%?0G3ANGR_0/(]_U_^M7'^-M-^V:#<3G_ (^+4F]_+V^GY=*[BL;7O^0-
MJ_\ UZ#^9KS\RM]33T^%ZZ=F>OAMEZ?HCY@KJ/!/_(QV_P#N_P!17+UU'@__
M )&/3_\ =/\ .OS_  K_ -LU>G,]]M_N/1PVZ]?U1[@;.QFY^PVW8\V?^?\
M/?&*7^QM*_Y\K;_P"%7X._X_TH_Y:_Y_O5[%EV7W+_(^GPR3MHNG1>7D9_\
MPC>AS?\ ,*MA^/Z_SZ#U]S1_PBGAW_H%6_ZUL58KF>S]'^3/9PV%P;Z+RT6_
MW&?#H^E0\P6-MQG_ )<_\^N/2M"&&"'_ )86WUZ>W^'],458KA>[]7^;/>PV
M%CVCY:+UZK\O\BO_ ,M?\_WJL36<$_\ KX/I^/<9Z]#_ $-5YH?W7^?P]\?F
M3UXJQ!W_ !_I7-B>OS_]N/9PT5IHNG1>7D5_L<\/$$_^CXXM+O\ #USVX]JT
M(;S]UY$\';Z<?_J'^>**6;_4GZ#^5>>?0X72W3;;3MVL:\,-O_RPG_/Z?R_
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M>OZC_&K'G031?O\ IQSZ_P"?3OQQSS8O-'\D_N/]&Q_3_./Y>^-^_ASY]O\
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M@C/<>OX]?>OG2&SOH>(/M-L/;V]N_P#3^?O/P;EF\K7H)HOLY*@GM@Y((/T
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M\/9(/$D.B;W>*.7Q)+J-MB)V=U<^6OK?P$F\'?\ !"+_ ((>1?'D>']&U/\
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M--<?M8?&-50 !5"^-F150# 5515 4=,$<<"OZ(O^#*S_ )/:_;%_[-9\,_\
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MZ>FA\\P_M-MX?O?@?/X6\&6VG:-\"O'6J>-/#.EWFKG4AJ"ZYKO]O?V1K1(
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M^%>T0^"=#AY\BYN?^WSG'OTZ_7'3M6Q#H.APX\BQMCQ_CW^G3_.7_9GG^/\
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M:(]GXQD'TSTQ^OUR>V\OP1[&&Z?+]#IZL57JQ0]GZ/\ )GL8;I\OT+%$'?\
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MMI!;Q&YFF7MO;&.?09%<EX\U>87?]G^6GD8]3GDXZ8_'\*X7N_5_FS]!QM7
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9W9YV>X>A0S3%4HPBU!P5W%;NG%OY:Z'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "S 78# 2(  A$! Q$!_\0
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M>_%>VU7P3X$TO0;AS<)_PIW]GG21;7NJ1RPQA+3Q+KUK9+J;&UN+[Q3?QO\
M::_IV_8Q_P"#5'_@EY^S!;Z5K/Q5\(>(/VO/B'9"*6YUSXTW9A\"?:T +/I_
MPI\/SVWAQ[1FSFR\57/BY"NT%R5R?Z7E545410JJ JJH"JJJ,!5 P
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MTJZ\*VWCO48]7\:V_A^>RL(9=(B\6ZI%'J/B..P:!=9O46YU 7$H#UYOX_\
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M&W3II4=GX/UW7H;0N(8[OQ!=RQH/-W']<:4=5?OK\NGX:_,TJ+EER+["2?\
MBLG+[I/E_P"W0IC]!]?Z&GTQ^@^O]#3,R*BBCI0!YS\6?B1H7PC^'WB;X@^(
MGQIWA[3IKE+97"3ZEJ#+Y>G:3:9^]=:C>-%;1* 2-YDP0AK^9C7_ (@>)OC5
M\2=5^(GCF_(UO4/*O91(]Q$VBZ>E_,EKHL-I=,UG;:3;6@MUM@%C>YDC-S('
M9G)^\_\ @JW\;)8M5\"_!30V;4);18_''B73HKM8+=KC<T6BP:O(9(U@M[6W
M\_4,S319DDM=C%V4'^8S]H/]I_XB>*+V]^#7PCN'6"XGCL_$?BO0UFU'5I;R
M+);P_P"$)[5V-S D1DMKFX(>1;Y2B0,^&/Y?Q5BL5F^:K*,'=T,$E/$2;:HN
MNX7<JK5^94>:-.G%)OVCJ-:MI?U%X3</X'(.&:G%>9I0Q^=\U' Z)XJGEL:D
MH1AA823CS8V=.I7K5).$?8T\/&4N2RG^@G[0O[7O[/\ \-?&4VC:?JT.K75M
MX9O=%U"2.Y<V=GK<FG//=&6U5I8'2[>6*V@OA"68J?*<Q!0/C/5OV]4TJ]A:
M'P/;6VA7N@6.F_;O(A>6^T"[MXI;!KB[M(+BW6TCD2>XC#JJX,7VA%VD1?DU
MXC\.7EK(NHW>GZU!I(FFTSQ9<^+/#&NZ7K']K@&>WT?3M2OYEM[R]\H1S3F>
M%!"K%=T9="E_P]\.;G5/AU!\;K+58-(\ Z?JL/AWPSH+7Y&JZM?W5U/:ZD^M
M6J1/8:<M@MHRG[=>B.Y6:,V\)1F%:9;DF'PU*4:V,A2E0H5ZO-6J1I2KRHND
MI4\-?2M5DZ\6HPE*:I1JSDXQI23^CS#/,1*&$^HY9/'4L1B<!E\W3IUL9.A4
MQL,6Z$L9[*G^Z=2&$K.G)4U1E/V%&BIXB2M_9G\&O^"A4_@?_@EI<_&CP'=V
ME[X@\%>,_$'@G0H]9L7U.QT^&"WN/$=I9:A%"\*1QV^F-]G@=V6(D)$.<&N>
M_P""7_\ P4Y_:]_:6^+^H^'?VD?!UGX=^'M[X?@UG1=?@^'NH^$],MHY+2YN
MX;R/7KE8[:\LKORX5A)EG,A<")CNS7XN7_C/P#\-O^".?@KPW!XVT3Q!XN^/
MOQR\;>,IO"^FWEO<S>'=#T[48?A3I6G23"[C$%W/J$JR,L6X7DDEP(4,,#2U
M^I7A?7+KPS\([Z.+5=9M6@T"QL=*M(]2O0NF6^C6-G90KINZWF-I%N1]BM:W
M2*69ED=<-7T^(QL\)1R2JZDY0J+#TY4J;BX8KZS76'A*35W^ZHMU8--ISA%7
M2;9^#9AA,%+%\:9>\GHQS"IFN-5+$XJ&(I8O)E@:-/%8BE1I-4^5UL:ZV'JQ
MK4X35*:FE)JTOT,_X*J_&W['X"\/_!_1-7@MK;QEI%WXR\27<-^L"7OA_3GC
MATK3TN8RY47VHS0WJQS1M;WUO;/$")4&/Q;\-^(;&*RN-,UO5_!,=OI?V#2=
M,NM=\3BRM!JS6L(.EW%M*P^RWDDIN9=-GN5CM9)+0PR,V65?(OV_OVT[7P=\
M3=6\"VUU=WWC3P9\ ?@OX8TG3;E(Y;+[1X@\*6_B6]UVZU 2K=03Z-#JRCS9
M466\>_,,<#!5$?X':_\ 'K5O$OB^;Q)XWO->\<I?ZC;#Q)IUMJ%OI*7MC;,J
M^5HFGW"KH\%S%'%YD5]=VT]RMT[RM)(S2%_C<\H8K'9[7Q$FE1PU94L/[2?*
MG3H1=DDVHQ4IN<YMV3DTKW5S]O\ #NEA<JX)P6%@IQQ&.I+&XN5/#N4Y8G&3
MC+FBURRJ.%!4*%-.5E3C)3<8W2_K*^&>KZ['I/@Q-7D\/Z_>1ZUKT/\ ;MMJ
MNF-J'A.\MU29XH+H/]FU!(K6:&9[K38A<%X$AVNI8U_0_P#LP_&?2OC)\-K"
M^@U""[U_P\(=#\11)/YTPN+:,+:W\ORHP&I6RBX5RHS)YBL2RDG_ #=?@[^V
M?XM^%GB2&_TZ_O-2\-6.KWFH:3X0\4:FVO:9:),&A@GEN)DB@74]-MGW;HP;
M">ZB:VDMC:\-_6S_ ,$NOVH?"/BCQ;X4UOP)<V47@SX@,WA37M&L7FW:?K$_
M.FW_ (@-Q/<1V6J)=VD\4=K'/L%L2+6%([Q OT62X_DQ-*F^90JTHTM9<RE&
M"BJ<U*[3<')Q;DY2=.R4I1BFOD/$;A:.)RO&8ZG?ZUE]:MB4E25#V?/.I+$X
M>5%N3@ITTI0C2C1A&M1?M(*I-SK?T@4445]J?SF3KT'T'\J6D7H/H/Y4M !1
M110 4444 %%%% 'X-?\ !Q]XS\9^&?\ @F?K?AGP;XMU_P %)\9OV@_V</@9
MXSUKPO?OI>O/\//B;\4-(T3QGI.GZC$#+9MK.D>;IMS+'AGL[FX@)*2NI_,'
M_@K#_P $MOV(_P#@EQ\%/V5/VO?V#_A+=_L[?M"?"[]M']ESP?9_$;PCX\^(
M5WJ7BSPMXU\6+X>\7Z)XXM->\4:MIVNV/B+3T8:I&+2U-R9[N _Z'=2VY_=#
M_@LO^QA\5OVZOV&/%_P@^!.I^'+#XT^%?B!\+/C;\+K3Q?,UIX7\1^,?@_XR
MT_QAIWA36]04_P#$ML_$4=G<::FH2#[/:W4UM)=-%:B::/\ )?\ :+\(_P#!
M8G_@K18_L[?LM?M _P#!.GPE^PY\&O!_[0OP:^-_QZ^/.O?M)?#3XLMJNG?!
M[6X]=G\/?"OP5X"U.ZUN"^\37OVA-/?75N(+.%K07E[ D=S)( ?7/QP_X+U?
M#/\ 9%^)_P"W!\&/VO?A%K?P@^)O[/6CZ5XW_9<\+6NMQ>(+G]MSP#XLCMM'
M\%S?"J:*RMX_^$NU#QM/%HFN^'(!J,OAVSN9+NZ>631M6BC]K_9I_P""H7Q1
M^*_[9WP&_8H^-'[,$WP-^)WQ0_X)^P_MH>.[*Z\;QZ_?_#7Q-)\0-,\)-\*K
MRRBTFU2[FATG5K+5;Z_DN+>[TW4GFT6XLGEM9YE_,C]LG_@E5^WK_P %/_VG
M?CY^U)\3M7LOV6/$'[%>I0^&?^"2WA:SO/!GBNV\4>+/ _B72?',GQO^+M]!
M%K0E\.?$[5M"TS2M+\.Z@EE=>'+:[66\TPOH$W]N=%\0?A3_ ,%;?"W[4W['
MO_!73P7^Q#X*^+7[0.K?L2ZY^RO^UK^QW_POCP#X U[P3XGG\?1>)X?&W@#Q
MOKNIR>"-1TC69-#TW4QI UO4]0T:RO)]*FCO;D_;+8 ^R/BQ_P %S/A]\!?&
MG_!532_BG\'O$"^%?^";=W^S5H6C7/A36H-6\4_';QA^TI::K:^%/"ND:/-9
MP6WAV[/BFQL](2\N;J\MH[*]?4+A0;9H)/%=%_X+-_M\^"?CM^R!X _:Q_X)
M8WW[./PP_;&^-/ASX.> /'E[^T/X(\9:]8:IXJTV?6-..I^%?#MI<W5M?V6E
M1B]U*SU Z<J^3=6B2)>(L)_%7X9_L^_M3_\ !5;QW_P<0^ +GX4>'_V:?VL/
M$'Q%_P""=OC_ $OX->)_B-X:^(?A;0_'OP,O_&_BZQ\!:]\3_!,U[X9N6\56
M&A0PRZGIDLEOH=YJENFH+%'#<%/IC]K_ /:8_P""@WQ@_:X_X(I_#_\ ;1_X
M)^6?[(UOX2_;W\ :EX>\9:5^T1\+_C':?$7Q'I7A6]TG6;#1/"O@?5=1\0Z'
MH\=K-)K$6J:RKP1Q""QEN#=R8;&I*2LU*4=5:T>9-\R5I.SLK/3;U/3P-&G5
MDXRITJEX5'+VE5PG!*A.<94H>TASRYXI62J:7;BK)GZ3_$__ (+H_'"3Q7^T
MKXM_95_X)S_$G]IC]DC]CCQYXX^'WQ[_ &B+/XJ^!/!$D^L?"R'[5\3[GX<>
M"-<9]<\2Z9X0M4N+B2\2*4WMM +L16T<R(O4?%?_ (+6?%GQ5\8?V<_A)_P3
M]_8VNOVN[[]H;]DO2/VO=)N=7^*GA_X37.D^ =7UE=%>RNH/$5NUDNIZ'?20
M6.LV[ZEYHU&8V]E'<Q02SU^-7BC_ ((Z_'SX%?'']JK1O&'_  2O\3_\%#?A
M[\7?V@/B5\6?AK\9?A;^WI:?LVQ1^ /B7JD^IMX"\??"_6O$VE6<^M:*+B6T
MO=0MM+EMM36:XCDN[VT%J$_;CX%?L#_$#X+_ /!4_P#9M^+WPY^"47PR_9,^
M%G_!,1_V?+&TC\8Z1KX^'_CZ7X@:-K\7PVF>;4Y=?\07EG:_;YY_$T%I/I5^
M\,UQ]LC:>*$^>YXV<N13J4U*M2A)QI)SIJ56HI2IN=%T^14XQYFY5K-J3E%2
MLOLJ>&X5P])5Y4,'BYT<MS#$X>%?&RCA\;5HX# SH4<7##YFL9]:EC:V(]G"
MG2RY3A"5%4ZDJ2G+ZX_X)V_\%$K[]M6^^//PM^*'P&\5_LQ_M,_LO^*M!\*?
M&OX,^*->T?Q9'IA\5:5)J_AKQ!X>\4:$1I^L:)K-M;78A=4#1M;K)'-=6]Q#
M.WQ1_P %P_A=X"^-_P :O^"0_P '_BIX=M_&'PU^(O[=!\->-O"=[=ZC9V'B
M#0[WP#J*W.GWDVE7EA?I%(/X[:[@F7D)*H9L_17[&'[,'QO^%/\ P4W_ ."I
MOQ]\>>#?[%^$_P"T+=?LXR_"#Q7_ &SHM\OBV/P7X)UC3?$^S3+*^GU;2SI%
M]=06LHU:SLA,\F;0SQJS+R__  5_^#'[4_CCQ5_P3]^-G[*WP(D_:)\2?LJ_
MM2M\8?%/PYM_'G@_X>W6I:%#X0OM-MUAUWQGJ6G:?$LU](D#M +VYA:2.0V;
MPF22/'&JM6RBO'$4ZE:<:\8S@J#G.M0H9G0]YT*<)>TY\-3<Y1A!JI'F<8M2
ML>CPY/+,N\1LKKY1C<)EF&K935Q&&Q#S6&'PF6YMFG ^:OV$,UQ6(IK"?5,[
MQE/#4:N)Q4*F$J^RA5KQJ4N=? _[=_["?[+?_!.3XZ_\$T?C?^Q'\,$_9]^(
M/BS]N+X>?![QA>>#_%?C:ZT[QC\//'=CJ-KX@\-^(M*\1>)-:L;VSN(H=J8A
MCP)9?-$I$)A^R?BG_P %?OC.WQ,_:'TK]E+]A#QW^TQ\&/V1?%^N^!_C]\7K
M;XE>#O L<'B3P=;F\\<Z5X"\-:WYNJ^)7\,06]\LUQ;QW!O)+4M!:+'+:_:?
M&_'O@;_@I3_P4F^//['6F_M ?L0Z3^Q5\#_V9OV@_#O[1WC#QGKOQY^'WQ4\
M3>+]1\%6EXNA>#O"VC>!I[M[5]1NKG9?7>HP1P0Q$3BZ40F"?XH^)_\ P2S^
M./PL_::_:SUW7?\ @G;K_P"W?\/?CO\ '#QI\9?AY\0_AI^V9!^SO<^'=#^(
M%]<:KJ7@3QKX'U77](MK_4-)N[N:U&J06-S'?0J9#>R6\L=M!\UBZF8866*J
MY)A<3@L!B<713E2R^I1E"='*YIU(8.6 Q=2G1JXUTX5JL<O_ '[I<GM*2?MS
M]OX=PG!N?T,BP'BAG>1\3\79'PYF=2-+,>,<#F%'%4,RX^P\X8/$<1TN+^'<
M%C,QR_A=8W%97@:_&">5+&?6'@\=*']E'VG/\?O ?[5'_!6/_@D;^T/\-#?G
MP3\5_P!CS]HCQ5H4>JVPM=4LDFAU:TOM+U&!6=([_2=3MK_2[SRI)(6GM97@
MDDA=';TBR_:.\8VW_!4;XCV?Q-_8KU_P3^T#X:_9 ^,NL? CQ7:_'L^(?#?Q
M;^$O@7Q9+=Z-!<^"-)BFT/0M4\8ZW:20PW]U!_;.E8^S3VDF5G/._&;]C?X\
M?LX?%3_@FY^TS^QA^RG;>-O#'[,'P;\<?"?QG^RA#\5_#^D>*O!EG\6+-M7U
M!])^(?BF[_L;Q-/X;\1:YK5OJFHH]R+^>S6\M;1[*^W6WV3KWP"^-'B/_@K-
M\"/VIW\"/I_PCT']AWQ?\-?%>MRZ[H5RWA[XCZ[X^DUZ'PA+917HU+4)H[*[
M#?VI86$NDRK#,?M2,%C;-4,T=2<9QQ$,8^*<GQN)=++_ &F#K8?&Y7AL-6QU
M&>)P\U%8/$4:U:#I5*=;"5$HXNFJ=2,9=53-N H83#5L-5R;%<.P\ _$CAG)
MH9AQ?]3XDRW..&..\\SS+^%,RPN2YSAIUZG$V3YEE>78B&-P>.RWB+!SG5X?
MQ=3%X2I6H\CK/_!6'P['_P $[OA5^VKX7^':>(_'?Q=\5>#OA7X8^"/_  D(
ML+N3XSZ_XP?P;K7@5]8N+(7.= O[#6;F:Y.F"9[.SBF>VC$N!S?Q/_X*E_&Y
M_BK\9OA_^RQ^Q!XO_:2T+]F+4+?0?VAO&UK\2O"/@JP\/^+X-*75_$?@_P '
MZ=K0.H>*=5\.0Q7UM=2VD,@N+VU>*&TVM:O>?)_PC_X)C_M*>%?^"B]GHFOZ
M/8?\.[/A)^T-\1?VR_A+*-<T*Y6;XK?$#PSI=IIG@\>'9=0N=>B@\)>(7O[D
M-<Z/::<4CO;NVO9FOHHQXO\ '3_@FK\:/ O[6G[57Q"NOV%-=_;@^'7[0?Q2
MU/XN^"?%'P^_:RA_9YUGP-+XH,]WXA\'>*O#E_KNC6NLF'4;B066I06ET6M(
MHV-[B=[6'S<3FG&KPE.K*ECL(J6+IY3BY4,#&=:53+\!BWB,WHPCEV:5?J6:
MYH\+"G.G@:]-X:$H0^JJK*O'[K). _HN0XAQN7TLPX6XAGCN',=XA\.T<SXL
MJ87+*6"XPXNR"&3>'>9XBOQKP#@5Q1P!P)3S_$8S"XOBS*\;'.\51Q.*CGLL
M#0RBM^@WQ+_X*]:[JOAG]BG4?V1?V;-7_: \5?MJ^'?'_B'P?X/USQKHWP]O
M= ;X:I)%XMT/4;W4$N-,;5-)O['6K>>:2]MK*2+2FFMY9#=0(>N^#/\ P5/\
M6_$CXZ_LO_ #QY^RC\1O@9XZ^-^K?'7PQXZTKXC79LKGP1XA^"OAPZX]SX7E
M&FPVWCKPSXA>*6"#6[)[>VMRR+#+>A&FD\[TG]B'QOX0_:,_X),>)OA%\!&^
M%/P3_9S\#_'1_B9X-F\>:/XIG^$&M?$WPE=WP\/7>M3ZA]M\9W=QXMUF_M9=
M7T6&]MIYQ+<?N+3RR/6?^"A_P#_:9NOV@_V/_P!M']EGX>^&_C7XU_9CN_B7
MHOB3X+^(/&&F> KGQ=X4^)WAS^P+F^\-^)M;EM]%MM8TD2W4@@U*ZA1W>SEC
M2Y2*X@/I1K<60I8K,:^,QD_J>.R.C7R["Y51J4,3@)8;(ZV;8O 0GAX9E*4:
ME?,N:G!U9R@JF'A0I5\,DOB*N6?1YQ..R#@S*>'.',.N)N$_%;,<LXSS_P 0
M,QPF;9%Q;2SSQ4ROP[X<XOQ6%SC%<$4*-7"97P2Z6+Q,,!A*6(GA,XQ&:8_*
ML[<Y?36@_M?MK7[?OCK]B+_A!S;Q>#?V=] ^.@^(']KJYOY]9\56OAV3P[_8
MGV4&&."&]ANDOOM;%Y(Y8VA52C'[:K^<;]B+XH?&CXN_\%I_CYXF^//P';]G
M7X@:?^P_X4T6]^'!^(7A7XG26FGQ_$/PS=:9JMWXE\&SW.C03ZI%<.Z:5)(E
M[;1PAIXQY@)_HYKZ7AS,JN:X7'XJI.I.$,\S?#895L//"U:>$PU?#TZ%*I0J
MTZ5:G.FI5(M5H*M=_O-;6_$/&S@C \ <0<(Y%A,/@</B<1X5>'&>9W++<XP^
M?8#%\0YWE&<XO-\PP>:X+&8_+L7A\;4H8.K3GEF*J9=RP_V2T'4N5R_CBZN;
M+P5XOO;,LMY:>%_$%U:LOWEN;?2;N6 KCG<)44C'>NHK'\0O;QZ!K4EV-UHF
ME7[W0X&;9;65IP2> /*#YSVS7T#V?H_R/QU;K2^JT[ZK3Y[?,\,_9$\"6_PT
M_9?^ G@R"V^R2:5\+/!\^I0;0I&NZUI%MKOB*1PH \R?7M3U*>0GYFDD9F)8
MDGZ+K,T66RGT;29M,,9TV;3+"73S#_JC926L3VABQ@>68#&4Q_#BM.DM$EV2
M7X(<FW*3>C<I-I[IN3=OE>WR"F/T'U_H:?3'Z#Z_T-,DBJCJ>I6>CZ??ZKJ$
MJP6&F6-WJ-[.Y 2*TLH)+BXD8D@ +%&QYP.V:O5\4?\ !0+Q_<^!/V:?%T.F
MS/#JWC2>Q\&6DD3 2QVVJ2-+JTR99<^5I=O=;@"N0V-PS7-C<3'!X3$XJ?PX
M>A5K-=_9PDXQ_P"WI\D?GIJ=^58"IFN9Y?EM*_M,?C,-A(N*NX^VK0A*=NO)
M3=2;7]S6RNU_+W^W-\=-9\0:I\7?B3;M'_PDGQ&U;4])T.?S?-"Z1.(]/TNP
MN!+<1_9M'LM&CCNH+N%4%E=0#S9?,8AOQ_U6+P'X!\-^'=4U'2QXRT-AH^K/
MIUAXID\&ZUJ5R=1MYQ>V>H"\N-2M=8L)$%Q!I]I+;75P7C6YDMY79U^OOVA[
M^>37]!LYQ>+I6D"\U@VTHD=+2X2TF^S"Q<%YIH=1C0N;>$,6F<Q&)\&1OF?Q
M;X0U7QYX>\.ZYJ,-MX8L!XD6""RLM5T_7-6U?38/*@U$ZQ:+(R:9<P-(J1Z=
M]F-M;C!8_:F!'Y_PI"CB)K$X]UE''XVI7QN(ITYRE2H4ZDW.U10J4H2E%5G1
MC53A*JH*7+#VLX_U]Q?@IX;*HY?@?90H9/E>#P&"IQQ&'ISJXC$8-4Z%.&'J
M5Z6(KN'+1^L5,/9T,/*M)^UJ2H8:I-\?OVS?#?B?X23?#.'PSKVNZ/=:L+O4
MK_4=)N+OQ9I<$-H\<-S<W^HZA=1![.21+65(1<WLELK^9,"0K7_V<?V8_@-^
MT;\'-"BNOBE\0? 2ZIXHN=<\6^ O"L>E>)O"TWB/2IVM+76GT?7K8WF@"]6<
M7[:?$MP(%GDO!;26[B2/Z!\(^(=2U33_  M\'_%7@/P)\3/@QJ^L:!X=3PS/
MX=TWP_XJMY;^6VAMKWP_XOTQ=,U)M6LV$MQ>+.39:A 9X;^9V4,WZ/Z]\.OV
M3/V-O L]KIVFP^!M*\4S1:A>V=K#/J7B(ZM);E!<WAFN9+V*PTZ58V:: ):7
M%O(\A%Q$\DB>EC,'1SI5<%@J&,K4<.JV+PV5QP]3,<=C:\%556:JX*C0J8&"
MP*<J^'HPQ\<56I\]/ZO2C*,OBJ?%L/"_*,+5R]8_).+*^*BZW$]+,,!3R2AD
MWNU'3Q& S&&9QS?%/,-,MK2PF45LHHKDE4S#%XCGI_ ?CC_@FWKFLZ]^S1\"
MOV<Y7^(6GZ)\1$\=:[I$\]I_PDOBKQ'9WNGW\NO:UXBMHETC1?#^FP^7#:Z;
M?1VNEZ0/,,37$T<<9_7O7?#^I>$+&]^$7CSPQ_PAGQ#@M7>;PSK<UDL=W"]R
M[1W>GWUE9PZ=?:3J+JXBN=-2YBFD+!RLZ2;?TH_X)+^&OA;X@_9VTS]H'PA8
MRW/BCXEWNOZ7JOB.ZT^[T^-])\.ZY<6%MIOAF"\177PQ/):+J<,\;3QWUW-)
M,ES)&D83Z?\ VUC^S%H_P0\0^,_VI]'M+OP%X<^R0V^JVFEWEYXRT[6=4N5L
MM(B\$W>C(->MM>N;Z:(6::?/%&TB;[P&UCD(]?#Y#/'X7+<+3^M4<53J8;ZI
MAX492JTJL8J.$PJPU91J1:G47M*,E"K*M4J*;A4<C\5S/C7$XO,\RSG'XBEF
M?UZ6/Q.8YEB9>QK8^6.JO$X['8BO2C!.<XQY:4W35.AAJ-*G3HPI4Z=.'\+'
M[>WPA7XI_$7XA?$;P+XHT[QIXW\*Z'X3\-_%CX>Z/=Z+/\1?A[HGA/0K32]&
MOKOPKI2?;M:T=-'BMEGU Q7-_!;FW>:6=%40?G#\+?V4OC%\;]0E@^%'@'Q#
MXJT#26BN];\47-PG@W1I8(#'Y^FVNN:PJVZZG<6^84M[-;V[1W#K& J)7[9_
M OPK^QGXT_:X\5?$._\ !'B7PI\:-1?5]%\":SX@OM>\,>)_&?AR+4W33=9U
MQ-+EM]!OO'%QH"6T6MV$=Q*EY9QR.BW%S&9*J_\ !3GXB>.]"O\ PK\'/"VJ
MWGPY^'GB[1;B?4+OPC9Z=:7?C;5K/44BETT:E%:O>V.J62"&>$6=W;WDEG<!
MVG9?,QX'$W"W$6'XEQ>0YAA,URJO1R/^WL9[58+#X7&X&--U*M7+L36J3Q%1
MRIJ2JX>A4Q#C4A4@JD+.C+]V\,?%[(</PSDJRC*.&<]S"OGM'(<CSK,:V<U/
M[*Q5:I"G3I9QD&!C#+,;B<-4<5E^/KU<OIU(U*57$X6M4IPQ,/R/_:<_9I\;
M?!_7-%U&^^'>C>![7Q7]F73O"]O<:KXCT;0].@TZ)?.L_' M-+T'6M78H);Z
MS_>75M+))/=M Q8-];_\$WOB1KGPN^,.FZ/8ZB;'3-:N[34;"S>&_P!0M!XE
MT>2'4(+O3;&UN!]JU*[M+=K%[RYG,8()5I(XHBWQ)X>^'?C+2K[3IH?$VKZE
MH,4=V]QX;\:ZRVO7ND6MQ=?O-2T.]\ZYNH9F<VYPB&!R["5HF+E/:OA!J=OX
M?\;Z)XHL5:_U+PQXHL9K^U@BU73TGBN+UH+N"2XGBML)):R!KFXBD^S20@HS
ME9DDD^-PV83I8F'*ZLE0JP=6K.JZG-'VL:*=ER1I)-QI\E.FE[K:3IN,S]XS
M7AJIC,IJ_6YX#$5<;@\30A1P.5_V:J-2I'$594:\9XG,JV+JU$IXA8VMF&)E
M7I3UJ4:D'AG_ *;G@_Q%:^+?"GAKQ/9R>;:^(=!TK68)-GE[DU"R@N.8SRC!
MI&#(?ND%><9KI*^!_P#@FO\ %VV^+_[*O@W48I$-SX6OM6\)75LKRLUC#83B
MZTNU99_W\8M]+O;2WC6;]YLBST(Q]\5^V4*D:U&E5B[JI3A-/_%%/\[G^>&9
MX*KEN8X_+ZT>6K@L9B,+.-[V=&K."ULK^[R.ZT?WDZ]!]!_*EI%Z#Z#^5+6I
MQ!1110 4444 %%%% $-Q<06L,MS=3PVUO"C233W$B0PPQJ,L\LLC*D:*.69V
M"@=34%CJ6G:I$T^F7]EJ,".8GFL;J"[B60 ,8VDMY)$5PK*Q0D, P)&"*_+S
M_@K5^R+\:?VOO@;\+O#WP83PCXRG^%/Q\\#_ !D\>?L\_$3QCXE^'WPZ_:B\
M">$M/U^VU+X*^,?&?A:*ZOM"LM3O]5TW7].FU#3]1\/3ZQH-A;Z_:2::\V/P
M%_:Y^,6CZ3^QQ??!C]BC]GO3/^"<7Q[^!G_!2;]@GPY^UW^S[XKM=9EN].\5
M?%SX@>%[SX.^(/#OCKX5>,8- \=?##QTEI:WVJZC:SK+XI\!6FH:8VFZ!JTE
MN2 ?VE5\"?MR_P#!-O\ 9R_X*%6WPZM?C_>_&.R7X7W'B*Y\,/\ "7XS^/?A
M*[OXGCTJ/4QK:^#-6T^#70@T:S.GOJ4,\VG%KL6<L*7MTDOQ'>_MA_\ !376
M?VV_B3^R)\+?"G[%OBW4?V;?@#^R]\8?C)+XI@^,'@EOB1>?&KQ1XUTCQQ9_
M#'Q%%XI\0V'@:R\-:/X0GU/P^GC#0O$LMU<?Z-?7<@G!M_!=:_X+5?$B3]J/
MX*^&OA+<_"CXY?LN?M%_M6P?LJ^!O'>C_L__ +2W@.3PSK/B(:_H&A^+HOC=
MXHU&?X,_%K3_  [XZT"ZL/$&E^$+;1+CQ#I,=W+X:NHY[*ZDA /TZ^ O_!*K
M]B_]F;]F;XN_LI_!;P!XC\&?#OX\VGB.#XO>)K/XA>,Y/B]XZOO$^G3Z5?Z]
MJ_Q;FUAO'"Z]:Z?.]OH^HV6K6C:,,R:;';RR3R2^%?LR?\$3/^"<?['OQU\%
M_&_P=X;\<^+_ (VZ!;ZM:_"K7/CW\<O'7Q<U3PG/+9L-<U#X=Z-XYUZ]M-/U
MC^S7D2]U+3;"6\M+.1Y$DM_EE7\__@E_P4+_ &JO#&J^*/V9_ ?PJ_9=TW]K
M#XH?\%6OC[^ROJWCZ6X^-?\ PS_YGPX^#VD_&+Q_\7KOPCK/C;Q#X];6-8M#
M%HNA^!]%\5Z%H27&+F+[)##-%/\ +?C;]JK]N+]IW_@HQ^QU\/[Q_P!E_P +
M?M+?LG_MU?MO?LZ:!XML_"WQ7E^!_BS1M&_98\%>)]0UW6O!\GCN3QO'J5U:
M^(+NRLH[7Q5%:13Q6\LL31B3S$XIVND[6:NKZK5?<]BXU*D$U"<X*2:DHR:N
MI+EDG9K24?=:V:T>E[_V845_'W\;OVR/V_/VFOC=_P $YM.T'4_V?_A%\6O@
MQ_P5;_:H_8T^)%AIG_"W]9^$GQ&^*?P7^"GBS4+;QE)IUAXL\/Z_?_"+7/!V
MJ7%TG@?79;C7],\:PZ7J']MR6-K-;C^C#]NC5/C+X=_8D^.GB#P"OP@U7Q_X
M9^#/B[Q!XKT[XE:5X\F^''B;1-"\&:IJ7CW0[6W\$>*O#GC329-?L+6_L?#M
M];>(UN=(EN;>>YFGDA,M,@^U**_F;^%/_!1/]NOXG0:)\._V5O W[(/@;PW\
M'O\ @EK^RQ^V;K6A?&&Q^-OB.;6K[XI>$_%%S<?#?POXCT#QU#=Z/HVC6W@A
MK'3M<\26GB;5V-[!<ZG<:A(D[OY)^R5^U_\ M7_M0_\ !4/X<?M3>'=;^&GA
M#X%_%K_@C_\ !O\ :3\3?!;6XOB1K]_H'PQU'XOZP_B?1?#?V3Q=I7A!_C./
M%MEJ=KI?CV\T+^Q9?!<EEIE[HSWL4DU ']7]%?SM_LT?\%5?VP_'GB+_ ()U
M?$SXS_#+]G*S_9N_X*;>.OB'X%^%'ASX:WGQ''QI^#=WH?A;QKXU\$:AX_UW
MQ/?S>"O'%MK.@^"+V#Q)'X<T/P[+I>IW]J=.%]:0S,=K_@KIK?[5VG?M[?\
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M=GX[>)/V@M=LOA_\(O OC;X,^'_VVW_9*E^#?ASX5_M+^(?VDK_P3IOC"S\
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M%?'/P1^&?[-]S^SU_P $RO&?PS\'?%70/B=>?$B3XP?&:7Q/X1\(>.O&-_X
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M-J7BOPRMO+-!J%EXG\'1GQ#I=]I,T,L+)JT1L9H]/#.8WN)5CD5E8BOYTO\
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MTL>(/!?CWP%K7A[Q7X?O;G2[^\TS4%L-4BM]1L+F2UO89XBJK].T4 ?"+?\
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M]^T7P#T)&/KQ78?.-MN[=V]6WJV^K;>K;ZMMMO5MO4^I)(TE1HY%5XW5D='
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M0H9[P3CL5@,ZP6)RR=-Y3/'<-X6$L33PL,4\#BZDG.K_ *.]%?GG^P7\-/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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D% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #  +P# 2(  A$! Q$!_\0
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MGP[^$%XF 1O1O#D=MN.1@G=;E<Y_A [5^">A?&GQU\"O%T_BSX?ZP-&US4_
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M5?$EM<)YMM=_#/QW;W$)VD2QC1&N(XV#@J5%S;V\G."-@*_,%-;6C9'[-&K
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MS]C1M4E4G3H\CKU84Z,93J1H1J0G44;RLXJ,*DY1IO\ *2YTRZM[<7,NF-'
M[E$N5:5XE8$J4+"5]C$JP7S"N\ [-VTD40UDL!5[6Y-SSMF2[C6!1Z&W:T=S
MQP#YXQSP>_Z*:M\"$T5CJM\U[H6EW/[F:XN;>[:>\CGMKB2._AL7MQ#J&FO-
M:3',:*D#B-2_EE9#\I_%'X?VVB067B31I([K1=1NI=/DN(%:);?6+:VAN+VP
MN;:2&![:X19EFB"(UO/:/'+'*SF0#+-.%\RRQSE4I)TZ="IB)M5:<IPITJE*
MG.;I-PK>S:KTYQJJDX+WHSY%R3J;\,>)>1\28BGAL-7C*5>?LJ%6,:GL)XCE
MJ3^J2K?O*"Q*C1JVIQQ$I3Y&N15(U*<-_P (%3\ O&(4$;=:OR<X))_LRUR<
M@#C)X]!C)S7D?A/.ZXZ\^'=7'7N;!NQXP<=?ICDBO6_!@!^ _CE,\KK5[QW4
M'2[(X'L2<X]\]Q7D?A/K/V_XI[5^!_V#GZ]#CTSW[=:^:/TD^A_V5?\ CR^,
MO_8L_#O_ -6GX:KZZN"?[1NF;=@:K9(HR2I"W4/S*N  <G!(+!L9)R#7R'^R
MOC[%\9/7_A&OAUC_ ,.IX:_H:^O+T!;QRLRMOU*T=H5Q\A^VQ@E^2=[   G&
M0,A<\D#TT/J3X4Z<VJZW?VD;!9KCP_J>G0.V"JSZT8='BD/?,3WP=<'.Y1TK
M_5K^&&A0>%_AK\/?#5LD<=OX?\#^%-$A2)%CC6+2]"L+% D: *BA8!A5  '
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(Y*^MO*Y__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #- 0,# 2(  A$! Q$!_\0
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MK:;]>GXM?F?;>3ZG\S1D^I_,U\DVG[:/P7NT$BZE(%/=-2\.3\^G[C67R<Y
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M+#5E.,(*\HTN5.+<U*"DU*T[VBW8^>O$.F-IBVL\8+V5]%YD,K G<Z$),AR
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MU-D\KV".4+*K!*CO?^"@_P#P4F_M'1/"E[XM\%VNG>)+37]'L]4L_ ?P^O\
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M/&5Q@#&1W/0'->J^+/V+]>^&O@GPU)X9T#4;GP_:^%?#EUX>L;>UNKV>2"Y
M*Q37,BLTUPB.6N97,8P0=J@"OS]^.WA[Q/X#L1JOB^VM-!DNIS'HNEW4\?\
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M$DWLXS=_Q/YJ_%>GZ>OB"^U[4;M8K&YU"ZG,32JKW3FZD\N$NTBG[)$"TDJ
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M/,1\LCKN"*Y((;S%)4@KM*GYCG%?77PF^%5YXMU>&VTJ*_7<X:ZGTPN(Y"S
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M!*J@$GA5 )QUY+#\*\N\6_"J7XAZ/>:+-!]HLM05P'N@6AC<*!\@Y9G3[^U
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M:=X9+23<8F**^T.!_;GX<\1V6L6-M?Z=?6U[9SHK1SV\J2QG.#C*GAEP-R,
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M78X!+8ZDG)(QG^5=SX,LYKF4R7"8MXR#NP1N=?F XS\HQEB2 !QGFJ'A[PO
M]ZL;W+LDB[V'E*"2>",[SQSGI_.O3Y+)42TT6RD-D-1G^P-=QJK2PQ-$9)7C
M1L*99 "H=C\A.[#=*YI2E&#E=))77>VEOF5&FF]/75Z:'F6K"7QCXI73;4E[
M?3 P+HN8XCG^/!^^QQT. !Z5Z7I'@K3[*U6[UR^A:RM)#<"1=J>4Z %BLO5
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M?G5^UM_P3=^$O[2<M_XT\,M;_#CXL30RNVNZ?;*VA>);D(=G_"2:5$$4SNX
M?5+/9<@?-,DQ&3]67?B[4H$Y6)RRYR05/4CMGT&.E90\8:[>2"-+H6RY"GRT
MRQ!QR6)'.23GI[5Z&4Y]C\CQ<<;EF*K8;$PO[T)2Y)QNFZ=2FWR5*<K*\91T
MNVG<YL1A:&,HRH8FG"I2=FU)7:_O0:5XR7=-7T3NC^2?XO?L@?&OX%^)9/#?
MCSP/K4$ZR2_8=4TRRN-5T#7(48A;K2M3M(I89E9,.89/+N(L[9(4*U2\+?LI
M?M"^-(TF\+?"+QQJELX!CN5T2YL[5@<<BXOEMHMO(Y#$=3V-?U?>(]>NX8W%
MVTNH;7W*MS,3&K@+ED0QL%)[X/<BO,-6^(?B+8T4$XM800JQ0Y55&W&!C';
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>OFE=@J@@ KB5.5E><K]?>EO_ .!'=[*'9?U\S__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !1 (P# 2(  A$! Q$!_\0
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MOP5KJ6LNJ1^&-8U1[".Y>*5+=[M8EF:.18RQ1@/D#_@W2_Y1E>!O^RI_%O\
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M=&XN=9U#5I99I]7U+5I[V_U2>:66^N)W<FORA^)O_!O3_P $Q_B9XSUGQO\
M\*L\8_#^]U^\FU#4=$^&OQ"UGPWX46]N)&DGETWPY<1ZKI^AP2,WRZ;HB:=I
M, &+6P@RV[]H?$GB/0?!_A[7?%GBG5[#0/#/AG2-1U_Q!KFJW,=GIFCZ+I%I
M-?ZGJ>H74I6*WL[&RMYKFYFD8+'%&[DX%?R+_M+?\'5.A:'X_P!5\)?LE?L[
M6OQ(\*Z3>7%C!\1_B?XAU;0H_$\D#M&+[0_!&@V']I6FD2[/-L[C6->MM3NX
M75KG1]+D0Q-OQ-B.$<!A,+3XDP^7SP\+QP.%JX)8JI%0C&$EA</1@JE.G&/)
M";C*E2^"#YI<L5Y'@5D_TCN+>(L^Q?@EF_&&%SBNJ=;BG/\  <43R+"5:F)J
MUL10>>YQF6*EA,7C:]5XG$8>%>GC\P:^L8BG["A[6K+]SOV,/^"2/[&_[!WQ
M&USXK_ ;P]XVC\<Z[X4NO!4VK^,O&M[XE%EX>U#4=,U74;33K0VUC:PR7]YH
MVEO<7,T5Q.J6:16[P1R7"S9'[4W_  1K_8)_:\^(-]\5OB=\+M4T7XC:RXE\
M2>*_ASXHU+P7>>*KA84@6]\1V%G]HT74]3\N*%9-7?2TU:Y$,2W=[.B;3_/)
MX4_X.JOCQ:ZM8R?$#]D7X9W?A]YX_ML/AOQCXR\.:N;52!<M97>LVGB6R:=0
MRF,2V7EAL(Y^<.O]2_[#/[=GP0_;_P#@W%\7O@O>ZC;#3[V/1/&W@GQ#';6_
MBOP)XD-K'=G2=:@M)[FUGM[F"3[3I.KV,\UAJMJ'>)XKJWO;.T\C)LP\/.(:
M+X>R["Y95HTYU,9#*,3ELL-%ST=;$X>CB8^_42Y75G1KJLJ;3G%TKV_2/$[@
MWZ:'@OF</&?C3/\ CK 9CCL/@^&<1XD9%QS2SNK#"6G3RW(LXS/)*Z>%P522
MJ0R_#9IE<LNJ8N,XX>M',.7VGSY^SK_P1N_8E_9@TWXSZ9\-/#GCV2/X\?"[
M7/@YX[N?$WCS4-9NSX#\1A3K.FZ*Z6UE#IES>2Q6EP=0$$]W%-96Q@DCC$T<
MWU[^R5^RA\)OV+/@IH7P%^"T/B&/P1H.IZYK,,WBG6%US7KW5/$.H2:CJ=Y?
MW\=II]LS23.L<4-I86=M#!%%&D 8.[_A#_P4X_X+X_$C]B;]J[Q7^S5\,/@1
MX'\90^ M&\)S^(?%'CG7/$,4VI:SXK\.:;XJBM]&TW09+)+73[#3-9T^W>>[
MN;NXN[X786&V@BB:?\_?^(I7]J#_ *->^"'_ (-_B#_\MZ\^7&7AMPWCYX*C
M2A@L7E,L;EU\%DV*<</[;$4ZN.H4:M.7*X5<32A.LXIJ=2DFI-1U^RI?1G^G
M#XV\(X3BG,LPQ7%'#GB)1X8XSMQ3XGY!"OG2RW*,9E_">;9CE^,A[:GB<OR/
M,,7A\LA6G3GA<#CYPG052L_9_P!46G?L#?L\Z7^VAJ_[>=GI?B>/X^:YX2'A
M"_N#XDG;PB]O_8-EX6?5T\._9PRZS)X;TZTT=G;4'TT6\7VF/3$U%FO3]IU_
M'/\ !K_@Z;\02>,-+L/V@_V7M"L?!-W<K;ZKX@^%7BO53X@T2"1T!OH/#GBJ
M&XLM<%LA+367]OZ-)*IW17 =!#+_ %L_"KXH^!/C9\.?!GQ8^&7B"S\4^ O'
M^@6'B7POKUB7$-_I>H1"2)GBD5)K6Z@<26M]97,<5U8WL%Q9W445Q!+&OT_"
MW$/"N=K&QX<K4%4>(J8['X98:K@\1*OBI157&U:%9*51UJD(QG7A*<?:149J
MG)I3_!O'WP8^D%X6U.%JOC;E>;/"1R?!<*<(YU5SK \39+1RCA_#U9X#AG+\
MURR<Z&#CE>$Q5:MA<JQ5/#UUA*M2OAY8RA"<\-_#I_P?"_\ )/O^"?G_ &.7
MQV_],GP\K^EC_@D)\$_@UK7_  2N_P""=6KZU\(?A?JFK:C^Q=^SA>:AJ6H_
M#_PG=W]_=W'PI\+RS7E[=W&D/<7=W=.QGN+JXDDGN9G>>:2261W;^:?_ (/A
M?^2??\$_/^QR^.W_ *9/AY7X_P#[,W_!!3_@OA\;?V=?@;\8O@A\>8M%^#?Q
M1^%'@/Q]\+-''[8GCSPN-*\ >+?#>G:[X4T\^&=.WV/AYK31KZTADT2U/E:7
M(C6053"5'UI_.I_4Y_P=6_L]_L6Z'_P2;^*7C_Q-\-/A!X+^-7ASQG\+H/V>
MO$FC^&?#/A7QM>^--3\?^';+Q-X=T6]TBPLM3UC3[KX:2^--0UG19))]-2VT
MR/5IX5N=,LY4\[_X,Q9_B')_P3(^*T7B<71\"V_[5/C6/X9M.TYA^QOX(\!3
M>*TLA*?+6V7Q))<,ZVV(C>273/\ OVE-?Q[_ /!2O_@BG_P60_9'^#MK\??V
MQCKGQH^$/A&]CM-8\7Z+\<-:^-UI\,O[8N[/3[6^\0Z?KER-7\-Z1K.H7%II
M_P#;EEI\NE+>O:VVIWMI-<6:S?WG_P#!LG^VI^S%^U)_P3E\(_#/]GKX2:9\
M -:_9=GM?AU\4_A+INK7>OVP\1ZW%<Z_%\3K+Q#JK-KNOVGQ/N6U?6[N^UQY
MM3L?$%OK6AR7-W9Z78WER ?R@>"O^5P[4/\ M()XZ_\ 42\0U_IU5_F*^"O^
M5P[4/^T@GCK_ -1+Q#7^G57/0WK?]?7_ .DGJYG\&7_]@,/_ $L*_P T[XY>
M#=!_;V_X.@]?^#WQYDU#Q/\ #?4?VJQ\--1\/3W4ZP7/@#X,^%)7M/!D1259
M;+1-<_X1"6TU-;.2"7R];U2[MWANY_,'^EC7^;E\%/\ E;+U3_L^7XV?^HKX
M[KQ^($IQRRG)*5.IF>'C.#UC.-X*TELU:333TLWW9^I>#<YX>KQYC:$Y4<7@
M^ \WJX3$4WRUL/5Y<0U4HU%[U.:=*FU*+33A!IWC&W^A]H'P2^#7A31M-\.^
M&?A-\-?#^@:-:0V&DZ-HW@;PSIVF:=96Z".&ULK*TTR*WMX8T 58XHU7'4$D
MFOX1?^#IS]F#X/\ P"_:7_9L^,OP;\&:%\-=>^,_@[QBWCJU\%Z?:^'-+U/Q
M/\.-<\-KI7B]--TJ*VL[/Q#=Z?XGBLM3U"TA@DO_ .QM-NIP]\MS<W'^@37\
M/O\ P=^?\CI^PI_V+OQU_P#3M\+ZX.-J-%\.8R?LJ?-1GA9TI*$%*G+V\(7A
M)13C[DG%\K2<=&FDDOJ?HKYEF$?&[AB@L=BW0S&AGV'Q]&>)Q%2EC*/]CXK$
MJ&)I5*]2G72Q%&G6BZL*DHU$YQE&4IN?Z9?\%:_C[XYUG_@W]\/?$NSU:]L_
M$/QL^&'[+NE^,]1>;S-0U"Q\<GPC?>,8)KA0N_\ X2 V]U::@2N)[+4+N%@#
M+D>:_P#!L=^R-\#+?]C/5_VEM:\">&O%?Q;^(OQ,\8>''\4>)="TW6+[PUX4
M\(#3-.L?#WAV2_M[@:9;7M\U]JVJW%FL%UJ,UU;V]W+-;Z=9QQ<M_P %1_\
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MS)?:U\6?B'\1EL9<;'N++P_<>'(4FNQ$6$?^EV0DSY;W4*$R+_5Y_P $[?\
M@GE\(O\ @G3\%YOAE\.KN\\4^*?$U];ZY\2_B5K%I!9:QXUUVV@>WLE2Q@DG
MBT?P]HL$UQ;Z#H<=U=_8Q=7MW=7M[J.H7MW-Y,,-Q%Q=Q5P[FF8Y!7X>RGAJ
M>)Q:^NUZ=3%8S%UH<M.G2A3::@I*FY-PC",(3<ISG4A3C^C8C._!;Z.?T?\
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H_5#_ #\"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #  C(# 2(  A$! Q$!_\0
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M>#=5FETFWN&):;2TM)6PR$G,UWXQS3EA'<$D\8#9Y., #/U_*OE+X@ZJUO\
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MX#^(-.\!ZW82:-J/QK^)'Q)^$NM>(?B9IUUXA>T\1ZM%?^#[3QA#H/A^31]
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M.$?^"9/B,Q^5\6]8TU9&P&U#1M,D"C;N#,ND^(-4DVG[HVHQ+< 'K7N7A_\
MX+/?\$V?$07[+^TIHMH[*C!+WPEX]&-Y*A3+:>&+R D'[V)BJY!9@* /U%HK
MX6TG_@IG^P3K*J]K^U'\+[:)F*^=K>HW_ARW3;C)EN/$.G:7#"@R,R2R(G?=
MBOK7P+\2/AY\4-$B\2_#7QWX.^(/AV<@1:[X)\2Z-XITB1B VQ=1T2]OK3>
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M*/C+PQ*OP#U_3_&NHV^GSC3M3E^'WACX@?#>'1-4CU>"Q@M[RPU=0#^GZQ^
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MF3Z]I-M>7NFB1PK3)87KW%I'.54SQPK-M7?@>V5\%?\ !+WX0_%#X$_\$_\
M]E7X7?&EBGQ2\.?"C19O&>F;Y)$\-ZMKTUWXB_X1"(RJLBQ^#[75;?PSL8'8
M^E.JLR!2?O6@ HHHH **** "BBB@ HHHH *:Z"1'C;.UU9&P<'# J<'L<'@T
MZB@#\Z_%?_!+K]E7QO\ !+XA_ #Q-I_CW4? /Q*\'^!O!FM,/&MW:>(M,M/A
MSXPUWQSX3U?PWK]E:V]YHOB"QU_Q#J+7&HP;TU#3G&D7]M<:;+>6UUH?$7_@
MG3\,OC'XIUWQ!\8/C#^T5\3=(O\ 1?&6B>%O 'B7QWX8MO OPRB\=6NGZ;K=
MYX#L/#7@/P_K,=\FCV']CV#>*]=\5VMK8WEX_P!DDOG@O(/T$HH ^?OC;^S1
M\,?C[IOAW2O'$&M6UEX87QLFF1>&=230ACQ]X%U[X>:^;@16DRS,?#_B/439
MG:GV;4/L]W^\,/EMXCX@_P"";O[*'B_Q9:^(O&G@(>-M 63P5J6M_"CQD-)\
M4_!KQAXM^'G@S5/A_P"$/'_B_P"&^MZ/>Z!K7CC2/"FKW>FKKKQ1-=E+*ZOK
M>YNM.L)K?[OHH \:^ WP&^'7[-GP\@^%'PETR;P_\/=-\1^,?$/ASPHKVPT;
MPA'XV\4:KXPU/PWX3L+2TL[71/"6GZUK6I-H&@6T7V31;*==/LREG!;PQ5/C
MU^SM\*OVE_#?A?P7\9?#T7C+P1X:\?>'OB'<>"-5BLM0\'^,=3\,0:FFDZ+X
M]\.:I97^E>+O"<=WJ2:O/X=U2VDL;C5]+T:^D!?3XU/N%% 'YUVW_!+3]D"P
M_P"%AV>E>";[0_"_Q \$_$7P#!X T"?1]"\ ?#G0_B9XJ\#^/M:E^%'A32="
ML]-\!ZII/Q"\ Z/X_P#"VH:6C2Z!XPN]6UJT4SWD0MOJCP;\!?!G@GXJ>*/C
M+87_ (IU3QYXR^&/PQ^$_B+4M?UO^TH=1\._">\\8ZAX;OY+86L"CQ#>7GCG
M7I]>U4,/[4=[4_9[?[/\_ME% 'XN_P#!P7:?:O\ @D[^U VW=]CL/!=^3C.T
M6OC?07W^VWUX^HK_ ##-0NM_A;5G!^Y'JF""<_=TZ08YP6^7@'.<>F0/]1O_
M (+SVWVG_@DM^V<X7=]C^'-C?\C('V7Q7X??<?0#U[5_EB270D\(:ZQSA/[2
M4D<D9LK60X_A)PA.#C/!(SP 75'J^G6?P>F\+:#_ &EH7P#U#59?#TC:A=:_
M\0_B)H&IOJ)M$ECGU&VL;6ZLH-5BDE>/[-;*MC-=6DB2,D<D9?Y@UGXN?#E=
M"N]'M/@#X"L]3%A/8VOBE/$GC"\U"TU)5DM3J\%O+J"Z?<)(K_:[:UG@\B*Y
M$<WS1EH:\JUJZM#OS-,/O9S''P,$]0V/?M^6:\PO[RV)D475P3GYE\A2 ?1O
MG]P1@>A]Z[_K>'BZ4J&#CAIPC:I*.)Q%;VS48)2<*UE3M*,IM4VTW/E?NPB>
M-ALNS"F\5]>SFIFE*M/FPU&IEF6X%X.#G7<J<:N!;GBDZ=6E2Y\3",XQPZFF
MYUJMOH;X6^(+W^U[%$OH(@\D=MY<LR11OYA"NC$KAC)D[N0H)/(Z5^J/A']H
MW6?AE9:)9Z[I.CZ^;+;=:)]JOY(;NQ6!V:"/[98EFGBCDC+BRN@ZLNT(VPC'
MX;Z!)J+M(^EKJ5U]@1;V?[%I4UVUM$9HX1<2K!N98Q--$F\K\KR*,C(SWB_$
M"ZN8XUN-<NI#$ZRQEK:4['7 5D(E('H!QP.17Z?PCXC5N&Z$Y8:6)I8VZE0K
M*<90CJHU+PJQE%KW;12BX\RM):67X5XH>"&$X[Q&%GF6&PM;*Y+$*5*IAL12
MK5)I3I<V&QN'J8><>5594L2J=6;E"HZ-2RERR_8"U_:+OO$<VJ0^(-3L;_\
MM:/5;NU>*3$TFI-<'58(3%&F]9K>X!*@B*.>VW1W!D3K^?W[87B1M>\;V4[W
MJS7&G>&/"VG2LO)6:VL!/*$QE2\,\T@92.'CQW(KPB+XH:GIDYN;'5(UF.6W
MMIS;@2&!96#94NC,CE0#ABN1QCS;Q#XEO_$=W->:GJ;3S3333,S6\F6-Q*TS
M+DO]R-F*QCG:IVBN[BWQ2J\19%2RK$RQ->M"NZGM:DI-J$'&=%.I*;E-QFZB
MA[J5.FW"\F^8\[PZ\"<-P;Q71S[!4L'A,)0P.(PL,-1A"+<\51P^%J>SI1IJ
M%*G]6PU.-11:]K-1DXPC#E?Z7_M@?\%)OCO^W9%^Q3X(^+.G>"]-T3]G;2K#
MPQH-QX5L+NUO?%.KL?#GA^\\5>))+RZN4AU&YT+PWH5G_9^DI9:3$UK-=16B
M3W<[GXB^.PQ\4;P]S8M_Z4-_C7FW@R5)?%W@M/[06=;7Q-I)@B^S3*<R:A;A
MT#LQ"\C/S#C!&"37I7QW!'Q0NLG)-C)VQTN#_C^GK7X]C<2\9B:F(:Y?:*'N
MVC%)J$5*RBE&TJGM)MI7<JDY/WI,_H[*<NI93@:6!HI^SI3K.+E4JUI.,ZK=
M/FJ5IU*DO9T50H04IM4Z6&H486IT::*'Q)R?A-\"B>S?%!<_3Q!H_O7N/[&)
MQ9?%7_>\(?I/>^U>(?$=2?A'\#"!TG^* !SV_MW1CCG Z_6O;OV- 5L?BID=
M6\(@=/\ GO?5R'HZ6M^7]?,^CKS_ )+-\$.0"/&3XS[>'-=;U%?4FGG(3W_#
MD<>OO7Q1\:?"OB;Q%X?N-9\$BZ;Q=X#N=*\6:/%8NZ7EU# ]U;ZE;VPB(DEF
M%G*\JVZ?/<(LL2AF(4[G[-_[2=CX_BM_"OBZ>*P\6P'[-:W4X2VCU5XR1]EN
M$PB6^IH1A!A8[P+A0LX9" C[KLVQSC^%C^8-?0O[,Z>9\</@)%SE_BU\,1AL
M9S_PF6C?>QQG\NF,CJ/G:S; P1C"L"/]U3G\<U]X?\$X?AGJ/Q?_ &T/V8O
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MW8QOL9P) >LUG0M%\163Z;KVE:?K&GNP=K/4K2&\MS(%9%D\J='5955W5)%
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M6UM%;VL-Q%%%&BKH6C?LQZIX8L)_%WQ8^+_A7QB]H#JNFZ;\,-,\0^&H]2#
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M"CRHR!U\VX:*,#G() KQ_P -L?[5U$YX^QV0SQC EF./Q]:_2+_@GS\$T_:
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MI4=7B7] :**!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?:=IYUNS?3I[Z2,QP2%[2RFN98G,ZHCH&?VX_P /?LR? O6M/:\MO%'BGQ)
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MRK-TX4.H;/ '<_%WCO\ X)Q?M+^"-T?B'X3>.+14>1XW_L*ZN5CW.'VAX(I
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MQI\.M \-^ ?$7AK2I="\#)J$&A:=XKT&_P!(O=#U+4]3O+S4-=:#5+2.UO\
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M_P !PQC<=.>6+4VW*,[;G4[ S:8HQP8[6XN2_:0#(H$?EG??$6]UJ_MYX99
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7Y7[KM'K'=?\ ;O6/HM'V1-1114E'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $3 DH# 2(  A$! Q$!_\0
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M)G@;1]2F2TT34IO#$%YK(U2+7]1E@TG1[?2+V]O;G5;FUL&MHI[F!73X%?\
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MQGN[B.QL]0NKN>UGU>\MW]A_9Z^'7COP#X2UF^^+.NZ-XH^+OCOQ)-XE\?\
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M6>'KS6[OQ.EEKGBNZU/6-/BLM1$[W=S;:7<2S0:G)<Q6]O#T?['/_!,_X_\
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MYWIC/S?FLUQJOP;\>)XBM8VDLED$6KVT0(CU/2KDJ)I$7!5Q-%B2+.?*O85
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M/?Z9)(G^@7,P1$D: ",JB8C#(K#1T7Q%XSMX+S4=(BENHM$N)-9GU,:1'?\
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M<)K5W8ZYK6B7@\*:O;^#H9=7U2]T[6+B*2QFBTTZ=+=6+W'V9]0ELQ=Z*M]
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M&ESVDL]E?0-!/"3')&ZD'*GAESC=D]&&>,<XYIIWWT:W7ZKN@MRN^Z/X[/\
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M''9:=%I*P/:>);%$M[*&RC%LUI;>,/$Z6;PLKVTFL7<JGS1$T7B@7: N,
M ^F./\]ZTI^UO+VOL]UR>SYMM;\W-UVVTWL9S]GIR*?7F<[:[6M;IOOKW-CP
M[_R,OA?_ +&GPS_Z?=/K_;?^'7_)/O G_8F^&/\ TR6-?XD'AW_D9?"__8T^
M&?\ T^Z?7^V_\.O^2?>!/^Q-\,?^F2QKXCC;;+O7%?E1/I>&_P#F+_[@_P#N
M0^=+H/J&O:AJUPI6TL]4U*+0[=U*F6YCN[B"YUR6-L$+"PDMM*##_6>=>XRL
M)I&0@D@$YSSGG))X)Z_B3UY//-:VKN\FJZF\C;F-_=C/3Y4N)%4 #  "@#
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MA:>D:9WN;O4[FVA*)@[F5R%P=Q%&VX&QD+G [D8Y[8YYP,CT'/O0?F'![^@
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M/FQZ=:I"[+GD>=(PFSG@%90"1G'%,_X1SX8:0YGO[J?6;Q>6EGN9)Y"0<8W
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M.>V(2"#CM_/TQGM^O;UJP..ORYQT_G[Y/(Z?K@,(YYQ@Y./0Y_AZ^W&?P[4
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M5&E4NESJ>KVGB.22TN& 1#%>[#$2MNR(V:^Q/A!_P=*?\%'?@M="W^*'PY^
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M8%EW*"-RY*[AW&X<C(XR.17]F7_!VW"8+']A9",?\3?X[8XQ_P P[X??R/\
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MY2,'R>3^\>@7.E;E+:2Y48W*-1N1N.]"3NVY7*!TP!P7#]5%?546N_LVQ1_
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M]L I,6TF\E5N04B/$"MGAYR#@[@AX)&TMP2OL8,=O-<RI!;0R3SN/D2)2[$
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MQSUSVSZ4 ')'?I].>@[9]R>.W YH] ,$CTXZ@^@.,@]<CFEYY_3N>G^?7O\
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M1_)A1PB[GR+&FZC8P1_9HK&:QAMBEO$IP\<D<2!8Y(V\QY'3;@;G_>,V2XW
MXW8[NVE("3(2<X!.UN/]EL']*I<MFERZJS<=/Z:[V^\RG*IS*34FHN\5+WDM
M;Z[[]KZ=+6. ^'LGQ,^RZC%\2;/PO;2VSVT6CS>&[B:1KV("1;A[Z%E$%MY)
M6);<0R2^;"Z/(4E292RT^)&F7OC>[\(0P:M'/I\@LY#=:!J-N+N^>/SVN=/N
MYM@N-&M(L0W6J+;"S^V.(([J0J37I0Y&1R#T(Z?G32J;A(53>BLJR%5WHC8+
MJ'(W*K8!8 @''(JK.T4F]'JY>\VM=+Z=^W1$<\6Y2E!>\M%%\L8OO;WK^EUJ
MVUV-31M'U7Q'K.FZ%HMG/J6L:S?0:?IUE &>:YN[EQ'$@'.%!)>1R0L<:LYX
M4U^^OP%^$^F?!+X<6'AB.2&;5I#_ &OXLU90JB]UJ>%1<X8D'['81HMG:Y(4
M0Q>8>7)/RA^Q+\!?^$>TY?B_XLL2NN:S;-%X,LKJ/$FF:-.")M:,3KF.[U1?
MW5H[!7BL=S#FY-?9OB*6?Q)JB>"[.9X[(0PZAXON[>15DMM(E9C::/&V&*WF
MO21O&P W0:6ES.Q7S8%F^-SW,?;U'A*,OW-&:]I)/2K65U:ZWA2NXK=.IS2U
MY(GZ1PKDZPE#Z_B8?[3B:=J,6M:%"5FG9_#4KI*4NL:7)#1SD6M =_$^K-XP
MF4_V7:_:+/PE V0DD1)@O?$+(<!GOBK6VF,<[+%7N  UTOE\[\<OC%X7^ _P
MQ\4?$WQ;>6UI8:!IUS<6Z74JPQWFH)!)+!;EF90L2[&GNG!Q%;12,3G;GTNZ
MNK+3+&6XE>WL-/TZTDFDD<I!:6-C9PEW=F8B.&VM+>,NQ8A(XXN20I-?P&?\
M%>/^"EOQ0_;2^,GB/X7_  1^)-AI'[.?AO4KWP%#HRS6]I'K=I87)37_ !K?
MD,-1U/4M?U"V:RT"UM'BAM-(BA$Z.;JY#_/I=%9/JWHOEZ=%MTW9]6WY/1_?
MIZVM<^$_V]?VP_%W[5'QH\3_ !2U.XOM6CU#5+K0?ACHJM+YLUM?7@LUU&"U
M?_5WNO7+1VUF C&VL(XUC^6"1:_NV_X(Z_L%>'_V%?V,? NE!=.U7XL?&G2]
M!^+WQJ\<J(X3K/B'Q-H]KJ&C>&["XG99!X;\$:)=V^BZ5!O\N6X2^U [C<J5
M_@S\ ?"/PG97'ASQL;N^U/5]$M[Z'3[74%\ZTMKYHDLEU.WDE+^:EI:FXATY
M0H\F>6XN#ME$>S_1W_9U^%FI:W\$?@OJ6O:J(+&?X3_#J:!#/<7]Z\+^$-&>
M,10QL=G[H@*C'"C "]J[,(E=Z:QBFOFVORZ];MF52Z2E?>3V]$_Q>EET2L?3
M$U_I5L3]IU[0[<J3E9-3M=W/3*Q/(<\=,'/3&>*SW\2>$8\^;XJTO(/*P+=7
M)(Z8'EV_(]/RR#TFM?AUX0L8_-EL+X0)D-=7U[IMID*<%WC=VDC5L$X(+ 8!
MZX$S:5\-(_D1X+AB#@6]Y+>8/?<+6W(!XX(;ZGFNXQU_J[ZOI>_^?X///BSP
M:& 76IY\XY@TN\9<@@#<6"-@]N.G-)+XHT"(NZ27TL*KN,QL'B0*><EI9%(P
M3C&,\#'6NATRS\*:?<;M,L+K[1<( %%O,[.F[<"$N00H! (8 >A(KHFLM.<?
MZ78M<C[PANV@(####,:2QQC:PX5B>,'DT!9WOU7E_E;^ON/!?%/QC\+>%#91
MSVNOZG<W\+2V5KI>CW-S/*-FH2N%" MF.+2[B2<6R3R+%Y;"*0L$KRC5?VOO
MACI=E=ZBVE>,-3TZVO([".]T;0;O5H]2FN[Z33M(.A6EI;RZMKEIJ=_"81J&
MF:;<Z=9ADFGNVC$S0_:-Y>6YCB\[PP;N*WCGBB$6GZ3>^7%<+Y<Z1Y:5XH[B
M/Y)D10LJ?))N6N!U"#PEJ.MZ=KM]X!U&\U+2+.^L-,9$GBM[6WU(L+Y1HJ7$
M6AR27*LZ/>7.GSWJQ22PQ7$<,LJ/K"5!+WZ<Y/JXU.6[WM;ETOM?6UF[/1"E
MSZV:5]DXW^[:_5^=TM-6>#W'[1%E8>)]4TG5?"&N0V(MOA_<^'Y8[1XM=NAX
MV\,6^N1QZYIE^T']GW6GW5S+I,\-L9VTYH'DOY$6:,G!U7X\^"[/Q9XO?6?A
M\-2\;?#;6?$7AS1]6M$TBYO'T!]7O]$$UEJMXWV_2Y=6N](==5TR&$(]KY-\
M@N;1)A%]E1VKZ@;>[_L^^MY(DQ;#4[#3)GMT=$21(V,CS1(8XXXV5=H*(BD;
M5P$DT.0SR2MHGAYC+,L\]Q+I%O)<7$RQ- LLICCB=YU@9X%F,K2+"S1@A&((
MJE&]_9->[9J-62UNKMNVSCHT][WTV$U.ZV[_  K[EZ/:VJU]3Y5N/VC]#T?P
M!JGC[Q1X9\064.CW]E9WUAHUJ?$%R;;4"IT^^L8[)9KR\@W2I'+#;6TUTC;Y
M88'3 K(O?VIO!LGA36?$%MX?\217-GX;U'6=*TGQ'IHTN]O;NSTZ\NUTC5=-
MDE_M+2)S=V4D$\$]O]H^SH;^&-HFC)^T'\/^';NW-O>Z3;I&\1BDA@M#';,C
M)Y;1M&@8-&4)38Q*E"4(VYKDK7X1>!-.U/5M;T:!=/U36YK.?4+B=IKV-Y=.
MLGTZR-K;:C)<PZ9';V4CVWD:7%8P21NQFCDD8N6I4-;TI7YKI*IHU[ON--:;
M/WKMZVLOB1:5]UMJW![ZZWO\NVE_)_.?A_\ :4\"Z]X9\<^*M/L]7&E_#N7[
M!KEP+&Z2"\OTCTBX6T\.(+-K_6K:ZM=:LKFPN;2Q,%T"R0&4()VF\'_M%>&/
M'>M0Z'X<T;6X+PS,]P=:AM]-5=+8:XEC?VT2W#RWSWEWX?OQ]A@!FLH!'<W?
ME+<1"OI0^!)5MFM;.YT.6W=S)+;S:7;K;RNTGFEWC@"*7,FV4NZLWF8?.5R*
M<GA#5XIHKC^R-#NY+<2"WN(0D5S )EV2F"26!VA\U<))Y;IYB_*VY<TG*C[U
MJ<M?A;JWY?=2U7*N;WKO=6326UW-I:7DO/W;7UZ7;M9:;:ZO2^GR;K7QL\/Z
M?JVA^-9/AK<7DL,NI^$]9\7G28'U^UT5%AEDMO#2K)-J<NDW/B*:U%S:WDR*
MUM#<7:V<]UY$;4KO]L?X4KHBZIK.C>,;/1KW1M3U!HM0T!X[Q[+2?#E_XEU"
MWN/#]ZUMJT3-IVG3Q6-O<Z>DNK7!C@M(&WJ6^MY-.OX587.@W:(,DF*.UN4Y
M(W$ %#CIDJA)QQD@5S1T+PO!?+J<GA_3[74%@AM5NKC0TBD6WMI?-M45C:F%
M6MY,M!("7A&5C<*2I:G1TYZ4VULXU6M+WMK%VW=FM$OLWU8XOH[7_NI_/2W3
M?OW/(/!_[0ND>-V\(GP[X,\96^E>)=?3P_;:CX@L#X9CL@)+A(;Q=,U-8-4>
MTG@MUO-.W6=K]IM9$VK&X"'$O_VL/AM8VFG7:Z5XPN5U35;#0]/M['P_=7M[
M<ZK?:;I&L&SAL=.CNI99+'3=;AGOT4^?:/%<A[?RDEN(_I*WBTQ(TAM8=+6*
M%A+##;PV\212[RZRQQ1 )'*'9G#HH<,S,#DDE@T;1CDG1-*;]XTQ*6%IS+).
MER\A/D?ZQ[E%N'D!W/.JREBZJU)2HW;=*7+T2JN^[WDXZZ-:I+9Z:Z.ST][U
M]W?TLW;TU]>_,?";XL^%?CIX7U"V@L]3TL6]CH>H?V;K<<5OKT6E:_I$6NZ#
MK(LD:0Q-#9W/F1;)9A+$E_8R,)+5T3V/X7:LOA'5M1\*:W)%%8ZANEN+3R0V
MF7JS0+"=4B* *B7UN(3*50JSB1I &\PCCK2"STZ[^WV5E#:7AD25[B"VMXY9
M70*H\YXXU:51&J1!9"1Y0"8V "NPFMK?64L9K;$-[$[OH\S8'E3$YO-"G8G!
M@FW,]EN.%+A00KL1E/E;?*G&+U2<N9Q_[>LKVWV3W+C=)7:;75*U_E?3KWZ(
M_CM_X.]O#4GAAOV'+6(M+I%UJWQUNM&N20ZM:OI_P_)M6=>#+:9"9#$20F.3
M[S$U_%J!N^7@[N,$@ YXP2<#'UXK^T7_ (.YM8O+O1OV"M&NX9%72-7^/;VU
MPS;E>.ZT[X=A[4*?GC:UDC93&Y)16"@D 5_&MX7T1O$WBGPMX82X6S?Q/XG\
M.^&DO'C,J6;^(-9LM'2[>)65I4MFO1.T2LK2+&4#*6!'ZEPV[9)A6WM]8;?D
MJ]5W^Y7/B,XUS*O;K[&R]:4$OQ?XF0;)B3E;?(.TYGM?4+U,G(X'(R  #G !
MH-DV""EOCY6QYUMU !4X\SDC?Q@9!+#@A@/NKXD?L!_$[P/-XLO]-\0>&]9\
M(^#M(?6]:\17(U:'[-I]GX73Q'K,]O%HFEZ_:ZXND3R1Z!<P>';S5-535Y8S
M=:39V"SWL-?QC^P#\8O"GBS5]!.I^%I=%TW7&TE?$UW/K @$#QZ#=6-Y?6.B
MZ/KEQ%->:=XETG45TW3?[6OHH);B*2'[79W5M#ZJQ>'E:U:&JNKW3TLVFK:/
M5:;Z['$\-65[TIZ.VEGWU36ZT>NWF?#S63Y8E;<DJ=Q\^U)9<.",^:=W"L-H
MSP0,?.NX%D_ "V_() $]J -Q56S^]P"WRY!P2!DC:"1]0^'/V5O%/B"S\26T
M.N:2/$VA?%/1?A0+)#<IH46KZIX:N/$L^IZEJT]HEZFF6$=K-ITKV6DW/F7B
MK+;RSVLD4DO7:Y^P;\9?#\&HWE[K_P ,7L;#7-=T&&]A\3ZD(M5N?"\&NMXC
MN=*BN?#]M=36NCWWAW4M)N$N+>UOIKT6T]E97.E7":B*>)H)V=6"?9W5]MM'
M=:JW_#L2H56KJE)JU[IIVU:UU5M4]_\ @'QD+64A2/)PR[A_I%N. H;D&7*G
M!'RD YR,9! /LLW'^JYS_P O%OCC?G)\W ^XV"<9^7&=Z;OL+5/V'?BMHME:
MZKJWBCX9:?HU]K&H:/8ZI=:[K\*7?]E66I7&HZC#ITGA9=:%A:WNE7>C.DNF
M1ZDVH?9KB/3VT:\M=4EPM2_9 ^)&@:G>:=X@UCPC9OX>\7>"/!OC>&SOM2O-
M0\)ZSXZ\3>&O#>E636\^E6-EX@N6?Q&U_!+X=U+4M(O;70?$ M]7:33)DH6)
MH/:M!_?WM_*NNGK9;NP.A56].2]6NOS^?HF]DV?+0M93WAY.W_CYMNN57_GK
MTRPYZ8RV=JL0GV:7UA_\"+?TW?\ /7T_7Y?O<5]]?$K_ ()Y_$;P#<)-8?$'
MX=>)_#,=ZNGZAXSM[G6[;PU97(\3Z[X9OC#J=II&KV>JQZ!=:/ GB*#2[FZU
M6PN]3MX+;3+ZW4WAY[PO^P'\;]?\7:-X:NW\/Z;::K>V49UR*75]0L3IT\_@
M4W-]9S0Z0ED\L5AX_P!*NK2'5+W2;>]NK+4])%Y%J=LMM)*Q>&<>95X<MF[N
MZ=EJ]&D[I=+7U6BN-X>LI<KI3OHM&GOMJFU;I?:]]>A\3FVE&?\ 5<';_P ?
M%OURP_YZ]/E//3&#G#*2?99LD?N<@@'_ $FW/)*CC$O(RPR1D#G)^5L?9/A#
M]C?6O'/A?PWXAT3QG86;ZG9)KFLKXATB_P!+T6TT*Y\>:C\/+-="UZW&HC7?
M$CZ]:6*7.@C3[=+*VUFSO[S4;:SAN77@?'G[*WQ.^''@"^^(_BBX\*6NBVEW
MX:B@TZ/6Y9=>U&P\8:9'K?A[6+&R-@ELUC?Z/<6NH+#/>V^J?9K@2KI[I#<&
M&EB*,I<BJQYN;EY6FFY7:LDUKMT>VNB)=&HES.G+EY>:Z::2LG=_)_IJ?.AM
MI0"<Q<=<7%N>Q/&)3DX!X&3G ZD GV64$C,.1U_TFW]2.#YN#TZ#/&#T(-5Z
M*WU[_A_P3/3L_O\ ^ 6!:RD@?NN1D9N+<<?)U)EP#^\7@X/WN/D?:?99?6'H
M3_Q\V^< ,>GFYSA3QUSM&,LH->BC7O\ A_P1:=OQ_P" 6/LLV0,P\G _TFV[
M$KU\W&,@X/0C!!P03 P*D@XR,="".0#U!(/!YP>#D'!!%)10&G]/_@&OX=_Y
M&7PO_P!C3X9_]/NGU_MO_#K_ ))]X$_[$WPQ_P"F2QK_ !(/#O\ R,OA?_L:
M?#/_ *?=/K_;?^'7_)/O G_8F^&/_3)8U\)QMMEWKBORHGU'#?\ S%_]P?\
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MMQ.B">(Q6UE83F+4+O4+NRTZ*T^V7MM#+T#?LU?'I['PKJNF_#WQ!K^F^-?
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M;:E K0 S:=<NEM?QAK2X=89G8?J?#?\ R)<)_P!S'S?MZOYZ(^*S?_D8U_\
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M_P"'6_\ P42\A4_X8_\ C$'\TL0=*TL$*R(%)SJ^.2&[\8)/'-1-_P $MO\
M@HF5!'['_P 8C\@_YA>E=SCI_:_J>?;G&.:Q;;=VVY/5MMMM]W)MMOS;;*EB
M92C*'L,'%-./N82C%Q37V7&5XM7T:6FFA_I%Z/KVC1G1]=T#6=.USP)XZL;#
MQ+HWB73[O38_#VH6/B:T;6]&\96^HWEREW?1>+HKNQL[>PLS.+6\;:UO 5G(
M]'Q@D'((R",<@CL1]>OI7XN_\$@-)_:3\.?L$:5\)/VF?AOXT^&_C#X'^/\
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M7=^']0U;Q596>MZM9Z8/#ECIVH:QK@L;O5;&W2.VM[:_N_MMM+)POP\_8O\
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M;=I]-/Q*4GQ>_:)2X\.:C8_!F>$3GQE+JNER)=R'4X89_%^F>$(-3U!K0_\
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MVMW>R:'>+8(+G4=)AU[5;.QB6S-G<6\-O?K%'>3ZU;WMDEO]GBBGF]+3Q_\
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MYZ-<7!(ENY.N=L0(5<5F>(/$$<$;R,0Y3Y;: <!W/1FQC:,<\_=09^\0!/\
M7]?U;N4^G;\DU_5V[=MW<_CI_P"#N.^:]M?V%F>3]X-6^.SB'))CB;3_ (?J
MC$'H7*D^OX5_&)7]?O\ P=7:@;Z+]BPRS>;<C5?C9)*O)V+)8>!!&.X4$(=J
M9RJA>.:_D"K]4X;_ .1-A/6O_P"I%0^&SC_D8XCTI?\ IF 4445[IY@4444
M%%%% !1110 4444 %%%% !1110 4444 :_AW_D9?"_\ V-/AG_T^Z?7^V_\
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MHHHH-@P#U&:9L7T'XC/MD9Z''!.#QP,4^B@32>Z3(Q%&.BC\A_3'_P!;M3P
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M5O\ _GO_ .0H?_C=%% !_:M__P ]_P#R%#_\;H_M6_\ ^>__ )"A_P#C=%%
M!_:M_P#\]_\ R%#_ /&Z/[5O_P#GO_Y"A_\ C=%% !_:M_\ \]__ "%#_P#&
MZ/[5O_\ GO\ ^0H?_C=%% !_:M__ ,]__(4/_P ;H_M6_P#^>_\ Y"A_^-T4
M4 ']JW__ #W_ /(4/_QNC^U;_P#Y[_\ D*'_ .-T44 ']JW_ /SW_P#(4/\
M\;H_M6__ .>__D*'_P"-T44 ;/AK5+X^)_"P,_'_  E'AO\ Y90]M<L"/^6?
LJ*_W#/ASS\/? 9_ZDSPO_P"F2QHHKX3C;;+O7%?E1/J.&_\ F+_[A?G,_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &( C0# 2(  A$! Q$!_\0
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M)_&#Q)X<N+[5?%%K<ZA:^)/$UE_R!=%YTM""G _NGE<],<8KQG4H1Y7']?\
MZ_\ GZUG_!.;_B3>,+'_ )]?&/\ [A#_ /6[>W:D\-A?JCLM;Z/[WO8Z<-F6
M,^MV;\K_ )GVA%\=_B9^X_XJ*UP<YSHVC8/UXYXZ>@].M:$/QL^)O_0<MO\
MP3Z-T[\>F?UZUXO#_P NW_ ZL0_\NW_ Z\ZRVLON^X^@^LOOKZ]?O[GN$'QF
M^(TW37+;\='T;]?_ *U=!#\6O'\PYURV_#1]&]?_ -7]*\/M,_N?P_+_ /5U
MKH+/M_P*M_JJ>\5]R_R%];Q?=_U\STZ\^*7CV&TN)QKEMYX  _XD^C]N??T[
MYZYK\C_%7[='[2/@^;QCKOB/XI:%HGACPQK.J6E[>7?@[1<V.F_VSMW'U8*
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MQCT46WILV_RN_P #J^K87K;[SO[SXU_$R*+]QKEM['^QM&[_ *CVKGIOCO\
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M?VB/#GA7X(6OPE\'> _V2_'GQ!T>TU;6/[2\36'BG_D0_'6B_P!N>'_^0_\
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MZM^98JO^Z_SMH\V'U_4_XT5T& 58JO1!W_'^E &?>=_^ USWPEF_T_XD0?\
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M?\:/_ >K'DSS'_48_4Y_^OGWKV#G"#O^/]*T/(]_U_\ K57ALY_-_P!1R/\
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M3PV#Q5[[VZ_,_-_7_#?BKPK_ ,AS2KFVM_\ H+6G_$RTV_\ 7_)^N:QX9O\
M/^?U&?<&OKC7O'FJZ]=7$%C/_9NCX_T/2K0<_P!E_P"?\*\/\>>#_)L/^$JT
MJ"VMK?\ YC%I:?\ +A_U&O;^OTI?6?/\?_MCP,5EV[PG2Z^Z[_3L>?P=_P ?
MZ58K'AF_>^1_R\=;.T[^_'],<_C6A-INJPBX_P!!N1]E_P"/S_0^?Y?Y'7%>
M@FF>0TUW18\_V_3_ .O1Y_M^G_UZS_/]OT_^O1Y_M^G_ ->@1H58AF\K_/\
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M/KX;>%Q_]?\ SS^8KT,E_P![U[+]3Q>(G_LF_5=?7S/RO\26?^@7'D'\?R[
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M &OZYOY/9M;+KN_^">G^+[OPIX)TSP?#JL]U]@MO$@L3]DZ?\3S_ )C&N<=
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M(\0\_P!OT_\ KUH>=^Z_SCI],].WZYK0\8>"?%?@F7_B:V.-/S_R%M)O._\
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M28-*^T_:M'TN]^UW=X=-YQZ_I@\8KL/A[^YM?%$X/_0+]?\ H-?X'_'V\/\
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MH//N/^?ZY_\  W_[&N_$OZSA/J=[6:=V^UGW\E<Y\,OJN*6,M?39;;6/G_\
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M/D:;^XLH+;3='T'_ $+2+2TM/^0?@_\ $BT7/3_/K5?Q5\2-#^#WASP_X_\
M%5C<ZUH]UX\\+Z+K&DVEG_:6I_\ "+_\A[71H>AG_F8O_P!=>'Z;^U%^S+J5
MKI\^E?&G1+G[59F]L[2[L]9TW4Q_U!=<_P"*;_XI_P 1'_/45R_QR^)VD^//
M^%;^#O!T^FZEI^EWFJ>-/$EW:7FL_P#(4_Y .A:)_P"GSI^O-?$<2<3?5<-?
M!YJF^:[5U>][]V][H_1^&^&<6L4HXO*GR<MHZ.R5N5-Z6VLS^>#]I?X5V.F_
MLW?\%A_V;-#-OJ=O\$?VF_"W[3GPX^R_\OWPO^*VM:#KPUD')R,:WK@YQC[N
M, $_UW_\$<_C-!\8/^":?[(_BK[=;W-QI7PW_P"$+U?_ +"G@7&@_P!BYY_S
MW]/YM_'G@G['_P %$_CA\,KZW^S:/^W-_P $]_%'^B?\_P#X\^%']OX]?^@'
M_D=?J#_@V_\ VD-5T']A3XL?!V?0[GQ)X@^#?QXU3[':?VQ_9NF?V7KNB\G^
MP_\ N!ZYZYKZ["YS]:RC*LWQCV44[KR2N[>O4\C$Y+BUG&:91A%;7F2ZV6KL
MNNUM+[?(_K@AO/)!\C_CW^O'^?\ Z_N*ZC1YOWEO/.?LWX\]_ICCBO/]!U[2
MO$FC:/KFE:I;:CX?UZS-[H]W:'T.#HH([>$_^18QD''7!XKN(9H(1_S\W'3\
M/_UXZ]O2O14OK:YD[Q>MT]+;[WMU[J]CS\5%QO%JS5TU:SNKIZ63W78] AF\
MZ+SSWX_#\/\ /':OC;XVSP7GCSSY_P#EULOL7)SCO_GO7UC#-^Z_#^7]/U/2
MOC_XJ0^=XWN#!ZX_R?\ 'MZUSXK12]'^4C!;KU7YHP--UF>&*W$'3\?\_P!<
M].<UU]GKU]-%_K\GI^&/\^O\ZX>S\@R\?Z_M:?Y_7/O7<6>@^([R(SP6/V;3
M_P#G[U?_ (EA[_E_GZ5Y^&6JTZ]O->1OB-G;MT]&'G7\W_+?OC\_7\O;U]*K
M_P!I6-GS/]FX[?G_ )]\&M#_ (17SAB^\5:;;<8^R:39^QQ^7?\ ^N:T(?!/
MAS_EOJNI?:/^7/\ T/O_ #''Z5Z%CSSCY?$G_/"#[3G_ /7WZ=?_ -=>#_$G
MQMXQAL+G^P_LWVC_ )]/^89T/^<<>V:^L/\ A5?G1?N-<_L[.?\ 1;NSX_'V
M[<_3FNAA^&'P_P!-A&JZYI7_  DEQ:_\O>K9_LSGTT/\O_K5T:(/JWE_7W'Y
M37G[2WQ&\!W5Q-XJ^!'C_4O#]KG[9XA^'NC_ /";?^4/P_\ CGKBOU ^ ^FP
M?$+PEX7^(VN?VWINC^*-'_MKPWX3\0Z/K7AKQ-_98P/^)YH?B _\)/X?\0_]
M2OV_D7GCR_\ -M['0_LVB:>/^/.T\/?\2W[!R?7WXZ]J]0O+R?3HM/OIY[FY
M^U<WGVN\XZ_A^O4>]<_UF^BE]SO^OZ'1]6\OP_X![AYT%G;9@@ M[7_ETQC[
M!CH/7K^7/XP:;YY^T3_\_7H#G/Z$<^OY5PV@ZE<0_P#+<W%O_GOTQ_GMSV%G
M-Y-KF'_G\]^3U^O3J,?RK=)6V3_K^O/OJ&WE^!X/\3H-*ANO/OH+6YT_5/\
MB2WEI=_]!3^OI_(>G'^*O@S\,O!\6HZK?>'+G6]/^Q_;?LEI>:S_ &G8<X(]
M_#O;FO<-3T?0]8E/V_PY;:WB\^VYN[/'_$TY_+Z<9]N]?7K/SKJV^S_9O[0_
MY?/],]>,G/.>V/Y8I_5WV>U^O^0'Q_\ \)Y\,M-_Y%SX9:)<]OM=W_Q,O?\
MPX %>T?#WPA/XPTNXU7Q'X5T33;>Z_Y ^DVFCG3"-+/U].F1C]:YC6/!/A6'
MQ;;WVA?V;=6]K>?\3C2;3_D6?[4Q_G ';VZ^[Z/XJ^V6H@@^TW/KWSC_ /7_
M )%&'Q.Z]?U77YO3S]0^K>7X?_:GF_B3PKX.\-R_O]"N;G_GS^RWG^>>?U]:
M\'\>:]\'=>L;B#7/@M\-_$EOQ8W@\6>&]%\2?\2OOHO_ !4![]"3Q^>:]?\
MC9/>VEK80""W_M"Y)O/LGVS1O[3_ +,&,ZR-$_Y&<@'@D9 (*\$''YP?$+XJ
M:'XPBU#2O#E]<ZEI^EZP;+6-6M+/^S!?_P#8#_ZEW^OMS7/B,5?X7?T?RZ?(
M\_%83926G:2_S1YOX\T+X9:EI?BC5O@[\%O[$UCP;HXUK1])^&5G_P 2SXE_
MV$>?!?\ 8?\ R+ _GW/7GXGA_9[\8_%J(WWQ-_9(U+PWX@^V?;='L[OPW_PC
M7_$K]=<USP_XDYY]/YU^G'AOP?H?Q(TOQ!\.=5GU+1/"_CSPYJGAC6+OP]>?
M\(YXFT'POKNB_P#$]UK0]<Z>'_$0^A_+-?SO_MR?\$\?VR_V4=4M]5\.>*OC
MK^T/\#[K_CS^+'P]UCQEJ6I:#I>,_P!B_%3P/X?\2?\ %/\ !_Y&GPG_ ,49
M_(>QEN)P>*M@\99/H_AUZ:NW7?4^0SGAR2Q7US!*35KM)/U:27?T/T TW]E?
MQ'X5EU"?0_V>M2MKC[']B_M;_A,-%TW3,'_F-#0_^$DZ\]?_ *U6/#?P-^*F
MFZ-;V^N6/C^VUC_C]O+N[O/!NI&_U3C_ (DO]N?\))_R+GYYY-?SKZ;J5]XD
MTO4/(\<>-M;^RV?^F?\ %8:S_:=AUS_;FA^(#_PD^/4'WHATV?\ Z"NN?^%)
MK/7_ .L.O/XU] N'%BM4[+UZ?)]NIX^'S%X--2RI]5=I[[7U2ZZG]4&C^&O%
M5GI?_%5:5]F^R^)/]#N]6\>>#?$OB;7M+QZ?\))_Q3_AS\3XTK8\-Z;H>C^+
M?#_BK5=6TWPEIXO-4O3J_P#PGO@W_3_^PYH?_"2_\5!_6OY9]-\$P:E+Y$\%
MSZ\ZQK)Q^'X_Y%?8'P3^!EC>>,O@//JNAVUSI^E^,/MMY:?;.F-:[>E;KA["
MK:]UV[K_ (8YO[<N]5N]NUWM\KV^1_2CKTT.L> _BQY$_P!I@U3X/ZI]CO,=
M?^0_T]?T']/YSK/_ (]-/_Z\17]%&CG[9I?BBQY_TKX)^//?G^?';-?SL6?_
M !Z_]NA_D:_G#QKP]L9E7YO[OT_KI^W^&^)_V/-/.UO^!]_0]_\ A5_R[?A_
M2OT \$P_NK?Z_K_C^F/7%?G_ /"__76_^>U?H!X#F@A_L>"?[-C5+O[%]LN[
MP?Z!S_G\,\5\OPET/9SQ_J?4'A7_ (]1^'_H5>\>%8?]%M_\\_RS[]_H37@_
MAK4]*_LNWGGO]-MOM5G]M^R?;/\ F%]/[:_^OWKZ(T"'_1=/G!S]JL_MO7].
M?_U_R'ZAAEMIVZ?X3X?$XG^OPZ?Y?([#['!-*>>O^>/7_.?:S/9P>;[_ -??
M_(^G:DHKT/JWE^'_  #GOY_C_P $L0P\_P#+M@?Y/OZ?T]N7\8>1#\.?%$^1
M_HNL:GGIS_GG_P#5740=_P ?Z5Y_XVF_XH/Q!<3G_1[76/\ 3/\ L%G6OY_S
MXZFN_+4_KCLGNMD_\C#,G_LBUZ/K_P $\/\ @GKVE>-M>\8>%;&^_LW^R[S[
M%K%W]C_X\=4_L7^WM"]^QX_R>7_:=U+]GO\ 9[M?"'B/X_?$W1-$M_&5[JFB
M>&[N[T?6O[3O]4T+_B??\R_Q_P#J-?*__#5W@?\ 9B^)?B#R/LVI>(/B-K!U
MJ\M/$-YHW^@ Z+_8/_$C_P ,=Z^;_P!L;XJS_MU:I\'_  Y8_P#"KO#>G_#G
MQAI7BC6#\0O[&_X1G7O[=UG0/^)U_P 5!_R, \)_V'SVXZU]5B$VVDF_1-]^
MR/%P[P=MUS6?5;^6MO0^N-!_;>_8FTW[/JNA_$86UQ=?\>=I_P ('XRTW4[_
M *#_ ) ?_"-]/T_*O)_B1^V]\%OB1:ZCX.T.?PCJ7B?7O[4T6SU:[O/&7_"3
M?IX;_P"$8_//KBB;X;_#GQ)\1O"_C&?QC^SQJ7_"&_VIHMGJVDWG@W_A)M!T
MO7<_V[HNA^OOGZ'L*Y>\^#-CX:UGX@>,?[5^&^MZ?_8_BBQT?_A';S1O[3O_
M .W=%']A?E_DUWX;"NS=GMM9]KVU7RT[OR1Y&*Q&+OTM?KVO_E;\#V#_ (*A
M^)3X/NOV5_%5Q -2_L'X5^ [W[)_S_\ _$F..I^@^OM7A_[&5Y!XP^(OQ@^)
MU]??9M0^(W@/P'>V?AZ[L_[2^P:7H6M_V#_;7]N8//0#VXKU#_@I7XP\ 7DG
M[*XG\?\ @#^S],^&_@31?$EW_P ))HVHCPEJAT7IKG]@9_0X] .!7SO^QS\9
M_ASX)^(OB#P=\1O%7@CPCI^NZQX7\%^#[O5O$G_(^:IKOC30/["T70]#\/\
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MFNEM;+[NGD5AMUHMU^:/=_#]F;'P]X?LOM0OC::-86YNM7YOI?+B !FX'08
MZ].N**Z#2/\ D%V'_7LG\VHKX)[OU?YL^N6R]%^2/R6_;+FAE_:+GL+GF"Z^
M&WA8,?<:UK_]?3'6OQ)\;?#>#[?J%CXJ^ 5Q]G^V:I96>K>"-8_YA?\ V _$
M'IZ>^*_7[]MR]\G]J.:'U^&WA8YQGKK6OG_/]*X&ST>#6+7[=Y'OU_EW_GZU
MOAG]5LWK?57UOU5N^^NYAB<.\5Y?-^?7^KGYG_!/X >![/6?$%]X<TKQ;X2N
M/%-G]B\2:3JW_(,\6_\ 0"_MP9Z>$_3I@#FOT(\!_!GX.WGA+6/AE\3? &A^
M/_#_ (HL]+LM8TGQ99G^S/\ N!G_ )E__L:>E=0/"MC#_P L,^F/?/\ GMW]
M:ZBRM/\ CW\_'^B^W^??UKFS+$?6TUHE9K332S3M\KG3EN'>$=]6TTTM[---
M=>Z1^>'C?_@F/JO@F_U#Q'\ ?$?_  G_ (?NKS[;_P *]\67G]F>.=!_Z@NA
MZYG_ (J#P\*\6T&SU7P=XHN/"OBKPYK?A+6+7_C\TGQ#H_\ 9O8_\@/C_BH/
MR]^E?N1IMY/#%^_G^T]/J,_X<=O\:V/$F@^#OB%H-QX<\?\ A7PWXV\+_P#0
M)\66G]I?8!QQH>N9_P"*?Z?US7YCF?"F%Q>N$;O=MIM[W;V];GZ=EG&F*PME
MC$K:+9;:+MV/YC_VV->TKP3\;O\ @F_^TG!_Q[_"_P#:0U3X+>)-6M/^A7^*
M^BZ_H/7O_P 5&?;^M?-__!+6;_A1O_!2S_@HA^S+/_Q+=/U[^U/B#X.M/^HI
MH7C3^WNQ'3PYKFN&OU@_X*T?L1?\8%?M#^,?@?KFMW-Q\&[/PO\ '71_ _B+
M/]I:!_PJCQIH&O9\#ZYUX\-]/<=SC/X@:E\0K'P'_P %AOV'_P!HRQG%MX/_
M &O?@_X7LM8U:T.#J'_"U_AEKV@ZZ/\ PH_["S[=^U?7Y;AL6N$<TP6+7PKW
M=M+)VMVT2V.#,<RPDN+LIS?"62DXJ:Z/F:3YNGVGN?U[_LO?%JQ\$^+;CX97
MQMM-\#^*=9'_  C=W_S#/"7CS7>FBGT\.^+/<?\ (Z#I7Z;V?[F6X@N(/LUQ
M;?\ 'YCGU],\$>G_ .O^<B'Q)!K&EZCH?G_\N>J:+>?:_I^G^(]Z_8_]E;XX
MGXP?"6PGO[ZVU+X@> SI?@OQY9_;,8U3 _L+QI_W-GAWG/OCM7!P5G>KR?&/
M;9MZ[NRU?Z]T>OXB\)_58K.<&M))-V6GO14GMIU>R/KF;4H(?W$&?Z8'^?IV
MKX_\5>)+Z'XW:/H<&E7.I:/JFC&]O+NTO/[-U/CC_/TQ7T!J6K_8_P!_/<<^
M_P#GUYXSTS7R_P"-O$ECH/Q:\/ZK??\ 0'/^E\_]!K\OJ>.>:^PS'$:V2TNE
M?RNE=_+S/R?#[*_;]%<^P--T?0],EMX-*TK3;;4/^7R[^Q_\3/\ ^M_G%>?^
M,-8OM1\4?V' +FXM[6S/^B6G_P!;K_A6QH_C"QU+[// /^/KMZ>OT_G^5>;Z
MEY\WQ&M]<@GNK;_0_L7^BW@_'^7]3UK>NOJV#5K.]GHK[VN-[OU?YL](L_#?
MV/\ Y"M]_9O_ $Z?\A/4^OI^%6/MD]G]H@T.QMK;K_I=W_R%/3C_ "?\+$$'
M>#^7X?\ ZB3ZXKG]2U*"SNO(\_'^>_;]"/Y4+9?(YSJ-'LYS^_OIQ]H_3I_G
MGL>!6/\ %K6/L>@V]C!_Q\75Y_\ K_/_ #STT(9O)BM_//\ I%U_RZ<Y^OMZ
M9KR?XG:P9KK1X/\ EV^V'GVZY_EC@48GK\__ &X%NO5?FC'\-S00ZI;SSS_9
MO^OOZ]?7C'.#W]*^F-2^PZEX<N(+>>VNO]#_ -#^R=^_^?\ Z^:^;]-FL;.+
M]_!:W-OQ_P ??^>OIQ7M'@*:":U_U'V;[5Z_0<?Y_GBO-R[_ 'N5_P ?GW.C
M$%?PKJ6JPBW'G_:;?J?\_7)_6O6+/4OWMO\ ;O\ 1N?Y_3Z?3KUZUX/9ZQ!H
M^LZA8WT&/[*O!R?\_CVYKN-2UC[9HUQY$_\ I'^1VZ]/T'<UZ>&W7>_ZHY\3
ML_3]&>T37<Y_U&+?TSC_ #Z_EUSS7G_C;4H/#7ASQ!JO_+Q:V>J7O;'^>O\
MDUT&FWAO+'3YY_\ GSR?R_SW]J^?_P!I?5_L7PYU""WG^S7&J7GV+I_]8?7_
M !KUK))^GZ/=[OYMG.?%_P ,?B=!IMK<6.N7UM;7'VS5/[&M/^?\:[^@_P 3
M5?\ :$_:*\?^&[_1_!OPD\1Z;HFGZGX;^V^,/%FDV?\ Q7-ACD:+H?/_ !3Y
M!Y[<YXS7S/KTT$.J#_CV^T6O_'GGG4_[+_\ U?X&N?\ %7Q/^"W@_0?[6\<?
M$;P!X2^RG[#_ ,3;6-&_M._U3OHO]A^'_P#D8?$7_P"O'IY#5[KO=??=?J-8
MJS3OLT]^S3_F\C^?_P",'@GQ'X/_ &A_&&E>&]6^+6M_%C0?$FJ7O_";7?CO
M6?\ A)O^$7UW_D!:UKGC@>(_?M^/6OT8^&_[47Q-TWPO_97Q-\ >";D:79Z7
M9>&_^%>:Q_9NIG2\?\@7C_BF/R^O>O+[SS_BI^VO\2/[*\*ZGJ7PW\4>#O"_
MAB\U;5LZ;]O.A:+D>-/^I?ZYK0U[X,ZKX/O[C^RO])T\7GVW_C[R?\_S[=JX
M/J_]F85MZW=[OWNMVKZ]SMQ&8K/<U6#5HN*5ME>R2\NJ3_S/T@^#/[15C/XM
M\/P:MX<UO3;>ZO-+^V:M=V>BZD;#\/I_];K7[(:/K$\(_P")5JOVG_I[TG6/
M^);?GKGZ_P#UO<5_+_H/PKU74O\ 3H=<-MJ'_+GTX[#/<]<^_P"=?7'PPF\?
M^#_[/\CQ'K?V>UO?^/NTO/\ B9_C[#/2IQ&*PF)5T[.*O==+)OH[].IEAX9M
MAL8H-:2DHJZ5O>DHK=6ZIGZ@?'C]B;]E#]JBUGG^-/P)\)ZEXH ^PV?Q,\*6
M8^&_Q+L>F?[#UWP_SQV.>^2#Q7X__%K_ ((&^*K._N-<_9S^/VB:WX?_ .7/
MP/\ &/1_[-U/3_\ N>/#XY_#P?Z]A7Q_XP_:6_X*Y> _%'B#PK!^VG_Q,-!U
MC5++1[OQ#\'_  ;XD^WZ7_S M:R>_P#PCGMZ9YZ]!X/_ &TO^"C^I77]E?&*
MQ\(_$G[+_IOVO2?$FL^"?[0_#P__ ,4QS_/OQBOBJ'C3E&3XQX'&9M;E;C9M
MW5FTKIO1:)):;;=7^JU_ /B'-\#''12?/%27*E9\T>:RY=[W7_#GJ&@_\$D?
MVA='E_XGGCC]GBV\0'_CS\/6GC#6?$FIW_\ W'/^$;_SVQS7J$/P'^(WP3E\
M'Z3\1O!]SX2UBUO?]#N^-2TS7NO_ " ]<\/]3GK^O>N'_P"'J'QB^%=K_:MC
M^PQIOBWQ1:_Z%_I?Q@_XEEA_W _^$;_/G.?6O+_#?_!?']KVS^,GA>W_ &AO
MA)\)?AO\%_[8^Q:Q:>"/#?\ PDG]@Z5_S M:US7/$'_0I_\ 4I_C[_6Y=XU\
M.8N__"JK[*\DKWMY]3XK,OHX\6X3"/&_V3)I7>B=VDV[VLWLK['[#^ ]'\1S
M0^?_ ,(KXD^SW7PW\>67]K?V/K/]F8K^6B#]I#]GJ;7M8\*P?&GP3IOBC2]8
MU31=8TG5L:9]@\4:%G^WM$_Y%OCG_/%?WC_!_P".WAOXS>"-.\9>#KVUU+3[
MFSTR]N_[)N_[2_XE;<:'K6A\ <GKG&<<]!7Y3?\ !2W_ ((Q? '_ (*&>!];
MU?P1#X4_9Y^/]U>?VY_PL'P[X"T9M-\=ZF%&=$^-N@HN[Q%T+#Q1\S^#&) /
M 4<_%F3X/C999CKJV\91E=--7N_O>B;[^1X^31EPXW@91:DKJ2::::T:LTF[
M--:GXT_"6\@UB+3]5TJ_TW4M'NO^//Q#I-Y_:6F'\?T[>H[U^C'PK\^[O]'_
M '%S<V]U_P ?GV3_ )<?3W';\Z^1OV;O^#:/X_?L[>.]&\<Z%^WKX=MK?0AG
M6/AEI7@'6A\-/%G_ !)/^0)KRGQ(&'AXYY4KD=" >OZ$:]_P2[_:BUZ7R(?V
MTM$^&^CVMX+VSM/!'P'XL/\ J"_VX/$G_%0<?_6YKY_+>"L5E;O%Z;Q^;=OT
M[&^99DL5?\3 TW4H-9L/B!_:O@#[3K'_  I/XH:U_I?_ ",UB="_L#O_ -BY
M_P 503_]:OKCX#S0:Q\*OA_JNE3W.I:?=:/_ ,2>[N_^@7P<?X8/IBO/_A9_
MP3J\<?"S7M8\1G]JC4O%MQKW@3Q/\,O$MGXB^&_]I:9?^%_'.BC0AHO_ ",G
MJ!XH_P >:^D/AC\ ?&7PK^'/@_X<Z5\8M$\26'@W1_[%T?Q#JWPVQJ=_I?\
MU',_7MR:^HR[+L6L6_KEK=/NTZGS&)6^CZ]/4ZB&SGA[G\<YSC_//^-6/L?M
M_P"/5T%G\-_B;=_ZCXMZ;]G/_/I\*]&_SWX//TKH(?A+XXF_X_OC%==/^B;^
M#>G7VX[?A^?M?5==NO;S]#F^K/L_Q_R/)_.\KOC/MG_/3]*_)C]NK]LSXM_
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M".MZV/\ F8O^9H]_3H:\Z7$63<LE@XQTC):J/\LEV]#T5P]C+IM]4WJ^ZO\
MJ?H5_P $L[R&\_8T_:WG@@_YESQ/967_ ()M?Z^W3_((KY^_:;E_LW]DSQ1?
M^?T\'>&++UY_MG0/3T[9[_F?K#]@_P"%?_"A_@=^WM\))]<_X2X>!/\ A*-&
M_P"$B^R?V;_;W_$FUX?VU_8?X\@\9'M7GVO?"OPY\>/A[X7^"WBJ?4K7P_X\
MT<V6L?V3_P 2W4_^)%HO]O']/;O[5_/F*Q,5Q?E>,T24F[:):2;M;;IVL?KN
M'PS_ -7/J>MVNK;>L;;L_!?_ (3;R9;C\>#_ #_R!UQ@UGWFO6.L8TK58/[2
MT^Z^G]I_7_//]/T(_:N_X)[^!_ ?A>XG^$D_BWPWK%K9_P"F7=YXD_M+4_KH
M?_"0<D>G3FOQ7T?4O%7A7Q'<>#O',]S_ &QG_0]6Y_XGVE_3TZ?\4MCO7[KE
MW&F#S3%+ NUK).]K;)==#\QQ7#KPK<E?=RT;\WNM3^W/_@C=_P %3[GXC3>&
M/V//VH/%=S<?$?3;1;/X$?%C6+LG4?BQI(/_ !)/!?C?6Q@CXB^%5^4'=M\8
MG:VTE2C_ - FG '2M/'_ ![?\A3_ -/>OY'KSS^6:_S"-!\1^3+;V\\^I6UQ
M:WGVW1]6TF\_L[4]"U3C^PM:T/7#_P B_P"(O^IIQS7]@O\ P3&_X*VW'QJ\
M,:?\ ?C[#<^)?VCO#-G]C\'^+/#QT?3M-^._AG0M& _MG6_^$A)Q\0O"@[#
M\9GL2<GQL\R/^R\7_:V#BY4ZC:E%*ZCS7N[:IIMN^UKW2:;26&Q2Q7^QO24=
MN[MIOIKH?O'K'_( \0_]B[XH_P#3+7\\$=[Y-E\(;'S_ /D Z1XJLKS@CG73
M_;WJ?7\Z_4^;]N3X2:QK'B'X<_V3XDT3Q!]CU7PQ>7>K7FCZ;IEAJG]C?V%_
MS+Y)], ]\8QTK\_H?AC9:=%<&_\ &7ALZA:^(_[:L_\ 0]9U/[!I?]BZ!H/]
MB_CXCT/'/'>OB<YQ5VFU9Z-KJM;OS]-/4^@R;#;KU_)KH?K3^SY^Y^ _PG@/
M_0GZ7[]S_G\/S]9F_P!2?H/Y5\2_#;]I;X5_#WX>^!_ ^JSZWJ>H>%_#FF:-
M>7>D^&]9_LR_!.<_Y'\Z7Q)^W[\"/#?_ "%=*^+5S_V"/ >LZEV_^MGOU[@5
MZ&%S+"?5$KV>BZ^2_,X,5EN+N[=6_P 6_P"O^&/M"?M^']:Y^?M^']:X?X/?
M'GX2?'[PE_PF7PD\56WBW1_^/*\M/L>LZ;J>@ZI_T!=<T/Q!^63@<'\>PKU\
M,[QTUT_1'C8C#O"-81[W3O?7=/=O;YGL'_++_/\ =JO-_P O/_ *)O\ GAC_
M #Q[?YXP.U03?ZJX_P"O35?YUX+W?J_S9[ZV7HOR1PV@:/8P^"/"Y^PVV;6S
MTO['^?<_K^/O7H$TW[K\/Y_T_4=*X_1_W7@CPOW_ .)/I?Z\^WU[5T$TW[K\
M/Y_T_4=*E[/T?Y,I;KU7YH^I[#_D%Z3_ -@RT_\ 1=%06'_()T3_ + ]A_Z)
M%%?(O=_XI?\ I4C[9;+T7Y(_#;]O74C9?M<S_P#9*_"_'_<:U\?K61X5\2?V
M;I=Q^_\ ]'Z_T_//U]LUK_\ !3#3O[._:&\/>)(3_P ??@/PQHUWWR#K?B#;
M^.,=.<_6O(/!-Y]LTJX@Z?Z'ZG/],X]OZ5OB=LK]'?\ X/\ P3 ^@+/Q)I6H
M_P#+Q_I'O]._U_#^6-#SH)O^OCM_7/N/\.:^0)OB%H<,OD>?]FN?^G2S^OTY
M^M=?X/\ B=/K$5Q97T^FW.H6O_'G=V=G_9O3]?UP/PQ7 \-=O2^_3S?D'UGS
M_'_@GUAIMYY/[C_ _P N^/;FNPAFGZ=O_K_X^^/7H,_+^C_$Z"\E^PZK_P N
MO08_E_GN/K7M&CZ[!-TGMKGM_P ?G^<9]:YGA=]._3U_NG1]9OU_'_@G<>)/
M#>E?$CPEXP\ :K]FN='\>> _%'P^UBT_ZA7CK1=?T#\?^0YU/\^:_P ^#]J*
M'Q'X5_8R_8W^*F;G_A8'[$?[0GCS]G#Q)=_\Q.P/PH\:'7O OKVT/Z>]?Z ]
MGKWV.ZM[ZQ@Q<6O_ !YXO/Z?IWY_.OX[_P#@H?\ "6""7_@LS\"+&Q-M_9?C
MSX7_ +=?PWM/32_'7]@?\)U_8?\ W,?]N?X\5OE^TL&WHT[WV>CWOOY#Q#:?
M,MT[Q\FFVK?-+8_:#XD? WXFV?A+PA\?OAE8GXL_"?XH>#_#'Q._M;P]9C_A
M.? G_"=:+_;VNZ+KFAY.0?[<_P"1I\)^G2N7_9%_:6L?@S\;O#_B/5-4'_"L
M/'EX?A]X[SU_LO71_P 2'6CH?.!X3\1^@.!_PD_6O</^"+?QXG^+7_!-C]E_
M59[[[3<> _#>J?#'6+L?\A.P_P"$%UK&A8X!_P"1<_L/Z'\C[#^U%^Q;\)/C
M-%J'BK2H/^%;_$BZL_\ D=_"=GHW_",^+L_]#QX'Z>(?_4T''X_!8G)?JF.^
MNX1M/F;:O;[5WUOWV/UW)>,\)FN3?V-Q%NHVB]-'RVB[Z]>6VO3[_P!7]2F@
M_MFW@\_[3<:#WM+S_B67_/Y\]Z^/_P!I"'_BJ/"\^/\ F#ZKQGZ'^?'?_#E_
MV)_B1XKUCX0'P!\8H/L_Q@^"/]E^"]8U:UN_[2_X65X# _XH7QH/^IB_X1S_
M (ICQOGD'/48 ]0^+5G_ &]%X7OO(N;;[+_:G_'V1_R"^G\C[_C7VJQ/UK!W
MZI7?R2^?0_*<RPZPN,EA8JT6VXN^G*W*VJTU5NOW,K^ _$G_ !)O(\__ $C2
M_P"GU^OXUZQIOBK2C=:?/KD]SIMO:_\ +W:<]/\ ]7^>E?+&@S3Z/?B^R/\
M.?Z_G7I_VR#6(;>?_EX]_P"7^?4_6O2R[$?6L(TUJM-=]';;<\?$WUM?KM?S
M/J";XAZ5>6OD>'+^VN?^GLYZC]#_ $]JY_1X;Z&Z_MS7/^)EJ%U_QYVG33+#
M_#U('7CWKP^SF@_T>"#_ $:X]^OJ.?R_R*] L]2OO*_?_P#'N?\ G[Z>G^?3
M\..^P'J']I3_ .D7TX_TBZ[_ %X]?\.GY>'_ !(O/WNGSXY-Y_7\?_K=.U>@
M?;)YHNG7]?IZ_P"<^M>3_$[]U%IX$'_,8TK^?YC^?;I7/B>OS_\ ;@+%F9[R
M6#]_BWQU_+\./\XZ5]$> [S][_K\_7'/_P"K\OQKYGTV\_X]_P!__GTY_P ^
MG>O</A[-^]__ %_AZ9P/R]R:\["?[XO7_(Z/^8/[_P!2QX\A_P"*MU">#K='
MZ=Q[?Y]*L:;J7^B_Z_\ S[<C@=?>J_CP?\3FWGX_TJS/ZGC\L?K^>/9S^3]H
MS_Q\<>OT[_R_R>G;&=EKZ=3G_P"8/S_'K\SW#X>ZQ]LT;6+&?_F%ZQCO_P @
MO7<]._\ GUKYO_:TU+R?#FCV/G_\?6L9L_\ 3/[-_M#5/^8%HO3L?ZU[!\-Y
MOL?]L>?_ ,O5GCZ?UX'_ .NOC_\ ;,T>#QY8>%_!VK7USHEOJFL?Z'XATF]_
MXF>@ZI_8O_$BUK0L#_D8O^9H/]3BO0Q&):P=_P ;=O.R"U].^GZ'XO\ QS^&
M^E:_\;K?5=5@U+3?%%IH^EV7B32?#WC#6?\ A!K_ $O_ )@6M?V'_P R_P#$
M0_2E\-_ 'P!]JM[[2O#GAO1/LO\ IMG=ZMH_]I:F=4__ %_3ZU[O\5/A[XCT
M**W\<:Y?6W_"4:]XD.B_$C5K.S_XF?BW5#HO_$B\:<_]@//C<^WK7/Z-Y\-J
M>OO_ *8-.Z<CI^'_ -:O/PV)^M]NWKT_KY'D9CAI89IQ3;O=))O7?IYM>1H:
M/INE>%93!!<6WV?[9]MN[N[_ .)EJ5__ -1K\>G]37<7FCZ5XJL+CR(/M7V7
MTL^,]/\ ]7]:QX=-U7RK>X\C3?3_ $N\X_G]>OO5>'6-<\-W6GWT\%L-/NO]
M"O+L_P#(3SZ_Y]:Z&N;_ &-ZWZO7?3K?N)8=12QB;6;JSLE;1:]+:V1Y_9V=
M]X*UFXL9X+D6_P#RY_0^O3/Z5[QILVN:G:^18ZY;>&^Y_P!#_3^W,^QZUH:Q
MH\'B32_MW_$MN;BU_P"//[(.GT__ %Y].E</>:E!H-K<6\]C_:?_ "^FT_YA
MGT[=#W]AU[<^'X<>'Q>][I^?Q7WW7VCHQ'$GM\*F_BBTV]G>-KZ:2WBSY_\
MC9#??\)OI]CKD_\ ;=QJG@_2[S1KN[O/[2U/_B1ZUK_]NZ+T],UY!KWQ"L?#
M<O\ 8?VBYN;C_E\M/^89^7O_ /JZ 5?_ &S/&&APZ#\)_&-C!<^&_%%KK'BC
M1-'U;P]G^U/[+&B_V]VZ?R.:^![SXD?;9;B"'2K:Y'V//VOQ#>#4M4_^9C_/
MY_QAXG\)O#<<9K973=]-M>UE;;LC_1#P=SMYKX=Y3BY/6R3<NZMNV]=NY]<0
M^)-#\275Q?6%_;7/]E_Z%>_:S_AQ[5XQXVT?0_&%AJ&N:Y9?9K>ZO-+LK.[_
M +'XL-4_Z N/IG^=>'?\+(\1Z/+?WT^NVVB:?=6?V(VEI9Z-INF7_KU[?SYK
MS?6/C-8W=UH^AP:[K?B0ZIK'V(W?_(-TNP_MWT]./\.M>!EO!>.Q+3P?,M?[
MR[/K8^]S+BS)LK36,S6,O=?NKE>MK6MKZ;'[0?\ !,?QYXC^"?Q0UCP/X5\1
MW/\ PJ_^Q]+\3_\ "/7?_+CJFN_\2'7?["_Z '/KT]*_IX\-^/+&\E\_K<=/
MM?\ S#+_ /'T_#_Z_P#*O^R[X5G\$W7A^^L8+FYM[K1_[:O+N[SQC_D.Z+SS
M_GI7] 'PQU+_ (23P;H^N:5??V;<&R_L6\_TS_H \YZ?G7];<)?7<JX>RG!X
MUMR27\S:2LEU;6Q_GWXC9A@\TXNS7&8%)1<M+))6;>JLE&^O0^^+.>"\B\^#
M%M<?\^G]<]_P^E%?.^@^,-5T>6W^W7UM<V]M_P NF?\ C_\ \D"O4+/QMH>I
M?OX=5MK;_IT^V?V;J8]O7/\ GK7Z!A\3=:_*_GIU^_1=]-CXWZMI>W2^WS['
M43>1_P \+;[/^G^>G<X]1GBO,(/]1Y''Y^_M[ _KV-<_/XD\.6?[^?5;:YN,
M'_E\]>_]*T/[>T.:7,%];>P_#\.G^>*=];F%EV7X&AYT_P!J_P!?<FWM1_GK
MV/Y\8K8A/D_Z_M_GU.0?_P!>>:Y__A)-#ABN//OL=<'T_+^F<YKC]>^(4'E7
M$&E$?:/^?O\ +_Z^,5N<UUW7WK_,L7FI_O1Y_P#Q\6OU_P#U=/Q].:H7GBJX
MA_X][[[-QW__ %8SZ_YQY=>7<_G8_M7[3G_(_P ^GYUCWNO:5#*?/GX_/UQU
M^M.X[K3FUC=73ZI6NM?*YW&L>,+Z&*XOK[5=2^S\#'VS_C^_+T^G&.OK\#_M
M@:_X<U[X5&Q^*GC_ ,?^ -'\4>//"^B^#_$/P^UC6O\ A)=!\=G6] _X07^V
M^,'X>>+/$?\ 8A\;#_D2\_\ "3# !!KZPO--\2:Q+;_\2JYMK?[)]ML[3[9_
MQ,_[+_Z#7O\ KGK7Y;_MN_&&^U+2[CP#X5O[;33KWAOQ19>//%EU9X_L'X7\
M_P!N_3_A+/\ B><]AH'B>N;$R<<%FN,4K*UDE*W2VEI+TT_R.;+(8S&<6\*9
M-A,I4GG?%*YFHJ2_U;O'5^[))W3=F?C?\5/VJ?AQXP^%?C#XB_MW0?$@_M3^
M#='\>>&/@_\ \*R\2?V;\-/[4_XG_P#P@OC37-#\/_\ %,_\)%XL\1X_X3<'
M_BB_^$+S7S?^SWXP\17GA+POX \2>*M-U*WUZ]_MKPYJWB&\_P"*9\)?&3O\
M,M<Y_P"1=^+']N:'X8ZYY_X3DCO7Q?\ M(:E!\9;^_\ %>DV)U*PU[6=+\%^
M#O!-UG3/#.G^%]"T7_D=-<US_D9P?%G7_A%AWZDCIZ!^SK!8Z-H-AH=]8ZE;
M>#]>_P")+\5-)U;.I:9X$U30M%_XD7C3P/KF?^*?\._\(YG_ (3? S_PA7XU
M^-YC4J9IAOJO//22=^:2>DD_YD];=S_3W@K@VGP9#ZSA:<.7/(\KO"'N1<>2
M3LZ?NV3;^SM\S^UW]BJ\_9@\>?"7P?\ $3X6_L]_"7X8:TO]J>%_'GA0^ M%
M'B;X:_$_0P#XY\&:YK8X!P"/!7BD8!\&@D*JLJC@OV^_V7/&/Q:\!>-_BG^S
MU?6_@G]H_0?A9XH\,:/J]I9D^&O'?AC!UW_A"_'.A^'_ &Q_PA)_ZCW!R>?Q
M'^ 7[4_QB_97UGQQJOAS2_#GQ(\0:[X/.B:QX3\6:Q_9OAGXECP,0? WC/7-
M<\/Y/B#XB>$S_P 4OXWX_P"*T\%_\(Q7P-^T7_P4L_X*D?&:[M['PK^TGK?P
MNT^ZL]4OM8\)_!RST;X)Z98?\3K_ ,*?_P O#WY!X_8O##A3-O$K^T\#A,UC
MDCR-*RE))S44DTEO*Z3LE=*_3I_)OCEPWCO#?B../?-GG!F?3:YGS.,)3DFX
M\SYES1<FK*7-:*]V][^ >-Y;'5_V3/AS8?%35?M7Q7\+^/?B?XF7X3_:QXC\
M#>!/"_\ R O'/PS\<?\ "0$^*/#_ (B/B+1-$^)_@C!(!Q@]#7Z(?\$S?VEO
MV0_V3/V-_"_ATW%MIOCCQWXPU36?B_XL\0:/_P 5+\2O'>,Z$/[</3P[X3\.
M?\B3X7ZDCQ.3WK\O]8^ 'C_XA?"7Q!X_@GMM2^/.@_\ "4:S\=[N[_MG4M,\
M6Z6=%_XD6M:'KG'_  D'Q$QWS_Q6F.:]:^#'[%_A;XX?L^?#D>.!\8M$N/#*
MZ7K%II-[=)X+U30-3UUM>?7#H.B,"==8^)$&6\4X8J?#4>=CN&]K$9?C,LQF
M:Y/BYJ;R1V4D^;F>S>CE>^^[WL?DF=1PB4<;A(<N3R2M>-M6EL^6-[/32Y^D
MW[47_!3C_@GK\5;4P>*O@1XV^)'Q TO1_P"Q='^(7AZ\_P"$)U.PTS_D/?V-
MKG7_ (2 =/\ BEO%GX<<5GZ[^U=\0/@U\/?"_P"TEX&_::_9X\?_ +*'A8>!
M+Z\_90/@_/Q?U_X7ZYG0==\9ZYXXU_I\9?"?B+_F5O"?_%&>O7CY'T'_ ()%
M_ _Q5?V\&J^*OC]_8_VS_3-)_P"%D?\ $L_7PW_GBO5_B=_P2[^$A\6^!]"@
M\9>/]$^"^@_\(O\ VQ\!K3_B9>!M>_L+I_;FN?\ (S]L^-^![YZ48:]M+[>?
M9'S"^IW5OE^GZ'Z4_L??%7PY\<OA%^W/\<? ^E:WHG@;XM>&O^$G\'6GBTZ-
M_P )-_9>N:+KH_XGG_"/_P#,P\=<8P,>E8_PQ\^'XC?!_P#<'_1?[4YZ?\R7
M_7KT]*S_ -C[P?H?PW^%?[<_P_\  VEC0_!_@VR.B^#]*M/^09H.E_V-KW_$
MET,?XC@>M;'PQ_Y*7\.()^/LMGJG/_<E_P#ZN@]<5\/B[_VQE>^[OY;_ '?@
M?4+_ '+RM^%CUCXP6<^I6MO!/I5M<?Z'CZX[?H<\_3UK\1_VJ/V+;'QYI=Q?
M:78_V;XAM?\ 3=(U:T_XENIV&J'L/\?3CBOWY\83:3#C^U;[3;;[*/\ G\]^
M1_G^?3\WOC_^U1\%OAMX[\+_  LU;PIX_P#$GB#QE_PC'V+5O#UGHW_"-:!_
M;FMC0?\ B>:WX@\2?\)/X?X.?^*3[Y!KZ%8EX.5U=.][K?>ZU7Y>9XSPR>Z3
MOZ/\TS^:_1]9U7PWK.H> /'$']F^(-+ZB[L_[-_[C6AG/<?YQ7J%GKVN:#=6
M^JZ5JNI:;?Z9_INCZM:7G_$SL/\ H!=_K_CW'Z ?MC? ?P=\>+76-5\'3Z)I
MOQ(\&_Z;_:VDWG_$SU#^PL9UKC_//M7Y#^#_ ![/";C0_%5CJ>G:AI=Y]BO-
M6^QZS_9A]/\ B>5^S<.<1QS7!K XVVUES6OLDM_*Q\!G62_5<7]<P;T=[V>G
MGL_4_I/_ &0/B?K?[7]A/\*O@_/HFB?M ^&/ @\9^)/#WC?Q&?#8O],T/Y=<
MUKP1@>+O[?\ ^0)SX7^Z.22 *]2TW]J+]H;6/$?B#PWI?C#_ (F&@:Q_8NL?
M9-&T;4M,_M3_ )CO';@Y_$=J_!WX$?$[Q5\&OBU\-_C%X'O_ .S?''PO\2?V
MUH^K6G;2Q_Q(=<T;!_YEWQ7X=_MPCWU_/O7ZD?L%:_\ \)OX%\=>/Y_^/CQ/
M\5/B?>]><_\ "9Z!SV_#TYZU\AQ9DBPN,6,^RVDKJRU\NNCZ+\SU^',3H]-4
MG?[GWVU/VI\*?L7?MS_$GP;X?\9:5^UM\+O#>C^,M'TS6K.TN_ 6LZEJEAI>
MND@_CQ_];BM'4O\ @EK^U1KTEQ_PDG_!0K^P[>Z_Z%+X5_\ $SS_ -S!XD_S
MG\:_5[X(_P#)&_@__P!DX\,?^F85Z3--_D_Y_(9]237/A<EPC2=][/ROH_3<
MX,5G6+NUV;2[VN^F_P#7H?&_[&?[$_@#]BWP)XH\+>%?&/C;XD>*?'NL?VUX
M\^(7C>\_XF>O:H".@&,_7T].E?5'_+3R/U[=/7KT_7\ZT*Q_^6G_ &^?^RU[
M&'PWU5-7Z.VKTT?7^ON/G\1B?K>,3?=7??;^OU/8/^6O^?[U8][-_H&H3X_Y
M<]4SG\Q@#_/K5B:;RO\ /\_;IVK'U*;_ (E>K_\ 7GJF./\ J"=O_KG\Z\![
MOU?YL^O6R]%^2(-._P"12\+?]@CPM5^:;_CX_P _3@_I^7K61%_R*_AC_L#>
M%OZU/--_D_Y_(9]234O9^C_)C6Z]5^:/L"P_Y!.B?]@>P_\ 1(HJ"Q_Y!&A_
M]@:P_P#15%?(O=_XI?\ I4CZ];+T7Y(_%3_@J#Y__"=WWV>QM[J?2_!WA;6A
MG@X_MK7P">^?7_.?E'X2ZQ;^5;^MU_IO7_\ 7_\ JK[(_P""@-G_ &E\>+C2
MIX#]GNOAOX7Y!!_YC>O_ %'O^'XU^:_PEO-5T&6WT/59[FYU#03_ &->7?\
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M7_+WGWS_ )XX_E_)A_P3KUZ']FG_ (+M_M,?!Z"<6WA?]H+P?XH\3^&[//\
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MJ>'/B%%I_P '?$>JVVB?$#2[/_BV_B"\L_[2_M[_ (04=/\ L8_"?_(K]/\
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M " O[<_X2#^7.?7BO=X?VTX)O^%;^.-5_LRVT_7K/Q19>)/^HA_87_$@_/\
MQ^N/EC_@HG^Q#8>%;GX3^%OV-/@[\2=;^)/CSQ[X[\,:QX>\$:QXR^)'V_\
ML+^P="_Y ?B#/_"/\ZWC_A*>_3UKT>\_X)O_ +9?P'^#?PW\1_%OX8ZEXDT?
M_CS\2>'O! T;QMJ?PE_ZC7CC0_#_ /R+_;CI[=J^PX=PW$F'QN;8S,,U<Y2U
MFY-MS;W^)N]Y.75[G\S^-?&WA%Q5PEPO@^#>%(Y TWS17*FEK922L]-%[W8]
M0_X;2\8^)/%&C^#O@[8_VEXG\4:Q_8GANTM/#?\ Q,[_ %3_ +#GB#'_ !3I
M\.<=L5ZA-\6KZ;Q';:Y\5/VT?A</"%K::79'X>_#/P&-2\37^IXXUG7/BGX@
M .OD<Y\+^$_"!ZC &,U^?_@_7O\ A5?Q+^'_ (^TJ"VU*X\&^)/MO]D?\Q._
MZ:%KNB_X9KJ+/PWX<TC6;F#2I_M/ABUO?MNCVEWH_4_]@/Q!_P B_P"(O"GX
M_7I7UV&Q.+PV*[WZZ6=U\UU/Y2^K81/=;]UT?_ /U7_9%\4V/BOX8?MX>(O#
ME]]I\/Z\#K/AO5S9_P!F:E?:7_8VO=^?_P!6?4UY!\6OBIJOP9\&W'Q-L8/^
M)AH/]EV5G_W'=%QU_ CC/O77_L?S06?P2_;0@@_X]_L6F&SM/32_[&U[L?P]
M#TJ'Q)\-]*^+=_;_  Y\1_:;G1]3S>_9.?\ F!:+[>_X]/I7SV*US>[W;37S
MU=O^ >]_S!679K\&C[.N_P!F_P"!][X;MO&7B.^\?^)!_P (U_PD^L6EYX\U
MG3M,O]4.BCI_PC_?_'M7B'PK_97_ &2?C-X<\#_'#QE^ROH?_"4:IH_VS1SX
MW_X3+_A)M"TO/]O:%_Q(_$'B3_BG_$7O],>M>P:#-\4_#?ARW\*V/B/3?[/M
M3]B%I=Z-H^..V!5>;_A/YK6YAU7XC:GIMMH-G]L-W_R#=,T'2M"X_P ^]?1=
M=CY]X9N^CUOWZW\O,ZCQ?\-_#?@GP1XW\5?#KX+^ +CQQ:^'-4_L?2O^$;YU
M[Q1WT77-<_Z%T?AFOA#_ (*/>19_\$R?'7_"?V/@#3?B!J@^&%Z?#WAW^QM-
MU.P\3_\ ":?V\!H9S_PD^?"?AS'OT'7FO5_"'QLTJ#7M _M7PI\2/^%??$:\
M&B_!7]H35O&&C>)/AE\=_%'IH>AX_P"$G\/^'?%?AWC_ (2GQ9R,_P#"#GI7
M\P_[;]G/#^USXXM[Z:Y^T6OCOQ.3:7>L:Q_9EA_Q)!^N.?8_6O9R-O$YLDM$
MFMM-K=K?U]QY&9X?ZMA-;O?\;_YFQX)A@FTO1[B"#[-_]?\ SSQS^%?J?_P3
M&F_XQJL9\_Z1_P +)\4?8_\ N.^,U_KZ?_7K\O\ P'#_ ,2'3_\ IULM,_R>
M^/;KT[U^G'_!-*'S?V8- X_YGW_T^_$W7OI[\?A7WO'E_JF4;[+\UOWV\SQN
M&]LV_JV^W8_M8^#P\GX0?"\C_H1/#'_IF/MTQ[5Z%-_J3]!_*O/?A3_R2KX8
M_P#8B>&?_3,:[&:;_)_S^0SZDFO*PO\ N:[V^?3YGS^+?^V/_%^K"?M^']:S
M_._>V_/_ "^=CC^?(_K5B:;_ "?\_D,^I)K'AF_TJWS_ ,_A]^/Z#\_;I6[V
M?H_R8*UUMNNW='K$TW[W_(/^?T/2N?UZ;_B3:QT_Y ^J>IY[_4^_;IUK0FF/
MFW'7^7^/^>>PKE_$LW_$A\09_P"@/JF/\CGU_P 37S#W?J_S9].MEZ+\D:!_
M<Z-X?@]++2__ $R]?\Y'TX-$TW[K\/Y_T_4=*KWG^JT;_N%?^F5JKS3?Y/\
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M;'YY^OMFM"SF\F[M_P!__H_VSGGN/\^G\C70<Y_,?X\^*G_"*_M<_P#!(_\
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MO?D]:_A)\!_%3X^_#?[/;V/B/3O%FCVI%Y_97B'1\]<?3'XYSGMSG[_\"?\
M!2;]H3PKH7_".:3X!\-_\(_='[9_9/\ :[?V;_:?KTS@_7/M7V'_ !"_.<7A
M.5Y7*_PM^]WM?3YM'@?Z_<-X576;0MO9..FE[-.VWZ:7U/[!]8_:N^%?@/P;
M<>*_!W]I7.L75X;+_A7MW_R$[#5#_P QK^W!ZX[GM7Y[V?[8'C__ (2VXU75
M;'^V[C5+O[;K'V2\UG^T^_7\OUXK^?\ UC_@H1^T;J,-O!H?A7X7>&Q:YQ_H
M9\1YX]^OT'>OG#QM^TK^U?XUCN+?5/BWK6FV]UC[7:>$[3_A'!^)'J.XQ^%>
MKEW@IFV%5VE:W57M=;;/[UV/'Q'BSE#LEFJLGM?S[)VU7IN?VO\ PP_;&\.>
M/+74/ASJM]J7A+QQJFC_ /%'VGBW_B6?;]4_Y@.B_P!N=ORQU]J_FG_X*$?L
MEZ5X/^+5O\8O@#I7]F>%_C(?%'B?1O#W_0/^,?@7_DNGP7_L3_F7_$7A,#_A
M*/!'_0Z>"]?/_0HU^4/A#XM?'#X5ZS/JWA7XB>)-0U#[7]MO?^$KO#XETPZG
MG/\ $3U]L+[5]X?$K_@H]XC^+WPI\3^"/B;\++FW\<>,_P#A!-:'Q"\$:P=-
M^P_%#P)C_A!?BA_8?0_$(^'MWA;QL<D'P7KIR%[_ "'%G@_G"PO-@T[J\K)7
MNXW=M$^S1^P^$_C5E&5YM]1QLT\ESJRES22Y>9QC>TY+E3<NRWV:9_0=_P $
MA?\ @I!8_M"?"K4/@M\3=5N?^%X_#C1\>&]6U>\_XF?CSPOH7_(=T77/^IB\
M)GWX\%G/2OMCQY9S^//[0,\_VG_3?MMGWZ#_ !].:_C0\!_$/7/!_BSPO^U=
M\.O^*:\4>#/$FF'XU>'M(4?V;8ZJ=@/Q-T713AAX;\6*H/C8'<%\&9 4?\(H
MQK]Q]>_X+2?!WP?JO]E>*OA7XV\-Z@+/2[W[7X>T<^)/#.O:7WUK0\]./R]J
M_..%,MS?,L9FN287*O\ A8CIKII'1V3V^%V[GZ;XP9/@\BAE7%&!:_L//%?G
MBTX1YES:RB^1.SO9R6O<^L/%7PXOIHKCR(+FYN/^GN\[X[_Y_'%>;ZEX;\1_
M9;;S]#^S:Q:_\>?B'2;S^S=3L!U_R.WU.:\ G_X+1_LL:CY_GZ'\4?;['X$&
MG>O7'3KWQW[<US^I_P#!7+]DJ[B\^#1/C5<_]0BS\(KIVI_4ZYDX_P ]Q7W^
M&X(XNZY3=K3;K=?W>Z/YRQ/%O#R?_(VM_P!O+O\ XM=%;KL?:^F_'C]J_P *
MZ-;^'(/'_P#PFWA^UO/MO_"/?$+_ (F6ICCK_P )QQXG/^.0:V/%7Q@\.>-K
M6WOO%7AS6_!/BCDW@L]'_P"$DTR_Y[5^6^I_\%;?@M=_:/\ A'?@1\6M2@^V
M?Z'_ &KXET7PY^HR.@_+/K7B^L?\%7/'\UU<?\(=\"/ &FZ?C_F;/$FLZEJ5
MAT_^OQ^E?49;X;<6XM)/*;7TO:UEW7NI:7/%Q/'_  YA&_\ A65UTT?KW[>:
M/W0^'GQ:TK39?L/_  F.B7/_ #YYUC^S=2_\N#U[=_Z_:'@GQM/,+?\ ?_9O
MM7_+W]L_M(?I_G\S7\<'CS]O;]IKQY'<00S_  W\.6_<>'? >C _AP?;^>*\
MGT;]L#]MCPI+<7'A;X^^);:WN[S[;=VFJVG]HZ9D]SD'('<#&>>1Q7T'_$#.
M([75[VNE?J]4MULVCR<+XL\./%I.2M?5MZ6OUWWU_P"!N?V#_P#!0CQ7/IO[
M-WA>"^@_TBU_:<_9S_XFUIV_XK37_P !^-?G]\0YOMG[?W_!/?P[_:NI:+;Z
M]\;?B?HMYJUK_P A.P_MW1M>_P"0(>.GOTX]*_.&\_X*E?&']I#PE\/_ -GK
MXT^!_#=MJ)^+_P &_&=G\3O#^KZSG7?^$%UKG1=;T/!'_%5_VWU/)YX.*^UO
MC;J4'A;]O3]C_P")OB.^M_#?PW^'/[4YL=8\;ZMC-A_;O_("&<?\)/K_ *9_
M,8%?F_$?"6:\.XOZIC%;-5[VSMR)W<KVY;6Z[>9^N\.<2</9O@\SQ+:_LFHN
M2*3]Z4I1:<8*Z;=Y6M%-]T?O%\<OVEO@[^PWX,^%]CKGA7QMXDT?Q1K.J>"_
M#?\ 9)T;3/L&J=/^)YST\6?UZBOF[XJ?M[7^L?L_7'Q&US]DGQ+XC^ _QDL_
M$_P^O+2[^*>C?VF#D:"!XXT/0!CX?^G@C'YYZ3_'CXP?#+XA:];ZK8V6B7/B
MC]G[Q)JE[XDTGXFZ/_9NI^ ]4UW_ )G37-#[^'?^$<_Y$CQ3T_2OS/\  GC?
MP[XV^//Q^U6]^*>M:=?_ +1GAOX8>"O"'@G2?"!'@?XE?$[0M:.A:YK7C< $
M:#X=_P"$>P,$J "2#D!3\=BL0\7BK875V>KU3:5G:[:>J>US]#X<X5P>4Y7E
MN-QF:?V':3EPS%:.SES6FE:45*]O?Y=)-]SF/VP/!_@[X8^#? _Q-^(VJ^"?
M^&@->T?POX+\.:MJVL:-J6F:#JG/]A:U\5-#_P"9@_X5/X<UP_\ %4^W3-?F
M!X$U'1?B!\1]8\??$?Q\?BAX7^$NKZG?^(_B:01IGQI\=Z)K(.@:-X'T(X/A
M_P .>%%.A%?"^,>-?&9\,'T)^O\ ]KOP'X \>?M&?%?Q]!X5T0^(-*\-:7_;
M'^F:SXVU/Q:-"T7/_%#^!S_R,'_($]^N*]/_ &:/V8[']FKX0?!G]LK5?#FG
M>+;?XL^/-+UKPW^RSI-W_:/_  J?X8>.M9&A:%\9^0/[ ^(?A/Q$?^$H\;^%
MP2/!9!&000/@<7DF*Q6+ES.T;N[V5KN_9;7MJ?U?PUXLX;*^'8X'$KVU2"]R
M"O-RG%*RBDY.*G**6B6D_O\ D#XA?LR?%/XJZ#<?MA_M>3^+O@7^S3=7FEDZ
M1X)71]2^.%A\+?[:']@ZVO@GQ!_R /A[D-N\3^+ /&GC'QF%_P"*)8L /U \
M$^%O@KX)NOC/\.OV<K'6]$_9_P!!_P"&=-:^'&E7>L?\))JFH:7KNC:%KW]M
M?VY@#/BSQ%KFM^*#[XZ5^?\ ^V!^U=X5UZ7]H Z'H>B?$?P/XRO/%%[XD\0^
M(;S_ (H;7O'G_$@_Y)7H?_,P>'?^$BT/_A*,'_F=/6O3_P#@GCK'CG6/V??$
M&J^/[ZYU+QAJEG\&[W6+O5O^@7_PFFOG0M%/_<N?V'C@>F#UKZ;AS#Y/AKX7
M"V;6\M).^M_>U=KW^U?S/R_QAXLXLXHRC*LUS>3R.$7:'"UN5<E[1ERZ6O!*
M5^5?%=G[L_LQWEQ_PMGXP7%C/_9MQ=6?BC[;]D_Y"?\ R&M _P#K?RX%?9%G
M#?6?VB?2I[FVN/\ E\Y_Y" Z?X?D/:OQO\8?%72?A7\0=0O]<\5>+?"5OKVL
M>/=$M+OP39_\3/7M4_MK0/\ B2:Y_P!2Z?UQTKQ_P)^U1\5-8M?%$_CCQQ<G
M[+X\\467AO[9J_\ 9O\ Q0?_ # N.?Y\XR<"OH=-=K:_F?S/BG)XK=V3T2;:
M5][*[2^5C]T8?AC\.=-UG_A,?^%<_"[3?$_2\\67?AO1M-U/K_@?UKYV^/WP
M]_8[^)T7D?&GPYX1\2:Q:WFEWGVOP1_R/-__ &%_U'/#_P#]?';(K\G_ !)^
MU%X5LXL^(_B;HF/^?3_A)-9\2:GUZ>_?_/%?-_BK]M[0]-EU"#PWX ^)'C;3
M]!O-,O?%_B&TL_\ A&_#-CX7UW6O^0WH?_,S^(/$7A,_\51_GCHP^&;3>KT?
M=]&_\]GWUV,-?/\ $^Q_ DVAV<__  46M_ ^E6VB>#[6[\,#1_#I/_'AI?\
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MV&,?\?@_S^6?QQ70]GZ/\F<2OS+?XE_Z4CT[SO\ CX_#'_UOUP/Q-<OXC_Y
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MAS?8OVL[:^( MS\*O"_^E#L3K6ODC@]B?RZ5YQ\/=>_M+2[>>X_TDVO^3_\
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ME?:/>_I8_3_]C\V,/PA_;W_LK7-$\2:?_P )&?['\0^'KS^TO#&O:7_Q/O\
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M]_Q//^YCT/I[5ZA_P4:_X2J;XH>!_P#A.)_[2\8?V/JEYK&K6G_(,O\ 2_\
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M:>.8=4S#HGAWQMXE/?\ LGPSK'I_@.W3MZUU&F_#CX[^*@;W0_@1\2/])/\
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M'G_::_9Z\)?$CQ1XH/CS[9\8M)^,&LCPSH/B?0M:'_"#>"_BIX''&@ >'/\
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M^.O[#_F?\FOE_P *Z]XCUC2_/\8_"K6_!%Q]C_T,:3K'_"2>&;__ *C6A_\
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MJ$@]PP(^O->OV>@P31>?!/:W/7_CTO/[2Z_YS^/:M PWUG:W%C8WUU;?:O\
M0OLEWZ?KG_/H:WP]?ZJGIWW7D^EMOZW.;$4/K5TFEIW_ ,FM>S]=#^ICX#^)
M-<^$NE^#]#.N:EJ7@_7O!_@/1?&%W>?\Q[4_[%T#_BM/Q_Q]:\W_ ."F7[6E
MC^Q;\#-/\<7&E6WC;QQXR\8?\(7\*_#VK7G]F^&/^$\_L7^WO[:US_J7?"?X
M?\)IZ=Z]9T?0O^*<\+V,YS]E\->%[+Z?\27OZ#M7YG?\%@/#?@?XG^"/V7_
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M0-!T+1/_ "N<_CVKTG_@I]\;-<\!_%#X3Z'X OM-MM'NOAOJE[>7EI_Q+?\
MB:?VT3QSV'Y]?>OR#%>,.;XKB)YQ@E;.%>RZ*U[>6BMTZ'Z]AO![*<-P]_JY
MC??R>R;>[D]WKJ_>=_O/YW]'_9P_;@\5 #2O@?HGANVSS=^+/$@_M(#IGL.?
MIZ\\UW$7[!_[8<UKY_BGXF_";PB!_P NEI:#4R/IPO;V/%>_Z]^T5XXO>=5\
M?_9O^XQW]<]A^E>+ZQ\<M*Y^W>./M-Q_U^:SJ7.?;OVZ=L^U;XGQB\1,TO\
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M!_\ "09Z_P ^?IV&C_ ']HS4HOMT$'PW\ 6X_P!-_P"*A\8:-_:?!X_Y%_\
MR.<UV'C#X;_'']FG7AX ^*GB/1+FX_L?^VO#=G_R#?$UAI?7^Q>/<_J*[CPW
MKT&I6OV[_A(]$TVX_P"?2[SJ?KQ]<_0UT9WQ9@\,[\.95PQDS7VI)3D[==5+
M5V3]6>?DN2XK%X3_ (5\UXEL^UE%I[;6T=_N9?\ V4O"OB/X>?MF_L_V/CCX
MC?VW<>,=9\3_  ^O-)TFS&F:9?\ _"<^#-?T(Z+CO_PEG]N?_JKZ:_X)5>";
M[X8_ []I+PMKFJW.B>,/%'C#^V?$EH-8.F_;_P"PB=!T+1?[#)Y_X13CPQZ#
MM@&OA7Q[XJ\1^%OB+\$/$5C]FN=8MOCO\+_$]E=^'KS^TM3O]+\"ZUH&O:[G
MK^7XFOTQA\!Z'X)_:^_:_P!$L8!_9^A >)_#=I=]M+\=:SH'CO0N/7.N?7CN
M:_-LYSC-<]Q7UK%YE&*V<8148ORLHQ5NVFS1]EEV7X3+,)]5PDG)W;O*3E)W
MUU;;=^KUWN>/_%33?^,H/$%]!!<_V?:^#]+T6\N_L?\ R#_^*+T#^PN..V/\
M.:\7O-'U6\U2>^L+'3=2S_Q);S2M6_XENF7^E:[TT4_Y]OK]@?&>SGF^-/QX
MGL8+G_D,?"^R^R6EG_:6=+_X0O\ $]/TK'T'X;WUGX7UCQQJG@;Q;<^"/"]F
M/$^L>(?['UHZ98:7X%UHZ]_;7_%0'_BGS^.37D?5OM6N][V[:[V_4[UB>E_+
M?_@_H?$_@Z;QQX/_ &)/C#X&UR#PE;>&/ ?Q3U3X+ZQ:7>L:S_PLP>)]#\9G
M_A!?!>A_\(__ ,4QR-</_%4$D^X S7Z(?L6_LNV&F_#Z#7-5\?\ C;1/^$H_
MM2R\2?#WP]H^C>&]3_M3^VCH.-<\<_\ (S_R]*^:/V1? =]\8?V0OVF/$<\-
ML?[4^+Y_:!\26EI>:-_:>@Z5KGC/0=>T+6O["Z>(/#WBP#0__!_CZ_MO^SW^
MS5XCT'0+:Q_X6!X2U+1SXOU2]_M;['K/]IW_ /Q.O^)[_8FAGH<_3TH_VK$O
MI97UTV7X;>9AB<3A,*^[?K?^M?S/SO\ @I+8CP[_ ,%!X-"@MK71[7XUBRT>
MTM/^09IYT(#03^/7\>PQ6?X]UZ?1_'_P@U:Q^S7.L:#^UG\'+VSM-6\-_P#"
M2:9?C^V<:[HNNZ'_ ,S!_P 4Z=<[>F*Q_P!FJ8S?"O\ ;HMS<&YN/^%V?\O8
M/3^VN_Z8_"OJ?]F3SYOVS/@M!/\ 9KG[+\5=3O?]+Y//@S7OR-?/_P#,XMV^
M[9'?B<3_ ,)&BM>]G;NO3[[[ZG$_#[4H/^&]OVU[Z?5?[;U#_AJ;4]%^U_:\
M#3]+/@K7]"T/P7HFA_\ ,O\ AWPIG/3@\9['IX9O.\4>()_^/G_BF^@_[#6O
MCUKYH^!]YY_[;'[;]]//<?Z5^UEJ@]^?!>O-G_/_ .KWCP3J4&I77BB^G _Y
M ^J_7_D-?A],U]"MUZK\SR,-=X._5I[W['[/_!F\\GX2_"^W_P"I/TO^?M^'
M\^PKU#[9[_\ CM>'_!^:X/PE^%_G_P#0G:6#_+U__57J'VS]U<8X'TSC]>?Z
M5]=AL2K=-M-NUNO^7RV/S;%W^N/?XG^;/R8^/\!UC_@H?^W7XCXNK?X<_P#!
M&K3?!@[?V?\ \)UXSU[7,>_;'ZU^5WP!\_\ X0CP_;S_ &FY%J=+^Q_9/^7#
M_BC/P_IZ\U^H/QAUF";]L#_@LG/8S_9O[!_X)P? G1;R[SS8:H=&U[7NO?\
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M#C?3+&3_ (*9WU[/86L]PO[,7P:47-U:$@8\:>/AC)QG '^1C/XH_#'QM/\
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M:K66?12763M$_7GXM?\ !/']BV]EU#5;Z?\ X4GJ%U>?Z99VGC#P;XD\,_\
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MP-X+T$9 ]/\ B>=L_3H:^-?V4;.Q'A?X?^1!_P ?6C_^\QZ_Y/\ ]:W^RO\
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MX_\ !.?ZMKMU_7T/YQ_VJ--\5:#^PI^S?\1Y[*YT3QQ^Q;^U1JG@N]M+L_\
M$ST'POXZUK_A;7@7\QH?X5]P>//V+?$7CSX^_%CX[_#*Q\-W/@_]HS_A%_C1
MX#U;_D)?8/"_Q7T70?'FN]_^ACUS7.O/;Z=1^V-#H?Q^\&_MP>%=#L?#9'C+
M]F_P'\:/#>D^$_\ D&?\)Y\"]:_L'7-:_P"QB_X1S7/\:](_8#_:*\?Z]_P3
M[_9'G\*P>+=;U'0?#?CSX+^)+3P1H^C?Z!_PJC6A_87]N:Z?^I<_L/\ #C%<
M_P!9^J^=_GOYZGKXG_=.E[+;^KG'Z/\ \$W_ (J:Q%;SZYJMU;=KS^R?#?\
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MGQ5_X0?P=??\(W\/_"_]J:S\:_C'=_\ (,\!^%]"T7^WM=T70\_\C!\1.?\
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MX2_"ZWNO^/W[)>:/IO\ ^$_;O_0UB\5>^N]^O>_GYG L,]-'_3OV/Q?\'_\
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M +CGQ _XIC\/3/TKG]=NOIU_"YZ%MKK1;:;+K;33Y6,CX@_!/X1ZE+XQ\8_
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M6GB31O#?AG_A/-=_XH3_ (KCGI_Q/.V<@]\UN\-Q$L'K=12OJVM+;=-+&/\
MPCR>EFV_Q;T_,_5K]GK0O!O@_P#9%_X+#:'X'\5Z;XMT>V_9O^!5[]KTF\_M
M+[!JNN^--?\ [=T771R/^$A\*>(N>>G0UZ-^R[@^#?@O<?\ /UH_7_N3- S_
M " S_2OR-_9EL/VO&^/G[7O[&_AI= \(>*/CQ<?$CPM^UGX6UVQ_X2'X:Z!I
MF@:EK6N:+XNUK6_#\LO]@:[;^),PP^*]X+0:W&YC@+&&/]>OV9(?)\!_!"?_
M (]KBU_M2RO,?]P#0#Z\?YSZ^0L3JDWK=)Z];I/KWN+#X9859JU:SB[77>+M
MZ[Z6OT/Z2/._>_YSU^F.O;]<57\_V_3_ .O6?--_I5QC_G\'MQ_4?E[]://]
MOT_^O7VRV7HOR1^8XO>7K+\Y%CS_ &_3_P"O6AX;F_XG-QT_Y _I_ASFN7\_
MV_3_ .O6AX5F_P")KJ&.OV/W!_P^M8YD_P#8UK]E]?)FV6K_ &Q^J/6)KS_C
MXQ^OZ?Y^H]JY?4KS_B:>%^?^8QJG;_J"^I_K^-$UYZ_R_+C^8_'WKG[R\/\
M;/A<S_\ 'O=7NJ?Z7D_Z!G1?3K_GBOAW=M[O5]WU9]R=!#>?Z?J&1^OYX_P_
M2J]Y-^ZN._YG_P#7]>_'I5?1YH;RZUB>Q%MJ5O\ ;/L7^B?\N'/_ !/=%_\
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M?%?X8_\ ">9]/^1CT/OT_GPX?$_[+YWZ^K[GK_5EVO\ C^A\K^#_ -F/Q_\
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M?VYCCQ!^O'3-=1K'[:7PD^">EW$^AZ5\'/@YI]K9\W?_ !)O[3T_K@#^>/\
M(Y_K-^O]?>8/=^KLGO:[MH]=C\C[+]E?X[_'^+[=I/PR_:0T2XU2S^Q7MW=^
M)-:TW3-0TO'U]<_D*L>&_P#@B'\:?M_G^(_'_P /_AOHW7[)JUY_PDFIY'\O
M\]J_5CQM^T)^TG>> _$'Q&GTKQ;<^!_"]II5[XDN_#VL'4M3L-+UT]M#/\O7
M/;-?G_XJ_:TUR:6XOM5GMO#>G?\ +G=^-_$G]FY/MH?Y>WN30(]H\$_\$TO@
M1\*[7[#XX_:3U+Q)<?;/MNL?\(]9?V;]O'?U_3Z>E>P:/\$_V&/ ?[^'P=J7
MC:XY_P!+\67G]I:9^/Z8]N]?D_XJ_:T_M[5-'T/P/X_\2:WK%U>?Z9_PKWP'
MK/C;3+#N=:USD\?Y]:['3?V>_P!L7XP77D>%?#GC_P ?Z?JG_,6^QZUX;TS\
M: \];?,_5^S^/'PD\-2ZA8_#+X2>&[;4-!_TW6+OPGX#_M+4]!TO^Q?[>_XG
MO?P^?^)'[=>!7D__  U%\8OBKXR\+_#_ ,.>/]2T3_A8VL?V+X/^UWG_  C?
MAD:IKO\ T'.G_(V']?K1^QS\!_VMOV)]9^(%]KGC'X%>&_ _Q0L]+T7QY\,O
MB;>?\))]O_L+_F-?VYX?_P"*G_X2+_D.8&/Y8KG]3^ _[,NCRY\8_'#Q;K?V
M7Q(/$]GX>^&7AO\ LW3-!U3^VO[>']A_\S/_ /JQSG%>@/ZSA'II?T_KJ?5&
MF_L*_'?Q))<S_$;XJ6VB?]!BT\/:/_:7X_VYX@Z?T[US^O?LW_L:?#V_\CXJ
M?'>VUO4?^?2[^) \2:G[C_A!_A_^8^G->?\ C?XP?"O4K6XOO$?A7XH?&/\
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MC^TM3L/\]OY5^R'C;_@HU?7L5SI6E>,;:VM_^/+_ (I.S]_T^GT-?FO\5/\
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MYP_C;X8ZK\0O%&H:K/\ $;4O"6C_ /(&L])\)^&_^$DU/^R\_P#0<\0?G_\
MKK/_ .&=?AEIL7G^,9_&WB3[+TN_&_CO^S?_ %'\_7''-=!>?LZ_%N\EN/\
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M/IW_  2%\'?9O#__  NGXMZ;_P 2&S%E9VG]L'3>N??_ #TKU#QM\;?VA?\
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M/AKW;\]U?SZ_I_D88C%8K$KEQ322T23LM/)66R3/U8U+]MBQ\-VMQ!X'\.>
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MF^K\K:??LCR__A6/A7^V=8UV?2O#?A+3]4UC5+VS^'OPRL]8U+PSX2TO7?\
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M\'>%_&EI=_;,_P#$KUWP7_;QZ<==;//U^M?FA^U##JM[^SQ\2-<L/M-UX/\
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M/^X+^./0]@>N>_S?^V;H.J>)-%\'Z5]NMM$T>U\8^*+W6-6N_P#EPTO^Q?\
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M"U^!!O?!^KVEY_Q+;#53K.@C7<Z'W_XIS.3^('I^@'[2&O3P^,O!\'IC/?\
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M^F6EIK!'_J/_ /UZ_'U]<;]?U_X<^I^M8-=5IY=O^&-"'0/V<_A++;Z[//X
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M_P")+_8?_0N]J[CQY^S?/\?O'%Q\1O%7A6Y\-:A=?Z;_ ,A?_A&^O_4#\/\
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ML/&_CB"YN=/TO]H3[%XD_LG'_"3Z]I?]BX_XD?\ V*?ASZ]/S^N/CQ-!9_\
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MFNY_MW\,Z[TZFONC]@_XD?$WX&Q?$"Q^&?PXU+QM\</BU9ZGHO@_PGX4O?\
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MN;3_ )\/\GZ]R#FCZM;6VVNW;Y!]96U_+].YH?"N#X'ZQ86^J^ (-$UO6/\
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M3_D%W_Q0UT?V#\"O!8]<G/BC\._;\MOMD^I7_P#:VJWUSJ6H6O\ Q^:MJ_\
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MXC\5Z[<ZQI?A?2/ ^K:4#I@_MW6U']M#QL3O(RP P#U//!Q^FG[%OQ-\<?\
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MP?'[]GWXH?"2:?[-J'BCP?\ \4W=_P#/AX\T+.O:%CZ?TKQ[/"XS5=>VFO\
MD>_AW]:P;?9-_AI^6I^.&O?%2QA^SP6/]FZW<77OQU^O? [#T]*X>::^UZ7S
M[Z>VM?[4_P"?O_H%_P"<]?3Z5Q_AOP3/IL6GP7W_ "&+7B]^U_\ +AJG_,=_
M3]*] AA,,N;^>V%P?^///'?V_IZU]0L-=)VW\O\ @'R+Q-FU>UFUOYOS-"SL
M_(M;>>WL;8]A^7\^GX?G7P/_ ,%(/"NJP_LY_#?XT^#C<_\ "8?L6_M"?\)/
M9WEIG_0/A?\ '3_B?:%_X2?QI\#C_P '_0]:_0";SX8K<06-Q<V_V+_3/I_G
MW/7VK/UCX>_\+@\)?$#X.ZY8_P#$G^-WPW\4?"/[7VL-4_Y#WPHUK'7_ )&/
M0NO]0*Y\3A6EL_2S]>GR_ [\NQ/^UV;W[_I?3\3N->^(7AS6+#_A=.E?\BO\
M4/ ?@/XZ^&Q:=]+\=:+_ &]_8O)Z^$_B-_;GA?C_ .M7R_>6<\/A?QQ?3P?\
M3C5/&'A>]UB[Y/\ S!<<C_N.=?\ #-?-_P"Q#\2/^$D_89M_#?C^XN=-U#]@
M7XV?\*Q^*EG_ ,__ ,!_CIK?]O>!=$YX'_")?&GP/KGA?U_XK[I7L]G\5-<\
M26NL:5X5^%>M^+;C4]8U2]^UZM_Q+-,_XGO_ % _?CZ?2O8R;$VPC3:3[-I.
MVWDSS\ZPW^U^5]UM?\NO<^2/B=XD%GXM\0003_9O?\/;\OTYKS_388/&UU<S
MWWB/1-$M]!L_],O-7O/7_H!]?4U]D?\ #+NJZQ?W'BKXC7WAOPW<77^FW@N[
MS^TN?\CCI^5>D:;\,?A)X5CT\0:5<^+=0M?^@L?\\^_UXKGQ.\FO/;_MYAAE
MM\OT/B?PWX5TJ\Q!I7@[QO\ $>X_Y^S_ ,2W3/Z?CBO:--^ _C&\!OKZQ\$?
M#?3_ /GTM+/^TM3'3]/ZGZU],3>)/)_<:'!;:)!_U";+Z9/^>?I7/S7D]X3/
M/_I-QCCKV_,?A_6N?ZSTO^/_  1_5GV?X_Y'G^F_!GX<Z#_R%3<^)-0_Y^]6
MYTSI_3\/SKT"&:QTV+[#X<L=-T2WYZV?8^O_ .OVK/FFGAB_?_\ 'O\ \_EW
MR.O&3V_^N*R)O%5CYOD6/VC4KCG_ )!-G^?UZ9_GT-8:^?XFYO\ G3S&XGGG
MQ]/_ *W3_P#7TK'G\B$^?_HW7_E[X_4Y]?\ ]7%<OJ6I:Y_SPMM$M_\ G[_Y
M"6#[\]/;T_&N7O#8PR^?JL]SJ=QG_E[_ .09]*1T&_-KUC_J+&"YU+4?^?32
M?^)ECC^GOWX]:@QKD\7[_P"S:;;_ //W_P A+5/\D=_SQR:Q_P#A*[&SM?(L
M9_LUM:]+2TX_E_/OGCT.?-XV@A_U'V;'7CVZ_P">M%P-"]T>QA%Q/JM]<W([
M_:_SR=#^GZUY_KMY8WEU^XM_^/3K_P PTX_^O_4XJQ>:Q!>77G^?]F%KC^?O
MZ8].?SQQ^I3?;.O_ "Z^WOU'_P!:C3R_ =GV?W/_ ",>]F\F:WG@G_X];SKQ
M[?H?_K57_MZ>6+]P/^W3/^<?X430S_\ +>?BUL_^/3GVSG%8_,,N?L_VFX/_
M "]^O^?\BGKY_B;_ %;R_#_@'0:;>:K/=>1Z?YSC_/7KS7M&@S3S16_GP7%S
M<?\ 'EV'Z^G?\A]/#]-@N(9?W'^>O4C]>GZUV$.I7T/_ "W^T]/^/3H/7_\
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M_B9?V#JG_"::]_87_EN#0\'CWKA]!U/6_P!HKXB^%_@/\)-<_P"$<^&'PO\
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MD!EPR@U^>W["O[76N?#'6=8_8F_:]US_ (1+QA\.;O5-%^&_C?Q"/^0]I?\
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M]^:QYM-G@E_Y^3G_ (^_3_\ 42>/SJQY,_E>?/?>A_Z!O;CI_AT[=ZY]?/\
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M\'VFWNKS%YZ#/I[_ .>G3J?L4\XM['R/LQ^V?\?8_E_^NEJ!RT-GYTMQ!/\
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MVI8'^VM _7G_ #C%?@!XJ^+7C'X;^,O#WQI^'.K6UM_;OAL_"3XO^'M6L_\
MBAO'?@/7N-"T7QQS_P B[CC_ (2D#_BB\U_01K&C^'->TO4/#GC'PY<W/@_7
MO]"\2:3=WFL>)-,U[2_^HYV[_J/2OE?XS?\ !+OX5^/-&UG5?V;/'&F^$;?7
MK/[%>?"?Q9K&LZEX&O\ 4]=Z:+H>N?\ (S^'_P#)KZ#+\M>$U:L[=5ZOKI^A
MY^(SI-J*2OM:UY>2M9OLE9>A\/\ @_4O#GC>UM]*^'(N?"6L:7_Q^?"?Q#>?
MVEJ=AI?_ $!=#USC_A(/#N??G/7T^4/VBO%5]KU_J&AP?Z-_8.CZI9?9/^87
M8?V$/^)[K0_[F/WK?\2_#?XC? '5-?\ AE^T+X.U+PW\2/A+>:7>^&_%EIK'
M_$S_ .$7UW_D!:U_;GA_/'_4K=L8Q6?J6F^(_!_PT\43^(_"MM_;'[05EI?A
MCPW=F\T;_A)O"7M_8?\ GZ]Z\C$XKZWC/JEWRK6^MKIW\UTT/U?A7(X\/\.9
MOQ#F"Y<YSV+7#,)+EDHR5GS1E9JZD_BBNA] >"?BI8^%?@MX7L;[[-]HM?!^
MEV7V0=/_ *_]/PY^%_&VO^#O%_AS5YY_ '_"2>.?MG]B^#]5TG_B7:GH/_0=
MUK_BGS_G^7L%G\*]5\8:9J%CI6J_\(3K&EG_ )%3Q99ZS_9IP?\ H.?SKQ[P
MKIOBKX2^.-0@\5:5<Z)/=?\ 'G=W>?[,U#_L!ZYZ?X>M>NL3HE?9);]DEW\C
M\XQ67RPTG*3]Z3;D[WNVVWU[MF#H/PR^-7CR^\0>(M5@\2>+9Q::7]L\;^(?
M^*D\<7^EZ%C_ (DW]M^(#QG &<9. #G''Z/_ /!,?]G7X'_$[XR:QI/Q&^&5
MUK>C_#GPWJGC2\^&7C?^V1IA\>'6O^)%K6N<C_A/_3_A%_7CTKX/T#XG:YIO
MCS]QJMS;6_VS[:1_+H/>OV@_X)I^*O\ A-OVEOB#/!]FMK?2_AOI>B_Z'S@\
MZ]Z__6^E5F$G'"QE&3B[7NFXOO>Z<7ION<N&2>+2DKK71JZ]-4UY'WA^U1\/
M=#^)'QS_ &?[?Q%8^$KG1]3^">JZ+_R+>C:;]OTO0M:_Y NA_P#"/<^'L_VY
MV_4U\SZE^S3X5\W4(/"WQ \6^$O],_Y!.K'1O&VE_P#EP?GZ_6O8?^"C7BKX
MQ>"?#G[-_C'X$:YIOAOX@>%[SQ1HOVO5M'T;Q)IE_I8T4Z]_8NN:%X@/_(N^
M_;\Z_*[QA^V!\</'G]H6-]\.=$^%T%KH_P!M\8:OX3_XJ35->U7C_D1]#\0$
M?\(_X=K[CA/Q)XOR#!K^R<WE))_:E*2LK:>]*2V5OT/B.).">',_Q;>+RI+>
M[45'N[Z):;L^F-2_9UU738M8U6^^(WP3TW1]+L_MMYXA\;_!_1O#>F6&>?\
MD.=>^:^(/'GQ]\._#;Q0(/ 'C#X7?&+P]I@^Q^+_ !9\*/A7X-_M.QU/7<_\
M2;0CX@\-C(SE1U&>.H..A^+7P"TOXRKX8\4?$;Q'XCU(:9::59?\(3:>(]8_
MX5I_98T5M=_MK6V/S#Q$0QW*" W&X$JN/+?'GP!TH_"7Q1??!;P/K=SI_@3&
MM>+]6\):/_:6F6&E]/[:US7.W\^*_5.'O'/CK-,SG@\WS6V4\DFG:WOJ$N5]
M+VDHO7L?!YAX3<)87#+%X12UE%.*<MN9<R[[72MJF?<'P'\*WWQRT;PQXD^)
MOBKQMXDM]>O-4LM8\)VGB3_A&_#)_L+H<^'SQCK_ /JKD/VC_P!G;X+^(]>^
M'\$NAZ;X:\+^%]'U0W>E:3>ZSINFZZ=<UO(.M]]?.3U'/]?;OV.=2@G^$'PO
M\^#[5<?8_'E[>7?_ ((#V[^_'?VKW'3=8\5:;XXN(/!WASP3<^(+6STNRL_&
M^K>#_P#A-O$W@/2^G]B^!]$\0?\ %,>'SSSXIYK\+S7Q XNS3B.I#-<WEG--
MNHE%3E%*'--1NE**?+&VC70_6\LX)X<RK*(2RG*ESVB^:23E>T=;R5UK=[^:
MUL?/_P (/V1?&.L6NG_\*K^"VI:)X?R?^*@\0Z/_ ,(1X9O]+'/_ "'/$'/3
M'].U?>'A7]A7PYH\7V[XM_%NU[_\4G\)[/\ M'/_ '/'B#WY[?6NP^'OA7QC
M#=:AKGB/Q'XD\;:Q==?$/BR\_M(6'0G^P_\ F5_#_P"/\\5L0:E#J6J7&E6,
M&I>/]8M;S[%_Q*?^09Q]/?\ +Z5XTL3C)-O#7;;;?-=NUVW\5WW/02P>#5L7
M9:625DD[:*R^2_ L6>I?#+X/V'V#X+?"33=-U"U_TW_A+-6_XK;Q-?\ M_;G
MB _\(QX?_GVKX7_:N^,'B33O!'C#Q'XQ\<7.I:C:^&S9:/I-WK'_ #%-=_XD
M.A?\2/C_ (1\#^W#V]N*_1BS^#_BKQ5%<#Q5XJMO!/A^UL_],\/>!_['_P!
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M7\J/[;_[2_B/]MW]H?\ X0;P;??:?A-X#\2:IX+^"GAZ[_XEO@;4-5T+6_\
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M5GN?#?B>V^"G@4Z-XXTE@VI60.N>(,:1K6B G_A(%8'<H!^564<8('Y$V?\
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M+6]0_P"?3P]9_P!I<^WM_/TZUOV6@_$;4I/W]AIO@#3[7_C\U;Q#>?VEJ?\
MGVX/:OJ&R^PZ#+;Z5X<L=$\-Z?:V1_Y!/_+^./RZ_E7'^,-2GATO6+'2C:VW
MVK1]4^V8_P"@I_8V<>G?Z]J^WP^6X3KNKOYJ[_.Q\3]9UWW??N_7S/-_ ?\
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MU<?'[P=X._X23POI>L^*/A]K'C>[\-_VEIFH#7<:]KNB^.,9\3^'_P#F!_\
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MJR5N5/5)+^7O8_H8O/'G]O3?;O'_ (XT2UM_LA_T2[\2:-INF9_Z@>A^'_\
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M/\C_ .O7C\.I>?:6\$\YN?M6>.O^<Y ]S701:Q8:E:V\\%]<_9_MG^AYL_\
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MG_/K^.*HC]]^X/\ Q[_;/\?0_P#U\Y_'UUIMIZ?\ X#Y6UC3=5\'ZU_95_\
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MMYM<US3KFX%Y_H?A[2?^)EJFO:I_T!=#_P"$?_#W[\U][_L?_";Q5H5AXO\
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M0GB31=-_M[^PM:_L'_BAO@?_ ,BQX@\._P#,K_\ ,X^-*^\/C-J7Q&^*FO\
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M;FWNKS[;9_Z9_:6F6&J?GU_SG/38BTC[9%<>>?[-T^UYX_R?S_2L+ON_O?\
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M-9T_4<C.<:,/#10X((/S8R""<\5MS?\ !/#]IJ&7_4?"[[/Q@?\ "8:S]?\
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DKQ0+J.A>'])TJY$=WE!):V,&X#/.07()Z'&1P:***XSU#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #F 2T# 2(  A$! Q$!_\0
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MZ?U9G]7LG_!3/X0Q;C#\)=0G'+8O_BQ\1K@,3G#$1Z_;#/0' 4 9&!6-=?\
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MMSU/0=3TK]>?^"1/[&?C7]LO]H[4-'L)[S1_@/X8\*:_X8^.6N0VEK+;>)_
M?C&V_LOQ-X&,E];7,#77CZ*$:79"$?;-,T^T.N6NTVAE4&?K;_P;D_L$SZIX
M \*_\% _C+X1?1M3\3:1>6_P$\':R8;RYTJT>>\TK7OB9=* 42XU22&[L/"
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MF^"SD3_1=-PBQF(.:\=\6'4I=;NKS4_"\/@^6]$4D>A6FC7NA:?:QPPQV_\
MH-A?[KA(G,?FR,TDNZ>21M_S!1ZR/!?B:S\/PWFF_'+P596.H>+/%$/_  C<
M_P 2+[0=3M;[2KZYTV7Q-J6E*JVEJ-=MX_.L+Y)#=WMG*8\&/*MY9XQ?Q$FK
M+I_B3Q(OBB[TNSMK:UU&'Q'_ ,)591V4\8O8;6QU83W,<D,9N6,D,<F(+AI8
MG594=09E[;V%-5UCKQCAU%UYY/5HW4:T8<L\';%1A[&,52A5O*ZG[?WG3:WX
M8E@7F&(EE[R#EG5S.=58"CQIA<;RSJ8*K6E4H9XY934K/'U*DL75PJC24:F'
M67OV<<5&7.6MN]W<P6L;(LEQ*D2-()2BLYP"P@BFF*CN(H97Q]U&Z5HVNAZE
M?0*UC8WUY=/J9TM+*VM3-.]PME+?/$L*.;LW"0PR.T0M#&L2.[3JZ^4<^TNK
MBRNK>[M7\NYMI4F@D\N.79*ARC>7*DD<F#_ \;JW0J1Q7KZ_&_Q79.]]H5MH
MGAO5KF?3)-4;3-!T\6.ISZ=:^1)J$UI.KV]G>7CQVZ7,%G9Q(T$<B&Y_>R1O
MY%-47?VLYQM:RC#G;3T;3YHI2B];2LI)Z.\;/[J;J)KDC&5UO*7*D[]4HN3B
MUUCLU9K6Z\_M/!WB"]U&XTN*R,<]M;7-U+/<F2"P$5M;M<$"^:(V^9R!;VSL
MZV\UT\<9G1&,H]$TWX47EO/H"7FJ6;ZAXAM=3\NQL(1J@TR+R-7L([K46M[7
M5-L#7T-C()HK43P6=V]VOV<VLEW;;7A7XV:C%$J>(KJV\[1M$N]/TB_ET+2M
M:NFM+RX2*ZT]DU.YMVN);J/4]8N+AF>X$MLSVK6L]LJP+YOXE^(OB'Q#X@.O
M"Y%C<P:E)J=H]G'%%.MV3,@NKBY$0N[N1K:7[($U">\=+!8;"::YBA#MTI8*
MG",[U*U1R5H-<BC%2CS7LVV[<T8N5D[J:6EEE?$2E*+C""47>2YG%R:?*HN4
M;M-V;ZQM;O?UE/@OHV@Z?K%]J^O6&K:OX.EOE\0^&;(EKK4B-,N6\K1[J[DL
M[)/L0QJWESV]S>[;2X29H#&D<GS_ *[_ &3_ &Q?_P!A9_L?S8O[/RUTQ,/V
M:#>2UZ%NB6G\YF\\!@Q*IF((Q8VM:L^H?VM)J5Y+J69V^W33-/<DW,<\4Y:2
M;>7,D5S/&2^XA)652 %QE@   <   #V'2LJ]6A-1C0H>QBG)OFESREJ^1\S2
M<?=:4XIN+E%35G*2-80E%MSFYMV\HK9M**TLI7Y6[OE:B]KO[)O@&_9Q\,X!
M('A_6,_58ISC_.#Z<FOE*P&^RMU!QN  )YQND(R1[9KZQ?#_ +..@XZ+X?UP
M'CJ1#<YSG@\C\OPS\G:7_P >=I]1_P"CC7,:'U9^T_X:M/%(\*_&3P=]JU'1
M-2\*>#?"/C4>;%</X5\>>&_#UEHCZ)J4$:+-IJ:MIVG6FIZ#<7&^UUB.6YCM
M;@7,)MVR?V1+FYE^(NNPS7-Q-#9_#'Q/#:0S3RRQ6D#:AI,SPVL;NR6\32N\
MK10JB-(S.5+$D\59_$S5OAG\0M7NH+*U\0>&=?TFQT;QOX)U4LVA^,?#\L$;
M2Z=?(IS;7MNW^DZ-K$&V]T?4$BNK:08='^J?AI\+=*\#?$RR\7>$M1FU+P#\
M5?@5K7CSP8U^RC7--TB^UVVTNXT3Q&B 1-K.BZIIUYI\UY!^XU:WC@U!5CEE
MG6FFTFDVDTDTFTFD[I-)I-)I-)II-)I)I-2TG9V3:NXMI-Q;33:;3<6TVKII
MM:-M73]=UH_\2^X&>/\ 1P>?6ZAS^E>O6YP?Q/3VQ_\ 7%>.:R=UC<#U,!Z#
M_GYA _*O7K=N>?7^?_US^E(:\ST+P]IVH:@KII<$USJE_=6/AS1(+>-Y9Y]:
MU^1K6%;>*-6>2>"U^U3QHBLYE$6U'.5K_2T_X)O_ +'?AO\ 8D_90^&OPBT_
M2[6V\:7&BV'B;XJZND<9O-9^(.LV<-UK4=Q=+EY[/0))!H&DH&$*65@MPL:W
M%W=22_Q3?\$:/V?+;XZ_MX?LT:!JEE'>^'O *^(/VB_%<$L1EB-MX/G2+P?]
MI0$*]O)XFL] MGCFRJG4LA729@W^B10,**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *_FQ_P"#I>Q%S_P3DT6Z(S]B^->E-G!RHF^&WQ,#
M," <$",X]217])U?SU_\'-FGB\_X)C:W/MR=/^+G@^XSZ";POX\LCV/WOM(0
M^S_D ?YA7PC(8?$B%#\H\?6X0,<$B>'Q9%DYY!PHY]<]^GD/@SP1\6-6T34_
M$_P^\$?%#4O#YU9?!6L:_P""K36KG2'UN^T^?5X_#&H7FF:?/%]OO=)M;G4H
M]+N)"\MA;SW*HT,+LOK_ ,) 1K'Q-@=2CCQ[I<I3'"@ZAXGA(QST\\ 'N,^V
M?,?AS\3M6^']GXCL[?Q[\7O!MC>:A:7D,7PX\22:1I$^HQ--9W=[KMC+=VUA
M<ZC'H\LUOIEX#]K2-I[1I$L[B5EUHJ3J14*L:$O>:JSJRHQC:,KWJ03E%R5X
M*R]YRY6TI,Y,=*E'"U'7P=3,*5Z:GA*6$I8Z=5.K3LUA:THTZJI24*TN9WA&
ME[6*<Z<$N2U'X<^,](GDMM8^''Q+T:ZCCLYI8-0\(ZU#.L.HSRVVFS21W>CV
M;K#J-S;SV]A,P\N^N()H;5I98G1>7N["*PG:TO[77-+ND +VVI:<+.X0-R"]
MM<-!.JL#N#% ''*DCFOH/7_VJ/BY#XIM=>\'_M ?&C53!H^D:=%J'CO7K2XU
M=8M(GOKBRTYK:+4=;TR]TO2;J^O9M(:X!>TEN[KRH+<G)\O^)GQ9^(_QI\16
M_B_XJ^-=;\?^)[31--\-0:]X@N(KK44T+1C<?V7IC7$,,)E@L!=W"6YF$DRQ
MN(C*T<<2I-2'LYRAS4Y\K:YZ4U4IRVUA-1BI1=])<L;V>FAKAZWUBA2KJEB*
M"JP4U1Q=&6'Q-*]UR5Z$JE65*I&VL'4G9./O-21P@2Q4AEOK@,I#*18$%2#D
M$$7F000"".0<8.:D:*-DD7^U R3.LLL<D%\IDD&X"20+'(C.N]B&9BWS-@\F
MJR1Y.%')_''T_P _ITZ72O#MQJ+H.5C) +A"Y&>RH""[<C W*&.!N&3BJ-&K
M7FH4H2G)NR23_3R_ C$XFEAH.I6G"$(J[E)KIKHM[Z72WOMW,=HY)'DD&J6D
MDDL8BE:<S1L\:A5529K3@!43#)A@J@ ]06K!,#$5N]-D,"[8D,L6-N6X82PH
MDIRS-F5G."/F "A?:K;X13M;M<L)YTCCDFDVB&&*..%4DF$MP&F3[2D$B7"6
M4#R/-#D1S-,'C2A+\.TA8B[TK519LJ%=4TJWO)XUBD5I$O8H[OY;V#R0TIC5
M;1I$C8(Z,&%>A/)\=!R4J;YXV<H*-2<H<\>:+J<E.2IJ:UC*<N5I-W5I*/ST
M>+LEG*4:>)C4<&XR4%33;6CC",ZU)SDEJJ<&JDH_#"2<7+R 6EPT80?8MH<N
M&-W8+,3C;MWM<+*8SC(C/RY^8#))ITFGW\LCNMFH#G=MMS (5SQB-4E957(X
M4'C/N*['6_ &JZ7&]S;/!JUI& 6DLTF$T:, T;2VLR+-$71HWVD-M\V.,,TC
M;!P+PJ#]T9&1@C^61WZ>E>9*,HWNFN6<Z;NFK5*;Y:D))J\9P;2E%VDN:+:Y
M90E/WL)CL+C::JX:K"K!VNXMWCS)-<\)*,X-K5<T%ULW9GV2JL/V<])1QAX]
M#U]6'=2L-Z"I/(X92#@XR.#C%?)NE_\ 'G:?4?\ HXU]76I!_9QTT#JNAZ\#
M[?N;[(X^E?*&E_\ 'G;>W])"<_\ UN_XU)V&]X_4'Q/=DYYMK'_TF3U%?IAX
M"^7PQ^SA@9_XQ&\1=>Q/Q3UK!.!]:_-'Q]_R,MS_ ->MA_Z3)7Z5^!#CPQ^S
M?Z?\,C^)#GH!_P 74U@=>O?)^G6@5OZO_7X%N]DD>UO5=V8!K;8&$6 OVA2"
MIB)R&P/O'_=S\U>R1-PQ'4!B,=>A[=>@'3GFO%)V/V&Z1D"%)84^_ Y(-Q&Q
M9A;JJ!B2=REF<'&[&1GW/18Q<:IIEN>5N-3T^W8 9^6>\@B;([@AB,'K[]*
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MPBG"J02?+?UX/ .!TQZGOGFO2=-N?!5M\*=:T35O#UW_ ,)HUV9=/U$V%SR
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M)ZZ+7=N[;;;;;;;NSZUT?_DWB'&.+#7PV>Q\O5<X_EQQSZ"OE+2N;.WQ[_\
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M^8+/&,<_P\CIC'/KG@;48F\4^%6N(9H(QXF\/EY%VW<*H-7LV9O,M&E.-IR
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MM(T^_P!*TY&'4&:&<;N65A\M '^34WP8U>RB"WMC<M.N7D*>:B(P7G:-H^5
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M1K^@3(@DMK6*&5K?4+"**:R!EFAE6XDK^\!X W51SUP,Y_48]0>W'3MR6O\
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MV5S;WEI<()(+JUFCN+>>,]'AFA9XY$.#AD9E..#5BH- HHHH **** "BBB@
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M D8( [>F.G0"J<F][-_S=?GW^:OYLE147[K:6ON]/E?;Y:>2'T445)04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %? G # 2(  A$! Q$!_\0
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M=+D8SD8]>U 77=!129'J/SI<CU% ;[:^FOY!1110 44$@=2!]:,CU%'GT[]
M"BDR.F1GTR.W7\J,CU''7D4"NNZ^_P K_EKZ:["T4FY?[P_,49'7(QZYHNMK
MZ]@NNZ^]?YBT4A91U8#ZD=^GYTH(/0@_3F@=U^3^3V?H^CZ] HHI-R^H].HZ
MCJ/PH 6BDW+P-PR>@R.?IZT9'J/SH\NN_P MK^EQ)I[-.V]FG;1/7MHT_1I]
M4+11D>HI,CU'?OZ=?R[T#%HI,CU'/ Y')]*,CU'YT!W\M_+U[?,6BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK_ '6^A]/Z
M\4ZH;C/D38Z^6^."<'!P<#DX/--*[2[M+[VD)[/23T>D4I2?E&+:4I/:,6TI
M-I-I-LIJQ0MF1&4 %5RBG!QR6("@ 'L3GC&*>\D8VY =7921N!"YS@J3W)SM
M SGGTS7B_P =/C+X0^ GPD\7?%WQK#>R^'_".CPW]W8Z=$DE]JMW=S)I^D:+
MIL=S)!#]NU34I;6PMEFEAC%S=1[Y5#9KYP^'?QW_ &M=>\8^#8/B%^RA:^$_
MAOXJU);?_A)?#'Q/T[7_ !!X.T^Z19=)U'QIX4NM-TP06C12!M3_ +)U#4Y[
M%PZI%-MR>;%YCAL+5C2J*4JCDHR4(.;BG+D4I*E&<HJ,]7*2@DE)MJ*;7T.6
M<'Y_G62X_/L)_9V$PF75*M*G_:&<9+D=3%U,-26(Q.%RK#9C7IULRS/#X=QE
MC,'AHS</:4Z=*4JM?#TZGWZ #M9",*.,$9P/ESP<C##!XX/':I0PR,#ENI]_
M\G\C7AUE\:?"%W\;M9^!D-W<?\)KX>\#:-\0=1A,.S3O^$?UW5)=%L_*NC^[
MDN1>P2.UNIWB/]X05S7LT4J\DNH$;L6)9<(JCDMS\H'<G  P36WMZ,GRJK3E
M)3]FU&I"4HU'O2DE-R51.UX-*>MU&VIXN*R[%Y?6PL<51K4WC\'2Q\/:4ZD/
M:4:U-U*%>'-&/-2K1C)TYJ\9*+LVT7Z9(NY2/3G\J0S1 J#+&"P4J-ZY8-G:
M0,Y(;!VD<'!QTJA?ZA;06UR5N(//2WFECC:506:*(RKP#NQPIX'0@C.12J3]
ME"51J_)"4[:ZJ"YI6TULDV[7MN[$TZ52K.,*<9.4I**:C)I-R4;NT791<E=O
M16=[#DPZNTA4+YA)^89&P?=)S\IQQSCCDCO3X4C\S<6!DWN=H89#8!8, >&5
M2#M(S@C( YK\_P#X,_M%_&+XG_LJ:Y\8_#OP]TCQQ\2[;QEXTT#1O!EMK\?A
MK3=6L_#?Q U/PJLKZS<1SPP2IIU@][*-A\Z1#"K O7W1HEX\UM837T0M;J2S
MMVN(I)O.:WNS;QFXMS*P0SR1R.T3W 4+-L4C!.!G0QM+%4_:0349647ROE=X
M*5E)WC=)KFBI.459NRDCU\_X4S3A?&ULNQTZ-3%Y7FN/R;$PHUZ=:4,90I4L
M1C9N--NHJ3IUX4Z5:5.%.I452G"3G3G$Z:F..!]?Y_\ U\5#'>VDR[X;F"5,
M9WQRHZ8W%,AE)4_."G!^^"OWABF/=VC2BV^U0"?:LOD^:OFF,L4#^7G=L+!E
M#8 W# .1BM'4ARN2G"RMKS1:6W7FML^_8\?V=1MQY*B<5S3M"?-"*WE)<EXI
M=7))+N.E8#^%>.Y/&>@ )(&3QC/ZDTP/("0[Q@$<(3R.G;/(&>O;K[U6NKE?
M*8Q*LKHV$X#JD@5BC.NY2?F "X#DN5 4#)7\N-+_ &Y?VA?'&H?$#5OAK^R.
MOC?X>_#WXG^.OAW<:[;?%O2M+\3ZT? 6I/IVNZAI7AG4/"CGSW:.5K/3I=4A
M>7:JB<$J3S8[,\/ERI1K4ZLY56TE3IRJ-*,8RG+W8RLH1E&<WR^[&4=[J_O\
M.<*9WQ92QU;(<-E\Z.!]@L9B\PQ^"R_#P>*KU,-A:;Q.-Q&&PZJXJO1JT</2
M=>$JM2G.,?ADU^JBX#9")G."5.<''&0._(XQNQ^%2KC>^ 0>Y.<'IT^M>"_L
MZ_'KPE^T9\+O#OQ4\&QWMEI&N)>6\^DZS$+/7=!US2+R;3=<\/ZU9%F\K5-*
MOK>6WO5$A\MT 95+X7W*"[M9I)4AN()&CV"5$E1VC+KN0.%)*;E!9-V-R\CB
MNB%>G7A2JT)1G"M#GBU)-RIJUY:-MJ+:3:5E+W9<LDTO(QF6X[*\;C<MQV$J
M8/&9=6GA\=A^22]C7IS5.I3JV3C"49N.CE9\U-QE*-2G*=RFM@')]#WP>_3U
M/-027MI"BR2W,$<;.(U>21$5G/1 S$ L>P')[5'+<1!HV\U!&5)+EU"\D*.2
M0#N8A0.220.I%:63^)I+76345=:VNVE?;2]_(Y)JI3C&7LZCYZD:<;0GK*4E
M%I>YJXIWDE=I?$DM2:1H@%WG /3D#N?<=,G(_P E&>/ !*GN/F_N\\C/)!R2
M!T]>]49)(Y(E.5X+$,Q^4@E0!G[NYMP"+]YMPQVS\C:5\:O%>J?MI>-_@%/;
M:<O@_P /_ GPW\1[.[$9_M,ZYK?BB;1YH9)-P5+46D18*1AI?NG.165>O2HO
MEJR]R+C%I6E+VD^9PBH7NG)0DU9-NWNIGH9?DV8YI#/)86$)1R/*<9G%6-23
MASX;!O!PKJ-XOGFJF/PL5!:OF>S23^Q2T9(;(PJMAS@[<G!7@XSGUY&:164N
M<+\Q+?-R01P"?I[_ *'J/#?A3\:O!WQCE^(UOX0OKBY7X;?$+4OA]XB%Q;"T
M6+6-$BA:^^R,S'[79R>:ICN5RC/N4?=->T)>6<BQA;B$/*H\M!+&7?G 55#;
MFX'4 C@UJJM%T:=6E4IN$Y63]I!145+EE?WEK&?-&2M:,X2C*TKHQQ^49KE>
M8XK*\SR[$8'&82& EB(UL/5IUHU,?@L/CVW"=.\83P.)PL^9Z>SK4Y72DK61
MA3\@ YP6;')SQ[?ED\\T\#Y&4A#GLI!/3/&#G."/H"#ZUF7<J +("9=L;%(H
MG!:9T#ED5DW%<%,,P!P1MQGBO /V;OCJ?CUX7\<Z\?#D_AR7P;\5O'OPS^S2
MWPU!KX^#+Z*U35A.(8/*2],Q"VQ5S"8F&\@C&3Q&'CBZ>$C_ !ZM.I5V^S24
M)2UNFVE.#=E9)JW0=#*<SQ.59KG%#+H3RC)Z^!P^*Q"G%ROF=3%T<,^1/F<,
M15P6)IPE%2C*4&KMV3^D"%(*[<ML0[,X(4-@$#.[J?3'/M4L.W:Q0$#>PY]0
M?RKY<T7X[R>(?VGOB;^SV^@-:CX??#'P/X^'B1K]&_M1O&E[?V1TI+!H%-JE
ME'9/(]X;B19GD"*D;*,^C_!3QA\0/&'@^XU;XG^!;7X;^(U\4^)]*LO#EOKL
M>OQS^'=+U:YL_#NM_;X[>V59==TJ&'4I;'RV>Q:5H'DD,9:G]9IRJ2HI3YHQ
M<W-PFJ:Y&E4BZCBH<T7**:<K[O97.S&\/9IEM*.)Q<,-0H2R[(<QBGB<-[:M
M@^(Z6+K9.J-%574J>SI8+$3Q,81E/"<]&.*A0E6I*?L55)-H=F .Y<G'KD*&
M(&>@!S^(Y&0*;'J%C(=J7=N[9^ZLR$_,6V\ Y^;!QZX..E?)/@WXW^+/$'[6
M7QV^"]['I$?A#X<_#[X8>)M#NHTD74I;[QI-X@%\+R=F%N;54T7,+ A2N%)W
M+SA6QV%P\L,JE2#EB<5#"4+3@U[>I&;BI-3T5H23W:T5M0P.09EFF%SO%8:A
MSTN'LHEGV8TJBE"I4P-+'8# 6H4Y0YJU5XO,L)RTX)R<7*6T6G]:+&%D9CD[
M<;,G@*RA6)]",=._O4J>6P;#!6)P5) (*_*0.2>#C/H<>M<[?ZJ8M!U35;,Q
M2RP:9J%];HYWJTMG;S31-M0EY(#(%^9<Y5@%."*^)?@[^T'\9?B?^R#X,^->
MB?#_ $OQ_P#$WQ%JNI6C^$-/UM/"^E7%E8>/]5\-S7L-_?(5MFL]#LSJ,D<A
M)N;B#RT+%UI5\?"ABXX.?O8GV4JCFDW3]E2G&$XMIVYHU*D$TF_>DKV;Y37
M\+YCC\NQ>:4H8?#8#"YS@N'L;[6O2HS^OX_ XS%8*351Q4:+PN4XCGK2G&,'
M&,)*\DS[_!!Y5@<<@C!! /4'//?MVIKLN[<1R%(Z\$,<'N,<D]^!]*S;6Z!M
M;.:?;;DV<+SI)(H$#LBAXWD;8&*2'8'('F$;@,L!6-K^N1V6C:QJ%M-:2S6.
MC:IJD;!]T?DV=G=S6\K*I):,RQ*LSKD=NXKIE5HP@ZM2</=]UI2C=56W^[LY
M74G:Z@[2L[\IXE+#8BO4GAZ5.I)PQ=/!TYJ$Y1=6I7P^'HRYU"4;0JXB+FTY
M*,=7IJ^H#)\H( PVX -R20>3SZ#D8]Z<KQMG:57!.<L.OY\=./8&OD[]CGXR
M>(?CC^SS\._BCXRCTRV\0^*+74I]0M[!T6SBEM=9N=/40 G."EK*%4 EF1EP
M2AKT7XV?&CP9\#O#.F>*O&=Q>6VD:EXG\.^%;<V5JUW<OJ_BG48-*TR)H(@T
MGDK<7*/.Y&(8MSO@ FIHXS"U:?ME5IP2BI3E.I!*G!QC-3G>;Y4U.%G-I7DK
M-W5_<QO"6>8'BC'<)5:%7$9M@,VS#)\71PT)UYXC'9?/DE3PRA3YJZ7)5BG"
M#O[*>EXR2]QPHR"<<#IDCUS[]O3BI1T&/2LQ+J JLOGPM&8U4R+(C)N (X()
M&6"Y4<9 W 8S5R*YMY0/*FBD^4',;JXP>,@J2"/7!..]4ZM/G=/VD%.-KP<X
M<ZOWCS*23TM>.S7=7\&-.HO:N4)KV=25)MPFDE#X;N44EHT];>G:>BFAE/1@
M?Q]\?SIU6,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDF
M?+? !.T\$X!X[GM]>W6GU'*,QN-H;*M\IZ-QT/UZ<\>O%&O2R?1O:_2_E>UP
MT6K3:6K2U;75+5:M72U6K6JW7A'QY^$'A3X_?"GQI\(/&\FI1:%XNTMK6:_T
MIX[?4-&NH9UN=+U;3YYTEB6]T;4K:VO[0R12;;B&)FC8':?A31/C=^T?^QSK
M'@'P+^U19^'_ (M?!SQ1K.D> /!_[2'@B.32/$VC:OJ,L5AH%A\7?!-]/_9]
ME;7<<8AE\4Z!JDMK<:C)''-I=N]RHK[U^,WACXL>)/ NHVGP;\;Z=X ^("7U
MG>Z3KFM^'E\3Z))%9N)I=(U;2)9[25],U#"V]V^GW,%^D!=K.5+@HZ_%OB7]
MF?\ :R_:(UOX=Z+^TWXW^#]A\(_ WBS0?'&L^$OA/HOBHZK\1]>\)7"W^@6N
MN:OXBN88M"T2WU>&'5+BTL+&[N;HHD"7L83S#\YGE*HI4UEL9?VA4G&%:JHR
M]G*+E%N,Y?"J;YIW;UBG*4).7NO]E\-<7EDLDJY5QEF_"G^HU:MF^-S'(,WJ
M9C'C#*\SI9;C(X7->$Z^ P52O0QN858Y/AJ>'H9E7P.,A2J1SS#1I8:.(AX2
MW[)7P1\7?\%'OBI9ZSH?B&YT^]^!/A/X@F&#Q?XCL!_PD^J>-+R2\E+17HN1
MIJF+<-.B<6>GR@J(HU<@_4'AN\U7_AXOXK\.'6-1;P[8?LH^#[RUT9K^XFTJ
M&X/C._LIKJ.TW>2TUS:);Q/=NAGE9=K,V*W?BI\"/CQ9_M(Z;^T-^S_XC\"6
ME_K?PW@^%OC_ ,+?$RVUN72+O2]/UV/6M&\0Z/=:!')<#4K,&[MYK.Z*QSF6
M-F=0IS'\9/V=OC?)\<O"?[2/P"\6>#-*^(L7@!_AM\1/"OC^+7?^$)\8^&OM
MB:OI\UO<Z!;W&H:?JFDZV9Y;:::/RWT]OLTBJ9"X\ZE0K8?ZZ\/ET:>*CQ72
MQ-6K"FE+%8:SC4JTZB2NX4W/EFVTJCOS<UD_M<;Q=@^*/[!AFO'&5K"8GP+I
M<!Y11SJM7G1X>XHRJ.!I7SFC3R.I5RCZ]'+Y8?"YW3K9E&O&K1KUXX>DZKCS
MFB:]K<'_  4+^-VG/JM_)X?T?]ECX;ZNFC7%S-+HIN'\4^+S->VEAO\ )BO)
MHXDA:0 2310L%W,E?/O[-7[.6F?M5_""Y_:7^+WBWX@S_%?XGZMXP\2^"O%&
MC>,M<TM_A1H5GXAU&S\(Z'X-L+.6'3;2SL-.TZ W\-Y9S/<SBX@NS(DK5]+_
M  ._9<^,GA']HCXC?M ?&'XDZ'X]O_B-\,O#/@VZT'2-%GTC3O"UQH^I:G++
MHWAJ!25/AD65W#)%/?22:A-?M<RS%0^!P'@+]F#]K7X(Z'XI^#?P=^*'PWB^
M!NM^(_$FL^&-5\3Z!KDOQ(^&&B^+=3NM8UC0O#T=GNT77I;*^O=270)M1:);
M%)[.61)OLXC?&&#Q,JV&Q>+P>9SP<WQ-R8>>+4WAWBL;A:N75*U*-5_\P=/%
MQ5W)455=.SE+F70LZX<PF&Q>4\+<=\'91Q#@^'O".-?B">'QV#P.-6083-X<
M:X#+<?6X<QL\7BUG-7*\PQ5'$Y?AH\2X3"*C3G6IN.%J_'_@J?Q1X<_X(]>/
M_L_BK5[G7],\7?$>V_X3"VNI;77]7-E\<KW3[G4YKBV$!BU>]E\R.Y^RJL+N
M)549)Q[G^V)\3KOQ3\8_V<OV<-6@^,=W\+M=^'.N_%GXIZ#\%M.UB\\9^.XO
M#C:7HNB^%[R?06CU:V\)+JUT=0\0)%<0KJL*16\CE3BO5=)_83\:Z3^PIXG_
M &3F^(5IJ/BWQ!J_B#4/^$^U/3Y9X;R35_'EWXM-_J=I J*E]<QS[;MX56%;
MA@ZKD8KU_P"//[-?CGQCXF^$GQ?^"OB_2O 7QQ^"VGZAX?TV]\0Z3>:IX%\9
M>$?$-E##XG\+>(-,TV[L]0$%W/;0W>EWL=Q(=.O(TF:UN#\M1#+LX^H4E2K5
M:=.GE>44ZZA15:JL70Q]:>:SCAIU**Q$JN$E2A&'M(QJ\CBYOF:?T.*\0. *
MW'.<YK6QV2YE3QGB#XQ9MD.8U,/B\KP66XCB?AGAK+N#L[QE;"Y;BL5@L#2S
MC"X^M@<52RS'/(JU7Z\LGBL.H4OD7]G*TU/P?^U5HVF? ;X7?M%>$/V??'/@
MOQ6_Q7\-?%[2O$EIX3\+^.]*FLW\+:YX3&N:Q>0:5-K,!NK+6]+LS+%=1^1<
M16T,HE->=_#OPU\.?#?QAU32_P!MR;XI>"/VBM6^,NIZA\-?C)>ZSXFT;X8^
M--'FU&5_ ?A[P1XATFY?PAH,-OHWV72+[PMJ(TF;4=1B>5K6XGDC:OTJ^%UC
M^V!=Z_+J'QIUCX-Z;X67P_=6EIX<^'6E^*+_ %<^(I (X=:O->UJ:S@^R0D>
M8FF0Z3,VW(DN\J2WS9\3_P!FG]L#X^Z'%\(_C1XZ^"=]\*9/%^D:SJOB[PMH
M7B:S^)%_H&@:]:^(M.L+.SNHSHFDZVT]A96UQKEK>K,L*SK#;,9Y"KAA*]/+
MJ$:<<RQ%2&*<Z=#%9#AJ%.K+GARTZTHYC46%HSE%OVL8R=.\G[/EDX'@4>+<
MLQ?$>:8;&YAP9PY@ZO#>491C^(,EXNS/-.(<12RA<18F&8X?.,9PC#"\0XS$
MSQL,IS;)\9E6%AFV 6347CXU<%3QM'])X3<(#"3N:2$RI<( 54.=L:!VP7?:
MADD:10I=@^1@BOP'^%GCS]M;X>_!K]JKQ#^SW\//A?XL\':9^T]^T/>WW]I:
MAJP^)&G6EOXK*^)]9T'1!&?#^M:EIE@+G5K+2I;I7OY(8HD&^8 ?OS;V;V\5
MK;QFY M((X()9@LC[;=!!&TCKSQ$6!&&,F^0DY)S\R_LO? #6_@3X4^*/AWQ
M'J6E^(7^(7QO^*GQ/BDTW3Y;6SM].^(.L07T6FW<,C.\MW'%YZ7=RNV&1=N<
M $'VLZR[$8W&8"4,35PE?ES[V*PTE3I^WK93A*.'G4J2I5Z,(PK04HJI"4'*
ME[JYK-?G7AQQGD_!N2<<U,?EW#7%=?$9QP)5PW"W$&5XRO@<?A,#Q#F6,S-T
M,/@<9ED(8K+\"X5\+BIXVI3PV)QW//"8_P#>T'^>GBOQMHG[-/\ P3/\$:S^
MSCXR\0:[_P +A\1^';+2/B';6"R^*[CQ)\9?%\]SXN\56&A0PRQ1>(A<76KQ
MV^A0*HAU>"&T($B%#Y?XG\)V?P]'@7Q5^R?\*OVT]*^.&B^+?"!OM5\9Z#X[
MC\/_ !+T>_UVSM/'EM\41JFM'39;*^T634M9BNX;>)=-N+2W@M1'N, ^XM*_
M8)O9?V>_C?\ LW^)O&B)X+\2_%/Q!\0?@;J?A^SN;77/A?#J6IP^*M%M[Z1R
MT%_=>'_%:W4MG]E*6XTZ;R$ <YKMO!GAG_@H3;OX:T+Q7XX_9WDT?2;ZR3Q%
MXOL?#7C&X\3^)]%L9XX[B.'0IWMM)T[5M3LHV%QJ+ZA<)Y\K,(E  /@O*\;4
MJ9=2Q$YQE1R6&'6(IX.MCG0JTL5%9FX5J&*R^-.>(K1H5J=1T9.5.+FXU%"<
M*O[10XZX1PM#B'%91Q!PQG683XYXIS?.)<8<0YQPVN*\BS_+,#B>&X5<NP/!
M&=87B-Y=A)9CPYFF6U\3E/U7.,)0Q&"A0H8JAF>"^9?VL]#TNQ_: F\9?M1>
M#_BMXF_93O?A/H6G^#=:^',^O2Z-\'_'3WU[+XXUOQ_IGAFYCUJ&>^MY-%?2
M?%J+>V^C0VL\$:P3132GLOVC-8\,Z-\$OV-H_@_X\UGQ)X$U']H_X)V6C>(K
M/Q9>:Q=Z]X2N=3NI!'?ZY).\^M1RN(8KBWNG-Q=^4R7",\5?2OQ4\.?MF2>+
M_$5Q\(_$OP1N_AWK^BPV-EX;^)N@>)UUGPO?"WEMKV>.Z\/_ &^RURRO7F65
M+2Z@M3"D3+,\@?"^47/[!KP?LB^"OV>= \:?V?X[^'/BG3_BCX3^(4^D)+IE
MK\3M.\6S>-UN)-'#9/AB76+N?3OL,;1W4.D[%A(92*[:F$QL(9Q3CAG7A5PL
M']=EA:M+$5)PGAI<L<34QE6.)NJ;2A1P6&E3O;VDXWM\GEG$W"=7*_#G$9SQ
M#@,%++\URO"8O*,@S/$X_*%@*W#_ !!EN(XAXDR/%\-T*O#V?9+7S#*,-FM?
M*<RSJEQ-2^MY@\)1QN%=6MH?MXZWK6CR?LIQ:5J6JZ=;ZI^US\*]-U.?2+Z:
MQ-Q:7 O_ +3;7Z1,GVJSE9$C&GON655 (9E6N>&GV>N?\%*?B_HU_$;C3]=_
M9!\)Z1>6PFELO.M-0\77L%U&UQ$\-Q;W3V\TB6<J/&T$@W*1*!C-\8_LQ_M?
M?&[Q?\#_ !7\8/B;\-]!TSX-?%#PIXW?P-\.].UYM'\8Q:4K1:YJ6MZCJBB]
M&KW"O*WAZRMUAL-.+NMU)*TBNOTOI'P$UZP_:U\7_M$RZCITOA_Q'\&/#WPM
MM_#K6T@URTU'2O$<^M7NJWM^Q-I/82V\R06\%INE,HWNQV@#H>&Q.*S/$^TB
MX0IYSE52,FK1G1HX7,J=27,UR\JE)72;?OQ=US1OX,\=PWPIPM0R.'$F19OG
M#\/O$C"8G$<+XG&5:.#SK-N,.#<7DF#I9AC,HPJS#&U,MR7$YA1JT7+!T4WA
MW6I5Z<Z3^!?^"??[+GP?TSQI\?O'%EIFM_VY\+/VG?'6D>"IY/&'B*33;>SL
M-,M+18[NQ.IQV>KW;6]S)!=WFJQW0D=8I]Q;!'(67A_X=Z%\<_'J?MRVOQ6\
M*?$_Q+\:9KSX,?',:]XFT/X1WO@N;4T7X;>%_"WB31-0?0_!&H6-F(='U?0=
M=-I-K.K+=7ZB9=0B-?;OPQ^ 'Q^^#/QW^)VK>"_$GP\U3X"?%WXBW'Q,\1Z+
MX@M=?@^('AW4K[2H;'5-*\,W5A VBSQ7%Y!;W]M/JSQB.+S+4AR%9?/?C!^S
MA^V-\>_"OB/X'_$OQU\#[OX1^*?$"MJ/C73/#/B.'XD?\(9::S#J<6DQ^'KI
M6\(Q^(9H(H=/76TO(5@42WMNK7&U5\[ZC4H9'@L-3PJK8F$\WFH2HMI*6:3F
ME-7@DYPY)0FO>2<G"\>9/[FIQE@L^X^XBS/._$'(IY%Q1P[P=/%<0PS_ #'!
M\7Y!@X93EM''8;*HU>%LPHYCG.79A@<7+.N$<3&EA<YH5:,%G7+5HNA^D%MM
MACBE\X31G9&+B699@UM%"SR-'()'+LVW]ZZD-*ZO*/\ 69/XI_LB0_MM2Z3\
M?Y/@3??LXV?@"7]I[XU211_$K3/'USXD74)/$*->2$^'M2M+8:>\36S6H:W:
M;<9BS%3&!^T.A:##HNE:7HEM]I2QT:UM--LWE):XEM]/MX[5&NI6#&7S(XMA
M=L,W.-RLI/@7[*_P&UGX!^&/B3H&L:GIVL3>-_C7\1?BE;SZ99RVD=MIGC;4
MH=0M-+N(Y26>\L50PSRKMC=0@4'::^@S3+9YCF&65*[KX2&&GC9+$9?6="NE
M+#X&-&E4J04Y>QJRIU%.%N5<D4]M?R'@GC/+>&.#O%3#/+LDSW,<^Q' 5+A_
M#\5Y33S'"U\-DV?\1UL=C\/E5/'Y:L#BZ.'KX'%5)3Q<U%8FK&C0J<[</BO]
ME*V^-B_\% ?VEK#X_77PYOO&DOP$^#DGVCX:6FO6_AXZ$=6UH:=%$GB&XNM2
MCOXW$SWC22B$YB>*-?F)\3A^)WQ.\)_\$S?C'XUTSQ7X@L=:@^.'Q0T/5_&$
M-^U]XGT+PC>_&:/0=:N=!ENI<"]L- GF31C'ON[/&+&!V5,_IWX3^ VO^&_V
MM/BW^T-<:W976A_$'X7?#WP!IVA16UTNJ6-YX0U#4[V\O[JXQ]GDM+D7D45O
M%'B12C%B00*_.+]I#X/ZE^S;^Q&?A9XG\7P'Q)XV_:EM=:\*_$#2C+IWAKX;
M:MXT^(K^*O#GBGQ=!?X@U72?#* G5K#42NFZE<R10R$(0P^8QF%Q^#PV/A*>
M80PDZO$RGF&(Q;KU:4<77RGZO6HTU*$^:LHU(4GRQ2A"KS*G!RDOVC(N*^$^
M+N*>'X4\/PE]>KXOZ.L(\/8'AVKA<LQ&*X8R_B]\6RP6&C',/J>'R]_4*^:4
MU5QT\;4=&I2PF9U*$,%7\DUOX5_LI^*_V@/V//#'[,OBGQ1\1=8U+Q-<:Q\7
M=(\/_$;Q1K&E7G@:R\.7-[=>+/B3>65_<KHFK:?XDM[.6&+4ULO[3U6XFTT
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M84?\+-^''_0_^"?_  J] _\ EA1RR_EE_P" R_\ D0YX?S1_\"7^9W%%</\
M\+-^'&<#Q_X))]O%>@<_^5"MS1O$WAWQ$)V\/Z]HVN):L$N7T?5+#5$MG8!D
MCN&L;B<0NZY9%DVEE!(! I23BDY)Q3:BFTTFWLKVW_K0:E&5[-.V]FG;\3<H
MHHI#"BD) ('<TM)-/9I@%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=&V>]THV>I6\<UG,]Q0!^POGQY4'<"YP@(Y8\D[3G! 4;RP.W:003V%N(F(
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M3K&WMEDCACL;9+8*MP1/=M"D2*EHMQ=!7EAA!64Q+)([,0B:372KG]W)D%E
M8!,L$,H&7( #1JS[B0J!2'*G J3SA_<8-G[A*ABH=E9P"W*@*7!'WEQM!) I
MEF>VF(Q#>3:I(WG,\L<-NK)+,,2RIOMI-[72!8;K?\LD>=ROA0$72+1$BCAL
M[*"&)ED6WAM[=((I44>6Z(MOL+0R!7AD"1O&45@3DJ+<=XLF[$4H =D#;0RG
M:[IN)4ML 9&$@?:83M$H0LN7FY&PMY<FX9PGR[VP ?E^;!W#)3!_>;3LSD4
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MR &##)"$#<Z#;ET /S* ZY(Z-E#\P(I@NXR(V"OB12P! 60#("_NF(D)=B%
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MAENM(FM%CL;B2&^AU0S7EM;+!;WC2W]I:O,C10+.BNERUPF4;M#<*N-RL 0
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M"V?E&02/F&2">!@AL&H6O%$C((Y&"G:60!OF+1*@**2X#&0G>5V((V+E<J"
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M\R.8QB2,R. >$(>^G*9&E4QF3C:TB;G902PADG_X^&A28M,J>9@M)(K JQ%
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M?A7^V/["TJQTX>(-9OM?UE8+="+_ %/5'CEU*XG=]TLC74L2.Q>1U&  @ %
M'YWWWQJ_:$@UUO!WA_7=/UWXE0>*8? FG^#=4\(>6FI>'+[P'=>(5^-%U)"8
M8TM8?$20:=#:VUZEM'H<K17JI>JV>-?]J/XH^)QX;^*^E^&TTKPCK-KX[T?P
MM?:SH7BB._\  UKX4O?AUX9\=^-/$&G*Z6E_I=IJMYXO\1:/8ZA8SRW>B:5#
M'8W/VEZ_6+^SHRQ9UMW<KY7G_9T6X$ 966 2IA]@ *<. %"X&025^P*-X5(
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MX8MK^IV?@'PO*K6^M:[=ZNW]HVL-W$UQ=:LEC9R+;^>ZG]*I-+@EC2%XK:6
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MM)\#O"2%5F+QA&5@@_?&0X5?NG^7<LP/RRR,&95C)B:.1B3AHVMY%6X27/W
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M-/#.K>"+SP]HEE+\2([B^ETW5K<2QS3K+!::.+2]N+>QT\ZA#/+?1 'Z/&<
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M?S%=U*B3!11D$-Y>P,QP CNC>FZG?:,E1L/)()R<!@QC*9*@%O,&W' VY;(
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MBW>Y^$/C_P"+8O@_XR\<_$^QTOP@NDZUI>D>$O$=KX=NDM?%$7B.'3SH]X?
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M'WUYX;MK^PTK5(M,5&@U"*QU&>\GM(I_-VI ]_J!0(I-W(6+'W0=!D@G'4<
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M%?WAU$Z(/&7@W0O'&M:5ITI D@TC3=6\07-II4<Y:2"Q5;=6*L0/S5K]IO\
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M-O$-QX;U:SEOQ<Q>#O OCKPGJ:W6FW'FZ7<3SW'B>TN=/WI)Y @E:3,D<34
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M=2CTB&1-'O['X?6LVG+/HL%JBB";5H?+O/(=2D;2RQC< E &[;_M'?LL^+?
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M9KF:2Q@22YF>20YW." ?&;_MO>*=.UO7_$&O> =)TGX8^%?A1JOB3Q*T>O\
MV[Q3:>-=(^+5S\+9'T^&*U%AJG@N_O6L[EM5W0726'FW<<%Q/"]O72K^V+XW
MO9K?1]+^ FKZWKZ>$?BMXXU"PM/$=Q:Q:EIGPZ?1(;-/!-KJ_AW3-7\6R>*F
M\110Q6_V&P339;<QXO'FA4_4ES\'_A2!]LF\%>&;2VL++Q+%+FWB&F/8^)YW
MU#Q+%J5H5%A?V%U=";5'COEDMX+\R3)%%,SNW*Z+H7P*MK'P#::<=(O!XPT;
MQ!H_P[O;O4;F^UG5=&U"-==\0Z;HFM73MJ*Z?*MI87THCN@B?9[$0HD5K&%
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M)\.?!21Q1+X=TP1Q>*E\<(OV:/ \7)*TR>(%XPFI)*Y=)XPK*QW##<URNH?
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M[37M9\3V<MEOT^]LM>\1ZA=:GXBU*TOK)H+JWGUV\O;M]2\J54G6>1-JC;M
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MT'Q9XA\+Z1J_B;POI7B#1/#NO7MG%+JFCZ5XJM(K'Q!96-X1YL4.JV<$=O=
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M25E%=6]DNY6'P^(C7HN6'K1BJD'*3IM1BD]6WT2W;['U+_P<1_\ *9']L?\
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MK%]#J%[+I&@P>')=4L]4O-"B>]T'2[F[N+JX)#*OJ?PZ\%Z_KG[+/A[P_P"
M[3Q/J5I8?&N\UCQUX4D\3:G(_B;PI;?$/4-3\9^%OA[XUU/4)-4U[P1:I.UM
MX1U(WMO/JVBV4>T1->1PI^FL=C%&?E>0A59(@WEMY 8MDQ$QE@2C+$=S.K1Q
MQA@6!9D&GVRLI4,J*XD$0VF,, >%W*7C3(C81Q/&BF&(*JJ&5@#\S-<^"WQN
MU/7-8DT/2M;\+ZVVK6FL^!/%3^/]1.G^&O@\G@NWT:Y^$%YIB7=T'\1/KOVY
M?[5>QO"PUA+Y;N,V4FW'D_9O^*?ANU\-Z!+HWB?Q9\.G\.^"IO'/@2Q\?WL.
MIZ_X\/P^O=!UO6H-9N]:%^EGIOBN6#5=22&ZM;*[1U\NU?RC7ZG"QMPY=4*N
MT:1%@S [(PRQ@'/R;%=U!3:2&.XM@$*+.$'/S$[LCD#:"2612H#".0\O&258
M@' /) /R2\"?LJ?%/2)O@5?>-O"\]W:?"GXC_"3Q%8:!'XQDU.7P_I^A_#WQ
M=X>\13:;';:G%:ZA/I&NZWHSW%TXE_M*&.2>*+=&SG;\'_ ?]HFR/@*S\4#7
M;CQAH5C\,9/#_CN+QS>_V;X4T_1-4-W\3M!U33H9H[37-0\0VLM_!;RWZW4E
MXMV]Q!<VYB5!^J,EG%(<DLIVXW+L#;@%"2;BA.^+:NPYV\?.KT-9Q."I:0*5
M,>%8*OE-M\R+:JA=LFW+'&]=S")XP0  ?GU\!/@I\9/A-X?U2%D?5=0U']G'
MPSINI67B+QIJ6LV.O?'2SO/$<VJW-S<7<TFH0Q7<&H6-E=ZE:75O"BCR(H=R
M).OA?A?]G/\ :%\3WUROCW2[WP_X*7Q]X^\4>'?"FG^--6T6.VBU;X#7N@:4
MD>GQ>*=:U22UMOBG<K<6MIJ&K1HJPQ:\+6UMW6TC_7HVD9R2\OF99EEW_.C,
MGEY7C8-J8"J4*;@)"IDRY>+>,*Z'<4?;N4L1DKQDLNUV9@%5B[,6"J#GG(!^
M4ND_L_\ QPO?C#\%/$GC?P_K/B'6_ OQ ^'?B35/'UWXW:30M&\(:7\*KGPY
MKVB66D&Y:QUC6+CQ=+-+?-;64<S!QJ2W;B4H=_XE?"S]I/6[OQUX,T"T\1#2
M]0\5?&;Q19>,QX\MM)M(])\7^&K"T\#Z%96PU%;W[7I]Z=4>=2XBTY[>"]*O
M%,(#^FOV&/=GS)=FYV\K]T(L, $4((@ (2-\1&) Q(=W3"A191!90'FWRN',
MN\>:C*NV/RVVX7REP$RI)  D+C((!^6GCG]G/XDK;>)O"UGX9\1^-OA3?:=X
MMMO#G@.R^)5QI]]IWC7Q'\._#5MIWB+4-=N]?>ZMM.L_$UCXLTLZ<\\NGM>>
M((]2^QI:B.->3M/V8_VC/[#\?Z+J7B#Q!9>(I?AUJ^A>"Y="U5M-TF?1M2\
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M3]+_ +);_P#//(^4A2S&-2@"H8XB3'$5 &TQJA4_,"#S2_981O*H$:58TE=
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MOD9@ &+$'S"%";G 4 L0JY90I^4 87((!-1110 4444 %%%% !1110 4444
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M#X]8SR:YKFHV&M6XL);+^S+M)'E;<\+^$?&>J?#;]MQ-,3XPZ^WQ$\/Z=8>
M+SXGQM'KNO:F/A?'I6HV>A&=["_N['3M=>?3U9K:R8P6RQVAEB2&5@#]+K35
M;;48HIM-OK#4()&;$]I<1W43)&R"18Y[9Y;<R)YL("&0,0P8J,U)!?"[EECM
MKBTG-K,(KM(9$GDMY0 SVLXBD807"@J2DH5P"&*[3FOR^\/_  Z^*W[-OAOP
MMXBT2+Q!?6GC/PMK]QXR\&_#/P_=MI.D^-;/X2OHW@>ST?PO?WM[?6>L:EXH
M FU;5'N8["XU*"V>]%I!")3PUIX/_:BDT_QEJ.EWWQ/\ Z]XATGQ7XVN;G0_
ML5O<ZWX\MOASX2B\.S:@LL,HN8;;7H]1M[[1F1;:^DADBE9]BR, ?L ;HCHH
M/.W&['\6"WF &/IR4SNSQUXIZS.<D_=(7;F-E8%CMW')QY8*M(QX98\$KCI^
M8>HW'[1&BSZ[X<UWQ+\;9O!J75[=:%XJ\/6<%YXSN/%5[\+_  YJOA[1YKR&
MW:2+PN?'\NOV$5N;$Z9)>)'I6KWT>EHKFQX9?]K+3]1UCQEXS7XE>)+M/'MS
MHE_X#T2[T_3= NO 47[.VH:I<7/AN AQ9ZI<_%S3K73+77/M$EU:ZG>S6\(;
M3FC+ 'Z:F9AM4M$9&_@!P"$&]]N3NW;"I&X  \G@TP7+<\*Q(+JH8%UC4[9'
M(4L&$+D(0I+,>PK\L/A4/VG?BGKJ:9XA\1?%GX>>!H?&?CJ?3=1BU)UU.^TJ
MZ^'F@:AX7M=0U[5[0:N^BZ-XPFU62/\ <H=0MU6RF8Q1@#H_A;\5?C;XV^!7
MQ4^*.OV'C+Q#>P>([;X3^'O#7AS4XM"O))?AKJ@\&?$/XKZ)J'AQ+J[2Q\4^
M);/5?$=M!IT4U_!IEC]DALQ),\: 'Z2K=2;=TDD2*-P+LI16VL,RY<@)& ZK
ML;$A;D<$4\7+-L D4,Z^:@\MMCHGRNN2-R[F(<9'F!58*K=:_(0^&_VK/BQ\
M&O&D?B_7?C#H>HP?!KQ#9>%]'T355\/ZAKGB2+XB7:Z?K;W@MH==O/$2>$+*
MRO=(%Y]FG=+B,SP1W3,B]C?7?[44NN>+(] \3>+[&QTCX97EQ\+AJ7]NZCK'
MC;1X_@S?QPW6M:;>:9_9,'Q,L?B6L-S_ &SJD]M?W/EI;G2[B#:Y /U/69W;
M:K)@#>QQACL8!D$;8;8_(67MZ$T-,Z,H8IM<[8^I:1\,WE_*"BX  WLP'XY
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M0 4444 %%%% !1110 4445</CCZ_I(:W0AZ?BO\ ,5_>7_P9H_\ ))/V[O\
MLLWPU_\ 5=Q5_!H>GXC_ -"%?WE_\&:/_))/V[O^RS?#7_U7<5?'\5?\D_/_
M +"7_P"G8GIY)_OC]?\ Y,_M6J&:WBG">8#F-MZ,K,C*<%6 92#M="R.IX9&
M*D$&IJCD91M!/+'"CU(!)_3)K\BDXJ+<I<L=+RO:UVEOTULOF?9O9Z7\NXQK
M=-H4!BJDE5+L548 "@9P%  "CH,G&,DTU;6,9&"!A5&UB,*HQM4@@JIQ\X!
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M &K;QHY==X.$ 'F/M"HNQ552=H7 !8 ?,P#')&:3[-%E20Q*1-"C&20LJ/\
M> 8MN!;"Y;.[Y5Y^48B\U@K-)*%&?EX6'!+ 11,)26220\9<;6#?+@X-20RF
M1Y5;*E" %9"A*D9##<274'*;U 1F0[>] "M;Q,RN=X=-^UA(X;$A)92=W*[B
M&"G(5E1A@JN)#&C AE#!N&#?,K#T93D,!VR#CCTIDSL@ 4'YLJ6& %+85#DJ
MPR7*J > "S$$+3+>1I-Q?*-G C)!RH9E$GW%.)&#%,$@QB-N"Q% $IB7(.Z0
M;=V )'"_,NW!4'! '*@C"M\PPW-"Q(I! .5  )9B1A=HZD\[>,]ZCFE,9&"
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M?10   # X HHHH **** "BBB@#_#?HHHK^B#\W"BBB@ HHHH **** "BBB@
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MC:?XRT/_ (1Z:R3PA<KH$NHG7YO^$IM99);U+W2H[6REN;4PWVT.A^9_BO\
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MIO"OABX01S^'M%FC%XVHK'+IEG)&FHO'Y3Z@D;0E$OVB_=M>HJW+1_(92O%
M'YI>*/VB_P!H'6?"OQ$U;2-4TOPS%J\GQ7\)> H=&\(3:EXB\&7WA/X8:;X^
MTGQ7?R:K,]AXBNXKVZN-&N-.^RV^GYCB1M]Z+F*+[Z^"&MZEXD^#_P ,M>UG
MQ"OBS6-6\#>&+_5_$JZ=#I UK5;K1[.;4;YM*MRT.G/+>O.)+.,[('5HU
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MHVOP7\867@BST31-/L--91K?B75+UKNXNV>;2]-%A=:=+YDK1R5Z3X8^/OQ
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M7ZM=>&&MM)N9K631M&\<Z7::IJVNI::1:ZM9,XCG@U2T9 #]!J:R(X(9000
M?4@'(&1S@'G&>M?CAXD_:3_:+T'QAK7BG5/&6G2_#;2OVAOBOIE_X4\/:!*O
MB8?#?X8?!32OB%X=\&V;W=E=M%XCU[4-4A3Q#,7:>2X:2V@F"PB.+Z4^'O[4
M_P 1_B%XRT'P(/ATGA;Q+J>FS^-(Y_%,FH:!X=\0> H(=-FAO/#YN7FUB+5H
M;K5(]$U%+JPGT^2Z@FN8ML0&P ^_:*_+#PA^VC\9CX-\$0:_X TSQ]\1O%$'
MCKQE-;_#73_$HT.7P/X0^(%UX-71K.5X=13_ (3/R8I-1EADOK&"ZM[/S$@2
M.[0#UCP;^T7X_P#B#\??AIH\%CI7ASX8>*]*_:%M[71+N]4>/+O4_A+KWP^\
M//<>)=(WG^S9$U2]UJ6VBLW6#3;*_BL]8::[EC>@#[WHID881H'?S&"+ND"A
M0[8&7VCA=QYP.!G I] !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 (0#U /!'(['J/H:  .@ P /P'0?0=J6B@!" 2"1DC.
M/QZ_G0 !G QDY/U/>EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#_,]_XA0/^"I@_P"7[]G7\?B3>?\ R@]J/^(4'_@J9_S_ '[.G_AR;O\
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M'F(0-G)K^H?_ (-X?^"6_P"TY_P3&\"?M,>'/VE;CX?RZI\6_'?@SQ)X;C\
M>(I=?LX['P_X2AT2Z^V23Z;92QW#SC<Q,CASDA3G</Z.\#T'7/0=?7ZT8'7
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M#?P0JZAH0\+WN/#VF!9O#:F/_B2E?LI4:;N@A)LUVPDP0G;F-"OJ  '0 ?0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=. ?^7#W'?\ "G#_ (+0?\$J?^C[O@#@CMXND&>O_3AR/_KU/L:]F_93_P#
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M5^8P_P""Q/\ P3 [?MP? G\/$=R??_H'>U2C_@L)_P $PF /_#;OP*..,_\
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MC.3:_P!3N+].W"O$#_++&?IE17YI#_@KU_P3/(_Y/7^!Y/<_\)#=]<?]@_\
M'FC_ (>]?\$S^W[:OP._\*&\_P#E>:F6+P4-\;A%?;_:*2O]]1&JX&XW>W!?
M&+[?\8IQ#K_YBS]+,CU'YBC(]1^8K\V/^'O/_!,\#_D]+X(=AG_A(+OOSU_L
M[T/?\>]'_#WC_@FA_P!'I?!'_P ']W_\K:7U[+UOCL(O^YFA^M4J/ 7'LG[O
M _&+TO\ \DGQ(_\ TG*6?I/D>H_,4M?FQ_P]T_X)I?\ 1Y_P2_\ ![>9_/\
MLS-/_P"'M_\ P37/3]L_X)_^#^\_^0*3Q^7+_F/P:]<3A_\ Y<7#P]\07>_
M?&S[>SX0XFE]_P#PC*WEN?I)17YN?\/;O^";/3_ALWX*9Z8_MZ^]O^H>?7_.
M#4@_X*V?\$W><?ME?!@D<D?VY?MQZ<:;Z]\<#M4/,<MCOF."5_\ J*P_ZUT:
M?\0Y\1'MX?\ '?\ XAG$_P"F2L_1[(]1^8I:_.$_\%:_^";W_1X_P6!/ /\
M;E_G)_[AE(/^"M'_  3@/'_#8_P9YX.-:U$?^XRHEFV50MS9G@5?;_:L/_\
M+REX:^)#_P";><>>7_&%\4Z_^81_@?H]D>H_,4M?G'_P]D_X)P=OVQ?@Z3G
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M?_4#C#_Z'#]",@]"#17Y[K_P51_X)Y  K^UG\)&#' ,>JZC@G., C3"&)(/
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M_P /ZUYM=Q2<5'YW[7>UEVL?9X%Q]BFZ5!O_ *\T_P#Y'K8<EC9X(^R6V/\
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M*\NI'FO[]5<O_3ZIK>_][R/L\%3Y>7V=2M#1<W[V<^;56OS/1JW3>Y:^SVX
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M:#J2YJ<6<F! 0#Y2C< 1E5)YQU) )//)(R3]:7;!_P \D_[X2DP!P, #@ =
L!TQGM17EN>KLZMKNUZL]KNW7MU^9]ZL++E5ZD6[*[5&%F[*[6NS=[>5C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %? G # 2(  A$! Q$!_\0
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M_FKH_P"'I?[<_P#TA _;:_\ #@_!3_YJZ/J5?^:G_P"#:'_RT/;+^67W2_\
MD3]S\+Z'\FHPOH?R:OPP_P"'I?[<_P#TA _;:_\ #@_!3_YJZ/\ AZ7^W/\
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M_.#Z\G_#ZW_@GO\ ]%3\6=/^B2?$?W_ZE[K_ %QSQP?ZR\/?]#C#?^%>'_\
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M%2C%M*4KN,6]9);V6[MUL"UO;7ETE;6WK:]OG8EHI-P.<=AD_K_A2T77=?>
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M_P *"^+9W9P H\!Z]ELG ! YY].]?XS7P^TFP\17MYX>N5LDN=0L9/L%]=.
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M]%,W'^X?U_PHW'^X?U_PHO\ U9_Y!\U]Z_S'T4S<?[A_7_"C<?[A_7_"B_\
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M6T9RX%R]4ZF.P>(P.$Q="G5_MGV4WA\1F>7TJU2-65&$L52;K\O/*E_I7_\
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M.9'VAR1N- &P9IP2/.E."1GS'[?C2>?/_P ]I?\ OX_^-1=>< 9[#H/8>U%
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M&"!D(W5^YZ_\&N?_  6"C%NL?@'X-HMJ'^RJ/C?H;"U\WRO.-N?(Q"9!$-Q
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MU\+KPW=M>65T;GX^:7+]IL;^Z%[=V4XDC8/:W5WNNKJ(;1<7+&:0[L@SZ?\
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M/_85KX!O7TV6S8JD5Y"EX\AD_=5\!D'.6)9G =I#C]ZS_,TH 9@JR,2RJ&;
M(&:\C,\-@</'#2P>/>,;@N>+A./LGH^1.5DUKTVY6KZ:_H/ASQ#Q/GD\YCQ'
MP;_JG/!XJ5'"R^L86O\ VI!.:EBK8=R<5[B7ORNU4I.R4VJ;EZ/]/Z&OKK]@
M7'_#;'[+?K_PN3P=C_P*?/Z8ZU\BKT?Z?XU]<_L#?\GL?LM?]ED\'Y_\"GKI
MX==^)<C??.LE?_E[@CQ_'AM^#7BFVK-^'7'=UV_XQ#B+0_TV8_N#ZM_Z$:?3
M(_N#ZM_Z$:?7^G+W?J_S/^&V'P0_PQ_(****184444 %%%% !1110 4C=#]#
M2TR0[8W;&<*3CUXZ?YYHW=EN]A--II:MJR5[7;T6O35K7IOT//?BCX\L_A?\
M-OB#\2=2L+O5=/\ AYX(\4>-M0TRPDM8K[4[3POHM[K5Q86<MY+#:175W#9/
M;V\EU-#;)*ZF:6.,,X_DAB_X/&OV5"D#K^QW^T@S2H[K&/$'PO>16$F;UV#^
M)(V%K 25AF4%I8P/W:YP/ZBOVNI"_P"RG^TZA7;M^ /Q:PY(;)/@/7<9&"#[
M\$=C7^-5\.M&T;6;O7AXD@\^W_L.66SO"R1M8WL[F.VN5D558I!(58P8$<H.
M'.*^GR' Y/\ V5FV/S7"5\;##8BA"=2A*473E-)N<J<'[ZAH[6:BHZ'-@<LS
MWBGB?(.%<@QN%R_$9S3S*EA:F-K4L/2KX_ 87$5_JL\1B'&E1C-T5&-:I.-.
M\KIN^G]Z#?\ !Y#^RE'A%_8V_:39B<$?V]\+@%X^^P_X2-BJ>C=,?G22?\'C
MO[*D)#/^QM^T@S 9!C\0_## !QR0?$6#U[]Z_A>/PYTR'0;71[U39^);+6+J
M+Q-?I+%/):1P6=S?0Z/% 1LGNKJ**+R<-G#L3RO-;0/ FBM-X8U34)=5NK+6
MKBS@CT^*SMS<V[7"SI<+J2-S:I"RH\;$$NH&_%>G#%^&E.C5J5HXY2ITJD[*
M.,=W&#:UC"VK6J3V9]U5\$/&2GF>3X2"RJ='%TZ4<?6EF^3PAA:DJE##XF=3
MFQ-W3PF)Q-#!8FHDW1QM6%"5&HW*M2_NL;_@\@_94#?\F<_M(NI&$VZ]\+@V
M\\*A8^(PJY)&YMQ 7)YQRY/^#QW]E:1G"?L;?M'NT7RR)'XE^%DK"0 ED3;X
MCRP51EF"\#)(P":_A4M/ FC6FM_9[J[)E6W>\.GR(5M&2YT[49PJ7D $H-B8
M8+F7: ?)24MPHSZ+^SOX0\ >+=?\7^"M?\/IJWC3Q5I7AO1OA/K'C+3M>?X>
MZ)XWUW4XH4L/'"Z!,+^PLM7L_-A\/:_*1I\=Y<6EQ=DB-HV[<GP/ N=T_:8:
ME7J7Z3JUJ4K/HH5%SRENDEK)M+J?#\8<&^(G F Q>)SO$9<W1S:.!C]5QN Q
MSE#VCIRFWAJLHPC%\O->\8*[3FM5_;"?^#R3]E%3E_V./VD4C!&2/$?PMED8
M=U2./Q(1YIZ(DCH&8X++R:<O_!Y#^RFP#']C7]I4+@G</$/PL=3T81!D\2,/
MM"QNCRQ-MV[L*S\5_)]I?_!.6TUGX:WWQ*F^)&J>'])M].M_%VI:3<Z-9W2Z
M3\-_"MEK6D?'GQ=87RW[VDMA\-/B7I4'@S3H(O/EU/3]8TW4KM[:9V04/$O[
M&?P]OGLKR;QAXGTCQ'XUOT\/^#+#3O#GAZ#P[I0TW]G/PY\:+*_\6I;WDM[+
M=ZC'='39_P"R(I9$#-/*PGCFB'T$>#>#^:/^Q8S=?\O*N]VO\C\V?$?$%I6J
M4'HVO=IZ6BF][=%)OM9]'%']:)_X/(OV4L#;^QK^TLQ/0#Q!\+MPQG.X?\)'
M\I]!SGG!XI?^(R#]E/O^QK^TJ,G'_(P_"[(/N/\ A(@0/4]*_C;\9?LD>"O"
MGB;X2^"I/B5=S>*/&7Q)\!^!_%EI9PZ-K,S:-XT\+:/XED\9>$[?2G+M;:9+
MJ;Z1;:5KLMO=:K+;F]@9;8/MZR+]C?X3>)TTFR\!?$'X@P:YK.CWOB&U;QKX
M?\-6FD1Z9I'QOTKX.:E:WMUI=_<,+V7^U[;Q';1VZMY$=I=6%V5DEMF;>7!?
M"'++_8L;HO\ GY4\O._?R?H9?ZS9_I^\P_O7M94W]^EENM]5ULTT?U\?\1C_
M .RL6$8_8T_:4,K;@O\ Q47PN\O<%8@._P#PD6%!Q@GG&:0?\'D7[*3K'+'^
MQO\ M)F&17E227Q'\*X<P .T<F&\2D;G5&_=[LYP S5_'A#^R?\ #>/P]<_$
M676/BM-X.T/5M6\.ZSX&'A?P^/B=J.LZ+\3/"OP^?6="TZ*Y>RN_"%S+XG2>
M5Y"FKV%Y:OIUQ$7O+:0^V^/_ -C+X2^&_C!>ZC>Z^VDZ3KGQH\7P>"? K2:>
M;*_\/^#?B;;>#H?AU>67F1>((/%NJ0>9=7,$,?V72Y9(K&=F:>)ZP_U-X/>V
M"QC_ .WZJ_7RZ_Y%_P"LG$"3;JX?35O]T]+;:+?KH[=%=W/ZGU_X/)?V4&5'
M'[&W[2I5T5U*^(OA6Y*LB,<JGB5B-K,R$D ?+DX+;0I_X/)/V41_S9K^TQ_X
M/OA?_P#-'7\%_P 5])T_0OBG\3=#TVT_L_3]%^(OC72=.LECE"V5E8^(K^V&
MG_OC)C^S/*@M%4@.[&0Y*(">!92 ""<=\A/;'\/OSUKJH\ \+5$IQP.+Y5>[
M]O*+[=7_ %<Y*O&.<TYN#JTK[V]G%]+[I=G9^:VU/] [_B,D_90_Z,U_:8_\
M'WPN_P#FC_S@TO\ Q&2?LH_]&:_M,?\ @^^%_O\ ]3%['\C7^?;SZ_\ CJ?_
M !-'/K_XZG_Q-;_Z@<+?] .+_P#"A_YD?ZYYQ_S]I?\ @M?_ ")_H(_\1DG[
M*'_1FO[3'_@^^%W_ ,T?^<'VR?\ $9+^RA_T9K^TQ_X/_A=_\T?^<'VS_GW<
M^O\ XZG_ ,31SZ_^.I_\33_U X6_Z <7_P"%+_S#_7/./^?M+_P6O_D3_01_
MXC)?V4/^C-?VF/\ P?\ PN]_^IC_ ,Y^N.O^'G_!W;^RS\3/B'X!^'-A^R'^
MT;IM_P"/_&OA;P3:ZE>ZY\-VLM*E\4:[8:+'J>I?8_$+W8L;=[T2N+:.6:3R
M6C"*&#C_ #O^?7_QU/\ XFO=?V7=C?M-?LXJ\<;C_A?'PD)8KME./'F@E0DR
M%7CVGD8# DY(K'$\!\-4L/7J4J&*P]2%&I*-656=1)QBW;EB[N]O16U-*/&.
M;3K4H3=*K&52,7!14;W:6_+TO\W;979_M76CK+&)L#$Q\Q2'9EV,%,1P695/
ME;-ZKA2Y9L'=DSOT)[%DP?TJO9IMM+5<EMT$1RQR>(4&,GCG')P.><5,22N"
M,890/<9//XU^$0C:I62;<55T;T:3YN^ZTW/UJG)-47)<LYPYN5)M+W+O7;=Z
M=^G4YSQ-_P @;6_^P)JW_INN*Q/A)_R3?P=_V [/^3UM^)O^0-K?_8$U;_TW
M7%8?PCR?AMX.R,'^P[/^3U=7^/#_ *\R_P#3D3U</_R(,5_V.L!_ZI*YZ/7"
M^*76*^TZ>3>L4 FGN7A&YELXY+-)I&CDCEA>2-)'93Y1D5 =DB$9'=5E7^D6
M^HSP3SR3AK8,L21R;(\2 K,)%P1*LBX4J_ V@@9S3/-/QY/[)WQEEU+Q9KVI
MZGIO_"11Z;J=C\/]9_X3?6'N-&U&]_:5UOXG"_MGN9Y&AG3X<WEM:1WDBL\:
MR3Z1&JVLBI'D:Q^R?\:K[Q;J'B.ST;PYI6JVGACQ/;3^-K?XA-+??$G5O^%]
M:?\ $_1H+RPCF!T:UN_!J2:1<7%S/&8+P06'V:2UV%?V+_X16P# K+.!B%'1
MO*=&BAD>41!7C)0.[ NP)9E4)D+Q33X3T_G]Y,<\8)VKY99F:/9$8D*MN8DL
MK'=L;_EFHH _+'0/@G\=[OQAXA\4>+_#V@23>,=3^,5UX;L9?'L=_:? ?6O&
M?BC4M>\*>/\ 3@JJ?%%Y9Z+>V$6KV&CK<_V3=0Q6L0\EWD3FO#/[*_Q1\-:3
MX=EUG2-4\=RVGB+26\>?#+Q1\0O".G^#OB%::7X-U_1O^$YL+S1X-/%MXB/B
M364U[4+GQ/>R>);H6EBTRR7-JCU^NO\ PBFGX/[R</QM='*,I#QR'85P85F:
M*/[4+8P&Z"@2LPR*8?"6G9&V:Z \PSN&D$GGS(,6[7"NIBG2U7*Q+)&SMPTL
MLC#) /EK]F_P'KOPQ^ /P:^'7B>#3;;Q+X,\ Z#X:UZUTG4)M6TN*]L-,MK:
MZ33M4D7S-1LH)HGBM+UP3=PJD[$%Z]H"J  '7   R'!X]1MXKT$^%K%M[237
M;R.4_>&4*5"8!4!%50K8Y   [=*4^%=,))W70R2<>>>_X4 >?;1_?7\G_P#B
M:-H_OK^3_P#Q->@?\(IIG]ZZ_P"_Y_PH_P"$4TS^]=?]_P _X4 >?[1_?7\G
M_P#B:-H_OK^3_P#Q->@?\(IIG]ZZ_P"_Y_PH_P"$4TS^]=?]_P _X4 <'"H\
MZ'YU_P!=%V?_ )Z+_LU[%7-+X6TU65PUUE&5QF<D95@PR,<C(Y%=+0 4444
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M9IJZT=FFTUYIM/HPHHHH&%%%% !1110 4444 %(V,'/3!S2TU\[&P,G' _\
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M+L@(_HA_XC%/V)O^C8/VG0>X9/A_P/P\3GK2K_P>)?L2N0A_9C_::!8X4E/
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MH:3]Q_ST'Z_X^_\ G!J3R!ZC_OA?\]A^7TP>0/4?]\+_ )[#\OIA^S?\]/\
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MPEILTXQ<79-*Z)J*09QSU]J6D6G=7U^>C"BBB@ HHHH **** "BBB@ HHHH
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MDE=722BY2D_==1_:_P#AQ(^JV>G>)M9T^QU3XM? OXT>,-+M] FN? ?B;4O
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MX:3QG_\ *K_.3[8_VB_+C_YYI_WRO^%'EQ_\\T_[Y7_"C_B)>8?]"["??_\
M<P_U"PG_ $'8C_P&)_BZ?\,1?ME?]&G?M%?^&D\9_P#RJ_SD^V#_ (8B_;*_
MZ-._:*_\-)XS_P#E5_G)]L?[1?EQ_P#/-/\ OE?\*/+C_P">:?\ ?*_X4?\
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M+#HQ&2>.'QP(A#*I)   +-C@ELG>2"1D@,1G'RCCBK?E+UYSG.<\],?E[?\
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MP"* +U%0P2>8I)8/SD,F-A# ,H1APP"D?-T;((X(J:@ HHHH **** "BBB@
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M7^VF*67[.RD O:+^S-XGTB^^$>G6?B;PCJO@;X>^%?BMX>\5Z%K?AO4+N_\
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MPKX[U2VU+P0]_K=JG@[Q%JNNZ5H_@W45US^S/"-C<VVIQBX'V2:&>YBGN!;
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M9X5: /8:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT=[@6NE3-K$\]X\#1"&022K%&L3LA]](!&" 1Z$9'K_.@*H)(4 MC<0!EL#
MR>IP.!GH.* /FZY_9J^#9NK2ZM?"W]FV<8D@U+2=/U"^L]"\5VTFJRZU!;>)
M].@FF36K/3M6N)KZPMY0D4,DILU LE:W/?>*/A+\/?&6KV&L^)/#EKJ>JZ9;
M:=9Z=>RS30S0V6E>)-*\5Z?;1B!X[=8++7](TZZAC*G+0>4P9)&4^I@ <
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M;F\N7E-LJ)([AI S8:N]P,DX&3C)P,G'3)]NWI2X&<X&<8SWQZ9]* "BBB@
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MB33;C3K.?P/J,\\N@>$]=N3:KO6UAU8NFKV6XH1Y]GMBPH((WD,I*T >K?\
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M)\?\WZ_L]]<C_BJKCM_W#O\ Z_O0W_!;7_@D^K!6_;U_9Z#D;@I\5W 8C^\
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M&4G;L[:W\C]15#=B![9!_EFG $$Y;/'3)_/GZ?Y[_EX/^"T7_!*@\#]N_P"
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-W-RQYK:[<U[>5C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %? G # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *9(,HXP3E3P#@_@>WUI]-;.UL=<'H,G\J+VU[:_=K^@G>SM=.SL
MU:Z=M&KZ7O:U]+VOI<^4OVJ/V>C^TCX,\'^#CX@?PHOA?XK?#;XG&]%H+K[<
M?AYXHT[Q%_99P08AJ LC;--@A=WF-]P8\9_;1_82\,?MBQ_"9=0\7:QX'O\
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M9HFI>#$\0ZAX8M?&7A+QKX+U"Z%ZWA'QOX>GNK&>_L[.]+7FFZCI]];7=E,
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M =,M/BG_ ,)K:V.HWWQ'^$?A/6-+^&J^"_"4WB&Y5]-\&S^+-#UZ^U>^T[3
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M:R3KI,]Y$\LUT0#]^?M$.UV\P;8QEVP<*,$\G'7 +8&3MPV-I!+6N[=2%:0
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M9F3$F-C@ED;)*C$B@H?F&W[W#,BGET#/-Q",9< F0PA2&#&0 G8$(W$[07R
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MC#3;#3ET#6/#-SX&U'PU#_9\M[X8U&74YKAO#/B)\4_VW_B-\)/'GAF^F^)
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MZ'=&R1M)'Y:$*%\M(_E<AC(PR]/6WDV^4\:>4059$8K$T<HQ*B1J5V%2 4Z
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M7R^<",J(U;)3FO<V;3[>02JL YY.\;6BG"EUBCN$D1&$PA=U4,L;1AB*TJ*
M.#\.^ _#'A.7Q%<^&/"FA^'+OQ=XBN?%?BRXT6SM-/;Q+XFO+6UM[_7]6,,1
M:\O[V*TM[9Y[OSYF@@CC<H@^;IVLY&:5V 8X=8_NK(D3#/E0MN8)N"QQNY94
MF50LL.P G5HH SDMY5VHL,4<,<<@6(283/\ RR6-50!%<,Z3H5\M!L\@';N
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%'1O>S3M:RN[WTLDV?RXYQ4%-R2@X1J*3=ER3ERQE=VLG+36UNMEJ6LXSD$
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MI^H:UI5U\3OC1X6US3-:BO;&[M9?#UY::7X5N[^'3K*&:QGU:2]FU#[#)
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MZ@'[HK=AE8^5)N4\QKM:0*Q/DN5!X$H&0,Y0_*V""*F\Y2#@%F"NP5?FSY9
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MGB2UGL;Q]5N?AOXKL])\<_#^*Y9+?2O%&FV]]Y,B;P?-/AM_P3)^ 7ASP?\
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M&?BO3-"U5K7;J&I:'X7MI=;U"TAA#K!&\5O+<W$;VX^6?@Y_P3&\!?"7XO\
MA[XVR_%CX@^,?&GA[QAIWC%7U?3O!^G6>J7>G?"B\^$:PZP='T.TU#4'O-'O
MKG7]2U&XOWU+5/%,\VIZC<W4;K;)I?$/_@FWX-^)?QK?XQ^)?B_\3+PIK?Q$
M\1:7X7NH_#%_:^&[SXD?"N\^$VJZ)X5UZ\T:7Q#X=\%V&CWUSK=AX:TN_MU?
MQ)-+>WU]=6K_ &( 'H?A;]OO]E?Q?X>M=>T+Q_=7\&KP^ ;KPU97/AG7[;Q%
MX\T[XGG4_P#A76H^$=#NM.@U#7[7Q:VBZQ_9,UO#%(5TFZ>[CB$>&\U^"?\
MP40^$WQ'^#7PN^*'CRSOO!%Y\:_C9\1?@5\+_!%AX>\1:_K?C/7O OB?Q1I-
MO#9:=!I#7VDQR:%X6G\3:L=72QM-*AM[\22 JK.EW_P3-^':^(/A7XVT'XF^
M/=!\>?!/X?\ P8\!_#;Q3':>&=0DT5/@N_C*+3-3N=,OM)ETW4&\1Z9XXUK3
MM?LY8$C8-%/9S6Y5HGZ[X8?\$^_ _P -M(^ -@_Q*^(7BS4O@'\9OC!\<-/U
M_78_"R:CXP\5_&AO&$WB:W\11Z?H-K9VNGV=SXROIM(&@P:5<V8M;2))Q&K
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M4L='L+^]GN$LVM+>"SN7R1M1^9\'_P#!/WPQIGC7P7\9/'/Q1\<>-OB_X?\
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MU74+%QX;\*^&?$NN>,_B1?VEH1='7]=GTQ/)M&9U /I6']KWX1^(]*\">)?
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M\/A^+24MVL9](BN)S=RW$[-Y]J?_  2@^".K>&O@SX?OO&/C;4'^ WPV\+>
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M4G**O!)[>]HM=.G4DHHHIE!1110 4444 %%%% !1110 4444 %%%% !1110
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M\KS"&6XV[6(F4 ^>-0_;9U#5]'UC7?!'@VP?P]I4WPS77_$FN7E[>:-\._\
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M<6PQXHEML07NKS;VN8-B$ H, '9-\69/!GP^\#Z_\1[%?^$L\<7VBZ78>&O
M=K>ZS-JNOZWI5QK2:;I-M?O#<331:78ZA>7<MT\5L$M)"[JSQJ?!OAO^W?\
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M(#  2R ;74*R8##Y" IVC W*C8RHQG:7X>T711J"Z3IMKIRZMJ=SK6IK:1"
M7VKW@@%WJ5R(]HEO;G[-!YT[?/(8P6).2=FB@",PQLV\@EL <L<8!# 8SC 8
M!@.QSZFCRER#E\@\8=A@;@Q48/W20 5Z$ #&*DHH C\I.1@X))(#,!EF+,<
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M*31]8;7+W7;WPYJOBVS2#2#8M?74%_X8TF^U6ROXX!I\\.G7,J2EUQ7<:O\
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M!>>,/$C7\VF>([:>S77OMT6CR%OK[X3_ +7OAKX@^)HO#GBW1[3P/J&K:/\
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MV%CXOO;/1[YKE?#1O9]/E=7NX!7F?A'X.?'C6_$_A?QM\1_#GQ#32?"?QO\
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MQ:;Q3IWQ8_:;T'7O$OB'QIJUSX-\3> M,U;Q7H_@GP;X'TB2_;3]'NX/$?\
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M*ZD,I1@58$$,A*D8P5)4\$B@ B*F-"KF12H*R':=X/(.5"K@CIM &*?2
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M8'AU(V[2#NR!M!^4MC=\N:FHK0P/DGXJ_LS1_$3QWJ7CB#XA>(/#*>)?A?\
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MWQ!"L#ZFH\%ZUIWB#1KNZ0[8F-SJ>CVLEY:Q !HFE@0!7('T>JJHPJA1TPH
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #(]1_G/\
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MZ_X)G]OVU?@=_P"%#>?_ "O-3+%X*&^-PBOM_M%)7^^HC5<#<;O;@OC%]O\
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M<&I!_P %;/\ @F[SC]LKX,$CDC^W+]N/3C3?7OC@=JAYCEL=\QP2O_U%8?\
M6NC3_B'/B(]O#_CO_P 0SB?],E9^CV1ZC\Q2U^<)_P""M?\ P3>_Z/'^"P)X
M!_MR_P Y/_<,I!_P5H_X)P'C_AL?X,\\'&M:B/\ W&5$LVRJ%N;,\"K[?[5A
M_P#Y>4O#7Q(?_-O.//+_ (POBG7_ ,PC_ _1[(]1^8I:_./_ (>R?\$X.W[8
MOP=)S@8UO4>O_@MQ^=+_ ,/8_P#@G(.O[87P<_'7+_\ ^5OXUG+.\ECH\VP"
M;U2>*PZ_]SLUCX8>)DE>/AQX@2_P<#\5R7_JCW[6N?HWD>HHK\Y1_P %8_\
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MPN[[H8_V;A2>P.">U0^).'XZ3SW)HR_EEFN @]=O=GBE*S[VL^@?\0D\6/\
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M[6OPBRZ(PQJU^2ZNQ2-E']FY(=P41AP[@JN2" I<2<.QTEGF5+I_O^$?;?\
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M*2\\(Z5!H,%G'<?V#I5LMGY:.(PO=?#W_@H#XX\#7GPK\;:O\&/@?\2OC/\
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MW!\F/+D"NRN?A'\1X$N9)/!>K3K;0F65[".RN(C;HZ1B6V,3-<RRP2.L=^!
M1;R/&EQY;.H/)>%?%'B/PG>F]\/:E_9MU):FP8FVM[R*ZM)F^T1B>"Y5X#)
MS"6&0KOBE16C*L 1Z]:_M#_%VUBLT'B8/]@U.+6EEDLK832.BQ0-%,8E59;*
MZ,?VJ\M" )K@JQSL!'/"IE"5L75S&G5N]*-7VD;-KE:=22:>MG96]U)6N&*P
M_'+K^VX>PN2U\ HTU;'5<30FJJ51UE)4/<Y4U3Y))?!*4I7<&I9.D? GXJZG
M-:)9^#+V[\^R&H'S9+&..ULY QAGU)YWBCMQ,%86WG.OG,C"+?L?;=TOX"_$
M/5?$FB^$GT2UTW4M;L=4O[)-0U#2;:)++36C$UUJ3Q7+-%BYDMHK=I@L3K*=
MK9*@W?#OQ\^)WAK2?%NF0:O]NA\50);7$M[AI;!4>1_/M&7YE6,W9%M;9*P@
MMCN3S5E\6/B58:GI>MV'BW48]:T"VFM=/U<):F>*&X7=<-(DL;K=+Y2';!,/
M+,@20_.BDQ*61MJ<*F93BW%2YJ\(RLI>\DO95+>YK%WLI-Q<;)-S&AXKUUF7
MM,+PI@I4,-%X#_?\2L17GAYR@ZLI8FDHQAB.55(<OO48\\9\]1PA9B^#7BZ3
M6];T%8-'FU+P^VGQW\$>I67E_9]3A$ZZI!(S[9+&*-HKAKE"8!!(DN_RV#&>
MV^"7C6\N9X;;3+.;[/;7UU*8;VTN%1+!(G;'DL^&O8IH;FV!(\V":*5,I)&6
MIVGQ3\?VM]J^HVOB2[%UKFH1:CJ$DL5I,UW>0M+;6#N9(!Y-M;0D0M8PE;:2
MW@2$QD;<7HOC3\3K-+G[!XNN[07']JB62"TL89(/[9,":@I9+<F>.0VZ16*'
M(LH8HD4JJ@#!?V-/WG+,%\2=JU/9-VM^ZWMRN[LM9>[8]6-+Q,HTX4Z,>%ZD
MG0HR;J4L5&,<1.%-UD[3JR]FJGM84TY-I>SO)-V5+P]\)_%/B33(M6L;+3OL
M(%\;H7NH6MM=V-QIKK%/I]Y%(ZO;2,[*(X)@DA;C:">4N_A/XNT^];3'T^PD
MODUC3=#VV>H6-Q<?:M8@ENK)S'O,B(\,4D2D &1E=4W;2!-9_&'XDZ?%:16?
MBB>.WT]+E8&GM+*Y)-_*)IGU!&@47UR[K\L[[F4=:@O/BK\0KV:>>XUUA<W^
MIV.NB2.SLDE&HZ4CQV%XDJQ[D%J'G80$@.)2O(I*.46UEC[Z7M6BNE]'[+2\
MFXJ]]$GO=&T*?B7]9K2FN&E1M:E3<*N_/)6;7O-JFHS;3OS2<%I'G$?X._$=
M6V?\(=?*Y8>7*YLQ:+%*]PC'S9)(XUEMOL<TDR[BT:.KR  \MNOA+XZTGSIM
M4\*W>G6MD5:ZN-2^S6UO9PM=Q::]]J'EM)>6]DMY/&J78@-ON5E=U8;:W-(^
M/'Q4T-+NWM_%=Y/!>&_NY;6ZM[6>.0WL9\VY#NI:+>#/M@3 CW$$'<,9EY\8
M/B7?V?B#3;WQCJ,MKXGM4M_$416+9=VD%U)>1P%C&\J+'=L\BK"50YRV2 0G
M+(HZ2>:<UFVH3A)+W?=M*\&TWRIM1BTI/EYI<K,^3Q/JU:EJ/!<*:G!*<ZN:
M^U<?:*-64H4X.$)1I\[IPO.,Y0IJ<H0E-QMW/P.^(UK?O80^'1?HUY'IT.MV
MC6IT9KR22%'D&H7<L2RMY=RHRRKC@!3P*K7/P5^)5C/+#+X&U'Y;Z]TQ)7@L
MUM7NK)<PW#2F81?8[D(8[:9F$<URIBC+/D&U:_&[XJQ:?;6'_"8ZM/IMH[SQ
M64PM);=&N!Y?F1[XUE#)+'$Z[RQ#*"" *;:?&GXIV4Q>+QKJK.56)HY&1X+H
MQ2O(R31-&RB3S;AGCF7:$P ,8Q3=;(+V_P"%97?-;VM'W=KQUA)M*75S3:;;
M2=TLI8#Q*<I-_P"I<Y)<B:_MJ+K.+C:J^2:5*<Z;YITH0G2A.2Y)SAJXG^"'
MQ.:X-O#X,OW:*VCOIY72Q"6:26K7<SZLYF(LK?RHY9;>2Y,<;I&[([(A*Y&I
M?"OQWHD4,FI>%M1TV.2[M=/B-Y%;6[37NJ3R6FG!QDL9/M,-P8ESN,8#*I4L
M:]#\/_M*_%O0;36-/F\1/K5GJNCS:-=QZH9FDB2.&58"9K:2!YV0S-;@N'Q!
M*R!PHQ7,Z[\:?BKXEM%TW7/&NJZK;QRZ-=JDIBCDCE\/3R7VD/;3,LLB&">[
MDDF=Y!),K%#@#!VE/AE482C6SAU6FY0;P_*FK64I<D6TU9W6EY+9:F6&7BQ'
M&2H5\LX,6!I2@H8JEC,V=6K3LY3G"$X247%ODY*DO>Y;N3ORIX^!/Q 9I?L6
MCV6H10BUC2YM;ZSFMGGNI7MX;?S S#[9/=130QV^[S))U:*-6D4J*.H?!SQ[
M867AV_FT 3+XGU>]T+1X[:6UN)+C5=-+/<VP,>XLRS1O$(4!=9(I4VAT<!;S
MXN?$2_>2>?Q5=CSKBROF-K%';QB\TR<SZ:5B6- OV:]N'FSMRSLS;CDYJGXG
M_$#^R;31#XDOO[,LKF]O(+?]T MY?R3F\O/- \^"<SW,TJ26I1\N<Y/-8>UR
M#77-5ORWK4;W3BDI?NT[64F[6?,UTT?H>P\3GR)5N#$E./M(/#YE*7L_9U%)
M*46H.:JRI6<8J*IQDE[TDXO;X1>/4_X2-'\-3))X1N$M?$<#&.&ZTWS--N=7
M:>> A9(X4M+>5&>10%,B*>'%5O"WP\UGQ; MWIYTFWM)=.;5K9]3O8]/2ZL!
MJ":8\"?)EGBO9(O,V,Q!G@S@W$89T?Q/\?VT\US#XFU$2S03QW3LT<JZA =-
M;3%-^909;TB*4[?M&6'<'M4MO'7C"RL;;2;#69[:QL+FY:$1V]D9(Y[NZM+L
MP!G3FTEU.UM[IHL;4V[!PJU#>42UIO'<KYT^:N^9WD^2_(HI6B_?25E*/NJS
M7+JZ?B%[&K"I4X94Y1H^SK4</B5&FO9)8E\E:;E->UUP\G*#]E43J_O*3]IG
M>)O"&J>#M631]4AM)+FY;.GRZ9<1WMEJ2I<_8Y8;6Y8 L5O%DMY1QLNDDA^\
MF!U.K_!OQ]HGV<:AH+6EQ<7=I;6FG2RP&Z>ZO+07\0FC<"3[(+(-<&1AL5(I
MF)VQ2%<O4O'_ (KUNZFU"_NK:ZU26YMY8KL6=O&UO)9NMT\%M$5\F".2;=*[
M(%+S,TIRQR+6J?%/XA:RMD-3\5ZKJ2Z;+++:BZ%L);9[F*[MDC>Y1?.N8X8;
MR[CB#$A(F2,;54"ES9:G-JIC;77LU[:27+?WE)-OHE:STYFFWNKJT>/%3RVC
M2I</2:P_)F5>H\6YNOR)0EAXTY0IQBZG,JD9IR;CS4K1M$V8_P!G[XI3V<]]
M;>#KQ[98H;BUN VFJNHK+/#"LNG>;.DES9N;A;E)HU,;6T+RAC&N1@WWPN\:
MZ=KA\/2>'7.MO9ZA?PVL/]F7=O<6VFW$-LUQ;3QW+Q^6TUQ'&LBL$\R:)<[I
M #U^H_'SXFZEX<\*:!!K;6<?A"UATJPO;-1'=36-JA$*W?F#;*50B,C!!50,
M8X/)7WQ.\>ZC-8W=_P");R1M-18;!LK#Y CO;74)RAM8U<&6XM;1S&[- 3$
M5*Y%=//PZK)U<W<KQ;:E0:;LN9<KIN5N9RY6W*ZBG=<SMY.#PWB?^_GBZ7"-
M.U6O"E3IRQ\FX*K5CAJDJGM6FZE*-&52"A%TY59Q3E['WYY/@Q\3H7V+X UR
M24+/<F,VD+E8;2402)]_!\YF\V/!_>(-Z;E!-1GX0_$/=J*1>#=9N%TJ1(=3
MN!80):VF\NJ745V7\G[(A1_M=UO\J(1.974(^WKIOVB/C;=)J$$_Q&UP-J2.
M]^ ;:!+OS,^9YL=K;%7)&02LD08?PJ:Q=-^-_P 6M'LH['3?'^N6EB8;.P$0
M>%XI(+"[O]2M8'CD@D)MTNM5N6GC;(N+1X;5]RP!:CFX><K1Q&;\NK3M2<M;
M\FU3EV2;:MJI<J:U-%'Q55--X+@1U+TO=^M9XH+W8RJW?L$Y2OSQIQBN5I0G
M4E'6FN$\1>&]0\(:Q?Z#KMO##JFF-:_;X(2ES$C7=DDT&PQ;D>0(P(5205PR
M_*03[MH_[,7B[6_#">)+'Q!X1O4_X0D>-+:QL;BYO[B]L0ES=RVEP)+>*'3X
M+&WM98FNRZVZZB[VY?S5 /@>MZWJNO:QJ.O:U.USJ.J3QWEW*S9:0I$+2W+%
M0!OCB"@E1C.< #@=38_$[QWI6F3:)IFO7=M9MH%KX7G2$QQF/1XKBXDET^(X
M&8+K[0_FCNQR>ISC@:F6JM4>*AB:U%R;A;$3A+E_>;N*<6TI0UZ.+:OH;\0Y
M?QYBLLX>>29AE.#S6C6A/-HRP<JN$JIJCS>S4JL:ZHQ<,2N5N<Y0G3O*,DVO
M/5\AE5O)0;E!P51B,@<;N0V,XR"0>H)!%.VP?\\D_P"^$I-H3Y0,!?E XX"\
M <<< 8XX]**\J4U=V=6UW;]]/:[MU[6/TJ&&GR0YZD.?ECS6HPMS<L>:VMK<
'W-:W2Q__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %? G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHH) Y)P/4T %%(&4C(92/4$$?G2Y ZG%&V^@DTU=--/9III^C5T_O"BDR/4?
MG2Y'J* NNZ[;K?MOOY!1110,**;N7D;ER,Y&1D8Y/'7@4H96&5((/<'-&ZOT
M[]/O#_.WSM>WK;6V]M;6U%HHHHVWT **,@=2!29'J/3J.HZC\*%KJM5Y:A^M
M[>=M[>G7MU%HHI,CU'YT +129'J/SI:/TW\O4 HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ IKXV-NQC!SG&,=\YXQ]:=4-QS!+PI_=MPV=O3O@$X^
M@)]*:U:Z:K7YH3M9W4I*SO&,5*4E;6,8MI2DU=1BVE)M)M)LSFD6(961"F%=
M!$54,IYW,Y&T*5R>#R,'H,U;$JYR67#;1@NI.XJ"<#/4 C !R<GJ*\$_:#^.
M'@S]F_X-^-OC/X\M[V;PUX(T>'4+NPTF..YOM5N[J>+2]#T'2H9I(8FO=:U.
MXM-/LTEFB4W5Y$C, V:^:?AC\??VQ?$/C7P1:_$O]CRW\&?#/Q?>F%?%/A7X
MJ:7XC\2^ K.=$FTW4?'7A6[TS3=EI<P.GVYM%O\ 4Y]/E#ILEQFN3&YGA,)5
MC1JPK3J)Q<W3HSJ<D9S5*-6;ITY^S@ZEOWLW&-E)J5HMQ^ERC@S/<ZR/,N(<
M*\KPV69=*O1PU/,,ZR+(ZV,K86BL36PF583,<32Q699IAZ+A+'X/#PDJ7M(4
MJ=1UJV'I5?T5S&2I!5LCY3NP#R5SCUSP>>OH:<!E@2H)!X((X[<XST[9]Z\$
ML?CSX&O/COK7[/\ !>71\<^&_ 6C?$/4(6@*Z<WA_7]5FT6R\JZ_U;7/VR"2
M5H =P0>8,@''N-NZ(9&\U64,^X[@0@0_,6YXV]"3PIZCI6D<1"3<8U*<Y1E[
M-QC.$YQGS<KIR4)R<*B35X2BI/\ E:/#Q^6XS*YX"GC\!/#2S' T<SI>WIRH
MNIA:])UJ&+I*K"#J4*L(RG3JQYH2C%M3W9H4US@9QD9P>W'?GM3?-B! \Q<D
M @9&<$X!QUP2" >Y!Q6;J>HV]K;S#[3 DXAEE2-I8PY6*/S'8(3EE1<,^.=I
MS6DY1A&4I_"HSDT]W&";FTMVDE=V3MUL90ISG*,80G-R:2482D[.4(WM&,G9
M.:;=K)7;:)51&P[C:[[P5SC)P5?WSM&<#D<GM4]O&L2JJ'.5 !))^5?ZG/Y@
MYKXP_8;^//BS]H7X)V_Q!\;66EV&N77COXG>'5M-*$RP+IG@WQWXD\,Z9.PN
M</\ :+NSTN&281Y7<Q=?D.:^T5>)0"6"! >K*  .3DG!XZ'OWXI4\7AJU*4Z
M56/LK0DVW",5&:O3YKSM"]THJ4M4]+['J\2<.9EPEQ'G'#&;<D\PR+,*N78^
M5&7MJ53,<+2ITYSHU80C&M25.M&G[6FG!SC)7O%HL5'*X0#. "0"2<#'N>U(
M)H2I82)M +$[A@*OWB>> O\ $>@P<XP:\E^.7CBZ\"?!WXJ>-=!-E=Z]X-^'
M?C+Q7I5E<2 QW%[H'A_4-3MXY54[C"\ULB.0""649!(S-:M1H4Y5:\E&E&//
M-NVL%JVDW'F[K6VF_4X\!E^*S7'8/+,(O]IQ^.P67T7*\80KX[&8/!TG5GRR
M5**J8NDYRFDHQ;DU9:^J-(AVYVN-RC@Y XR.A/&"#[Y!%*AC8LJ A@TF?<A@
M&]LGK^GI7SY^S3\1M4^)_P  O@M\3/$EO:6NN>/OAQX2\3ZS#:EA:P:IKFF6
MEU=01*Y##R6<1[6PR<*0,@'W>"YM&E9X+JVF4-,C-'/$X657/F(VUSM:/:1(
M#@HP(;&#6M.K0J4^:G+DC))PYG&'.I)2A[KDK.<9P<4F[J2<7)--SFN5X_)<
MTSC+,93=3$Y-G>89)6E2C.I"%?+L?B\NQ\HU8T^65.=;!R]G-\L9QBFKWLM-
M5V]2,G@<_CQ41V?*1(C [B,,O(4'=CDYVC[V.G>J]W<VJ>3%-=QP222*8E\U
M4DE93G8G.XJ2"&*@\9YKQKQQXK^)&F?$OX9>'?"WP^M?$/@'7CKW_"?>.SXD
MM]+N?!+V5M%-HEO:Z*8Y)]9.L7;RVTT49C^SI&)7;YP*RJ5E1BY)J4FH\L%K
M*:E)03C%/F:YFU=)I6>ONNRPV7U,=5ITU:ES4Z]:%2M*-&#6'I5:\N6I5<(2
M?[EQC&,G*I4<:4$YR47[7&(OF96SD<#VXP1S@_7OCVJR,8&.E8C7MK"522>"
M&:Y?;#$\L:O(8V(<1J6!.TD@H!E3D8SQ6C;W,,@RDT3KA1E9%;D@G!P203G.
M#@XR>G-$9TXQYY5(1E)>TG&<X1<8Z1YI*4HN,5)\G-))<RY6^;0YE&M*G2K5
M*<_?E.*DH3<'&,IP4U-PLXR<'9IM732DVF6Z*K)>VDK.D=S [1 &14D1F0-G
M:6 )(!P0"1@D$9XJ='21=R,KJ>ZD$<=N._M6BE%N24HMQ:4DFFXMJZ4DFW%M
M:I22;6J36HY)PDH33A-QYE"2<9N.GO*,E&3CJO>47'5:ZJ[J***8@HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *CE+"-R@!8*=H8D G'&2,D#/4CD5)4<P8Q2!25
M8HP5E&64D$!@,')!YQ@YQBB[6J7,UJHWMS-:J-WHKM)7Z7OT!?UI?\$XM^BE
M%O9-7NOGS]H?X+^$/VC_ (.^./@MX[>_M/#GC;35TRZOM'GBM-3T>ZMITOM)
MUW3;BYBEBBO](U:TM;_39)8I +JWB=D89!^!-'^._P"U!^Q)K7P_\!_M<P^&
M/B_\#?$_B71_AWX*_:A\#Q3:/XB\/ZKJSP:9X4TGXR^!-0N'MK1-05#;R>-?
M#VJ2Z=<:G*D4^F6KW"JWZ"?'+PA\7/%?P]O;'X(>.]/^&GQ(BNK*]TGQ%K?A
MV/Q7H4D5I<I<3:/K.CRSVDLFF:J$^RWSZ?<Q:C:V\LDUG.DXC=?A;Q/^RG^V
M#^TCKWPZT?\ :L^('P9L_@QX#\5^%?'>M^"?@WHOBV+5_B5XC\%W\>HZ%:>(
MM7\3SQ0:3H$&L00:I<V6FV-U=W:HMO'?H$,A^5SC#SBZ<LNP>:RQTYW5;ZY:
MCB9SE^]P&+;K/_8\,JE6K3G.,::<?]GE.4N27[EX98G*_P"PJN5<;\0<!SX(
MQ%?-\;FG#^:TLQCQIEF;4<KQBPF<<&U\ORZ52AC\QJ+)\#2I4<UJY=BU2JT^
M(L#[/#0QT/ 3^QM\ /&7_!3?XN:;KNA^*I[.Y_9^\#?$MH;+QIXQT_'B[4_'
M5_+>WJR+K+/_ &9^Z0IHB(;'3Y=P%ND;@'ZL\-W^LV?_  4Z\:>&QK6K7/AS
M2OV/_!=U;:%)=W4^GVDK>.[^UFOUL@WV5KNZMXHK=KLQM/.R>6SL>*Z7XN?L
M[?M!V/[3NG?M)?LW^*_AY::AJ_PPM_A/\0_"/Q6M_$+:1?:38Z]%K.B^)-&O
M_#<$]T=2TQ#>PO97*K'.\T.Z145R&_&[]FOXX7OQW\&_M0_L[^+O!.B?%+3?
MA^_PL^(/AGXDV&M/X-\=^$6O(M7LY8+_ $"";6-)UC2-7$DU@D<,UA)&[)>%
M&;>O#2R_&818^K@,!3AB:G%M#%8B<81A4Q.$Y7[6=*:LW)4I3Y)7<?:7UNDC
M[+%\9Y7Q5_86&SOCG+,;EN*\!H<#974XAKXFK1X2XLRM8'#RPV;4YY%6Q62+
M&QRR>'P6<866:8:O3Q-"M6C1I2K*/(:;XEUNU_X*3?'RVDU74)/#OA[]D?X<
M>(+;0+F^F;1);R;Q3XPEO;VVTK<T,=].EK%;RRHHEE6)D!W1X'SE^RS^S1I_
M[8/P3U#]J3XT^-OB;_PN7XMZYXO\5^"?$N@>.]>T2X^#?A^TU_4+7P;H'@.Q
MM)(M,L[?2M*TZUFO;6^LKC[9.9;74/,@N"*^H/@#^R1\</!O[2GQ(_:*^-?Q
M2T/X@ZA\3_A9X9\#7_A_0]%N-"TOPA<Z%JNJWCZ+X6MW\UO^$3CM[Y);)K]Y
M=2?4Y+Z:Y98[E57@? W[*/[7WP*T#Q5\$?@E\5_AA9? ?Q!XG\3:UX2UOQ?X
M<UZX^)OPGT7QEK$FMZ]X>T'["PT77Y$U&[U.;1+J_DMTTM9K56CN$B5#SQP>
M*4\-B\;@<UJ4)2XH>'I/%*N\(\7C<-5RNI6I0K-K_8Z>+C&,FW1]HXZRFG'T
MUGW#&$PF(R3A7C_@S).)Z&0>#<)\3U,/F&#P%?+^'\)G-+CK*LNQU3AK'UL5
MC*>;ULIS'&X2ME]!\38/!JA3K8K#\F!K_#WPT\,>/_#W_!+/PA\6? OB3Q'J
MOQ-_9C^/WQ ^,27UI-=6#?$*Q\%?&WQ;9^/K/Q)86$BC5K7Q#X:_M1+^U,(@
MCUEENXX@L<8'W-\:_B ?VH/C3^Q1\'_AAXKU*S\&^*;-/VM/B'J7A_498Y&^
M'/A>PLKCP1HEU-8OO.G>*O$NIV<'ER'[/>Q0S)F14*CZ%_9%_9GD_9K_ &84
M^!OQ'\50_$&*#4/B7J/B?Q7J$"VYUS3_ !CXH\0:[/<ZE;2*L45[)IFI1-J2
M",0M<Q3LJBOBO_@CY\(%L=!^,7QIN==O_%>C:KXY\1?"7X(:WJ>9)(O@/\-O
M%6NQ>%8]/9EPNF7&H7E]!"UL1;7%OI-HR B,5A2P&/PL,CRJLY2I9M@\JI9C
M4Y.>-/%<.8J6,Q?M+QM".-P=2CAX.5U5G%I.3DHOISOBGA7.ZOBQQ_3Q67YC
MF' W&'%F,X%XAAE5:.'XICXIX>&1Y=2IX'$4:>'PLN'\PP6><78+#8_"5OJ=
M#$4J#I8*=*BJ?Z-?M5_$_4/@I^S7\=?BOHUJMWJGP[^&/B_Q!I5G+"L\)UC2
MM(GFTZ3R97A6YABNQ!<RJ[JKB%E);H?RNU[]A;1;S]AWQ)\9)?BY\7HOVCM;
M^!&O_%7Q5\8[/QYKUUJ/BK4==\#WOB+5O#FI:-,QTVZ\(WD-W)I5IX;CL_)L
M(8+,VZ@QHQ_9[XJ_#C0OB_\ #+QK\,/%UK+=Z!X\\-:SX4UM(B]N_P!BUJPN
M;">XB*#=YUN)UG@#?*98D+C P?S#_P"&2/V][WX&:A^RKJ/[0'PRM?AC9^$]
M2\%:3\6-+\-:Y'\8M<\)QZ7+IGAK1M<MY(_^$>MKZUC6WM=?UVU9Y-0TN(Q6
M=K%-/+(GN<0X:565:AB*=3$X5Y?7IX6-.C*NHU50K15U3=.2G.\4JBJ4I)+E
M<US14OA_!?B/!9)EN%GEO&^0>'^>8+Q.X:XFXEJ\447B7F_"6'PV!Y<'@E_J
M_P 2+-UEV:0S#$YAPU_LE'%PQN'Q"JXAX.+P7SY\9/C%K7A/]CG_ ()Q?!K0
M;KXBZ5I/Q_T?P#I?CN]^#UG>W7Q"E^'OA;X>2>(/$7AWPHFFW$%U:ZEX@"6]
MI?:M;RRSKIRWS6T2R%9HMOX>:2/AO^TO^S[K7[(GP8_:U\"^'=?\5#PC^T7X
M2^)V@^+XOAKJOPYU/2+MK;QSJ-QXGU^ZL;/QAX9U*UM+NUU2TDFO;NUNKBRO
M;1EO?,C^RO'/[$/B3Q+^SI^S7X#\-^-=.\'_ !T_987P/K'PS^)5IH\]]X>_
MX2GP9HLFBW.GZQH]R\&I7/A#Q+93WEEJ-A%>6TOD2JRW#&.-']%^&>D_MX7G
MC70+CXQ:_P#L_P"C?#_2&N3XBTOX>:/XRUKQ)XKDEA;:MOJ&O-8VWAVV6[D%
MR;2*UUL;;>.V6[V'<OCPR?%_7*,\54K4Z'U?((T*]'!UE5PDJ678&G54:T\7
MB(T'"=&I3J<V&JIJJXU+S7/#]!Q/B)P2^&,SED*X1Q^+_MGQIJ<4X+B'B3/<
MFPW$6+XOXBXEK9!G&#X<P7"^-AQ#@XY-CLIKY%[3/LNQ.3YIEF#H>QP%-5:^
M*_.CXMZ!\.]$_:7^..K_ +?FG_&2P\-^*O&V@-^S3\;="U/Q;:?![P+X.2QM
M(=*\-PZ]X2O5A^'?BNSUU;RZUC4O%-I96VK+=0!+Z>!!$/K/XZ>(;G3OVTO^
M"<V@Z#XCUR7PUK>C?&9Y6M=6GN;#Q9I]GX!T1K&]UJ=)'@UF7R@EZ+Z?>TCR
M^;&5:1G-KXX_ W]N7XOZ-\6O@Q=^//V?9_@I\3&U/2K7Q+J?@KQ-#\0_"OA/
M5RL-QIMKHMO=:MX;UO6K:S\U;+6KV\TE([C9*U@N!7H]_P#LEWMG\2_V*]>\
M->)O)\)_LL^&?&/A*\T[6HKFXU3Q5:ZYX)TKPOI=W'(@,,<MK<Z<U[>+</\
M9TBFCCMRTF0-H9=F4'CJ.&PZJ)PRJ4,=6H5,/52HYQ5Q$VN;%3>.E&E'FE*G
M+"2C&:4DX)17B5N*>%(X?AW'9WQ-E689O@^#.-.'Y9#DN/KYMPQEV Q?A%6R
MSAO,:-&OPUET^'<ZQ6?SAEV89!"6;T9Y@JV;O,<)5K5<1/\ ,SQ1XA_9J^)W
M[07[;6G_ +;?Q@U/0=4^%?BG2O#/P>\)1?$O6/!>C^%OAM/X/L-3TOQ#\/\
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MK]2T[3]9TW4--OA'<VFH0S6M];R*6BFMY%DM[FWE7@F.1#)%)C!"EB#TSC>
M?!GA7X=>&]%\&^"]%TOPQX6T*U>STC0]+MDL]/L8/,:1H+.W!PBM<S3W#O\
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M'&AS^'=<T[#C3=0-C%-,/ML#/PGC?]L_0H==MO OA30M8TSXBZ?\7/@?X/\
M$7AWQ]I5G8W%WX#^*?Q&M_ E[XFT)-+UG48[A;27SX"U^UE?6EZT45Q9#^$
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MOB#3=/UL7'V""18+FSL[QXYY7@ (!]=A@3@$$C&1GD9&1D=1D<C/:D+J#@L
M<9P3VYY^G!YZ#!KXJ\&?MR? 7QQ\3O#_ ,+M%U7Q$OB+Q7,-)T"YU#18+'1K
MKQC9^%[7QGJO@.>_^W3:G;^*](T.]@FU:QOM+AL+2Y,MI%J$MPCQ+R'Q&_;I
M^'ND:#\2X?!-IXDE\1^'_ _QHU;X=^)?%GAJ]L/A;\1_%/P:\,7^N^*O#OA[
MQ%#<_:M<N]*6QG>2)+&UBNH[6]2QGN6A; !^@8EC*APXVD!@V>"#T(]<^U*7
M48RP&>![_3'7'?T[U\%Z5^WS\(G\&:;KOB/0OB7H'BR67X::?%X'U;P2='\4
MZO??%/3+B?PCJWA[3]4U6WTU_#FNR:9K<-EJ=_JUG&L^E75G-Y5V;>*X[#6?
MVU?@7X?^*T7P8U75M<LO%XN+'1]6O'TF+^P/#GBG4_#P\7Z=X.UV[AU)[S3?
M%.I>'Y([VVLXK&>QE,D=NU\DX:% #[%# Y((('.1S_+Z5%]H@V>9YB[,$YYZ
M#<3QC/ 5CTSQ]*^(O"G[>7P+\5^']6\32P?$/PCH-CX!U3XHV%[X\\$7WA?_
M (2[P+I6M67AZ]USP9!-<27NJHVKZCI=O!:&V@O)?MEM(+?R[A6.)\6_V[O!
MGPKT_P"), ^''Q6UOX@?#KPMIWCJ/X?CP_I%CKGCKPW/XDT;PUJ>I>%Q#K5]
MN719M9@74K;4XM*N@RIY5O,K^90!]]++&P!5P0V-O8G*[Q@'!^Z=V,=*%FB;
M;M=3OQM /)R"1QU&0">0.E?&E[^UIX/T/5O%>E:QHWC#4->TSQ)X!\,:-\,/
M"WA:YU'XHR^(_&/@./QX^A7FE_VD+.[N;'1I!?ZE+#J%K::5:_+>7"M)%OYS
M5_V_O@#IUKX>OFB^(^IZ?XA\%+\0=;U#2O .JW=I\/\ PG!XIE\':C>_$*;[
M3;2>%Y]!\4PW-AJU@3?7MKY#R"">!?-(!]X;TX^8<@D?\!^]^7>E!# ,I!!&
M00<@CV->"_#3XZ^#_BCXP^(GA+P99>([N3X;:Q_8'B/Q->:7!:>%IO$-N8_M
MVDZ??-J+ZC<7*1R1R(]SI5I;W$)^T6=Q=Q9DKW:'_5J=VX$L5;:%!5G8I@+Q
MMVD;3U(P3R30!+1110 4444 %%%% !1110 4444 %(P#*RD A@00>A!&"#CG
M'K2TA( ))P "23T '))^E 'B/QM^#T?QG^'Y\%W'B75O!5S;Z_X1\7:5XD\/
MVFEWUYHFO>"O$FG^*-(FCTW7+74=,U&V.HZ;;F]L=0M[BTNH0T4T3QNRGYOM
M_P#@G_\ #"YT?Q%I_B?Q/X[\3ZUXLM/B"GBWQ3<7&D:+>ZYK_P 0+OPO>7/B
MF'3?#UEINB:3JFA2>%=#ET%-+TZULX)K2Y>]MKDW$HD^V-?\:>%?"S:$GB/7
M=.T0^)M<A\-: =2G%JNJZ]<VU[>6VEV;RA4EN[BVT^\F@CW#S5A.PLS(&\<N
M_P!I/X27>D>%=3\)?$+P/XKMO&U_86/AM[/Q-IPLM5M/^$WM/ .O:G9W?G%+
MM-(\27L.C316YDG;6'CTV*&6ZFCB8 \9N/V*XKNX/C>3XX?%"3X\#QA9>+4^
M/%M!X/C\312:=X?U#P=#X7A\)Q>'T\ +X/;PSJ^MV4FB_P!B"*&YU*XO0ZWA
M#C'O?^"?/@$Z1;>'O"GCOXE?#_1M1\,6GA/XD0^'K[09+GXHV5CXTG\?B]UZ
M^U#2KRXTG5[KQ#>7RW6L>'?[-O;W1[V71+@KI\,,8;'_ ,%%_P!G6X/@7Q"G
MBJ"Q\"^)OB5\5OA-JGBWQ()] B\+>+_A-!J,FJVTUG<6R7%];ZV^G2FPN(4*
MO:?Z7DP;F7ZV\3_&_P"$O@WP1IWQ(\2^/O#NF>!M96R;1?$KWHGTW6UU&)9[
M Z-):K.^JB[A82V_V!+CS(PSKE58@ \3^+/[)6D_%'Q/<^([;XA^./ 7_"2>
M!M.^&/Q0T[PI'H@M_B=\/-(O[Z_T[PWJ=SJ%C>7>B26QU76K1M6\.2:9J4]A
MJTUK)+Y6Y#YCXC_82\&:?X?_ &@K_P $W6O7GCSXY?#GQ'X,\9R^(=7MO[(\
M<:BEC;6/PPUC6D6S/V&^^#FD6EKX9^'$]GL.A>%[.UTY7+QQ/#].R_M)_ M-
M1\"Z2GQ/\*RWGQ.L=.U#X?20WWGZ;XLMM8DN8=(;2=8BC?296U6XLKNUL(GO
M4EN;FVG@A1YHF0>/?$/]N/X!>#[4W&G>.?"_B>UTKXF^%/AOXYEL-63RO"">
M+-3ET;^T[R0[5NXX-7A.F*E@;DS7K);QYD90X!\6^)O^"?WQ@T+QO\#/$'PV
M\1Z1JVO?"GX+?#[X:Z5XW\2:O-<V5OXM\->+X_$OCWQSX^\(ZI8WZ^/9_&>H
MO-JZ+'>V5Q;:VWVZ-D=59OK31?V$OA[X=TKXC^%K#Q+K*>!/B"?$TEOX9L?#
MW@VVU#PE>>-/%7_":>)I=#\;6VB1^-+F/4O$4MU>"#6]:OK>WMYC9QKY$<:C
MUCXA_M8? SX:_ [_ (:/U?QI;:G\'Y+W2+1/&'AB*;Q!:SR:QXBC\*0^1#81
M3W3-:ZP?LFHPB$3VMQ#/!-$DT31CIF_:+^!J^,[#X=7'Q.\+6?C;4=&@UZV\
M,W6I+::G_9MS92:C&]T'"P07,VGPRWL-C-+'>S6L4ES%!)"/,H ^>_B[^PE\
M/_BW<>,;N;Q=XMT.\\8>)[+Q)K7V5-$US2K\V7PW/PP&E7WAS6[2[TG4H(?#
M>9M,O+N'[;I.N2'4K219 2;5E^Q!X%TR&71;3QMX]C\+7OPY^$7@+6/#,UWI
M3Q:M/\%]8TS5O WB.34?L27L&N*FDV^GZY;V[G3=8TN2XM;JW?RXBO;WG[:G
M[.D&L_"31K3QW#JZ?&WQ9KW@;P!J>C6&I76DZIXE\.6D=]J%BE]#9D(GV>:.
M2"^D8:;<!E,5TQD16[_XY_M!?#/]GCPOX;\6?$_5;O3]%\4>/O"?PXT:[L=.
MN-5DF\1>,-1%AHZ3QV44[PVRRK+-<W13;!%"\CX7>P / +S]A3P5KSZ[IFN?
M$#XBZAX$NA\4]6\"_#N6;0H=!^%_B+XVZ7XAT;QSKGAK4K;2;/Q#?SQZ?XL\
M36F@VFN7UW9^'++7M0@TVWB%RRKZY)^S;X01?B' -5\3VY^*?PU\)_"G6[FS
MU^;3;[3_  _X*T/5=*TB;0;RT$5[!J4L>J7<E[)!-$TI;>QVH4?+^%?[77P?
M^(_CWQ]\,$\5>'-(\?\ @OQUXU\)1^%IM8MIM5UJV\&6EGJFHZU:QKA/GTR\
M&IOIH<WMO807%W)#]G@EDB[GPW^T5\%?'^@^,=?\#?$+PUXNTWP!87&J^*VT
MB\%Q-I^G6]A<ZBEV+>2-)+BSO[:TG^PW\ :SNQ'*;6XF:)EH ^>O@Q^PA\.?
M@WJ.FZW8>+_%_B37-*\?Z3\0&N)K?0-#L;C5-(\%7'@32+.?1-!TNPL(+2'0
MYO-OKIHGU35M1VZAJ%U/,&+XVH_\$^? USH4'A+0_B3\3/"7AF[\)>'_  9X
MZT_2KC0;F?XB:+X3\<3>/?##:YJ>HZ3<7VEW^F:A=W^DW4F@R6DNH:#=?V?>
M/(B)LW?@G^WA\%OB=X#\">+/&/C'P7\/I_BK=W%QX%\/W_B*XNM2N_#MUK,F
ME>&[O7)+RRL7T/4/$<T.W38+SR[2YD(M;.XN)AL&[X3_ &Q/#NN>-+[PWXC\
M/MX)T?1[[XYKKOB;7+ZWM;#2K3X)>(=)T6[U2[:1U%O#JRZG]I7S%$D?E&!A
MYIVT =W\4_V<QX_\5>$/B/X-^(OC#X._$[P;X?U+P9:^,_!]OH&K2:KX&U2:
MQOI_"NOZ%XJTS5M!U6TCU*PMM5TZXFLS=Z/>R7[V,T7]HW!/EGB?]B&Q\0R^
M+K.W^-/Q?T3P3\4],TO3OC?\/["]\._V9\7KK3-&LM!U/6[_ %@Z.?$?@_5?
M&6D:9;:7XNO/!FKZ-+KFGJ(9O++X7W#PE^T_^SYXOT9M>\._%WP3?:0)O$Z/
M=/K$-H+9_".EP^(/$J7:7QMYK-]%T&YM]8OH[J.%H=,E6]VFWRXGNOVA_A9=
MW7@BU\.>-?"/B!/&]IH&N6-Q;>(]/ABD\&^*=+UG5M%\36+R3HNH6NJ66@ZC
M=Z?':&6XN;*RN[N.(V\#R  X'PU^S'=>$?CSXB^..E_%/Q==+XBT_3- 7X?7
M_A_P-=>&?#WA#0]&BT_3O _A75Y=!7Q5X=\+I?0)KLEAINJQ_:M=+75R[PLL
M2Y7Q!_8W^'GQ T#XHZ#JNI>(H/\ A:/Q8\/?&F6_ TV[;PUX\\+VVC6NA7VG
M:?>Q3Z=>:98#1K>YN--UB"]M+JY:1I%*;4KN_#G[6_[,_B7PQXE\8^'?C/X%
MU;PQX5M]'U#7=8LM:6XM+:T\1R20>'[FV.WS-0M]=G@DM=&DTU+M-2O$DM+/
MS;E3%5N#]J7]GK4OAA:?&FR^*OA.Z^&-_JMQX>L?%T5W(;+4-<MM2DTFYT*T
MAD@2\N=1@U.*:SN+"&W:ZCN;>:)HE:)RH!PD?[(_A:^T*:RUSQ-JVJ:GJ'PB
M\=_!W6=6TC0_"?@U-3T/Q]>RWNHZRNA>%]*L/#]EK]G)/));75G9QI/*%ENE
M=^:K>)OV/= U76KOQAX:\=^./!'Q"C\1^&/%'ASQOI$FB:I>>&-3\,?#.P^$
M[_8]'U[3;_1-1LO$?A+3TBUS3]2LIX9KZX-U&R/9VS+T^E_M@_L_3>+?C-X(
MO?B#8Z1J_P !;'PEJWQ&N-=M[C2-+TK2_'&D6NL>'+JUO)X4M;E+RWO;:VCM
M8'DOVO)8K?[.TLT0>_J_[8G[,.@^'O"WBG6?C9X%T[0O&MIK5_X7O+G5-C:M
M:>&;NPL?$\T5J(C>0CPS=:G8P^(DN;>&31&G!U-;95<J ><:?^PU\*K#6/@+
MK\>I>-9=4^ ]WXSU.WN;G6HS)\0]7\>376L:MJ?Q$98S_;4UEXONSXVTF&W%
MG%IGBF"TN[,1Q6L2#SSP#_P3<^%O@37AXA'C/X@:_?P:]X"U>SGOI-#MKB.#
MX;_$Z3XJ^'K?4KRST^.^\07UQKP^Q:UKNKW%QJ^K:>\:W-R#%%Y?V59?&_X3
M:EXNU?P+IWCS0-0\5:!HEIXCUK2;*Z-T^FZ)?6EOJ%KJ%W=0(]E%!+IUW::B
M,W.]=/NK:]=5MIXI&S/^&B_@2%N&/Q9\"C[+X3T#QU.I\06(=/!WBK57T+PW
MXD$9D#OI.N:U&^E:9=QJT=WJ"FTA+3X2@#PWXG?L5>$OBS\;/#GQOU[Q;XJL
M=3T'7?AUXK/A5(= U/0IM<^%MY>WWA*33[O5],O=9\,0&:_F;Q#8^'[ZRM=?
MF$-Q?>;);Q%=FU_9&T&#X%?$#]GN?QYX\O?!?C'7==U;1;R2XTJ/7? UKKWB
M$>+9-!T;4K>S@?5]'M=9-PBKXA2^GNM.NI=+OI;FS8K7?3_M6_LWVC?$5;OX
MS^ ;0?":UO;[XBRW>NV]M!X5L=-OH=,U&^U"XF*0O9Z?J=Q#IE]=6LEQ!::C
M(EE.\=RPBJQI?[4/[/\ K7B'PMX4TSXJ^%+KQ)XUL[6_\,Z,MY)'?ZI;ZA!-
M=:8$AFAC-M/J]M;7%QH]I>?9[K5889)-/AN%4F@#SCX??L>>"O /P-^)'P)B
MU[7]5T7XKZMXRU_Q?KQM=$T*\_M?QQ,LVK/HND>'['3M#T6Q25"T&GZ?90V\
M*,0NXN34?BW]D/0->\0W/C;P]X\\?> O'L.O>%/$_AKQAX=ET&XN_#6J^%_A
M_J'PQVQZ;J^FWNF:M8ZUX3U>]LM<TW7+74+2[+)*GE/;6^SV'Q3^T-\$?!/C
M4?#KQ=\3_"'AWQN/#DOBZ;PUJVJPVFI6?A>"WU.ZDU_4(Y<)IVE>1HVJLEY?
M26\,AL+I(V=XF4<;+^V-^S!!X1M?'4WQL\"Q>%[W7+CPS:ZC)JA62;Q#:V7]
MIW&B+IQB_M,:G#I>=5>S:S$PTL'4@AL@9P >(Z]_P3O^#WB.W^&UKJVI>,[D
M?#/P?\8/"\3MJUJY\9ZI\:7OM5\2>._%>^T"77BS1_%VJ:GXR\)3QQQP>&?$
MMPE[I*6\:1QQ^Q:9^R]\/M%^"/PN^ ]MJ?B1_#?PCO\ P5K6CZS=7ZS^)=3U
MOP7??VU;ZSX@OO*']IW^L:F)]2UR<Q;[R\N9YF 9R1UU_P#M-_L_Z;J/@72K
MWXM^"8;WXEZ=I6K^!T_MFWDA\0:;KH3^P;VVNHB]K!!KKR+#HK7DUM_:USNM
MK 7%PCQKYK\1/VX/V:/AGX=^('BC7_B/I\UG\,K[1+/QG96%KJ-UK.C3Z]KD
M'ARTF;3XK/[5<:;;ZI,;'4KZUBN+73+I)+:_F@E5D4 \Y;_@GQ\-+SX@_$#X
MA:CXQ\>:I+\0-)^+FF/IDTVC1MI$'QE_LJ;7Y(M;73CKVK'1+C1K.3P;9ZO?
MSV7AV-I+>U@\ERM=)I?[&NE:/\2- ^+!^(NOZIXQ30O /ASQ_>ZYX.^'NL1_
M$FW^'D+:=HM_=07/APMX-U>>QEAL=1U#P4VEI<6]G%,8PY8M[G:_M&? ZY\9
MZ+\.8OB;X7/CC7["PU#2O#<NH+'J=S#J>FG6-.@9&18H=0O-)5]3MM,FECU"
M;3XI+R.V:W1I!Y/X;_;3^!'B_P"*OC#P-X<\;>&]4T7P-\.=(\?^)O'MOK-N
M-"TEM8\7:IX/@TF>64QJ!)=Z+A;R+?;232?9TD,M %_XQ_LG:'\7_%NH^))O
M'GCGP;9>,?!EE\-_BUX=\,3Z.-,^)_@"RU.^U>U\-7USJ&FW6J>&'BNM4U6"
MXUWPG=Z3K%YIVK7NFRW/V9L5ZY\/OA+H/PSF\>'PS+?I'X[\4'Q9?17,@FMM
M-O?[!TOP_;6VD(6+0VUG9Z)8[5?+81%#,02/5XF1XXWC.Y'1&1CG)1E!4G(!
MY!!Y /J*?0!\R_!+]G_5O@YKWQ3UR\^*OC/XCM\5_&4_C'5+/Q/I/@_3[?0]
M8N;.WT\SZ)+X?T?3KD6<.GV=I:)!>RW4KF%9I)'F+.?+5_86\!:?X-@\':#X
MI\<Z--I?@_X?^%- \3Q76DZCJNAS_#?QOK/CGPWXDMK34K&?1KW6AJNM7<-^
M+W3I;>73_*BVNR\_=E% 'Q)I?[%?A;1?&WQ&\66/BK4S9?%:3Q3JOC;0;CPM
MX#NY+[Q=XP\.0>&_$/B_2_%4_A]O%.@7FH*CZQ_8FE:E!H2:C)*B6B6[",=7
MX=_9LBL?%U]>ZKK%S?>%-(^ &C_L]_#RSD<S:SH6A2"Y/C;7KR\D 0ZGXD.G
M^%88I+<$QV^BQI(J+*Z5]844 ?(B_L>_#Y_"W_"(R:IXG.F'X9?"+X4HS7=J
MMQ#X=^"U[;7GAJX65(2S7]_<64<NI.3MD2615$?"U2M/V+_A];6WBNT;Q%XR
MFM?&/AGXW^%=2A.HP))'I_QXU=]4\42PR"%E6XTKS6M]";9MM[=4$JRLO/V1
M10!\?_$W]C7X8_%V[^!USXMF\1_9O@5I&JZ'H>F07EK]B\5:1JOA ^#Q8>-K
M:2WEBUB/3D"ZUI\8*6\6J_Z0T;\K7@^N_P#!,/X7Z[\.?AK\,[OXB_$^YT#X
M?>"M:\ W\NLWFB>([_QSIVM^([#Q->^(?$,FJ:=)%9>,YM6LY"/%>A1Z?JYT
MJ[GT]Y @C,?Z<44 ?+OP_P#V:K+P%\7OB%\8F\7^(O$_B#Q]X>B\*/9WT&A:
M#I&E>&[._%]8VDEKX:TW3G\1Z[9REX+/Q=XB:^UZ#2"=)6\\AN/"?"W_  3N
M\)>#KKXC:OX?^)WC6#7/B'X2O? LE]K>@_#[Q2NF>%-6\82^,]4T_5[;6O#5
MU;^/;^XNI5T9M>\8KJ>JQZ+;V]M!-&88Y!^C%% 'P O[ ?P^O3\/])UWQ5XN
MUWP1\.OA]K7PYT[PKJ5KX>6XU;3?$6D7^C>()-7\76UC'XPFT?4(=3GN+;PB
MFKKX9L[F"SGATU&@45-%^PW80_!SQ#\&5^)^N?V)XABTG1KK5_\ A6_PDCUA
M_!VE:>=%L/#UX]MX7AAU#4-/L/(.G^,IT7Q?I<MI;7ECJL=[$'/WS10!\!>*
M/V OA_XYOM9;QAXN\7ZYHMQ\(KCX-^']&NK?089-%T"1M"E>_P!7U^TLDU_X
M@7MKJ/A^QU?P^OCN\UI=(O9M6>';%JMQ =JX_8LM9=%\*16OQ6\7:)XS\'7?
MC1=,^(7AKPS\.O#^L7GAOQ_I*:-XH\(ZGH>G>&(O"]Y87=M;V5Q9ZH^F)K5A
M?V<%S%>!XP3]QT4 ?)2?LD>!AX#^#'P_DUKQ=-I_P)\$^*/ _A35)K^&;6=3
MT[Q?\.KWX;:E>ZW>.N;O5$TB_N;SSHDMHAJ!1TC\M0E=)X2_9XT3X=Z_XA\9
M^#M1U)_%&J?"OP)\+;.+6[N2ZTBVTWX;V-Y:^&KR*.+RY8;J22Y$E_("5=AN
MV,1S](T4 ?DMH7[$WQXT?P-K7@N_\>:=XIGU#Q_HOQ8TSQGK6HVEIX_TCXI:
M+KSZ_;^-KKQ1H_ABSN?%T[&?^P'TKQ;'J6G/X6M9-'EBE@U*Y4>ER?LO_%>Y
M^%'C/X7ZA:>"]3N?B-XLNO'OC3XAW'B77--\;ZIX^DUC3=;T[QF7T73;;18+
MO1[ZPM%L]%L].MM%72M+L="6T%@9"?T>HH _+7Q)^R5^T5XJE.I:K\2@OBK6
M/!EU\-OB-XRT[5K;3M=^*/@1];DURTT34S:Z#%8^#&L+J:XM]+U/P=9VFK66
MGW^I))=3O<R12]9'^RU\0K&;3IM)\,> M,30?BKHOQDT:QLO%_B-+"V\4^'?
M":^$-*TZ."YTZYB308],6-Y;22"4W-^EQ=SDK=O'7Z/44 ?D*?V!_B:8)-0D
MU3P;<^.K;X@:W\1M,\:W-GH<FGV^L>(=$A\/:[:0?#&3PQ/\.;;3_$&E0P0:
MU&=&EEN9[5-365;Z5]OJ=G^S/\=M,\6:IXATO4?"6EZ'XQ\*Z'X4^)GP^TG5
M&TWP;\0(M \(2>$;'4[B&RT*UU#PC,FFF.V:Q\'W.FZ?<I#;1WEO-;Q*J?I/
M10!^25G^P_\ &JV\.>)_#6H^-AKUQXA\(_"/P'I7B:[\1F&[\!>'/@5XDUGQ
MM\.+KPOIT.BQV%UK-GXHU:-=8?7;>_&J:190QO="<,).K\=?L;>/_B3ID-KX
MLT[PO)=S?&O1?CCJU]I7C+7]/O-1\2Z9HFB^']5T:;RM.CT\>"/&VFZ*+/QC
MX8AT^&WO;+4+J&)W8+C]0J* /S<\$_LQ?%SX<_%7Q'\3_"FC?"BTM_%?B37/
M&FJ>"'@M[FPM_&?B&SM;34_$.D>*KCP^?%6EM+):07;Z3;7PTN>42B2!-ZLO
MG[?L,?$:X?4]*U"[T2^\ -9_%V'P9X!D\5ZG%9_#34_C7HVHZ1XZ\0^%_$,&
MBQ>)+S4;N+6]8&B6NMZA>Z;X82Z_XE5LKY8_K'10!^4#?L5_'*Z\%^,/"^L>
M,_#_ (CUGQQX:\*> =;\>>*6MM?\3CX9>"+'4K3P_P" [:&[T7^Q$CCN-9U;
M6#XKATVT\30ZY>_VN+N:ZB05M^%_V-OB3X'\=W/C7PG9_#NWL]4L-!@\1>&?
M$$B>+KCQ'JV@^![7P#9^)KWQMKOA^X\6Z9KR:%86*SW.BW]K;W=[%/?R6_G7
MEPK?J)10!^8FO?L?>/?$.E_L\Z3=>'_ ]O!^SAKMEKG@R6W\8^)5;5H-.C22
M/POXTC.GE/$/A._U*VL-0U#2$-G!-+I]BS([0D'SFU_X)]>.;77?B%XCDN-(
MU"^\?^'?&_A8R3>)Y;75]$TSQWXLM?'&JN^OPZ!)>^)KFR\26<,NA7VO_:-1
MTS2XX=)6Y-LK+7[ T4 ?E]JW[)7QQU+7O^$YM-?\/:+\6(=?\(>-+3XJVFIF
MXU6'Q1X6^'T/PQG4^%KC11X5?1O$WA>W@7Q'IDUA<VES>Q1W5O!#<112BI:_
ML5^.;7P=XD\&G2?"<]IXV^&TWPT\7:K)XY\42:[J\5_XHU;QIK?BR\O[C3IQ
M<:]KOB#5'%\JI#;K8@001Q*D<8_4RB@#\U[']F#]H:+XG>+_ (HV/CKPSX1\
M7>-K#P_X5DUW18+;;X6\"VVN:9J.K6%II%CHNF6GB_Q3!8V$FFZ'XK\:?VKJ
M.GV-Y/86\L%G#:Q)^DR A0",8R , < D+P"1C&,8[=AT#J* "BBB@ HHHH *
M*** "BBB@ HHHH *1L[6P"3M. " 2<< %OE!)Z$\9Z\4M% 'SG^TY\$=4^/G
MPB\3_#[1/$D/@GQ5<SZ/KG@;QS_9L6J3^#/%OAK4+/6M"UNWM)G1A*-2M!9Z
M@;26*6?0;J_L4E!N-I^1?AU_P3B'PWN=<@TGXCQ7'AZV^)WP%\9_#319] *G
MP#H/PS\9Z%\3/B;I$%X+YFNM0^,?Q"L+[7]2N1#';Z)*-+>UCFDMG#?J-10!
M^?GA+]CGQ7I&I:&FO^,O"FJZ%X'\=?M ^*/!L%IX8:VO)=,^.ND>((FM-762
M22WLM4\+ZMKLJ6M_IPN9+S1D^SM/#(Q08WB_]B#7M5^!/[-GPVT+QE9GQA^S
M3JECKOA_4]5N?$VB>%?%-[%8:IH]W9:PG@[5].\1:?"+'43-IM[8W$MS:21X
MVAI92/T<HH _*OQ-^P#\0-=OO@YHFD?$7PMX/^%'PW;X5ZM-\-=#MO&D>@:'
MXD\ >-)/&'B.Z\)VJ>)(E\01^/S/]AU+5/B+)K>KZ4;=Y]-V_;9@/3?!_P"R
M5\3=+\)_#SX9>+/'/@+7O 'P6^*_@+Q]\,[JP\'7EIXIO=#\$:WJ.K1:9XT-
MUJ<^G7'B)H;NVM]/UK2S'''>6\FJWZ7,Q%O+^@]% 'P[X@_9+UO4/V:_B7\#
M]'\9V%AX@\8?$3XD?$GP_P"*KO29GT_1-6\9?%S6?BKI%C>:;:WD5Q>6>ERZ
MN-&O;BTN;"YNX[<O&BHP)\[TS]B'7K3XX^(/BGJ\_P ._&.E^-O%-G\5]:L?
M%2>.+B\\,?%>#P%:^#Y9/#6C6GB"+PCJ7@TS6BSVNFZ[ILNH6=C=:C%]LNKB
MY#C])J* /S3^'G['?QD\ 6'PXU2+XB^#Y]1^&GQ5UCQCX>^'EIIWB34/ ?AC
MX>>(O# \,>(_ASX'U3Q'K$WB6P^VI!%K7AR74KHZ5X1U*XDTO3K?^Q[>)C[)
MX_\ A-\;/C9\"?".D^*]4\&^!OC%HWCCP?\ $8QVL%YK_@JWU#P;XJ36M.\.
MZHD=R+Z]M;K2(HM,U6YLKR6.:9KB2$O'(I'V110!^?FO?L1?\)3 ;;7?%Z+%
MJ7QE^,GQ3\0SZ%IQTS49K3XO_"KQ[\,KK1=*O'NI;BUN=%7QL]]:ZG)<)*+#
M3K6PBC5A\NK^R]^R=J_P.\.^+-&\2P^ +[7-7\#^'/AS8^,_"LWC:YU/6?"_
MA/3=:TW1QXML_&&L:E:6DL2:JUU%IOAN.+2X[JZU'*"-;3'W=10!^7%]^P5\
M0TT>+P3HOQ.\*1>"?&?PP^&'PM^+DFJ^$9)_$8TKX6ZQ?ZIINI?#2>TNXK/2
M+S58M3N+2XCUE;BUM+B&#41:W4T:H-36O^"?M_K.D^)M*;XBVEJFL77Q=U'3
M'CT(S+I^H>//'?AKQUX9EN;=[F.WOTT>\\,VMEX@,ZM+JUI<W:6CV@-NL'Z9
MT4 ?EMXX_8&\??%KPQXPU?Q_\2O">E?&+QY\2OAOXHUS6O!OAB[3P?I?@3P?
MX8'PS\8_#[PS8:E=)JUM;_$_X67OB/0=>U&]N9Q8ZEK[WMC9HNGV@7<^&W_!
M/V7X<:/9Z-;^/X-7@T/XQZEXI\)&XT>:UF\.?!O2/ .O?#_X4?".WN8KV29H
MOASHNK0VT&KKM?55AFDN8$DN9V?]+:* /QW_ &@_V)?B+HGP6\%:/\*_$6K7
MOB+P/\,_V9_A6+[P3HUI9>*=.A^"WC?1M?UKXI:380W=G_:NN"QTZ4:7X?MD
MFNWOKL3P36Y27/H/A#]G7XN>./V1M%^&]UX.\ _#?XA:)X\UG6_"^L>)[KQB
MFNZ=:SZWJ&H6'Q2>\\.:S%XH\,_%+6#J,^LZI;+K$EL]X9M)U"!-&O)K&+]0
M9D=UPC!& )1\;MLG16*;D5P 3\K,!DC\"%64'<H4GD@$'+<[VP,JN\_-M#$"
M@#\T_B5^PO\ $'XAVWQ!TS4_BSI^JV/B^Q^ ?BBUU/4--U?1_$C?%SX&Z=8Z
M2VKZ[J7AO4K%+SPEXTM;,W&I:;8166IZ?>7#R6MV3# R^8ZM^R#^T%I?Q$^'
M:_#V+X/^#Y+_ .%7[1&A?%WQG'HOB?Q;H-SX@^,_C+PO?R:OH+>*=2NO&8\7
MWVG:5J.IWMQK6KZIH4M_MM+R%+(VJO\ L!3"&+#@;<>K!L\] ./ZT ?"'P?_
M &2?$OPG^+VE>)-$\6Z)I7PMT+X9Z3X!O_"VAPZY)K_Q0N]'\,>'O"VDZO\
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M;2M0MKBPU+3-0MK>\L[J"2*6)< F7"4=7%JW=#C4A+X9)^C/1****DL****
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M/[2T[_G_ ++_ ,"H/_CE>:_\**^#/_1*O '_ (2^C_\ R'1_PHKX,_\ 1*O
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MM+3O^?\ LO\ P*@_^.5YH/@9\&#D#X5^ #CK_P 4MH__ ,A4'X&?!D?\TJ\
M_AX6T?\ 7_0ZQC9J]WN^GF^]G^!T:=-3TO\ M+3O^?\ LO\ P*@_^.4?VEIW
M_/\ V7_@5!_\<KS0? SX,-G'PJ\ <>OA;1__ )#I?^%%?!G_ *)5X _\)?1_
M_D.JLN[^Y?YB;2T?Z_Y,]*_M+3O^?^R_\"H/_CE']I:=_P _]E_X%0?_ !RO
M-?\ A17P9_Z)5X _\)?1_P#Y#H_X45\&?^B5> /_  E]'_\ D.C3N_N7^877
M?\'_ )'I7]I:=_S_ -E_X%0?_'*/[2T[_G_LO_ J#_XY7FO_  HKX,_]$J\
M?^$OH_\ \AT?\**^#/\ T2KP!_X2^C__ "'1IW?W+_,9Z5_:6G?\_P#9?^!4
M'_QRHVU?3%)#7]F &569KJW1!N!((9Y%5^<*0A8AB 1UKSG_ (45\&?^B5>
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ML T@B#_>0L0?NM&) ?FVJ=^P#.20 :CN-3M;*"6ZU"6+3K2W!\^[OIHK>UB
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MKRWC)7C)<VG,G9/1VTOW8?&4,32]M3DG3TM)-N^C?PVYDTEJFD_UZHD $GH
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MR.F1CH3C(Z\@8_6I*P4D]OR:_-(WV(;>WAM8(K>WBC@@A4)%%$H2-$'1550
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M>*YK]D'XB_$SQSJ?QOMO'GQ+\/?$.S\/^+_"X\&7>A>'[#P_ WA[Q'X'\/\
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M./HXM_--6DNCWOC5H1J6E%\LDK::-ZWOS)>JL[KNMK?!'['_ .WGX _:@O\
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ME+69T"G\N?@_J7@'X9_&?X-^)/B5X?/@'POX%\+_ !1^ =OK'B7Q%<^,=&\
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M$7*M#,DJLCQ2*3NC92&5B&R":_)SXV_\$Z=9^&_C[7?VH?\ @G'XPTK]F?\
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M9-?FU^WG^QGKWQI?PC^T-^SAK]E\*OVXO@!:7^I_!#XG,D<&D>,-)D(N=7^
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M6JLT]4]-EV_S.Z51)-.,URJ'_+N5[5)04;:.^M1<UOAM*_PLLT5 )6)Y V[
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MBDBGUJ#2VAD^>*/3XXM^U%4?H.MG&LC2!F^=0KQ@1B-B,_O"-F\R$8!=G).
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MVL^++3PIXC\/>*K*VMI9[%?!,]XFJZSJ4$5Q]KT<+>:?:312*U?6WQ=_9T\
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M3/!%]XP\0?#]UU2"_P!%MM*^(L%\;W3+5H8MD^@VT>J3C1D1E-E:^3:I(]O
MB#S3_@H1^Q7H/_!0+]DWXI?LH^(O'OBKX:V/Q(M-)QXN\'3*U[I%[H&I0:OI
M?VRQ=XK:_P!$O[BU6VUC2'(CU&U9DE? KV\LIXKDHK-<5&4G*FG-<LH_ N=I
MP24DI<S2NYN/+=NS/S3C+$</SQD8\+93B,'0IX:I3FZ]&M1JRG3QF+E2HUHX
MBK4G"KAL'6P>%J0<:*]OAJ\E3BI11]K:-KVG>(M-L]7T2]LM7TG4[07NFZOI
M5U;ZAI6H6LJ[K>ZL;^SFGM[NVF4AH;BW>2*9"'C8@@5^1'_!12Y@\.?M;_\
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M<SQV/C@<OP5.O6H4GB,PQ:PN)CA\'3=3FKU)0<:=.G5J2<N6Q^LZSCRQDH4
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M'<ME?>ROZV"BBB@84444 %%%% !1110 4USA6/7"DX^@-.IK$*K,Q 4*22>
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MJTL*NEM)=W3>8\JVZNS6L>[R;<L?+C4$@^#?&CX;?$/Q=HGP0T3P=%X(L4\
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M&C DAAN!(P2#R"00,$]2,4^@# Q_G\??UHKB2M?U;^]G7;7Y6_$*;PX/L?\
M)_\ UTZD"@9QWH:ZI>\OA?GUU%)-V7V7?F[VMI;Y[GX^_P#!3C3M=^ _B/\
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MK-K%=Z5XB\+ZQ8:YI&I0SIYD,UCJ&FS7%E<0NASYJ7!"L"A3<"!TR.Q;;N)
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MCFKX9SG&I1DH5$K2YKJ,H]5>-]?Y7;1NVVA[9;CS [N&4^9D YC8J&5U+HN
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M5[X,L-2O-*U+P!\.?#UQ<V^E_P!N:38-JGQPMI-9OK**>.;35UNVTM'O$O3
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MS5(ZTVDUJKMI7Z;;+1:K4B4(S^)7NK?U]Y^0?B7_ ()&?"?PGX@U/QO^Q?\
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M.*=2$ ]:F45)6DKJZ?S0$)@C4'^$,225W!LDY/S [LGN<Y/?->*?&?\ 9R^
M?[1&B-X<^.?P;^&WQ=T@1>7#9^//"&A^(Y;$'<?-TN\U.SFOM)N%9V:.ZTRY
MM+F,DM',K$FO<-JGM_/ZT;%Z[1GU[_GUJX2G2LZ<G=;)R:MZ..J^6G=&<Z4)
M[I7NFVDKNU]^CWZGY%W7_!&']D;1III_@QXK_:F_9E2643R:=\ /VF_BGX0T
M5IR2SRC0=?UGQ1H\:R'R_,M[:UBMG$4:I;HJX*'_ ()<>+D8VMG_ ,%)O^"A
M%KIV<"Q?XJ^$KF[,1QA)-3N/ ?VMV*C'G?+(<YW$\G]=2BD@D D=,\XQZ \
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MM%5%**45>RT5W=_>,****8!1110 4444 %%%% !1110 4444 %%%% !1110
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M]RRB92]J"XR?"'Q?\%^+OA]X>^)]GXBM[#PCXB0KI6I:Y<6UB;PR:C/I=@)
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M/+HGAWQ#\,#X,?P]JF@:?HLUKK7V?Q.LNO1ZP=?#V%DUC%'H#M;1!?7OCO\
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MWXC>+Y_A_P"'[G4=36X&F^$(+?Q"UNFH2:Q-+%:Z/J$&IOC9Y:>JZ/\ LJ?
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MA=:OK6H^+]$B\->*+?Q'>/M;6=/UK2;>V@N+&\@:"62T20;)(HBO3Z5^S_\
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M#T'3'X>GTY-)@>@_*EHH *3 QC QZ8XI:* $"J.@ ZG@ <GDG\3R?7O2T44
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M?IOD>H_,49'J/S%?F,/^"Q/_  3 [?MP? G\/$=R??\ Z!WM4H_X+"?\$PF
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MW/\ PD-WUQ_V#_QYH_X>]?\ !,_M^VK\#O\ PH;S_P"5YJ98O!0WQN$5]O\
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MH_,49'J/S%?GT?\ @JA_P3T7[_[6GPC7C<,ZCJ&=G3?SI@PI/ 8\$\=::?\
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M2E&G*,D^:+]I-V:O9VO9V:VV)H[&S*DBRMCZ8MK7';O@9ZX_7@#F=+&S#?\
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M_I]4UO?^]Y'V>"I\O+[.I6AHN;][.?-JK7YGHU;IO<M?9[< #R4^IM[;IVX
MZ8Z_I5B&TM\?ZFU]L0+Q['Y??VSCJ:;5F#HWU'\J\K$Q<K/VE:/)=:5JFM_^
MWO+\3Z_ MSY6Y3]QQ^V_>O9W?8<+>W! $5L>0<?9TY QV Z=1CO^)J;R8/\
MGA;Y_P"O=,^W\/0XR?I0O4?4?SJ>O)K=W.LW';]_4]?YCZ_"<LY4[Q:M9/WY
M:W:U>W>WH/AA@QGR+;([?9USG&!_",#/MR>>N*L>7'@XBAS[P#CKVQ^?_P"J
MDA^[_GU-35Y=;W_>YJJY?=M[>J[WUOK+0^XP-Z?+[)\D='*+2FI/N^9.UDK6
M0](XRA_=0%2!D"$*2.PW8P.<\]:MP0Q<9MH<<<X4=B?Z@=?7@#%1Q?ZH_P#
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MEOKW3$E>"S6U>ZLES#<-*9A%]CN0ACMIF81S7*F*,L^0;5K\;OBK%I]M8?\
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M#YE*7L_9U%)*46H.:JRI6<8J*IQDE[TDXO;X1>/4_P"$C1_#4R2>$;A+7Q'
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>W/TZ&%GR0YZD7/DASM48).?+'F:5]$Y<S2Z*R/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %? G # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **.G6DR..1R<#D<G&<#WP"<>G/2@
M!:*:70'!=0<J,%@#ER0HP3G+$$*.Y! S@T@DC+!!(A<KO"!UW%"VT,%SG:6^
M7=C&[C.: 'T4A90 2R@$$@DC! &21[ <D] .: RD!@P*L 5(((8'H01P0>V.
MO:@!:*3(R1D9&,C(R,YQD=1G!QGK@XH#*PW*P9>1D$$9!((R..""#Z$$'D4
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M$U_PS8+X2'AG78/ >I71\&ZY8*AO$TO5KC0KZ.\V2F*XB*,3]4?%WP+KS_\
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MJ?'G2_%O[4O@;Q;X;O\ _@FM\%=0_8;^&VI^*]-O[;3/BS\1+SQ'!/\ $?\
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M?\0/C#XB_:L\3Q?#GX%_!O1UT_POX^USXA:?:Z[JWC?PAXM7Q;J=MH'@*_\
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MV21<C>6/.S.,^4T@X)( D0, .IR#3=R*4#,JYD#E5*;45A@! NW;@X=G8,6
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M96# 2,SIN,EN1M.YFQG&*_/G2/V__!]KKNH:9KFC7>I0:QX^NO#WPX_X1F"
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M1DXUN1TLQM.47&I[D)3G-4JLH0DJ55T_MHH 0(QUD?S6(C0LP4++++O7,@=
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M4DB(98@@D$5)NCV*OF8 (5#)(K>65&U'!8DKG)&78MD@+UQ7AWP-^+UA\7O
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MU@N!X@N+?7H=.B\1WUM--J%_)8:7J>H3V>G2R9M%CA18SRL'_!/CX>:)X?\
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MQ.*EF->-3'X6GA:]I+G>'C+%5Z=*HG"Z4*V88^3MR.+Q%3E:5243X L_V!O
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M"I.;I\49O!U(>SG[:>"Q/-3Y\7-04:U"KRJ,\=C91M;E6*JQ@HJH[?F_9_\
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MO;0;DE)1;M)IM+75+=[6_$=1112&%%%% !1110 4444 %%%% !1110 4444
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ME1J1K5:$*+@LQQ>-RNI[.<W2QN5YEAZKI2PDV_V)\Y%P79@&<)DQMD.S! I
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M7(49QDD 9P3U)'7'^1DTZH+B3RHFD9MB+EI) ?F1 I.44J^]RP50NTD[N.<
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MJ,/>P]*@DYUL)7A)\F&IQI\].<J<6HT)X:[YOTJTS]FCX5:?X8\/^"/[+O\
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M,C.#Z@C\O4>XR#V)J)[B*-Q&S?,Q"@= 7/*IN)"!V&65&8,R@E0<5^=.M?\
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MU.!W_'I5*?4K2VA^TW$R06P"LUS<21VUNFZ3RE5YKAXHU=I-J*C,&9G7 YX
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MMI([NQE26%KF%TN8&2:#RQ(;BW(DVS0",^:TJ;HPOS;AUJ42I)'O F"(#(K
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MK:SOL[Z6=GW1)13$?>N[!7DC!Z\''Z]:?2VT+:L[/=?UTO\ F%%%% @HHHH
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MMX?_ &6;']CT2_$?6_@WH.K:+KO@F#Q%X\N]3\5?#C6/#5]!K'AO4/ WB?\
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M6_\ Q.;;PY+I=_)!(GFM7]6LMJ[9_>+EE&2%,99U;/S[#M:-EPCH5)9!C)J
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M[HX#A^5O^[6X8Z[_ ''[;>+O /[-?C#XTCXYQ?M)Z!X>\41:=I]B=,TSXB>
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M0DVFTM(NS?\ 7_ )]I3YE!SC&;VIR?+-Z7=HM7=EJ^R)Z***184444 %%%%
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MV<!MS%?6EJ8/M$GF37T+R1RF,*K7"ALQ*:^EJ "BBB@ HHHH **** "BBB@
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M_AE_ZD6J5_91^V%C_A5N@X_Z+1\",_7_ (7'X'_S]*_C7_X,[?\ DM?[:_\
MV3/X9?\ J1:I7]E'[86/^%6Z#C_HM'P(S]?^%Q^!_P#/TK^&/'#_ )+7._\
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MAG_U&/$5?4^#?_):\$_]C/$_^[)[?BU_O><_]B[A_P#]9;A@_P [4?='X?\
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M1X>NUM8_#VD[?$,=GXLO[O3_  K>7NDW*^+&MI8-0U-T4P"351>0W+"X62.
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M -)Q7^OM_P $D_\ E&%^P3_V:S\(?_4.TVO\@F\_X\[C_KG<_P#I.*_U]O\
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MLC)&1$]>G:#K^F>(["QU?1-0M=3TG4[:*_T^]M65X;FTF52DL3ACO5T.\-@
M!E7&X$UK3JTZJKRISC.*E0UBTU>]FO)IZ:I'D8[*,VRV5*>/RO,,'&2FD\3A
M*]!:K1_OJ=)M-)N\>965TV?Y&G_!7S_E*!^W1_V<)XQ_]&0U^<=?HY_P5\_Y
M2?\ [<__ &<+XQ_22'^5?G'7^BG##OPUP];_ *$N6K[L)0/Y:S=)9IF%I1E?
M&5W>+NM:DM&^ZZK\607@)L;T#_GUN/\ T1(!_.O]@S_@EHP7_@F]^PYE@H/[
M,7P@SGG(_P"$/TT$* 0=V67!Y],9K_'RO"PLKW S_HMQGU_U$F,?C].W-?[
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M#]#_ "I:1NA^A_E43^"7^%@1GI_VU7^8K_,>_P"#I/\ Y2Z>.?\ L@/P*_\
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M&E?N9_P;?A6_X*^?LW @EET?XH,.P _X036023WXSA>W7OQ^D\<I/@SBB_\
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MY/\ U9XXG*G%<]/@N49J:E*SXES1).+LUI!WT:6BO=I'^4;_ ,%)_P#E(O\
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M^S</C/\ ^C/ ]?SDGI^*_P Q7]&W_!J[_P I;-%_[-P^,_\ Z,\#U^D>(?\
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M$J2*FWZ<H 1NA^A_E4;?>/T/_H)J0]#]#49Y<X[@X_[YJ9_#/_!+\F'7Y/\
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MI/!)G;(O_"(Z:<'!!Z@="*_Q^[X9LKO& ?LUSZY_X]Y.F3SGZ_4X.*_V$?\
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M_.6,H( ..0N?H#P3\=?A=\+O'?[1VC^./B!HOA+Q#??$[[9I=KKL-W!++O\
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M% !1110 4444 %%%% !1110 4444 5YGVD*K,&RF=@WL S<9C R58(P+ [D
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQF4X'[#W[0; 8P?[<^$([#C'_">]NGX4G_#4/QG_ .C'/V@__![\(?\ YO:
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MC6"XD>0@'Z"WGQ!_;/T\VR7_ ,+OV=;&34+M;*PBN_BUX@MY+^_=2%L;<R:
M/.O" <(F]L *%SBK=SXQ_;:M;:XN;SX0? &"U@@::9Y?BAXD$>U06=96?P\J
M;1R<N2I)XY-?"FB^&_CMIGQDM/B+=_L__M2ZKX.T6?PSJ7AGX=37?P?^PV,O
MAS1M3TU$NKNZ^($LAO[^XOOM5W<*?,DD5&=R43&'KG@G]HO6/$UOKEQ\*_VT
M1I45YXBN+'PW'XP^%OV71-.U273=4\.VMIN\;%+_ %[1=3AU72KR\N5DLY-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9EUK6XVTV7P<TKW3N@T2/4W.)N: ./\ "7Q+^*EG>6-AXF_:D^.W_"'6VC^
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MR,P8FOMJO%/="BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7&"",C&#G&*O^S\?_P! >*_\)L1_\I#ZSA_^@K"_^#X?_)'ZI45^5G_#[/\
MX)/=/^&]/V>LY48_X2NYSE@&4?\ (/Y++\P'4KDC(R:<?^"V/_!*"-]LG[>?
M[/D; *Q63Q5=1L%?(0D/IZD!R&"DX#D';DBH>!QZ5W@L59:_P*_:_6BE^(_K
M.&T_VG#Z_P#3ZG_\E\C]4:*_++_A]E_P2?8NJ_MZ_L]%DQO_ .*NG^3=]W>?
ML7R;@#MW8W=LTG_#Z_\ X)1C_F_7]GC_ ,*^4_I]B/\ GCTK/ZMC/^@+%?\
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MX+\)W5S<R-/<W-QX=TN6>XF8 -++))92.[L%7+,Y)Q7Y[C_@LA_P2Y[?MR?
MCC_J:9OY_P!FTO\ P^0_X)<GK^W'\"6/;_BJK@=>W&FU/M(]TO\ MZ/_ ,D:
M+(\[D],GS5^F7XU_EA#] _\ A / O_0A^#O_  F=(_\ E?2?\(#X$_Z$3P;_
M .$UI'_ROKX 7_@L?_P2ZQ_R?#\"^/3Q3<<?^4T8_*D;_@L7_P $O6.X?MO_
M  (P>,MXEN6.1QU&GCMCM^='M::UE.*7^*'ZR+CP]Q#/^'P_GE5_RT<JQ\Y>
MMOJ>RZN_5'Z!#X?> VY_X0CP:I]!X8T0]#P<M9J??H,=O6E_X5[X#SG_ (0G
MP=GU_P"$8T//Y_9?;]*_/H?\%B?^"8';]N#X$_AXCN3[_P#0.]JE'_!83_@F
M$P!_X;=^!1QQG_A);@9P?3^S^,8Q^?KFE[>AUK4X^<ZE-+TOS[_\$UAPMQ74
M;4>$^)]KW60YI5O_ -NT<%*2]6K?.Q]_'P#X#!Q_P@O@TX[_ /",Z.,_@+!A
M^1-)_P *^\!$<^ O!IR<G_BE]'()Z9_Y!_)KX#7_ (+"_P#!,/&!^VW\"F'3
M_D8[EOY:<<\_K3O^'PG_  3)SD?MM_ L#T/B2Z&/P_LX>_Y\T>WPO7%X9>M:
MFEZ:S-O]3^,=_P#5'BMKIR\,Y\W?T_LW]3[Z_P"$ \"#_F0_!H';_BF=('_N
M/I?^$ \"_P#0A^#O_"9TC_Y7U\"_\/A/^"97?]MGX%G_ +F*[QSWS_9I%)_P
M]^_X)G$Y7]MKX'8/0#Q#=$<]A_Q+??I[TOK&$_Z#<)_X44O_ )85#@SC.3:_
MU.XOT[<*\0/\LL9]]_\ " >!?^A#\'?^$SI'_P KZ/\ A / O_0A^#O_  F=
M(_\ E?7P2/\ @KU_P3/(_P"3U_@>3W/_  D-WUQ_V#_QYH_X>]?\$S^W[:OP
M._\ "AO/_E>:F6+P4-\;A%?;_:*2O]]1&JX&XW>W!?&+[?\ &*<0Z_\ F+/O
M7_A ? G_ $(G@W_PFM(_^5]'_" ^!/\ H1/!O_A-:1_\KZ^#_P#A[S_P3/ _
MY/2^"'89_P"$@N^_/7^SO0]_Q[T?\/>/^":'_1Z7P1_\']W_ /*VI^O8!;X_
M"+_N8H?_ "XJ/ 7'LOAX'XR>E].$^)'^64,^\/\ A ? G_0B>#?_  FM(_\
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MCH\VP$6]5?%8=?=^_9K'PO\ $R2T\./$":_N<#\5R7_JC^Y),^XV\ ^!0./
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M*5GWM9] _P"(2>+'_1K/$Q_X?#[C.2^]<-I'Z&9 ZG%)D>H_,5^>P_X*H?\
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M^UG\)&#' ,>JZC@G., C3"&)(/ YXXS@T'_@JI_P3R4$M^UG\*% ."3J^H
M\<$G2\ Y."#SG\,VN)>'7JL\RAKO',L#-?\ @4<4XOY/RW+7A#XLR7-'PL\2
M;/:_ /&*>G>W#3_,_0@D#J0/K29'J/S%?GR?^"J'_!/0XS^UE\*%)(4;M3U$
M[CC)4?\ $K&2!DX'. 3TYIG_  ]1_P"">6"W_#6WPEVC&3_:6HX&XD+D_P!F
M8&XE0,]20.><I\3\.+1Y]DR?9YOEL7\XRQ:DOGZB?@_XOWT\*?$IKH_^(?\
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MMP ?H<'T(Z<?A:^PV@5?]"MA\W7[-; 'KQ]W.#Z'//UQ34ZGZ?U%79/]4O\
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IZG'Z=:7;!_SR3_OA*3_/^<T5Q.?G4_\ !L_\S['ZL^DX^7[J'^9__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image_015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %? G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/Q5BT'6_#_@+Q-X/M?BQ8S>--(@\$^-_^$)F\5>$;SQ-^<?[<W[2OQD^*_\
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MDT7Q#^T+\&/A1X1\1:]XI^"DO[1GPY@\*>&"WBLQ^ /"@4?(00#ZLT3]M/\
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M02>$/V?M*\8_"-X?CIXT\">+/'J?#3X6_#_]F7PSXJF\!1^!M%\(_!D>$)O
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M+V6XNK!Y9/PP_P""?W_!.;_@GEXU^/'_  54T?Q?^P=^QEXJTOX=_M^MX+\
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M@;^T3\,-&\4^&IM4U5!\0_A?X6\'^-?%5KKB^$O'_B[Q7X2\*>"[+PC]?T4
M?FMJ?_!-CX":M^SE^T!^SIK?BSXJZ_=?M5^+[3X@?M&?'#5_$FA7_P =?BOX
M_&H>';B'Q?K>MCPQ_P *_P##<8A\"Z!X:\(^#_"?@'PM\)/!/A+2XO!7P_\
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MQ_%7PCX-'[/.G>'_  9/KG@'5C\/M;@_X2GXM#XK>/?)^'C1>$)8YO""R?\
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M^%OL_EVU?45% 'YG?%W_ ()H?!OXI>,_V</BC'\0OCO\-/BC^R#\&_$7P;^
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M/1],\/'P_ [0>*M*^)FNKXVB\1S>*HKE/*B1;:U4Q-\C:+_P2J^&MGX/\,?
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M%\.+L@,2REFC)/D?Q)_9 \;>-_&?C?Q3\//V]/VV?@%IOCSR[CQ/X ^&>O\
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MB^%OQ?\ C1\(OCGXF75AXJ^%'A#XS_#232[<Z&W@GXE?"[XY:3H.B^.OA/\
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MP9XM\+^,S:7,7Z26/P ^"W[%'_!3O]BWPA^R;\,/ _[/W@?]I7]G?]L#PO\
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M7Q7XS\71^-?#<7C&-EN%E\ZU^SM^S%\"OV]?B7^W]\8OVM/A=X<^.?CCPO\
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M@S\%- U^&Z/P&\WPK\/K?XE>.[SX:P^#?&/C#XM^//$'CGQ5.[_\(D8/U9\
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MLL^$?^"K'P5_9E\ _"7PY\(?V6/C1^Q+\6?B?\>/V4?A-IFA_#;]GCX\>/\
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MU;69_A?\:/!.M^'8;?XA^#/C/X;=?!H_X3&T\6*$7X5?#*-(8SX4E) .8O\
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MH_$$&LZ#\%O&&B_L\>'OB48?"^B^+YO#/@Q/CGXP^,J^%?"^B>&(40Q6THE
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M_.5;CTGQ%^T1\<9OV9_V0= \.>._BIKGQ&TWX;>)_P!I.34/A7I7Q;^-6O\
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M28PHC$BYR" #G/4=<=><<8Q328^93*B,Z!/*:15Y&T9W$CK@?B<"ORC\$_\
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M"37_  UX>\0:'X7G^!'Q7^*_@G]IT>.=?\/>#H_@@)9%(]7M/^"TW[*^LO\
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M:1XN^ 6B>%/%OC_QIKUMX7^ OB7X4^%U_MZ6%K.:VB@C@?I/_!,C]BK1=/\
M >CZ+\(M9M-%^&?PF^-_P+T&P'Q?^/,^G:[\(?VD=7UO6?CA\./B9I;?$68?
M&7P]XN\0:RWB9+?XN2>-AX3\:BV\9>"H_"OBGP]:WD(!X_XV_P""N7P1\$^?
MH]K\'_VC/'?BIOBK^R=\%_#W@CP/X:^&+^)?%GCW]L[X7GXM?!'1-$D\0_&/
MPGX8T.!]!*^%O&WB?QAXL\'^%?!WB]3--._@AF\6KXK\=?\ @N7\&_@WK'[7
M?PRTOX#?$CQG\=?V3/V?/CE\>]1^'5G\:_V.-3M?%.B? ?6_ ^B>,M)UW6OA
M+^TC\7_&7P-DA/CK1/$\L7Q?^%7@SQ=/X,T3Q>?!/@CQAX[\,-X$F^N/A_\
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M\:>$/"&B>(+GQ[X[\6CPW)XGC[SX:_\ !6?]FCXDZO=7&G:;\6_AIX&\./\
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MU^T%^SKID?AOQ?\ $KSK;P?X7\6_";]FJ6%0GQ7\;>-X?G'P1^Q-XC^*NK_
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M?#$7[5J?L\'P3XA\8?%OQ3'XP^$'Q9^*ESX+_:A\7>!O!_@GX@KXC8?M,_\
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M?V:_A7X8\-3^#M?\:^#8H/"WA'XJ_&'Q5>1ZY+%?VWA/QKX8\6^#K>]\1?\
M@K)^R;X CU5[:/\ :/\ B1;:-\7?A5\$-<OO@W^R+^U3\6-)T7X@?%<Z+)H.
MA#Q#X;^$$WA;6M;B\/>(=!\07GAKPMXE\4>,XK?7O#-K!X,O?&GC#P5X1\6
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M<+XE^V=#_P""G?[&'B+5-3T'3OB#X_1/#_PT\=_%?4_%/B3]F[]I;P5\.9?
M7PC?PO%\5=:T3XJ>*?@WX:^&GB+7_AAK/C;PEX8\<>$?#7BVX\9>%/'6O0^
M[KPQ;?$%3X2JAXB_X*E?L:>&/#\>MZUXM^,5O=7&J^/](N/A]'^R5^U_??&O
MP_J/PM\(> /'OCA/'?P*3X'R_'#P#_PC/@#XH_#'XE/-XL\$^&$?P'XY\/\
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M\4/'O@?Q/\/?@7XG\<_$+Q7\#M>OM.\>?&'QO\8M>'QP^&'QIT+]ES_@F/\
MM!K\/?A[\*?AVO@30_ A\4_%K]A.6#_A-O$-YXU^.'Q>?PGXWF\#_ISXI_;P
M^&*_LN?M#_M,_#S2/%OC";]G+2?%=YXM^&GQ"\$_$W]G7XEV'B'P_P"#='\=
M6O@[QCX"^,'P^\*_$CX=7?BKPMXB\/>)?#$_BSP28IO"&O>'O&*BYM9(I%[3
MQG^W5^RGX \'ZM\1O%WQ0.A^$- UCXZ^'M:UN[\&?$-8;'5/V:O&3> OC=;S
M,?#'G/\ \(CXITN318-D;CQC/"Q\#-XJ$D2S 'Y;_P#!2?P1^T-XH\3?\%#/
M"7AKQC^V'XV\ ?%S_@D#\=_"'PA^ ?P^^$O_  L?]GSQ5\=$^''[3&@ZYX1D
MUS0?@AXF\2>&_B[/;Z_X!N_!T9^*_@WQ;\9/%>O1^"-/_P"$WL?"5OX/\+>=
M?M?_ !$_X*P? ^XU3X=_#'XF?';X@>"=,^*OB-;?]H>/X!+JOQ.G75_@-\(O
M$?@;P3-HO[,'_!,?]MV/Q%\&Q\1->^-@N_$GA?\ 9*\*>)[8>!/#O@/QI^U'
MX4\9GR_'7Z1>(/\ @J=^Q9X1\'2>+=<\4_&FTM+6]\;6OB7PI!^QU^V/>_%3
MP,? D/@'Q#XWUSXI_!C0?V>;[XJ_"+0(]%^*WPN\0KXG^*/@[P?X2\46_C[P
MQ-:3-'XBCD?ZE^&'[2'PI^+OCGXD> / UUX^O-<^$NM'0/%^JZK\&?C)X+^'
MK>(3(5U'1_!_Q1\=?#[PY\-?'VN^'C!+%XLT/X:>,/%EQX1E::'QC';W3M&
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MOX#/V+_^3QOV4<?]',_ ;/\ X<W0/ZU_?G_P=C_\HP_"?_9UGPJ_]0KXLU_
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MR^&49?X91?Y-GP1_P55X_8$_:*_[%/3S_P"7+H]??^F_\>-A_P!>D'_HL5\
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M_P""Z)TYS_R.<VMM]<Q6W;ZWC"6BBBN@X HHHH **** "BBB@ HHHH ****
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M.?\ )N<[_P 7$O\ Z9IG\-\9?\E92[VH_F?[-L?^KC_W%_\ 013Z9'_JX_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'.;6V^N8K;M];QA+11170< 4444 %%%% !1110 4444 %%%% !1110 4444
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MV*S3*9X3!J\FXNW31MV?];G\>_\ P;FD+_P6>_8V(_Y[_'_I_P!FI?'8=O\
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MFS3V?H_R8'R[_P %6O\ DQK]H/\ [$"7_P!2GP>/Y"OT4TW_ (\;#_KT@_\
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MM7\$Z_JDAC6ZN=#T3PC'I6E?#V$>(FLBO_"0>#[*V@%M*'BXC_AIC]NP\_\
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M5[\:MJ>CCP)X1&E:KJ_EBQ&L:OIO]@I!<:R8]1>,330O*$>2/S$621&^,_\
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ML 4444P"BBB@ HHHH , ]12;5_NC\AWX/YCBEHHLNRUWT6OKIK\P_P"'^?<
M .@ ^G%&!UQSZT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ%#JJ:2UL)"G]N:]I*N?+:15DD*DX8E@>S45XM%\;O!-Q<6]M9?VS=K=V/\
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M110 4444 %%%% !1110 4444 1;?]EOS'O[>W^<BC;_LM^8]_;V_SD5^7?\
MP^E_X)1?]'Z_LZ?^%];_ /Q%'_#Z7_@E%_T?K^SI_P"%];__ !%=?]GYO_T*
M\3_X+K__ "DX?[0P/_0RI?\ @</\S]1-O^RWYCW]O;_.17 P_#'X=0Q"W@\
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MI5S_ &9YEC8?V>3&8T&DQR?V&C*=-B5)%MA(BJ/,;$@W?"W_  ^$_P""8O\
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MT=,L7OK"RTIV?2H])F>"1[6.W=OW"QM$B9"A%"X'Q)_P]<_X)U?]'=?!D_\
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M3_Y>'_$#?&G_ *-1XJ?^*UXN_P#H;/T(_>^C_F/\*/WOH_YC_"OSW_X>J?\
M!//_ *.U^$'_ (4B?_&J/^'JG_!//_H[7X0?^%(G_P :H_UJX=_Z*'AG_P 2
M'"?_ "\/^(&^-/\ T:CQ4_\ %:\7?_0V?H1^]]'_ #'^%'[WT?\ ,?X5^>__
M  ]4_P"">?\ T=K\(/\ PI$_^-4?\/5/^">?_1VOP@_\*1/_ (U1_K5P[_T4
M/#7_ (D&$_\ EX?\0-\:?^C4>*G_ (K7B[_Z&S]"/WOH_P"8_P */WOH_P"8
M_P *_/?_ (>J?\$\_P#H[7X0?^%(G_QJC_AZI_P3S_Z.U^$'_A2)_P#&J/\
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M@U_8WA_7_ NLZ%\*V\2>$P?B#XM7QOX&!\+GQD/!W@P^('#^-V7PD2_3:O\
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MNSM913U=E9M6TON[KO>^O9+V$6G)RCJO=YGNDY2<EJHMVYDM-M(I*T?=(O\
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MOPD^.?Q/^"_A6QN?^+-^._'GPDUCQ#=WG_(^:IX$\::_H'_":?V&<?\ "/\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image_016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %? G # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO&%?+ F,!V0.%.#PH;)& QX&>&/ R: )<CCD<\#D<GT'K33(B@EG10 Q)+
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MX%S_ !BTKP_JVE?$?6O"W@6:R^(.I>'? 7C+1=8\/>*=.TD->6D4UO?WEO)
M0I^J?V#]%_X(\>.?VFO"^O?L9?!CQ[XC^+O@?PGXCUG3_B]JG@O]HB7P;\.=
M/U2WL[+4M,'BSXKS-X;T37O%<-^MO'I&FH^IW:6LHNUA:$%P"U\.?VYO^"D_
M[5WQ#_:\^&G[*?[/?[.GAG2OV5OVE/BE\&KWXR?'OQ%X\N? OQ%3P@^F7&B>
M!_"7ASPI?Q^(9O&@M[R5?&/B:\O].\$^&UO],M=*TS5YDF6+GO@I_P %#O\
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MAGX[T[Q;X\^%_P 5?A\-5CUVR\(_%'X7^*+_ ,(^,]+T?74CA_MC0Y-1T_\
MM#1K^6&*XDT^^MX[A!-&Y/QC_P %$EC/_!1W_@BPS*A9?CK^TEY;,%)5C\![
MD'83R"1P=N"1P:R/^#?[P7JW@+]@_P 1^'=4^&OCOX0K%^U7^TQ>:-\./B7;
MZC%XZ\*^';[XASW.A:;XDEU-YKF]U./3GA:XNQ<W43R,T2W,QA9ZZ[_@H)X:
M\1ZM_P %"?\ @CEK>E:!K&IZ-X9^.7[0UQXDU:PTZZN].T"WU'X)7%EI\^LW
MD$3P:=#?7A%K:R73QI/<$1(2W% 'Y4?MP_ ?XE>//^"N'[8?[1W[.=I/<_M9
M?L0?LL_LG?M#_ RQMKN>V;Q]I=KJ_CO3?BW\%-6B5A!J.A?%3X?6NJ:-:6DR
M3-:>*$TN]AB\V16/V'^VA^T1\._VM/#W_!"K]HOX8WBWO@OXH_\ !1KX'>)M
M-2<HU[HFHR>"/B/9:WX<U6,?-9Z]X7UZWU+P[K%I((Y[35-/NK>5$="M?2'P
M:\/^)8/^"W7[<GB:YT#6K;POJ7[&W[*^E:;XEGTJY70=7O-,UWQY+?:)9ZC)
M$+2\NM/_ +32\N+>"5Y09TBD"@5^4W[37[-_QG_9:_X*;?L4_ _X8_#;Q)XM
M_8L^/'_!2#P;^VYX#U[0+"_U+1OV=/BG8^&?$&C?';X=W[6L$ECX:\$>.M1\
M0Z7\1_#,$S6UE;7EQXFCMAFTF:@#[ _:YN_"_P"QG_P5$\1?MS?M=_ O7OB]
M^R/\3OV=_AW\(O!?Q[T;P/>?&#2?V-_&7@SQ'JU]XM/CSP7;V6K:GX,\&?%$
M:UI=]/\ $+PYHUZMM=Z(+'6)H8ID"_4?[1FG?LK:C_P2@_;C\??L?6WPEN_A
M'\7_ -G'X]^/XM<^!T>CVW@KQ?KVL> M9CU+6D'AJ1[9=>EFC2/68EM[2[^W
M(UO?V\5RDJ+Z!^T5_P %5OV9OV6?BWXM^$/[3?A/X[_#6STZRTN?0O'EY\"?
MB)X\^%'Q6TS7+*-Y(_!GB;P-HOB2RO;O3-0EGT75M&U&QM]0$T#%H6M72=OR
M3^!WPC\5S_LC_P#!=3XV_"3X)^/O@A^RS^U/X6\?^*OV3/@=KWAC5/!/B#6+
MW3O@IK.A?$'XJ>'_ (3&SAU+X?V'Q9\8207_ (>T5;"PNM7CM5U)].5[@D@'
M ?M0:E_P3AU3_@B-\+?#EI'^SUXA_:JUO]ESX,:-^S5X>^"Z^#)_VBF_:;'A
M3PNO@2?P!!X)-SXZTOQ%H/BL07NNW=K)#;VFFPZPVL/';LR'[[_:/LO'-G^V
M7_P;Q6GQ2;[1\3+#4/VCK;Q[</\ O)6\9P_L?Z?#XFD>4R3EIGU=;SSY!-()
M)-[;V#9/US_P3>_8]_9L^%/[+O[*/Q \.?LQ_"#P)\6Q^SS\()=?\8:5\*_"
M^B^.[?71X#T6/53<:F--D\06FKS74ES_ &BRW0F:9IQ/(6PH\S_;N\->)=5_
MX*1_\$7-5T;P_K6JZ-X6^*?[8%WXHU;3["^O].\.6EY^SB;*RNM=U!8WBTZ&
M]O7%I;37TL8N+EA#&7D.T@'Y^_&3]H_]A']FW_@M+^V_KG[<E]\/='\/:[^Q
MS^RK_P (==?$'X::G\1+>X&DZ[\4[GQ&;"+2_"7B--/W)/;QR><T+W LI"Y?
MRW"?3'_!%WPAI&J^/OV]/VE?@'X)O?A?^P/^TW\5?A[XN_9)\!W%I-X>T7Q
MWAWPG<:-\7/C'X/\ W"Q+X(\+?%'Q4;.XTFUCM[!-1&EOJ3Z?!-(\,?K'P9\
M"7FH?\%GO^"A.K^)/!<U]X)\3?LA?LD>'K?4M8T%;KPIK$D&L?%?^UM'AN=0
MM6LM5N'@NHFU?3UAN8U6X19W='"MXG^SYXEU?_@F7^T#_P %+?V>_P#A!?&M
M[^S1X?\ AOJ7_!0C]EO3?#?AO6=;\*>'M.\3IJME\9?@/X,CLX76SU2'XI6\
M'BG0?!>FL#!I'BF[&DV4%A;#8 ?-/[?_ ,$_%_\ P4T_:._;?U/X=R333_\
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M/OVN_@K%)<IXMOK'1X6M=$N?C!\.;D6.I:[=1Z9I][K?AZ&.7S[Z8.0#@_\
M@HI^S[\!-&_;>_X(X:1I'P/^$NF:1XB_:C^+FEZ[86/P_P#"UG8ZQ9P_ G7K
MVVL-6L;?1HXM4L8)E%U;I<K);VFH10-A6!S^YG@OX<^ OAW;WEE\/O WA3P+
M8ZA>_;]4L?"'A_3/#%G?ZBT:1?;+NVTBQM(;ZX$ 6,W,@<G;C<,9'Y5?\%&/
M#OB+6_VXO^"-NJ:'H.LZQI?AG]J;XOWOB74M,TZZOK'P]87'P,UNS@O=;NK>
M-X=,M9[ITMHI[MXHY)V6)"SD+7[(D@ DG '))Z >IH _$[]H10?^"[7_  3T
M9%C-P/V)?VUUA9\*06\0?"<[?, +HA(!8H"<#.#BJ'@K]LW]O7]JCXI_M%#]
MCKP'^RC;_"O]E[X^:E^S]XN\*?'GQ%\1++XV?$+Q#X/M=%O/&>OV<?A2>UTK
MX9Z->-K1D\ OX@L?%5CXGTZT^VI=6]O)LCZ?X]>&_$6H?\%O?V O%5CH&L7O
MA;2OV,OVQ]-U;Q';:;<SZ#INH:OKGPODTK3]1U-8S8VEWJ<=M<O8VUQ*KW2P
M3&-&",1^8_[?_P 9?V/_ !WXP^+OCS]E'PY^UQ\!O^"P7A[58?"7PZM/A'\)
M/B]X.\6_%[X@:%J2:-X<T[XG:(FD2_!KXL?"+7[6T07OBKQE-<6UAX:5;G3/
M$%H42"8 _JUL_/FL[.:_@A74S:VYN;:*5Y8X;IXTDN+:*Y*J9[87 =;>>:-7
M=568J2-M?S"_"SQ=^S__ ,$^_P!J_P#;7\#?\%0O@_I^E:7^UY^T=XH^(WP<
M_;C^*/@,_$'X,?$KX9>-;*RL?"_P2\:_$F[TK6K?X3ZG\.[>VN=$M_#/B@Z'
MX=6UG&HP72&\$DW])OP^_P"$QG^'G@*;Q]:6%IX\?P9X3N/&\-FZ&U@\9W>C
M6#>++:U2 /;1VR:P]ZMM/"9(%C&(]J'>/R$^+'_!83]A^;3_ (E? ;]IKX-?
MM(:!XU@N_$O@G5OV=?B#^RI\2_%VI?%2UMKZ?2M+3P<NC^'=?\ ^,M*\;-]E
M?PW=C7/(F6Y@FO\ ['"DDJ 'JW[9'C[X0_LL_!']BO1?A7\#/@C\0_A+XV_:
M\_9K^#?P_P##.H6.FZCX&\ Z+\1-:U2/2/B-\,1IR76GQ:_HMJSZGX:U:TN=
ML$4_GP,PD44?M"_M:_M3^(?VOM9_8<_8=\$_!F7XC_#WX,:)\>/C!\5OVB;S
MQD/AYX-T3QWXAU'0O 7A/0/"W@*YTSQ#XOUSQ'J&B:]?ZE<RZM86.DZ=;LJK
M=32K!7Y#>%_V8_C_ /![_@F)_P $S?A5\1?AYXR\->(=/_X*O?!SXE^'OA%>
M077BOQ%\!?@-XH^.?C;Q)X*\$>*KEVN)M$3X<>$M?T>#69WE>U\)+(-&CD2P
MLOEZ/]M[7/BK9?\ !87XPZ_\)/\ ALJ3QWX<_9$^$&AZ9XH_X)_>#/AO\4)_
M#OA'4?%_BS4/$/A;]J/P7\06DLI=<O[SR-6^$QM2FJ0Z:]_J6G1R& JP!]H_
MLM?\% _VV_&_PW_X*5>*?VC/AY^S/X7\9?L#W'Q*\#MX'^&&I_$6\;4_'G@+
MP)!\0=(UO7=6\0:G);3?#[QOX:OK74K&"QU"+7--19+.XD24''G=A_P43_X*
MC>)_V-_#O_!2'0_V3/V=/"O[.^D?"3P_\8_%_P $/&_C#QB_[1GCGX=6VAV>
MK^-_''@G5]&0>#/!#KIIU/7/ G@[Q/#X@U/5/#UG;V^M7^F:G=PB7-_9UUW]
MF*+]@+_@H_\ L[_ [0?VD='_ &F[3X._&CXF_M(>$OVM/"&K^'?VK/B#X]^+
M/PX\01:-\2O%NE75G;PZQ8^*#:+HGAK_ (1:.;1=-MK.TT.V$,L823Z:M/#7
MB1?^" ">"WT#6E\8Q?\ !,K^P9/"ITV[_P"$B37/^%#M8C1FTCROMPU3[8/L
M@L?)^T?:!Y(3?Q0!Z/\ M5_M6^#K;3_^"9OCO1_A/X!^+'AG]JC]I[X5:+X5
MU/X@:3!J.H_#2P\>?#;Q+XRT_P"(?@0$DZ?XTTV*QAM+:Z=S<6\=Y?Q1Q,"
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M6?@;!)XI3QSX2\/S:7IWA?PQ?:_!H5WY^J26WGW<2JVU_P $?_!&@^'/$/\
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M0Z?X@UO6-+T^]TOP_HU]=.L%I?ZW=:=;7-QFVAG>9&0?/GA7P?\ '#X,^/\
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M(DO$Q!!+)+B-N!G_ &,?B#=>-=<TBX\"&3X367B7XXZKX8T4>*HK?2TC\9^
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M1C!'?&2<T^BB@!K X.S:&[$C@?E[4 'C=@D9Y'3I]>_XTZB@!.<CICOZ]_\
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M566)Y0OW)%2171&=@I*-E6; ))C(WID<.JL2,5==0PP5W<]/\_Y^HXI@CQG
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M \C><1<H3-P"?*"L2Q7G*'#D*652N"91*& (1\DJ-I 5@6P3D,0 44[F7.[
M. 2"*_E$^%G_  4__:JOO%?P]_99^,.N^$?A[K?C70/CYJGQE^)_Q*L[N+QA
MX0@OM2^,%MX%T7P=J_A^#0?#FC>(_#VF^'-%C\#OJNGZK_PE&FV,NI->AP';
M^@C]A7QYXN^*7['G[,GQ%\?27EQXU\9?!WP/K_B>XOBCWM[JU[H4/GZI>D$;
M;J^91=3^7NC$MP50E!NH34HJ2UC*]GWL[/[GH/76\*D;2<7[2G4IW<;7Y?:0
MAS)77O1YHZZ29]<4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &EP#CVW$G@!<D9)/
M'7MU[]*HW6IV=DJO=W$%K&Q55ENIX;9&=Y8X(T4S.I8R2RI&I QO=%)!=:LS
M9;Y% 9B <,2$4!OO-CDYQC'U_'P'XC_!!/'OBJ7Q2WCS7M(ED\)WGA8:5&MK
M=Z-9VD^H6VIR:M9VLZA8]8MKFVA,5T[-MCP, #) /<I=7T^'S?-N[6)HDCD=
M9[JV@*I-*88';S95*1W$@VV\CA4G)Q$SG(K0CD65=R'*G:1ZX95<;AU4E6!V
ML P!!(&17R;K/[-5UX@U'^V-2^(.IS:A+%H:LL^BV4\,W]BV]O8JFH*&"7D:
MV<*7%K#A(;+63/J5L"\S ?4FFP"UL88O,FFVI'F2<EYV81HI\V5U5Y6!&!(X
M+[=JDD**3:5K]79>NK_0"S+<I$X0@D[0['H!'G:6!/WV#8'EK\YR, TW[4FY
MD"MN1@IR57D[22,L,A%),A'"$%3S7 _%;_A/&^'WC'_A5]OIMS\16\/ZDG@M
M-9O1I^EKK\UK)!9/=7K07"6WDRR>='));S1^9&F]"I-?FG\ K?\ X*!:'XJ\
M,O\ &O3_ !7JNGQ_#Z'PWXD33?$_@C5?#T.KZC8FSAUQ;F*.UNY_%FB^)DNM
M6U74E@32QX9N+.-;6XNU:-$YQWU=JD:;Y8RE:<DW%/E3LM-9.T5HG)-I-J+:
MNK6\VE^;1^MAN4!8,LBE=Q^9&R45RAD7 .5)&4P=S*0P&,XDBD65-ZD$%F7(
M(891BA&1W!4@CJI!!Z5^4/P3TW]N:U\=? -_'USXTD\,:1KWQ6A^+$GB#4]$
M,7B'P9>P7A\&ZWK5I92326'B:SU."&'2='L99DFL9H+EWC7S(Q^KD!!C&T<
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MD44-S;:%;6]XZ27EOH(@NY(V=DDNHK%([AT:0F1D:979&D)<J06)8FO\^/\
MX-]_^"A?[<G[0'_!37X7?"[XU_M3_%_XF_#W5/A[\2[V_P#"7BS7XM0TB\N-
M(T>SN=/DNH1:1/,]K=2/<1,7W*Y'..*_T*;T%;2Y!)8BQO 2223^[;J3R:?&
MG">-X+Q<\EQN)IXJ7U3ZY3JP4ES4\13QD8OWM5=TJGNO56V2:,N',ZH9W&CB
M:&&E1A[9QYY--R:J8:\;:2T;OJM]GT/SA_X)2_\ )LOB#_LO_P ?/_5H>(*W
M?VW(/V$/AKHLOQB_;<\6^'/!'A[7[=OAIIWBGQOXAU^QTJWFU-7NOL&B6FD?
M:(-)UN[M;=D.JVMLEU+:QE9'WGG"_P""4O\ R;+X@_[+_P#'S_U:'B&OR8_X
M.V+:%O\ @G'X WQH^[]I/P)(VY1G=_9.NJV/=E7:3Z'VQ7SOAME-//H\)9)5
MJ.C3S3#Y;@YUDDW256G7M)*SOJOZT/U#QZQ<L#XC^(^+BKRH9YBZB3VTPN1+
M];'UIIW[<O\ P0_U[4?A[X;TS]K;X5:C>Z)KD6E_#KP]#XX\;32P>)-<:VT'
M3IM+AFM2\>J_:+J&#3KKS5BAENGDV[G8G]H?A=\+/!OPB\&Z7X'\ ::FD>%M
M,:[NK*Q\Z>[>6YU2Z.HW][>75R[S7-U=7LDMRTN8\O(25-?XQ_P.AM1\<_@0
M!;0E6^.7PB8@QIG>OQ&\,ON#J%E4,_ELP60?<*]&R/\ :UMR3;P$X),,1) P
M,E%S@9.!GMD_6OT[Q+X!P7 6)RW"8+'5,?2QM/$58U9PC!6HNG3?+%1BU[[F
MGS:Z:*UF_P 8X7XBQ&?TL1*M0C25!I0DFGS\TW%WUZ6OLO5WTFHHKQGXP_&G
M2O@SI7A_6]:\,^*?$&G:WXHTGPQ*?"MC#JU_IDVL7(M+:]FTI;B/4+VV61T>
M2+3;>[NE@WS&$+&U?ETI*$>:6B32O:^LG9;:[_=U/JSV:J[_ .M/^Z/Z5\%2
M_P#!1GX&1_!SQ_\ &I=-\:R>&_AK\1+7X:>*--72K+^W;/7+V\M[2TNOL(U$
MG^SW-U!)<*SKJE@6:*]TR"5"M>U?!_\ :9\"_&KQ1\1?"GA_3/$NBZS\-?\
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M'PV_Y%>'_P"PNI_Z<PI^;_\ P2E_Y-E\0?\ 9?\ X^?^K0\05^3_ /P=K_\
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MH/Y5_D"_\%8O^4FO[<W_ &<#XP_]&V]?Z_2]!]!_*O\ (%_X*Q?\I-?VYO\
MLX'QA_Z-MZ_?? '_ )&W%/\ V*\!_P"I5,_._$7_ )%.$_Q?I _JA_X,X?\
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M/'[_ )*R'_9/8/\ ]ZYP^&W_ "*\/_V%U/\ TYA3\W_^"4O_ ";+X@_[+_\
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MU?XM?[UP-_V:#PV_]468'^.7_P %&?\ E('^VI_V<I\4?_4HNJ_K+_X,YO\
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M_P!&V]?Z_2]!]!_*O\@7_@K%_P I-?VYO^S@?&'_ *-MZ_?? '_D;<4_]BO
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M $UZ_7YEX,?\CGP]_P"OV3_^D8@_9_I%?\EWXH?]CC%_^HV0'^>_\#_^2Z?
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MWU_X'_.K%5X_OK_P/^=6*_C&'PK_  P_](@?MCW?R_)!1115B"BBB@ HHHH
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M9X\3X3$8W*,10PM*5:K).T(J[^&2O][2VZG\Z?\ P;+_ /*7+X._]DR^+O\
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MU:[73^G?%R,H8K@5-7OX/^&C7*U*ZED>8VLDV^CNMUV/\=K_ (*,_P#*0/\
M;4_[.4^*/_J475?UE_\ !G-_R /VZ?\ L:_A=_Z;=?KY2_:V_P"#9'_@HO\
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MT"O/B]\,M/719-1\8:+:1^(;4W6CM+=[7NH0@F9I$\K_ $9EW *KE2YR,$C
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M3XG?"^6*2:/QUX8F".T-RRZI;R2*B[I52]+39ML.6$9N_P#1SA8X%&Y%$O\
MPLSX?+]G#>,_#X?4YH/L*_VG#YUT]QNAA"Q8#AGDPBJRJNX?,!U9.G1FU&-&
M-'EE2<O9SD_;2]O!QE-2>C6D4H]&^NZ46O;3E.<U##2M=+2\YZMV>[V?=]3X
M"\(*/^'M7Q8? R/V3O :@CN#XQU4Y(X!R789]3[9'ZERHHCD("J0C$,6V!2
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MGRHT01H%A4#*1AB2??JYK6_M+6EPL+OO$-Z[B)1YCQ);NRPX(.3(Q48'WC@
M@],L1&]"KI?]W-/TG3JT_FOWB379O>]BJ=5T*^'JQYW.->A"$:;2J<U7%8.'
M/%MI15*ZJSDY1Y84VT[I'YH_\$P_#NB>*/V5?$&E^(-/@U;3S^T1\=+QK6X,
MBP/<VWQ3U^2"5TA>(/L=0WEONB;&'C8<5]5>.M _9G\"ZN+CQQ!H6FZUJJW.
MLVMG>7>M3W<D4#HC-IVE0W-PL<"W#$K%9V\$1W&-8MBJ@_*;]CG]L[0?V5_A
MIXL^$_Q+^ ?[5T_B>S^-7QCUN6;PA\!_%/BGP_=:5XA\=ZQJFDWVF:[;.MO>
M+=6DT4T20J!^\^7Y=M?1FJ_\%(OV<->UG3O$FL_LL?ME:EKVEVDEEIVK77[+
M/C-[RTM9Y%FE@A<70"(\J+(5P<,.,#(KY/*<]R;+<KP&"QN84,/6PN$H86I[
M6->*E4H1J1GRJ.%JRLG):246M=^O](>*WA#XF9OXC\8YQD_!V;9KE&8Y[BZ^
M7YG@:F45L)CL.\-DRCB,-/\ UDC*=&HXN4)NG#F3O:Z:7TS:ZW^R MS=36UW
MX:BO;Z31U>Q>77GN[)KZ\E&C*VG3'=I=W<7<%Q=;"('MHH_M=QBU!6O3?#/P
M+^"4NE:;JOA#0+.+3+OQ1IGCR/5=,U&\O$U;5M-AGMX;]KS4+N[G.G 22I/;
M021V<[GS! <J1\!/_P %!/V9)1JLJ?LI_MFPW.IP36>IWUK^S+XXCO94N;:^
MM/M(G>],DD\=OJ-Y#'."TT23M&I"J@3K=%_X*?\ P*\.Z/I7A_1OV;?VU['2
M-$L;;3=-LX/V7_&BQ6]G9PK;PQ*/M)+*(U&[>6+MEG+,2:]'_6OAO_H<X->O
MUK_YW'Y^_!'Q<6G_ !#[B#Y+*'^7$S_&VFI^H\D4<^HW$<B!X[C3;2*5>0'B
M>340R9!! *DCY2#Z'->#^/\ X:?LZ^%] L=7\?:+HNA>&M&T^R\,VDU]J6K6
M6E)9-<_:+&UN;:WOTAO)HK@%TN[V*>\8[@UPRX6OD'_AZE\(//\ M(_9X_;=
M#&-8R/\ AF+QEDHA<HNW[3CY6D<CCC<>>F,'Q-_P4L_9X\9Z:VC>*_V7?VS?
M$&E/<073:?JG[+?C.YM3<VIS;S&)[G;OB.2A[$DD'-'^M?#?7.<&O7ZU_P#.
M\/\ B"/BZM_#[B#[LI_^B4^C9O$7['U[J-QJ-W>^'+:^FO$TG-U+X@TVVUUK
M>RBU:U<6WGI%?:>D3P26][>036T[?)&"645VWAOX7_ 'QM/XG\2^$=,TV]U3
M4+*]T+4M;L[S6)9-/FU/3IQ/;P6-[<+8Z==VMO=/-$8+.&ZM97C<%&6,U\43
M_P#!1#]F.\N$N;G]E#]LBYN$BM[>.2?]EOQO,4AM+6*QM841[THL<-I#%;Q(
M%"A$7C.6J]HO_!2SX#>%CJR:1^S;^VY8GQ+KE_XAUR6?]F+QH)+C6+Z*"&:\
M1#<8+2QV\,>R!1$J1KY:!BV2/%7#_->GFF%JN\':'UAM>SJ1J-VE@%?W8MI+
MJM6C2'@7XOUJ6*5/P]XAE*6&FN5?V-'2FJE>3DY\4P;2C%I*,9/G=[/X74\%
M^!O#*_\ !3OXA^"WLRWA_3/V0_A986-@MU>6]S;_ -A^+M8>PO5O;6>"[@N8
MV4,ES#/'.SER[MO8']$[7]GGX/6<NLW$'@]#=>(+J6\UF[N-5U^]O-0N9FLW
MEEFN[W4[BY'F-I]F6CBECB/D ;,/('_-']EOXC2?'O\ X*$_%SXW^'_AK\9_
M W@)?V?_  1X&@OOBQ\.M3\!OJ6O:?XFU._N8[&#57:>4I:WL*N%..,XR#C]
MF,#W_,_XT</UJ-:&9RHUH5XULXQ^-4X1K12AC:E.I3B_;4,.Y34:<N9QC*&O
MNR?7?QDP>(RW.>#<LQM+ZOF&5^%/ASEV/P<JM"K5P>,PV38Y5L/6^KXK&4Z=
M6FZD.>G[>4XMKG49/ECY)#\#/A9;ZEINKP^%D34=(U"RU33;@ZEK3"UO].FN
M+BRG$+:@;>3[/-=7#K%-%)"WFE9(W54"QZ;\!_A+H:ZNVF>$+:S.N7]SJ>L.
M-3UIWO[V\NUO;F2XFGU*241RW(60VT;I:K@1I"L8V5Z_@>_YG_&@@$8(!!Z@
MC(/X&OH#\B/G^U_9Y^$WAE]+U'PYX5M]"7PY=W>L6]K9SW5Q'<ZA'HUQHT,U
M[+>W%S<W*QZ=<2P+;RRO <^8\9E425>'[/GPBN[S1-4O/"0OKO1;%[71GN]8
MU^Y@TNUNI+2\N+>ULY=4>SCAENK6&8Q_9V564!0J$J?:KBV6>WG@!V"=75F'
M_308?_OH?*<=CQS3XXA$L:+T10I.3G"J%7I] ![#GGF@#R&3X _"26-XI/",
M;)(")!_:>N*9!]EEL4\QEU%7D\FSGDMK;>S?9(MBVWE>3#Y<O_"B/A2=6T#7
M&\*12:KX6T6U\.^';N;4=:E_LG1[*[%];6MM#+J#6WF1W8$IOI(GU"4_NYKJ
M2,E#Z]@>_P"9_P :,#W/U)/Z$T >$ZE^SI\(+MM5O5\)6D&KZEH=QH+ZTMQJ
M%WJ%EIUQH_\ 8,IL3=WMPEK+_9(%HT]O''<2* [RO/\ O*]/\(Z39Z#H.C:-
MI\<D-CI&F6NCV43R,^+/38Q!;2$.S/YCQC+LS%R?ODMDGIBBGMC!R"."".AX
M]/0Y'J*AMK9;9"BL6!=GY[%SEL<GJ<GK@=  * +%%%% !1110 4444 %%%%
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MD6.S'[N&60RKE&"21[_++A-WU(W[<?[)>6'_  OKX?=2N#J5V>,\C_CP/7N
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M>YV#V<)D&:8ZG4K4*=!TZ5E4<\51IR3<%-<D)RO-<K6L;OF?+:]K^3C,YP6
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y<_\
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M[777N_VI=,T.8:$9-8\2^-?VB]$M;*_\27VH6O@O3;Y]6\1QR'6M=O=+O?\
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M@R16MO;VT88AF"VELEJD4C<H9,0EF\G"_+D@@[FU:Y3H"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ,
MCU'^<_X'\C1D>O\ G_(/Y5^5G_#[3_@D]_T?I^SU_P"%5<__ "OH_P"'VG_!
M)[_H_3]GK_PJKG_Y7UU?4<=_T!8O_P )ZW_RDP^L4/\ H)PO_@^'_P F?JGD
M'H0:*_*S_A]G_P $GQ_S?K^SWUR/^*JN.W_<._\ K^]#?\%M?^"3ZL%;]O7]
MGH.1N"GQ7<!B/[P!T_)''4#'3GI2^I8U/7!XI>;P];?M_"[A]:PK^'%X9_\
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M /!++'R?MR_ ,C//_%53'G\-/Q^@JE&6[5E\_P!;%1R[,I.RR_&N/=87$/\
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MWR/4?F*,CU'YBOS&'_!8G_@F!V_;@^!/X>([D^__ $#O:I1_P6$_X)A, ?\
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MM_M%)7^^HC5<#<;O;@OC%]O^,4XAU_\ ,6?I9D>H_,49'J/S%?FQ_P />?\
M@F>!_P GI?!#L,_\)!=]^>O]G>A[_CWH_P"'O'_!-#_H]+X(_P#@_N__ )6T
MOKV7K?'81?\ <S0_6J5'@+CV3]W@?C%Z7_Y)/B1_^DY2S])\CU'YBEK\V/\
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MT5R/4?G_ )]#2Y!Z$&OSL_X>O?\ !.@D#_AK[X/$^G]KZCZ$]],Y[]?<TO\
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MQJ&@M:7%Q=VEM::=++ ;I[J\M!?Q":-P)/L@L@UP9&&Q4BF8G;%(5R]2\?\
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M:U-%'Q55.[P7 CJ7I^[]:SQ07NQE5N_8IRE=3C3C%<KM"=24=::X'Q%X=O\
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%V\K'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image_017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %^ G # 2(  A$! Q$!_\0
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MMTTO6+OX?>%_$</A^^U6YU_3K70+?6FLI->N3=0:2MW)8WBP^8:9_P %?_V
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M]HT?2=(AT[2IHKBSCN[F:UMI[ K$]RE[; '\_OPI^&G_  4V_;Z_:B_X*O\
MB/X!_P#!4KXZ?L^^,?V1OVXKKX9? 3X2:RFE^)/V:KSPWIME8>($\.^//"RZ
M3<ZS_8US;+)I1.F?;(XXV>XO-+U22:3'0_\ !2;]LOPYXY_:6UWX/_#3]M'_
M (*^:-\:/V>? 7A7X=?'GPM_P3.^!FC>.?@!X<^+ES82ZU/JOBI]>TU=4.OZ
MC/J8CO=%M-?NH[72M-M],2YM=0M-0<_T ?L=?L'^$?V._B;^VG\3O#GCSQ%X
MRU']M']HJ_\ VAO$NFZWIVG:?9^"=2O=&MM(7PSH<EB\DVHV,/E37!U"_,5Q
M+YT</V>,0%Y?S\^,W_!#GQ)KG[2WQY_:._92_P""D/[7_P"P[-^TQXETSQ[\
M9/AS\%KSP_>>"_$OQ$T_35TJ;Q?##JQM[BSNM0M4WW-K(;M8[F:Z:VGAMIEM
M(@#XI_8/T;X[_P#!=;_@C?H'PW_:'^-FJ^'_ (J_!W]M+1M/U+XQ^)?AS;S^
M+?&^D?LP?%?0/&&B1^-O UGKGAJ'1O&NNZ/%%X>\0W?]IS/I^LP2:I=VFI7
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M:_NO!W@B#3].^)!U'0M2U>ZT_1%M;IM)&AZII#Q/J]_)<_:S]G$/ZR_LN?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?"35?!UEH-X^K2?&'6%N? OBZ";4O"%O_8L>C:EI&I0W8O;LVEF ?TPT444
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MX?6WC5/"?Q,OM-\*7T^DQ:YXKTK4=:E@2U^TW\YLK/R/PS^,_P #OVT?V?\
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M?X=\/"RO=3T72]$OE@O3U?[5O_!/+X6_'?X43I\'O"'PLT[XJMX1^ W@_P
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M_OM3=?%MI>3/Y?\ #;X$?\%+/BI\"=!T/Q)\5OV^=#\.W7C/XX:[=^%8]?\
MCI\+?C1X$^(?@+]B?Q[JOARWU?XG>,=>N?&GC7X;?$?]H:?P=_PC^AV-_)X"
MB\86U[I&@0PZ?/!&@!_8O17X(?\ !-;PS^V[\$?%W@_X4?&CQ3^U5XF^'6O^
M%O@+XMN=4^-NE#XUWB_$'Q/^S3K/B'X]>%M=^,7B'7M/\2?#GPQX<^+6GZ0V
MCVOV;Q>@\37<O@VQ2RLM1DNK?][Z "BBB@ HHI" P*GHP(/)'!&#R,$?4$$=
MJ /R>^/W_!27]@*[C^/O[/7[0^C^*]>MO!FB#_A,?A=XQ^"WB3Q)IOQ>T'_A
M9?AGX9+%\.-*&FZAIOQ0A/Q!\2>%-.2PTMI+PR:IINH+:_9<W$?'Z#_P4C_8
M6^ ?P8'@7]GKX5?$+PAXB\/:E\7/"VB_LI?#O]EKX@>'/B-X+\6_#3PII?CW
MQA>>-O@]H7A73M1\'^&4TSQ9X2\1:AXUU."WTC6[3Q5I]Y9ZMJ%Y<SK#Y'X,
M_P"#?_\ 9Y\'^)UUQ/C-\4-0L-'T^TTCP;IT?A+X.:#K6DZ;;?';P+\?&_X2
M[QWX=^'^F>-/BSJ\OB+P#I>B+XA^)6L>(=:M]"N]12"\2\N/M0^D_BQ_P2F\
M%^._BY\4?V@? /[07QK^"7QL^*7B_P 5Z]JGC?P4O@76+:Q\,>.O@_\ #;X-
M^*_ $7ACQAX4US0[W0M0TCX7>'=>M-0OK>77=*\0M<W%EJ"6K1VJ 'H>A_\
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M%[*1]OB*WG'5_!3_ (+'_LY>+O@CX"\5_%/3?B]X#^-.M?#C]G/Q%??!6\^
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MD7+6R:9:RGSP >2?M2?\%H_@=\/OV:_B!\1?V?=*^(_Q0^,6D_![X@_$?2O
M4GP3^*%Q'\-;OP'XUU7X9:E%^T3:PZ/8W/PCM+#XBZ!X@\+WD?BBYTVYEN]
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MCWC6?C:7X<>$O#>L_%_4] BT*PM?#'B'XG:CXCUS1E:^GM[TSWTSD K?$O\
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M\D\N[NS22R,2\DCN[$LQ-;!ZK]?Z&O9/S06BBB@ HHHH **** /'/BG^SM\
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M)NMJB:M\0?&-]&F=L<WB'4@GS @Y6*XC# @D8;(Y/%?U[?\ !KEJ%O:_#/\
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M[&E:Z]UK=-MMZ[KW(I+R;;_(]7HHHIDA1110 445^.'[$W_!23Q;^TK^V_\
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MDE[;!'21V/KU !1110 4444 %%%% !1110 4444 %(>GXK_,4M(>GXK_ #%
M"T444 <)\1?#.H^*O#KV&F^-]:^'\UO<&^F\0Z');Q745K%97L$\,LER5A2V
M"W(NVD<@0SVD$QXC-?S*_P#!?'3O$'AK_@GQ=>'=:^(/C?XC,_Q,^%6J1^(?
M&-MI=C>7MG-K/B=+23^SK:T?4H+%RKSV%WJ-[;"ZDEN+>WL8X[98H_Z$_"^N
M_&KQ[X?^(&B?$?X6V?A*SO["ZT;0'TWQ5;6^HZCI^JV>K65[<RNKZLFF7D"?
M8VMV5Y/)>X$N)-I2/\;?^"E/[,OQC_;'^!.J?LS7?CGP/'XPT74_ ?BO1O'U
MEHNK/I7C#_A&'U^UTCPOJM^C@ZKKR0ZAJ9NIM,MGCM+M#((IFFN+:'P>*L%B
M,?PYGN"PE'V^+Q.5XNAAZ47!3JU9QI.-.,Y3C"\^1J/-**O97BY'ZYX!<1Y-
MPAXV^%'%'$>84\KX?R#CSA_-<XS&K"O5HX'+\-6QBQ&+JT\-0Q&(E3H+$4I5
M/8T*TU!SFJ<U3F?Y_=%?L%XX_P""%O\ P40\%ZI;Z1!\-O"_C&[O$O)K*/PI
MXSL9)+BVLF02SF+7;?0WA7$B'$I7JV&(1C7B-U_P29_X*'64%]=W'[-'B1;3
M3?M1O;H>*_ART,"V89KEF(\8;_W2J25"%R,!5)90?Y,J\*<3T9.%3AW.HR3M
M99;BJBOY2HPK0?JIM>9_T7Y?](KP#S2A'$X'QH\,*M&<5-.KQMD."GRN_P 5
M#,L7EF(A*Z:<)X>,TUK'9O\ .NO[ ?\ @V+\:-X5\ ?M%+=Z+=7FEI\2M"UJ
M6^LKJ![UAI7PR\5RW]I9:.Z+/J5Q;V2K>&.WN%F:$R>5#,8GQ^,'@?\ X(G?
M\%#/&]UI%HGPET?PPVNZ0FN:7+XI\8Z-;P76FR16\T=Q&VC-K;-NBNH7$2(T
MV"P\O<C@?TF?\$G/V-_B;_P3M\(>-_#'CK7?!>H_$WXI^+=+O)=2 U>X\)_"
MV"PL9-"#ZN;BWM3=/JK7,\MIJM[!9Z5)!]F0Q/<+%-!]_P"&O#/$&#XIP68X
MS)\PP>"H8?'QJXC%X>6&@I5L(Z5.*C6E"I.4YM)*%)VU;:BFS^.?IT>._@UQ
M1X!<2\%\,>)?"'$O%&:YSPC6P63\/9M3SO$5*.6\00Q^-K5*V6T,1@</2P^%
MI3J2GB,PI\SY:=.$ZDXQ?[[?"?X5?#:&73?BEI?@7PUI.M7ML7\(7=G9C^TO
M#7A"ZT;3]'LM%BN7(:U>[TZQCNM4LHTC2VN[J6Q?S39I*?H,]5^O]#7$> =
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M@CAFC6,?H=7\@GAW]K;_ (*B_&'XE?'FW\.:=^U=\'/!?Q(\,^%;VU\#:GX
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MX_A633OB1H&O?!W3?#,GP[M_%VJ7,OAG49_$MEH-QYL]\ ?LG17X?_''0?\
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M:2J':Q*K@.1\@&<9;)KUFO$/A!<7.HZ[\8=7:VNX-/U#XBE-,:]3RII(]/\
M#6@V-V# S&:U,%]#<026MRD-Q!+'(LL,;<'V^@ HHHH **** "BBB@ HHHH
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MGAF'2]*%Y8Z?JNE:A;K?P)YTM[>6EE#!::D=1CC2.U6PN)3&OU1X7^,'PO\
M&D-U<>%O'?AK6K>SG6VN+BTU.#R%N'O-3T]8(YI6BCGE^VZ-JMJ4@:1EFL;B
M-@&C(KC/%_B.:Z@UOQ/X"\*:E\0I;33(X-2T(Z;:QZ#XLAL+J62*STS4]9EL
MK>76+.4W<$,]H-0L[=VDBO;9Y/(9#[UY.Z?SND_O2OOU%_6FWX-_F<-;:G\&
M+6TAU&'4?&?@"R:18!%9^)=8AM-3%F)%6&UTB+5-5NGM TTDKO:Z782%D)U
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MW>H6>AZ]<>$IKVSNB)/-N(/MVCHRM&6CDA;:7WCKP'>)IOA/PW\/]'UJRDU
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M';2>2?4HEDRX/VY/V]=0U+Q/X<\-?!G4/$WCOPE>6]O8^#7_ &??B3HS>)?
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M +0/@?2]3^(:QV7PPM_"WA?0?'&K_"W5K]_$4.D:W-=?\+0AB%C'<>J> /\
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M[OXC;:QKM[<6%WXFU:U42FVM9_$$M@VHVMO8/*TEG'ILED(I"7?S'9F/K]%
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M\+_!MIJ?A_Q!<7-G>3ZSH]_!I"76GZE-=:?83RW=K+',\EE:LSDV\6WZ3HH
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MC4_#WQ$UR,6%M8HNG6.J+<0O;^%O_!5/]NWXG?#G5/VIDO/@SH_PZ^'/C/\
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MU7QG_P ++_9KE^,/@N[T?3M)^'LW@/X0/)\!K6VTC7/%BQZA;P0WD]K-<L$
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M\5>)-,T.&:XU;5K;2[>.::UT>RCM[@2ZMJ(L]-,T,MO'=/<(T0_G'\0?&O\
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M<VN>+('\+Z''I6H+IJ2WTNIZW:+8?9]0DM%26Y^T7<4\L9#NC;B2?X_#<_\
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MMM/O)K6OUCH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDB2>=',;IUD,AE!)<L6FTM+K3E;6C::=U)VN[]GNDNUQO\^G2^FJ6W1?UO\
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M1LB@M[>-8H88D"X6.*-%1%' 50*LT4 )SZ#\S_A1SZ#\S_A2T4 )SW _ _\
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MWLK.3.^V@;/!S&O/UXJ Z1IISBSA0G^)%V'\"I'-/VG>,7_7HQ.EVG)?-_\
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
AHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>ex15-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex15-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  D &<# 2(  A$! Q$!_\0
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C[:IW/0O %HEII=PJ,[ RY^8Y[4445W4_A1\IC&W7DWW/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>28
<FILENAME>iinn-20231231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 25 13:11:04 UTC 2024 -->
<xs:schema elementFormDefault="qualified" xmlns:iinn="http://www.inspiratechnologies.com/20231231" xmlns:srt-types="http://fasb.org/srt-types/2023" targetNamespace="http://www.inspiratechnologies.com/20231231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="iinn-20231231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="iinn-20231231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="iinn-20231231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="iinn-20231231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet" id="iinn_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement" id="iinn_r_ConsolidatedIncomeStatement">
        <link:definition>995302 - Statement - Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement_Parentheticals" id="iinn_r_ConsolidatedIncomeStatement_Parentheticals">
        <link:definition>995303 - Statement - Statements of Comprehensive Loss (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3" id="iinn_r_ShareholdersEquityType2or3">
        <link:definition>995304 - Statement - Statements of Changes in Shareholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ConsolidatedCashFlow" id="iinn_r_ConsolidatedCashFlow">
        <link:definition>995305 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/General" id="iinn_r_General">
        <link:definition>995306 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/SignificantAccountingPolicies" id="iinn_r_SignificantAccountingPolicies">
        <link:definition>995307 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/Deposits" id="iinn_r_Deposits">
        <link:definition>995308 - Disclosure - Deposits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/OtherCurrentAssets" id="iinn_r_OtherCurrentAssets">
        <link:definition>995309 - Disclosure - Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/PropertyandEquipmentNet" id="iinn_r_PropertyandEquipmentNet">
        <link:definition>995310 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/OtherAccountsPayable" id="iinn_r_OtherAccountsPayable">
        <link:definition>995311 - Disclosure - Other Accounts Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/CommitmentsandContingencies" id="iinn_r_CommitmentsandContingencies">
        <link:definition>995312 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue" id="iinn_r_FinacialLiabilitiesatFairValue">
        <link:definition>995313 - Disclosure - Finacial Liabilities at Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquityDeficit" id="iinn_r_ShareholdersEquityDeficit">
        <link:definition>995314 - Disclosure - Shareholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses" id="iinn_r_ResearchandDevelopmentExpenses">
        <link:definition>995315 - Disclosure - Research and Development Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/SalesandMarketingExpenses" id="iinn_r_SalesandMarketingExpenses">
        <link:definition>995316 - Disclosure - Sales and Marketing Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses" id="iinn_r_GeneralandAdministrativeExpenses">
        <link:definition>995317 - Disclosure - General and Administrative Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses" id="iinn_r_FinancialIncomeandExpenses">
        <link:definition>995318 - Disclosure - Financial (Income) and Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/TaxesonIncome" id="iinn_r_TaxesonIncome">
        <link:definition>995319 - Disclosure - Taxes on Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ShareBasedPayment" id="iinn_r_ShareBasedPayment">
        <link:definition>995320 - Disclosure - Share-Based Payment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/RelatedParties" id="iinn_r_RelatedParties">
        <link:definition>995321 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/SubsequentEvents" id="iinn_r_SubsequentEvents">
        <link:definition>995322 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy" id="iinn_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables" id="iinn_r_SignificantAccountingPoliciesTables">
        <link:definition>996001 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/OtherCurrentAssetsTables" id="iinn_r_OtherCurrentAssetsTables">
        <link:definition>996002 - Disclosure - Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/PropertyandEquipmentNetTables" id="iinn_r_PropertyandEquipmentNetTables">
        <link:definition>996003 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/OtherAccountsPayableTables" id="iinn_r_OtherAccountsPayableTables">
        <link:definition>996004 - Disclosure - Other Accounts Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/CommitmentsandContingenciesTables" id="iinn_r_CommitmentsandContingenciesTables">
        <link:definition>996005 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables" id="iinn_r_FinacialLiabilitiesatFairValueTables">
        <link:definition>996006 - Disclosure - Finacial Liabilities at Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitTables" id="iinn_r_ShareholdersEquityDeficitTables">
        <link:definition>996007 - Disclosure - Shareholders' Equity (Deficit) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpensesTables" id="iinn_r_ResearchandDevelopmentExpensesTables">
        <link:definition>996008 - Disclosure - Research and Development Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/SalesandMarketingExpensesTables" id="iinn_r_SalesandMarketingExpensesTables">
        <link:definition>996009 - Disclosure - Sales and Marketing Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables" id="iinn_r_GeneralandAdministrativeExpensesTables">
        <link:definition>996010 - Disclosure - General and Administrative Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables" id="iinn_r_FinancialIncomeandExpensesTables">
        <link:definition>996011 - Disclosure - Financial (Income) and Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/TaxesonIncomeTables" id="iinn_r_TaxesonIncomeTables">
        <link:definition>996012 - Disclosure - Taxes on Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ShareBasedPaymentTables" id="iinn_r_ShareBasedPaymentTables">
        <link:definition>996013 - Disclosure - Share-Based Payment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/RelatedPartiesTables" id="iinn_r_RelatedPartiesTables">
        <link:definition>996014 - Disclosure - Related Parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/GeneralDetails" id="iinn_r_GeneralDetails">
        <link:definition>996015 - Disclosure - General (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesDetails" id="iinn_r_SignificantAccountingPoliciesDetails">
        <link:definition>996016 - Disclosure - Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable" id="iinn_r_ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable">
        <link:definition>996017 - Disclosure - Significant Accounting Policies (Details) - Schedule of Change of Our Financial Results in Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable" id="iinn_r_ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable">
        <link:definition>996018 - Disclosure - Significant Accounting Policies (Details) - Schedule of Change of Our Financial Results in Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable" id="iinn_r_ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable">
        <link:definition>996019 - Disclosure - Significant Accounting Policies (Details) - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/DepositsDetails" id="iinn_r_DepositsDetails">
        <link:definition>996020 - Disclosure - Deposits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable" id="iinn_r_ScheduleofOtherCurrentAssetsTable">
        <link:definition>996021 - Disclosure - Other Current Assets (Details) - Schedule of Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable" id="iinn_r_ScheduleofPropertyandEquipmentNetTable">
        <link:definition>996022 - Disclosure - Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable" id="iinn_r_ScheduleofOtherAccountsPayableTable">
        <link:definition>996023 - Disclosure - Other Accounts Payable (Details) - Schedule of Other Accounts Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails" id="iinn_r_CommitmentsandContingenciesDetails">
        <link:definition>996024 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable" id="iinn_r_ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable">
        <link:definition>996025 - Disclosure - Commitments and Contingencies (Details) - Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofLeasePaymentsfortheCompanysRightofUseAssetsovertheRemainingLeasePeriodsTable" id="iinn_r_ScheduleofLeasePaymentsfortheCompanysRightofUseAssetsovertheRemainingLeasePeriodsTable">
        <link:definition>996026 - Disclosure - Commitments and Contingencies (Details) - Schedule of Lease Payments for the Company's Right-of-Use Assets over the Remaining Lease Periods</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails" id="iinn_r_FinacialLiabilitiesatFairValueDetails">
        <link:definition>996027 - Disclosure - Finacial Liabilities at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrarGpi3WKEtaAw66u01Fz01dWXY8Co/0nt/EYPpxJQpmucNPntkKGDUIzqiVXTghuh97D+3HoPuNe26jHPIaw4lyMqYvKxFlhkbYBWIUcgKRoJ/travtspQtU2Bzfjb2zOjTVkVWS8tD/cenVlshsSuvI61kcurHTnf7bi/aiMvKs5kJ2lHUdB1A51Zvlxfi4hXCDE5TwMWPCsMitxojF1/teoN1QVVrLEecvm/wpwexWIWYq9DGlvp] CSR-->
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable" id="iinn_r_ScheduleofFinancialLiabilityTable">
        <link:definition>996028 - Disclosure - Finacial Liabilities at Fair Value (Details) - Schedule of Financial Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails" id="iinn_r_ShareholdersEquityDeficitDetails">
        <link:definition>996029 - Disclosure - Shareholders' Equity (Deficit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofShareCapitalTable" id="iinn_r_ScheduleofShareCapitalTable">
        <link:definition>996030 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of Share Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable" id="iinn_r_ScheduleofMovementinWarrantsOutstandingTable">
        <link:definition>996031 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of Movement in Warrants Outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable" id="iinn_r_ScheduleofInformationabouttheCompanysOutstandingWarrantsTable">
        <link:definition>996032 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of Information about the Company&#8217;s Outstanding Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofSharesTable" id="iinn_r_ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofSharesTable">
        <link:definition>996033 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of Loss Per Share Calculated Using the Weighted Average Number of Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofSharesTable_Parentheticals" id="iinn_r_ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofSharesTable_Parentheticals">
        <link:definition>996034 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of Loss Per Share Calculated Using the Weighted Average Number of Shares (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable" id="iinn_r_ScheduleofResearchandDevelopmentExpensesTable">
        <link:definition>996035 - Disclosure - Research and Development Expenses (Details) - Schedule of Research and Development Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable" id="iinn_r_ScheduleofSalesandMarketingExpensesTable">
        <link:definition>996036 - Disclosure - Sales and Marketing Expenses (Details) - Schedule of Sales and Marketing Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable" id="iinn_r_ScheduleofGeneralandAdministrativeExpensesTable">
        <link:definition>996037 - Disclosure - General and Administrative Expenses (Details) - Schedule of General and Administrative Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofFinancialIncomeandExpensesTable" id="iinn_r_ScheduleofFinancialIncomeandExpensesTable">
        <link:definition>996038 - Disclosure - Financial (Income) and Expenses (Details) - Schedule of Financial (Income) and Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/TaxesonIncomeDetails" id="iinn_r_TaxesonIncomeDetails">
        <link:definition>996039 - Disclosure - Taxes on Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable" id="iinn_r_ScheduleofDeferredTaxAssetsandLiabilitiesTable">
        <link:definition>996040 - Disclosure - Taxes on Income (Details) - Schedule of Deferred Tax Assets and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable" id="iinn_r_ScheduleofTheoreticalTaxTable">
        <link:definition>996041 - Disclosure - Taxes on Income (Details) - Schedule of Theoretical Tax</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable_Parentheticals" id="iinn_r_ScheduleofTheoreticalTaxTable_Parentheticals">
        <link:definition>996042 - Disclosure - Taxes on Income (Details) - Schedule of Theoretical Tax (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails" id="iinn_r_ShareBasedPaymentDetails">
        <link:definition>996043 - Disclosure - Share-Based Payment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable" id="iinn_r_ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable">
        <link:definition>996044 - Disclosure - Share-Based Payment (Details) - Schedule of Options to Services Providers and Advisers Outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable" id="iinn_r_ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable">
        <link:definition>996045 - Disclosure - Share-Based Payment (Details) - Schedule of RSUs to Services Providers and Advisers Outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable" id="iinn_r_ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable">
        <link:definition>996046 - Disclosure - Related Parties (Details) - Schedule of Shareholders and Other Related Parties&#8217; Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofBalanceswithRelatedPartiesTable" id="iinn_r_ScheduleofBalanceswithRelatedPartiesTable">
        <link:definition>996047 - Disclosure - Related Parties (Details) - Schedule of Balances with Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/SubsequentEventsDetails" id="iinn_r_SubsequentEventsDetails">
        <link:definition>996048 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-sub-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-sub-2023.xsd"/>
  <xs:element name="ScheduleOfChangeOfOurFinancialResultsInBalanceSheetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfChangeOfOurFinancialResultsInBalanceSheetsAbstract"/>
  <xs:element name="ScheduleOfChangeOfOurFinancialResultsInComprehensiveIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfChangeOfOurFinancialResultsInComprehensiveIncomeAbstract"/>
  <xs:element name="ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract"/>
  <xs:element name="ScheduleOfOtherCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfOtherCurrentAssetsAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfPropertyAndEquipmentNetAbstract"/>
  <xs:element name="ScheduleOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract"/>
  <xs:element name="ScheduleOfShareCapitalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfShareCapitalAbstract"/>
  <xs:element name="ScheduleOfMovementInWarrantsOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfMovementInWarrantsOutstandingAbstract"/>
  <xs:element name="ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract"/>
  <xs:element name="ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract"/>
  <xs:element name="ScheduleOfSalesAndMarketingExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfSalesAndMarketingExpensesAbstract"/>
  <xs:element name="GeneralAndAdministrativeExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_GeneralAndAdministrativeExpensesAbstract"/>
  <xs:element name="ScheduleOfGeneralAndAdministrativeExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract"/>
  <xs:element name="ScheduleOfFinancialIncomeAndExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract"/>
  <xs:element name="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfTheoreticalTaxAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfTheoreticalTaxAbstract"/>
  <xs:element name="ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract"/>
  <xs:element name="ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract"/>
  <xs:element name="ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract"/>
  <xs:element name="ScheduleOfBalancesWithRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract1"/>
  <xs:element name="ChangesDuringThePeriodAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ChangesDuringThePeriodAbstract"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract3"/>
  <xs:element name="ChangesDuringThePeriodAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ChangesDuringThePeriodAbstract0"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract4"/>
  <xs:element name="ChangesDuringThePeriodAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ChangesDuringThePeriodAbstract1"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract7"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract8"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract9"/>
  <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract10"/>
  <xs:element name="UnlabeledAbstract11" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract11"/>
  <xs:element name="UnlabeledAbstract12" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract12"/>
  <xs:element name="UnlabeledAbstract13" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract13"/>
  <xs:element name="UnlabeledAbstract14" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract14"/>
  <xs:element name="UnlabeledAbstract15" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract15"/>
  <xs:element name="UnlabeledAbstract16" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract16"/>
  <xs:element name="UnlabeledAbstract17" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract17"/>
  <xs:element name="UnlabeledAbstract18" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract18"/>
  <xs:element name="NetBookValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_NetBookValueAbstract"/>
  <xs:element name="UnlabeledAbstract19" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract19"/>
  <xs:element name="UnlabeledAbstract20" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract20"/>
  <xs:element name="UnlabeledAbstract21" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract21"/>
  <xs:element name="UnlabeledAbstract22" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract22"/>
  <xs:element name="NetBookValueAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_NetBookValueAbstract0"/>
  <xs:element name="UnlabeledAbstract23" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract23"/>
  <xs:element name="UnlabeledAbstract24" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract24"/>
  <xs:element name="UnlabeledAbstract25" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract25"/>
  <xs:element name="DeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DeferredTaxAssetsAbstract"/>
  <xs:element name="StockIssuedDuringPeriodValueParValueCancellation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_StockIssuedDuringPeriodValueParValueCancellation"/>
  <xs:element name="StockIssuedDuringPeriodSharesTradableWarrantsExercise" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_StockIssuedDuringPeriodSharesTradableWarrantsExercise"/>
  <xs:element name="RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue"/>
  <xs:element name="EvaluationOfFinancialLiabilityAtFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_EvaluationOfFinancialLiabilityAtFairValue"/>
  <xs:element name="PrepaymentsOfLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_PrepaymentsOfLeaseLiabilities"/>
  <xs:element name="ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans"/>
  <xs:element name="IssuanceOfOrdinarySharesissuancesPursuantToATM" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_IssuanceOfOrdinarySharesissuancesPursuantToATM"/>
  <xs:element name="TradableWarrantsFinancialLiabilityAtIPO" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_TradableWarrantsFinancialLiabilityAtIPO"/>
  <xs:element name="ShareBasedCompensationUnderwritersFeesAtIPO" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationUnderwritersFeesAtIPO"/>
  <xs:element name="ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital"/>
  <xs:element name="SalesAndMarketingExpensesTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_SalesAndMarketingExpensesTextBlock"/>
  <xs:element name="GeneralAndAdministrativeExpensesTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_GeneralAndAdministrativeExpensesTextBlock"/>
  <xs:element name="ConversionFromIFRSToUSGAAPPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock"/>
  <xs:element name="FinanceIncomeAndExpensesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FinanceIncomeAndExpensesPolicyTextBlock"/>
  <xs:element name="SeverancePolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_SeverancePolicyTextBlock"/>
  <xs:element name="ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock"/>
  <xs:element name="ScheduleOfSalesAndMarketingExpensesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock"/>
  <xs:element name="ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock"/>
  <xs:element name="ScheduleOfTheoreticalTaxTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfTheoreticalTaxTableTextBlock"/>
  <xs:element name="ScheduleOfBalanceWithRelatedPartiesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfBalanceWithRelatedPartiesTableTextBlock"/>
  <xs:element name="ForeignExchangeReserve" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ForeignExchangeReserve"/>
  <xs:element name="SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable"/>
  <xs:element name="SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsLineItems"/>
  <xs:element name="AnnualDepreciationRatesOfPropertyPlantAndEquipment" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment"/>
  <xs:element name="AccountsPayableToRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_AccountsPayableToRelatedParties"/>
  <xs:element name="FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityTable"/>
  <xs:element name="FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerms"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms"/>
  <xs:element name="WarrantsOutstanding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_WarrantsOutstanding"/>
  <xs:element name="Subcontractors" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_Subcontractors"/>
  <xs:element name="GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesTable"/>
  <xs:element name="GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems"/>
  <xs:element name="FundsRaisingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_FundsRaisingExpenses"/>
  <xs:element name="EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue"/>
  <xs:element name="ForeignCurrencyTransactionsGainBeforeTax" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ForeignCurrencyTransactionsGainBeforeTax"/>
  <xs:element name="FinanceLeaseInterestExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_FinanceLeaseInterestExpenses"/>
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationsOtherIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_DisposalGroupIncludingDiscontinuedOperationsOtherIncome"/>
  <xs:element name="DeferredTaxAssetsFundRaisingCosts2021" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_DeferredTaxAssetsFundRaisingCosts2021"/>
  <xs:element name="DeferredTaxAssetsFundRaisingCost2023" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_DeferredTaxAssetsFundRaisingCost2023"/>
  <xs:element name="DeferredTaxAssetValuationAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_DeferredTaxAssetValuationAllowance"/>
  <xs:element name="TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized"/>
  <xs:element name="ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"/>
  <xs:element name="ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors"/>
  <xs:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod"/>
  <xs:element name="ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"/>
  <xs:element name="ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested"/>
  <xs:element name="RelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_RelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable"/>
  <xs:element name="GeneralDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_GeneralDetailsTable"/>
  <xs:element name="AdditionalOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_AdditionalOfferingCosts"/>
  <xs:element name="AggregatePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_AggregatePercentage"/>
  <xs:element name="DepositsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_DepositsDetailsTable"/>
  <xs:element name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_CommitmentsandContingenciesDetailsTable"/>
  <xs:element name="AggregateBudget" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_AggregateBudget"/>
  <xs:element name="PercentageOfApprovedBudget" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PercentageOfApprovedBudget"/>
  <xs:element name="ProjectBudgetAggregateAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ProjectBudgetAggregateAmount"/>
  <xs:element name="RoyaltiesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_RoyaltiesPercentage"/>
  <xs:element name="ContingentUponFutureSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ContingentUponFutureSales"/>
  <xs:element name="ReimbursementAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ReimbursementAmount"/>
  <xs:element name="FutureLeasePaymentsDiscountedInterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FutureLeasePaymentsDiscountedInterestRate"/>
  <xs:element name="FinacialLiabilitiesatFairValueDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_FinacialLiabilitiesatFairValueDetailsTable"/>
  <xs:element name="PercentageOfPayFees" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PercentageOfPayFees"/>
  <xs:element name="ShareholdersEquityDeficitDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_ShareholdersEquityDeficitDetailsTable"/>
  <xs:element name="ShareholdersEquityDeficitDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareholdersEquityDeficitDetailsLineItems"/>
  <xs:element name="AggregateOfOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_AggregateOfOrdinaryShares"/>
  <xs:element name="OrdinaryShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_OrdinaryShare"/>
  <xs:element name="SoldOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_SoldOrdinaryShares"/>
  <xs:element name="TradableWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_TradableWarrants"/>
  <xs:element name="NonTradableWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_NonTradableWarrants"/>
  <xs:element name="FairValueWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FairValueWarrants"/>
  <xs:element name="PercentageOfExercisePrice" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PercentageOfExercisePrice"/>
  <xs:element name="PercentageOfExerciseOfTradableWarrants" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PercentageOfExerciseOfTradableWarrants"/>
  <xs:element name="PercentageOfAgreementWarrants" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iinn_PercentageOfAgreementWarrants"/>
  <xs:element name="TaxesonIncomeDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_TaxesonIncomeDetailsTable"/>
  <xs:element name="TaxesonIncomeDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_TaxesonIncomeDetailsLineItems"/>
  <xs:element name="ShareBasedPaymentDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_ShareBasedPaymentDetailsTable"/>
  <xs:element name="CapitalGainTaxRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_CapitalGainTaxRate"/>
  <xs:element name="OptionsIssuableTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_OptionsIssuableTerm"/>
  <xs:element name="ShareOptionsVestingPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareOptionsVestingPeriod"/>
  <xs:element name="EquityPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iinn_EquityPercentage"/>
  <xs:element name="RSUsVestPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iinn_RSUsVestPeriod"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_SubsequentEventsDetailsLineItems"/>
  <xs:element name="RestrictedStockUnits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_RestrictedStockUnits"/>
  <xs:element name="AdvisoryBoardMembersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_AdvisoryBoardMembersMember"/>
  <xs:element name="BrokersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_BrokersMember"/>
  <xs:element name="DevelopmentEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DevelopmentEquipmentMember"/>
  <xs:element name="EmployeesAndDirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_EmployeesAndDirectorsMember"/>
  <xs:element name="EmployeesDirectorsAndSubcontractorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_EmployeesDirectorsAndSubcontractorsMember"/>
  <xs:element name="Exercise16Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_Exercise16Member"/>
  <xs:element name="Exercise6875Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_Exercise6875Member"/>
  <xs:element name="ExercisePrice55Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExercisePrice55Member"/>
  <xs:element name="ExercisePrice55OneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExercisePrice55OneMember"/>
  <xs:element name="ExercisePrice55TwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExercisePrice55TwoMember"/>
  <xs:element name="NonTradableSharesOptionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_NonTradableSharesOptionsMember"/>
  <xs:element name="NonTradableWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_NonTradableWarrantsMember"/>
  <xs:element name="OfficersAndDirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_OfficersAndDirectorsMember"/>
  <xs:element name="OrdinarySharesNoParValueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_OrdinarySharesNoParValueMember"/>
  <xs:element name="PlacementAgentWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PlacementAgentWarrantsMember"/>
  <xs:element name="PreFundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PreFundedWarrantsMember"/>
  <xs:element name="PrivateWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PrivateWarrantsMember"/>
  <xs:element name="ServicesProvidersAndAdvisersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ServicesProvidersAndAdvisersMember"/>
  <xs:element name="TwoThousandAndNineteenPlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_TwoThousandAndNineteenPlanMember"/>
  <xs:element name="WarrantsToPurchaseOrdinarySharesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_WarrantsToPurchaseOrdinarySharesMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>29
<FILENAME>iinn-20231231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 25 13:11:04 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ConsolidatedBalanceSheet" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ConsolidatedIncomeStatement" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ConsolidatedCashFlow" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofOtherCurrentAssetsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofOtherAccountsPayableTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofLeasePaymentsfortheCompanysRightofUseAssetsovertheRemainingLeasePeriodsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofLeasePaymentsfortheCompanysRightofUseAssetsovertheRemainingLeasePeriodsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofGeneralandAdministrativeExpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofTheoreticalTaxTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_SellingAndMarketingExpense" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_PrepaymentsOfLeaseLiabilities" xlink:href="iinn-20231231.xsd#iinn_PrepaymentsOfLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="iinn_PrepaymentsOfLeaseLiabilities" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue" xlink:href="iinn-20231231.xsd#iinn_RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="iinn_RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="iinn_EvaluationOfFinancialLiabilityAtFairValue" xlink:href="iinn-20231231.xsd#iinn_EvaluationOfFinancialLiabilityAtFairValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="iinn_EvaluationOfFinancialLiabilityAtFairValue" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInLeasingReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInLeasingReceivables" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans" xlink:href="iinn-20231231.xsd#iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" weight="1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrarGpi3WKEtaAw66u01Fz01dWXY8Co/0nt/EYPpxJQpmucNPntkKGDUIzqiVXTghuh97D+3HoPuNe26jHPIaw4lyMqYvKxFlhkbYBWIUcgKRoJ/travtspQtU2Bzfjb2zOjTVkVWS8tD/cenVlshsSuvI61kcurHTnf7bi/aiMvKs5kJ2lHUdB1A51Zvlxfi4hXCDE5TwMWPCsMitxojF1/teoN1QVVrLF5n+iKtxxsWqR6WGzXxblMAM5udaq1OVg=] CSR-->
    <loc xlink:type="locator" xlink:label="iinn_IssuanceOfOrdinarySharesissuancesPursuantToATM" xlink:href="iinn-20231231.xsd#iinn_IssuanceOfOrdinarySharesissuancesPursuantToATM"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="iinn_IssuanceOfOrdinarySharesissuancesPursuantToATM" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="iinn_ForeignExchangeReserve" xlink:href="iinn-20231231.xsd#iinn_ForeignExchangeReserve"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="iinn_ForeignExchangeReserve" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_SellingAndMarketingExpense" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestBearingDepositsInBanks" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestBearingDepositsInBanks"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_InterestBearingDepositsInBanks" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_AccountsPayableToRelatedParties" xlink:href="iinn-20231231.xsd#iinn_AccountsPayableToRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="iinn_AccountsPayableToRelatedParties" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofLeasePaymentsfortheCompanysRightofUseAssetsovertheRemainingLeasePeriodsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_ProfessionalFees" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OfficersCompensation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_LegalFees" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLaborRelatedExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLaborRelatedExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherLaborRelatedExpenses" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_FundsRaisingExpenses" xlink:href="iinn-20231231.xsd#iinn_FundsRaisingExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="iinn_FundsRaisingExpenses" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralInsuranceExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralInsuranceExpense" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostMaintenance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_CostMaintenance" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_Depreciation" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TravelAndEntertainmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TravelAndEntertainmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_TravelAndEntertainmentExpense" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralExpense" order="11" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" xlink:href="iinn-20231231.xsd#iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" order="3" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>30
<FILENAME>iinn-20231231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 25 13:11:04 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ConsolidatedBalanceSheet" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ConsolidatedIncomeStatement" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ShareholdersEquityType2or3" roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ConsolidatedCashFlow" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_General" roleURI="http://www.inspiratechnologies.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_SignificantAccountingPolicies" roleURI="http://www.inspiratechnologies.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_Deposits" roleURI="http://www.inspiratechnologies.com/role/Deposits"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_OtherCurrentAssets" roleURI="http://www.inspiratechnologies.com/role/OtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_PropertyandEquipmentNet" roleURI="http://www.inspiratechnologies.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_OtherAccountsPayable" roleURI="http://www.inspiratechnologies.com/role/OtherAccountsPayable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_CommitmentsandContingencies" roleURI="http://www.inspiratechnologies.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_FinacialLiabilitiesatFairValue" roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ShareholdersEquityDeficit" roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquityDeficit"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ResearchandDevelopmentExpenses" roleURI="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_SalesandMarketingExpenses" roleURI="http://www.inspiratechnologies.com/role/SalesandMarketingExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_GeneralandAdministrativeExpenses" roleURI="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_FinancialIncomeandExpenses" roleURI="http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_TaxesonIncome" roleURI="http://www.inspiratechnologies.com/role/TaxesonIncome"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ShareBasedPayment" roleURI="http://www.inspiratechnologies.com/role/ShareBasedPayment"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_RelatedParties" roleURI="http://www.inspiratechnologies.com/role/RelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_SubsequentEvents" roleURI="http://www.inspiratechnologies.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_AccountingPoliciesByPolicy" roleURI="http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_SignificantAccountingPoliciesTables" roleURI="http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_OtherCurrentAssetsTables" roleURI="http://www.inspiratechnologies.com/role/OtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_PropertyandEquipmentNetTables" roleURI="http://www.inspiratechnologies.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_OtherAccountsPayableTables" roleURI="http://www.inspiratechnologies.com/role/OtherAccountsPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_CommitmentsandContingenciesTables" roleURI="http://www.inspiratechnologies.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_FinacialLiabilitiesatFairValueTables" roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ShareholdersEquityDeficitTables" roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ResearchandDevelopmentExpensesTables" roleURI="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_SalesandMarketingExpensesTables" roleURI="http://www.inspiratechnologies.com/role/SalesandMarketingExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_GeneralandAdministrativeExpensesTables" roleURI="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_FinancialIncomeandExpensesTables" roleURI="http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_TaxesonIncomeTables" roleURI="http://www.inspiratechnologies.com/role/TaxesonIncomeTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ShareBasedPaymentTables" roleURI="http://www.inspiratechnologies.com/role/ShareBasedPaymentTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_RelatedPartiesTables" roleURI="http://www.inspiratechnologies.com/role/RelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofOtherCurrentAssetsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofPropertyandEquipmentNetTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofOtherAccountsPayableTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofLeasePaymentsfortheCompanysRightofUseAssetsovertheRemainingLeasePeriodsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofLeasePaymentsfortheCompanysRightofUseAssetsovertheRemainingLeasePeriodsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofFinancialLiabilityTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofShareCapitalTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofMovementinWarrantsOutstandingTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofInformationabouttheCompanysOutstandingWarrantsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofSharesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofSharesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofSharesTable_Parentheticals" roleURI="http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofSharesTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofResearchandDevelopmentExpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofSalesandMarketingExpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofGeneralandAdministrativeExpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofFinancialIncomeandExpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofFinancialIncomeandExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofDeferredTaxAssetsandLiabilitiesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofTheoreticalTaxTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofTheoreticalTaxTable_Parentheticals" roleURI="http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofBalanceswithRelatedPartiesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofBalanceswithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_GeneralDetails" roleURI="http://www.inspiratechnologies.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_SignificantAccountingPoliciesDetails" roleURI="http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_DepositsDetails" roleURI="http://www.inspiratechnologies.com/role/DepositsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_CommitmentsandContingenciesDetails" roleURI="http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_FinacialLiabilitiesatFairValueDetails" roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ShareholdersEquityDeficitDetails" roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_TaxesonIncomeDetails" roleURI="http://www.inspiratechnologies.com/role/TaxesonIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ShareBasedPaymentDetails" roleURI="http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_SubsequentEventsDetails" roleURI="http://www.inspiratechnologies.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#DocumentAndEntityInformation" roleURI="http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_StockholdersEquityAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_SellingAndMarketingExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ChangesDuringThePeriodAbstract1" xlink:href="iinn-20231231.xsd#iinn_ChangesDuringThePeriodAbstract1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iinn_ChangesDuringThePeriodAbstract1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_StockIssuedDuringPeriodValueParValueCancellation" xlink:href="iinn-20231231.xsd#iinn_StockIssuedDuringPeriodValueParValueCancellation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract1" xlink:to="iinn_StockIssuedDuringPeriodValueParValueCancellation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract1" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract1" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract1" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract1" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract1" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_StockIssuedDuringPeriodSharesTradableWarrantsExercise" xlink:href="iinn-20231231.xsd#iinn_StockIssuedDuringPeriodSharesTradableWarrantsExercise"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract1" xlink:to="iinn_StockIssuedDuringPeriodSharesTradableWarrantsExercise" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ChangesDuringThePeriodAbstract0" xlink:href="iinn-20231231.xsd#iinn_ChangesDuringThePeriodAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iinn_ChangesDuringThePeriodAbstract0" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract0" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract0" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ChangesDuringThePeriodAbstract" xlink:href="iinn-20231231.xsd#iinn_ChangesDuringThePeriodAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iinn_ChangesDuringThePeriodAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue" xlink:href="iinn-20231231.xsd#iinn_RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="iinn_RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_EvaluationOfFinancialLiabilityAtFairValue" xlink:href="iinn-20231231.xsd#iinn_EvaluationOfFinancialLiabilityAtFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="iinn_EvaluationOfFinancialLiabilityAtFairValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PrepaymentsOfLeaseLiabilities" xlink:href="iinn-20231231.xsd#iinn_PrepaymentsOfLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="iinn_PrepaymentsOfLeaseLiabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInLeasingReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInLeasingReceivables" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans" xlink:href="iinn-20231231.xsd#iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_IssuanceOfOrdinarySharesissuancesPursuantToATM" xlink:href="iinn-20231231.xsd#iinn_IssuanceOfOrdinarySharesissuancesPursuantToATM"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="iinn_IssuanceOfOrdinarySharesissuancesPursuantToATM" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ConversionOfStockAmountIssued1" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TradableWarrantsFinancialLiabilityAtIPO" xlink:href="iinn-20231231.xsd#iinn_TradableWarrantsFinancialLiabilityAtIPO"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="iinn_TradableWarrantsFinancialLiabilityAtIPO" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationUnderwritersFeesAtIPO" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationUnderwritersFeesAtIPO"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="iinn_ShareBasedCompensationUnderwritersFeesAtIPO" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_InterestPaidNet" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/General">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsGeneralTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_CompensationRelatedCostsGeneralTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/Deposits">
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositLiabilitiesDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositLiabilitiesDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DepositsAbstract" xlink:to="us-gaap_DepositLiabilitiesDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/OtherCurrentAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/PropertyandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/OtherAccountsPayable">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue">
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ShareholdersEquityDeficit">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/SalesandMarketingExpenses">
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_SalesAndMarketingExpensesTextBlock" xlink:href="iinn-20231231.xsd#iinn_SalesAndMarketingExpensesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="iinn_SalesAndMarketingExpensesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses">
    <loc xlink:type="locator" xlink:label="iinn_GeneralAndAdministrativeExpensesAbstract" xlink:href="iinn-20231231.xsd#iinn_GeneralAndAdministrativeExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_GeneralAndAdministrativeExpensesTextBlock" xlink:href="iinn-20231231.xsd#iinn_GeneralAndAdministrativeExpensesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GeneralAndAdministrativeExpensesAbstract" xlink:to="iinn_GeneralAndAdministrativeExpensesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/TaxesonIncome">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ShareBasedPayment">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/RelatedParties">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock" xlink:href="iinn-20231231.xsd#iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FinanceIncomeAndExpensesPolicyTextBlock" xlink:href="iinn-20231231.xsd#iinn_FinanceIncomeAndExpensesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iinn_FinanceIncomeAndExpensesPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_SeverancePolicyTextBlock" xlink:href="iinn-20231231.xsd#iinn_SeverancePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iinn_SeverancePolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedStatementOfComprehensiveIncomeTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/OtherCurrentAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/PropertyandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/OtherAccountsPayableTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/CommitmentsandContingenciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialGuaranteeInsuranceContractsClaimLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialGuaranteeInsuranceContractsClaimLiabilityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialGuaranteeInsuranceContractsClaimLiabilityTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpensesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/SalesandMarketingExpensesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables">
    <loc xlink:type="locator" xlink:label="iinn_GeneralAndAdministrativeExpensesAbstract" xlink:href="iinn-20231231.xsd#iinn_GeneralAndAdministrativeExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GeneralAndAdministrativeExpensesAbstract" xlink:to="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/TaxesonIncomeTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfTheoreticalTaxTableTextBlock" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfTheoreticalTaxTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="iinn_ScheduleOfTheoreticalTaxTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ShareBasedPaymentTables">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/RelatedPartiesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfBalanceWithRelatedPartiesTableTextBlock" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfBalanceWithRelatedPartiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="iinn_ScheduleOfBalanceWithRelatedPartiesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable">
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="srt_CondensedBalanceSheetStatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_RestatementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OtherAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OtherShortTermBorrowings" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ForeignExchangeReserve" xlink:href="iinn-20231231.xsd#iinn_ForeignExchangeReserve"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="iinn_ForeignExchangeReserve" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_StockholdersEquity" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable">
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedStatementOfIncomeCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedStatementOfComprehensiveIncomeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="srt_RestatementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_SellingAndMarketingExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_ProfitLoss" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable">
    <loc xlink:type="locator" xlink:label="iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsLineItems" xlink:href="iinn-20231231.xsd#iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable" xlink:href="iinn-20231231.xsd#iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsLineItems" xlink:to="iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DevelopmentEquipmentMember" xlink:href="iinn-20231231.xsd#iinn_DevelopmentEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iinn_DevelopmentEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment" xlink:href="iinn-20231231.xsd#iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsLineItems" xlink:to="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable">
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfOtherCurrentAssetsAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestBearingDepositsInBanks" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestBearingDepositsInBanks"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfOtherCurrentAssetsAbstract" xlink:to="us-gaap_InterestBearingDepositsInBanks" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfOtherCurrentAssetsAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfOtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DevelopmentEquipmentMember" xlink:href="iinn-20231231.xsd#iinn_DevelopmentEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iinn_DevelopmentEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AccountsPayableToRelatedParties" xlink:href="iinn-20231231.xsd#iinn_AccountsPayableToRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="iinn_AccountsPayableToRelatedParties" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofLeasePaymentsfortheCompanysRightofUseAssetsovertheRemainingLeasePeriodsTable">
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable">
    <loc xlink:type="locator" xlink:label="iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityLineItems" xlink:href="iinn-20231231.xsd#iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityTable" xlink:href="iinn-20231231.xsd#iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityLineItems" xlink:to="iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_NonTradableWarrantsMember" xlink:href="iinn-20231231.xsd#iinn_NonTradableWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="iinn_NonTradableWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofShareCapitalTable">
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfShareCapitalAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfShareCapitalAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfShareCapitalAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued" xlink:href="iinn-20231231.xsd#iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised" xlink:href="iinn-20231231.xsd#iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerms" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerms" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" xlink:href="iinn-20231231.xsd#iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired" xlink:href="iinn-20231231.xsd#iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms" order="21" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePrice55Member" xlink:href="iinn-20231231.xsd#iinn_ExercisePrice55Member"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrarGpi3WKEtaAw66u01Fz01dWXY8Co/0nt/EYPpxJQpmucNPntkKGDUIzqiVXTghuh97D+3HoPuNe26jHPIaw4lyMqYvKxFlhkbYBWIUcgKRoJ/travtspQtU2Bzfjb2zOjTVkVWS8tD/cenVlshsSuvI61kcurHTnf7bi/aiMvKs5kJ2lHUdB1A51Zvlxfi4hXCDE5TwMWPCsMitxojF1/teoN1QVVrLGpCYznvzAG4nU0eXOiB0EY] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="iinn_ExercisePrice55Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePrice55OneMember" xlink:href="iinn-20231231.xsd#iinn_ExercisePrice55OneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="iinn_ExercisePrice55OneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePrice55TwoMember" xlink:href="iinn-20231231.xsd#iinn_ExercisePrice55TwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="iinn_ExercisePrice55TwoMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_Exercise6875Member" xlink:href="iinn-20231231.xsd#iinn_Exercise6875Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="iinn_Exercise6875Member" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_Exercise16Member" xlink:href="iinn-20231231.xsd#iinn_Exercise16Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="iinn_Exercise16Member" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_WarrantsOutstanding" xlink:href="iinn-20231231.xsd#iinn_WarrantsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="iinn_WarrantsOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofSharesTable">
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_SharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_EarningsPerShareBasic" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofSharesTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LaborAndRelatedExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_LaborAndRelatedExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLaborRelatedExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLaborRelatedExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_OtherLaborRelatedExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_Subcontractors" xlink:href="iinn-20231231.xsd#iinn_Subcontractors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="iinn_Subcontractors" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationNonproduction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationNonproduction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_DepreciationNonproduction" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForParticipationLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForParticipationLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_PaymentsForParticipationLiabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable">
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfSalesAndMarketingExpensesAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfSalesAndMarketingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfSalesAndMarketingExpensesAbstract" xlink:to="us-gaap_ProfessionalFees" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfSalesAndMarketingExpensesAbstract" xlink:to="us-gaap_OfficersCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfSalesAndMarketingExpensesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSellingAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfSalesAndMarketingExpensesAbstract" xlink:to="us-gaap_OtherSellingAndMarketingExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfSalesAndMarketingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable">
    <loc xlink:type="locator" xlink:label="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:href="iinn-20231231.xsd#iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesTable" xlink:href="iinn-20231231.xsd#iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="us-gaap_ProfessionalFees" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="us-gaap_OfficersCompensation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="us-gaap_LegalFees" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLaborRelatedExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLaborRelatedExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="us-gaap_OtherLaborRelatedExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FundsRaisingExpenses" xlink:href="iinn-20231231.xsd#iinn_FundsRaisingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="iinn_FundsRaisingExpenses" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralInsuranceExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="us-gaap_GeneralInsuranceExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostMaintenance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="us-gaap_CostMaintenance" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="us-gaap_Depreciation" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TravelAndEntertainmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TravelAndEntertainmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="us-gaap_TravelAndEntertainmentExpense" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="us-gaap_OtherGeneralExpense" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofFinancialIncomeandExpensesTable">
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfFinancialIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue" xlink:href="iinn-20231231.xsd#iinn_EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="iinn_EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="us-gaap_FinancingInterestExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ForeignCurrencyTransactionsGainBeforeTax" xlink:href="iinn-20231231.xsd#iinn_ForeignCurrencyTransactionsGainBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="iinn_ForeignCurrencyTransactionsGainBeforeTax" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FinanceLeaseInterestExpenses" xlink:href="iinn-20231231.xsd#iinn_FinanceLeaseInterestExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="iinn_FinanceLeaseInterestExpenses" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DisposalGroupIncludingDiscontinuedOperationsOtherIncome" xlink:href="iinn-20231231.xsd#iinn_DisposalGroupIncludingDiscontinuedOperationsOtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="iinn_DisposalGroupIncludingDiscontinuedOperationsOtherIncome" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxAssetsAbstract" xlink:href="iinn-20231231.xsd#iinn_DeferredTaxAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="iinn_DeferredTaxAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DeferredTaxAssetsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxAssetsFundRaisingCosts2021" xlink:href="iinn-20231231.xsd#iinn_DeferredTaxAssetsFundRaisingCosts2021"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DeferredTaxAssetsAbstract" xlink:to="iinn_DeferredTaxAssetsFundRaisingCosts2021" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxAssetsFundRaisingCost2023" xlink:href="iinn-20231231.xsd#iinn_DeferredTaxAssetsFundRaisingCost2023"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DeferredTaxAssetsAbstract" xlink:to="iinn_DeferredTaxAssetsFundRaisingCost2023" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DeferredTaxAssetsAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxAssetValuationAllowance" xlink:href="iinn-20231231.xsd#iinn_DeferredTaxAssetValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DeferredTaxAssetsAbstract" xlink:to="iinn_DeferredTaxAssetValuationAllowance" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable">
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfTheoreticalTaxAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" xlink:href="iinn-20231231.xsd#iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:to="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfTheoreticalTaxAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable">
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:href="iinn-20231231.xsd#iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable" xlink:href="iinn-20231231.xsd#iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ServicesProvidersAndAdvisersMember" xlink:href="iinn-20231231.xsd#iinn_ServicesProvidersAndAdvisersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="iinn_ServicesProvidersAndAdvisersMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_EmployeesAndDirectorsMember" xlink:href="iinn-20231231.xsd#iinn_EmployeesAndDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="iinn_EmployeesAndDirectorsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable">
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems" xlink:href="iinn-20231231.xsd#iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable" xlink:href="iinn-20231231.xsd#iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_OfficersAndDirectorsMember" xlink:href="iinn-20231231.xsd#iinn_OfficersAndDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="iinn_OfficersAndDirectorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OfficersCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofBalanceswithRelatedPartiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_RelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" xlink:href="iinn-20231231.xsd#iinn_RelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="iinn_RelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_RelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_OfficerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnusualOrInfrequentItemNatureOfEventOrTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnusualOrInfrequentItemNatureOfEventOrTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_UnusualOrInfrequentItemNatureOfEventOrTransaction" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesGeneralDisclosuresLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_GeneralDetailsTable" xlink:href="iinn-20231231.xsd#iinn_GeneralDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="iinn_GeneralDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_GeneralDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_GeneralDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_GeneralDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PreFundedWarrantsMember" xlink:href="iinn-20231231.xsd#iinn_PreFundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="iinn_PreFundedWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PlacementAgentWarrantsMember" xlink:href="iinn-20231231.xsd#iinn_PlacementAgentWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="iinn_PlacementAgentWarrantsMember" order="2" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="iinn_PreFundedWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_SharesIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_SharePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AdditionalOfferingCosts" xlink:href="iinn-20231231.xsd#iinn_AdditionalOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="iinn_AdditionalOfferingCosts" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AggregatePercentage" xlink:href="iinn-20231231.xsd#iinn_AggregatePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="iinn_AggregatePercentage" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_PaymentsOfDerivativeIssuanceCosts" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShortTermInvestments" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/DepositsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DepositLiabilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositLiabilityLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_DepositsDetailsTable" xlink:href="iinn-20231231.xsd#iinn_DepositsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DepositLiabilityLineItems" xlink:to="iinn_DepositsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_DepositsDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PledgingPurposeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PledgingPurposeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_DepositsDetailsTable" xlink:to="us-gaap_PledgingPurposeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PledgingPurposeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PledgingPurposeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PledgingPurposeAxis" xlink:to="us-gaap_PledgingPurposeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PledgingPurposeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PledgingPurposeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PledgingPurposeAxis" xlink:to="us-gaap_PledgingPurposeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IL"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_IL" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PledgingPurposeDomain" xlink:to="us-gaap_DepositsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Deposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DepositLiabilityLineItems" xlink:to="us-gaap_Deposits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DepositLiabilityLineItems" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_CommitmentsandContingenciesDetailsTable" xlink:href="iinn-20231231.xsd#iinn_CommitmentsandContingenciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iinn_CommitmentsandContingenciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_CommitmentsandContingenciesDetailsTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AggregateBudget" xlink:href="iinn-20231231.xsd#iinn_AggregateBudget"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iinn_AggregateBudget" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfApprovedBudget" xlink:href="iinn-20231231.xsd#iinn_PercentageOfApprovedBudget"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iinn_PercentageOfApprovedBudget" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ProjectBudgetAggregateAmount" xlink:href="iinn-20231231.xsd#iinn_ProjectBudgetAggregateAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iinn_ProjectBudgetAggregateAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherReceivables" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_RoyaltiesPercentage" xlink:href="iinn-20231231.xsd#iinn_RoyaltiesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iinn_RoyaltiesPercentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ContingentUponFutureSales" xlink:href="iinn-20231231.xsd#iinn_ContingentUponFutureSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iinn_ContingentUponFutureSales" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsForRent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ReimbursementAmount" xlink:href="iinn-20231231.xsd#iinn_ReimbursementAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iinn_ReimbursementAmount" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManagementFeeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementFeeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ManagementFeeExpense" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LeaseCost" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FutureLeasePaymentsDiscountedInterestRate" xlink:href="iinn-20231231.xsd#iinn_FutureLeasePaymentsDiscountedInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iinn_FutureLeasePaymentsDiscountedInterestRate" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_FinacialLiabilitiesatFairValueDetailsTable" xlink:href="iinn-20231231.xsd#iinn_FinacialLiabilitiesatFairValueDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems" xlink:to="iinn_FinacialLiabilitiesatFairValueDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PrivateWarrantsMember" xlink:href="iinn-20231231.xsd#iinn_PrivateWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="iinn_PrivateWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfPayFees" xlink:href="iinn-20231231.xsd#iinn_PercentageOfPayFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems" xlink:to="iinn_PercentageOfPayFees" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockDividendsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems" xlink:to="us-gaap_StockDividendsShares" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionExercisePriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems" xlink:to="us-gaap_StockOptionExercisePriceDecrease" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails">
    <loc xlink:type="locator" xlink:label="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:href="iinn-20231231.xsd#iinn_ShareholdersEquityDeficitDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareholdersEquityDeficitDetailsTable" xlink:href="iinn-20231231.xsd#iinn_ShareholdersEquityDeficitDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="iinn_ShareholdersEquityDeficitDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareholdersEquityDeficitDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareholdersEquityDeficitDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareholdersEquityDeficitDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareholdersEquityDeficitDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareholdersEquityDeficitDetailsTable" xlink:to="srt_RangeAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareholdersEquityDeficitDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PreFundedWarrantsMember" xlink:href="iinn-20231231.xsd#iinn_PreFundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="iinn_PreFundedWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_InvestorMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_BrokersMember" xlink:href="iinn-20231231.xsd#iinn_BrokersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="iinn_BrokersMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AggregateOfOrdinaryShares" xlink:href="iinn-20231231.xsd#iinn_AggregateOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="iinn_AggregateOfOrdinaryShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_OrdinaryShare" xlink:href="iinn-20231231.xsd#iinn_OrdinaryShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="iinn_OrdinaryShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalUnitsAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalUnitsAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_CapitalUnitsAuthorized" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_SoldOrdinaryShares" xlink:href="iinn-20231231.xsd#iinn_SoldOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="iinn_SoldOrdinaryShares" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TradableWarrants" xlink:href="iinn-20231231.xsd#iinn_TradableWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="iinn_TradableWarrants" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_NonTradableWarrants" xlink:href="iinn-20231231.xsd#iinn_NonTradableWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="iinn_NonTradableWarrants" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDividendsReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDividendsReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ProceedsFromDividendsReceived" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfferingCostsPartnershipInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfferingCostsPartnershipInterests"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_OfferingCostsPartnershipInterests" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FairValueWarrants" xlink:href="iinn-20231231.xsd#iinn_FairValueWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="iinn_FairValueWarrants" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfExercisePrice" xlink:href="iinn-20231231.xsd#iinn_PercentageOfExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="iinn_PercentageOfExercisePrice" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfExerciseOfTradableWarrants" xlink:href="iinn-20231231.xsd#iinn_PercentageOfExerciseOfTradableWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="iinn_PercentageOfExerciseOfTradableWarrants" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_InterestExpense" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoninterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoninterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_NoninterestExpense" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_InterestExpenseOther" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BenefitsLossesAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BenefitsLossesAndExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_BenefitsLossesAndExpenses" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonUnitAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_CommonUnitAuthorized" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_SharePrice" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherUnderwritingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherUnderwritingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_OtherUnderwritingExpense" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfAgreementWarrants" xlink:href="iinn-20231231.xsd#iinn_PercentageOfAgreementWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="iinn_PercentageOfAgreementWarrants" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_PaymentsOfDerivativeIssuanceCosts" order="33" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/TaxesonIncomeDetails">
    <loc xlink:type="locator" xlink:label="iinn_TaxesonIncomeDetailsLineItems" xlink:href="iinn-20231231.xsd#iinn_TaxesonIncomeDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_TaxesonIncomeDetailsTable" xlink:href="iinn-20231231.xsd#iinn_TaxesonIncomeDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_TaxesonIncomeDetailsLineItems" xlink:to="iinn_TaxesonIncomeDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_TaxesonIncomeDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IL"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_IL" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_TaxesonIncomeDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_TaxesonIncomeDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_TaxesonIncomeDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPaymentDetailsTable" xlink:href="iinn-20231231.xsd#iinn_ShareBasedPaymentDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedPaymentDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareBasedPaymentDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareBasedPaymentDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareBasedPaymentDetailsTable" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareBasedPaymentDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TwoThousandAndNineteenPlanMember" xlink:href="iinn-20231231.xsd#iinn_TwoThousandAndNineteenPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="iinn_TwoThousandAndNineteenPlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AdvisoryBoardMembersMember" xlink:href="iinn-20231231.xsd#iinn_AdvisoryBoardMembersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="iinn_AdvisoryBoardMembersMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_EmployeesDirectorsAndSubcontractorsMember" xlink:href="iinn-20231231.xsd#iinn_EmployeesDirectorsAndSubcontractorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="iinn_EmployeesDirectorsAndSubcontractorsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_NonTradableSharesOptionsMember" xlink:href="iinn-20231231.xsd#iinn_NonTradableSharesOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="iinn_NonTradableSharesOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_CapitalGainTaxRate" xlink:href="iinn-20231231.xsd#iinn_CapitalGainTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_CapitalGainTaxRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_OptionsIssuableTerm" xlink:href="iinn-20231231.xsd#iinn_OptionsIssuableTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_OptionsIssuableTerm" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareOptionsVestingPeriod" xlink:href="iinn-20231231.xsd#iinn_ShareOptionsVestingPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareOptionsVestingPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_EquityPercentage" xlink:href="iinn-20231231.xsd#iinn_EquityPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_EquityPercentage" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_RSUsVestPeriod" xlink:href="iinn-20231231.xsd#iinn_RSUsVestPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_RSUsVestPeriod" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="iinn_SubsequentEventsDetailsLineItems" xlink:href="iinn-20231231.xsd#iinn_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_SubsequentEventsDetailsTable" xlink:href="iinn-20231231.xsd#iinn_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_SubsequentEventsDetailsLineItems" xlink:to="iinn_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SubsequentEventsDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_RestrictedStockUnits" xlink:href="iinn-20231231.xsd#iinn_RestrictedStockUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SubsequentEventsDetailsLineItems" xlink:to="iinn_RestrictedStockUnits" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_OrdinarySharesNoParValueMember" xlink:href="iinn-20231231.xsd#iinn_OrdinarySharesNoParValueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iinn_OrdinarySharesNoParValueMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_WarrantsToPurchaseOrdinarySharesMember" xlink:href="iinn-20231231.xsd#iinn_WarrantsToPurchaseOrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iinn_WarrantsToPurchaseOrdinarySharesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodStartDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodStartDate" order="40" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>31
<FILENAME>iinn-20231231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 25 13:11:04 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total non- current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Shareholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and Shareholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Loss before taxation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Total comprehensive and net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Total net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at the beginning of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash, cash equivalents and restricted cash at the end of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsAbstract_lbl" xml:lang="en-US">General [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_CompensationRelatedCostsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US">Revision of Prior Period [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Total comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAbstract_lbl" xml:lang="en-US">Deposits [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAbstract" xlink:to="us-gaap_DepositsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US">Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfOtherCurrentAssetsAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfOtherCurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfOtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Schedule of Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfOtherCurrentAssetsAbstract" xlink:to="iinn_ScheduleOfOtherCurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl0" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US">Property and Equipment, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Cost, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Cost, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated depreciation, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Net book value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US">Other Accounts Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Schedule of Other Accounts Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:to="iinn_ScheduleOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Present value of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract_lbl" xml:lang="en-US">Schedule of Lease Payments for the Company&apos;s Right-of-Use Assets Over the Remaining Lease Periods [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract" xlink:to="iinn_ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted lease payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US">Finacial Liabilities at Fair Value [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInsuredFinancialObligationsWithCreditDeteriorationNetClaimLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInsuredFinancialObligationsWithCreditDeteriorationNetClaimLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInsuredFinancialObligationsWithCreditDeteriorationNetClaimLiabilityAbstract_lbl" xml:lang="en-US">Schedule of Financial Liability [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInsuredFinancialObligationsWithCreditDeteriorationNetClaimLiabilityAbstract" xlink:to="us-gaap_ScheduleOfInsuredFinancialObligationsWithCreditDeteriorationNetClaimLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US">Liability Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders&apos; Equity (Deficit) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Shareholders&#8217; Equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfShareCapitalAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfShareCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfShareCapitalAbstract_lbl" xml:lang="en-US">Schedule of Share Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfShareCapitalAbstract" xlink:to="iinn_ScheduleOfShareCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Number of Warrants, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0" xml:lang="en-US">Number of Warrants, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average exercise price, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted-average exercise price, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Aggregate intrinsic value, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0" xml:lang="en-US">Aggregate intrinsic value, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl1" xml:lang="en-US">Aggregate Intrinsic value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract_lbl" xml:lang="en-US">Schedule of Loss Per Share Calculated Using the Weighted Average Number of Shares [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract" xlink:to="iinn_ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US">Research and Development Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xml:lang="en-US">Schedule of Research and Development Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract_lbl" xml:lang="en-US">Sales and Marketing Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="us-gaap_SellingAndMarketingExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfSalesAndMarketingExpensesAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfSalesAndMarketingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfSalesAndMarketingExpensesAbstract_lbl" xml:lang="en-US">Schedule of Sales and Marketing Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfSalesAndMarketingExpensesAbstract" xlink:to="iinn_ScheduleOfSalesAndMarketingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingAndMarketingExpense_lbl0" xml:lang="en-US">Sales and marketing expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_GeneralAndAdministrativeExpensesAbstract" xlink:href="iinn-20231231.xsd#iinn_GeneralAndAdministrativeExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_GeneralAndAdministrativeExpensesAbstract_lbl" xml:lang="en-US">General and Administrative Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GeneralAndAdministrativeExpensesAbstract" xlink:to="iinn_GeneralAndAdministrativeExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract_lbl" xml:lang="en-US">Schedule of General and Administrative Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract" xlink:to="iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US">Financial (Income) and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfFinancialIncomeAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract_lbl" xml:lang="en-US">Schedule of Financial (Income) and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Taxes on Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="iinn_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfTheoreticalTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfTheoreticalTaxAbstract_lbl" xml:lang="en-US">Schedule of Theoretical Tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:to="iinn_ScheduleOfTheoreticalTaxAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Taxes on income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Taxes on income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl" xml:lang="en-US">Share-Based Payment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of options, Outstanding at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of options, Options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average Exercise price, Outstanding at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average Exercise price, Options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of Warrants, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">Number of RSUs, RSUs outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Non-Current Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade accounts payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other accounts payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Current lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US">Operating lease liabilities, current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Financial liabilities at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-Current Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Long term lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US">Operating lease liabilities long-term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Share capital and additional paid in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract" xlink:to="iinn_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract0" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract0" xlink:to="iinn_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per ordinary share, basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Basic loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per ordinary share, diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Diluted loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of ordinary shares outstanding basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted average number of Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of ordinary shares outstanding diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract1" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract1" xlink:to="iinn_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ChangesDuringThePeriodAbstract" xlink:href="iinn-20231231.xsd#iinn_ChangesDuringThePeriodAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ChangesDuringThePeriodAbstract_lbl" xml:lang="en-US">Changes during the period:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="iinn_ChangesDuringThePeriodAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract2" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract2" xlink:to="iinn_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Issuance of ordinary shares and private warrants, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Issuance of ordinary shares and private warrants, net (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of placement agent warrants (Note 9)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of ordinary shares (pursuant to At-The-Market (&#8220;ATM&#8221;) facility)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of ordinary shares (pursuant to At-The-Market (&#8220;ATM&#8221;) facility) (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of share-based payments (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted share unit (&#8220;RSU&#8221;) vesting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted share unit (&#8220;RSU&#8221;) vesting (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract3" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract3" xlink:to="iinn_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ChangesDuringThePeriodAbstract0" xlink:href="iinn-20231231.xsd#iinn_ChangesDuringThePeriodAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ChangesDuringThePeriodAbstract0_lbl" xml:lang="en-US">Changes during the period:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangesDuringThePeriodAbstract0" xlink:to="iinn_ChangesDuringThePeriodAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xml:lang="en-US">RSU vesting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xml:lang="en-US">RSU vesting (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract4" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract4" xlink:to="iinn_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ChangesDuringThePeriodAbstract1" xlink:href="iinn-20231231.xsd#iinn_ChangesDuringThePeriodAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ChangesDuringThePeriodAbstract1_lbl" xml:lang="en-US">Changes during the period:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangesDuringThePeriodAbstract1" xlink:to="iinn_ChangesDuringThePeriodAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_StockIssuedDuringPeriodValueParValueCancellation" xlink:href="iinn-20231231.xsd#iinn_StockIssuedDuringPeriodValueParValueCancellation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_StockIssuedDuringPeriodValueParValueCancellation_lbl" xml:lang="en-US">Par value cancellation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodValueParValueCancellation" xlink:to="iinn_StockIssuedDuringPeriodValueParValueCancellation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Initial Public Offering (&#8220;IPO&#8221;)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Initial Public Offering (&#8220;IPO&#8221;) (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Purchase of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of financial liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of financial liability (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Tradable warrants exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_StockIssuedDuringPeriodSharesTradableWarrantsExercise" xlink:href="iinn-20231231.xsd#iinn_StockIssuedDuringPeriodSharesTradableWarrantsExercise"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_StockIssuedDuringPeriodSharesTradableWarrantsExercise_lbl" xml:lang="en-US">Tradable warrants exercise (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodSharesTradableWarrantsExercise" xlink:to="iinn_StockIssuedDuringPeriodSharesTradableWarrantsExercise_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOW FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Loss for the period (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share based compensation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share based payment &#8211; officers and directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Share based compensation &#8211; placement agent warrants (Note 9)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Issuance cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PrepaymentsOfLeaseLiabilities" xlink:href="iinn-20231231.xsd#iinn_PrepaymentsOfLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PrepaymentsOfLeaseLiabilities_lbl" xml:lang="en-US">Prepayments of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PrepaymentsOfLeaseLiabilities" xlink:to="iinn_PrepaymentsOfLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">(Decrease) increase in trade accounts payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xml:lang="en-US">(Decrease) increase in other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOW FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xml:lang="en-US">Proceeds from sale of short-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans" xlink:href="iinn-20231231.xsd#iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans_lbl" xml:lang="en-US">Receipt of simple agreements for future equity (SAFE) and convertible loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans" xlink:to="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Issuance of private warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Exercise of option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_IssuanceOfOrdinarySharesissuancesPursuantToATM" xlink:href="iinn-20231231.xsd#iinn_IssuanceOfOrdinarySharesissuancesPursuantToATM"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_IssuanceOfOrdinarySharesissuancesPursuantToATM_lbl" xml:lang="en-US">Issuance of ordinary shares (issuances pursuant to ATM)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IssuanceOfOrdinarySharesissuancesPursuantToATM" xlink:to="iinn_IssuanceOfOrdinarySharesissuancesPursuantToATM_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract5" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract5" xlink:to="iinn_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US">Conversion of convertible loans to equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TradableWarrantsFinancialLiabilityAtIPO" xlink:href="iinn-20231231.xsd#iinn_TradableWarrantsFinancialLiabilityAtIPO"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TradableWarrantsFinancialLiabilityAtIPO_lbl" xml:lang="en-US">Tradable warrants financial liability at IPO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrantsFinancialLiabilityAtIPO" xlink:to="iinn_TradableWarrantsFinancialLiabilityAtIPO_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationUnderwritersFeesAtIPO" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationUnderwritersFeesAtIPO"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationUnderwritersFeesAtIPO_lbl" xml:lang="en-US">Share based compensation &#8211; underwriters fees at IPO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationUnderwritersFeesAtIPO" xlink:to="iinn_ShareBasedCompensationUnderwritersFeesAtIPO_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital_lbl" xml:lang="en-US">Share based compensation-placement agent warrants against additional paid in capital (Note 9)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" xlink:to="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xml:lang="en-US">Other expenses (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl0" xml:lang="en-US">Other expenses (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl" xml:lang="en-US">Interest income from deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl0" xml:lang="en-US">Interest income from deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Finance expenses (income), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl0" xml:lang="en-US">Finance expenses (income), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_lbl" xml:lang="en-US">Comprehensive and net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue" xlink:href="iinn-20231231.xsd#iinn_RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iinn_RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue_lbl" xml:lang="en-US">Revaluation of simple agreements for future equity (SAFE) and convertible loan at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue" xlink:to="iinn_RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_EvaluationOfFinancialLiabilityAtFairValue" xlink:href="iinn-20231231.xsd#iinn_EvaluationOfFinancialLiabilityAtFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iinn_EvaluationOfFinancialLiabilityAtFairValue_lbl" xml:lang="en-US">Evaluation of financial liability at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EvaluationOfFinancialLiabilityAtFairValue" xlink:to="iinn_EvaluationOfFinancialLiabilityAtFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInLeasingReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables_lbl" xml:lang="en-US">Decrease (increase) in right of use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInLeasingReceivables" xlink:to="us-gaap_IncreaseDecreaseInLeasingReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Decrease (increase) in other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property, plant, and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US">Investment in short term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Issuance cost in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_OrdinarySharesNoParValueMember" xlink:href="iinn-20231231.xsd#iinn_OrdinarySharesNoParValueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_OrdinarySharesNoParValueMember_lbl" xml:lang="en-US">Ordinary Shares, no par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OrdinarySharesNoParValueMember" xlink:to="iinn_OrdinarySharesNoParValueMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_WarrantsToPurchaseOrdinarySharesMember" xlink:href="iinn-20231231.xsd#iinn_WarrantsToPurchaseOrdinarySharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_WarrantsToPurchaseOrdinarySharesMember_lbl" xml:lang="en-US">Warrants to purchase Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsToPurchaseOrdinarySharesMember" xlink:to="iinn_WarrantsToPurchaseOrdinarySharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Ordinary Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Ordinary Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsGeneralTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock_lbl" xml:lang="en-US">GENERAL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:to="us-gaap_CompensationRelatedCostsGeneralTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xml:lang="en-US">Schedule of Change of Our Financial Results in Balance Sheets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherShortTermBorrowings_lbl" xml:lang="en-US">Loan from the Israeli Innovation Authority (&#8220;IIA&#8221;)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherShortTermBorrowings" xlink:to="us-gaap_OtherShortTermBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ForeignExchangeReserve" xlink:href="iinn-20231231.xsd#iinn_ForeignExchangeReserve"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ForeignExchangeReserve_lbl" xml:lang="en-US">Foreign exchange reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ForeignExchangeReserve" xlink:to="iinn_ForeignExchangeReserve_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedStatementOfComprehensiveIncomeTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl" xml:lang="en-US">Schedule of Change of Our Financial Results in Comprehensive Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract6" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract6" xlink:to="iinn_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract7" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract7" xlink:to="iinn_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract8" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract8" xlink:to="iinn_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract9" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract9" xlink:to="iinn_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract10" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract10"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract10_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract10" xlink:to="iinn_UnlabeledAbstract10_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract11" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract11"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract11_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract11" xlink:to="iinn_UnlabeledAbstract11_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract12" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract12"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract12_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract12" xlink:to="iinn_UnlabeledAbstract12_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract13" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract13"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract13_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract13" xlink:to="iinn_UnlabeledAbstract13_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" xlink:to="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract14" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract14"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract14_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract14" xlink:to="iinn_UnlabeledAbstract14_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment" xlink:href="iinn-20231231.xsd#iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Annual depreciation rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment" xlink:to="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositLiabilitiesDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositLiabilitiesDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositLiabilitiesDisclosuresTextBlock_lbl" xml:lang="en-US">DEPOSITS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositLiabilitiesDisclosuresTextBlock" xlink:to="us-gaap_DepositLiabilitiesDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">OTHER CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestBearingDepositsInBanks" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestBearingDepositsInBanks"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestBearingDepositsInBanks_lbl" xml:lang="en-US">Institutions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestBearingDepositsInBanks" xlink:to="us-gaap_InterestBearingDepositsInBanks_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGrossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGrossAbstract_lbl" xml:lang="en-US">Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGrossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions_lbl" xml:lang="en-US">Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract15" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract15"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract15_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract15" xlink:to="iinn_UnlabeledAbstract15_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract16" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract16"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract16_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract16" xlink:to="iinn_UnlabeledAbstract16_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract17" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract17"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract17_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract17" xlink:to="iinn_UnlabeledAbstract17_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract18" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract18"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract18_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract18" xlink:to="iinn_UnlabeledAbstract18_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NetBookValueAbstract" xlink:href="iinn-20231231.xsd#iinn_NetBookValueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NetBookValueAbstract_lbl" xml:lang="en-US">Net book value:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NetBookValueAbstract" xlink:to="iinn_NetBookValueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract19" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract19"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract19_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract19" xlink:to="iinn_UnlabeledAbstract19_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract20" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract20"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract20_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract20" xlink:to="iinn_UnlabeledAbstract20_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract21" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract21"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract21_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract21" xlink:to="iinn_UnlabeledAbstract21_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract22" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract22"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract22_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract22" xlink:to="iinn_UnlabeledAbstract22_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NetBookValueAbstract0" xlink:href="iinn-20231231.xsd#iinn_NetBookValueAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NetBookValueAbstract0_lbl" xml:lang="en-US">Net book value:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NetBookValueAbstract0" xlink:to="iinn_NetBookValueAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">OTHER ACCOUNTS PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Employees&#8217; salaries and related liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AccountsPayableToRelatedParties" xlink:href="iinn-20231231.xsd#iinn_AccountsPayableToRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AccountsPayableToRelatedParties_lbl" xml:lang="en-US">Related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AccountsPayableToRelatedParties" xlink:to="iinn_AccountsPayableToRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of Lease Payments for the Company&apos;s Right-of-Use Assets over the Remaining Lease Periods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract23" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract23"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract23_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract23" xlink:to="iinn_UnlabeledAbstract23_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted Average of Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate - operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Lease liability, weighted-average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Lease Payments for the Company&apos;s Right-of-Use Assets over the Remaining Lease Periods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract24" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract24"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract24_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract24" xlink:to="iinn_UnlabeledAbstract24_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FINACIAL LIABILITIES AT FAIR VALUE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialGuaranteeInsuranceContractsClaimLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialGuaranteeInsuranceContractsClaimLiabilityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialGuaranteeInsuranceContractsClaimLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of Financial Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialGuaranteeInsuranceContractsClaimLiabilityTableTextBlock" xlink:to="us-gaap_FinancialGuaranteeInsuranceContractsClaimLiabilityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Total finacial liabilities at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl0" xml:lang="en-US">Financial liability fair value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHAREHOLDERS&apos; EQUITY (DEFICIT)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Ordinary shares, Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Ordinary shares, Issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Movement in Warrants Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual term (in years), Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract25" xlink:href="iinn-20231231.xsd#iinn_UnlabeledAbstract25"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract25_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract25" xlink:to="iinn_UnlabeledAbstract25_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Warrants, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Number of RSUs, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average exercise price, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual term (in years), Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued" xlink:href="iinn-20231231.xsd#iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued_lbl" xml:lang="en-US">Aggregate intrinsic value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued" xlink:to="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xml:lang="en-US">Number of Warrants, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average exercise price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual term (in years), Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised" xlink:href="iinn-20231231.xsd#iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised_lbl" xml:lang="en-US">Aggregate intrinsic value, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised" xlink:to="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of Warrants, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Number of RSUs, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average exercise price, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerms" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual term (in years), Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" xlink:href="iinn-20231231.xsd#iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited_lbl" xml:lang="en-US">Aggregate intrinsic value, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" xlink:to="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl" xml:lang="en-US">Number of Warrants, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average exercise price, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual term (in years), Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired" xlink:href="iinn-20231231.xsd#iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired_lbl" xml:lang="en-US">Aggregate intrinsic value, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired" xlink:to="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual term (in years), Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of Information about the Company&#8217;s Outstanding Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Exercise Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_WarrantsOutstanding" xlink:href="iinn-20231231.xsd#iinn_WarrantsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_WarrantsOutstanding_lbl" xml:lang="en-US">Warrants outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsOutstanding" xlink:to="iinn_WarrantsOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xml:lang="en-US">Expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Loss Per Share Calculated Using the Weighted Average Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Total number of Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_lbl" xml:lang="en-US">Schedule of Research and Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LaborAndRelatedExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Salary and related expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLaborRelatedExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLaborRelatedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLaborRelatedExpenses_lbl" xml:lang="en-US">Materials and related expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLaborRelatedExpenses" xlink:to="us-gaap_OtherLaborRelatedExpenses_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLaborRelatedExpenses_lbl0" xml:lang="en-US">Related NASDAQ IPO expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLaborRelatedExpenses" xlink:to="us-gaap_OtherLaborRelatedExpenses_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Share based payment (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_Subcontractors" xlink:href="iinn-20231231.xsd#iinn_Subcontractors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_Subcontractors_lbl" xml:lang="en-US">Subcontractors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Subcontractors" xlink:to="iinn_Subcontractors_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationNonproduction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationNonproduction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationNonproduction_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationNonproduction" xlink:to="us-gaap_DepreciationNonproduction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_SalesAndMarketingExpensesTextBlock" xlink:href="iinn-20231231.xsd#iinn_SalesAndMarketingExpensesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_SalesAndMarketingExpensesTextBlock_lbl" xml:lang="en-US">SALES AND MARKETING EXPENSES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SalesAndMarketingExpensesTextBlock" xlink:to="iinn_SalesAndMarketingExpensesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of Sales and Marketing Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock" xlink:to="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professionals&#8217; fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfessionalFees_lbl0" xml:lang="en-US">Professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficersCompensation_lbl" xml:lang="en-US">Salary and related expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OfficersCompensation_lbl0" xml:lang="en-US">Salary and related expenses &#8211; officers and directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSellingAndMarketingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherSellingAndMarketingExpense_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingAndMarketingExpense" xlink:to="us-gaap_OtherSellingAndMarketingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_GeneralAndAdministrativeExpensesTextBlock" xlink:href="iinn-20231231.xsd#iinn_GeneralAndAdministrativeExpensesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_GeneralAndAdministrativeExpensesTextBlock_lbl" xml:lang="en-US">GENERAL AND ADMINISTRATIVE EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GeneralAndAdministrativeExpensesTextBlock" xlink:to="iinn_GeneralAndAdministrativeExpensesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of General and Administrative Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:to="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Director&#8217;s fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FundsRaisingExpenses" xlink:href="iinn-20231231.xsd#iinn_FundsRaisingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_FundsRaisingExpenses_lbl" xml:lang="en-US">Funds raising expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FundsRaisingExpenses" xlink:to="iinn_FundsRaisingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Number of options, Share-based payment expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xml:lang="en-US">Number of RSUs, Share-based payment expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl2" xml:lang="en-US">Share-based payment expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralInsuranceExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralInsuranceExpense_lbl" xml:lang="en-US">Insurance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralInsuranceExpense" xlink:to="us-gaap_GeneralInsuranceExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostMaintenance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostMaintenance_lbl" xml:lang="en-US">Office maintenance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TravelAndEntertainmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TravelAndEntertainmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TravelAndEntertainmentExpense_lbl" xml:lang="en-US">Travel abroad</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TravelAndEntertainmentExpense" xlink:to="us-gaap_TravelAndEntertainmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherGeneralExpense_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralExpense" xlink:to="us-gaap_OtherGeneralExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl" xml:lang="en-US">FINANCIAL (INCOME) AND EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Financial (Income) and Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancingInterestExpense_lbl" xml:lang="en-US">Interest on financial liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingInterestExpense" xlink:to="us-gaap_FinancingInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ForeignCurrencyTransactionsGainBeforeTax" xlink:href="iinn-20231231.xsd#iinn_ForeignCurrencyTransactionsGainBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ForeignCurrencyTransactionsGainBeforeTax_lbl" xml:lang="en-US">Foreign currency transaction income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ForeignCurrencyTransactionsGainBeforeTax" xlink:to="iinn_ForeignCurrencyTransactionsGainBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DisposalGroupIncludingDiscontinuedOperationsOtherIncome" xlink:href="iinn-20231231.xsd#iinn_DisposalGroupIncludingDiscontinuedOperationsOtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DisposalGroupIncludingDiscontinuedOperationsOtherIncome_lbl" xml:lang="en-US">Total expenses (Income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DisposalGroupIncludingDiscontinuedOperationsOtherIncome" xlink:to="iinn_DisposalGroupIncludingDiscontinuedOperationsOtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">TAXES ON INCOME</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxAssetsAbstract" xlink:href="iinn-20231231.xsd#iinn_DeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetsAbstract" xlink:to="iinn_DeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US">R&amp;D capitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxAssetsFundRaisingCosts2021" xlink:href="iinn-20231231.xsd#iinn_DeferredTaxAssetsFundRaisingCosts2021"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DeferredTaxAssetsFundRaisingCosts2021_lbl" xml:lang="en-US">Fund raising costs 2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetsFundRaisingCosts2021" xlink:to="iinn_DeferredTaxAssetsFundRaisingCosts2021_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxAssetsFundRaisingCost2023" xlink:href="iinn-20231231.xsd#iinn_DeferredTaxAssetsFundRaisingCost2023"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DeferredTaxAssetsFundRaisingCost2023_lbl" xml:lang="en-US">Fund raising costs 2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetsFundRaisingCost2023" xlink:to="iinn_DeferredTaxAssetsFundRaisingCost2023_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfTheoreticalTaxTableTextBlock" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfTheoreticalTaxTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfTheoreticalTaxTableTextBlock_lbl" xml:lang="en-US">Schedule of Theoretical Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfTheoreticalTaxTableTextBlock" xlink:to="iinn_ScheduleOfTheoreticalTaxTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Theoretical tax credit at applicable statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Non-allowable expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" xlink:href="iinn-20231231.xsd#iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized_lbl" xml:lang="en-US">Temporary differences and tax losses for which no Deferred Tax Asset is recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" xlink:to="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">SHARE-BASED PAYMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Options to Services Providers and Advisers Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors_lbl" xml:lang="en-US">Number of options, Reclassified to employees and directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors_lbl" xml:lang="en-US">Weighted average Exercise price, Reclassified to employees and directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors" xlink:to="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average Exercise price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers_lbl" xml:lang="en-US">Number of options, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average Exercise price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Exercise price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod_lbl" xml:lang="en-US">Number of options, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average Exercise price, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of options, Options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Exercisable ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average Exercise price, Options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of RSUs to Services Providers and Advisers Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of RSUs, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested_lbl" xml:lang="en-US">Number of RSUs, RSU&#8217;s Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" xlink:to="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Shareholders and Other Related Parties&#8217; Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfBalanceWithRelatedPartiesTableTextBlock" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfBalanceWithRelatedPartiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfBalanceWithRelatedPartiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Balances with Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfBalanceWithRelatedPartiesTableTextBlock" xlink:to="iinn_ScheduleOfBalanceWithRelatedPartiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnusualOrInfrequentItemNatureOfEventOrTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnusualOrInfrequentItemNatureOfEventOrTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnusualOrInfrequentItemNatureOfEventOrTransaction_lbl" xml:lang="en-US">Nature of transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnusualOrInfrequentItemNatureOfEventOrTransaction" xlink:to="us-gaap_UnusualOrInfrequentItemNatureOfEventOrTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Exchange (losses) profits arising on translation to presentation currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForParticipationLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForParticipationLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForParticipationLiabilities_lbl" xml:lang="en-US">IIA participation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForParticipationLiabilities" xlink:to="us-gaap_PaymentsForParticipationLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue" xlink:href="iinn-20231231.xsd#iinn_EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iinn_EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue_lbl" xml:lang="en-US">Revaluation of financial liabilities at fair value through profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue" xlink:to="iinn_EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinanceLeaseInterestExpenses" xlink:href="iinn-20231231.xsd#iinn_FinanceLeaseInterestExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iinn_FinanceLeaseInterestExpenses_lbl" xml:lang="en-US">Finance expense in respect of lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinanceLeaseInterestExpenses" xlink:to="iinn_FinanceLeaseInterestExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxAssetValuationAllowance" xlink:href="iinn-20231231.xsd#iinn_DeferredTaxAssetValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iinn_DeferredTaxAssetValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetValuationAllowance" xlink:to="iinn_DeferredTaxAssetValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Theoretical tax credit at applicable statutory rate: 23%</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Related parties transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US">Previously Reported [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DevelopmentEquipmentMember" xlink:href="iinn-20231231.xsd#iinn_DevelopmentEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DevelopmentEquipmentMember_lbl" xml:lang="en-US">Development equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DevelopmentEquipmentMember" xlink:to="iinn_DevelopmentEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and office equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl" xml:lang="en-US">Financial liability [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NonTradableWarrantsMember" xlink:href="iinn-20231231.xsd#iinn_NonTradableWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NonTradableWarrantsMember_lbl" xml:lang="en-US">Non-tradable warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NonTradableWarrantsMember" xlink:to="iinn_NonTradableWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant purchase [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePrice55Member" xlink:href="iinn-20231231.xsd#iinn_ExercisePrice55Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExercisePrice55Member_lbl" xml:lang="en-US">5.5 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePrice55Member" xlink:to="iinn_ExercisePrice55Member_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePrice55OneMember" xlink:href="iinn-20231231.xsd#iinn_ExercisePrice55OneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExercisePrice55OneMember_lbl" xml:lang="en-US">5.5 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePrice55OneMember" xlink:to="iinn_ExercisePrice55OneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePrice55TwoMember" xlink:href="iinn-20231231.xsd#iinn_ExercisePrice55TwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExercisePrice55TwoMember_lbl" xml:lang="en-US">5.5 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePrice55TwoMember" xlink:to="iinn_ExercisePrice55TwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_Exercise6875Member" xlink:href="iinn-20231231.xsd#iinn_Exercise6875Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_Exercise6875Member_lbl" xml:lang="en-US">6.875 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Exercise6875Member" xlink:to="iinn_Exercise6875Member_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_Exercise16Member" xlink:href="iinn-20231231.xsd#iinn_Exercise16Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_Exercise16Member_lbl" xml:lang="en-US">1.6 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Exercise16Member" xlink:to="iinn_Exercise16Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ServicesProvidersAndAdvisersMember" xlink:href="iinn-20231231.xsd#iinn_ServicesProvidersAndAdvisersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ServicesProvidersAndAdvisersMember_lbl" xml:lang="en-US">Services Providers and Advisers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ServicesProvidersAndAdvisersMember" xlink:to="iinn_ServicesProvidersAndAdvisersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_EmployeesAndDirectorsMember" xlink:href="iinn-20231231.xsd#iinn_EmployeesAndDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_EmployeesAndDirectorsMember_lbl" xml:lang="en-US">Employees and Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EmployeesAndDirectorsMember" xlink:to="iinn_EmployeesAndDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">Restricted Stock Units [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xml:lang="en-US">RSUs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="iinn_OfficersAndDirectorsMember" xlink:href="iinn-20231231.xsd#iinn_OfficersAndDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_OfficersAndDirectorsMember_lbl" xml:lang="en-US">Officers and Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OfficersAndDirectorsMember" xlink:to="iinn_OfficersAndDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_OfficerMember_lbl" xml:lang="en-US">Officers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficerMember" xlink:to="srt_OfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PledgingPurposeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PledgingPurposeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PledgingPurposeAxis_lbl" xml:lang="en-US">Pledging Purpose [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PledgingPurposeAxis" xlink:to="us-gaap_PledgingPurposeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Ordinary shares capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Purchase price of per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Purchase price of per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Pre funded warrant, per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Pre funded warrant, per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl" xml:lang="en-US">Exercise price of per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Direct offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl0" xml:lang="en-US">Offering cost (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_AdditionalOfferingCosts" xlink:href="iinn-20231231.xsd#iinn_AdditionalOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AdditionalOfferingCosts_lbl" xml:lang="en-US">Additional offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AdditionalOfferingCosts" xlink:to="iinn_AdditionalOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AggregatePercentage" xlink:href="iinn-20231231.xsd#iinn_AggregatePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AggregatePercentage_lbl" xml:lang="en-US">Aggregate percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregatePercentage" xlink:to="iinn_AggregatePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfDerivativeIssuanceCosts_lbl" xml:lang="en-US">Issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:to="us-gaap_PaymentsOfDerivativeIssuanceCosts_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfDerivativeIssuanceCosts_lbl0" xml:lang="en-US">Issuance costs (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:to="us-gaap_PaymentsOfDerivativeIssuanceCosts_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_lbl" xml:lang="en-US">Incurred accumulated losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:to="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US">Employees monthly deposits rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Deposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Deposits_lbl" xml:lang="en-US">Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl" xml:lang="en-US">Fixed annual interest percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AggregateBudget" xlink:href="iinn-20231231.xsd#iinn_AggregateBudget"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AggregateBudget_lbl" xml:lang="en-US">Aggregate budget</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateBudget" xlink:to="iinn_AggregateBudget_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfApprovedBudget" xlink:href="iinn-20231231.xsd#iinn_PercentageOfApprovedBudget"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PercentageOfApprovedBudget_lbl" xml:lang="en-US">Percentage of approved budget</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfApprovedBudget" xlink:to="iinn_PercentageOfApprovedBudget_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ProjectBudgetAggregateAmount" xlink:href="iinn-20231231.xsd#iinn_ProjectBudgetAggregateAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ProjectBudgetAggregateAmount_lbl" xml:lang="en-US">Project budget aggregate amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ProjectBudgetAggregateAmount" xlink:to="iinn_ProjectBudgetAggregateAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Total funds received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RoyaltiesPercentage" xlink:href="iinn-20231231.xsd#iinn_RoyaltiesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_RoyaltiesPercentage_lbl" xml:lang="en-US">Percentage of royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RoyaltiesPercentage" xlink:to="iinn_RoyaltiesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ContingentUponFutureSales" xlink:href="iinn-20231231.xsd#iinn_ContingentUponFutureSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ContingentUponFutureSales_lbl" xml:lang="en-US">Contingent upon future sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ContingentUponFutureSales" xlink:to="iinn_ContingentUponFutureSales_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Rent payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ReimbursementAmount" xlink:href="iinn-20231231.xsd#iinn_ReimbursementAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ReimbursementAmount_lbl" xml:lang="en-US">Reimbursement amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ReimbursementAmount" xlink:to="iinn_ReimbursementAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManagementFeeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementFeeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ManagementFeeExpense_lbl" xml:lang="en-US">Management fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementFeeExpense" xlink:to="us-gaap_ManagementFeeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total expenses related to the leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FutureLeasePaymentsDiscountedInterestRate" xlink:href="iinn-20231231.xsd#iinn_FutureLeasePaymentsDiscountedInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_FutureLeasePaymentsDiscountedInterestRate_lbl" xml:lang="en-US">Future lease payments discounted interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FutureLeasePaymentsDiscountedInterestRate" xlink:to="iinn_FutureLeasePaymentsDiscountedInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfPayFees" xlink:href="iinn-20231231.xsd#iinn_PercentageOfPayFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PercentageOfPayFees_lbl" xml:lang="en-US">Percentage of pay fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfPayFees" xlink:to="iinn_PercentageOfPayFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockDividendsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockDividendsShares_lbl" xml:lang="en-US">Ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockDividendsShares" xlink:to="us-gaap_StockDividendsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionExercisePriceDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionExercisePriceDecrease_lbl" xml:lang="en-US">Exercise of per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceDecrease" xlink:to="us-gaap_StockOptionExercisePriceDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Warrants fair value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl" xml:lang="en-US">Expected term of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AggregateOfOrdinaryShares" xlink:href="iinn-20231231.xsd#iinn_AggregateOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AggregateOfOrdinaryShares_lbl" xml:lang="en-US">Aggregate of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateOfOrdinaryShares" xlink:to="iinn_AggregateOfOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_OrdinaryShare" xlink:href="iinn-20231231.xsd#iinn_OrdinaryShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_OrdinaryShare_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OrdinaryShare" xlink:to="iinn_OrdinaryShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xml:lang="en-US">Warrants exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shareholders approved</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalUnitsAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalUnitsAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl" xml:lang="en-US">Authorized share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsAuthorized" xlink:to="us-gaap_CapitalUnitsAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SoldOrdinaryShares" xlink:href="iinn-20231231.xsd#iinn_SoldOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_SoldOrdinaryShares_lbl" xml:lang="en-US">Sold ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SoldOrdinaryShares" xlink:to="iinn_SoldOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TradableWarrants" xlink:href="iinn-20231231.xsd#iinn_TradableWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TradableWarrants_lbl" xml:lang="en-US">Tradable warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrants" xlink:to="iinn_TradableWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NonTradableWarrants" xlink:href="iinn-20231231.xsd#iinn_NonTradableWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NonTradableWarrants_lbl" xml:lang="en-US">Non tradable warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NonTradableWarrants" xlink:to="iinn_NonTradableWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDividendsReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDividendsReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromDividendsReceived_lbl" xml:lang="en-US">Proceeds received (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDividendsReceived" xlink:to="us-gaap_ProceedsFromDividendsReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfferingCostsPartnershipInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfferingCostsPartnershipInterests"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfferingCostsPartnershipInterests_lbl" xml:lang="en-US">Additional offering direct costs (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfferingCostsPartnershipInterests" xlink:to="us-gaap_OfferingCostsPartnershipInterests_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FairValueWarrants" xlink:href="iinn-20231231.xsd#iinn_FairValueWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_FairValueWarrants_lbl" xml:lang="en-US">Fair value warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FairValueWarrants" xlink:to="iinn_FairValueWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices_lbl" xml:lang="en-US">Granted to underwriters (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued_lbl" xml:lang="en-US">Tradable warrants to purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfExercisePrice" xlink:href="iinn-20231231.xsd#iinn_PercentageOfExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PercentageOfExercisePrice_lbl" xml:lang="en-US">Percentage of exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfExercisePrice" xlink:to="iinn_PercentageOfExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfExerciseOfTradableWarrants" xlink:href="iinn-20231231.xsd#iinn_PercentageOfExerciseOfTradableWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PercentageOfExerciseOfTradableWarrants_lbl" xml:lang="en-US">Percentage of exercise of tradable warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfExerciseOfTradableWarrants" xlink:to="iinn_PercentageOfExerciseOfTradableWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xml:lang="en-US">Fair value of the financial liability (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Non-cash expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoninterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoninterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoninterestExpense_lbl" xml:lang="en-US">Non-direct expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpense" xlink:to="us-gaap_NoninterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseOther_lbl" xml:lang="en-US">Cash expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BenefitsLossesAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BenefitsLossesAndExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BenefitsLossesAndExpenses_lbl" xml:lang="en-US">Profit and loss (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BenefitsLossesAndExpenses" xlink:to="us-gaap_BenefitsLossesAndExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Options exercise shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0" xml:lang="en-US">Vested grant share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl1" xml:lang="en-US">Number of vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonUnitAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonUnitAuthorized_lbl" xml:lang="en-US">Authorized share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonUnitAuthorized" xlink:to="us-gaap_CommonUnitAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherUnderwritingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherUnderwritingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherUnderwritingExpense_lbl" xml:lang="en-US">Underwriting discounts (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherUnderwritingExpense" xlink:to="us-gaap_OtherUnderwritingExpense_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrarGpi3WKEtaAw66u01Fz01dWXY8Co/0nt/EYPpxJQpmucNPntkKGDUIzqiVXTghuh97D+3HoPuNe26jHPIaw4lyMqYvKxFlhkbYBWIUcgKRoJ/travtspQtU2Bzfjb2zOjTVkVWS8tD/cenVlshsSuvI61kcurHTnf7bi/aiMvKs5kJ2lHUdB1A51Zvlxfi4hXCDE5TwMWPCsMitxojF1/teoN1QVVrLHiCnfNaTRPSx/rKKVo5ilXHoDsmJ3hL+o=] CSR-->
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfAgreementWarrants" xlink:href="iinn-20231231.xsd#iinn_PercentageOfAgreementWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PercentageOfAgreementWarrants_lbl" xml:lang="en-US">Percentage of agreement warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfAgreementWarrants" xlink:to="iinn_PercentageOfAgreementWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US">Corporate tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Carryforward tax losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_CapitalGainTaxRate" xlink:href="iinn-20231231.xsd#iinn_CapitalGainTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_CapitalGainTaxRate_lbl" xml:lang="en-US">Capital gain tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CapitalGainTaxRate" xlink:to="iinn_CapitalGainTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_OptionsIssuableTerm" xlink:href="iinn-20231231.xsd#iinn_OptionsIssuableTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_OptionsIssuableTerm_lbl" xml:lang="en-US">Options issuable term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OptionsIssuableTerm" xlink:to="iinn_OptionsIssuableTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareOptionsVestingPeriod" xlink:href="iinn-20231231.xsd#iinn_ShareOptionsVestingPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareOptionsVestingPeriod_lbl" xml:lang="en-US">Share options vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareOptionsVestingPeriod" xlink:to="iinn_ShareOptionsVestingPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Contractual life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0" xml:lang="en-US">Number of grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_EquityPercentage" xlink:href="iinn-20231231.xsd#iinn_EquityPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_EquityPercentage_lbl" xml:lang="en-US">Company&#8217;s equity percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EquityPercentage" xlink:to="iinn_EquityPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_lbl" xml:lang="en-US">Number of authorized ordinary shares increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RSUsVestPeriod" xlink:href="iinn-20231231.xsd#iinn_RSUsVestPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_RSUsVestPeriod_lbl" xml:lang="en-US">RSUs vest period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RSUsVestPeriod" xlink:to="iinn_RSUsVestPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Purchase of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RestrictedStockUnits" xlink:href="iinn-20231231.xsd#iinn_RestrictedStockUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_RestrictedStockUnits_lbl" xml:lang="en-US">Restricted Stock Units (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RestrictedStockUnits" xlink:to="iinn_RestrictedStockUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl" xml:lang="en-US">Exercise price of per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock" xlink:href="iinn-20231231.xsd#iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock_lbl" xml:lang="en-US">Conversion from IFRS to U.S. GAAP</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock" xlink:to="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock_lbl" xml:lang="en-US">Government Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinanceIncomeAndExpensesPolicyTextBlock" xlink:href="iinn-20231231.xsd#iinn_FinanceIncomeAndExpensesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_FinanceIncomeAndExpensesPolicyTextBlock_lbl" xml:lang="en-US">Finance Income and Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinanceIncomeAndExpensesPolicyTextBlock" xlink:to="iinn_FinanceIncomeAndExpensesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Current Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SeverancePolicyTextBlock" xlink:href="iinn-20231231.xsd#iinn_SeverancePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_SeverancePolicyTextBlock_lbl" xml:lang="en-US">Severance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SeverancePolicyTextBlock" xlink:to="iinn_SeverancePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PreFundedWarrantsMember" xlink:href="iinn-20231231.xsd#iinn_PreFundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre-Funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PreFundedWarrantsMember" xlink:to="iinn_PreFundedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PlacementAgentWarrantsMember" xlink:href="iinn-20231231.xsd#iinn_PlacementAgentWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PlacementAgentWarrantsMember_lbl" xml:lang="en-US">Placement Agent Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PlacementAgentWarrantsMember" xlink:to="iinn_PlacementAgentWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IL"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_IL_lbl" xml:lang="en-US">Israel [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsMember_lbl" xml:lang="en-US">Deposits [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsMember" xlink:to="us-gaap_DepositsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PrivateWarrantsMember" xlink:href="iinn-20231231.xsd#iinn_PrivateWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PrivateWarrantsMember_lbl" xml:lang="en-US">Private Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PrivateWarrantsMember" xlink:to="iinn_PrivateWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_BrokersMember" xlink:href="iinn-20231231.xsd#iinn_BrokersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_BrokersMember_lbl" xml:lang="en-US">Brokers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_BrokersMember" xlink:to="iinn_BrokersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NonTradableSharesOptionsMember" xlink:href="iinn-20231231.xsd#iinn_NonTradableSharesOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NonTradableSharesOptionsMember_lbl" xml:lang="en-US">Non-Tradable Shares Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NonTradableSharesOptionsMember" xlink:to="iinn_NonTradableSharesOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Share Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TwoThousandAndNineteenPlanMember" xlink:href="iinn-20231231.xsd#iinn_TwoThousandAndNineteenPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TwoThousandAndNineteenPlanMember_lbl" xml:lang="en-US">2019 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TwoThousandAndNineteenPlanMember" xlink:to="iinn_TwoThousandAndNineteenPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AdvisoryBoardMembersMember" xlink:href="iinn-20231231.xsd#iinn_AdvisoryBoardMembersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AdvisoryBoardMembersMember_lbl" xml:lang="en-US">Advisory Board Members [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AdvisoryBoardMembersMember" xlink:to="iinn_AdvisoryBoardMembersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Black Scholes Model [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_EmployeesDirectorsAndSubcontractorsMember" xlink:href="iinn-20231231.xsd#iinn_EmployeesDirectorsAndSubcontractorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_EmployeesDirectorsAndSubcontractorsMember_lbl" xml:lang="en-US">Employees, Directors and Subcontractors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EmployeesDirectorsAndSubcontractorsMember" xlink:to="iinn_EmployeesDirectorsAndSubcontractorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementDomain_lbl" xml:lang="en-US">Revision of Prior Period [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedBalanceSheetStatementTable_lbl" xml:lang="en-US">Condensed Balance Sheet Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_CondensedBalanceSheetStatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems_lbl" xml:lang="en-US">Schedule of Change of Our Financial Results in Balance Sheets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="srt_CondensedBalanceSheetStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedStatementOfComprehensiveIncomeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable_lbl" xml:lang="en-US">Condensed Statement of Comprehensive Income [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedStatementOfIncomeCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedStatementOfIncomeCaptionsLineItems_lbl" xml:lang="en-US">Condensed Statement of Income Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="srt_CondensedStatementOfIncomeCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable" xlink:href="iinn-20231231.xsd#iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable_lbl" xml:lang="en-US">Significant Accounting Policies (Details) - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable" xlink:to="iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsLineItems" xlink:href="iinn-20231231.xsd#iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsLineItems_lbl" xml:lang="en-US">Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsLineItems" xlink:to="iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityTable" xlink:href="iinn-20231231.xsd#iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityTable_lbl" xml:lang="en-US">Finacial Liabilities at Fair Value (Details) - Schedule of Financial Liability [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityTable" xlink:to="iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityLineItems" xlink:href="iinn-20231231.xsd#iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityLineItems_lbl" xml:lang="en-US">Finacial Liabilities at Fair Value (Details) - Schedule of Financial Liability [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityLineItems" xlink:to="iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Schedule of Movement in Warrants Outstanding [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Schedule of Information about the Company&#8217;s Outstanding Warrants [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesTable" xlink:href="iinn-20231231.xsd#iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesTable_lbl" xml:lang="en-US">General and Administrative Expenses (Details) - Schedule of General and Administrative Expenses [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesTable" xlink:to="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:href="iinn-20231231.xsd#iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems_lbl" xml:lang="en-US">General and Administrative Expenses (Details) - Schedule of General and Administrative Expenses [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable" xlink:href="iinn-20231231.xsd#iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable_lbl" xml:lang="en-US">Share-Based Payment (Details) - Schedule of Options to Services Providers and Advisers Outstanding [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable" xlink:to="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:href="iinn-20231231.xsd#iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems_lbl" xml:lang="en-US">Schedule of Options Outstanding [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable" xlink:href="iinn-20231231.xsd#iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable_lbl" xml:lang="en-US">Share-Based Payment (Details) - Schedule of RSUs to Services Providers and Advisers Outstanding [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable" xlink:to="iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems" xlink:href="iinn-20231231.xsd#iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems_lbl" xml:lang="en-US">Share-Based Payment (Details) - Schedule of RSUs to Services Providers and Advisers Outstanding [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Schedule of Shareholders and Other Related Parties&#8217; Benefits [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" xlink:href="iinn-20231231.xsd#iinn_RelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable_lbl" xml:lang="en-US">Related Parties (Details) - Schedule of Balances with Related Parties [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" xlink:to="iinn_RelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl0" xml:lang="en-US">Schedule of Balances with Related Parties [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_GeneralDetailsTable" xlink:href="iinn-20231231.xsd#iinn_GeneralDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_GeneralDetailsTable_lbl" xml:lang="en-US">General (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GeneralDetailsTable" xlink:to="iinn_GeneralDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesGeneralDisclosuresLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems_lbl" xml:lang="en-US">General [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PledgingPurposeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PledgingPurposeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PledgingPurposeDomain_lbl" xml:lang="en-US">Pledging Purpose [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PledgingPurposeDomain" xlink:to="us-gaap_PledgingPurposeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DepositsDetailsTable" xlink:href="iinn-20231231.xsd#iinn_DepositsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DepositsDetailsTable_lbl" xml:lang="en-US">Deposits (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DepositsDetailsTable" xlink:to="iinn_DepositsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositLiabilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositLiabilityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositLiabilityLineItems_lbl" xml:lang="en-US">Deposits [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositLiabilityLineItems" xlink:to="us-gaap_DepositLiabilityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_CommitmentsandContingenciesDetailsTable" xlink:href="iinn-20231231.xsd#iinn_CommitmentsandContingenciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_CommitmentsandContingenciesDetailsTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CommitmentsandContingenciesDetailsTable" xlink:to="iinn_CommitmentsandContingenciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinacialLiabilitiesatFairValueDetailsTable" xlink:href="iinn-20231231.xsd#iinn_FinacialLiabilitiesatFairValueDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinacialLiabilitiesatFairValueDetailsTable_lbl" xml:lang="en-US">Finacial Liabilities at Fair Value (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsTable" xlink:to="iinn_FinacialLiabilitiesatFairValueDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems_lbl" xml:lang="en-US">Finacial Liabilities at Fair Value [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareholdersEquityDeficitDetailsTable" xlink:href="iinn-20231231.xsd#iinn_ShareholdersEquityDeficitDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareholdersEquityDeficitDetailsTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Deficit) (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareholdersEquityDeficitDetailsTable" xlink:to="iinn_ShareholdersEquityDeficitDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:href="iinn-20231231.xsd#iinn_ShareholdersEquityDeficitDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareholdersEquityDeficitDetailsLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareholdersEquityDeficitDetailsLineItems" xlink:to="iinn_ShareholdersEquityDeficitDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TaxesonIncomeDetailsTable" xlink:href="iinn-20231231.xsd#iinn_TaxesonIncomeDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TaxesonIncomeDetailsTable_lbl" xml:lang="en-US">Taxes on Income (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TaxesonIncomeDetailsTable" xlink:to="iinn_TaxesonIncomeDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TaxesonIncomeDetailsLineItems" xlink:href="iinn-20231231.xsd#iinn_TaxesonIncomeDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TaxesonIncomeDetailsLineItems_lbl" xml:lang="en-US">Taxes on Income (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TaxesonIncomeDetailsLineItems" xlink:to="iinn_TaxesonIncomeDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPaymentDetailsTable" xlink:href="iinn-20231231.xsd#iinn_ShareBasedPaymentDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedPaymentDetailsTable_lbl" xml:lang="en-US">Share-Based Payment (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedPaymentDetailsTable" xlink:to="iinn_ShareBasedPaymentDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Payment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SubsequentEventsDetailsTable" xlink:href="iinn-20231231.xsd#iinn_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SubsequentEventsDetailsTable" xlink:to="iinn_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SubsequentEventsDetailsLineItems" xlink:href="iinn-20231231.xsd#iinn_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SubsequentEventsDetailsLineItems" xlink:to="iinn_SubsequentEventsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AccountsPayableToRelatedParties_lbl0" xml:lang="en-US">Amount of accounts payable to related parties, due after one year or beyond the normal operating cycle, if longer.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AccountsPayableToRelatedParties" xlink:to="iinn_AccountsPayableToRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AdditionalOfferingCosts_lbl0" xml:lang="en-US">Amount of additional offering costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AdditionalOfferingCosts" xlink:to="iinn_AdditionalOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AggregateBudget_lbl0" xml:lang="en-US">The amount of aggregate budget.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateBudget" xlink:to="iinn_AggregateBudget_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AggregateOfOrdinaryShares_lbl0" xml:lang="en-US">Number of aggregate of ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateOfOrdinaryShares" xlink:to="iinn_AggregateOfOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AggregatePercentage_lbl0" xml:lang="en-US">Aggregate percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregatePercentage" xlink:to="iinn_AggregatePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Percentage of annual depreciation rates of property, plant and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment" xlink:to="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_CapitalGainTaxRate_lbl0" xml:lang="en-US">Capital gain tax rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CapitalGainTaxRate" xlink:to="iinn_CapitalGainTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ContingentUponFutureSales_lbl0" xml:lang="en-US">The amount of contingent upon future sales.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ContingentUponFutureSales" xlink:to="iinn_ContingentUponFutureSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for conversion from IFRS to U.S. GAAP.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock" xlink:to="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_DeferredTaxAssetValuationAllowance_lbl0" xml:lang="en-US">Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetValuationAllowance" xlink:to="iinn_DeferredTaxAssetValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_DeferredTaxAssetsFundRaisingCost2023_lbl0" xml:lang="en-US">Fund raising costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetsFundRaisingCost2023" xlink:to="iinn_DeferredTaxAssetsFundRaisingCost2023_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_DeferredTaxAssetsFundRaisingCosts2021_lbl0" xml:lang="en-US">Fund raising costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetsFundRaisingCosts2021" xlink:to="iinn_DeferredTaxAssetsFundRaisingCosts2021_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_DisposalGroupIncludingDiscontinuedOperationsOtherIncome_lbl0" xml:lang="en-US">Amount of other income attributable to disposal group, including, but not limited to, discontinued operation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DisposalGroupIncludingDiscontinuedOperationsOtherIncome" xlink:to="iinn_DisposalGroupIncludingDiscontinuedOperationsOtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_EquityPercentage_lbl0" xml:lang="en-US">Equity percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EquityPercentage" xlink:to="iinn_EquityPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_EvaluationOfFinancialLiabilityAtFairValue_lbl0" xml:lang="en-US">The amount of evaluation of financial liability at fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EvaluationOfFinancialLiabilityAtFairValue" xlink:to="iinn_EvaluationOfFinancialLiabilityAtFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue_lbl0" xml:lang="en-US">Revaluation of financial liabilities at fair value through profit or loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue" xlink:to="iinn_EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_FairValueWarrants_lbl0" xml:lang="en-US">Number of fair value warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FairValueWarrants" xlink:to="iinn_FairValueWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_FinanceIncomeAndExpensesPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for finance income and expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinanceIncomeAndExpensesPolicyTextBlock" xlink:to="iinn_FinanceIncomeAndExpensesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_FinanceLeaseInterestExpenses_lbl0" xml:lang="en-US">Amount of interest expense on finance lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinanceLeaseInterestExpenses" xlink:to="iinn_FinanceLeaseInterestExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ForeignCurrencyTransactionsGainBeforeTax_lbl0" xml:lang="en-US">Amount before tax of foreign currency transaction realized and unrealized gain recognized in the income statement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ForeignCurrencyTransactionsGainBeforeTax" xlink:to="iinn_ForeignCurrencyTransactionsGainBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ForeignExchangeReserve_lbl0" xml:lang="en-US">Amount of foreign exchange reserve.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ForeignExchangeReserve" xlink:to="iinn_ForeignExchangeReserve_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_FundsRaisingExpenses_lbl0" xml:lang="en-US">Amount of funds raising expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FundsRaisingExpenses" xlink:to="iinn_FundsRaisingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_FutureLeasePaymentsDiscountedInterestRate_lbl0" xml:lang="en-US">Future lease payments discounted interest rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FutureLeasePaymentsDiscountedInterestRate" xlink:to="iinn_FutureLeasePaymentsDiscountedInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_GeneralAndAdministrativeExpensesTextBlock_lbl0" xml:lang="en-US">The entire disclosure for general and administrative expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GeneralAndAdministrativeExpensesTextBlock" xlink:to="iinn_GeneralAndAdministrativeExpensesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_IssuanceOfOrdinarySharesissuancesPursuantToATM_lbl0" xml:lang="en-US">The amount of issuance of ordinary shares (issuances pursuant to ATM).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IssuanceOfOrdinarySharesissuancesPursuantToATM" xlink:to="iinn_IssuanceOfOrdinarySharesissuancesPursuantToATM_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_NonTradableWarrants_lbl0" xml:lang="en-US">Number of non tradable warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NonTradableWarrants" xlink:to="iinn_NonTradableWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_OptionsIssuableTerm_lbl0" xml:lang="en-US">The term of options issuable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OptionsIssuableTerm" xlink:to="iinn_OptionsIssuableTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_OrdinaryShare_lbl0" xml:lang="en-US">Number of ordinary share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OrdinaryShare" xlink:to="iinn_OrdinaryShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PercentageOfAgreementWarrants_lbl0" xml:lang="en-US">Percentage of agreement warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfAgreementWarrants" xlink:to="iinn_PercentageOfAgreementWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PercentageOfApprovedBudget_lbl0" xml:lang="en-US">Percentage of approved budget.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfApprovedBudget" xlink:to="iinn_PercentageOfApprovedBudget_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PercentageOfExerciseOfTradableWarrants_lbl0" xml:lang="en-US">Percentage of exercise of tradable warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfExerciseOfTradableWarrants" xlink:to="iinn_PercentageOfExerciseOfTradableWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PercentageOfExercisePrice_lbl0" xml:lang="en-US">Percentage of exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfExercisePrice" xlink:to="iinn_PercentageOfExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PercentageOfPayFees_lbl0" xml:lang="en-US">Percentage of pay fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfPayFees" xlink:to="iinn_PercentageOfPayFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PrepaymentsOfLeaseLiabilities_lbl0" xml:lang="en-US">The amount of prepayments of lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PrepaymentsOfLeaseLiabilities" xlink:to="iinn_PrepaymentsOfLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ProjectBudgetAggregateAmount_lbl0" xml:lang="en-US">The amount of project budget aggregate amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ProjectBudgetAggregateAmount" xlink:to="iinn_ProjectBudgetAggregateAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_RSUsVestPeriod_lbl0" xml:lang="en-US">RSUs vest period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RSUsVestPeriod" xlink:to="iinn_RSUsVestPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans_lbl0" xml:lang="en-US">The amount of receipt of simple agreements for future equity (SAFE) and convertible loan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans" xlink:to="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ReimbursementAmount_lbl0" xml:lang="en-US">The amount of reimbursement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ReimbursementAmount" xlink:to="iinn_ReimbursementAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_RestrictedStockUnits_lbl0" xml:lang="en-US">Amount of restricted stock units.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RestrictedStockUnits" xlink:to="iinn_RestrictedStockUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue_lbl0" xml:lang="en-US">The amount of revaluation of simple agreements for future equity (SAFE) and convertible loan at fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue" xlink:to="iinn_RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_RoyaltiesPercentage_lbl0" xml:lang="en-US">Percentage of royalties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RoyaltiesPercentage" xlink:to="iinn_RoyaltiesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_SalesAndMarketingExpensesTextBlock_lbl0" xml:lang="en-US">Disclosure of sales and marketing expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SalesAndMarketingExpensesTextBlock" xlink:to="iinn_SalesAndMarketingExpensesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ScheduleOfBalanceWithRelatedPartiesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of balances with related parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfBalanceWithRelatedPartiesTableTextBlock" xlink:to="iinn_ScheduleOfBalanceWithRelatedPartiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of depreciation on straight-line method, over the estimated useful life of the assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" xlink:to="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of general and administrative expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:to="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of sales and marketing expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock" xlink:to="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ScheduleOfTheoreticalTaxTableTextBlock_lbl0" xml:lang="en-US">Disclosure of theoretical tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfTheoreticalTaxTableTextBlock" xlink:to="iinn_ScheduleOfTheoreticalTaxTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_SeverancePolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for severance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SeverancePolicyTextBlock" xlink:to="iinn_SeverancePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl0" xml:lang="en-US">Number of warrants, exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted-average exercise price, exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Weighted average remaining contractual term, exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl0" xml:lang="en-US">Number of warrants, expired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted-average exercise price, expired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Weighted average remaining contractual term, expired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Weighted average remaining contractual term, forfeited.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Weighted average remaining contractual term, issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Weighted average remaining contractual term, ending balance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors_lbl0" xml:lang="en-US">The number of options, reclassified to employees and directors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod_lbl0" xml:lang="en-US">The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers_lbl0" xml:lang="en-US">Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested_lbl0" xml:lang="en-US">Number of RSUs vested under share based payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" xlink:to="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors_lbl0" xml:lang="en-US">Per share price of weighted average exercise price, reclassified to employees and directors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors" xlink:to="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationUnderwritersFeesAtIPO_lbl0" xml:lang="en-US">The amount of share based compensation &#8211; underwriters fees at IPO.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationUnderwritersFeesAtIPO" xlink:to="iinn_ShareBasedCompensationUnderwritersFeesAtIPO_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital_lbl0" xml:lang="en-US">The amount of share based compensation-placement agent warrants against additional paid in capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" xlink:to="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareOptionsVestingPeriod_lbl0" xml:lang="en-US">Share options vesting period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareOptionsVestingPeriod" xlink:to="iinn_ShareOptionsVestingPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised_lbl0" xml:lang="en-US">The amount of aggregate intrinsic value exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised" xlink:to="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired_lbl0" xml:lang="en-US">The amount of aggregate intrinsic value expired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired" xlink:to="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited_lbl0" xml:lang="en-US">The amount of aggregate intrinsic value forfeited.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" xlink:to="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued_lbl0" xml:lang="en-US">The amount of aggregate intrinsic value issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued" xlink:to="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_SoldOrdinaryShares_lbl0" xml:lang="en-US">Number of sold ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SoldOrdinaryShares" xlink:to="iinn_SoldOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_StockIssuedDuringPeriodSharesTradableWarrantsExercise_lbl0" xml:lang="en-US">Tradable warrants exercise.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodSharesTradableWarrantsExercise" xlink:to="iinn_StockIssuedDuringPeriodSharesTradableWarrantsExercise_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_StockIssuedDuringPeriodValueParValueCancellation_lbl0" xml:lang="en-US">Par value cancellation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodValueParValueCancellation" xlink:to="iinn_StockIssuedDuringPeriodValueParValueCancellation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_Subcontractors_lbl0" xml:lang="en-US">Subcontractors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Subcontractors" xlink:to="iinn_Subcontractors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized_lbl0" xml:lang="en-US">Temporary differences and tax losses for which no Deferred Tax Asset is recognized.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" xlink:to="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_TradableWarrants_lbl0" xml:lang="en-US">Number of tradable warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrants" xlink:to="iinn_TradableWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_TradableWarrantsFinancialLiabilityAtIPO_lbl0" xml:lang="en-US">The amount of tradable warrants financial liability at IPO.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrantsFinancialLiabilityAtIPO" xlink:to="iinn_TradableWarrantsFinancialLiabilityAtIPO_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_WarrantsOutstanding_lbl0" xml:lang="en-US">The amount of warrants outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsOutstanding" xlink:to="iinn_WarrantsOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock_lbl1" xml:lang="en-US">Conversion From IFRSTo USGAAPPolicy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock" xlink:to="iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl1" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested_lbl1" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Number Of RSUs Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" xlink:to="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_GeneralAndAdministrativeExpensesTextBlock_lbl1" xml:lang="en-US">General And Administrative Expenses Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GeneralAndAdministrativeExpensesTextBlock" xlink:to="iinn_GeneralAndAdministrativeExpensesTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl2" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl1" xml:lang="en-US">Interest Income, Deposits with Financial Institutions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SalesAndMarketingExpensesTextBlock_lbl1" xml:lang="en-US">Sales And Marketing Expenses Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SalesAndMarketingExpensesTextBlock" xlink:to="iinn_SalesAndMarketingExpensesTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BenefitsLossesAndExpenses_lbl0" xml:lang="en-US">Benefits, Losses and Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BenefitsLossesAndExpenses" xlink:to="us-gaap_BenefitsLossesAndExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AdditionalOfferingCosts_lbl1" xml:lang="en-US">Additional Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AdditionalOfferingCosts" xlink:to="iinn_AdditionalOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDividendsReceived_lbl0" xml:lang="en-US">Proceeds from Dividends Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDividendsReceived" xlink:to="us-gaap_ProceedsFromDividendsReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PercentageOfExerciseOfTradableWarrants_lbl1" xml:lang="en-US">Percentage Of Exercise Of Tradable Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfExerciseOfTradableWarrants" xlink:to="iinn_PercentageOfExerciseOfTradableWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl0" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ChangesDuringThePeriodAbstract_lbl0" xml:lang="en-US">Changes During The Period Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="iinn_ChangesDuringThePeriodAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Numbers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl0" xml:lang="en-US">Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl0" xml:lang="en-US">Condensed Statement of Comprehensive Income [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NetBookValueAbstract_lbl0" xml:lang="en-US">Net Book Value Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NetBookValueAbstract" xlink:to="iinn_NetBookValueAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_BrokersMember_lbl0" xml:lang="en-US">Brokers Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_BrokersMember" xlink:to="iinn_BrokersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl1" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Options Reclassified To Employees And Directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PercentageOfApprovedBudget_lbl1" xml:lang="en-US">Percentage Of Approved Budget</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfApprovedBudget" xlink:to="iinn_PercentageOfApprovedBudget_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl0" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract18_lbl0" xml:lang="en-US">Unlabeled Abstract18</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract18" xlink:to="iinn_UnlabeledAbstract18_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract19_lbl0" xml:lang="en-US">Unlabeled Abstract19</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract19" xlink:to="iinn_UnlabeledAbstract19_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract16_lbl0" xml:lang="en-US">Unlabeled Abstract16</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract16" xlink:to="iinn_UnlabeledAbstract16_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract17_lbl0" xml:lang="en-US">Unlabeled Abstract17</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract17" xlink:to="iinn_UnlabeledAbstract17_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_lbl0" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract21_lbl0" xml:lang="en-US">Unlabeled Abstract21</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract21" xlink:to="iinn_UnlabeledAbstract21_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract22_lbl0" xml:lang="en-US">Unlabeled Abstract22</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract22" xlink:to="iinn_UnlabeledAbstract22_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract20_lbl0" xml:lang="en-US">Unlabeled Abstract20</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract20" xlink:to="iinn_UnlabeledAbstract20_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract25_lbl0" xml:lang="en-US">Unlabeled Abstract25</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract25" xlink:to="iinn_UnlabeledAbstract25_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl0" xml:lang="en-US">Short-Term Debt, Percentage Bearing Fixed Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract23_lbl0" xml:lang="en-US">Unlabeled Abstract23</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract23" xlink:to="iinn_UnlabeledAbstract23_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract24_lbl0" xml:lang="en-US">Unlabeled Abstract24</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract24" xlink:to="iinn_UnlabeledAbstract24_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonUnitAuthorized_lbl0" xml:lang="en-US">Common Unit, Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonUnitAuthorized" xlink:to="us-gaap_CommonUnitAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Number of Shares, Period Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ReimbursementAmount_lbl1" xml:lang="en-US">Reimbursement Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ReimbursementAmount" xlink:to="iinn_ReimbursementAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl1" xml:lang="en-US">Other Operating Income (Expense), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_OrdinarySharesNoParValueMember_lbl0" xml:lang="en-US">Ordinary Shares No Par Value Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OrdinarySharesNoParValueMember" xlink:to="iinn_OrdinarySharesNoParValueMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl1" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationNonproduction_lbl0" xml:lang="en-US">Depreciation, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationNonproduction" xlink:to="us-gaap_DepreciationNonproduction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl0" xml:lang="en-US">Capital Units, Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsAuthorized" xlink:to="us-gaap_CapitalUnitsAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGrossAbstract_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGrossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_OfficersAndDirectorsMember_lbl0" xml:lang="en-US">Officers And Directors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OfficersAndDirectorsMember" xlink:to="iinn_OfficersAndDirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ForeignExchangeReserve_lbl1" xml:lang="en-US">Foreign Exchange Reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ForeignExchangeReserve" xlink:to="iinn_ForeignExchangeReserve_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDerivativeIssuanceCosts_lbl1" xml:lang="en-US">Payments of Derivative Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:to="us-gaap_PaymentsOfDerivativeIssuanceCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl0" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOther_lbl0" xml:lang="en-US">Interest Expense, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued_lbl0" xml:lang="en-US">Class of Warrant or Right, Unissued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl1" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl1" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl0" xml:lang="en-US">Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract10" xlink:to="iinn_UnlabeledAbstract10_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract11_lbl0" xml:lang="en-US">Unlabeled Abstract11</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract11" xlink:to="iinn_UnlabeledAbstract11_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract14_lbl0" xml:lang="en-US">Unlabeled Abstract14</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract14" xlink:to="iinn_UnlabeledAbstract14_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract15_lbl0" xml:lang="en-US">Unlabeled Abstract15</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract15" xlink:to="iinn_UnlabeledAbstract15_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract12_lbl0" xml:lang="en-US">Unlabeled Abstract12</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract12" xlink:to="iinn_UnlabeledAbstract12_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract13_lbl0" xml:lang="en-US">Unlabeled Abstract13</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract13" xlink:to="iinn_UnlabeledAbstract13_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl0" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Ending Balance Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl0" xml:lang="en-US">Investor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract_lbl" xml:lang="en-US">Schedule Of Rsus To Services Providers And Advisers Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract" xlink:to="iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl0" xml:lang="en-US">Warrant, Exercise Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsMember_lbl0" xml:lang="en-US">Deposits [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsMember" xlink:to="us-gaap_DepositsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract2" xlink:to="iinn_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract1" xlink:to="iinn_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue_lbl1" xml:lang="en-US">Revaluation Of Simple Agreements For Future Equity SAFEAnd Convertible Loan At Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue" xlink:to="iinn_RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract4" xlink:to="iinn_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestBearingDepositsInBanks_lbl0" xml:lang="en-US">Interest-Bearing Deposits in Banks and Other Financial Institutions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestBearingDepositsInBanks" xlink:to="us-gaap_InterestBearingDepositsInBanks_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract3" xlink:to="iinn_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract0" xlink:to="iinn_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans_lbl1" xml:lang="en-US">Receipt Of Simple Agreements For Future Equity SAFEAnd Convertible Loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans" xlink:to="iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract9" xlink:to="iinn_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract6" xlink:to="iinn_UnlabeledAbstract6_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SeverancePolicyTextBlock_lbl1" xml:lang="en-US">Severance Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SeverancePolicyTextBlock" xlink:to="iinn_SeverancePolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract5" xlink:to="iinn_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract8" xlink:to="iinn_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract7" xlink:to="iinn_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl0" xml:lang="en-US">Other Nonoperating Income and Expense [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Deposits_lbl0" xml:lang="en-US">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl0" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfChangeOfOurFinancialResultsInBalanceSheetsAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfChangeOfOurFinancialResultsInBalanceSheetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfChangeOfOurFinancialResultsInBalanceSheetsAbstract_lbl" xml:lang="en-US">Schedule Of Change Of Our Financial Results In Balance Sheets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfChangeOfOurFinancialResultsInBalanceSheetsAbstract" xlink:to="iinn_ScheduleOfChangeOfOurFinancialResultsInBalanceSheetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerms_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Sales And Marketing Expenses Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock" xlink:to="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PrivateWarrantsMember_lbl0" xml:lang="en-US">Private Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PrivateWarrantsMember" xlink:to="iinn_PrivateWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl0" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables_lbl0" xml:lang="en-US">Increase (Decrease) in Leasing Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInLeasingReceivables" xlink:to="us-gaap_IncreaseDecreaseInLeasingReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised" xlink:to="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl0" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_EmployeesDirectorsAndSubcontractorsMember_lbl0" xml:lang="en-US">Employees Directors And Subcontractors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EmployeesDirectorsAndSubcontractorsMember" xlink:to="iinn_EmployeesDirectorsAndSubcontractorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_IssuanceOfOrdinarySharesissuancesPursuantToATM_lbl1" xml:lang="en-US">Issuance Of Ordinary Sharesissuances Pursuant To ATM</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IssuanceOfOrdinarySharesissuancesPursuantToATM" xlink:to="iinn_IssuanceOfOrdinarySharesissuancesPursuantToATM_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract" xlink:to="iinn_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Employee-related Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PercentageOfPayFees_lbl1" xml:lang="en-US">Percentage Of Pay Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfPayFees" xlink:to="iinn_PercentageOfPayFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract_lbl" xml:lang="en-US">Schedule Of Shareholders And Other Related Parties Benefits Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract" xlink:to="iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationUnderwritersFeesAtIPO_lbl1" xml:lang="en-US">Share Based Compensation Underwriters Fees At IPO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationUnderwritersFeesAtIPO" xlink:to="iinn_ShareBasedCompensationUnderwritersFeesAtIPO_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_WarrantsToPurchaseOrdinarySharesMember_lbl0" xml:lang="en-US">Warrants To Purchase Ordinary Shares Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsToPurchaseOrdinarySharesMember" xlink:to="iinn_WarrantsToPurchaseOrdinarySharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DevelopmentEquipmentMember_lbl0" xml:lang="en-US">Development Equipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DevelopmentEquipmentMember" xlink:to="iinn_DevelopmentEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancingInterestExpense_lbl0" xml:lang="en-US">Financing Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingInterestExpense" xlink:to="us-gaap_FinancingInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NonTradableWarrants_lbl1" xml:lang="en-US">Non Tradable Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NonTradableWarrants" xlink:to="iinn_NonTradableWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AdvisoryBoardMembersMember_lbl0" xml:lang="en-US">Advisory Board Members Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AdvisoryBoardMembersMember" xlink:to="iinn_AdvisoryBoardMembersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl0" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NetBookValueAbstract0_lbl0" xml:lang="en-US">Net Book Value Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NetBookValueAbstract0" xlink:to="iinn_NetBookValueAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl0" xml:lang="en-US">Payments to Acquire Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DeferredTaxAssetsAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetsAbstract" xlink:to="iinn_DeferredTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock_lbl0" xml:lang="en-US">Compensation Related Costs, General [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:to="us-gaap_CompensationRelatedCostsGeneralTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnusualOrInfrequentItemNatureOfEventOrTransaction_lbl0" xml:lang="en-US">Unusual or Infrequent Item, or Both, Nature of Event or Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnusualOrInfrequentItemNatureOfEventOrTransaction" xlink:to="us-gaap_UnusualOrInfrequentItemNatureOfEventOrTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FutureLeasePaymentsDiscountedInterestRate_lbl1" xml:lang="en-US">Future Lease Payments Discounted Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FutureLeasePaymentsDiscountedInterestRate" xlink:to="iinn_FutureLeasePaymentsDiscountedInterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl0" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl0" xml:lang="en-US">Condensed Balance Sheet [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl0" xml:lang="en-US">Payments to Acquire Businesses, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ForeignCurrencyTransactionsGainBeforeTax_lbl1" xml:lang="en-US">Foreign Currency Transactions Gain Before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ForeignCurrencyTransactionsGainBeforeTax" xlink:to="iinn_ForeignCurrencyTransactionsGainBeforeTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl1" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExercisePrice55OneMember_lbl0" xml:lang="en-US">Exercise Price55 One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePrice55OneMember" xlink:to="iinn_ExercisePrice55OneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl0" xml:lang="en-US">Other Current Assets [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl0" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_StockIssuedDuringPeriodSharesTradableWarrantsExercise_lbl1" xml:lang="en-US">Stock Issued During Period Shares Tradable Warrants Exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodSharesTradableWarrantsExercise" xlink:to="iinn_StockIssuedDuringPeriodSharesTradableWarrantsExercise_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ProjectBudgetAggregateAmount_lbl1" xml:lang="en-US">Project Budget Aggregate Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ProjectBudgetAggregateAmount" xlink:to="iinn_ProjectBudgetAggregateAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_EmployeesAndDirectorsMember_lbl0" xml:lang="en-US">Employees And Directors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EmployeesAndDirectorsMember" xlink:to="iinn_EmployeesAndDirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl0" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl0" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_EvaluationOfFinancialLiabilityAtFairValue_lbl1" xml:lang="en-US">Evaluation Of Financial Liability At Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EvaluationOfFinancialLiabilityAtFairValue" xlink:to="iinn_EvaluationOfFinancialLiabilityAtFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Disclosure [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AggregatePercentage_lbl1" xml:lang="en-US">Aggregate Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregatePercentage" xlink:to="iinn_AggregatePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl0" xml:lang="en-US">Other Noncash Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockDividendsShares_lbl0" xml:lang="en-US">Stock Dividends, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockDividendsShares" xlink:to="us-gaap_StockDividendsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl1" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FundsRaisingExpenses_lbl1" xml:lang="en-US">Funds Raising Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FundsRaisingExpenses" xlink:to="iinn_FundsRaisingExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued" xlink:to="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialGuaranteeInsuranceContractsClaimLiabilityTableTextBlock_lbl0" xml:lang="en-US">Financial Guarantee Insurance Contracts, Claim Liability [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialGuaranteeInsuranceContractsClaimLiabilityTableTextBlock" xlink:to="us-gaap_FinancialGuaranteeInsuranceContractsClaimLiabilityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExercisePrice55Member_lbl0" xml:lang="en-US">Exercise Price55 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePrice55Member" xlink:to="iinn_ExercisePrice55Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficersCompensation_lbl1" xml:lang="en-US">Salary and Wage, Officer, Excluding Cost of Good and Service Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PercentageOfExercisePrice_lbl1" xml:lang="en-US">Percentage Of Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfExercisePrice" xlink:to="iinn_PercentageOfExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl0" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl0" xml:lang="en-US">Warrant, Exercise Price, Decrease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_CapitalGainTaxRate_lbl1" xml:lang="en-US">Capital Gain Tax Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CapitalGainTaxRate" xlink:to="iinn_CapitalGainTaxRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ChangesDuringThePeriodAbstract1_lbl0" xml:lang="en-US">Changes During The Period Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangesDuringThePeriodAbstract1" xlink:to="iinn_ChangesDuringThePeriodAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl1" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl0" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OfficerMember_lbl0" xml:lang="en-US">Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficerMember" xlink:to="srt_OfficerMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfChangeOfOurFinancialResultsInComprehensiveIncomeAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfChangeOfOurFinancialResultsInComprehensiveIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfChangeOfOurFinancialResultsInComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Schedule Of Change Of Our Financial Results In Comprehensive Income Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfChangeOfOurFinancialResultsInComprehensiveIncomeAbstract" xlink:to="iinn_ScheduleOfChangeOfOurFinancialResultsInComprehensiveIncomeAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DeferredTaxAssetsFundRaisingCost2023_lbl1" xml:lang="en-US">Deferred Tax Assets Fund Raising Cost2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetsFundRaisingCost2023" xlink:to="iinn_DeferredTaxAssetsFundRaisingCost2023_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions_lbl0" xml:lang="en-US">Property, Plant and Equipment, Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NonTradableSharesOptionsMember_lbl0" xml:lang="en-US">Non Tradable Shares Options Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NonTradableSharesOptionsMember" xlink:to="iinn_NonTradableSharesOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Other Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl1"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract_lbl" xml:lang="en-US">Schedule Of Information About The Company SOutstanding Warrants Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract" xlink:to="iinn_ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_OrdinaryShare_lbl1" xml:lang="en-US">Ordinary Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OrdinaryShare" xlink:to="iinn_OrdinaryShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl0" xml:lang="en-US">Restricted Cash, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl2" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_Exercise16Member_lbl0" xml:lang="en-US">Exercise16 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Exercise16Member" xlink:to="iinn_Exercise16Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl0" xml:lang="en-US">Derivative Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired" xlink:to="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl0" xml:lang="en-US">Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl0" xml:lang="en-US">Conversion of Stock, Amount Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PercentageOfAgreementWarrants_lbl1" xml:lang="en-US">Percentage Of Agreement Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfAgreementWarrants" xlink:to="iinn_PercentageOfAgreementWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl0" xml:lang="en-US">Previously Reported [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ChangesDuringThePeriodAbstract0_lbl0" xml:lang="en-US">Changes During The Period Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangesDuringThePeriodAbstract0" xlink:to="iinn_ChangesDuringThePeriodAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl0" xml:lang="en-US">Stock Option, Exercise Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManagementFeeExpense_lbl0" xml:lang="en-US">Management Fee Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementFeeExpense" xlink:to="us-gaap_ManagementFeeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_Exercise6875Member_lbl0" xml:lang="en-US">Exercise6875 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Exercise6875Member" xlink:to="iinn_Exercise6875Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl1" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl2" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositLiabilitiesDisclosuresTextBlock_lbl0" xml:lang="en-US">Deposit Liabilities Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositLiabilitiesDisclosuresTextBlock" xlink:to="us-gaap_DepositLiabilitiesDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices_lbl0" xml:lang="en-US">Adjustment of Warrants Granted for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders Equity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_Subcontractors_lbl1" xml:lang="en-US">Subcontractors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Subcontractors" xlink:to="iinn_Subcontractors_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExercisePrice55TwoMember_lbl0" xml:lang="en-US">Exercise Price55 Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePrice55TwoMember" xlink:to="iinn_ExercisePrice55TwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfBalancesWithRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule Of Balances With Related Parties Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:to="iinn_ScheduleOfBalancesWithRelatedPartiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ServicesProvidersAndAdvisersMember_lbl0" xml:lang="en-US">Services Providers And Advisers Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ServicesProvidersAndAdvisersMember" xlink:to="iinn_ServicesProvidersAndAdvisersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl1" xml:lang="en-US">Professional Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl1" xml:lang="en-US">Selling and Marketing Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors_lbl1" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Weighted Average Exercise Price Reclassified To Employees And Directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors" xlink:to="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherSellingAndMarketingExpense_lbl0" xml:lang="en-US">Other Selling and Marketing Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingAndMarketingExpense" xlink:to="us-gaap_OtherSellingAndMarketingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock_lbl0" xml:lang="en-US">Government Assistance [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl0" xml:lang="en-US">Payments for Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Other General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl0" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DeferredTaxAssetsFundRaisingCosts2021_lbl1" xml:lang="en-US">Deferred Tax Assets Fund Raising Costs2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetsFundRaisingCosts2021" xlink:to="iinn_DeferredTaxAssetsFundRaisingCosts2021_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl0" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl1" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NonTradableWarrantsMember_lbl0" xml:lang="en-US">Non Tradable Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NonTradableWarrantsMember" xlink:to="iinn_NonTradableWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl1" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_WarrantsOutstanding_lbl1" xml:lang="en-US">Warrants Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsOutstanding" xlink:to="iinn_WarrantsOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfBalanceWithRelatedPartiesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Balance With Related Parties Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfBalanceWithRelatedPartiesTableTextBlock" xlink:to="iinn_ScheduleOfBalanceWithRelatedPartiesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TravelAndEntertainmentExpense_lbl0" xml:lang="en-US">Travel and Entertainment Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TravelAndEntertainmentExpense" xlink:to="us-gaap_TravelAndEntertainmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl1" xml:lang="en-US">Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PreFundedWarrantsMember_lbl0" xml:lang="en-US">Pre Funded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PreFundedWarrantsMember" xlink:to="iinn_PreFundedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl0" xml:lang="en-US">Labor and Related Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl0" xml:lang="en-US">Legal Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetAssetLiability_lbl0" xml:lang="en-US">Fair Value, Net Asset (Liability)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:to="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_OptionsIssuableTerm_lbl1" xml:lang="en-US">Options Issuable Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OptionsIssuableTerm" xlink:to="iinn_OptionsIssuableTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TradableWarrants_lbl1" xml:lang="en-US">Tradable Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrants" xlink:to="iinn_TradableWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareOptionsVestingPeriod_lbl1" xml:lang="en-US">Share Options Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareOptionsVestingPeriod" xlink:to="iinn_ShareOptionsVestingPeriod_lbl1"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfMovementInWarrantsOutstandingAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfMovementInWarrantsOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfMovementInWarrantsOutstandingAbstract_lbl" xml:lang="en-US">Schedule Of Movement In Warrants Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfMovementInWarrantsOutstandingAbstract" xlink:to="iinn_ScheduleOfMovementInWarrantsOutstandingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostMaintenance_lbl0" xml:lang="en-US">Cost, Maintenance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Option Forfeitures In Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl1" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Issued Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RoyaltiesPercentage_lbl1" xml:lang="en-US">Royalties Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RoyaltiesPercentage" xlink:to="iinn_RoyaltiesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PlacementAgentWarrantsMember_lbl0" xml:lang="en-US">Placement Agent Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PlacementAgentWarrantsMember" xlink:to="iinn_PlacementAgentWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoninterestExpense_lbl0" xml:lang="en-US">Noninterest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpense" xlink:to="us-gaap_NoninterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLaborRelatedExpenses_lbl1" xml:lang="en-US">Other Labor-related Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLaborRelatedExpenses" xlink:to="us-gaap_OtherLaborRelatedExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of General And Administrative Expenses Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:to="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FairValueWarrants_lbl1" xml:lang="en-US">Fair Value Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FairValueWarrants" xlink:to="iinn_FairValueWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceDecrease_lbl0" xml:lang="en-US">Stock Option, Exercise Price, Decrease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceDecrease" xlink:to="us-gaap_StockOptionExercisePriceDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl0" xml:lang="en-US">Stock Repurchased During Period, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SoldOrdinaryShares_lbl1" xml:lang="en-US">Sold Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SoldOrdinaryShares" xlink:to="iinn_SoldOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl0" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment_lbl1" xml:lang="en-US">Annual Depreciation Rates Of Property Plant And Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment" xlink:to="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Depreciation On Straight Line Method Over The Estimated Useful Life Of The Assets Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" xlink:to="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TwoThousandAndNineteenPlanMember_lbl0" xml:lang="en-US">Two Thousand And Nineteen Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TwoThousandAndNineteenPlanMember" xlink:to="iinn_TwoThousandAndNineteenPlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AggregateBudget_lbl1" xml:lang="en-US">Aggregate Budget</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateBudget" xlink:to="iinn_AggregateBudget_lbl1"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract_lbl" xml:lang="en-US">Schedule Of Options To Services Providers And Advisers Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract" xlink:to="iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherShortTermBorrowings_lbl0" xml:lang="en-US">Other Short-Term Borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherShortTermBorrowings" xlink:to="us-gaap_OtherShortTermBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_StockIssuedDuringPeriodValueParValueCancellation_lbl1" xml:lang="en-US">Stock Issued During Period Value Par Value Cancellation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodValueParValueCancellation" xlink:to="iinn_StockIssuedDuringPeriodValueParValueCancellation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralExpense_lbl0" xml:lang="en-US">Other General Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralExpense" xlink:to="us-gaap_OtherGeneralExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl2" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfPropertyAndEquipmentNetAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="iinn_ScheduleOfPropertyAndEquipmentNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl0" xml:lang="en-US">Proceeds from Sale of Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized_lbl1" xml:lang="en-US">Temporary Differences And Tax Losses For Which No Deferred Tax Asset Is Recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" xlink:to="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl0" xml:lang="en-US">Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AccountsPayableToRelatedParties_lbl1" xml:lang="en-US">Accounts Payable To Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AccountsPayableToRelatedParties" xlink:to="iinn_AccountsPayableToRelatedParties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralInsuranceExpense_lbl0" xml:lang="en-US">General Insurance Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralInsuranceExpense" xlink:to="us-gaap_GeneralInsuranceExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl0" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinanceLeaseInterestExpenses_lbl1" xml:lang="en-US">Finance Lease Interest Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinanceLeaseInterestExpenses" xlink:to="iinn_FinanceLeaseInterestExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl0" xml:lang="en-US">Deposits Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PrepaymentsOfLeaseLiabilities_lbl1" xml:lang="en-US">Prepayments Of Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PrepaymentsOfLeaseLiabilities" xlink:to="iinn_PrepaymentsOfLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue_lbl1" xml:lang="en-US">Evaluation Of Financial Liability Including Safe And Convertible Loan At Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue" xlink:to="iinn_EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AggregateOfOrdinaryShares_lbl1" xml:lang="en-US">Aggregate Of Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateOfOrdinaryShares" xlink:to="iinn_AggregateOfOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DeferredTaxAssetValuationAllowance_lbl1" xml:lang="en-US">Deferred Tax Asset Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetValuationAllowance" xlink:to="iinn_DeferredTaxAssetValuationAllowance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfTheoreticalTaxTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Theoretical Tax Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfTheoreticalTaxTableTextBlock" xlink:to="iinn_ScheduleOfTheoreticalTaxTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ContingentUponFutureSales_lbl1" xml:lang="en-US">Contingent Upon Future Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ContingentUponFutureSales" xlink:to="iinn_ContingentUponFutureSales_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl0" xml:lang="en-US">Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_EquityPercentage_lbl1" xml:lang="en-US">Equity Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EquityPercentage" xlink:to="iinn_EquityPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RSUsVestPeriod_lbl1" xml:lang="en-US">RSUs Vest Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RSUsVestPeriod" xlink:to="iinn_RSUsVestPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinanceIncomeAndExpensesPolicyTextBlock_lbl1" xml:lang="en-US">Finance Income And Expenses Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinanceIncomeAndExpensesPolicyTextBlock" xlink:to="iinn_FinanceIncomeAndExpensesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfferingCostsPartnershipInterests_lbl0" xml:lang="en-US">Offering Costs, Partnership Interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfferingCostsPartnershipInterests" xlink:to="us-gaap_OfferingCostsPartnershipInterests_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DisposalGroupIncludingDiscontinuedOperationsOtherIncome_lbl1" xml:lang="en-US">Disposal Group Including Discontinued Operations Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DisposalGroupIncludingDiscontinuedOperationsOtherIncome" xlink:to="iinn_DisposalGroupIncludingDiscontinuedOperationsOtherIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl1" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Depreciation On Straight Line Method Over The Estimated Useful Life Of The Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract" xlink:to="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForParticipationLiabilities_lbl0" xml:lang="en-US">Payments for Participation Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForParticipationLiabilities" xlink:to="us-gaap_PaymentsForParticipationLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" xlink:to="iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl0" xml:lang="en-US">Stockholders&apos; Equity, Reverse Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_IL_lbl0" xml:lang="en-US">ISRAEL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TradableWarrantsFinancialLiabilityAtIPO_lbl1" xml:lang="en-US">Tradable Warrants Financial Liability At IPO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TradableWarrantsFinancialLiabilityAtIPO" xlink:to="iinn_TradableWarrantsFinancialLiabilityAtIPO_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl2" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherUnderwritingExpense_lbl0" xml:lang="en-US">Other Underwriting Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherUnderwritingExpense" xlink:to="us-gaap_OtherUnderwritingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital_lbl1" xml:lang="en-US">Share Based Compensationplacement Agent Warrants Against Additional Paid In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" xlink:to="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl1" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RestrictedStockUnits_lbl1" xml:lang="en-US">Restricted Stock Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RestrictedStockUnits" xlink:to="iinn_RestrictedStockUnits_lbl1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>32
<FILENAME>iinn-20231231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 25 13:11:04 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ConsolidatedBalanceSheet" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ConsolidatedIncomeStatement" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ShareholdersEquityType2or3" roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ConsolidatedCashFlow" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_General" roleURI="http://www.inspiratechnologies.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_SignificantAccountingPolicies" roleURI="http://www.inspiratechnologies.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_Deposits" roleURI="http://www.inspiratechnologies.com/role/Deposits"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_OtherCurrentAssets" roleURI="http://www.inspiratechnologies.com/role/OtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_PropertyandEquipmentNet" roleURI="http://www.inspiratechnologies.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_OtherAccountsPayable" roleURI="http://www.inspiratechnologies.com/role/OtherAccountsPayable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_CommitmentsandContingencies" roleURI="http://www.inspiratechnologies.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_FinacialLiabilitiesatFairValue" roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ShareholdersEquityDeficit" roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquityDeficit"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ResearchandDevelopmentExpenses" roleURI="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_SalesandMarketingExpenses" roleURI="http://www.inspiratechnologies.com/role/SalesandMarketingExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_GeneralandAdministrativeExpenses" roleURI="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_FinancialIncomeandExpenses" roleURI="http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_TaxesonIncome" roleURI="http://www.inspiratechnologies.com/role/TaxesonIncome"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ShareBasedPayment" roleURI="http://www.inspiratechnologies.com/role/ShareBasedPayment"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_RelatedParties" roleURI="http://www.inspiratechnologies.com/role/RelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_SubsequentEvents" roleURI="http://www.inspiratechnologies.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_AccountingPoliciesByPolicy" roleURI="http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_SignificantAccountingPoliciesTables" roleURI="http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_OtherCurrentAssetsTables" roleURI="http://www.inspiratechnologies.com/role/OtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_PropertyandEquipmentNetTables" roleURI="http://www.inspiratechnologies.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_OtherAccountsPayableTables" roleURI="http://www.inspiratechnologies.com/role/OtherAccountsPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_CommitmentsandContingenciesTables" roleURI="http://www.inspiratechnologies.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_FinacialLiabilitiesatFairValueTables" roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ShareholdersEquityDeficitTables" roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ResearchandDevelopmentExpensesTables" roleURI="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_SalesandMarketingExpensesTables" roleURI="http://www.inspiratechnologies.com/role/SalesandMarketingExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_GeneralandAdministrativeExpensesTables" roleURI="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_FinancialIncomeandExpensesTables" roleURI="http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_TaxesonIncomeTables" roleURI="http://www.inspiratechnologies.com/role/TaxesonIncomeTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ShareBasedPaymentTables" roleURI="http://www.inspiratechnologies.com/role/ShareBasedPaymentTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_RelatedPartiesTables" roleURI="http://www.inspiratechnologies.com/role/RelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofOtherCurrentAssetsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofPropertyandEquipmentNetTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofOtherAccountsPayableTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofLeasePaymentsfortheCompanysRightofUseAssetsovertheRemainingLeasePeriodsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofLeasePaymentsfortheCompanysRightofUseAssetsovertheRemainingLeasePeriodsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofFinancialLiabilityTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofShareCapitalTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofMovementinWarrantsOutstandingTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofInformationabouttheCompanysOutstandingWarrantsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofSharesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofSharesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofSharesTable_Parentheticals" roleURI="http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofSharesTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofResearchandDevelopmentExpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofSalesandMarketingExpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofGeneralandAdministrativeExpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofFinancialIncomeandExpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofFinancialIncomeandExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofDeferredTaxAssetsandLiabilitiesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofTheoreticalTaxTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofTheoreticalTaxTable_Parentheticals" roleURI="http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ScheduleofBalanceswithRelatedPartiesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofBalanceswithRelatedPartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_GeneralDetails" roleURI="http://www.inspiratechnologies.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_SignificantAccountingPoliciesDetails" roleURI="http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_DepositsDetails" roleURI="http://www.inspiratechnologies.com/role/DepositsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_CommitmentsandContingenciesDetails" roleURI="http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_FinacialLiabilitiesatFairValueDetails" roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ShareholdersEquityDeficitDetails" roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_TaxesonIncomeDetails" roleURI="http://www.inspiratechnologies.com/role/TaxesonIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_ShareBasedPaymentDetails" roleURI="http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20231231.xsd#iinn_r_SubsequentEventsDetails" roleURI="http://www.inspiratechnologies.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_StockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_SellingAndMarketingExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ChangesDuringThePeriodAbstract1" xlink:href="iinn-20231231.xsd#iinn_ChangesDuringThePeriodAbstract1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ChangesDuringThePeriodAbstract1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueParValueCancellation" xlink:href="iinn-20231231.xsd#iinn_StockIssuedDuringPeriodValueParValueCancellation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract1" xlink:to="StockIssuedDuringPeriodValueParValueCancellation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract1" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract1" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract1" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract1" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract1" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesTradableWarrantsExercise" xlink:href="iinn-20231231.xsd#iinn_StockIssuedDuringPeriodSharesTradableWarrantsExercise"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract1" xlink:to="StockIssuedDuringPeriodSharesTradableWarrantsExercise" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangesDuringThePeriodAbstract0" xlink:href="iinn-20231231.xsd#iinn_ChangesDuringThePeriodAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ChangesDuringThePeriodAbstract0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract0" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract0" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangesDuringThePeriodAbstract" xlink:href="iinn-20231231.xsd#iinn_ChangesDuringThePeriodAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ChangesDuringThePeriodAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="us-gaap_StockholdersEquity_0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="us-gaap_CommonStockSharesOutstanding_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue" xlink:href="iinn-20231231.xsd#iinn_RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="EvaluationOfFinancialLiabilityAtFairValue" xlink:href="iinn-20231231.xsd#iinn_EvaluationOfFinancialLiabilityAtFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="EvaluationOfFinancialLiabilityAtFairValue" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentsOfLeaseLiabilities" xlink:href="iinn-20231231.xsd#iinn_PrepaymentsOfLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="PrepaymentsOfLeaseLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInLeasingReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInLeasingReceivables" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans" xlink:href="iinn-20231231.xsd#iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfOrdinarySharesissuancesPursuantToATM" xlink:href="iinn-20231231.xsd#iinn_IssuanceOfOrdinarySharesissuancesPursuantToATM"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="IssuanceOfOrdinarySharesissuancesPursuantToATM" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ConversionOfStockAmountIssued1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TradableWarrantsFinancialLiabilityAtIPO" xlink:href="iinn-20231231.xsd#iinn_TradableWarrantsFinancialLiabilityAtIPO"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="TradableWarrantsFinancialLiabilityAtIPO" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationUnderwritersFeesAtIPO" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationUnderwritersFeesAtIPO"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="ShareBasedCompensationUnderwritersFeesAtIPO" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_InterestPaidNet" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/General">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsGeneralTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_CompensationRelatedCostsGeneralTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/Deposits">
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositLiabilitiesDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositLiabilitiesDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepositsAbstract" xlink:to="us-gaap_DepositLiabilitiesDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/OtherCurrentAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/PropertyandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/OtherAccountsPayable">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue">
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ShareholdersEquityDeficit">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/SalesandMarketingExpenses">
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="SalesAndMarketingExpensesTextBlock" xlink:href="iinn-20231231.xsd#iinn_SalesAndMarketingExpensesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="SalesAndMarketingExpensesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses">
    <loc xlink:type="locator" xlink:label="GeneralAndAdministrativeExpensesAbstract" xlink:href="iinn-20231231.xsd#iinn_GeneralAndAdministrativeExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="GeneralAndAdministrativeExpensesTextBlock" xlink:href="iinn-20231231.xsd#iinn_GeneralAndAdministrativeExpensesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpensesAbstract" xlink:to="GeneralAndAdministrativeExpensesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/TaxesonIncome">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ShareBasedPayment">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/RelatedParties">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ConversionFromIFRSToUSGAAPPolicyTextBlock" xlink:href="iinn-20231231.xsd#iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ConversionFromIFRSToUSGAAPPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceIncomeAndExpensesPolicyTextBlock" xlink:href="iinn-20231231.xsd#iinn_FinanceIncomeAndExpensesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="FinanceIncomeAndExpensesPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeverancePolicyTextBlock" xlink:href="iinn-20231231.xsd#iinn_SeverancePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SeverancePolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedStatementOfComprehensiveIncomeTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/OtherCurrentAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/PropertyandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/OtherAccountsPayableTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/CommitmentsandContingenciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialGuaranteeInsuranceContractsClaimLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialGuaranteeInsuranceContractsClaimLiabilityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialGuaranteeInsuranceContractsClaimLiabilityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpensesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/SalesandMarketingExpensesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfSalesAndMarketingExpensesTableTextBlock" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="ScheduleOfSalesAndMarketingExpensesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables">
    <loc xlink:type="locator" xlink:label="GeneralAndAdministrativeExpensesAbstract" xlink:href="iinn-20231231.xsd#iinn_GeneralAndAdministrativeExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpensesAbstract" xlink:to="ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/TaxesonIncomeTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfTheoreticalTaxTableTextBlock" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfTheoreticalTaxTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfTheoreticalTaxTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ShareBasedPaymentTables">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/RelatedPartiesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfBalanceWithRelatedPartiesTableTextBlock" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfBalanceWithRelatedPartiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfBalanceWithRelatedPartiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfChangeOfOurFinancialResultsInBalanceSheetsAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfChangeOfOurFinancialResultsInBalanceSheetsAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfChangeOfOurFinancialResultsInBalanceSheetsAbstract" xlink:to="srt_CondensedBalanceSheetStatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_RestatementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_ScenarioPreviouslyReportedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_CondensedBalanceSheetStatementsCaptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OtherAssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OtherShortTermBorrowings" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForeignExchangeReserve" xlink:href="iinn-20231231.xsd#iinn_ForeignExchangeReserve"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="ForeignExchangeReserve" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfChangeOfOurFinancialResultsInComprehensiveIncomeAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfChangeOfOurFinancialResultsInComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedStatementOfComprehensiveIncomeTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedStatementOfIncomeCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfChangeOfOurFinancialResultsInComprehensiveIncomeAbstract" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="srt_RestatementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_ScenarioPreviouslyReportedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="srt_CondensedStatementOfIncomeCaptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_SellingAndMarketingExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_ProfitLoss" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable" xlink:href="iinn-20231231.xsd#iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsLineItems" xlink:href="iinn-20231231.xsd#iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract" xlink:to="SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DevelopmentEquipmentMember" xlink:href="iinn-20231231.xsd#iinn_DevelopmentEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="DevelopmentEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable" xlink:to="SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AnnualDepreciationRatesOfPropertyPlantAndEquipment" xlink:href="iinn-20231231.xsd#iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsLineItems" xlink:to="AnnualDepreciationRatesOfPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherCurrentAssetsAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestBearingDepositsInBanks" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestBearingDepositsInBanks"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherCurrentAssetsAbstract" xlink:to="us-gaap_InterestBearingDepositsInBanks" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherCurrentAssetsAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="DevelopmentEquipmentMember" xlink:href="iinn-20231231.xsd#iinn_DevelopmentEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="DevelopmentEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccountsPayableToRelatedParties" xlink:href="iinn-20231231.xsd#iinn_AccountsPayableToRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="AccountsPayableToRelatedParties" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofLeasePaymentsfortheCompanysRightofUseAssetsovertheRemainingLeasePeriodsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInsuredFinancialObligationsWithCreditDeteriorationNetClaimLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInsuredFinancialObligationsWithCreditDeteriorationNetClaimLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityTable" xlink:href="iinn-20231231.xsd#iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityTable"/>
    <loc xlink:type="locator" xlink:label="FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityLineItems" xlink:href="iinn-20231231.xsd#iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInsuredFinancialObligationsWithCreditDeteriorationNetClaimLiabilityAbstract" xlink:to="FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonTradableWarrantsMember" xlink:href="iinn-20231231.xsd#iinn_NonTradableWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="NonTradableWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityTable" xlink:to="FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofShareCapitalTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareCapitalAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfShareCapitalAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMovementInWarrantsOutstandingAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfMovementInWarrantsOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementInWarrantsOutstandingAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrarGpi3WKEtaAw66u01Fz01dWXY8Co/0nt/EYPpxJQpmucNPntkKGDUIzqiVXTghuh97D+3HoPuNe26jHPIaw4lyMqYvKxFlhkbYBWIUcgKRoJ/travtspQtU2Bzfjb2zOjTVkVWS8tD/cenVlshsSuvI61kcurHTnf7bi/aiMvKs5kJ2lHUdB1A51Zvlxfi4hXCDE5TwMWPCsMitxojF1/teoN1QVVrLGi8pZYVvQvpd+OssSlysPF] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued" xlink:href="iinn-20231231.xsd#iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised" xlink:href="iinn-20231231.xsd#iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerms" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerms" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" xlink:href="iinn-20231231.xsd#iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired" xlink:href="iinn-20231231.xsd#iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice55Member" xlink:href="iinn-20231231.xsd#iinn_ExercisePrice55Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="ExercisePrice55Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice55OneMember" xlink:href="iinn-20231231.xsd#iinn_ExercisePrice55OneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="ExercisePrice55OneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice55TwoMember" xlink:href="iinn-20231231.xsd#iinn_ExercisePrice55TwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="ExercisePrice55TwoMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Exercise6875Member" xlink:href="iinn-20231231.xsd#iinn_Exercise6875Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="Exercise6875Member" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Exercise16Member" xlink:href="iinn-20231231.xsd#iinn_Exercise16Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="Exercise16Member" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsOutstanding" xlink:href="iinn-20231231.xsd#iinn_WarrantsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="WarrantsOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofSharesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_SharesOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofSharesTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LaborAndRelatedExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_LaborAndRelatedExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLaborRelatedExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLaborRelatedExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_OtherLaborRelatedExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Subcontractors" xlink:href="iinn-20231231.xsd#iinn_Subcontractors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="Subcontractors" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationNonproduction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationNonproduction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_DepreciationNonproduction" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForParticipationLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForParticipationLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_PaymentsForParticipationLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSalesAndMarketingExpensesAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfSalesAndMarketingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSalesAndMarketingExpensesAbstract" xlink:to="us-gaap_ProfessionalFees" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSalesAndMarketingExpensesAbstract" xlink:to="us-gaap_OfficersCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSalesAndMarketingExpensesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSellingAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSalesAndMarketingExpensesAbstract" xlink:to="us-gaap_OtherSellingAndMarketingExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSalesAndMarketingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfGeneralAndAdministrativeExpensesAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesTable" xlink:href="iinn-20231231.xsd#iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesTable"/>
    <loc xlink:type="locator" xlink:label="GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:href="iinn-20231231.xsd#iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfGeneralAndAdministrativeExpensesAbstract" xlink:to="GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesTable" xlink:to="GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="us-gaap_ProfessionalFees" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="us-gaap_OfficersCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="us-gaap_LegalFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLaborRelatedExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLaborRelatedExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="us-gaap_OtherLaborRelatedExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="FundsRaisingExpenses" xlink:href="iinn-20231231.xsd#iinn_FundsRaisingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="FundsRaisingExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralInsuranceExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="us-gaap_GeneralInsuranceExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostMaintenance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="us-gaap_CostMaintenance" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="us-gaap_Depreciation" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TravelAndEntertainmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TravelAndEntertainmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="us-gaap_TravelAndEntertainmentExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="us-gaap_OtherGeneralExpense" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofFinancialIncomeandExpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfFinancialIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue" xlink:href="iinn-20231231.xsd#iinn_EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="us-gaap_FinancingInterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForeignCurrencyTransactionsGainBeforeTax" xlink:href="iinn-20231231.xsd#iinn_ForeignCurrencyTransactionsGainBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="ForeignCurrencyTransactionsGainBeforeTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceLeaseInterestExpenses" xlink:href="iinn-20231231.xsd#iinn_FinanceLeaseInterestExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="FinanceLeaseInterestExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DisposalGroupIncludingDiscontinuedOperationsOtherIncome" xlink:href="iinn-20231231.xsd#iinn_DisposalGroupIncludingDiscontinuedOperationsOtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="DisposalGroupIncludingDiscontinuedOperationsOtherIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAbstract" xlink:href="iinn-20231231.xsd#iinn_DeferredTaxAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsFundRaisingCosts2021" xlink:href="iinn-20231231.xsd#iinn_DeferredTaxAssetsFundRaisingCosts2021"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsFundRaisingCosts2021" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsFundRaisingCost2023" xlink:href="iinn-20231231.xsd#iinn_DeferredTaxAssetsFundRaisingCost2023"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsFundRaisingCost2023" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetValuationAllowance" xlink:href="iinn-20231231.xsd#iinn_DeferredTaxAssetValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetValuationAllowance" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTheoreticalTaxAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfTheoreticalTaxAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheoreticalTaxAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheoreticalTaxAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheoreticalTaxAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" xlink:href="iinn-20231231.xsd#iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheoreticalTaxAbstract" xlink:to="TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheoreticalTaxAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="ScheduleOfTheoreticalTaxAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfTheoreticalTaxAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheoreticalTaxAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable" xlink:href="iinn-20231231.xsd#iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:href="iinn-20231231.xsd#iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract" xlink:to="ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ServicesProvidersAndAdvisersMember" xlink:href="iinn-20231231.xsd#iinn_ServicesProvidersAndAdvisersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="ServicesProvidersAndAdvisersMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeesAndDirectorsMember" xlink:href="iinn-20231231.xsd#iinn_EmployeesAndDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="EmployeesAndDirectorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable" xlink:to="ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable" xlink:href="iinn-20231231.xsd#iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems" xlink:href="iinn-20231231.xsd#iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract" xlink:to="ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable" xlink:to="ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" xlink:href="iinn-20231231.xsd#iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OfficersAndDirectorsMember" xlink:href="iinn-20231231.xsd#iinn_OfficersAndDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="OfficersAndDirectorsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OfficersCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ScheduleofBalanceswithRelatedPartiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:href="iinn-20231231.xsd#iinn_ScheduleOfBalancesWithRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" xlink:href="iinn-20231231.xsd#iinn_RelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBalancesWithRelatedPartiesAbstract" xlink:to="RelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_OfficerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnusualOrInfrequentItemNatureOfEventOrTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnusualOrInfrequentItemNatureOfEventOrTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_UnusualOrInfrequentItemNatureOfEventOrTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <loc xlink:type="locator" xlink:label="GeneralDetailsTable" xlink:href="iinn-20231231.xsd#iinn_GeneralDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PublicUtilitiesGeneralDisclosuresLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="GeneralDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="PreFundedWarrantsMember" xlink:href="iinn-20231231.xsd#iinn_PreFundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="PreFundedWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PlacementAgentWarrantsMember" xlink:href="iinn-20231231.xsd#iinn_PlacementAgentWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="PlacementAgentWarrantsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PreFundedWarrantsMember_0" xlink:href="iinn-20231231.xsd#iinn_PreFundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="PreFundedWarrantsMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsTable" xlink:to="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_SharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_SharePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalOfferingCosts" xlink:href="iinn-20231231.xsd#iinn_AdditionalOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="AdditionalOfferingCosts" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregatePercentage" xlink:href="iinn-20231231.xsd#iinn_AggregatePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="AggregatePercentage" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_PaymentsOfDerivativeIssuanceCosts" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShortTermInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/DepositsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAbstract"/>
    <loc xlink:type="locator" xlink:label="DepositsDetailsTable" xlink:href="iinn-20231231.xsd#iinn_DepositsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositLiabilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositLiabilityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepositsAbstract" xlink:to="DepositsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositsDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IL"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_IL" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PledgingPurposeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PledgingPurposeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositsDetailsTable" xlink:to="us-gaap_PledgingPurposeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PledgingPurposeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PledgingPurposeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PledgingPurposeAxis" xlink:to="us-gaap_PledgingPurposeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PledgingPurposeAxis" xlink:to="us-gaap_DepositsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositsDetailsTable" xlink:to="us-gaap_DepositLiabilityLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Deposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepositLiabilityLineItems" xlink:to="us-gaap_Deposits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepositLiabilityLineItems" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsTable" xlink:href="iinn-20231231.xsd#iinn_CommitmentsandContingenciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsandContingenciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AggregateBudget" xlink:href="iinn-20231231.xsd#iinn_AggregateBudget"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="AggregateBudget" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfApprovedBudget" xlink:href="iinn-20231231.xsd#iinn_PercentageOfApprovedBudget"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="PercentageOfApprovedBudget" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProjectBudgetAggregateAmount" xlink:href="iinn-20231231.xsd#iinn_ProjectBudgetAggregateAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ProjectBudgetAggregateAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherReceivables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltiesPercentage" xlink:href="iinn-20231231.xsd#iinn_RoyaltiesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="RoyaltiesPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ContingentUponFutureSales" xlink:href="iinn-20231231.xsd#iinn_ContingentUponFutureSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ContingentUponFutureSales" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsForRent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReimbursementAmount" xlink:href="iinn-20231231.xsd#iinn_ReimbursementAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ReimbursementAmount" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManagementFeeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementFeeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ManagementFeeExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LeaseCost" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FutureLeasePaymentsDiscountedInterestRate" xlink:href="iinn-20231231.xsd#iinn_FutureLeasePaymentsDiscountedInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="FutureLeasePaymentsDiscountedInterestRate" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="FinacialLiabilitiesatFairValueDetailsTable" xlink:href="iinn-20231231.xsd#iinn_FinacialLiabilitiesatFairValueDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="FinacialLiabilitiesatFairValueDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrivateWarrantsMember" xlink:href="iinn-20231231.xsd#iinn_PrivateWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="PrivateWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsTable" xlink:to="us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PercentageOfPayFees" xlink:href="iinn-20231231.xsd#iinn_PercentageOfPayFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems" xlink:to="PercentageOfPayFees" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockDividendsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems" xlink:to="us-gaap_StockDividendsShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionExercisePriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems" xlink:to="us-gaap_StockOptionExercisePriceDecrease" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDeficitDetailsTable" xlink:href="iinn-20231231.xsd#iinn_ShareholdersEquityDeficitDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDeficitDetailsLineItems" xlink:href="iinn-20231231.xsd#iinn_ShareholdersEquityDeficitDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="ShareholdersEquityDeficitDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_InvestorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BrokersMember" xlink:href="iinn-20231231.xsd#iinn_BrokersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BrokersMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PreFundedWarrantsMember" xlink:href="iinn-20231231.xsd#iinn_PreFundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PreFundedWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsTable" xlink:to="srt_RangeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsTable" xlink:to="ShareholdersEquityDeficitDetailsLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AggregateOfOrdinaryShares" xlink:href="iinn-20231231.xsd#iinn_AggregateOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="AggregateOfOrdinaryShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinaryShare" xlink:href="iinn-20231231.xsd#iinn_OrdinaryShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="OrdinaryShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalUnitsAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalUnitsAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_CapitalUnitsAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SoldOrdinaryShares" xlink:href="iinn-20231231.xsd#iinn_SoldOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="SoldOrdinaryShares" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TradableWarrants" xlink:href="iinn-20231231.xsd#iinn_TradableWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="TradableWarrants" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonTradableWarrants" xlink:href="iinn-20231231.xsd#iinn_NonTradableWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="NonTradableWarrants" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDividendsReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDividendsReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ProceedsFromDividendsReceived" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfferingCostsPartnershipInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfferingCostsPartnershipInterests"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_OfferingCostsPartnershipInterests" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueWarrants" xlink:href="iinn-20231231.xsd#iinn_FairValueWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="FairValueWarrants" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfExercisePrice" xlink:href="iinn-20231231.xsd#iinn_PercentageOfExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="PercentageOfExercisePrice" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfExerciseOfTradableWarrants" xlink:href="iinn-20231231.xsd#iinn_PercentageOfExerciseOfTradableWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="PercentageOfExerciseOfTradableWarrants" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_InterestExpense" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoninterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoninterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_NoninterestExpense" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_InterestExpenseOther" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BenefitsLossesAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BenefitsLossesAndExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_BenefitsLossesAndExpenses" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonUnitAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonUnitAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_CommonUnitAuthorized" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_SharePrice" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherUnderwritingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherUnderwritingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_OtherUnderwritingExpense" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfAgreementWarrants" xlink:href="iinn-20231231.xsd#iinn_PercentageOfAgreementWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="PercentageOfAgreementWarrants" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDerivativeIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDerivativeIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_PaymentsOfDerivativeIssuanceCosts" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/TaxesonIncomeDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="TaxesonIncomeDetailsTable" xlink:href="iinn-20231231.xsd#iinn_TaxesonIncomeDetailsTable"/>
    <loc xlink:type="locator" xlink:label="TaxesonIncomeDetailsLineItems" xlink:href="iinn-20231231.xsd#iinn_TaxesonIncomeDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="TaxesonIncomeDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IL"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_IL" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsTable" xlink:to="TaxesonIncomeDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentDetailsTable" xlink:href="iinn-20231231.xsd#iinn_ShareBasedPaymentDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="ShareBasedPaymentDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NonTradableSharesOptionsMember" xlink:href="iinn-20231231.xsd#iinn_NonTradableSharesOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="NonTradableSharesOptionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_StockOptionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_BoardOfDirectorsChairmanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvisoryBoardMembersMember" xlink:href="iinn-20231231.xsd#iinn_AdvisoryBoardMembersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="AdvisoryBoardMembersMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeesDirectorsAndSubcontractorsMember" xlink:href="iinn-20231231.xsd#iinn_EmployeesDirectorsAndSubcontractorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="EmployeesDirectorsAndSubcontractorsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandAndNineteenPlanMember" xlink:href="iinn-20231231.xsd#iinn_TwoThousandAndNineteenPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandAndNineteenPlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CapitalGainTaxRate" xlink:href="iinn-20231231.xsd#iinn_CapitalGainTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="CapitalGainTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsIssuableTerm" xlink:href="iinn-20231231.xsd#iinn_OptionsIssuableTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="OptionsIssuableTerm" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareOptionsVestingPeriod" xlink:href="iinn-20231231.xsd#iinn_ShareOptionsVestingPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareOptionsVestingPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityPercentage" xlink:href="iinn-20231231.xsd#iinn_EquityPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EquityPercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RSUsVestPeriod" xlink:href="iinn-20231231.xsd#iinn_RSUsVestPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="RSUsVestPeriod" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inspiratechnologies.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="iinn-20231231.xsd#iinn_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="iinn-20231231.xsd#iinn_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedStockUnits" xlink:href="iinn-20231231.xsd#iinn_RestrictedStockUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="RestrictedStockUnits" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/dei/role/document/Cover">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="12.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityListingsTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="13.0"/>
    <loc xlink:type="locator" xlink:label="dei_NameChangeEventTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NameChangeEventTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_NameChangeEventTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="14.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesNoParValueMember" xlink:href="iinn-20231231.xsd#iinn_OrdinarySharesNoParValueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="OrdinarySharesNoParValueMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchaseOrdinarySharesMember" xlink:href="iinn-20231231.xsd#iinn_WarrantsToPurchaseOrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="WarrantsToPurchaseOrdinarySharesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444254265456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodStartDate', window );">Document Period Start Date</a></td>
<td class="text">Jan.  01,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INSPIRA TECHNOLOGIES OXY B.H.N. LTD.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001837493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 Ha-Tidhar St<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ra&#8217;anana<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">4366504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">15,652,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=iinn_OrdinarySharesNoParValueMember', window );">Ordinary Shares, no par value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares, no par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IINN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=iinn_WarrantsToPurchaseOrdinarySharesMember', window );">Warrants to purchase Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants to purchase Ordinary Shares<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IINNW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Dagi Ben-Noon<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 Ha-Tidhar St<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ra&#8217;anana<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">4366504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+972.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">6230333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The start date of the period covered in the document, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=iinn_OrdinarySharesNoParValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=iinn_OrdinarySharesNoParValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=iinn_WarrantsToPurchaseOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=iinn_WarrantsToPurchaseOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444249554032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorTable', window );"><strong>Auditor [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ziv Haft<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel-Aviv, Israel<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444251085216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,041<span></span>
</td>
<td class="nump">$ 6,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="nump">2,320<span></span>
</td>
<td class="nump">7,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">589<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">7,793<span></span>
</td>
<td class="nump">14,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets, net</a></td>
<td class="nump">1,011<span></span>
</td>
<td class="nump">1,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">506<span></span>
</td>
<td class="nump">411<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">1,517<span></span>
</td>
<td class="nump">1,674<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">9,310<span></span>
</td>
<td class="nump">16,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade accounts payables</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other accounts payables</a></td>
<td class="nump">1,026<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Financial liabilities at fair value</a></td>
<td class="nump">1,470<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,984<span></span>
</td>
<td class="nump">1,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities</a></td>
<td class="nump">588<span></span>
</td>
<td class="nump">873<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non- current liabilities</a></td>
<td class="nump">588<span></span>
</td>
<td class="nump">873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Share capital and additional paid in capital</a></td>
<td class="nump">61,259<span></span>
</td>
<td class="nump">57,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated losses</a></td>
<td class="num">(55,521)<span></span>
</td>
<td class="num">(44,235)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders&#8217; Equity</a></td>
<td class="nump">5,738<span></span>
</td>
<td class="nump">13,631<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and Shareholders&#8217; Equity</a></td>
<td class="nump">$ 9,310<span></span>
</td>
<td class="nump">$ 16,166<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444254796624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 7,320<span></span>
</td>
<td class="nump">$ 8,183<span></span>
</td>
<td class="nump">$ 4,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">746<span></span>
</td>
<td class="nump">1,328<span></span>
</td>
<td class="nump">1,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">4,063<span></span>
</td>
<td class="nump">5,375<span></span>
</td>
<td class="nump">6,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other expenses (income)</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="nump">12,133<span></span>
</td>
<td class="nump">14,893<span></span>
</td>
<td class="nump">12,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeDepositsWithFinancialInstitutions', window );">Interest income from deposits</a></td>
<td class="num">(318)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Finance expenses (income), net</a></td>
<td class="num">(529)<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">4,230<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before tax</a></td>
<td class="nump">11,286<span></span>
</td>
<td class="nump">14,976<span></span>
</td>
<td class="nump">17,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Total comprehensive and net loss</a></td>
<td class="nump">$ 11,286<span></span>
</td>
<td class="nump">$ 14,976<span></span>
</td>
<td class="nump">$ 17,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per ordinary share, basic and diluted (in Dollars per share)</a></td>
<td class="num">$ (0.93)<span></span>
</td>
<td class="num">$ (1.39)<span></span>
</td>
<td class="num">$ (3.24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of ordinary shares outstanding basic (in Shares)</a></td>
<td class="nump">12,095,477<span></span>
</td>
<td class="nump">10,794,594<span></span>
</td>
<td class="nump">5,306,225<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeDepositsWithFinancialInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest income derived from funds deposited with both domestic and foreign financial institutions including funds in money market and other accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (b)<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeDepositsWithFinancialInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444251971536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Comprehensive Loss (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per ordinary share, diluted (in Dollars per share)</a></td>
<td class="num">$ (0.93)<span></span>
</td>
<td class="num">$ (1.39)<span></span>
</td>
<td class="num">$ (3.24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of ordinary shares outstanding diluted</a></td>
<td class="nump">12,095,477<span></span>
</td>
<td class="nump">10,794,594<span></span>
</td>
<td class="nump">5,306,225<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444251824736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Shareholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Ordinary Share Capital</div></th>
<th class="th" colspan="2"><div>Additional Paid in Capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 304<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 10,430<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (12,066)<span></span>
</td>
<td class="num">$ (1,332)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="nump">2,661,095<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ChangesDuringThePeriodAbstract1', window );"><strong>Changes during the period:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_StockIssuedDuringPeriodValueParValueCancellation', window );">Par value cancellation</a></td>
<td class="num">$ (304)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">304<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Initial Public Offering (&#8220;IPO&#8221;)</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13,969<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">13,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial Public Offering (&#8220;IPO&#8221;) (in Shares)</a></td>
<td class="nump">2,931,472<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of financial liability</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12,203<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">12,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of financial liability (in Shares)</a></td>
<td class="nump">2,113,905<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Tradable warrants exercise</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,378<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">9,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_StockIssuedDuringPeriodSharesTradableWarrantsExercise', window );">Tradable warrants exercise (in Shares)</a></td>
<td class="nump">1,705,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ChangesDuringThePeriodAbstract0', window );"><strong>Changes during the period:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">RSU vesting</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">RSU vesting (in Shares)</a></td>
<td class="nump">655,603<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ChangesDuringThePeriodAbstract', window );"><strong>Changes during the period:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of share-based payments</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share-based payments (in Shares)</a></td>
<td class="nump">24,631<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,703<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Comprehensive and net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(17,193)<span></span>
</td>
<td class="num">(17,193)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">52,987<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(29,259)<span></span>
</td>
<td class="nump">23,728<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">10,091,706<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ChangesDuringThePeriodAbstract0', window );"><strong>Changes during the period:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">RSU vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">RSU vesting (in Shares)</a></td>
<td class="nump">1,240,204<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ChangesDuringThePeriodAbstract', window );"><strong>Changes during the period:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share-based payments (in Shares)</a></td>
<td class="nump">7,030<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,879<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Comprehensive and net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(14,976)<span></span>
</td>
<td class="num">(14,976)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">57,866<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(44,235)<span></span>
</td>
<td class="nump">13,631<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">11,338,940<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ChangesDuringThePeriodAbstract', window );"><strong>Changes during the period:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Issuance of ordinary shares and private warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,806<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Issuance of ordinary shares and private warrants, net (in Shares)</a></td>
<td class="nump">3,031,250<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of placement agent warrants (Note 9)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">131<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of ordinary shares (pursuant to At-The-Market (&#8220;ATM&#8221;) facility)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">26<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of ordinary shares (pursuant to At-The-Market (&#8220;ATM&#8221;) facility) (in Shares)</a></td>
<td class="nump">17,566<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share-based payments (in Shares)</a></td>
<td class="nump">37,972<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted share unit (&#8220;RSU&#8221;) vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted share unit (&#8220;RSU&#8221;) vesting (in Shares)</a></td>
<td class="nump">1,226,448<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,427<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Comprehensive and net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(11,286)<span></span>
</td>
<td class="num">(11,286)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 61,259<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (55,521)<span></span>
</td>
<td class="nump">$ 5,738<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">15,652,176<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Less than thousand dollars</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ChangesDuringThePeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ChangesDuringThePeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ChangesDuringThePeriodAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ChangesDuringThePeriodAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ChangesDuringThePeriodAbstract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ChangesDuringThePeriodAbstract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_StockIssuedDuringPeriodSharesTradableWarrantsExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tradable warrants exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_StockIssuedDuringPeriodSharesTradableWarrantsExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_StockIssuedDuringPeriodValueParValueCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Par value cancellation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_StockIssuedDuringPeriodValueParValueCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444254204944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOW FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (11,286)<span></span>
</td>
<td class="num">$ (14,976)<span></span>
</td>
<td class="num">$ (17,193)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation expenses</a></td>
<td class="nump">1,427<span></span>
</td>
<td class="nump">4,879<span></span>
</td>
<td class="nump">6,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Share based compensation &#8211; placement agent warrants (Note 9)</a></td>
<td class="nump">59<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue', window );">Revaluation of simple agreements for future equity (SAFE) and convertible loan at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_EvaluationOfFinancialLiabilityAtFairValue', window );">Evaluation of financial liability at fair value</a></td>
<td class="num">(306)<span></span>
</td>
<td class="num">(108)<span></span>
</td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Issuance cost</a></td>
<td class="nump">205<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PrepaymentsOfLeaseLiabilities', window );">Prepayments of lease liabilities</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInLeasingReceivables', window );">Decrease (increase) in right of use assets</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(99)<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Decrease (increase) in other current assets</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="num">(490)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">(Decrease) increase in trade accounts payables</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">(Decrease) increase in other accounts payable</a></td>
<td class="num">(190)<span></span>
</td>
<td class="nump">496<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(9,756)<span></span>
</td>
<td class="num">(9,647)<span></span>
</td>
<td class="num">(6,685)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOW FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plant, and equipment</a></td>
<td class="num">(206)<span></span>
</td>
<td class="num">(263)<span></span>
</td>
<td class="num">(182)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Investment in short term deposits</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(7,120)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sale of short-term deposits</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">4,594<span></span>
</td>
<td class="num">(7,383)<span></span>
</td>
<td class="num">(182)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans', window );">Receipt of simple agreements for future equity (SAFE) and convertible loan</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of ordinary shares</a></td>
<td class="nump">2,128<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Issuance of private warrants</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance cost in cash</a></td>
<td class="num">(454)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of option</a></td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_IssuanceOfOrdinarySharesissuancesPursuantToATM', window );">Issuance of ordinary shares (issuances pursuant to ATM)</a></td>
<td class="nump">26<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,721<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">3,453<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">30,195<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(1,709)<span></span>
</td>
<td class="num">(17,030)<span></span>
</td>
<td class="nump">23,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the beginning of the period</a></td>
<td class="nump">6,839<span></span>
</td>
<td class="nump">23,869<span></span>
</td>
<td class="nump">541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the end of the period</a></td>
<td class="nump">5,130<span></span>
</td>
<td class="nump">6,839<span></span>
</td>
<td class="nump">23,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of convertible loans to equity</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TradableWarrantsFinancialLiabilityAtIPO', window );">Tradable warrants financial liability at IPO</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(310)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationUnderwritersFeesAtIPO', window );">Share based compensation &#8211; underwriters fees at IPO</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(264)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital', window );">Share based compensation-placement agent warrants against additional paid in capital (Note 9)</a></td>
<td class="num">(73)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_EvaluationOfFinancialLiabilityAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of evaluation of financial liability at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_EvaluationOfFinancialLiabilityAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_IssuanceOfOrdinarySharesissuancesPursuantToATM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of issuance of ordinary shares (issuances pursuant to ATM).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_IssuanceOfOrdinarySharesissuancesPursuantToATM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PrepaymentsOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of prepayments of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PrepaymentsOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receipt of simple agreements for future equity (SAFE) and convertible loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revaluation of simple agreements for future equity (SAFE) and convertible loan at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationUnderwritersFeesAtIPO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of share based compensation &#8211; underwriters fees at IPO.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationUnderwritersFeesAtIPO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of share based compensation-placement agent warrants against additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TradableWarrantsFinancialLiabilityAtIPO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tradable warrants financial liability at IPO.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TradableWarrantsFinancialLiabilityAtIPO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInLeasingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from lessees arising from lease agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInLeasingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444247461024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>General [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsGeneralTextBlock', window );">GENERAL</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 - GENERAL:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">Inspira Technologies Oxy B.H.N. Ltd (formerly: Insense Medical
Ltd.) (the &#8220;Company&#8221;) was incorporated in Israel and commenced its operations on February 27, 2018. The Company operates
in the medical technology industry in the field of respiratory support technology engaged in the research, development, manufacturing
related activities, and go-to-market activities of proprietary products and technologies. The Company is developing the following products:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">The INSPIRA ART (Augmented Respiratory Technology), which
is a respiratory support technology targeted toward utilizing direct blood oxygenation to boost patient saturation levels within minutes
while the patient is awake and spontaneously breathing. The aim is to reduce the need for invasive mechanical ventilation, with the potential
to reduce risks, complications and high costs.</td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
     </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The HYLA blood sensor, which is a non-invasive optical blood sensor designed to perform real-time and
continuous blood measurements, potentially minimizing the need to take actual blood samples from patients.</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                    </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The INSPIRA ART100 Device, an advanced form of life support system better known by the medical industry
as a cardiopulmonary bypass system is being designed for use in surgical procedures requiring cardiopulmonary bypass for six hours or
less.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">2.</td><td style="text-align: justify">The Company&#8217;s products are in the development stage. The INSPIRA ART100 device and the INSPIRA ART
has not yet been tested or used in humans. The Company&#8217;s products have not been approved by the U.S. Food and Drug Administration (the
&#8220;FDA&#8221;). The INSPIRA ART100 device was submitted to the FDA for 510k clearance in September 2023, and the Company expect FDA
approval by the end of the first half of 2024.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">3.</td><td style="text-align: justify">On December 26, 2023, the Company entered into a purchase agreement (the &#8220;Purchase Agreement&#8221;) with an institutional investor in a registered direct offering (the &#8220;Registered Direct Offering&#8221;), pursuant to which the Company issued (i) an aggregate of 1,375,000 of the Company&#8217;s ordinary shares (the &#8220;Ordinary Shares&#8221;) at a purchase price of $1.28 per share, and (ii) pre-funded warrants, (&#8220;Pre-Funded Warrants&#8221;), to purchase up to 1,656,250 Ordinary shares, at a purchase price of $1.28, less $0.001 per Pre-Funded Warrant which were immediately exercised). In addition, pursuant to the Purchase Agreement, the Company issued warrants to the institutional investor to purchase up to an aggregate of 3,031,250 Ordinary Shares at an exercise price of $1.28 per share (&#8220;Private Warrants&#8221;). The aggregate proceeds received by the Company from the registered direct offering were approximately: $3,424, after deducting placement agent commissions and additional offering costs which totaled in approximately $454. In addition, pursuant to the Purchase Agreement, the Company issued Placement Agent Warrants to purchase up to a total of 7.0% of the aggregate number of Ordinary Shares sold in the transaction, or warrants to purchase up to 212,188 Ordinary Shares. The fair value of the Placement Agent Warrants on the issuance date was $131 and it was recorded as part of the issuance costs (see Note 9).</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">4.</td><td style="text-align: justify">The accompanying financial statements (the &#8220;Financial Statements&#8221;) have been prepared assuming
that the Company will continue as a going concern. To date, the Company is at its development stage. Therefore, the Company has suffered
recurring losses from operations and negative cash flows from operations since inception. As of December 31, 2023, the Company had incurred
accumulated losses of $55.5 million and expects to continue to fund its operations through fundings such as issuance of convertible securities,
Ordinary Shares and warrants and through Israeli governmental grants. There is no assurance that such financing will be obtained. Considering
the above, our dependency on external funding for our operations raises a substantial doubt about our ability to continue as a going concern.
The Financial Statements do not include any adjustments that might result from the outcome of these uncertainties.</td></tr></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">5.</td><td style="text-align: justify">Our offices are located in Israel. On October 7, 2023, Hamas terrorists infiltrated Israel&#8217;s southern
border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Following the attack, Israel declared war
against Hamas and the Israeli military began to call-up reservists for an active duty. At the same time, and because of the declaration
of war against Hamas, the clash between Israel and Hezbollah in Lebanon has escalated and there is a possibility that it will turn into
a greater regional conflict in the future. As of the date of these Financial Statements, these events have had no material impact on the
Company&#8217;s operations.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">6.</td><td style="text-align: justify">Although we do not currently conduct business in Russia and Ukraine, the escalation of geopolitical instability
in Russia and Ukraine as well as currency fluctuations in the Russian Ruble has had a negative impact on worldwide markets. Such impact
may negatively impact our supply chain, our operations and future growth prospects in that region.&#160;As a result of the crisis in Ukraine,&#160;both
the U.S. and other countries have implemented sanctions against certain Russian individuals and entities. Our global operations expose
us to risks that could adversely affect our business, financial condition, results of operations, cash flows or the market price of our securities,
including the potential for increased tensions between Russia and other countries resulting from the current situation involving Russia
and Ukraine, tariffs, economic sanctions and import-export restrictions imposed, and retaliatory actions, as well as the potential negative
impact on our potential business and sales in the region. Current geopolitical instability in Russia and Ukraine and related sanctions
by the U.S. and other governments against certain companies and individuals may hinder our ability to conduct business with potential
customers and vendors in these countries.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">7.</td><td style="text-align: justify">These Financial Statements were authorized by the Board of Directors on March 19, 2024.</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsGeneralTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation costs, including compensated absences accruals, compensated absences liability, deferred compensation arrangements and income statement compensation items. Deferred compensation arrangements may include a description of an arrangement with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares (units) issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 710<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482969/710-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsGeneralTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444254145184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 </b>- <b>SIGNIFICANT ACCOUNTING POLICIES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying Financial Statements have been
prepared in conformity with the U.S. GAAP. The significant accounting policies followed in the preparation of the Financial Statements
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>A.
Conversion from IFRS to U.S. GAAP-</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has retroactively converted its historical
Financial Statements that were prepared in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;) to present
such Financial Statements in accordance with U.S. GAAP. This is the first Financial Statement presented according to U.S. GAAP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is an Israeli company, and its business
operates in the medical technology industry in the field of respiratory support technology and intends to focus its commercial efforts
mainly in the USA. The Company&#8217;s both long and short-term intentions are to conduct clinical trials in the U.S. with the goal to
receive FDA approval as a first and major milestone.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The significant differences between IFRS and U.S.
GAAP as they relate to these Financial Statements are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(a) Leases</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under IFRS, prior to the adoption of U.S. GAAP,
the Company, as lessee, applied the single lease model that is similar to the accounting for a finance lease under U.S. GAAP. The expense
recognition presented a higher portion of the total expense earlier in the lease term as a combination of straight-line depreciation of
the right-of-use asset and the effective interest rate method applied to the lease liability results in a decreasing rate of interest
expense recognition throughout the lease term. In addition, the presentation of the lease expenses in the statements of comprehensive
loss is different. Under U.S. GAAP it is presented as lease expenses, while under IFRS it is presented as depreciation and interest expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under U.S. GAAP, there is dual classification
lease accounting model for lessees: finance leases and operating leases. The Company, as lessee, classified all its leases as operating
leases and recognizes a single lease expense, including both a right-of-use asset depreciation component and an interest expense component,
on a straight-line basis throughout the lease term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(b) Financial Liabilities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issued tradable warrants to investors
in its initial public offering (the &#8220;IPO&#8221;) and warrants to its pre-IPO investors. Under IFRS, warrants issued by the Company
were classified as financial liabilities and measured at fair value with changes recognized in profit or loss. However, under U.S. GAAP,
those warrants are classified as equity instruments due to the change in its functional currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon transitioning to U.S. GAAP, the Company has
re-evaluated the classification of its warrants and determined that they meet the criteria for classification as equity instruments. Therefore,
the warrants have been reclassified from financial liabilities to equity in the Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This reclassification has been applied retroactively
to all periods presented in accordance with the requirements of U.S. GAAP. Consequently, the Financial Statements for prior periods have
been adjusted to reflect the reclassification of warrants from financial liabilities to equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the change in determining the warrants
classification, the Company had changed its IPO expenses allocation between equity and issuance expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(<b>c) Change in Functional Currency Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under IFRS, the functional currency is determined
based on the currency of the primary economic environment in which the entity operates. However, under U.S. GAAP, the functional currency
is determined based on the currency of the primary economic environment in which the entity generates and expends cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of this change, the Company has reassessed
its functional currency and determined that it now aligns with the currency of the primary economic environment in which cash receipts
and payments occur, in accordance with U.S. GAAP requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This change in functional currency reporting has
been applied retroactively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management believes that this change in functional
currency reporting better reflects the economic substance of the Company&#8217;s operation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(d) Government Grants </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under International Accounting Standards (&#8220;IAS
20&#8221;) (under IFRS), the Company capitalized government grants according to revenue forecast and recognized financial expenses over
time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, under U.S. GAAP, the Company will recognize
royalties only when it starts to generate revenues. This differs from IFRS, where the Company recognized capitalized liability, financial
expenses and lower grant in the research and development expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>The conversion from IFRS to U.S.
GAAP based USD as our operational currency and following other U.S. GAAP differences, resulted in change of our financial results. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>U.S. GAAP differences as of December
31, 2022:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Note</b></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">IFRS<br/>
 (previously reported)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">U.S. GAAP</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Other current assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">2A(c)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">591</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">589</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Right of use assets, net</td><td>&#160;</td>
    <td style="text-align: center">2A(a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,107</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,263</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade accounts payables</td><td>&#160;</td>
    <td style="text-align: center">2A(c)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">152</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other accounts payables</td><td>&#160;</td>
    <td style="text-align: center">2A(c)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,217</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,216</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current lease liabilities</td><td>&#160;</td>
    <td style="text-align: center">2A(a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">329</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">268</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Financial liabilities at fair value</td><td>&#160;</td>
    <td style="text-align: center">2A(b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">368</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long term lease liabilities</td><td>&#160;</td>
    <td style="text-align: center">2A(a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">728</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">873</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loan from the Israeli Innovation Authority (&#8220;IIA&#8221;)</td><td>&#160;</td>
    <td style="text-align: center">2A(g)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">398</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign exchange reserve</td><td>&#160;</td>
    <td style="text-align: center">2A(c)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,928</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share capital and additional paid in capital</td><td>&#160;</td>
    <td style="text-align: center">2A(b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,814</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,866</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accumulated losses</td><td>&#160;</td>
    <td style="text-align: center">2A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(39,064</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(44,235</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left">Total Shareholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: center">2A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,822</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,631</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>U.S. GAAP differences for the year
ended December 31, 2021:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">IFRS<br/>
 (previously reported)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">U.S. GAAP</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,909</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,070</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,951</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,980</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,572</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,937</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses (income)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,432</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,964</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest income from deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Finance expenses (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,523</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,230</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss before tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,955</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,193</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Taxes on income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">16,955</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">17,193</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Exchange (losses) profits arising on translation to presentation currency</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(845</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">16,110</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">17,193</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>U.S. GAAP differences for the year
ended December 31, 2022:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">IFRS<br/>
 (previously reported)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.
GAAP</b>  &#160;</span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8,054</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8,183</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,325</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,328</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,391</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,375</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses (income)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,770</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,893</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest income from deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(192</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Finance expenses (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,497</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">275</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss before tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,273</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,976</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Taxes on income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,273</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">14,976</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Exchange (losses)profits arising on translation to presentation currency</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,138</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">12,411</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">14,976</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>B.
Use of estimates:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of Financial Statements in conformity with U.S. GAAP
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent
assets and liabilities at the date of the Financial Statements, and the reported amounts of expenses during the reporting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Items subject to such estimates and assumptions include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">stock-based compensation expense;</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">fair value financial liabilities;</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">recognition, measurement, and disclosure of contingent liabilities;</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Interest rate used for lease liability measurement.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of issuance of the Financial Statements,
the Company is not aware of any material specific events or circumstances that would require it to update its estimates, judgments, or
to revise the carrying values of its assets or liabilities. These estimates may change, as new events occur and additional information
is obtained, and are recognized in the Financial Statements as soon as they become known. Actual results could differ from those estimates
and any such differences may be material to the Company&#8217;s Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>C.
<span>Foreign Currency</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The currency of the primary economic environment
in which the operations of the Company are conducted is the U.S. dollar (&#8220;USD&#8221;). The Company&#8217;s funding and expected
revenues are mostly in USD. Thus, the functional currency of the Company is in USD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Transactions and balances originally denominated
in USD are presented at their original amounts. Balances in non-USD currencies are translated into USD using historical and current exchange
rates for non-monetary and monetary balances, respectively. For non-USD transactions and other items in the statements of income (indicated
below), the following exchange rates are used: (i) for transactions &#8211; exchange rates at transaction dates or average exchange rates;
and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization) &#8211; historical exchange
rates. Currency transaction gains and losses are presented in financial expenses (income), net as appropriate. The functional currency
of the Company is USD.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>D.
Property, Plant, and Equipment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost. Depreciation
is computed based on the straight-line method, over the estimated useful life of the assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Annual rates of depreciation are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Computers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Development equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and office equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">6-15</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Leasehold Improvements</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">10</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>E.
Leases</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company implemented Accounting Standards Update
(&#8220;ASU&#8221;) 2016-02, Leases (Topic 842) (&#8220;ASU 2016-02&#8221;) using the modified retrospective approach for all lease arrangements
as of such date. The Company leases office space and vehicles under operating leases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Arrangements meeting the definition of a
lease are classified as operating or financing leases and are recorded on the balance sheet as both a right of use asset and lease
liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the
Company&#8217;s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the
right of use asset is amortized over the lease term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The lease liability was measured at the present
value of the remaining lease payments, discounted using the Company&#8217;s incremental borrowing rate. The weighted-average&#160;rate
applied was 9.60%. Right-of-use&#160;assets were measured at an amount equal to the lease liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For operating leases, interest on the lease liability
and the amortization of the right of use asset result in straight-line&#160;rent expense over the lease term. Variable lease expenses
are recorded when incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>F.
Research and Development Costs.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Research and development
expenses consist primarily of payroll, payroll related expenses, subcontractors, and materials. Costs are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>G.
Government Grants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company receives royalty-bearing grants from
the IIA for approved research and development projects. Under Israeli law, royalties on the revenues derived from products and services
developed using such grants, are payable to the Israeli Government.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Royalties payable with respect to grants received
under programs approved after January 1, 1999, are subject to interest on the dollar-linked value of the total grants received at an annual
rate of London Interbank Offered Rate (&#8220;LIBOR&#8221;) applicable to dollar deposits. In September 2021, the Bank of Israel, which
determines annual interest rates, published a directive which stated that annual interest at a variable rate linked to the LIBOR rate
for loans in USD will be replaced by the Secured Overnight Financing Rate, (&#8220;SOFR&#8221;), in January 2024. The amounts of grants
received and recorded into income should be disclosed for each period presented. The research and development grants are presented in
the statement of operations as an offset to related research and development expenses. Companies are required to pay royalties in connection
with such grants at specified rates, up to the total dollar-linked amount of such grants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>H.
Finance Income and Expenses.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finance income is composed of interest on deposits,
while finance expenses are composed of interest on senior secured credit facility, bank charges and net currency exchange rates differences.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>I.
Current Taxes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The current tax liability
is measured using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments
required in connection with the tax liability in respect of previous years. The Company has no tax liability due to its carry forward
losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>J.
Share-Based Compensation.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Share-based compensation
expenses related to employees, directors and subcontractors&#8217; options or restricted share units, (&#8220;RSU&#8221;) which recognized based
on their fair value, which is based on the fair value of the underlying Ordinary Shares as to the de-minimis exercise price using the
graded vesting method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes compensation expense for
grants of share-based awards to its employees based on the estimated fair value on the grant date. Compensation cost for awards is recognized
over the requisite service period, which approximates the vesting period. Share-based compensation is included in research and development,
selling and marketing and general and administrative expenses. Forfeitures of equity grants are recognized as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All issuances of stock options or other equity
instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value
of the equity instruments issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>K.
Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issues warrants as part of its financing
activities or compensation arrangements. Warrants are derivative financial instruments that entitle the holder to purchase a specified
number of the Company&#8217;s ordinary shares at a predetermined exercise price. Warrants issued by the Company may have various terms, including
expiration dates, exercise prices, and conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies warrants as either equity
or liabilities upon issuance, based on specific terms and conditions and in accordance with Accounting Standard Codification (&#8220;ASC&#8221;)
815, Derivatives and Hedging. Warrants are classified as equity if they meet the criteria for equity classification outlined in ASC 815-40.
Otherwise, warrants are classified as liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>L.
Severance</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Israeli labor law generally requires payment of
severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The Company&#8217;s pension
and severance pay liabilities are covered mainly by insurance policies. Pursuant to section 14 of the Israeli Severance Compensation Act,
1963 (&#8220;Section 14&#8221;), the Company&#8217;s employees are entitled to monthly deposits, at a rate of 8.33% of their monthly salary,
made in their name with insurance companies. Payments in accordance with Section 14 relieve the Company from any future severance payments
in respect of those employees and, as such, the Company may only utilize the insurance policies for the purpose of paying severance pay.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>M.
Basic and Diluted Loss Per Share</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic and diluted loss per share is calculated
by dividing the loss attributable to equity holders of the Company by the weighted average number of Ordinary Shares outstanding during
the financial year, adjusted for Ordinary Shares issued during the year, if applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>N.
Fair Value Measurements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures and discloses fair value
in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;), ASC 820, Fair Value Measurements and Disclosures (&#8220;ASC
820&#8221;). ASC 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value,
and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to
sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such,
fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing
an asset or liability. As a basis for considering such assumptions, there exists a three-tier fair-value hierarchy, which prioritizes
the inputs used in measuring fair value as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 &#8211; unadjusted quoted prices are available
in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 &#8211; pricing inputs are other than
quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration
with observable market data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 &#8211; pricing inputs are
unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the
non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant
management judgment or estimation. Level 3 inputs are considered as the lowest priority within the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; "><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This hierarchy requires the Company to use observable
market data, when available, and to minimize the use of unobservable inputs when determining fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of cash is based on its demand
value, which is equal to its carrying value. Additionally, the carrying value of all other short-term monetary assets and liabilities
are estimated to be equal to their fair value due to the short-term nature of these instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>O.
Concentration of Credit Risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains certain cash balances in
a well-known Israeli banks and U.S based banks.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s operating expenses are denominated
mainly in New Israeli Shekel (&#8220;NIS&#8221;), and therefore, subject to foreign currency risk.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>P.
Cash and Cash Equivalent</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash equivalents are highly liquid investments
that are readily convertible into cash, typically with an original maturity of three months or less from <span>the
date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Restricted
cash consists of funds that are contractually restricted to bank guarantee due to rental agreements. The Company has presented
restricted cash separately from cash and cash equivalents in the balance sheets. </span>Bank deposits with maturities of more than
three months, but less than one year, and which are not restricted are included in short-term deposits. Such deposits are stated at
cost which approximates market value. As of December 31, 2023, December 31, 2022, the Company had short-term deposits in the amounts
of $2.3 million and $7.1 million respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Q.
Segment Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
has a single operating and reportable segment. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), who is the Chief
Executive Officer, evaluates the performance of its business based on financial data consistent with the presentation in the accompanying
Financial Statements for the purposes of making operating decisions, assessing financial performance, and allocating resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>R.
New accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-indent: 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><span style="text-decoration:underline">Accounting
Standards Adopted in 2023</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><span style="text-decoration:underline">ASU 2023-03
</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In July
2023, the FASB issued ASU 2023-03 to amend various U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) paragraphs in the
ASC to primarily reflect the issuance of SEC Staff Accounting Bulletin No. 120. ASU No. 2023-03, &#8220;Presentation of Financial Statements
(Topic 205), Income Statement&#8212;Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity
(Topic 505), and Compensation&#8212;Stock Compensation (Topic 718): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin
No. 120, SEC Staff Announcement at the March 24, 2022 EITF Meeting, and Staff Accounting Bulletin Topic 6.B, Accounting Series Release
280&#8212;General Revision of Regulation S-X: Income or Loss Applicable to Common Stock.&#8221; ASU 2023-03 amends the ASC for SEC updates
pursuant to SEC Staff Accounting Bulletin No. 120, SEC Staff Announcement </span>at the March 24, 2022, Emerging Issues Task Force (&#8220;EITF&#8221;)
Meeting; and Staff Accounting Bulletin Topic 6.B, Accounting Series Release 280 - General Revision of Regulation S-X: Income or Loss
Applicable to Common Stock. These updates were immediately effective and did not have a material impact on our financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In June
2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820), &#8220;Fair Value Measurement of Equity Securities Subject to Contractual
Sale Restrictions&#8221; which clarifies that contractual restrictions on equity security sales are not considered part of the security
unit of account and, therefore, are not considered in measuring fair value. In addition, the restrictions cannot be recognized and measured
as separate units of account. Disclosures on such restrictions are also required. The amendments are effective for Fiscal years beginning
after December 15, 2023, and interim periods within those fiscal years on a prospectively basis. The Company expects that ASU 2022-03
will not have a material impact on its Financial Statements and related disclosures. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Accounting
Pronouncements Issued but Not Yet Adopted</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In November
2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU expands public
entities&#8217; segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the CODM and
included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items,
and interim disclosures of a reportable segment&#8217;s profit or loss and assets. All disclosure requirements under ASU 2023-07 are also
required for public entities with a single reportable segment. The ASU&#8217;s amendments are effective for all public entities for fiscal
years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption
permitted. We are currently evaluating the impact of this pronouncement on our Financial Statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In December
2023, the FASB issued ASU 2023-08, Intangibles&#8212;Goodwill and Other&#8212;Crypto Assets (Subtopic 350-60): Accounting for and Disclosure
of Crypto Assets, which addresses the accounting and disclosure requirements for certain crypto assets. This ASU requires entities to
subsequently measure certain crypto assets at fair value, with changes in fair value recorded in net income in each reporting period.
In addition, entities are required to provide additional disclosures about the holdings of certain crypto assets. The ASU&#8217;s amendments
are effective for all entities holding assets that meet certain scope criteria for fiscal years beginning after December 15, 2024, including
interim periods within those years. Early adoption is permitted for both interim and annual periods. If an entity adopts the amendments
in an interim period, it must adopt them as of the beginning of the fiscal year that includes that interim period. We do not expect this
pronouncement to have a material impact on our Financial Statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In December
2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. Under this ASU, public entities must
annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that
meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than five percent of the amount computed
by multiplying pretax income or loss by the applicable statutory income tax rate). This ASU&#8217;s amendments are effective for all entities
that are subject to Topic 740, Income Taxes, for annual periods beginning after December 15, 2024, with early adoption permitted. We are
currently evaluating the impact of this pronouncement on our disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444247302896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deposits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAbstract', window );"><strong>Deposits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositLiabilitiesDisclosuresTextBlock', window );">DEPOSITS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>NOTE 3 &#8211; DEPOSITS:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; ">The Company&#8217;s deposits consist of three short-term
bank deposits with maturities of more than three months but less than one year. The deposits are in dollars and bear annual interest.
<span>Interest earned is recorded as finance income, net in the statement of operations during the years
for which the Company held short-term deposits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2023, the Company had a
deposit in USD at Leumi Bank (Israel) in amount of $2,040, including interest that bore fixed annual interest of&#160;6.18% and a
deposit in NIS in amount of $280 that bore fixed annual interest of&#160;4.85%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, the Company had deposits
in total amount of $7,120.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositLiabilitiesDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for deposit liabilities including data and tables. It may include a description of the entity's deposit liabilities, the aggregate amount of time deposits (including certificates of deposit) in denominations of $100,000 or more at the balance sheet date; the aggregate amount of any demand deposits that have been reclassified as loan balances, such as overdrafts, at the balance sheet date; deposits that are received on terms other than those in the normal course of business, the amount of accrued interest on deposit liabilities; securities, mortgage loans or other financial instruments that serve as collateral for deposits; for time deposits having a remaining term of more than one year, the aggregate amount of maturities for each of the five years following the balance sheet date; and the weighted average interest rate for all deposit liabilities held by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481047/942-405-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1406<br> -Paragraph (e)<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1406<br> -Publisher SEC<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.12)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositLiabilitiesDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444247472224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>NOTE 4 - OTHER CURRENT ASSETS:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">176</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">254</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Institutions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">164</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">276</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted Cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">432</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">589</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444247249312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 5 - PROPERTY AND EQUIPMENT, NET:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">For the year ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leasehold<br/> improvements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Development<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Furniture<br/> and office<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; font-weight: bold">At January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">121</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">229</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">116</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">499</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">152</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold">At December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">172</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">381</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">705</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">At January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold">At December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">199</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Net book value:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; padding-bottom: 4pt">As of December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">70</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">28</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">308</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">506</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">Less than thousand dollars</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">For the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leasehold<br/> improvements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Development<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Furniture<br/> and office<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; font-weight: bold">At January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">84</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">64</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">81</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">236</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">263</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold">At December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">499</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">At January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold">At December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Net book value:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; padding-bottom: 4pt">As of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">70</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">29</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">204</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">108</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">411</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">Less than thousand dollars</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444247385920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrentAbstract', window );"><strong>Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">OTHER ACCOUNTS PAYABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 6 - OTHER ACCOUNTS PAYABLE:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Employees&#8217; salaries and related liabilities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">388</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">396</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">354</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">332</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">267</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">470</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,026</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,216</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444361967760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span><b>NOTE 7 - COMMITMENTS AND CONTINGENCIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>A.</b></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Royalties to the IIA:</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 57.4pt; text-indent: -0.7pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In September
2019, the IIA approved an application that supports upgrading the Company&#8217;s manufacturing capabilities for an aggregate budget of
NIS&#160;4,880,603(approximately $1,500,000). The IIA committed to fund&#160;60% of the approved budget. Eventually the project budget
concluded in the aggregate amount of NIS 4,623,142 (approximately $1,333) The program is for the period beginning October 2019 through
November 2020 and the Company received total funds in the amount of NIS 2,773,885 (approximately $800) from the IIA. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>According
to the agreements with the IIA, The Company will pay royalties of&#160;3% to&#160;3.5% of future sales up to an amount equal to the accumulated
grant received including annual interest of LIBOR linked to the USD. Repayment of the grant is contingent upon the successful completion
of the Company&#8217;s research and development (&#8220;R&amp;D&#8221;) programs and generating sales. The Company has no obligation to
repay these grants if the R&amp;D programs fail, are unsuccessful or aborted or if no sales are generated. The Company had not generated
sales as of December 31, 2023; therefore, no liability was recorded in these Financial Statements. IIA grants are recorded as a reduction
of R&amp;D expenses, net.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>During October
2023, the IIA has approved a support of another development project of the Company at an aggregate budget of NIS&#160;3,850,869 (approximately
$1,062). The IIA committed to fund&#160;40% of the approved budget. No funds have been received by the Company yet. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Research
and development grants deducted from research and development expenses amounted to&#160;nil, $106 and $694 for the years ended December
31, 2021 and 2020, respectively. As of December 31, 2023, the maximum obligation with respect to the grants received from the IIA, contingent
upon entitled future sales, is $871 plus LIBOR interest. In September 2021, the Bank of Israel, which determines annual interest rates,
published a directive which stated that annual interest at a variable rate linked to the LIBOR rate for loans in USD will be replaced
by the SOFR, in January 2024.The Company has obligations regarding know-how, technology, or products, not to transfer the information,
rights thereon and production rights which derive from the research and development without the IIA Research Committee approval.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>B.</b></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Lease Commitments &#8211;
Operating Leases:</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span>In August 2022, the Company entered
into a lease agreement for its facilities in Ra&#8217;anana, Israel. The lease agreement is for a period of 69 months commencing September 1,
2021, and the Company began to pay lease and related expenses after completing 3 months of lease. The Company has the option to shorten
the period and terminates the lease agreement after completing 45 months of rent by paying an amount of NIS 500,000, (approximately $153).
This amount of reimbursement will be deducted monthly in NIS 30,000, (approximately $9) if the Company terminates the agreement after
45 months of rent. The annual lease payment, including management fees, as of December 31, 2023, is approximately NIS 69,000 ($19). As
security for the obligations under this lease agreement, the Company provided a bank guarantee in an amount equal to three monthly lease
payments plus the Israeli value added tax and an unlimited guarantee according to the terms specified in the contract. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span>The total expenses related to
the leases were $371&#160;for the year ended December 31, 2023, and $333&#160;for the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span>The right-of-use asset and lease
liability are initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease
or, if that rate cannot be readily determined, the Company&#8217;s incremental borrowing rate based on the information available at the
date of determining the present value of the lease payments. The Company&#8217;s incremental borrowing rate is estimated to approximate
the interest rate on similar terms and payments and in economic environments where the leased asset is located.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span>The Company has various operating
leases for vehicles that expire through 2027. Below is a summary of the Company&#8217;s operating right-of-use assets and operating lease
liabilities as of December 31, 2023, and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December&#160;31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating lease liabilities, current</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">290</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">268</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liabilities long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">588</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">873</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">878</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,141</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Weighted Average of Remaining Lease Term</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.33</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4.2</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Weighted-average discount rate - operating leases</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9.6</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9.92</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lease payments for the Company&#8217;s right-of-use
assets over the remaining lease periods as of December 31, 2023, are as follows:<span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">357</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">290</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">220</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total undiscounted lease payment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,011</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Interest*</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(133</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">878</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify">Future lease payments were discounted by&#160;7.98%-15.04% interest
rate.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>C.</b></td><td style="text-align: justify"><b>Legal Claims</b></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">In the normal course of business, various legal claims and other contingent
matters may arise. Management believes that any liability that may arise from such matters would not have a material adverse effect on
the Company&#8217;s results of operations or financial condition as of and for the years ended December 31, 2023, and 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">On December 12, 2021, the Company terminated its employment agreement
with Dr. Udi Nussinovitch, one of its founders who served as the Company&#8217;s Chief Scientific Officer since March 2018. On February
24, 2022, the Company sued Mr. Nussinovitch for breach good faith and his fiduciary duties as a shareholder and former officer of the
Company. On November 9, 2022, the Company received notice of a complaint filed by Mr.&#160;Nussinovitch, as well as a complaint filed
with the regional labor court in Tel Aviv, Israel on November 8, 2022. Mr. Nussinovitch has alleged certain deficiencies in the Company&#8217;s&#160;Extraordinary
General Meeting of Shareholders held on Friday, December 17, 2021, resulting from his status as a minority shareholder. In addition, with
respect to the labor dispute, Mr.&#160;Nussinovitch is seeking renumeration and the issuance of Ordinary Shares. A partial hearing was
held in the regional labor court on July 19, 2023, and the parties were required by the court to file their positions on a stay of the
proceeding pending the decision on the case initiated by the Plaintiff in the District Court.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">A pre-trial was held in the district court on January 21, 2024. During
the hearing, the court suggested that the parties consider the possibility of resolving the case through an out-of-court arrangement or
mediation. The parties agreed to a mediation process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of the date of these Financial Statement, the Company believes that
the claims will result in no payments by the Company.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444247208480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finacial Liabilities at Fair Value<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Finacial Liabilities at Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FINACIAL LIABILITIES AT FAIR VALUE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 8 - FINACIAL LIABILITIES AT FAIR VALUE:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December&#160;31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Financial liability (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">26</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Non-tradable warrants (2)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,459</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,470</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">26</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>1.</b></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Financial Liability</b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company agreed to pay fees of 7% from the
funds that will be received in an event of exercise of the Company&#8217;s tradable warrants which created a financial liability. The
financial liability was designated to be measured at fair value through profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial liability fair value as of December
31, 2023, and 2022 is $11 and $26 respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><b>2.</b></td><td style="text-align: justify"><b>Private Warrants</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 26, 2023, the Company entered into
the Purchase Agreement (Note 1 and Note 9), pursuant to which it issued unregistered warrants, to purchase up to an aggregate of 3,031,250
Ordinary Shares at an exercise of $1.28 per share. The Warrants were exercisable immediately upon issuance and will expire three and a
half years following their issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants include cashless exercise mechanism,
according to the terms specified in the agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants may create obligation to transfer
cash to the investors at fundamental transactions according to fair value of the black Scholes model that include variable inputs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Therefore, the Company accounts for the warrants
as financial liability instruments that measured at fair value and recognized financial expenses or income through profit and loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants fair value as of the issuance date
and December 31, 2023, were $1,750 and $1,459 respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The key inputs that were used in the Private Warrants fair value as
of issuance date were:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">risk-free interest rate 4.00%</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">expected volatility 66.71%</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">expected dividend yield of 0%</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">expected term of warrants &#8211; 3.5 years.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The key inputs that were used in the Private Warrants fair value as
of December 31, 2023, were:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">risk-free interest rate 4.00%</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">expected volatility 66.63%</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">expected dividend yield of 0%</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">expected term of warrants &#8211; 3.5 years.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444248699312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' Equity (Deficit) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' EQUITY (DEFICIT)</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9 - SHAREHOLDERS&#8217; EQUITY (DEFICIT):</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>A.</b></td><td style="text-align: justify"><b>Share capital:</b></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Number of shares as of<br/> December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Number of shares as of<br/> December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 4pt">Ordinary shares</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">100,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">15,652,176</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">100,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">11,338,940</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since the Company&#8217;s incorporation in February
2018 and before its IPO, the Company issued the following Ordinary Shares: (i) an aggregate of 27,566 Ordinary Shares for no consideration
to the Company&#8217;s founders and certain advisors; and (ii) 1,877,196 Ordinary Shares as bonus shares for no consideration to existing
shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2020 the Company issued an aggregate of 756,333
Ordinary Shares to investors as part of a loan conversion and non-tradable warrants to purchase an additional 169,019 Ordinary Shares
upon consummation of its IPO. The warrants are exercisable into Ordinary Shares of the Company at an exercise price equal to the initial
public offering price which was $5.50 and are exercisable for three years after the IPO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 18, 2021, the Company&#8217;s shareholders
approved a 12.5 to 1 reverse split of all shares (issued and unissued) on the basis that every 12.5 Ordinary Shares in the capital of
the Company be consolidated into 1 Ordinary Share, such that the authorized share capital of the Company following such consolidation
is NIS 310,000,000 divided into 24,800,000 Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2021, the Company&#8217;s shareholders
approved an amendment to the structure of the Company&#8217;s share capital (both authorized and issued) by cancelling the par value of
the Ordinary Shares in addition to implementing an additional reverse split at a ratio of 2.94 to 1, pursuant to which holders of our
Ordinary Shares received one Ordinary Share for every 2.94&#160;Ordinary Shares held.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2021, the Company&#8217;s shareholders
approved an amendment to the structure of the Company&#8217;s share capital (both authorized and issued) by cancelling the par value of
the Company&#8217;s shares such that each Ordinary Share with par value of NIS 0.125 will become one Ordinary Share with no par value.
The authorized share capital of the Company following the reverse stock split was NIS 310,000,000 divided into 8,435,375 Ordinary Shares,
with no par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2021, the Company&#8217;s shareholders
approved an increase in the authorized share capital of the Company to 15,000,000 Ordinary Shares of no-par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 16, 2021, the Company completed its IPO
on the Nasdaq Capital Market whereby the Company sold 2,909,091 Ordinary Shares and tradable warrants to purchase 3,345,455 Ordinary Shares
(inclusive of tradable warrants to purchase 436,364 Ordinary Shares pursuant to the exercise of an overallotment option granted to the
underwriters). The tradable warrants have an exercise price of $5.50 and they are exercisable for five years after the IPO date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the IPO, the Company issued 2,113,905
Ordinary Shares and 1,149,582 non-tradable warrants to investors and 16,587 non-tradeable warrants to brokers in connection with the conversion
of Company&#8217;s previously issued financial liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate proceeds received by the Company
from the IPO were approximately $14,490, after deducting underwriting discounts and commissions and additional offering direct costs totaled
approximately $1,543. The gross proceeds were $16,033.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total non-cash direct expenses in IPO were as
following: (i) fair value of 436,364 tradable warrants that were granted to underwriters totaled in $589; (ii) The Company issued 145,455
non-tradable warrants as underwriters fees; the warrants will be converted into Ordinary Shares of the Company at an exercise price equal
to 125% of the IPO price and be exercisable for three years after the IPO. As of the date of the IPO, the tradable warrants fair value
was $264; and (iii) the Company agreed to pay to a promoter 7% of the proceeds from the exercise of tradable warrants. The payment was
measured at fair value at the grant date. As of the IPO date, the fair value of the financial liability was $310.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total non-cash expenses were $1,163.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company had non-direct expenses
as following: (i) cash expenses amounted to $722 and (i) non-cash expenses amounted to $123 (22,382 Ordinary Shares issued to service
providers).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total IPO expenses direct and non- direct, cash
and non-cash were: $3,551.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total IPO expenses allocated to the profit and
loss were $546. Total IPO expenses deducted from the equity were $3,032.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year 2021 the Company issued an aggregate
amount of 655,601 Ordinary Shares in connection to vested RSUs and additional 24,631 Ordinary Shares in connection with options exercise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 17, 2021, the Company&#8217;s shareholders
approved an increase in the authorized share capital of the Company to 100,000,000 Ordinary Shares of no-par value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2022, the Company
issued an aggregate amount of 1,240,204 Ordinary Shares in connection to vested RSUs and an additional 7,030 Ordinary Shares in connection
to option exercises.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 4, 2023, the Company entered into a
sales agreement (the &#8220;Sales Agreement&#8221;) with Roth Capital Partners, LLC, as sales agent, pursuant to which the Company could
offer and sell, from time to time, through the sales agent, Ordinary Shares pursuant to an At-The-Market facility (&#8220;ATM&#8221;).
During 2023, the Company sold 17,566 Ordinary Shares under the ATM. On October 23, 2023, the Company terminated the Sales Agreement and
the associated ATM, effective immediately.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 26, 2023, the Company completed
the Registered Direct Offering, whereby the Company sold (i) 1,375,000 Ordinary Shares at a purchase price of $1.28 per share, and
(ii) Pre-Funded Warrants, to purchase up to 1,656,250 Ordinary Shares, at a purchase price of $1.28, less $0.001 per Pre-Funded
Warrant. (iii) Private Warrants, to purchase up to an aggregate of 3,031,250 Ordinary Shares at an exercise of $1.28 per share (Note
8.2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Pre-Funded Warrants were exercised on the
same day and the day after the transaction in full in an exercise price of $0.01 per share and the Company issued 1,656,250 additional
Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate proceeds received by the Company
from the registered direct offering were approximately $3,424, after deducting underwriting discounts and commissions and additional cash
offering costs totaled in approximately $454.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issued the Placement Agent in the
agreement a number of warrants equal to a total of 7.0% of the aggregate number of Ordinary Shares sold in the transaction, total to 212,188
warrants to purchase up to 212,188 Ordinary Shares, were issued. The Placement Agent Warrants were substantially on the same terms as
the Warrants issued to the investor in the offering, except an exercise price of $1.60 per share. The Placement agent Warrants were exercisable
immediately upon issuance and will expire five years following their issuance. The Company accounts for the Placement Agent Warrants as
equity-classified instruments (as part of additional paid in capital), based on an assessment of ASC 718. The fair value of the warrants
at the issuance date was $131.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Those cash and non-cash issuance costs were accounted
proportionally to issuance expenses and decrease of additional paid in capital, according to the ratio of the liability versus equity
in the Registered Direct offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2023, the Company
issued an aggregate amount of 1,226,448 Ordinary Shares in connection with vested RSUs and an additional 37,972 Ordinary Shares in connection
with option exercises.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>B.</b></td><td style="text-align: justify"><b>Warrants reserves -</b>Composition and movements:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.8pt; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">The following table reconciles the movement in warrants outstanding
at the beginning and end of the period:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.8pt; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted-average exercise price</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted average remaining contractual term</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in years)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Aggregate</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>intrinsic value</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold; padding-bottom: 1.5pt">Balance as of December 31, 2022</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">3,121,095</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">5.58</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">1.74</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">4,667,915</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">212,188</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">131,555</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Balance as of December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,333,283</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5.47</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1.83</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,799,470</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">2.</td><td style="text-align: justify">The following table summarizes information about the Company&#8217;s
outstanding warrants as of December 31, 2023</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Exercise Price</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Warrants outstanding</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December&#160;31,<br/>
 2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiration date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Aggregate</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Intrinsic</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>value</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">5.5</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,640,455</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">15/07/2026</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,214,614</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">5.5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,057,350</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">15/07/2024</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,691,760</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">5.5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">277,835</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">15/07/2025</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">497,533</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">6.875</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145,455</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">15/01/2027</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">264,008</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">1.6</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">212,188</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 10pt">28/12/2028</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">131,555</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,333,283</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,799,470</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.8pt; text-align: justify"><b>C. Loss per share:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Loss per share has been calculated using the weighted
average number of shares in issue during the relevant financial periods, the weighted average number of equity shares in issue and profit
for the period as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Loss for the period</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,286</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">14,976</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">17,193</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Total number of Ordinary Shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,652,176</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,338,940</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,091,706</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Weighted average number of Ordinary Shares</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">12,095,477</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,794,594</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,306,225</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-102; -sec-ix-hidden: hidden-fact-101; -sec-ix-hidden: hidden-fact-100">Basic and diluted loss per share</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(0.93</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(1.39</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(3.24</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444250566464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 10 - RESEARCH AND DEVELOPMENT EXPENSES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Salary and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,429</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,458</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,543</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Materials and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,082</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">204</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Share based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">663</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,392</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,792</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Subcontractors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">304</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">850</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">496</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">291</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">188</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">IIA participation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(106</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">268</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">213</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">47</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 4pt"><span style="font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,320</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">8,183</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,070</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 985<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//985-730/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444247424192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sales and Marketing Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpenseAbstract', window );"><strong>Sales and Marketing Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SalesAndMarketingExpensesTextBlock', window );">SALES AND MARKETING EXPENSES:</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 11 - SALES AND MARKETING EXPENSES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Professionals&#8217; fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">348</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">527</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">520</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">248</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">282</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">220</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">503</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,215</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">746</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,328</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,980</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SalesAndMarketingExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of sales and marketing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SalesAndMarketingExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444250926576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_GeneralAndAdministrativeExpensesAbstract', window );"><strong>General and Administrative Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_GeneralAndAdministrativeExpensesTextBlock', window );">GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 12 - GENERAL AND ADMINISTRATIVE EXPENSES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Professional fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,432</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,390</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">766</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">716</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">545</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Director&#8217;s fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Related NASDAQ IPO expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">546</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Funds raising expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">675</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,984</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,696</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Insurance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">557</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">363</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">129</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Travel abroad</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 4pt"><span style="font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,063</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,375</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,937</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_GeneralAndAdministrativeExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_GeneralAndAdministrativeExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_GeneralAndAdministrativeExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_GeneralAndAdministrativeExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444251444544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial (Income) and Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Financial (Income) and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock', window );">FINANCIAL (INCOME) AND EXPENSES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 13 - FINANCIAL (INCOME) AND EXPENSES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left">Revaluation of financial liabilities at fair value through profit or loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(306</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(108</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,995</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Interest on financial liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Foreign currency transaction income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(233</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">113</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Finance expense in respect of lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(143</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"><span style="font-size: 10pt"><b>Total</b> expenses (Income)</span></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(529</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">275</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,230</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444249633600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Taxes on Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES ON INCOME</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 14 - TAXES ON INCOME: </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>A.</b></td><td style="text-align: justify"><b>Taxes on income:</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">The Israeli corporate
tax rate was 23% in 2023 and 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>B.</b></td><td style="text-align: justify"><b>Net operating losses carry forwards</b>:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Carryforward tax losses of the Company
as of December 31, 2023, amounted to approximately $24,000; however, a full valuation allowance of $7,000 was recorded against the potential
future tax benefits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The deferred tax assets and liabilities
are composed of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net operating loss carryforward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,519</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,324</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">R&amp;D capitalization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,335</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,005</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Fund raising costs 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">275</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fund raising costs 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,012</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,670</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,012</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,670</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net deferred taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>C.</b></td><td style="text-align: justify"><b>Theoretical tax:</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left">Loss before taxation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(11,286</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(14,976</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(17,193</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Theoretical tax credit at applicable statutory rate: 23%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,596</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,444</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,954</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Non-allowable expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(244</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,026</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,527</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Temporary differences and tax losses for which no Deferred Tax Asset is recognized</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,352</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,418</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,427</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Income tax benefit</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444249422064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Share-Based Payment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED PAYMENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 15 - SHARE-BASED PAYMENT:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the Company established a share
option plan (the &#8220;2019 Plan&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The options to employees are granted under Section
102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company makes awards of options and restricted
shares under the 2019 Plan, which may be issued at the discretion of the Board of Directors from time to time. Under this 2019 Plan, each
option or RSU is exercisable into one Ordinary Share of the Company. The options may be exercised after vesting and in accordance with
vesting schedules which will be determined by the Board of Directors for each grant. The maximum term of the options issuable under the
2019 Plan is 10 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following are the significant stock options
and RSUs transactions with employees, Board of Directors members and non-employees made during the year ended December 31, 2021 and the
year ended December 31, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 21, 2021, the Company&#8217;s Board
of Directors approved a grant of non-tradable shares options to purchase 13,605 Ordinary Shares and share options to purchase 21,768 Ordinary
Shares. The vesting period is three years commencing on the grant date. The exercise price per share was NIS 0.37($0.12). The contractual
life of the options under the 2019 Plan is ten years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 16, 2021, the Company&#8217;s Board of
Directors approved a grant of 81,633 non-tradable shares options to purchase up to 81,633 Ordinary Shares to a director. The share options
vesting period is up to three years from the grant date. The exercise price per share was NIS 0.37 ($0.12). The contractual life of the
options under the 2019 Plan is ten years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 12, 2021, the Company&#8217;s Board
of Directors resolved to increase the pool of options available under the Plan to 25% of the Company&#8217;s equity, on a fully diluted
basis. As a result of the increase, the number of authorized Ordinary Shares available pursuant the 2019 Plan was 4,180,898.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">On November 2, 2021, the Company&#8217;s Board of Directors approved
a grant of 2,658,188 RSUs to employees and officers. The RSUs represents the right to receive Ordinary Shares at a future time and vest
over a period of three years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 2, 2021, the Company&#8217;s Board
of Directors approved a grant of 10,000 RSUs to the Company&#8217;s advisory board. The RSUs vest over a period of three years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 24, 2022, the Company&#8217;s Board of directors approved
a grant of 536,141 RSUs to employees and a grant of 22,500 RSUs to the Company&#8217;s advisory board members and an additional consultant.
The RSUs represent the right to receive Ordinary Shares at a future time. 555,500 of the RSUs in this grant, vest over a period of three
years, with a 1-year cliff period, and 3,141 RSUs vested immediately on the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 24, 2022, the Company&#8217;s Board of
Directors approved a grant of 29,400 Ordinary Shares options to medical board members, which are exercisable to 29,400 Ordinary Shares.
The share options vesting period is up to three years from the grant date. The exercise price per share was NIS 10.84 ($3.08). The contractual
life of the options under the 2019 Plan is ten years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.2pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 6, 2022, the Company&#8217;s Board of Directors approved a
grant of 285,713 fully vested RSUs to an officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 19, 2022, the Company&#8217;s Board of Directors approved a
grant of 30,000 RSUs to an employee. The RSUs vest over a period of three years, with a 1-year cliff period, commencing on the grant date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">On November 22, 2022, the Company&#8217;s Board of Directors approved
a grant of 165,000 RSUs to employees. The RSUs vest over a period of three years, with a 1-year cliff period, commencing on the grant
date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There was no grant of options or restricted shares during the year
period ended December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of all granted options was estimated
by using the Black Scholes model, which was aimed to model the value of the Company&#8217;s assets over time. The simulation approach
was designed to take into account the terms and conditions of the share options, as well as the capital structure of the Company and the
volatility of its assets, on the date of grant based on certain assumptions. Those conditions are, among others:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(i)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The expected volatility is
between 50%-52.4%</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(ii)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The dividend rate 0%; and</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt">(iii)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Expected term &#8211; three years.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The valuation was completed with the assistance
of an independent valuator based on management&#8217;s assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">During the year ended December 31, 2023, the Company recorded share-based
payment expenses to employees, directors and subcontractors in the amount of $1,427.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">During the year ended December 31, 2022, the Company recorded share-based
payment expenses to employees, directors and subcontractors in the amount of $4,879.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">During the year ended December 31, 2021, the Company recorded share-based
payment expenses to employees, directors and subcontractors in the amount of $6,703.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;The options to services providers and advisers outstanding as
of December 31, 2023, December 31, 2022 and December 31, 2021 were as&#160;follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/>
 December&#160;31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended <br/>
December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/>
 December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average Exercise price NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average Exercise price NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>&#160;Number of options</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>&#160;Weighted average Exercise price NIS</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">114,512</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">3.058</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">87,833</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">0.37</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">165,987</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">0.37</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Reclassified to employees and directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(71,260</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,326</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,401</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.367</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,721</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,086</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,134</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.37</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Options outstanding</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">105,111</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4.085</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">114,512</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.058</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">87,833</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Options exercisable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">94,242</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.267</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">82,257</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.71</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">62,715</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Share-based payment expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">19</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">54</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">279</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The RSUs to services providers and advisers outstanding as of December
31, 2023, December 31, 2022 and December 31, 2021 were as&#160;follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/>
 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/>
2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/>
 2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">18,266</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,833</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,234</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">RSUs outstanding</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,433</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">18,266</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">RSU&#8217;s Vested</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">25,067</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">14,234</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Share-based payment expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">33</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">16</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The options to employees and directors outstanding as of December 31,
2023, December 31, 2022 and December 31, 2021 were as&#160;follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year ended<br/>
 December 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year ended<br/>
 December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year ended<br/>
 December 31, 2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of options</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted average Exercise price NIS</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of options</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted average Exercise price NIS</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>&#160;Number of options</b></span></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>&#160;Weighted average Exercise price NIS</b></span></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">386,260</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">0.37</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">448,120</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">0.37</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">296,038</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">0.37</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Reclassified to employees and directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,260</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">95,238</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,309</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,544</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28,571</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.37</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">57,551</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.37</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,872</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.37</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Options outstanding</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">357,689</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">386,260</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">448,120</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Options exercisable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">350,131</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">342,757</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">347,069</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Share-based payment expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">47</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">174</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">394</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The RSUs to employees and directors outstanding as of December 31,
2023, December 31, 2022 and December 31, 2021 were as&#160;follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/>
 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/>
 2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/>
 2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at beginning of year</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">1,727,842</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">2,002,587</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 64%">Granted</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,016,854</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,658,188</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,087</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,626</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,215,615</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,225,973</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">655,601</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">RSUs outstanding</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">445,140</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,727,842</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,002,587</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">RSU&#8217;s Vested</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,097,189</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,881,574</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">655,601</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Share-based payment expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,352</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,618</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,014</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444249539024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 16 - RELATED PARTIES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The following transactions arose with related parties:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Transactions and balances with related parties</span><b>:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Shareholders and other related
parties&#8217; benefits</span></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Salary and related expenses &#8211; officers and directors</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,761</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,923</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,042</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share based payment &#8211; officers and directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,009</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,745</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,876</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Balances with related parties</span></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nature of transaction</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 11%; text-align: left">Officers</td><td style="width: 1%">&#160;</td>
    <td style="width: 64%; text-align: left">Salaries and related</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(314</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(292</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Directors</td><td>&#160;</td>
    <td style="text-align: left">Compensation for directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(40</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(40</td><td style="text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444257085856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 17 - SUBSEQUENT EVENTS:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 22, 2024, the Company&#8217;s Board of Directors
approved a grant of 320,000 RSUs to employees and options to purchase an aggregate of 80,000 Ordinary Shares to service providers under
the 2019 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date these Financial Statements, options
to purchase 40,499 Ordinary Shares are vested and 133,329 of the RSUs are vested and their underlying shares were issued immediately after
the grant approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 5, 2024, the Company&#8217;s Board
of Directors approved a grant of 517,000 RSUs to executives. <span style="-sec-ix-hidden: hidden-fact-144">None</span> of the total amount of RSUs are vested as of the date these Financial
Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 27, 2024, the Company&#8217;s Board of Directors
approved the issuance of warrants to purchase up to 220,000 Ordinary Shares to a service provider in connection with certain investor
relations services. The warrants have a term of 6 months commencing on May 20, 2024, and an exercise price of $2.25 per share. The warrants
will be forfeited in the event the Company terminates the service provider agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444251116496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (11,286)<span></span>
</td>
<td class="num">$ (14,976)<span></span>
</td>
<td class="num">$ (17,193)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444253715376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444254705168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock', window );">Conversion from IFRS to U.S. GAAP</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>A.
Conversion from IFRS to U.S. GAAP-</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has retroactively converted its historical
Financial Statements that were prepared in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;) to present
such Financial Statements in accordance with U.S. GAAP. This is the first Financial Statement presented according to U.S. GAAP.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is an Israeli company, and its business
operates in the medical technology industry in the field of respiratory support technology and intends to focus its commercial efforts
mainly in the USA. The Company&#8217;s both long and short-term intentions are to conduct clinical trials in the U.S. with the goal to
receive FDA approval as a first and major milestone.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The significant differences between IFRS and U.S.
GAAP as they relate to these Financial Statements are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(a) Leases</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under IFRS, prior to the adoption of U.S. GAAP,
the Company, as lessee, applied the single lease model that is similar to the accounting for a finance lease under U.S. GAAP. The expense
recognition presented a higher portion of the total expense earlier in the lease term as a combination of straight-line depreciation of
the right-of-use asset and the effective interest rate method applied to the lease liability results in a decreasing rate of interest
expense recognition throughout the lease term. In addition, the presentation of the lease expenses in the statements of comprehensive
loss is different. Under U.S. GAAP it is presented as lease expenses, while under IFRS it is presented as depreciation and interest expense.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under U.S. GAAP, there is dual classification
lease accounting model for lessees: finance leases and operating leases. The Company, as lessee, classified all its leases as operating
leases and recognizes a single lease expense, including both a right-of-use asset depreciation component and an interest expense component,
on a straight-line basis throughout the lease term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(b) Financial Liabilities</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issued tradable warrants to investors
in its initial public offering (the &#8220;IPO&#8221;) and warrants to its pre-IPO investors. Under IFRS, warrants issued by the Company
were classified as financial liabilities and measured at fair value with changes recognized in profit or loss. However, under U.S. GAAP,
those warrants are classified as equity instruments due to the change in its functional currency.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon transitioning to U.S. GAAP, the Company has
re-evaluated the classification of its warrants and determined that they meet the criteria for classification as equity instruments. Therefore,
the warrants have been reclassified from financial liabilities to equity in the Financial Statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This reclassification has been applied retroactively
to all periods presented in accordance with the requirements of U.S. GAAP. Consequently, the Financial Statements for prior periods have
been adjusted to reflect the reclassification of warrants from financial liabilities to equity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the change in determining the warrants
classification, the Company had changed its IPO expenses allocation between equity and issuance expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(<b>c) Change in Functional Currency Reporting</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under IFRS, the functional currency is determined
based on the currency of the primary economic environment in which the entity operates. However, under U.S. GAAP, the functional currency
is determined based on the currency of the primary economic environment in which the entity generates and expends cash.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of this change, the Company has reassessed
its functional currency and determined that it now aligns with the currency of the primary economic environment in which cash receipts
and payments occur, in accordance with U.S. GAAP requirements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This change in functional currency reporting has
been applied retroactively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management believes that this change in functional
currency reporting better reflects the economic substance of the Company&#8217;s operation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(d) Government Grants </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under International Accounting Standards (&#8220;IAS
20&#8221;) (under IFRS), the Company capitalized government grants according to revenue forecast and recognized financial expenses over
time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, under U.S. GAAP, the Company will recognize
royalties only when it starts to generate revenues. This differs from IFRS, where the Company recognized capitalized liability, financial
expenses and lower grant in the research and development expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>The conversion from IFRS to U.S.
GAAP based USD as our operational currency and following other U.S. GAAP differences, resulted in change of our financial results. </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>U.S. GAAP differences as of December
31, 2022:</b></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Note</b></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">IFRS<br/>
 (previously reported)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">U.S. GAAP</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Other current assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">2A(c)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">591</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">589</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Right of use assets, net</td><td>&#160;</td>
    <td style="text-align: center">2A(a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,107</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,263</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade accounts payables</td><td>&#160;</td>
    <td style="text-align: center">2A(c)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">152</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other accounts payables</td><td>&#160;</td>
    <td style="text-align: center">2A(c)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,217</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,216</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current lease liabilities</td><td>&#160;</td>
    <td style="text-align: center">2A(a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">329</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">268</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Financial liabilities at fair value</td><td>&#160;</td>
    <td style="text-align: center">2A(b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">368</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long term lease liabilities</td><td>&#160;</td>
    <td style="text-align: center">2A(a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">728</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">873</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loan from the Israeli Innovation Authority (&#8220;IIA&#8221;)</td><td>&#160;</td>
    <td style="text-align: center">2A(g)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">398</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign exchange reserve</td><td>&#160;</td>
    <td style="text-align: center">2A(c)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,928</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share capital and additional paid in capital</td><td>&#160;</td>
    <td style="text-align: center">2A(b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,814</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,866</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accumulated losses</td><td>&#160;</td>
    <td style="text-align: center">2A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(39,064</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(44,235</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left">Total Shareholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: center">2A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,822</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,631</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>U.S. GAAP differences for the year
ended December 31, 2021:</b></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">IFRS<br/>
 (previously reported)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">U.S. GAAP</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,909</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,070</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,951</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,980</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,572</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,937</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses (income)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,432</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,964</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest income from deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Finance expenses (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,523</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,230</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss before tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,955</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,193</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Taxes on income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">16,955</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">17,193</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Exchange (losses) profits arising on translation to presentation currency</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(845</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">16,110</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">17,193</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>U.S. GAAP differences for the year
ended December 31, 2022:</b></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">IFRS<br/>
 (previously reported)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.
GAAP</b>  &#160;</span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8,054</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8,183</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,325</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,328</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,391</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,375</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses (income)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,770</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,893</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest income from deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(192</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Finance expenses (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,497</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">275</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss before tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,273</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,976</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Taxes on income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,273</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">14,976</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Exchange (losses)profits arising on translation to presentation currency</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,138</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">12,411</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">14,976</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>B.
Use of estimates:</b></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of Financial Statements in conformity with U.S. GAAP
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent
assets and liabilities at the date of the Financial Statements, and the reported amounts of expenses during the reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Items subject to such estimates and assumptions include:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">stock-based compensation expense;</td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">fair value financial liabilities;</td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">recognition, measurement, and disclosure of contingent liabilities;</td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Interest rate used for lease liability measurement.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of issuance of the Financial Statements,
the Company is not aware of any material specific events or circumstances that would require it to update its estimates, judgments, or
to revise the carrying values of its assets or liabilities. These estimates may change, as new events occur and additional information
is obtained, and are recognized in the Financial Statements as soon as they become known. Actual results could differ from those estimates
and any such differences may be material to the Company&#8217;s Financial Statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>C.
<span>Foreign Currency</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The currency of the primary economic environment
in which the operations of the Company are conducted is the U.S. dollar (&#8220;USD&#8221;). The Company&#8217;s funding and expected
revenues are mostly in USD. Thus, the functional currency of the Company is in USD.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Transactions and balances originally denominated
in USD are presented at their original amounts. Balances in non-USD currencies are translated into USD using historical and current exchange
rates for non-monetary and monetary balances, respectively. For non-USD transactions and other items in the statements of income (indicated
below), the following exchange rates are used: (i) for transactions &#8211; exchange rates at transaction dates or average exchange rates;
and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization) &#8211; historical exchange
rates. Currency transaction gains and losses are presented in financial expenses (income), net as appropriate. The functional currency
of the Company is USD.&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant, and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>D.
Property, Plant, and Equipment</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost. Depreciation
is computed based on the straight-line method, over the estimated useful life of the assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Annual rates of depreciation are as follows:</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Computers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Development equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and office equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">6-15</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Leasehold Improvements</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">10</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>E.
Leases</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company implemented Accounting Standards Update
(&#8220;ASU&#8221;) 2016-02, Leases (Topic 842) (&#8220;ASU 2016-02&#8221;) using the modified retrospective approach for all lease arrangements
as of such date. The Company leases office space and vehicles under operating leases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Arrangements meeting the definition of a
lease are classified as operating or financing leases and are recorded on the balance sheet as both a right of use asset and lease
liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the
Company&#8217;s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the
right of use asset is amortized over the lease term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The lease liability was measured at the present
value of the remaining lease payments, discounted using the Company&#8217;s incremental borrowing rate. The weighted-average&#160;rate
applied was 9.60%. Right-of-use&#160;assets were measured at an amount equal to the lease liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For operating leases, interest on the lease liability
and the amortization of the right of use asset result in straight-line&#160;rent expense over the lease term. Variable lease expenses
are recorded when incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>F.
Research and Development Costs.</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Research and development
expenses consist primarily of payroll, payroll related expenses, subcontractors, and materials. Costs are expensed as incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistancePolicyTextBlock', window );">Government Grants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>G.
Government Grants</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company receives royalty-bearing grants from
the IIA for approved research and development projects. Under Israeli law, royalties on the revenues derived from products and services
developed using such grants, are payable to the Israeli Government.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Royalties payable with respect to grants received
under programs approved after January 1, 1999, are subject to interest on the dollar-linked value of the total grants received at an annual
rate of London Interbank Offered Rate (&#8220;LIBOR&#8221;) applicable to dollar deposits. In September 2021, the Bank of Israel, which
determines annual interest rates, published a directive which stated that annual interest at a variable rate linked to the LIBOR rate
for loans in USD will be replaced by the Secured Overnight Financing Rate, (&#8220;SOFR&#8221;), in January 2024. The amounts of grants
received and recorded into income should be disclosed for each period presented. The research and development grants are presented in
the statement of operations as an offset to related research and development expenses. Companies are required to pay royalties in connection
with such grants at specified rates, up to the total dollar-linked amount of such grants.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinanceIncomeAndExpensesPolicyTextBlock', window );">Finance Income and Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>H.
Finance Income and Expenses.</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finance income is composed of interest on deposits,
while finance expenses are composed of interest on senior secured credit facility, bank charges and net currency exchange rates differences.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Current Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>I.
Current Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The current tax liability
is measured using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments
required in connection with the tax liability in respect of previous years. The Company has no tax liability due to its carry forward
losses.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>J.
Share-Based Compensation.</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Share-based compensation
expenses related to employees, directors and subcontractors&#8217; options or restricted share units, (&#8220;RSU&#8221;) which recognized based
on their fair value, which is based on the fair value of the underlying Ordinary Shares as to the de-minimis exercise price using the
graded vesting method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes compensation expense for
grants of share-based awards to its employees based on the estimated fair value on the grant date. Compensation cost for awards is recognized
over the requisite service period, which approximates the vesting period. Share-based compensation is included in research and development,
selling and marketing and general and administrative expenses. Forfeitures of equity grants are recognized as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All issuances of stock options or other equity
instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value
of the equity instruments issued.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>K.
Warrants</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issues warrants as part of its financing
activities or compensation arrangements. Warrants are derivative financial instruments that entitle the holder to purchase a specified
number of the Company&#8217;s ordinary shares at a predetermined exercise price. Warrants issued by the Company may have various terms, including
expiration dates, exercise prices, and conditions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies warrants as either equity
or liabilities upon issuance, based on specific terms and conditions and in accordance with Accounting Standard Codification (&#8220;ASC&#8221;)
815, Derivatives and Hedging. Warrants are classified as equity if they meet the criteria for equity classification outlined in ASC 815-40.
Otherwise, warrants are classified as liabilities.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SeverancePolicyTextBlock', window );">Severance</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>L.
Severance</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Israeli labor law generally requires payment of
severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The Company&#8217;s pension
and severance pay liabilities are covered mainly by insurance policies. Pursuant to section 14 of the Israeli Severance Compensation Act,
1963 (&#8220;Section 14&#8221;), the Company&#8217;s employees are entitled to monthly deposits, at a rate of 8.33% of their monthly salary,
made in their name with insurance companies. Payments in accordance with Section 14 relieve the Company from any future severance payments
in respect of those employees and, as such, the Company may only utilize the insurance policies for the purpose of paying severance pay.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Loss Per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>M.
Basic and Diluted Loss Per Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic and diluted loss per share is calculated
by dividing the loss attributable to equity holders of the Company by the weighted average number of Ordinary Shares outstanding during
the financial year, adjusted for Ordinary Shares issued during the year, if applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>N.
Fair Value Measurements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures and discloses fair value
in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;), ASC 820, Fair Value Measurements and Disclosures (&#8220;ASC
820&#8221;). ASC 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value,
and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to
sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such,
fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing
an asset or liability. As a basis for considering such assumptions, there exists a three-tier fair-value hierarchy, which prioritizes
the inputs used in measuring fair value as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 &#8211; unadjusted quoted prices are available
in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 &#8211; pricing inputs are other than
quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration
with observable market data.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 &#8211; pricing inputs are
unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the
non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant
management judgment or estimation. Level 3 inputs are considered as the lowest priority within the fair value hierarchy.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This hierarchy requires the Company to use observable
market data, when available, and to minimize the use of unobservable inputs when determining fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of cash is based on its demand
value, which is equal to its carrying value. Additionally, the carrying value of all other short-term monetary assets and liabilities
are estimated to be equal to their fair value due to the short-term nature of these instruments.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>O.
Concentration of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains certain cash balances in
a well-known Israeli banks and U.S based banks.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s operating expenses are denominated
mainly in New Israeli Shekel (&#8220;NIS&#8221;), and therefore, subject to foreign currency risk.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalent</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>P.
Cash and Cash Equivalent</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash equivalents are highly liquid investments
that are readily convertible into cash, typically with an original maturity of three months or less from <span>the
date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>Restricted
cash consists of funds that are contractually restricted to bank guarantee due to rental agreements. The Company has presented
restricted cash separately from cash and cash equivalents in the balance sheets. </span>Bank deposits with maturities of more than
three months, but less than one year, and which are not restricted are included in short-term deposits. Such deposits are stated at
cost which approximates market value. As of December 31, 2023, December 31, 2022, the Company had short-term deposits in the amounts
of $2.3 million and $7.1 million respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Q.
Segment Information</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>The Company
has a single operating and reportable segment. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), who is the Chief
Executive Officer, evaluates the performance of its business based on financial data consistent with the presentation in the accompanying
Financial Statements for the purposes of making operating decisions, assessing financial performance, and allocating resources.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>R.
New accounting Pronouncements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><span style="text-decoration:underline">Accounting
Standards Adopted in 2023</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><span style="text-decoration:underline">ASU 2023-03
</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In July
2023, the FASB issued ASU 2023-03 to amend various U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) paragraphs in the
ASC to primarily reflect the issuance of SEC Staff Accounting Bulletin No. 120. ASU No. 2023-03, &#8220;Presentation of Financial Statements
(Topic 205), Income Statement&#8212;Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity
(Topic 505), and Compensation&#8212;Stock Compensation (Topic 718): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin
No. 120, SEC Staff Announcement at the March 24, 2022 EITF Meeting, and Staff Accounting Bulletin Topic 6.B, Accounting Series Release
280&#8212;General Revision of Regulation S-X: Income or Loss Applicable to Common Stock.&#8221; ASU 2023-03 amends the ASC for SEC updates
pursuant to SEC Staff Accounting Bulletin No. 120, SEC Staff Announcement </span>at the March 24, 2022, Emerging Issues Task Force (&#8220;EITF&#8221;)
Meeting; and Staff Accounting Bulletin Topic 6.B, Accounting Series Release 280 - General Revision of Regulation S-X: Income or Loss
Applicable to Common Stock. These updates were immediately effective and did not have a material impact on our financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In June
2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820), &#8220;Fair Value Measurement of Equity Securities Subject to Contractual
Sale Restrictions&#8221; which clarifies that contractual restrictions on equity security sales are not considered part of the security
unit of account and, therefore, are not considered in measuring fair value. In addition, the restrictions cannot be recognized and measured
as separate units of account. Disclosures on such restrictions are also required. The amendments are effective for Fiscal years beginning
after December 15, 2023, and interim periods within those fiscal years on a prospectively basis. The Company expects that ASU 2022-03
will not have a material impact on its Financial Statements and related disclosures. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span><b><i>Accounting
Pronouncements Issued but Not Yet Adopted</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In November
2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU expands public
entities&#8217; segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the CODM and
included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items,
and interim disclosures of a reportable segment&#8217;s profit or loss and assets. All disclosure requirements under ASU 2023-07 are also
required for public entities with a single reportable segment. The ASU&#8217;s amendments are effective for all public entities for fiscal
years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption
permitted. We are currently evaluating the impact of this pronouncement on our Financial Statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In December
2023, the FASB issued ASU 2023-08, Intangibles&#8212;Goodwill and Other&#8212;Crypto Assets (Subtopic 350-60): Accounting for and Disclosure
of Crypto Assets, which addresses the accounting and disclosure requirements for certain crypto assets. This ASU requires entities to
subsequently measure certain crypto assets at fair value, with changes in fair value recorded in net income in each reporting period.
In addition, entities are required to provide additional disclosures about the holdings of certain crypto assets. The ASU&#8217;s amendments
are effective for all entities holding assets that meet certain scope criteria for fiscal years beginning after December 15, 2024, including
interim periods within those years. Early adoption is permitted for both interim and annual periods. If an entity adopts the amendments
in an interim period, it must adopt them as of the beginning of the fiscal year that includes that interim period. We do not expect this
pronouncement to have a material impact on our Financial Statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>In December
2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. Under this ASU, public entities must
annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that
meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than five percent of the amount computed
by multiplying pretax income or loss by the applicable statutory income tax rate). This ASU&#8217;s amendments are effective for all entities
that are subject to Topic 740, Income Taxes, for annual periods beginning after December 15, 2024, with early adoption permitted. We are
currently evaluating the impact of this pronouncement on our disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for conversion from IFRS to U.S. GAAP.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FinanceIncomeAndExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finance income and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FinanceIncomeAndExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SeverancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for severance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SeverancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444250572160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock', window );">Schedule of Change of Our Financial Results in Balance Sheets</a></td>
<td class="text"><b>U.S. GAAP differences as of December
31, 2022:</b><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Note</b></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">IFRS<br/>
 (previously reported)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">U.S. GAAP</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Other current assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">2A(c)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">591</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">589</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Right of use assets, net</td><td>&#160;</td>
    <td style="text-align: center">2A(a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,107</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,263</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade accounts payables</td><td>&#160;</td>
    <td style="text-align: center">2A(c)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">152</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other accounts payables</td><td>&#160;</td>
    <td style="text-align: center">2A(c)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,217</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,216</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current lease liabilities</td><td>&#160;</td>
    <td style="text-align: center">2A(a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">329</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">268</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Financial liabilities at fair value</td><td>&#160;</td>
    <td style="text-align: center">2A(b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">368</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long term lease liabilities</td><td>&#160;</td>
    <td style="text-align: center">2A(a)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">728</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">873</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loan from the Israeli Innovation Authority (&#8220;IIA&#8221;)</td><td>&#160;</td>
    <td style="text-align: center">2A(g)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">398</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign exchange reserve</td><td>&#160;</td>
    <td style="text-align: center">2A(c)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,928</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share capital and additional paid in capital</td><td>&#160;</td>
    <td style="text-align: center">2A(b)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,814</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,866</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accumulated losses</td><td>&#160;</td>
    <td style="text-align: center">2A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(39,064</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(44,235</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left">Total Shareholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: center">2A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,822</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,631</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedStatementOfComprehensiveIncomeTableTextBlock', window );">Schedule of Change of Our Financial Results in Comprehensive Income</a></td>
<td class="text"><b>U.S. GAAP differences for the year
ended December 31, 2021:</b><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">IFRS<br/>
 (previously reported)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">U.S. GAAP</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,909</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,070</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,951</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,980</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,572</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,937</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses (income)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,432</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,964</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest income from deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Finance expenses (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,523</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,230</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss before tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,955</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,193</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Taxes on income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">16,955</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">17,193</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Exchange (losses) profits arising on translation to presentation currency</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(845</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">16,110</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">17,193</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><b>U.S. GAAP differences for the year
ended December 31, 2022:</b><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">IFRS<br/>
 (previously reported)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.
GAAP</b>  &#160;</span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8,054</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8,183</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,325</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,328</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,391</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,375</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses (income)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,770</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,893</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest income from deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(192</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Finance expenses (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,497</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">275</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss before tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,273</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,976</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Taxes on income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,273</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">14,976</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Exchange (losses)profits arising on translation to presentation currency</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,138</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">12,411</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">14,976</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock', window );">Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets</a></td>
<td class="text">Annual rates of depreciation are as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Computers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Development equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and office equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">6-15</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Leasehold Improvements</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">10</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of depreciation on straight-line method, over the estimated useful life of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedStatementOfComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedStatementOfComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444249539024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Other Current Assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">176</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">254</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Institutions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">164</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">276</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted Cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">432</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">589</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444251444544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><span style="text-decoration:underline">For the year ended December 31, 2023:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leasehold<br/> improvements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Development<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Furniture<br/> and office<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; font-weight: bold">At January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">121</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">229</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">116</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">499</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">152</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold">At December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">172</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">381</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">705</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">At January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold">At December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">199</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Net book value:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; padding-bottom: 4pt">As of December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">70</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">28</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">308</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">506</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">Less than thousand dollars</span></td>
</tr></table><span style="text-decoration:underline">For the year ended December 31, 2022:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leasehold<br/> improvements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Development<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Furniture<br/> and office<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; font-weight: bold">At January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">84</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">64</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">81</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">236</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">263</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold">At December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">499</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">At January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold">At December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Net book value:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; padding-bottom: 4pt">As of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">70</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">29</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">204</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">108</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">411</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">Less than thousand dollars</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444249609600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrentAbstract', window );"><strong>Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Other Accounts Payable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Employees&#8217; salaries and related liabilities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">388</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">396</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">354</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">332</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">267</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">470</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,026</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,216</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444247385392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Schedule of Lease Payments for the Company's Right-of-Use Assets over the Remaining Lease Periods</a></td>
<td class="text"><span>The Company has various operating
leases for vehicles that expire through 2027. Below is a summary of the Company&#8217;s operating right-of-use assets and operating lease
liabilities as of December 31, 2023, and 2022:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December&#160;31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating lease liabilities, current</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">290</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">268</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liabilities long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">588</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">873</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">878</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,141</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Weighted Average of Remaining Lease Term</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.33</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4.2</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Weighted-average discount rate - operating leases</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9.6</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9.92</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Lease Payments for the Company's Right-of-Use Assets over the Remaining Lease Periods</a></td>
<td class="text">Lease payments for the Company&#8217;s right-of-use
assets over the remaining lease periods as of December 31, 2023, are as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">357</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">290</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">220</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total undiscounted lease payment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,011</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Interest*</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(133</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">878</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify">Future lease payments were discounted by&#160;7.98%-15.04% interest
rate.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481440/840-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444247462288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finacial Liabilities at Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Finacial Liabilities at Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialGuaranteeInsuranceContractsClaimLiabilityTableTextBlock', window );">Schedule of Financial Liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December&#160;31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Financial liability (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">26</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Non-tradable warrants (2)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,459</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,470</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">26</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialGuaranteeInsuranceContractsClaimLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the claim liability for financial guarantee insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -SubTopic 40<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialGuaranteeInsuranceContractsClaimLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444250623008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Deficit) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' Equity (Deficit) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">Schedule of Share Capital</a></td>
<td class="text"><b>A.</b><b>Share capital:</b><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Number of shares as of<br/> December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Number of shares as of<br/> December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 4pt">Ordinary shares</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">100,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">15,652,176</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">100,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">11,338,940</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Movement in Warrants Outstanding</a></td>
<td class="text">The following table reconciles the movement in warrants outstanding
at the beginning and end of the period:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted-average exercise price</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted average remaining contractual term</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in years)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Aggregate</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>intrinsic value</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold; padding-bottom: 1.5pt">Balance as of December 31, 2022</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">3,121,095</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">5.58</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">1.74</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">4,667,915</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">212,188</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">131,555</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Balance as of December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,333,283</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5.47</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1.83</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,799,470</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Information about the Company&#8217;s Outstanding Warrants</a></td>
<td class="text">The following table summarizes information about the Company&#8217;s
outstanding warrants as of December 31, 2023<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Exercise Price</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Warrants outstanding</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December&#160;31,<br/>
 2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiration date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Aggregate</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Intrinsic</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>value</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">5.5</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,640,455</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">15/07/2026</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,214,614</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">5.5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,057,350</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">15/07/2024</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,691,760</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">5.5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">277,835</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">15/07/2025</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">497,533</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">6.875</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145,455</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">15/01/2027</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">264,008</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">1.6</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">212,188</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 10pt">28/12/2028</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">131,555</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,333,283</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,799,470</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Loss Per Share Calculated Using the Weighted Average Number of Shares</a></td>
<td class="text">Loss per share has been calculated using the weighted
average number of shares in issue during the relevant financial periods, the weighted average number of equity shares in issue and profit
for the period as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Loss for the period</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,286</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">14,976</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">17,193</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Total number of Ordinary Shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,652,176</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,338,940</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,091,706</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Weighted average number of Ordinary Shares</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">12,095,477</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,794,594</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,306,225</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-102; -sec-ix-hidden: hidden-fact-101; -sec-ix-hidden: hidden-fact-100">Basic and diluted loss per share</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(0.93</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(1.39</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(3.24</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444248542848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock', window );">Schedule of Research and Development Expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Salary and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,429</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,458</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,543</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Materials and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,082</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">204</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Share based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">663</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,392</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,792</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Subcontractors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">304</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">850</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">496</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">291</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">188</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">IIA participation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(106</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">268</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">213</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">47</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 4pt"><span style="font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,320</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">8,183</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,070</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444249436640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sales and Marketing Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpenseAbstract', window );"><strong>Sales and Marketing Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock', window );">Schedule of Sales and Marketing Expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Professionals&#8217; fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">348</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">527</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">520</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">248</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">282</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">220</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">503</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,215</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">746</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,328</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,980</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of sales and marketing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444249511056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_GeneralAndAdministrativeExpensesAbstract', window );"><strong>General and Administrative Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock', window );">Schedule of General and Administrative Expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Professional fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,432</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,390</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">766</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">716</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">545</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Director&#8217;s fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Related NASDAQ IPO expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">546</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Funds raising expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">675</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,984</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,696</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Insurance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">557</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">363</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">129</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Travel abroad</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 4pt"><span style="font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,063</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,375</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,937</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_GeneralAndAdministrativeExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_GeneralAndAdministrativeExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444249623904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial (Income) and Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Financial (Income) and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Financial (Income) and Expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left">Revaluation of financial liabilities at fair value through profit or loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(306</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(108</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,995</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Interest on financial liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Foreign currency transaction income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(233</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">113</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Finance expense in respect of lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(143</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"><span style="font-size: 10pt"><b>Total</b> expenses (Income)</span></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(529</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">275</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,230</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444247230304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Taxes on Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">The deferred tax assets and liabilities
are composed of the following:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net operating loss carryforward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,519</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,324</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">R&amp;D capitalization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,335</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,005</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Fund raising costs 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">275</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fund raising costs 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,012</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,670</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,012</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,670</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net deferred taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfTheoreticalTaxTableTextBlock', window );">Schedule of Theoretical Tax</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left">Loss before taxation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(11,286</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(14,976</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(17,193</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Theoretical tax credit at applicable statutory rate: 23%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,596</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,444</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,954</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Non-allowable expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(244</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,026</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,527</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Temporary differences and tax losses for which no Deferred Tax Asset is recognized</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,352</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,418</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,427</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Income tax benefit</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfTheoreticalTaxTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of theoretical tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfTheoreticalTaxTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444247406288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Share-Based Payment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Options to Services Providers and Advisers Outstanding</a></td>
<td class="text">The options to services providers and advisers outstanding as
of December 31, 2023, December 31, 2022 and December 31, 2021 were as&#160;follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/>
 December&#160;31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended <br/>
December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/>
 December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average Exercise price NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average Exercise price NIS</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>&#160;Number of options</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>&#160;Weighted average Exercise price NIS</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">114,512</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">3.058</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">87,833</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">0.37</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">165,987</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">0.37</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Reclassified to employees and directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(71,260</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,326</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,401</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.367</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,721</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,086</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,134</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.37</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Options outstanding</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">105,111</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4.085</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">114,512</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.058</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">87,833</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Options exercisable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">94,242</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.267</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">82,257</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.71</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">62,715</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Share-based payment expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">19</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">54</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">279</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>The options to employees and directors outstanding as of December 31,
2023, December 31, 2022 and December 31, 2021 were as&#160;follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year ended<br/>
 December 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year ended<br/>
 December&#160;31, 2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year ended<br/>
 December 31, 2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of options</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted average Exercise price NIS</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of options</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted average Exercise price NIS</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>&#160;Number of options</b></span></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>&#160;Weighted average Exercise price NIS</b></span></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">386,260</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">0.37</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">448,120</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">0.37</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">296,038</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">0.37</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Reclassified to employees and directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,260</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">95,238</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,309</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,544</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28,571</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.37</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">57,551</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.37</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,872</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.37</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Options outstanding</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">357,689</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">386,260</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">448,120</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Options exercisable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">350,131</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">342,757</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">347,069</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Share-based payment expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">47</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">174</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">394</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of RSUs to Services Providers and Advisers Outstanding</a></td>
<td class="text">The RSUs to services providers and advisers outstanding as of December
31, 2023, December 31, 2022 and December 31, 2021 were as&#160;follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/>
 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended<br/> December&#160;31, <br/>
2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/>
 2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">18,266</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,833</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,234</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">RSUs outstanding</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,433</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">18,266</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">RSU&#8217;s Vested</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">25,067</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">14,234</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Share-based payment expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">33</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">16</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>The RSUs to employees and directors outstanding as of December 31,
2023, December 31, 2022 and December 31, 2021 were as&#160;follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/>
 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/>
 2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended<br/> December&#160;31,<br/>
 2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at beginning of year</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">1,727,842</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">2,002,587</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 64%">Granted</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,016,854</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,658,188</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,087</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,626</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,215,615</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,225,973</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">655,601</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">RSUs outstanding</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">445,140</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,727,842</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,002,587</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">RSU&#8217;s Vested</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,097,189</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,881,574</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">655,601</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Share-based payment expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,352</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,618</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,014</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444361967760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Shareholders and Other Related Parties&#8217; Benefits</a></td>
<td class="text"><span style="font-size: 10pt"><span style="text-decoration:underline">Shareholders and other related
parties&#8217; benefits</span></span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Salary and related expenses &#8211; officers and directors</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,761</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,923</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,042</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share based payment &#8211; officers and directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,009</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,745</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,876</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfBalanceWithRelatedPartiesTableTextBlock', window );">Schedule of Balances with Related Parties</a></td>
<td class="text"><span style="font-size: 10pt"><span style="text-decoration:underline">Balances with related parties</span></span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nature of transaction</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 11%; text-align: left">Officers</td><td style="width: 1%">&#160;</td>
    <td style="width: 64%; text-align: left">Salaries and related</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(314</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(292</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Directors</td><td>&#160;</td>
    <td style="text-align: left">Compensation for directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(40</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(40</td><td style="text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfBalanceWithRelatedPartiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of balances with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfBalanceWithRelatedPartiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444346331744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 26, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 01, 2021</div></th>
<th class="th"><div>Mar. 18, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesGeneralDisclosuresLineItems', window );"><strong>General [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">310,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Purchase price of per share</a></td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Pre funded warrant, per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price of per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Direct offering</a></td>
<td class="nump">$ 3,424<span></span>
</td>
<td class="nump">$ 454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AdditionalOfferingCosts', window );">Additional offering costs</a></td>
<td class="nump">$ 454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AggregatePercentage', window );">Aggregate percentage</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDerivativeIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax', window );">Incurred accumulated losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesGeneralDisclosuresLineItems', window );"><strong>General [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares</a></td>
<td class="nump">1,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Purchase price of per share</a></td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=iinn_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesGeneralDisclosuresLineItems', window );"><strong>General [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares</a></td>
<td class="nump">1,656,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Purchase price of per share</a></td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=iinn_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesGeneralDisclosuresLineItems', window );"><strong>General [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesGeneralDisclosuresLineItems', window );"><strong>General [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares</a></td>
<td class="nump">1,656,250<span></span>
</td>
<td class="nump">212,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Purchase price of per share</a></td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesGeneralDisclosuresLineItems', window );"><strong>General [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares</a></td>
<td class="nump">3,031,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesGeneralDisclosuresLineItems', window );"><strong>General [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares</a></td>
<td class="nump">3,031,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AdditionalOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of additional offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AdditionalOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AggregatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AggregatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDerivativeIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of a derivative security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDerivativeIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesGeneralDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesGeneralDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=iinn_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=iinn_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=iinn_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=iinn_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=iinn_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444247363760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Lease liability, weighted-average discount rate</a></td>
<td class="nump">9.60%<span></span>
</td>
<td class="nump">9.92%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Employees monthly deposits rate</a></td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term deposits</a></td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 7.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444251844784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - Schedule of Change of Our Financial Results in Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems', window );"><strong>Schedule of Change of Our Financial Results in Balance Sheets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">$ 432<span></span>
</td>
<td class="nump">$ 589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets, net</a></td>
<td class="nump">1,011<span></span>
</td>
<td class="nump">1,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade accounts payables</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other accounts payables</a></td>
<td class="nump">1,026<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current lease liabilities</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Financial liabilities at fair value</a></td>
<td class="nump">1,470<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long term lease liabilities</a></td>
<td class="nump">588<span></span>
</td>
<td class="nump">873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermBorrowings', window );">Loan from the Israeli Innovation Authority (&#8220;IIA&#8221;)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ForeignExchangeReserve', window );">Foreign exchange reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Share capital and additional paid in capital</a></td>
<td class="nump">61,259<span></span>
</td>
<td class="nump">57,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated losses</a></td>
<td class="num">(55,521)<span></span>
</td>
<td class="num">(44,235)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders&#8217; Equity</a></td>
<td class="nump">$ 5,738<span></span>
</td>
<td class="nump">13,631<span></span>
</td>
<td class="nump">$ 23,728<span></span>
</td>
<td class="num">$ (1,332)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems', window );"><strong>Schedule of Change of Our Financial Results in Balance Sheets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade accounts payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other accounts payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Financial liabilities at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long term lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermBorrowings', window );">Loan from the Israeli Innovation Authority (&#8220;IIA&#8221;)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ForeignExchangeReserve', window );">Foreign exchange reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,928)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Share capital and additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,064)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders&#8217; Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ForeignExchangeReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign exchange reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ForeignExchangeReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedBalanceSheetStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444449072448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - Schedule of Change of Our Financial Results in Comprehensive Income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedStatementOfIncomeCaptionsLineItems', window );"><strong>Condensed Statement of Income Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 7,320<span></span>
</td>
<td class="nump">$ 8,183<span></span>
</td>
<td class="nump">$ 4,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">746<span></span>
</td>
<td class="nump">1,328<span></span>
</td>
<td class="nump">1,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">4,063<span></span>
</td>
<td class="nump">5,375<span></span>
</td>
<td class="nump">6,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other expenses (income)</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="nump">12,133<span></span>
</td>
<td class="nump">14,893<span></span>
</td>
<td class="nump">12,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeDepositsWithFinancialInstitutions', window );">Interest income from deposits</a></td>
<td class="num">(318)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Finance expenses (income), net</a></td>
<td class="num">(529)<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">4,230<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before tax</a></td>
<td class="nump">11,286<span></span>
</td>
<td class="nump">14,976<span></span>
</td>
<td class="nump">17,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Total net loss</a></td>
<td class="nump">$ 11,286<span></span>
</td>
<td class="nump">14,976<span></span>
</td>
<td class="nump">17,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Exchange (losses) profits arising on translation to presentation currency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,976<span></span>
</td>
<td class="nump">17,193<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedStatementOfIncomeCaptionsLineItems', window );"><strong>Condensed Statement of Income Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,054<span></span>
</td>
<td class="nump">3,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,325<span></span>
</td>
<td class="nump">1,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,391<span></span>
</td>
<td class="nump">7,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other expenses (income)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,770<span></span>
</td>
<td class="nump">13,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeDepositsWithFinancialInstitutions', window );">Interest income from deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Finance expenses (income), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,497)<span></span>
</td>
<td class="nump">3,523<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,273<span></span>
</td>
<td class="nump">16,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Total net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,273<span></span>
</td>
<td class="nump">16,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Exchange (losses) profits arising on translation to presentation currency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,138<span></span>
</td>
<td class="num">(845)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,411<span></span>
</td>
<td class="nump">$ 16,110<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedStatementOfIncomeCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedStatementOfIncomeCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeDepositsWithFinancialInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest income derived from funds deposited with both domestic and foreign financial institutions including funds in money market and other accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (b)<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeDepositsWithFinancialInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444254438992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsLineItems', window );"><strong>Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment', window );">Annual depreciation rates</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iinn_DevelopmentEquipmentMember', window );">Development equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsLineItems', window );"><strong>Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment', window );">Annual depreciation rates</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and office equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsLineItems', window );"><strong>Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment', window );">Annual depreciation rates</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and office equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsLineItems', window );"><strong>Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment', window );">Annual depreciation rates</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsLineItems', window );"><strong>Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment', window );">Annual depreciation rates</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual depreciation rates of property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iinn_DevelopmentEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=iinn_DevelopmentEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444252009952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Deposits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositLiabilityLineItems', window );"><strong>Deposits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Deposits', window );">Deposit</a></td>
<td class="nump">$ 280<span></span>
</td>
<td class="nump">$ 7,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate', window );">Fixed annual interest percentage</a></td>
<td class="nump">6.18%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PledgingPurposeAxis=us-gaap_DepositsMember', window );">Deposits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositLiabilityLineItems', window );"><strong>Deposits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate', window );">Fixed annual interest percentage</a></td>
<td class="nump">4.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositLiabilityLineItems', window );"><strong>Deposits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Deposits', window );">Deposit</a></td>
<td class="nump">$ 2,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositLiabilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1406<br> -Paragraph a<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1406<br> -Paragraph a<br> -Subparagraph (2)<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1406<br> -Paragraph a<br> -Subparagraph (3)<br> -Publisher SEC<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1406<br> -Paragraph a<br> -Subparagraph (4)<br> -Publisher SEC<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1406<br> -Paragraph a<br> -Subparagraph (5)<br> -Publisher SEC<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1406<br> -Paragraph c<br> -Publisher SEC<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Industry Guide<br> -Number 3<br> -Section V<br> -Paragraph D-E<br> -Publisher SEC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositLiabilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Deposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.12)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Deposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PledgingPurposeAxis=us-gaap_DepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PledgingPurposeAxis=us-gaap_DepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444253546560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Current Assets (Details) - Schedule of Other Current Assets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfOtherCurrentAssetsAbstract', window );"><strong>Schedule of Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestBearingDepositsInBanks', window );">Institutions</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted Cash</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Others</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 432<span></span>
</td>
<td class="nump">$ 589<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestBearingDepositsInBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For banks and other depository institutions (including Federal Reserve Banks, if applicable): Interest-bearing deposits in other financial institutions for relatively short periods of time including, for example, certificates of deposits, which are presented separately from cash on the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481309/942-210-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestBearingDepositsInBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444254566624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Beginning Balance</a></td>
<td class="nump">$ 499<span></span>
</td>
<td class="nump">$ 236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Beginning Balance</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">506<span></span>
</td>
<td class="nump">411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Ending Balance</a></td>
<td class="nump">705<span></span>
</td>
<td class="nump">499<span></span>
</td>
<td class="nump">$ 236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Ending Balance</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Beginning Balance</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Beginning Balance</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Ending Balance</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Ending Balance</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Beginning Balance</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Beginning Balance</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Ending Balance</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Ending Balance</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iinn_DevelopmentEquipmentMember', window );">Development equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Beginning Balance</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Beginning Balance</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Ending Balance</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">229<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Ending Balance</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Beginning Balance</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Beginning Balance</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Ending Balance</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Ending Balance</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iinn_DevelopmentEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=iinn_DevelopmentEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444253558144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accounts Payable (Details) - Schedule of Other Accounts Payable - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract', window );"><strong>Schedule of Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent', window );">Employees&#8217; salaries and related liabilities</a></td>
<td class="nump">$ 388<span></span>
</td>
<td class="nump">$ 396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AccountsPayableToRelatedParties', window );">Related parties</a></td>
<td class="nump">354<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued expenses</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">$ 1,026<span></span>
</td>
<td class="nump">$ 1,216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AccountsPayableToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accounts payable to related parties, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AccountsPayableToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444256117328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> &#8362; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>ILS (&#8362;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AggregateBudget', window );">Aggregate budget</a></td>
<td class="nump">$ 1,062<span></span>
</td>
<td class="nump">&#8362; 3,850,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">&#8362; 4,880,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PercentageOfApprovedBudget', window );">Percentage of approved budget</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ProjectBudgetAggregateAmount', window );">Project budget aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,333<span></span>
</td>
<td class="nump">&#8362; 4,623,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Total funds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 2,773,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ContingentUponFutureSales', window );">Contingent upon future sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153<span></span>
</td>
<td class="nump">&#8362; 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ReimbursementAmount', window );">Reimbursement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">&#8362; 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">Management fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">&#8362; 69,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total expenses related to the leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_RoyaltiesPercentage', window );">Percentage of royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FutureLeasePaymentsDiscountedInterestRate', window );">Future lease payments discounted interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.98%<span></span>
</td>
<td class="nump">7.98%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_RoyaltiesPercentage', window );">Percentage of royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FutureLeasePaymentsDiscountedInterestRate', window );">Future lease payments discounted interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.04%<span></span>
</td>
<td class="nump">15.04%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AggregateBudget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of aggregate budget.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AggregateBudget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ContingentUponFutureSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent upon future sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ContingentUponFutureSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FutureLeasePaymentsDiscountedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future lease payments discounted interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FutureLeasePaymentsDiscountedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PercentageOfApprovedBudget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of approved budget.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PercentageOfApprovedBudget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ProjectBudgetAggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of project budget aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ProjectBudgetAggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ReimbursementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reimbursement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ReimbursementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_RoyaltiesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_RoyaltiesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for investment management fee, including, but not limited to, expense in connection with research, selection, supervision, and custody of investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444254008480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilitiesAbstract', window );"><strong>Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">$ 290<span></span>
</td>
<td class="nump">$ 268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities long-term</a></td>
<td class="nump">588<span></span>
</td>
<td class="nump">873<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 878<span></span>
</td>
<td class="nump">$ 1,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted Average of Remaining Lease Term</a></td>
<td class="text">3 years 3 months 29 days<span></span>
</td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - operating leases</a></td>
<td class="nump">9.60%<span></span>
</td>
<td class="nump">9.92%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444251136672">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of Lease Payments for the Company's Right-of-Use Assets over the Remaining Lease Periods - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract', window );"><strong>Schedule of Lease Payments for the Company's Right-of-Use Assets Over the Remaining Lease Periods [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(133)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 878<span></span>
</td>
<td class="nump">$ 1,141<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Future lease payments were discounted by&#160;7.98%-15.04% interest
rate.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444253699648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finacial Liabilities at Fair Value (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 26, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems', window );"><strong>Finacial Liabilities at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PercentageOfPayFees', window );">Percentage of pay fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liability fair value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,470<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockDividendsShares', window );">Ordinary shares (in Shares)</a></td>
<td class="nump">3,031,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceDecrease', window );">Exercise of per share (in Dollars per share)</a></td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrants fair value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="nump">1,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.71%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1', window );">Expected term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_PrivateWarrantsMember', window );">Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems', window );"><strong>Finacial Liabilities at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1', window );">Expected term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Financial liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems', window );"><strong>Finacial Liabilities at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liability fair value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PercentageOfPayFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of pay fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PercentageOfPayFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period an equity-based award is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=iinn_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444253673632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Finacial Liabilities at Fair Value (Details) - Schedule of Financial Liability - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityLineItems', window );"><strong>Finacial Liabilities at Fair Value (Details) - Schedule of Financial Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total finacial liabilities at fair value</a></td>
<td class="nump">$ 1,470<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Financial liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityLineItems', window );"><strong>Finacial Liabilities at Fair Value (Details) - Schedule of Financial Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total finacial liabilities at fair value</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=iinn_NonTradableWarrantsMember', window );">Non-tradable warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityLineItems', window );"><strong>Finacial Liabilities at Fair Value (Details) - Schedule of Financial Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total finacial liabilities at fair value</a></td>
<td class="nump">$ 1,459<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=iinn_NonTradableWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=iinn_NonTradableWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444241339584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Deficit) (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 16, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 01, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 18, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 18, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 26, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 17, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 01, 2021 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareholdersEquityDeficitDetailsLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AggregateOfOrdinaryShares', window );">Aggregate of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">756,333<span></span>
</td>
<td class="nump">655,601<span></span>
</td>
<td class="nump">1,240,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_OrdinaryShare', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,435,375<span></span>
</td>
<td class="nump">24,800,000<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,877,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">310,000,000<span></span>
</td>
<td class="nump">310,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Warrants exercise price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shareholders approved | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitsAuthorized', window );">Authorized share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310,000,000<span></span>
</td>
<td class="nump">310,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">reverse split at a ratio of 2.94 to 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SoldOrdinaryShares', window );">Sold ordinary shares</a></td>
<td class="nump">2,909,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TradableWarrants', window );">Tradable warrants</a></td>
<td class="nump">3,345,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfferingCostsPartnershipInterests', window );">Additional offering direct costs (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Gross proceeds (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FairValueWarrants', window );">Fair value warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">436,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Granted to underwriters (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Tradable warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PercentageOfExercisePrice', window );">Percentage of exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PercentageOfExerciseOfTradableWarrants', window );">Percentage of exercise of tradable warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value of the financial liability (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Non-cash expenses (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpense', window );">Non-direct expenses (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Cash expenses (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BenefitsLossesAndExpenses', window );">Profit and loss (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options exercise shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,329<span></span>
</td>
<td class="nump">7,030<span></span>
</td>
<td class="nump">24,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonUnitAuthorized', window );">Authorized share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock Issued During Period, Shares, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Purchase price of per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Pre funded warrant, per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherUnderwritingExpense', window );">Underwriting discounts (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering cost (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PercentageOfAgreementWarrants', window );">Percentage of agreement warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDerivativeIssuanceCosts', window );">Issuance costs (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareholdersEquityDeficitDetailsLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options exercise shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock Issued During Period, Shares, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Purchase price of per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareholdersEquityDeficitDetailsLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shareholders approved | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareholdersEquityDeficitDetailsLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareholdersEquityDeficitDetailsLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,656,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shareholders approved | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Purchase price of per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant purchase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareholdersEquityDeficitDetailsLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,656,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Purchase price of per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant purchase [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareholdersEquityDeficitDetailsLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,031,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareholdersEquityDeficitDetailsLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AggregateOfOrdinaryShares', window );">Aggregate of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,019<span></span>
</td>
<td class="nump">2,113,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDividendsReceived', window );">Proceeds received (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Granted to underwriters (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpense', window );">Non-direct expenses (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BenefitsLossesAndExpenses', window );">Profit and loss (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareholdersEquityDeficitDetailsLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TradableWarrants', window );">Tradable warrants</a></td>
<td class="nump">436,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareholdersEquityDeficitDetailsLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AggregateOfOrdinaryShares', window );">Aggregate of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,226,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareholdersEquityDeficitDetailsLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Warrants exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shareholders approved | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_InvestorMember', window );">Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareholdersEquityDeficitDetailsLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NonTradableWarrants', window );">Non tradable warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,149,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=iinn_BrokersMember', window );">Brokers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareholdersEquityDeficitDetailsLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NonTradableWarrants', window );">Non tradable warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AggregateOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of aggregate of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AggregateOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FairValueWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fair value warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FairValueWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_NonTradableWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non tradable warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_NonTradableWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_OrdinaryShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of ordinary share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_OrdinaryShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PercentageOfAgreementWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of agreement warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PercentageOfAgreementWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PercentageOfExerciseOfTradableWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of exercise of tradable warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PercentageOfExerciseOfTradableWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PercentageOfExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PercentageOfExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareholdersEquityDeficitDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareholdersEquityDeficitDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SoldOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of sold ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SoldOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TradableWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of tradable warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TradableWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentOfWarrantsGrantedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment for noncash service expenses paid for by granting of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentOfWarrantsGrantedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BenefitsLossesAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of expense recognized during the period for future policy benefits, claims and claims adjustment costs, and for selling, general and administrative costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.5,6,7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BenefitsLossesAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonUnitAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of common units of ownership permitted to be issued by a limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonUnitAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total aggregate amount of all noninterest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfferingCostsPartnershipInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs incurred in connection with the offering and selling of additional partner interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 5.D.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfferingCostsPartnershipInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs incurred during the period, such as those relating to general administration and policy maintenance that do not vary with and are not primarily related to the acquisition or renewal of insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 720<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479448/944-720-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDerivativeIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of a derivative security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDerivativeIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDividendsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends received on equity and other investments during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDividendsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=iinn_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=iinn_BrokersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=iinn_BrokersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444247422912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of Share Capital - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfShareCapitalAbstract', window );"><strong>Schedule of Share Capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, Authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, Issued and outstanding</a></td>
<td class="nump">15,652,176<span></span>
</td>
<td class="nump">11,338,940<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444251728640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of Movement in Warrants Outstanding - Warrant [Member]<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Movement in Warrants Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Warrants, Beginning Balance | shares</a></td>
<td class="nump">3,121,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average exercise price, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 5.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term (in years), Beginning Balance</a></td>
<td class="text">1 year 8 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value, Beginning Balance | $</a></td>
<td class="nump">$ 4,667,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Warrants, Issued | shares</a></td>
<td class="nump">212,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average exercise price, Issued | $ / shares</a></td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term (in years), Issued</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued', window );">Aggregate intrinsic value, Issued | $</a></td>
<td class="nump">$ 131,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod', window );">Number of Warrants, Exercised | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue', window );">Weighted-average exercise price, Exercised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term (in years), Exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised', window );">Aggregate intrinsic value, Exercised | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Warrants, Forfeited | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-average exercise price, Forfeited | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term (in years), Forfeited</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited', window );">Aggregate intrinsic value, Forfeited | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod', window );">Number of Warrants, Expired | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue', window );">Weighted-average exercise price, Expired | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term (in years), Expired</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired', window );">Aggregate intrinsic value, Expired | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Warrants, Ending Balance | shares</a></td>
<td class="nump">3,333,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average exercise price, Ending Balance | $ / shares</a></td>
<td class="nump">$ 5.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term (in years), Ending Balance</a></td>
<td class="text">1 year 9 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value, Ending Balance | $</a></td>
<td class="nump">$ 4,799,470<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants, exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term, exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants, expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term, expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term, forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term, issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term, ending balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of aggregate intrinsic value exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of aggregate intrinsic value expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of aggregate intrinsic value forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of aggregate intrinsic value issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444251112928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of Information about the Company&#8217;s Outstanding Warrants<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Schedule of Information about the Company&#8217;s Outstanding Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_WarrantsOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">$ 3,333,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic value</a></td>
<td class="nump">$ 4,799,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=iinn_ExercisePrice55Member', window );">5.5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Schedule of Information about the Company&#8217;s Outstanding Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_WarrantsOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">$ 1,640,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Jul. 15,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic value</a></td>
<td class="nump">$ 2,214,614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=iinn_ExercisePrice55OneMember', window );">5.5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Schedule of Information about the Company&#8217;s Outstanding Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_WarrantsOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">$ 1,057,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Jul. 15,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic value</a></td>
<td class="nump">$ 1,691,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=iinn_ExercisePrice55TwoMember', window );">5.5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Schedule of Information about the Company&#8217;s Outstanding Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_WarrantsOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">$ 277,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Jul. 15,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic value</a></td>
<td class="nump">$ 497,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=iinn_Exercise6875Member', window );">6.875 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Schedule of Information about the Company&#8217;s Outstanding Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_WarrantsOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">$ 145,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Jan. 15,  2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic value</a></td>
<td class="nump">$ 264,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=iinn_Exercise16Member', window );">1.6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Schedule of Information about the Company&#8217;s Outstanding Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_WarrantsOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">$ 212,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Dec. 28,  2028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic value</a></td>
<td class="nump">$ 131,555<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_WarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_WarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=iinn_ExercisePrice55Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=iinn_ExercisePrice55Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=iinn_ExercisePrice55OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=iinn_ExercisePrice55OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=iinn_ExercisePrice55TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=iinn_ExercisePrice55TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=iinn_Exercise6875Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=iinn_Exercise6875Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=iinn_Exercise16Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=iinn_Exercise16Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444253744864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of Loss Per Share Calculated Using the Weighted Average Number of Shares - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract', window );"><strong>Schedule of Loss Per Share Calculated Using the Weighted Average Number of Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the period (in Dollars)</a></td>
<td class="nump">$ 11,286<span></span>
</td>
<td class="nump">$ 14,976<span></span>
</td>
<td class="nump">$ 17,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Total number of Ordinary Shares</a></td>
<td class="nump">15,652,176<span></span>
</td>
<td class="nump">11,338,940<span></span>
</td>
<td class="nump">10,091,706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of Ordinary Shares</a></td>
<td class="nump">12,095,477<span></span>
</td>
<td class="nump">10,794,594<span></span>
</td>
<td class="nump">5,306,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share (in Dollars per share)</a></td>
<td class="num">$ (0.93)<span></span>
</td>
<td class="num">$ (1.39)<span></span>
</td>
<td class="num">$ (3.24)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444247385392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Deficit) (Details) - Schedule of Loss Per Share Calculated Using the Weighted Average Number of Shares (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract', window );"><strong>Schedule of Loss Per Share Calculated Using the Weighted Average Number of Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share</a></td>
<td class="num">$ (0.93)<span></span>
</td>
<td class="num">$ (1.39)<span></span>
</td>
<td class="num">$ (3.24)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444254622960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses (Details) - Schedule of Research and Development Expenses - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Schedule of Research and Development Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salary and related expenses</a></td>
<td class="nump">$ 4,429<span></span>
</td>
<td class="nump">$ 3,458<span></span>
</td>
<td class="nump">$ 1,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLaborRelatedExpenses', window );">Materials and related expenses</a></td>
<td class="nump">$ 1,365<span></span>
</td>
<td class="nump">$ 1,082<span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share based payment (in Shares)</a></td>
<td class="nump">663<span></span>
</td>
<td class="nump">2,392<span></span>
</td>
<td class="nump">1,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_Subcontractors', window );">Subcontractors</a></td>
<td class="nump">$ 304<span></span>
</td>
<td class="nump">$ 850<span></span>
</td>
<td class="nump">$ 496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationNonproduction', window );">Depreciation</a></td>
<td class="nump">291<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForParticipationLiabilities', window );">IIA participation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(106)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total</a></td>
<td class="nump">$ 7,320<span></span>
</td>
<td class="nump">$ 8,183<span></span>
</td>
<td class="nump">$ 4,070<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_Subcontractors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subcontractors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_Subcontractors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationNonproduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationNonproduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLaborRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of labor-related expenses classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLaborRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForParticipationLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments related to participation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483170/926-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForParticipationLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444254108592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sales and Marketing Expenses (Details) - Schedule of Sales and Marketing Expenses - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfSalesAndMarketingExpensesAbstract', window );"><strong>Schedule of Sales and Marketing Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professionals&#8217; fees</a></td>
<td class="nump">$ 348<span></span>
</td>
<td class="nump">$ 527<span></span>
</td>
<td class="nump">$ 520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Salary and related expenses</a></td>
<td class="nump">248<span></span>
</td>
<td class="nump">282<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Share-based payment</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">503<span></span>
</td>
<td class="nump">1,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSellingAndMarketingExpense', window );">Other</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Total</a></td>
<td class="nump">$ 746<span></span>
</td>
<td class="nump">$ 1,328<span></span>
</td>
<td class="nump">$ 1,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfSalesAndMarketingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfSalesAndMarketingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of selling and marketing expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444254847296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses (Details) - Schedule of General and Administrative Expenses - General and Administrative Expense [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems', window );"><strong>General and Administrative Expenses (Details) - Schedule of General and Administrative Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">$ 1,432<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 1,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Salary and related expenses</a></td>
<td class="nump">766<span></span>
</td>
<td class="nump">716<span></span>
</td>
<td class="nump">545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Director&#8217;s fees</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLaborRelatedExpenses', window );">Related NASDAQ IPO expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FundsRaisingExpenses', window );">Funds raising expenses</a></td>
<td class="nump">260<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment</a></td>
<td class="nump">675<span></span>
</td>
<td class="nump">1,984<span></span>
</td>
<td class="nump">3,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralInsuranceExpense', window );">Insurance expenses</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">557<span></span>
</td>
<td class="nump">363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Office maintenance</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TravelAndEntertainmentExpense', window );">Travel abroad</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralExpense', window );">Others</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Total</a></td>
<td class="nump">$ 4,063<span></span>
</td>
<td class="nump">$ 5,375<span></span>
</td>
<td class="nump">$ 6,937<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FundsRaisingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funds raising expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FundsRaisingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralInsuranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralInsuranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general expenses not normally included in Other Operating Costs and Expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLaborRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of labor-related expenses classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLaborRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TravelAndEntertainmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses incurred for travel and entertainment during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TravelAndEntertainmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444253565296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial (Income) and Expenses (Details) - Schedule of Financial (Income) and Expenses - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfFinancialIncomeAndExpensesAbstract', window );"><strong>Schedule of Financial (Income) and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue', window );">Revaluation of financial liabilities at fair value through profit or loss</a></td>
<td class="num">$ (306)<span></span>
</td>
<td class="num">$ (108)<span></span>
</td>
<td class="nump">$ 3,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingInterestExpense', window );">Interest on financial liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ForeignCurrencyTransactionsGainBeforeTax', window );">Foreign currency transaction income</a></td>
<td class="num">(233)<span></span>
</td>
<td class="nump">530<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinanceLeaseInterestExpenses', window );">Finance expense in respect of lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(143)<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Others</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DisposalGroupIncludingDiscontinuedOperationsOtherIncome', window );">Total expenses (Income)</a></td>
<td class="num">$ (529)<span></span>
</td>
<td class="nump">$ 275<span></span>
</td>
<td class="nump">$ 4,230<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DisposalGroupIncludingDiscontinuedOperationsOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other income attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DisposalGroupIncludingDiscontinuedOperationsOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revaluation of financial liabilities at fair value through profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FinanceLeaseInterestExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FinanceLeaseInterestExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ForeignCurrencyTransactionsGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ForeignCurrencyTransactionsGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfFinancialIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfFinancialIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents interest incurred for borrowed money which was used to produce goods or render services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444253769616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TaxesonIncomeDetailsLineItems', window );"><strong>Taxes on Income (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Carryforward tax losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TaxesonIncomeDetailsLineItems', window );"><strong>Taxes on Income (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TaxesonIncomeDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TaxesonIncomeDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444249406512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Details) - Schedule of Deferred Tax Assets and Liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 5,519<span></span>
</td>
<td class="nump">$ 3,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">R&amp;D capitalization</a></td>
<td class="nump">1,335<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DeferredTaxAssetsFundRaisingCosts2021', window );">Fund raising costs 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DeferredTaxAssetsFundRaisingCost2023', window );">Fund raising costs 2023</a></td>
<td class="nump">70<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease liability</a></td>
<td class="nump">8<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">7,012<span></span>
</td>
<td class="nump">4,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DeferredTaxAssetValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(7,012)<span></span>
</td>
<td class="nump">4,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DeferredTaxAssetValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DeferredTaxAssetValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DeferredTaxAssetsFundRaisingCost2023">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fund raising costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DeferredTaxAssetsFundRaisingCost2023</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DeferredTaxAssetsFundRaisingCosts2021">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fund raising costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DeferredTaxAssetsFundRaisingCosts2021</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444254176256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Details) - Schedule of Theoretical Tax - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfTheoreticalTaxAbstract', window );"><strong>Schedule of Theoretical Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxation</a></td>
<td class="num">$ (11,286)<span></span>
</td>
<td class="num">$ (14,976)<span></span>
</td>
<td class="num">$ (17,193)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Theoretical tax credit at applicable statutory rate: 23%</a></td>
<td class="num">(2,596)<span></span>
</td>
<td class="num">(3,444)<span></span>
</td>
<td class="num">(3,954)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-allowable expenses</a></td>
<td class="num">(244)<span></span>
</td>
<td class="num">(1,026)<span></span>
</td>
<td class="num">(1,527)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized', window );">Temporary differences and tax losses for which no Deferred Tax Asset is recognized</a></td>
<td class="num">(2,352)<span></span>
</td>
<td class="num">(2,418)<span></span>
</td>
<td class="num">(2,427)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfTheoreticalTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfTheoreticalTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary differences and tax losses for which no Deferred Tax Asset is recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444247992416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Details) - Schedule of Theoretical Tax (Parentheticals)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfTheoreticalTaxAbstract', window );"><strong>Schedule of Theoretical Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Theoretical tax credit at applicable statutory rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfTheoreticalTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfTheoreticalTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444241033760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 24, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 24, 2022 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 12, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 16, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 16, 2021 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 21, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 21, 2021 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 21, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 22, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 19, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 06, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 02, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_CapitalGainTaxRate', window );">Capital gain tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_OptionsIssuableTerm', window );">Options issuable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareOptionsVestingPeriod', window );">Share options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise price per share | (per share)</a></td>
<td class="nump">$ 3.08<span></span>
</td>
<td class="nump">&#8362; 10.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_EquityPercentage', window );">Company&#8217;s equity percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease', window );">Number of authorized ordinary shares increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,180,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_RSUsVestPeriod', window );">RSUs vest period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested grant share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,329<span></span>
</td>
<td class="nump">7,030<span></span>
</td>
<td class="nump">24,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable ordinary shares</a></td>
<td class="nump">29,400<span></span>
</td>
<td class="nump">29,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment expenses (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,352<span></span>
</td>
<td class="nump">$ 4,618<span></span>
</td>
<td class="nump">$ 6,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iinn_TwoThousandAndNineteenPlanMember', window );">2019 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Contractual life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=iinn_EmployeesDirectorsAndSubcontractorsMember', window );">Employees, Directors and Subcontractors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment expenses (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,427<span></span>
</td>
<td class="nump">4,879<span></span>
</td>
<td class="nump">6,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=iinn_NonTradableSharesOptionsMember', window );">Non-Tradable Shares Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,633<span></span>
</td>
<td class="nump">81,633<span></span>
</td>
<td class="nump">13,605<span></span>
</td>
<td class="nump">13,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,633<span></span>
</td>
<td class="nump">81,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Share Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,768<span></span>
</td>
<td class="nump">21,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise price per share | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares grant</a></td>
<td class="nump">29,400<span></span>
</td>
<td class="nump">29,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares grant</a></td>
<td class="nump">555,500<span></span>
</td>
<td class="nump">555,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,658,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_RSUsVestPeriod', window );">RSUs vest period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested grant share</a></td>
<td class="nump">3,141<span></span>
</td>
<td class="nump">3,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment expenses (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member] | Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares grant</a></td>
<td class="nump">536,141<span></span>
</td>
<td class="nump">536,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,713<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member] | Advisory Board Members [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares grant</a></td>
<td class="nump">22,500<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Black Scholes Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Black Scholes Model [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_CapitalGainTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital gain tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_CapitalGainTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_EquityPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_EquityPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_OptionsIssuableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The term of options issuable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_OptionsIssuableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_RSUsVestPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>RSUs vest period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_RSUsVestPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareOptionsVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share options vesting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareOptionsVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of increase (decrease) of non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=iinn_TwoThousandAndNineteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=iinn_TwoThousandAndNineteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=iinn_EmployeesDirectorsAndSubcontractorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=iinn_EmployeesDirectorsAndSubcontractorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=iinn_NonTradableSharesOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=iinn_NonTradableSharesOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=iinn_AdvisoryBoardMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=iinn_AdvisoryBoardMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444256172208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment (Details) - Schedule of Options to Services Providers and Advisers Outstanding<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=iinn_ServicesProvidersAndAdvisersMember', window );">Services Providers and Advisers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems', window );"><strong>Schedule of Options Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding at beginning of year | shares</a></td>
<td class="nump">114,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average Exercise price, Outstanding at beginning of year | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 3.058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors', window );">Number of options, Reclassified to employees and directors | shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71,260)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors', window );">Weighted average Exercise price, Reclassified to employees and directors | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted | shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average Exercise price, Granted | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 10.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers', window );">Number of options, Exercised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,721)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,086)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average Exercise price, Exercised | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod', window );">Number of options, Forfeited | shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average Exercise price, Forfeited | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Options outstanding | shares</a></td>
<td class="nump">105,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average Exercise price, Options outstanding | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 4.085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 3.058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, Options exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average Exercise price, Options exercisable | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 3.267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Number of options, Share-based payment expenses | $</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=iinn_EmployeesAndDirectorsMember', window );">Employees and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems', window );"><strong>Schedule of Options Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding at beginning of year | shares</a></td>
<td class="nump">386,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">448,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average Exercise price, Outstanding at beginning of year | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors', window );">Number of options, Reclassified to employees and directors | shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors', window );">Weighted average Exercise price, Reclassified to employees and directors | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted | shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average Exercise price, Granted | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers', window );">Number of options, Exercised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,544)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average Exercise price, Exercised | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod', window );">Number of options, Forfeited | shares</a></td>
<td class="nump">28,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,872)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average Exercise price, Forfeited | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Options outstanding | shares</a></td>
<td class="nump">357,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">448,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average Exercise price, Options outstanding | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, Options exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">342,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average Exercise price, Options exercisable | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Number of options, Share-based payment expenses | $</a></td>
<td class="nump">$ 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of options, reclassified to employees and directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share price of weighted average exercise price, reclassified to employees and directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=iinn_ServicesProvidersAndAdvisersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=iinn_ServicesProvidersAndAdvisersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=iinn_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=iinn_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444254522448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment (Details) - Schedule of RSUs to Services Providers and Advisers Outstanding - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems', window );"><strong>Share-Based Payment (Details) - Schedule of RSUs to Services Providers and Advisers Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrants, Beginning Balance</a></td>
<td class="nump">1,727,842<span></span>
</td>
<td class="nump">2,002,587<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSUs, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,016,854<span></span>
</td>
<td class="nump">2,658,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of RSUs, Forfeited</a></td>
<td class="nump">67,087<span></span>
</td>
<td class="nump">65,626<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of RSUs, Vested</a></td>
<td class="nump">1,215,615<span></span>
</td>
<td class="nump">1,225,973<span></span>
</td>
<td class="nump">655,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs, RSUs outstanding</a></td>
<td class="nump">445,140<span></span>
</td>
<td class="nump">1,727,842<span></span>
</td>
<td class="nump">2,002,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested', window );">Number of RSUs, RSU&#8217;s Vested</a></td>
<td class="nump">3,097,189<span></span>
</td>
<td class="nump">1,881,574<span></span>
</td>
<td class="nump">655,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Number of RSUs, Share-based payment expenses (in Dollars)</a></td>
<td class="nump">$ 1,352<span></span>
</td>
<td class="nump">$ 4,618<span></span>
</td>
<td class="nump">$ 6,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems', window );"><strong>Share-Based Payment (Details) - Schedule of RSUs to Services Providers and Advisers Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrants, Beginning Balance</a></td>
<td class="nump">18,266<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSUs, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">22,500<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of RSUs, Vested</a></td>
<td class="nump">10,833<span></span>
</td>
<td class="nump">14,234<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs, RSUs outstanding</a></td>
<td class="nump">7,433<span></span>
</td>
<td class="nump">18,266<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested', window );">Number of RSUs, RSU&#8217;s Vested</a></td>
<td class="nump">25,067<span></span>
</td>
<td class="nump">14,234<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Number of RSUs, Share-based payment expenses (in Dollars)</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of RSUs vested under share based payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444250874224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Details) - Schedule of Shareholders and Other Related Parties&#8217; Benefits - Officers and Directors [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Shareholders and Other Related Parties&#8217; Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Salary and related expenses &#8211; officers and directors</a></td>
<td class="nump">$ 1,761<span></span>
</td>
<td class="nump">$ 1,923<span></span>
</td>
<td class="nump">$ 1,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based payment &#8211; officers and directors</a></td>
<td class="nump">$ 1,009<span></span>
</td>
<td class="nump">$ 3,745<span></span>
</td>
<td class="nump">$ 5,876<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=iinn_OfficersAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=iinn_OfficersAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444254024512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Details) - Schedule of Balances with Related Parties - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_OfficerMember', window );">Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemNatureOfEventOrTransaction', window );">Nature of transaction</a></td>
<td class="text">Salaries and related<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related parties transaction</a></td>
<td class="num">$ (314)<span></span>
</td>
<td class="num">$ (292)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Balances with Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemNatureOfEventOrTransaction', window );">Nature of transaction</a></td>
<td class="text">Compensation for directors<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related parties transaction</a></td>
<td class="num">$ (40)<span></span>
</td>
<td class="num">$ (40)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemNatureOfEventOrTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the nature of an event or transaction that is unusual in nature or infrequent in occurrence, or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483613/220-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemNatureOfEventOrTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140444449068032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 27, 2024</div></th>
<th class="th"><div>Feb. 05, 2024</div></th>
<th class="th"><div>Jan. 22, 2024</div></th>
<th class="th"><div>Mar. 24, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 22, 2022</div></th>
<th class="th"><div>May 19, 2022</div></th>
<th class="th"><div>Nov. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Purchase of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,329<span></span>
</td>
<td class="nump">7,030<span></span>
</td>
<td class="nump">24,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Purchase of ordinary shares</a></td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_RestrictedStockUnits', window );">Restricted Stock Units (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Exercise price of per share (in Dollars per share)</a></td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">555,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">2,658,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517,000<span></span>
</td>
<td class="nump">320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_RestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_RestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>109
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M!\W8C8.8QEX ,2R7%3D5@@LRXD(4HOUM'-)%98[B=ZF;2]/0^F@TXSM?@G4
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M-M<DNW[03;2H7 WNA385[8:E::$@;8#9+X30QXD]8&C*Z5]02P,$%     @
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ME"5C3WIPMYHXGO8(<DBDIJ#J9P\SR'/-I/SX49,ZS9S:\/3YA?V3$:_$+*F
M&<N_9RN93IR1@U:PIKM</K##GU +,@XF+!?F+SI4V,AW4+(3DA6UL?*@R,KJ
MES[7@3@QP.$% U(;D+9!<,' KPW\UQH$M4%@(E-),7&84TFG8\X.B&NT8M,/
M)IC&6LG/2KWN"\G5UTS9R>E"4@EJ':5 ;(UFK%#9D^IEW0/ZBPF!/J)OBSEZ
M_^X#>H>R$CVF;"=HN1)C5ZKI-8F;U%/=5E.1"U-A@CZS4J8"_5ZN8'5.X"J_
M&^?)B_.WI)=Q#LD ^?@*$8_X%H=FKS<G%O/YZ\UQCQJ_60K?\/D7^.[*A!6
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M5G?%IE,[TE0M]6?*-UDI4 YK1>D-(N45K[K4:B#9UO1M2R95%V@>4]79 ]<
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M$K@J!"<2EF/GQK^>Q<;?.OPH8*OVUL0H60CQ9#:WV=CQ3$+ (-6&@>+?!J;
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MW4YIB)38B?3(A@HV;JA \2C1 =$CDW'0WG;1BPW)A'B3]KZ+7H[0@!P!3M(
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M(:YR"A$J@9R;Q/!)9/A/'ZXZ=G].'2)^UZ:5]CX&%Z9B+9OU9#JY$UD)5J4
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M;CJ8GYB<%J5)J;G:J(5B99Q*VG [1'<Y016 **EW1,5P9":)@AS-U,7$:-"
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M:0+&YP;FB@^T0?_!\O)_4$L#!!0    ( #-+>5@B*0'[>R   'I?   8
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M#QVH<=*%UO.PM1CI7](J77'ZMH \#/C?6G-Y8!<UL NH!5#/:CCGB8XB;;^
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M+Z;6*JH8N!RAW4DQN7C)?38D7>L[:SFD#VGC0DS(.&R(.=S8@P28,D%;C$"
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MI^"7(9::)'IR=77%> 1I^Z[H<U: \OH%8$0&@:>[=K:WRD?N7]F)J7>0<0!
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M-TT-H5'J:UC!4R);<*+4GFCVQ(E47PV@A6F3-^$#2%(GEOQA:WL1G;WR"0]
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MNM2['MPX(!J1-X;BM156RI66J=T6>BZB, DZON%<'0QS0#=IXS]02P,$%
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M[YT<[3G&$[[49L$O3">FKDW!'Q%(!(86X/G4F#I\H0/:-^CG_P-02P,$%
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M$W#:[5%E8ZIV]# DCN%KIAI.G;T,1=8,>_2Y\WL+D9,_'9)]0, '0%S.0>^
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M#-.'&<S2Y_3WQ\4\?7B"]*]%^K!*5^<(7X0\3_CA\2F%,( K^,^(-\[?=)R
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M/$VEL,SI;P!:5J#SN3%^LV$'VS\6H[\ 4$L#!!0    ( #-+>5CZ?\+R8P(
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MD8/]J;;9VA7_T=0>_4#$FC*)<EAIRGYOI%U-U+Y7!XJ7U@F67&E?L<M,?RI
MF 1]ON)<[0)3H/WX1'\!4$L#!!0    ( #-+>5AD.J)K0P(  (H&   9
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M+/7/ H0)T,]SSM5Q8C88?C_)&U!+ P04    "  S2WE8G'S-YJ(A  !3:
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M21W"4(Q$P)#,N,B6S.,@-QWNK&E9UH XGG_9T3P=";'K(?YY3JK,PJD]&!7
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MT>7L0AC2?74$(62Y,7 0^F@Z QI]\A$M1O- A]/9%*ER>7ZJ;FVTR+.85R#
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MZ@3HW%:&4Y'D<F(MI7^"YDR#3B5Y>BAJCESRM@\9Q[!I6]DXUGO;'&:/]"W
MJM&]_ITV5FHJ[QPF R?RS"OUM[]<GE]<O@9'LDR^G+#+A9P%:_+9R/JOW<C
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M($"PCX$Z[TA\P*A33US33ELXC?1'6^+_V(_F<.QKG.6H<U@T*;)@&O$&87/
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ME36@_:64YF%B W0/^O0/4$L#!!0    ( #-+>5A=4=%"<0(  &D%   9
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M]-N29B%J%T#G*Z7LSG 7]-,U_0-02P,$%     @ ,TMY6%C7L,NM P  / D
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M3OCAF0CD3,.6$7I-X2M4S.ZT)VS4AO46<YZ2TH@7,X"/%5=(8R7K36X+/@[
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MZ&S8PJ8-[)GS>U7,4=G]M)W0P+7M[!]VK'^LDY@SJ\Q**O$/9G"K=44?7F9
MN4$;:HAR"?^YPOFDZ$/Y8KN'[WFNU_R!'[EQQ%P_B5\.^VX0C-U)Z,&!ZXZZ
MZXZ.ONZ/\A$I)1D0)3QPI7AI-'S:L=WG@8/H^SWP986PD#EE3'M'QL8@9<!4
MEJF@: 1#TT6/R6;+I']OW-3KYK@496EA[,6BO=Q%/;%&)636]VUWH(<ZEV'V
MCC^BHM0,^(0J%9J,E$BQFX?MO$*;_^TFQ+$.FHKG8% 5<$+\GI$K?0JSY5+A
MDALDSD8)2NPI//*\0N>2Y[PDX$96%.A8<VJ#G4'@^LQWO4D$T3 :@S],0@C=
M.$[<B1\YK7"83TH8V]D8(O#).(HBYZ:EGL&[YI]#V7R!PO1&;I[60O7ZA^D$
M1"<( I>- Z(3)K0AM4(WF4S<,#DHN;B37'RTY&[+IO36-6Q.'JZ]=R6+-2^?
MW[X9,S]Y_T*#G1_WB?'@OL>+L:GA%+::?'D$/Z<?\YU<?W*_G<_@KI';'GGO
MLZW=V!#)K,IV>KM]I3=2$?AN''IN&%$K&GD)/6-8#,QE/@G+#]LE7I2X0>3M
MEH36;N*[2>S52UB2N..@AQ%!.$G<* B<>#A.:"*,NDU\NR !%H>4IL:.%>I6
MM&P\\IF='G?*W:GL*&TEG;:2H[7UF]0:[NCZMF4D3ZN<V]#XJFMGKWK!/FN#
M?9<P:JN],CM,H=Z6\D^3TF%%OIPCEE1ONOVK;O]-N[^S33;EZZI#&4;8% !9
MI;96BMY]CR0:6%#QH+1)Z:A)>-I]@0H_HF+S$G@-;M/G6LF%, X)OI="K12;
M^-!GSI^4ZFR6)>2]3:<^^RL JE=L3"4L=">VDB6N/PF<+Y)*;X]65P?OVSK8
MJWV[>N=3!;3R]&+GARQ] (O9Y$H*2RQ ,@G=:!)"Y 9>[#(644*TL6-O(!-Y
M93'SERX\\8:3 .B]Z ^#B?T&0PJ5TWUR'?4>JP6J9?TDUU0XJM(T[]9NM'OU
MSYK'[FYY\Y/A(U=4W#3DN"!3;YA0J57-,[SI&+FNG[YS:>@A73=7],L%E5U
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M$I4MH'PAI=DY=H'^[DW_ %!+ P04    "  S2WE8?";*(@<#  !Y!@  &0
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MHT#G&R'TT\(XZ/^0+/X'4$L#!!0    ( #-+>5C=>P9CM 0   X.   9
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M_OTDV?'2X(11]F)+\CWGWG-D7<4U%R^R %#HM:1,CIU"J>K.=65:0(GE@%?
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M#80)T-]7G*O=Q"3HKLOD#U!+ P04    "  S2WE8VAE*/C8&  "M*@  &0
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M(,P$/;[B7.T[IB!J"N#X+U!+ P04    "  S2WE8S3MJEY@"  !V!P  &0
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M:S*3U@)+'$><[1'7T<I-#TQMC%IE0PK]%5>2J[=$Z63\36; T;SB' J)9D*
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M#E#O-XS)UXGNO>U1&_\%4$L#!!0    ( #-+>5C5!O=YU@8  .TO   9
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MP8 ZICO:I3L"TWVW6!1)$0>"A7*NE#^PB()R-CZR!%OST5YZDXE6 5-"7:T
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MB@4ARTJ!_'[)N7A^4_[ [H3_[']02P,$%     @ ,TMY6.40<U"Q @  I@<
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M_O/G)&&G&\4 YX\\6OT/4$L#!!0    ( #-+>5B:^""@_@(  +@(   9
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MO9DZ0X>DL*)%IN_$_B^H#/4,7R(R97_)OIKK.20IE!9Y!48%.>/E/_U1!7$
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M55'4CY^T WPNRC]W#^?B/U!+ P04    "  S2WE8X]Q29%<"  #I!0  &0
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M#>K[.6/R^:(TT/[\,/L/4$L#!!0    ( #-+>5AU#)L16P,  .L)   9
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M,<#W&R'T\\(<T([:RW\!4$L#!!0    ( #-+>5AF3Z@TP0(  "H)   9
M>&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;+56;6_:,!#^*U963:VTD9#PMBY$
M*K!J2*M4]6T?JGTPR4&B.G9F.X3^^]E.R* +V9#8%^*7>YZ[Y[#O[!>,OX@8
M0*)-2J@86[&4V:5MBS"&%(L.RX"JG27C*99JRE>VR#C@R(!28KN.,[!3G% K
M\,W:+0]\EDN24+CE2.1IBOGK! @KQE;7VB[<):M8Z@4[\#.\@GN0C]DM5S.[
M9HF2%*A(&$4<EF/KJGLY'6E[8_"40"%VQD@K63#VHB?S:&PY.B @$$K-@-5G
M#5,@1!.I,'Y6G%;M4@-WQUOV:Z-=:5E@ 5-&OB>1C,?6R$(1+'%.Y!TKOD*E
MIZ_Y0D:$^45%:=M7'L-<2)968#5/$UI^\:;*PPZ@.S@ <"N ^Q;0.P#P*H!G
MA):1&5DS+''@<U8@KJT5FQZ8W!BT4I-0_2_>2ZYV$X63P0/>@$ JGW,:LA30
M^0PD3HBX0!_1X_T,G9]=H#.44/00LUQ@&@G?ELJO1MMAY6-2^G /^.BZZ(91
M&0OTA480[1/8*N Z:G<;]<1M99Q!V$%>]P-R'==K"&CZ[W"W)1RO3J)G^+RC
MD_C\39FBN814_&A*7,G;:^;5-_A29#B$L:6NJ "^!BMX_ZX[<#XWB3X1V5X*
M>G4*>FWLP11S_JJ*2H%YA"3>(,*$@,;#TDITK.:2;&#(=,5:!V[/<1S?7C>(
MZ==B^JUBGC#)<5EEB"ISF(;0)*25Y%@A_3^$# _J&-0Z!JTZYH)C(.CY!M(%
M\,8#V$IPK(83D>UI'=9:A__I#@Y/F8(3D>VE8%2G8-1^!QG/&,<2S 74@R:Y
M)<>GG8/F='017>_*^(M1&9Z]TW92X"O3C04*64YE6<OKU;KA7YD^]V9]HAX"
M9=_^35.^(FXP7R54( )+1>ETANJ:\+(SEQ/),M/<%DRJ5FF&L7K, -<&:G_)
MF-Q.M(/Z>13\ E!+ P04    "  S2WE84@ER*Z<#  "(#0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970V-RYX;6RM5VUOTS 0_BM60 @DMKRU:3?:2.L* HF7
M:1OPV4NNK843!]M9-WX]YR1+T]8- _:EM9V[Q\_CE[OS9"WD#[4"T.0NX[F:
M.BNMBU/75<D*,JJ.10$Y?ED(F5&-7;ET52&!II53QMW \R(WHRQWXDDU=B'C
MB2@U9SE<2*+*+*/R?@9<K*>.[SP,7++E2IL!-YX4= E7H+\6%Q)[;HN2L@QR
MQ41.)"RFSIE_>NX/C$-E\8W!6G7:Q$BY$>*'Z7Q(IXYG& &'1!L(BG^W< Z<
M&R3D\;,!==HYC6.W_8#^KA*/8FZH@G/!O[-4KZ;.V"$I+&C)]:58OX=&T-#@
M)8*KZI>L&UO/(4FIM,@:9V20L;S^IW?-0G0<_.B 0] X!+L.@P,.8>,05D)K
M9I6L.=4TGDBQ)M)8(YII5&M3>:,:EIMMO-(2OS+TT_$UO0-%<#T_Y(G(@+R<
M@Z:,JU?DB%SAF4E+#D0LR!P6("6D!!W(F5*@%:%Y2CXR>L,XTPQ1CLC7JSEY
M^?P5>4Y83JY7HE1HHR:N1J9F/C=I6,UJ5L$!5GY /HE<KQ1YFZ>0;@.X*+'5
M&3SHG 6]B'-(CDGHOR:!%X060N>/=P]ZZ(3MLH<57G@0KUE.C<M)J^4\M2U3
MC3*PHY@K?JH*FL#4P3NL0-Z"$[]XYD?>&YO$)P+;$CQH!0_ZT.//&)$P]DBJ
M6;XD7"A%$BKE/0:B-96I37L-&%6 )AK=QL.A?S)Q;[N:]HW",!BT1EM<ARW7
M82_7LR21)>X-W&&P5& ]OS7"L#/OV-NAMF\2179B44LLZB5V^8)FQ9LYKES!
M-.7L%S6AT$8OVIO;#\/A#D&+D><-[11'+<51+\5W)08%29DRVYP(A6$"KXQO
MX]@+9#^.Q':L1WLR@M$!%>-6Q?@?5-CBQFR\-_MH]R#TSO4HH5LB3EH1)[TB
MOFRN&V"B([P)U?<V&2?[YWE'1>]D?Z_"]S89RNO5<2WPK)O4O!LQK7G%L^R'
M'^QHL5@-HLZ^;3/MY%*_E^DWRDM:5R<<ZR.:)V#EZ._-?F0CN6_60S+8D P>
MGWKX)GU;\T^#]40)Z*G0MI5O<J[?F^%L!ZFCWRK_'U*F-48] ="VZ$W>]?^<
M>+N2#PCM!?D;H?\/5 MU.S5M!G)9E?I8-(@RUW79UXZVSXFSJHC>&9^99T95
M*V]@ZC?*)RJ7+%<8'A<(Z1V/\*K)NNRO.UH45>5\(S36X55SA4\ED,8 OR^$
MT \=,T'[^(I_ U!+ P04    "  S2WE8,>/S"V(#  "9"@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970V."YX;6RM5FUOVS80_BL'K1M:8(FL%[\DLP4D48<5
M6(>@:;</PS[0TLDB*I$:2<?N?OV.DJ(Y BT$6 ##XLO=HWN>HXZW/DCU59>(
M!HYU)?3&*XUIKGU?9R763%_*!@7M%%+5S-!4[7S=*&1YZU17?CB;+?R:<>$E
MZW;M7B5KN3<5%WBO0._KFJEOMUC)P\8+O*>%3WQ7&KO@)^N&[? !S9?F7M',
M'U!R7J/07 I06&R\F^ Z75G[UN!WC@=],@;+9"OE5SOYD&^\F0T(*\R,16#T
M>,0[K"H+1&'\W6-ZPRNMX^GX"?WGECMQV3*-=[+Z@^>FW'@K#W(LV+XRG^3A
M%^SYS"U>)BO=_L.AMYUYD.VUD77O3!'47'1/=NQU.'$(%F<<PMXA'#O$9QRB
MWB%ZJ4/<.\2M,AV55H>4&9:LE3R LM:$9@>MF*TWT>?"IOW!*-KEY&>2S^R(
M&B@!'T0F:X2W*1K&*_T.+N"!SEB^KQ!D 9]+E H-SU@%Y$.[7QY2>/OF';P!
M+FA;[C43N5[[AJ*RV'[61W#;11">B2 (X:,4IM3P7N28/P?PB<[ *7SB=!M.
M(J:874(4_ CA+(P< =V]W#UTN*<O=P\FV$1#AJ(6+SJ#-Y6%/V^VVBCZ=OYR
MZ=[AQFY<6T^N=<,RW'A4,#2J1_22'[X+%K.?7)J])ECZ2F#/](P'/>,I].17
MJ35LD2HF@F%'9LN/2[T.9=&BV.+YF%P$0;A:K/W'4UU<9O'5<F26NLR6P54T
MF#WC,A^XS">YG)X'X@*9PIP;8/1KFHJ6MW1NM&%F;Z3Z!HH9O(8P^M[%MWO3
M_#3"<'XUINNPBN(X'K%U65W-8S?9Q4!V,4GV-RDN6$7W5,L*CW3S:706G(6#
MRCC&.X=1, O'>7-9S<.EF\ER8+*<3AO6C51TRT+.BP(5BHR*,)7/-HD5'5":
MT@&%0\FS$H2$%,F,DMM^]3>T;X!KNG8SN1/\GW'5[%18.E2(YN%(!I=5'*Q&
M,CBMSLFP&F183<K07SF6\Q8%%MRX:$QBN&L%N K8*^&D_Q^G$\L_N;1K5+NV
M^=&0R;TPW5TWK []U4W;5HS6;ZGOZMJD_V"ZINTC4SLN-%18$.3L<DD)5%TC
MU$V,;-K68"L--1KML*3>$94UH/U"2O,TL2\8NM'D7U!+ P04    "  S2WE8
M[QR]DWH"  "_!@  &0   'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6RM55UO
MVC 4_2M6)DVMM)$OVFX=1"K-IO:A$FJ[[6':@TDNQ*H39_8-T'^_:R=DM +&
M0R5$[.M[SO4]CD]&*Z6?3 & ;%W*RHR] K&^]'V3%5!R,U U5+0R5[KD2%.]
M\$VM@><.5$H_"H)SO^2B\I*1BTUU,E(-2E'!5#/3E"77SQ.0:C7V0F\3N!>+
M FW 3T8U7\ #X/=ZJFGF]RRY**$R0E5,PWSL7867Z=#FNX0? E9F:\QL)S.E
MGNSD-A][@=T02,C0,G!Z+.$:I+1$M(T_':?7E[3 [?&&_9OKG7J9<0/72OX4
M.19C[Y/'<ICS1N*]6MU U\^9Y<N4-.Z?K=K<B]AC66-0E1V8=E"*JGWR=:?#
M%B \WP.(.D#T&C#< X@[0'PL8-@!G-1^VXK3(>7(DY%6*Z9M-K'9@1/3H:E]
M4=EC?T!-JX)PF#SR-1A&!W!;9:H$=I("<B'-*?O('N@=RQL)3,W98P%* XJ,
M2T88=C+E&BHLVI Y'?E(N[&<?M95GK25HSV5PXC=*6(P[&N50_Z2P*<V^EZB
M32^3Z"!C"MF Q>$'%@51O&-#U\?#HQWP]'AX>*";N#^9V/'%>_@.J?_K:F90
MTYWYO4OWEG>XF]?ZR*6I>09CCXS"@%Z"E[Q_%YX'7W9I]I9DZ1N1O=!SV.LY
M/,2>;&N(I&&F(1?(./WJ6E)X1EH;Y-B@TL],<X1=XK9%/KLBUE.723"P;]MR
M6[1CDM+_)+5-^EM7NP2]<!9I6*::"MN;T4=[%[YRYO,J/B%W;LWT'TUK[7=<
M+T1EF(0Y40:#BS./Z=8NVPFJVAG(3"'9D1L6](4!;1-H?:X4;B:V0/_-2OX"
M4$L#!!0    ( #-+>5@>LQA!#!   &<# 0 9    >&PO=V]R:W-H965T<R]S
M:&5E=#<P+GAM;*W=:V^C5A['\;>"TJIJI6YLP':<-!.I$^YW.MO=!ZM]P-A,
M@FH;%TAFLNJ+7WQ)" X^MM-O'W0<YYP/!Q-^X@!_<_TU+_XH[].TDK[-9XOR
MP]E]52VO>KUR<I_.D_(\7Z:+^C=?\F*>5/6/Q5VO7!9I,EUWFL]Z2K\_ZLV3
M;'%V<[U^+RINKO.':I8MTJB0RH?Y/"F>/J:S_.N',_GL^8W?LKO[:O5&[^9Z
MF=REG]+J]V54U#_U7I1I-D\7998OI"+]\N'L5_DJ'JX[K%O\*TN_EJ]>2ZM5
M^9SG?ZQ^L*<?SOJK$:6S=%*MB*3^YS&]36>SE52/X\\M>O:RS%7'UZ^?=6.]
M\O7*?$[*]#:?_3N;5O<?SL9GTC3]DCS,JM_RKU:Z7:'ARIODLW+]?^GKINUH
M="9-'LHJGV\[UR.89XO-O\FW[0?QJH.J[.F@;#LHQW90MQW4G0Z*O*?#8-MA
ML+N$?1V&VP[#8SN,MAU&QZ[#Q;;#Q;$=QML.X]V5'N[I<+GM<+G301[LVW#]
MYRW7WUW&Y;XN+QM[=VOO[_*\N>7=[;V_R_,&EX_>XO+S)I=WM[G2W]?E>:/+
MNUM]_U*>-[N\N]WW=WG>\/)ZR_<V^]5ZI]22*KFY+O*O4K%J7WNK%^L]>]V_
MWA>SQ2J$/E5%_=NL[E?=?+I/BO0?'^O=>"I%R5,=+Y7THY96238K?Y*^EWI2
MN6I12ME"^GV15>7/]9OUZW_>YP]ELIB6U[VJ'L8*ZTVVB[0WBU3V+%*6_'Q1
MW9>2OIBFTX[^[H'^B@#HU>O_\B$HSQ_"1T4H^DEQ+BF#GR6EKRBO5WKS3\<0
M;T\!?_ANK(Z47XY@-3'[Z\/=N20K:U;>K^B'!O<DR:,M<LS*&B=XQZ^K*5:-
M]'/]$<HG#-,Z!3Q^G/;[QMDA.6))2R?GDKJ6Y,NNW>+H[HHJ_?Y)DW[\_J?]
M@_&.UY3#FG^\)A_6 K$6Y(_U1ZYLQ[97"8_XL[T\A$0']LAEO:/W1X>4^(@5
MZHOVZU:LJ2_9KJY9]81L_X]7-Y+L*IV7_^T8Z,>-..@65T?$5^4RF:0?SNI#
MWC(M'M.SFQ^^DT?]7[I"DL0T$M-)S" QD\0L$K-)S"$QE\0\$O-)+""QD,0B
M$HLAK!69@Y?('(CTF]MDF57)3+JKI^]2E7R3BJ1*NW)2R)R:DR2FD9A.8@:)
MF21FD9A-8LX&NUQCJQ-*CS?]<V5XW7M\G7_D$CT2\TDL(+&0Q"(2BR&LE7_#
ME_P;"O,O7*Y.#=:S_;)\2#[/4JE*BWE7_@F94_./Q#02TTG,(#&3Q"P2LTG,
M(3%7_+<O]Z6G-"DZ)\OD,'P2"T@L)+&(Q&((:X7BZ"441\(_C/4\6LJWT?B8
MEE6VN).6:9'E7:<O/PJU4[.1Q#02T\4?FKIW9S+>V]%\;T?KO1WM]W9TR$_:
M)3&/Q'P2"T@L)+&(Q&((:T79Q4N470C_8O5O:3')RE1:%MDD7678YG2C])?T
MX\L//W6%VL:]>#414<_[X_9$Y';32!Z\:B7WS\>#=C--.,938^CMP/KGLM)>
MHD$NT3QFB1:Y1/N8)3KD$ET2\TC,)[& Q$(2BT@LAK!6Y(Q?(F<L/J66+ZHB
MF50/R4R:95\ZSZ8)A5./F$A,(S&=Q P2,\6;4# SLM[=TR97P"$QE\0\$O-)
M+""QD,0B$HLAK!5^ER_A=WD@_.;+9/'TPW=C1;[XI932/Q^RZFEUW#5)%U5R
MUYF&0O+4-"0Q[?*(L]$ZN42#Q$P2LTC,)C&'Q%P2\TC,)[& Q$(2BT@LAK!6
M%LK]ES!<W0(J2,/@8?ZYGF3F7Z3DH;K/B^Q_Z53*BVFV2(JGYD;#29$F96<R
MBOU3HQ'5M*TV?!6. WG<'U_N3))U=+$&JIFH9J&:C6H.JKFHYJ&:CVH!JH6H
M%J%:3&GML'QU8[8L#,O?/OV^N=@@N-)P@-A_?OKVW3TU<<]3I\2H9J":B6H6
MJMFHYJ":BVH>JOFH%KQ[+PK?W3-"UR!^SSC:@:8T@:8(K7_5658?[]T5R:+:
M'.QU1IH0.?D0C]0T5--1S4 U$]4L5+-1S4$U=ZN]G@3(JJHJE^TY@-?1[J*O
M]MNM_(Y6RF"DRNUF ;H*(:I%J!936CO!FGH*67CO\?/5T_6-<3O3ULXH4]]N
MOLM!?V<KWQ[73!./[>3P02L@4,U$-0O5;%1S4,U%-0_5?%0+4"U$M0C58DIK
M)UY3#K&Z5T.0>)L2LL_K$K+EMH0L_;9,%V5:2C]F"TG+9[/Z /$GZ2_I^\X,
M%/HG'\Z1FH9J.JH9J&:BFH5J-JHYJ.9NM5'K<&ZH[![,O6TU&,GCW8.YMZU&
M?7FP>RQ'CC]$M0C58DIK)UM3Z""+[_9>%5E+T2Q92/_QT]5EB<YR6#%R<GRA
MA0ZHIJ.:@6HFJEFH9J.:@VHNJGFHYJ-:@&HAJD6H%E-:.S:;4@AY<WLR^9T"
M,EH0@6H:JNFH9J":B6H6JMFHYJ":BVH>JOFH%J!:B&H1JL64U@[1I@A#%E=A
M''-+] %"<&/M[?N[:N*N)\?ANP=BO+^KB:Z#A6HVJCFHYJ*:AVH^J@6H%J):
MA&HQI;6#KBG]D,6W__O9(IL_S,53;+3X ]4T5--1S4 U$]4L5+-1S4$U%]4\
M5/-1+4"U$-4B5(LIK1V:3<F(?,E/L=&:$5334$U'-0/53%2S4,U&-0?57%3S
M4,U'M0#50E2+4"VFM/87.C>E)HJXU$3_MDPGJ]L-'_-94F6SK'KJRDVQ<FIN
MHIJ&:CJJ&:AFHIJ%:C:J.:CF;K5V/>9..::'+M)'M0#50E2+4"VFM'8<-L4D
MBO@^;GV^G.5/:5K^+&E942=C7I12LIA*GQX^3[9G(U=OB2;JXD6<G)6DIJ&:
MCFH&JIFH9J&:C6H.JKFHYJ&:CVH!JH6H%J%:3&GM4%6:4%7PB;J"EK>@FH9J
M.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:6U0[2IJ5'$-35_^PYSL7]R
MHJ+/+$$U'=4,5#-1S4(U&]4<5'.W6NL.\X%RL3N'?ULB-AA?[!05^AVM1A=]
M=><.<W3\(:I%J!936CO9FMJ9^J4HV8)\\8]_%LET72[X:?/E-L_?KR^<9PO9
MDP.-U#14TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40U2)4BRFM':1-J8XRY.?9
M:.$.JFFHIJ.:@6HFJEFH9J.:@VHNJGFHYJ-:@&HAJD6H%E-:.T2;PAU%_*R*
MZ*&8W-<1NOKVQ2.^NT*LG9R?:,T.JNE;[?6L:2R/U)UIDW%<,[.CF:R.^CL7
M9:WCFMGHFCJHYJ*:AVH^J@6H%J):A&HQI;4SJJF+4<15'=M)\OH;PCI#B;PW
M_A;5-%33M]K!4#JJF8F.S4(U&]4<5'-1S4,U']4"5 M1+4*UF-+:$==4Q"CB
MBIC-L^2..@V(UL6@FH9J.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:6U
MH[.IBU'XNA@%K8M!-0W5=%0S4,U$-0O5;%1S4,U%-0_5?%0+4"U$M0C58DIK
MA:C:U,6HXKJ8$T\#BK53\Q/5-%334<U -5-]^V@91;X8[7S#H'5<,QL=FX-J
M+JIYJ.:C6H!J(:I%J!936COQFM(7]4#IR_Y''O_PW5@=*;](/5$"HE4OJ*:A
MFHYJQE9K/0NZ?Z[NW-EFH@NUCENHC2[40347U3Q4\U$M0+40U2)4BRFMG8!*
MDX#B!Z\<NJRB=CQFHN,Y!<<UT\2#.3F4T"H25#-1S4(U&]4<5'-1S4,U']4"
M5 M1+4*UF-+:$==4D:CB*I+UP_)$5U/$_4\^C$.K1%!-1S4#U4Q4LU#-1C4'
MU5Q4\U#-1[4 U4)4BU MIK1V8C;5*?5+^FK*EJ1"E-0T5--1S4 U$]4L5+-1
MS4$U%]4\5/-1+4"U$-4B5(LIK1VB366**GZ(S,&9]?#-E'E8__=V:GU<.TT\
MG)-##JT<0343U2Q4LU'-0347U3Q4\U$MZ-AGY%&]R^SL,V%'.[7_IEF$#B[N
M6*@R&H[E<7,QKATY31V'*J[C..:Q\&+BY.,TM'@#U714,U#-1#4+U6Q4<U#-
M134/U7Q4"U M1+4(U>(#H7;X,?-J4T2BBHM(CGO,O/JV<D*5!_+N<=DQK33Q
M@$Z.-%(S4,U$-0O5;%1S4,U%-0_5?%0+4"U$M0C58DIKQUQ32*(>44CR=[XW
M2^R??)"(UI>@FHYJ!JJ9J&:AFHUJ#JJY6^WU]V;M?!V6U]%DMS+2[V@CCW:^
M, L=>(AJ$:K%E-:.M*; 0Q7>^]R^B%O'UL<\*::K&Y6;KZP67N)%:SU034,U
M'=4,5#-1S4(U&]4<5'-1S4,U']4"5 M1+4*UF-):>3IH:CT&??P2[P M^$ U
M#=5T5#-0S40U"]5L5'-0S44U#]5\5 M0+42U"-5B2FN':%,^,A"7CQRZQ+OM
MWKITJX[>GDH\LITF'L[)(8?6=*":B6H6JMFHYJ":BVH>JOFH%J!:B&I1Q_ZL
MC(<7\LX9AKBCG=RZ_-S.):7))7%1Q^YD^=?I8U;FQ=-VUKSYA7C"+%["R<=Z
MZ+-(4$U'-0/53%2S4,U&-0?57%3S4,U'M0#50E2+4"VFM':F-E4D Y6?,*.%
M):BFH9J.:@:JF:AFH9J-:@ZJN:CFH9J/:@&JA:@6H5I,:>T0;0I+ZI=_:\(\
M>'O@K+R])?JX9IIX,"=''*D9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:6U
M(ZXI^QB(RSX^SI+)']*GR7T^JY/.SZ?I3#S11A]&@FH:JNFH9J":B6H6JMFH
MYJ":BVH>JOFH%J!:B&H1JL64U@[0IHAE,.(GVFA1"ZIIJ*:CFH%J)JI9J&:C
MFH-J+JIYJ.:C6H!J(:I%J!936CM$FT*7@;C01<L>LVFZF$I%4G76N(C[GYR8
MZ.-24$U'-0/53%2S4,U&-0?5W*UV^>H$T,[)'P]=H(]J :J%J!:A6DQI[1AL
M"F$&XD(8_=LRG:PJ_JJTF'?&(%KH@FH:JNFH9J":B6H6JMFHYJ":>^"OO[-R
M=IN.Z$-34"U M1#5(E2+*:V=CDU-S4!<4R,Z52G])?G)MVS^,!>?O43K:E!-
M0S4=U0Q4,U'-0C4;U1Q4<U'-0S4?U0)4"U$M0K68TEJ9.FSJ:H9\7<T0K:M!
M-0W5=%0S4,U$-0O5;%1S4,U%-0_5?%0+4"U$M0C58DIKAVA35S,\]%B6[;3]
M,9\E53;+JJ?.W$0?OX)J&JKIJ&:@FHEJ%JK9J.:@FKO5Y/[KDYCG0V6P<R(3
M7:J/:@&JA:@6H5I,:9M$[)7W:5II297<7,_3XBZ]36>S4IKD#XMJ]8TCK]Z5
MBO1+G9CRU:_*6>_-^Q_EJUNYXWU=OC*ZWC?E*ZOK?5N^<KK>=^4K?_U^KQGF
MS?4RN4O]I+C+%J4T2[_40^Z?7PS/I"*[NW_YH<J7]5_WF?0YKZI\OGYYGR;3
MM%@UJ'__)<^KYQ]6"_B:%W^L/Y:;_P-02P,$%     @ ,TMY6'%FZHU?"
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M_$QIN;28A0E[]HK9VD*6T5)2\84CD6M/P#F<\D!&N9!&>7:G*)S9F%A:JR@
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M'V#OS^,XVQWD!/O]H,;_ U!+ P04    "  S2WE8GWN.?YP$   _%0  &0
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MTX'Z"_*RH2LGDN6F)[IG4G589IBH)ABX#E#/8\;D9J)?4+?5P5]02P,$%
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M!NL,#[E\CQIC(I],B(42AH_JQ\_6L:IU)SX,T^7K:&;(,QFQ9R[X@V]QK=@
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MS_U4)YHWJW\66/VCP_X?4$L#!!0    ( #-+>5AG_%)"3 (  &@L   :
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MM__/\=.S[&T[O.2SZ9^UZS]02P$"% ,4    "  S2WE8!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M #-+>5AS+K,\[P   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( #-+>5B97)PC$ 8  )PG   3
M  "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ,TMY6+6Q
M,ED]!P  <24  !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( #-+>5@S/VV<+0(  * %   8
M  " @8$/  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  S
M2WE8CM\>+-H$  "4%0  &               @('D$0  >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&UL4$L! A0#%     @ ,TMY6&?M6AU]!   -Q   !@
M         ("!]!8  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0
M   ( #-+>5C>D8'^TP(  + '   8              " @:<;  !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  S2WE8!.T>:MH(   Y1
M&               @(&P'@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!
M A0#%     @ ,TMY6#UA)"A/"   ]BD  !@              ("!P"<  'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( #-+>5CJA_=!# P
M +P<   8              " @44P  !X;"]W;W)K<VAE971S+W-H965T."YX
M;6Q02P$"% ,4    "  S2WE8(BD!^WL@  !Z7P  &               @(&'
M/   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ ,TMY6 [S
M3X\T P  ' <  !D              ("!.%T  'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"% ,4    "  S2WE8;QNE$F0"  !!!0  &0
M    @(&C8   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (
M #-+>5A4-AXM10,  .T'   9              " @3YC  !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L! A0#%     @ ,TMY6'M4'6R  @  =04  !D
M             ("!NF8  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"
M% ,4    "  S2WE8A6P0.)X,  !-'P  &0              @(%Q:0  >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( #-+>5C&-0&X.@4
M )0,   9              " @49V  !X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L! A0#%     @ ,TMY6%WW_]6F#0   R@  !D              ("!
MMWL  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  S2WE8
MR/_IO]L"   :!@  &0              @(&4B0  >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;%!+ 0(4 Q0    ( #-+>5@KK+8KD (  )L%   9
M      " @::,  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%
M  @ ,TMY6$E"\X<D P  DP8  !D              ("!;8\  'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  S2WE81@MG>]L"   S!@
M&0              @('(D@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M 0(4 Q0    ( #-+>5B+9Q\L1 0  #H)   9              " @=J5  !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ ,TMY6$)'[\MA
M"@  PB$  !D              ("!59H  'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"% ,4    "  S2WE8<K)A^^X"  "O!@  &0
M@('MI   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( #-+
M>5C'<8%+N0,  &0(   9              " @1*H  !X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L! A0#%     @ ,TMY6/I_PO)C @  B 8  !D
M         ("! JP  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M    "  S2WE89#JB:T,"  "*!@  &0              @(&<K@  >&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( #-+>5B<?,WFHB$  %-H
M   9              " @1:Q  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L! A0#%     @ ,TMY6.!>PHFI!0  _0T  !D              ("![](
M 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  S2WE8HE^<
MU%D"   W!0  &0              @('/V   >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;%!+ 0(4 Q0    ( #-+>5AKMT=U, ,  -P'   9
M  " @5_;  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @
M,TMY6%U1T4)Q @  :04  !D              ("!QMX  'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6Q02P$"% ,4    "  S2WE86->PRZT#   \"0  &0
M            @(%NX0  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4
M Q0    ( #-+>5AN\]_85@(  $D%   9              " @5+E  !X;"]W
M;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ ,TMY6 K >UL8!0
M%PT  !D              ("!W^<  'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"% ,4    "  S2WE8QMJF"+T"   "!@  &0              @($N
M[0  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( #-+>5A.
M3)[H> (  (<%   9              " @2+P  !X;"]W;W)K<VAE971S+W-H
M965T,S8N>&UL4$L! A0#%     @ ,TMY6'PFRB(' P  >08  !D
M     ("!T?(  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #-+>5B\%"GL=@8   \\   9              "
M@04% 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ ,TMY
M6#U--CZN @  .@<  !D              ("!L@L! 'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6Q02P$"% ,4    "  S2WE8VAE*/C8&  "M*@  &0
M        @(&7#@$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0
M   ( #-+>5B4-<<6#@8  #@@   9              " @005 0!X;"]W;W)K
M<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ ,TMY6,:6B<A7 P  Z@X
M !D              ("!21L! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q0
M2P$"% ,4    "  S2WE8)-7)3K("   ,"P  &0              @('7'@$
M>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( #-+>5C-.VJ7
MF (  '8'   9              " @< A 0!X;"]W;W)K<VAE971S+W-H965T
M-#@N>&UL4$L! A0#%     @ ,TMY6-4&]WG6!@  [2\  !D
M ("!CR0! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    "  S
M2WE8Y1!S4+$"  "F!P  &0              @(&<*P$ >&PO=V]R:W-H965T
M<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( #-+>5@5=;F=HP@  /YH   9
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M970U-2YX;6Q02P$"% ,4    "  S2WE86<_FN$83  #Q+ $ &0
M    @($I1@$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    (
M #-+>5CCW%)D5P(  .D%   9              " @:99 0!X;"]W;W)K<VAE
M971S+W-H965T-3<N>&UL4$L! A0#%     @ ,TMY6)5.O"*7!   AA4  !D
M             ("!-%P! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"
M% ,4    "  S2WE8%LU9;+H$  "*&   &0              @($"80$ >&PO
M=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( #-+>5AU#)L16P,
M .L)   9              " @?-E 0!X;"]W;W)K<VAE971S+W-H965T-C N
M>&UL4$L! A0#%     @ ,TMY6&%>3VRH @  +0<  !D              ("!
MA6D! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    "  S2WE8
MP<4(0I #  !Y#   &0              @(%D; $ >&PO=V]R:W-H965T<R]S
M:&5E=#8R+GAM;%!+ 0(4 Q0    ( #-+>5@*\G9$%@,  ,0)   9
M      " @2MP 0!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%
M  @ ,TMY6!R'8%XN!   ,!   !D              ("!>',! 'AL+W=O<FMS
M:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    "  S2WE8T\D'D7X#  !V"P
M&0              @('==P$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+
M 0(4 Q0    ( #-+>5AF3Z@TP0(  "H)   9              " @9)[ 0!X
M;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ ,TMY6%()<BNG
M P  B T  !D              ("!BGX! 'AL+W=O<FMS:&5E=',O<VAE970V
M-RYX;6Q02P$"% ,4    "  S2WE8,>/S"V(#  "9"@  &0
M@(%H@@$ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( #-+
M>5CO'+V3>@(  +\&   9              " @0&& 0!X;"]W;W)K<VAE971S
M+W-H965T-CDN>&UL4$L! A0#%     @ ,TMY6!ZS&$$,$   9P,! !D
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M=#<T+GAM;%!+ 0(4 Q0    ( #-+>5@Q6H;KLP4  (8X   9
M  " @;2L 0!X;"]W;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @
M,TMY6)?U#.AO P  ]!8   T              ( !GK(! 'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    "  S2WE8EXJ[',     3 @  "P              @ $X
MM@$ 7W)E;',O+G)E;'-02P$"% ,4    "  S2WE8;?GP'GL%  !L,0  #P
M            @ $AMP$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ ,TMY
M6&?\4D), @  :"P  !H              ( !R;P! 'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ ,TMY6(:F8T@, @  82L  !,
M         ( !3;\! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %, 4P"\
)%@  BL$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>188</ContextCount>
  <ElementCount>374</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995300 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995301 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995302 - Statement - Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995303 - Statement - Statements of Comprehensive Loss (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement_Parentheticals</Role>
      <ShortName>Statements of Comprehensive Loss (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995304 - Statement - Statements of Changes in Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Statements of Changes in Shareholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995305 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995306 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995307 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995308 - Disclosure - Deposits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/Deposits</Role>
      <ShortName>Deposits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/OtherCurrentAssets</Role>
      <ShortName>Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995311 - Disclosure - Other Accounts Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/OtherAccountsPayable</Role>
      <ShortName>Other Accounts Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995312 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995313 - Disclosure - Finacial Liabilities at Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue</Role>
      <ShortName>Finacial Liabilities at Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995314 - Disclosure - Shareholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ShareholdersEquityDeficit</Role>
      <ShortName>Shareholders' Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995315 - Disclosure - Research and Development Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses</Role>
      <ShortName>Research and Development Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995316 - Disclosure - Sales and Marketing Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/SalesandMarketingExpenses</Role>
      <ShortName>Sales and Marketing Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995317 - Disclosure - General and Administrative Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses</Role>
      <ShortName>General and Administrative Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995318 - Disclosure - Financial (Income) and Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses</Role>
      <ShortName>Financial (Income) and Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995319 - Disclosure - Taxes on Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/TaxesonIncome</Role>
      <ShortName>Taxes on Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995320 - Disclosure - Share-Based Payment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ShareBasedPayment</Role>
      <ShortName>Share-Based Payment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995321 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995322 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/OtherCurrentAssetsTables</Role>
      <ShortName>Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/OtherCurrentAssets</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Other Accounts Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/OtherAccountsPayableTables</Role>
      <ShortName>Other Accounts Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/OtherAccountsPayable</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/CommitmentsandContingencies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Finacial Liabilities at Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables</Role>
      <ShortName>Finacial Liabilities at Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Shareholders' Equity (Deficit) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitTables</Role>
      <ShortName>Shareholders' Equity (Deficit) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/ShareholdersEquityDeficit</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Research and Development Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpensesTables</Role>
      <ShortName>Research and Development Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Sales and Marketing Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/SalesandMarketingExpensesTables</Role>
      <ShortName>Sales and Marketing Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/SalesandMarketingExpenses</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996010 - Disclosure - General and Administrative Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables</Role>
      <ShortName>General and Administrative Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Financial (Income) and Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables</Role>
      <ShortName>Financial (Income) and Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Taxes on Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/TaxesonIncomeTables</Role>
      <ShortName>Taxes on Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/TaxesonIncome</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Share-Based Payment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ShareBasedPaymentTables</Role>
      <ShortName>Share-Based Payment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/ShareBasedPayment</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Related Parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/RelatedPartiesTables</Role>
      <ShortName>Related Parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/RelatedParties</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996015 - Disclosure - General (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/GeneralDetails</Role>
      <ShortName>General (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Significant Accounting Policies (Details) - Schedule of Change of Our Financial Results in Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable</Role>
      <ShortName>Significant Accounting Policies (Details) - Schedule of Change of Our Financial Results in Balance Sheets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Significant Accounting Policies (Details) - Schedule of Change of Our Financial Results in Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable</Role>
      <ShortName>Significant Accounting Policies (Details) - Schedule of Change of Our Financial Results in Comprehensive Income</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Significant Accounting Policies (Details) - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable</Role>
      <ShortName>Significant Accounting Policies (Details) - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Deposits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/DepositsDetails</Role>
      <ShortName>Deposits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/Deposits</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Other Current Assets (Details) - Schedule of Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable</Role>
      <ShortName>Other Current Assets (Details) - Schedule of Other Current Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/OtherCurrentAssetsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable</Role>
      <ShortName>Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Other Accounts Payable (Details) - Schedule of Other Accounts Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable</Role>
      <ShortName>Other Accounts Payable (Details) - Schedule of Other Accounts Payable</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/OtherAccountsPayableTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Commitments and Contingencies (Details) - Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Commitments and Contingencies (Details) - Schedule of Lease Payments for the Company's Right-of-Use Assets over the Remaining Lease Periods</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofLeasePaymentsfortheCompanysRightofUseAssetsovertheRemainingLeasePeriodsTable</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of Lease Payments for the Company's Right-of-Use Assets over the Remaining Lease Periods</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Finacial Liabilities at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails</Role>
      <ShortName>Finacial Liabilities at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Finacial Liabilities at Fair Value (Details) - Schedule of Financial Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable</Role>
      <ShortName>Finacial Liabilities at Fair Value (Details) - Schedule of Financial Liability</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Shareholders' Equity (Deficit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails</Role>
      <ShortName>Shareholders' Equity (Deficit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofShareCapitalTable</Role>
      <ShortName>Shareholders' Equity (Deficit) (Details) - Schedule of Share Capital</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of Movement in Warrants Outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable</Role>
      <ShortName>Shareholders' Equity (Deficit) (Details) - Schedule of Movement in Warrants Outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of Information about the Company???s Outstanding Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable</Role>
      <ShortName>Shareholders' Equity (Deficit) (Details) - Schedule of Information about the Company???s Outstanding Warrants</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of Loss Per Share Calculated Using the Weighted Average Number of Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofSharesTable</Role>
      <ShortName>Shareholders' Equity (Deficit) (Details) - Schedule of Loss Per Share Calculated Using the Weighted Average Number of Shares</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of Loss Per Share Calculated Using the Weighted Average Number of Shares (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofSharesTable_Parentheticals</Role>
      <ShortName>Shareholders' Equity (Deficit) (Details) - Schedule of Loss Per Share Calculated Using the Weighted Average Number of Shares (Parentheticals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Research and Development Expenses (Details) - Schedule of Research and Development Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable</Role>
      <ShortName>Research and Development Expenses (Details) - Schedule of Research and Development Expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpensesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Sales and Marketing Expenses (Details) - Schedule of Sales and Marketing Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable</Role>
      <ShortName>Sales and Marketing Expenses (Details) - Schedule of Sales and Marketing Expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/SalesandMarketingExpensesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996037 - Disclosure - General and Administrative Expenses (Details) - Schedule of General and Administrative Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable</Role>
      <ShortName>General and Administrative Expenses (Details) - Schedule of General and Administrative Expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Financial (Income) and Expenses (Details) - Schedule of Financial (Income) and Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofFinancialIncomeandExpensesTable</Role>
      <ShortName>Financial (Income) and Expenses (Details) - Schedule of Financial (Income) and Expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/TaxesonIncomeDetails</Role>
      <ShortName>Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/TaxesonIncomeTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996040 - Disclosure - Taxes on Income (Details) - Schedule of Deferred Tax Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable</Role>
      <ShortName>Taxes on Income (Details) - Schedule of Deferred Tax Assets and Liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/TaxesonIncomeTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Taxes on Income (Details) - Schedule of Theoretical Tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable</Role>
      <ShortName>Taxes on Income (Details) - Schedule of Theoretical Tax</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/TaxesonIncomeTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996042 - Disclosure - Taxes on Income (Details) - Schedule of Theoretical Tax (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable_Parentheticals</Role>
      <ShortName>Taxes on Income (Details) - Schedule of Theoretical Tax (Parentheticals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/TaxesonIncomeTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996043 - Disclosure - Share-Based Payment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails</Role>
      <ShortName>Share-Based Payment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/ShareBasedPaymentTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996044 - Disclosure - Share-Based Payment (Details) - Schedule of Options to Services Providers and Advisers Outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable</Role>
      <ShortName>Share-Based Payment (Details) - Schedule of Options to Services Providers and Advisers Outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/ShareBasedPaymentTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Share-Based Payment (Details) - Schedule of RSUs to Services Providers and Advisers Outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable</Role>
      <ShortName>Share-Based Payment (Details) - Schedule of RSUs to Services Providers and Advisers Outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/ShareBasedPaymentTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996046 - Disclosure - Related Parties (Details) - Schedule of Shareholders and Other Related Parties??? Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable</Role>
      <ShortName>Related Parties (Details) - Schedule of Shareholders and Other Related Parties??? Benefits</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/RelatedPartiesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Related Parties (Details) - Schedule of Balances with Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofBalanceswithRelatedPartiesTable</Role>
      <ShortName>Related Parties (Details) - Schedule of Balances with Related Parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/RelatedPartiesTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="ea0202167-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996048 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/SubsequentEvents</ParentRole>
      <Position>75</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate in us-gaap/2023 used in 2 facts was deprecated in us-gaap/2024 as of 2024 and should not be used. ea0202167-20f_inspira.htm 16156, 16185</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate in us-gaap/2023 used in 2 facts was deprecated in us-gaap/2024 as of 2024 and should not be used. ea0202167-20f_inspira.htm 16162, 16191</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate in us-gaap/2023 used in 2 facts was deprecated in us-gaap/2024 as of 2024 and should not be used. ea0202167-20f_inspira.htm 16168, 16197</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 in us-gaap/2023 used in 2 facts was deprecated in us-gaap/2024 as of 2024 and should not be used. ea0202167-20f_inspira.htm 16174, 16203</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 10 fact(s) appearing in ix:hidden were eligible for transformation: dei:DocumentPeriodStartDate, us-gaap:EarningsPerShareDiluted, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  ea0202167-20f_inspira.htm 17711, 17712, 17713, 17714, 17715, 17716, 17806, 17807, 17808, 17853</Log>
    <Log type="Warning">[DQC.US.0099.9533] The following elements are in the presentation linkbase of http://www.inspiratechnologies.com/role/ConsolidatedCashFlow but are not included in any calculation relationship in the filing.

ShareBasedCompensationUnderwritersFeesAtIPO, ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital, TradableWarrantsFinancialLiabilityAtIPO

All elements appearing in the face of the financial statements should be included in a calculation relationship somewhere in the filing. Items not included in the financial statement calculations but included in the presentation are referred to as parenthetical items. These usually appear as a referenced item, or as a value in parenthesis describing that the value reported includes another specific amount.  These values should be reported in a seperate link role for parenthetical items.

This rule will produce an error irrespective of a fact value being entered for the item(s) listed above.

If the item is an additional disclosure in the cash flow statement then make sure that is included as a child of one of the following abstract items: {nonCFabstracts} - ea0202167-20f_inspira.htm  - ea0202167-20f_inspira.htm </Log>
  </Logs>
  <InputFiles>
    <File doctype="20-F" isDefinitelyFs="true" isUsgaap="true" original="ea0202167-20f_inspira.htm">ea0202167-20f_inspira.htm</File>
    <File>iinn-20231231.xsd</File>
    <File>iinn-20231231_cal.xml</File>
    <File>iinn-20231231_def.xml</File>
    <File>iinn-20231231_lab.xml</File>
    <File>iinn-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
    <File>image_008.jpg</File>
    <File>image_009.jpg</File>
    <File>image_010.jpg</File>
    <File>image_011.jpg</File>
    <File>image_012.jpg</File>
    <File>image_013.jpg</File>
    <File>image_014.jpg</File>
    <File>image_015.jpg</File>
    <File>image_016.jpg</File>
    <File>image_017.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://fasb.org/srt/2023</BaseTaxonomy>
    <BaseTaxonomy items="867">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="47">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>116
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0202167-20f_inspira.htm": {
   "nsprefix": "iinn",
   "nsuri": "http://www.inspiratechnologies.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "ea0202167-20f_inspira.htm"
     ]
    },
    "schema": {
     "local": [
      "iinn-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023_def.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023_lab.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023_pre.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-sub-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "iinn-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "iinn-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "iinn-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "iinn-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 297,
   "keyCustom": 77,
   "axisStandard": 18,
   "axisCustom": 0,
   "memberStandard": 26,
   "memberCustom": 20,
   "hidden": {
    "total": 149,
    "http://www.inspiratechnologies.com/20231231": 40,
    "http://fasb.org/us-gaap/2023": 105,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 188,
   "entityCount": 1,
   "segmentCount": 51,
   "elementCount": 754,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 867,
    "http://xbrl.sec.gov/dei/2023": 47,
    "http://xbrl.sec.gov/ecd/2023": 4,
    "http://fasb.org/srt/2023": 2
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/dei/role/document/AuditInformation",
     "longName": "995300 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "a",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "a",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
     "longName": "995302 - Statement - Statements of Comprehensive Loss",
     "shortName": "Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R5": {
     "role": "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement_Parentheticals",
     "longName": "995303 - Statement - Statements of Comprehensive Loss (Parentheticals)",
     "shortName": "Statements of Comprehensive Loss (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R6": {
     "role": "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3",
     "longName": "995304 - Statement - Statements of Changes in Shareholders\u2019 Equity",
     "shortName": "Statements of Changes in Shareholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c24",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c24",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow",
     "longName": "995305 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.inspiratechnologies.com/role/General",
     "longName": "995306 - Disclosure - General",
     "shortName": "General",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CompensationRelatedCostsGeneralTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CompensationRelatedCostsGeneralTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.inspiratechnologies.com/role/SignificantAccountingPolicies",
     "longName": "995307 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.inspiratechnologies.com/role/Deposits",
     "longName": "995308 - Disclosure - Deposits",
     "shortName": "Deposits",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DepositLiabilitiesDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DepositLiabilitiesDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.inspiratechnologies.com/role/OtherCurrentAssets",
     "longName": "995309 - Disclosure - Other Current Assets",
     "shortName": "Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.inspiratechnologies.com/role/PropertyandEquipmentNet",
     "longName": "995310 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.inspiratechnologies.com/role/OtherAccountsPayable",
     "longName": "995311 - Disclosure - Other Accounts Payable",
     "shortName": "Other Accounts Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.inspiratechnologies.com/role/CommitmentsandContingencies",
     "longName": "995312 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue",
     "longName": "995313 - Disclosure - Finacial Liabilities at Fair Value",
     "shortName": "Finacial Liabilities at Fair Value",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficit",
     "longName": "995314 - Disclosure - Shareholders' Equity (Deficit)",
     "shortName": "Shareholders' Equity (Deficit)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses",
     "longName": "995315 - Disclosure - Research and Development Expenses",
     "shortName": "Research and Development Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.inspiratechnologies.com/role/SalesandMarketingExpenses",
     "longName": "995316 - Disclosure - Sales and Marketing Expenses",
     "shortName": "Sales and Marketing Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iinn:SalesAndMarketingExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iinn:SalesAndMarketingExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses",
     "longName": "995317 - Disclosure - General and Administrative Expenses",
     "shortName": "General and Administrative Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iinn:GeneralAndAdministrativeExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iinn:GeneralAndAdministrativeExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses",
     "longName": "995318 - Disclosure - Financial (Income) and Expenses",
     "shortName": "Financial (Income) and Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.inspiratechnologies.com/role/TaxesonIncome",
     "longName": "995319 - Disclosure - Taxes on Income",
     "shortName": "Taxes on Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.inspiratechnologies.com/role/ShareBasedPayment",
     "longName": "995320 - Disclosure - Share-Based Payment",
     "shortName": "Share-Based Payment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.inspiratechnologies.com/role/RelatedParties",
     "longName": "995321 - Disclosure - Related Parties",
     "shortName": "Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.inspiratechnologies.com/role/SubsequentEvents",
     "longName": "995322 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R26": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iinn:ConversionFromIFRSToUSGAAPPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iinn:ConversionFromIFRSToUSGAAPPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables",
     "longName": "996001 - Disclosure - Significant Accounting Policies (Tables)",
     "shortName": "Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.inspiratechnologies.com/role/OtherCurrentAssetsTables",
     "longName": "996002 - Disclosure - Other Current Assets (Tables)",
     "shortName": "Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.inspiratechnologies.com/role/PropertyandEquipmentNetTables",
     "longName": "996003 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.inspiratechnologies.com/role/OtherAccountsPayableTables",
     "longName": "996004 - Disclosure - Other Accounts Payable (Tables)",
     "shortName": "Other Accounts Payable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesTables",
     "longName": "996005 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables",
     "longName": "996006 - Disclosure - Finacial Liabilities at Fair Value (Tables)",
     "shortName": "Finacial Liabilities at Fair Value (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FinancialGuaranteeInsuranceContractsClaimLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FinancialGuaranteeInsuranceContractsClaimLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitTables",
     "longName": "996007 - Disclosure - Shareholders' Equity (Deficit) (Tables)",
     "shortName": "Shareholders' Equity (Deficit) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpensesTables",
     "longName": "996008 - Disclosure - Research and Development Expenses (Tables)",
     "shortName": "Research and Development Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.inspiratechnologies.com/role/SalesandMarketingExpensesTables",
     "longName": "996009 - Disclosure - Sales and Marketing Expenses (Tables)",
     "shortName": "Sales and Marketing Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "iinn:SalesAndMarketingExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "iinn:SalesAndMarketingExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables",
     "longName": "996010 - Disclosure - General and Administrative Expenses (Tables)",
     "shortName": "General and Administrative Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iinn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "iinn:GeneralAndAdministrativeExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iinn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "iinn:GeneralAndAdministrativeExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables",
     "longName": "996011 - Disclosure - Financial (Income) and Expenses (Tables)",
     "shortName": "Financial (Income) and Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.inspiratechnologies.com/role/TaxesonIncomeTables",
     "longName": "996012 - Disclosure - Taxes on Income (Tables)",
     "shortName": "Taxes on Income (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.inspiratechnologies.com/role/ShareBasedPaymentTables",
     "longName": "996013 - Disclosure - Share-Based Payment (Tables)",
     "shortName": "Share-Based Payment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.inspiratechnologies.com/role/RelatedPartiesTables",
     "longName": "996014 - Disclosure - Related Parties (Tables)",
     "shortName": "Related Parties (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.inspiratechnologies.com/role/GeneralDetails",
     "longName": "996015 - Disclosure - General (Details)",
     "shortName": "General (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:SharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockOptionExercisePriceIncrease",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:CompensationRelatedCostsGeneralTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesDetails",
     "longName": "996016 - Disclosure - Significant Accounting Policies (Details)",
     "shortName": "Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable",
     "longName": "996017 - Disclosure - Significant Accounting Policies (Details) - Schedule of Change of Our Financial Results in Balance Sheets",
     "shortName": "Significant Accounting Policies (Details) - Schedule of Change of Our Financial Results in Balance Sheets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:OtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c38",
      "name": "us-gaap:OtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable",
     "longName": "996018 - Disclosure - Significant Accounting Policies (Details) - Schedule of Change of Our Financial Results in Comprehensive Income",
     "shortName": "Significant Accounting Policies (Details) - Schedule of Change of Our Financial Results in Comprehensive Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
     "longName": "996019 - Disclosure - Significant Accounting Policies (Details) - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets",
     "shortName": "Significant Accounting Policies (Details) - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c41",
      "name": "iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c41",
      "name": "iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.inspiratechnologies.com/role/DepositsDetails",
     "longName": "996020 - Disclosure - Deposits (Details)",
     "shortName": "Deposits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:Deposits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:DepositLiabilitiesDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:Deposits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:DepositLiabilitiesDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable",
     "longName": "996021 - Disclosure - Other Current Assets (Details) - Schedule of Other Current Assets",
     "shortName": "Other Current Assets (Details) - Schedule of Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable",
     "longName": "996022 - Disclosure - Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net",
     "shortName": "Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentAdditions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable",
     "longName": "996023 - Disclosure - Other Accounts Payable (Details) - Schedule of Other Accounts Payable",
     "shortName": "Other Accounts Payable (Details) - Schedule of Other Accounts Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails",
     "longName": "996024 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c69",
      "name": "iinn:AggregateBudget",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c69",
      "name": "iinn:AggregateBudget",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable",
     "longName": "996025 - Disclosure - Commitments and Contingencies (Details) - Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities",
     "shortName": "Commitments and Contingencies (Details) - Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofLeasePaymentsfortheCompanysRightofUseAssetsovertheRemainingLeasePeriodsTable",
     "longName": "996026 - Disclosure - Commitments and Contingencies (Details) - Schedule of Lease Payments for the Company's Right-of-Use Assets over the Remaining Lease Periods",
     "shortName": "Commitments and Contingencies (Details) - Schedule of Lease Payments for the Company's Right-of-Use Assets over the Remaining Lease Periods",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
     "longName": "996027 - Disclosure - Finacial Liabilities at Fair Value (Details)",
     "shortName": "Finacial Liabilities at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iinn:PercentageOfPayFees",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iinn:PercentageOfPayFees",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable",
     "longName": "996028 - Disclosure - Finacial Liabilities at Fair Value (Details) - Schedule of Financial Liability",
     "shortName": "Finacial Liabilities at Fair Value (Details) - Schedule of Financial Liability",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FinancialGuaranteeInsuranceContractsClaimLiabilityTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c76",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FinancialGuaranteeInsuranceContractsClaimLiabilityTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails",
     "longName": "996029 - Disclosure - Shareholders' Equity (Deficit) (Details)",
     "shortName": "Shareholders' Equity (Deficit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c79",
      "name": "iinn:AggregateOfOrdinaryShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c79",
      "name": "iinn:AggregateOfOrdinaryShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofShareCapitalTable",
     "longName": "996030 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of Share Capital",
     "shortName": "Shareholders' Equity (Deficit) (Details) - Schedule of Share Capital",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable",
     "longName": "996031 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of Movement in Warrants Outstanding",
     "shortName": "Shareholders' Equity (Deficit) (Details) - Schedule of Movement in Warrants Outstanding",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c103",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c103",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable",
     "longName": "996032 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of Information about the Company\u2019s Outstanding Warrants",
     "shortName": "Shareholders' Equity (Deficit) (Details) - Schedule of Information about the Company\u2019s Outstanding Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iinn:WarrantsOutstanding",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iinn:WarrantsOutstanding",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofSharesTable",
     "longName": "996033 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of Loss Per Share Calculated Using the Weighted Average Number of Shares",
     "shortName": "Shareholders' Equity (Deficit) (Details) - Schedule of Loss Per Share Calculated Using the Weighted Average Number of Shares",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofSharesTable_Parentheticals",
     "longName": "996034 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of Loss Per Share Calculated Using the Weighted Average Number of Shares (Parentheticals)",
     "shortName": "Shareholders' Equity (Deficit) (Details) - Schedule of Loss Per Share Calculated Using the Weighted Average Number of Shares (Parentheticals)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R62": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable",
     "longName": "996035 - Disclosure - Research and Development Expenses (Details) - Schedule of Research and Development Expenses",
     "shortName": "Research and Development Expenses (Details) - Schedule of Research and Development Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LaborAndRelatedExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LaborAndRelatedExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable",
     "longName": "996036 - Disclosure - Sales and Marketing Expenses (Details) - Schedule of Sales and Marketing Expenses",
     "shortName": "Sales and Marketing Expenses (Details) - Schedule of Sales and Marketing Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProfessionalFees",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock",
       "iinn:SalesAndMarketingExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProfessionalFees",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock",
       "iinn:SalesAndMarketingExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable",
     "longName": "996037 - Disclosure - General and Administrative Expenses (Details) - Schedule of General and Administrative Expenses",
     "shortName": "General and Administrative Expenses (Details) - Schedule of General and Administrative Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c115",
      "name": "us-gaap:ProfessionalFees",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
       "iinn:GeneralAndAdministrativeExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c115",
      "name": "us-gaap:ProfessionalFees",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
       "iinn:GeneralAndAdministrativeExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofFinancialIncomeandExpensesTable",
     "longName": "996038 - Disclosure - Financial (Income) and Expenses (Details) - Schedule of Financial (Income) and Expenses",
     "shortName": "Financial (Income) and Expenses (Details) - Schedule of Financial (Income) and Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iinn:EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iinn:EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.inspiratechnologies.com/role/TaxesonIncomeDetails",
     "longName": "996039 - Disclosure - Taxes on Income (Details)",
     "shortName": "Taxes on Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable",
     "longName": "996040 - Disclosure - Taxes on Income (Details) - Schedule of Deferred Tax Assets and Liabilities",
     "shortName": "Taxes on Income (Details) - Schedule of Deferred Tax Assets and Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable",
     "longName": "996041 - Disclosure - Taxes on Income (Details) - Schedule of Theoretical Tax",
     "shortName": "Taxes on Income (Details) - Schedule of Theoretical Tax",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfTheoreticalTaxTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable_Parentheticals",
     "longName": "996042 - Disclosure - Taxes on Income (Details) - Schedule of Theoretical Tax (Parentheticals)",
     "shortName": "Taxes on Income (Details) - Schedule of Theoretical Tax (Parentheticals)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfTheoreticalTaxTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfTheoreticalTaxTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails",
     "longName": "996043 - Disclosure - Share-Based Payment (Details)",
     "shortName": "Share-Based Payment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c120",
      "name": "iinn:CapitalGainTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c120",
      "name": "iinn:CapitalGainTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable",
     "longName": "996044 - Disclosure - Share-Based Payment (Details) - Schedule of Options to Services Providers and Advisers Outstanding",
     "shortName": "Share-Based Payment (Details) - Schedule of Options to Services Providers and Advisers Outstanding",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c155",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c157",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable",
     "longName": "996045 - Disclosure - Share-Based Payment (Details) - Schedule of RSUs to Services Providers and Advisers Outstanding",
     "shortName": "Share-Based Payment (Details) - Schedule of RSUs to Services Providers and Advisers Outstanding",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable",
     "longName": "996046 - Disclosure - Related Parties (Details) - Schedule of Shareholders and Other Related Parties\u2019 Benefits",
     "shortName": "Related Parties (Details) - Schedule of Shareholders and Other Related Parties\u2019 Benefits",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c176",
      "name": "us-gaap:OfficersCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c176",
      "name": "us-gaap:OfficersCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofBalanceswithRelatedPartiesTable",
     "longName": "996047 - Disclosure - Related Parties (Details) - Schedule of Balances with Related Parties",
     "shortName": "Related Parties (Details) - Schedule of Balances with Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c179",
      "name": "us-gaap:UnusualOrInfrequentItemNatureOfEventOrTransaction",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c179",
      "name": "us-gaap:UnusualOrInfrequentItemNatureOfEventOrTransaction",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.inspiratechnologies.com/role/SubsequentEventsDetails",
     "longName": "996048 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202167-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/OtherAccountsPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER ACCOUNTS PAYABLE",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Accounts Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Accounts Payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r817"
     ]
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrentAndNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet",
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accounts payables",
        "label": "Accounts Payable, Other, Current",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "iinn_AccountsPayableToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "AccountsPayableToRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": "us-gaap_AccountsPayableCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related parties",
        "documentation": "Amount of accounts payable to related parties, due after one year or beyond the normal operating cycle, if longer.",
        "label": "Accounts Payable To Related Parties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet",
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade accounts payables",
        "label": "Accounts Payable, Trade, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r19"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": "us-gaap_AccountsPayableCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Accumulated depreciation, Beginning Balance",
        "periodEndLabel": "Accumulated depreciation, Ending Balance",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r173",
      "r443"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet",
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated losses",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r85",
      "r179",
      "r440",
      "r457",
      "r461"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "iinn_AdditionalOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "AdditionalOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional offering costs",
        "documentation": "Amount of additional offering costs.",
        "label": "Additional Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet",
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital and additional paid in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r600",
      "r823"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Share Capital",
        "verboseLabel": "Additional Paid in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r474",
      "r747",
      "r748",
      "r749",
      "r798",
      "r828"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_AdjustmentOfWarrantsGrantedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentOfWarrantsGrantedForServices",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted to underwriters (in Dollars)",
        "label": "Adjustment of Warrants Granted for Services",
        "documentation": "Adjustment for noncash service expenses paid for by granting of warrants."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tradable warrants exercise",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r44",
      "r107"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_AdvisoryBoardMembersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "AdvisoryBoardMembersMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advisory Board Members [Member]",
        "label": "Advisory Board Members Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_AggregateBudget": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "AggregateBudget",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate budget",
        "documentation": "The amount of aggregate budget.",
        "label": "Aggregate Budget"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_AggregateOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "AggregateOfOrdinaryShares",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate of ordinary shares",
        "documentation": "Number of aggregate of ordinary shares.",
        "label": "Aggregate Of Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_AggregatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "AggregatePercentage",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate percentage",
        "documentation": "Aggregate percentage.",
        "label": "Aggregate Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r634",
      "r646",
      "r662",
      "r690"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r637",
      "r649",
      "r665",
      "r693"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r641",
      "r650",
      "r666",
      "r685",
      "r694",
      "r698",
      "r706"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_OtherGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable",
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable",
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable",
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment",
        "verboseLabel": "Number of options, Share-based payment expenses",
        "netLabel": "Number of RSUs, Share-based payment expenses (in Dollars)",
        "label": "Share-based payment expenses (in Dollars)",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r346"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance cost",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r280",
      "r408",
      "r742"
     ]
    },
    "iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "AnnualDepreciationRatesOfPropertyPlantAndEquipment",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual depreciation rates",
        "documentation": "Percentage of annual depreciation rates of property, plant and equipment.",
        "label": "Annual Depreciation Rates Of Property Plant And Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r174",
      "r206",
      "r238",
      "r248",
      "r250",
      "r255",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r373",
      "r377",
      "r392",
      "r438",
      "r512",
      "r600",
      "r613",
      "r761",
      "r762",
      "r808"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r182",
      "r206",
      "r255",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r373",
      "r377",
      "r392",
      "r600",
      "r761",
      "r762",
      "r808"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r255",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r373",
      "r377",
      "r392",
      "r761",
      "r762",
      "r808"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Current Assets:",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r626",
      "r629",
      "r642"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r626",
      "r629",
      "r642"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r626",
      "r629",
      "r642"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable",
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable",
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails",
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307",
      "r308",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_BenefitsLossesAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BenefitsLossesAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Profit and loss (in Dollars)",
        "label": "Benefits, Losses and Expenses",
        "documentation": "The total amount of expense recognized during the period for future policy benefits, claims and claims adjustment costs, and for selling, general and administrative costs."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board of Directors [Member]",
        "label": "Board of Directors Chairman [Member]",
        "documentation": "Leader of board of directors."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "iinn_BrokersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "BrokersMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Brokers [Member]",
        "label": "Brokers Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r642"
     ]
    },
    "iinn_CapitalGainTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "CapitalGainTaxRate",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital gain tax rate",
        "documentation": "Capital gain tax rate.",
        "label": "Capital Gain Tax Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalUnitsAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalUnitsAuthorized",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Authorized share capital",
        "label": "Capital Units, Authorized",
        "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r171",
      "r585"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalent",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r98",
      "r203"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r98"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "iinn_ChangesDuringThePeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ChangesDuringThePeriodAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes during the period:",
        "label": "Changes During The Period Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ChangesDuringThePeriodAbstract0": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ChangesDuringThePeriodAbstract0",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes during the period:",
        "label": "Changes During The Period Abstract0"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ChangesDuringThePeriodAbstract1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ChangesDuringThePeriodAbstract1",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes during the period:",
        "label": "Changes During The Period Abstract1"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r175",
      "r176",
      "r177",
      "r206",
      "r228",
      "r229",
      "r231",
      "r233",
      "r236",
      "r237",
      "r255",
      "r270",
      "r272",
      "r273",
      "r274",
      "r277",
      "r278",
      "r282",
      "r283",
      "r285",
      "r288",
      "r294",
      "r392",
      "r465",
      "r466",
      "r467",
      "r468",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r500",
      "r521",
      "r545",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r724",
      "r744",
      "r751"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre funded warrant, per share",
        "verboseLabel": "Pre funded warrant, per share (in Dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Movement in Warrants Outstanding [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightUnissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightUnissued",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tradable warrants to purchase",
        "label": "Class of Warrant or Right, Unissued",
        "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r68",
      "r439",
      "r499"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r264",
      "r265",
      "r572",
      "r760"
     ]
    },
    "iinn_CommitmentsandContingenciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "CommitmentsandContingenciesDetailsTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Share Capital",
        "verboseLabel": "Ordinary Shares [Member]",
        "netLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r604",
      "r605",
      "r607",
      "r608",
      "r609",
      "r610",
      "r747",
      "r748",
      "r798",
      "r821",
      "r828"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, Authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r500"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, Issued and outstanding",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r80",
      "r500",
      "r518",
      "r828",
      "r829"
     ]
    },
    "us-gaap_CommonUnitAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonUnitAuthorized",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Authorized share capital",
        "label": "Common Unit, Authorized",
        "documentation": "Maximum number of common units of ownership permitted to be issued by a limited liability company (LLC)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "us-gaap_CompensationRelatedCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationRelatedCostsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "General [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsGeneralTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationRelatedCostsGeneralTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/General"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GENERAL",
        "label": "Compensation Related Costs, General [Text Block]",
        "documentation": "The entire disclosure for compensation costs, including compensated absences accruals, compensated absences liability, deferred compensation arrangements and income statement compensation items. Deferred compensation arrangements may include a description of an arrangement with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares (units) issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r298"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r185",
      "r187",
      "r193",
      "r434",
      "r448"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computers [Member]",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r137"
     ]
    },
    "srt_CondensedBalanceSheetStatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedBalanceSheetStatementTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Balance Sheet Statement [Table]",
        "documentation": "Disclosure of information about condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r209",
      "r725"
     ]
    },
    "srt_CondensedBalanceSheetStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedBalanceSheetStatementsCaptionsLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Change of Our Financial Results in Balance Sheets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r209",
      "r725"
     ]
    },
    "srt_CondensedStatementOfComprehensiveIncomeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedStatementOfComprehensiveIncomeTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Statement of Comprehensive Income [Table]",
        "documentation": "Disclosure of information about condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r209",
      "r725"
     ]
    },
    "srt_CondensedStatementOfComprehensiveIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedStatementOfComprehensiveIncomeTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Change of Our Financial Results in Comprehensive Income",
        "label": "Condensed Statement of Comprehensive Income [Table Text Block]",
        "documentation": "Tabular disclosure of condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r732",
      "r746"
     ]
    },
    "srt_CondensedStatementOfIncomeCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedStatementOfIncomeCaptionsLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Statement of Income Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r209",
      "r725"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ContingentUponFutureSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ContingentUponFutureSales",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent upon future sales",
        "documentation": "The amount of contingent upon future sales.",
        "label": "Contingent Upon Future Sales"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ConversionFromIFRSToUSGAAPPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ConversionFromIFRSToUSGAAPPolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion from IFRS to U.S. GAAP",
        "documentation": "Disclosure of accounting policy for conversion from IFRS to U.S. GAAP.",
        "label": "Conversion From IFRSTo USGAAPPolicy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockAmountIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible loans to equity",
        "label": "Conversion of Stock, Amount Issued",
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36"
     ]
    },
    "us-gaap_CostMaintenance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostMaintenance",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_OtherGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office maintenance",
        "label": "Cost, Maintenance",
        "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered."
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r113",
      "r358"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Direct offering",
        "verboseLabel": "Offering cost (in Dollars)",
        "label": "Deferred Offering Costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "iinn_DeferredTaxAssetValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "DeferredTaxAssetValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Asset Valuation Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_DeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "DeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_DeferredTaxAssetsFundRaisingCost2023": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "DeferredTaxAssetsFundRaisingCost2023",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fund raising costs 2023",
        "documentation": "Fund raising costs.",
        "label": "Deferred Tax Assets Fund Raising Cost2023"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_DeferredTaxAssetsFundRaisingCosts2021": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "DeferredTaxAssetsFundRaisingCosts2021",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fund raising costs 2021",
        "documentation": "Fund raising costs.",
        "label": "Deferred Tax Assets Fund Raising Costs2021"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net deferred taxes",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r796"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D capitalization",
        "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r796"
     ]
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incurred accumulated losses",
        "label": "Accumulated Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Tax",
        "documentation": "Amount, after tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r300"
     ]
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees monthly deposits rate",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r654",
      "r655",
      "r669"
     ]
    },
    "us-gaap_DepositLiabilitiesDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositLiabilitiesDisclosuresTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/Deposits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DEPOSITS",
        "label": "Deposit Liabilities Disclosures [Text Block]",
        "documentation": "The entire disclosure for deposit liabilities including data and tables. It may include a description of the entity's deposit liabilities, the aggregate amount of time deposits (including certificates of deposit) in denominations of $100,000 or more at the balance sheet date; the aggregate amount of any demand deposits that have been reclassified as loan balances, such as overdrafts, at the balance sheet date; deposits that are received on terms other than those in the normal course of business, the amount of accrued interest on deposit liabilities; securities, mortgage loans or other financial instruments that serve as collateral for deposits; for time deposits having a remaining term of more than one year, the aggregate amount of maturities for each of the five years following the balance sheet date; and the weighted average interest rate for all deposit liabilities held by the entity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r66",
      "r146",
      "r153"
     ]
    },
    "us-gaap_DepositLiabilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositLiabilityLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r731"
     ]
    },
    "us-gaap_Deposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Deposits",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposit",
        "label": "Deposits",
        "documentation": "The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_DepositsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits",
        "label": "Deposits Assets, Current",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "iinn_DepositsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "DepositsDetailsTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositsMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits [Member]",
        "label": "Deposits [Member]",
        "documentation": "Amounts held on account by the entity representing a liability to the depositor. Deposits may take various forms (for example, demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits) and may be categorized in multiple ways (such as, foreign and domestic, interest and noninterest bearing)."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_OtherGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow",
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable",
      "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r42"
     ]
    },
    "us-gaap_DepreciationNonproduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationNonproduction",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation, Nonproduction",
        "documentation": "The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r42"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r491",
      "r504",
      "r505",
      "r506",
      "r508",
      "r509",
      "r510",
      "r511",
      "r513",
      "r514",
      "r515",
      "r516",
      "r532",
      "r533",
      "r534",
      "r535",
      "r538",
      "r539",
      "r540",
      "r541",
      "r559",
      "r560",
      "r561",
      "r562",
      "r603",
      "r605"
     ]
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liability [Member]",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r57",
      "r58",
      "r489",
      "r491",
      "r504",
      "r505",
      "r506",
      "r508",
      "r509",
      "r510",
      "r511",
      "r513",
      "r514",
      "r515",
      "r516",
      "r532",
      "r533",
      "r534",
      "r535",
      "r538",
      "r539",
      "r540",
      "r541",
      "r559",
      "r560",
      "r561",
      "r562",
      "r587",
      "r603",
      "r605"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet",
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities at fair value",
        "label": "Derivative Liability, Current",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r52",
      "r53",
      "r54",
      "r59",
      "r208"
     ]
    },
    "iinn_DevelopmentEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "DevelopmentEquipmentMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development equipment [Member]",
        "label": "Development Equipment Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Directors [Member]",
        "label": "Director [Member]",
        "documentation": "Person serving on board of directors."
       }
      }
     },
     "auth_ref": [
      "r753",
      "r822"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPayment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHARE-BASED PAYMENT",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r305",
      "r336",
      "r337",
      "r338",
      "r595"
     ]
    },
    "iinn_DisposalGroupIncludingDiscontinuedOperationsOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationsOtherIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofFinancialIncomeandExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total expenses (Income)",
        "documentation": "Amount of other income attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group Including Discontinued Operations Other Income"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r654",
      "r655",
      "r669"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r626",
      "r629",
      "r642"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r626",
      "r629",
      "r642",
      "r686"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r626",
      "r629",
      "r642",
      "r686"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
      "http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per ordinary share, basic and diluted (in Dollars per share)",
        "verboseLabel": "Basic loss per share (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r215",
      "r216",
      "r218",
      "r219",
      "r221",
      "r226",
      "r228",
      "r231",
      "r232",
      "r233",
      "r234",
      "r389",
      "r390",
      "r435",
      "r449",
      "r588"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofSharesTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per ordinary share, diluted (in Dollars per share)",
        "verboseLabel": "Diluted loss per share",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r215",
      "r216",
      "r218",
      "r219",
      "r221",
      "r228",
      "r231",
      "r232",
      "r233",
      "r234",
      "r389",
      "r390",
      "r435",
      "r449",
      "r588"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and Diluted Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Theoretical tax credit at applicable statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r354",
      "r367"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "presentation": [
      "http://www.inspiratechnologies.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r794",
      "r797"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": "us-gaap_AccountsPayableCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees\u2019 salaries and related liabilities",
        "label": "Employee-related Liabilities",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r817"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Black Scholes Model [Member]",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_EmployeesAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "EmployeesAndDirectorsMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees and Directors [Member]",
        "label": "Employees And Directors Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_EmployeesDirectorsAndSubcontractorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "EmployeesDirectorsAndSubcontractorsMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees, Directors and Subcontractors [Member]",
        "label": "Employees Directors And Subcontractors Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'.  This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r166",
      "r189",
      "r190",
      "r191",
      "r210",
      "r211",
      "r212",
      "r214",
      "r222",
      "r224",
      "r235",
      "r256",
      "r259",
      "r296",
      "r339",
      "r340",
      "r341",
      "r363",
      "r364",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r388",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r420",
      "r452",
      "r453",
      "r454",
      "r474",
      "r545"
     ]
    },
    "iinn_EquityPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "EquityPercentage",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company\u2019s equity percentage",
        "documentation": "Equity percentage.",
        "label": "Equity Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r634",
      "r646",
      "r662",
      "r690"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r643",
      "r659",
      "r687"
     ]
    },
    "iinn_EvaluationOfFinancialLiabilityAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "EvaluationOfFinancialLiabilityAtFairValue",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Evaluation of financial liability at fair value",
        "documentation": "The amount of evaluation of financial liability at fair value.",
        "label": "Evaluation Of Financial Liability At Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofFinancialIncomeandExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Revaluation of financial liabilities at fair value through profit or loss",
        "documentation": "Revaluation of financial liabilities at fair value through profit or loss.",
        "label": "Evaluation Of Financial Liability Including Safe And Convertible Loan At Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "iinn_Exercise16Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "Exercise16Member",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.6 [Member]",
        "label": "Exercise16 Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_Exercise6875Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "Exercise6875Member",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "6.875 [Member]",
        "label": "Exercise6875 Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ExercisePrice55Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ExercisePrice55Member",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.5 [Member]",
        "label": "Exercise Price55 Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ExercisePrice55OneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ExercisePrice55OneMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.5 [Member]",
        "label": "Exercise Price55 One Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ExercisePrice55TwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ExercisePrice55TwoMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.5 [Member]",
        "label": "Exercise Price55 Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants fair value (in Dollars)",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r6"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r111"
     ]
    },
    "us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finacial Liabilities at Fair Value [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINACIAL LIABILITIES AT FAIR VALUE",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueNetAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueNetAssetLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of the financial liability (in Dollars)",
        "label": "Fair Value, Net Asset (Liability)",
        "documentation": "Fair value of asset after deduction of liability."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_FairValueWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "FairValueWarrants",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value warrants",
        "documentation": "Number of fair value warrants.",
        "label": "Fair Value Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finacial Liabilities at Fair Value (Details) - Schedule of Financial Liability [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "FinacialLiabilitiesatFairValueDetailsScheduleofFinancialLiabilityTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finacial Liabilities at Fair Value (Details) - Schedule of Financial Liability [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_FinacialLiabilitiesatFairValueDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "FinacialLiabilitiesatFairValueDetailsTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finacial Liabilities at Fair Value (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_FinanceIncomeAndExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "FinanceIncomeAndExpensesPolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Income and Expenses",
        "documentation": "Disclosure of accounting policy for finance income and expenses.",
        "label": "Finance Income And Expenses Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_FinanceLeaseInterestExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "FinanceLeaseInterestExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofFinancialIncomeandExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance expense in respect of lease liability",
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease Interest Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialGuaranteeInsuranceContractsClaimLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialGuaranteeInsuranceContractsClaimLiabilityTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Liability",
        "label": "Financial Guarantee Insurance Contracts, Claim Liability [Table Text Block]",
        "documentation": "Tabular disclosure of the claim liability for financial guarantee insurance contracts."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total finacial liabilities at fair value",
        "verboseLabel": "Financial liability fair value (in Dollars)",
        "label": "Financial Liabilities Fair Value Disclosure",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialLiabilitiesFairValueDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Finacial Liabilities at Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancingInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancingInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofFinancialIncomeandExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on financial liabilities",
        "label": "Financing Interest Expense",
        "documentation": "This element represents interest incurred for borrowed money which was used to produce goods or render services."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exchange (losses) profits arising on translation to presentation currency",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r395",
      "r396",
      "r397",
      "r542"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "iinn_ForeignCurrencyTransactionsGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ForeignCurrencyTransactionsGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofFinancialIncomeandExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency transaction income",
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain recognized in the income statement.",
        "label": "Foreign Currency Transactions Gain Before Tax"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ForeignExchangeReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ForeignExchangeReserve",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange reserve",
        "documentation": "Amount of foreign exchange reserve.",
        "label": "Foreign Exchange Reserve"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r638",
      "r650",
      "r666",
      "r694"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r638",
      "r650",
      "r666",
      "r694"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r638",
      "r650",
      "r666",
      "r694"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r638",
      "r650",
      "r666",
      "r694"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r638",
      "r650",
      "r666",
      "r694"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r653"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_FundsRaisingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "FundsRaisingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_OtherGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Funds raising expenses",
        "documentation": "Amount of funds raising expenses.",
        "label": "Funds Raising Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and office equipment [Member]",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_FutureLeasePaymentsDiscountedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "FutureLeasePaymentsDiscountedInterestRate",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future lease payments discounted interest rate",
        "documentation": "Future lease payments discounted interest rate.",
        "label": "Future Lease Payments Discounted Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      },
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r523"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expense [Member]",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "iinn_GeneralAndAdministrativeExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "GeneralAndAdministrativeExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_GeneralAndAdministrativeExpensesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "GeneralAndAdministrativeExpensesTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GENERAL AND ADMINISTRATIVE EXPENSES",
        "documentation": "The entire disclosure for general and administrative expenses.",
        "label": "General And Administrative Expenses Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_GeneralDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "GeneralDetailsTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralInsuranceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralInsuranceExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_OtherGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance expenses",
        "label": "General Insurance Expense",
        "documentation": "The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales)."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expenses (Details) - Schedule of General and Administrative Expenses [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "GeneralandAdministrativeExpensesDetailsScheduleofGeneralandAdministrativeExpensesTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expenses (Details) - Schedule of General and Administrative Expenses [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GovernmentAssistancePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GovernmentAssistancePolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Grants",
        "label": "Government Assistance [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for government assistance."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406"
     ]
    },
    "country_IL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "IL",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DepositsDetails",
      "http://www.inspiratechnologies.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Israel [Member]",
        "label": "ISRAEL"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO [Member]",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r626",
      "r629",
      "r642"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable",
      "http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Loss before tax",
        "terseLabel": "Loss before taxation",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r86",
      "r117",
      "r238",
      "r247",
      "r249",
      "r251",
      "r436",
      "r445",
      "r589"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r263",
      "r528"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r528"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/TaxesonIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TAXES ON INCOME",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r350",
      "r355",
      "r356",
      "r361",
      "r365",
      "r368",
      "r369",
      "r370",
      "r469"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable",
      "http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax benefit",
        "negatedLabel": "Taxes on income",
        "terseLabel": "Taxes on income",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r143",
      "r223",
      "r224",
      "r240",
      "r353",
      "r366",
      "r450"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r351",
      "r352",
      "r356",
      "r357",
      "r360",
      "r362",
      "r464"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Theoretical tax credit at applicable statutory rate: 23%",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-allowable expenses",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Decrease) increase in trade accounts payables",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInLeasingReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInLeasingReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease (increase) in right of use assets",
        "label": "Increase (Decrease) in Leasing Receivables",
        "documentation": "The increase (decrease) during the reporting period in the amount due from lessees arising from lease agreements."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Decrease) increase in other accounts payable",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease (increase) in other current assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r641",
      "r650",
      "r666",
      "r685",
      "r694",
      "r698",
      "r706"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r630",
      "r710"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r630",
      "r710"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r630",
      "r710"
     ]
    },
    "us-gaap_InterestBearingDepositsInBanks": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestBearingDepositsInBanks",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Institutions",
        "label": "Interest-Bearing Deposits in Banks and Other Financial Institutions",
        "documentation": "For banks and other depository institutions (including Federal Reserve Banks, if applicable): Interest-bearing deposits in other financial institutions for relatively short periods of time including, for example, certificates of deposits, which are presented separately from cash on the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r69"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash expenses (in Dollars)",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r121",
      "r192",
      "r239",
      "r407",
      "r529",
      "r611",
      "r825"
     ]
    },
    "us-gaap_InterestExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseOther",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash expenses (in Dollars)",
        "label": "Interest Expense, Other",
        "documentation": "Amount of interest expense classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeDepositsWithFinancialInstitutions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeDepositsWithFinancialInstitutions",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest income from deposits",
        "negatedTerseLabel": "Interest income from deposits",
        "label": "Interest Income, Deposits with Financial Institutions",
        "documentation": "Interest income derived from funds deposited with both domestic and foreign financial institutions including funds in money market and other accounts."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r144",
      "r145"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r201",
      "r202"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r655",
      "r656",
      "r657",
      "r658"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestorMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investor [Member]",
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r804",
      "r805"
     ]
    },
    "iinn_IssuanceOfOrdinarySharesissuancesPursuantToATM": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "IssuanceOfOrdinarySharesissuancesPursuantToATM",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares (issuances pursuant to ATM)",
        "documentation": "The amount of issuance of ordinary shares (issuances pursuant to ATM).",
        "label": "Issuance Of Ordinary Sharesissuances Pursuant To ATM"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation \u2013 placement agent warrants (Note 9)",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salary and related expenses",
        "label": "Labor and Related Expense",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total expenses related to the leases",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r599"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements [Member]",
        "verboseLabel": "Leasehold improvements [Member]",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalFees",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_OtherGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Director\u2019s fees",
        "label": "Legal Fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Payments for the Company's Right-of-Use Assets over the Remaining Lease Periods",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofLeasePaymentsfortheCompanysRightofUseAssetsovertheRemainingLeasePeriodsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofLeasePaymentsfortheCompanysRightofUseAssetsovertheRemainingLeasePeriodsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted lease payment",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofLeasePaymentsfortheCompanysRightofUseAssetsovertheRemainingLeasePeriodsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofLeasePaymentsfortheCompanysRightofUseAssetsovertheRemainingLeasePeriodsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofLeasePaymentsfortheCompanysRightofUseAssetsovertheRemainingLeasePeriodsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofLeasePaymentsfortheCompanysRightofUseAssetsovertheRemainingLeasePeriodsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofLeasePaymentsfortheCompanysRightofUseAssetsovertheRemainingLeasePeriodsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofLeasePaymentsfortheCompanysRightofUseAssetsovertheRemainingLeasePeriodsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofLeasePaymentsfortheCompanysRightofUseAssetsovertheRemainingLeasePeriodsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofLeasePaymentsfortheCompanysRightofUseAssetsovertheRemainingLeasePeriodsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofLeasePaymentsfortheCompanysRightofUseAssetsovertheRemainingLeasePeriodsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and Shareholders\u2019 Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r114",
      "r441",
      "r600",
      "r745",
      "r754",
      "r800"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r170",
      "r206",
      "r255",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r374",
      "r377",
      "r378",
      "r392",
      "r600",
      "r761",
      "r808",
      "r809"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non- current liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r73",
      "r74",
      "r75",
      "r76",
      "r206",
      "r255",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r374",
      "r377",
      "r378",
      "r392",
      "r761",
      "r808",
      "r809"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Current Liabilities:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ManagementFeeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ManagementFeeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management fees",
        "label": "Management Fee Expense",
        "documentation": "Amount of expense for investment management fee, including, but not limited to, expense in connection with research, selection, supervision, and custody of investment."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r523",
      "r611",
      "r824"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r269",
      "r301",
      "r432",
      "r451",
      "r490",
      "r491",
      "r552",
      "r554",
      "r556",
      "r557",
      "r563",
      "r582",
      "r583",
      "r591",
      "r592",
      "r594",
      "r602",
      "r763",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r269",
      "r301",
      "r432",
      "r451",
      "r490",
      "r491",
      "r552",
      "r554",
      "r556",
      "r557",
      "r563",
      "r582",
      "r583",
      "r591",
      "r592",
      "r594",
      "r602",
      "r763",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them.  The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOW FROM INVESTING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r100"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOW FROM OPERATING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow",
      "http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofSharesTable",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss",
        "negatedLabel": "Loss for the period (in Dollars)",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r100",
      "r118",
      "r168",
      "r184",
      "r186",
      "r191",
      "r206",
      "r213",
      "r215",
      "r216",
      "r218",
      "r219",
      "r223",
      "r224",
      "r230",
      "r238",
      "r247",
      "r249",
      "r251",
      "r255",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r390",
      "r392",
      "r447",
      "r520",
      "r543",
      "r544",
      "r589",
      "r611",
      "r761"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r655",
      "r656",
      "r657",
      "r658"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r638",
      "r650",
      "r666",
      "r685",
      "r694"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "iinn_NonTradableSharesOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "NonTradableSharesOptionsMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Tradable Shares Options [Member]",
        "label": "Non Tradable Shares Options Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_NonTradableWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "NonTradableWarrants",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non tradable warrants",
        "documentation": "Number of non tradable warrants.",
        "label": "Non Tradable Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_NonTradableWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "NonTradableWarrantsMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-tradable warrants [Member]",
        "label": "Non Tradable Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoninterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoninterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-direct expenses (in Dollars)",
        "label": "Noninterest Expense",
        "documentation": "Total aggregate amount of all noninterest expense."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_OfferingCostsPartnershipInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfferingCostsPartnershipInterests",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional offering direct costs (in Dollars)",
        "label": "Offering Costs, Partnership Interests",
        "documentation": "Costs incurred in connection with the offering and selling of additional partner interest."
       }
      }
     },
     "auth_ref": [
      "r758",
      "r820"
     ]
    },
    "srt_OfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OfficerMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Officers [Member]",
        "label": "Officer [Member]",
        "documentation": "Person with designation of officer."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r822"
     ]
    },
    "iinn_OfficersAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "OfficersAndDirectorsMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Officers and Directors [Member]",
        "label": "Officers And Directors Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficersCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_OtherGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable",
      "http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable",
      "http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salary and related expenses",
        "verboseLabel": "Salary and related expenses \u2013 officers and directors",
        "label": "Salary and Wage, Officer, Excluding Cost of Good and Service Sold",
        "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r247",
      "r249",
      "r251",
      "r589"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofLeasePaymentsfortheCompanysRightofUseAssetsovertheRemainingLeasePeriodsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease liabilities",
        "terseLabel": "Present value of lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet",
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "verboseLabel": "Current lease liabilities",
        "netLabel": "Operating lease liabilities, current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet",
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "verboseLabel": "Long term lease liabilities",
        "netLabel": "Operating lease liabilities long-term",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r415"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet",
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use assets, net",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable",
      "http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate - operating leases",
        "verboseLabel": "Lease liability, weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r599"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average of Remaining Lease Term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r599"
     ]
    },
    "us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesOfLesseeDisclosureTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Payments for the Company's Right-of-Use Assets over the Remaining Lease Periods",
        "label": "Lessee, Operating Lease, Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r130",
      "r131",
      "r132",
      "r133"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carryforward tax losses",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "iinn_OptionsIssuableTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "OptionsIssuableTerm",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options issuable term",
        "documentation": "The term of options issuable.",
        "label": "Options Issuable Term"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_OrdinaryShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "OrdinaryShare",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "documentation": "Number of ordinary share.",
        "label": "Ordinary Share"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_OrdinarySharesNoParValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "OrdinarySharesNoParValueMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Shares, no par value",
        "label": "Ordinary Shares No Par Value Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": "us-gaap_AccountsPayableCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet",
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r600"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Comprehensive and net loss",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/OtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER CURRENT ASSETS",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Other General and Administrative Expense",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r827"
     ]
    },
    "us-gaap_OtherGeneralExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherGeneralExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_OtherGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "label": "Other General Expense",
        "documentation": "Amount of general expenses not normally included in Other Operating Costs and Expenses."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIncomeAndExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial (Income) and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLaborRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLaborRelatedExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_OtherGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable",
      "http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Materials and related expenses",
        "verboseLabel": "Related NASDAQ IPO expenses",
        "label": "Other Labor-related Expenses",
        "documentation": "Amount of labor-related expenses classified as other."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofFinancialIncomeandExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Others",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeAndExpenseTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCIAL (INCOME) AND EXPENSES",
        "label": "Other Nonoperating Income and Expense [Text Block]",
        "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance expenses (income), net",
        "negatedTerseLabel": "Finance expenses (income), net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other expenses (income)",
        "negatedTerseLabel": "Other expenses (income)",
        "label": "Other Operating Income (Expense), Net",
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r757"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total funds received",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r507"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "verboseLabel": "Research and development expenses",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_OtherSellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherSellingAndMarketingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Selling and Marketing Expense",
        "documentation": "Amount of selling and marketing expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_OtherShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherShortTermBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan from the Israeli Innovation Authority (\u201cIIA\u201d)",
        "label": "Other Short-Term Borrowings",
        "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r498"
     ]
    },
    "us-gaap_OtherUnderwritingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherUnderwritingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriting discounts (in Dollars)",
        "label": "Other Underwriting Expense",
        "documentation": "Costs incurred during the period, such as those relating to general administration and policy maintenance that do not vary with and are not primarily related to the acquisition or renewal of insurance contracts."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r818"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r636",
      "r648",
      "r664",
      "r692"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r639",
      "r651",
      "r667",
      "r695"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r639",
      "r651",
      "r667",
      "r695"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over-Allotment Option [Member]",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "us-gaap_PaymentsForParticipationLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForParticipationLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "IIA participation",
        "label": "Payments for Participation Liabilities",
        "documentation": "Cash payments related to participation costs."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent payment",
        "label": "Payments for Rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsOfDerivativeIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDerivativeIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance costs",
        "verboseLabel": "Issuance costs (in Dollars)",
        "label": "Payments of Derivative Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of a derivative security."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Issuance cost in cash",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds (in Dollars)",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r371"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property, plant, and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investment in short term deposits",
        "label": "Payments to Acquire Short-Term Investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "iinn_PercentageOfAgreementWarrants": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "PercentageOfAgreementWarrants",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of agreement warrants",
        "documentation": "Percentage of agreement warrants.",
        "label": "Percentage Of Agreement Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_PercentageOfApprovedBudget": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "PercentageOfApprovedBudget",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of approved budget",
        "documentation": "Percentage of approved budget.",
        "label": "Percentage Of Approved Budget"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_PercentageOfExerciseOfTradableWarrants": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "PercentageOfExerciseOfTradableWarrants",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of exercise of tradable warrants",
        "documentation": "Percentage of exercise of tradable warrants.",
        "label": "Percentage Of Exercise Of Tradable Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_PercentageOfExercisePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "PercentageOfExercisePrice",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of exercise price",
        "documentation": "Percentage of exercise price.",
        "label": "Percentage Of Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_PercentageOfPayFees": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "PercentageOfPayFees",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of pay fees",
        "documentation": "Percentage of pay fees.",
        "label": "Percentage Of Pay Fees"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_PlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "PlacementAgentWarrantsMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Placement Agent Warrants [Member]",
        "label": "Placement Agent Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790"
     ]
    },
    "us-gaap_PledgingPurposeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PledgingPurposeAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pledging Purpose [Axis]",
        "documentation": "Information by pledging purpose of pledged asset owned."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r596",
      "r601",
      "r726"
     ]
    },
    "us-gaap_PledgingPurposeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PledgingPurposeDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pledging Purpose [Domain]",
        "documentation": "Pledging purpose of pledged asset owned."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r596",
      "r601",
      "r726"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "iinn_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants [Member]",
        "label": "Pre Funded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r260",
      "r261",
      "r586"
     ]
    },
    "iinn_PrepaymentsOfLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "PrepaymentsOfLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments of lease liabilities",
        "documentation": "The amount of prepayments of lease liabilities.",
        "label": "Prepayments Of Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_PrivateWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "PrivateWarrantsMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Warrants [Member]",
        "label": "Private Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromDividendsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromDividendsReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds received (in Dollars)",
        "label": "Proceeds from Dividends Received",
        "documentation": "Dividends received on equity and other investments during the current period."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of private warrants",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of short-term deposits",
        "label": "Proceeds from Sale of Short-Term Investments",
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of option",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r14"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_OtherGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable",
      "http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professionals\u2019 fees",
        "verboseLabel": "Professional fees",
        "label": "Professional Fees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r611",
      "r826",
      "r827"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total comprehensive and net loss",
        "negatedLabel": "Total net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r184",
      "r186",
      "r199",
      "r206",
      "r213",
      "r223",
      "r224",
      "r238",
      "r247",
      "r249",
      "r251",
      "r255",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r372",
      "r375",
      "r376",
      "r390",
      "r392",
      "r436",
      "r446",
      "r473",
      "r520",
      "r543",
      "r544",
      "r589",
      "r597",
      "r598",
      "r612",
      "r736",
      "r761"
     ]
    },
    "iinn_ProjectBudgetAggregateAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ProjectBudgetAggregateAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Project budget aggregate amount",
        "documentation": "The amount of project budget aggregate amount.",
        "label": "Project Budget Aggregate Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAdditions",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Property, Plant and Equipment, Additions",
        "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/PropertyandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT, NET",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r138",
      "r141",
      "r142"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cost, Beginning Balance",
        "periodEndLabel": "Cost, Ending Balance",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r172",
      "r444"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet",
      "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Net book value",
        "terseLabel": "Property, plant and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r437",
      "r444",
      "r600"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant, and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r138",
      "r141",
      "r442"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/PropertyandEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_PublicUtilitiesGeneralDisclosuresLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PublicUtilitiesGeneralDisclosuresLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "iinn_RSUsVestPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "RSUsVestPeriod",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs vest period",
        "documentation": "RSUs vest period.",
        "label": "RSUs Vest Period"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r269",
      "r299",
      "r301",
      "r331",
      "r332",
      "r333",
      "r430",
      "r432",
      "r451",
      "r490",
      "r491",
      "r552",
      "r554",
      "r556",
      "r557",
      "r563",
      "r582",
      "r583",
      "r591",
      "r592",
      "r594",
      "r602",
      "r605",
      "r759",
      "r763",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r269",
      "r299",
      "r301",
      "r331",
      "r332",
      "r333",
      "r430",
      "r432",
      "r451",
      "r490",
      "r491",
      "r552",
      "r554",
      "r556",
      "r557",
      "r563",
      "r582",
      "r583",
      "r591",
      "r592",
      "r594",
      "r602",
      "r605",
      "r759",
      "r763",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815"
     ]
    },
    "iinn_ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receipt of simple agreements for future equity (SAFE) and convertible loan",
        "documentation": "The amount of receipt of simple agreements for future equity (SAFE) and convertible loan.",
        "label": "Receipt Of Simple Agreements For Future Equity SAFEAnd Convertible Loans"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r631",
      "r643",
      "r659",
      "r687"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "iinn_ReimbursementAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ReimbursementAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursement amount",
        "documentation": "The amount of reimbursement.",
        "label": "Reimbursement Amount"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_RelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "RelatedPartiesDetailsScheduleofBalanceswithRelatedPartiesTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties (Details) - Schedule of Balances with Related Parties [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Related parties transaction",
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r424"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425",
      "r807"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofBalanceswithRelatedPartiesTable",
      "http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Shareholders and Other Related Parties\u2019 Benefits [Line Items]",
        "terseLabel": "Schedule of Balances with Related Parties [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r524",
      "r525",
      "r528"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/RelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTIES",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r470",
      "r471",
      "r472",
      "r526",
      "r527",
      "r528",
      "r549",
      "r551"
     ]
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Research and Development Expenses",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Table Text Block]",
        "documentation": "Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable",
      "http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "verboseLabel": "Total",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r348",
      "r816"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Research and Development Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expense [Member]",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RESEARCH AND DEVELOPMENT EXPENSES",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r349"
     ]
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r234",
      "r257",
      "r258",
      "r364",
      "r387",
      "r388",
      "r389",
      "r390",
      "r409",
      "r419",
      "r420",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r632",
      "r644",
      "r660",
      "r688"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r633",
      "r645",
      "r661",
      "r689"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r640",
      "r652",
      "r668",
      "r696"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r234",
      "r257",
      "r258",
      "r364",
      "r387",
      "r388",
      "r389",
      "r390",
      "r409",
      "r419",
      "r420",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r733",
      "r743"
     ]
    },
    "iinn_RestrictedStockUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "RestrictedStockUnits",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (in Dollars)",
        "documentation": "Amount of restricted stock units.",
        "label": "Restricted Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable",
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails",
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSUs) [Member]",
        "verboseLabel": "Restricted Stock Units [Member]",
        "netLabel": "RSUs [Member]",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r210",
      "r211",
      "r212",
      "r214",
      "r222",
      "r224",
      "r256",
      "r259",
      "r339",
      "r340",
      "r341",
      "r363",
      "r364",
      "r380",
      "r382",
      "r383",
      "r385",
      "r388",
      "r452",
      "r454",
      "r474",
      "r828"
     ]
    },
    "iinn_RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Revaluation of simple agreements for future equity (SAFE) and convertible loan at fair value",
        "documentation": "The amount of revaluation of simple agreements for future equity (SAFE) and convertible loan at fair value.",
        "label": "Revaluation Of Simple Agreements For Future Equity SAFEAnd Convertible Loan At Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_RoyaltiesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "RoyaltiesPercentage",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of royalties",
        "documentation": "Percentage of royalties.",
        "label": "Royalties Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails",
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share (in Dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SalesAndMarketingExpensesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "SalesAndMarketingExpensesTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SalesandMarketingExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SALES AND MARKETING EXPENSES:",
        "documentation": "Disclosure of sales and marketing expenses.",
        "label": "Sales And Marketing Expenses Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Previously Reported [Member]",
        "label": "Previously Reported [Member]",
        "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r210",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r224",
      "r234",
      "r364",
      "r387",
      "r388",
      "r389",
      "r409",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r727",
      "r728",
      "r729",
      "r730",
      "r750",
      "r755",
      "r756",
      "r799",
      "r802",
      "r803"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/OtherAccountsPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Accounts Payable",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfBalanceWithRelatedPartiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ScheduleOfBalanceWithRelatedPartiesTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/RelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Balances with Related Parties",
        "documentation": "Tabular disclosure of balances with related parties.",
        "label": "Schedule Of Balance With Related Parties Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfBalancesWithRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ScheduleOfBalancesWithRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Balances With Related Parties Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfChangeOfOurFinancialResultsInBalanceSheetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ScheduleOfChangeOfOurFinancialResultsInBalanceSheetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Change Of Our Financial Results In Balance Sheets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfChangeOfOurFinancialResultsInComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ScheduleOfChangeOfOurFinancialResultsInComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Change Of Our Financial Results In Comprehensive Income Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Change of Our Financial Results in Balance Sheets",
        "label": "Condensed Balance Sheet [Table Text Block]",
        "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r732",
      "r746"
     ]
    },
    "iinn_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/TaxesonIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Depreciation On Straight Line Method Over The Estimated Useful Life Of The Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets",
        "documentation": "Tabular disclosure of depreciation on straight-line method, over the estimated useful life of the assets.",
        "label": "Schedule Of Depreciation On Straight Line Method Over The Estimated Useful Life Of The Assets Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Loss Per Share Calculated Using the Weighted Average Number of Shares",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "iinn_ScheduleOfFinancialIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ScheduleOfFinancialIncomeAndExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial (Income) and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ScheduleOfGeneralAndAdministrativeExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of General and Administrative Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of General and Administrative Expenses",
        "documentation": "Tabular disclosure of general and administrative expenses.",
        "label": "Schedule Of General And Administrative Expenses Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Information About The Company SOutstanding Warrants Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInsuredFinancialObligationsWithCreditDeteriorationNetClaimLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInsuredFinancialObligationsWithCreditDeteriorationNetClaimLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ScheduleOfLeasePaymentsForTheCompanysRightOfUseAssetsOverTheRemainingLeasePeriodsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Lease Payments for the Company's Right-of-Use Assets Over the Remaining Lease Periods [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ScheduleOfLossPerShareCalculatedUsingTheWeightedAverageNumberOfSharesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Loss Per Share Calculated Using the Weighted Average Number of Shares [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfMovementInWarrantsOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ScheduleOfMovementInWarrantsOutstandingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Movement In Warrants Outstanding Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ScheduleOfOperatingRightOfUseAssetsAndOperatingLeaseLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Options To Services Providers And Advisers Outstanding Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfOtherCurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ScheduleOfOtherCurrentAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/OtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Current Assets",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial (Income) and Expenses",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfPropertyAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ScheduleOfPropertyAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Net Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r524",
      "r525",
      "r528"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/RelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Shareholders and Other Related Parties\u2019 Benefits",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Rsus To Services Providers And Advisers Outstanding Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfSalesAndMarketingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ScheduleOfSalesAndMarketingExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Sales and Marketing Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ScheduleOfSalesAndMarketingExpensesTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SalesandMarketingExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Sales and Marketing Expenses",
        "documentation": "Tabular disclosure of sales and marketing expenses.",
        "label": "Schedule Of Sales And Marketing Expenses Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of RSUs to Services Providers and Advisers Outstanding",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Information about the Company\u2019s Outstanding Warrants",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Options to Services Providers and Advisers Outstanding",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r48"
     ]
    },
    "iinn_ScheduleOfShareCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ScheduleOfShareCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Shareholders And Other Related Parties Benefits Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Movement in Warrants Outstanding",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share Capital",
        "label": "Schedule of Stockholders Equity [Table Text Block]",
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "iinn_ScheduleOfTheoreticalTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ScheduleOfTheoreticalTaxAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Theoretical Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfTheoreticalTaxTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ScheduleOfTheoreticalTaxTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/TaxesonIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Theoretical Tax",
        "documentation": "Disclosure of theoretical tax.",
        "label": "Schedule Of Theoretical Tax Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DepositsDetails",
      "http://www.inspiratechnologies.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r252",
      "r253",
      "r486",
      "r487",
      "r488",
      "r553",
      "r555",
      "r558",
      "r564",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r584",
      "r593",
      "r605",
      "r764",
      "r819"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r252",
      "r590"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinComprehensiveIncomeTable",
      "http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Sales and marketing expenses",
        "label": "Selling and Marketing Expense",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingAndMarketingExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales and Marketing Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ServicesProvidersAndAdvisersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ServicesProvidersAndAdvisersMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Services Providers and Advisers [Member]",
        "label": "Services Providers And Advisers Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SeverancePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "SeverancePolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance",
        "documentation": "Disclosure of accounting policy for severance.",
        "label": "Severance Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow",
      "http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation expenses",
        "verboseLabel": "Share based payment \u2013 officers and directors",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Exercised",
        "documentation": "Number of warrants, exercised.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average exercise price, Exercised",
        "documentation": "Weighted-average exercise price, exercised.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term (in years), Exercised",
        "documentation": "Weighted average remaining contractual term, exercised.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Weighted Average Remaining Contractual Terms"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Expired",
        "documentation": "Number of warrants, expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average exercise price, Expired",
        "documentation": "Weighted-average exercise price, expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term (in years), Expired",
        "documentation": "Weighted average remaining contractual term, expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired Weighted Average Remaining Contractual Terms"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable",
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Forfeited",
        "verboseLabel": "Number of RSUs, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term (in years), Forfeited",
        "documentation": "Weighted average remaining contractual term, forfeited.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited Weighted Average Remaining Contractual Terms"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average exercise price, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable",
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Issued",
        "verboseLabel": "Number of RSUs, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average exercise price, Issued",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term (in years), Issued",
        "documentation": "Weighted average remaining contractual term, issued.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Issued Weighted Average Remaining Contractual Terms"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Warrants, Beginning Balance",
        "periodEndLabel": "Number of RSUs, RSUs outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted-average exercise price, Beginning Balance",
        "periodEndLabel": "Weighted-average exercise price, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319"
     ]
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term (in years), Ending Balance",
        "documentation": "Weighted average remaining contractual term, ending balance.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Ending Balance Weighted Average Remaining Contractual Terms"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term (in years), Beginning Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of RSUs, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration date",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date",
        "documentation": "Date the equity-based award expires, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334"
     ]
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options, Reclassified to employees and directors",
        "documentation": "The number of options, reclassified to employees and directors.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Options Reclassified To Employees And Directors"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails",
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares grant",
        "verboseLabel": "Number of grant",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options, Forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Option Forfeitures In Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable",
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options, Options exercisable",
        "verboseLabel": "Exercisable ordinary shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average Exercise price, Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of options, Outstanding at beginning of year",
        "periodEndLabel": "Number of options, Options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r311"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average Exercise price, Outstanding at beginning of year",
        "periodEndLabel": "Weighted average Exercise price, Options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r311"
     ]
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options, Exercised",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Numbers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable",
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails",
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307",
      "r308",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable",
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average Exercise price, Exercised",
        "verboseLabel": "Exercise price per share",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average Exercise price, Forfeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average Exercise price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of RSUs, RSU\u2019s Vested",
        "documentation": "Number of RSUs vested under share based payment.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Number Of RSUs Vested"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average Exercise price, Reclassified to employees and directors",
        "documentation": "Per share price of weighted average exercise price, reclassified to employees and directors.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Weighted Average Exercise Price Reclassified To Employees And Directors"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r309",
      "r328",
      "r329",
      "r330",
      "r331",
      "r334",
      "r342",
      "r343",
      "r344",
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Information about the Company\u2019s Outstanding Warrants [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedCompensationUnderwritersFeesAtIPO": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ShareBasedCompensationUnderwritersFeesAtIPO",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation \u2013 underwriters fees at IPO",
        "documentation": "The amount of share based compensation \u2013 underwriters fees at IPO.",
        "label": "Share Based Compensation Underwriters Fees At IPO"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation-placement agent warrants against additional paid in capital (Note 9)",
        "documentation": "The amount of share based compensation-placement agent warrants against additional paid in capital.",
        "label": "Share Based Compensationplacement Agent Warrants Against Additional Paid In Capital"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term of warrants",
        "label": "Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term",
        "documentation": "Period an equity-based award is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Options Outstanding [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ShareBasedPaymentDetailsScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment (Details) - Schedule of Options to Services Providers and Advisers Outstanding [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment (Details) - Schedule of RSUs to Services Providers and Advisers Outstanding [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ShareBasedPaymentDetailsScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment (Details) - Schedule of RSUs to Services Providers and Advisers Outstanding [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedPaymentDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ShareBasedPaymentDetailsTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareOptionsVestingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ShareOptionsVestingPeriod",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share options vesting period",
        "documentation": "Share options vesting period.",
        "label": "Share Options Vesting Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price of per share",
        "verboseLabel": "Purchase price of per share (in Dollars per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, Exercised",
        "documentation": "The amount of aggregate intrinsic value exercised.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, Expired",
        "documentation": "The amount of aggregate intrinsic value expired.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Expired"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, Forfeited",
        "documentation": "The amount of aggregate intrinsic value forfeited.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Forfeited"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, Issued",
        "documentation": "The amount of aggregate intrinsic value issued.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate intrinsic value, Beginning Balance",
        "periodEndLabel": "Aggregate intrinsic value, Ending Balance",
        "terseLabel": "Aggregate Intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Warrants, Beginning Balance",
        "periodEndLabel": "Number of Warrants, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of authorized ordinary shares increase",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Number of Shares, Period Increase (Decrease)",
        "documentation": "Number of increase (decrease) of non-vested options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails",
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercise shares",
        "verboseLabel": "Vested grant share",
        "netLabel": "Number of vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price (in Dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "iinn_ShareholdersEquityDeficitDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ShareholdersEquityDeficitDetailsLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareholdersEquityDeficitDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "ShareholdersEquityDeficitDetailsTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Deficit) (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "verboseLabel": "Ordinary shares capital",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders approved",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total number of Ordinary Shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtPercentageBearingFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtPercentageBearingFixedInterestRate",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed annual interest percentage",
        "label": "Short-Term Debt, Percentage Bearing Fixed Interest Rate",
        "documentation": "The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term deposits",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r735"
     ]
    },
    "iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "SignificantAccountingPoliciesDetailsScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r204"
     ]
    },
    "iinn_SoldOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "SoldOrdinaryShares",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sold ordinary shares",
        "documentation": "Number of sold ordinary shares.",
        "label": "Sold Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r175",
      "r176",
      "r177",
      "r206",
      "r228",
      "r229",
      "r231",
      "r233",
      "r236",
      "r237",
      "r255",
      "r270",
      "r272",
      "r273",
      "r274",
      "r277",
      "r278",
      "r282",
      "r283",
      "r285",
      "r288",
      "r294",
      "r392",
      "r465",
      "r466",
      "r467",
      "r468",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r500",
      "r521",
      "r545",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r724",
      "r744",
      "r751"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r25",
      "r166",
      "r189",
      "r190",
      "r191",
      "r210",
      "r211",
      "r212",
      "r214",
      "r222",
      "r224",
      "r235",
      "r256",
      "r259",
      "r296",
      "r339",
      "r340",
      "r341",
      "r363",
      "r364",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r388",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r420",
      "r452",
      "r453",
      "r454",
      "r474",
      "r545"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DepositsDetails",
      "http://www.inspiratechnologies.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r165",
      "r252",
      "r253",
      "r486",
      "r487",
      "r488",
      "r553",
      "r555",
      "r558",
      "r564",
      "r571",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r584",
      "r593",
      "r605",
      "r764",
      "r819"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r235",
      "r433",
      "r463",
      "r485",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r500",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r508",
      "r509",
      "r510",
      "r511",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r519",
      "r522",
      "r523",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r545",
      "r606"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r235",
      "r433",
      "r463",
      "r485",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r500",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r508",
      "r509",
      "r510",
      "r511",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r519",
      "r522",
      "r523",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r545",
      "r606"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r635",
      "r647",
      "r663",
      "r691"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockDividendsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockDividendsShares",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares (in Shares)",
        "label": "Stock Dividends, Shares",
        "documentation": "Number of shares of common and preferred stock issued as dividends during the period. Excludes stock splits."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of financial liability (in Shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r24",
      "r45",
      "r107",
      "r279"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares and private warrants, net (in Shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Units",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r45",
      "r79",
      "r80",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial Public Offering (\u201cIPO\u201d) (in Shares)",
        "verboseLabel": "Purchase of ordinary shares",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r79",
      "r80",
      "r107",
      "r465",
      "r545",
      "r566"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares (pursuant to At-The-Market (\u201cATM\u201d) facility) (in Shares)",
        "verboseLabel": "Stock Issued During Period, Shares, Other",
        "label": "Stock Issued During Period, Shares, Other",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSU vesting (in Shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r79",
      "r80",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share unit (\u201cRSU\u201d) vesting (in Shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based payment (in Shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r79",
      "r80",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of share-based payments (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r79",
      "r80",
      "r107",
      "r315"
     ]
    },
    "iinn_StockIssuedDuringPeriodSharesTradableWarrantsExercise": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesTradableWarrantsExercise",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tradable warrants exercise (in Shares)",
        "documentation": "Tradable warrants exercise.",
        "label": "Stock Issued During Period Shares Tradable Warrants Exercise"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of financial liability",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r25",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares and private warrants, net",
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r25",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of placement agent warrants (Note 9)",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial Public Offering (\u201cIPO\u201d)",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r79",
      "r80",
      "r107",
      "r474",
      "r545",
      "r566",
      "r612"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares (pursuant to At-The-Market (\u201cATM\u201d) facility)",
        "label": "Stock Issued During Period, Value, Other",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_StockIssuedDuringPeriodValueParValueCancellation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "StockIssuedDuringPeriodValueParValueCancellation",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Par value cancellation",
        "documentation": "Par value cancellation.",
        "label": "Stock Issued During Period Value Par Value Cancellation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSU vesting",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r79",
      "r80",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share unit (\u201cRSU\u201d) vesting",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r79",
      "r80",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of share-based payments",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r25",
      "r107"
     ]
    },
    "us-gaap_StockOptionExercisePriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionExercisePriceDecrease",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of per share (in Dollars per share)",
        "label": "Stock Option, Exercise Price, Decrease",
        "documentation": "Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "us-gaap_StockOptionExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionExercisePriceIncrease",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of per share",
        "label": "Stock Option, Exercise Price, Increase",
        "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Options [Member]",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of ordinary shares",
        "label": "Stock Repurchased During Period, Shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r79",
      "r80",
      "r107",
      "r468",
      "r545",
      "r568"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet",
      "http://www.inspiratechnologies.com/role/ScheduleofChangeofOurFinancialResultsinBalanceSheetsTable",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Shareholders\u2019 Equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r82",
      "r83",
      "r102",
      "r501",
      "r518",
      "r546",
      "r547",
      "r600",
      "r613",
      "r745",
      "r754",
      "r800",
      "r828"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Deficit) [Abstract]",
        "terseLabel": "Shareholders\u2019 Equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHAREHOLDERS' EQUITY (DEFICIT)",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r205",
      "r281",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r296",
      "r386",
      "r548",
      "r550",
      "r570"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse split",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "iinn_Subcontractors": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "Subcontractors",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subcontractors",
        "documentation": "Subcontractors.",
        "label": "Subcontractors"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r428"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r428"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r428"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SubsequentEventsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "SubsequentEventsDetailsLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r429"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails",
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "iinn_TaxesonIncomeDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "TaxesonIncomeDetailsLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_TaxesonIncomeDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "TaxesonIncomeDetailsTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary differences and tax losses for which no Deferred Tax Asset is recognized",
        "documentation": "Temporary differences and tax losses for which no Deferred Tax Asset is recognized.",
        "label": "Temporary Differences And Tax Losses For Which No Deferred Tax Asset Is Recognized"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofBalanceswithRelatedPartiesTable",
      "http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable",
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals."
       }
      }
     },
     "auth_ref": [
      "r753",
      "r806"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "iinn_TradableWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "TradableWarrants",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tradable warrants",
        "documentation": "Number of tradable warrants.",
        "label": "Tradable Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_TradableWarrantsFinancialLiabilityAtIPO": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "TradableWarrantsFinancialLiabilityAtIPO",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tradable warrants financial liability at IPO",
        "documentation": "The amount of tradable warrants financial liability at IPO.",
        "label": "Tradable Warrants Financial Liability At IPO"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TravelAndEntertainmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TravelAndEntertainmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_OtherGeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Travel abroad",
        "label": "Travel and Entertainment Expense",
        "documentation": "Expenses incurred for travel and entertainment during the period."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "iinn_TwoThousandAndNineteenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "TwoThousandAndNineteenPlanMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Plan [Member]",
        "label": "Two Thousand And Nineteen Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_UnusualOrInfrequentItemNatureOfEventOrTransaction": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnusualOrInfrequentItemNatureOfEventOrTransaction",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofBalanceswithRelatedPartiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of transaction",
        "label": "Unusual or Infrequent Item, or Both, Nature of Event or Transaction",
        "documentation": "Description of the nature of an event or transaction that is unusual in nature or infrequent in occurrence, or both."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r41",
      "r135",
      "r136",
      "r139",
      "r140"
     ]
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantExercisePriceDecrease",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercise price (in Dollars per share)",
        "label": "Warrant, Exercise Price, Decrease",
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "us-gaap_WarrantExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantExercisePriceIncrease",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of per share (in Dollars per share)",
        "label": "Warrant, Exercise Price, Increase",
        "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant [Member]",
        "verboseLabel": "Warrant purchase [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r604",
      "r607",
      "r608",
      "r609",
      "r610"
     ]
    },
    "iinn_WarrantsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "WarrantsOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding",
        "documentation": "The amount of warrants outstanding.",
        "label": "Warrants Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_WarrantsToPurchaseOrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20231231",
     "localname": "WarrantsToPurchaseOrdinarySharesMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase Ordinary Shares",
        "label": "Warrants To Purchase Ordinary Shares Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of ordinary shares outstanding diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r233"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
      "http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofSharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of ordinary shares outstanding basic (in Shares)",
        "verboseLabel": "Weighted average number of Ordinary Shares",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r233"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-9"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "926",
   "SubTopic": "230",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483170/926-230-45-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481309/942-210-45-4"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.12)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "720",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479448/944-720-25-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483613/220-20-50-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.14)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481160/942-230-45-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04.5,6,7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "985",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//985-730/tableOfContent"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481440/840-10-50-2"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Subparagraph": "(Note 3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481418/840-10-55-40"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "(e)",
   "Publisher": "SEC"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(4)",
   "Publisher": "SEC"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(5)",
   "Publisher": "SEC"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "c",
   "Publisher": "SEC"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Publisher": "SEC"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482969/710-10-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-5"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation",
   "URI": "www.leiroc.org",
   "URIDate": "2013-08-21"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-11"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Industry Guide",
   "Number": "3",
   "Section": "V",
   "Paragraph": "D-E",
   "Publisher": "SEC"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(b)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-16"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 5.D.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-4"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>117
<FILENAME>0001213900-24-025316-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-025316-xbrl.zip
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MJ,*C7U]6;O7Q9]V[#P)V[_I=8^V..Y2_'T;?9;@U]&-4Q(O;V9.C2(%)@+9
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MY.K@!6VAB4K8FAS2&2S1P7*8@A4AL5U'Y^[)JA3_+L"F $J_QMZ-*!>_H#+
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MH"^E0MP96U/!?=(.0@8F*OG/^98J[.]V@I8-FS9LVK#I'?JP!KH2#5J/:Z#
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M"6C;0D_#3&;&<#'3IY:\+ /OHU&($#-9WC)F#?K7F-"#D^#T'KK6>L0C!H#
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MM^M#1,H+4H6Q8:ZVO4SC2]AG[7O@3 +;*(%WX (PQX'*)!4R5N9!9W.8N&"
M#50:RUQN@B)I"' ]XCV 2],)%KT&8&IP^X0P#>.><<9)"<@F ]=(TXTEYM]-
M":XQR<E0R<=1%FYA[_+,TT-24/Y=8@&6VA;=(=>;.Y>)A<O$T(_BRMPFGQP
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MG &^H2Z/-B6A6:7_=,'Q+5V,.?Q<NU?6"_8:+YC,J5M5#^PWU0,+U0/[3?7
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M!N^P,=\H"XH)3\!2I!'G K/V_AC@3C%8&%F,G\K]3=TO3EX5E"*G5O_0X$C
MZ0-!YQIP"&>A1].<?34#TVQSX-PX/(^S;+PB0E^Q0*O1!.P4I1VDS.Z&O5>T
M>$2E#V@3\DXHVY^'J=')%K"^,^-KIBK?LO/5$VTDNE#<IC_6LY$XI\U^8!EI
M@"&#N7>81Y!4;CS/!93&-PO2*7W&$S -QJPY,OBMPH%:N5<DZ!PK[EZ>B1B)
MJ[(397$B4")A;%+EN#+U 16Q\S0 S2J1,8Q<5#PGSX!/^4)-<.)3V=8O)SB5
M4VIF_29G/*DEQFDG#PYGL@%2^]G'-C'(":*VB[V]EMC;V7NE,9M#,J_SV9;"
MN(YXOO_V!99$Q5LD,>Q6>L]+P<I92)"AF1M2PL@319" =I^_?D%U/',W,;W$
M.(SN^?X+MX@'%VP\-A=J0P/'V=/S'$!=G61F7 @76Y?82,2P608BRH#1ZOE,
MTL5Z1T1Y)!U5$^ Q+^< )N@2)09!:WF'_B@2GV2R=9J:(7,'P,!#T2$D;-R-
M,^Q6PJ(<7.G?4RF^^#-S[3G(-(*,TL-]> 55"G;>G\1%+/U+ Y>%*<,92A@*
M2<)NMUP-9-1,DN;D- $5I2''TBST%4&5.)OA-(%+^PHIOX+5Q,A4Y2()7,BN
MT;M:GAAW)]LP4G@U"D;)#'QG"V.P$!_A-+V-R1(LDC-)QQEK%,^\*A1Q>?J\
M=B/P-3';UR7<OV#,2@CN-APZ*5Q\=8;:2V1<W<K*5TX0,/'J@W]SV9TR_ >?
M$UK8@\Y%VAQA;PO^/"=DXH(6NG/L<%I5%I$;9OL"=4X$K)RLB'*VGB0FUAR)
MLY3'JG6C&E+.JY[7$P7%:BLS3<PBP-6B=GO(Q[K20@_^EM:DIH^= D\*Z8-9
M'L^8U[#^PZW[K""8HT1&J[#E2H 6YPM:I2WK%-ZTO!)^1F.FF'DH)9R6F>HR
M-$$HJK\L>5E[,G,FL9V-%6G@5 7&\6&AYX"6'[J/:'FU1I^&\S9U+_"\NF78
M2EEG OD"&%^9/,XTDB(R 0C&*-?@8C:EX96"["F90V=%Q7)Q!4Z(;1$Y^7P(
M$9JPM+G"&0*FOC?T9UMYNA7Z,[?T6$^;2G-,^KBS]=@U($V+QA"#6ODC7;2E
M2C/&WFO;JT\&6X^'L[P$USC6867EI!K<FC)WXJ2)D%Y)_QL2B+2(G0B(A.TE
MA1[?X_"6-\$!S=]PUXV:<ZH3L(0+<>4B]_NJ9.6AA"6FVR6!LM) P0SA;:F*
MVOZ$M3O*=$K$NG#UGIU<Z!34!/XT0O>W,K.08=T0#I0.LVZ4&)]FSJ T*>$J
MM>P\R!K&*H60-R<$*I,)TBIEL?.X_/CP<G[%EAFG@/+"#F-B8%1J[R'$'+,O
M=+7G&%,ZXTO%:"]3OJD!X2^#\.8HW"FP51*SE91525(.?'',[[*TT3%7;)E*
MI4C-K4]:LGW5 4P&=DWFLK)OSGP):XFWM#GE[D?-7CL!)-[R)V%9F8<SPK2Q
MF!=$AO6J.2MO,,;<3(]IE<!4C2Z.G%/"U?ECMOJ32V9]I=(@HB))"EZ%A#%<
MBI(B9WAJ<DB\:L@0")JGG5BSZX&#RYN@L_3P5<;-$F/IAV A9+E!DV59YB+M
MVY((PLC@@!5OHW@.0JZ$\U5!%@TPX0@"[^I%JY[U41RE&<A[.A%7!$<N:7F6
MM.:PPC'!:,LDPRH%U@[K7AC\<EBEF,ICZ0%Z!K-!>$1P5**]"OQXD9/,,T&\
M/&U \9YBU^$$O43"O$30[CCB?EI2.WJ:K$>8VO,I#6,B&.#M2BH@][\3$G=+
M<'&[4^XNW#KWEAM_X!\L <9T6+L:[2]GT=,LAMS A0=D/]R^?_VN6VM7G"8S
M@EYCTP3\Y-G1H+D.9@;=='Z0GU=J!N/[%JJ^CL]:D<Z,09M^:EBC88U'Q1I.
M^,OV]1 (92PO?1I^X51W^93L8+3BGX32[YVHKZN!>M/40"W40+UI:J :8=\(
M^WL1]CR(Z;L34G926MX\\(09ZL-=S,!/@4G/UZ+8/QRV7^, ;SRES>=**?6F
M?6#/9B@,P&095_I)K(I&I#X50J^*U&H4NB1T$P^J!+JK(1>*!+FE@H@;,/D1
MC_)!B&_%+O^RM_]N.9\TA/KPA$HA:9N2=9)9IIL,)WF[61R-W=)(Y$8B/RI"
M=_+QG)XQ077JH\Z\J<^1\6 64%6/ _<>I&35<E<QQ?04U[)?,MI"/BX!8(:4
M^+)SIYAGG!9;'.9'XX,U#!KU%.I'@]WC+<05*3=JQV.Q8601F>1W2AR  L$T
MO(O/U/!GPY^/BC]KQF#;E+]72>T[X$ANDO7*KXS.UM#V!E$)P5(45FT4.86"
MD%/A45CJ@HA?LP#. -&P"JQ=CNV,MLP/95G$Y]D\L)M8VP3T^H9BUV#CZSIW
M6S]5UNM[7&I&1,.)6;Z"DDB9?RGC%OX[47%960QDS:@Y'\2/H!\WXKMAAC4R
M@UM-H\OH-"@K X1J',:8X,K*_G]M4Q5DOSC3RDUY/'4OTDSV$IS%A=[%NV)%
MX1";L="YUC73TR*[C. @=:L)M7T>L?7D':2$ER/.S2Q@T0YRVYAY='#>;E$I
M[B!-OYE:#$2*4MS_SZB&V'-'%EH>;0VPDBF;.5\WD,W<MMM.9GI:M))FBJJN
M#'6*N>)9V7FCBR6C)96##N"#;F"A6AI%^2"X44L# M= 7?ZTX^ K?2Q#/Y"F
M \!S.P#<^MM*%X!;M6JJ7VV%-K<:/'S[XEK;@I9APQA@5*HPC*8^H\MY*#6Z
M!U_M]'.?.LS<:>H!%D2B[I$6W>53JG*@YWX087(=9QT?Z$)')//GIW_T.^_%
MI_X_7[1$3ZH3&8IN$FRWS#>]DT/XYL17T21U?^D]/_55Z/_[O3AI][MPR2<X
M6SS]PRCX!A:&9J$#W<)GGG.(SSD8(PAZE\^<:NOQD<+>\?/%<1\N.Q^#Z3U5
MXHOTXWR,KP8+D2%(Z@0G-L>!OJMW<G@!EQ]%"@O)_NI/0.&=^[-O,G9^6GGK
M8RZ/A,5F?_W+WMXO'\ OOY+9-]'^K']_D&Z+?WSVVS>ZY(L_B6)X>>]$%W^W
M/P,9P"/&2IB/X W%<S\H$=KQ()TOMU_ GO<C#+V:-P8' 'L2X8'MPYYX?G9Q
M</*/B_Y[T3\Y.?T#=]S_C@WOU=IGO26?VKC1GZE;2#J__7SZ^1/^]G-'/^2
MMO5"9D7U?,7SBS_.WHM7KU_MM\1I].V;C,3>WFLZ4 ("@IL<1Y?^:7KIB_/C
M@_+TCKN_G>)Q %W*)"J4U^_,[=B9LZ"C_NE77-#?TS$1#5]I_M)D\_?3O[\0
M1)^%"N#D A8R?6P7@(6;?:2&)]V/1%"SW* H(W*I2L@#[/(T)[' /5RXKTNM
MTKC0)8TFB(/H<!'9'_!AY^#DK/*#09RF6*$%BW](_/:UJV 66SZ&C2;<523#
M\AA:? [5WM41.,=(OH/,&#ZCI 20EM3,K;N.3*=*RZU7Y0,K4>DJX,EE>US9
MZHK]<PZDG=-.1U[_N("OG18:JD5G9'0BA8H581;O=&>:R>MEHU$)P%S_.MR;
M[;:+X!P%FP''D7AN5U_YUC'<CB UV.I,595JW884[L.J7)&EA=8?A),.YBJ7
MRK<L="!949[#16G5C#+Z28$<E\1T40;[-,%-MU].4Q59 [O2T^0:VPX,>)VU
M1DD#;RYA$.'OL=4'&;G:"D,WP@?:CB&VYN>K[=?**AO K2=.&[RQW=!B1C[U
M,$ZM4:--G0;.9J*.-@.(IEP?R%IO2 JZ*[R>7VJ8O=I6,\>%7LF%^N9^K%)^
M O6-S3'@/&RL83U3_:ZYC[A"*@JT&\YS:D^XP:[T&YTR78?W7-XL2]KGI(R^
ME\&@859TH?W<MV-<8[_"+>C46@C BDF-LTZ0APBBF<S!$"LF">YM+&,R,MSS
MM;;YPIP6$'$JU?P'[V>':YBRY;DNJBJT76W#K^V%=JH[+>0,$XWVO[B+]YN4
M4T%F*W=/E4)2@^HG"=@9%=@EA]ECV%3/E4D&8<DA[9]4&=^VXO-M4_&Y4/'Y
MMJGXW$C:KE==!PZ>016WP'.-(-(.-$P>!2F7E)>6/@YZP;8E,@[3.!U%\Q:_
M*3]PP \L<@8(;2TF6\*)OR,H0C("&X[1]Z@=67L/G/H%QX#'=9K4;YQ>E5,*
M]8XXG>85D48!R5*<@NWV30,S4X=X98X;0I@1; S!^<(&%9B1<I=J<;@GB .
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M92;0)!SPO:RWR!:N+ZLEVH.H51H@GC2?(5%#.3I6GMTBG]T46,0H@#H:F>V
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M<H9SQ94(9LYXL?3KHRI^><G9P/,85A"6(+[Q=LVI'BM;\T-F:S9!W46%@\G
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MN50\K*BDJN\6!YS2$-0#%7V1Y%PJC- 337 SF%EM8*A3[LX=[\?A%^ZWB.]
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M6E8W:H[M,^'A3KM;'YKLR+7/[%DGU00F=0@'J^@K42WY;-$2AS[$_5<=RMG
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MGV_/Z]B! ]JD232\/A4<N=1ELMSD?XB8DJ(!^"D^T_UP5Z3<HP-2;HR4>W1
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MGPDY^]W^IF-K,TX _\DTQ9T[BT\ N Y\>*9<_<"9\E ;S]2/"]5CX KXI,8
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M6#I1*\X@Y4J"&4\BSK?%(P$9#O"1S[01E@YW(7IAQD5CE_,Y@>P=Y/P>-$V
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MJM*N 6T"P/">1'>*BOK%+]5O+";YNEXV]2+U$#QZ+$MBVH;E((OY])H3 M+
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M)M_[1R"#4?$9"F0(E#Z^OG/C)H.R=JA=8L13-H9X^K'HYL5_=D%-%^4HJDD
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MRZ/4S[GRXZ, Z%35X-5^7.X0$KY?<- -O*["(A/5+<?S*-2]G'N^I["A(!"
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M\2:2 INB!,>">@P.9:E**6_;'$%_-1 T9L6RV:PDLQ)$W6545YZJ<:*FLJL
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M%640YDU)15E)I$+"UAUC$KI+^-\W3;[<0!HBB=\9MZ%.>YQ_*YWGU<H%!):
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MHN+2V$^FV#XDH7Z3!O8=,*)_T8+E^!EJCF\C*I1>.DKEA5F"KFX:SMDE-@8
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MH(38JFHNRZSFDGZL#GF>2U96N2 [-BANHE=Q;0@S;90:&:+]ZN54U"FZ.AK
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MTUH321SJ\Y:@^8Z<GV(EZN*I&O7E6"FJ,0"'#_4E_C Z+DH!C)D"#"VO(P$
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M@*K#V$Q,S[W 7WJ!UHY5A@6V+F8PJW,TN;,M-.2S'*.Z=0FB,XT!GN1E R]
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M2./0I^BKI76LGL(OB*P-V</K:K@TL*:GC$AI850K%%7(;P5O)[-BBG(GD A
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MB;,Z:S]QKLJ?W#H1%EH'$Q7MU>4GXF38O$R1&XS_9]?E:)N.^R$I0'X6-P_
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M$H^V-U427WS9LLM<ON6R]XVK*D,X[#<SL'>"RKPHG5W F!G*ZZJQKF'DJW/
M3NMZXQ_IKYG//Q7E.;+2IZG+3'=^D\ZBH.O(1P;76A\<TF=FWQ*5I5(P/11K
M#ZOYCKJOM!**YU:J#548'3U[GG1Z9"0X+^TO_5&;L@[ZPNKJK!@7K>_&,DMJ
M^-:@]'3*&--I7:>74I;<:1KS);.,U.2(8!CO"50N#LP-:?]VF5U:_D.-$/Z5
M'P23ZAY-!WV^U!54>#N"'?D@HR/8;V>,<)A(J:QT+/L*66\ NBAN\#;+SOCZ
M3WH>S7ZG\MR;_5:AK"L/?*J@N<P5T01-/#+"7B\,[<MN@ _A"6\*HBI=<>3=
M7+@V:K&NZ3!6RR8**[EM%KQU=9'/IJGQ)02%WE8P4DB#8RK,M Q,!,)$.4]L
M%2%/WQBNG7P*^KR3KJL3>9 =X#87Z6E923?@Q!#["MES\DQ&=,"_LZ(1\L.0
M>U:;Q+DQ?+Y(B]J<\>YB]^_AB8K63)0K>4\MQDI+L+K0=J!U"C1,[JU[S6 ;
MHF1:%G/MXU3<!81H 3<>*3H&H/F-1"UMM4P!"\2+9I%GGZCC3[1F-G416BLD
MKJNVFE0<5&X<2JNT'P$54$)J^"1A" K#.='*7MU3%U*(TLQ]# K+E])%8C^*
M*Z.'QSC5W!@[8B7VQ,2D*L(8?S3@ BDB,0XN/FI2Y)Z+&))U0A+/4@*R8KZ0
MK&C]H>Z:[J'3IW3(J3N%$9]"=3\GN8MJIBS)#?YM8]BO]GK*Q(H4YQB >;_,
MJ'BIY2A.'?I@<<6 (*=G.,@,=G>D#I[,]1O)''EH_Z,W3W4_OWDJD1'5+S,/
M%E,HTCQ:5Y0&4%21U>;XL;*V2B7T'$+\=?I[[;DZ_LX3>!</J ;$31&#85,D
M.JTD<B+'+#Q-UO"CP_%3%M2L8/#TN?>:^\FPVM TT2FL#.QG4=C%)""1ZQLT
M3='ZA-K ]2H-N<VDD> Y7:I)3!FLR9TK%#5Z8E;T6;?!"$B#KA3"?09/=^<C
MC;G1H:EV>FM9'O)EXTM6D\9%3O/6N+A>DZ.WM76U0*Z)!!H\0BI6:G);R$F)
MH<7I>(RKN<8#B]QE<G,4+-[B61%[B33B=(IV.Y:.=>Y*F53.F[;ACA75(&R]
M6621S*XMM;LZ@R'%Q65NKNEN=5,RR:9\>E;E$EHZ72+NT>:Y'YR5VD6\@_E7
M>!)#@/:T10IP2XF4\1/[%W0%KBXQ7NNM:!_R0D4GR84N_:WL\,CC;'YH,Q,;
M.K!7%;5*)8%+1JR:7C)A3+<CF$A>[6L$/6HK611_MN.5LQV6%G(#M-_@5=U9
M>9X-K7G3,)8>CKXY#F,L-K#[3LC,P[*SLI<2#3V@N$D/1PT9VZPQ D6HV)'_
MYO7:,ZU(D&E4U28K& T5?UX.=B$&GH4*"U?YF @][_L4E:.)"BXO0H#. =RV
M3HUD1V)$VK>HL*#TYH"_>6CO!#((BE,+:]=#=XB<B4W.Z.O8=Q07F45TU'$C
MAUU(,=I@^[WC$LXU)=^365K,G:J=*X'HX,?'/?T0J>XT?-V@6$+6P'O+K.YQ
MJ%7BFN]CDC=VDE>E_]JSZ)U64X-)9$W\+(.8S[3X4!<[W$<IQZA#?[KC;/>%
MOC-: *K*2I(TJNI"+FT&W(2722H/L LT&K]L$.SF/V@R*@]L8M.^+8?T&3T!
MBP2T!?:?.#L3;FZ@_I'"RJ>1D^R2;( K+9Z_V1:DDR_R0GLGX#2"JX*]*]H4
MT^)SBZ([$38\]GVU 6C7G8@>?M;Y^8#:R,(UZ40.04"; %S!5^*!N@1OJ!6$
MXG7DO:RRC5L\-FYQ:YQVT)O+UM6WSH0KA*[]\4XJ5D%-G.2SV0(.4'GZ7]]M
M?\<_@P?&?O[H85X467N&2[>_=SD8QJ%<-/F/L?WK.R0-_K.M[?D,&$52Q[ZH
MK1;?:5ZAS>PB\O';?(M9:GZD*;ZHT\6:>=!!]&:@S3[%(W?E#- ]93@[Y._\
MF<L4X8U/'CYZ0J_$57\??// 2ZY[ZD%)9JR$EY:+C 6FJWR:!YWVOJC# L&"
M<-")/W<&1_]7\XK\P+M"=\K=V:MW-FNYL\E:KF8M=S99RXW W@CL[_[^?T_>
M]%Q!"5-;)<I*P9IZ'\#P*$^E4$QP(C7FGUBU3N*J\S74Q(X$N39H&BXS%S>2
MJ+G17_HZJ@"AV.KPD2+@.OP@GH*7:ZPTY#_5%J$O2H5L3L^Z1W8.RN ;/I.Y
MXV%$+1"A08?P3&TVX683WN F? -JJV+BHE_ $$UZ^*$U(S(HA!T,[LV>_"KV
MY%TU*UZ&F2'?+AG"[?8,#2T>,?F)S@J%L$LX5N'QZY+8AYA1^VQEQ%(KSZ=@
MJAO>%26D7%/%<5R%N--2$"XCD;1)4_DB).VH]!%D!_K*CRY=Q(9^TI*?:CK=
MXH28U?HXD&:4FN#TM<*KV#VMED/;',C-@;S! XF<Q52QY(_/+IMB4M#5)\NR
M 7,O=_]@JUKL',@B<GS@X<+$GJ47O%]]^)^LFV7)C ,<D]1S?09:8X[B2-63
ML+!-:)35G%R(S3;?;/-;VN8')-^W_EE,WHT1H#H1K)SXGA#L"A^[;'-L[?L^
MB<@:9@YLEDI[]>A7R$]7,SHU+@DI;50)*8=I7FN5H,][^L,AK4G2Z:'D?Q/E
MX%G6DS.M)40>#068F2L"0-<YZ&ND(E!;6XKY>%DWO"VM_LL^]\SS@=,P3NMT
M[FM I.FVYC?)OPLTSJ#,K-'>$)HL<K]=[84 <U7R7WC5] :@;<[R[%1[G(K&
M (AB:YY"KI\_5F#%BPK<$K& R/&3\)'6\"=_IJ\=E@DWM/,_R5Z_\B'77?^%
M?.'G/KX_DT66HZ$/1AOTTU\_N=BX]"]A<VJD4)=+]B;IDGUWH1#6/\(B#'+^
MB_12JGD#I&\MA;&AGGKR(M<R..7A ]2K3I?9DM'T@H%HS4&JU_'G2&%/RK1U
M_ [4R(QG5J**VD^I5&KKM&Q0'TK?FE^JX*&S+/2G:T9&5_G7<Y%J.K-Y\']0
M>Y4?QQB#E<@S;O$U-N3D0T>V=C121!&,#KE+0)G7-H6R!%J#;.C@$(A-(!$;
MI?3#"*?"N>JDBH4(KU8'OFNO<8O1630=!^^$90U#W@4?Y6K=*BH*-_;-QKZY
M00%Y.$CAXOW3+I .SM]*8W '2N(*H*5UY5 ?VO5:!'8/N<*;@[$Y&#=X,'JP
M,J&7>G7(J8<H)3>&H,?%-"C;:?4<2;&-F+0I=R$Q55#I:$BX;R?+4Y#1^I:>
MHOQC64OG.%!NYNELNBPY%J1D;=T:X=29.V$/?S (UTT_*][E,R$52I>BPOQH
MKAF,@^=P@Q$D9$:GF"SKS<G=G-R;5&E5K7%;N-5S5FA:6=HM-[WN)'=3U:L'
M>8KJ"5JKVH6)0XH5>5TCOCB/HL')8"\;\+6EG =VWE/7+:(Q+D'>&U_VSB_?
M,<]1 ;QJES(6E=7-F^^Q\NC-X=L<OAL]?"CN[A3>F;]$OK6>0U^D[A&K?BN+
M_UWFU@E^9% T=2,\U4I78WF5M4A7:';!^7(M1EH8.$9/%*-?FN8;(".:56,:
MY_!(M*WH64I[,MU8GYMC=.-QJW!KJNXR;LI+Z"LRJ51!,$'R)>-_\BHX0H55
M<#!^C&LX,_H)I[3$'N2VDXY^\9RCG+;I'V.Q^.I<D9,]BA4]=YR.A8S,M4AH
MY4"(Z26N'UN:J=F3OF7'$C]H6-'"2@X?D?WY$\:R.8N;LWAS9S'L2@G9WI#%
M*,X%Z:-W(,R<Y(8)'-52^>MZK'7C522XUK#9%LOQK)C8WA?CSR'%^>[MM0VB
MW&+:A4$??4D'Y1:'\#8 BAW75>K6LJHOHX" ,6 _YQCSHB*_MKD2JO\"4=UB
MMMI!&71/KFF_81(!R'1X"U&'.3H8$Z?:_)#226<#"MX?(MJ"87WI0LT.-;%)
MQ4=O-BT[&WGY*>3E[ZE:"@)^GC!L>(LCX'[#"-X)!XQ*V[#:CBI9(16I$Y*O
M,P_S_449W7>V?V=WT[^SVK^SN^G?V4COC?1&\3>'+1.V4K(ZO4AGPH.2!J#?
M(,?+&6),BGV:O/AS*?@:U;)VM:U?E+S>;-4O;:N^7N1*$-JM@4:)3<VH6(+W
MT.@N;:L6OSM;ML#L#Y+<:TO&-EMULU4_D52=2F$8QZUFZ:6!F]#&E:JP*YF@
M.B#;7"Y4"KV?M! X// \V\C>S8:^%2=/K0/LU#XA5+.Z8Y6T&*6_,[*4LTMA
M+V;"J#S;[-7-7KUIX2L%L,)0EK_G5#X0ZN8"F^TV*D1QQX2EJS:[\]9W9[@1
M/U%-^EWMMCVL"P"1S;#EFGS"_;6;0/U:%%X$KY\O44Y.<_I;:6#Q_.O? /\F
MR,]C1U@YB%T(\\DJ_#31[P''$@..>_7LC=25TS^8]HES,DRY5I3QJ_02[%:/
M#%EV;^N2%&#$%>L"AK= (C.S6#QG%Z#U&'@KRQ6L^O Y/:E^UX7SSV>K-+/%
MT,=SQG4Z+=XSV)?%]"<5USX4[66$&OBFF?=0SSV@K*6"Z3<5RFOQ:4()@UM^
M%<3K+'Y:95*/?U8SDS:-<+J%2@M?&J&IK2XKESEC$YK;.IHH^9E^DDR  $#"
M=%6&*] N/6=+F/'/FUCX?H7D36JK4-+4I>$9V43R/:50%37!3#CF.I=XB5XH
MF5! 8':<UUPU4O*.& !&[NP)K4R>HV-@P:1-'3"1_+V"4(7DE74ZSR\J6G \
MT7]G$EEO55%R6P0S'"LN88ZL7SG)._FA .P$VWD-_N;5Y2STNHN<45"$&YT?
M%RV"C*?ORJ#EPC<+[F2GP%N=#VU.UN%[E'3-5 WB3*-[C7QWF?P.95'(>"!P
MDM)U<JYHVB4=HWA*'XY3Q]4-P/'GQW_SJ*Z_YQXB=%4,1DX,AC4<M&=SFMM+
MASJ_++$N7&<"L>KYRDEY>=]3<7]Q 8@1TF4Y.1/P8Y(F*,/J>JHA2_HH8L)>
M>5-A&=. I3,K,M\[..\79 ?9=BY_SD#]RV0$G;\)-N$%>@=X% 8B.XI_#H!I
MHR,2&:F6OFBS_D1QELE<3(4A"RC$2OG>F3MNPU0BN!7)'4,2G5;\A:0)9KD<
M-?_9^L9719:14'J>-B*J3ZHE_1H_'30T-'Q'^ URYMT8OOD];TE\+Q5)RLXR
M,OOR*)"_7"MEL@KG@>/8KK**_\)%%"S7&*8X%&)H@*DF4LVX6@=EVM$Q6V<!
MT3.H9*Z E\);087<PST/^6;0Q!NB&-/%'<1T!S#!UJ0^L$M//4[+R HD>P8&
MD_/A]QK01YD)*39FX>-VA'G1C,FX0?_-RJU2=T9#38N:APP"66L3K,D!PZJP
M5FRL&D60G4W<=\@Y@=.MA=!U-<VYM),)DVQM%1% J':9+G"(U]9JH)=E4)(F
M +T"^V_T+=%96L\=6']8>.-GCQL*(5#S\H^J, )1Y$/P@Z,#@6*S"78E=$VG
M1MOZ,F!V]*S0)D)CZD+NUT;2_J<QL'K!4"-:[B$O'? CY#-)(/N1C,S073D,
MP1$P!G<OHYP:R*IXC% F UF#BH9F*8BCQ[)_.F!!PMB)!Q8,5[)00'U3,1T6
MFY8AXN7 ##!)K3]\W[P /!)Z>E<7-I/&4MT^CM8KL,\S4SV_C4Y&OM,8*K?/
MSL']#@J"$]SD.2MQ(PF74D1%)C02XE[0:DV7*.-PIG6$@Y?1T57]W(,QU_C,
M5>#?<DG0?=A[3&#=K, :0Z6C$ESW'QAMQ4,+*E+)$+!7C$@3S\.S0$?@@ZP2
M("-#S)(U[5!/W%.2_KF.\ 5Z/U[Z,Z<'8%\GX9<XSPWR2,A[R=<5C'<E7^N]
M[-)S<G586X*E5V)OLN(%>B):,W4_Q6?5!:S$I&,E\N>8^W)(9SWMH?X[&E(;
M?$>^<%$:21Z0H? 7??-'^16VC-]P9 @V*/M4IE_RZ+#ST7'N:0 =WA4[R#Z@
M.18"VUK]>/A\NIUJ(1Q/C%,7=,WL $PAG-FK$NWG[@^IUILF"KCDI-(Q%U[W
MG L-S?AE%UDU#/VZ9[:RL6'" * _](S2G6!]!C.OB 8J\SQC/ 7E)PIIAXTD
M##M9D4(=?'D6&'&C^'=^5O^[@M,A\L1<)V84N'04*4XV%E9OKX3#>%&$V T;
M:T$46?8[,+O<HG[S>_SCBM;V-D5KJT5K>YNBM2_F$#"%Q//W"PEU!C;XSP7$
M1?/9"27N@$AX6Z%K@>P%R,[FLF%P%IA9D3 IHF>69+RHL8 FDOVN_Y^]-VUJ
M(\O6A;_GK\BH6WT"XDU4DIBK^E0$QKB*OK;A&E?7V_?+B43:0ME.9:IS %._
M_JYI#SD)81L01A^ZRT .._>PQF<]JT2+5I-&.Q?H=$##."3PA7;,W :7QOBI
MQ%&Q!Q 8IX\EMU=B022.6&AN(0IT;\$*S#V:,+2BF\:V1:Z(I=#S3Q/_'^!W
M8)G+L#\<4IX&.S00;Q=JYC21!J?4L.?]Q?GIAR/_Z,-'?^,W6/7AIF,*N)=X
M<,F@W^>K!N8J"3.B+W$L*0<!*2AJ,4SOEKY+YN44^[.\:E*:31$!TTZ5C0AC
M(^1Y.B+*3PZI_KMDN^I:@;X'YSB!G\#\OR;C&7;U"&.'.).:?UPG$-SFM*;F
M#Z/P)07]8/L2F\-/Z%E)=SW,,E'#64Y^P 1?J#D<F$N5>3#%VS3%IIE;?5K=
M.7,JVF6RS&P9VE,LZQN!B1:E6_,RGH$7!BMY>3O'RW5O)R=+HR3]$GCL6''<
M  ^Q1$_1UB19R#/-%BRW9I,VC_AJ"EKIS81-ZVXK=#1W,LY0TSC*[7AUUAGK
MN-Y%.V/ 5=9OB@IGJ\#\!-7,14A&;@N2*_ XLR8"BB+AE8ZM/.T!D6O =%VG
MM@ML :8 [1/=D=67PXDMNG2HB.O-=&Z%U;N.2<K1X @DO<]S>Z.8NUH.WX/+
MO%A-BI40>&>8ULU@QP[V Y14.Y53Y"TX1=6R\EIN^75T'>GR=/SST;NC#S3A
M>C6#BB]!AB/E@3'P(/<(63%XX/D\*K!/)-QRFF>ABIV8=SUIH/,(_M$,9@8#
M=N^8ZJ7'@S >N74",0*'_@^V6 1SKX]Q=)+_U"L91L7!!FGFIAO34;DA-S4U
M?M.+TI6UYG34KSQ$E-'$(W,&@?/JBM+0EYEV$.VNT:78U&L/#NXL1AI=3="I
MQ)D=ZU"_20V'XW3NLH"TZ4Z2<T0KBLW!43@)IR;<P^)+4!,$Y*$FWA)N!3?
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M;\(1Z!$N_7(^\/<PFJQ(J>Z*R1M,EH+AFF8> ^5@1E/0B21LHERW'V>F#S:
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M&ZV>();&0J3,HV02E_@Z;6;3HGG_!N,5OJ\"B&?N@AN$(\8XLG_P-3BBF3F
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M(2;[3A=28.(V-J0 (N(/3C72J;M!4Q2,4MB^>7QK'$9/(#)M9H0,0W]BY=2
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MG;N[LJL- %+V7I(F6XFZ@K>BA:(3 QM13_6">YT'\^!1C&!F"H5+'* 1O\.
MOOO:@#B^L*2FO"*<WZWA>!PCL=VX=O3=<6T&W+ '$8.Y7Q5G1,P,!CG':BL?
M0^A$R30UJHM:!AT(X3IC&<.<(:"C+"()).^2G)U3R,LT4$BE@26'UX2S:)^5
M7];'[X&/W_6W/GU<[D'ILS*S./P*@KZ.SC>%<J 3B.,BP82^5:&.E=>XE[1)
M7D[8ZBL(VU-F(RED*%)\)[=DFG/&GDH)ZHRD:T'_T#OM 3=:8:@&W+HD9UMA
M-4JSXHC8"\I+E#1<KEBU]FO\_ )LZ>3GX=RO+58,JAEREH6I]!.)<E.^Z&@I
MD["L?L9:"#[TUOSF)DC%PK;U0J:GP!3V7BS\5$I;KR[-;@R6=T%P02K,;KJT
M"[BG=280WELP=9"DKUW&(&8#T:\F[.EZFSWT-OOF^^R&PAY=L&1V5QDU@2*0
M-F-LDU5U51KX5J;2_JC<Q/%5TIXD-0E!LR B(J5R4G!-($7-QDRBM/?4S1-6
M-);:EG'1J4=$6Y8C#<O,1V4N5="9"4X0_XX8]&S*$X]J85FUOY&;[7U+-UM&
M0Y2Q! 32=?S1S(#,S?@K0'%-/,0S952^1EE361OS&ZQS>=VP$T+!DVO6V'LC
M,&JPN#U7;"<1!KX2L;=UL%66_W:G45<&X+8R)6Q4CZ;!7!<GQ[3AI.+AK901
M?*#:NHT68N-*52#JV"H8LPMUMNGX&+4/HEUE&,/7N8CO(Q?Q7__K<&__\)=O
MK(1M6;I88BX6,E-7N-<1N2N@&0>I2L2/#-L7ST-[ RJY$M$;U#H'6]RA5/;8
M2[_L_=T:O,(MSV?5$=[M;LF*ZN_U65F-L[)@H[=L;?)B&/.,U/?Z'LUD/JF&
MF(P5RT0.)C*@84FV9OZV]4:'Z8)@Y!HR3$Z5O"R_S8G[<]*(;!$[A4. P@00
M\*"U^_ZP?M4C;53;<8;,&>X>E6SQ3ZU[K%J:OXPHI@9=F=HREFYGD=3:87^^
M&TL+&,(9,$4/&: UV"I2,L7"P*;9-N!%5(F"10U@R(X*HEP:2R1)JK;3[-9E
MG--A);DP1_DX4@CY%'I$ITETE EL4]H6PPAY&)9!*-!M1$*W"97X;S=3V.&Q
MNHR)NYTHA6Y-&;1KYRR(H\(TY*FI=UI'";X![!#LDS7NL($[/.RO<8?/YA3H
MVHDV,IL/=?>?2C\L2\%*5%JL<.E'RYQZ%) A,LLZB],,4Q,A=]WH".V(/JJ5
M<DA(+M#E&U2/@4]WC23=[\\8TO&M%R.>0)=RN\4<!"2R-E2:&4B6M<.=1(DE
M45_)>,XC#N&(JD<QWL=4%I11XN7QW.2CB]J5JA<'[.\VGH65<;#_/?]=UJ.K
M3,_-)NMSRUNX2^8=(S'48(VPGUUUWC(CM]/5'9UN[^2?]PC,0VS'MNJ[=:;R
MMJ-19YAW:6'$6<"XIQ"(.:U/;.&S>81G2YQ;'K.2?%\KL>WO!5-GJK4PRRB4
M74K/V-(2C2]-=@J[FLN?VRLWJWAX[&[_LX_L1]AT:"; 8Q*+U"V'=SLR^&!\
M#@1N(CE>$TL'#W*N>_+ 0%N&F0OM41.=H^6G-+OMO!=NYI8.A3(Y9TSVP62Y
M'$KY*$[SDD2\O^AYUT)F;66YIB-U,A/C^C4%V%\%ST>$8\%_,M&3P<!J]ZE:
M32=42_#6:S2*?87_X9FN-TV"22^E18Y77P0#ZW#N)^7%4#C3!:.<2RC('X=%
MN&@N7M )U1;1L1O=7IML3U"MVU4R;@B@6SB:%Y;N>O7277_)TEWJE&1C()L+
MAQ#E=2ZB'!P\.S,>4G@BKCR+1J;!9@?RMDA!Y(:;S#SJL%\XFKZ29A8!<MFX
M0U/IC\NL4K3OC54<7>J.-]56GV2#O:"3WYV<;E_IP).(DTM;8EOP27XZT,X'
M;?OE2E)="W:QG>J.S&%Q]KM'+2$S390K@*S%M/5L[EGJ1;AA5L97K)$1-4/6
M+%<HI?=D_@I\[CH,OT- (ZKZB<HRB=\A/L2ED0TJ?558NS/:H_G-GF/D,E>A
M/Z5F[ZBGLUMS)_65FW//P4*SV!*\US3.Z! V[ ],H[DT4&! 0L7\QX/'Y\E;
MQN1?G[:N?>MI&O1*O#;O#MC^7 /*\G6-_A8F#DUM!-Q6QO!+[F<B[:'1>O+<
MP?U"O3WDKZ!*D!;@&C/62=FPUZB1-+S0OTI#09N',]R(:&=N@U$->X8H!2J/
MW]D4+"2#G:XRQ=LJ\'+D*Z/\-W@"87(EO]<;$7XA9CCE .V=VB*6 P_OV-V$
M.2HT-?,5/(RO^HG"%N8/]%6"R/0W]O"[;STNC+T$6WL2X=O=X=<  H;''Q.:
MSI!?_);_6''?ZN+&$6(NOT<-$EZEL5C4H));45$"Q,FO5!*)-> &'1//H,?A
M5>Q<W"@6U4PXUUSKVYY_ GOTUG<[,VT0DYC E[ASI-.RB:4]MS$7XQ!>3UCT
MS8 \54^&KNT\[85524P63$ @/=/K,/=Z16W+4C@FJ->P_V1<$:GIQ+_,L#JJ
M8%:O6M:TBL:OT>2&IN6\P1+>!8OT'KOZL)4RTEO$O4S]\!Q"VY:)P_H70VG(
MF%&SK-49J_8FY>6L7^6Q0F\4BTDC&7QEL$BU:Q^YY5M0#^61] ,D-UXZ\]HN
MFS@L_%K=![-CIX" )M7%#:BXV'0M#\\2_[4:L7\SV*<NOP-DY*QWK]7(ETJO
M+[UQ:-W'7 5HF;_K:X"GD[I\BRE0M0&JW>8H8J7%5>"E6==6?O$+>,\4\&"=
M FZF@ ?K%/!WTQFK3?*P5^^)5\]<9"ANQJ#[V1,' P5$DJDCM%%9:Z=9SP#I
MSRI66]/-J<HVUSU1GT=E/&>;';MREYFN<QVK66(89G5WUUF:J (+N^>A>7D*
MMIIN.C<Q?R J"O:^%@RW)9C&D^1QT#]WV]%-PF;DCBNU7:!Q2N$W)%@+FB5H
M2*2\14T8\@*SMU?<%WJ$07NM+>:<,V"F;?'K<LR V(G%SK2%[GO#MF3>WI:Z
MI:M9P.VIM961A-2?78_>Z4#=-36Z0YYYM5\I##"5"+!?9,K6M0)K_'/W4RGN
M/2Y'XKGGGR)8@<!I.JZYK#%VF$\ESR2-]E2LKD.77]D])VN8\7-$@W*:E)?3
M>-/NLII?8LM#'92KU5EQJ E=TVI]NPU&481N&LV$^W*]5Y[K7M']-"D8?JF*
M&Z5T)V(F.*U$F 26+A3M5;XIDT_'^.85!MG'$;5W=HN-^'FL9DVQ>)V:UN6Z
MHJX8AB&VF%)X!A4R-96UW0,WZW%;AC-S! !F01(/8(GD88Q&4#G';#OR.+A3
M8'Q[G=A?;^QGNK'G:2X2[9:A[* D<6]<PU9@VZ4BV@H#,,'0>5KE7VY62O@M
MK]#UK"$W%]!M+$#R9B/4Q P-@0NQS&,4YM/VL:PK,9[KMF-R#9O@J295I/9,
M0E*.)'55=D55!U7AZU!-5_:N0 ,H0JH?RR]B%\;A0-+74J2S,1@SQCQ-C)E
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M\FK3;U1U5;Z5MASC!KA8J)650I@<W/(>S]"BT3[.S49NF+6M3ZP5MQ)72Q5
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MEH*-9AS#,JTDU(=Y)'2D2$5TEDW+Q"N%84*(@%$*%<BL7-#W[SY,GY7 +[O
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MGU=2,NX-VW@$O72]H-^,(T_S<RE[I]_X-0Z6+&_1:!?^L9&+B'5AVKH7T:/
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M[QY*,Z$%[UM6-JB'[9YR-S#,Y@H,TP*&V?PS@V'^=$=!;_XCCGG_E6*_2V
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MPMDPIA"-X0LU\) 7":P2E+!?CXPY8,X1L*8  Z/,;5VO0]ER^&V$*58DW*=
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ME1]Q%#[<TU% ZI5<"M4([HW(_=6Y>!+GXD$Y6;H;MX\_]O;V#I"')61E68H
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M*(4_FSRB6G"ESS'A3'$*."Y4S$RG6UT4L]% Y@8#^);F%-E@-MZ"J.B'*3T
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M07GBL%'S_U9S&\C"JJ@%M=CM$HZ'I<$+CEA9:H^G6@FN:5?%S8@?9]/P,@E
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MT8DQ];A2;>@^1=["<O  "Q<^H!-]8G0 G3UD4%95%T!^T?W".Z.VN^38:%<
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ML2;'_+U9?!3Z@E9AC21GNSW#.3WV?@C4C'>$B&@D@NU%39,8P?T-EXPA"Z)
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M:S)$'6O,^,S"1$\_#>A)CK,1[B23VKD0?#_U9H*R\)%H/+7A&^&+3>(H VE
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M %M; R_]VKGNW%QTE8?OW6Y_V\V\)S\?9-50J*3H]!!R^QNRYA::93/F6WR
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M&P%_G@404 GV]*.KE9ADJV1 MKUS]A\BIFMV:;KFT=_/Q6)VF64GYE &^L1
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M=#+A0V^][S'S":Z7H?P:?)KI]N!9!;OXE8TM&A"L @.84\S=3&T$RK"Y4 5
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M2VXVFS37+P@V\QE#7J*J)UG0Z]_-9%%B*4FP?VS(\+XQ"+U0M#N^ X<R5]8
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M%GMELSGW-/IT+=M)6RC+W'H:!"O6MV]')9;+G9E1$:7]ZS6ZH_L*=E6EDCQ
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M*_!JMR?L$Q";!._V'$70NO1HCBUY)7EZY],$1( 2UB#  4C9VE__9F95X4*
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MJ-\XU<&)$$0 L0*C0Y'FFF[P&C3X*ZZ<W2D!1Z<"#04L%05C"9=0P!^,;IG
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MM!$3!;],+0Y;;L;< B!BB 4DJ&*E2?\K7D"?TW$T %'A VL7!KKHY"Q8OA0
M:">ZLV!]_2DDX1_Q0Y_T[#"(W SJ%N5PY6&_U!RFP:YJ][3=E?;$R0.>S%Y1
MOE6( V1\ U_J[ROK56+!/H*S3^X_B6K)$+<(O0DKUOWN,=]:]RTV3H1W *#I
M!KP9/M@YV*. FHS@4T6Q_J7?: 1AS-J3JRV>1;100A [-LOQQX.YQLRB]!U"
MM7A3%#0>X#%H7\QF8<C]IY5E82<U^<9IR1VUW:+EXP]\"XI8Q=>P%0./2S):
M)#Z66&WWP>+B QS\/Y/]IG[TC5*RZUSC&5LEO/CS'L0CU#8\XL*D-G(KTWO&
M+WP.(6<I''W)BF;Y=WHC_ [[G5A*GY9"^;!02P2^E'MJ41;IE<"_-NR,WG^0
M)\@[OT<9$O!K0/]P2X:MM)4X;97PQ^Q G 7:[@LUOE-[+&0L7UX_7,E?V$A?
MMH/-W&.+'K0^*9%Z"A!LH-2=P>;OJJ,VW_<?O&/>G?'"#&?@YYWQA.7*^-/]
MZ7]_$.P *Y1*PB>1Z3\HJ?A!I%^+"V=$\$GJF1F- HK&+&Y^11.N/6F1EG;R
M+MIQ19A(0I %L'.P!X]\S=I</6C>=VP%. V&'"&9_3X^G-P?2R"W#.263^7L
MI):VD!K=(7@T)R,;FFK.YX9NLAR-,9N)N=Y4D*-39H3Z5V%9!9O^A^.2M2E-
M\0 /(.0N^--_:@;&*.EBZ1>]6"J$"X<N%MN0@I11PL6BDE9.+G[RY\*3]A3E
M4\D?!4'DZC-T']T'V(_S(-,HW6L@C")+B?ZF./,L1S:UX.J9^?4,H1REGY5C
M32!MT>; 8Z^DUBD<PX*2&@+YBBYT!,;CGY8PNT-80,8_UL<D!%U)>,Z& AH:
M6*9QV*'"FYR&ECK5;'S08[0QJ.W7(^D2MD_AV5'6+#BTL%:D  U;D:VH8W#H
M!50]8GF./Q)+3 ?SKQS"+OH'&E7HE8F)+M:J')8&4F53Y1)-DO.3CMB+C)DF
MK,49GOHY[\3J!2AI[-HR"S\0<W<XIRY(@[&ZIVB^&'%'4U'$$!))B8:G;5<W
M2*3$8 >+_K VSJ%J.#]]_!;5T:"H.JH0M,W]$W#1S+!_&5T=NU1U2M'? -__
M:2R%WPF\.F,>WIMEW[ H^RI$:ONWR8WS0CIAIZLRQ.>ST'9@GPM3',QJ,%+F
M-+?2MX;O@F"M^.9%^.02[A]?(*I<::+C5*(F8G!5B![L/-(;*8)]%'4"%./T
M_T!=A8.<AO]5'PH9 E:AA855JKAH4P_&/V)0&-6-Y.-#N$*D48HL AU4G=(;
M^5O@23.3U<F E::$!M2S7M7>U#47PCLBD#N-3C/]!L8<O,X?9X+N\U@=L%#1
M81+@79(0$ \:S$56PX*[!($'#P[T<(AH_'YAC&/#2$-\]^^A8(H&KI4Q2Q;,
MX@ T$;;?%*B?L";YM,"M%QEB^==?@;]G]Y&T=L')>2ZX6>)=N>%1X##0#@V2
M&4UG7:NE!9:,+&FDYI\&@U^Q42AH:K-<@2BU%I<<&BPFL2?DI'!+.^GJBT3?
MJVQ2="3MDRK5B.)>""A>PQY1:H.\24+>C!OD32:!BR^ZP>G\8CB=O7.^0KW^
M]B ^>2 ZXY-=4*'<[LBHJ#]3J-@EI3\C[+:=_LP(TP]+S7[" @5/A+T=1Z<H
M!9XC:I/._W#NOB[ /YBP&M)W]ZO')7D^W7[[=(#.3RC*2^9KI,.01-6&H2?X
M4W%T'4QYC\-)0MGY4+>DF(5.369$21U[JC#L?9?*+Z+VC6?LY;-Z].A61.M4
M^"^)3\*$0V1&%9J^+ =%::5(_;X_C9XF.(NITA%_*33H1XI$U?SEQ4:_,Z_,
M_ZAF)31!$M,@L-DKE91LHLHFQT-*=CS\5?&'"ZJP=D'8@5^\R9LZB[5>_%G=
MBF!.Q-9 ')\^>!GQ/Q"OY+L@;(Z-0]VDV8/(YZ..U^*9+?F:-3?''?+G<.$+
MB,*Z.$57 ^N$K<-Q8]_!K\Q##6>"??)?A*C R,:]:4_\%'XX.4^Z0[%!%CTD
M'TF*^DC T>UYBIW>4UT"3,74:"'P4-EJ=.QG<6E.JI\=[25%A()/1B-!WRCF
ML.3*2XDY_BAW$A-D$/YWG?=^)[E@@L<4./[D4'Z-(^@H[H[JR<:1\XSR>"+>
MJ>^3U(L9 #;I)/G?Q)XL&(HAR97H^&OROS$Y:6*RFSJOPS905\CO3#XOBG1*
MT%@]_K!PPP.<707.QY*W!X+#\T+@PBG/PH0ZM6'(:,5;1L]7UM)<L)& "]?
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M8"\=50EU48[U1=*I.YLQ7U@.F[WA]\.1J$_UA=N2O^FF?+/R0&R<%W,Y?5:
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M=E9UQP0MJ[DP-/J:BP[LUE9M&#IMU4;'!(+7?1@&==U'AW5K*T<,VBN14CS
M4PBXH'^2F);98GYNUC\I/>C3&!R,AI UM,Y8$<,]22#-4'8-D;&B4F0]=$S
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M/S?JGF2N6JF%UQ"Y)W)/Z1>/I.ZQ\&K0/4E S4YXJ66#IWO, XVZ)Z4/O*K
M Z^I/5/OP!;#/:GGP)<-E>XQ#S3JGI0_\"@ J9D]V>@"D&*X)_4<^%H#D-S=
MC>Q?X_-T8D]3'9DAHZ&4S4ZO)($[%&_SNV#8 2<,B^;VF-VHC(YCBV5.-,BQ
M)C3IAAW'LN=8BI;_S%N_EWA<<A-_+?S OG]E/0+@&O@!M#(1OZ(N\U\@+_K8
M2&4T#Z#L\Z/A 'A:9C<9@#UZ(['&!&R0(.4;_&9^2>Y/NM8,/=M$/NJ13NK!
M3]V<EZ==9!KB"[F+3(MZYGWG:8FPL>R(DC;YB:&4U%LU2$8RE3)3LCSXW;Y;
MN.]Z;J>IV^S2TK"HP=^F,=50^ VAG]LS5;,WT#:GR]/4,C,@K=JFV;^JW(=6
MF]J39;6G#S;'OAC2EGJ49;8C'K/ ;62V&=H_,SV;UKY26\_)X8:>D]3DV=QU
MC\,.FYMVN^V@-=,W*/><I3O;4!\S-.VO)RM&;Z#GAS]:@F SB45U(:@B06GH
M@YXR8-CEMB8#)-,"H(E6$IQJRB5M"K- _V!DF#UYBZ*D)6D3<' J4,O#H4$X
M])ZAYD]1;0H.:FW>K]*4B\4=]IIO%S;&H?*QA*TGY50\A:0O?!AT9&"H"CP/
MBMY5DK= +I;D P/S@:KWAF;QB>![S0><FJLE^<!$RA%* [FF1B/UUG50)DOA
MR[2]J")O9C!(;5&G :H\TWN*UE6>[6E0MT\5U.V8H-WA9XTJ_-Q8AB^]&OJO
M_QRHBOFS+]%Y3N(R8"G^JSB7(N:Q:%8(TOHAF:G9#-4.]>2AV5.Z;B8U>T:-
M8ZTBQ3(8*#V]RXVMV?MI'.M^>2^'@^KUKB2$0L<TEZVL:4B2]/4VF*?U@\9)
MBKF&&Z\;2OX=70?:FM1O$#0#RO&>K-2DKW.3XPF?H&L8E#,?WL<L4Z/#A.?#
MP)V_E>0X_WFYFE0*=/R(XL](_3K^^7\<'DIG-IA-WTI7U@/$^@;\O0#.!+R5
M%,/\6?IJS1;HW]+A8?1CS(#ACQ,74<FW*RHBWMH"#/197GCU8%0U_3],ZUN^
M/:0&83DR;FE_F-Q_O/.?I=O7.=SSV+/N[,G/T@7DSY Z%RXB0U]+_NHX_AFF
M$"+QDC:;:'7G >O;X1V IP(^>([)GERO05@OHNE!!NUH'PGN(+\\N5ZTD16:
M&39BD*7/]LGDM,U?[D;G%S=7Y]=CZ?;T_:\7EY\N/YR?WDB7?_PIO3OZ]>CB
M2/IT>W+TR_'=:(=+NKB\A6NXO93.SB_&%^_/QY^DF]OQ[>GGTXO;&V9K*<WO
MYXX4/+H+WW*FOO0/Z5_@90+0T4.2]@VJ]9@#+_PO:6H%UD])B5$[GX0B&EKM
M\%>3C.4&H+R?(^/66X!UE7$-9DAA7%E>\'H+_0,_E/+^B>U/9JZ_\%:5'<E9
MGK(V+"=OUBN+0MRAO)0.I>O33Q#O$^EJ?'T+^?%M##H7=5+9A:/:H;""!^41
M!PGB29;G^D#Z;@>/DA<2&(HJZ*4 G^VFX"KB?;%\*LH:37E$T-YP/:R&WT)W
M"G@SVP$'H]O4EN$1N+-F%I3F/G'GOQRCQZ(EUPAL305'%!)BK?1HBW\*GT(L
MNX/>:#9?33["4^N.":ELX9](EE8*0)QO[]L_0+A5Z$ =Q5!LR6E9KBE'MFRJ
M!-PD5S84BRG;I531YZ9$E6'F4826X;%9_>C.X <AP[LHYAXS^IN(T:/ LW0'
M''!O!TO&C_]?BJ A"&^P01Q;P[NN^RN,5<'"/KIRO; RA&:S=17V5:VKH:J:
MH3'D,U5G4EB-1JH Y*ZZ:!=4R%00[A$5ED3(%"#R5'"5+>P@*:H;:#!XKUB4
MQM9"'$:5L!A5?I;<^WM[$@O<956V"-GVBEDE G<9[3L9P:$+W9CX'M_(#\"W
MI*I!,:L$S<K3>8#H/%3SD_I:0^<J;7;*TQGGI<@4.2DUU'CD7Q%%9J&4O@VB
MDUY-%!U4DTKDR#(5CKJ,<11U5G$E(5.%;#A3PM3R<\CY)%L5F5&%;.K!2.\-
MS*JE*!1M?+H@QNZ#&&IM00R409%PCM^%,:W?[> QX2=#-[]8)"/,RRCZU&0<
M0T%]=MG$,=[1Q.GX"E=41D6PF,46/S+?9T2W;FP]7-9>[86%YO:AYAN)N+G
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MM9]!:,M\@H2] ,$Y]N_1GG\%TP?P ?K\Z"_O<%L*N-B9Y?OVO3T)XVS.%)I
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MWA/*P0V/(25@I?!B;TW$D+"&+*]<52%M+]L&H+9+I O7>4X,;Z#!+&]+I"L
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MLUZ*U=;_)D6/3^QENOJ1HA[VE=6;P[\D5[-\,^*C%*E&),HI!\L7[I!T*Y*
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M0(-'P33.\6_-T5.4EB/7D+SDT3A7U)9CW;2,Y1+T?LM!;U(T<PFXUG+ F[>
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MB8>U'S$1#UW,J_WB ;5P82H>Q NZ\0_9NGA(@D8M'I(_8B(>Q(N[B8BT:I9
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M1R_#9SB(&.P9ZN.^[)W&Q2%]O;%NVNW##3++I?="?(_?^P9B@@83B<C""JL
M,2K!$5WCDZ3WI$#$MU(B<-I 6NJ8PE];/LO]0L]R'04YAUL2H.3($CVWQU(
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M >975AVS99OM^K!NFZW\"U!+ P04    "  V2WE8+,'J?D\#  #P"@  '0
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MS   '    &5A,#(P,C$V-S Q97@R+3%?:6YS<&ER82YH=&WM7>MOV\:6_RY
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M=I[)8>I0=QBI3'UN !L/;D&1P44A#*P-,P\<SW^"H<$?5-I6KSD:.E3L([V
M3/S$H-/["J]-I=X7GEU5EL(=YWN7:I!K4W+4"QU4@ZU9;',LF%V%:M:RN2@Q
MQ1U%T<IFLRS5Y\&%:V&3*_"ZE?:12NGN ?N)$(S5L" W4;EJ\X6M!U:L7PI0
M!USIUUW#WH342[F^)-WD)-GI?L"M[]J:*^X<56/G2T^FC6I_8BF%8J5C 58F
M32M89MDG*G\%+8Q4]TQKY5_&*5NO%R)U;>XMUE!_HD6XFZZ<53U5$Y/IZAL-
MQ'$:-=I4-7&'4 @N-13F7/-U'7HU#]5*+22$YN^TEX;(T4"G)&R1+V1GCHWE
MV(::[%L#):%7?RI4_VAJ1Y>G4N<X#*PNSK#!#A@==M[@U.1!\27LL2A3-WN(
M6.</Q(UVP8NCMK_O "3P.[[5#6\];(8@14<(6X =PM7T2V %&YA7!$'22%84
MKC5)SV;81E>:T"3,[3RBCX5%6UPV1+B\25G4*^X5GVA$E[52651Q46DV+4E'
M4NR[2&.CSG2M&1RB6^<X%KTM$DF&TU+X*I82@91\349Q@2SU%P+XP)2D66!V
M?-=W[2M,PX%O2E79,XN5[(,Y4&H.2O? U>#9[GF6G%/%]E!@V%4U:)&:M7CS
M7!U;Z]Z8DCFG$A\%?=./I_GQ7F+K\ I?E;]HENVE+"TU[']2ZMBP=?F5H0->
ML5GCJ8@#G.%U2+A?0(,-8#LHJRL0ZC6S@3/R\]R#1(.\F5'NJ)@>G8YXE:+\
M7:+!=.7 ,#0KP5O'" S%E_2$*X&'E(B+:S8$MP'1G3UL+G=?"-1A2RL#Q96L
M\O.8=#)O-L0861VZH'BE7!/$)%=?!>3CH7(1"]=9:)Z@^HI!19-390[<UUP+
M+E&9A5&5NS!"BUYU6=&"L\O:')H-9F+>!%'S?$1.=;N&,A-Y.-5A57JER^,A
M0D1SR"=SUH5(KRX"< X>NR(, C1S_8H:0$2I<I%GD[@H(!GY4@(<>;@W_NX4
M[PC-)H&&'M2,V%EGJ#%5JIGVKE;4:L_J$"\5LZGJRSHPM-7@& 50DOI$DJ^4
MQ:W2&X8Y["?F@'1=*=T=P2,BI^I%!!+<@97B?2'>P^Z=\^V];.$T/>^B6_M$
MM."T$\>)OBR;=+G0+-S=YC(;1#M2)]IKO@([6\'0\/G%+ C2GMNX=^&?>"01
M"SOFZWGHV<6P4R17HK,6=>Y[2_)QQW"+& VDL&=;7'@"R)CHZN<&<38WJW92
MQ2[Q,;1EB7=BJ+6O<L6&2AT>=K&_=W[8W;";Z+[I@N+"9_?UQ+]:?<%OM4:<
MLIQ5!5;47-5!VQ%!KZ2NTT$X88M=K\P5UL5(0Q,')141[<2>U]% Y6MFHS4J
MR<99Z;MQ4[5R;3?>W <9>5_:[A]<VHZD7X:AXU86?B&DLVI< !$ZSA+ L!&\
M4L>HZY(3*VI)Z#_^-JIG?BW_SA60=+OW2#I!TNW>(^EN E?V*LMSQBH<TXT#
M=\\)>?$5S0*S":M.KKE_$BTZ?YD#"LGPH@?R_:.QIU8O&><BZ'UF!OL)$TXL
MJ;3@9;_G2R>PU::]4#H)-IUR[HC:H)03W%1%EY&X5C4FQ.XG;(\( *$KCD,#
M0?(P.0)O+12?Z/_U%/.I*:;UFJ%3MQL:TJC$X=C)@Q>#9^B9$]2_5L1V1.KK
M$@JVS(&FDXQD$?%IL>Z.K36V$3J()#S<\+HW4J'&%69\CK.YE"E<J1#2==%3
M^\;;T,E'Y\^[_B5 E4UXWF0?2[)!O\=A*XY\C1UFVM1IM<%]V_6%XQK*'!9.
MXIA%A34%8GRS\^YVF/8DQAO4M?A".6VZHD!T3?%:V;7WB+=1<K?[T+XX?'EX
M_,'\2M402G, NB;%7.X&LBN8>L$^)T:$4A ]J'.,Y996ZALO9,VP+C#^5U:.
M0KYC\V\\9X/'=!7P(.+@Q]A?$Q>($_K]EY,R SWS5."RD3DZ>HT@8RPV%?82
MWF&\LF=Z<_&6^9":@^H,><%3&L#.2H<'8'> $9::9L?F>SN;@WZ9X[=>WN%@
M",*),7=*T\_RYO0C#IMK[BCBW?06,%VNE>$V)G-PZ>M^=OW>;UFE %/,.7(+
M<M#.O5M@Y5OVRE[>AW>BTH9#:^'9('<DLB_W>1H/@<E051A2:+@DP$<WSW*\
MTAB=Q#-8]X?OO%N<4 &,V'GC1G0#MWD\H,UYK A8=;:*9VP>IJYR52.Y UB
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MCHX#EFI33T.A14M;-T4TSC.).&42EHD-505A$/,NS!4R!,-B-K7B.]M@P[F
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M>W5;/(O8R*:%NXFB,I\\9".[P/;UX257 8LBFC"1*7*%%:-"KS%)X%ECXA\
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M1"4SP"?LA>01BY,8AXPDK?1>9E,VD3%\P!^52!-EQ_J< V7@6)K!"1 &]HF
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M%PFE6MHH#DLT)G+/_<JU%AM7>8,II%0QEFA$V)\P -;XUY[<KTI_OGJ[6 C
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M8#V:3$8Y"D '(E5LG'&_YF&]-M Q518 R40K,_X)=@8E5*5D5XE\7F;? P4
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MI!+!U!N)(7":5=V-KW=VMSCH*:^VG27Y6^\&E0Y@[5@RP!8B!2A#D_" \>%
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M'B_<,&C0,>BHK5U"4;LIQJ/JR?X?+X%H:$>6P0?L_]Q06R)I!RJ*@]5;M:6
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M<-<^>]3U'2^B-JEOC\ />Y!K:S2J2XKB3XHX]P-BU#$AEZYV;\DB=@)&I,'
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M2BK)5PU"(78F8&HSDO\?4$L#!!0    ( #9+>5A0_ND_T X  &J[   5
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MU@0>Y.EA(\\/U*]VSGU(=!=00H^1EU E.2/485&6C<YX(^F=I2(B+9BD^7Q
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M\[/%FI)@<TR\+:DKOK:F%(/.N@;5:D>O/)C^YJ$TOIYVJX]FJ768KFPJ-=?
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M,SUESTVTSGX:S])D%4;>'V21-5#.6,]3L+.TZZ/GTR<2N5Y,KB//)3>LYLP
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MV4](XGA^#,SNGDS%#^)M,FA6B79XCCF7[^.!L_:^>IC;>OMZ4S-6EE4"()G
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M9P1%,N6Z*Y4A<AR02Q,E@B>B9#GV)M55J934(V;04@(/=DGE9#5,!24J\":
M)<V"&$K8J#FVW:?#"H:C+HH6+$CK)'/_[ATZ$KL\I_KDY(A$K.->7@9U]R?%
M;?OLT8D65YNL+,YE&&Q)G)#%9<KX+%Q0Z"T+BTN;44)]CP5-5F@QXXS D9SC
MHS;'K$10\EP+8&:/LN<K)VC/I?56Y",#\X0>(JI8"H8JVI[2!/76-F1X93/P
MIE<[V'8]D3NF!Q-VRD\=GSV40S&\HYF;O0(^8U)Z(ZW >CYIO"=)ISE[>(C(
M UW#YW0N'G5TW6PAUV8_%B<#8BH6*R8.Z(B "%V>@CTN*YYM1O%YD"><3L9
MM]B>GH(.(DR<].ZA^'\YSK/NO X>M*$^R%/?-3V)_ H+;8+YS9:9^]QURSP6
M9J?@#X\+L5)]?P")8.[F-J0SQ+O6%FFJ!=XFX2S8E5ZAB'^%.I AK[/3)Q*Y
M'OV*[\<.;BGW^9G&CCZ\F I%^Q$PSW, _C4]4WOZ]U)<S?'@55U'@!88'WYJ
M8W4R]?F=V'8^$M0J/09N5S>XRU)-?9P^YXZ]J5E:2T(L]1*ZV W>XCL+HR7Q
MDB[O<\1QJ7W.IZ&D5F1:*F;W+=4HU9)U8'PYD52M24W",Q@99I6:BXH(C<B_
MK1;J1/Q;?7XGH<6C0ZW28V%3M@GXM]74Q^G?[MB;ANM@&Z5*+T5W5".RKZ=/
M&R\:46"UR8W5M]>CL8Y[,BIU#/HB"9/[\<=4%=D\Z*2>5$ME[;YL&KVRCM79
MU.5V:EOX*$"K%%APB34!/[.8]CB]S)*YR=E6*Q(L'Q/ ]!!#7FZU[-G3[/\?
M.;X3N)UM=T9F8GNS?SC>0^A J?+2VRRKU2'.@V48K3/8G/LP36HM=^KO)HK*
M$2:==<31Q/Q)W:[8R1V=5)05VL@%<4U1K^X2KR//)3=,MGLJ@1HF[LVD:22^
M6:C$C*^CYWW.,(I;(#.+990Z*V3@ZFLCSHXL9H#2OGU+(.XL[8T7?T4HTB$D
MA?B.7;E0QS!KF5_AD(<^2E/7'<ER/YS3KU"*?0A)#5-%0E#O0T7S^;+B 8=3
M_TM$$[SFAU1<%BM^0 H+I:1LYNLV5O[WWVL4"N5_R9;XW__7FS>O_OO+I\_?
M_\]__\O=I$^_!-__N/CCA^W#+\_!W4GZ^/&'Z,<??O[PV]W\.?9_V+I_O//_
MF;Q-;LD___CANZ]/[]V+Y-U_G9U]N/WY[?;IZ/B7=]O%;>1$'S?>=U]^/DV<
MV>-?_I*^>W_VQ[OWBR__^N6OQ^';=U1(I[]<;Y[^^9^;=>I>7@?)UY\_GMR=
M__&[]_E?\X=5NOKQAY/_]]T_PNOTDGSXRV__N#YW'O_L/W_Z_9?MST]G_NKK
M_2]'7\[OW(>?;\)_OJ4"V";QYC^3NP]'?RQ_N__PQ]5O\\]?/W^Y_6MR\M8E
MP6<_7L6WZ?;\+^^_NFGTCWFP_.'>>^MXG[8_Q]]__><'_Q]WBZ/WL^_?_]?6
M?UIZ?U[]Z_CD]/OYXZ<OU\?Q)R]Y"G\[>_\V(>'E^__\_#FZ^+@Y_N6/8/O'
M[..?@[MWY%]7WM&[TU_^Y]7Q[<V;-]:>F*C8WNK@U*%,*D6@^BKN54#,=7?W
ML<5#:A^D:[.'K4W+(S9_#,VAWGT\4:AKLY?7LC"&^B]__<'$%M<^LUMER0CA
M^J2EE1*,H7W_%P-@JX_L/?8S@G0W6:R6:?SHK^&!MO@).WL4$;-69*SQ"717
M>*M3L6@.!XQ)6%46M;*Z>E:%4_U6R;#POGO1*M"-U@A+0CUE06[ZQ^P*?S0Y
MPTVN[.U$ ]L+" FJ%%XZ5%ZR.)47;?M&@;"*!VC[WO BC.-K"C,#X=CQW=2G
MGRSN8LH_G7!K>\_K9Q9]+V+#FO/M=J;=#,P[&"@+>!JVR("@:/Q6[)(DYP&5
M V%< )N3YMBC:,P *-WZLFZAB%;S/.<$>0/8\TAMF66N;NY94ZXK"5V>6:@9
M-0;H)N*YP$+1HSV*3O$XJTQ3"#@]NDZ=B.7E5//#D#B?ACUWWTC[ZY+K $WQ
M6F#2#LFOU_2? ?W3Q',=/S[X)_V6VXGGIWLOQ, 77$GE)?LLG<BJ>B]6E^4-
MB0F%DIY_%B=D2_QPPTY%]-!/SU2-HX"1UI6CSWBC\Y=1;QU4HVF\D"Z<^S"B
M8]^03'V*<8'GT$'$IA.I)<KZ^N@"#"=I)CO.9R2;]*#/9-UTK#XX,):2 #>\
M;AHL!I37#SQ)6<_9_#%B;G+YL23H<YH!!_;<1V/A&@$MO4S0=[[2>[>X< TC
MQ5<8S4\LQC:UP>=.&?0R?G>?O8F(F[=DO@R#310N4A=AM733F:;-$^"F<L=O
M)*LB%LW*4] ##3W+>!LG=_"JKLG 4E.A.$WY*6$I+VAO*,ELQQ3RCN%RB E.
MR3[JX*A2I!W\?#+DN<2FY-05N2XV-8D)GR_8[?'N^"2FI]Y/3O25).P98<\S
M;[MU-1M_QAG?M &\=+P^NU(4+DG,,O$=_XS ;T'MX8?WH4VET]AO]E""SL>N
MEN1RZ;DDBA&//EP28[CT,!(-'S#@-+6VWU&<E.?AW'GZXB6K5>BSZ#UU1P8Y
MO!JS,='59XRZ2EJ<L0=X2WSZNP?.;##</P&U:4I5BB%:H[^AY/;B1*8@+5EN
MO%7/[R,)2,2J12QFBS4EQF;*'@/L.8#:WI]LY!.2.)X?J[-RP2^CT.$L(I(W
M?%H&SA&G,,)08%1E#@:I<C"0/E6!2BQ)6:MMD&<\W2;4'+#Q+]@?,V'!ES80
M44*[L9/6-1A@_=4W!2'<6,>D#J(H]0S$M 9X(2^H9J"@ZPJRPJUF("0*7LY
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MDSW-BC_2:1Z1)?V#N?.D%K-3'6P,V<\&:TX=+/@GG3F[Y((X,6EIAF) 533
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MS]&A]HN/] ^3^#S(6XMCI/1C<'CP!WK)5Z6Y\K#!+RZW8W)D 3E_Z8Z"%6T
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MF6<%DV6ID/@\R!G]0EB-$+*8;4GD/!!!X6"+&6E&S+\@7;,E?FE[,=.=!*2
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M'LVL)0'8O-M/'#D&ZZ$)@(MF #LT$" I%I6>&Z<<:UFSDR=]G2LEMTC1$<B
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M9U[9M:78-&GDJ=%7I#]DHBL_AHX([4D@.YOLLCW/;*_[A,4R[1)D!@^F5@B
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M5@3F-D&B;KF&>Z9LTS6LF@R@ :*1T$_]>(M$_2,H.$Z_?"<N  $"B83U%[!
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M&XL/\SGP2^[I&OV%_#3?Q: ,5 (W,-FAS<$*6SX_( #LO*@I<P%F4[5M4X]
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MU);#[+4I^_[SBH')M?.$@Q&QH>RZ\0YZU$CLH=X]5;&PX\Q1094;:)U7HUR
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M-;FOU?*7X0/>!.:9@8,-BR.*(8",&1=;"%"GXHVNM<LR"!%"\=.OLPO.995
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MHG@86=&<W$)$81T^2VKD'XU#=%#)T0P@;*U)M=S#21Q]1ELHH1 T1QCW*#3
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M+7HPESO WC?PK.]Y5@ UP>%U"/O9^<UB&=TN/DPFUY2*,D<42E03 #P#R*8
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MH6JD)R<AM8@=1RNVNF.X1+M^\,CNA62U&IP.V>K^POE2^:GVB;/I<>('F0(
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M2ZSL!@A";7M#]--9]%11O@Q\R$(MN>#<7_#<?@I/C/B8P=<IA0%D\GUSGH]
M:F=.J-2VK0^+*OH1]<J[M7'GDV_HD(=J/)%,^19*?5F$.JF7@X:VYS_N(*:]
MHL?MNG6QV:D@%4F[8'2IHXEIN'Y4;]N4!>\(H5,"R^14'LJM!F.59T0_]#=9
M!8_\*2_X)I\<6#9A@"2!9>/G&1%8YG8J]5]E$=7],MTQ,SUC4GO2<(C)FP.+
MC)C&X+2199\+,=VO5=Z(2<-3OVPN;ZY'1WZYO4@A!["R1$<S#,9""8X,E@HP
MB]2:.*JN\-?27\)T2FWFKV7BIV\D]=@3-HF!9"J&,8G>E3>BSP<QMZ[1)FR9
MM*[JNY*9]OOVK1G8)>.([!W,,;RARQ@\Y\]\6S[!M@'WE/QA"%[7MF"V2?*
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M:XL803%V9$8SC!C5WQ;] ^T-2@GEQ4Y,3L]27+OJRE7?"2)X_>[/ILI*C0L
M1O,:[C* +2VW6R=_UXL,ZA985+IP.RYK!V;WZB73W\NQU;W9CF6M'4FUYE=D
M(K:E7GW-YA(3?J!I,ZAXS,FJ.<V626_![+A*8JISZO@"7U7.E+ZCH8J<'AK3
M2YPQT09_/N7J)CC7-M+7BA^Q ['S/6OS;.38T?PZ;N 'LA3$URM2TCRN8GBO
MYOL\C)L!>K"E&R2?\D@;<X0VJ=Z5XG7^1]X\ -Z,>(:A'I!7Q0K8;192EG8Z
M6N"GMMVOB8_J5#Z$3#S3>$I:M2<48K"/RV+4OO$XO :&K =.8T%6DT5>3^)
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MN&.8J8#++9;L"KB"Z: $7.4A]MB^EKIU2X=N-S*D*[&=C;K)2OV1?EL2W@<
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M-H[#/(\VQU,!P2ZMU3FRK 6 .C",Y+\A>1MYYO59$0"2_D3X>LEBMF4_Y=/
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M*(6IM:3SLFRI*$#O2:UT,Y[U-F=_:*'/:!4VFK=H=U.I9*55F3FP2+NT6M1
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M/5S">Q2LT6-EMQ/C0$T8EE':RAQN,9NJ>YRF)[T._+1(V,HNUX2/>[XH<U[
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M3U7F+F3MJM'&?ASX<4CO$\Y;OG5\<![I.EG/?#]QO/(O(T;[Z7KC!4_$DI)
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MB1C42/[1[1P=^"E<*X=*$S[NTYP:UYO,T3A9?LI,Q">QZ1O;-YL;J;_966[
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M@@'["&G9?#[IL5)]4V1, MMN)ZHIG>_=/-.O7&J$!RR\CZ1HBQ%("T(SS(O
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MNWE44FO\-TI9F4U6IF:F5%I69E9.9<H^'4_9<(S3I#ERRLJ!E$S-"=F5.>7
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M6J#;>I4=.F;[2?2:/SF_7&,53D/F?VC-SJLN$[?R%'BPL19=JCY[16'C ?]
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MY>&E)\]A7R+%VC0!,,R*)W21JJE(;H?7ER(-_$?&'6'3!>IP(UNG[@HX2GL
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M>:P)ZWYAATVVQB>#^^)%%0IPFP?+#BZR<?6(+(F!W^BRG-@O[_ZXBDUZB@G
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MQ."^]RGARJ_3XBB&X.<3(D30R-G'$8/.\***$4?S\#:TD0*O)B/>Q@?9E*A
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MZYMM(RQIV/5+J3]>6#:ZIBJM6//5,ZQ.J?.3@1WQ^\%DOSKE6?[,(9!>3Y5
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M>LB 4F.T,GJF@[A^ W9?&L64J./8 MDC',Y?1J/=][7W'?CN<7=O!=187@<
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MAU(:K4_:UN[]*J']L7Y*:?"^SA$X0J@X$((2@G)( 'JL/#,J!H!$M)@;ZDP
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MS,]\FNI0UY>6OO(@;[4@$OH7IOLO8RG16H:5S51G*-V-#)'LY*E##\(D"3+
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MYJ;=]4I?P"-]PN0*/QHX;EU6FI:/E#$\??#:.^GLV .K_J"R5QHH%VJ@]=U
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MZ0[6VC1L]^8)[43,0G$TIL4QL=P=L'=-<&38DH/%T:/Y10VX1&/U"O\ME^Y
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M:<",_FQB!$Z!S*PN<>+]^AP),CDDXA>LSQ'QA22F5 5ASTTLV]#;W\%29R^
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M$),(HD ",VH,Z@\YZCP83LM*C>[@%-0!C]=LWXXMQBN3.K[W);854Y]JG_1
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M:R2]%Z]%=Z[HO6E[>(L5S:[X]S/1/JC-XB$+QD4MPACNAB1A6N*'U[>Y 3O
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MPV]U=NHE647?*84 ?J&VN\VWD+>8I5*;9/81\7ERUU7]9;.;C=3:7PU; N@
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MQ9UK'6,;<+]!^U*DZ6,UM0,0 =Y/OP)-<G5!B<Y>;F#\?DF)R2YU^_+=T2H
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MG"H#' 7)(C_$[#B]&Q[BJ#%DNOG0Z!* 0[M!(D+U8L=A?CP]\A;E7X9R,B(
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MF5^Z_-']S+VG3&/4^:KIY6O\?[K'B!Z+WVV6#N\#K/_L^;:+/S5X(4F/MHB
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M!WQ>>7^-$A3]Q1Y#<A9KJ!]5Z-FZ.Z9X6STKY">9<8ZV35H@G4#XS7.-ZQR
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M08<*FNK^5_/Z_\..''S^/U!+ P04    "  V2WE8*/SMVN-!  !;0P  #0
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MM+;U]0\,#@W_&AF=FIZ9G9M?6(3!$1N;6]L[NWO[J-.S\XO+*_2_Z__P>@#
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M7^8]K1O'HYZ;NRF.#FBN7UU1%1^ E)@CO9.&6\59DB"XW?:=TO^RE_K 9'<
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MX4?WMHRQR(KM6Z[265OSF0YIE7+0*<LK'JN2+8I^:,YVGB#'_NG&<>%L1GO
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M^JPG/VHPG^$.,%U5'-J"[N92FE<T65@C";%._D!6>G'KYMW]($5[O;3O0R$
M+?/XX4>)-=.KRWV"XJ#Q+!T,(48$7+IC1HSD3D&:PX6@F.=SW=>&OHJG4+\Z
M-KX#R.8+![K9O01LUD<R6:H"7)8+5'[('6#""'NO4>L1Y %@I 8+ /+O8 ,:
M0W%^ "&7QH*\Z*#K2>J2;2T7IU5=N?]Z0F6Z.FO-UX0P3P:LL80;R)UI+"4H
M>C,$!.=LP;9BBW+_$AS</M5\@_]?P+)#=1^K016&X%Y--T9,V,VZ>^]2HQ3N
M1\,.>1L#C]L#D5+(^B:B.[]38C";*R*4#>:4C?TAMO)2@,+9OD6&<BK8GN6K
M#P]6X>]%&5NM)UNB,FL+^P@):@"GKB/CE@S<.R?/#UXO7GV2(^G<O=@.CS^:
MYQI%^0T0>^PEX\ETM>R(8]J"]5N?.+^1)&WC^]Y1,Y%5[D2DH)/R-WR:3B:C
MF*?<Y[GF=*FNG(IZABZ/UL^LQ9^%TIX>(3KV#Z^5&='E% -P%*T_0EA26:^8
MUV/0DDL]G^_Q9JKNQPO>R8'I! ,C9/JN7JSK:FY;$,T &":WILQ,,2O#?)!/
M-G<QIEE94NM:CIW(?X!<EC9L[Z[I;LH3*H3H:I O!S0]J:18V;M4?-]L*% 0
ML][VC6P$*X5N1IA'8]GJ9CO>P]@EFN:$]U*22-'NBLC..#DW^[: HIJ_52Y'
M-NW9"(2CF[LI?0 Q'@F;CNXF5]B9;@OUM6]"^7Z:ZF7M4VEO/\H1K@77A*/=
M^+>NHJ\,#<LZ6G5)7(_ 8&ZE:*>SLP";J2CCH!H1HHSNMR.[LM0F.(_VAC]^
M5'AEG?BQXJ@@LCCJ2RY%:52"@=;MLC7=J72CLVIVH$IQA5@QW\\^D7A]B 9W
M!I"H;W[8NIX+.XE=_ 84?__^MEAYY@L'4)#@053ZB\DR>C&=CZ,>A;2\]15Z
M%^6AR<$DJ*) M<\S+AA=YJR0XE';:%$U_.$\1D&*5[Z/!U/M+.*5;:T6;6!&
MG1.&M^4=F@A)L9O7;\T35]=4.MJ"K$OW,B\_C@3YT"RZ+>E2VX;.<PS6D--M
M?<E+'"#'@-+=?3R^&^\U4[R\>6VV=O32RP =.?J/P>5C!W)Y&+\9XNCG-$_H
M[N7N\_1]6@S%R^1W1V_]NW3U3HO:U0:H69S_Q=#^2V0%Y"8^%I$$H";VI>QC
MZ2)-/Q6&]:DTT3]1D8Q0I=)4?+(W*E)25"CN;L]=6JQ:6KZ4:A[FP35YP_L;
M'4Z>;;=@(L/',$'4(F5U>L@'_50:7?#[-D^7<+1(^&DM\QS%SY)6WIO<KBEM
MT <9SF"3)!.T+>)53DX,U068U#&4T3G [)5QSM*7V:G+_<.!WR<?F^;:1 I5
M#J>!6G*'<D-O_G%=>M[6@AV2%BVQ(GN0^CO H*D[_#>8'H-?@0&B%J>L:U-\
MQG&.5P_&W@A558?V_C02N\(9UJNYD2EVR,I2=O6B&.<,M9C!F)?M"U=*2,#B
M:X8F6-E6'Q)-D$?D?-4P,$QCPJE_$#9NZ&MD>WN;6%MEX !;V<Z![U;NS(N_
M>CVUN/MW7\+1TE*P[&,FE"G7KWEJV-[EK([_2H2=)\NBM ?1!1Q ,5N_9=#*
MG=FUQ%;O\,C^^9'!8J^G/OI!W?-JZJK5EO8/YBKUYC$.LE0(SE@H-@J5:R29
M8-"@WQU*G^4E(SN<HZ ?S5-NTRR93LV0X)XI4RZ5;_.Z>LV 58,::OYU#FPB
M9,^WB,Y-56;/+SK5>#UN&<RX,T#_D_$$#=XH)GA-B)S=?G/P!P D<S?:]0XG
MOR]QDQ1UI9?;91%^JSTAV<#4T9]DM%CR1&?<];HLE/AI_%8'X49^YV,@7^CP
M]#3$A1Z#O$VZ_@?NN94Y$4&[WP'83CY=6V,I)DA#0)M\CM?Z!TEQC^C-&M,^
M7ZJN*TL" CPW4X, (B$ Z A+%-$:,A]-<G$'B*WOMT^Z(8*%\%U,&\'Z;'PH
M%*[(AUD9X9/'FC;Q5P^R>)68",4(S['=U6O((4C/JP.^B7 6XJYA/_S)1F1&
M7N-$"N_(95"*A_>1^\OIF]8,0\-"%Y%(O'CZJP.V4?M6\YU4\'/SU.;YM2=@
MFY,8D>5*+R<6$HQ\N>EXL?)9'N?VW#%"M54L)Z\]36.V$CA_NH!X$[,S, UK
M^ 4I67O<X0=?BS;"AT1W2/@WOZS_8ASG:TL3Z#/YQFSJE(.]*"Y5<_AX)YZ0
ME;_TDWWU7I2$]ME(XHRGNCII[\E>+_1D&/O(G?(^L^ =HRU^%Q%B=%'T-NP6
M(LUQ0FF>U]6;EI 3G%?Z2)KBK1-.>;S,Q+^"#Z0$[6EI-_.E??>68^\S P3-
MI=]'JKVN<:AV(QTL/E]%WS\@;=]_\-I]X*7(P/.6FCF,?5#(QFM%M7:U<OFY
M- ]H4X;D1U.S,4LNB^]D#;L_8@'<_P5W "ES]*L(ZF$L$1/RQQ6>^,GAR/J6
MP$(<B,4?_6""@#G@HG=(Z6%W9G>L=&2"XX; PY# H3.=20K'TEGO%>E_8DL'
M-V1'QC&" J[B!&';KWBV%!:RA-RYH_,&&6*QY??%$25)W7\Y=YLC_@3@JGKI
MX_^M=8R8+-H(R7B^<<0/V"?DHCW -#B]&"L/MD6[%O4BZ\ )649'@T/?+)'5
M<U=&-1VH*FRAET!C9H:M#WPFRTBUWP.H#2-^M&K(%2L)DTC(<]HKDT[^D 1<
MAH\\UG"<$'0X[5]</#M3F=QT+"M!3&M9^>S!W6.K>)\41]X!'"KX-;AF"]4C
M*M0-DIPEM2^)Q#8/>-.^, DYE'(/J:O28N="A9#=D3Y".!@)Y%ID, '<^(:O
MW5' ^\#A1%Q*4)P6*.Y:YM1L-/XWZ*!*_T,#<BC/T2> /]+0E:1&BG<<DA.L
MYN/X4Q&^R'_.\ACM2\Q$/ZWZ8E=T0F"U3*"^(<U9>KV]H_T.$%,UF6/ID%#<
MG/94N*J.%J9XS3#(S('F6I]X>A#Z!!UQP^J\2HZRC[Q0/D\B1[OM($[B&A+,
M568J?9Y?'DG? =1F&SA;IZL+&B@<3YY^SN/0:;6@;=//P,BBA'KS_.0FGZ/]
MD&,#H0]1XDT%08+=Y4XR8LQLDSXA@CJL?5/#*D'<7-/N_,L/6]HEO(K7[1YR
M-W$&UAHLVW&E9HHT.G7K:14K)"@4D+#KW%[K_)3+X]9,V'#4CI T+/:%S<__
MEHQ[,5&#)JNV*K.J^?I>)%&748#D,0-^5-^\]_X=H.[M@X@"!6^G0>UT^PG3
M/[P4NMM=@FOPRV_B._T"8+.9AB-WK<;)8_:_WBLJ2XIH1\0*J+]-]]3$U-G3
M!.ULGH>Q=>2.V6RMG?<.$J^OZQB(O*33%89?;_H*[W4QW!!<VD2["#6;& 6,
ME:WP[F?QX:T^CS7<3F12_D[^3]FE=H ?DX>U^1:X\S2#(^4;,8\>]^_B] L%
M7H6MU[-UI2U%U8;CZA]2D_@2Z+V+CI=RO^_<C#3/9VJ64EWR3,>[3<49;;<V
M\H_AIUFR17C;9JP71U28^?#,E,64\587E?-HEZIH%B'*8'D^1AU<Q(J4O$1Y
M]."/H6/==2>?943[U\WIT*7W">>'O_5[=!EU$FJLKXX7YI_4"R(^0C1TFC,:
MO!X(O_&<UM%H6ARGBN>'.4:+TMG]5CWC[!"C_8_VT4N$"_@0WP'(5M&9_X!L
M0;<_YAP)(EW$;Q;/I\L-OU&O:3DGB!GQ5O[NF]O#_RW0@K/J6_U+?8199%^S
MZ=5S[_MKLJGHB-[H=:RG,GO Z<K&+YBO**?^WR,VM@64O%3+7V]>A0R-R[:%
MKXB0[$@!K8K[L;7(4YI85"65T]DRRMCE_5/EE%IA].-#?$CN$@A>:4[\<54Y
M_>,73Y.E!_KDL0B7VQTJ+Q[48]']NK$:GX^2)NHX"<'AQ!<\"DVVF8K"XR]H
M<Q'I7D \D=V9JB]@18=O=X!(C_FLEOE&BT"?&]['TO; LUP/@V[<'G?JWZ7H
M#M*-V6-I]%OMUQHU1R?#7HT%J6![T^"/. >P9):$7'O,QA)J"$TMX3\XXP7!
M\\><,[HB[6H6=Z!O$T/VR>+N ""T%TT/\],P,FI_$9]YBQS=FED@1]7:[H9J
M=X+KX7'C:RJXP84?R+*MY53\E50^[0S5"KO-<7S:M5\E8[U0U2;=U3@LE':[
M&X1E<):0KAJ*GDL9YLPN[*.&)3]>]<TH=\P^^7+X3/DH>B%<.Y)%AE2+DR^
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MSH*MH><B(\#4-[49JMX9*!Z+>-9T(::B ]AJ&M-@5U;YA#7I_C_])Y6K)H(
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M"(TZ6Z> ND'P."C)2 5[TZ2J%*2_+6W"SY*CJG_,88R_CKV*,)_+(4_YAFP
M]%"&2+RIM=RYZ_EMM9C08[2&8FU+)I@\^!4R*TXM'UJQZJ2OP30XE[4AY3U.
M*2_-NZL/<L^6?8TM+3-5J(FNPAU!=2<TW*\^QWS>.7X@+D) ?S"?+&R3E'B
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M9)_>>=Q1^+=#&6[T3'>FWMM3R"!+U"6,G=J,?;(H\4!^QJUX>K/ELQ%'\YQ
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M"US7)3.(2IO'DD.C#.X _65PZ*[SP=A?:M3H[ZINK0;?"(]3EJ8APE#EU1X
MX=";7R:G;\[_7J?!U7-AU<U@1P;\[(W^Z_P\W":BRNO)*,78MVO"KY$^O7^V
MF/ANC;"T#A_\S>'0_C528W:/)32X!_MT\KE2BG6"U=0Y'_%30GK SP(+6EW
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MCV7S"FJ"%*5&LVT<=Y]2M7%-Y[T<(!L.SP^ LB*_C23GDJ#!.J^5#DJ[ 7>
MZY:)QE"'*_OSV"D>7^60$2'M7?=%$\3$!LMMG/GC.\"%D[_-_.S5X_&RU; 7
MM4Z9PD,]@H:ATPPU["1X).JS=BNI!I]>.&_> 1:ML:]#7R29D_XO8:Q> 0LA
MH950-I].1\.4CJ6;9Y^M8;O41R)TG_LWMYI=EPF?Y3[XQ')QZRLS<YM;L_JJ
MCK]7QVD5AX00/M!-T<%& 94Y[JR=L?&!7G@V=]4D\W\P,_KU*[J=PO];#Y%P
M!FF+1^(L5A-2;R.W,YPI?.+M?C01]<!0"<\=7;9>Q,[\YCEM/CZXS+<*SJ0&
M>^M:^1Y#I=M5W]BE\$]6;UF+3CLE2[C%91-'\AG=?DB@ICF=?S^"+*GKB8G!
MZOXEA1G:[>Q#6,^^T?O3Y<5!#]]!R\0=M2XA@4(EA5]4G*=T([HIGGQKH4P8
MC4E,8.K2T@AC8$8#^?((#K6F0/T1CDVBQNJ[4<-W-5V(@@T?/T4\0&#$?]_2
M#H,@/]X!>AE.XEAJ9E<;[>Q>^&OHS&% 534$AYGTH$$ADC6TR+1AERU[M$NP
MI= 75\W@4FW!'W6OWM72L&Q6_%2LVO5<0;\UO%$K^'NA>L!WR[G]PFA,N_D^
M 6R,AE0Q'@ATJ<^9M$6-D*9A=UD8L>3^UAL[O6LQ8'R,+5U:OSDED*':_ZV.
M]X=I(\6*155W]S)C''V:;%UX\TQECF=Z>T-$/\[WI%.".T!8,G9X5?(V_P[@
MF!0#>=@EOA<%WQF"X._7R])$B[\R/ HF0Y7VX6^:$Z'O ,JS<Q*14R>F4X6?
M-[N2Q1-N![QZ?01*H.Y!MH\(MJQ[BY*!%7'%UDF92CB\YW],[=KL3NX _,,U
MNWSM7:B/G<BL"""G]>16,[*K4."<1H['LJU-N93R==72A+M;=2F^83B52WR^
ML.$\B+3#VIE!Q;NA->;#*U7KGX[S*?#$I] T7YN/B_]>#JG:6.A+!'UW#G29
M--ZG5RBV!?X[96NO:VT63<8E)\QF5X[&]V2S8_/<.2$Y4:0T?ERA$+],S9I5
M6UE%7:ZERS/W(7@R,W\J0<K4LWUHOM[QU*I&\KU+3?V@IJYMV !0CUI=EW47
MP<Q"'N'#NC<3L500"U4K\QJ:9=C:CK=E,4L:DJ%L11>4HOOUD;[??.#ITW.P
MF_Y,_<SZ8;$1F[DQSS&\0I<P/4.Y8&C&B!1K#48FF,K=$H6'3E.8$X#Z,"C;
M(UD64_)<CX'_F%C3AP9^E'\][4\MU\]OW!99,.OSG;#U8@ P./? P_(3$HH^
MG^CV^BO#S*@G) 4H[=<8U$.[9I=NH3'IM\5&!KQ'\T-6[.7KNT:Z'BVVD>5;
M(_3NJ;DZ3O"]DK*_4"J]7)W<U@Z_?MI'4Y<&+NJNX;&]6P:T0!G'^$[@2\VD
M@$CF%Y?34"JMAAUMLH3JF0KK%S[,](W*<F++KQ\'@1]!^_E<Y2\$%(182#V.
M-J>KK5N>C)5L\(D)\$8/. BW)/KAIH4/9^<TI3TO3I3SWWRG4<KP9J>YV@G9
MV8&OU)87>SMUVO!9T80[N06W&R=/X&BP[ZC%80?P!+CPW.K[!>R=1?A)[CPS
M:QOTT%4N@<PVJEC.;$@DJ2F#0PQ%%5#,-U_QN[.H<(Q.4OYGE88Q?G@FV8&*
M08>>T('DH;H(BU$ZUX6!%9,$(S5=7YX$(R=+2OD3"!!1KB8UXKDTYPTB7]QC
M(<#(6K)GWIOH ?KQ@9=ZR<D<Y(JVCBY7% .EO)6[FZVT:<XM.[&G B^/G1F<
MH]M&Q-N-V'-)DY44<WJX=FPT:0^?U@XYD:D3X.(FAD_OR7OEE<ZNU<$^NZ.^
M/.A!KO4?$YZC2^'Y4J"=JA#+T+4]<E2\N3$%&<LI&C(-@IO380!S%G]_H'0D
M>"N[^-+ZC4)ZDE\8B)&1'/ A0ISN &S,EI0PQ[F_<B_.U#JMN4@(9C/]Z'7G
MHE[6N&_'JNI&;E%(+;*QJS%\LO9$M4I)DCPF^Q#P7>\" X8>O#V!+CI;8Q2G
MJ;JL5I^C;6@(&.\ ?3"D7+XB8PE\(C1(_[KUO>;3]@P=77M?ZPA=V=:\F%TJ
M6?;SGIU.<.K)812BG;"+S3%M/.1!;>,\EDKCYP0[1>-69W:P!9(VTU_@R#K%
MW8WX285+RM)#K5Z#IB=W@,K&7XG7?PR6 IH[&OT7+ O!K/LX4;R^=3(C9'@X
M123K\1]$M\CBS'BF.UQ+C?9>J!$Y>CF1FRZ^.2UR#GB=!IS+SB_EHZ@Q@$7<
MF';6_$Z53%@(F662Z)V(FG:47L;R)$L/<R0MN!(K_,UIR&0P*&X5?O)RL>BE
M'LHPZG==\EDN 1UF]K9;1K3Y\#DRZ .Z##'QP'\-$14I@)%G2F]:)?P,' L2
MJN=;7#-WHJCH+ZP8<RU=K/0CW%PVHWK4_]S\+.GRX1T@//TH5,@?,B3M?L2&
M'#KHDZ% ;CKZ^%7X$_?E/YM?ZH'A71=)VZ54^=>;12*<^<9>DLQ=U[9/!X,"
MW<-D$MQ_1J8."FCGQ*;J:V6Q:Z6;+%>N9(AS:3MT!CSUG3LR,T&T5A^-0CF/
M4]7,,./<M^,'A?-OK^$_6DZB[@!/@FE0VKU=S.@(Y-E H'L<D Y1)2.@_0;U
M,$TX>UBS+KTNQIJ_C-TME3UY F]R\'4':@0/I<CO%EY;YE@RK28&<ZP0FTL0
MNU![/4WO6'3_(MMQY?Y)O%#-I2^6N^C%CUANP'\ _0)R@Z(YUPY3[@#XU$B!
MTK#_"'L4N7,SC-V/>/TD.I2YE9D9G;$>X*84D-,?RAM&6*(J54PL_B>J?&D_
MG[DS0T]UG#. RC3TY,<G4"SXWKTC[>YS#4-%E<H)''3T;8.4E>#&NTTA;0,:
MT?:P2DQ0X>CEO":*.:;:<0C!O4;H%^ *'S/\!@J@JG%/QKX-75I#NH*.)&X>
M8TA0[D<2B+5$%GPL%YH+GKJ;=3V7 3]@H5OP3P W-JZ WD7=B(O?^-1!1ENZ
MF@*RA&FB7LERO[D#J-'_<[Z<N\TZ%UH2O31%]]^(H\.-6Y"#S0-W .*N#$M$
MD+%N5TY_]D7&5C44?NM\2,9/OM9O66E@..9G=3H@>(1W><"OP:KRB66S;-W]
M2VJP/LHG*JP#5(H.$ \Q$U#WMYT3M)P26W ][Y3>T>W./M 4'KGT_UY7W_(5
M$V]00J[Z@J"@Y38*^\QI7MMPSYQ4VZSCQJ[ +AD=I#?E[BXTE.?AYRIP$5%T
M]6%E94^;@6&D2FAJX:U @Y"4\,][#R8+(>]>GP>AN2?"A5BSX-!$L#TX5F_)
MC7AY 3T_:$[FXY#N]B[QE2NXG^9EJIH?^;/OLU7KT:_D.<:J#;N44! ,!11+
MK''S:FF_SA@[84XO+B RSMK2/H<E\^_O Y-C=ETK-^O"5O\LR:(8\P5;PUXI
MVWY:6-H%VYLN"+=G. $PHJC2PY9@YKGP03/J6: P9]EE9(WS19-'L,![*X0Q
M5YAOHK^EHQ49D!]I]XYAQ&?B%X02RV+BK_JAT57:(/*;'PF4025X[U-S:Y!4
M-6?B2S(\-3_&Y.$./(X'I&<_0;7==#)/L(N9TGY1V^BUF]>A?\THIX/IBKJ2
MBE;1T$LPJOL+__D-<8QEIN^,CQ*&H=30?&6"G_I^6L[ZJ(Y5+ X($[HS?;#^
MBK[/WG@9]X8D(G25!DL]#[+K7CP;A*V%=8U5[F6!R(/5 $CW_MOI@RL!H#."
MC*(J(K."47.D#?%:XNCP*U_SN.EW7%0!A@&QJ;0BME!=F($7QT[QJ<#4[_FS
M6B[/E+YSH$VV,1F1?_;IOJ2Y<B;MV .V6HYT&YLOL()/.Q_U5Y+::.>O(#?4
MX-Z";O+*8V\F^\O%V^] MMMPW.<S6 8,UW3CJULS5?EX7*M5L?:<]XT-.1ZL
MKY9>N;Z1T_9+>_%<8Y=EP!TM9GQ),_\+' EF!#N (X5:QXB/-/I#03'I.V.Z
M27I3YYT1H)AP)LSZ<RD R\YS:WA.%8U&)I4CA?% C)OY[^4A[IS?JCJ\5&R-
ML6\[6=^0I%+GKS=4-;WNE#D9^-%G_"C3L=+,8.Y]J]H! P%WI;_+"[F@X!QU
M3X_;<Q:T&!><.<%=8!QZI+MQ!V!8'J8<>?@-0?9H5YHT/:UD.Y$K3;XMP$XY
M5->2?:Y7^<^I)#0/"EZ?<T\*?89R<@C4B.VB]R?H0:X\,A^\[BJ3:?WY,MM*
MT$ULC=CALGK,G_UVI''&!R\^S.[F YLE_FW(,((,0QYWZ?B?57UCA2%#:Q09
MK)D8[-\!*(*Y4"P(W:,./G89.K0H,DXG:5#F6=?,9@9[)#Y*II,ZK6!/E<<<
M]"%V2DS_QENP>W^1=P=H0[XW)+L!*C7?,\]>0ZJ!T1S00]3]E/B+]BM#!\%=
M:$+YT!D;W)7=<%N,!8JCLP6E&(OM,3QL".*&D[%$83A*1H\$(C_;B_V\XI^?
MOY+("M7NOS9_,\& 'D1"^L%TH2S^]?#2>)>A0K@[W6YS('5K:>UOOTR):#VE
M-3I>5(OA]TR1.ED/1NU!5J7H?O3U;7GW^MI:DAD1RCZZY#:]XVTHE@ =@^NP
M*F[,0@'N$ZH 16Y"_KB^&B#Z+ #4*)'G??O1U4X^W]!23C8EOO#&CEMXF'FX
MY#7HCQ/!)_(PD4>]/1.,J'^AS-_GTLO_Q+=^GQL7FT5,GS!4_'M5TB8FKW(?
MY^G,8*]*[;+]]'S!/MDAFICWV%$(4I-EB0M+2%"U"ZH?/H(@UPQ0W8?#):LY
MKT6'VQYGSC=WT==WM"FFWLODC&;!F;5\ZO;UE=H,28K*P=:P^)<IM5=@LSM
M_?R1!)+KL@S)E#0 _@2AP(BC&/JN,N?\*%5_K"E<YR?.3])5'0%E"U6L9\5>
MS>DD\],G5#X$<QH*P!RR?I=WWR]7>XU($.TYDW[_ZDMD9A1TKVVPJ"DP$E+A
M.'?5))$\VF+3$F;S_#/7\S27Z 7_1<.W^AN*7[K7,T%4W19Y]H,L5.#UG#L
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M0@N]5P'I/?30I"?4T-?O[F]W_]D_=G;OFSOSWCWGG9G/?>?<S^?,O+O9NQ7
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MQXBIV$17V;'_@?;?D?W? 0O]?T+VOX#];UPH "G>O7\?#X\"H "XS6R5"O#
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M=:>\!)8L&\R4")?/ _]R3&-V'JV9VV.K9?(,$7[3%"VW_)T>C\4H==L*HZ^
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M(F(T(#QXR2J;'(\Z*5];''4)E)=L13&+:2(^IELYY:9WW@%6[@#M=&F^EOQ
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MG''0UW%W#<7VF^(/#FK0"*WUW2;O2IYX)]\<;38:TNU#!7$MM=I%,HV]%8<
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MJ!I5,@!SR&&0.<[@PSR21SWZ\<UR]OJ-SJE[)%<RF6[>5U^9A\S%B57'8L<
M=^<=S6A#JSV#-'(K1R0.=Z-A<$':PP>HQ@]<>AP*WGF"Q-5XB;?LHWA&"3NK
M2=TT[VE:[:V_EU"."="E["FESM*;E[JO=65MKOFNG?:Q#XA@^SR/,05XW$$Y
MR026*XY]SVR!ZXKY:US3GT/XC:7X[TLF*WNG73O$42DJL]I-M2.Z= ,%K64)
M)NQ]TN#GBOI7Q1K<5QI\MS I=HT+/&HW[E&=Q7(SGDYZ'COQCYOU+Q5IMY'/
M&-CCE)$8D%<'NI'KZ 8([5\IQ'+#*>'FZJ3A5CB*#3?,ITI77+OJUI);VNDK
M+3Z'*XXB*DK--TW2JVM9PDK6[.Z6ZO9[:[_9/A75(G\B>)U*2;>5PP;H6P<G
M .5([>G%>TVT*RPH_P#>Y!SGMUX!'3_///PU\&/%*:LFK:.9"9=)^S7=JQ;+
M/;2$QNIXY$;JH)Z ''I7V3H%['<VPD@9PR*H9&;."1@G!XQQQP3R*^YX8S.&
M.P=.K"47[1./*[-\\&XR2TZ-;7OKU/DL\PDL-B9JSLY<VB=K35X^>]T^B:>R
MWIW-SLN)4).5<CG/;Z&BMB33UF=I2G,AW'!XR?3 HKZ/W_[O_DQX-WY?^!?\
M _I?_:&_9J\/WJ-J/V2W;3"6:2*ZM%N8;,@;O-BEQ]JM"F.'AE0@XQTS7Y9_
M&7P!\4?AMH-[KO@7Q-X@/AYH)[=X[34I/$OAZ[LV5EDMI[2^=[NR=5++Y:W
M0#(4'"U_17>:G8ZLESIVI);RQR1M%<6LZ>8K1N-K*4(*MP3D+@_3BOQX_:P\
M%Z]\%M0O/$7@B*[OO /B$W!U[PK<)+=:(&D.6,*2%S:"4%]OEE6C<!@<"O\
M*K%J$H.4J46I1:YD^6<&[ZN4;.VO71W9_8^#Q>(I)TZ=6].Z?L:O+5HRM:]Z
M57GA=Z:QY6NFI_.[XW\1Z?X@TK6-+\46TEA>26-[I::E9JSVDOF,TB02Q,?.
MLI"7D\II080S$!N":\5^'>F?V_I6D^#/%MW=PG0-<:\\-:]9S1I/<Z?/(I$4
MPG1H7*&&-I%;!8I@YW-7L7[0$]G_ ,).U[H-JVG0:C,'BCNN(HGDDRL4K8'F
M0HSE0S\[1D]*X#PEX+U;7=5DM=1U;0M$N+73[S5;5$FNG>Y6RC>::WM8HT,4
MCW"Y:V1B@$HVJPW$'RZF%JU\)'"PYJM7FOA/90Y\1"=I7C%1;<^97TY7*R=D
MS[#*,SHX+$_7/9TL&G1E]?C*JXX'$T6XQ;DIIK#5HW3A*,W2=[/E5CU6YN3X
M;\20H 9K:2 (EQ*J117S0D*\SV\>(XI"[;CL&T$D* .*]=\(06M_<73%8T^V
MC<6C "(\A&W/.< X')/KC%?+NHPI<Z3_ &YI>K76K2:7,D=W#<(8Y(K=L99(
MRS2!5;E@>" 3U3->D>"?'L=JML9 JD;"3NSM((Y))YP.W..F":^5KX>K#"PI
M3FY3@_B::<G[VEG:S3LM>UO(_1<'CL+/&2Q%&DH0DE[M^;E5EKIH[;J6J:=T
MWH?9>CZ;>R^%/$5MHEO9:AK&F0M="QOYG@@FCB:.(L^P.[K$CM/Y:)F7;M!
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M/RWVFGZ8N8QQGD'ZUY=XFG_XK[282,$:JH0YZEM(O&8 'J3BO5-2*FUM005
MU#3P!U&3<H .W'N!QUYZUY!XF0GXCZ$C@JS:Q H7&3SI%X. .2,'.>GX#FJ=
MN?=;22;Y='9]NKVU^\QJ/[*C>\M^R3^_>VR>Q[M:PN\2A05&,DG''/3OS[>N
M?2NDLK<JZ9Y7"@8ZX/ZG_/%0VEO^Y48)VJG. .V.?<XYSGM["MNSBVE01P O
M)P3G(P ">I]O2E%/EU=W9[I;W>NU]=]36^L4E=))Z?UI8VK>$;[4Y"Y8K\Y
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MPJ"2Y0&T9B?EVB=$4$X^_P '-?J-93R:?<EUG,41VMQR'3MQGD$']:ZKP?\
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MX2+]\FQC%G.#^%'[$EAX0L/BA\75\27_ (BL?VE;X17OQ5\(R'3[3P-8Z?\
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MSL3R2<]ZZ6WSY@ Z>@]!C^59FBVD.F:/I^EVY9K?2=,L--MFD8-*\&G6D-G
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M:_).2BTU%WNG9/1]DWH?G^:8>,%/JZ;T5M-^_70]ZL92I^>0-D_*.P.0!G.
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MI0">J"C@1)L2F/6]#7Q(<FS(]G0O+&V[AOB<UT]]F?:CHC8$#N5HQF&Q<9$
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MYE-YA:/(FI@A.TL52A!NC7<.[E.1?C/YJ^)=QWBKDI/E]9:2+\M\VZ=>EJ9
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MP9S-EIWZ3FF&*(NG\._SH=I[CGFC?8!1GKKY-4$,$\_&M@BN;U*?[H*:.(Y
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MQ.%IN->5CBX,2-(F/JW$B%%Y#PW1?+I#7-2/N,#XF;%-*!7 E;55UE[6J'M
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M6! 5$:[V(3'ZQ,F@QDK,STAQZ7"? 37>OK;58X\Y)E-KG4-M5\;%D7V\L9<
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M]?"<<:_-G"_52:GZC+.!XUY;?!IC Z.!>WW'WK!,*'VZMR#F#-XC8J'/N&&
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MP>'WV9\8K_SM*7^P7V8Y^-CU0IC(X=N ?R*UZR/?*W R/;OU=N1UC<,W2RW
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M'@$-L?'C\Z&+8#:3U? ;CS2_BK4CND$39"C%D43-D!2B;1DD 9IX1$3RPB2
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MY6O2F^K;<*;&&(;D^P#SX<Q4J91Q&COH5HC<O<9H].W:%]T?:)0!N'2[G8U
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M4U';+AIL2!&4WE&*=!#I+5%1$! BO0DHB)101$ "!*)TJ=*5*M)KI'<B741
M2 #I)%%Z(*$&",GE^^^9<^?,_#/WW'O6GMDS>_;:[YKG+<]ZWKVH?ZC+@.OZ
M.GHZ !H:&L#S\PM G0-H_^?I_VC\Q\C_J0T:ZG? C:LTK!?T+](( 2[<H+EX
M@X;:!Q $ &@N_]\3 /]CT%RX>.GR%=JK=/0,YQ,:KP,NT%R\>.'2Q<N7+UTZ
M?QMR_AYPZ<9EEEOR]Z^P&K^@%?)AN_L^N>"J\(/:;G:3<8*(@N.;,#IZ#DXN
M;A[1VV+B$I**2LHJJFKJV@\?Z>@^UM,W-3.WL+2RMG%ZZ?S*Q=7-W=?/_VT
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MZ'JY9S7GXCLKQF46&F%N?MT!>\&SM)T#[^NPIZ0/1$[L]( =[6 ^1X=MF;N
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MOZ<NI5)U,N?E_"I'EGZ6<2QKC[$72VJYFNG$W5RCM]B<EP6RKHK8'*&)!IN
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M.,FC;G%PAN2-B^[=82&E#':_;?OY")O=<%VOI'D$PM0ND #!,E !C-E;,51
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MW;-6ZGT14&1_T*L:3YBV/_8JLK;@MY^AAC8Z71 \.7N_3"7[T-;)JW'6@1Q
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M]TY'0S?QFZ'@FJ4 RXZ64,NN'.]HRZ$N!GO49.O8M]N2B \?E#W*"U\]S&A
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M@C')(C0"=1B]0E5^-O6?G%PTNNM7FOC'T4G6E->0/]>C=._TWJB5MO+^7VU
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M-LV94UGE[4NW\\0H++MO#P.B*VZ(\0=<[FW0?C=>AMEU?LMH ,-O-C]3:#M
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M 40"[%_I9%-$WFG-LQ]#P>// 4R>_.*Z6)2JO6E]-586:- EKZLB3C*O,C/
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M7^-27K=X^945D@S":(6]L="^*CI.L/QHU==#"R*QD,7E*>2_#UNJHQ;'?K>
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M9F>LS,_PCWTF)/;(ID/?CX&IY.),*AX\W0L]![!.22V/P^A3&,:-9K=,_8#
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M>@Z@?PHZ?N:[L-"[J7,,/+F+D;/AF/.->4:UB2&K":P:0 +*-JS5J(*1GN<
M)E\'T.E-:QVR2()VW80]*OW5.4 +I#DN=[7KQN20BOEX5BS8AAT#0A!0<\7G
M (KDH(Z-51IB]Q@]OQET0&4\NTY/>TXM;Y\5I&F= RY1*&9=ZE&"J(,>/<-
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M%>Y7;2N+DNE7X7QP-TI4RZZ[4X[?C)CW"55URQ?<XX\.WX6!NG.O_"-KVO-
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MD!J*BI000FB! (&H2&\" DJ5WGL@=*0+B$@"01)JZ#VA1DK8?@??\9[9L_^
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MBX%#(?:20G,HT3\J:M?I7F?5_#F 1K]W#KCRC\0?J?_\\-Y9@MI3:223,";
MJ%<S0D6;V-?!O"-9)&OO$N">=ZD\X50!*RV8  ]<710@?[7K<]L:&"6)[MPW
M)(H2?6T=Q49E)FK'T?72 V*^B4!,920<^A=9N:\/8NN8J[8G>U7UR- ANFVI
M/.> RW,4NH3Y[)O48+!"D/U"]QJ']4K4*1@.E>\M60^^ 76ZOS_"0)5[Y !2
MIS<.4C&PZ$&M<1=\PT$9B]*I__A[&7;6A@)/PV@W7OP#692=2CU>TV6$\]2>
M<C.!W-+;KDA97[>3IH@FY5,KM]4U=E>Z:,*MRDRYD+2@#"=*?OWG01]&Z3W#
M1!'<D3_*'-5Y6W,NMIWWK-1GR^&0<-;4/CZ_\P<R/SS\JUY\ ^6&4Q0@:/9:
MVYP#G%3L$AMF[(H[F!2&M9P29_\,PEI?E-9WA)XJB39!)G-I_9K.(Y,=\\OA
MI6 !=FCP#03]G,7'5GD']:+-$[)$)XUU%"G_FES5K8R/!&O&M((Y4MU#;*FC
M"U**#MSXBF*#0.]Y*0XS<F%VH*<J1"5TT<L*8U9B)_/5?CK:$]RK="R:#K'E
M:5X&+J\,\\D(^'M5H;&)Z')T71U0"5\6J!J4!RYX("R'3E3+LBT/8OCJ)E0]
M,/]NZJJ0@.Q6]H]9XC\7J@+O_T-_\$C'E4H>F[C?]?'_CI-Y%4/I5,($WS:E
ML?N%'S"K,7<7/=GDZ3_^R:J0,)G?S/<N<1U$2K<GFVA2[\%".YSBPVFBY)EP
M4D@>HA2J_IJB'+F_([UB0G9*+ON^!BF@!G"\PFC>.M5G]AFMZ.?F2]=H"ESR
M]_V.DJ-=/NMHIW--]?CC:J>(V]=?JT*&DY?+-6MZ0]MZ=C(-CWI4-K-?-;7$
MLFX%?/382)5W54XMISS]6?LL4*Z5G3LIU'5;MKL+.%ID\B*FAA4_+ER05W!=
M>Y5@)OS9Y+.0-(SGT4_9!P62_#?D4@3!Y=K6X-WY;PL_UW20 ^)[H=M_JYXQ
M(? EAA);'8P;M<+-ADG_U&C=FBD"[E3_&I:'KH"Y1;/=]UN>L=8&._"GY[GO
M?@/N%#:WU#:D("J (8.P_\;K/8O.4I_7)%0JTKVZ4DZ')9ULOG_KE[Z9RJGT
MF#17-L3VP3+I*").1R*#/!&U'\_Z1ZN$"K*MP9>+/1:67_,[G!A%O[U8>P^3
M]DKHU6.+2PXAR6]N0NQ@HO.5!M/YK.IC=-CE%\N@J;8F!K4<STNZ:LXW_[C,
M*-_^JS<77Q,SC@XD_!K$8PQM>3I UM-,OPH,]FS[(3/*@;/H<:Q^P4[A*@G=
M$6['/'; $TA5()YQG^AIMK?B5L;1)VV&]XM8>*3>+)@ M^$/LR#ZH*(TGK\V
M T5K<U-!63,SLC-4?'=/0&&(-V2^1*%^S/:T'S-N1NLM?LSKA3F$_"@E3<+$
M=LU!A;J[KW6OM60+]J47_^D4F,RM2>OC>9-"N=_=+^QYQW(QMK4_ >=.MW*V
MH*0?^WW!5[4%K'==CL7[G2%^X2RE\TP\52K-IKE,F4^SL(6X(Y=1ZGU?431W
MAUW&7PI6>7+8GBGE\(X:*-8S4KLNBP36D=O0#2-0CGCEL&W1A*HW%[4; U>M
MGG+, "U3IK2$V]VDX^\"31PET=2$0COJS$[7K<XR78WL.W6?IEVX8QM;VA&G
MATVX[>4_T@H0O1I&?'%#U\A6W)VX]2?Y$P4W=73O[ L5K1B(IW\,-0V0$/]A
MYI>K1%_LI2S><.'5M:N\466JVJ+[ 4V!PQ4^[9DG/D^]>YN>&=OMCFKO]LFT
MM6T<V[H2;6,->'3'D;KE:\T<T<X:!>40Y=_@8_CG"UF0])94YIYWWJ&74Q,&
MZ'E=?R%,_QG@A6#6M>S+[;R6B#>/[J:;?SH'0*AUYL:E,O"2^1?>8<("-7]T
MHITAB6Q:G%_\O8P&!6IDOMM3==%+U [2$$OS<IW;*$)N<%T-6.B"^R"*CS%L
MBMMY:3]MK7H%4>[W8'EQ8K)=, 7%XAHYU_(H2_4N@TIX]/;6HEDB42_Y"\&%
MTL!5L=PF#.,!*#\N*/BY:3'\WHDZ=21[>,#/$M/AK0,A -7%\1;FS3-LE22,
M89%"_6+DL>Z-Q8WK6AO4+R@T"4R(L<:'7K<J<B:/529^;NY+%5;P3H#\YT?1
M*)]Y\-7HT+:*('DJ<NFM< ++JS8*_=WOSNWB>((#[V:-12- $?L7N=,O$V/'
M264B]_<*L")!_E#PZV_@"66.-;AX-]_RMT] 28ZEKY\E]6N*FCT\V=$FLH^(
MV?K-S;4X2<?&Y*U-A3,5+# _8? QV,'!^;J?KY/@0VB%U()T;X3>0G3BDR3[
M[\ZG[ NT&R"*UB&6.D#2#/V'BV#A/V"!NNRP XG9"UIYDOC#A W?%$Z1?^L0
M]^RG[A=C!U(HXP:(U$7\*"D,IQ?%K/*HN8EI;\W'W*@L0":U2!MC,'D _:LN
M,%M44>$]KTF<..RF^&V]H.3UG /8ZE6CMZS5M5XV_P[F6BW%_JT#V=O1*XZ]
MJD<=^#4?#.E"G2[*-E3'*<8O?="NVB;2KFV<7$&@#MG/8I#T!5=P]?;1 MP^
M;5=)1WU5O,5QK.74\!Z">F5.'L*]B^1K=37LE#G7EKC:_)+GM,F=Y<18-78P
MF<9P>H$<W^5KP<]+J6EI'SL(8IDYYM.8,+97P1+^YNJ+C&TM?NY(2TDI)/$]
M>A(OZN\N?7/R::#FZ.PAG&I5 D%=#J9?MSXLO5.3/:_97?)-2[WW;*.+=FLT
M2Y9-MF;R)/=B'N^][_2$E@>1MFOE;]+^-G1(M[E/)NOG%P0M'NX;40*L?)[U
MXUCMU\Q[SHKL?F\-)B4GF=9/CSPO-[H[PO? &W>;5#?;D\4<KP&+0K>&#'['
M6 C'?>&W[1#"[?Y0%ZVGPN?IN4XGW60^7O\T83'1#"U\DL&)F";HC5<;7I.D
MN[#Q7AYLSRCTEWFN\<W-*VV+F"_J1_0@KPL+'WC6_2L7^%!E[54%.S14R(B&
M)-GE%:=U%G+ABT)+G\T'P)2ET*O#A2*%1&K>?Q$M^:G8KK+&GV[\PC?\!\!O
M31X8RL:09?'-?'(C76E!?5MR71M;G-< +V#R=85;WS\V7;YW^2+7A56]RLAR
M](K FJ^4EP8Y;.O;G0?=#'V)_5R$[M WB,[%WQQ^'69+-'-:^T(GTI02WS7#
MIO1B!%*U[J=,1C>8-]O%>WNKY3GE2(1>HW=ZB&Z)%.,84(OF3.FZ3W^YZMXX
M"K(3IF*;/)-+L(A15%<A[*I>V_&!TNV8QYND;1\;J.JIL!<4M#8W-(%+9KM>
M<X=]+9Q:P[].!&\39.6U#F.7EIKB9%2[Z;8E$"M1=SFR\V?^>MK(I*KHIB23
MXDB:B6^UZ<61B>[6<_!K:B+%&P&^+4%S?#I[)EC)G7*%OJ=9$H&@(+WJ]A>Y
M!3W6O(DV92KJ2[^RU==[A:M[/7GE!N/+11[+!&<L'C>.+;7,X)>P)_8@JQ;U
M6P4C%6D6DP]GMPEG]IE8G#E"O7^+V?$U*<@4.(Z\6ZGU1JI=8(H:;+G%+^6[
MBB!V<QPO>FZD.9X\/LN&%TW;#.6/,-9DHI??+W8D<+@,=(X'JU&E1WJS9(*<
MY\ECK5 RT8K"&:X09#VJ$)W>_UO HF/T,MZZ8B&H0S_5O 7+![>5XWJB7I6$
M_+ \*LH<E,Q7MDXWLW.B<3RCE\31;5J-$PWT\7F:(.0@-,S"M1"G9$:X(7B?
MQ^*"\.]%^0$)ERQ^!\DAM2.6-8Y=&YOG-0KTDH4/27Z9KYS?.\FAH^D57GU\
M<ZWT1=M9DMU66JR5E'LEL>&7BL)1V_X? \,-]W/ C9/4/ *A(L@HV5W3Y8Q)
METQ7LK##AG#NX3!>/3HT]\-S*Y90K@PTC-W(U#CN4Q5)V]UEQ.9[=4.ABEBE
MOZ_?XR[6RJ!<870#\P;_GID1H A;* 7SC,$S)8 4_C2%%B*Q15UE=\LGUL(@
MT7Y+2M#;SU&8M5.]@Z#Q*XS&11"-R48+=-/X6C!*1\T&S3H4KOPP>BV^.B&Q
ME%&T"Y>"XW6#F&>?1:X1TQ8K@ID1K(9C!U"8SGN?,U-0VJ^@)R3?M$/E5,/:
M()4?!**KG$UWH2[,48CHSVUC_@#(4Y/V2/C-4HDQ?K\@&))?ZC+1LJV 3]<,
MV-J R$1R)!^!7*?XCS<"3UO *+&][/!S -CHXL;,;<I(%/I$W0:,NKET0M?D
M(>F>2#^T'Z_7"#*Z>:<.<N9*6)^PKFVJ;D+7/+"].'#A\YW,0C)JBWT^GF_#
M>#68=[2^48;AY]%5Z[!9 S/L'TBD PK*,J6&&?'WFS^A'')=2!N\P#<\^QG#
M?./8F,IBU@ !J6;>!/EY"S?L@7TW8!+H++!?'"#*9J#!9+M\QDG@D4V4%T++
M(LJE4K-60;5)JN?##.E6@LUW4=O$+\(I5UV0XUW I6;_Z-V&I6$Q<8V#DB'[
MT&;,TI')N%<E+& '_A8+LATN*%AL/2/:VZ6ZXZVAE57Z:[ON]92Z[N/@BAPJ
MWB@,PYG8+5TTK^[<NP)\?W!BR\YQ^VT#&5N>Y.JUIJPAF#9F0YAY'H7_/65;
MD7%D]Q3Z;.>PGVK2++B>]BMV@4>=^TAG[( NVO@WOVI_+1;Y"$6R?3*ST'U4
M 2U[.EP$QO4ZP+R+\IOK.^/H]7@"4HYG#%1H[*^]OTWG,B2^B<,O/1+R!+ ]
M7$LL!O;?OF.AX"-#WXELSL@2P&W!KWS@,6MN_(V]SS%#L%<:9X\M";6>>8YF
MN6C'G!S;E5A0,HK+^DP$/1R'Z,\0>HE^3FC]S5GSA^UQ$[1UE+H4+OALY,Z_
M\=#G(Z9;!9&J<R.W06MV(A.X[D-"?(0D4YA#[47]CV$4GV&#5^/\6(04?L]P
MVAERF&[%ZMHW=[>GXZQ<@\>2 )Z %""ZEN &YMU:N*U-I"8\,-"[=!;<K%/M
M-E^#RVM.L9+TF7:_O3-JE.U"L0G'[":"(FB)F.CG>E@>2Y_Z* Z6;L96)8JP
MR8YT;3_;?\)>X4X>JSG=\@\>":<P\N@\$GN*33^*E;W_&ORSUC!5YJZ&[G%_
MDW:C_X6IO=)!R^8R$Y,\W^G[7OO/RMIW_!]NY%GG-P1 \NIP,P='?OMUOOL3
M$QVRY'322&BP"L+>N.'#B"FVMRTNO!CEM.'9"ZO2+H </[7>#BF/%@8S&#!F
MCGSE&'!BZ4D]E'N0.#ZJ'C_O6][./%XO< /BI<T>E],,BC825OH:4/=?=::)
MX#MQD8/&CX-F-^HBN?_C^2D4A_XP8MAR$I3\62DU[&GR]IT&3)R5[<7BO:R'
MXP4ON/,?OQ7V_T]4"2!1G4:8M=*_75'#N&FXD_?S#__+GN6])YF1G1^@/P]!
M<6R-QD]:F#__!2%+^F1>9C1EH+8V)(A!25.-TR*^Z;8F]30+7%5P!$T5-;<#
M8P3.AYV%2[V1DDZ ER'AS:.5P)L5KL>H[EVHU42(5.&3M[(L3QR2=F053ZW?
MMRS-;2]<?G<3T2EV2<!.XD3['!#25!\]U,9S>&.T<C[!0F^<IMY6WZVTA-A&
M[X2_WGJ2G:54GZADRI/XPO*>\ 7[/DSHO@Y%.0HI-?^Q$:1,T8P\59W/;T7\
M+'&BW<&[H7U:$,G)!?I.;:SH9X-82<=+]U_IKMLH;26^!@4&O<8LEHW[G?S/
M_\$5?Y81JVIJ#PHN=W!2O](-1#X"(4/0RX'VQFW/,^*N"MT!W/2X\&U2Z=I]
M6'QRS0H(#F!_N/=(",5U^W+U7-BE[:I(@6J!GIU+PZ2A,^4>?AX\4FANZ^Y!
M&Z3'0L@\?),0E!V*ZPGX>4AQ2;/K@%1*)Z@EK'(^0/CNO1PWM4B1A^=/_I$\
MJIZ@Q&]>HD1W94F.[[.64*UM.0TF>(#VK+8CY=<N,_&'P!W\@QQR5X^7>DSM
MP#,B6#@[SF=V"[+Z+85T_^Z);>8X6J.T=WX)8AY6NGYDI*^4UA!O5GB\Z:FF
MZ!B(S8HC6!V-*S:/;F"^DO>L-"R3,<(E4\@3$RN/N9B_17XWNEU&+C,@-QHY
MC+[3PWX(7U OON1IYD8[ F"&/GGHW19R$0[2FA^9!/5JW*FCB*!5EA/5#'*0
MIJ/!;/3"RO=SM,O6L[@;*9+'605E1BZI)866NA"E3(E)L+*&(ZF\87<$(FRB
M/P')KH;UV3-U%L_8;9P#&.SZNFTF?+A@KRD:^8+C[D@9NN89H29L;A/YK'X,
MWZQ^% Z7$IV7EMJ"%;9QX":M;-8LKA='(=*N3XY_",H</R3JPDLQIZHL.69E
MI2:N$\U@HGG]..CET3G@'?*ME.-=O5V/H494/BCN8MCB;:^BR\C\2QDQ;V\Q
MU0[W'U=ZGP-D.*@+P5[(*:;&/V*W_WIFKK5L2ID>\E$K<B>MUYLQ41JWP<>*
MAS7%+H<J!?B6JJY4U*2Y=7)?7G%W$7#>$1\:6K&=[)>GHE^H6Z*4<PB)V#\<
MK9*" SWJ928OD73>E\R 9^[@U82<:/P4OP]J/ L(MYUZB6&MKH"1N%:#^2K&
M-7,#F$:R@R.)/@7%7'_*0O4S&4-'$VVO]ER<M0 K#"2&1GX[K+AZ=(39K6P.
MF'3?O!EJUO9(QKSYE!8<V9;D//0$;SK#;SA+_=NPD6S_=P,G^6@MIL&W[%:V
M4RI>X/0:9G_Z'* >I&F?NN-I'X1\=@[XX'^J0V;L,GA-N3H_$7DJS[>^=AP>
ML[4-;X$Q6MG$LVZTWVY_L.Z;IE/E7-K_S=:%+!;Q#;OM7@^B;S.<H8?*'4\;
MS*^TRIQ<.(5-G-KF(5RW3C4+":Z8AA>97O?A04]ZUG C<Z;>0<X**D^LU&HL
M$>> 9\WH\)=M6.B.>WF]NK"==@E1"IU8@W#F=[3C;7#?7IMTW0>K%F GQETJ
ME</+"P;7#(^EN .W2J&@@L.V@U6D(;3@]CG K)-X#A#@.//JI@7L_S52EPW)
MD$L,2G%+.,GX<.$< ,2H)>;%Z/\88DCX]&C@+TC@+57K4!G?ZCV/8J2&/Z5D
MAJ:O^P(K(1(D/L%S@/XH5$$BF]]5DTERXLE$15^NXBR+1AOX3:K*-=P6=I!H
M5=?1.@8MGV^"SR']3R20AE3/.?J="-J]1G)!9338;[[X&RX/OY1J-^:F]KI0
MMX(::%E3JW3=#:]\K-Y;^:UZ)!!6&I0V]ZPY,%^9CMLR2BY5L(S?W=W./,W=
MPG5 L7*:G[ :Z>,J\G-M*#4U;:TPL=8/)7;LBER%%@ R>OMM;$!9/91(0\,+
M<V]7+I4 LAT_L\C?U+7?3T>9/-1P9S(,47NU?V<\0"(HD"9 ?KZ_23L'4*^\
MA]R_$[R1D) >[=D_,/;5@VF',R3DJ/&O /C0*NCUJM$IDK@"D%U;7GEHVF^S
MQ35T3W$US^X<$'[*#"92_MT8RQ/)R4L/=CTTL= 6EC;DE,.=N7VAR[RWGC/<
M2+PI)_O[PR/ P>60SI6K(9\\'K-]-N9&&=$N5,W/_KV-E#D'.!B%H?9/BB9.
M8*<JYX#$H#FC$U:D[#F@4)_[',#"=/,<\&-H'G7"C90_!Q1-:W004?,3ITD[
M%U%_TN?CS^0L)[H\&R;]*B5V<X-T&<\!/^W/.L\!4^'1KO:[+&.H#=J_._W,
ML=3,S^0<\"DE[QQ@?]1Q;"IE4A4%DM'^*[1.ES!1I5YW6O?[V)?FD-1"R0[9
M/XE],G@.Z.5FS%R.7_IGC9-3KKZCT^"^M[%SG+[#=[)8/9*Z7CT)+0*3],P6
MD]F;U_^&]VK6P4(5=W@1\?U)D"V.IBJ(,:)TQ6C,;4O:QTH2_<_#K1&@3>ZV
M-)L_]O:K2KN3UI 7/S%XDS7"3[ GU!^FHBUHPZXTB_Z<6Y$7XU^Y4[=9,8%[
M_.R,);ARFLDBG13>'9%X;-7J-Q^1:J"4]X+5M;I7)*'-5K'B2@\+LXK_@A56
MZ=+M;E??>R=OFV*-@/P=N<-0D2F5F:^*&7YX@AOFA3UQ ,J?XXLO<7867KL;
MZ2Z==O@#U/>3H0/2(+OX[.-I=VGP#PUZ"G^RKV(V*R+\Y81B2SIHV*%O=(#7
MFE;@?(L*?8 .,8V=WG);::="'4K0OY_A]/U*;88EZ]0\VB"6M)\S7/Q<%*90
MIJCZEDS5GN/ET#)J(QC;ZW!8 >E*\SGD5J\O5S+Y:RU2F'GU5&BW,H%E*[95
MLY!7\GEI\\/YS0IKOV7@3%8*=LNJ:#995?EM9E6^F$9U; 5\!SYAT&)]N+U5
MLYG2P4KCLW?U/58OBFN5]RZS53P&@2GKU>E?T_4;E=(2<VL BLF_.?8DY+(?
MY<4]V))\O6__DFP?09C03SD'=+7?]7=?:JS%.:<#\?3VJ]ZPQ&7"+U,OC<G\
M7UEOIG2YTGY9_JS^$<NJ0NWXB'*V9?K>!72K7VYM:^&7% V"&30T@F+U^](P
MX0>0OW_2(RJ7##2.'G^0N6FEZUN6!YJBA^A<Y"KM>'<.<-:7N4"MU635)JU)
M5[IS+-_?ROGMTR;N"X(Q;=CQC1)UFS"^Z4;--3CX$''8SB4O8YWPF2.U5_*%
M=$[C5RTF$<5?BQ4N?3XX,X&7.(-[JQB3<2D9R$MG<Y:/\P'>ANL^Z\]8"\\6
M,\2NFV:\_9QFR!)]E)]4EYC:,DTMZ^9H/LL.W4$^SN\D00U%&VM^+[=%PD%_
MGDSIX1Y#&P=76;#;3TZ1#1.,6#$A@PB&!<05C3?T3,E>WSD[51_?FV.-V?0\
ME>1<:#,]E/M]$/WC )3-CPAC=.*AR@A!9=WWRYZBZT?5#+X!"_Z35'2!E_'P
M&>)ZE0.RT#YG3GA0QZU(^,/\^JAM?=E5S]/KU>2=\ ,ICHD^H]=Y=F!^MFI$
M_5CBX>"1.?EGM*=G.02[KM+C-<OW9F;B3-6PN@7[*B$OR:0%,M38L[IT0V-'
MRHE(K3($VAW7ET&MIB64\UJLN0*'=-E:K"HL3NDJCER"+AJB(ACD96X^(GAT
M&GI8Z;WZSEO"HW?Y39Y?K-DB6.BI]M3VKF#I'1&_EKHK9M+EZ5]"9PHN2%X3
M> ">K0M^#R^Q1'RD8D^LFT?[,.#"=/HPV@],>ZH9>>OW)V'NS-W*(D>9,/,)
M$U&3+>^2#3D>B/E7:-["J<R)Z'J:\JF@<MI*KX$)+8C5J!H]IJ:2DJK5.;&G
M&;:CIEEFI?7:LRRZ+//A0* GB9%U:\_(WX'T@/"Q0CTC_'G,8H'SR8;B*#:E
MRI:C'6@[:;OUMFOG+XK]7]1<-9*1W_Q1$(7(S;KND'4]#YB3Q6GU.NWV2S6O
M7G$.H& "EXI>C-E8F,ECN@Q=NU,/551V2;D]_>K]>10#PKO[P8^DQ_/3],#?
M%85ZP;]$&K"2KW!;BP^N"S.K?>KD&<R91.*]TE]^M$O$8@,'/AK?$_NPW>_F
M*>J?:*$F&&^73[Z@&%W;WFR[?F([>3K>?L)0P0V4B,C3]>?=,GO1F/+J > V
M#0D7NRV$M"*"782;!"&'Q*7.V-]$9P#+-P&5N7\I-Y>;\4KV49FLOZ_X[S]O
M]$-V@0'?WUE^NNP1\F,JF%2*CM&],0UQ-B"?< 8./S%?4$UY8N$TIWR5,"MT
MZU$LUT_=XXD(5CY]W_'5%CAJL4/@R1BT_:PYF,XW,\_6U<2_CJ-34RV125:0
M/COA5H;-5,R'E]FUQ(R@G,GP)-O&U.>_Y\39G\?Y/93FMUH&;*603,/2'F<4
M0QO(XB2%6#K(I1>4RTK5Z1  ,_L3V(4G[^B4=$H?L#F'&K.]34I*H]FBYN9&
MJ!+ZP3^"KV'.OM(XJ8E0S07.GG^Z.5".6+#$NOM"LABH027E^.;@I*+GX<'I
ME=2Q@A])QC^]U](N>PTX:8P'Q$-9?&UPHVZ)T^V1TMNS^/(*B[(U5&][9$!P
MQ-\1&OT_K;HR$"@APQK<=PZH+8KDV(4"=Y#R%-/^&8&.GK3-T91H<S)3*%S5
MZA*1ZFSTBHR8[;W5+/UM0R9\/U(MM+TIFS)$NS9R#K@<C3\'S'UK5Z=<[3\'
M$.A-LCL[:ORZ,G5L'19D>MITO+\]IL@;DT^U7K11G>?:GBT,A1N2*Y,@'&J.
M5?_]RZA1'ZQ;CG?YC#:;IL8YH),/-9<FP*XY5W8.X#\%EB+2EG<Z9P%JC"5K
MA(Y^5#3D0=B*$7GLW<PD4IX<U#MPHHB)5-."7ND9]OHI]!L-4^U127"SJN@_
MFIZ3N8)4I2;-RUP\Y:'*SO/)?!>H%OO>6_N;)H"0UZU7"O#KGX9U8=QJ()@?
M@XGVI\*C\'3OXLFIV=O2- E$B;2:;NE7- ]$<3QB4MO(T%^L^0C\>%9[QGW$
MOIYV[612\?X@UBA11N^@3-5NFU"LO=FROB-:@:?2/\4%RVF^J]^0N6Y]JGJ6
M3+M%!!]FUUWM!$$E5WU5D@M#H6?9.4@[2LI'2I?D?%3O):0,.73J MI Y36I
MPA'4HQ+S !RL?N)&^]/LU\G$,+6JP=G\8:__N# !50PF2SH;<]],<$V,KN)T
M36%VSUJ_QZ^,(1_&L0Y3.*I+8"Q *.-W]W/ 8<-9"5+^1)/*O[X.+'<_U2K6
M"H3.;S%OY]7''0=*>$MM+>?(U<8J=[7S8^C]2'Q6'[1@[C5_OL]"FD(EJ&IG
ME?]&FM-Q*_CNZ0O\0?9U"!#ER%]T5IK65P*F%[B]<?Q:<-8NK6_MHP?50OLI
M1S#K;V15G=7:(":J<'M%L!A79&V';2U@X'L43.DG58B4?>3Q;'U#@#L11G>+
M1NX54QPH\'O:H]U>^CPFG :G7*ZP:=.TI4331(,7H9E3_HMMF4HK>[I;F),7
MU/X%IA[ZKP<+E6OX6W;VLPA4-TWHY*WU<.],@?Q ,;6_5W#WH7 ;A;^!^O6/
M!/$/R%_%-L=2ZJO$W"/I.TU>$S<NR=>DF#_76XI*$L9U)VXVO;KP[EV1D.I_
M55B=L]8#([9)_7PDDLHS!XOP38MI*-RS1>.DJF32?F%M,4E6EA!@($!>*R(7
MHCHMW2<4R7R[_35<088J)M-WM;$-!T=Q!(\0?M)>XWR( ^X"SQI;X&$*_E"X
MT98!&TAJ*G& +RNUC"BHY2[H7S#U)("QJ[Q*I^*1CDU-C"/[M?S<S7JO&"%^
M;?;2>(4<0SX;I(K9DHZTHD<]=WR;.'JQAG<WR=V@\9GBWXSTSQEK3>K.SA"9
M=ZWJ)"-F*@-AG7:5DAJAIE@^%;LK'5XVNY:TQBQ\8@(9+1I@LXA5 (D]3?GS
MQ>%S29@_E]R9WQP3]=[.EL.<.0;30DE)HD@\?Y\_'!_K$QTX_82D0#LL<%/8
M<KKVX1/ED]F[OX:&\[:S$?_F_\6>[<! C9HT-]&#"L_F4HC\9"@48EV'A8_[
ML]7U>];NF(Q>+O8H+2E-20U[:2:>1^J(T+R@\>CT7II>^UWD TI1>&Y$'0]Q
MF&7%>'0Q3I3@3E?BS#>=^ND14;*NI_RCW))>KV)$[G;)>!Y'<H&AJ8<OT%[7
M)'TY>,] .-T7;19M\OW-A&31L_*#5E<=WO4=[:&'H^5-ON90=)*?K_-&T3O4
M7%7[[8S'4(KI/']]KL&2CM@XDKT4M(Y/-/QOCU]=R/*$<4SIK\AOQF?;_^4)
M:%J?1,_O;'6</$ ^2[RGIDGQ?HR#2Z18DD9;'?@F0F72G&,NQTW#7S9$K6'.
MCN+\[XHMZ5X5/@?<I]@OW<ASO*V4P-N2<)B$5AD4-4[(+!:*T&$3#!EXU 2#
MTI5Y,^:"RFN?KWCI<M5+?G2,M$WE2.CGH.<K+O^^<'F.L629/3GIL[C_RW")
MA@YW3HN#]R,@T:Y?VS=?G@,VIK934O'LY;07Q3NXG+-*<%IL88XC.RVAPMH.
MI/<M.IJ^N&K3,JZ,?2LCE>/7A54YGLMTG3\$7M-^=%R!M2M0IP_X?&=1W3M7
MAV%^E5-LLOUEKCP?&_@%,*D7WG**!(\6\UM+L$_NHE=U]_3_977FV1>:!-*2
M^C6G(TS1B'DM^#H6_LAG0Q5B^^207H!YHU:\/==]5%CI'$".=U'Z"6>$XN_R
M)OISB/<!O_*<X*FOR4?=L]=/F?,0G-WZ#$HJ!G5#Q:YRXMJB!<5R_H3"IA(]
MS:@W\?)U&2#KOH3[1"[AG_)@TZYB4\,LP59KNX.S3"D'\;)2+[]8B<G9--?!
M:S%5=XI,>;;$1S:X;"2BBPMT)_?>P(9YY<=+2L$Z\+0CMP5@P7T#/E@$/)],
M2ZQR=DGE- %"\J@H70SQQJQKZK51,,%'_(:D4HTP5)U8R#+R3XX;H25\B/XH
M#?7@$53=^&=SS=L::J<29/Z.TID!_PH;Q$A?&D<LJA@R$2&2T?89(^"&;HB\
M9;V6,O'@R9UJS >12QFT?QM>I^N_*U!XI%FKVQV(NH$4H5P]1/6C(@A28W8,
MS?6)?]8[&-IY_X5$( 70+3AXC(IN%QKFL:): ]\ T=GTD_HE?65"WX_LOV?'
MGH)(\;P;*D712'L2%-:K(8PO3-E[B3^H,#\Q&9-Q;OPT)&1C:VND@(V7C7PA
MU"YW<>)'G]KVCB,F?0>FD7F$7YEM\BH3*;/>!_IB"4>81,W?]#3Z2__PK4_5
MGLO^<PXP)\]N$BF:G1WLK::4#M,V*H@IHET 48HSP2&5&0@0^XV:D=(UTN+C
M,M3;X#.W)_V*O>@RSNRK! <GVG4DW[>A<P"]ER83^ A63NPNLG<=M7_7]:@J
MM&$2^O1'"6\%#.[1/Q)S68K9V$]"W90\\D%-MXS* 6-S2:/E<*]JJ(YFR3!4
M_*PJ=.4\CC$_Y/0;<L5>CC>Q?=0:FGAO)K#X$JA]_.GKPXGOYX"P=C80]=23
M<?@[!15:GVFAY0#Q[9A,^,-%&Y6*.4:EX(\>#,%100*$)1E/(<(74N:;4'/T
M$A 6. V%0&'-.W9512XM2=90F&'5SFY0/):)P-D?S$#)0%U30%VTT@;/[X1W
M7/R'=XWM-1_]():]EQ3%E$BV=J&VCH:X&8)_$>UW\ARDK'K/5I]WXNXB,-%*
MLR5[LGU4["R=!M#W$Y(#DBWF0]XK%7F]HR.;Q^ANO_KZX";=!?O/KSP>5^V-
M-DVK>=L\7UI.$'%VZC,<%WNXAG[U"G QYMYW -,^YUFJ)?!$GC8BY^%WRD*U
MF>RWI^8I!!LA)\QO>PT"W7(3]XV,[-I1[\RI#@UGK4FT#J'I7]G?8CCJZC)*
M?G'/@&)85'::?7EY%[=.^T'&(XZP'HY"A@\=37$SS'U&/ [",F+KFN(%.R,;
MLW]0"8^OUO3/9^]M3)Q*E*^,GP/L E'=HN#"/->H[LTD#K&D0TR,]YB I /M
MRHB8IGGFDY[,?D/)V9G IB\G>^\GS@$35G%R%T[;]EZ<'!WOG9[1:1H]NTPT
M0O7L545D\R&5R?T]&O3D[8(":UWOA<\3Z09M[?A%+'J5IYMBJ:^(QIUE;5NT
MMM!^QT(%XZ;RN);D]+EN6(=A3@RI3$!<JQ$<0M=2;(>PZ[=M2YDX4055H\>)
M74>':7Z1DOM\YBN&$/4W.T\;V]"@H2#-+;E[C9BW.JSWRT<B.<X!3.ZM%O.I
ME. \DM'-#0)3*-*99'^3&O)THA[&V)/&]]E7D_S5,E/?H#%4NC!J4)7GI$UI
M3I;CKC0KH $!@@;^PSB:")$8"X0^Z<+UQ1<A("_&ML\!&%IW!:.J'46!D$@8
M4E"1L+<%$:]SVC?5IG2MSR"84E-,]_YDF*MP99B)^X>!=.0^+X2%^K95:%BS
M.=P;E$D<%[+++Y.&N6[H3IH67=<Q$S':+Z^Z/W_\UTD_NL=CA7VA]$GHHQ7V
M6NK(>F.DV4_*^+V)'(6RDGGQI49K!'?6R'KT%>N'/^T$ZU4^D\<\-?I0+COA
M"9E\3N-(K<*&>I(54H!!)>Y]"<&H$)'&,Q2DCH8&SZQC>6)9*)4[4@XOVY^:
M@[X43 E"N_CD#[]2/<NM!^ .9=3<-W1I/AMWYT981$M(]PYBC4Q'T9.G,D7T
M\GXD'DB%J?8X5+LOG6VT#R\/E!!^QG7Z)S6[3CE&L8.96ANH$]V7Q4\1.8JH
MVF_IN&7PAM!7YJJ@R:%? K)5'#D5FDCQ&(8[EEKU\NU#N;44!SY.?H*X0_4/
M@^O#@5BXGB+J>D%%0\+\#J.K+Z&ALOE7NF@ZB>GV>C/LC[3"[2K%( X05&>D
M)S5APS3_A2UQBN>N9!EK5\:&?+_R?<G@IZL-X_?O_SI@<Q0W&$MRS>+/33.:
M_+6N*%"7[F/CJH\KZ4*J7\/E4KU[M.->?*SY[!R>,Q3^><VD[]Y\B>G'&JLL
MOOGUAV?.-_/NS[\^*)4MBC>K1I_-P B0>9'*O*"":2IAN]L8]RUY&[JCH/Y"
M!#+D4N'8_!LZGX@;;J0H%K=AHA;^BQ(JUO:6F23<5? 2W,^^J2&.ZAHVNCVU
MYND:(*EQBU)Q#OB01>SA, 6G98[W9>>Y!)0?67#KY$"< PL:H2Z3;9ECT'N!
M2E_T!N2N4+8TY\4Z&0..0*G/&\(M&B?0MC+&>(.&>C_OP[(@&R&PG:1\V6V'
MB0.Q4?-UJ0")Y#''IEK(5TN]WFQ<*]]<T*7O*0'UV>$X$]36EM=&3_/T=EVY
M_49S2EFE'6'2:MI5F1!7I' D-Z+>GND2I]8;[?,T]^*P71SS"KLLVTID2<K0
MM2RA]'5WDPR<3://DK+"%$_,RN82UX:(PCD COKZR^+2?.V4&4,5?2_;WH"N
MQ*&,2JS*2Y>'XW#Y1WW)(D^>L9?H%/"J])J664P7F,0+6F*8K/8.WDRR@'[I
M<EV_/7+I-N&QP!'>RT#-5:7<%NH=,A %-&91IULV1G#U=RP,E-V23S'M'%PR
M4M<3]U_+RK83A[<V/2^U,2S[#5@,H;)X9ZD'),VTA9!X.ZHV3N,RD=J!S/QO
ME2\EQ#<N% 9LCDRD?46^8*6HB7OW[TB-'2PD-7Y"[%^JXK604U2MP3]U6]!X
MJ]<?U_1P1*SI$6\,Y;W8X=?O>U+?DFKNR"4&-PEE^5^*UTJ[@C)J7!4P)I^M
MG :!CY'Y"1_P)Z ,N--_<BH'ZBUCND!RQCE@/2=EN@Z/73<S-GIT(_$RUZ;O
M<9 $_9;Y35F1=+%6MR(^U5M-I^< ^?^X33/"LW@S=D-KXCST)%7(\GV>&__M
M+%';L^7=_JW"GK3HBMG>][OE[38_;F1=8.+ZL9)1(T;NM<6UJONS5;D3*I)[
MDW\I)[E7#S-0%HDV?:,LEW06);]VND1?^E"JJU+=W8D92[Z^6KD=KKF]!-C6
M_/YR/2TM>VI:>&CBHK:'-Q'\2 W^RQO_SA8;@#P'R&PX4(_/ 2'-BWMN':\%
MT'T4UVK767XI17Y U%QG$5+]UK1#?4_D[O.AW4%FQU^6*]3VT.4XE[<8?\'&
M*,LE3 HG8CD*D?DVS/)M3'F" 5M4K;:D6ZVN8%F>Q#VA$\5_;\8X-V4_.PL9
MW@2YOQD/5NU=><=F=&-ME@E9O7Y53GOPZL@P_W=_$PCUSZA/^C0*-*JF65@.
M+4&$6&-]^!0=$UZ'UO-!7C3@)#G Z4MAHBW-H8Y?VRT_H6-W2ZK&&MV'1+IF
M!F3*E2>#:64H"=N_4DS_TU9"_J>M/ <T&@.#S@$YDT,+L]$XH&0=]83D@U/;
M-5"KHQ)[O?5%Q@[U\X$*(Z*5.\)[X.+FEXD_K($*!R!.!]?<NTJQ%($%SG!'
MJWU- :0N=C&*%+BO%"Q%8=/G.UC*3TE:!W*-M:+'ENK:4IA+!.D7XY9:6S[*
MI!VQGC#2QN2I'99D]^BY^VJ/@W+7MDKL75/X[XYN*5R)5=.$DE(:H/K68S[C
MF#&=2#_V3=_4!&+Z!^$H M Y-H\?''2B'/R[&9KNRGD.N-[J"2TJ79.&91$N
MN8QN3,A;NV"%!Y"#&\5&T#L1#*VW\OV4HZ$087G-\M+7!;E9MV=^S;:,*Q;&
M$2O0Q*)@Y1NC 7W-X/K#_;H)6U\<B' ."+_$%$$3).B6/(:18+S6O652Z1L/
M.DD& =?JS7 .N^BC\;QHXZ=C'76DAMURZP-G)<_O+%,]-<47J=$DL<FE:GY!
M2MZD[:QHF6=11X1BDR0,+KSWVE9G?:!JN'YZ6WKEW?0(;RHCWQ3E]@V;9U6$
MR7^6S'^@+JB.,J1:+02>\4-9C)C[@R 0MBZ#FZI%=1"*&R9LOSPIOP+JA.^B
M'8X*CY5O;BN,0P;7T563G(??\(HG* ;"*3\EM+W&L]AZ+?IFD49RH19C[_1!
M6#I;G<WT^H\0PWCCL?T3R+"Y@*IA3<JR9OU4=ZTI#_R>Q$PA'\C"WQ0[?=">
M@DE-Z2DV\T5+J#>8;L D($>0FA4[<6HTQ;N?,]4Z/@IINV#PQN!9(.CD<[K5
MN'D?:;W;4)]>_[ F;@OZM@V#G80*=22*M9WP?#'H#!TT@U3Q(4W:R'_)%4=1
M:K:H'(V\O/4R1U3I.F=Y:CM/O%G\$Z4C/S]66R)H-=P$[X0KKR@,PV*W=W=W
M[YFO_<QKCC]\=9;K[LY--*2:+?"9OK4PN2YI,M;SI@:#+6I])3(FZ!AUMP+L
MT2DDV%MB .=5T9]]X)&B4#7I?!A&N=+QT9D\VQWKUQ/>;\>).X7,1^SK;XGO
M;,VPCT-]HLL8K2'AXW?0N+0Y1,BSD!--XRRB":CBR0RKJ_6R^D8V0^(1>4T,
M7J&0Y^@SX92"P3W>'?=#UJ<'KJF[GRFV!$(Z?NXB#D8$^@LR;TBA^H Y]0O3
M?,R*9V ?IS%^WQ3]O (I<K5RK:U-:Y4']/2HL='?ZF=BBU*,W4-J!2-:J1JQ
M0%)3\K &%H&(6@L"K+T0QH\8V?7$/UJ7 TI[V3]C:K2*AUPB&G9MNQD7^G#=
MO-%-Q:<,U(F\<T"7XED9>:&7X$^)G:Y/#659YW)(M6]IR0(A!'&O3\ I)ECB
M#^SS-5ZEP_74([EN1TE..9\]VI  NJVIE5. KM7O&J[^*K9J1J^<A4=*1]UV
M_VI#4\9ZUE-5^!='7/!O++U.UFW?*059H"!&1<4.$01RW<ZJ/(1"RIKK-N#.
MD]+/,N^"]*6*?+)*H+GU!&L)",357P]_ZL\7FO*Y^2B&]1EVN2E(7M\VT-I6
MWB!K=]ZY+4C5B#/W5Q^HI>5E8TN@Y6M(>IG+MBA8-$K9W*"42@JDK^!>L:(X
M]B7[B838K2ES_ZK0^ J7_LIBO::S8Y1"V1(+4KKNT(![_KNIYCV>QY3!&1J
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M!V*1HN*;-S]!-J\IGE:J*';J[VH.RR9)N4.,, 9\+9#@.V,+XVX+;5D&3_I
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MIF>!&B9V*UE!OH]X!>97,E(>$M+W$LH&E5*=/65]S=98W#U 6.MSQ[)TH3,
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M3#6/55B2XR'<(0UG4O[TJ8575H0[Y"$'>,#<6D77?I:@_5U_(YE$G(PB*7V
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M)3FW2WYRQS1C*41OK#UP*Y5F0GH\7A$\GCRE@U_ 3OBLL&%&)SMYLLNOAXL
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M)':H?\HU>,!_A\)V#AP-&[@VT[A5E:V7YQ1:X^?!]\"'%/?\YMU3Q46GR4<
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M=-A_2H,;.NMUA(]1^=#E!Q,RQ<XSPN^@(-8CTN_LQG"*LGGGP62H2!A1G>1
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MFV\\/1[BLC5J>0+E_7YP.;)9 90O'!7V,6U-)02A^4Q55#.X7]/HS'#K*6:
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MI+.NUQ]*?YS!&IV]EW1"##O_3.R+6.1Q):)MXZ=9.\>K%84]^(THS79FWV?
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MT5V%'^]HKBP1[7N!+=^AD9F("Y^3+PW3G=G@@BJ%9$6C2B<!1#ZM]V>WI^1
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MG5HH,RT.*?2[X?YK<+15\P!."" /2-JP,4P>RQ',E?<BT3FALZCCF;1W[>L
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M9:-10;$<DY=M%2=#[P.SC>6;+^5P)IUWAWTV)K;K J?U1/I9L<D38=KPV2/
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M\\[?O1>+BASN(]S<>0U>->_W/7V7;"@>3F_1M<)+:6U/#?JU]USE.)V6XN1
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MY[!FH@F3#X7N)/R(G%NR"):"H(U_P$>$7DPV2;O7!K].=OQ28Y'9N; !Q-N
MG8KK80;IRZHW]%\Y%5>-Y6)+@B+B!ZI!*K\Y AR%R';Y(X!G7FRD**KU9$1_
M6]U&9ZCY.XI@%H%LS\8SU4&9/^N/C<')3_<SZD"?@ BWZH/K@=Z,]WR#DK34
M'P />N&H8@_C0LX/W1FD+L.X.KJM1OV=-V+ G=33E7=%U4E!%,(7S)K]8:@[
M0;'&IG=P1).?;4&=)>/GY7^5TQ'E()%)B/*I^"MM+NCI$\$>IG:G6C.])4X^
M-;S!,P7X^\P#_ &+%O\><,/ZD>.IGC[ ,D",QSMR)R7__'F@&KF>&!3J1:9-
MVZSOR4ME6?.UW<)0C@ +"_,/GQO-/8H["16)>OKD[R@QP!EQP-#CN=)2+[+
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M4YS<'I :KEM0JQ%H<T.J>88%T6A07PSIB]OS3A[C1\_K"LQW-L-SQM?7RND
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MU4"#HMG./3EKW*!H7'N 4T$<(B,951A%,L\:'K$Y&-M&<A=65&1N-!TVZ<+
M-12?O8EUW8XV(->6E!^HHOX=;DLQL+MN)<UXK?O*S$O'))WCKE]-3J.)]C F
MDK)./?KO"$4T5[JY+MGYZJWXWXJT_A9[JZ#77@:O8G-4];$F^T95OWR,*K\3
ME95-I^YAY/(?;M*L48WL<\]F0#^U>00KXGKX[BW#&13-QN<,[!17L 6-<7,:
M8S>R>CB?_U5386-Y>NT/3ZS?R*E53?%ROP+:*&I^+GV=,D_H>SA%[6N;I7KQ
MG;\TT?[<W*DPPU9CW7LPV^\='?!W"EB.O7V)$'/[!I;-\+/=T]0?#-:]<L_?
M\F0M\"^'^*<<?GZ1J!1C+XW]6^LCU%@0-/SG*1VHZ?AZ.MP&!"H#\'+@2#$P
M6#[+$[>3\/ N518!ED\Z2NC8+_YC@7A$4.EA3# "'2RLEBA>/SA8G488=R!(
M]I]_&Z\>L=$!K%;XZ8OL%;*A8B R.P(!$L-O@\5GP]I/ P%$]3T]*KA]PVAV
MFE<%USZXT3.T'S_*P*-R.&C[[#CHCD8+]13_P2K3 :5^7=6[4/@T7HN6DR[4
M[[E:J!3"O4L\I%33@?&"O/0$V#XM:']+B\FF19.#YDM^*Z[RYRV(9Q.&$#*:
M+1'_>E8=^KOIQ8,D6.,Z3_ #H8?",2H1$U@]S#"G..43@W%>R+G[!##9NT=X
MGPYL"-;P9X7&9WO08.09KZ_\=" 'B7CDP'^(O1ER'>S'O^?7K0,;K-LP50%#
M$SH]UF"#V)C4[WP35(^DC6D<_*UNA4)LK"<=$*8<?"UN4J #95[7\F+$E<XS
MCK[Z4A7$M"2_E02/Y.<(ZV'D)(MSZ&^G"%_2416G1!)ZZ  $I0ZHGC<;UMI,
MZ[V./#0^H@.:BQD)N=W0A&<':P&.#3V(*L5;O*?]8S[R+T9COZ[[X>+G5SD9
M_K;*XNL^*F[!M%J'**9BD82/IZ.],@- VZZ* L:_6EW6ML;_,MMRR:M">H(8
MTH2]W*JM?LUI=\;,&6*-(VP%93BZ,'!64LY+Q 9YX7NZ7DMCVZYTYE><ZB>N
M]8]!3!%2KT9=*[:D7J*J#>(DMWPR@LO<E1"*8_F];VL'#H1XUORPH(U!I(K&
M5ZJ.&CS62$\X1 <0:!-R#QQ/*A&?^LTV*\K<"_9#-6+^&=LJFNZ+\6D9.U9J
MA.3NV<;3V"@NN]))%6M6%EV\KENH(#[3",GCP8N^\9);\D_J1Z5DI%Z@12M#
MK28=XMRE!CH*4B8L^2!@);VO <40!"ET(2>.W!,3: !;F.>'K,WQMPU[/1A6
MF$2UV(^L=W1BO,D"A:G[01E3Z\.>0<K&-9BE][]Y%OV\J,[3U@T6]>CGS<;Y
M>LO07L;87=QF4  -_"YR]*VJ Z@'2PMJY#>K4'3WAJ>C<#]V^KP)8\>E@T6U
MLU7O=*U?5K2B<;!]QQYTX&TJ0IM:64L:1-2F*\>4'Q@<N;E[+99,D]XZVXA%
M/AFZG1<Q-'F]"5^X^F%S\Z][3:80Q^LZ\B9'ET>0*(4*1H:TJN):)4>\^& "
M3^=]'1]FG*W'K\PUE/YP_.9G[CTT;>")?WWB32HC!N@ RHKVD_?;$@:)?*,(
M-D6:_1100N,RQ+T*"-#":BNS]\,X=$5:@@X*E?GFRV-S5Y"G?V]+B_O\:B%!
M2TY+!.@\]</HB:S0'3,MT;N_3H?H_;C&$6*J;:_U)*G[A;T\2FMFV^A4L;"8
M1FM8B?HYYS*U,Z;)_NR[!,:&+3/#&WE1-T#+W"]_[/-#L[PD"K8>T&X*AQ@R
M&EC#D.L=K[RSTYBY+Q5/E<$!]6J]R?97W2\<?E[#M5^IRL?UJHGL,1"?0OH_
MW.F9$K,YT\N4Q F3FT* 0)^6ETIPQ+-^YPT[GX<WO0UBMGL5J=+'#YZ683QU
M!0N:&95QJ/WXZR/CM;!8X"N[EI9I: @; 'CGXZ4@/M_]_>E N@]BYFZ%<]5]
MOKS:B7RS%W9#6%+0GF_/;BMW%C^%NK1S^6'R77Y9U%PA3*5FQ'.-YB16G[B[
M%]H)I0/E<"-NX'PXOZ>-U.Z%ENR*KK'.<"FI(S7=0?7(*&PTDYR^L-V-NRF]
M]G(N7_!_4CV>CY ZGL7"?NJ6=%3K5"6Z63,^=$C]F17>F*KG-W-A.KY+F/.I
M\: /+N^H19EJO(R@L16-V ^K:QZ?GS 4;QC/M""M^E3,E/SF*XM36SR"O "/
M3.JT>X3H,VCQ:O9LP9[;XKV>NV_N3$07!(WHEU+>>O_Q$1@79%";2/;S^,5O
M![7MV0I&=,#V;O[TQ]"!T9C(CE6A/=E.?U,Z@+YS3CRO!=U_TH;\1Z)(43LQ
M2C+A=&#3"3](R_$DTP'7$WYCNV?<S$('[-TC- F]#K9+=_\;-1Y(1DK3T@==
MP4^,BQ?;CC[^ZXSE<2(^Z#'MGG\Z]8,,C%!JE6^!,CYB6;<E7FRA R,E+M(6
MPLR1JVZ?UYF05>K8":[!*[L&+]?:1()$YHVHL(JHE:!5YV6)K"J!7VM,8'G,
M//ILLZ85%=[*Z8OL%+R-\;*]@-K.Q1H<&]"!*T:'A]"B0JA#[@0)>HV5([<6
MI2H5WA*?*]"D(^W@9/>&FK<@Y)@T_6ZZ'>;;SIVD+WH66N_X?BN[ZM9:L/W;
M<N>I4DAGE4Y^I7 6G(41RGO-[7;G7K_!6R/G?-#=.I:'4FLS$,.RHEJ<9TYI
M W_)ADAV]H'%&L8&Z2X5F, "FVQ;E+-$?;@*WI1E'IF[M=!B ,D,$*]P)9#*
M'=+&QR^.XPJMN@K*JRNZ]B=*+)&B]9/OOK]N8U!G6MSRT1VOJ1=[,.*J[OW=
MLE\XS1!B0?J KVU!KJ>7K? B<TV+XVZ(;SE\U$^WQ?RMNB-=!F4-@+9O]*[#
M;$AK8 WX4GZIE[,:PLSMT&C/O^B$VYRET<@I+R=E'@0>"FTVX%]=*NSACG3#
MHD84(*ZG1CJ=/5 Y1"_XAT!E9\%;5W[/].173^E[N!'W;"2OCVI@B"ZRKH.P
M#I' 6W6MW%?5KZ;EN 84S\SZQO]96L<^N3J>"?TVYXL\9N.+WLYUE>[6O#(;
M]^[&C39QUPK"Z(.1T2FAXEYAP8(%-A"9RHXH9D)>D(IG>IP%_RQ&IOEVRSF5
MCJ536N!-<X;S/IB*:9\Y,L$<Y$ IV];]4+>YB"\<V#C!V"PK]?ZFC$]IEX>[
M:R#&WR?R=J"D4Q"G^;@)+G%&.Q\WGJ0 =>IS$"G>:\ED$3&?P2/:3S +/[.K
M/1@;*(F8>]WX-]<5ZE!FZ.3/-6U>U;C+UK344(Y\DW&VSN#5+G?4@>$3T1C+
M[P,BLN['4LUOV2%\%AA-Y!$6UR/PSJJ?'8!B<FS?P)X=%*R/.G6-9AI:?G-\
M53/\K4R[:$K2LJ C3?5US;0V@B(D>US]GHE_SY??9\V7O)18 ^W>?[AX/8K+
M!Y>C=19DK\.-O 8?C6KZSO(SQ$#)]QRHEV#:B\,(K'_3)I2NZ$XLVKLF-2A?
MSN>??<C$)_R&^0EUE?>X)**_H+$E_8 .L!]ZG1##ALSC>[A'[C6%V=6POL(&
MFI( UY+7#X?#_-CPA:H2ELNMNN0:82!L/PFN^T@"GMV[T7XJ1_)R($J,EXKU
M$O/6?T:&E_LSP"EF#*$)1CE&'7A^$VY:&Q+'H**.%:(U!_MVRY*(A45ULV(3
M'D,'9.C6FI-\O ?\ Y[)A@K:FM_0BI:?@&OD#.YK%'@7@(^I_ZH&-9[(?QP0
MX)&P0C(Q8CZD!</G:8U 5%+*'DV N3M(HYXB]YI1/6LWP1XDH.:#G:Y<RNH0
MNB/B$1L,H@7NTTYE@+H#'#<&'SEDK6)B#_^&7,PZ%(M?" B@M;P&^U'^P#2M
MH"($7/<[,)ZAG6EO%2G&^4<7]7]R(; <6EL%I\DI'_(JT\8$-#Y,<U#=1//7
MMD9K]NYT$7@HZQ(\&_:Y_1"TTZUYU8WBR O27$1_NTNA X*O&?@7^&,=Q.#9
M[_3 1N_.RA[9Y\TF*Q$&U3G(H63"$ORN.MYOE1_/L@SMOL,>/+.?=*E=Q N$
M+6+3Y15QA-,!9,49;;'@$["YMSMX::YNX.85/F%3,,("#(/WC&%H>%NX4M@_
ME:;:G.?%\V( "65L3G#]\D45WO6[J[B-J8*BRM.>?T $.J#1%@[H_B!BQ>J"
MPQ(0Q902%0H8.KBOTE/%FY\2^R*)_"ZH#4D'K P;5A&U[]0"@K.(9!-&^4WY
MD#L>6?%,[OV>/25KV52/-36R-U6%3"BY%Q^PBC3=&00-KA *>XJ #?1)C'K0
M(R G?NK<K7YF,30&N4&#52B%G%,EY"$>/6AU.N[Y_(.7<>S7SEI8PU'C^:'[
ML1;&/6,QFU)8"5":%F,2!2#$"O;?[8.'7)0?3_O#E'P7I9>*_^>7YMHN03YI
M5#YH^J6P:&ABZ(]B!_/4L=\[9V+R!+^WB3FI7XS.WM<XRWT)WW-EY$&)(ZO>
M<G.YLAK\V_)S?SM 17M!@GAZR"!(T9Q6NX/>7I\X>AEI5,?" RR4WEHW-NOW
M2'Z:W:_7*Q9OZ$=L*F7._]Q<6GH%_M?\.9?"L_3S_D!]'QD?UN+B[!]FE^FS
MPY\= Q)773[OM?DUP4(8L$CM9?6MI4%T$GL69^5,R%TCR6<HNXD_?W*==HM[
M"BNXHN+P22SQ]5FR]PF0!RG)XC@NQT[EOJ4@<Z6K7-F2L.=/'S*[FA$"VZ;D
M$+Z)NV[E<DP[*D=6C9)EV7.N!]@+^2)GKYML#?Y6/1-QVR.$\:)F)&!=G^3V
MY8&SU&8Y]I+V.?%_(JX $M(S,E]N4#<=[+,N_;JR-*>Q*U*73 >>XQZD)QX]
M_MP6SJ['B00.$^-/+6>9"*%KZ4!<Z_;<(YHA;&&M[3(RZB8U82GL@A-B'<9K
M=LN#5JM_N_FBR$NA_?XW#& _X;#!/6O;<6X*_WQ>44(NK<LA HY]0AI!MZJF
M5N)O7O'XTR6R=0 ";QR!D:,D=]J#"6,K.D!.,B$%8FDZ*@G'X?\_I!L7R C*
MAP.98V:;DW%/4!\^I+X220,;>Z2$D0&-+,^\F/]Y=#4&0FDSUT;L5=SZJR//
MY;9<'LY-.](^!RPPA([^?>50G[7'TL5IPOZ:K-GOYL23%0S+R\%SFMX5N6VT
MY/%+A'%-?B1TU*=W9]!*_.OI$[YU2FW/?&J2,[%Z5I?SZUL;N;Y4J<,0$&A*
M!\;P6.B3?AVCD\17X%1I<NDI B .G'_.H,UY8;/MVP=3:M?A\G&RW\T<;4YF
MNV[YT,.0-55N8)> !<,D8O$0@03!K$JF^&SQO!QW<\;1+.18Y-H%-B/HM!MT
MFX=]V?CH5(PX';@)?+VSFL7/CA[)SXO1XA53)V#Q)XX+M($>.K$8\P>'UTY"
MLL0SG*9:S+Y,:TZO\T*$H;$.\R5B1U3#!T;G0H=6U=DZ$A"+VISC=$#LZ ZW
MXJ5CTJ& 'P&\EI=D,DL'PL/PT/6SL'2;ELC]C4=Y,1>$\4BMDVF+_\L8_4ON
M 4S\T.EI!5EAGNWVX!-%K(;NC;!!?_&OS*]$+H6-PN H-N(!E8ET @ #%JG;
MSC/O9V+9G*2MOZ^JQRV_U8P,Q_)@*]?$\]Z+DF6HMZZ2_1-4H0D'P<_T:;\Y
M=5\*9G[Y*'O<;RR"5F01D>GC"*GG=TB_MHO^>C+]ZVYM/_UL8Z6W[88/6/*^
MC)A>#;VQ<.>R_DHK.N'3)[6[/!(:N"OY*[H.>3BNM*A*""IO1EWOK*!]9G\R
M1YKW;8/+*]^-C%[G138=P+Z(@998OVS5. FRG'<E6J2_"\VY$YHN$I9&$$,X
M[QJ?+QWP\H!*1(O)21R5RY&"IH\.WIR'%T"S.))C@FBV24$6^538+YHY'5A8
MG_Y2X=DV =O<%IXOH;R3^A#WW7RP_9P&N?8."P^/4!Q,R':JC@[LS].!Z_?I
M0/=:7IO926S+80=VH0/KVO<7]Q..>,P)B),EM2#T?W])&VNC R<>X^B<$$U9
M^\HV_#G,^:1S$$8)9Z<#?/G')_II 71@61Q&FN4T8:"6P>@ F [L<6I2W!*V
M("<C=^A 8BX=P'J::C$1*^@ Y9 ._#*A [N-FBAW.K#:1KL7>6([AK6!_U0W
M)_#_4/,;DLN35@TQ?*7\+AU@T8V@ RN?P*B^4YHK.<7(P_,DC\&.>88<<HJZ
MS+]S!''DA__]GEW\_WC/+ORHGS[Y;U!+ P04    "  V2WE8ULSEN/P" @!M
M'@( #0   &EM86=E7S P."YJ<&>DNPM4$U??-SJ*2KU@O%111-(^J+1%1:N
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M7P_J^!?9N]26[2@N%PG\0^4XTZ?-"I2Y>>V241>S;AT2NWO'^UJ!.V-E>-*
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M>?Z%X?B3^3U[^"W^=@D-(98>_EM,*L$\9?Q9I(6*VOV\G(3]^V5YV$^E/5:
M/L%]7L Z,;GCHU]JG%']3%(9^U@I"9AW2(1G9,MQRNY21W*P2-VKYE,TB@0L
M@X+N+OU[36&A%?BT_N1)*["6JG<P$,AN^F$M!EE"7S8<[ZET\>57C.M&8['E
MI'(</NCJM!2)'X2:A$>V[B$PZ*<HM../[C/YGSVS MN>4\G&>2(=#4HS+8\,
MN7@R:[M?S X>V$-.F/*_H5*DQ1%_HLKIO[;V[^^\="B1Z4HF:%:<H< *]$*9
MI?\V:D"(R JLICTGLD%8NSR%M#44*$JSK)'T8[1*SYP^O0AK?&;FWM47/>1*
MD_1%SC7:6'#1&5*=NX50VD'C%"O0 ?+*SABXO(ECM59@TK+1DA*96@+:"__&
M^'XI0NK1G9R:(DADP$&S_L%_#)SDII'+UX9U>L/9V-WWA]^R^\CI'1::;(;\
MHA=#U<G45XX*+<9(*LE 2&(L6H\U0SGGS#'F!SJBK.^W*FD^UM42M3%$&DJ$
M:168#$GCH5_3,J:!97E77>1;\A(P-XX5^!==*S$%Z*?,D6K&"6XE13*AXW^2
M$K,X88-<\4&MG*!5+V,%0:3^%(%W^-M76H%XR5/<W_XR*?SQ #I]PP12GPH-
MV3MMPZ"U+SG@]G034I]^,J/!?B')"+!23!7E331SGT@0>=UADI<VX*X*3KQQ
MRSMD#/PH\C5'B@0F;\90R.12)YKP=\M9EE>!:7$?K)#H=/R 5AVUCS3Q>>2L
MD0DK?\LZ(VK6$\A SP2F'*':HLP%/198JU2J?E2XJ/WKH/*15()-52SWYI:9
M(RT;T5G"&F+-,^0B19?,M\.3R<*28#>4(5^JC76_0:=.2I^19.$-FML-T,73
MA/#Q$9-M#BR7Z >AE"A9^4TRZ)X;K8EURG@K0(KW]%;CA,]];GN+2?HT27@9
M'#U898;JE=\-B[3#"701GE4<FMM$W@-%J;J/A(^ 'TIO25(M(NY:ON6VS(/>
M"W+("1Q.H(9\""V#O+3;"7\3=MU[VR*L4":QN,W[&#.229PT&\&'FVSQO*^?
M#IO9DA/QPKI)AT"F$/7!L%DB=EK1 0XL(H%,T<F.*.SI[AN&-%^K=]R==+XD
MBU]9F_3 $F_$\A50(CBA)(6U9:IX'R%\TJJG.ZO XQT;$9VOKVBTUQ]FYI%E
MFL/F40[+G3I,1Z!G1BUB].DC\:L_U=WMRKS#*)V$Y_F54]2V#=4>:MHC/"^^
M@.7?D.756BKN]W8C\E*BB!-S6#P8W5&YBIMU6[=#<<4K<@!9C-(:A0.B\^[(
M)>+;5LSM(<IK)+[L<,_TK>^>^PA/%F%?$+:DX,&2N^1.7VO"T(!D-&"GAHI]
M7076M!RR O7R7VA?/;4$]WXJ><1)<&@ER**Y,IYD!0;F8SY@)F?;(U9 ?9R>
MG]!?W(:TZA!TA[XD)B9;[>XW>P=YY9#<N0Z#=N/Q:^M<SY1'G*K4'80>F)I7
M&>/'%;WP3WZYFD@OZK!+SWWCL,EB>!=0E.WWMC6(0CS7*Z0D*%TA:]_%B"B\
MN<^44EW#V4K/M $K (P=82/?)1$OS%EPDO/$^/@1AS,9BD.G''(,^1$1>=U]
MIV($,(.4+:6([("0/HQI#@PDD5@"OY=WSG(?OI\T8+R\FM1FZ)V@/E*-G(.U
M5H T#A'ARSG0[9C!9[]H(C;"CZN1J$T;''T/^3E5!TM@;'&DV5@_#H1[.'#S
M#<LR&/'Y[_83WU#1[4+#B:T3[%U*(9/)]"9-7RJZB\0\!'O"0R4[[M>%\EET
M_XOFQD\CTFT=T;Y2'6*:01])']NX-O855C64L4T]2-7:B&/U)4J"2CPVI]W.
M:^>\,GV\*U]4>LX*V&,+J83#PO[1.N>&P @!:7] \#+)_;<>#2M%IY[0O-BN
M5B#5Z9O6-57DG% Z_">/1[B8"/;D,3AH[G:U1?:#8KL8:N4N0R>,*B@4U$TG
M 4IHNIZ(S!^MC.=X)FTDY=^ LQ7X<7*EQK>*JMDTCE^EF#[=>I/=(=V(_!)Z
MN?GCT]^16VE#5L#9>(QZG3X'&8H4Q]^S K6>!0;2JSB[#.@_)6A*!@ZERLR4
M1>%9G':XD[_VWQV"2LGF[[AAU^Z(]I)PSZ^#4#]^90_D7 ]-F,A1?QLJ_:X9
MI//C.I,: @?)KDTLJK" G:@5^(D,96$A]#=Q6(3J5A>Y'GA3V785VT>_FV3X
MM,$ON"H8>84_R9 SSZ]R(5Q3YG[JA-Y3&X-!]5_X^N[2C=++@4XYCX\,>]"^
M4?>6/W@<-@HQ6K'CN3@B)7;^Q/TARD2M0[V.%D'U+SDO]EF!'2_(!&F&!F<K
MQ66'*M$;,M"NET4/(MI)*;);H^A$Y$;B**3Y0L1?;IY;)KY<Q]G_67%:V[ W
MNVT8YZY"3[^6%7/*V\;SL.7G]#22]BZFL*G%FO(2RU9EUC?5DZNBEZ+#Y"]4
M3N):J ><^%RR,^%^"F-R>2Q!22QW5?'.@P*7E\G>MF2&G_>*!).Y]@PG>W5?
MV@!/Q9S7905.LDY@0\&0+';R,)&]V6*6O"(=X\^\1=OL\FHNDQ[OBO&"UUXA
M+9WB?^8SA02D-^'+9.\7!@YKI=L,L,H7U(F*C4*N5#'BVA>[=G_ZH#'.]W9U
M]X3T]7B1HOZ$X^&,X['-)YY<Z=8$AUS?NT?JTDH5+#;?OIXCA]%OUA;FA Q7
M7(=C!AYPLD<J#B@,J1F<7"B4\<%Q\;3K<>N7C-/=H!J:5\H&.3(*<S@@5L&"
M">_-<F+>.TC"]U>/[\&OCJ]FTJ9QN\Q%MQOA:'7)?LORG#S29Y)TEL=W[BM&
MCLYVVRI/&RVT6(&2([VLJ'H2HD.)EW*Q+9959II[,M&<NV%U37[XQ[#J*TU%
M58O38L:@[W]EY26_EE^+?Y8_'O\LUPHL-E-+MPBO5J\:\A#85PQ*[73^MHI?
MGG9X'0X+DZ_Q)>:[F:<P C\E2>NJ(-DC!3'OJ2LI"FU%WN-_L-=[2;I/Y$1&
M#;Q;:S >;%M=(W:[/L,]DT+D?'#LU[[RGF#;-':D.0@3N"L.R57K@H:=OGI:
MV0:1?LR7:" G8(PSN0%!^NPC[B/2:?IE'-]^::W=P<9&N9^@ CT\D-SCMXJT
M(&&GSCG\LY6'[7IF#NNQ<>IKWA5?951&O7ZKBGX:=XX^&%</*@L1I0[:HLVD
M$ML,5B!XTH(>JW+XCV>-[2#MNM-BJ?%SDMA;^8(FS[2\$1'OK9F=W!>3(=UD
M$)J4YG;H?Y-8KIU>ZL?_.3MY=6AS;;'^:R2Z$]^ \4Q8_O>3>JF LYM)K[,"
M!>!:9+MR>Y<9?'UGC>0QUCJ\&)J8/;EM^Q[Z!OS(-Q'Z@$2FS@XD*@E8K!2=
MB>PN.$R8"2F!;,(X6RSG]'H^G$:'1S@>RP9"DB=V<&8PMT@:%RJ(,,KG3ITZ
M,*TMGQPOIU0KH%>2IMDG8XOGY;6VX"E-TE50IT>IVNM1/T--A0@>ZZGETQ))
M<;TCVD3DB;>$80D%B+(7O/OPK__-E][YO_E2-$'^*3G^;_8/"WHT5N#SOCNT
MCDWC?/F%,9^) MX4S#N=88G%DAD9UR!AKW3+\23Z3X;1#;SM(7Q-O"BIL99%
M:X)'.6[@*<=?(>;UI'O<0ZJ^9Y?91V7>GKA/UZ0J5KZ-BUXZ+C0M$?4-;+JT
M?=6A1>'=WWB]CCC.T'4Q6L/9C:YKK ##_(GP/]'15#1.S!PFW%ZH\RZ>%=G6
M/19%&V8S%\Q>:-@#:T@2NM/X7/A=U/7UJ:]T1;(EI5<*"\?/(B6<K$$;0]57
MH1=_7-*Z7J6\(2SC_L;^!2V34Z<UX/GRI471B$UO".>JJ-Z#1>W<\H!L9^WS
M!Y8):.#K<3K8QWT?T''S ST\KK \?0TDYDH,HE$I__TYO4H5DGBD]N:[=?Y+
M_WAW,ZW*9?EIXZV#%7%5O; \KTD1='(.?ZFCD^?7R2^N[BN-*[WE5\A96&P8
M5_E;EF+V^"/=?*9<N9Q9&[*IK4 S0$V1VKE']2-7JJ>]K\V:475_?LMM4:+7
M8:2&-6W^LYO(VP#L\S1B9J85F+X C;<XLR'-P>>6(RQ; P^=HCXG\D5%V<.T
M+]6))0.BZZ'$HCTE]Y7O"H9>Q+""6$D.2Z=-4+[;\QW8TIA@^9&1M4*M2,)\
MIN/O! 9CHNZ%]"F)&B;);[^#9FG([4]68)&[<OP:=2:7)$3- 7U[<XIF&>F1
M&RC3^Z!<JFFZLGJV9D;"35(\ZO'\FD/7SE#L7S=W^Z?E)Y=\/&=,#]BE[^WK
MI>35XOY+3Y]Z<_/6KM&'[6V<!1Q2[0%$L(Z7?!"<@_27PNK=O.[N/JB$M=V0
MBC+[O1?6IQ</<]DQ_870R[@!90MT)AS:FTX85KUOR'QK")!.J(@DP].M3A_"
M='SM/+1&YCN.QO"PA73#I005J/X7]S54NNJ1^M:A%^-''[/L&^&>;OL\'#"'
M]B%M])?0O%+^%:>I:K">/M>/$96-[5!#ERI/AIW;9 7^'$O&JXK(_.<+E?M)
MNU[58$2DB/)3W*8SZ2=-$:213^C47SXQZ;W 06CM?5V!J4!168'7+Q6(T+C0
M/*I<XHAG?M0KNKU(Z_W0 OEK<<:SEK*O5B6+)D#29A680W6+KK2<=:!=FI%A
M#WMZ+M\T7#/\@=JTB>^"?BS@\.JR?& #O8P#IHE!HL(P,W?=#EX]3PAKL[H<
M)6](^1620\ #$:YD6VE@>0CIL9I=F^N'W\7T&GPYR#H"R7=R"[/ 4LT-(A:C
M52L6=9Z\%0N&G:^)B#H3%QAL!9J,)A4JH>;6>4DGZO0JL5@WKBN2^[6.(XI&
MQ0UIWH"9NZA?%NDFT O\E:'9E,2^\7B"GZ_O,K['%N&/D>-\U-4^T2M YD;A
MOG7:H*$*P4[)$4W,!??>,])M&EZ=_QSBPY:8\[;8"@<K<)U8BJV68-L'D,]8
M1^J(Y4!XUA+U7LU)35**UZ^T4/FU>0P7,J6PA5)9S'ELY=\LN8QY"3I)N0@M
M\3HN\T=WZ2#T('V!UW%YA+^!U2;$+B-S(('7-IF_/2M4;DM'=WN1V30S+ $+
M[4<<6&)B >\4<>U+,?-^&CYC-H,YF=&]"C"/FC>R>?1+B>)ILM$H/4$JB3S?
M&B&7'$-45C7'8Z4>D0]+L.HCCIWW!#/&&=%D-CY"U_2#W0L;:#:::IX:-/#A
MNCB7ZUY[B02UO_Q=+J\ 90[ *DJS_T7].PJQ@Y= SHT/$]V!#.[6Y$(#F]6+
M.%%SBT,W9AL-4AX:"HJ+?F?HZ'2Z#:M/:'%KI"U2CZ><A<J&*QJR;LF0N<-.
MSFU(J>Y[I).^MKHF9NI]UWF'?^\Y-./TX*E L,[U5=$7\$MBV7-+ &8B)6,7
MLH? P3WM4GV:E(3CBRQJ5[()H:(N=4X_$0'P(*F )-).$U:A0/*TC[#_+)E>
MB+6X$N]NL:[+Z^.6\QJH=JS$R9U%+Q=-0F/@B;MCX!,2_@\U@^;>KY+Z*9=U
MR^RV6RA"LY37K_R+%=]H"/3(D#$HENNL>'B>%?C05</?KG1%],9[Z+T7@@%3
M>&PECE"4032>!4X.)'%8J\\>2?7A#_-(]BX,*1Z@3\.^TY3AC;<'1+.4<:D/
M(F(-WJ$J2.,WG&Y/=OD, _8W?XXKA^+!SH<LI*32AR.WY#.7A!\,6YSNE\JS
M I^)'%/L)\])9TP+R_I#MT)S"&?,QEW>U]FERM>O->>[%W6[#%4XU_]GD3C0
M*68,:=["V2 6*--;-$D7V0']=R$9(S0%!"<6MS&W6H'W48+]A+=KVO^L5QSA
MN[TT,PX?>2KX4&A>WICAF2<G1Y,*^]_7%]4V'_UXCJ#O 5^#/S.:=#UUG^28
M_U <J7+W;)V]542:%!L"HHAH_VJV?:&',K9>/H&/FUPP(B$'(FV,^@#ER3#B
MB($<CJUY9[Y:.AJXR1*& V6%D\L/M':+)LP3XEN!H% 3Z0-V8R[DS!:Q7 9$
M5ZN_97O",H_GA</5U#(T0-XD1?/X8$DTV?_1-0RPLX(*3JR/RJK+VR[.GJ,*
MBP_LC>AYY^0_?[5K[<KD%S%'@O4'!6MTG5C ^[+Q54K_MK*F91FP2@D6APQO
M\1L@Q&8%.8N%=K[]F:G%1[/1_-VD6]VE]_5VLSA/;C$U@Z.SBZ @ QAHZA;1
MT12/DNR1DN$0#XM/)]$09O"W(X4TU+#6EMH#:_RLP*L&DR7:72>L1:[^>2J0
MRQMX%T#,7[.PSDS'$MT9B"K3=_\FZH2#!!PY)GH?\ #/.Y,50"!O3?[Y:Q;/
M+TQ-R5>5^ <+6D;8K@//=<OR.:X'LKH5I-'A]6Q]\5/FMU; '#/BS=M./\1:
M)3*2'F P5,J?J!G:(LD8KEY6G#&JK2E"?8^0\_]1=+"4Z,)8YFC^/]'X7.6?
MIQP:4HQ):ZM%.7W0@][NL'UB-QUBMN.&Y>D=>1M]'R2UGS%45_'-U$,LT ]7
M(6.VI-':3.VHYK6 @ZY']429W(&6\7CHVV%%_3F7'RP!!KK!.Z=784@S)!F&
MJ9J5@R0]DC)=4LDZLU2_U<):#<EEDF21R68.= N6;,ZFW%U]H"/YR"G\+*)_
M-,0Y,I+?'C?V CJ2B32&<[LL7MR6>6'$KV"Y1GP=1\!31!SX$<9)MS3:CG_.
M_C$Q7G01=%J=)S0'U%@!@DZX; )#O'_D*X*@QP(RW>G$-T@&QJB3>K[)T$HD
M(H+R@2L>:+("Q[G7\53<PZ>5.N<H.8Z0&";?+(2%99S6_CM0-%./0T*=L,B5
M=$&7Z!,J%-IMJ:M91XQ(E6;R\F%>4(!0W;>L# _ J%KO:ZTC16:CEAO6YK0L
MR1@B58#T/.H->9^7)\6\%LZJ*B%89BU\-,1MX!D4K2*B].9(DY.WO.XWD7L1
M/!@7342;KP<GQ9VRC$@'^$/L\E7=*HG@[H?MGTT4@3A=WG//:.Z ;ED!4N_9
M27.C"&Y5_O?_V0S]1GC+TG/-"1*)S5QWY;UW^=X'18]'L3?J.@(2C42.3@]%
M'S=3T.W1*0'$,8?@3X\>=G7'3)J(LOM1^":%KNCB7#(@70%S@15XO45CBU\C
M.=W_P.@@/,[X:"IY_1;IM1=IP_[%FKWOWE!WXVUO8W>$:EN5Q04Q2 3#]\*\
M BARYA+_^TKAKH3=%O_N4LY:HRHF)LE/X83D4I84U0V,CT6P]VX"=;/)DKXO
M0:D:@]H*7 XT9LI[XJE/M-'9P[&D*P;?$U6T2E/H,[7TFHOF$O%@X-W^[>6$
ML$(M[>2O6:OGJ=P$P^QPYQV#$-RB=T@[3P HN/.]BX9:!R=:@7^V,,'BLYS
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MM%](%&92&V5C3'3WXQB_6:'?=25?Y-L(+\#W/QW:!5$8ZF?3+:0Y34"O'EJ
M"^,37KJ?S!P:*Q^UJ**$\E<U7G&^YIN2I_&X<^A[^#(4+EK.>F0CJ/M7\KZO
M>KOMA,S>@,7[@ EN 97&A0:_ $:PW C4.H#[>*'QN(_!K!@)IB98W/#^"AC
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MR81:F'<0E5K6X.T( <">C5#O K5C3O:+J\U$1S2W)9YR,URW<M?6T MER']
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M-$'0$:VI ON((W>8/+_?M)D^ZR3;1C 11ER^>EH[<"U&;*T;382W6JE9QO>
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M'\BQJ+U<IFO["[3"@S6D"2?[=&_G@):+UX#HN!YE(0[#*\>@<N>Q0.U-Q::
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MORAB2?W31>E>I6)?WM^R<F?L4P4^6Z7S?ULOYY]SV8Q>UTWWM4_VCH8O!;N
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MPED/?C7YW&/XJ(KTVYNR"-\?\;? Z6A6/-N"^9S 5J#S==N:Z3,%[FPOM'D
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M6%/>4U;3JWE@(TCNZ9"Q4(L3.MWHKG6]0G8?I"]&I7*?*^R$QW $2R]W3M-
M\E#^B;/7SH9 =.K>6P8?K&P""N[SCI^TPEO;'\.F<!N!R;.X)RQF>W7NHPVK
M"\4^$K.%RVLZRJF\ZC=%2S3BR+[N_TU$#.EOP\\]I')-49T;>:]^)>I5_JNS
M_K$1()$T_X3P+=BCR\%\^W-X'GQC(SQT9>)5F.KY_\86=MG'%B;M!5K"MT%F
MG*4MIV<R44!ST%[BB"F^ZWOZA!L:@C_O7X27D\7P31S^G/>+GZ]]/&/:OY='
MGZR%WCO=A[M= #)\?^6K.2331V&P<29(]C?[_^_54;/AWZNC"Z&!A\"NN\;*
M0DLJJWF^VMB+Y?=RYD$5Y=K9&AY=S_N3LT"U"#^ %$G,3&!,P=\C^Y68\V?M
M0TC9K&<=^6>M.:I!Y*+I(Y(I364C_*Q!.9XFOC9=?Z#]6&6[X=#XJ1C'CX #
M#0ZR$40VPCX9?Z^"/[A'L-)Z@^*_6RJ.V-0S=XP<<=?*;5YZ806G$\\*1<TX
M1U[;O^SE9-\^41(>M"L13Y).&J;,N2V])Y<V!<1@VL##AQ.Y8W2&$5)^P2G7
M"^H&+*HM;,LR[D@+ITHUSF!O7JWZ8 [DR_)Y-\D8E<X;/?.)JFOKG_[Z>CPU
M<D2,\1K%*[ZJZO(,6JI2MU/51D0/_,V=./+&$]4GD8<C:I$W:A3]' 3 8V:>
M\_5$;BM9@6T8$77D#"3.'T0N-^C'M'2J$*OJL\]*)[U&/.Q#3AR[1^F5-L+S
M-'\6),^P/H5"@#,A/:5>76<C#"V!Y6ES=DJPN &Z?D1RCGXP> >%C#J8L$2=
M!',;@-$U/I<]@QP&'>KA:RZ)(F/*6*%E/WL96AEW!AJF26**IC_/V0)0YG;4
M85(&==]H7X0>_-8)TJ$16(C/IN..M] 4,C0+8G![$IJBWDE928,>+8X> 8!7
M1QIY8^ZQ!3;"/>X.2L]RVB0W8:[YY"[A@23UYBGZQ!3/WH+\#4Y_F8(Y\8-3
MC"#5SZMQ,<GA[IU %MUX7@M?(5,':T A'A_)  18[8&Y9CHO&8!?1(W"5-4#
MT2^6WX*_MQ'0V;&@7MTW_F0C+(<-*N&K)S)U0(25WLIGZKWG;BS/MD OT,#F
M &.AQ0NC PG43'WR;I1.'.=#)>PCQA]MA'R4'F2_36Y4FA2+S=9[!2<"ANH>
M!8XBPQ**<W6I<[5W7SZ&_.]#BZ",*&LD=F0 0G='1X3L*2FIT*WF/K+?9V-1
M#]@(&?, 9"U8GQ"OA;/! 5JVHH\L?GBW-<NC/##;J\G%$>^LT[K<E"^'P?$V
MS/3!SD6O ZQT@8I%!7-(UG15 C95AW@EOKY*M?C7T8*KF?P74VE'19;-= BG
M $EB8AN_T.-QF".]=.)S\'NJK*R$7#Q%E@0@XW9Q\NO7\),5Q/V94O7RQ&OC
M8OP<G&_2'$9N4I(\S$E1S.AX&X$JEEX-+8H^$@D=:#9Y3>!(X9VV,"OI_>ND
MES9"NC;AICGD+@9M'=XD?;4SRGAY_!3<4#*8]?J5EC@)ZW,@D5+\'8ER,H=*
M/8D'X75NHY123@V.;#QG[VB-W4KN@^"H*)'RA7(ZQDA&K^,/9#BR2:;R7ZOQ
M$$B,BR'J!QMA5)E?]Q-Z4=G,R*\GDT:FVPA%>-2(2L9SDBC-Y[)#-[G0K[]W
M(2Y^.0Z]-.LSIXC3VJ3 ZOV'.AH9/"T<KY".PM?Y_MJ]>>]E)I)2B\%0$:O;
M!^^N@^T/^/P+0@S>KBU.V[UZQB%EUQ2R]PYPLH6\\QXF)N\>E [S*8:09EK.
MCW3EA(T \,/03!,SR:K .,"TE:T4A,IL%?S.>/-*T!H<"#_?HNVCT.^-N!!3
M<,I&4+"7L(TF\\>8QOK$4_$0"[#RL&G6PJ+A]*D $=>SL!4A!L--K_^=R*O%
M@1AV F(J\C7ECB+3NK@=_GT=!'3P.ICK,+KM#%FB1RPL]N^\>D@+TG<Z^KN9
M6(;2?5%F'NIF"52G6/8V"G.V=B&5]@ZBHQKLK%6T8N1HY&+^V*W[EO)*98E@
M(7T1OUPVG'A.EU4_U0N8??EV2I6<NB Q7=0@070_]=L'.QQAT/73-2.81=*D
M->EW*B\YBDB#8HQAN-O3C7V'1D5:4AE9L!,*[;<<R^L9R7:68$H3!YB=QIVL
MK<L"$U:XU??^\=8=;A=("ADD;1J>(\OW5LV].5?'W&4P(!FG'BSI#UG^]%U7
M[ 25GZOW>19>F8'3_@BML$"8.0C4AD$OTYII/Q=00^(8D2'XS2BA]*2-,.QJ
ML!'F3G[#%\&7Z.6["G,97?CR$BT?^W$=(HZ&Q[(@0$& JB1&Y25*E6=C/TMH
MK$.SLU80#U>@OKE]\*O 1IGN:YTH&)'R)M821_H%X-2^_.5P=VOXF>*.NEM=
ME4$W9,4IRB7<^5M"W),$%8'>'KE22409!:W5)1<.?,/I,ZHB-LN[1#@%VV%-
M Q0YNMULX'O4HIJ!D;S*3K:/8L7F(87ZML7UPI@AVU>-=YLM"5/-; B<U?HM
MG$WH(US6'*!L<6<V95Z4F".4V*K;N!A*H>N%"\W3M'SCSQ(RZ=?/))Z!C!Q8
MO,X0L1P HS96@_NQ\=!L^9/*@^22@ E:!/U1G=0^K-)I9(*R_)](6'V[):RC
MX_ CW*_0HR9$+S/>1R_*^9>7YE^<Y"=#,VKA_X^H;X]+ZO[_9VO+=5%69I:6
M;+-RRXI:J9G*66ME9<JZ:7FCYLJ,C,Q,5."L3$U-6;-RTY19J9DIF;?R=O)*
M-\,DQ4N*0(6$!"C@$0Z'WV&?Q^/[^Z\>^(!SWN?U>E[>Y_5^O2K&4?OJ/A(O
M7C+,AW_>U)UT0$@V88OU(5PQG!U+R:4L#M)/PHQUV!T0!V\3YF\J)]1_-'!;
MO6Z7K4LKP8&2LTOC_^3!\5_N?Q5&Y^M#Q+1!59N0$VF,'ZPD8UD!]#>W3>GC
MU.>+__WH0$!6).9>JK7>[VNT1U:$?]6,OM2XI>8*C=1MEO;AF+,-ZH<<.LY\
M[*Y.B(BI$9.HR.Y]41^U)_T.# 5/N:ZMB#4 ZS2.IK#G/][/=SGM^6-P[>W7
MA^6RRKS3?#%GC,3&%BJC;RUFJ!B^%6_AY ,8X21U&7C('A4L,^+18^ROF:02
M:+<WP6@%SSJ<^Q1*WF>_''@=EQ7ICPG5C_*9N<#8/8)Z)X6 S&Y\ U!I@S_/
MDM*LWHY&Q4-+2$OI!$LU5!GL=\"B4[O8L\99!& 2X\<>C1B<@[D?^:O-=@-@
MZP8S;NS.UXQ@#2$%M4)?%SJKK]=V"O7AF>IA"2U+&^UH;R@%!L+GP665=-",
M6\->-&8QB=/-IQX^'2N\NLME<"WG7.[OB9O+)'#F#X6T:\^>"S\$!$51NYEA
M#:IWK$MTVAA?Z?;O0)3TR;1H7E,([;^^8AZO=04>^[6$2:*6I^6>Z6'L,AZ@
MGP*/4:$YF_S=16B1?=ZK_!**#O$Q1+P-DENE:M?BMYIX>J?TDH^+H2EY H\+
M% +XT(A'6':,J:Q?T"(JJ7FK\F/.@3W*=2I2DUZZO!IUT\$A;G:W'P;3HIT5
MM"<(95-O,!(TW3CZ:5K1/ UX:K$D)" *<(*;PG+$2''8/TA24OU?"1RFP124
M/71:.[B@Z: ^28YXELCKEX&WPN"<FY%<@9OVBU%WV*L,1<VX0/5H/D8Q\>#
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M>\ NG :3/]0^3CL(9Y7)ZX:L.</6EE?.W5:[>QZ9<22=-NP\B2G.;V&'3"M
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M"AX#/?X?6>\>UL3UO8O'HM)6,=X0!27M1Q0M(EY E$NFUBH?1$RM512$J*B
M$5.+2(20J:(@ J:6*A64U%*)J!"1FW+)  %BJQ@0(4*$D$0)MY 9(6%(9B9G
MTN]Y?N=WGO.'/EY"9L_::[_K??=>>RUB-T.]78;[$X+[TJF990/X;^"Q*^"
MAN["XTP0-R9?#,UJ_.KO#^R@E6-8=M3X4C'?CWD.*K]A".I-[!GI[)/7Y25
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MMA[]2MK"OFR5]=&>8E2(L!IHU F6B(*&_O./K#G_R_5XS5[BK?PQH**Q<_W
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M,+O6V_P%T3*.[8 3FFF+T(((/'_BH9ML+KH\H+W"?2.QBHG^,E+W%*%A_YT
M/KH]M69RFCTB:!,ZJN9$.@D\/!OB]68M2=QW$@D$I8^5.SEJWX]^(0BK1 )&
M/YAW<PH:$@3'7,V[)62\M9]@ZL9V (.1;8:726=T^VV;1>G5],,D4'^+N.(^
MG%298%P^7G(Y%6)("$KR\7B6:4H .>;HILRK(K:?><_D[K%0)&SBO"F9U3J
MET,G>B,/5KT62Y  \])N1/T"(L'K.6 MVD43C4R%O!??0UQWMNLGS,L2)#G
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M9R889$=,(1DCM*7E);Q>#;_\'2@?*"N*$YS&J\_)*MCI2$;3KM<62FCK[83
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MA/W:&OR9G#CA,>IGF)P0W<#<1!R;AI[):WY4=0%)<"V4ICM)!Y  B=XYQEK
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M'XQQ%J-8$C+H5@4KL\"CY">,M,O@$ZBA=4.?G+C8!?9L,VB4\H]_FVR^QW/
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M,>>CU+B11+ +V)[.VM7]JF)TV\YV ^,*TYYN@Z816W,G1[5(!Q$DE#@+D._
M1E?24X$&^B(R,N2GJ"9'07/@U/X>44HY0%-037F>(/J-YROE^%+:^R1#24HS
M\S'8#,U#E0RT2.W1X] ?T@!D^M@)L)U>L<P6&IR7#/W0!KW?3KQK(PG#?_38
M/Z2"6S'2ZR/?%/_B:F.8,&S%$^A8K8Q]L6PU;#Q#R%>O$?J>;-T2L:';4U_
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MBRS/[E$($M"5XY)?K)TC(R.-V4)L"PSRZ>[8WO(:"^5WHQ"OL+KJK/YBJI6
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M4=1?HPBRME3TMVTD?+H@52S'8=R1IF+^R!DWNB,.?#H=.X#JX7^DD@0Z%2\
M5 YH>[]_&/$-\S ,-2<[;$4&:I1$JG_<H1$96[C''+GM+L:#V;H&5?@<J>08
MYX61#=-:^'9#=%)V_1*%N0H^,8A&E\61RJ(T@YC7&H>Q7@.'@1XWJ6D26Z W
M!@@:'W.JPMZ<I=FAX_U0NKO?O()!Y2 -?N!U%[^,/RL1F'* QQ;*G/6'+)2#
M)M$=(FEJ.!$53.[.>:(P/9,.D@O4FA*5V[1_?"2WN+.*)1L56/>R0(_QKKI(
M\K\N1G%.6[M(-IY1B\K";H//PYIRU^85_@C2QG.-=I$MM&6&5>+>DB'FVTI2
M<FT85[.;@YTD.Z0T@XV% J2Z-6.!B&^CV!ZW4#)YOM@TN%>*F6( !=T; 4I)
MM([^W[9'B.(/*%CO_Q^9T0:_-J%XR-+;L_*=NL;<P0ZP?8U!,!]LZA!O(=$6
M,68 J<"3M,M'._I+X81TOT C<VJB?2+6>Y=IG/]B!.7MQ7;CC_VF%?2\V]H/
M9D9X(Z=+7\M&\VVL!>QW&48F1EZ!0@$*M?0!;Q[Y <G -;\@8_+WLA_,4=T>
M5--YZ;B%XB??KN^R4'S3.HO;1=G,/X%3*]$[<$+#IBK;G6B(RGU3GYSP&\,.
M/DHZ(RUA,.4=SFS%QIUE&<]?0RI'AV60:@',*RN:1R0_DYW$'(@^Q#DE/E;]
M<%F(CM3J'/;9)&@NN=A?["(Z!S?>)>(-:5)=D-39!MT*TYI#:4WL16B0E+;H
M$;:G&,W^[VNPM+QW(S$O>1;Q=7@-'LV).C&JBRJI-(_.&DXP\]LS9#UAFD5U
M]E+C_C3D/P/*DK6C$VR[(<$+@\@!\6B1T?#[#6K GNL-]S;+3'/+D:AFALY]
M-\E],=XS(RW+9-!>-6R^Y+P<D6;$E\EQCQ8?F3'J V9R3G0DE>[\F.H0XRM^
MI''9I@'U\/@HD]4I M11 GAD2+;,AZ/KKJDY.7EN9*!]U*-(L5MYUTS34'O<
M&L5.G6L]14NY";#R4NT>5N*:"OYG:%*#29;NY6NW]W]Q]>9139Q?&'#ZPY8J
M8JJH*-O8HM)*,;6"N$"F:I5:BM%J14&)2A4P8J2(! @9%2$J0FJM4E&(2(&B
M0$0V62,$B)9BV,,BA"1*@!#(" E#,C/Y)G[K^?[AP EG,O.^]][G>=ZYBQ"E
M@0X7U7/G[=(T5MJ[S!G[*0=V,'R.B)] 1;I?+L^LK09@<^&GDGZ3,-,_XGE'
MIG6MD8&5/6Z0<GJ/-H-0/=?+%O'A-0[FOKMB.M0YHVSD/SLVVU!H,6PB72.(
MK7#9&<B2:H]DUQORKL] GZ'?:F6HFR!9OZ(=JBBE)%&WF)LI/((:M4AV,^:#
M?L[*?3H5=;&BKC!ZD-)%/W)CO-9=. BUS9 3B'5@NRJ9_1N'P4ON@LOF/]?\
M S5T=>B$ENAAF'S3G;F$%8(OX<U=#NT?X9I(.Z8(/3"0 6+T3A_>Y[")="=;
M%K8OK&Z3UKNHF(@AO++4L^[".9*ZJJ?21-IIR844K&VQ!O]I,!^J]^*L8S'E
M\4+-3N,F3EN52S-(W("6N&K#:^U0X=^C!LD5=B0D9W] C+89<.XOKYUR<+'J
M'W'G38RGI>$+/!1@"K]D).L1JUG\<QMZ@L%B;U" R\,\^7V9*V'F#2^K1R82
MDR#"N B$#R!0(WVYU[:BX#KRRIG!\R,4#X;MU6A?Q;&S%<^J8U<;'#9G.C><
M^+HX3K8W?:+://:;-,N_%F2/^&O3CB#%<CJ7NJZKS&WG]AYWX4*62!-L]/VI
M+8KF"#4:7U01 BD.B<37I?ZEI:/7!E\*1-# C],-PL^$H6Z A&_TI2'T[/%H
MH?;Z$$3X1"<:\R&/I*?L-39#+=,XD6$7S77XC'FD&* /ZJJSERA;@S7"OJTT
M]*?25DNC52ZA5^:P#;V_\(C85?\EL?%^<4'/X5_TA'"<-Z#NB<WJ64_X*M1(
M\*^#X+3=, ?8.U3W.NHO[,"Z5-J?A<QE:Z6/XK=-1VUA15(:3DX?E7JV!I6S
MKX.4B__.JAWO2-9C?T*G* #>QU\&R2VU4;.H,T1&*5A^ <I Q-'F8Z./$/K_
M.>G7UMR8#%A,A*I;@:""FH4E<S;2B7T2R24365I"&N<HK-=/_X+WPB$I.AZR
MVT0*$22EY^FE:%)-A#*538,3%&NAD4-:_AE#=CU83&[RLY3/7L87X6W",DB4
MPAP&1?<EFB=@G[K>R1ZT1JV5DJ50&T/)19T)FGL /4XPT:7EWG--L3Y7.&2\
M139/$SZL5371[.,S.W$O%!SF33"MD=-B_&'>3A,IZ\*OJ3[(P1/%P"\_CL_^
M..OKTS+% 2,Z;Y2]"R_2C,4$:HMG?!*A7X\M9$W3D JC'TO\,_88WQP&O;>$
MR8T#%&0W_@E"/FB)A]%?F$ASR[U *;Z;OSRDLY9#Z.OZ,Y#<&<EXS#%W[?%.
MK8!]&NWHJ$M:W>I2K0]Z,#WS"J3@XPWM4?7R22]0,J>F_\H ;.HL=^JOFTCR
M13 SI1 7XVG1L%5C^NN<7"B)A1;WU_"#L!HOLK;9]9J[M[^<TJ".$YCSTT9X
MN>;JFP'AC$=R4Y!ABE,[I1HY__7&3A]LFQZT10'S/!M,P%G-BMS7D8<]0/>$
MR['8E@E_OO:.&M"FQ@M]9PGJ#:5<M+-%[=7*R*@\F9J_S)UVM<I;8&#V>3"7
M0&%GH-]GM^B<[NB;J\V9 ,5PHHG4R]X"VS=FKGY>5N)9D<9Q:M?Q)R2H4YQQ
M%F6(T#W&8ZPGA]/P[9[^GL#T[!.& R$(="92P+3AC:ZSG=$>]5Y'?6CN@CD/
M0Q9KKYAGJW*ZMMZM* B+!5%G0IXY]T#P1N$$850Z7F&<^)+.W*]/'Z95W7 '
MDP($S2WA0'. 6"^[N7X2/9'-8AKCFH@G^.$W:"3$/(:U$TU'A[1 HUND.-,:
MR5(4^A_M)$2D98RV[E^)J)^&7IT2RK?VE&&6QPB%LH(PW03SF:DUN?.-G2%$
MOY%KSGB?5LXS5V\L0_?#."]:+C2GYCPQ @VU(<TR9C=8;LXN-6=9BIT<9F8%
MW\&P-P?*G[ 5ELH:*HN*5FD%]8.>35671CJF#M7 :8TI/^'\G]*GL3C]$-*4
M/7C&#N!^'5YG_R80R@H*HSIIEZ<,\Y\:B.WPWBH=O4K=!!]*L$7W \]T%5<N
M3,U%PN1FT(GMCOCJ+<3H"Q0TD99YFDA//KR]O0Y:SX KD.EF)Q!)@45R89*.
MMS0("@]BQ<G3$G1\^WA(\1RV?'<S=8.N*$$BE<!><3[2NFWH;\***T:QX>Y]
MY@7.@%ZXF&'W.D>FQ2"[B2A>7_:/;>PM!7063_E#90]53"@'@N[NUNZ]!SV&
MNLYG)C@BZ,;#L^FS$[7#MXW$[;#WPZ?$: S4."#^T-#11)JUT)J[Z[Z/?_X8
MMT/RLX;H<\#'PE-DQ#<*,EA!#98%R,!!@JX]5S62D5R0_!/FRI>>J\N K#(3
MRZO:PW-;"DL[WP4[*\CUX-78/^LVP+P7@$,@L0^C97;T)"] ^R 4_Q;ID_-3
MJ!9MI70DD^#O\B(6) H1.0&P;3+X-E3K<P,<N7FQB36;(H#D7FWA^*)Z[8A*
M!)5RZX4?(=GX8N$\ME^[Y IU+=M=6U?Y2'D4H1AW,QZP@O67D&B%9.X1N/2Y
M:BS=V"!Y 6GW\^QWZ5>X%]H,J[@2X-?NFA/#LGEC=PE(;K.1([.OXW0%\7'X
M_"DE<"T@*"L>9BH37U=$1&6/9RZLZ:Y9DVTBG4;N&RG'Q.@>2+[%W,3$R1'=
M&A>E$KVKM.QYE]PJ0]<<>=X$>6>4^D/+RGVZY,\[KSTKR!I^G]MS;D9>N:UO
MUQCUM-'%98K*G1 WT*S1K5@&QXHCT5-)B)N\FN=PAC\/M2P88@THEI=\Z&'5
MS\DO&NU?5%LT6ENS0;&0",T3P%*5=A*R_9"-4/ZKC6_$8S0:2<EGE0_45S7G
M%[(!+?^J+L5>Q%FK36NRML*_I]N%0EJ>"E]& *&-@I\;07\,E*<U")<=PUOH
MVBS<BM4\\,+IRS+L/FJIO5V/>\+6*CU3OR@M:[1J$1'Q8DRDDV,N>4 *M-8
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MZ!K@<<KI:8&Y*J/.A649M,5)"'M-^'1)IVB-UX[?QYP^=2L4*IYV4R"G2M7
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M1H8B[RIZY'04I0+)%F_U1%W252ED@BU<3;8;X<HY?Q&K^C%[RGB: <SW^J6
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M2Q[#'48J_^^+<!-/$^&F*"M5&#QKB5++4G\E]%&/\)3N_>F^,X0VY_RCNRX
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MO'#.@=<""^R-/N-50=@VW(Z_7<>8P>N42LQ7?Q>[,Z'H<IG&MZ(_M&N8GY;
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M^:&%RS5([FPBW0LLA#8!R[Q\M2U$*-3NIW![<-)59,"_HR8NET71)R#W<H[
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MC9;'X,SKYBYNGNQMR'ZLVMPG&%U#?[\&D33'6CHR=LKO3%U#3QC/A0JU?(1
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M]G/Y OHOKS'>\FPV5['*8LUXLS-FYRO V-B\V?;4,^JHLFINM+72)R=4Q%P
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MG []*SGRMG&#PLL[ E-OZUA5<":&\G,G),OK F PV]S.4@BGGW$)96W<$K_
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ML7*\AC.6'Q#=WEM@P_&M<XB< ^U)TJ<UUCP&WLA=WLH$]/SL$"Y2GU&S Z(
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MNOA05WQM"/%@(V%)35>5#J@YUV ]L R,2K'A[OULMN%VZSF]F<KBJ:N,:&C
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M(&D[\4O!<OJT$.RQ@&(=IE479I1FG;7?>0/MY8J_DL,WKA>Z2ZAH4[HD1T!
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M4QEUWY+""FV%;FP2G@_7+4($)Z>4!I)_RQ</Y=70Y7WK 7'<&&G2!?Y=A;N
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M0 7#JDSYI4[K#;_E6>E:HVN#:^[PKHVH4^]X"#[$L12NY-\M_2\L^A,1JU#
M)J\^4U:*VN' [2F]/?F"NY$$P;WU.Q--A27H^\Y@(PVI[1->\ZH- 6GKX_QM
MQO35/L@.8!+9"M<BA[A0\X%\1WQ@>7=F:<U )>V@ L4"_Q7KM\2,B>0#;!$V
M2^SUI0R)5&K*U< 1 4U$5PK>:< 99LQQV+M6!=X@^-#**#4M]KK\$DLFXUA1
MU-#_!*!DI[34SHCE(PMX[>-1GQG]84T",V8F>YOEN%;EYY*.[C;8M/\)8Z!
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M#EWX)Y(9\[)B<D4? &_BO,(I_+7*N=#MX!HC#KX43W:*\KH)8P&9AO60:E4
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M FM>"XH(+UH2)^2VDK!^#>\Y*+:7V5UYD(XR0ME]3OQ($DF/,X06KWPS2UX
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MU^DXHH$J8ZZB!/>"U11 G1_8ZP'&! 41C(O10'7T#UOZ78;)%:=Q4?/. M,
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M\40 7[(VB^V\TP1,6%4_KR+9$<^0 ;.,)W!A&XDQ2S N@D$K1DS.XI\VL)K
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MKP!*$'ZE+.G[W6GLM>FVV@ $PQ,4WI2>LMS7058R]O 9$\S&*"]%\0MGXI)
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M5U^;LYY1/G\KJ(],^$E8_/>U$+[/'8"0 @.N&1,:AL>F*G#FZ*&\(OQ1OS2
M'^7KP9TQLBE1<_ D<P57ID=7AZ%^HI!\O<W\=%7;)4.=K= NA]0DN0['W(L#
MZ!W &,_A!I"#(Y9#K8KN@.TQ%X%M-\GE_3=/-"]-K"DW?WN_;V0E!\[)#6.I
MH9LOQ^\ ]&!(%U<U5Z*8#D]68@ZDT9];:2O^"X (3H.-E#SB*DN] [#U?#R0
MWIV/QT5F05RJB<8%/P(V<.?0GJVS?-"X@D7%D,&BY![T+P7OEZB!J0O7,(\
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M"B>(%CB*J#!NG3X)^*ZY,SX_HLSL3I@^<.+EM?W,(5Z-DGZ>NU!5)30)_4B
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MN2NO8. 7\;;?@D("^=3YXV-U3;='GJC5B7=3JR#G 0^_#=?6R8D^%BI$!C0
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M:\VMYL](O(/+R%4EP38=)XA/*'@TO:ED7-N_4HU$?[YWYA>/378^909EADR
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M'HV%JH;8>]F^J+PYG#YV]IIGKJ&_4<3PQL>RS#=QZ;]MWL>1#UK[FX[9VU[
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M#%8]W[3<.ST;94E*8,CZ.6BF5Y-WIVBP@_NMX"-7N'_A1\5K \Z"1L,TO@A
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M[-&:40AH&DU/=)^8]V9$)Q]"Z+^'TI_]86WTO,LPM"FC<T-H#<<H0<MN8T[
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MW=TH:M4*)(S,Z1^%$=@QT-E8-3#I.Q<TF3'Z*9"<#VO"N;Y6%<']=$#&+$H
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M_2('Z408/D@+*3PUL8K(LK2#M]1\146B&M9W6 @45F.5NT3J?,!B<VY&JYT
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MQ&/Y&#=1GX9F2U7-Y&S]8L32D92O99N$Y(%M=W=N\7@?P&+5^*]!D2,#W0H
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M^5G>IC2MW- #H31FXH\\RUN_N5TX"JF-<1LIW'*K?:7[]*O3OBB?_AR/QNC
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M?"3F<!)KN7K,Z;=MN:'+]&09^L?R9V5A% 6M=ZW#DV'BN']ZI%!@M/KB=?B
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M>T[6UC+U&+;^'JHCY'W;I^K,\M<@)J!AT N.,H]YL3 T556.BCD\9"3,"'=
M79T?L:EX[$1!YX,I\4';9 U;QUR&VRJQ7=H;@E=Y74[XYSJM"?T6Y1&L2?7[
M'17QO\6Z!-WMS8Y%$XSFD+E<?POSMA=*/J=A+1\IGM%S7M%8LI Z.K8%SICI
MR*S,<#+P/1?RZB"2?'WG./V[U]#FCM#-]Y9>X_TB26-KG;2T%.+^WV0FD8$)
M9Y1/'WQO)OJK413RM0#\^S.C(?VRVR(*;9!2[1I"ACL>6,#5H^C0C#]./7N
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MJE-(3"92"L6G<OA7B;Z7IY9V+MQPPC85A6C='9F.1Q!=(O!@S$\;8AQ)-R]
MBE'GU?1K@ =8+<%2XE4AVP5@P/Y0ZI5':XWC'/+[C"H-RU59C7ZEC99/56K@
M-_:%U?E@TPOC2]?9/\?Q_MW<.-:$FCT$#9?9C&<KU:2,T8PD3/I5,$\94#R
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M9E )WB*<#+*(\^7%WF:!8G9O\OV9?A&X;[=)K!;V<)J3"[7I<.BG6LR-\L"
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MN&Y-Y)K&"V2L\',[G%9=@='GG I2.4W;$6P+41/K6=^#S(C)QIO].^$5;O+
M2B\5:[)Y]63-R?8W.2N[W"T4MII><Y774]CQ73R&=WP9E#V@:L=U);Q%FFS
M^U(ATO@=,7J5,YCT4^5P&GN8<,YQ?4F@1/A6-EJ[IA7GH#@$.]II/8$Q ;1W
MN$3"8]'-0IGS%8<'ZGKRW'@NGZN/F!:>N)B]='K>\VYYS3@L<'DJLLX GQ.0
MHUV(N%2O*0IC/F8>##/A0B($XC3=U)[1YHW$ELK7K[X[U,"F8CI$_0_<"L0O
M$7J&3V--JD/J??(?-1A/''J$22['=ITW]B"!*X!%;XY^JVI\+427*^\5<W\-
MN5D=_+!G1TVODER*%V-W<9[<GTM9SZ-4=O\.XLUXI-J%#X7!(C:EO3V\=\WU
M;]H',8@?,M)\)-?$A18$4IU 0(G79./\@Z]TSQH4:]F<XJJ8D1#F(Q'(0+>8
M>(84RT@[&SZ_Z[VEFQ1R7:,]3O7Q-F@OY'2Y^U&.7>)=DCG+0(GR;LP#;JW=
MFUF)$*A%IVZ#9+Q$S'.BS5\2)+$QVH)2M1R,-]QF]KB36?,J#K*/P\#B%EEP
M)>=&>H<RNM0INH<:LF((3C-U'R*$.N5;R>3%.^DWGQHKLZ7VP&^E?$_HI7@]
M0NN2F8R2]5X?R=N<V*KIPW_A*MN@GDXYDG#QX@X;<9@+GB_6NT7,G9W<.TG?
M7M=G++7&5OJ9#_C^F#3N#77OF#'!5/?NB#Q!+F>TVV2GBWPW3L=6AW+0E#(W
MX&FH 90L4(]WXX9VB'#"FXS3@A96R4+.%W&NBD]X#QF!.<3?$\Y':..O(T,7
M7UM\XXSB.J3[V*(7!KLW4(G9E-C]=*.PX,LBAW.78Y7I_+#*4T'RIH8MZ>9I
M4=V3].7KS[BO-Q-L;@8R#\0>F KR;!>\F"X2GY@BLR-#5K/6H45+/&^->BDG
M==K?\3G!I^"[OQ?DW>2% W9[#(:%KDOK4YL70/]RKVZUW>3\Q/^LJ.:,E7#W
M)_A/J8V&1D/E$*?G6TT?K3FKDM<%4MSQH(I)#:PX$/>'PH"73K3.7,I2]CS;
M?ZY8]F59[*3G$CU/M'Q'M!_6YNJ\$9P9M7W!JI-9B#U>/]*A @3TT 6*!*Y1
M'*% L]ME#(EB.V@AM^24:&4>2?B>MJG<^^!HTS2L+_:)Q8EM4$(">-@MZAJP
MRNI['"M#"L^<9][ZAA'G;%(:@'&GH:9%9+Y#Z?MW[[E[UTT5)\PF(JXNR-UM
M=3JP)'4T836^<X^%]!C@U+U1FXSW M@C80,P2H<$]Z;<QO4H3-3S9>W11-+)
MBD"35O^7K%4A*\/"M&W0@1Y\ T)Z4,1)2U0_W7UW73>6X78%2&4#H08N'TX"
M2$>N,I%2A9&NMF.GPMVNT,6[BPZK'D0BW\Z[\B0^E2@[SRH6IE O=SMIM3IE
M^4GF_<F0BAW_!CS\4 CFFG2R@L7)L3H<DY9:FSK,::Y0,E@/J^P)^-HVM78Z
MWVIJMSS?Z7/:@ZH?0 _-;XNLA1CG9'MJ][8I]]M7\0Q?3JON"Y0/?SAOH304
MNMA^#/Q2OX(0=\:?")5<2*M>[+A4>;_):?+V=9+F%U'-FLPWO\D'_V E!%^9
MN]?Z@V^1G*;/B;O$L7]=H8/[ER\-Z!3?RY5K%!DF#><]C+1(>!A$O1#:>*\5
M.8Y+G@ZD!3U"VW4S&:6]%MHC==L@EC;'%B>>@+'F?C5*M#Q$@!O!TYW&(&>C
M.1N#?0[1[#D_8A:#[-7H44A=$7%Z29_U4&&5N2\K'(^1YO5V<+7,"BLKT-(V
M0WSPK5+ -MI2$BCJVZ?/MV%G**2N+JV*!(9O6*16,1=,WU441&@&F>30^L)D
M;N%';GD4G(MW!*(Y>_KDS.:&0BW%%Q5MB4()809WQO##X1$/$*UWGJ&=7 GO
M56S*\LB(H?;GH\T[0K+GI5R$@9;8QRU?_CX ,G7$0@Z*$QRAD2R/>%X_^1U!
MOS=_;YZW ;F49^QJ@-)ZZ&[P/$)>HD>[C:Q_'QH6$O_Q_8O#>]C.TKPA+BZC
MB2D%]%_F#%2D<4J,$IA[,=$5"QL12<NT7EY>)455.:A0EM[TZ2]RZ]QKLY@:
M1MB7QHG+P>#\_#/4O0TIB)&^,+;XN/>Z(XUO6961<'^*@;E$^S72(57C?;J)
MD.O63,,$E  : /!NL%(#'70]VWN'@ -+-P-_5[ZGU=YVZG<HMX2Z\_<#=A76
MY0R$8->0\9:I'6>EB 4_;=?8 #,X:2RJZFHVFU968'$L2P0W1+")7E2J(O^+
MB-"Y>KJQ7BZT<R>9'EA>6<M_ Q%AL4Q:WI)K@][0X_R"_96O@CN;QO4;ON@'
M]Q)!PQ;]MV\V95]/@>%2'$#W=LV8X9:-V <$R@"28A9 AL%6CRQ:*BU9['=B
MF7*]Y*+$LMFI>-=U:.N(7?(VJ+$@3/GX9Q'W #VD[Y%UJ<_?8(EA76R^]J;O
MU&*>>ONHA<K<U*Z.$8P!BNVSUQT=WUL7HT+RYX;431=8D]=/SK4JKQ0CJK=!
M08'K\KS=].Y_A'-F%S,-6%E*:9W^NN2B?5KW+W8HT_;>1U=A[J7R CD0KZRF
M3^Q],\)56K5PW:=Z>LIDT8$'K;@/T">M!7A" 3,NU#;ELW9*#WU(;I:B4QY6
MK97C9KW.(XJ\\6%.;%7H>J1.363]PH)4P7SIK>;0SC0SXF-C R762E7Y8JP9
M*?XJ@59)#PZQ&.30?80^X;TP3HGHY5L>QM$H"7S&$VPC7-HE^!IW"GUWX%6]
MB5S=#ONU.JH"35G*3I[<T9[!0X"N$U3">V&T0WU(L!?]&@WK44Q;ZE#\!DX<
M6IM\>,7$346!\W/@O7QXQ*5U8C&^(DWPG).Q-,9I^] IL;2#'2XVN(N=0Q;R
M\SO#AS$J_0YC6)6@?;K""S4ZN38_"S/NYK#O%'F,&'W)*^BA_"%]"@ZJ^OE?
MPZ1_)2> U5M7T54^A0[Z%+P,7@Z@\!Z,H6BK=PFKD@ORGD5)!#VG19VXA:F8
M\-^\Y36CXS<<Z)'206EMYRW\&K;>/9TR('"^-G)6KW$$Q=7\2P!R&JYJ3P<;
MO0-*9LC;(,FIH:;5)'G/BSD:%""V>V'%6<L.406?<HH)B-SWUPQ#M=N')ODT
MB_<826*LJ1H<G<<LN M9Y00WMXLI+"X&X%Q___RV!'&>0:582')C6_QJYTV6
M51JKO"L?+Z-"PYXIQ9P]W_CL].F 57C M%UWIP2T%HZTD*X?#N&?;_6*(!)1
M$&+SM[F;S1EB:6CJ5JEUQJ7WOM$!6]G:I391 Z%*7V^O.3)Y88">7ZFHD#,0
MR9K4O02+D:(?#LV'+OTBQ)/STE;J2@U>\=)DZ"B_JB#3]6IP8Y]QKBGQH9-F
M.^7I!Y5S7"SO%0% SHA:L[(!1]YZ[__%V'L&-?5%;Z-1JA3IO80J2)?>I(@T
M$0-([U*D&2(B$" D%.DE% $! 94N37KO'02D2^BA2"=!@0 !+K_;WGEG_G?F
M?ECGP]DS^YQ]]M[/>IXY:Z_5O!6;MVM[AV9/EM$;6MB-'K%0$9A=93(=&(E<
MPTXX-\T8IKEYHM,6NR#UKW*LNA!URZE^ZU0A*U0"=76S%>UBKN-NX-*NLFP-
MZPG8*[>UP"-&:TM<UHL?DW,]&)T+WVP_K\?E%77$Y<[LL^7>!>I$/S6OF^?@
M+%"JWFON7S +-)!\A[4CNE6\ !KV%'/8%NA"WUR(+(!^GQ0&4EN8+]-L]=TO
M=2'T/5-CKR;N,O5U'-KIJ)GK:F/K"["+?Y\+V&:%1$LKJ$SDN<OZNI'O^!7I
MLE)DAG_TN"R&'+Z7L>$YW>?./.XS%8Y(<74'G%^^N*JH*)J%Z3*VK.J+=^>P
M54_#1;;A3%C;RG5!IUC3V78ZCWJ42CYJ*;4^86H[T[,]W4OWB_X;5,'Z\H)8
M!F7YSX:T/N5(_:LZ99MU%OP1)4[JV50[\);)4[8KNMO*S!S(7#;"7A9"LU;'
M8V$R:XT=:]0_9OX5 \VFBA3W0<J6Y?$17YP""YKC&1<\@O[[:8BS*#,?*=SE
M)/OUISISS[;#E?*S_8.O:(]/1W4MVSIL7YLZ.B+(SVTE\P[J9QN>E<JTOF@\
MS:VI["I7 DW5MLEU-JOD.A:"T*6?OM;I&MCHKW_TP4;/<.3[RYCCGQV=9CNP
MG>8(+PRNM:12]DH,!@/YEJZ7+QZ$%PZYE.#8S%2$?MF2MCH65I2"Y3$SLZT7
M_)$];6:F8,5AD)P>+@11WMFY4]]P[]N"2(VD->GI'&@=@GK99X!7P)E@[P+)
M%W%:?PUP7\MQ>GTYU--?VYNNYVM^U:K2NC/)PCFG*VO;'J#UY:R;)L /IF#Z
MLEG.]*:3@TZQI<!B9QP+)L<?;^@M$-*JXH+-07[!(7HG"W,)C791XN%@SI'N
MBZ"?24(M&FO;'!&)76EZ"D]?/D6;<SO]!I+#*-Y#J+:9%"D+"PJA#G:J6K$F
ME"4CX+?@"I&"QL#8V<S Z JP6%'HENX2RB=U)/FG+N <9'A542DFHTJ*\^M"
M4(J>C%/CFL7OV%I9[L(EI]YG/>; >ZR)T^+J<BWFBU:6K0K3<H V*HP)8QH!
M/J0/ZAX]-4D'=G749X\CX0_P*ABJ#]=LJ%UJ:,*>6C4V;Q$W/+O0FT.F[]AU
M!A=IQ5)PTMLH!F:;=35;9[I.N,P6-DXYIILU10G?\^0-A13C'V$(5H_"? 1]
M$)0X$K4I&:4@?9]/=81U?ROSIE=_-$V653BV-/J[1+FA]#>7TU\1>M:?SDH%
MY<B':C/;\=9>)<#973N87J+'0@(1:^<O+3']35?AWW8L&8KIH%9/8M6J)M)[
M#=UR,2D"'RI>U=>U3RN+7Q6^;QG5]Q3;C,IJ";>GDH8LZ%9<"T [NE"0,)@4
MTP>\@#\ZGL00ZUN)O8MZK*V/A82?<(AK_YA4ME@KI12ZWM/F%&V=CE.Y;WX(
M.;%Y%PCA!?U(VQ]B9[T!D*F^&55"OV["E.JG=!5U-X-Z T',%CUHL(M)6Y;F
MM++/Z@JU.R=G*T8U0BQOBD'FL<G7J?RYV+WQKX,7COZ,LRDK^55%>E_AO1T4
M[SLX<,C^!E1"584F&D*-R^VS3(CV ^=;:'I70G..E:;\@DK=9ADSM_)S@#F"
MA9A:N;GCPLBW2=:_S[U[D\WJH7ZKP&[0/1NH^UZ/[;U):8W5S1G$&DO##UV>
MZLD*F9:&]IDZYC<_XPDS"TX6YV@7W5_FI\=Y"G"^I:U74['&4AU42+=YH#_>
MT@%1D 6FH]L-SF6YUWS2-IOG>6J&N,?VO UK[#<QFF_EFJA7:N[.]'"U37;.
MIF7Z!/QL5E@OUCSS@C1EO%7STATZ,+!2\W^&^,:ND,'87-;V@(0XXG&SJ3H@
M-33]>>/,P4D'C:NE=IPRV]8V5LV>,: ^LMS-MWER:=D*]'7E!N"VD*OP;^'S
MU9[_K;NKNRXO]Y"S99S:;,72GYJA-IY7O%\R,YZJ.#@J._$X$$:<!HT5<"P5
ME(W[B;;HOIW]%9LKSU6F<:D(H[O4/.G$0=;>RNB):KR8$27.9MUI3LTIDEJT
MT0@J*&%DDD_351D[MJI-2QP\/1VEIYA(I,J$V5TZCV+.NE4$9O F:_IW1WJ!
M5*U6Q3COWFMV9-^96;IB1&HAU*P;+I9BAUGJ0T86)J"W.,3[ Q1M+78-Y\WG
M=XD/B6=0L@W>*:77BP;;LK:B6,8F3,,^)]F4#(05A^BV',%-Z26#'7OAI)%:
MK1DG"P_+P0Z8PM1BJSVDR$7XYN;D3M*.V9-M:^Y(H 6N\A2.4UKW?WHMA.&,
M+GN!^IQ9-WWV2/?/+M-+MWI%S=Z SU6#R&(+ZYU,VU1GKU?OG6IR*"6[^,/#
MRY3\5V* -:#NCN@.*KPNYN)2HQ:SE8M^T)94]YALK%_X4JG\F96NC](GQMWE
MK4GC&<W/$NZS?KY_+7=EKYW,))J;OE"E@3L\XSWVF^]G(S Y8WM]S64Y4C/E
M_R!DT,RS/A0D"@Z$*EE-PAX'K@,!NXJ0".5*VH7=E-V:H.393>EL>75G'_[V
M4L7BUZ=V,1UU+V(QE?TY9)C1V=S\7<;K!XT3TBVQ3C.5Y<KZ7]PY12;K@K1[
M]H+R-?*M=TH]H)D*#7VSE>! OF,IBX5:K]"EW) .YZ-(.-UD^9NCS+/>AGI;
MP0ZL:7;Q^"F8]C&KWDF#V2]I#JF>7SO-OBEK@NT_D[776EQ5JU%K6TW)2X6I
M44=U-X!0(%FK(7H/Q+%W?>_7"8A^/NA#UW<;RVCFH8(^:5;K,VI/QCD_2R<F
M.8F=.;-'NH_CS&@+:OI9@U5>8&X !R'H7.I;Z2O\;003))W+ =.IP\ [,'][
M:J 7W7^T6R:4=3W0\9KB,C< :G(VOHDZ5QY,6@GD*I:R;K$Y?".M.$67'6F$
M\S@-QQ;CN#'B:))H:;">%;8R >:#MF$\ZEZFFG[?ABHX36>*_ZG(7[X_&SIY
M/63_BS>"I6P]Y-!6OB"Z&A_TL@1&B3/[OF.X/==^?])VF%)59W*_M1&6E:TX
MH-;6TC$A^F]D,&;QMV:!M=UR4+AH0?RKB"U7@,3@-HHQEU2%=6>9 W/TH?:(
M9#L3$8'G?0M1%LZW0/$Q+K.W\>Q0+L=OHO7(D6*GNS)I)*::.6KA?I^#O1$$
M<&%+O#V&,C+N56W#5!UQ4\?DR0$M>>E>$TRAPLVSM'C;LG27D=5YV!UED<,&
MUI*NSUP6GF[4"VSY]-1;KIZ"FG2#6B)(VWT=S[\J3@YETV(E"?_7^+Y-PL;:
MKM9@8T0VSW=+;U0+O7:F[Q4$W;3<W3+S?^!S?Z/)(9!: O"/^<O=&,$O5)B5
M;S'"%USX16%5TQM HFG1#<#^<N7J05JM4,3W>U,RU "'-YZ=1@L:K^\1D]L?
MD!2NWN-0D^\::\!\_W<UHX\X&$JE2@"N(Z]3Z2Y2;@!A<<3P>S> +M8(G?%]
MO<+C_(C_*S=%@CJ'.L<>QN54^^J'BNQU3R[3U'KN_ED)U$,;BX<SS,"8Q6 F
M:X^9^@.47%E_AMH\6?KW&#[[%R3UO.<N]I55K9'OLS+=RFW'Z_N$.#>L!IJJ
M\PC'VS9WRZXC5*E; UV*X'V6UJSQ Z$P%K0J74\1R.L;[M'!UVG^R=K+I-=_
M>523V+N</U_U NXB,NNN/G>X&:_"1U> WD@T3GU]Z@;0R'VM70>[5C<C4:Z0
M#_A=)J/T'5/"FFIL)_(=_;+:MV73K:!H_O>_JO>[QOV![EXIR,;3L]IP.6<.
MSW]3FXN71Z??;C?"W/4*HA[8E1VX"NS/98&)M."\T%D'*C> 7EDX/4YF%43F
MP1IW <:V-_0W%+AB5BR)4VATP/PAF33Q7='>YYJVO0@7$,K\!C#:"(,=W0"D
M$0-+5)#S.S> DZL=U;7;MP9=R-X D!TX5^7 &\ PZPEF<OCMV[=Y\3W2YPW%
M:=7/CM !V]E'04R.:7443Y=FV:A/K";3 W,4EZA^W0"$+G)/:6X *4M7R([]
M#14:Q*Y'OEDV<'[@]*,RU7S'^I$R8H@+>X2X##&;!E:1[%]>:KC9U:?O9Y2X
M(VI6!CB4]*<Z7.W"F1I0$5\QI0.RIHRR]=<2DP4YQZ?'091<]74-\9:Z?U(G
MY2<LLD/CXJH:?[)UH3]Z0?V'UO8L'Y4R/531M=#T@3BUI$;VH'EM8],X:QV^
MJP^_R#*, 9FN/&V 5)V(X]FU;P /DZZJ;@#[_)B6&X#Q67 I]G6'&V(5S74#
MP)R++W TNB9\Q=3Y Y[7Y'Z D^^Q:QG4%S+3:RL?T*09=)EY$U;V?2]+E4E;
MY3O-5GQD<[CS<NF]I2?S=J.CD"YJ\N-D37O%RY41&[OBR")TQ\__C_P+".+;
M5M5_W#'_8T)U\IB.C=S<JP\=5TIT>?^KK*JA)L,YFYMP6])IB"WOY1.H7;^M
M!,[-[QN4S!^,UQ>(:N4(])"66YF?Y"_,0)<+&,T\64P<+KMP+E]T9W843U1G
MO_2;S @=V#K8OD/">_4E(-"QA&-;7]?&;JN,9".GZ9(3_W(6#K2%FIF$_C5/
MZ:?^#5JW437'A54NHW85#Z,OU7&! ]? YNA<0Z!S(-4]U.X(?;-7F(>(P7-.
M[A]'NQU$':[BQ'U8,G$BJ(OA=/E_,4;T[^VH=E@%XKDFI&\ ]T?0JC$H1)2T
M':T'$VOXI#H!%6G=Y:*[@;I?H)=H\^]J8%TOR:Y1=\S+$IJK/OM\XBZVZT._
M<'Z"NQ+Y<>_>38'I[O+924LR_]:-,'WB73=U!PBYHU?*0  XGK>'ZR]>C^8"
M94I5V2P]KGFQHLL=WW$]:G;4[A=BE:6NBJH)RASB?4M*O6:LH;LD_:S1H3<
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M5'W@^_J.26P-(]F7/Y^#X48[JK<R>(!\)4Z52%EW'4&UI\(]BR?'$JRM1,N
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M'54D"M(U'GO-B%U.*A(/N^8>QXRL:P^,(W.D<#'-8@5">]< +/LI7'+R_0V
M>B<.DI<VH(O+^NK.&N#F;3'.F)T'C=2MFW:B$<52O58-1="H\.W:D<&("G%F
M>M4X[]5<1MBSJ7\KT2J\&-^J@A%T.9,5SLRM4""F[HA$P]]%-G4]FZ0WQ1;J
M#J16TBS8DZMG4HS/_FXU\D>O_SVPTB]@,R=W\Y;;NRO:(#.\^$ODS&;KNU[3
M/.[UJD0Y(T>;+^72I>M+(W4V:)WZ"=AH5SZ^ J11U9WKR<U_+K5F#B-%V?$(
M2!))2@I\8O@:OT%ZR Q L*H\N![K8#D19UK^3R" 5Z)$_E6RX0Y7GF#->C4[
MYJ3+-?1JKE);'Z_9\%Q<>'AL\T[5/3;KE64R=%.\S%\VBSI<#HRR^'.W194,
MI[0^A)O'Y)T&5V%(HG@QE3U[$,+K\5E6U=BZ P>[:""FY$CYD0=D_8AF3X4C
MU/F7V$ECJS=1]M56D^_4N!_DZ[A/H;);P/ JL*RRI(=]",+W2ULA=CR-)(GP
M5^_ B,7&!]7,^EAY5]M]))^.;!J)?)YXS'OF<MI3&X1ZQ,R6.>-.7;R\%5L<
M+[E)CEYX^%;Z6TW-H%7%]JFDW!%@= [YU9<3!))3_.I+[0W@[O+H6F0]UF7_
MK'!'MKF_%F;CC?$\ZT(5KM"[+3.[Y?WBDH(]7ZA<V/4KOHC^\='JNQ8IPQ];
MNJM,F,\K# F:*4P9@ME][-?;8 @?71; 9->'.Q8O0-U%90?,,86Y:-+]?1GR
M@9;8 =GH? ]*]/EK'X]+[?IL1GDGTE5@C:-555)Y7JS!% I]H<#9OW*0UE=9
M_S1AO"A)_,+]Z=@WK0^2%<?WB/PGZ*Y6>YW !  6 DE,.6VR231;B -]Z?VW
MPJL(5*X:KF[M0*HK$[%_GK>;IG>+7.&Y+.7O_V!.4C\?;^=PV1'W>*R&.,I,
MCHBV3<P6/>")ZUS49H]O6I<9'X;+XUS0(NW,6+$.;*X!3K< -_!? "-6*YBX
M:ITC8!6GT:F(C-C'Z_HY@R&^UVPV 3> /M-FQV9M%Q\_NOE=,]G9V:%6@G_Z
M%4ZF2O7?A;\QFKP^'V()QYU;G 'X;"82WKT3,OE<OY[*;<YM0K' 7H%F">X!
M7S;I=VZPA]E]O&A5K4M-R,!,CBJ#UTMU6YV4 Q%H._J]J5V*]OO87>A/*YC*
MQ&$M@FQ';A))WA"^3JL2XL]0&%L2M=$X<Z+G5B3)VLZ'A1R85$+_H%\G%1;U
MVD7"V9%K6J5!_I5+E![6/QIPX6N53#LED,)MV5E&.KTUK_6C^Y8KBVZ/<(]/
MJ@K=FF?REA8YGO1-J*F:VVX:4SL9\]&6J7%Q/@**?!GNC4_*+AOVCML@O9_G
MF>O^5UR4H=PP9_-Y5>7O5..1+=OTMZ(=[X:XZ>B-OO\L,S@$IC'9\E]5G1S8
M]66.(8D;5O4]I[I_N2\38A[4%-OB*E;L,!\15/0@IR3- H'(?%P(%=)\_$%3
MA;LLZTSCC[212\D#/G\K[^YK&FQ."6;A=%'_D8K$W@&6KN?")S)87$6@?V*O
M^;10A6F@P%TV@"9[7_QP__V!SY^IF4S44!SC",?7-+X(4\"56.T,N([Y6Y9^
M^X]IKJ0L.I2UM@\=WYM0S81 E[3%P9PW7-R)CRB8BT=UB3 M:>8'%:("LC6D
M%9,LM/ZBFP IU!A/T@<F,K+DY/"WI XM+SR.+WMN /?;A>&C[6R8AJA:G5;U
M(+=U57*/,TY)#*1'E6JI/B4?-SN^)KR]3%(S@1='! 8&N92YVPK>!5L9!W[:
M%Y,1%,WY9ZE.^A$SFT-U59P_A7<NWO%;H<,35-[B)-8NOL+SO6J5U>(>7+D>
MY[TFV*HD^Z6Z1[ I8L$6:=C0/I'!B+K0<8HQ#8KE!< [V;XI"BH?].\C&,G]
M@YDOWKU4JAFP?;@G]3GE3,>F*3XUQ+'!:V@@C:PV#NJ,)*Q0A+_:E0/6:L6J
MM*R-WI))MM<8=QO;)5=;(<S)9Z8<J4:LR5'W[0#=VSDGMEHCEO)CN_\,'.^=
MTEAET17J0I-V+-O^!5@*9W&R(% CH&D?) MT%,X/33Y0#O3^9H>C>MHR]6_I
M[EZG(7P,%5'BY;W62.KE\MT:;SU5_G[$QON UL9RUZ_&JIOMA>L( )Z9\0EL
M-,'"AKO3R4U\MI#2XMN=[PD@&%J=(AKQ[J[B:BZVMW%\6:_-K4=,W43Z)/EG
M(!G^!\Y8U6TE)F#7+8<;R]27&YE#'-D/5\S5GW:8SO91.A#:6]L**8;:SAG,
MU06JE[;'YD&[P:8Z-X!WD08-)M49<8;!BJKA'0QP6=S"JED?*$;Q*C*N52.0
M).J@G0X7V&/+/HW^5<F7OE91K,R"I4*W1Q=#O<0J)@?Z5/AK9F#:8.)L^CF,
M6YJJ4\1/7:G^8&!^J<^#I4E=6L%%\NJ/IJ@>R<W!>\SW2ZNJN#VU"5_VC<AV
M\AF,M;M3B=8K"@SO)<N);7'W:W]B,!=JL,1_4&&[*E41@;%B\^'B<W")[8 X
M('&KAO-:$/#IC%G/14036J>=QZ8BM[QMM3[2IA5+"WTR/'RFPY3[.GL2+:5,
MLR3%<RHWAZBC;_X3R_M+61]]R<;!NY:Z.="]5H+PW%4<B*^%7E.L#%#.UA4N
MN^7.2\">5^'2?BS> -[LIBS8+9Z[>;YOB9)M ER!++(7W*OM*?>](I28B=79
M7M6K<CL?;.M32N4).F19'R!+W( 4RW;#9&( @D )8((:'C4!49&'!JYW='6$
M]*"ID'57=/VV9)@__1T,T*)>NITYRZ*(?3C'_(+KM3R&L5QU/MG< 1>&7@KL
M,:LW6+,<(VW5='&[C%?BR>V]<CQ-3>F]EF;E..H#R_69PE5FT9/_(.3FHN,A
M#W#B-P#2BY$U_9<:.;OB^X%()MGV5[&F<F(R+!#+O[K0]<EO,5?!JL_YLF<L
M+KD75\70C\(V5C_7)CMQ/=H@&+OO%K&E/YC[=G#_<[B2GE"M^K779M4(6HYH
M@9GS!A#_ Z9W50Y3S*6"\6(U^@+:X[%T:+-PO,UZ+G!EP6VB/A+3THNHV9Z&
MZ:Y_Q 1E+8R=(2C@7#M,J->I:^>'#!69QTN\MI[L][T[@72W+ 3!@3/QT2?H
MMZ-=!C&XKU"=' %Q'E98D<R&J':&;=;Q8+'7/[#BD2<=Q);N=^>ZKA]C/U>Y
M,^:P32T?V4S6+G@7N?NB@CY7/_L"K!_UXN+WBG029U>_]Y'(/NZ=%\VVG9M]
M)[O]ZDO4NH>L%9EL\>LG=(%.@ _.^0K"+:ZHL.3?,N=_5H.D3K-_8)>ST.*T
MN,I^.$\"58P*%29U.87^WJM5#KM..KQT8VXO)S^K<-]IBW N3F\U@J8$)%Q+
MVRA.'_/6OX,5.K+>$7$"3+"4-LVE@P45>'"*354J<ZPC*7=9;[4=#\X[?R4>
M-(1I;19A-9Y+>1#I\ZJH1[9FK6X:[(.3&2&921L9;OU]Y\)4+$."+UGU<X1&
MO\3VH0. MK>/]3Q"FPS(K5W^L 6RE'BW+)AA)=&*E]M\G48A+MI8@2 [/FSN
MV*.+<:76-ZO$O8-&6<,;:SK>KW@6INH(HL'E]7B>9:8AP?^E[X?F6<:N7V=_
MVU;?G%S'$@;0S@M$@\O%7AK,.'Z6*2A"%;RO0*ICQ0^X8?\==J*B<5NY!;O^
MI-7Q:,6<D%4KO:0U?4?3CFD5&=TB:,"9I8>2U9+F_53,7\^:@M^H+M%C5YH?
M5OXRLCI1)#LS6^60H@4;VY4E2XMY2Y[QQ]/']*'+B\D59Y*)C%P)92V_/\@3
M)@K]]./1^9KV<"WSH2,E_?!$U"%A3#G[KQ_OXIF-K#8=V+C(\(YU55<%)[$V
MXOVV/) XQG;^>ISVI1Z4M]M2:L5VUY*QK:0A6O0(SC2*SA8+M,BUP-ZO^II1
M.'%226UIWO@C210RV7WB*_<%FFMP56JE@7T&%3?"95#U/E;M65:MF5%6;@8G
M0WGU,,=0A XD(J H!/X+Z7K-E79>,2D\$MB2M5=O\YKCW2Q5]<YOP)59\XSH
MF_+,TT.H*-CDFUGFEF:HX,^*JF]#(J.L]QY\C WT(3R?H^VAW<SVYEE\UK02
MVHL6[#Y_LW^>+/WNST;0)ZU.(68E6GJO\RJL8S>"&:+J<H3,H6R#Q'"*MTSB
M$9CE];7K_$KP=]B3K&XI"]A#K&K,X3^K=$;LBNUV.P^(D3_V>?X\'TT7LW.H
MC++,6:RJ:YM2/Y!*6:  5XFF_X^9MG/=RL'[U\#=:]ZT3NB?;DY*S$]%,Z28
M"N^N[YQL:<"<63OSU/4#-PE* ^[DL95NGD.9]G::1*H9[U)+\H*I=(,?8)U^
M3\I(%)?':1V%AC['1R/I_9CYJ(XT:OK7#HJF/C> F'^BD@H/6K'WHRG>VEGN
MS%&I?'4F-)UKF-,#N[GY25F#ZYJ:,JY'P10MEAZIYA^98&;="!;I'9CCI3;4
M3P]3&>X#H816=L+9IEN?P7FU\Z!II,I^:#"HN_DZ>\TN J4=)0I^$<\91C33
MLZ<BU]B6P_>HQ]'Y#1H=U+,%N8]GQX6@*S],0J6,,971%74V0 V, $K&BNH>
M"H<PG;V6<?=[:8[KZ%GFT[?=LGJ,Z&YGL^"9L^KW_K9HWN?J^=Y&Z_3:*4&"
M:EXIR($\LC5>3&3IW]ZG@Q/ZB%WR].I,5X<T):O\!C]7L>#,!]2#WP\HDD:#
MJ\7>]/C^'5+D2_P1@F]Z(OUNA.(R^WJ<9X!72.<'<W;RDV0A^7=Y\I6AJLZ/
M ]&YH05SUQQX/8SM5R^^=IG8YY%HRH2DTO+3%K1'"Z7162_K0)RX# LKVYY/
MRK.ZB"F[20,W0^V2G7H)(ACAL2BBZP90"T8BX>)#JRVYT<M,ORIANI=:T+^Z
M-X /OCK@]#X5X:G6QQA?8'C:U$A @ZY85JF[1I^L[\4[TG+(>GVSE+272 5
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M?2^,T87?@GF.'1>9Q2;S<S\F?0XW8B:(,&)X5\2[R?[2$L78Z<QO;/_P]<+
MDI)W7+'\RQEM +JH>#,HV)[6//CNP4I"V7!Y]H(V'^"%(AG ?:$_P<8O[ /
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MN7XFVV D<*/GH>*7N6ZECQ4F@U!SQ<=="FT_>U^7BC;:A5!149"L7&'W Y!
M+<&AQ3W$K_6A.9]B2"4E<UO01WWMZJC(^K.4<T&3^VCV+81Q21Y3Z #%Y9RN
M&@I7*[H7O+_/AC:?I976PTDJ9G3?X )>A\(5J5&_%T67S\*R.*)9#H_3MS7\
M2RA/"^NJ+Q"\CL;,(^.Y@"IDQWHL4LC@[D/BN@2R32F$Y'7(TL4F"Z>GNM!.
MX%.O B?(25/C&?;MDF?FSY4KT@*3D/[?IWOI.B,9T;9>@E772LZN;'A(W0D:
MU2L(?9(K5QQR>&)J^>+81"%[2."XHJ1.W(D?.>("D8_23:Y]OY#O2?R2[TXS
M#U-UM,N2J7_WMKODEVQ2A3E2]7SI\8SR[X<:@M/NNGC\28R\HRQM @ ;&!F,
MA=LV,<A4#-$49VC?,9*!ID+;:_?.-,%)(5NHH\&P3BGUAGSH$D>#5N;G!',*
M_GS*TUN2>0CJ=5?++*FC,;6T-T-Y/C.7$D#6D&04WZ-J9Y&41XE8>@9NJ=&#
MIHXW2<#ER%-U7FT#3S*R6ITO>CSU*M?2;Q+4$H;>&*QB:%0O^C>%W?PVO*WF
M+:U+H:"]\]DN$G8OKUVH3>B]^]@AGN^2R88J1O0F,OB[9GS9@(K +^NTE@XW
M8R+V:"O[\X-^_WM6Y:/ TA,\(MQ;LN,^,-6<7W&0Z3=ELI:AYC=?M;A6D6[_
MX"I8/_P&"2-X@PP484"AC!X2Y@CK$G6T;3'<F%KJB&]T"#^$)4-[X(X)[;5\
M'2K[NTG2A .3.&*/_HU^GZ+F:([P\]GI<><*'V<?XDX'X3@C@12SNE/DR3$:
MUO2)ES#:7TU;IYPE-OG80V4E<"U[&5$!0CZ'%ZD,IP=P7U)VF&U\5X?.FZ7I
M@.EW#X<*FII>]N/<P98@G)Q4RG1O#\LPKZGHX[R3T?!6UJ':;V^S'WNHSFC/
MJ]A[B-QO/)SH=#=N<A_0YVAPQ#KA;@30/,+.S'EJ6P>/!EF[*[Z>,-_7[)XT
MFD)?[==T]L:):;H&I@CPM\! 1@H,Y'U&'K7$E.;B0!W%K8N$RS&R25/\]M3R
M.K\"Z+*1\J BGDR=1GO^5J@<\2G[L\F.,1[*S^E<>]).3P44AN>;L,MY-*+4
M4.?NCP:&CVNY)P'8>+$0&\M2*[GO/@Z,95F[ZN J22'A <4>8IZPB4'/L]!4
M*_S1J"*/4;U;(T%^4\)6RFJ_-983FT]29P?&;QA%YD..YL1)Y![9<_W8_[=+
M3EOIG<WU@?&O,P^N?D>E^67G2SP>T SQL;7)N(DO&')!_4YFKU*F-W3C3_SQ
M\!_X,"!UZ9&K_;Y\(^C^7#4 PM>35V*UG6J7PI8,%,J"H:2U)")J;+,==D+I
M![4W4@F]D]AH?0CC4^AA)%&=04$5+M7;O?>>KQ]=R\^!_J10U$XD("\MCBJ0
M81,@$NH%1R)7%)Z9$7V&)K8<FA$;+AZ0STL!F"DC<L;P] 2.WR["*DP880$\
MNIP>6E,;4GR/\;QW8[W#L>-C8) VW=I\/I-]LW) T\MHRDM5,UO[]Z!NX4M]
M"PMI>-@]8@Y$.SB_-EHQ6G<A8R?U].FRBH>S1UJD2@R4B0^/V)%QH8#:ETOK
M#VJEC'+D7]+-VFV<;P#'6#_*"V(%"GX8.^1HW7$[_PD [/$1X8QR 9*JU;!C
MP7I=YH,DFBUC?57XJZ:C+4.ZI5FTN3_ $-;&;TMSFB[V>L#K.M D(UF0;?_V
M6]<R=\G-;A4'"^_^S&U0,KC*IQ/V&G80(<'Z)[65(_6#YI8D06C9*XY^U)QJ
MA__,0).]9/ZR+OQ[PQ@[3X#7L<G_F%6CKQ4H>Q0XM_5<NAF%FJ@(AN,J6L/@
M9U[E&]84GLNUKHVX].M3<S;LCP/F](75N@^/V:1?EQK*/CQKC=/RW>K1@P93
M%+]7I8PH\-V *S5"O(2@EYHJ;_ IQY^I]3>)S#>^>*G4Y,Z+J_RS[[B V@64
M3_-A<$<:'MVH];5ZOK X&-*6@9!-UX=)K8"%GFH*@1+I0:%%#6%%ZE&N'J0F
M6WM\HXJWE)-/>_K>_<N+@3LI<8]2EY"'$/T@D7"(3A?ZL%FC/G]RHQ*QFA:$
MF](C*KQJ\76O?R?UF6%#:$=<>+D\3QIMU[%=8C:ZYBW7.-[M?*5.=*5GJ^4-
M%3#5D4<9B.4#U?7]56%9]\H=Z2H>6]W*:'*CA\%\0_))>??!I:)V]+.O2AZ
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M@5$&]B4K.2#J;(X&E3^AVD(8V989B$$3+#",(%,JYE4CK-0I^"&Z*NL#^O%
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M8^C>TGKBA*&)[I653,"F$.H56% ]4A)T-/R$+V:24:!#/_H^.4>Q.479)Z!
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M[\=M+B"^GA?S&LT(J.0H?QQLYQ"2%7FS0!9]KF';QE*CG6V9+Q^@B^D^Q?,
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M(JOFU;"URF^0H]M5=+44_*1F'[*?TL5WI;H6E-&]!^K-LE/YC;YIJ.3PG O
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MY;GJ[.K:[M>K/:[MU[=?F?>K"RY5>I%NRNU1A9NRNUKLW>WE8__94$L#!!0
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MR/,2N/L25>@041H'C*E'A 'I20 G$!ZB*H8MB_1?T$+M$\"XEW68"C UWM,
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M^"V?GCOLL=([%FY( @G 0;!& )$O&&:!]R</19 7B%W(NM7UL'85-+ZT%<P
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MSOJ)9Q#X$?*[:@LA@P2()@.6+A42X'<YGHQ;Z/YA!/*[5AD50;6)>&67C(_
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MY/H:I\]VICK8+,$%AE#T"6LE% #23Q56&XB3V4W#,)'9#TR"01S=?P1P*Q3
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M;C"ZTM[)%!'=G^FJT<:9.T?[.J"A0G)QB&?IIR63#1B$JI5,/)G)U^SOS>$
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MQ3^6+U\X?_1P;)Y(46]V_O##JMP[OR?SY:<*!%9 M=;X80+\ZOX-4&R!-=Q
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MP@+OFMYYZ/;%,KE4@4XLM.Y>:F<]R91W>Y=3]#E#WXAD>33Q/MO#'3>GBKG
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MXGG-A[=^&54AU)080B<0=<".:P I6&S\W0@=;ML#TNGOW\-&:[5)A8LVP81
M2S$(*PRT12K-L^']Q3LIXNY&J;,@M6BBX8(4G'N"YOGXT1G-$0@O=!"5@*U[
M/@VW*)5<) T=06:T'] $$$!DLW$P:MR((::AN!@6@\4YRCL7-->/^S&5LRQ9
MNI2\^*%08L^CH2!Z21T Z\[\A8@\O@;$0&\W8*5@W!%%N+AB7:>J+$ATLW+"
M.PL8#0[4;1)40*GN4#V[/2UJ46>VZ<VY%VZ-G*L5K^PW.QZ9C3; WL9I*I.
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MM" 'DE57$/ELN.A4W@*GNEK%'OVR5J&+A78P3V/^=N85.^*J&,_\&?Q^=)?
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MO;.2"J^4LF)/H&C --^3., =-V+_?K:T-*T8%X&.NGI([?R@VX!\@-$IT0:
M4%\Q=$F2"#IGDU,@M1_LDYQ4^7?U4RT+M_ 5DGH6(K^$%]/3AP$2,9+\17%O
M+LG2IO,^">HO"<:()R7@?Y.Z/[@;^_(+O9W\Y[!;!*IBU^@[X.TR^FQ]_J<5
MSH_HT7R#U&7U#JDB"]NA1[4M^0W/'?R9[1\61A5-U*^%"(9Z7ASOVM<D-__B
M2@[FZ3FUD#_</AC;;0QBJR;(7?UH VPWM/'68!I:JLUP$G@5W"^TUG*$OQ+1
M< *67PN7@ E'(<*/+09WDIZLC9V0*?<0Z*?]>/<*I*0%DDU=#7HXFQZPK:*_
MO\J]Q:K03GDX&_[W<YA4PTHZF:<=<LEFR9_TN)@,)DRJV;L6M= ^\J?KU6X5
M:0K Z,ZXYV>.-U4'BZ7%XNQ4\]X_]Y^HW=T%6#!<#L77*-39)VM4;G;D,"FY
M-)8AM2T\FT,&L>[9CERFB4:,/GJQ%CW#5^]T+5I:6NIA?*Y2FG)GP#E?@H[O
MJ<\UH/8 DW(-,!BZVRK-NPD96;5>O12Z!O2/A Z;]@%QULLDRLHX70G67Q"*
M:X"5L5!>^@,6^E)9+>)/&CR_%J7L(L(OIED)VZ>35UM6G >][R'PD&)\L-DU
M8 :.(,29IUY-$ XAXGK(E7GD:O$<JA?%F.UW#5".?*5B_\\SO4E_#N8D:V72
M4/ U0+24+]&%*T<N0<E^"ND;9'ZF^\WL8H$0EI#QPU-/4P):N7G55RXH'4+N
M^]]GX6N4J"#]TAC_JP^[UX"4F^LQ&7*L]<_HY83*"J (+,I+3(XT^WB#+>TM
MF)T-ZX%G]OW\3NMUZ&M(I1,O[W1\AJ9/7-O91MR5KGE"_I>9\&0?J$=8.9/U
MPH\!["/.RO36G6O +9=SU@351T90YW\7;9K\O@8T0GH02<"ZC78(+=@6]P1U
M$&7-HQMU8=V(!K%L(2A!\%]*)IBE+-O&9SC/#;6H=\DVPE\SW )L39]=3:^;
MC"S3'(WL,6&,>T^C<-Q8NY6&7/2#)+*M96HP?SE.9]6LKC%V?T/+2E.8SV*M
M >8N+N%#\C!?5(VTX) ?1J-+:4)F+6/Y\@<NR4E:TW7:]V])+H.UN&4K8:BE
MW$Q^,ZEHY4\OY\#/QB@L7BO#X1N"'.7;6ML0DNXXRW@>1<>4TLN@QI# J4(1
MTSYUND,,I#2@D$&7#$CF:G=8+NTBA/^=EDW'Z^'8L.RHI:1+$YQ6QVD;-1:V
MNUB-=Y\"KEA'HI=9EIW?5,>T*H+RMJDU>&+WR<A[.S.0K<TG?TX[%H7VGJ0O
MV7+<"ZW'0O"/PD]M,6SQ-T66E5/W3".=]=-Q)1;7@^JM(,/&-@9,%0SK9ZX;
M-8%K-#S*N)3$ZZPZ9'%(/V#4\A <5#W]F E\J&Q#QMZ[Q [K,@BX!AA/%,!.
MGV.)=S]]+LIR:I*P"MUYU9K5O8^O;_Y5?*K=JF>6;<9>WV;^\0EW7\4U8"4C
MDSNZC0-GTD-XA-V/=?=H8\8SXD)6?U&CB3N!Y ';P(?S>+JQW>,0"J/1?4G#
M0[R@7YFY!5/6Z0^J>\)_-?;^:/]CTO,V@\'&FU?G7<TDH8[!,'Y;<_ !8[UE
MDWF$'5]R\5ZJ3;_.L%9:F_W(YFL/2-X992>)!8,64Z<I,O"N>TT@B Q=$VBM
MG>ETO+7NV[]XS^CW!HV8NWI=N<K]U;VZ^V:58,D;2GIK4*JO_!8?<%5%H"$,
M!QUTLMW#H2EH7$,Y<>VEBRYMQ)BS<+QDX$UE8-Q<'\Q>TJ)JE^+A4:P:S'*U
M]N=GC$?R"U./C?[Z:P".5WVWO#3@J M(01$OJ15\Q3B#YAAUFUEB:ZK'''Q:
MQVG8"%5BV34Q4YBTC4FX+LE633]$@<K,0OW&TH[90:]1>-!&%V1N0Q-[MD>!
MX5Z-)W"T3E2WW;7 =2CR=X[-=GN[E/6NL@B^:UJ7#NY\\>09,\K"^YF8U'J;
M.<[H&G!G>:*-'*R"34>L(%AP(:V<5=O+5#>()W-&'G0D/<"%=T/IL!1=]ZJZ
MD6R,VT56FC>YL-D0&;ECL670^*7,=*$A(\"A7I5FTPX+-M%LW0AO?SY6&IM5
M4"9-(D!5K#&F,Y:RX1=2;W] PZH)6HHO',18BH=AZ*@[AAN\8=YL%VL1J"UT
M6864,)T*OZ6&04Q-O6@@U]/D?N^$J=^882;.KC?E=#RV6(8HN8)M?:C5BQR(
M)PYR&0"FOP$3)DY_+!?;EN2&W;":EE".C.Y2HOTY,1(S_!'5A-?V*^MX^K/E
M%5A9*<7S<,ZU3L(;OL((WF).Y%^]!L2Q88PL=.^YOH<J88BCA!1",#80I^IX
M-AJU3*0D(6MU2+=[F53!PV%E9F) 0SFMV/D@:.8:X)EIRF$A;Q^&0:3_EH)%
M(5;2S#,BP+)YB$B(<R6H TAY4RM46^(&40@JG'\[DMF:$C."YUBBR^I@9<<@
MH@ELBUI<,?G.06U?%#*H5(HC&\,ME)&C'2EE'^N^0]KY%&B*<.RO,&J%6)7N
MBZN$C-_+\< [0GYJ$\<_3P15='']Z&ZL6GDUO(]OL,0E@V2MU4*A"6VZ^AG\
M 4IJ+!U?_B+59:6T8^ HU<'3<95?W0TIMJBU"Z?C':!ANMP5LCHVZA,GU9%K
M\,C"WC6NF<+ ?=QUZ#XYG+0JOO9P-Q(P]*ZO;18OY NTQ]#+F3;S2?*MI_JZ
MNW:,=IIT&!3O 8ENX)E[HU]#A0.B4<(?!?#BV <ZN&BL/&KZ(Y9.#Y.%T]\V
M:R7Y'I!R%N18@W9KA KSOX2N<6EIZR!)T- INU_?;-0?6"=@CTZ'<!:7$MM(
MFJ2N>64FBRWSD^'$C#;1"05)R8/P5FFWBFVO?_=3#3<WONEDAH&@E+ZDE%H<
M(@,.J3;F;>[CB)4< L<O;-(N GW B _)Z J*WAUR00V&,.EC;J+S%W&'DC 6
MA'^:OE>,G+T)8'/Q>5<Z:U;$..W2O!EF<0RF-5F5%]SST>GS=-+>3:C?60D_
MK<-%"B?"07&$IYB&'.^5Q0<=)JP4/T<KP,_S7/2=E3C#NW[L+%''$@R(HT]"
MK%;D0A'!( ^%LW2=1Q*ZC)E[1K@<!_B:P--$OHRGA2221+*:XBFI%?/>$5>9
MJ6GIU<FT<4[#,P.$)".%%RB<K2]XAJ@=A\^7K^P*>(V@A-JZKHC396]('/Z1
MNBW:96\::,>C4-N@%Y]_DDWJI%-UOXV.R?B7)J;LBMCPANJ30X<RC5NP65JM
MDZUO&V"W9EV6'X)?$$BG##J\=L[\3Z7,A:,D0MZK)LZ88-4_<4T*&*B/56CU
MRRWT"B2_K,X\ 4:R-7!W4,1!2-N>X/4PP_EE#4F8Q .K\5".3?/TY&E680RT
M&K7'-6,Q^2['[AGU:WW\5N/G98M>HJ[/_9Z;8;HB/X!0R1OFXCH(5U#_]X22
M#C*G7O/C4; G+J<8;YUDE:133Z?T".OX.5/>1:?!?7W98,(V2S7LP8X;7-EC
M8ATZ-P R9DU 4<SY=RV3(1Q!"<JDE7#@O8#!7E8ES$:"\?A!Y]+=40*3Z79C
M<W&DA?KXVTG!=]Y_%[9-I$4L.'O@$(%&@0J%Z=FOC&]%+77O7P/V<)KZWVM;
MK<Q]\H4"6U7EZ@QM)";U/?E2JUTT77TTU,:TXF0&0I/2O+P[,4O!72#1: 9,
M S6#0"@_C0Z-S/LVMJ@GT V)+>,!$PZ'V.JN,N^$ "U^,T_SDHE>@VZ33+2"
M\C6 R/@JS>^*KI>5PTJW5\XINI4"LSZ#GD1&_5H1!&JD=+.1'0A#:E>Q)F$"
MZ_)XE0*DJYJ,L%,$OUHC[7!N>L @$DN,IZ$X=<$4):& #P/R0$S.2*<8O)2"
M[U-75K)6^"28'7/HX:<@681;[0GRF)R>862-+-^N4[U*7Y?=KZK06C[_A\BX
M.K7MIJYKY\,[5(%9K91/(W#=Y=M0Y7^W_BZ3$4:@S!,5[UB() XBH&1:O[B[
M@GKB;EOPJ:.#^TXJI9 #R-/C.DYX3OTK337Z*W9L,8%D.1_\&@='@>*#B../
M(>1NS?Z=(Q1@'NQ4=#SXUG>\ZAC88N5&)RRT^Q4K%GVI;)P]SK%[I_]2*$_M
MU6I&I" ]]Y\..YF!-CJ*3Q=IG+)EB7JIBU,[VE8=5.OZ?_7B'Q<Z562GIH1?
M,G<^ON"S$=]5TXY&A_+TV(@<^P9,_L&85@R*#'K35Y0+G,Z2L@*_V@:\CS2L
MJ^CP>T*Z2O<QWNOKKB(IJ8CX8)E WXF%\OPUX!3\$WO#S.3<GR3M"L$DH_;3
MH7P!:$7R5W@2E%J<5L/,A!;,^LA_I&R;4?(J83V'Z$8<+W%.:K#TIZ8RDT(P
M-_B9L]6]NZ,DGF&.#:EHIHL'$Z^$ #NH ]3U4GIH+Q!=\[('X%L"YDHPSH4)
MLX#F)4D/OA49$HD8L@$5]EBT$B>D7>Q8. Y!$\H1<-:S3+TO"!9?K8X,.NAH
M8;L?P-_1K![A0/@S5>%>6>%'00_<\J#'YIQ%+.LV9'0>;G]62,_5;D8D=_,5
M1]^0Z;>'YCC^CE J+'<W"]?A1OLU@)9 C=>9\#L@!@M@$&%^@HYL$6OV$^\@
MM&UIW-_0))(Q>DZ_)CT7%DS[2EDR*UR_OQ<PH:_0SYATO@+.Z6S[;*24!W<(
M\8G6NZ.SL_?7= K/'^6#^&3IQF*C*(3+@9]D&FGB(@Y)C96)=!HD#2+Y\/()
MY="5?\6A/7F#.).)DBF8,RC5Z]AY349S-)W!D<9K:ML$UG4-P!@+1QJ#,'=U
MB?!*N+15"[8$-OH;X@QG/*8,L+X8Z5(FQ5N@!MD%3[/0+'=11./+W:*)Z'VI
M+JD@TY^(9+589NF:+1A&'S0',L82ZC#[R@R+6XV9]E#9J/DN9,.74^#=G;.;
MS%*YUHP]S<IUL]U+S/5%#3I[<C4=[MF9Y<-;I/:>1-P]7/0ED%0^NL@YB 5S
M8K.ZVIBP-5?E)]< )$QUQF'TW9#:A/8OK''B.Q;([[JMNCZ/@V/^12$-V\13
M[].=0/I7$1Y#M@'L!)) %!N1ZY+,1%+\.RLWE'K"#-JW*+H$+X,9!*N.5A.X
M*R=VE.> U-_8+,*FQ_<O".@>CL-OJ'1!,<?DQ1<-E%W>0972%B3:'0:N0EG>
M>@53.MJVQ3P#^O%"F3#A>LLJ#7F_P5O'YKWV]<RBK=JI=C]^,H]+;K[%!K:Q
MTR1TFZ"9A<0IS/W$%1(;[L,MJY]T&_UV^*HI\<--OLL!UV3'OS9Q:N1VC*C+
MP#\2ZSV%7E4**]&"E<8E+90C1$.'3V^"I#Y!M[N-:DI!&%WI]*85&U*48E/A
MXNTJA/# 0',+_DS,MXK042^8MS3'_,,*7!'&/UKN:./&U:W"PMD8/83QRJMW
MKKZW/05SX *KG-MHIFTQ=XL]4&X<T^^&A VPAD5:/ JJ4M]H)FOK(Y^F[:W?
M+V/?&(4X(&;%@5?0-IXMMD=@7>Q.%Y#F1)<<3#YV#7"Z!MPS=86RC$H\4&3Z
MS<HR_612PL5RRX7::GM]?'I@T+CU6WQF6G<M4+-<9$,.B.-:CO#T(Y,[A7R2
MF^]TN#0(Z#S-3!Z3R'*FVM'#.GX,1,TOW]?F\*6^"R-KR^57+7U!-"': 6#8
M+E6/XPSKG,[A>]-E\(=?Q_LT 5+;;_/(SKZPO(W+)$D^?B5%W]?%UZZ&35UX
MS_)2P-0=[!/;RMX>H,,Z)+:@%JC?9M(U2^+D%Y D40ID2K&!.ADPYR?K=]FX
MKF!D-&:Z;$M0VV\*PZ*X$!K?;RCVC;*#8C"!EF).00/]I!A']SN4'P>[*A6.
MKB*"Q;62K53J20C3!B1U4*DJU.U(97(5;9$2+!^V6 P133IC^YOKX$DX/MW=
M7M3!W0#AGJ!R_(L)]U:7O!VHZ,3QD%:[-#+TEQWFK-/_APL2T:5MISDI)"@D
MT,K /$,; RJG9%\4'- ">?"54ZXIW;W)^49;A+L8XNZD2%H8=?T<F&P5%FTM
M@_-&E<\2& *"1M#*X15@7SG+!57AK@<07+:;G!]T,I:?%U\"LI']M2RA)W,L
M''\#8YT<=G1T+($6=U,FL4J.URL_ LOB#%PPKB<*9C?&$.0QB!@\&<C7YKWM
M3\SZ3^OA3F.M.!-:_],/5] 'Y5__^/S3X@J5CG<=U4]_0,%V&CG$&GBD25*B
MN>>#Y#5_8Y(D=^GETKX(1FR6LW($\#BV6GT:=!TV$OF6]AH)E[7EL9$)2G!7
M8J+1P!P&W/\63:U9@/5)4+ 8*$'QCA<S.RA8E*L5[[5<@G#5*V=X,<<8C.O
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MVL01!*8L=C33H+;CM&KCY)/Y4E,FK4]H/7_%SOGNHR[3XVL %<36 &MP"L7
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M"V'R?Z,6HW+]Y3C@>ZIS#& L 0\BWQX#/F\8,LYPTYUU23$=SVL.5+8)<L<
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M8E]3+/O;N:AYT2#2?6/*(<GF8QD2)WBZOPJA@GD*A5"5>T<0TK6.OZJV\JS
MLMQ.]S>$>_E2:&+='=C$R(GQ9NWM365/DC7M#T.EE986-&<2)DE6CVGE#CLT
M/5/EX.V@^<#O7#9IDA+V?<:4)!>JK@P/N5)AL-Z4'E[>_]5B9GS+0E]'Z/,5
MVZ7M!,5G8>M][3)T+TI>5V4-FQT\ 9ZTMM_+5FE<I$?:9O=NETG9I.NZ91[\
MV.=<67/#-M1AWVD.O7CD=OJ\U+/78M$,5EK+,> L'V5'C$^E3;$S5W4$85F
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M_7ZT<-5]X<SL2LUU2DV?;I2+^I?Q ! +_!C0=;"57;RF3K ^FLQ!33W*X#M
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MD O<JLJTV<.T$KC?6T#]C'?BXEO",#?IKA3@5QTEBLYKRAZCVZ*!0HQ4!7)
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M.]^%RM3A#.TS=!>:6ZWCL&(\>B%N<2Z*Y51.OK*3RM#%9T:%[G>\I)E\9,]
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M4HIYW>B!B$"][I[&G&K&YEI*0"132IU+HTMTI9%LR:!\9=7"PFZMCDOP.VX
MUKYU'Q_?\*FX*V *^=;Y>S25AE,5^_-?<@>QGQP [_LBYY\(9T/I%2\C$.8P
MXH,F?>O%EY\MM6O2_6,$G9D>*1L:^3M<>T^?W"?0@IE>$1F@/DD/HYJNW 5W
M5W^=Z;UOX(TWK=_TO=+2BDBYY#"N11N)HA;E^U+PR\/3-#-J]VZ^<[2+.Y$3
M$QP\5^H3P#NV#I%';19,MY !M6G^/S^]6C^WU&%WN,X4'ZW_RB.W=,<KY F6
MRF+10B;29TD QR2>OK,J&<N]&]M<PNY@2=5_'T1U*W^Y[P.FX0<"S+")0SD;
MGZ3A]0+OOZJ7CTJ2N+9W)?T7*S;NFT'$W*XU&-AG)G;D#(]=BLQ] J^E/7\P
M6[RTH%%VV4VL\LXB9^E@CY=='TJZ));#VA.NUAN\'KFP3^(B?!)?E7GC*N(:
MJS![VZZE&9[44W!/=/S7$%7LHUMJ3($OWLR)7MIB S(06?QNZGPSB[;YQ/MQ
M\Y+6?V]>^YV:"+]X^?9*1,XJS;I8N$[R<O%'Q_@WR2JU;UG_K6$:R=PHSL4A
MH$]?(4TLYOLZ__7*.Q,>B9[R<I8BB_D JAZ=DFV.Z^[N=ULG6V3T6O0LNZ3F
M!6UCEGZ_?^75Q<:1^,+A*J_,2P*R8BO)2J><")STV6;G3?W:%.E4Y:9_)O0]
M32$0LO;J,=V;5!C*0.B3Y@^Q;$"0:P!-1V>P653D$:S>K&KNH7V#"2JDCE/D
M(3AK==C?;: #C3,R649\R!2( 3(XEW/X^1W\^>KOI1VG0NWUJROQS^='#"*_
M5@G+06*B>XQ=[JS]Z2<:SBS/I[PBXN9[KDP.:OX^[U_1>/'SWMO2.)O+$Q<F
M*PQURQ<OC.NA49D-A3<^_3Z(;7ZX,Z4A)JI_U,T?MRKY*TTK/LZ$/B> FFKL
M.\$7/02$5Q9%V3DA4%:]B=[TM(FOO)T#3$+$/QAF[]QC>G^IE^$171OGOWOL
MG9U0^LVD6>>3-V>=5! XQ&V,O9)X41 _%NBAFFM'U<D ,M@8"[%M#>4>-P1%
M+3[0:GWQ&CDFV4SW2V)#J45O7G3/EJ&4Y<M_.@1[>S3Z4'\;<Q(M.1<O/PRE
MVGHZ(OYA6<EO%55U#(\R%L^DU!$1@?C@-YT?:1=?/!11X:ZDR.E)!V<.+%(R
M\E!EJ6F4 V1YLUGS(2#[-DI5EW:@8I( 1G,&6YF PKO,+5DSYQ]WE3\0NKJ%
MXOS@%RLL:S,H;BBM+M<^L )[,A&F./_,SM?;&<UX2\,G,S0%CS'\=#_UF$;5
M=)@,6*1RJZ@XM0R9:>^0.I+.4DPW#TV=&*U_,H^RF->X?EOL^F]F]5'F/(F]
MH=LKLKU/5;C]/;'I[6R(H5++ )>1X&>B_JPZM*[7I]*II;\Y/$FOI@4\5Q>A
MM[.A9:-RX(EJNQ;#OIO>U136_];,Z,ZD*> ]GQ,MI[;>]PK/^_TO7P%NP.?U
M5+BHP0PA3*[^8A/*G&/?DO2N*<0&3 =%\_GJ2Z]2B_I5>=#U4]7?)(I@J?W+
M2ZH_':TAKXMJ>+UQ2!+B\W>^KR86$3^D &'ODI-=W1@M^<IPF3&RC?JC7'YL
M5Y"/IT[CXX.)P. O>?R7@$U4@M?:BA4S-X_B.75&10UTQG99.P<%+A::ZIX\
M[#\U\'Y,>_G]+1NF/W9R,]_?WW2DXJ6AXJUB],PT___Q@-/_RXN*=P*:309\
M(,93NJ$-8OBIR9HC47F<1*=$!JAMGBM!EXV\R8#!,^ R/@^KL7\&!,UN4VA1
MGD<RF3:9\%PZNA)+!G0&+1$+NK9O ?\*7B<#PI?)@(&\LD":;U=CB!5D0!2E
MT^P0[",N5>^<3/.2A,L3EDX8R(#M\S]+6 LP@>_LA_%%*]3QZZK;M1 3#W;8
M/L"'F-CW^O%X;DI;83S(DOMA8(L2Y!QZO3'4]1J)RYJ##)AW"DL.YBGS,5GS
M( ,^_K,O! +-C>!#9.D#<#JC[<]OP^[X7V*@@OJ@N9@?<I*N.Y,!U'E6WY#N
MH-E=_ZK5&YCRQ%8/AC4:$&<Z^[VX.)L-]G+2R+]U.;E%R "Z&AYB@7)=%!GP
MM4*"Q$AYYPLK]2UZ4L7H'A8@^">,YU.8"1G0M4,&H),7@,NM0,>*-57@LLC/
M8=.K>F3 /9*6Q"\:_9^\O +94'0#$*M)N_0N#Y&W<\H)J# &W;92[0#?IV,L
M+KW4;U. EJ-Q4R\)$.T0F+K.7)&%G-QN-@-7WFK#MRVWJ'*4*ZK>+8);HZYM
M.U;+Y%2/UH<5"LFU>X_8)9ZB?8DZ&I$D;)\2LAB$W< 1X?^0AG8(SC15[VZ?
M*[%JNY,!,4W09/^%Q;"> S? [D+\0IT&)=U74R#3@YTBP;,;%$^>@DBS/(<$
M8[!)7ROV2R09L'/'%9S-<2U ?5:-20-B?_Q?P[G%TM2%0EYIX(@J\/,>] P=
M=C6\?S6;RY>J[?$(!L@+3LLG7;>B(%S0-W0>2!IY&1S0X#T..\7EDW@L_AV6
MX\$N0NMF1\"$\F+@N5V/1-E*T/)C.NB,(AD@;F DKSN5NC]IV 0^?7SV29))
MN\1:=NVQ9G(W_^LAKA).NP1.UR)3D4L=BF^R"]:2Y6S\Y7A=]MP^>$_8Y1;'
M^?=7#]60 5<H//NHGT"SNW9.(>ZR!9#BAO$^(FLQB0YT?XX,N+%RKIR[XAXK
M,+)MFW!$JHZQ6"[W.E[OTA%O;M-A<I$A!")[.#3FZAH0!T ]0YDW- W/2&;%
M@&=R[W#C@H<;FZ1@DC4C08R-R/P5"W0C ]YSK)(!_7."NI?(@'1&SR5L,>5;
M&B)S,0G6C&:@W<5L7@TB \:C>,F :HVQ;NA(4?ZDL+Z)=4O9DO=#V_6%E6N3
M=X_&(,@DX["HK>LK"7(;-Q!^70EM2^#A6O=Z*P%B_M)F9N@I<Y_XYHY-3MRH
M]%^^^2U-2?T;';6!2C69Q&F*LT?^K;J._'O>=CD8VF-Q_Y@,*+Y$\MY4H2 Q
M NT0'B$N^;>_&+FXD>1Y.I.GVUH6FO.V:G,(M#=R'"-M:FD _]&8Y6\HC!RD
MOU"$*8;7?P:\*8!E^UH5RU[R6Z&YJ^:2AGRD1F3U)M&9!X4MY%T"C?<D00\8
M)?.PIR,$?O\+'I-V S+ ^VW?*26X8&NHXK1JXGGMWBFR'_ZAM_6'*6(SBN*4
M$Z:S,/6[ZCSFVC"]T^EU-J*R(XG.DB(I'*/8FY1 GK[?&]84^" %VF%/":<T
MTU.@&_C]6\<\0EF1(NE.&/"98;X8JO:4U" LYV<O:)^^8AE<(7Z?9*BLMKDK
MN:)8PSW;$_:&$HQK_\YN)0,H9T=M8S+(@%,K+0K7DRA@6 "!V'GHI4A@,Z9T
MPI>&]&$A"-9;V&;DCQ@(@_"^2G$8"[(/#+=:^=B#.!%]"M1]1A4_>_991UQE
M2X7H>G@+VO$6B$Y70KJ!/G!!)\9E#DF_"RGH]T,[Q$'@.1A:BWL)9V3)T-HX
M[A):X-X$QA]!3WE?)6YX!;T]+3\:PE4?=/(4&V9PYQ]6_TJE7 Y%93K$*905
M[,)*P$"WYCW)@)11V& B$ET#Q6I-*43M(K&\-'&(:#?35<\)YY4&A3"?8'-7
M,]V'T!B>BE@8HR<]9?BNTS438KU71<C:MGOI3E/SL=IFFUH)L8>#,L[MTS@@
MN@:(U6980M"TYW5U^PLND3XL3@I11N^$=CSZ0D4)B&:LT$H<1;JU/)Z&;U[D
M]3Z&C4Q+MK8RP$O[AGT?%FZ&A5(0S>SZU%B5[Z(HV'UNO7W_M_ 2:2'_8TIZ
MN?'IS(5D_S'/E\+J7_!_5BES>H3[< XA7K,=)ZDJI)',/4> E0HD'CI*_ \,
MJ^TBL**,+S!:WV!=Y[+!I)#176RK9X#]MGFF=>:ON0O0RETR8));Q+58@G[C
M]]+XN<PQ4-M+26U#"YRQA"6 " (FT#E'M!D9\#-FG^MD!.]\*P][LD\0\)0#
MS[FB_1A5%%_XJ"E%$;5"SX+'SGI92.$>>00]"@/2;C/0K\A)(R?V),81UW!4
MQ-K>L P]<.8+TC5*P%"/\)) 8'2@T@B13R:4X@D;,J O$[B\#\9JDY8:JMOW
MB4+NP%-K%_O8CA<A;DQ@=WR,)AD0^M*ED3-^<9ZM5P)!?)/]HIKT9F3L%X7@
M,4^4U-9%#NU(W(?_C%.10%KH*-L\@KKX^>'TN<*?$V+PZ+^-!2B0.4%'-T.8
M*+A=+)$!(LZAP1(6*S]B2>M.87!-V"7/G;SF=N*;(R0Q*42=##C*+LPK.*6X
M]A;\E$(=1A^* 6?HZ :1F6)@=QT*W/DU3I&]73( J^,]CA\A"%+2\/D(2:4
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M\;FD=U\9EF&6')/>B)]%,0YEXTQ(M=AMC8H3H;",!+KJE/QHYVJIK],1N:+
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MYKYQ+M1_#&8BS7-?B5V.VDE$E_.\7Z(A/=Z"UE$T9+:>4\<?$Q7AJZ"51Q=
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M2:]D4QTW8\U7SKW*^FW#]M(]V93J!TD)>A![6%LZW*DJ??1<3$( 4QW*'+S
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MRHQ97<(\,E>G/$Y755(VPWEB&9\*_W I5!KZY9;LWY74RQ/Z\W<M$JJ8CT:
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M:??Z#3/U'T9YCORZ85T(6 L^"=Y_>=: .]_PC<$+CI3O>I7!>1BPOH.YOJ2
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M?[-R1O(W5=TRW1L;*Y'K>./L*FA0\*:A;GM_ -+<=CB*@]A>E?=PPU<U6H'
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MUK2T%'&KB5@P%?+YC?^G 0+]\QQYF9-)>#$@<JB -@P^FC]N!]BADV4 D8>
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M"BWY]K&-?2?<$U>Z?XZAH=[N&*)R&X-\J2XN2&T98WQK!,[4AD"(S/4B2-=
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M!&P!N,T!L(U[B,_,UG>[;E_L@7&_53=F-R3=FS3;12^T[DOIR?!.+Q<S9Z3
M8FH :3?-5NA(/XP?9N;M&J=O#\I>C+=2!/J[W"7CZ3!['E2P4P2MPE]9.+L!
MB7'?N90;O+.@_4U]8^)/YY H#.&6C_3;+4MZR8P@V ,$E'#6ZA@5Y'5K5,.G
M.LR)VK0A04UCE&K'?33+RVG)F/Q';#9R[]U/0X)E*<APMFL<T&4\MGMM,>]:
M,(Q*LR3_M;'?%%4*2(1%LS49 2A-PA%A(_D!7)XXV-KS0U P2U<%NC[5\V7M
M(J'J$Z $2<51ITN0EQ59B [Z73S:.5MR;4AP@/PI;R4<9SP*/RC>5"\H<3^8
MS[M4D7=4B""+](2=/5RS#&$S=R4U>R? IE039:?7\SMK)5N&BT<()Y2[,_;"
MM<:PA%/6R:XK*F:/NV^7Q/XL3G)?CR;"T,3^?"7QMGP-<+[_/)@OI+ 8FE-=
M><$)>O&T_7QL9'<8T1KUH^R?X4^9D\0LGK1)W$R?0 <C^*G]B.=IGG-:36O7
M.D.\ART* @5 ..\03/8[Z"1$=K)EEG"[ P?0]MSUR"M"<V8C^-"G=*%U:-+^
MU6SV<M?CD3SK75'GI-NL3WV/<WF>K;["B$,WDM_F)Z&!Q\W,?E4'GC1#&O1U
M%%:M7E27:,-4!M*WC)>T- ]88;C6\#74HP4OH*:=Y!..*0AT]S0,T@9Z@R)6
M,)#^!/R4>.=7H)FW#TQ732;X\AWMAGGC/=!MA%!A8RH;VK%W4QYC"-N,'_P#
M+&=/8220FAJ>PT:E[8QGQT8,C4^;N3Y^6RQ+E21U(*P4.-08HBGH^ K_W7M
M,M%JRRO"T6&Z-A[&U)(')+L84#R2:8X)+9S+G#DY8!)IB/1N3N[8ZME58[U>
M/'TE\%B#9:C:[+::D0T(#C$1:=,T6-0B;"IHW8P0**%T)PQ(FL!;LBSRDTT6
ME0EZ#4UC1.TY]9])Q7/AS=FRX]$FR%G3=K_&8YJ-3>EUO$\.-7J-B?P"8:D@
M"=!X*]8"J G4QK5UCS-@%O<YP1'XXSY@91D>_E)T/L+*N S?:S] ,ZQY+Z,>
M5LA#*^ C'=O: <'3YM>F \WRTXX[/@>@HD7'-BO3CV )1O*D<2K-++;&0JN(
M:+!>0/.)^-<D7W+6S#6[1Z#!14OA+;LNK'HG%+B[>WC,KH9'"VI,W@CXJ6Z-
MTE,YN7:1=:\3.V# !0H9&P5D:U"3-R JH:B=!&TTV<8.2*V:4:4UOA"= L.K
M1*:-B5/.CKME[9DK>?N'3-MRG5EAK=LS]<-Y4B\9S9$!-N[R4%^ (E(R7@D2
MZC$WO0*_YCQ*<.(@86J;U-[3E=.NVD57&L&&,B $2^&+1VPF_##X!%-44XWA
M:DI?I8?5U=)&:F+N.BHSGY[WR?9C-6[N\2FQ^_X+X'V0$!Z9X^Q/70B[7X='
MLNIF_]"5@<5$\D.:%W_!T7?-<*E<I,!E*T=HP49H%XT<L^=5G;K\=8;J,_@_
M&)QG]%WU0(-X%TQ-K,<@6SD 'AV(>C;K';R/JQ@EA'%=F0G+>T1JA?/-0[/.
MI'\"5\-2*KQGQ[UU!K _3'/ GS7&.BW(<H6"U''Q3C1PE\D-?@YD,GL8"K=%
MEH7$?K0\XI;@.+YD(%O<W^&- *F270E4A:]#_\1%N=J,&&(;# _-V(;<NH>_
M1C6L"=TZGKQE&;;Y?":S..8L060G40V09,G"6.[]E ;47CR9Z>Z=(_LQR]S=
MG]D>#),%.^=7+9-.PKM4GE=Y3EWOUQ35.IA./1-PUX<=G.?0#;A.A'S09A%;
M698%TG7: !.Q7NTF R*XCB'.PR4,H/@#9D8?Z,ZHF%NA^)<MM&J]MJ;GE,^]
MOI3<O.OUJ<SS?AEP9=!R38+@#!Y;<R%X@!.<_+VS1(5-\%Y,$DNTI9]KL>%9
M+J ?:<F"D2LP)="F\[XO)G,5$;=,2D&H^,/APN+1Y'^;GIJ\/D *, 7-2#8D
MYLZ)_[W>R&<R=A'N@E0.E<S8+8K@Y2>LS*@":_C[GU"[\+W=>9;1/+V$[&%/
M]?-CRSBY(/55=A>)6WWS%Z][X>)8J.7A/56/::?5W<,%"VOZ"UK[ZH#V+)9=
ME@<#6&3A]LR;U>))UU)Q4J O-ZP>1H;K+,Q8TI';FP$;O)[[ XSZ4_?&T=R1
M(<^Y?@RN3(WO!UQG<(K9$B(?(9\GV1%U5E/5!G0J(IB!)%Z[*\^84B*4?.CJ
M,2@^ $9VT_>G?3\_M,R0[0Z-VH.W9PXL'&/;E+DEW/OB*!/^>EY^ W++84AD
MMEF@;J*]@&$IJU+3MSO/5%A,Z6*0$>I$-7 <16L$^N.6%E*V\?,I6/$^?.F:
M;G]G*SQ#)7DU[!56);? ]M9VA;G$?2/.E_U<O/5<-A<[)S(1]B<:6SD+(_FX
M+DJB>3@)*E(&F#_N5U,>-&CHHR5 R4[Z(: FNG1B,PB8<[$6\VH3!.<0ZKQ%
MM.?[J$CJQ,3Y/]+%=I-(2)0AA[W)[U<;1VBG@%([X=>L1\LG"::A=[C]V\%T
MVS':X7**!.C?0>5+1P4/]7LV-Z8LZ5,DYGX'A5D\D5VIE(Z,>>)+2_UGM[=X
MFEW73UYJU^BR8+.@H*WH&(^Q8SY?0;2?YT5B3I8\?(F?ZIB\:H']1"W'$Q><
M7D<+QE46JC%.%L@=>:_NAVJ<N)VE\M,?G2\VV(!T'*)K$/X%&/$FBPF(/?0C
M\_138R]!RX()PK4A!E<-6$PFF'+Z8Q2;^J5F$1/JUDW/5?+Y HOOUP9%),/U
M7%'VS^=5Z$FE1(GS/0Z5I(X3--4RD>=KL")?F> ]QYTC[B-U[N=\B63")83^
MY$VF)9P#9F*YUO8=.B*;5VPT6F0YV& M(8V6PQ]QXPW=ZV[)\TJW"ONV#_I*
M;[U<O,,^JF2V^7Y-.:YJ!N]_0;@LSLN3$>X8*^8:2\ZG!:[,[!4B4C*GD*WD
MSK#5X0#WOM2D\L!Q>0UJ77M7C>'7V/Y/&Q 8(@@V\8<%/["> ==RFYS;9')C
M(@)?RNV/MSIFI6J11Z'B[;EL%E4.S/Q]>C.MK!4]#+TZ$JQJJ^XS+)!1+QZY
M3TO0WJ5[8RI_YR:0SBB#QRI \F6 U(U.E T22C.;B$I@9>'"-F9V4SX?"@WX
M(S[4NKG)0NEVG>^ !)F;9*R"#K PRN4>OFW;E(0I]: ->7F\#S=_:K,IRBF
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M?ZI$M1O]Q93#P2'4QZTY"H\S?_(DV.<T'S9%"/*&\ID9)+-3%NB<A"*29@6
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M6_N!RJ<\AU\9<9QQ-_-*[WI<CBHL$VP2OB7] G-"5X8](W4=*)-<3"C>+_$
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M;C.J'N2,CE)VK-K;S35,1RN;V\;!6X7<]?BUNTM-?>_-]CC!H.N8ZUT)J1_
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M\XQ<+(;L9%%6!4 =VL;6P?>>6<(J?53JZBB5<J#=M"0&%<0>)O'JRO_)CT]
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MN36S_B+NT<C3Z&XCVGY8A*4Y:9+%?0#BAB;5J0T:[IF,IFAY)M=]=W-4?56
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M\9A+/OVOT5A)&WPE62W4,\,QIS,80,.8X5VD1L1JGE0V#7-Z.5)IC*7/5'G
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M;P0SH<F_MCTK9&<4H#/[0GL#/U8;8ZK/6> ,=N-$KT)XYD X/?A))]T5P1V
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M]J,+4LK*O6L<_M.H>EB/0<O2N-HPPT0O%2ED $8R0"&Z>]L=\4W771WU'&_
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M;G;PUN/W*L+88K9YQ?:+!WWY=Y<]G!ESOL[05GFS9A[M+V-2>CY6^%VHT=R
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MW"NQ(><(-B]G>L,T'BDF&YT^?U0P[PG&:-ZD:2*=(,R/RAB@8?OB9 ="T;>
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MS_]!S9/\WUAV1D9Q3'HG],UA6 NX>*"AZI1*R[LLB2Z.8.G[.+.?%*U["C8
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MG=K8UE2_I#W*<-4-:=*T<?OX=B"4ECC[CPXP<(!U/9?U(7\:_Y1G>S!@JY:
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M-/1,C@+>;BVONXC-F7HLF0S=#"6,W?# SA[H,.:SE^0HP=8N=L"0^I:UM":
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M].&NP:WBT*+WK'(0)O@[Y@-$:FQ7'FAB="5#5($UFS$2C&DB%TA\'IVA65'
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MT\YCZK:UD[I],DCLG-OT7_N:I;HOD.GHHP+YX:"G#?_\_2C5=/?0C&]7<WJ
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MKM=?D>)SV^TY$!'"T7,0K82@W,KR&L&YGIO?]T_97;8RKROM5=JTN>K @HE
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M!0<JCOP@9OW,T$^WG<?R[)YA4>8.UT&%L'R@/("D1F5^QIW Y'5.4I[CVT1
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M?./;[-;]/CCLB/(C8WP7\:7'E^.)=H*?1)GG+QI\K'U5^G#<X&.&J\W+7 W
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M9LF\DAJ4&M(7"Z26^\>)3G? U;H(FN&G,)'-U11Q7DEN6-TSY(7T=CZF3MT
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MFD7*3^U=F?W J;,D4-UH$?T#MVE4NT2*:M3<($H4:3^L[TE>B\W A,9K<!\
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MT-IQH[L)-[19+201O-5)I!W=,8&EZP0D=N3( V$5"+XVS-!/":7&YV^8SC5
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M@G@C(>1OZ14>%\0E7%>L_59_I>=-J_=KGWX6^ 2Q)H!N%4'/9$G(\9KZ[UQ
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MX=</AZYX\W-6#1V\7VU@'XC-I2,;3D.<@HDHW)MW@22= =2U_ZT+<B$,4L2
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MXY^7]Y6]>P=SH7Q#$;5SOWL=*\U7M#FOY4;]O>BI)"?>YCK2:M_I-XA9F6N
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MQIW9AEJEF0V&;IX>G?+U#@PN?U, KFH$E,K> TXX'.L'LZ\5<@!92)*IK(L
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MD)DB?=>'/$0HRN;+6(TX_(I30N_V9&1]B_I&OTJ@JZTO,38JL<.#L)A>=BY
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M%FH87#7KP<6=JO3VM8S7?ZG;S^99D'+9*G>Y$?W?*D(5)XU<7;(._;?<5TY
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MC9WH0D[_?]1]]U-37_1M5 05D0X" BI-I(E4J2K2I4LO$1$I(:#2 H1$0;J
M@(""$'J1$H&$4!,Z(M)[(B4!17JB$"*$\/B\F3?SG3?O'WAWYLS<G\XM9^V]
MUSIW[EX)$-8%B((YQ?.](OTVS65?0.X:+6SI'"I2]9>T:B3"IF62Q%G()#HI
M6'GAW+>"TRH"-^(+[7TL]OR*KSWT3+C<[W*)177-MG)+2MI5&US<GFY\XQA
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M:YY(T"LE;,A2FVJ'-E S&IS"]9=Q?NT0[$MV9DP"V8/6MAFL=)MV#D=OT<:
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M:_ 9C$'.=B.CY=0$)(/ZGB91#)%9FDGZ208OM,"]@^*LR+!HCP+G=7O[D/"
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M]E7&JN-);5LA6TA9UQ:WD1F]65WO[N5673Q+MSWVXI=)I'*-:8?H):CVB\"
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MNF$3BQ>VZ3[P1RL@5(O]=B[B(1%I0@:MV:NN8M0P"J;+8FYQ*2ZZ-^Z$L]1
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M7*T@=6?K DG2;IBBNXE&_L8@ZO9?T25 7E[$([4N*IQ=USLB^?3H&EX$N:3
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M:[J';7VX"#VSR=1I4 S5#E\=A-8:WP^.<_?L1:+>:H)Z27<?M+9.2$74QF]
M.6\+O(D6Z\NJT,*T^W2(%,IZ3J=U">[P4&*MB,*?RD)$?FGR4N5(Y"@\&4-P
M)(E_1U"-*'%55(5?U)O!BQ^>YNSH([/LQPFM0\[]Y-%U;-V(1J5T\\5]1=2Q
M,E4,.Q:P'0+V]BS7]U\T>, !T<7L[%<;#AH3)6(=B5FQ)>,*-BJM-,U@60X#
MF>P +G.U;Z)F>3H/,M -M S-,[]=_([$"Q=5%D:KU5D^496.3UG75,&FN^<$
M2 KS">JJ'K.K<C.NUJ X3UFD?JCC[(%D<&Y*:N:E!&=6T*(L;J^KX Y)(C($
M#(SQI5TT^?=BB<;IG=;'Z/]^P13@;&Y/UOAR[",0T"F;WP%-EI,E*.0$]689
MCIV/="9\SWX]Z=4O?BQ+#P/0 $S>!^$L;"FAWI\&@A>3P-V%P 9/@'.05FW1
MPT 2"[I T_/BC/U@Y8@_B_V:JG^,_,C9.:A8S]:/6BDL]WUU"R/UL,6*D%-$
MS290U$<2=T"Z+9*HV/8,#^,=MR69EU3:@.,:#!R1A9P;S<CZVG23EK$#MD=]
MN7X$H4S,J\Z7#,!:OW$UI7L!TBW+OV%=]M9W5IP.XG:3"S _6NU5-:\,+G4C
M"\1&@AM%B$/T++C#[4RTZ3@,2;/N?%G_=B#01;T1>_T__H_ )&9-< Q(@[P5
M4$B)=4BX3X3E'W8/@?MR_-_Z]+9@Y25C*0F( "A>O-!;_J(Z'S;51?4%7XX\
M+C"-[6.JAQ;F93+8-H$\1'2WL.=/[[7G(T&B]D&\+D>0N%9)!)1=LOHN_8*=
M.7U'1U,),]10\#*5(XD:%(H\2.H/E/J(W1^L&I(:XCYZU+350KS59R",EV69
MRD5PBJ?3LC0.,)^46[^/'N02@O6;,>P025>LB/VDY\ZV3$V]U^N]_JP;S^\A
M4V6W8HFW#CO#Y(C"98L)-.UNNA)QA'HM!UDR__8@.*Z:*DVK%&[T,3BYK$\>
M :[7;A0\FKGP6][]45N]SGRS%D!8>S%ENKZCD+LAA66#?GZ,^NQS"I>KP-U-
MEYHUWM?S%-=Y$U(,<J$%S.&6X]QR_*BTLL;..2B#7GAU=F4*=_/EK7-)":#I
MX*XLX2OCU(=5%,'>L(N>%];"3I. D0U#<./1:G"CS_S;.=E"IM^)W?:]8N!Q
M)G?QK#3U 6:]7+?*0,J\6?/3F5+*U$K9%Z91JROKJ#[' /3F9"81Z6C#9A(Z
M7EUR:8=[\!*!ZA:(3SGMO/DIX/41 )'K4QLY8SMT7I*'C^^PR3IQ-+3TCU]Z
M/*7M6"  B"ZX0-R)5;_CYO)1?]$R!%3F$E>1_]!HU->3@Z+64]1#%N;"?&[\
MWCA!V!+#AN0;(*7E\%=T=#U2+V?^EKM]2O,VK?R ($&VJZ,5A6@0D0<<6H=&
MHUOCB^1:?(NT^GU.Q))RJXA76+MH_.26A_1_N0?LO$T1^ GIEY%XMO,FG]3A
ML0R V_00NQ&EGNFTLKJMLV);119!"0P #Y6K.&!L8/^8ICH-(<K&^ "YQ3_@
M[/)2RETYI*OGBIP5XM3?YYK%2_(V65GI!<_%$B5T"Q>B0:<TQ3>S&  NGVR'
M MP1>==I?-NA-M3K ";[Z&L+$NQZ#'K3R2Q?@2N>30HQN<Z')AI3&<-YT/J=
MKFL.WHX2T8MMC2B2Q5NJ8[DULS*\^;%A+TWRR( 5N^64ELI8TNHVR%UC9Z]G
M6OXT4G]@"KWK?8$3V %'6L2T7V62'_S69X<]H!U(L1#@3<';/=1O&#N0/*:9
MW"-Q)OK2KN]T^^N7V=AL8'?7KTIO)SD)'1Z9%P\Y^/Q\L+VZ/S\MVQ$4S?5?
MP642QW!]A64 Y,FH#XP;IF3[G223CQ]0N.'QYY? +$:_$L'. '1I5';B87<(
MTI[2'C[3W\H:K1R"CD#=(/96\"*8?9:B_6A"_8D\[)Z\7I.PV(3']O[TZT_F
M\UKM+N:AJF<OG(J0SG5WC7H)5%C$>6XE$+OO4^*(FVC<HT_CXXOF^20K=377
M)K[=326Z)*7;RTDVKM6H<G/[#YG, &S50AL+/HG1AYJQR.#W-W:N/>7DADQ?
MGSLTH_B66U,4NSQC[:6)\%[(Y9![)/>YFW4I)A2'8JI\X[@,1V;)8OI+7W:"
M7;IQ_)()L:W+>D/1(HN]=OO:[QW%E&/O "?K6,,$;4KHDH:^.<87RCZUEGG#
M9,L_QRFQ]6Y5 .(>I@;9LFF@.HP+V))7VS2 :\42FE05UAH;LY>EA(X:"X]O
M4OG'7]2W03F9N7LOL/JV5=>_<FXSYPT&4>VJ*3MZG8B-EZ9J!QS;6(T?5(O/
MX=@3!/L%V%XTZ)X9N/X6 2D)&V$ ..6/[5AT%7/:2YXM$-R.X5V9S>BW2 U=
M'_W^ANDD@=_K;J+3TO+'!HKD38.&\;\Q9S-.EHO(G\ 77*$5'^PD"H2E>!&7
MNIK1T8BBL59!DH79N/JSTFE7"_MKE$?!H5^L*)&#!O7UJ>U#^ /45S=IF=YB
ME^)48\OIPR+A22)B23R=9+-(F^^1%K[1T')6=#)M4V=" :;NBF$U2'O]-2!^
M>%$*'7U002U-/M3#&L_\_L_<XN7;.!N+KGE6ID,6UMFFWOQD4&J'H\@,=O >
MFF,/41Y17>3F-Y@BI]*/W](@<]-S\W/0T KM/.CI_' 3J[ K%'8F 8CH'N Y
M&^<L)0R8QW$2V*.K4&U_:#P98B->YHQ[1)GTS6VTJ;#\K7-=*\I!*];]=>@8
M0#VJD]DPML<M5=OO=-J?)[Y$5E,??L6&&)5LT/G&D#8WI;8:"EFG \)6[4AB
M9?%B,<-=.X;Q\[UAPN,-BKQ_)&GVZSZ_BWT\FRSR&8#NEP&1?8>F+21$^"JQ
M+_TCU88RLN SOL^AA>YMCDUL\(R>$\R%YMKKBO"BB$FVG3RZWH$O3V.FRQV_
MRLF,=<_(%TY=7"B-65?,+@W([*+Y9K?J IF=@%\;*.XTK2_)87$S247!MUE_
M9ZN_(0FHI>/SD>.KJOM='I?G0#N-LJTE8LQTC]*<5$(7^EC?&$N%X@4_>0<'
MBQ?@T,G[=Q=V^"#"'WX:*Y#.)#ONT>_5V>IAI1[6WP'LP2^&_09Q4L$K&]T&
M+9.M2A(]Q]"8;EMD6_U#KU=8G%8V# _A7!<="<3;<8[88):^-D\2<".&2>^_
MMKR7=YV#,K5^&FQRV]H-?)%Z-835O1F+UA">[Z(+-]>31JABC5 .=8MBRD/M
MB072J>NS/I*SQ@R 9=U_H\O)/FG!<; "J,PLKNWU/%F&5@B3AP H-H^)AB4E
MSJ#S^Y+@<P%0@P82)]*%)<#-@,31%+\EG^\TB,J$<%M:!:0;-DQ>33#*^'/:
MR-$_SH\SC@%P1$5DW=V4!$>O!ARH4'V]Q0L5ZRL2) 53WC:_B:G$5U8+8U34
MVU20=@X&=9-I?R:BRC8P UXOGZ=?"U>V,R$C4[1(0O8GLA;!B2,]E1HV/>::
MHL3\QHK/D#)G7IQLM%0('/16IO5>NJ :0="*N+)2MY[R[.QW@5\P?ES%4.=1
M;(?]S;&P:Q2E3KKJ+XS79PKBWCB2("W3%9>)-HG'T8?$+0>$7[Q*;> >O#RB
M_E73L?C?L]GG]MT&.1Y<.7GX9')+5N&XER2,K-RP+D5I',8WO T!(V9<@X:&
M%ELG1+(>UC>-$8Q]O5ZVF,]>4&&?HJI1'!9V8AH)L(5C&YI<%TRI6]5=U:RO
M.C34T<%IL5K\"HM>Y" D1]N&BS.?QWSO0[2;^FA"PIN[K*]/;&@I3^]H)0UX
MF$%^6CSST#8NO*FA1VU3_H@6=/!QGO;G>F\2.1^0F*ST8AMMNP?Y''[.,_/#
ML]K;2YR*B;?[9F[W\<.66$6$?,J,[IV]I/7JB]Q]9<"+<)Z+R<4W !=_ 51/
M&.PNK1ZZ]#\-,UN^Z_$T8/ENR-#&3('+_A,6OXH^,\.[R:R"]2U"_@,C-89!
MH[6:T-0P6]A?[<$F-3]2GYQ7<K;RIB%ST7M? "=,3_,#3H0K+W!V1W3L\S0\
M87EPM8]+B^=J5T3T%9ZGKXKJDEF?&7;L"QT<CD"'XV^<:+F8DA%P+?:'\M/;
M9Y<B60$'+/&*XN<(MA?N"VJ=5>D7X;^ZO"S,:1@T7O[QS)LGNN<^U@Y<!>B>
MX^&^-Z!F*@-1NW<%P%/,,L'2KQX>R'J5=G\Y2/@]<U6]"I5;Q:0!%G4GH:5&
M0PTY+WUDT-.G#BPLC7?^/G58N^G\D85%I6,$ 1_.K57R^-U2W^(WVN(W^WWX
M;CY*QCN_U0>?_PB@D"HHF&%SVM+CR:O^UXERG.<*3 ],^CM+.C3NJ:^6P:&(
M-FD>0*?0TV6M\&7%!S+^-ZX9>N6%Z["6GXKH+ /P #X"E $ @' XYVGI_^^G
MLC[P]YVYD^B0&.0PE@B\/WY%+2A4H\+YXZF.I8@^+_3C W1I\"_ %0#H?KSU
MC1.*Y?SG "*GGCH(?UB//U<Q;"H4R7E/A?4RZ^^%%S[*ETL^AY]GS@&*+1M/
MUXU8 ]^RO@$H[NB[?6<]F1GUJ7-%'UDJ%DX,+!?V[(8&CXT^ HB?V& M,YQ[
M_]1)^?)!Q\BJ_B, S],@( -@[D4=^>/\.?RBZQ%G2S.P+6]UL\ ;*P]@O<?Z
M*PP\DL/<RVT-5N]?OAJ0I7E,%LLXPOH&$]::,Z%PR$JO..O'S8)\6EAKX7!F
M/. Q,T7S3,@F1B/R%IRP+)J%_>>L__<$X;\YEF^^TKC!7 C@ #COLU0VE@58
M>">G"C*<"?+JY7ER@AF&JD.9)Z2$">/_=KFC<T_C'MB(N5-^(:_QU*U76MH+
M.D<7'S&OC5C7_;<"_[ *VC;T[M"_.X* N][4OT=C3UG> 32_7=XL0-F'-30\
M.?'O\O^_7ZD;X&%X!UTK,06Z1[]/K=RMIX-<&(!3!0Q T3ZM $7\\IT!6 D%
M$8\A%-%#&JALZX !>&/&K/N2FY4;RCM')WL9@$4-3[KQLX-XT/[%-PQ )Y$!
M6!Z95(_Z%?4HS!S>O<4 +*0OT3VQY.#-5 ;@DAG:\S@6?D!;\Z1((ZC<H9:2
M87.H^E^OE4YK2GX[KWT8KAJFLU3.OSZB!S7N*ZL!\K3."3?24&]F-)%OX)RR
MYQF ;7FP;EO*I*KD[C=XISMS^O<298358TVA,^H!I6L+U\ZAD]3"8T^@FE]Q
MLO$D,0"G&QB 2$C-K_FFLBUR"_;U&9)9_]PWUM=194F#B1>TM&Y[)YHQ $Y+
MS.X/>(G9[?].H1N#K+H9@%_F? P *_.;-+!I.>+'""6TD,H=7$958L*05XZF
MBOFK# )^@)=! XY_PS<L1%^\&$^A\J+I;/<%">GD/5JAR--+\0/XRO+?DLO7
MKNT?7%4YSY/'>I4P< G(DJ*W<SJ^#DNY= RMYD%QT9PXRHX-0="C4 ASN;^@
M+_(6*UE4S4$ZFV;O)-P3.K56YP"GFHU3<]NW]\BRZ:]8/;8\"#D02BB<RIT(
M'SJBCX H%C_@D%K0'KK$Z<#=B7;B.8IH *&;@ZN>D8]ZV??UJ@3]<8.Y",/5
M#=]+?U^@B-;S%#%Q.513X=:^=CG)?;4,]=N9V4QAF#F\R:G]+TJR-Y9^:WV$
M_GOTP!UJ*RP&G[G, .R>OO7.K^'SSJ2N/.KB@6)BQ 0>)15+Y:VGL^DI@YJR
MM@Z9%&&FA1H% 1&M"REBZK&>5*64K:/@I':I7'!UC-KH08@!XL#]@=VL0)RL
MQ< G%\7)#*PYLNX8"39^#7P 7-*'9HG0V1\QB5BN#IQ&+9P)!.\J#HR'PU>Z
M9_RI-[OI[/>98Q5,DFY36"+5 IKO%Z#V%_L9@,V)8P&RYQ030T"%)^WJJ'&%
M;$R^KE^#Z/2^K@9D0D]R]Y@. C/O_?*_>]D(3$*ZQV+I>:Q_1TI8Z.P:S*%*
M\%[H_ D@>%]1%[WZ/%257$'V36LIDP:W@#$WD&]ZU6S8XYI\'U12/XY,"$CN
MG8)W.H$7,LK*"%-$'IJZE00#<'5/EP$ YC%99P%GQGH:?*CX&)Y92*';?0ET
M90!&6F1V<JD)ED)NTZ<3PCX$,4^3%ZAL.6(BXJ"X_P"4'_8,WOT'OI"!!I/R
M02> M*'70DZ;96DWM:F\4#J;8THZ>85R1BN0 8C_XC"R6+:T?TE/;K92MG#S
M>5'62V,_JS %=',7'K3R<#FL8.P%9S&P#W4'O+C+ !#U[1F )MF.AP>DQ\S\
MU)0PLST [Y0N+*1X@,.[0;,DTPW5* ;@WG:;]I+Q_*V6Z6648NKG'W==-.1:
M.VM(G<^GCS,O%Y99"1?M\?Q?$S,W]9#.YCU-7J9PH6D&=^'@+1R4$A)+Y5X^
MH'VCGZK]![%9Q^9TDF(93NN8N:2G-I/A\E;"_A*ED!S48Y0  R!U[<A7EZE%
MJM0!*$6*R>A-T&X(^"1EGV2 !OTUX*=6"-+9F6?Q5)O#M[!I!N#D[8#!@,R5
M9.TK6@5J#DVKVLA2Y'M\%N734?\WXN&%$4H(N, ,/JA]"SULWWA4,%B),@W+
M70Y*^6G$7.0.] .30!>9LW40CE^%L%'5M5^',L_^%8)Q"D5*@GJ1+1Q,G$:=
M3%8>H8HVL2AK%DY1'?BI-&_]Z5^;UGDAJ\8Y]EFK\W2V*F6;^ W%HJX0"'*[
M3FBLF@$@X)1OZ@8A/?-3QA^G&/V-MZ8.,N.1I5X$\H,:YSM*KX"7';Y[KI0)
M[1V-HQ:)A<3'><MAT_"3'?N:HLW\5'!]+&IU2'B>'<L78X^L*%FO&D)-T._,
MTXSPC<VOB<,ALS1P/=QD'RTR$>:#_,OL X#13)(Y^M,:PTX7'G^H(8V$,  O
M4_^Q+XPYX'0Q@];8SOITGZ5'Z3_OW_">IOFR-MFJ9^ U)3;F&>5!_7WV9&'X
M;KH;S1!/4WN%N  >E'):S[CTMQB\@( 2'^^"EP_HK.DSS ;ZH3\61 92 XOH
MPLP*<&J$<.Q*Y63^/F:/ <CX4VK9RJ/4MWB)V?$Z%R,.)[0J([[-$CI#GA_#
M^V[VJ#( ?Z1H4DQJ?RAB[OPY2A&\N ,F/B:"E_?;S_HQ)24Z<@>E :]O \+1
M;2#B80I%/)8FG-4)HH)FF7K3F(6M.VA7.XO:?AF[:5I.Y!,>.&X%]LGJ,P #
M$CTI#(#N#ZLCR+_,ZD-SF;=#*.)9-&%XIRQ5>,YIC_YS"$P7GF=N&JL!9LI2
M))P";F66J',04);LWY1.A*TAB '(X@,"0^[[HTZ0Z@E;E(=Q)4P1ZY)KREQ=
M%[OTEUD#@1[,.]WW&8"8(<K-@@_TN79FK.6!3"R4%:XRAQKAG4J!:$(&\6GJ
M &@ZBX N$_!$A+Q2,U5'2R?_36:#TC]_90"J?9C%]<)JCW93+-6? 7CK=)&>
M+0G6KM/0_G/3;8^9RTYK9CG+G=\/8%:M"'46VG=X7N%QC#&0(JE-O1A.8@ X
M4HA.!9P*U?_!M^4^6S6:L7N_#+@4BL(Q)Z>VEBPBXH!TV*IP(+R/K_<?[%QT
MUC6R=CFU5SK,B]DU3H$7\JZ@W*%1Q:LL G-%6.8JWZCK\,4M.-'P/I;<15&A
M_/MS$+6:ZJ;B%"CE$]AX0ND+Y%(L]#@_!]T-O"B* '&JW\NB*(/BEU$'VB@W
M6YI@_P&/Q>H-)@2US.TK3Y<1HHB>&PIM]_[5:=HMIH9'(I@#*G%_X>Z@J-7?
M;@)Q_8=]V6,YPW56L-R52JKEC!1T5DK/;^]F@!4^8;H;S&6S[G$*O\H M++L
M6S#Y E_]-;8L'"U 93J)6 2\4Y6-A2YPO$#2+,0=I7S2V!\./CB41Q$/1B@2
M%ORT&OH%7[0 \N^ ! #>+[\+ 7#JKN<8#^_JM*@O2=I_HTJLOW64/1=BEJX;
M\ P/IE^UA3+K_-\C,=UW05Q_L:NOF/NM9JZA/4>K:><Z0(]40M]('+>N?Y\E
M8,>*H91;(]2+5>&#QS;4ZYW*IWUA#T\=L="R!PCAWE:#X'X\@5:?P4PLO(L!
MV+N/H#X 7T*M82FIP5"ZCLQMIL9X%7Z:8JGH%;^_=I_JMO>+"8P9?*$ ^ [L
MEA(=CI!0;?SLEYP747I2Y2K\J!Q$-&4 *!*?SFL3O(COWO0MT2HJ%OU#?Z&/
ME<Y!GKZ"N,;VY(&O2!0LCV;M#BITW-]L:E$WSB@,MMH'4J(+I."C5:0[3,BZ
MM^^F'6,YBL-B7G"6\60SM?O2WRWPPA<0$:*P^2\0M6^7)Q6$=92O>HP'JBPE
MYBTXY/A3-?3I;*MHJF-3E[!WHFM0Q+!J! / /:RSK>9?'@+ICIM:G9*@"[_N
MI:A;@4EL(9;3]&O0N*8M*GB)A[[:G53X\>__B@13<RU61YF@EL,[-?AVZ)C"
ML]BD;M7D3_GY2GNEYV^JGU&_B+;^]RGBY4PPU#O/P=T\HZ^ES)I\<3V1FY@G
M2WXJ'1'YBI-5XR:\6DB% 7BXE<X\C"K,I"FDT*_))@@R #V2)#FF3$QP_@/X
M%>ULO\99>8O59N9TIDQL[YU$(0N[M,Z_.A]44Q3IG7A2OHL_#<A2H#S,P4H_
MQ[00IW:?Z(=AX.=X6"(-$>4 H!"W3RM+>B10A7K7+2[ =Z/^YZ<:TL^O=Z$4
M'B]#V65JDW3 0_S/+/D0*9+XB!L1R%]6%OQJG#KR*_+>QKVCL?\SXH'_*V+.
MN\=6(3>,=8Q:3"8,EQ(S0"3)RU=?+'B'0PQ="HD'((I$)CN\VR9$#'<GG592
MON A*@,AOSR#-SU_(,H9^(,)=()VX8L!<F"[#=]>8JVK_NJ&Q+]GDP['NPJY
M<]88 #R(5(D:>C59V$]C^^<=9+29.(+IM4PJ__MTXS(F"AI\5^D8,-NN:E3%
MQBTM[\2H4J_IRQIH]7'XX@:4")'* #$!,NXHOZ7@MOMZ"G>'EIO7J&F4V.1!
M@6YJ<_J,U$&HZBMPZF]92K2FS $1T1-]K'ER29Z9927HW7V)?[7H_PP:_3_2
M_&%R[K(;,2YHR:^B7&AA@0">RDLD1?Q:5?_#M!:GC9F["HR*.K8)N<8:%?7%
M%;"8S+.PGOTW=P6ZH\0B$?]O3?BO8U&F6@U;, !#+U!,<EF#SU'UF^=F6/HX
MH$QH*YUIK/^J20EBY!ESRB?_IFST^\>MWP=_?0WNY;WVCBA=/G]&/1D@$<[Q
M3YXK_I$KF7D)ZJSA&;Q61<@]VR4O$0,1CX#9_(_4[R.7X)NRG TY(Z]CUS\L
MY/S54\[,V;/F"-#%=U-")$G2S&*0R)K 5/^A5[1SGU&:K-1+$#K;\EE6<CU%
MN^5T+:VZ_.0]$>FF8R5E_KZ@5RZ0_XW_.<%*KJ7H*";F;>2\[4 ;&WZX?;:/
M[:IP7R7M67]!I>H/=S(<QV^(.I2+:;U.<B0L.L5),ZO*DV_HL/E= _FP*&.F
MQPKS_=]A!1,ABBI0W/SBU?Y^HR\;!N]NRRFNSX3K"/F(^E__A^N_3S\.(A7B
MIA?%^<._3R ?L(DNR%+U7^EV]JDN1(S5,ZE4T;"WE2J_-3XL-S%N4UH@LUY3
ML=&<0+\&2K!P"3##NS62B8=) G\5NN,WZ\<V3?9OQ5./0$0S,$6BO .,S.IZ
M\@JB6OJ9\T2GLNK3#M:4^V,IE'_O!SY^%=YM%2(ZR'L.C/05JH6V N@_EQ$D
MA[(0\\)-SO\.K# F3DR[_49(<'0#:9FKH5HMO*D%ID3;2S$ 3(EB^N4+PG+0
MV*.&L,C_><HLD=+ ?<2(UO^=MO 9N)ML]$R>I&)9.6%V[>RXG*'6*\Y0;5<W
M^+\37GB.:7=BZBE:_#?>[4P<V'ZY^U3'XEC^0F*WLW>T1&*Z 8D/V"OCOG/+
M8IJ&.CM)M\RD>9@0X;W[N<P";( /^4SH7US<N3R83S8@+EN4Y((?.B-&(OYO
MIKYCHU6U<W-KZ=(G)[0@"&K4OP[I?U*%6ML*XX8O3#.!7X%!CM#OX+]V;C)9
M&P-D '*89>]"0B_B2*% %"'18>O@N\P + G,@I:RR6Z@O^04.I79P/08D=UD
M_Y\?@E.&\Q_![>SM*MKGOY?1'],5C7/A/4Q3&>5(=\AD%_=YZ,+%(>KU3OK3
M\X??C$\"V(649OFE H3VH%5,AXUZ.C\%)7L15V.I$-+(DF?OE0?=O2#>/Y1G
M'RG:BXB(5B5_A-QT@&R7YK5)S>LS,QM[,LG-6AD2">#Z)>)*;U50:7%CBECU
M3X__-O]*HXWQM\]ZWH[LTBCS__#C8_TM!R^STQ].\KR(/VIB=LF$4)(2.::>
M.%G6HR9[WM*:8M+7')O2\%<=_$S>YL"&J<\!#MU\MX?.)R>2?ZW/\7_]ID/M
MF16MO]Y<.Z,^8UP-M3Q6A5G56,L32IMGG7,GU\?UA0MX3<M;!B9S/(8/_A1/
M&UC?5/+;SLAL+DCZ1.]MY_Q%5PF;T#Q%&2<Q/><#BOZQZ)I ;%*(]Q*$A6+?
M;4?R3 S1]*6Q=M,O-A)?II3+JSZ;4'_DC;>[?K1T;.V#)-*B_;UL<Q/B8-'Y
MV#CX2_AOF\6F&/I)2A3> @U.-AHZUJ6(47T7"2+=4 ZJ;/E<R"TB#9U"-5JP
M8[&DY =^L7^KX&<Q2O!\23R,)E1/$@X[/-(>A/_U[RF<3L!#>L!G0DR(A53)
MG3?M9TD@M/[L+<_$>6ZJ8+%KYK^W6@G]O([-\:OX2-$WPB)\XQ9KB:9*.(\L
M5>?FT+01Z3_Y'IZKQS?Z#Z!<]!GATPF+L5NI"Y6@\'E6^IT->#V3:E,-@@;^
M^-AH7S7]0K8 "O4A"9K@8?[#CM5Z3+ O3+@^P7348R@K_MEDE8S'FXGK.%,9
M))H!..=!/Y %SVI[%F;-[%2L!3\^MX)I@5@<8]T:,M<52)6;S5!V8^=] S"=
M+6,!>/*?,?4=22GD/=!@U:$\6@#A@.@Y*<T3Q()\O")66O,<);W#VB/6<^&;
MKSDR6;#P;8$PY4W99H[XIZH!H0+>=EUW!$P\[I+@^U&P WP*9$CY3HPBNU"J
M24WXV'!-.2KL&R6T'.<:I!U!O5E-5:#HEE)M@FU& &N@"Q[/[KBUWR#%U'[>
M$ BF)/0("_%:"T?!RWM/J89\$?7:(Z..O:@^)&A$R+.%0E[;@. >#/R"?$K\
MD7^\NG;%NI%^]<P4U9L$?=,*1:B_ZA<8-XS7'SF[_L3YMA7:BQ958B-=F)DL
MPCX;PNSN(\,I2QW8PG-46"65G\(LQTO@CA9/SG74^7;E$-U?R+;@OAS#V$74
M7(#(8XQ/OV^")P>E;U6K-GGU,9'\'5^M9HR1S_WOS<OO"3_"I6[\43(T*1DH
MV='BVYJD+CF&6JPC-+GLP2CO/YX99EDBNM[:LTQ<!WO%\6-ID.&1%7AB.S\Q
M)493E%+?,7?YE]B8.Y4%+\M%4=PD'$4W(_M0P8L:]DL/X%PI#6^+ZN)W;:P\
M> </Z0]FKMXZ(]#:Y@Y3.C]EX[\)@ZWO[]-.^X1)D,3+EF3Y BI[<<W3G=44
M5,_1:L+!;ZEG^OKW*P,BR7804\5??>-:F2F^?@*2OJ\NW")E**3;<0R5(@SL
M%'P?%&01MHN^)+KHZ1F5W1C0=$:Y*+U$.+E-354WBB?W_:RX_N/WT7,<]DK+
M@E,-V![PQZ>VGH,!$#9'JPC9V+!0OXTLZ?+-@&)W+\F%+E(8 !%[7RLS\\CW
M&G^*X X0_6D[Z=J#;)_56P9Z!DTMH?O8HV^A,>,BBN;H5 9 !C-+(J!1#( U
M0BRIM$.S%S8/L,8M7=X9_PO"5$XN'Q>1Z"];<=M%B17#3]Z+Y[UH>W_1I;+-
M?!H$S2I>VZQTD3RP@=%\^1L5GT:1)3WN%.[;> # #Z/6M W![-!G#>=0:^;=
M?S;);D^!]IK;KT(Y X_P.?F0\:/X%HFC$@8@F &(1_!6JQJUFMW8+"$@PN:T
M?Z_4)KI4](H9N5V6+Y2T<]_WMSA56W\5_LEF^0#DV+"\O+#/OWJTAY4K>9,M
M03LW#3K8A*5C&\'"1:2*9\>HU8G)\F,Z"-.:0Q\>BRR[%%Q);FRQJ4YI'-PP
MRQ?-6PR4_]Z6I%9MD5G,M4[.OOI[FKRTU3A'GZ+#];YF\A8J'5WZS@+:W73;
MH4&J(2!X]]'DV_]-%]]:0UR.-SRJWF^APAPV7WGGQ$>9%N0VR^]\MG\<HR9H
M#_]%&#%LQ,Q1]Q<*'2B<A]5;[L3Y-;^%M-L<R":-X*6\\TXB1![M>2(=^5R3
M6;X.$(HM\8:WP&KD%MP@,J6^X]LQS^PM9F*Q.7!JB@VGOJ Z%UG?'8ZM+E]M
M?Z5V EN0-_EAR_U'&DS:JZ 4AP7'"AWBL_^WP_=K8:A?%AG6'A8QLX&9B-G=
M/<T1P(Z>\'"!<+X!..#K?BFAQ;8N*9_@MJTB)7VR<%_?G3N %S.7#V1)P6[<
M<MZJZA::LF&)2MEW\YC90QNR-FE.2#P\H$>60%K!H&6W'XB;-NG9V_F8%,-\
MI&;W">NF%KX#)T=_V8K%\6"_)*:\%AQ*A<:,(/,;=4[A<?.H7Z&!RJP*<K]Q
M,/SPO- !$BE1OI-BM(G6G##[%K9PE$/:''Z=(JN>93-W+%V]I[EYIJU:^8%7
M$0^R38"GW*"AT3M:)2^X=U9#<)*KV\&EA:XA7>>W+&CC@4Y.P'[37,55TR+'
MZ:'2;QD A)MG#_#]_K+WYHB&"/0 E44?M&8[U%ZB#@4J0!L\\NU=4U-:L^XF
M?_EQ:&]0:!2;*'*V7'4?Y]6ZCI<PA+GFO"[C5],@!-M)P,X^KT5RI-3:+"_L
MP3S1RJLK&J]O!WM1;(]/EYDX>?X2"LV<CBHHB[Q#)=X^S15*HL#O6$@.]#Y(
MQ'^N^"&$R"%5J[5)PX)<0\,XB=%BYWXC)0;]2-_B[%Q*\@A[UM%^YL_X:+S3
MVP=N-K;"]/S77N/AJN3*VYVN;">'YY/!2Q@L<5D6FSSW[7*IQ"PH94_A.:B-
M'LH1,%DQCIODDVDB3RJLUY0?APBF)RENX#VW6V@O&UM<2"%H].ER[UPUK[2
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M;XD1*W'Z?4*5L)7E.^>B@>P>'7OG@TJ^832)48&6$ZNR[017QK]22ZO0.3W
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M+4CK3:TJ:-*.SKJ^NKB'%W,&LF"9I!./S6!$R!T8Y#F>-X',HG-=/FS5A9J
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M+D#NAF?8[EBO1*+5NBBWR!++,<-\DQE.%%N5@JN9G[( 4M*]>YJ+&F]-&VS
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M6@ 2=T$3-BT;F/4$4$EF \E3JN"!,[7)9IF.W10%I%T)MIF>Q?</*0_$V>H
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M8(FV0N8 I=PDE7X)S0CA=J]3D5+ *AN1:"M*"!%(?9RA3SBRT+?YX=/K^([
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M?[A;@\$(QN7U<8N@C\R_R&-:LC*REDK.#U;INCNO;CM?>=/%K&*'J>[][ZP
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MPK-<[S5$6O>5I4D>6# 0/79_T.- 6+TT(9!L,)87N][(UL_/KUOK*?I46&K
MPAUW4_>"?M?&V"<?6?Q^*,[?8:UYPI,F+*R4]NF_=V])A;%FZZWZ:<H6&Q-J
MK_[=!G9#SW98C39$&&,;&X3JA[H&Z80\0S0'KUH:U6G7R*U9L"6Q>FWIU L/
M@0,V/3R$?R)* S+M]N:*E/6< 9$9;D."-GDEQ;R3)=^Q]%"V,9UG\3HG2WGM
MSC'L=OE.A) I<OCB\<&5->MB(F7@W+@)NQXK7;4^ #XW^,[8*39O,Z9L%P C
MG:_(\=T=E5[?(6-)$'SR09X;E'[JV2#H]W:2.W3$AS_KBL).G]&PUU/2PRC/
MXSE:4T&T/;[-Z)9(!!_-DVC6G^-\>(E+L-)5.PBGAJP;+_BIZ/;[JW+@AJ*2
MH%OMF(<A@5) B(-)76LS4J^Z.0FY8XH7WVXJF'/ZY/K]U99IK1/!\O(UA L3
MU@TE:,%SPKJ=JU=V57GG?G-(7AHPGA)L;VA4G*3U@'!@O#;'H;LS$D:#$I9U
MOR.IJ?R-_3!B L<\JBGMAJ@HR2@*RMA4X!<S[[%L64[7&4.8Z0WQY8YPH7M9
M-NDES/.6HWW8[U,PR"]46RX+ 6#1>?F*D H\U,8+J@XUGTQ2_L^J;DZ"?C,&
M&EL>&[FKM5.G_C@.^>J D<?7O'BU52R^4%CSJZ.D4-M ZHA\)1FC?(.%F=)F
M:J0;?2/'B<YS[!8_S[_"#'C[RP&C%LO5W$\ X<<QU/ I.@BW#5*9?*.6^$H-
M#[XE2O:E5#D"*\LQ)<I8G%5^[;*46AEL:3'U'J+8F_^\,L[P-6UKDY%A+50)
M/77(_[\D;EAC"21@X!RU#%*L;DUT?U?7WG)2^,J >)_&10X.U+*?KU]W V3,
M?LFZ?.TEG7!R-9#EG*W?_5IH<"PSR(]7QW@5LX)!6J<C)GK]H#P(,!"A*^)Q
MQRN+1&1@FP'BW77B1J!@?-O(:KYC;#B K>NU@2.'D%$6%0S.D<V!+^E8913X
M]</.A!"9!B6#]15E@0POY"GTIRW9ZIX]D.\_VUZ938R7&'X.>.GYW-9J6Z5.
MS< C.DPP#!5&@C-+]$N)?K2#6L1WNMX(&9!9[4E8Y),#%T)$T<+'S-:N&"70
M'^0@><GBBCYK,)N#9-^^NZ,/[>C'C<)E>/]%;:2R8"BF\-[5"]Q"RI4V.CPF
M9SAU@[1+B7E.&1R(W3E\7Q43 =#%B%7W-D-=:DW/=77SA68.C]R?JGJ.*)^N
M?,_7GBD0*JF8+0=D_E=S",C+X&4:FS7R]D^T,E-J^)0UXF= *;_%XDXN]6^@
MTA0G0@(!W@7 /0.2.-AA.2;#;>M1!:[^6SYPL5Q=>D=#IU3(W(7?\/J")PJE
M7B+_6L(HFK>ELE+3X+VS_.ZP&TGJM%2+DUF^.JWD*'M"Q )G^T@9IN<U0@UT
M2Q25LYG5[/D94H.X)1K@),-K)2GK0:U<A3FKT3^Z."I44S!Z#_;6%$I.9=IJ
M4F4MH_W2)C'S&_)T1-+ASK=$*+%;(FQR*_[3O.U]6XCM<T(@)HE)&S=<'RY]
M5XW)%345_5Y9]_XO+Q('5Z$7(7%>Q!'/%!O:)Y_O%N>_K6@^J)BM#!8S 8BY
M+2!TY#SS9[<Z#/1-"X5;\V,W]'G[[7Q>3[&E83SEV3]!7#$WS8E%,0!8GEFT
MF7K>$\7S2L7%^$H:_4Q2TVZRSX,OQC)VD87(FFG-+V-?C8+O;F_RWA4>39.(
M$HDA/K%,G$5H,,?EZZ+'6R"F;TG9>I=^*$PJ](]X3*@M39TOX$F&"A. (Q$A
M9DP1ONM4I2E8L+5C/>M\V@U=^H"J0.LTD\&\W_$C24C L$$Y:JT9C^SB]O$K
M1>72;IECLQZMS6%34FZD<2,CME&%U+[']RRL0T3Q/5&8"=-_#>)QQ</8> UM
M4B-S6^-IG;WBA:+B<F[,6F<SUMS,F,C?/07C2'@UG"E.12HUJTV 3:N*:1&&
M2=IJ+M#Q<4X3GFR5,U<-V[4Y[UXM2=QXHG<B*D3-EN03W*',\3C6BP%D+S#
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M+0KGC<XNWZ-;VD6,YFHDTYM/"9-<T6'16W'_SHE&&<0HNV*NN:T)@>@I&@)
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M=+Y[=KRI_N+PZ_ '!L^@ #3AI=L@5UMDZ^M0A16#.#GP'O%GR['2^V#A(>H
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M/*!A3L;7OFT[ 9#'Z?=%OL/X60-4!RJCA_;$P2@X^"K@:9[P6:B.H$"Y^AL
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MF8.J<\*_&OO^%6MO#_3U,/']K7VT7@%Q5\!4\;F:J?0[,]2U=P?Y%,?^M!9
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M.,LILECQQ+/8B!KH5R1DN*F?MQJ4"6IF&MLSR==BT3=3O;/0:P=6&F:U^5S
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M<88029S'%3]I (4JR\*5%A@C3@E19;,\UU6CV\7O!&6X4@"F.$J.>4RGA+M
M^2&W1,+PMH'O@^V3RG@8KXR"6_<FXW%3]A"(Y]=Z1WMW8F-_C]1/-X<]M.>2
MS\!;2'SM?2V.F-KXRFC(3U$*36= %0@!%S)Y=M93J4P/(ZOKX?,MUY3+R^=:
M?$,0_N,OD%3D_BN3AT52DP@;R$W>=L?L<*7-.\#SEV,RZ;VTKKSR*9*(O?MA
M8B\OG]_,J(H25/!*F.R(,"$;2X+1@!JMK\<# MN@(NR#=!+_H(VD;KZ6^LR5
MG2N&^N'>]$@PNMH 'O1[N+9T:23P0:[*3/.;<\_!^BFOBWW<'UT\8Q):3Q(^
M%,:;.X0Z,VQ<WY]U/0=:KG7]=$Q,$";6=8DTE-0X^?3S32-=JN5&XWL^.QEV
M&3*\5=[:/.A/J ?;J5++[/Q*=8TCPI53C<&3SZX?B3D561<>-BV0+25%>Z:/
M3-'H- R\;=3!%<X_RW 9-E=4*"6ACBO=Z\BH-#4& ]Z4"YPW&6H$Q0Q&T1L^
MO___" 8/WO]#V7L'-?7$\:)15*1([RU*D0[2>Z(B(""]*55 NH!("Q*(TGN4
M*ETZ2(GT3J0+2.\@):'W1(H!0O+XO7ESY\U[]\Z[[X^=G3/GG)D]W]W]E-T]
MNS0_K=*_J J(E;<ZV\=]?K[&^X806604LRDG?_S0XVGVV%J.=]9JG/_/$_G>
MEU-O$H3- K1$7L=OJAL_+D]S]/.(^5X4?0,^U)6!_SM.!'@L<GIVV]0!HT3P
M#*)..,T25Y PQJ0AK^IQ 3JR>]$MW2<6R&JA':ZH$W9QD)-7O)099NO8L.*<
MH1:5J(!E^<W%1)?*;;05YR#'TI 8$E?D7R+4$I;LR3?,6\ ^,/?O+XA^5#YM
M3T;R;7&'(HO0O!^0,29!5OXMB*W*+:[HX\^G=8[HI,KHRKO-50[D[C.5^Z5/
M3<RV#?_T&-_@&/^E*CL32?TIY/WWE^(B390_L^<!:]'0:5;2WW:/_,Y?ON7P
M'N"@7$]HUY5'C(B3$^: =,INZ"OVSO_V/>T29X+ >VRHZSVC/CAL7;<8\:@V
MJ6_=A0\_SX* V.&SW&*E[9;>*?,>4@U)'O8\E](?D8/Q#IZ!5]D@$=SQFDW7
M%3/:+ ;/CX*3NRP+_X";839R(A$VKK.DFCD*+T>_*\\T8%_^^1@^P[*\P:I'
M%YKUSK:VC4I,S* HVG@R,7G_@)0I:2O1G<^O8RJ[,-=*1??^*A</ZK=0W^:[
M08&!-NYX5J?R/?H$4)50*OF<36DW0WO["RK91V=3 EIZ%*:6"?#JRJB+&#+[
ME)COC21*#2B(2.$=#CH6&G7U>UK[#!=9F.]D_"QKQ5();<<C"N@.7IS:Y1N(
M7C\7+VZ@!)?T(O3G,CO.H_'B*!)O$5@F<N$9#[U=:*/YS2U8[!,C;,QNHNV5
M?>F.&:U'LK3D3J/P_4M[#4XK[[,=W"O&HX^B/J)R?2V%P0K3RK:%VH'\X6VJ
M17!2'90GV1]<):+-Q-:WN/(@-=._Y&>:Z;$FN6AO6'2@LX=!PZP:Y:1P.:D(
M2"R-^SU<9(L?Y"!#MB-0!C6MU2QA9A7NTGI:B5IAZWY4EFH'\0=J<ZK>4V4U
M#V>W$YS,L[EY+&3B$.4K:&@Y)S]8AQHI4=?/)O^<P"T6>YDC2/>,3GSI[5_(
MP.U/AX&A8R>]"AO/6!T!;Z@4-KX*<'RHO8&;'6(#'GABS/0Q,RE5C;&&J%-1
M:[U[O?:VA7LZON"H2NG;6+[>\(1TOI!=:HX,!<)XR&EE;^'G(:KSM0!:O9Q=
M6&-)Y\PTE+-@VQP6+Q.+I,6KU^"\$!;#*"N8>CO&9*0,E3G*,.?ZG['TN0PX
MN50Z$)M16E+43HX^%'V11OOMF=.S8\L&L5'VR)::QKK6F9EQM7GI22NV]JH"
M?HX?!" V1\C$7C5"*F.46K%N3_/U!J.NL;V"L5&*>;+AAK[7YHR8!T.!G&DE
MFTGPFEO4V>$\#W1366C]B.YN#.8/M(<C*?YCPSM!0[7W5L_[-BT_/QZLY:'^
M64:ZLM"A&WDV@B,5+8E"F/7ZHX%414EA[J3F"4<]8[MLD6>B$46KL?:V9W#V
M5S:["*YT3V_4W.DM[>;[4E'VS>$KA5<Y8.=[P+./D\H!%<[F#H24$AP8S=2X
MZFQD5(><K*>(''][,I2^WC[IR^YFT:I4GZ8O+$W-1/JK\ZOL6@/P4:>=D)"T
MA(^029:#P&18\_H:NX*2P';*3&7Y89)ITE;_.SWZC3D.:X?T]?0<FT]#NZAM
MM 1+F_2/D^V9GN)M(]>*:<T1/W_C,A/CA637P93GNO'@HIN?QF"*YC&RO#^V
M-GX.[/P:Y=@B JJHUT1]9=RI,\SY*B]6-'Q.+0)D+@H/O_Q_.H?_1=+Q?]EG
M&<[:IPEPNG7*Z]M_SBJ]&X+6$WKX)=-.S%SSQOF7FTG)AHCVH=OZK9I*35N
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M*J]2?YWU1WF2.7-1-"2]P"SG4J67_%E9MM&Y9?BBLZJ8K DNJ2E_GS)^[A:
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MRO*_N3R_OOG:H>=T6F&9S::S5$+^"J[,OOC'RGK/_>1B_ ZMQK?^/=WB![_
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MD(N76I-G(ZF3<54-D&IUI2W51MA#E<?Q=_AY+:YE4AASHNJ<8A7@J6?#T4"
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M!YA90W=O,V$<NQROZ)?Q@/U'!;BL[Z$%JX@_>F?V!& KPP/ZC43 U^(4483
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ML(&)WTL*^.'.(*_K9,$)B/&8!BS<+GT47+2$@PY7?F+Y+Q(CI_%*RJN@[WB
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M[8T?&:U#9&KK@9R,I#:^'M#*HT W/SD\0&U$CM8:O;9+*R5;F[>"(-D60V?
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MTC)8WO_YHI/);U[3I7+FQ&Y\=X>[,]UX1./'QZ'B$;_Z3Y!0Y W*_/G*[J@
MZLFO5!N:2Y!IPZG;"_JVCW==<AZU!.41J$88WSP-3XBH^=6W(UG\NK-/JUX@
M%+S]/^(?P7S^_.F$=$KHBWV2MA8T4'35$UG4ND';WF)FCN[66K]^\+&A7N%'
M^D*&&=]BV8K=W>DR^IXK"UC88NKAB%GCEU.+JQ]Q"559^."F3[@NK@][J*+F
MOE\+5>GZ".R_%IKB9!'S"WX4P<G[NT>='/!CU\A(G[ST9E,K."!U>CB?D'/A
M=XG?U)Q!R<[LUZTZF[^T.A: 7Z;[_P]_!]IP?L><28&<_LO_*J4TYZHAVX_7
M&ZYKZ?2&#=RS51Q;;7-WZQA^H[D4_5+UZ=L:WJ%Z$<'N,TN?W?U^_KK\--XV
M4J;08GY0PEV6A^?%(H6G!#WUQH6.KJ/$(HW/('.8:N,1WP*0VS-SGE\,Z7K%
MEN&*0]V5-3-O/8Y43O@WJ&Q(F<P]A2D%N&<N+86UN!M5?\F=IVW^:"5ZNO_9
M#/&3#8[P^Z9.WKE7W<)T80$WL:!>>B^^SHEL3]VB/?[ >(_6(PH@4J&'ZG"R
M,RA7;/Q$;C)X3\A#,W%$L=4Z^&BTPHD>,BTK3>':TAW.^[";+"#1"*: '?J#
MLF(!0MR%FRS GF=D>WMQ[W!=.JVJP>I<8U[;=%QUJ,_.X1Y-C8R!F?7UB2=F
MC8IECBT9%R;Z;\UH%H8O1^N4,-Z*7QVZJ23+V_#]?"6Y]Q':62OHYZ='11'-
M]>^'Z68B/I^Z.U0_B&O+6W!I#3]%[I-D".\GE<GX@I=@ GSY34?09BIV)1<-
MW75'Y7E?%Y<8&ND^M7.*4GQERM^B^62BW+'NDK+NZFB^)>Q&769KG]NWO_58
MF3!V0;"]RZ&?#U'IY#&B ](+19(G,/YRS.XWJ2$!=]8U3A0^$WYL[$1SVE.D
MBXW#;U1/Y1%LUO="*Z=0/8N$B8X%7K1A$_62XV;)V:I9T.92LF6F;8+UD^*,
M(2W,0(U&D'K\0JUP2NY9%T9)7;1V^]:TOZS(4'6$IKA#3H_=_*K8&@O@;:T.
MC9)$ZCM*HM_V5]R5=,VK;[Z[^*@4]R7B[YTQ(?T96ED-E3N_U'U5]A!,\.&@
M8Q0+$%F5O5Q(RIL9C;V"LS[T*YN__F%?R9[");L0D_6AXVH>,=60Q(^]B1_?
MBKSQ^[B4%L^C:I=9<OEIH6IOAK5::$I$6IY;^>A:_^]+#1IO[$KYDTO4'JE&
M35BK^_]Q&E-J&7S=U92[+#;>LCMHM1R VR('L@#L(#BA0YFQI3J^)WR#7*76
MXX)*P$S;6K<U!FSFJ$;KZ#=3L0QYP=[00(&2NH[#%W+%^_JJUOX50JNG3LJQ
M(JG?E54;@TZ>S6M_GVO#2G7RW*X;]8D;]A).#U[N2<C8NG']H;AC:L//FU[U
M%/&40X\;Y4NM$5F7UPE!O)U<^PR@G2.XCK<FAXXXJ%5\[WO@<.='T'+#5XZV
M01ZY*/N0V3>*M<@!H<A,Z]*ZE8BJ/,_IP+SDI\&,4>JATN*]JZ4KJDC:U9+(
MHGNP)OASV#[+U]II+ !Y6S/H%N;X >L15353Q<*#SAK!''WR[WN&+:J[L!1G
M+*B4_HA-FV^P-1.Q&%XD3E07$9M.M'GDZM=EV7(ZJM 35>%I48ILBH]UUDQM
MJ3_'YTA?2GEY_X"1 .ZEJ3!U@AC9L2G#')J&I\'D_%L/4X5VNC;KD7>:U@UN
M66FQ ![DH?.WOV0/6]R]'GPME):8*+6(>C1W1*];F7SKY^+9^B&F%OIX^N6"
MD]J/3,]6@U4+SAE6@V09O0(X9$5_U^%%MB-^<FBA_V8.]YD&C;,G9=73Y08*
MSFHHJ0ND%%E(Q;\Q,G?05+5[77Y=.,"@;M:WS/1.9/U7!F<*Z&1$$EP4=8,\
MN3&YWM0*44PU-1?7[G'H),E;)'S$0HSL*@7-+D8<)=\:D__&G^D4F[Q3I(#/
M\64!L48P1>,WT 9$7/H7O %=E7'>ZG"LQE7P?M;?FON7[\0\YCM6C !/II,N
M2#/G8,+*RDPD=^'(.Q;PF 4$, LA9*\[KJNKVJEX/I_\RI*&V M! ?,]\P(O
MM5PVXON1WR1:7)1235-/%]4Z5Q(FK4YF*O:2?>\<I50E!%)KB'KY./HQW@)M
MJB^S.N0N20)]=<1#JGOHSUK4_I%%L?=Z*;?FYVZ^^SC_+5BZ7 _SG%W4O2E_
M&D1'DCY<5.>+K[6S5+Q[NC[#$_^$ J?ROK>:<X<6(*/A->^_3/_UNEEW9Z2_
MM*P32C$/ 8]AD_&$S%8S<(;$\%YD/J*68(ZC COF9=.MWU$B!N/2DI@RH\&;
MTW_+<IDL@+S/I^G0WX"BQ\>Y+>'E"W6C.UMHU>\*>V9O-*DX@N4UY=MO;7IL
MN'Q/AS]Z='E!BX_@XS30E$..?C/I^66-&DM8WQ5+>*7;>K,A;-5U^9%>LHF
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M=CM/L%H:56BN*_@I][BF..VLMUO; N5BR&1GNS&SL7H%QCFA%VW2)2MJPXU
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MAQ? MS+"5V//C4_8)=LTC6K*"06]_H"D"<-7<^CZXNOE+,""AY+# @0\!%A
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M<Q99!QLV8Q]J*&(!?9(:Z2:9(\K?$*6(5&SV008;#'&<;?@_1T$VH_#ER[.
MK#\XRGU0F!EGP\T6-7K%V-^MK0 "U,#2#Z]!?Z/A^\ _5.M>Z%_K(_0W4DP!
M<7:8/WE_Q,RP@'W'4?VH[*4T"QGS A/OAF6+NM*ZIZ0<L'#W\T?*SL%!$ TO
M<,#V6ZCU#GC6[Q;TE^.O8F(@"?.<P5@B+R4 =YJ8>O"/J71=+@X3*_.)[9P\
M00@[@7'*[5-L9,9YGQU<IB%"AO&P!+J8,I,O9H9& (5!5-J//1;PW62Z!$IQ
MM@&5A $LL0&S7SH4!UH&<]^*AM> /3I_=W_F-!2.UQG^'2C1_:0]B*<+.]]J
M$!T-LH@#<8%S/D8E;BQ@IO:67<9VP(()% L%0$%I;(< 822-#9>47XOP^^^\
M_@I;L@#^O;9S801M[A<O<&#)G]M\*[B_/+\#"7IL6'2PZ_0X-68OB,[O-<(T
M-\EFNH8.PBM-F% ^=I#Z!BS(#10-R%F256%ZYYYA%!,]1*9\"D7YKKGF>N9^
MG6'8+,K\VZ->/;!,6W#YV\+(GL$V;/<_^8EE^L"Y8V:8JOERV U8#O,@9!][
MR0F$3;I2>#K3B>T)*2![Z4[8&3\"N_@:DS:E=P9I2!$<96<35 HU0LP$$NY
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MRUEW]NOMR<UGA"P6L*H.V9TPQU$/H,]%H;"]6/!A*'PEHV8#^]_C;O4?#)B
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MVN9F]H9)(W]4K\&9J=3OW@+'53_J/A4=JNUQ>62;<JNJ\'7/D3.W#4+L:8>
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M@-<\\":JGQ-Y"!BM<273@X2?'T@[YBX!LTP=01YK\(R$J<;OR\SVT1EU5]F
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M-_99\LJ9E Y<=JB(%1CG,8\@D J4)M-NS_M-8'OFN\@I)/.:/_X;7@A/WD,
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MINO8:,[99XS8R@XUWL9T&0MW6=TMC>0WY3,7IU@N?ZR>K?A#4-:/4?X+"\9
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M9B<VDA=Z06YWQ9]H._J>M+]),1X0!VUE%U-!C'9'$_.O)>X1O5?UM*-<'/V
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MS"RGL+<)"T47@%M$LM[(CP&AY&L\[-)Y4&@Q:14^PWNCGV9,IUMZ8^O9^K!
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M'QD8^CF)$^G**2G)D"-HA&G7+A(RWW6<H90/"<11\G9^KK_1^ 26!2=QT(;
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M(.0S9WHMCQ*.C1,!:;[W6?A=_Q=[/[",.6BDV8%@)S>M7'>%LR_M[C.V)W!
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M!L8>8?CLB5/,^TA^LZABRL498K?ZN-SY06^G%RZA'UA67VV#^_ST8+C+I:+
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M>LXP[P-O!UJ+WPH+X6;C7$DP&YE09RN9)J.!(+S]\M:U*'*;+9$;'2-RY):
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MD><Y]F;RIE;)]G,A9IL,702J.1"8Q272$AA]W!::^20A[K&OLC1/N)=T9C!
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MPI"0#-/;541T(7,\7_4B#B(6\*,5\D(7+Z2JW315R2OP!_-P?J:.U&X;!2T
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M!EQ0Z5W3< G-@OGU!0BEMO RE^E?RF>GU#!%C2Z+J0X]&$W)RY COT8H=RG
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M(? )9TFX(0J(K),DQ>?I:J@ GC0<@L/%;!96H40G$^GF/4?8<PW\D^0,S+]
MW%1AFXND@GY,:TG!%H,\/&:'KE8RY9&)-16L?,3V-_!R45<BM@K4:(1S[F&Z
MD\A<H]8!68QI"LAYH"+N/_F]6)]@6A$29(SI;C^X8H=K\ ]A<2Y7T*:/X7W'
M]I*SN$FWD+C5L!IR"\?>-<<MD]E*X?T70YO*(=R*;/T5N#&:I07,Y3B]:1,[
M ',S?:&?Y8?F;">"P:")YP!^AV?!HL$8I3 ];S#ZE<.[A?PB/;9M,ZN;KY1/
MPMXJ\-18V_EN)6<RA_XG.9^@@:9KXD*(\1;>8W-K&<]4(\UW:*0,]M/'8I%B
MBIV6]!Y.[)/%S,*DA7;:MU GW"STI+#0M;LI5'&'G\-KZ9DIQS6MS,48/+C"
M- 062ALIZMV"SN2L))^5LP 5'2=V@@?XYD@=Z2'P^QB/R@J)LE7;:7L4N1)/
M9%8E\2%8@_4JG8P*D<31U$HD+-6H#O<LQBNSV',O"T[V:N1K\$3LKW)_L0PD
M4Q:08#O/F?]F-,K[<!G.-U:>D'UDI]45*EQE\=:-R 3;==*A3PZU*_9R?9+)
M*;A%:KB8.GXCQSO"$Q\]0XU3?PUXH-Q&?(V)5 K:+O59)@N;BGQ<BU/?Y/OZ
M?#WAX6#Y&"/S$FZ^(9>"YREHFHGE+OB66(MV.ED>VFG9^DO]<9,HV2F?(WBJ
M^\I6OAO,MM-F$[!O:;-T%H!-FR0JYN2LT..R2+ZYY31*7UJ?..'].CX6:CD%
M-N 9D3@CDW0F=N,)S8PN/CGUN7F(<A%W)+ "1,4T2(R58KF;L*,\%*<?M],2
M5PT_3-D=ZV#0#4ZRKNX[!?@J.\U5UL^G YY*X:C8=WWWYQ(/(L4L$![$P@<B
M37!^@Z)1W/G.J!AH,I1)3S+=;)7("G.RE@H:]T2$J]6\0YR#)%7! V>L1Q.C
M">C>T( *=S.QE($.%A$8P6Y#F9[E%"2>S!=$J3F.U* &X:BI5VE--.'I!?(9
M"W)M+UO']\'?5=^Y063DS,5-FUG'T1GRF<B:Y\2&:^1C?:VDZ! KCSD/5!NY
M(OE\+ !Q*3,.-;-F2@HVFP+0_ :OSA2V+YU8\$X0%XI;P3;NR6U@L\DKGRS'
M$M2+B7!8%8FVD-,[.+.014" A!R[C&P&IY9)#?&FA_/X(HK/#A6Q-U#D45/N
M@Q77&[C.((AT]<1>JC3YCRZ TG7X^O3/P6[BP_@Y4#;/3?&U-J\$;&]1U.PK
M,QX&]<:'H>.;8T[R 2\"UPV&6SEO)+5H,\P$#&/XP/B&9EJ_Q(VSA @2M4B<
MVC5C'R0WN/D7600:I9^2L^+LKOGXX<^;W*.'&OG=?AI]3?U IW4EJ>75W"KZ
M65!A^:R-7(#L;8"81"H>9CD(> 9&5TV3Q$?&_YE\6F5=LY\#V2[*%PMX9GHC
ME,V9A_6JN#,HLNV<2DD#<>:@G;9/ZB+\ ^!M:M(%_TQR/8R<>L3*#,TZ))ZM
M,8D+3WT),DW^V4)7D-Y8;Z?=90VB\;BTA;D&]V^6NB!?8=\(,BS?HR=;B2.Z
M888'$HHE%!.[C+R9(,,X6T['(Q7'99LG2TSO%V#/_UQ^Y(R6\%!8]N%PT6Z0
MAID_!0],O@G;<6@@[RK@:WKFV"ZB^_73$9KND)W6[::)@S#]R5M<#<]!^%3B
M(6,9+J8-$F'N0I<"TX]Q=*RTB+/43OM:,(%(-7ZD5S.78\OI'M;4)*B6-5B'
MI5I0L -+-AP;N741KS#>NVK=0*RO!^_,4)Z^9N$9K)-88W@R2>XI8*GE@:UP
M EK0,Q<;'73"'IM%*M@!^0[S;V:X"EC-7F$JN"8J[PI>I,]6&+V*NU4P(Q(+
M-4LT4)>N$;ZG4S$Z3W<W,^=@?P\1;O&DY]QZVT\$WW\PV<"?+<A0]WS4REFV
MSKJ*;(TV-]%%<AIE?[0VV%B)L(QH5L\*B3ET0"$%]Q)E"<9%LDCC#W;:K70)
MM@WM7,FB?R5XVJY"9R*1QM<RU(3F'/Y7X&>)LE6QCU0))"WDE)0,TG,*YIF-
M#1G0?!D7]VI6.,W'WM88];[$)I! ,;X/ *2.9I<[XKI"69#)DO-D3%^ UG$>
M5NH)!I9 >:Y"9*?5>K5(N@+"<+1%D4-OT<_DD^[(7#2+Z= N<ZH"E:;#]?CF
M9F@ZAP,*$UT5*E9.^6Q,3,R#'9%H9"N*.S2KM#G(3']\QZ_T$Z1:<H<Q,&1=
M.[YB<D\BEGL+?Y-,YC@F>\%>!.,R$@CR#/S.T2;)])  BJH?E0X\MG(DWJ_+
MZ?CT J-X^ER ^K<<\_M*AL<JLBMY4_\"?[,W+HA@[V=U0;G#L)A"&)_J^)9V
MD!YMJT9B<6_4$>2@/L@\?&A@>P42"ARP9LN=>[:K'-<^A2-G N(.=*E6-MA#
M;+")27\!#4G'*M64]DT3+A&VM@O\#*,B]F*\IDD_$_$Q:]T$44HRV!;.[6XV
MLC+?UC&<D,-MG$6$,Q 9T>RCE2WZW&A^'NF('/Y3Z/7ZL'P:^$;BR5F<&/>!
M[7(%2($:A\3">1A/Y!9]GN],S,.EA>R$#P5HBY9Q<K-@N^IV$KD5%Y-3*ZQK
MD!"0?DF@5791X=57D*GJBLHAN$;(H;X1ZMK>]!D[P,3(=\0JUXUOB(EO@2;V
M,(YS'/#*W.!8(9PI7P[NE3,PJ7IW12PD\F(N+^K820.L%GV=8O"Y0>JLJM +
M]!JJID2D=06HM)B?RW;A8@._F9_-G O@J^13:!+E-XHNKH%9;8C]%L10F(BL
M\!J,EM0T8=Q<9#?.5ZT S>.K)OFE'"?;+TBL@8("?]-44"0:#*+ ,:3$$O_G
MB,(9^0Y8<=CD*QG<>PTDF%Z>)K5VV@QV*/[8(@ LBJ>.A0Q-ZHO>F,TB9GS?
M;0H5QX,*_%1IBX[G:J9"8PS0-*^43]4%0Z(.X0KLR5"V+!8_@.JL4%>E92?>
M46FHXN?)I^98*62M75AP _'D>_0I:B2#$_ U%B'.$RV3+P:]QBTE6"HUJG4K
M'UI7"Z*,PA/^N<2Q2P)1<QXF-FES$<@/:%J>=;T FU4KR0^Q] )D=X5U%?&9
M+8?C@_B!/OJ !"OA@L58@"%;6\C.,'> !.L<Y&.;1.@DJ-_^;+A(&)BA43C5
M]8NS8">Y!R$0_PYV9?@0&X&7"?4&!]YVAV-9&C6T!P\_^>H!#;0;$PH5AJM1
M8T\S<;X)+I9_^&9E.1/W&B@S:&<@=!!+U3-<::<YDGY]$@^*HPS1*,I1F]XR
MZ")<0VK+/6U7$38Y SPQ^:(M3,=,5?E*L#79P)OY.L+ *N9,>:+(9\_U^JU\
M(KA$#<9L4(G-@[R(7?_YS1G$7D4^LDGAA,##_2W,"6!"E4!L'AQJTGLF-G2(
M\-"-'0C#Q )^B@&)"2[@S,3$>?-:E\'&65C4P!'S1]\<._B6G6I&9P(O",L5
M7GL-U=>W\&AOT.DCO&XGRV',3ALP8AHS[T2:!")8>/U),J0?AF1;+UV<@/A4
M4^#0Y=78$-[$<&0=Y\SE4C#GN]$5SNKYT'89F8[L,$ISQU,E70Q+23%HW06Z
M%\AVJM)4+8V\KOAFR=W">PHO(@SW:_$6%P\GO]S>Q*/)/Q3HC/4GV9$&7S>#
MG594%^NO*5^#C6;W8GJ1-]\92<%"\_;@V[4'#9(I33=:V*B9,>EQNG&3;.>$
M][XW$"%E:97AN,C2V<[>;N+G*:;)@HQK0RV%D-/PD#/Y6%&;H'KH%]Y6"XN[
M/$]8 Y+1B2$0#6V"B(/&HN26.!8(^R4ITOSXC.WR^.GH^IY9I6KY0M#)&E 8
M"UA9<<' SPC=5B3%%,6;O0B7!^K'N,ZH&0PS2W)YKHI]$I?7HQ+&=B/:(IZ-
M?(\GJ'WCF[HL>89#N*09ZJPTC*_XN227S\*CBG4;[Y>WJ_0UI4K&-,GDR,N/
M\6:#2#F+7B"#C+SKY P[K2D<WL,H&C)F@33<075R2%,OF9:"3"0_!+/P7B-;
MX1*L+6@(+1H9RN%\B$VE3"+!H '96+OZ*.LXDIIF9.4+W?ANA-^O9-.I=O5\
MV50=AR'4*SZ0KR+;Q@\5[(-$WJC:.4HE8; G&17,?LX:!?#!4]>##==?@$PU
MY($X>)[YF=BJ(P)3C/<Z$-C$.RE?68?6SI3YF:P_EE,M+V3O-0W1B6A,<Z*1
M'6^Y5!H+>JVK*?4U!_ QJ^E G3O,)&<(SO<JXY8 ?PJW. M;#T6Z?8*7G[I5
M/SX!N@ZCY\AXQB%&5][I5=P"PC>QJ'?#W'LN:V^*WM&58[V$>X+1OVFH:%0^
M%?<:S/!7!0QUCE\ ;3/I'0CHN2(AF3>-"MHL0TH4U;<T]@KKUOH!FU>S^,4:
MDUY$..$%QLM0OMSG+J ;Q9.0?3@_\W07U_NQ=2D2>__$U] O^AKJ'?5&K7J(
M21S"_E'\G"QQ/ 3G- QI"GBBJ+@E&&\0N@9*3= )Q=[(C&;2QW:92+^5",]
M]RFRA3.Q/\GI.B+9\.)GK#Y+N(0BX3M>'7UUA]<MX*KE,ZFW50\AXQMT[@H?
MR6GB'1F)% .WT_(\NT)5^FS>Q)#'0YDHQ;>VX_$1K<(Y2-3JI>>G9['#C(HL
M-T%,=(<)&\T]!,V($R0K>Q;@X86F>ITL*)F>R4*2*,,7A*N.,V=9W8&4G#H)
MYZLAVBUR-;$55!B'1 VA2EX>,P0OC$YO[$0HU>6![*@@A#BE'QTISRJ,U@VR
MK!["WQ7NAR(/(7ZDLD.6##5S.S66Y (UQ_]9+00!;V@RP<;9*X4A_U) RM5
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M]WB94-VU$U>013BDCG4SEXID*2;]9,(?+\TD?,SBK-5TI1M>IF29]G"6V&I
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M!5]9+PCV413H5J94$#XV,6=BGTZ//4"\#/P)("<VM4E_ES=0;>4@;-TM JX
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M9RC'A4_9\WW>FI;V*<(?ISX,NC \.%2.LFZ%MP/*"3(O*@XPNMTL>VRUI).
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M"KQ>B@(X\K.+L!#\<9R!Y\!29!/UGF( U O2^(T"Z#J,PM$@K/M,EKTV7"_
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M2>=^QEJ:#*!&7F  [317:!>>98#M&V53)4M)4:--J.UL ^"EDT'F3,"=8K?
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MF_:#[:^.\W1/D92XB+#LD=&['ODQ@WG>ZXO\[RK%C7+,AMJ?W6?T+2+(#VS
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MY;XHT^*EB+T[I?V&)VIWP!A3"6.,$FIJ%=J"ISDCN0@Q+N*"5C\&#$QF"QE
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M<FCO%@YM\G!? PI@$D'99HX4X:L'^Y0;'MR<7W-("@[&;0-PP+:#L"_#7I%
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MQZ)\:D3U7C?4;]4[(O9];S"L%",VEWAI4*86H-T<%.U$S"#TAA6<VYL,267
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M[AC3W>X9(==>?/D5<X,9\GM&ED:_P9+M"LL[&3S!$KD>N%MD2!.S>'V(5N,
M37Q%4@IS!*U17M9"Q?7A;[YH#G*6L=:8+T?D23D]I"M<NWL&K7YCF&),C>P"
MMYMQ=QJK6G5-&'M>Z4#P#@6VB?" L">B(SA,S[4M.+DE^4#]V%I"^&'^=*'(
MS)20T+CRV0\7MPZTN?0$@(F1F@$(''"UG>TG]/1Q[#!&K/,:)FF:QS&R?2MU
M.Z3XS"6HSN?+SW186A?,PW@1'O(UB:64P^**M_35XMI[PE@=;O2N&<!OLL81
MR$H?:&C]B;D1)&.\4>^U\6,&Z^CP#X#O 9,3N^'",>9V-&EX3F&H(*AP;74+
M<?NHV1^I9LYQ%D_,/IY)M']TZB#A9$[QJ//#V=*W1E%0VH>)5G 0(XOM^5.?
M+%S*V"W2<_U*CA*/?6[5V0.:^D&I!K; XK$GA0&++P,;75&8"$6PP'A;E6W*
ML)8R@(A.YB&$G\S#/-D[GHWV&;37%"PJ$<NCLGV['4NR"[XADN<\["^3+E@/
M7'55&3'%::$-!*?PJFHWOSYL-W_,_U+Y"K>4H.*,O:3'1:*JQW6*_ZQ$'4][
M"6+L<(JF$M4V+*+L5;?CX89FDN'"3>,#/'C5DV+T6CX1E^[GCJ 6Q\(/M^2Q
M,2*'%8CE^$KDH=:I*TA]'P!.*9!:&T4:+^T1UJ?Z_Q!-?.C!IZTX%WEJ2^&N
MH*%HEU:=AOP-+@\?GA>)/F>HK#<YVHKU+0^<JZL93  "XX['Q?G<Z_<;2L0W
MSZ;Z!]:TU(\XN^Z,SK?$&JH6; [.=:(;[M5#Q17[F0.Q&W0+>X07:'%E=!2-
MJ]9A7F28=NV:7V;ZJ&XCML7R1*52F+.+IT9Y\Y0UD$(^<R-/NW-$?]$ACP9Z
MK-AV8!G[$KF(A 3;<:6G0?.&S986.5TFG\EK38X&6(OC_E2AU#\#:1[-TS0$
MM':[>=CFLKI"4DC['V#10&8[I_3>&\71U[?5M(^T[&: )QV K<%-"O.P!]\0
MJU$2^?$H@PX6YF) [$3!B)>V>"8RB*$P6F%[CZ@M]-:-2C_P0E9Z1$S*+T#'
MQ\[#%!Z2=-9$>)[K*E6:A^V"93LI>:NM0M\X,QAC9Q?XPMIL;[F)OC[G^N\Q
M3GY^-QQL5:ZE6+ &7'5LZ,<3P=#(;',35_?.)UUMYL8Y_(P-Q[.&^9F*"1$7
M':XD'IZ<0Z[[R51H.&X;A8"!DW.V<UL)>C5,-WF-O%?^40O5MBIC'K8</(,I
MN5HJW]\CMRH(-)66;R[> MH"3LN>&##N,59[)_7U.+=5-E[MIZE.^CR_$WSI
MV(6#VVS(U'N7/K,,4N^!@X#Y40_N$ZF7;MP^#RY:4]Q!(5I<]1,*%+HU#;CT
M=<!9TAZQ/%FK$9'SJ%@SU)JO4^KYW+SGULKPJP'VR9)6&5-PK)5%%EX<Y9YL
M,W[CX,!IM:'T"W-.^SUI:G)<>)*,+[0!9F^.U]XSMMRI,0\[?RBP]@\=.!<I
M\V>NF?C^(^S$ARV5AOY1S,;Z=1VOZV\$9'SCG2%>)-(,A/,PQ?$/_C05.J"8
MD#M^AG,]^\I<3-KT]=$2 VQ/IHTI\].I&TM9U=AHTVZ!5/L^<0_PD;[9^UTR
M)J(D8%RY;'30GI6T"#ZG[;[QNQG2ICSN$=D?9,YM(%X#]XF'CD*98(3PQ8LG
M7;&(^G20NA] 4T6:1I[\X$RK-+R[A6_<D3[4M<TY8-0><O7A1\G5R[#PEX2T
M\@"XO)6!LEQ$1N?VS\.BW2LI+^Q>C,FWO=YYTO=CLAMZ9[)UVS0U/C_#&._[
MHVN_LIWB9G%'=PD-/!2#$2?@Y9>':@0]II(8<"*CSX^QSO)&%IA5_:.U9U3M
M@=0,=!9ZVHPY(+.B\B"H7I7T,RAR9 =R5^[($ZWQEDOG6OJO]RW#OZ3-IFHL
M0T^*;)_\P)S)1&J]^]W_Z+4Z%=SO#@FIK79=]8FA4"4T>@150ZYH+R="2QDA
MU$'#F9X.5":R:T[D_HA01RN1\R*.5*Z_>?EJ(O9LKQU31<T)QR;5#T9O3:\T
M?3R3W#</^RA/<O'M(HTFU<L]G;YQ1KKFN_X-4$L#!!0    ( #9+>5@]:]:Y
M"OD  (<$ 0 -    :6UA9V5?,#$V+FIP9\R[>SB3?QP_/"'DE'.(R3$YE4BA
M+<DI29)#3DOD&$O(9#:1<PA%*58YEE,R*:=A#B')F8G9%#F,>V'NVLRS[_,\
MU^_YY[FNW^]Z?O\\]ZY[U[7MOC_[O#_OU_OU?KWN>]N;VIN''+QH:6,)X>+B
M@MS@/"![,Q#S_U[];VW_#?*_.P;77CM$C)\+L>\.-Y<R9)\8%[<8UUX7! J!
M</'^7P= _N^-:Q\W#^]^/GZ! X*< QH.0O9Q<7/OX^'FY>7AX7P:R_D<PB/&
M*W[DA-E^"0=O/N4P2?T'V:_Y5<[7=4A='0943]Z\&R]P0%KFD*R<FKK&4<UC
M!H:GC$Z?,3:_8&%I96UST?&:D[.+ZW4W']];?OX!@4'A$9'WHE#1]Q,>)B8E
MIZ2FY>0^>9J7_^QYP9OBDM*R\HJW[S[4XQL^-G[ZW-1)[.KNZ?W2US\R.C8^
M,3DU3:)0%W[^6ESZO;Q"_[.YM<W8 ?_^^R\N+@CW_PC]_S4N,4Y<^WAXN'GX
M_HN+:U_4?P>(\? >.;%?W,R!SSM,0EG_ ;_D^>S7=1T"*B>O E(W[PX?D%8U
MH*C1_POM_XSL?RVP^/]/D?V/P/Z?N$@0(6XN3O*XQ2!P")M]]$T:Y/_W.X_B
MP\.'#]^#X=QJSP[BK]AICYY_W(U4Z_JV:2&GUA(TJ#JDFIG=*WZL+M!SPN"
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M)O\+EIR)AZQHOOZ^)%(>>&SJQKWW/69+\4:Z9C]][Z>9J]X(U5?R\ ^[U2-
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MD!CX-7\ LH,I#!2 B%M#A'*L(5QCN5.B7D__]NY!1*/V(/'>3U.R9FH9@=
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MUCBGI* &&#OTY Y"*EME-QL>@HC#";*DF.=7H(*F)RI8YO2HM5YZ,^6P2WU
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M#R6AT*]9W? L,F!')C6S!0:81I@>0MW.0Y8*78-]P'P!&L]!:Q>T?C:+J)=
M:N2P1@I6J$T7M+T >/QK[)&O3=DID@7&DY/P>LG%ER8B$9)!SF[;+%)&@>UA
M:9DWK!!V$6&^_+[7VQILA\D>),1.WF)D6P'I,H[U(Z2[80J+ET_8PLK?>7F"
MYH[Q@H+\-^*I@;HU)6%"FH>UNW\(E?_K9M%VB[&^!#%T, > %S#?.%\>3?$'
M-FCIS*.8(3A7&YP]!%-.MVP<9L52$&D$?A8?93;J"F J<^]*^JHM4G:YR:MV
M'G<0C-8(,#Q1D;)!4\M6N0;YU\BHVJW%:+._;6(&R!_R.VKY4/8+]K1FIE7
M)*--+J&W2*4%&"**"O[&"9F>*1FD^R_@NCT1=FDA=S<ZY0QI/Y1G+GP/\9E@
MF56NY-V[MS@[8N4E/T^@)3.OH009>$!F[18S"B4_'\&Q=+T;W&!O#Z%^L@<W
M37"A^Y)%31VC@#\Z^E@%EBZ],:DE)NH=JIS8IC<:$7L!E6LY_F9L.T2FZQ\Z
M:N+&LJ,[7IQ]ASVG>!C TC071$&U/0A+BF\A:NTOW8IJM5;I YSLG1/:+6N3
M1YE? E.]Z1KS'GN00_A:T1622U=L<.<<;\$ 5:240N9"#5A,F)ZE%IK8"$<'
M2D[L[.3].7<>]PY[8U>&S4]?P)&".__MK-T"?'K;5,#F>:P F'5]E*T75"2X
M^T8-0!(+X=<:ZS^,X3NH0VF;1DE;=C'==\C5+?<M"[+>SI96O:%Y!YC=$42(
M8$.1H":<YDD79;2 @4Q-]A"VOCPIHG;:G?$$+ 6"=A8T>@EBJ#]+[00QQT[1
M,H^ (CX@/]E4$PM-\:._:FQYBO:A!@_LFG3 Y-UW]2<OCAI&Y]Q*+P(U]R"\
M(AP@9&-(9-Z&C73L!]S:6\"1<HO0D8Z3 XT6+N<S+Z.:NXWQ;3!P%6AV'C,8
M2B4(M F6$W?/CR\ <UGA95C_Y3V(),M'IR?_'2(HCW'/6!LQ;5Q2%VO(X:%G
MWTW-*+OF[ .7VI2&#6F2P0C <0]"RNJZ+Q],0C/X7+\;IK9HJC^O"5@,>"/3
M)+7;<LR N1K+V-DG>]$DQ'"04WE*IB94/1%,+P+O54B%BJQZ'1[3P]XFSU0Z
M<GQBZZE5N];FD6UD.ENK::1!RSWXTT)>C,)E@9M%G8MJ 35O(E'7QQ\HR1MG
ML:3".TY! 3OD0VQC#P[H[6K:2&TSXEAIV7E$$AFRIO<**0$F,Q[0:].0++XR
MECI[+,)Z+3$K T^S_+;:I7_=AJ&SK\?.FN015P?/9%W;K8?/E^'J$ ]9)DQS
M-FD/LA_KNQO,\'[1 Q,&=KHK]:9[NPAB9&KCVF8QBNF,']9I":M8@1ED(@30
MCL!0_':AY3=B[[Z!BX GT4R5].U)OG0>K7%>=#][B  U)(#*^6OP!5P209#E
M0D6F0^LF:9'^3(<YEBR3=_W% OP0RHBRTTM(,<+HC$38':#VQ-#LNW) Q^LO
M7(#U+(4*G//S(TG?G_O'P8<YTL2%1@%ZV0?"F,?!%PSQW526/#V9BNS)(A5M
M=)*%T($B! !+-2*V"C*B0&PTM17J!#Y?0#Y25*9CDR):58B#E%D^F[';.A&2
MK2^N3D1.TVBWG\>)/Q8='4K&?;1*B;0'C]IWXZ9J>SGL-??T52.G<0(+C">[
MSU@A);-!>A7HZX!T<6PD)2LU+*@R*E*MRBTK'HU0+,H6/.J=YBGO-KKX+/\+
M$CY,N$T@R5"'>I$S&Y3&-0J ;-^#B&TAI]B]%!Q1='^0HAH]<BCA-?B<:0,2
M;.PE4>3.IJ&4-_7CVA&B?&A#8*Z.\B+C;HS=L1W7O)5?:VM?)4YJ_EUB'ZBD
M8&4P UZ<SH"=?T7@1_-1A]*]#'<?&#* _$R6Q'RP@!^]O!LQO4#-3U &(Q="
M1.8$775UD>Z7Z!99\2P?WEQ5.B?%_F2O8V_%3]!UHBAZM&BF#K9#K,6SEB5K
M+ZM'"Z2_Z'J,&<'BRSX#FQ=?7 ,[RCG@8H!996#O IXLC'^NDK-QC;X1SU8,
M"D<A.Z7_\.:0)B\DKG4.!H=(06+UC&A13"Q[$*K(,;)87O8/V('=)RPS((I1
M Q;Z R9$+X/=YX;PU'M%:J C/<9MN.%L5.<]C-$([(A]K.BC%GEJXJ@&L,28
M2#,(IADY2!LGCE?=^5;QD2TOP7&?P.X;F?X ^,)U\G[H@)_V;_>%)'R9D1+^
M0I<*OYM,Q$WYE_'N]*SN^S)KY@MDDCQ;H)$J.N5/F:0ETI,]@7S: (#MVH-P
MIA:0E28#QQ<1* 3^P!U&T[NYVBQ=ML[JB0!QEMGXMD+\A>_H,X9M&8I/8WDW
MW:S4TN"TWCCT6>II^'P3#B^:7A/AZ0;GG\5VG&X[^/N>ET:^_6>[_:L>'\'9
MFA]S@<[_ZH_6?1KS;@Q85Z]/S EXHS9G>CA.$ >XBR:RU2;@OB9Z)!]*WE,.
ML_00IO2H^0_V(+=%DY#>8L8-W?E$!4>V;GG2VM*%*%ND%%ISS/2Z-U;P;;PW
M;_.7D_L^./_'<^R)129;(!F>Q4EFM5DM*YJ)1"$Y=DET^DVLL<</!$?LU<0:
M$=W.[N+?0V$R #G9<#:X*]_(85_(MY0_'Y4?-F$:5_]99E#MY)T!=FM@R-O?
M!>N%%;_EOKVX]R98Q^KBA,[/]V/XU2EK+569O'#;$%7DGP_]7ZR^FK&=."(%
MA]O?9KA*^&C?.31ESY$Y+5XX+OA\)LP$W%S82.9T9;.RE8,H]P4YEL-X+1XQ
M?6K(KJTE,6+7U@&T <B>=.,YM>;^";G:J90IQFJ<Z*C@+T!TS8)NR^:G,451
M< H?T5XFH" SG6Y%R4]J4T+E6Z<A#Z&/)\POM4=,--B+H_;_.YKFNHHQ;FM$
MH>V.>I\JR:^_571=$.H#;E+UP&-/]R!=<-G /<B'#>+0U "'&TPU%'$RB6@'
MI@4JB^K<2D6D&TVZN2%6ZI:;C(@O!HU'*8QL_[>R$16U#0.%0>Q_YT*3GDJ5
M?N@SRF'_P$#I^XLY'4:)L_+PU0*_]!JO@#8%\"GSJBU5 6D[VB _:&01O!$O
MT^3TC,X[CK\:2++(JXV.5BNLVAGI#-W6:, _PC^0PNJWZ:(&*.KES CV!%N>
M,]@[ BVA\H<KVOR[-N'&4#Q!R&5A[@40U4/FT3,0E(\)L:>,(;CU(C),NK'B
MVUFR S&OP6&64Y7:KZS<\NONJLX205GGH"UDP!Y'6D3,N#""OK?I!ROR(Y,P
M)J,M[@M#' 4MA8$*.Y^]-] )E\3(@&\XI0P[.;(5&ZF2S/0QSW48Y;@J@^"_
MWFE4.]B_.9.'$I8_63Z<4,5=AUB246S^]U\KKF.,V2->[L>O.F6UQSR^)_%%
M]<Z]^>R.JBS0B-EQOS&.<(/#;6#4-3!X@?!02X;FPKSD%4 6@:G-K)Q K7:V
M*;2!R6>_)9:!.9YVBY];QQ9&BZ0_-<L8.9@^&M;YVB-]?Y4P_ZI(CJ[(L8^\
M IQ5.1-\W_E!5=!]HR3,&<SW2475\2J#U<I6DW.-8Q@!C^N!FZM&CR\ @=_)
M7F+!P6JC/;D_Q,3%?USA^V5%(P)0JDL6?+X&^A%*4V">(=F',Z]CNJ ?AM8*
MF>8LH;J/S473+;&EI!6VR2A&AR4Y_L;Y8)"Q3+=]\D13649@H/ZEB:*C=KJ,
M0RW34EE3V(_)-#%@@R/;=E@'*QGIH ^JL4T0_ \+<J "-<10X^ADDWJQ1CQ,
M93H8<WC<!VI8U$J)O4^^"JS7!2IEQM@YVC<U/A7[7AU[! @FLM42V(*1S+NH
M@J5S$]4M>F\Q/>0/;4_+P+S88[\B%+PV+TVBHW48J?X5?0?Q+4W_Y6;D#W5.
MP.N*OW7) 5Z,(V8448_MP4X'LP^$,"59HJ /,--5I+.;#C/%=EB;RC-#4:)>
MW[7UMG7D&1%@N0\%=S" K-"F0&ZH$G<%@SL4C<?0YJ4L*^"KA&'#TX9?O:G%
M'V7QSRNXUT1)BQL<AUV'8TE)="$:.1P.Z'F!K4P5UN7=0K8"2QE ]+;*M^_@
M#AG@IL@]7D*<=,521Q>&>&>F@TBX!%-9^H5@-\^M/<C!EC/%7M4-<RG:D:FO
MTWP%MZ$TV7),/RF+)9[ 6*#OK,6& 'D;%&CW'F2Z=X&<19V$\5D5SZ"TNO\Q
MZN9U_,[:NIE1WBI.1R[[9:A,W'2/L24TJKB39[KOYKSYQT>3XJR]\^YSPBU<
M.D8'-&?:@?8+!*+[6>,!6]QY^J^E=EQ*D2GH0'>_-*E='*T"^*>V"+\!<_H9
M&Y?&U' 6X_@0RQ[R%8ESW:^#76QF_MAS'"!<:HCYW\602-@IEBJHL; 1S\$+
MS9Z"A(*5C$N@0BW*YQI@GV*8/FLR7U;_&FT&ON6XTX<]WQ1L*;O)W;A#-KQ[
MD&2\T_OW3>,+#9XV6[]BXJWYN)A7@A# 90Z7\V< C<2\;/:0UY'==PV$Z?#Y
MG@RF(2IFO@G4QY(T"8%U%'O!V@<: (^B@!',>(1E\0JL,HNIF27U";>6O1!Y
M3R+VAGY-WB"08 .]I[ ?$2SY[D"Z3=LP79]X9;>XNB7FSAZDY6F+O^@:MIQ(
M#51T5/U5%NN)-/W+,R*@.C<S=<I^$@[8;4SM,&Z#CDQ==C_\H.D9Y@F6$J#1
M7<<T92GE(^A)3X':SG]ZF;3MX?FSTF>O_0CRL<OMDBYHF;S*<0T!'V8%"OQ>
MVA^Y?703/M-,]%(;Q\Z78 &+01=+@-WP[O><-%C.O.$)%CN/KNG5;FV(N'EA
MOJGW]Z]ZCDD;I5].8FQWE^(G1WIT=5W-9:-%1KC^,NFYC*S=AU@_,JBC1R/4
M8'[DDT4CL*+!A+JAM<H]"'_D9!<TJ0#791OSH&25(+F.MKRM/,)2HQJ,[J@R
MZ'U+!GIWM$MT$0-W<)>P'3+H(R5!;;#=5G@@(@XCT HBF-SL4:P41A%L9M@
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MVR><U?#IR0D>L[CN.)*NC,.CHM;3<(K#7[IW)G#JN/,WE,]+[K^*]^\$GI5
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MN7\QK<<\B;*T>"S7Y)^R+9?[NFN2%(VC/0Y/7O>7Y-IU]WF9]@5]SGO'K';
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MS6:3M5</\'-[0^K[\J/7M<,-7C]E'+YJ/\Y-G_Q8IL\W@DM])\7"*!Y:'IT
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M58VZ\O!PCTL1+<?X=:%&DW"M5X_ZKRT]UK@1MA7_.2M?PR@AOMGTWUS("@F
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MKGINTX8*_F.K=^7\\NKU-EO8*;S E) >P@__O<9Z%<CY:\2@_SG ZZVPFR1
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M6\6-PM D"+G@^@;MFC1_.XE?M_8-P6<".^&\2G6GL""=$1+S+,A:GWA\28C
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M61":!@MR$,0># (SQ@5(*=+?*[Z$KV'IR$&F&!?W^'].5WL94=!-3?(N$_L
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M+*US+XN._=_N8BKULR!_0?)U*3-C9G^%CC+E4:V^ZHPL+D[LCNX[Z#Q(>$=
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M?N<=Z!WZ,HF.6*2ET>]12UF0\<_P?0]ITB Q&< :H/^2_HTB5/\M+; ;'I:
M3&$:*6'U T5^O$C_!)\38+R$@J1BZ[FS7407*P<#<8G,QL@J>H;:T002$6!W
MME>C-]^Q($\1U#-()(@-[IAQZB<VYJU4[%K\=_BN$)"&V),'@^ "'X*NJ$!G
M$0!TJY3/$=X&#L-%2SF@!WJ"!>& ;[^$UFG/#FR"&G#OY?_) XO_OVYR@\SS
MO<10I%B9_ERO4LB'R9[]!Z473RFWJ$@-).)*%3?./3? )4GZAK;S+?$MHGF1
MAJ6 67M317WN,AJ/[R[ZS5F(GMA00'[[.[)&PIQ7FKBF]?UBN8)4RP,\OP'Q
MC5F_\%,M@:Y=:,V/GX4EQKDVY]&?0#]_;*'%L@25VP<;??V,DS&#]O-5X2_8
M+W40,UG/WUP83A_&MQ_I-R#M:+^WU_[B^9$+?\Q,=3(4^]#MZ]08,X3G6'6/
ME$A][)^*X4C+,9W+R)M))").1P!A;ZLK$#/?V(S6'YNRL7><G'18$5 A)0FT
M?G&X[JYZQ;KL345917D%C'UMTI ;>KL;2>P8^VNL&>]PT='ALT$213:1P\.U
MX[BQ+%<#!^>DX<5/>07V)2-Q,[?=(RBH%.>P'N,66T=,X^?_ OUWEM2#&Q%
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MJ^FG5.E/")UE Q0DI?:H:9>"+T5J',:S 7R9G(! #IA-D4<ET0F<$"T'JS"
MIJQ37@PVH-.?\==%UG9"L<68Y&^NX'602,;A@_D%F<.Z)$&+;).U])4S(<D\
M@@NSG[\S=;[M2[XO^)_=!(Y7DF33O(4&N:_)H'7W;,[J/N5HQ\XE$#Y3#DW"
MD660OIRZYW*<=<< 1S3G5.AA($;*QV^[3?IJ\/'?+K3)P\=\HV7WD!:'DRMW
M.>GB]&?WFX=L0!J!)H0K3O#18@/ZW'#+=Q;(#[$TF0WQ3NH"[5QT#[2K02E
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M_>6?DPU;#Q%:FXD)?<FR<P+=*T$/7&8#3G!@(<HUA0V00Y/U\E99_*)MC6S
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M^M^<G+%!X'.=_X)-+Q $3WU5+/>X*/=#<G,0['4L:]".92SD2\HIQ])90FQ
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M LS@Y\^*Z)$KJ,/KM*F[WFP ?P/K3.9A\D.E?X?/?/I'/:7G9GU,/"_ASDF
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M9F]2)R<MW_MZ7Q7@;__[&2YU*/9+@IN/]TNI@2BWPGN?4C**W2E@'+5ANJW
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ME1)]<+-P(*/X1IF3=_#F9'VJ?</!NS3?CS:UH_\6S:^O#R]V@Y4+[F;RF52
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M5L"^9@D2.1;9POZ)%SO7_'>BV0ZKA@PW[*QHM$#N=RW9\.'G;N0ZTI4!CDB
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MQ;[,M.,X?"U&],<R8A,FLE^'/"8$_-4?@)5I*3RA7CE#O<(7"(;P!C[:D$2
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M^L^T$JLH'6Z8"PXYG$9&-ARIV TAQ<N('&?*'8ZV.S9>C+H]:0VE@5$H75)
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MY1K8]V^+##B-+(&#%(?#\.3!,%/P;685A,:DA^CV9[@[I#R."KQJV<NG^P_
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M#=_T&*/T8.NX'[?XC=7.Y [++[P<PLE?@-O:I-4+J$Q^V'X^Y3+UEERPCZE
M3A?M:W;FI[,\'I,0+Z"TI)H9_/K+"WZ:OL!^INF'/=%W7YG>H'C1]##G,&-)
MDL).I!ZL#69RKSV&HB74''TX?MCIH4D/V0VHJXD$H_ ;':A!O:;(;-A1$FK3
M338=C6&%E)^IC]$,X=7.7K+PJ]@@4$E8W\5:LR\46I!#3]AFR UHZS355/?
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MUA5F=$/$$Z+X<$THR[^W.JJU/ME"^^MW3#9G'Z6;6M4RA0_^O::C^EN%MZI
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M_H3/RDKO\1_G_4.TG&Z(A)>G<GY.RB]'H]7<>DD?7&=69607CU4XV(>G9C]
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MDD**YTO=X.&4$_Y1#T^5<.MWXXW\FJ(E!W<Y#Q]OLZ;TFPFP&TB>S:(CG7G
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MZHB$\)LH?KTC[L+K?AM-30O9ZX;J[EE-YY'.!+7Q8;U?M6"MO+:/LXE\!V(
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M#UFVUSM_JWZVFQ2G&8*K_*8"RC3E^EI(+1=J/0)B^(QXV[9@&7'#N%(;(A9
MOQM?K&<?O)GK*OF'#86_@I=48:#M&?5@LOQA'Y%\^,YS4I1R;:,C;<JN7.$(
M$<0TH4XS<D,>**/TVZ\L]@!I=\GVRG6=58S[&2*ASTBU+#4327/ Y_N/&_#_
M"C8@^SBW==5V*[>J\M&5\J\J$RC:BJCX9FJ56@MC+0DN'6Z/56 7_H F!")M
MBNZHW&<Z'FT,J9^"(IX'C9CUA!-C,T:T.\FF!:0(C[K;C[I/=,V:]?I;_.D7
M7'S.1S';F;?8L 0+4.&=: 4:/L;0YU[W<Y%3>RBK57J*5CB#Z2T V:R#'076
MRT. D3<. 1)6F@JZ#\)CT7 <#E<4NSY5K&GEVV&#6:XX#+)XS-72"=_J^\!3
M\\]+L"'#9ERM7?/T(%(ZU_2[0Z[)8OUWA9[T=U,-?55:#UYQ!5"3O26:$?+7
MG)K%0K9O+LD (\P3-8E6AT\1)7-)U<3[^DCX['F%2<F82,UZ\2RV=Q:C?:'5
MN.#1& "CNG$15'$VLA+;+%+=LE+TSCVD79!I]X :(!$_5:X@I?/0)O>)&Z&=
MD$FC#MFQLXCF"1Y]*LU&\8.CQ4.EJ6;>R0)[R[?XTI:#]3G(FNUV^T+MEV"_
M3Q!= -72V%O!4 $-5/.$'@+M/)&& O6[OT@EU*RI<P:*%HOB^H2"FGH)=9T/
M%'JL0W%0,JVNN%8!JB4P*8Y!<A]K@PA^EOMEJ>-1<^>*KO59H,ND.4B4J^Q
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M I0HX3%TTQ)(I-E0O'80?:MIO7+%-X^7U6D2'=4;<\8P>>*W_^+!W?\N_P-
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MGH_X-VSCOYYH_&O\H.!UQ7]_2"-@TW168?Q9[OI)M,&GFEX)6/UX>1]$E$9
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M-)R[EX)?BQ@,B[2M(LBV_1;%J4F+>0"#:NYP'2BC&A8,7_;YZUU3'2N9#KC
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M^<D$,%OT4;9Q9GY354)U2.2Y ,DKOQ6"*?TWFV.5J7'? IZ,&WPJ_#MB%!B
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M:F;^FS)WW#$ Y5<&$'[]W@;190Q;]G*:F_/?X<O'>I#EW@LR7^>0HF5AD<C
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M$)+%5^$= 9:X<O_*NTL27P*1A3QG0(0KQI*IA,7PG"L7PF<>\VR9$/%9O@Z
M+_'J99T#]PMOXF4_,E$%HMC"V_PO!;9UPP$4XO''-5WH^Y-Z2!C'=E)A5N%!
M:\6=;9#4(D^5M0U2Y%T 8KFJ'?5@"!=&W]05\P0J.R#R.%TNI.WTZ)U*%BKR
MZ,1"N[%!?9+I<:VU<*^T$5?$8W_Q\3&Z\A.!-4$"SX*+X$GZK&75 \A7.",
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M;7GUG\<*&ATPX+C=HZBCO-U#+<H\ ^Y, E\,BWH?JE#0V;TL"B#>Y[0F4"/
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M!-1:MG(#GO\K33-/C\VP\3)WSNF^/!@B[+[O$;_W<DM+PT!U$#I2B3K5*3:
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M[$7@DP>J&ML@HC/O[*815O7\8+;#F %;5=#JEURC:%!?(B35,_7RA@H!Q Z
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M,#(Q-C<M,C!F7VEN<W!I<F$N:'1M4$L! A0#%     @ -DMY6"T.5:Z[!@
MDR,  !T              ( !2<\# &5A,#(P,C$V-S Q97@Q,BTQ7VEN<W!I
M<F$N:'1M4$L! A0#%     @ -DMY6+D;XPZL!@  XR(  !T
M ( !/]8# &5A,#(P,C$V-S Q97@Q,BTR7VEN<W!I<F$N:'1M4$L! A0#%
M  @ -DMY6".";?$4 P  ; L  !T              ( !)MT# &5A,#(P,C$V
M-S Q97@Q,RTQ7VEN<W!I<F$N:'1M4$L! A0#%     @ -DMY6'\..L M P
MG L  !T              ( !=> # &5A,#(P,C$V-S Q97@Q,RTR7VEN<W!I
M<F$N:'1M4$L! A0#%     @ -DMY6"S!ZGY/ P  \ H  !T
M ( !W>,# &5A,#(P,C$V-S Q97@Q-2TQ7VEN<W!I<F$N:'1M4$L! A0#%
M  @ -DMY6$:&B].')P  M<P  !P              ( !9^<# &5A,#(P,C$V
M-S Q97@R+3%?:6YS<&ER82YH=&U02P$"% ,4    "  V2WE8/$^%H5P,  ")
M/P  '               @ $H#P0 96$P,C R,38W,#%E>#0M-E]I;G-P:7)A
M+FAT;5!+ 0(4 Q0    ( #9+>5CU&\J3#A<  ).A   =              "
M ;X;! !E83 R,#(Q-C<P,65X.3<M,5]I;G-P:7)A+FAT;5!+ 0(4 Q0    (
M #9+>5@]/&*[EQD  )Q! 0 1              "  0<S! !I:6YN+3(P,C,Q
M,C,Q+GAS9%!+ 0(4 Q0    ( #9+>5A0_ND_T X  &J[   5
M  "  <U,! !I:6YN+3(P,C,Q,C,Q7V-A;"YX;6Q02P$"% ,4    "  V2WE8
M+BTDZ.U0  !-.P4 %0              @ '06P0 :6EN;BTR,#(S,3(S,5]D
M968N>&UL4$L! A0#%     @ -DMY6+4X]P[^M0  #5T) !4
M ( !\*P$ &EI;FXM,C R,S$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( #9+>5A+
MI_(H04X  )PZ!0 5              "  2%C!0!I:6YN+3(P,C,Q,C,Q7W!R
M92YX;6Q02P$"% ,4    "  V2WE8R0AO=UU-  !N4   #0
M@ &5L04 :6UA9V5?,# Q+FIP9U!+ 0(4 Q0    ( #9+>5@T\+.\:F<  %YK
M   -              "  1W_!0!I;6%G95\P,#(N:G!G4$L! A0#%     @
M-DMY6"C\[=KC00  6T,   T              ( !LF8& &EM86=E7S P,RYJ
M<&=02P$"% ,4    "  V2WE8U!*\"S67   KF   #0              @ '
MJ 8 :6UA9V5?,# T+FIP9U!+ 0(4 Q0    ( #9+>5@S&?EBBB\  #,Q   -
M              "  2! !P!I;6%G95\P,#4N:G!G4$L! A0#%     @ -DMY
M6+[I) M^CP  &90   T              ( !U6\' &EM86=E7S P-BYJ<&=0
M2P$"% ,4    "  V2WE8$(3_YQ^? 0"%I0$ #0              @ %^_P<
M:6UA9V5?,# W+FIP9U!+ 0(4 Q0    ( #9+>5C6S.6X_ (" &T> @ -
M          "  <B>"0!I;6%G95\P,#@N:G!G4$L! A0#%     @ -DMY6!=;
M(G;&70  GV    T              ( ![Z$+ &EM86=E7S P.2YJ<&=02P$"
M% ,4    "  V2WE8,5)PT550 0"560$ #0              @ '@_PL :6UA
M9V5?,#$P+FIP9U!+ 0(4 Q0    ( #9+>5AZ.]X,#W\! /J) 0 -
M      "  6!0#0!I;6%G95\P,3$N:G!G4$L! A0#%     @ -DMY6 5.\AG8
M;P$ )7<!  T              ( !FL\. &EM86=E7S Q,BYJ<&=02P$"% ,4
M    "  V2WE8BDX) PJ( 0"HD@$ #0              @ &=/Q  :6UA9V5?
M,#$S+FIP9U!+ 0(4 Q0    ( #9+>5AX^R@G]U\! +YI 0 -
M  "  =+'$0!I;6%G95\P,30N:G!G4$L! A0#%     @ -DMY6#+Q2^"N7 $
M;W,!  T              ( !]"<3 &EM86=E7S Q-2YJ<&=02P$"% ,4
M"  V2WE8/6O6N0KY  "'! $ #0              @ '-A!0 :6UA9V5?,#$V
M+FIP9U!+ 0(4 Q0    ( #9+>5AI!D"1L^\  (W\   -              "
H 0)^%0!I;6%G95\P,3<N:G!G4$L%!@     ? !\ TP<  .!M%@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>ea0202167-20f_inspira_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iinn="http://www.inspiratechnologies.com/20231231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="iinn-20231231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iinn:OrdinarySharesNoParValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iinn:WarrantsToPurchaseOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-26</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-26</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2023-12-26</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-26</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2023-12-26</startDate>
            <endDate>2023-12-26</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">iinn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:DevelopmentEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:DepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:DevelopmentEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:DevelopmentEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:DevelopmentEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:DevelopmentEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2023-10-31</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">iinn:NonTradableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">iinn:NonTradableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2021-06-01</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">iinn:BrokersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2021-12-17</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-26</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-26</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-26</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">iinn:ExercisePrice55Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">iinn:ExercisePrice55Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">iinn:ExercisePrice55OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">iinn:ExercisePrice55OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">iinn:ExercisePrice55TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">iinn:ExercisePrice55TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">iinn:Exercise6875Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">iinn:Exercise6875Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">iinn:Exercise16Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">iinn:Exercise16Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:NonTradableSharesOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-21</startDate>
            <endDate>2021-02-21</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-21</startDate>
            <endDate>2021-02-21</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2021-02-21</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-21</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2021-02-21</startDate>
            <endDate>2021-02-21</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:NonTradableSharesOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-16</instant>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:NonTradableSharesOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-16</startDate>
            <endDate>2021-05-16</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2021-05-16</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-16</startDate>
            <endDate>2021-05-16</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2021-05-16</startDate>
            <endDate>2021-05-16</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iinn:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-16</startDate>
            <endDate>2021-05-16</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2021-08-12</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2021-08-12</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-02</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-02</instant>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2021-11-02</instant>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-24</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:AdvisoryBoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-24</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-24</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2022-03-24</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-24</startDate>
            <endDate>2022-03-24</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-24</instant>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2022-03-24</startDate>
            <endDate>2022-03-24</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iinn:TwoThousandAndNineteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-24</startDate>
            <endDate>2022-03-24</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-06</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-19</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2022-05-19</instant>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-22</instant>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2022-11-22</instant>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:EmployeesDirectorsAndSubcontractorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:EmployeesDirectorsAndSubcontractorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:EmployeesDirectorsAndSubcontractorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-22</instant>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-22</startDate>
            <endDate>2024-01-22</endDate>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-27</startDate>
            <endDate>2024-02-27</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="ils">
        <measure>iso4217:ILS</measure>
    </unit>
    <unit id="ilsPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-21194">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c0" id="ixv-28">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-40">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-21195">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-21196">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-21197">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-56">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c0" id="ixv-68">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-21198">001-40303</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-78">INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-21199">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-21200">2 Ha-Tidhar St</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-21201">Ra&#x2019;anana</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-21202">4366504</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c0" id="ixv-21203">IL</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="c1" id="ixv-21204">+972.4</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1" id="ixv-21205">6230333</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName contextRef="c1" id="ixv-115">Dagi Ben-Noon</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c1" id="ixv-21206">2 Ha-Tidhar St</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c1" id="ixv-21207">Ra&#x2019;anana</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c1" id="ixv-21208">4366504</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c1" id="ixv-21209">IL</dei:EntityAddressCountry>
    <dei:Security12bTitle contextRef="c2" id="ixv-153">Ordinary Shares, no par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c2" id="ixv-158">IINN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c2" id="ixv-21210">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c3" id="ixv-167">Warrants to purchase Ordinary Shares</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c3" id="ixv-173">IINNW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c3" id="ixv-21211">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c4"
      decimals="INF"
      id="ixv-21212"
      unitRef="shares">15652176</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-21213">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-21214">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-21215">No</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-21216">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-269">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-276">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c0" id="ixv-282">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-297">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-303">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard contextRef="c0" id="ixv-21217">U.S. GAAP</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="c0" id="ixv-348">false</dei:EntityShellCompany>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c31" id="ixv-21218">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c31" id="ixv-21219">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c31" id="ixv-21220">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c31" id="ixv-21221">false</ecd:Rule10b51ArrAdoptedFlag>
    <dei:AuditorName contextRef="c0" id="ixv-21222">Ziv Haft</dei:AuditorName>
    <dei:AuditorFirmId contextRef="c0" id="ixv-21223">1185</dei:AuditorFirmId>
    <dei:AuditorLocation contextRef="c0" id="ixv-13286">Tel-Aviv, Israel</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="-3" id="ixv-21224" unitRef="usd">5041000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c5" decimals="-3" id="ixv-21225" unitRef="usd">6783000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DepositsAssetsCurrent contextRef="c4" decimals="-3" id="ixv-21226" unitRef="usd">2320000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="c5" decimals="-3" id="ixv-21227" unitRef="usd">7120000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c4" decimals="-3" id="ixv-21228" unitRef="usd">432000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c5" decimals="-3" id="ixv-21229" unitRef="usd">589000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c4" decimals="-3" id="ixv-21230" unitRef="usd">7793000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c5" decimals="-3" id="ixv-21231" unitRef="usd">14492000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="-3" id="ixv-21232" unitRef="usd">1011000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c5" decimals="-3" id="ixv-21233" unitRef="usd">1263000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="-3" id="ixv-21234" unitRef="usd">506000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c5" decimals="-3" id="ixv-21235" unitRef="usd">411000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent contextRef="c4" decimals="-3" id="ixv-21236" unitRef="usd">1517000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c5" decimals="-3" id="ixv-21237" unitRef="usd">1674000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c4" decimals="-3" id="ixv-21238" unitRef="usd">9310000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c5" decimals="-3" id="ixv-21239" unitRef="usd">16166000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c4" decimals="-3" id="ixv-21240" unitRef="usd">198000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c5" decimals="-3" id="ixv-21241" unitRef="usd">152000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c4" decimals="-3" id="ixv-21242" unitRef="usd">1026000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c5" decimals="-3" id="ixv-21243" unitRef="usd">1216000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c4" decimals="-3" id="ixv-21244" unitRef="usd">290000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c5" decimals="-3" id="ixv-21245" unitRef="usd">268000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-21246" unitRef="usd">1470000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-21247" unitRef="usd">26000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-21248" unitRef="usd">2984000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-21249" unitRef="usd">1662000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c4" decimals="-3" id="ixv-21250" unitRef="usd">588000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c5" decimals="-3" id="ixv-21251" unitRef="usd">873000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c4" decimals="-3" id="ixv-21252" unitRef="usd">588000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c5" decimals="-3" id="ixv-21253" unitRef="usd">873000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:AdditionalPaidInCapital contextRef="c4" decimals="-3" id="ixv-21254" unitRef="usd">61259000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c5" decimals="-3" id="ixv-21255" unitRef="usd">57866000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c4" decimals="-3" id="ixv-21256" unitRef="usd">-55521000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c5" decimals="-3" id="ixv-21257" unitRef="usd">-44235000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="-3" id="ixv-21258" unitRef="usd">5738000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="-3" id="ixv-21259" unitRef="usd">13631000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c4" decimals="-3" id="ixv-21260" unitRef="usd">9310000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c5" decimals="-3" id="ixv-21261" unitRef="usd">16166000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-21262" unitRef="usd">7320000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c6" decimals="-3" id="ixv-21263" unitRef="usd">8183000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c7" decimals="-3" id="ixv-21264" unitRef="usd">4070000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c0" decimals="-3" id="ixv-21265" unitRef="usd">746000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c6" decimals="-3" id="ixv-21266" unitRef="usd">1328000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c7" decimals="-3" id="ixv-21267" unitRef="usd">1980000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-21268" unitRef="usd">4063000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c6" decimals="-3" id="ixv-21269" unitRef="usd">5375000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c7" decimals="-3" id="ixv-21270" unitRef="usd">6937000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c0" decimals="-3" id="ixv-21271" unitRef="usd">-4000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c6" decimals="-3" id="ixv-21272" unitRef="usd">-7000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c7" decimals="-3" id="ixv-21273" unitRef="usd">23000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" id="ixv-21274" unitRef="usd">-12133000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c6" decimals="-3" id="ixv-21275" unitRef="usd">-14893000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c7" decimals="-3" id="ixv-21276" unitRef="usd">-12964000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions contextRef="c0" decimals="-3" id="ixv-21277" unitRef="usd">318000</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions contextRef="c6" decimals="-3" id="ixv-21278" unitRef="usd">192000</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions contextRef="c7" decimals="-3" id="ixv-21279" unitRef="usd">1000</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c0" decimals="-3" id="ixv-21280" unitRef="usd">529000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c6" decimals="-3" id="ixv-21281" unitRef="usd">-275000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c7" decimals="-3" id="ixv-21282" unitRef="usd">-4230000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="-3" id="ixv-21283" unitRef="usd">-11286000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c6" decimals="-3" id="ixv-21284" unitRef="usd">-14976000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c7" decimals="-3" id="ixv-21285" unitRef="usd">-17193000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c0" decimals="-3" id="ixv-21286" unitRef="usd">-11286000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c6" decimals="-3" id="ixv-21287" unitRef="usd">-14976000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c7" decimals="-3" id="ixv-21288" unitRef="usd">-17193000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-21289"
      unitRef="usdPershares">-0.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c6"
      decimals="2"
      id="ixv-21290"
      unitRef="usdPershares">-1.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c7"
      decimals="2"
      id="ixv-21291"
      unitRef="usdPershares">-3.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ixv-21292"
      unitRef="shares">12095477</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c6"
      decimals="INF"
      id="ixv-21293"
      unitRef="shares">10794594</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c7"
      decimals="INF"
      id="ixv-21294"
      unitRef="shares">5306225</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c8"
      decimals="INF"
      id="ixv-21295"
      unitRef="shares">11338940</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="-3" id="ixv-21296" unitRef="usd">57866000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="-3" id="ixv-21297" unitRef="usd">-44235000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="-3" id="ixv-21298" unitRef="usd">13631000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="c11"
      decimals="INF"
      id="ixv-21299"
      unitRef="shares">3031250</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c12" decimals="-3" id="ixv-21300" unitRef="usd">1806000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c0" decimals="-3" id="ixv-21301" unitRef="usd">1806000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c12" decimals="-3" id="ixv-21302" unitRef="usd">131000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c0" decimals="-3" id="ixv-21303" unitRef="usd">131000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c11"
      decimals="INF"
      id="ixv-21304"
      unitRef="shares">17566</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c12" decimals="-3" id="ixv-21305" unitRef="usd">26000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c0" decimals="-3" id="ixv-21306" unitRef="usd">26000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c11"
      decimals="INF"
      id="ixv-21307"
      unitRef="shares">37972</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c12" decimals="-3" id="ixv-21308" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c0" decimals="-3" id="ixv-21309" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c11"
      decimals="INF"
      id="ixv-21310"
      unitRef="shares">1226448</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c12" decimals="-3" id="ixv-21311" unitRef="usd">1427000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c0" decimals="-3" id="ixv-21312" unitRef="usd">1427000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c13" decimals="-3" id="ixv-21313" unitRef="usd">11286000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c0" decimals="-3" id="ixv-21314" unitRef="usd">11286000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c14"
      decimals="INF"
      id="ixv-21315"
      unitRef="shares">15652176</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="-3" id="ixv-21316" unitRef="usd">61259000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="-3" id="ixv-21317" unitRef="usd">-55521000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="-3" id="ixv-21318" unitRef="usd">5738000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c17"
      decimals="INF"
      id="ixv-21320"
      unitRef="shares">10091706</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="-3" id="ixv-21321" unitRef="usd">52987000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="-3" id="ixv-21322" unitRef="usd">-29259000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="-3" id="ixv-21323" unitRef="usd">23728000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c21"
      decimals="INF"
      id="ixv-21324"
      unitRef="shares">7030</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="c21"
      decimals="INF"
      id="ixv-21325"
      unitRef="shares">1240204</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c22" decimals="-3" id="ixv-21326" unitRef="usd">4879000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c6" decimals="-3" id="ixv-21327" unitRef="usd">4879000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c23" decimals="-3" id="ixv-21328" unitRef="usd">14976000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c6" decimals="-3" id="ixv-21329" unitRef="usd">14976000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c8"
      decimals="INF"
      id="ixv-21330"
      unitRef="shares">11338940</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="-3" id="ixv-21331" unitRef="usd">57866000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="-3" id="ixv-21332" unitRef="usd">-44235000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="-3" id="ixv-21333" unitRef="usd">13631000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c24"
      decimals="INF"
      id="ixv-21334"
      unitRef="shares">2661095</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c24" decimals="-3" id="ixv-21335" unitRef="usd">304000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c25" decimals="-3" id="ixv-21336" unitRef="usd">10430000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="-3" id="ixv-21337" unitRef="usd">-12066000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="-3" id="ixv-21338" unitRef="usd">-1332000</us-gaap:StockholdersEquity>
    <iinn:StockIssuedDuringPeriodValueParValueCancellation contextRef="c28" decimals="-3" id="ixv-21339" unitRef="usd">-304000</iinn:StockIssuedDuringPeriodValueParValueCancellation>
    <iinn:StockIssuedDuringPeriodValueParValueCancellation contextRef="c29" decimals="-3" id="ixv-21340" unitRef="usd">304000</iinn:StockIssuedDuringPeriodValueParValueCancellation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c28"
      decimals="INF"
      id="ixv-21341"
      unitRef="shares">2931472</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c29" decimals="-3" id="ixv-21342" unitRef="usd">13969000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c7" decimals="-3" id="ixv-21343" unitRef="usd">13969000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c28"
      decimals="INF"
      id="ixv-21344"
      unitRef="shares">2113905</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c29" decimals="-3" id="ixv-21345" unitRef="usd">12203000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c7" decimals="-3" id="ixv-21346" unitRef="usd">12203000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <iinn:StockIssuedDuringPeriodSharesTradableWarrantsExercise
      contextRef="c28"
      decimals="INF"
      id="ixv-21347"
      unitRef="shares">1705000</iinn:StockIssuedDuringPeriodSharesTradableWarrantsExercise>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c29" decimals="-3" id="ixv-21348" unitRef="usd">9378000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c7" decimals="-3" id="ixv-21349" unitRef="usd">9378000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="c28"
      decimals="INF"
      id="ixv-21350"
      unitRef="shares">655603</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c28"
      decimals="INF"
      id="ixv-21351"
      unitRef="shares">24631</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c29" decimals="-3" id="ixv-21352" unitRef="usd">6703000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c7" decimals="-3" id="ixv-21353" unitRef="usd">6703000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c30" decimals="-3" id="ixv-21354" unitRef="usd">17193000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c7" decimals="-3" id="ixv-21355" unitRef="usd">17193000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c17"
      decimals="INF"
      id="ixv-21356"
      unitRef="shares">10091706</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="-3" id="ixv-21357" unitRef="usd">52987000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="-3" id="ixv-21358" unitRef="usd">-29259000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="-3" id="ixv-21359" unitRef="usd">23728000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-21360" unitRef="usd">-11286000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-21361" unitRef="usd">-14976000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-21362" unitRef="usd">-17193000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c0" decimals="-3" id="ixv-21363" unitRef="usd">111000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c6" decimals="-3" id="ixv-21364" unitRef="usd">54000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c7" decimals="-3" id="ixv-21365" unitRef="usd">25000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-21366" unitRef="usd">1427000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c6" decimals="-3" id="ixv-21367" unitRef="usd">4879000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c7" decimals="-3" id="ixv-21368" unitRef="usd">6703000</us-gaap:ShareBasedCompensation>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c0" decimals="-3" id="ixv-21369" unitRef="usd">59000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <iinn:RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue contextRef="c7" decimals="-3" id="ixv-21370" unitRef="usd">-3515000</iinn:RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue>
    <iinn:EvaluationOfFinancialLiabilityAtFairValue contextRef="c0" decimals="-3" id="ixv-21371" unitRef="usd">306000</iinn:EvaluationOfFinancialLiabilityAtFairValue>
    <iinn:EvaluationOfFinancialLiabilityAtFairValue contextRef="c6" decimals="-3" id="ixv-21372" unitRef="usd">108000</iinn:EvaluationOfFinancialLiabilityAtFairValue>
    <iinn:EvaluationOfFinancialLiabilityAtFairValue contextRef="c7" decimals="-3" id="ixv-21373" unitRef="usd">-480000</iinn:EvaluationOfFinancialLiabilityAtFairValue>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c0" decimals="-3" id="ixv-21374" unitRef="usd">205000</us-gaap:AmortizationOfFinancingCosts>
    <iinn:PrepaymentsOfLeaseLiabilities contextRef="c0" decimals="-3" id="ixv-21375" unitRef="usd">-7000</iinn:PrepaymentsOfLeaseLiabilities>
    <iinn:PrepaymentsOfLeaseLiabilities contextRef="c6" decimals="-3" id="ixv-21376" unitRef="usd">-51000</iinn:PrepaymentsOfLeaseLiabilities>
    <iinn:PrepaymentsOfLeaseLiabilities contextRef="c7" decimals="-3" id="ixv-21377" unitRef="usd">-12000</iinn:PrepaymentsOfLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInLeasingReceivables contextRef="c0" decimals="-3" id="ixv-21378" unitRef="usd">5000</us-gaap:IncreaseDecreaseInLeasingReceivables>
    <us-gaap:IncreaseDecreaseInLeasingReceivables contextRef="c6" decimals="-3" id="ixv-21379" unitRef="usd">99000</us-gaap:IncreaseDecreaseInLeasingReceivables>
    <us-gaap:IncreaseDecreaseInLeasingReceivables contextRef="c7" decimals="-3" id="ixv-21380" unitRef="usd">-24000</us-gaap:IncreaseDecreaseInLeasingReceivables>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c0" decimals="-3" id="ixv-21381" unitRef="usd">-190000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c6" decimals="-3" id="ixv-21382" unitRef="usd">-99000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c7" decimals="-3" id="ixv-21383" unitRef="usd">490000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c0" decimals="-3" id="ixv-21384" unitRef="usd">46000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c6" decimals="-3" id="ixv-21385" unitRef="usd">59000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c7" decimals="-3" id="ixv-21386" unitRef="usd">91000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c0" decimals="-3" id="ixv-21387" unitRef="usd">-190000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c6" decimals="-3" id="ixv-21388" unitRef="usd">496000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c7" decimals="-3" id="ixv-21389" unitRef="usd">172000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-21390" unitRef="usd">-9756000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c6" decimals="-3" id="ixv-21391" unitRef="usd">-9647000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c7" decimals="-3" id="ixv-21392" unitRef="usd">-6685000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="-3" id="ixv-21393" unitRef="usd">206000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c6" decimals="-3" id="ixv-21394" unitRef="usd">263000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c7" decimals="-3" id="ixv-21395" unitRef="usd">182000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c6" decimals="-3" id="ixv-21396" unitRef="usd">7120000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="c0" decimals="-3" id="ixv-21397" unitRef="usd">4800000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" id="ixv-21398" unitRef="usd">4594000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c6" decimals="-3" id="ixv-21399" unitRef="usd">-7383000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c7" decimals="-3" id="ixv-21400" unitRef="usd">-182000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <iinn:ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans contextRef="c7" decimals="-3" id="ixv-21401" unitRef="usd">7195000</iinn:ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c0" decimals="-3" id="ixv-21402" unitRef="usd">2128000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c7" decimals="-3" id="ixv-21403" unitRef="usd">14279000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c0" decimals="-3" id="ixv-21404" unitRef="usd">1750000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c0" decimals="-3" id="ixv-21405" unitRef="usd">454000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c0" decimals="-3" id="ixv-21406" unitRef="usd">3000</us-gaap:ProceedsFromStockOptionsExercised>
    <iinn:IssuanceOfOrdinarySharesissuancesPursuantToATM contextRef="c0" decimals="-3" id="ixv-21407" unitRef="usd">26000</iinn:IssuanceOfOrdinarySharesissuancesPursuantToATM>
    <iinn:IssuanceOfOrdinarySharesissuancesPursuantToATM contextRef="c7" decimals="-3" id="ixv-21408" unitRef="usd">8721000</iinn:IssuanceOfOrdinarySharesissuancesPursuantToATM>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" id="ixv-21409" unitRef="usd">3453000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c7" decimals="-3" id="ixv-21410" unitRef="usd">30195000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="-3" id="ixv-21411" unitRef="usd">-1709000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c6" decimals="-3" id="ixv-21412" unitRef="usd">-17030000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c7" decimals="-3" id="ixv-21413" unitRef="usd">23328000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c5" decimals="-3" id="ixv-21414" unitRef="usd">6839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c20" decimals="-3" id="ixv-21415" unitRef="usd">23869000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c27" decimals="-3" id="ixv-21416" unitRef="usd">541000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="-3" id="ixv-21417" unitRef="usd">5130000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c5" decimals="-3" id="ixv-21418" unitRef="usd">6839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c20" decimals="-3" id="ixv-21419" unitRef="usd">23869000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ConversionOfStockAmountIssued1 contextRef="c7" decimals="-3" id="ixv-21420" unitRef="usd">12203000</us-gaap:ConversionOfStockAmountIssued1>
    <iinn:TradableWarrantsFinancialLiabilityAtIPO contextRef="c7" decimals="-3" id="ixv-21421" unitRef="usd">-310000</iinn:TradableWarrantsFinancialLiabilityAtIPO>
    <iinn:ShareBasedCompensationUnderwritersFeesAtIPO contextRef="c7" decimals="-3" id="ixv-21422" unitRef="usd">-264000</iinn:ShareBasedCompensationUnderwritersFeesAtIPO>
    <iinn:ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital contextRef="c0" decimals="-3" id="ixv-21423" unitRef="usd">-73000</iinn:ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="-3" id="ixv-21424" unitRef="usd">93000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c6" decimals="-3" id="ixv-21425" unitRef="usd">106000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c7" decimals="-3" id="ixv-21426" unitRef="usd">29000</us-gaap:InterestPaidNet>
    <us-gaap:CompensationRelatedCostsGeneralTextBlock contextRef="c0" id="ixv-15772">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 1 - GENERAL:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;1.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Inspira Technologies Oxy B.H.N. Ltd (formerly: Insense Medical
Ltd.) (the &#x201c;Company&#x201d;) was incorporated in Israel and commenced its operations on February 27, 2018. The Company operates
in the medical technology industry in the field of respiratory support technology engaged in the research, development, manufacturing
related activities, and go-to-market activities of proprietary products and technologies. The Company is developing the following products:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The INSPIRA ART (Augmented Respiratory Technology), which
is a respiratory support technology targeted toward utilizing direct blood oxygenation to boost patient saturation levels within minutes
while the patient is awake and spontaneously breathing. The aim is to reduce the need for invasive mechanical ventilation, with the potential
to reduce risks, complications and high costs.&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
     &lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The HYLA blood sensor, which is a non-invasive optical blood sensor designed to perform real-time and
continuous blood measurements, potentially minimizing the need to take actual blood samples from patients.&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
                                                                                                                    &lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The INSPIRA ART100 Device, an advanced form of life support system better known by the medical industry
as a cardiopulmonary bypass system is being designed for use in surgical procedures requiring cardiopulmonary bypass for six hours or
less.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;2.&lt;/td&gt;&lt;td style="text-align: justify"&gt;The Company&#x2019;s products are in the development stage. The INSPIRA ART100 device and the INSPIRA ART
has not yet been tested or used in humans. The Company&#x2019;s products have not been approved by the U.S. Food and Drug Administration (the
&#x201c;FDA&#x201d;). The INSPIRA ART100 device was submitted to the FDA for 510k clearance in September 2023, and the Company expect FDA
approval by the end of the first half of 2024.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;3.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On December 26, 2023, the Company entered into a purchase agreement (the &#x201c;Purchase Agreement&#x201d;) with an institutional investor in a registered direct offering (the &#x201c;Registered Direct Offering&#x201d;), pursuant to which the Company issued (i) an aggregate of 1,375,000 of the Company&#x2019;s ordinary shares (the &#x201c;Ordinary Shares&#x201d;) at a purchase price of $1.28 per share, and (ii) pre-funded warrants, (&#x201c;Pre-Funded Warrants&#x201d;), to purchase up to 1,656,250 Ordinary shares, at a purchase price of $1.28, less $0.001 per Pre-Funded Warrant which were immediately exercised). In addition, pursuant to the Purchase Agreement, the Company issued warrants to the institutional investor to purchase up to an aggregate of 3,031,250 Ordinary Shares at an exercise price of $1.28 per share (&#x201c;Private Warrants&#x201d;). The aggregate proceeds received by the Company from the registered direct offering were approximately: $3,424, after deducting placement agent commissions and additional offering costs which totaled in approximately $454. In addition, pursuant to the Purchase Agreement, the Company issued Placement Agent Warrants to purchase up to a total of 7.0% of the aggregate number of Ordinary Shares sold in the transaction, or warrants to purchase up to 212,188 Ordinary Shares. The fair value of the Placement Agent Warrants on the issuance date was $131 and it was recorded as part of the issuance costs (see Note 9).&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;4.&lt;/td&gt;&lt;td style="text-align: justify"&gt;The accompanying financial statements (the &#x201c;Financial Statements&#x201d;) have been prepared assuming
that the Company will continue as a going concern. To date, the Company is at its development stage. Therefore, the Company has suffered
recurring losses from operations and negative cash flows from operations since inception. As of December 31, 2023, the Company had incurred
accumulated losses of $55.5 million and expects to continue to fund its operations through fundings such as issuance of convertible securities,
Ordinary Shares and warrants and through Israeli governmental grants. There is no assurance that such financing will be obtained. Considering
the above, our dependency on external funding for our operations raises a substantial doubt about our ability to continue as a going concern.
The Financial Statements do not include any adjustments that might result from the outcome of these uncertainties.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;5.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Our offices are located in Israel. On October 7, 2023, Hamas terrorists infiltrated Israel&#x2019;s southern
border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Following the attack, Israel declared war
against Hamas and the Israeli military began to call-up reservists for an active duty. At the same time, and because of the declaration
of war against Hamas, the clash between Israel and Hezbollah in Lebanon has escalated and there is a possibility that it will turn into
a greater regional conflict in the future. As of the date of these Financial Statements, these events have had no material impact on the
Company&#x2019;s operations.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;6.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Although we do not currently conduct business in Russia and Ukraine, the escalation of geopolitical instability
in Russia and Ukraine as well as currency fluctuations in the Russian Ruble has had a negative impact on worldwide markets. Such impact
may negatively impact our supply chain, our operations and future growth prospects in that region.&#160;As a result of the crisis in Ukraine,&#160;both
the U.S. and other countries have implemented sanctions against certain Russian individuals and entities. Our global operations expose
us to risks that could adversely affect our business, financial condition, results of operations, cash flows or the market price of our securities,
including the potential for increased tensions between Russia and other countries resulting from the current situation involving Russia
and Ukraine, tariffs, economic sanctions and import-export restrictions imposed, and retaliatory actions, as well as the potential negative
impact on our potential business and sales in the region. Current geopolitical instability in Russia and Ukraine and related sanctions
by the U.S. and other governments against certain companies and individuals may hinder our ability to conduct business with potential
customers and vendors in these countries.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;7.&lt;/td&gt;&lt;td style="text-align: justify"&gt;These Financial Statements were authorized by the Board of Directors on March 19, 2024.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CompensationRelatedCostsGeneralTextBlock>
    <us-gaap:SharesIssued
      contextRef="c32"
      decimals="0"
      id="ixv-21427"
      unitRef="shares">1375000</us-gaap:SharesIssued>
    <us-gaap:SharePrice
      contextRef="c32"
      decimals="2"
      id="ixv-21428"
      unitRef="usdPershares">1.28</us-gaap:SharePrice>
    <us-gaap:SharesIssued
      contextRef="c33"
      decimals="0"
      id="ixv-21429"
      unitRef="shares">1656250</us-gaap:SharesIssued>
    <us-gaap:SharePrice
      contextRef="c33"
      decimals="2"
      id="ixv-21430"
      unitRef="usdPershares">1.28</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c34"
      decimals="3"
      id="ixv-21431"
      unitRef="usdPershares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssued
      contextRef="c35"
      decimals="0"
      id="ixv-21432"
      unitRef="shares">3031250</us-gaap:SharesIssued>
    <us-gaap:StockOptionExercisePriceIncrease
      contextRef="c0"
      decimals="2"
      id="ixv-21433"
      unitRef="usdPershares">1.28</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:DeferredOfferingCosts contextRef="c34" decimals="-3" id="ixv-21434" unitRef="usd">3424000</us-gaap:DeferredOfferingCosts>
    <iinn:AdditionalOfferingCosts contextRef="c34" decimals="-3" id="ixv-21435" unitRef="usd">454000</iinn:AdditionalOfferingCosts>
    <iinn:AggregatePercentage contextRef="c36" decimals="3" id="ixv-21436" unitRef="pure">0.07</iinn:AggregatePercentage>
    <us-gaap:SharesIssued
      contextRef="c37"
      decimals="0"
      id="ixv-21437"
      unitRef="shares">212188</us-gaap:SharesIssued>
    <us-gaap:PaymentsOfDerivativeIssuanceCosts contextRef="c0" decimals="-3" id="ixv-21438" unitRef="usd">131000</us-gaap:PaymentsOfDerivativeIssuanceCosts>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax contextRef="c4" decimals="-5" id="ixv-21439" unitRef="usd">55500000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-15875">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 2 &lt;/b&gt;- &lt;b&gt;SIGNIFICANT ACCOUNTING POLICIES:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying Financial Statements have been
prepared in conformity with the U.S. GAAP. The significant accounting policies followed in the preparation of the Financial Statements
are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;A.
Conversion from IFRS to U.S. GAAP-&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has retroactively converted its historical
Financial Statements that were prepared in accordance with International Financial Reporting Standards (&#x201c;IFRS&#x201d;) to present
such Financial Statements in accordance with U.S. GAAP. This is the first Financial Statement presented according to U.S. GAAP.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is an Israeli company, and its business
operates in the medical technology industry in the field of respiratory support technology and intends to focus its commercial efforts
mainly in the USA. The Company&#x2019;s both long and short-term intentions are to conduct clinical trials in the U.S. with the goal to
receive FDA approval as a first and major milestone.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The significant differences between IFRS and U.S.
GAAP as they relate to these Financial Statements are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;(a) Leases&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under IFRS, prior to the adoption of U.S. GAAP,
the Company, as lessee, applied the single lease model that is similar to the accounting for a finance lease under U.S. GAAP. The expense
recognition presented a higher portion of the total expense earlier in the lease term as a combination of straight-line depreciation of
the right-of-use asset and the effective interest rate method applied to the lease liability results in a decreasing rate of interest
expense recognition throughout the lease term. In addition, the presentation of the lease expenses in the statements of comprehensive
loss is different. Under U.S. GAAP it is presented as lease expenses, while under IFRS it is presented as depreciation and interest expense.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under U.S. GAAP, there is dual classification
lease accounting model for lessees: finance leases and operating leases. The Company, as lessee, classified all its leases as operating
leases and recognizes a single lease expense, including both a right-of-use asset depreciation component and an interest expense component,
on a straight-line basis throughout the lease term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;(b) Financial Liabilities&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company issued tradable warrants to investors
in its initial public offering (the &#x201c;IPO&#x201d;) and warrants to its pre-IPO investors. Under IFRS, warrants issued by the Company
were classified as financial liabilities and measured at fair value with changes recognized in profit or loss. However, under U.S. GAAP,
those warrants are classified as equity instruments due to the change in its functional currency.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Upon transitioning to U.S. GAAP, the Company has
re-evaluated the classification of its warrants and determined that they meet the criteria for classification as equity instruments. Therefore,
the warrants have been reclassified from financial liabilities to equity in the Financial Statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;This reclassification has been applied retroactively
to all periods presented in accordance with the requirements of U.S. GAAP. Consequently, the Financial Statements for prior periods have
been adjusted to reflect the reclassification of warrants from financial liabilities to equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Following the change in determining the warrants
classification, the Company had changed its IPO expenses allocation between equity and issuance expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;(&lt;b&gt;c) Change in Functional Currency Reporting&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under IFRS, the functional currency is determined
based on the currency of the primary economic environment in which the entity operates. However, under U.S. GAAP, the functional currency
is determined based on the currency of the primary economic environment in which the entity generates and expends cash.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As a result of this change, the Company has reassessed
its functional currency and determined that it now aligns with the currency of the primary economic environment in which cash receipts
and payments occur, in accordance with U.S. GAAP requirements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;This change in functional currency reporting has
been applied retroactively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management believes that this change in functional
currency reporting better reflects the economic substance of the Company&#x2019;s operation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;(d) Government Grants &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under International Accounting Standards (&#x201c;IAS
20&#x201d;) (under IFRS), the Company capitalized government grants according to revenue forecast and recognized financial expenses over
time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;However, under U.S. GAAP, the Company will recognize
royalties only when it starts to generate revenues. This differs from IFRS, where the Company recognized capitalized liability, financial
expenses and lower grant in the research and development expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;The conversion from IFRS to U.S.
GAAP based USD as our operational currency and following other U.S. GAAP differences, resulted in change of our financial results. &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;U.S. GAAP differences as of December
31, 2022:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Note&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;IFRS&lt;br/&gt;
 (previously reported)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;U.S. GAAP&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Other current assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;2A(c)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;591&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;589&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Right of use assets, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(a)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,107&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,263&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Trade accounts payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(c)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;152&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other accounts payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(c)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,217&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,216&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(a)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;329&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Financial liabilities at fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(b)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;368&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Long term lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(a)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;728&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;873&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Loan from the Israeli Innovation Authority (&#x201c;IIA&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(g)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;398&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Foreign exchange reserve&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(c)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,928&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share capital and additional paid in capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(b)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53,814&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;57,866&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accumulated losses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(39,064&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(44,235&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Total Shareholders&#x2019; Equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,822&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,631&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;U.S. GAAP differences for the year
ended December 31, 2021:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;IFRS&lt;br/&gt;
 (previously reported)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;U.S. GAAP&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,909&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,070&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Sales and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,951&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,980&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;General and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,572&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,937&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other expenses (income)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(23&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Operating loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,432&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,964&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest income from deposit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finance expenses (income), net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,523&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,230&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Loss before tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,955&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,193&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Taxes on income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Total net loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16,955&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;17,193&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Exchange (losses) profits arising on translation to presentation currency&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(845&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total comprehensive loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16,110&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;17,193&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;U.S. GAAP differences for the year
ended December 31, 2022:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;IFRS&lt;br/&gt;
 (previously reported)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;U.S.
GAAP&lt;/b&gt;  &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8,054&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8,183&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Sales and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,325&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,328&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;General and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,391&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,375&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other expenses (income)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Operating loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,770&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,893&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest income from deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(192&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finance expenses (income), net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,497&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;275&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Loss before tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,273&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,976&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Taxes on income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total net loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,273&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,976&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Exchange (losses)profits arising on translation to presentation currency&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,138&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total comprehensive loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12,411&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,976&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;B.
Use of estimates:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The preparation of Financial Statements in conformity with U.S. GAAP
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent
assets and liabilities at the date of the Financial Statements, and the reported amounts of expenses during the reporting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;Items subject to such estimates and assumptions include:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;stock-based compensation expense;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;fair value financial liabilities;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;recognition, measurement, and disclosure of contingent liabilities;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Interest rate used for lease liability measurement.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of the date of issuance of the Financial Statements,
the Company is not aware of any material specific events or circumstances that would require it to update its estimates, judgments, or
to revise the carrying values of its assets or liabilities. These estimates may change, as new events occur and additional information
is obtained, and are recognized in the Financial Statements as soon as they become known. Actual results could differ from those estimates
and any such differences may be material to the Company&#x2019;s Financial Statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;C.
&lt;span&gt;Foreign Currency&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The currency of the primary economic environment
in which the operations of the Company are conducted is the U.S. dollar (&#x201c;USD&#x201d;). The Company&#x2019;s funding and expected
revenues are mostly in USD. Thus, the functional currency of the Company is in USD.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Transactions and balances originally denominated
in USD are presented at their original amounts. Balances in non-USD currencies are translated into USD using historical and current exchange
rates for non-monetary and monetary balances, respectively. For non-USD transactions and other items in the statements of income (indicated
below), the following exchange rates are used: (i) for transactions &#x2013; exchange rates at transaction dates or average exchange rates;
and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization) &#x2013; historical exchange
rates. Currency transaction gains and losses are presented in financial expenses (income), net as appropriate. The functional currency
of the Company is USD.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;D.
Property, Plant, and Equipment&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment are stated at cost. Depreciation
is computed based on the straight-line method, over the estimated useful life of the assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Annual rates of depreciation are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Computers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Development equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;6-15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Leasehold Improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;E.
Leases&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company implemented Accounting Standards Update
(&#x201c;ASU&#x201d;) 2016-02, Leases (Topic 842) (&#x201c;ASU 2016-02&#x201d;) using the modified retrospective approach for all lease arrangements
as of such date. The Company leases office space and vehicles under operating leases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Arrangements meeting the definition of a
lease are classified as operating or financing leases and are recorded on the balance sheet as both a right of use asset and lease
liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the
Company&#x2019;s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the
right of use asset is amortized over the lease term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The lease liability was measured at the present
value of the remaining lease payments, discounted using the Company&#x2019;s incremental borrowing rate. The weighted-average&#160;rate
applied was 9.60%. Right-of-use&#160;assets were measured at an amount equal to the lease liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For operating leases, interest on the lease liability
and the amortization of the right of use asset result in straight-line&#160;rent expense over the lease term. Variable lease expenses
are recorded when incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;F.
Research and Development Costs.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;Research and development
expenses consist primarily of payroll, payroll related expenses, subcontractors, and materials. Costs are expensed as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;G.
Government Grants&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company receives royalty-bearing grants from
the IIA for approved research and development projects. Under Israeli law, royalties on the revenues derived from products and services
developed using such grants, are payable to the Israeli Government.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Royalties payable with respect to grants received
under programs approved after January 1, 1999, are subject to interest on the dollar-linked value of the total grants received at an annual
rate of London Interbank Offered Rate (&#x201c;LIBOR&#x201d;) applicable to dollar deposits. In September 2021, the Bank of Israel, which
determines annual interest rates, published a directive which stated that annual interest at a variable rate linked to the LIBOR rate
for loans in USD will be replaced by the Secured Overnight Financing Rate, (&#x201c;SOFR&#x201d;), in January 2024. The amounts of grants
received and recorded into income should be disclosed for each period presented. The research and development grants are presented in
the statement of operations as an offset to related research and development expenses. Companies are required to pay royalties in connection
with such grants at specified rates, up to the total dollar-linked amount of such grants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;H.
Finance Income and Expenses.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Finance income is composed of interest on deposits,
while finance expenses are composed of interest on senior secured credit facility, bank charges and net currency exchange rates differences.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;I.
Current Taxes&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;The current tax liability
is measured using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments
required in connection with the tax liability in respect of previous years. The Company has no tax liability due to its carry forward
losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;J.
Share-Based Compensation.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;Share-based compensation
expenses related to employees, directors and subcontractors&#x2019; options or restricted share units, (&#x201c;RSU&#x201d;) which recognized based
on their fair value, which is based on the fair value of the underlying Ordinary Shares as to the de-minimis exercise price using the
graded vesting method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognizes compensation expense for
grants of share-based awards to its employees based on the estimated fair value on the grant date. Compensation cost for awards is recognized
over the requisite service period, which approximates the vesting period. Share-based compensation is included in research and development,
selling and marketing and general and administrative expenses. Forfeitures of equity grants are recognized as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;All issuances of stock options or other equity
instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value
of the equity instruments issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;K.
Warrants&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company issues warrants as part of its financing
activities or compensation arrangements. Warrants are derivative financial instruments that entitle the holder to purchase a specified
number of the Company&#x2019;s ordinary shares at a predetermined exercise price. Warrants issued by the Company may have various terms, including
expiration dates, exercise prices, and conditions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company classifies warrants as either equity
or liabilities upon issuance, based on specific terms and conditions and in accordance with Accounting Standard Codification (&#x201c;ASC&#x201d;)
815, Derivatives and Hedging. Warrants are classified as equity if they meet the criteria for equity classification outlined in ASC 815-40.
Otherwise, warrants are classified as liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;L.
Severance&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Israeli labor law generally requires payment of
severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The Company&#x2019;s pension
and severance pay liabilities are covered mainly by insurance policies. Pursuant to section 14 of the Israeli Severance Compensation Act,
1963 (&#x201c;Section 14&#x201d;), the Company&#x2019;s employees are entitled to monthly deposits, at a rate of 8.33% of their monthly salary,
made in their name with insurance companies. Payments in accordance with Section 14 relieve the Company from any future severance payments
in respect of those employees and, as such, the Company may only utilize the insurance policies for the purpose of paying severance pay.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;M.
Basic and Diluted Loss Per Share&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic and diluted loss per share is calculated
by dividing the loss attributable to equity holders of the Company by the weighted average number of Ordinary Shares outstanding during
the financial year, adjusted for Ordinary Shares issued during the year, if applicable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;N.
Fair Value Measurements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company measures and discloses fair value
in accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;), ASC 820, Fair Value Measurements and Disclosures (&#x201c;ASC
820&#x201d;). ASC 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value,
and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to
sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such,
fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing
an asset or liability. As a basis for considering such assumptions, there exists a three-tier fair-value hierarchy, which prioritizes
the inputs used in measuring fair value as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 1 &#x2013; unadjusted quoted prices are available
in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 2 &#x2013; pricing inputs are other than
quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration
with observable market data.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 3 &#x2013; pricing inputs are
unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the
non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant
management judgment or estimation. Level 3 inputs are considered as the lowest priority within the fair value hierarchy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; "&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;This hierarchy requires the Company to use observable
market data, when available, and to minimize the use of unobservable inputs when determining fair value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of cash is based on its demand
value, which is equal to its carrying value. Additionally, the carrying value of all other short-term monetary assets and liabilities
are estimated to be equal to their fair value due to the short-term nature of these instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;O.
Concentration of Credit Risk&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company maintains certain cash balances in
a well-known Israeli banks and U.S based banks.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s operating expenses are denominated
mainly in New Israeli Shekel (&#x201c;NIS&#x201d;), and therefore, subject to foreign currency risk.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;P.
Cash and Cash Equivalent&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash equivalents are highly liquid investments
that are readily convertible into cash, typically with an original maturity of three months or less from &lt;span&gt;the
date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;Restricted
cash consists of funds that are contractually restricted to bank guarantee due to rental agreements. The Company has presented
restricted cash separately from cash and cash equivalents in the balance sheets. &lt;/span&gt;Bank deposits with maturities of more than
three months, but less than one year, and which are not restricted are included in short-term deposits. Such deposits are stated at
cost which approximates market value. As of December 31, 2023, December 31, 2022, the Company had short-term deposits in the amounts
of $2.3 million and $7.1 million respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;Q.
Segment Information&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;The Company
has a single operating and reportable segment. The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), who is the Chief
Executive Officer, evaluates the performance of its business based on financial data consistent with the presentation in the accompanying
Financial Statements for the purposes of making operating decisions, assessing financial performance, and allocating resources.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;R.
New accounting Pronouncements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-indent: 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;span style="text-decoration:underline"&gt;Accounting
Standards Adopted in 2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;span style="text-decoration:underline"&gt;ASU 2023-03
&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;In July
2023, the FASB issued ASU 2023-03 to amend various U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) paragraphs in the
ASC to primarily reflect the issuance of SEC Staff Accounting Bulletin No. 120. ASU No. 2023-03, &#x201c;Presentation of Financial Statements
(Topic 205), Income Statement&#x2014;Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity
(Topic 505), and Compensation&#x2014;Stock Compensation (Topic 718): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin
No. 120, SEC Staff Announcement at the March 24, 2022 EITF Meeting, and Staff Accounting Bulletin Topic 6.B, Accounting Series Release
280&#x2014;General Revision of Regulation S-X: Income or Loss Applicable to Common Stock.&#x201d; ASU 2023-03 amends the ASC for SEC updates
pursuant to SEC Staff Accounting Bulletin No. 120, SEC Staff Announcement &lt;/span&gt;at the March 24, 2022, Emerging Issues Task Force (&#x201c;EITF&#x201d;)
Meeting; and Staff Accounting Bulletin Topic 6.B, Accounting Series Release 280 - General Revision of Regulation S-X: Income or Loss
Applicable to Common Stock. These updates were immediately effective and did not have a material impact on our financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;In June
2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820), &#x201c;Fair Value Measurement of Equity Securities Subject to Contractual
Sale Restrictions&#x201d; which clarifies that contractual restrictions on equity security sales are not considered part of the security
unit of account and, therefore, are not considered in measuring fair value. In addition, the restrictions cannot be recognized and measured
as separate units of account. Disclosures on such restrictions are also required. The amendments are effective for Fiscal years beginning
after December 15, 2023, and interim periods within those fiscal years on a prospectively basis. The Company expects that ASU 2022-03
will not have a material impact on its Financial Statements and related disclosures. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;Accounting
Pronouncements Issued but Not Yet Adopted&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;In November
2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU expands public
entities&#x2019; segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the CODM and
included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items,
and interim disclosures of a reportable segment&#x2019;s profit or loss and assets. All disclosure requirements under ASU 2023-07 are also
required for public entities with a single reportable segment. The ASU&#x2019;s amendments are effective for all public entities for fiscal
years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption
permitted. We are currently evaluating the impact of this pronouncement on our Financial Statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;In December
2023, the FASB issued ASU 2023-08, Intangibles&#x2014;Goodwill and Other&#x2014;Crypto Assets (Subtopic 350-60): Accounting for and Disclosure
of Crypto Assets, which addresses the accounting and disclosure requirements for certain crypto assets. This ASU requires entities to
subsequently measure certain crypto assets at fair value, with changes in fair value recorded in net income in each reporting period.
In addition, entities are required to provide additional disclosures about the holdings of certain crypto assets. The ASU&#x2019;s amendments
are effective for all entities holding assets that meet certain scope criteria for fiscal years beginning after December 15, 2024, including
interim periods within those years. Early adoption is permitted for both interim and annual periods. If an entity adopts the amendments
in an interim period, it must adopt them as of the beginning of the fiscal year that includes that interim period. We do not expect this
pronouncement to have a material impact on our Financial Statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;In December
2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. Under this ASU, public entities must
annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that
meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than five percent of the amount computed
by multiplying pretax income or loss by the applicable statutory income tax rate). This ASU&#x2019;s amendments are effective for all entities
that are subject to Topic 740, Income Taxes, for annual periods beginning after December 15, 2024, with early adoption permitted. We are
currently evaluating the impact of this pronouncement on our disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <iinn:ConversionFromIFRSToUSGAAPPolicyTextBlock contextRef="c0" id="ixv-15882">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;A.
Conversion from IFRS to U.S. GAAP-&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has retroactively converted its historical
Financial Statements that were prepared in accordance with International Financial Reporting Standards (&#x201c;IFRS&#x201d;) to present
such Financial Statements in accordance with U.S. GAAP. This is the first Financial Statement presented according to U.S. GAAP.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is an Israeli company, and its business
operates in the medical technology industry in the field of respiratory support technology and intends to focus its commercial efforts
mainly in the USA. The Company&#x2019;s both long and short-term intentions are to conduct clinical trials in the U.S. with the goal to
receive FDA approval as a first and major milestone.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The significant differences between IFRS and U.S.
GAAP as they relate to these Financial Statements are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;(a) Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under IFRS, prior to the adoption of U.S. GAAP,
the Company, as lessee, applied the single lease model that is similar to the accounting for a finance lease under U.S. GAAP. The expense
recognition presented a higher portion of the total expense earlier in the lease term as a combination of straight-line depreciation of
the right-of-use asset and the effective interest rate method applied to the lease liability results in a decreasing rate of interest
expense recognition throughout the lease term. In addition, the presentation of the lease expenses in the statements of comprehensive
loss is different. Under U.S. GAAP it is presented as lease expenses, while under IFRS it is presented as depreciation and interest expense.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under U.S. GAAP, there is dual classification
lease accounting model for lessees: finance leases and operating leases. The Company, as lessee, classified all its leases as operating
leases and recognizes a single lease expense, including both a right-of-use asset depreciation component and an interest expense component,
on a straight-line basis throughout the lease term.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;(b) Financial Liabilities&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company issued tradable warrants to investors
in its initial public offering (the &#x201c;IPO&#x201d;) and warrants to its pre-IPO investors. Under IFRS, warrants issued by the Company
were classified as financial liabilities and measured at fair value with changes recognized in profit or loss. However, under U.S. GAAP,
those warrants are classified as equity instruments due to the change in its functional currency.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Upon transitioning to U.S. GAAP, the Company has
re-evaluated the classification of its warrants and determined that they meet the criteria for classification as equity instruments. Therefore,
the warrants have been reclassified from financial liabilities to equity in the Financial Statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;This reclassification has been applied retroactively
to all periods presented in accordance with the requirements of U.S. GAAP. Consequently, the Financial Statements for prior periods have
been adjusted to reflect the reclassification of warrants from financial liabilities to equity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Following the change in determining the warrants
classification, the Company had changed its IPO expenses allocation between equity and issuance expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;(&lt;b&gt;c) Change in Functional Currency Reporting&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under IFRS, the functional currency is determined
based on the currency of the primary economic environment in which the entity operates. However, under U.S. GAAP, the functional currency
is determined based on the currency of the primary economic environment in which the entity generates and expends cash.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As a result of this change, the Company has reassessed
its functional currency and determined that it now aligns with the currency of the primary economic environment in which cash receipts
and payments occur, in accordance with U.S. GAAP requirements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;This change in functional currency reporting has
been applied retroactively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management believes that this change in functional
currency reporting better reflects the economic substance of the Company&#x2019;s operation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;(d) Government Grants &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under International Accounting Standards (&#x201c;IAS
20&#x201d;) (under IFRS), the Company capitalized government grants according to revenue forecast and recognized financial expenses over
time.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;However, under U.S. GAAP, the Company will recognize
royalties only when it starts to generate revenues. This differs from IFRS, where the Company recognized capitalized liability, financial
expenses and lower grant in the research and development expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;The conversion from IFRS to U.S.
GAAP based USD as our operational currency and following other U.S. GAAP differences, resulted in change of our financial results. &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;U.S. GAAP differences as of December
31, 2022:&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Note&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;IFRS&lt;br/&gt;
 (previously reported)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;U.S. GAAP&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Other current assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;2A(c)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;591&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;589&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Right of use assets, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(a)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,107&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,263&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Trade accounts payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(c)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;152&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other accounts payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(c)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,217&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,216&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(a)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;329&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Financial liabilities at fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(b)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;368&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Long term lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(a)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;728&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;873&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Loan from the Israeli Innovation Authority (&#x201c;IIA&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(g)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;398&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Foreign exchange reserve&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(c)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,928&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share capital and additional paid in capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(b)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53,814&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;57,866&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accumulated losses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(39,064&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(44,235&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Total Shareholders&#x2019; Equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,822&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,631&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;U.S. GAAP differences for the year
ended December 31, 2021:&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;IFRS&lt;br/&gt;
 (previously reported)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;U.S. GAAP&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,909&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,070&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Sales and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,951&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,980&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;General and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,572&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,937&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other expenses (income)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(23&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Operating loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,432&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,964&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest income from deposit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finance expenses (income), net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,523&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,230&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Loss before tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,955&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,193&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Taxes on income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Total net loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16,955&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;17,193&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Exchange (losses) profits arising on translation to presentation currency&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(845&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total comprehensive loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16,110&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;17,193&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;U.S. GAAP differences for the year
ended December 31, 2022:&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;IFRS&lt;br/&gt;
 (previously reported)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;U.S.
GAAP&lt;/b&gt;  &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8,054&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8,183&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Sales and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,325&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,328&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;General and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,391&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,375&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other expenses (income)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Operating loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,770&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,893&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest income from deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(192&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finance expenses (income), net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,497&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;275&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Loss before tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,273&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,976&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Taxes on income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total net loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,273&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,976&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Exchange (losses)profits arising on translation to presentation currency&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,138&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total comprehensive loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12,411&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,976&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;</iinn:ConversionFromIFRSToUSGAAPPolicyTextBlock>
    <srt:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="c0" id="ixv-16017">&lt;b&gt;U.S. GAAP differences as of December
31, 2022:&lt;/b&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Note&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;IFRS&lt;br/&gt;
 (previously reported)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;U.S. GAAP&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Other current assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;2A(c)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;591&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;589&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Right of use assets, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(a)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,107&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,263&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Trade accounts payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(c)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;152&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other accounts payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(c)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,217&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,216&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(a)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;329&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Financial liabilities at fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(b)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;368&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Long term lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(a)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;728&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;873&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Loan from the Israeli Innovation Authority (&#x201c;IIA&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(g)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;398&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Foreign exchange reserve&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(c)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,928&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share capital and additional paid in capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A(b)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53,814&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;57,866&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accumulated losses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(39,064&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(44,235&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Total Shareholders&#x2019; Equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2A&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,822&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,631&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <us-gaap:OtherAssetsCurrent contextRef="c38" decimals="-3" id="ixv-21440" unitRef="usd">591000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c5" decimals="-3" id="ixv-21441" unitRef="usd">589000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c38" decimals="-3" id="ixv-21442" unitRef="usd">1107000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c5" decimals="-3" id="ixv-21443" unitRef="usd">1263000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c38" decimals="-3" id="ixv-21444" unitRef="usd">150000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c5" decimals="-3" id="ixv-21445" unitRef="usd">152000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c38" decimals="-3" id="ixv-21446" unitRef="usd">1217000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c5" decimals="-3" id="ixv-21447" unitRef="usd">1216000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c38" decimals="-3" id="ixv-21448" unitRef="usd">329000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c5" decimals="-3" id="ixv-21449" unitRef="usd">268000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c38" decimals="-3" id="ixv-21450" unitRef="usd">368000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-21451" unitRef="usd">26000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c38" decimals="-3" id="ixv-21452" unitRef="usd">728000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c5" decimals="-3" id="ixv-21453" unitRef="usd">873000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherShortTermBorrowings contextRef="c38" decimals="-3" id="ixv-21454" unitRef="usd">398000</us-gaap:OtherShortTermBorrowings>
    <iinn:ForeignExchangeReserve contextRef="c38" decimals="-3" id="ixv-21455" unitRef="usd">-1928000</iinn:ForeignExchangeReserve>
    <us-gaap:AdditionalPaidInCapital contextRef="c38" decimals="-3" id="ixv-21456" unitRef="usd">53814000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c5" decimals="-3" id="ixv-21457" unitRef="usd">57866000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c38" decimals="-3" id="ixv-21458" unitRef="usd">-39064000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c5" decimals="-3" id="ixv-21459" unitRef="usd">-44235000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c38" decimals="-3" id="ixv-21460" unitRef="usd">12822000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="-3" id="ixv-21461" unitRef="usd">13631000</us-gaap:StockholdersEquity>
    <srt:CondensedStatementOfComprehensiveIncomeTableTextBlock contextRef="c0" id="ixv-16221">&lt;b&gt;U.S. GAAP differences for the year
ended December 31, 2021:&lt;/b&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;IFRS&lt;br/&gt;
 (previously reported)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;U.S. GAAP&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,909&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,070&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Sales and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,951&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,980&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;General and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,572&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,937&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other expenses (income)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(23&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Operating loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,432&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,964&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest income from deposit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finance expenses (income), net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,523&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,230&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Loss before tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,955&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,193&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Taxes on income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Total net loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16,955&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;17,193&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Exchange (losses) profits arising on translation to presentation currency&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(845&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total comprehensive loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16,110&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;17,193&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;b&gt;U.S. GAAP differences for the year
ended December 31, 2022:&lt;/b&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;IFRS&lt;br/&gt;
 (previously reported)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;U.S.
GAAP&lt;/b&gt;  &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8,054&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8,183&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Sales and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,325&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,328&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;General and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,391&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,375&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other expenses (income)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Operating loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,770&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,893&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest income from deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(192&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finance expenses (income), net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,497&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;275&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Loss before tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,273&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,976&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Taxes on income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total net loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,273&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,976&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Exchange (losses)profits arising on translation to presentation currency&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,138&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total comprehensive loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12,411&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,976&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;</srt:CondensedStatementOfComprehensiveIncomeTableTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c39" decimals="-3" id="ixv-21462" unitRef="usd">3909000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c7" decimals="-3" id="ixv-21463" unitRef="usd">4070000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c39" decimals="-3" id="ixv-21464" unitRef="usd">1951000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c7" decimals="-3" id="ixv-21465" unitRef="usd">1980000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c39" decimals="-3" id="ixv-21466" unitRef="usd">7572000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c7" decimals="-3" id="ixv-21467" unitRef="usd">6937000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c7" decimals="-3" id="ixv-21468" unitRef="usd">23000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OperatingIncomeLoss contextRef="c39" decimals="-3" id="ixv-21469" unitRef="usd">-13432000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c7" decimals="-3" id="ixv-21470" unitRef="usd">-12964000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions contextRef="c7" decimals="-3" id="ixv-21471" unitRef="usd">1000</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c39" decimals="-3" id="ixv-21472" unitRef="usd">-3523000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c7" decimals="-3" id="ixv-21473" unitRef="usd">-4230000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c39" decimals="-3" id="ixv-21474" unitRef="usd">-16955000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c7" decimals="-3" id="ixv-21475" unitRef="usd">-17193000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c39" decimals="-3" id="ixv-21476" unitRef="usd">-16955000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c7" decimals="-3" id="ixv-21477" unitRef="usd">-17193000</us-gaap:ProfitLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c39" decimals="-3" id="ixv-21478" unitRef="usd">845000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c39" decimals="-3" id="ixv-21479" unitRef="usd">-16110000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c7" decimals="-3" id="ixv-21480" unitRef="usd">-17193000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c40" decimals="-3" id="ixv-21481" unitRef="usd">8054000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c6" decimals="-3" id="ixv-21482" unitRef="usd">8183000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c40" decimals="-3" id="ixv-21483" unitRef="usd">1325000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c6" decimals="-3" id="ixv-21484" unitRef="usd">1328000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c40" decimals="-3" id="ixv-21485" unitRef="usd">5391000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c6" decimals="-3" id="ixv-21486" unitRef="usd">5375000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c6" decimals="-3" id="ixv-21487" unitRef="usd">-7000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OperatingIncomeLoss contextRef="c40" decimals="-3" id="ixv-21488" unitRef="usd">-14770000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c6" decimals="-3" id="ixv-21489" unitRef="usd">-14893000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions contextRef="c6" decimals="-3" id="ixv-21490" unitRef="usd">192000</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c40" decimals="-3" id="ixv-21491" unitRef="usd">4497000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c6" decimals="-3" id="ixv-21492" unitRef="usd">-275000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c40" decimals="-3" id="ixv-21493" unitRef="usd">-10273000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c6" decimals="-3" id="ixv-21494" unitRef="usd">-14976000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c40" decimals="-3" id="ixv-21495" unitRef="usd">-10273000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c6" decimals="-3" id="ixv-21496" unitRef="usd">-14976000</us-gaap:ProfitLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c40" decimals="-3" id="ixv-21497" unitRef="usd">-2138000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c40" decimals="-3" id="ixv-21498" unitRef="usd">-12411000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c6" decimals="-3" id="ixv-21499" unitRef="usd">-14976000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-16621">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;B.
Use of estimates:&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The preparation of Financial Statements in conformity with U.S. GAAP
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent
assets and liabilities at the date of the Financial Statements, and the reported amounts of expenses during the reporting period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"&gt;Items subject to such estimates and assumptions include:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;stock-based compensation expense;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;fair value financial liabilities;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;recognition, measurement, and disclosure of contingent liabilities;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Interest rate used for lease liability measurement.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of the date of issuance of the Financial Statements,
the Company is not aware of any material specific events or circumstances that would require it to update its estimates, judgments, or
to revise the carrying values of its assets or liabilities. These estimates may change, as new events occur and additional information
is obtained, and are recognized in the Financial Statements as soon as they become known. Actual results could differ from those estimates
and any such differences may be material to the Company&#x2019;s Financial Statements.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0" id="ixv-16662">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;C.
&lt;span&gt;Foreign Currency&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The currency of the primary economic environment
in which the operations of the Company are conducted is the U.S. dollar (&#x201c;USD&#x201d;). The Company&#x2019;s funding and expected
revenues are mostly in USD. Thus, the functional currency of the Company is in USD.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Transactions and balances originally denominated
in USD are presented at their original amounts. Balances in non-USD currencies are translated into USD using historical and current exchange
rates for non-monetary and monetary balances, respectively. For non-USD transactions and other items in the statements of income (indicated
below), the following exchange rates are used: (i) for transactions &#x2013; exchange rates at transaction dates or average exchange rates;
and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization) &#x2013; historical exchange
rates. Currency transaction gains and losses are presented in financial expenses (income), net as appropriate. The functional currency
of the Company is USD.&#160;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0" id="ixv-16675">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;D.
Property, Plant, and Equipment&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment are stated at cost. Depreciation
is computed based on the straight-line method, over the estimated useful life of the assets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Annual rates of depreciation are as follows:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Computers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Development equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;6-15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Leasehold Improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <iinn:ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock contextRef="c0" id="ixv-21500">Annual rates of depreciation are as follows:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Computers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Development equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;6-15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Leasehold Improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;</iinn:ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock>
    <iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment contextRef="c41" decimals="2" id="ixv-21501" unitRef="pure">0.33</iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment>
    <iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment contextRef="c42" decimals="2" id="ixv-21502" unitRef="pure">0.20</iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment>
    <iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment contextRef="c43" decimals="2" id="ixv-21503" unitRef="pure">0.06</iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment>
    <iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment contextRef="c44" decimals="2" id="ixv-21504" unitRef="pure">0.15</iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment>
    <iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment contextRef="c45" decimals="2" id="ixv-21505" unitRef="pure">0.10</iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-16755">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;E.
Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company implemented Accounting Standards Update
(&#x201c;ASU&#x201d;) 2016-02, Leases (Topic 842) (&#x201c;ASU 2016-02&#x201d;) using the modified retrospective approach for all lease arrangements
as of such date. The Company leases office space and vehicles under operating leases.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Arrangements meeting the definition of a
lease are classified as operating or financing leases and are recorded on the balance sheet as both a right of use asset and lease
liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the
Company&#x2019;s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the
right of use asset is amortized over the lease term.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The lease liability was measured at the present
value of the remaining lease payments, discounted using the Company&#x2019;s incremental borrowing rate. The weighted-average&#160;rate
applied was 9.60%. Right-of-use&#160;assets were measured at an amount equal to the lease liability.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For operating leases, interest on the lease liability
and the amortization of the right of use asset result in straight-line&#160;rent expense over the lease term. Variable lease expenses
are recorded when incurred.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c4" decimals="4" id="ixv-21506" unitRef="pure">0.096</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0" id="ixv-16771">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;F.
Research and Development Costs.&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;Research and development
expenses consist primarily of payroll, payroll related expenses, subcontractors, and materials. Costs are expensed as incurred.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:GovernmentAssistancePolicyTextBlock contextRef="c0" id="ixv-16778">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;G.
Government Grants&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company receives royalty-bearing grants from
the IIA for approved research and development projects. Under Israeli law, royalties on the revenues derived from products and services
developed using such grants, are payable to the Israeli Government.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Royalties payable with respect to grants received
under programs approved after January 1, 1999, are subject to interest on the dollar-linked value of the total grants received at an annual
rate of London Interbank Offered Rate (&#x201c;LIBOR&#x201d;) applicable to dollar deposits. In September 2021, the Bank of Israel, which
determines annual interest rates, published a directive which stated that annual interest at a variable rate linked to the LIBOR rate
for loans in USD will be replaced by the Secured Overnight Financing Rate, (&#x201c;SOFR&#x201d;), in January 2024. The amounts of grants
received and recorded into income should be disclosed for each period presented. The research and development grants are presented in
the statement of operations as an offset to related research and development expenses. Companies are required to pay royalties in connection
with such grants at specified rates, up to the total dollar-linked amount of such grants.&lt;/p&gt;</us-gaap:GovernmentAssistancePolicyTextBlock>
    <iinn:FinanceIncomeAndExpensesPolicyTextBlock contextRef="c0" id="ixv-16788">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;H.
Finance Income and Expenses.&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Finance income is composed of interest on deposits,
while finance expenses are composed of interest on senior secured credit facility, bank charges and net currency exchange rates differences.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</iinn:FinanceIncomeAndExpensesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0" id="ixv-16826">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;I.
Current Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;The current tax liability
is measured using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments
required in connection with the tax liability in respect of previous years. The Company has no tax liability due to its carry forward
losses.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0" id="ixv-16834">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;J.
Share-Based Compensation.&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;Share-based compensation
expenses related to employees, directors and subcontractors&#x2019; options or restricted share units, (&#x201c;RSU&#x201d;) which recognized based
on their fair value, which is based on the fair value of the underlying Ordinary Shares as to the de-minimis exercise price using the
graded vesting method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognizes compensation expense for
grants of share-based awards to its employees based on the estimated fair value on the grant date. Compensation cost for awards is recognized
over the requisite service period, which approximates the vesting period. Share-based compensation is included in research and development,
selling and marketing and general and administrative expenses. Forfeitures of equity grants are recognized as incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;All issuances of stock options or other equity
instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value
of the equity instruments issued.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:DerivativesPolicyTextBlock contextRef="c0" id="ixv-16847">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;K.
Warrants&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company issues warrants as part of its financing
activities or compensation arrangements. Warrants are derivative financial instruments that entitle the holder to purchase a specified
number of the Company&#x2019;s ordinary shares at a predetermined exercise price. Warrants issued by the Company may have various terms, including
expiration dates, exercise prices, and conditions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company classifies warrants as either equity
or liabilities upon issuance, based on specific terms and conditions and in accordance with Accounting Standard Codification (&#x201c;ASC&#x201d;)
815, Derivatives and Hedging. Warrants are classified as equity if they meet the criteria for equity classification outlined in ASC 815-40.
Otherwise, warrants are classified as liabilities.&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <iinn:SeverancePolicyTextBlock contextRef="c0" id="ixv-16857">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;L.
Severance&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Israeli labor law generally requires payment of
severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The Company&#x2019;s pension
and severance pay liabilities are covered mainly by insurance policies. Pursuant to section 14 of the Israeli Severance Compensation Act,
1963 (&#x201c;Section 14&#x201d;), the Company&#x2019;s employees are entitled to monthly deposits, at a rate of 8.33% of their monthly salary,
made in their name with insurance companies. Payments in accordance with Section 14 relieve the Company from any future severance payments
in respect of those employees and, as such, the Company may only utilize the insurance policies for the purpose of paying severance pay.&lt;/p&gt;</iinn:SeverancePolicyTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent contextRef="c0" decimals="4" id="ixv-21507" unitRef="pure">0.0833</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-16864">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;M.
Basic and Diluted Loss Per Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic and diluted loss per share is calculated
by dividing the loss attributable to equity holders of the Company by the weighted average number of Ordinary Shares outstanding during
the financial year, adjusted for Ordinary Shares issued during the year, if applicable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0" id="ixv-16902">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;N.
Fair Value Measurements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company measures and discloses fair value
in accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;), ASC 820, Fair Value Measurements and Disclosures (&#x201c;ASC
820&#x201d;). ASC 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value,
and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to
sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such,
fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing
an asset or liability. As a basis for considering such assumptions, there exists a three-tier fair-value hierarchy, which prioritizes
the inputs used in measuring fair value as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 1 &#x2013; unadjusted quoted prices are available
in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 2 &#x2013; pricing inputs are other than
quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration
with observable market data.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 3 &#x2013; pricing inputs are
unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the
non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant
management judgment or estimation. Level 3 inputs are considered as the lowest priority within the fair value hierarchy.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;This hierarchy requires the Company to use observable
market data, when available, and to minimize the use of unobservable inputs when determining fair value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of cash is based on its demand
value, which is equal to its carrying value. Additionally, the carrying value of all other short-term monetary assets and liabilities
are estimated to be equal to their fair value due to the short-term nature of these instruments.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0" id="ixv-16927">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;O.
Concentration of Credit Risk&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company maintains certain cash balances in
a well-known Israeli banks and U.S based banks.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s operating expenses are denominated
mainly in New Israeli Shekel (&#x201c;NIS&#x201d;), and therefore, subject to foreign currency risk.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0" id="ixv-16937">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;P.
Cash and Cash Equivalent&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash equivalents are highly liquid investments
that are readily convertible into cash, typically with an original maturity of three months or less from &lt;span&gt;the
date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;Restricted
cash consists of funds that are contractually restricted to bank guarantee due to rental agreements. The Company has presented
restricted cash separately from cash and cash equivalents in the balance sheets. &lt;/span&gt;Bank deposits with maturities of more than
three months, but less than one year, and which are not restricted are included in short-term deposits. Such deposits are stated at
cost which approximates market value. As of December 31, 2023, December 31, 2022, the Company had short-term deposits in the amounts
of $2.3 million and $7.1 million respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ShortTermInvestments contextRef="c4" decimals="-5" id="ixv-21508" unitRef="usd">2300000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c5" decimals="-5" id="ixv-21509" unitRef="usd">7100000</us-gaap:ShortTermInvestments>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0" id="ixv-16980">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;Q.
Segment Information&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;The Company
has a single operating and reportable segment. The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), who is the Chief
Executive Officer, evaluates the performance of its business based on financial data consistent with the presentation in the accompanying
Financial Statements for the purposes of making operating decisions, assessing financial performance, and allocating resources.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-16988">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;b&gt;R.
New accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;span style="text-decoration:underline"&gt;Accounting
Standards Adopted in 2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;span style="text-decoration:underline"&gt;ASU 2023-03
&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;In July
2023, the FASB issued ASU 2023-03 to amend various U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) paragraphs in the
ASC to primarily reflect the issuance of SEC Staff Accounting Bulletin No. 120. ASU No. 2023-03, &#x201c;Presentation of Financial Statements
(Topic 205), Income Statement&#x2014;Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity
(Topic 505), and Compensation&#x2014;Stock Compensation (Topic 718): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin
No. 120, SEC Staff Announcement at the March 24, 2022 EITF Meeting, and Staff Accounting Bulletin Topic 6.B, Accounting Series Release
280&#x2014;General Revision of Regulation S-X: Income or Loss Applicable to Common Stock.&#x201d; ASU 2023-03 amends the ASC for SEC updates
pursuant to SEC Staff Accounting Bulletin No. 120, SEC Staff Announcement &lt;/span&gt;at the March 24, 2022, Emerging Issues Task Force (&#x201c;EITF&#x201d;)
Meeting; and Staff Accounting Bulletin Topic 6.B, Accounting Series Release 280 - General Revision of Regulation S-X: Income or Loss
Applicable to Common Stock. These updates were immediately effective and did not have a material impact on our financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;In June
2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820), &#x201c;Fair Value Measurement of Equity Securities Subject to Contractual
Sale Restrictions&#x201d; which clarifies that contractual restrictions on equity security sales are not considered part of the security
unit of account and, therefore, are not considered in measuring fair value. In addition, the restrictions cannot be recognized and measured
as separate units of account. Disclosures on such restrictions are also required. The amendments are effective for Fiscal years beginning
after December 15, 2023, and interim periods within those fiscal years on a prospectively basis. The Company expects that ASU 2022-03
will not have a material impact on its Financial Statements and related disclosures. &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&lt;b&gt;&lt;i&gt;Accounting
Pronouncements Issued but Not Yet Adopted&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;In November
2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU expands public
entities&#x2019; segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the CODM and
included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items,
and interim disclosures of a reportable segment&#x2019;s profit or loss and assets. All disclosure requirements under ASU 2023-07 are also
required for public entities with a single reportable segment. The ASU&#x2019;s amendments are effective for all public entities for fiscal
years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption
permitted. We are currently evaluating the impact of this pronouncement on our Financial Statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;In December
2023, the FASB issued ASU 2023-08, Intangibles&#x2014;Goodwill and Other&#x2014;Crypto Assets (Subtopic 350-60): Accounting for and Disclosure
of Crypto Assets, which addresses the accounting and disclosure requirements for certain crypto assets. This ASU requires entities to
subsequently measure certain crypto assets at fair value, with changes in fair value recorded in net income in each reporting period.
In addition, entities are required to provide additional disclosures about the holdings of certain crypto assets. The ASU&#x2019;s amendments
are effective for all entities holding assets that meet certain scope criteria for fiscal years beginning after December 15, 2024, including
interim periods within those years. Early adoption is permitted for both interim and annual periods. If an entity adopts the amendments
in an interim period, it must adopt them as of the beginning of the fiscal year that includes that interim period. We do not expect this
pronouncement to have a material impact on our Financial Statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;In December
2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. Under this ASU, public entities must
annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that
meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than five percent of the amount computed
by multiplying pretax income or loss by the applicable statutory income tax rate). This ASU&#x2019;s amendments are effective for all entities
that are subject to Topic 740, Income Taxes, for annual periods beginning after December 15, 2024, with early adoption permitted. We are
currently evaluating the impact of this pronouncement on our disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DepositLiabilitiesDisclosuresTextBlock contextRef="c0" id="ixv-17070">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;NOTE 3 &#x2013; DEPOSITS:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; "&gt;The Company&#x2019;s deposits consist of three short-term
bank deposits with maturities of more than three months but less than one year. The deposits are in dollars and bear annual interest.
&lt;span&gt;Interest earned is recorded as finance income, net in the statement of operations during the years
for which the Company held short-term deposits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2023, the Company had a
deposit in USD at Leumi Bank (Israel) in amount of $2,040, including interest that bore fixed annual interest of&#160;6.18% and a
deposit in NIS in amount of $280 that bore fixed annual interest of&#160;4.85%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2022, the Company had deposits
in total amount of $7,120.&lt;/p&gt;</us-gaap:DepositLiabilitiesDisclosuresTextBlock>
    <us-gaap:Deposits contextRef="c46" decimals="-3" id="ixv-21510" unitRef="usd">2040000</us-gaap:Deposits>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate contextRef="c4" decimals="4" id="ixv-21511" unitRef="pure">0.0618</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:Deposits contextRef="c4" decimals="-3" id="ixv-21512" unitRef="usd">280000</us-gaap:Deposits>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate contextRef="c47" decimals="4" id="ixv-21513" unitRef="pure">0.0485</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:Deposits contextRef="c5" decimals="-3" id="ixv-21514" unitRef="usd">7120000</us-gaap:Deposits>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c0" id="ixv-17083">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;NOTE 4 - OTHER CURRENT ASSETS:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;176&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;254&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Institutions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;164&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;276&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Restricted Cash&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;432&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;589&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="c0" id="ixv-17088">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;176&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;254&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Institutions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;164&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;276&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Restricted Cash&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;432&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;589&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent contextRef="c4" decimals="-3" id="ixv-21515" unitRef="usd">176000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c5" decimals="-3" id="ixv-21516" unitRef="usd">254000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:InterestBearingDepositsInBanks contextRef="c4" decimals="-3" id="ixv-21517" unitRef="usd">164000</us-gaap:InterestBearingDepositsInBanks>
    <us-gaap:InterestBearingDepositsInBanks contextRef="c5" decimals="-3" id="ixv-21518" unitRef="usd">276000</us-gaap:InterestBearingDepositsInBanks>
    <us-gaap:RestrictedCashCurrent contextRef="c4" decimals="-3" id="ixv-21519" unitRef="usd">89000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c5" decimals="-3" id="ixv-21520" unitRef="usd">56000</us-gaap:RestrictedCashCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c4" decimals="-3" id="ixv-21521" unitRef="usd">3000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c5" decimals="-3" id="ixv-21522" unitRef="usd">3000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c4" decimals="-3" id="ixv-21523" unitRef="usd">432000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c5" decimals="-3" id="ixv-21524" unitRef="usd">589000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0" id="ixv-17183">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 5 - PROPERTY AND EQUIPMENT, NET:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;For the year ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Computers&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Leasehold&lt;br/&gt; improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Development&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Furniture&lt;br/&gt; and office&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; font-weight: bold"&gt;At January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;121&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;229&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;116&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;499&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;152&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;206&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold"&gt;At December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;172&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;381&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;116&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"&gt;Accumulated depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"&gt;At January 1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;111&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold"&gt;At December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;199&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"&gt;Net book value:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; padding-bottom: 4pt"&gt;As of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;70&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;308&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;506&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Less than thousand dollars&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;For the year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Computers&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Leasehold&lt;br/&gt; improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Development&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Furniture&lt;br/&gt; and office&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; font-weight: bold"&gt;At January 1, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;84&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;64&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;81&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;236&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;263&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold"&gt;At December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;121&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;229&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;116&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;499&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"&gt;Accumulated depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"&gt;At January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold"&gt;At December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"&gt;Net book value:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; padding-bottom: 4pt"&gt;As of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;70&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;29&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;204&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;108&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;411&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Less than thousand dollars&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-17188">&lt;span style="text-decoration:underline"&gt;For the year ended December 31, 2023:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Computers&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Leasehold&lt;br/&gt; improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Development&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Furniture&lt;br/&gt; and office&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; font-weight: bold"&gt;At January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;121&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;229&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;116&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;499&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;152&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;206&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold"&gt;At December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;172&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;381&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;116&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"&gt;Accumulated depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"&gt;At January 1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;111&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold"&gt;At December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;199&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"&gt;Net book value:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; padding-bottom: 4pt"&gt;As of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;70&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;308&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;506&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Less than thousand dollars&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;span style="text-decoration:underline"&gt;For the year ended December 31, 2022:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Computers&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Leasehold&lt;br/&gt; improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Development&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Furniture&lt;br/&gt; and office&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; font-weight: bold"&gt;At January 1, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;84&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;64&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;81&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;236&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;263&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold"&gt;At December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;121&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;229&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;116&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;499&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"&gt;Accumulated depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"&gt;At January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; font-weight: bold"&gt;At December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"&gt;Net book value:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; padding-bottom: 4pt"&gt;As of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;70&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;29&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;204&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;108&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;411&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Less than thousand dollars&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c48" decimals="-3" id="ixv-21525" unitRef="usd">121000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c49" decimals="-3" id="ixv-21526" unitRef="usd">33000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c50" decimals="-3" id="ixv-21527" unitRef="usd">229000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c51" decimals="-3" id="ixv-21528" unitRef="usd">116000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c5" decimals="-3" id="ixv-21529" unitRef="usd">499000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c41" decimals="-3" id="ixv-21530" unitRef="usd">51000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c45" decimals="-3" id="ixv-21531" unitRef="usd">3000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c42" decimals="-3" id="ixv-21532" unitRef="usd">152000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c0" decimals="-3" id="ixv-21533" unitRef="usd">206000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c53" decimals="-3" id="ixv-21534" unitRef="usd">172000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c54" decimals="-3" id="ixv-21535" unitRef="usd">36000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c55" decimals="-3" id="ixv-21536" unitRef="usd">381000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c56" decimals="-3" id="ixv-21537" unitRef="usd">116000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c4" decimals="-3" id="ixv-21538" unitRef="usd">705000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c48" decimals="-3" id="ixv-21539" unitRef="usd">51000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c49" decimals="-3" id="ixv-21540" unitRef="usd">4000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c50" decimals="-3" id="ixv-21541" unitRef="usd">25000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c51" decimals="-3" id="ixv-21542" unitRef="usd">8000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c5" decimals="-3" id="ixv-21543" unitRef="usd">88000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation contextRef="c41" decimals="-3" id="ixv-21544" unitRef="usd">51000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c45" decimals="-3" id="ixv-21545" unitRef="usd">4000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c42" decimals="-3" id="ixv-21546" unitRef="usd">48000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c52" decimals="-3" id="ixv-21547" unitRef="usd">8000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c0" decimals="-3" id="ixv-21548" unitRef="usd">111000</us-gaap:Depreciation>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c53" decimals="-3" id="ixv-21549" unitRef="usd">102000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c54" decimals="-3" id="ixv-21550" unitRef="usd">8000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c55" decimals="-3" id="ixv-21551" unitRef="usd">73000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c56" decimals="-3" id="ixv-21552" unitRef="usd">16000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c4" decimals="-3" id="ixv-21553" unitRef="usd">199000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c53" decimals="-3" id="ixv-21554" unitRef="usd">70000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c54" decimals="-3" id="ixv-21555" unitRef="usd">28000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c55" decimals="-3" id="ixv-21556" unitRef="usd">308000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c56" decimals="-3" id="ixv-21557" unitRef="usd">100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="-3" id="ixv-21558" unitRef="usd">506000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c57" decimals="-3" id="ixv-21559" unitRef="usd">84000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c58" decimals="-3" id="ixv-21560" unitRef="usd">7000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c59" decimals="-3" id="ixv-21561" unitRef="usd">64000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c60" decimals="-3" id="ixv-21562" unitRef="usd">81000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20" decimals="-3" id="ixv-21563" unitRef="usd">236000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c61" decimals="-3" id="ixv-21564" unitRef="usd">37000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c62" decimals="-3" id="ixv-21565" unitRef="usd">26000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c63" decimals="-3" id="ixv-21566" unitRef="usd">165000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c64" decimals="-3" id="ixv-21567" unitRef="usd">35000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c6" decimals="-3" id="ixv-21568" unitRef="usd">263000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c48" decimals="-3" id="ixv-21569" unitRef="usd">121000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c49" decimals="-3" id="ixv-21570" unitRef="usd">33000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c50" decimals="-3" id="ixv-21571" unitRef="usd">229000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c51" decimals="-3" id="ixv-21572" unitRef="usd">116000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c5" decimals="-3" id="ixv-21573" unitRef="usd">499000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c57" decimals="-3" id="ixv-21574" unitRef="usd">22000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c58" decimals="-3" id="ixv-21575" unitRef="usd">1000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c59" decimals="-3" id="ixv-21576" unitRef="usd">8000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c60" decimals="-3" id="ixv-21577" unitRef="usd">3000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c20" decimals="-3" id="ixv-21578" unitRef="usd">34000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation contextRef="c61" decimals="-3" id="ixv-21579" unitRef="usd">29000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c62" decimals="-3" id="ixv-21580" unitRef="usd">3000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c63" decimals="-3" id="ixv-21581" unitRef="usd">17000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c64" decimals="-3" id="ixv-21582" unitRef="usd">5000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c6" decimals="-3" id="ixv-21583" unitRef="usd">54000</us-gaap:Depreciation>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c48" decimals="-3" id="ixv-21584" unitRef="usd">51000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c49" decimals="-3" id="ixv-21585" unitRef="usd">4000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c50" decimals="-3" id="ixv-21586" unitRef="usd">25000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c51" decimals="-3" id="ixv-21587" unitRef="usd">8000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c5" decimals="-3" id="ixv-21588" unitRef="usd">88000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c48" decimals="-3" id="ixv-21589" unitRef="usd">70000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c49" decimals="-3" id="ixv-21590" unitRef="usd">29000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c50" decimals="-3" id="ixv-21591" unitRef="usd">204000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c51" decimals="-3" id="ixv-21592" unitRef="usd">108000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c5" decimals="-3" id="ixv-21593" unitRef="usd">411000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c0" id="ixv-17926">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 6 - OTHER ACCOUNTS PAYABLE:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Employees&#x2019; salaries and related liabilities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;388&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;396&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Related parties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;354&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;332&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;267&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;470&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,216&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c0" id="ixv-17931">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Employees&#x2019; salaries and related liabilities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;388&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;396&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Related parties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;354&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;332&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;267&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;470&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,216&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent contextRef="c4" decimals="-3" id="ixv-21594" unitRef="usd">388000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent contextRef="c5" decimals="-3" id="ixv-21595" unitRef="usd">396000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <iinn:AccountsPayableToRelatedParties contextRef="c4" decimals="-3" id="ixv-21596" unitRef="usd">354000</iinn:AccountsPayableToRelatedParties>
    <iinn:AccountsPayableToRelatedParties contextRef="c5" decimals="-3" id="ixv-21597" unitRef="usd">332000</iinn:AccountsPayableToRelatedParties>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c4" decimals="-3" id="ixv-21598" unitRef="usd">267000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c5" decimals="-3" id="ixv-21599" unitRef="usd">470000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="c4" decimals="-3" id="ixv-21600" unitRef="usd">17000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="c5" decimals="-3" id="ixv-21601" unitRef="usd">18000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="c4" decimals="-3" id="ixv-21602" unitRef="usd">1026000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="c5" decimals="-3" id="ixv-21603" unitRef="usd">1216000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-18004">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span&gt;&lt;b&gt;NOTE 7 - COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Royalties to the IIA:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 57.4pt; text-indent: -0.7pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;In September
2019, the IIA approved an application that supports upgrading the Company&#x2019;s manufacturing capabilities for an aggregate budget of
NIS&#160;4,880,603(approximately $1,500,000). The IIA committed to fund&#160;60% of the approved budget. Eventually the project budget
concluded in the aggregate amount of NIS 4,623,142 (approximately $1,333) The program is for the period beginning October 2019 through
November 2020 and the Company received total funds in the amount of NIS 2,773,885 (approximately $800) from the IIA. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;According
to the agreements with the IIA, The Company will pay royalties of&#160;3% to&#160;3.5% of future sales up to an amount equal to the accumulated
grant received including annual interest of LIBOR linked to the USD. Repayment of the grant is contingent upon the successful completion
of the Company&#x2019;s research and development (&#x201c;R&amp;amp;D&#x201d;) programs and generating sales. The Company has no obligation to
repay these grants if the R&amp;amp;D programs fail, are unsuccessful or aborted or if no sales are generated. The Company had not generated
sales as of December 31, 2023; therefore, no liability was recorded in these Financial Statements. IIA grants are recorded as a reduction
of R&amp;amp;D expenses, net.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;During October
2023, the IIA has approved a support of another development project of the Company at an aggregate budget of NIS&#160;3,850,869 (approximately
$1,062). The IIA committed to fund&#160;40% of the approved budget. No funds have been received by the Company yet. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;Research
and development grants deducted from research and development expenses amounted to&#160;nil, $106 and $694 for the years ended December
31, 2021 and 2020, respectively. As of December 31, 2023, the maximum obligation with respect to the grants received from the IIA, contingent
upon entitled future sales, is $871 plus LIBOR interest. In September 2021, the Bank of Israel, which determines annual interest rates,
published a directive which stated that annual interest at a variable rate linked to the LIBOR rate for loans in USD will be replaced
by the SOFR, in January 2024.The Company has obligations regarding know-how, technology, or products, not to transfer the information,
rights thereon and production rights which derive from the research and development without the IIA Research Committee approval.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Lease Commitments &#x2013;
Operating Leases:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;span&gt;In August 2022, the Company entered
into a lease agreement for its facilities in Ra&#x2019;anana, Israel. The lease agreement is for a period of 69 months commencing September 1,
2021, and the Company began to pay lease and related expenses after completing 3 months of lease. The Company has the option to shorten
the period and terminates the lease agreement after completing 45 months of rent by paying an amount of NIS 500,000, (approximately $153).
This amount of reimbursement will be deducted monthly in NIS 30,000, (approximately $9) if the Company terminates the agreement after
45 months of rent. The annual lease payment, including management fees, as of December 31, 2023, is approximately NIS 69,000 ($19). As
security for the obligations under this lease agreement, the Company provided a bank guarantee in an amount equal to three monthly lease
payments plus the Israeli value added tax and an unlimited guarantee according to the terms specified in the contract. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;span&gt;The total expenses related to
the leases were $371&#160;for the year ended December 31, 2023, and $333&#160;for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;span&gt;The right-of-use asset and lease
liability are initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease
or, if that rate cannot be readily determined, the Company&#x2019;s incremental borrowing rate based on the information available at the
date of determining the present value of the lease payments. The Company&#x2019;s incremental borrowing rate is estimated to approximate
the interest rate on similar terms and payments and in economic environments where the leased asset is located.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;span&gt;The Company has various operating
leases for vehicles that expire through 2027. Below is a summary of the Company&#x2019;s operating right-of-use assets and operating lease
liabilities as of December 31, 2023, and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating lease liabilities, current&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;290&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;268&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Operating lease liabilities long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;588&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;873&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;878&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,141&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Weighted Average of Remaining Lease Term&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.33&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4.2&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Weighted-average discount rate - operating leases&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9.6&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9.92&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Lease payments for the Company&#x2019;s right-of-use
assets over the remaining lease periods as of December 31, 2023, are as follows:&lt;span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt;
 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;357&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;290&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;220&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total undiscounted lease payment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,011&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Interest*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(133&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;878&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Future lease payments were discounted by&#160;7.98%-15.04% interest
rate.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Legal Claims&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;In the normal course of business, various legal claims and other contingent
matters may arise. Management believes that any liability that may arise from such matters would not have a material adverse effect on
the Company&#x2019;s results of operations or financial condition as of and for the years ended December 31, 2023, and 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;On December 12, 2021, the Company terminated its employment agreement
with Dr. Udi Nussinovitch, one of its founders who served as the Company&#x2019;s Chief Scientific Officer since March 2018. On February
24, 2022, the Company sued Mr. Nussinovitch for breach good faith and his fiduciary duties as a shareholder and former officer of the
Company. On November 9, 2022, the Company received notice of a complaint filed by Mr.&#160;Nussinovitch, as well as a complaint filed
with the regional labor court in Tel Aviv, Israel on November 8, 2022. Mr. Nussinovitch has alleged certain deficiencies in the Company&#x2019;s&#160;Extraordinary
General Meeting of Shareholders held on Friday, December 17, 2021, resulting from his status as a minority shareholder. In addition, with
respect to the labor dispute, Mr.&#160;Nussinovitch is seeking renumeration and the issuance of Ordinary Shares. A partial hearing was
held in the regional labor court on July 19, 2023, and the parties were required by the court to file their positions on a stay of the
proceeding pending the decision on the case initiated by the Plaintiff in the District Court.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;A pre-trial was held in the district court on January 21, 2024. During
the hearing, the court suggested that the parties consider the possibility of resolving the case through an out-of-court arrangement or
mediation. The parties agreed to a mediation process.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of the date of these Financial Statement, the Company believes that
the claims will result in no payments by the Company.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <iinn:AggregateBudget contextRef="c65" decimals="-3" id="ixv-21604" unitRef="ils">4880603000</iinn:AggregateBudget>
    <iinn:AggregateBudget contextRef="c65" decimals="-3" id="ixv-21605" unitRef="usd">1500000000</iinn:AggregateBudget>
    <iinn:PercentageOfApprovedBudget contextRef="c65" decimals="2" id="ixv-21606" unitRef="pure">0.60</iinn:PercentageOfApprovedBudget>
    <iinn:ProjectBudgetAggregateAmount contextRef="c65" decimals="-3" id="ixv-21607" unitRef="ils">4623142000</iinn:ProjectBudgetAggregateAmount>
    <iinn:ProjectBudgetAggregateAmount contextRef="c65" decimals="-3" id="ixv-21608" unitRef="usd">1333000</iinn:ProjectBudgetAggregateAmount>
    <us-gaap:OtherReceivables contextRef="c66" decimals="-3" id="ixv-21609" unitRef="ils">2773885000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables contextRef="c66" decimals="-3" id="ixv-21610" unitRef="usd">800000</us-gaap:OtherReceivables>
    <iinn:RoyaltiesPercentage contextRef="c67" decimals="2" id="ixv-21611" unitRef="pure">0.03</iinn:RoyaltiesPercentage>
    <iinn:RoyaltiesPercentage contextRef="c68" decimals="3" id="ixv-21612" unitRef="pure">0.035</iinn:RoyaltiesPercentage>
    <iinn:AggregateBudget contextRef="c69" decimals="-3" id="ixv-21613" unitRef="ils">3850869000</iinn:AggregateBudget>
    <iinn:AggregateBudget contextRef="c69" decimals="-3" id="ixv-21614" unitRef="usd">1062000</iinn:AggregateBudget>
    <iinn:PercentageOfApprovedBudget contextRef="c69" decimals="2" id="ixv-21615" unitRef="pure">0.40</iinn:PercentageOfApprovedBudget>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c70" decimals="-3" id="ixv-21616" unitRef="usd">106000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c71" decimals="-3" id="ixv-21617" unitRef="usd">694000</us-gaap:OtherResearchAndDevelopmentExpense>
    <iinn:ContingentUponFutureSales contextRef="c4" decimals="-3" id="ixv-21618" unitRef="usd">871000</iinn:ContingentUponFutureSales>
    <us-gaap:PaymentsForRent contextRef="c72" decimals="-3" id="ixv-21619" unitRef="ils">500000000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent contextRef="c72" decimals="-3" id="ixv-21620" unitRef="usd">153000</us-gaap:PaymentsForRent>
    <iinn:ReimbursementAmount contextRef="c72" decimals="-3" id="ixv-21621" unitRef="ils">30000000</iinn:ReimbursementAmount>
    <iinn:ReimbursementAmount contextRef="c72" decimals="-3" id="ixv-21622" unitRef="usd">9000</iinn:ReimbursementAmount>
    <us-gaap:ManagementFeeExpense contextRef="c0" decimals="-3" id="ixv-21623" unitRef="ils">69000000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense contextRef="c0" decimals="-3" id="ixv-21624" unitRef="usd">19000</us-gaap:ManagementFeeExpense>
    <us-gaap:LeaseCost contextRef="c0" decimals="-3" id="ixv-21625" unitRef="usd">371000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c6" decimals="-3" id="ixv-21626" unitRef="usd">333000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="c0" id="ixv-18083">&lt;span&gt;The Company has various operating
leases for vehicles that expire through 2027. Below is a summary of the Company&#x2019;s operating right-of-use assets and operating lease
liabilities as of December 31, 2023, and 2022:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating lease liabilities, current&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;290&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;268&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Operating lease liabilities long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;588&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;873&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;878&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,141&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Weighted Average of Remaining Lease Term&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.33&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4.2&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Weighted-average discount rate - operating leases&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9.6&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9.92&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c4" decimals="-3" id="ixv-21627" unitRef="usd">290000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c5" decimals="-3" id="ixv-21628" unitRef="usd">268000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c4" decimals="-3" id="ixv-21629" unitRef="usd">588000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c5" decimals="-3" id="ixv-21630" unitRef="usd">873000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c4" decimals="-3" id="ixv-21631" unitRef="usd">878000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c5" decimals="-3" id="ixv-21632" unitRef="usd">1141000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c4" id="ixv-21633">P3Y3M29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c5" id="ixv-21634">P4Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c4" decimals="3" id="ixv-21635" unitRef="pure">0.096</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c5" decimals="4" id="ixv-21636" unitRef="pure">0.0992</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-21637">Lease payments for the Company&#x2019;s right-of-use
assets over the remaining lease periods as of December 31, 2023, are as follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt;
 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;357&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;290&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;220&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total undiscounted lease payment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,011&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Interest*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(133&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;878&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Future lease payments were discounted by&#160;7.98%-15.04% interest
rate.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c4" decimals="-3" id="ixv-21638" unitRef="usd">357000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c4" decimals="-3" id="ixv-21639" unitRef="usd">290000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c4" decimals="-3" id="ixv-21640" unitRef="usd">220000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c4" decimals="-3" id="ixv-21641" unitRef="usd">144000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c4" decimals="-3" id="ixv-21642" unitRef="usd">1011000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c4" decimals="-3" id="ix_0_fact" unitRef="usd">133000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c4" decimals="-3" id="ixv-21644" unitRef="usd">878000</us-gaap:OperatingLeaseLiability>
    <iinn:FutureLeasePaymentsDiscountedInterestRate contextRef="c67" decimals="4" id="ixv-21646" unitRef="pure">0.0798</iinn:FutureLeasePaymentsDiscountedInterestRate>
    <iinn:FutureLeasePaymentsDiscountedInterestRate contextRef="c68" decimals="4" id="ixv-21647" unitRef="pure">0.1504</iinn:FutureLeasePaymentsDiscountedInterestRate>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c0" id="ixv-18318">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 8 - FINACIAL LIABILITIES AT FAIR VALUE:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Financial liability (1)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;26&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Non-tradable warrants (2)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,459&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,470&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;26&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Financial Liability&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company agreed to pay fees of 7% from the
funds that will be received in an event of exercise of the Company&#x2019;s tradable warrants which created a financial liability. The
financial liability was designated to be measured at fair value through profit or loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The financial liability fair value as of December
31, 2023, and 2022 is $11 and $26 respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Private Warrants&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 26, 2023, the Company entered into
the Purchase Agreement (Note 1 and Note 9), pursuant to which it issued unregistered warrants, to purchase up to an aggregate of 3,031,250
Ordinary Shares at an exercise of $1.28 per share. The Warrants were exercisable immediately upon issuance and will expire three and a
half years following their issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The warrants include cashless exercise mechanism,
according to the terms specified in the agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The warrants may create obligation to transfer
cash to the investors at fundamental transactions according to fair value of the black Scholes model that include variable inputs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Therefore, the Company accounts for the warrants
as financial liability instruments that measured at fair value and recognized financial expenses or income through profit and loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The warrants fair value as of the issuance date
and December 31, 2023, were $1,750 and $1,459 respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The key inputs that were used in the Private Warrants fair value as
of issuance date were:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;risk-free interest rate 4.00%&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;expected volatility 66.71%&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;expected dividend yield of 0%&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;expected term of warrants &#x2013; 3.5 years.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The key inputs that were used in the Private Warrants fair value as
of December 31, 2023, were:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;risk-free interest rate 4.00%&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;expected volatility 66.63%&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;expected dividend yield of 0%&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;expected term of warrants &#x2013; 3.5 years.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FinancialGuaranteeInsuranceContractsClaimLiabilityTableTextBlock contextRef="c0" id="ixv-18322">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Financial liability (1)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;26&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Non-tradable warrants (2)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,459&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,470&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;26&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FinancialGuaranteeInsuranceContractsClaimLiabilityTableTextBlock>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c73" decimals="-3" id="ixv-21648" unitRef="usd">11000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c74" decimals="-3" id="ixv-21649" unitRef="usd">26000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c76" decimals="-3" id="ixv-21650" unitRef="usd">1459000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c4" decimals="-3" id="ixv-21651" unitRef="usd">1470000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c5" decimals="-3" id="ixv-21652" unitRef="usd">26000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <iinn:PercentageOfPayFees contextRef="c0" decimals="2" id="ixv-21653" unitRef="pure">0.07</iinn:PercentageOfPayFees>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c73" decimals="-3" id="ixv-21654" unitRef="usd">11000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c74" decimals="-3" id="ixv-21655" unitRef="usd">26000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:StockDividendsShares
      contextRef="c36"
      decimals="0"
      id="ixv-21656"
      unitRef="shares">3031250</us-gaap:StockDividendsShares>
    <us-gaap:StockOptionExercisePriceDecrease
      contextRef="c36"
      decimals="2"
      id="ixv-21657"
      unitRef="usdPershares">1.28</us-gaap:StockOptionExercisePriceDecrease>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c0" decimals="-3" id="ixv-21658" unitRef="usd">1750000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c6" decimals="-3" id="ixv-21659" unitRef="usd">1459000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="c0" decimals="4" id="ixv-21660" unitRef="pure">0.04</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="c0" decimals="4" id="ixv-21661" unitRef="pure">0.6671</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="c0" decimals="2" id="ixv-21662" unitRef="pure">0</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="c0" id="ixv-21663">P3Y6M</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="c75" decimals="4" id="ixv-21664" unitRef="pure">0.04</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="c75" decimals="4" id="ixv-21665" unitRef="pure">0.6663</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="c75" decimals="2" id="ixv-21666" unitRef="pure">0</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="c75" id="ixv-21667">P3Y6M</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-18485">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 9 - SHAREHOLDERS&#x2019; EQUITY (DEFICIT):&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Share capital:&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Number of shares as of&lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Number of shares as of&lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; padding-bottom: 4pt"&gt;Ordinary shares&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;100,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;15,652,176&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;100,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;11,338,940&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Since the Company&#x2019;s incorporation in February
2018 and before its IPO, the Company issued the following Ordinary Shares: (i) an aggregate of 27,566 Ordinary Shares for no consideration
to the Company&#x2019;s founders and certain advisors; and (ii) 1,877,196 Ordinary Shares as bonus shares for no consideration to existing
shareholders.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In 2020 the Company issued an aggregate of 756,333
Ordinary Shares to investors as part of a loan conversion and non-tradable warrants to purchase an additional 169,019 Ordinary Shares
upon consummation of its IPO. The warrants are exercisable into Ordinary Shares of the Company at an exercise price equal to the initial
public offering price which was $5.50 and are exercisable for three years after the IPO.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 18, 2021, the Company&#x2019;s shareholders
approved a 12.5 to 1 reverse split of all shares (issued and unissued) on the basis that every 12.5 Ordinary Shares in the capital of
the Company be consolidated into 1 Ordinary Share, such that the authorized share capital of the Company following such consolidation
is NIS 310,000,000 divided into 24,800,000 Ordinary Shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 1, 2021, the Company&#x2019;s shareholders
approved an amendment to the structure of the Company&#x2019;s share capital (both authorized and issued) by cancelling the par value of
the Ordinary Shares in addition to implementing an additional reverse split at a ratio of 2.94 to 1, pursuant to which holders of our
Ordinary Shares received one Ordinary Share for every 2.94&#160;Ordinary Shares held.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 1, 2021, the Company&#x2019;s shareholders
approved an amendment to the structure of the Company&#x2019;s share capital (both authorized and issued) by cancelling the par value of
the Company&#x2019;s shares such that each Ordinary Share with par value of NIS 0.125 will become one Ordinary Share with no par value.
The authorized share capital of the Company following the reverse stock split was NIS 310,000,000 divided into 8,435,375 Ordinary Shares,
with no par value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 1, 2021, the Company&#x2019;s shareholders
approved an increase in the authorized share capital of the Company to 15,000,000 Ordinary Shares of no-par value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 16, 2021, the Company completed its IPO
on the Nasdaq Capital Market whereby the Company sold 2,909,091 Ordinary Shares and tradable warrants to purchase 3,345,455 Ordinary Shares
(inclusive of tradable warrants to purchase 436,364 Ordinary Shares pursuant to the exercise of an overallotment option granted to the
underwriters). The tradable warrants have an exercise price of $5.50 and they are exercisable for five years after the IPO date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Following the IPO, the Company issued 2,113,905
Ordinary Shares and 1,149,582 non-tradable warrants to investors and 16,587 non-tradeable warrants to brokers in connection with the conversion
of Company&#x2019;s previously issued financial liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The aggregate proceeds received by the Company
from the IPO were approximately $14,490, after deducting underwriting discounts and commissions and additional offering direct costs totaled
approximately $1,543. The gross proceeds were $16,033.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Total non-cash direct expenses in IPO were as
following: (i) fair value of 436,364 tradable warrants that were granted to underwriters totaled in $589; (ii) The Company issued 145,455
non-tradable warrants as underwriters fees; the warrants will be converted into Ordinary Shares of the Company at an exercise price equal
to 125% of the IPO price and be exercisable for three years after the IPO. As of the date of the IPO, the tradable warrants fair value
was $264; and (iii) the Company agreed to pay to a promoter 7% of the proceeds from the exercise of tradable warrants. The payment was
measured at fair value at the grant date. As of the IPO date, the fair value of the financial liability was $310.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Total non-cash expenses were $1,163.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In addition, the Company had non-direct expenses
as following: (i) cash expenses amounted to $722 and (i) non-cash expenses amounted to $123 (22,382 Ordinary Shares issued to service
providers).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Total IPO expenses direct and non- direct, cash
and non-cash were: $3,551.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Total IPO expenses allocated to the profit and
loss were $546. Total IPO expenses deducted from the equity were $3,032.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year 2021 the Company issued an aggregate
amount of 655,601 Ordinary Shares in connection to vested RSUs and additional 24,631 Ordinary Shares in connection with options exercise.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 17, 2021, the Company&#x2019;s shareholders
approved an increase in the authorized share capital of the Company to 100,000,000 Ordinary Shares of no-par value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2022, the Company
issued an aggregate amount of 1,240,204 Ordinary Shares in connection to vested RSUs and an additional 7,030 Ordinary Shares in connection
to option exercises.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 4, 2023, the Company entered into a
sales agreement (the &#x201c;Sales Agreement&#x201d;) with Roth Capital Partners, LLC, as sales agent, pursuant to which the Company could
offer and sell, from time to time, through the sales agent, Ordinary Shares pursuant to an At-The-Market facility (&#x201c;ATM&#x201d;).
During 2023, the Company sold 17,566 Ordinary Shares under the ATM. On October 23, 2023, the Company terminated the Sales Agreement and
the associated ATM, effective immediately.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 26, 2023, the Company completed
the Registered Direct Offering, whereby the Company sold (i) 1,375,000 Ordinary Shares at a purchase price of $1.28 per share, and
(ii) Pre-Funded Warrants, to purchase up to 1,656,250 Ordinary Shares, at a purchase price of $1.28, less $0.001 per Pre-Funded
Warrant. (iii) Private Warrants, to purchase up to an aggregate of 3,031,250 Ordinary Shares at an exercise of $1.28 per share (Note
8.2).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Pre-Funded Warrants were exercised on the
same day and the day after the transaction in full in an exercise price of $0.01 per share and the Company issued 1,656,250 additional
Ordinary Shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The aggregate proceeds received by the Company
from the registered direct offering were approximately $3,424, after deducting underwriting discounts and commissions and additional cash
offering costs totaled in approximately $454.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company issued the Placement Agent in the
agreement a number of warrants equal to a total of 7.0% of the aggregate number of Ordinary Shares sold in the transaction, total to 212,188
warrants to purchase up to 212,188 Ordinary Shares, were issued. The Placement Agent Warrants were substantially on the same terms as
the Warrants issued to the investor in the offering, except an exercise price of $1.60 per share. The Placement agent Warrants were exercisable
immediately upon issuance and will expire five years following their issuance. The Company accounts for the Placement Agent Warrants as
equity-classified instruments (as part of additional paid in capital), based on an assessment of ASC 718. The fair value of the warrants
at the issuance date was $131.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Those cash and non-cash issuance costs were accounted
proportionally to issuance expenses and decrease of additional paid in capital, according to the ratio of the liability versus equity
in the Registered Direct offering.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2023, the Company
issued an aggregate amount of 1,226,448 Ordinary Shares in connection with vested RSUs and an additional 37,972 Ordinary Shares in connection
with option exercises.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Warrants reserves -&lt;/b&gt;Composition and movements:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.8pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;1.&lt;/td&gt;&lt;td style="text-align: justify"&gt;The following table reconciles the movement in warrants outstanding
at the beginning and end of the period:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.8pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Weighted-average exercise price&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Weighted average remaining contractual term&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;(in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;intrinsic value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-weight: bold; padding-bottom: 1.5pt"&gt;Balance as of December 31, 2022&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"&gt;3,121,095&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"&gt;5.58&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"&gt;1.74&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"&gt;4,667,915&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;212,188&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;131,555&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;3,333,283&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;5.47&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1.83&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;4,799,470&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;2.&lt;/td&gt;&lt;td style="text-align: justify"&gt;The following table summarizes information about the Company&#x2019;s
outstanding warrants as of December 31, 2023&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Warrants outstanding&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;as of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;
 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Expiration date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;5.5&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,640,455&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;15/07/2026&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,214,614&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;5.5&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,057,350&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;15/07/2024&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,691,760&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;5.5&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;277,835&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;15/07/2025&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;497,533&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;6.875&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;145,455&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;15/01/2027&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;264,008&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;1.6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;212,188&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;28/12/2028&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;131,555&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,333,283&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,799,470&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.8pt; text-align: justify"&gt;&lt;b&gt;C. Loss per share:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Loss per share has been calculated using the weighted
average number of shares in issue during the relevant financial periods, the weighted average number of equity shares in issue and profit
for the period as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Loss for the period&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,286&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;14,976&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17,193&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Total number of Ordinary Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15,652,176&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,338,940&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,091,706&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Weighted average number of Ordinary Shares&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12,095,477&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,794,594&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,306,225&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102; -sec-ix-hidden: hidden-fact-101; -sec-ix-hidden: hidden-fact-100"&gt;Basic and diluted loss per share&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.93&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1.39&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(3.24&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock contextRef="c0" id="ixv-18494">&lt;b&gt;A.&lt;/b&gt;&lt;b&gt;Share capital:&lt;/b&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Number of shares as of&lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Number of shares as of&lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; padding-bottom: 4pt"&gt;Ordinary shares&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;100,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;15,652,176&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;100,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;11,338,940&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c4"
      decimals="INF"
      id="ixv-21668"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c4"
      decimals="INF"
      id="ixv-21669"
      unitRef="shares">15652176</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c5"
      decimals="INF"
      id="ixv-21670"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c5"
      decimals="INF"
      id="ixv-21671"
      unitRef="shares">11338940</us-gaap:CommonStockSharesIssued>
    <iinn:AggregateOfOrdinaryShares
      contextRef="c78"
      decimals="0"
      id="ixv-21672"
      unitRef="shares">27566</iinn:AggregateOfOrdinaryShares>
    <iinn:OrdinaryShare
      contextRef="c0"
      decimals="0"
      id="ixv-21673"
      unitRef="shares">1877196</iinn:OrdinaryShare>
    <iinn:AggregateOfOrdinaryShares
      contextRef="c79"
      decimals="0"
      id="ixv-21674"
      unitRef="shares">756333</iinn:AggregateOfOrdinaryShares>
    <us-gaap:SharesIssued
      contextRef="c80"
      decimals="0"
      id="ixv-21675"
      unitRef="shares">169019</us-gaap:SharesIssued>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="c81"
      decimals="2"
      id="ixv-21676"
      unitRef="usdPershares">5.5</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c82"
      decimals="1"
      id="ixv-21677"
      unitRef="usdPershares">12.5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssued
      contextRef="c83"
      decimals="0"
      id="ixv-21678"
      unitRef="shares">1</us-gaap:SharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c84"
      decimals="1"
      id="ixv-21679"
      unitRef="usdPershares">12.5</us-gaap:SharesIssuedPricePerShare>
    <iinn:OrdinaryShare
      contextRef="c85"
      decimals="0"
      id="ixv-21680"
      unitRef="shares">1</iinn:OrdinaryShare>
    <us-gaap:CapitalUnitsAuthorized
      contextRef="c86"
      decimals="0"
      id="ixv-21681"
      unitRef="shares">310000000</us-gaap:CapitalUnitsAuthorized>
    <iinn:OrdinaryShare
      contextRef="c87"
      decimals="0"
      id="ixv-21682"
      unitRef="shares">24800000</iinn:OrdinaryShare>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="c88" id="ixv-21683">reverse split at a ratio of 2.94 to 1</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c89"
      decimals="2"
      id="ixv-21684"
      unitRef="usdPershares">2.94</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c89"
      decimals="3"
      id="ixv-21685"
      unitRef="ilsPershares">0.125</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssued
      contextRef="c86"
      decimals="0"
      id="ixv-21686"
      unitRef="shares">310000000</us-gaap:SharesIssued>
    <iinn:OrdinaryShare
      contextRef="c88"
      decimals="0"
      id="ixv-21687"
      unitRef="shares">8435375</iinn:OrdinaryShare>
    <us-gaap:SharesIssued
      contextRef="c89"
      decimals="0"
      id="ixv-21688"
      unitRef="shares">15000000</us-gaap:SharesIssued>
    <iinn:SoldOrdinaryShares
      contextRef="c90"
      decimals="0"
      id="ixv-21689"
      unitRef="shares">2909091</iinn:SoldOrdinaryShares>
    <iinn:TradableWarrants
      contextRef="c90"
      decimals="0"
      id="ixv-21690"
      unitRef="shares">3345455</iinn:TradableWarrants>
    <iinn:TradableWarrants
      contextRef="c91"
      decimals="0"
      id="ixv-21691"
      unitRef="shares">436364</iinn:TradableWarrants>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="c90"
      decimals="2"
      id="ixv-21692"
      unitRef="usdPershares">5.5</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:SharesIssued
      contextRef="c92"
      decimals="0"
      id="ixv-21693"
      unitRef="shares">2113905</us-gaap:SharesIssued>
    <iinn:NonTradableWarrants
      contextRef="c93"
      decimals="0"
      id="ixv-21694"
      unitRef="shares">1149582</iinn:NonTradableWarrants>
    <iinn:NonTradableWarrants
      contextRef="c94"
      decimals="0"
      id="ixv-21695"
      unitRef="shares">16587</iinn:NonTradableWarrants>
    <us-gaap:ProceedsFromDividendsReceived contextRef="c78" decimals="-3" id="ixv-21696" unitRef="usd">14490000</us-gaap:ProceedsFromDividendsReceived>
    <us-gaap:OfferingCostsPartnershipInterests contextRef="c4" decimals="-3" id="ixv-21697" unitRef="usd">1543000</us-gaap:OfferingCostsPartnershipInterests>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c0" decimals="-3" id="ixv-21698" unitRef="usd">16033000</us-gaap:PaymentsToAcquireBusinessesGross>
    <iinn:FairValueWarrants
      contextRef="c0"
      decimals="0"
      id="ixv-21699"
      unitRef="shares">436364</iinn:FairValueWarrants>
    <us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="c0" decimals="-3" id="ixv-21700" unitRef="usd">589000</us-gaap:AdjustmentOfWarrantsGrantedForServices>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="c4"
      decimals="0"
      id="ixv-21701"
      unitRef="shares">145455</us-gaap:ClassOfWarrantOrRightUnissued>
    <iinn:PercentageOfExercisePrice contextRef="c0" decimals="2" id="ixv-21702" unitRef="pure">1.25</iinn:PercentageOfExercisePrice>
    <us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="c78" decimals="-3" id="ixv-21703" unitRef="usd">264000</us-gaap:AdjustmentOfWarrantsGrantedForServices>
    <iinn:PercentageOfExerciseOfTradableWarrants contextRef="c0" decimals="2" id="ixv-21704" unitRef="pure">0.07</iinn:PercentageOfExerciseOfTradableWarrants>
    <us-gaap:FairValueNetAssetLiability contextRef="c4" decimals="-3" id="ixv-21705" unitRef="usd">310000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:InterestExpense contextRef="c0" decimals="-3" id="ixv-21706" unitRef="usd">1163000</us-gaap:InterestExpense>
    <us-gaap:NoninterestExpense contextRef="c0" decimals="-3" id="ixv-21707" unitRef="usd">722000</us-gaap:NoninterestExpense>
    <us-gaap:InterestExpenseOther contextRef="c0" decimals="-3" id="ixv-21708" unitRef="usd">123000</us-gaap:InterestExpenseOther>
    <us-gaap:SharesIssued
      contextRef="c4"
      decimals="0"
      id="ixv-21709"
      unitRef="shares">22382</us-gaap:SharesIssued>
    <us-gaap:NoninterestExpense contextRef="c78" decimals="-3" id="ixv-21710" unitRef="usd">3551000</us-gaap:NoninterestExpense>
    <us-gaap:BenefitsLossesAndExpenses contextRef="c0" decimals="-3" id="ixv-21711" unitRef="usd">546000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:BenefitsLossesAndExpenses contextRef="c78" decimals="-3" id="ixv-21712" unitRef="usd">3032000</us-gaap:BenefitsLossesAndExpenses>
    <iinn:AggregateOfOrdinaryShares
      contextRef="c0"
      decimals="0"
      id="ixv-21713"
      unitRef="shares">655601</iinn:AggregateOfOrdinaryShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c7"
      decimals="0"
      id="ixv-21714"
      unitRef="shares">24631</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:CommonUnitAuthorized
      contextRef="c95"
      decimals="0"
      id="ixv-21715"
      unitRef="shares">100000000</us-gaap:CommonUnitAuthorized>
    <iinn:AggregateOfOrdinaryShares
      contextRef="c6"
      decimals="0"
      id="ixv-21716"
      unitRef="shares">1240204</iinn:AggregateOfOrdinaryShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c6"
      decimals="0"
      id="ixv-21717"
      unitRef="shares">7030</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c0"
      decimals="0"
      id="ixv-21718"
      unitRef="shares">17566</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:SharesIssued
      contextRef="c96"
      decimals="0"
      id="ixv-21719"
      unitRef="shares">1375000</us-gaap:SharesIssued>
    <us-gaap:SharePrice
      contextRef="c96"
      decimals="2"
      id="ixv-21720"
      unitRef="usdPershares">1.28</us-gaap:SharePrice>
    <us-gaap:SharesIssued
      contextRef="c97"
      decimals="0"
      id="ixv-21721"
      unitRef="shares">1656250</us-gaap:SharesIssued>
    <us-gaap:SharePrice
      contextRef="c97"
      decimals="2"
      id="ixv-21722"
      unitRef="usdPershares">1.28</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c34"
      decimals="3"
      id="ixv-21723"
      unitRef="usdPershares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssued
      contextRef="c98"
      decimals="0"
      id="ixv-21724"
      unitRef="shares">3031250</us-gaap:SharesIssued>
    <us-gaap:SharePrice
      contextRef="c34"
      decimals="2"
      id="ixv-21725"
      unitRef="usdPershares">1.28</us-gaap:SharePrice>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c99"
      decimals="2"
      id="ixv-21726"
      unitRef="usdPershares">0.01</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssued
      contextRef="c99"
      decimals="0"
      id="ixv-21727"
      unitRef="shares">1656250</us-gaap:SharesIssued>
    <us-gaap:OtherUnderwritingExpense contextRef="c0" decimals="-3" id="ixv-21728" unitRef="usd">3424000</us-gaap:OtherUnderwritingExpense>
    <us-gaap:DeferredOfferingCosts contextRef="c4" decimals="-3" id="ixv-21729" unitRef="usd">454000</us-gaap:DeferredOfferingCosts>
    <iinn:PercentageOfAgreementWarrants contextRef="c4" decimals="3" id="ixv-21730" unitRef="pure">0.07</iinn:PercentageOfAgreementWarrants>
    <us-gaap:SharesIssued
      contextRef="c100"
      decimals="0"
      id="ixv-21731"
      unitRef="shares">212188</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="c101"
      decimals="0"
      id="ixv-21732"
      unitRef="shares">212188</us-gaap:SharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c4"
      decimals="2"
      id="ixv-21733"
      unitRef="usdPershares">1.6</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:PaymentsOfDerivativeIssuanceCosts contextRef="c7" decimals="-3" id="ixv-21734" unitRef="usd">131000</us-gaap:PaymentsOfDerivativeIssuanceCosts>
    <iinn:AggregateOfOrdinaryShares
      contextRef="c102"
      decimals="0"
      id="ixv-21735"
      unitRef="shares">1226448</iinn:AggregateOfOrdinaryShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c11"
      decimals="0"
      id="ixv-21736"
      unitRef="shares">37972</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c0" id="ixv-21737">The following table reconciles the movement in warrants outstanding
at the beginning and end of the period:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Weighted-average exercise price&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Weighted average remaining contractual term&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;(in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;intrinsic value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-weight: bold; padding-bottom: 1.5pt"&gt;Balance as of December 31, 2022&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"&gt;3,121,095&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"&gt;5.58&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"&gt;1.74&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"&gt;4,667,915&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;212,188&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;131,555&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;3,333,283&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;5.47&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1.83&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;4,799,470&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c103"
      decimals="INF"
      id="ixv-21738"
      unitRef="shares">3121095</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c103"
      decimals="2"
      id="ixv-21739"
      unitRef="usdPershares">5.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c104" id="ixv-21740">P1Y8M26D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="c103"
      decimals="-3"
      id="ixv-21741"
      unitRef="usd">4667915000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c104"
      decimals="INF"
      id="ixv-21742"
      unitRef="shares">212188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c104"
      decimals="1"
      id="ixv-21743"
      unitRef="usdPershares">1.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms contextRef="c104" id="ixv-21744">P5Y</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms>
    <iinn:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued
      contextRef="c104"
      decimals="-3"
      id="ixv-21745"
      unitRef="usd">131555000</iinn:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c100"
      decimals="INF"
      id="ixv-21746"
      unitRef="shares">3333283</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c100"
      decimals="2"
      id="ixv-21747"
      unitRef="usdPershares">5.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms contextRef="c104" id="ixv-21748">P1Y9M29D</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingEndingBalanceWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="c100"
      decimals="-3"
      id="ixv-21749"
      unitRef="usd">4799470000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="c0" id="ixv-21750">The following table summarizes information about the Company&#x2019;s
outstanding warrants as of December 31, 2023&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Warrants outstanding&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;as of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;
 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Expiration date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;5.5&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,640,455&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;15/07/2026&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,214,614&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;5.5&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,057,350&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;15/07/2024&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,691,760&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;5.5&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;277,835&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;15/07/2025&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;497,533&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;6.875&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;145,455&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;15/01/2027&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;264,008&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;1.6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;212,188&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;28/12/2028&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;131,555&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,333,283&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,799,470&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c105"
      decimals="1"
      id="ixv-21751"
      unitRef="usdPershares">5.5</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <iinn:WarrantsOutstanding
      contextRef="c106"
      decimals="-3"
      id="ixv-21752"
      unitRef="usd">1640455000</iinn:WarrantsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c106" id="ixv-18914">2026-07-15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="c105"
      decimals="-3"
      id="ixv-21753"
      unitRef="usd">2214614000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c107"
      decimals="1"
      id="ixv-21754"
      unitRef="usdPershares">5.5</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <iinn:WarrantsOutstanding
      contextRef="c108"
      decimals="-3"
      id="ixv-21755"
      unitRef="usd">1057350000</iinn:WarrantsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c108" id="ixv-18930">2024-07-15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="c107"
      decimals="-3"
      id="ixv-21756"
      unitRef="usd">1691760000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c109"
      decimals="1"
      id="ixv-21757"
      unitRef="usdPershares">5.5</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <iinn:WarrantsOutstanding
      contextRef="c110"
      decimals="-3"
      id="ixv-21758"
      unitRef="usd">277835000</iinn:WarrantsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c110" id="ixv-18946">2025-07-15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="c109"
      decimals="-3"
      id="ixv-21759"
      unitRef="usd">497533000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c111"
      decimals="3"
      id="ixv-21760"
      unitRef="usdPershares">6.875</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <iinn:WarrantsOutstanding
      contextRef="c112"
      decimals="-3"
      id="ixv-21761"
      unitRef="usd">145455000</iinn:WarrantsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c112" id="ixv-18962">2027-01-15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="c111"
      decimals="-3"
      id="ixv-21762"
      unitRef="usd">264008000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c113"
      decimals="1"
      id="ixv-21763"
      unitRef="usdPershares">1.6</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <iinn:WarrantsOutstanding
      contextRef="c114"
      decimals="-3"
      id="ixv-21764"
      unitRef="usd">212188000</iinn:WarrantsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c114" id="ixv-18978">2028-12-28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="c113"
      decimals="-3"
      id="ixv-21765"
      unitRef="usd">131555000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <iinn:WarrantsOutstanding contextRef="c0" decimals="-3" id="ixv-21766" unitRef="usd">3333283000</iinn:WarrantsOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c4" decimals="-3" id="ixv-21767" unitRef="usd">4799470000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0" id="ixv-21768">Loss per share has been calculated using the weighted
average number of shares in issue during the relevant financial periods, the weighted average number of equity shares in issue and profit
for the period as follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Loss for the period&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,286&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;14,976&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17,193&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Total number of Ordinary Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15,652,176&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,338,940&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,091,706&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Weighted average number of Ordinary Shares&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12,095,477&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,794,594&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,306,225&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102; -sec-ix-hidden: hidden-fact-101; -sec-ix-hidden: hidden-fact-100"&gt;Basic and diluted loss per share&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.93&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1.39&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(3.24&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-21769" unitRef="usd">-11286000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-21770" unitRef="usd">-14976000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-21771" unitRef="usd">-17193000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c4"
      decimals="INF"
      id="ixv-21772"
      unitRef="shares">15652176</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="c5"
      decimals="INF"
      id="ixv-21773"
      unitRef="shares">11338940</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="c20"
      decimals="INF"
      id="ixv-21774"
      unitRef="shares">10091706</us-gaap:SharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ixv-21775"
      unitRef="shares">12095477</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c6"
      decimals="INF"
      id="ixv-21776"
      unitRef="shares">10794594</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c7"
      decimals="INF"
      id="ixv-21777"
      unitRef="shares">5306225</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-21778"
      unitRef="usdPershares">-0.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c6"
      decimals="2"
      id="ixv-21779"
      unitRef="usdPershares">-1.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c7"
      decimals="2"
      id="ixv-21780"
      unitRef="usdPershares">-3.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="c0" id="ixv-19126">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 10 - RESEARCH AND DEVELOPMENT EXPENSES:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Salary and related expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,429&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,458&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,543&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Materials and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,082&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;204&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Share based payment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;663&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,392&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,792&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Subcontractors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;304&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;850&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;496&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;291&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;188&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;IIA participation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(106&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;268&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;213&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;47&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,320&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,183&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,070&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock contextRef="c0" id="ixv-19131">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Salary and related expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,429&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,458&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,543&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Materials and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,082&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;204&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Share based payment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;663&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,392&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,792&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Subcontractors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;304&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;850&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;496&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;291&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;188&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;IIA participation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(106&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;268&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;213&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;47&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,320&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,183&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,070&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock>
    <us-gaap:LaborAndRelatedExpense contextRef="c0" decimals="-3" id="ixv-21781" unitRef="usd">4429000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c6" decimals="-3" id="ixv-21782" unitRef="usd">3458000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c7" decimals="-3" id="ixv-21783" unitRef="usd">1543000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:OtherLaborRelatedExpenses contextRef="c0" decimals="-3" id="ixv-21784" unitRef="usd">1365000</us-gaap:OtherLaborRelatedExpenses>
    <us-gaap:OtherLaborRelatedExpenses contextRef="c6" decimals="-3" id="ixv-21785" unitRef="usd">1082000</us-gaap:OtherLaborRelatedExpenses>
    <us-gaap:OtherLaborRelatedExpenses contextRef="c7" decimals="-3" id="ixv-21786" unitRef="usd">204000</us-gaap:OtherLaborRelatedExpenses>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c0"
      decimals="0"
      id="ixv-21787"
      unitRef="shares">663</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c6"
      decimals="0"
      id="ixv-21788"
      unitRef="shares">2392</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c7"
      decimals="0"
      id="ixv-21789"
      unitRef="shares">1792</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <iinn:Subcontractors contextRef="c0" decimals="-3" id="ixv-21790" unitRef="usd">304000</iinn:Subcontractors>
    <iinn:Subcontractors contextRef="c6" decimals="-3" id="ixv-21791" unitRef="usd">850000</iinn:Subcontractors>
    <iinn:Subcontractors contextRef="c7" decimals="-3" id="ixv-21792" unitRef="usd">496000</iinn:Subcontractors>
    <us-gaap:DepreciationNonproduction contextRef="c0" decimals="-3" id="ixv-21793" unitRef="usd">291000</us-gaap:DepreciationNonproduction>
    <us-gaap:DepreciationNonproduction contextRef="c6" decimals="-3" id="ixv-21794" unitRef="usd">188000</us-gaap:DepreciationNonproduction>
    <us-gaap:DepreciationNonproduction contextRef="c7" decimals="-3" id="ixv-21795" unitRef="usd">94000</us-gaap:DepreciationNonproduction>
    <us-gaap:PaymentsForParticipationLiabilities contextRef="c7" decimals="-3" id="ixv-21796" unitRef="usd">106000</us-gaap:PaymentsForParticipationLiabilities>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-21797" unitRef="usd">268000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c6" decimals="-3" id="ixv-21798" unitRef="usd">213000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c7" decimals="-3" id="ixv-21799" unitRef="usd">47000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-21800" unitRef="usd">7320000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c6" decimals="-3" id="ixv-21801" unitRef="usd">8183000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c7" decimals="-3" id="ixv-21802" unitRef="usd">4070000</us-gaap:ResearchAndDevelopmentExpense>
    <iinn:SalesAndMarketingExpensesTextBlock contextRef="c0" id="ixv-19281">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 11 - SALES AND MARKETING EXPENSES:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Professionals&#x2019; fees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;348&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;527&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;520&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Salary and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;248&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;282&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;220&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Share-based payment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,215&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;61&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;746&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,328&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,980&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:SalesAndMarketingExpensesTextBlock>
    <iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock contextRef="c0" id="ixv-19286">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December 31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Professionals&#x2019; fees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;348&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;527&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;520&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Salary and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;248&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;282&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;220&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Share-based payment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,215&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;61&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;746&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,328&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,980&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock>
    <us-gaap:ProfessionalFees contextRef="c0" decimals="-3" id="ixv-21803" unitRef="usd">348000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="c6" decimals="-3" id="ixv-21804" unitRef="usd">527000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="c7" decimals="-3" id="ixv-21805" unitRef="usd">520000</us-gaap:ProfessionalFees>
    <us-gaap:OfficersCompensation contextRef="c0" decimals="-3" id="ixv-21806" unitRef="usd">248000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation contextRef="c6" decimals="-3" id="ixv-21807" unitRef="usd">282000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation contextRef="c7" decimals="-3" id="ixv-21808" unitRef="usd">220000</us-gaap:OfficersCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-21809" unitRef="usd">89000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c6" decimals="-3" id="ixv-21810" unitRef="usd">503000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c7" decimals="-3" id="ixv-21811" unitRef="usd">1215000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:OtherSellingAndMarketingExpense contextRef="c0" decimals="-3" id="ixv-21812" unitRef="usd">61000</us-gaap:OtherSellingAndMarketingExpense>
    <us-gaap:OtherSellingAndMarketingExpense contextRef="c6" decimals="-3" id="ixv-21813" unitRef="usd">16000</us-gaap:OtherSellingAndMarketingExpense>
    <us-gaap:OtherSellingAndMarketingExpense contextRef="c7" decimals="-3" id="ixv-21814" unitRef="usd">25000</us-gaap:OtherSellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c0" decimals="-3" id="ixv-21815" unitRef="usd">746000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c6" decimals="-3" id="ixv-21816" unitRef="usd">1328000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c7" decimals="-3" id="ixv-21817" unitRef="usd">1980000</us-gaap:SellingAndMarketingExpense>
    <iinn:GeneralAndAdministrativeExpensesTextBlock contextRef="c0" id="ixv-19415">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 12 - GENERAL AND ADMINISTRATIVE EXPENSES:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,432&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,390&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Salary and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;766&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;716&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;545&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Director&#x2019;s fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;241&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;239&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;111&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Related NASDAQ IPO expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;546&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Funds raising expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;260&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share-based payment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;675&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,984&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,696&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Insurance expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;557&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;363&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Office maintenance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;129&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;115&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;104&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Travel abroad&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;105&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;65&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;68&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;46&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,063&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,375&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,937&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:GeneralAndAdministrativeExpensesTextBlock>
    <iinn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock contextRef="c0" id="ixv-19420">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,432&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,390&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Salary and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;766&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;716&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;545&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Director&#x2019;s fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;241&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;239&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;111&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Related NASDAQ IPO expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;546&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Funds raising expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;260&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share-based payment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;675&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,984&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,696&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Insurance expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;557&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;363&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Office maintenance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;129&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;115&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;104&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Travel abroad&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;105&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;65&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;68&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;46&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,063&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,375&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,937&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock>
    <us-gaap:ProfessionalFees
      contextRef="c115"
      decimals="-3"
      id="ixv-21818"
      unitRef="usd">1432000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="c116"
      decimals="-3"
      id="ixv-21819"
      unitRef="usd">1500000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="c117"
      decimals="-3"
      id="ixv-21820"
      unitRef="usd">1390000</us-gaap:ProfessionalFees>
    <us-gaap:OfficersCompensation
      contextRef="c115"
      decimals="-3"
      id="ixv-21821"
      unitRef="usd">766000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="c116"
      decimals="-3"
      id="ixv-21822"
      unitRef="usd">716000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="c117"
      decimals="-3"
      id="ixv-21823"
      unitRef="usd">545000</us-gaap:OfficersCompensation>
    <us-gaap:LegalFees
      contextRef="c115"
      decimals="-3"
      id="ixv-21824"
      unitRef="usd">241000</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="c116"
      decimals="-3"
      id="ixv-21825"
      unitRef="usd">239000</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="c117"
      decimals="-3"
      id="ixv-21826"
      unitRef="usd">111000</us-gaap:LegalFees>
    <us-gaap:OtherLaborRelatedExpenses
      contextRef="c117"
      decimals="-3"
      id="ixv-21827"
      unitRef="usd">546000</us-gaap:OtherLaborRelatedExpenses>
    <iinn:FundsRaisingExpenses
      contextRef="c115"
      decimals="-3"
      id="ixv-21828"
      unitRef="usd">260000</iinn:FundsRaisingExpenses>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c115"
      decimals="-3"
      id="ixv-21829"
      unitRef="usd">675000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c116"
      decimals="-3"
      id="ixv-21830"
      unitRef="usd">1984000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c117"
      decimals="-3"
      id="ixv-21831"
      unitRef="usd">3696000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:GeneralInsuranceExpense
      contextRef="c115"
      decimals="-3"
      id="ixv-21832"
      unitRef="usd">300000</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense
      contextRef="c116"
      decimals="-3"
      id="ixv-21833"
      unitRef="usd">557000</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense
      contextRef="c117"
      decimals="-3"
      id="ixv-21834"
      unitRef="usd">363000</us-gaap:GeneralInsuranceExpense>
    <us-gaap:CostMaintenance
      contextRef="c115"
      decimals="-3"
      id="ixv-21835"
      unitRef="usd">129000</us-gaap:CostMaintenance>
    <us-gaap:CostMaintenance
      contextRef="c116"
      decimals="-3"
      id="ixv-21836"
      unitRef="usd">102000</us-gaap:CostMaintenance>
    <us-gaap:CostMaintenance
      contextRef="c117"
      decimals="-3"
      id="ixv-21837"
      unitRef="usd">91000</us-gaap:CostMaintenance>
    <us-gaap:Depreciation
      contextRef="c115"
      decimals="-3"
      id="ixv-21838"
      unitRef="usd">115000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="c116"
      decimals="-3"
      id="ixv-21839"
      unitRef="usd">104000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="c117"
      decimals="-3"
      id="ixv-21840"
      unitRef="usd">84000</us-gaap:Depreciation>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="c115"
      decimals="-3"
      id="ixv-21841"
      unitRef="usd">100000</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="c116"
      decimals="-3"
      id="ixv-21842"
      unitRef="usd">105000</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="c117"
      decimals="-3"
      id="ixv-21843"
      unitRef="usd">65000</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:OtherGeneralExpense
      contextRef="c115"
      decimals="-3"
      id="ixv-21844"
      unitRef="usd">45000</us-gaap:OtherGeneralExpense>
    <us-gaap:OtherGeneralExpense
      contextRef="c116"
      decimals="-3"
      id="ixv-21845"
      unitRef="usd">68000</us-gaap:OtherGeneralExpense>
    <us-gaap:OtherGeneralExpense
      contextRef="c117"
      decimals="-3"
      id="ixv-21846"
      unitRef="usd">46000</us-gaap:OtherGeneralExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="c115"
      decimals="-3"
      id="ixv-21847"
      unitRef="usd">4063000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="c116"
      decimals="-3"
      id="ixv-21848"
      unitRef="usd">5375000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="c117"
      decimals="-3"
      id="ixv-21849"
      unitRef="usd">6937000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock contextRef="c0" id="ixv-19628">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 13 - FINANCIAL (INCOME) AND EXPENSES:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left"&gt;Revaluation of financial liabilities at fair value through profit or loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(306&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(108&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,995&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Interest on financial liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Foreign currency transaction income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(233&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;530&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;113&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Finance expense in respect of lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(143&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt; expenses (Income)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(529&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;275&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,230&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="c0" id="ixv-19633">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left"&gt;Revaluation of financial liabilities at fair value through profit or loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(306&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(108&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,995&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Interest on financial liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Foreign currency transaction income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(233&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;530&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;113&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Finance expense in respect of lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(143&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt; expenses (Income)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(529&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;275&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,230&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <iinn:EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue contextRef="c0" decimals="-3" id="ixv-21850" unitRef="usd">306000</iinn:EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue>
    <iinn:EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue contextRef="c6" decimals="-3" id="ixv-21851" unitRef="usd">108000</iinn:EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue>
    <iinn:EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue contextRef="c7" decimals="-3" id="ixv-21852" unitRef="usd">-3995000</iinn:EvaluationOfFinancialLiabilityIncludingSafeAndConvertibleLoanAtFairValue>
    <us-gaap:FinancingInterestExpense contextRef="c7" decimals="-3" id="ixv-21853" unitRef="usd">59000</us-gaap:FinancingInterestExpense>
    <iinn:ForeignCurrencyTransactionsGainBeforeTax contextRef="c0" decimals="-3" id="ixv-21854" unitRef="usd">-233000</iinn:ForeignCurrencyTransactionsGainBeforeTax>
    <iinn:ForeignCurrencyTransactionsGainBeforeTax contextRef="c6" decimals="-3" id="ixv-21855" unitRef="usd">530000</iinn:ForeignCurrencyTransactionsGainBeforeTax>
    <iinn:ForeignCurrencyTransactionsGainBeforeTax contextRef="c7" decimals="-3" id="ixv-21856" unitRef="usd">113000</iinn:ForeignCurrencyTransactionsGainBeforeTax>
    <iinn:FinanceLeaseInterestExpenses contextRef="c6" decimals="-3" id="ixv-21857" unitRef="usd">143000</iinn:FinanceLeaseInterestExpenses>
    <iinn:FinanceLeaseInterestExpenses contextRef="c7" decimals="-3" id="ixv-21858" unitRef="usd">-42000</iinn:FinanceLeaseInterestExpenses>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c0" decimals="-3" id="ixv-21859" unitRef="usd">-10000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c6" decimals="-3" id="ixv-21860" unitRef="usd">4000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c7" decimals="-3" id="ixv-21861" unitRef="usd">-21000</us-gaap:OtherNoncashIncomeExpense>
    <iinn:DisposalGroupIncludingDiscontinuedOperationsOtherIncome contextRef="c0" decimals="-3" id="ixv-21862" unitRef="usd">-529000</iinn:DisposalGroupIncludingDiscontinuedOperationsOtherIncome>
    <iinn:DisposalGroupIncludingDiscontinuedOperationsOtherIncome contextRef="c6" decimals="-3" id="ixv-21863" unitRef="usd">275000</iinn:DisposalGroupIncludingDiscontinuedOperationsOtherIncome>
    <iinn:DisposalGroupIncludingDiscontinuedOperationsOtherIncome contextRef="c7" decimals="-3" id="ixv-21864" unitRef="usd">4230000</iinn:DisposalGroupIncludingDiscontinuedOperationsOtherIncome>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-19755">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 14 - TAXES ON INCOME: &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Taxes on income:&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"&gt;The Israeli corporate
tax rate was 23% in 2023 and 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Net operating losses carry forwards&lt;/b&gt;:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Carryforward tax losses of the Company
as of December 31, 2023, amounted to approximately $24,000; however, a full valuation allowance of $7,000 was recorded against the potential
future tax benefits.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The deferred tax assets and liabilities
are composed of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Net operating loss carryforward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,519&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,324&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;R&amp;amp;D capitalization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,335&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,005&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Fund raising costs 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;275&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Fund raising costs 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Operating lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,012&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,670&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,012&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,670&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Net deferred taxes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Theoretical tax:&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left"&gt;Loss before taxation&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(11,286&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(14,976&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(17,193&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Theoretical tax credit at applicable statutory rate: 23%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,596&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,444&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,954&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Non-allowable expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(244&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,026&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,527&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Temporary differences and tax losses for which no Deferred Tax Asset is recognized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,352&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,418&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,427&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;Income tax benefit&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="c118"
      decimals="2"
      id="ixv-21865"
      unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="c119"
      decimals="2"
      id="ixv-21866"
      unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:OperatingLossCarryforwards contextRef="c5" decimals="-3" id="ixv-21867" unitRef="usd">24000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsNet contextRef="c5" decimals="-3" id="ixv-21868" unitRef="usd">7000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0" id="ixv-21869">The deferred tax assets and liabilities
are composed of the following:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Net operating loss carryforward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,519&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,324&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;R&amp;amp;D capitalization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,335&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,005&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Fund raising costs 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;275&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Fund raising costs 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Operating lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,012&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,670&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,012&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,670&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Net deferred taxes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c4" decimals="-3" id="ixv-21870" unitRef="usd">5519000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c5" decimals="-3" id="ixv-21871" unitRef="usd">3324000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-21872" unitRef="usd">80000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-21873" unitRef="usd">66000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="c4" decimals="-3" id="ixv-21874" unitRef="usd">1335000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="c5" decimals="-3" id="ixv-21875" unitRef="usd">1005000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <iinn:DeferredTaxAssetsFundRaisingCosts2021 contextRef="c5" decimals="-3" id="ixv-21876" unitRef="usd">275000</iinn:DeferredTaxAssetsFundRaisingCosts2021>
    <iinn:DeferredTaxAssetsFundRaisingCost2023 contextRef="c4" decimals="-3" id="ixv-21877" unitRef="usd">70000</iinn:DeferredTaxAssetsFundRaisingCost2023>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="-3" id="ixv-21878" unitRef="usd">8000</us-gaap:OperatingLeasePayments>
    <us-gaap:DeferredTaxAssetsGross contextRef="c4" decimals="-3" id="ixv-21879" unitRef="usd">7012000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c5" decimals="-3" id="ixv-21880" unitRef="usd">4670000</us-gaap:DeferredTaxAssetsGross>
    <iinn:DeferredTaxAssetValuationAllowance contextRef="c4" decimals="-3" id="ixv-21881" unitRef="usd">7012000</iinn:DeferredTaxAssetValuationAllowance>
    <iinn:DeferredTaxAssetValuationAllowance contextRef="c5" decimals="-3" id="ixv-21882" unitRef="usd">-4670000</iinn:DeferredTaxAssetValuationAllowance>
    <iinn:ScheduleOfTheoreticalTaxTableTextBlock contextRef="c0" id="ixv-19959">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left"&gt;Loss before taxation&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(11,286&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(14,976&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(17,193&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Theoretical tax credit at applicable statutory rate: 23%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,596&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,444&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,954&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Non-allowable expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(244&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,026&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,527&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Temporary differences and tax losses for which no Deferred Tax Asset is recognized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,352&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,418&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,427&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;Income tax benefit&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:ScheduleOfTheoreticalTaxTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="-3" id="ixv-21883" unitRef="usd">-11286000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c6" decimals="-3" id="ixv-21884" unitRef="usd">-14976000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c7" decimals="-3" id="ixv-21885" unitRef="usd">-17193000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="2" id="ixv-21886" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c6" decimals="2" id="ixv-21887" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c7" decimals="2" id="ixv-21888" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="-3" id="ixv-21889" unitRef="usd">2596000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c6" decimals="-3" id="ixv-21890" unitRef="usd">3444000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c7" decimals="-3" id="ixv-21891" unitRef="usd">3954000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c0" decimals="-3" id="ixv-21892" unitRef="usd">-244000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c6" decimals="-3" id="ixv-21893" unitRef="usd">-1026000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c7" decimals="-3" id="ixv-21894" unitRef="usd">-1527000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized contextRef="c0" decimals="-3" id="ixv-21895" unitRef="usd">-2352000</iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized>
    <iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized contextRef="c6" decimals="-3" id="ixv-21896" unitRef="usd">-2418000</iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized>
    <iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized contextRef="c7" decimals="-3" id="ixv-21897" unitRef="usd">-2427000</iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0" id="ixv-20087">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 15 - SHARE-BASED PAYMENT:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2019, the Company established a share
option plan (the &#x201c;2019 Plan&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The options to employees are granted under Section
102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company makes awards of options and restricted
shares under the 2019 Plan, which may be issued at the discretion of the Board of Directors from time to time. Under this 2019 Plan, each
option or RSU is exercisable into one Ordinary Share of the Company. The options may be exercised after vesting and in accordance with
vesting schedules which will be determined by the Board of Directors for each grant. The maximum term of the options issuable under the
2019 Plan is 10 years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following are the significant stock options
and RSUs transactions with employees, Board of Directors members and non-employees made during the year ended December 31, 2021 and the
year ended December 31, 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 21, 2021, the Company&#x2019;s Board
of Directors approved a grant of non-tradable shares options to purchase 13,605 Ordinary Shares and share options to purchase 21,768 Ordinary
Shares. The vesting period is three years commencing on the grant date. The exercise price per share was NIS 0.37($0.12). The contractual
life of the options under the 2019 Plan is ten years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 16, 2021, the Company&#x2019;s Board of
Directors approved a grant of 81,633 non-tradable shares options to purchase up to 81,633 Ordinary Shares to a director. The share options
vesting period is up to three years from the grant date. The exercise price per share was NIS 0.37 ($0.12). The contractual life of the
options under the 2019 Plan is ten years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 12, 2021, the Company&#x2019;s Board
of Directors resolved to increase the pool of options available under the Plan to 25% of the Company&#x2019;s equity, on a fully diluted
basis. As a result of the increase, the number of authorized Ordinary Shares available pursuant the 2019 Plan was 4,180,898.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;On November 2, 2021, the Company&#x2019;s Board of Directors approved
a grant of 2,658,188 RSUs to employees and officers. The RSUs represents the right to receive Ordinary Shares at a future time and vest
over a period of three years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 2, 2021, the Company&#x2019;s Board
of Directors approved a grant of 10,000 RSUs to the Company&#x2019;s advisory board. The RSUs vest over a period of three years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 24, 2022, the Company&#x2019;s Board of directors approved
a grant of 536,141 RSUs to employees and a grant of 22,500 RSUs to the Company&#x2019;s advisory board members and an additional consultant.
The RSUs represent the right to receive Ordinary Shares at a future time. 555,500 of the RSUs in this grant, vest over a period of three
years, with a 1-year cliff period, and 3,141 RSUs vested immediately on the grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 24, 2022, the Company&#x2019;s Board of
Directors approved a grant of 29,400 Ordinary Shares options to medical board members, which are exercisable to 29,400 Ordinary Shares.
The share options vesting period is up to three years from the grant date. The exercise price per share was NIS 10.84 ($3.08). The contractual
life of the options under the 2019 Plan is ten years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.2pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On April 6, 2022, the Company&#x2019;s Board of Directors approved a
grant of 285,713 fully vested RSUs to an officer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On May 19, 2022, the Company&#x2019;s Board of Directors approved a
grant of 30,000 RSUs to an employee. The RSUs vest over a period of three years, with a 1-year cliff period, commencing on the grant date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;On November 22, 2022, the Company&#x2019;s Board of Directors approved
a grant of 165,000 RSUs to employees. The RSUs vest over a period of three years, with a 1-year cliff period, commencing on the grant
date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;There was no grant of options or restricted shares during the year
period ended December 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of all granted options was estimated
by using the Black Scholes model, which was aimed to model the value of the Company&#x2019;s assets over time. The simulation approach
was designed to take into account the terms and conditions of the share options, as well as the capital structure of the Company and the
volatility of its assets, on the date of grant based on certain assumptions. Those conditions are, among others:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(i)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The expected volatility is
between 50%-52.4%&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(ii)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The dividend rate 0%; and&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;(iii)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Expected term &#x2013; three years.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The valuation was completed with the assistance
of an independent valuator based on management&#x2019;s assumptions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;During the year ended December 31, 2023, the Company recorded share-based
payment expenses to employees, directors and subcontractors in the amount of $1,427.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;During the year ended December 31, 2022, the Company recorded share-based
payment expenses to employees, directors and subcontractors in the amount of $4,879.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;During the year ended December 31, 2021, the Company recorded share-based
payment expenses to employees, directors and subcontractors in the amount of $6,703.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&#160;The options to services providers and advisers outstanding as
of December 31, 2023, December 31, 2022 and December 31, 2021 were as&#160;follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt;
 December&#160;31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended &lt;br/&gt;
December&#160;31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt;
 December&#160;31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted average Exercise price NIS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted average Exercise price NIS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;b&gt;&#160;Number of options&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;b&gt;&#160;Weighted average Exercise price NIS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;114,512&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;3.058&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;87,833&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;165,987&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Reclassified to employees and directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(71,260&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,326&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,401&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,721&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20,086&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,134&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;Options outstanding&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;105,111&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4.085&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;114,512&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.058&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;87,833&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;Options exercisable&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;94,242&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.267&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;82,257&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.71&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;62,715&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;Share-based payment expenses&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;19&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;54&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;279&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;The RSUs to services providers and advisers outstanding as of December
31, 2023, December 31, 2022 and December 31, 2021 were as&#160;follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt;
 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt;
 2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,266&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-137"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-138"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,833&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,234&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;RSUs outstanding&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,433&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18,266&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;RSU&#x2019;s Vested&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25,067&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,234&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;Share-based payment expenses&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The options to employees and directors outstanding as of December 31,
2023, December 31, 2022 and December 31, 2021 were as&#160;follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Year ended&lt;br/&gt;
 December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Year ended&lt;br/&gt;
 December&#160;31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Year ended&lt;br/&gt;
 December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Number of options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Weighted average Exercise price NIS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Number of options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Weighted average Exercise price NIS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;b&gt;&#160;Number of options&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;b&gt;&#160;Weighted average Exercise price NIS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;386,260&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;448,120&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;296,038&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Reclassified to employees and directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;71,260&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;95,238&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,309&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,544&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28,571&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;57,551&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,872&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;Options outstanding&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;357,689&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;386,260&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;448,120&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;Options exercisable&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;350,131&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;342,757&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;347,069&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;Share-based payment expenses&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;47&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;174&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;394&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;The RSUs to employees and directors outstanding as of December 31,
2023, December 31, 2022 and December 31, 2021 were as&#160;follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt;
 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt;
 2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;1,727,842&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;2,002,587&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 64%"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-142"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,016,854&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,658,188&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67,087&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;65,626&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-143"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,215,615&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,225,973&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;655,601&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;RSUs outstanding&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;445,140&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,727,842&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,002,587&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;RSU&#x2019;s Vested&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,097,189&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,881,574&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;655,601&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Share-based payment expenses&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,352&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,618&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,014&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <iinn:CapitalGainTaxRate
      contextRef="c120"
      decimals="2"
      id="ixv-21898"
      unitRef="pure">0.25</iinn:CapitalGainTaxRate>
    <iinn:OptionsIssuableTerm contextRef="c0" id="ixv-21899">P10Y</iinn:OptionsIssuableTerm>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c121"
      decimals="0"
      id="ixv-21900"
      unitRef="shares">13605</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c122"
      decimals="0"
      id="ixv-21901"
      unitRef="shares">21768</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <iinn:ShareOptionsVestingPeriod contextRef="c123" id="ixv-21902">P3Y</iinn:ShareOptionsVestingPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c122"
      decimals="2"
      id="ixv-21903"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c124"
      decimals="2"
      id="ixv-21904"
      unitRef="usdPershares">0.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c125"
      decimals="2"
      id="ixv-21905"
      unitRef="usdPershares">0.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c125" id="ixv-21906">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c126"
      decimals="0"
      id="ixv-21907"
      unitRef="shares">81633</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c127"
      decimals="0"
      id="ixv-21908"
      unitRef="shares">81633</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <iinn:ShareOptionsVestingPeriod contextRef="c128" id="ixv-21909">P3Y</iinn:ShareOptionsVestingPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c129"
      decimals="2"
      id="ixv-21910"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c130"
      decimals="2"
      id="ixv-21911"
      unitRef="usdPershares">0.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c131" id="ixv-21912">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <iinn:EquityPercentage
      contextRef="c132"
      decimals="2"
      id="ixv-21913"
      unitRef="pure">0.25</iinn:EquityPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease
      contextRef="c133"
      decimals="0"
      id="ixv-21914"
      unitRef="shares">4180898</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c134"
      decimals="0"
      id="ixv-21915"
      unitRef="shares">2658188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <iinn:RSUsVestPeriod contextRef="c134" id="ixv-21916">P3Y</iinn:RSUsVestPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c135"
      decimals="0"
      id="ixv-21917"
      unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <iinn:RSUsVestPeriod contextRef="c136" id="ixv-21918">P3Y</iinn:RSUsVestPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c137"
      decimals="0"
      id="ixv-21919"
      unitRef="shares">536141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c138"
      decimals="0"
      id="ixv-21920"
      unitRef="shares">22500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c139"
      decimals="0"
      id="ixv-21921"
      unitRef="shares">555500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <iinn:RSUsVestPeriod contextRef="c140" id="ixv-21922">P3Y</iinn:RSUsVestPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c141"
      decimals="0"
      id="ixv-21923"
      unitRef="shares">3141</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c142"
      decimals="0"
      id="ixv-21924"
      unitRef="shares">29400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c140"
      decimals="0"
      id="ixv-21925"
      unitRef="shares">29400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c143"
      decimals="2"
      id="ixv-21926"
      unitRef="ilsPershares">10.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c143"
      decimals="2"
      id="ixv-21927"
      unitRef="usdPershares">3.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c144" id="ixv-21928">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c145"
      decimals="0"
      id="ixv-21929"
      unitRef="shares">285713</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c146"
      decimals="0"
      id="ixv-21930"
      unitRef="shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <iinn:RSUsVestPeriod contextRef="c147" id="ixv-21931">P3Y</iinn:RSUsVestPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c148"
      decimals="0"
      id="ixv-21932"
      unitRef="shares">165000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <iinn:RSUsVestPeriod contextRef="c149" id="ixv-21933">P3Y</iinn:RSUsVestPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c67" decimals="2" id="ixv-21934" unitRef="pure">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="c150"
      decimals="3"
      id="ixv-21935"
      unitRef="pure">0.524</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c151"
      decimals="2"
      id="ixv-21936"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c151" id="ixv-21937">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c152"
      decimals="-3"
      id="ixv-21938"
      unitRef="usd">1427000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c153"
      decimals="-3"
      id="ixv-21939"
      unitRef="usd">4879000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c154"
      decimals="-3"
      id="ixv-21940"
      unitRef="usd">6703000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-21941">The options to services providers and advisers outstanding as
of December 31, 2023, December 31, 2022 and December 31, 2021 were as&#160;follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt;
 December&#160;31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended &lt;br/&gt;
December&#160;31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt;
 December&#160;31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted average Exercise price NIS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted average Exercise price NIS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;b&gt;&#160;Number of options&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;b&gt;&#160;Weighted average Exercise price NIS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;114,512&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;3.058&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;87,833&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;165,987&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Reclassified to employees and directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(71,260&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,326&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,401&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,721&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20,086&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,134&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;Options outstanding&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;105,111&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4.085&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;114,512&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.058&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;87,833&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;Options exercisable&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;94,242&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.267&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;82,257&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.71&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;62,715&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;Share-based payment expenses&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;19&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;54&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;279&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;The options to employees and directors outstanding as of December 31,
2023, December 31, 2022 and December 31, 2021 were as&#160;follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Year ended&lt;br/&gt;
 December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Year ended&lt;br/&gt;
 December&#160;31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Year ended&lt;br/&gt;
 December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Number of options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Weighted average Exercise price NIS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Number of options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Weighted average Exercise price NIS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;b&gt;&#160;Number of options&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;b&gt;&#160;Weighted average Exercise price NIS&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;386,260&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;448,120&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;296,038&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Reclassified to employees and directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;71,260&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;95,238&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,309&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,544&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28,571&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;57,551&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,872&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;Options outstanding&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;357,689&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;386,260&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;448,120&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;Options exercisable&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;350,131&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;342,757&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;347,069&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;Share-based payment expenses&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;47&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;174&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;394&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c155"
      decimals="INF"
      id="ixv-21942"
      unitRef="shares">114512</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c155"
      decimals="3"
      id="ixv-21943"
      unitRef="ilsPershares">3.058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c156"
      decimals="INF"
      id="ixv-21944"
      unitRef="shares">87833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c156"
      decimals="2"
      id="ixv-21945"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c157"
      decimals="INF"
      id="ixv-21946"
      unitRef="shares">165987</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c157"
      decimals="2"
      id="ixv-21947"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors
      contextRef="c160"
      decimals="INF"
      id="ixv-21948"
      unitRef="shares">-71260</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors>
    <iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors
      contextRef="c160"
      decimals="2"
      id="ixv-21949"
      unitRef="ilsPershares">0.37</iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c159"
      decimals="INF"
      id="ixv-21950"
      unitRef="shares">29400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c159"
      decimals="2"
      id="ixv-21951"
      unitRef="ilsPershares">10.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c160"
      decimals="INF"
      id="ixv-21952"
      unitRef="shares">16326</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c160"
      decimals="2"
      id="ixv-21953"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers
      contextRef="c161"
      decimals="INF"
      id="ixv-21954"
      unitRef="shares">9401</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c158"
      decimals="3"
      id="ixv-21955"
      unitRef="ilsPershares">0.367</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers
      contextRef="c155"
      decimals="INF"
      id="ixv-21956"
      unitRef="shares">-2721</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c159"
      decimals="2"
      id="ixv-21957"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers
      contextRef="c156"
      decimals="INF"
      id="ixv-21958"
      unitRef="shares">-20086</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c160"
      decimals="2"
      id="ixv-21959"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod
      contextRef="c160"
      decimals="INF"
      id="ixv-21960"
      unitRef="shares">-3134</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c160"
      decimals="2"
      id="ixv-21961"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c161"
      decimals="INF"
      id="ixv-21962"
      unitRef="shares">105111</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c161"
      decimals="3"
      id="ixv-21963"
      unitRef="ilsPershares">4.085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c155"
      decimals="INF"
      id="ixv-21964"
      unitRef="shares">114512</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c155"
      decimals="3"
      id="ixv-21965"
      unitRef="ilsPershares">3.058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c156"
      decimals="INF"
      id="ixv-21966"
      unitRef="shares">87833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c156"
      decimals="2"
      id="ixv-21967"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c161"
      decimals="INF"
      id="ixv-21968"
      unitRef="shares">94242</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c161"
      decimals="3"
      id="ixv-21969"
      unitRef="ilsPershares">3.267</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c155"
      decimals="INF"
      id="ixv-21970"
      unitRef="shares">82257</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c155"
      decimals="2"
      id="ixv-21971"
      unitRef="ilsPershares">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c156"
      decimals="INF"
      id="ixv-21972"
      unitRef="shares">62715</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c156"
      decimals="2"
      id="ixv-21973"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c158"
      decimals="-3"
      id="ixv-21974"
      unitRef="usd">19000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c159"
      decimals="-3"
      id="ixv-21975"
      unitRef="usd">54000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c160"
      decimals="-3"
      id="ixv-21976"
      unitRef="usd">279000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c0" id="ixv-21977">The RSUs to services providers and advisers outstanding as of December
31, 2023, December 31, 2022 and December 31, 2021 were as&#160;follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt;
 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt;
 2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,266&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-137"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-138"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,833&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,234&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;RSUs outstanding&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,433&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18,266&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;RSU&#x2019;s Vested&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25,067&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,234&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;Share-based payment expenses&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;The RSUs to employees and directors outstanding as of December 31,
2023, December 31, 2022 and December 31, 2021 were as&#160;follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt;
 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt;
 2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;1,727,842&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;2,002,587&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 64%"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-142"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,016,854&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,658,188&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67,087&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;65,626&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-143"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,215,615&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,225,973&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;655,601&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;RSUs outstanding&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;445,140&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,727,842&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,002,587&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;RSU&#x2019;s Vested&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,097,189&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,881,574&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;655,601&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Share-based payment expenses&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,352&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,618&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,014&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c169"
      decimals="INF"
      id="ixv-21978"
      unitRef="shares">18266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c170"
      decimals="INF"
      id="ixv-21979"
      unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c173"
      decimals="INF"
      id="ixv-21980"
      unitRef="shares">22500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c174"
      decimals="INF"
      id="ixv-21981"
      unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c172"
      decimals="INF"
      id="ixv-21982"
      unitRef="shares">10833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c173"
      decimals="INF"
      id="ixv-21983"
      unitRef="shares">14234</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c175"
      decimals="INF"
      id="ixv-21984"
      unitRef="shares">7433</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c169"
      decimals="INF"
      id="ixv-21985"
      unitRef="shares">18266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c170"
      decimals="INF"
      id="ixv-21986"
      unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested
      contextRef="c172"
      decimals="INF"
      id="ixv-21987"
      unitRef="shares">25067</iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested>
    <iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested
      contextRef="c173"
      decimals="INF"
      id="ixv-21988"
      unitRef="shares">14234</iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c172"
      decimals="-3"
      id="ixv-21989"
      unitRef="usd">9000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c173"
      decimals="-3"
      id="ixv-21990"
      unitRef="usd">33000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c174"
      decimals="-3"
      id="ixv-21991"
      unitRef="usd">16000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c162"
      decimals="INF"
      id="ixv-21993"
      unitRef="shares">386260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c162"
      decimals="2"
      id="ixv-21994"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c163"
      decimals="INF"
      id="ixv-21995"
      unitRef="shares">448120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c163"
      decimals="2"
      id="ixv-21996"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c164"
      decimals="INF"
      id="ixv-21997"
      unitRef="shares">296038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c164"
      decimals="2"
      id="ixv-21998"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors
      contextRef="c166"
      decimals="INF"
      id="ixv-21999"
      unitRef="shares">71260</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors>
    <iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors
      contextRef="c166"
      decimals="2"
      id="ixv-22000"
      unitRef="ilsPershares">0.37</iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c166"
      decimals="INF"
      id="ixv-22001"
      unitRef="shares">95238</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c166"
      decimals="2"
      id="ixv-22002"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers
      contextRef="c162"
      decimals="INF"
      id="ixv-22003"
      unitRef="shares">4309</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c168"
      decimals="2"
      id="ixv-22004"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers
      contextRef="c163"
      decimals="INF"
      id="ixv-22005"
      unitRef="shares">-4544</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c166"
      decimals="2"
      id="ixv-22006"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod
      contextRef="c165"
      decimals="INF"
      id="ixv-22007"
      unitRef="shares">28571</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c165"
      decimals="2"
      id="ixv-22008"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod
      contextRef="c168"
      decimals="INF"
      id="ixv-22009"
      unitRef="shares">57551</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c168"
      decimals="2"
      id="ixv-22010"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod
      contextRef="c166"
      decimals="INF"
      id="ixv-22011"
      unitRef="shares">-9872</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c166"
      decimals="2"
      id="ixv-22012"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c167"
      decimals="INF"
      id="ixv-22013"
      unitRef="shares">357689</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c167"
      decimals="2"
      id="ixv-22014"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c162"
      decimals="INF"
      id="ixv-22015"
      unitRef="shares">386260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c162"
      decimals="2"
      id="ixv-22016"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c163"
      decimals="INF"
      id="ixv-22017"
      unitRef="shares">448120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c163"
      decimals="2"
      id="ixv-22018"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c167"
      decimals="INF"
      id="ixv-22019"
      unitRef="shares">350131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c167"
      decimals="2"
      id="ixv-22020"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c162"
      decimals="INF"
      id="ixv-22021"
      unitRef="shares">342757</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c162"
      decimals="2"
      id="ixv-22022"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c163"
      decimals="INF"
      id="ixv-22023"
      unitRef="shares">347069</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c163"
      decimals="2"
      id="ixv-22024"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c165"
      decimals="-3"
      id="ixv-22025"
      unitRef="usd">47000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c168"
      decimals="-3"
      id="ixv-22026"
      unitRef="usd">174000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c166"
      decimals="-3"
      id="ixv-22027"
      unitRef="usd">394000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c5"
      decimals="INF"
      id="ixv-22029"
      unitRef="shares">1727842</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20"
      decimals="INF"
      id="ixv-22030"
      unitRef="shares">2002587</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c6"
      decimals="INF"
      id="ixv-22031"
      unitRef="shares">1016854</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c7"
      decimals="INF"
      id="ixv-22032"
      unitRef="shares">2658188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c0"
      decimals="INF"
      id="ixv-22033"
      unitRef="shares">67087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c6"
      decimals="INF"
      id="ixv-22034"
      unitRef="shares">65626</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c0"
      decimals="INF"
      id="ixv-22035"
      unitRef="shares">1215615</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c6"
      decimals="INF"
      id="ixv-22036"
      unitRef="shares">1225973</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c7"
      decimals="INF"
      id="ixv-22037"
      unitRef="shares">655601</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c4"
      decimals="INF"
      id="ixv-22038"
      unitRef="shares">445140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c5"
      decimals="INF"
      id="ixv-22039"
      unitRef="shares">1727842</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20"
      decimals="INF"
      id="ixv-22040"
      unitRef="shares">2002587</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested
      contextRef="c0"
      decimals="INF"
      id="ixv-22041"
      unitRef="shares">3097189</iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested>
    <iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested
      contextRef="c6"
      decimals="INF"
      id="ixv-22042"
      unitRef="shares">1881574</iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested>
    <iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested
      contextRef="c7"
      decimals="INF"
      id="ixv-22043"
      unitRef="shares">655601</iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="-3" id="ixv-22044" unitRef="usd">1352000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c6" decimals="-3" id="ixv-22045" unitRef="usd">4618000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c7" decimals="-3" id="ixv-22046" unitRef="usd">6014000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-21049">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 16 - RELATED PARTIES:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;The following transactions arose with related parties:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Transactions and balances with related parties&lt;/span&gt;&lt;b&gt;:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Shareholders and other related
parties&#x2019; benefits&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Salary and related expenses &#x2013; officers and directors&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,761&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,923&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,042&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share based payment &#x2013; officers and directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,009&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,745&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,876&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Balances with related parties&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Name&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Nature of transaction&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 11%; text-align: left"&gt;Officers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Salaries and related&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(314&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(292&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Compensation for directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(40&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(40&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c0" id="ixv-21067">&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Shareholders and other related
parties&#x2019; benefits&lt;/span&gt;&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Salary and related expenses &#x2013; officers and directors&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,761&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,923&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,042&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share based payment &#x2013; officers and directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,009&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,745&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,876&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:OfficersCompensation
      contextRef="c176"
      decimals="-3"
      id="ixv-22047"
      unitRef="usd">1761000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="c177"
      decimals="-3"
      id="ixv-22048"
      unitRef="usd">1923000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="c178"
      decimals="-3"
      id="ixv-22049"
      unitRef="usd">1042000</us-gaap:OfficersCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c176"
      decimals="-3"
      id="ixv-22050"
      unitRef="usd">1009000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c177"
      decimals="-3"
      id="ixv-22051"
      unitRef="usd">3745000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c178"
      decimals="-3"
      id="ixv-22052"
      unitRef="usd">5876000</us-gaap:ShareBasedCompensation>
    <iinn:ScheduleOfBalanceWithRelatedPartiesTableTextBlock contextRef="c0" id="ixv-21122">&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Balances with related parties&lt;/span&gt;&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Name&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Nature of transaction&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 11%; text-align: left"&gt;Officers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Salaries and related&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(314&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(292&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Compensation for directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(40&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(40&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:ScheduleOfBalanceWithRelatedPartiesTableTextBlock>
    <us-gaap:UnusualOrInfrequentItemNatureOfEventOrTransaction contextRef="c179" id="ixv-22053">Salaries and related</us-gaap:UnusualOrInfrequentItemNatureOfEventOrTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c179"
      decimals="-3"
      id="ixv-22054"
      unitRef="usd">314000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c180"
      decimals="-3"
      id="ixv-22055"
      unitRef="usd">292000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:UnusualOrInfrequentItemNatureOfEventOrTransaction contextRef="c181" id="ixv-22056">Compensation for directors</us-gaap:UnusualOrInfrequentItemNatureOfEventOrTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c181"
      decimals="-3"
      id="ixv-22057"
      unitRef="usd">40000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c182"
      decimals="-3"
      id="ixv-22058"
      unitRef="usd">40000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-21167">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 17 - SUBSEQUENT EVENTS:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 22, 2024, the Company&#x2019;s Board of Directors
approved a grant of 320,000 RSUs to employees and options to purchase an aggregate of 80,000 Ordinary Shares to service providers under
the 2019 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of the date these Financial Statements, options
to purchase 40,499 Ordinary Shares are vested and 133,329 of the RSUs are vested and their underlying shares were issued immediately after
the grant approval.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 5, 2024, the Company&#x2019;s Board
of Directors approved a grant of 517,000 RSUs to executives. &lt;span style="-sec-ix-hidden: hidden-fact-144"&gt;None&lt;/span&gt; of the total amount of RSUs are vested as of the date these Financial
Statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 27, 2024, the Company&#x2019;s Board of Directors
approved the issuance of warrants to purchase up to 220,000 Ordinary Shares to a service provider in connection with certain investor
relations services. The warrants have a term of 6 months commencing on May 20, 2024, and an exercise price of $2.25 per share. The warrants
will be forfeited in the event the Company terminates the service provider agreement.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c183"
      decimals="0"
      id="ixv-22059"
      unitRef="shares">320000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="c184"
      decimals="0"
      id="ixv-22060"
      unitRef="shares">80000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="c0"
      decimals="0"
      id="ixv-22061"
      unitRef="shares">40499</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c0"
      decimals="0"
      id="ixv-22062"
      unitRef="shares">133329</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c185"
      decimals="0"
      id="ixv-22063"
      unitRef="shares">517000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="c187"
      decimals="0"
      id="ixv-22064"
      unitRef="shares">220000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="c187"
      decimals="2"
      id="ixv-22065"
      unitRef="usdPershares">2.25</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c4"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c5"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c6"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-5"
      unitRef="usdPershares">-0.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c6"
      decimals="2"
      id="hidden-fact-6"
      unitRef="usdPershares">-1.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c7"
      decimals="2"
      id="hidden-fact-7"
      unitRef="usdPershares">-3.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c6"
      decimals="INF"
      id="hidden-fact-8"
      unitRef="shares">10794594</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="INF"
      id="hidden-fact-9"
      unitRef="shares">12095477</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c7"
      decimals="INF"
      id="hidden-fact-10"
      unitRef="shares">5306225</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c13"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c13"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c13"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c13"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c12"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c13"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="c13"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="c12"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c22"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c23"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c6"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="c22"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="c23"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="c6"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="c23"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="c22"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:StockIssuedDuringPeriodValueParValueCancellation
      contextRef="c30"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:StockIssuedDuringPeriodValueParValueCancellation
      contextRef="c7"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c28"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c30"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c28"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c30"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c28"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c30"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="c28"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="c29"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="c30"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="c7"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c28"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c29"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c30"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c7"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="c28"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="c30"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c17"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="c6"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="c7"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue
      contextRef="c0"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:RevaluationOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoanAtFairValue
      contextRef="c6"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="c6"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="c7"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="c0"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="c7"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="c6"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="c7"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans
      contextRef="c0"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ReceiptOfSimpleAgreementsForFutureEquitySAFEAndConvertibleLoans
      contextRef="c6"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c6"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="c6"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="c7"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c6"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c7"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c6"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c7"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:IssuanceOfOrdinarySharesissuancesPursuantToATM
      contextRef="c6"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c6"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="c0"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="c6"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:TradableWarrantsFinancialLiabilityAtIPO
      contextRef="c0"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:TradableWarrantsFinancialLiabilityAtIPO
      contextRef="c6"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationUnderwritersFeesAtIPO
      contextRef="c0"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationUnderwritersFeesAtIPO
      contextRef="c6"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital
      contextRef="c6"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital
      contextRef="c7"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherShortTermBorrowings
      contextRef="c5"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ForeignExchangeReserve
      contextRef="c5"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="c39"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions
      contextRef="c39"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c39"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="c7"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="c40"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c40"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c6"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="c6"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="c52"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="c77"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod
      contextRef="c104"
      id="hidden-fact-88"
      unitRef="shares"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue
      contextRef="c104"
      id="hidden-fact-89"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms contextRef="c104" id="hidden-fact-90" xsi:nil="true"/>
    <iinn:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised
      contextRef="c104"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c104"
      id="hidden-fact-92"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c104"
      id="hidden-fact-93"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerms contextRef="c104" id="hidden-fact-94" xsi:nil="true"/>
    <iinn:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited
      contextRef="c104"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod
      contextRef="c104"
      id="hidden-fact-96"
      unitRef="shares"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue
      contextRef="c104"
      id="hidden-fact-97"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms contextRef="c104" id="hidden-fact-98" xsi:nil="true"/>
    <iinn:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired
      contextRef="c104"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-100"
      unitRef="usdPershares">-0.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c6"
      decimals="2"
      id="hidden-fact-101"
      unitRef="usdPershares">-1.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c7"
      decimals="2"
      id="hidden-fact-102"
      unitRef="usdPershares">-3.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:PaymentsForParticipationLiabilities
      contextRef="c0"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsForParticipationLiabilities
      contextRef="c6"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherLaborRelatedExpenses
      contextRef="c115"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherLaborRelatedExpenses
      contextRef="c116"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:FundsRaisingExpenses
      contextRef="c116"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:FundsRaisingExpenses
      contextRef="c117"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinancingInterestExpense
      contextRef="c0"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:FinanceLeaseInterestExpenses
      contextRef="c0"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:DeferredTaxAssetsFundRaisingCosts2021
      contextRef="c4"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:DeferredTaxAssetsFundRaisingCost2023
      contextRef="c5"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeasePayments
      contextRef="c6"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="c4"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="c5"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c4"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c5"
      id="hidden-fact-117"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c6"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors
      contextRef="c158"
      id="hidden-fact-121"
      unitRef="shares"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors
      contextRef="c158"
      id="hidden-fact-122"
      unitRef="ilsPershares"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors
      contextRef="c159"
      id="hidden-fact-123"
      unitRef="shares"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors
      contextRef="c159"
      id="hidden-fact-124"
      unitRef="ilsPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c158"
      id="hidden-fact-125"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c158"
      id="hidden-fact-126"
      unitRef="ilsPershares"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod
      contextRef="c158"
      id="hidden-fact-127"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c158"
      id="hidden-fact-128"
      unitRef="ilsPershares"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionForfeituresInPeriod
      contextRef="c159"
      id="hidden-fact-129"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c159"
      id="hidden-fact-130"
      unitRef="ilsPershares"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors
      contextRef="c165"
      id="hidden-fact-131"
      unitRef="shares"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors
      contextRef="c165"
      id="hidden-fact-132"
      unitRef="ilsPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c165"
      id="hidden-fact-133"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c165"
      id="hidden-fact-134"
      unitRef="ilsPershares"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumbers
      contextRef="c167"
      id="hidden-fact-135"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c165"
      id="hidden-fact-136"
      unitRef="ilsPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c171"
      id="hidden-fact-137"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c172"
      id="hidden-fact-138"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c174"
      id="hidden-fact-139"
      unitRef="shares"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested
      contextRef="c174"
      id="hidden-fact-140"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c27"
      id="hidden-fact-141"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c0"
      id="hidden-fact-142"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c7"
      id="hidden-fact-143"
      unitRef="shares"
      xsi:nil="true"/>
    <iinn:RestrictedStockUnits
      contextRef="c186"
      id="hidden-fact-144"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0" id="ixv-22213">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-22214">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentPeriodStartDate contextRef="c0" id="ixv-22215">2023-01-01</dei:DocumentPeriodStartDate>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-22216">0001837493</dei:EntityCentralIndexKey>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#hidden-fact-19"
          xlink:label="hidden-fact-19"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-39"
          xlink:label="hidden-fact-39"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Less than thousand dollars</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-19"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-39"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Future lease payments were discounted by&#160;7.98%-15.04% interest
rate.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
